<SEC-DOCUMENT>0001193125-21-030991.txt : 20210208
<SEC-HEADER>0001193125-21-030991.hdr.sgml : 20210208
<ACCEPTANCE-DATETIME>20210205174420
ACCESSION NUMBER:		0001193125-21-030991
CONFORMED SUBMISSION TYPE:	424B5
PUBLIC DOCUMENT COUNT:		35
FILED AS OF DATE:		20210208
DATE AS OF CHANGE:		20210205

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			I-Mab
		CENTRAL INDEX KEY:			0001778016
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			E9
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		424B5
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-251050
		FILM NUMBER:		21597556

	BUSINESS ADDRESS:	
		STREET 1:		SUITE 802, WEST TOWER, OMNLVISION
		STREET 2:		88 SHANGKE ROAD, PUDONG DISTRICT
		CITY:			SHANGHAI
		STATE:			F4
		ZIP:			201210
		BUSINESS PHONE:		862160578000

	MAIL ADDRESS:	
		STREET 1:		SUITE 802, WEST TOWER, OMNLVISION
		STREET 2:		88 SHANGKE ROAD, PUDONG DISTRICT
		CITY:			SHANGHAI
		STATE:			F4
		ZIP:			201210
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B5
<SEQUENCE>1
<FILENAME>d98473d424b5.htm
<DESCRIPTION>424(B)(5)
<TEXT>
<HTML><HEAD>
<TITLE>424(B)(5)</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Filed Pursuant to Rule 424(b)(5)<BR>Registration No. 333-251050 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Prospectus Supplement </B></P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g98473g25k48.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(To Prospectus dated December 14, 2020) </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">I-MAB</FONT> </B></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This prospectus supplement is part of a registration statement on Form <FONT STYLE="white-space:nowrap">F-1</FONT> using a &#147;shelf&#148; registration
process that was declared effective by the U.S. Securities and Exchange Commission (the &#147;SEC&#148;) on December&nbsp;14, 2020 (the &#147;Base Form <FONT STYLE="white-space:nowrap">F-1&#148;).</FONT> This document consists of two parts. The
first part is this prospectus supplement, which includes supplemental descriptions of certain aspects of our business and financial information, as well as updated disclosure of certain information previously disclosed in the Base Form <FONT
STYLE="white-space:nowrap">F-1.</FONT> The second part is the accompanying prospectus, which describes more general information. You should read both this prospectus supplement and the accompanying prospectus, together with the additional
information described in this prospectus supplement under the heading &#147;Where You Can Find Additional Information.&#148; If information in this prospectus supplement differs from information in the accompanying prospectus, you should rely on the
information in this prospectus supplement. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are responsible for the information contained in this prospectus supplement and the accompanying prospectus
or contained in any free writing prospectus prepared by or on behalf of us that we have referred to you. None of us or any selling shareholders identified in the Base Form <FONT STYLE="white-space:nowrap">F-1</FONT> has authorized anyone to provide
you with additional information or information different from that contained in this prospectus supplement and the accompanying prospectus or in any free writing prospectus filed with the SEC, and we take no responsibility for any other information
that others may give you. The selling shareholders identified in the Base Form <FONT STYLE="white-space:nowrap">F-1</FONT> are offering to sell, and seeking offers to buy, our ordinary shares, including ordinary shares represented by American
depositary shares (&#147;ADSs&#148;), only in jurisdictions where offers and sales are permitted. The information contained in this prospectus supplement and the accompanying prospectus is accurate only as of the date of the document containing such
information, regardless of the time of delivery of this prospectus supplement and the accompanying prospectus or of any of our ordinary shares, including ordinary shares represented by ADSs. Our business, operating results or financial condition may
have changed since such date. Neither this prospectus supplement nor the accompanying prospectus constitutes an offer to subscribe for and purchase, any of the ordinary shares or ADSs and may not be used for or in connection with an offer or
solicitation by anyone, in any jurisdiction in which such an offer or solicitation is not authorized or to any person to whom it is unlawful to make such an offer or solicitation. You should not consider any information in this prospectus supplement
or the accompanying prospectus to be investment, legal or tax advice. You should consult your own counsel, accountants and other advisors for legal, tax, business, financial and related advice regarding the purchase of any of the securities offered
by this prospectus supplement. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman"><B><I>In reviewing this prospectus supplement and the accompanying prospectus, you should carefully consider the matters
described under the captions &#147;<A HREF="#stoc98473_4">Risk Factors</A>&#148; beginning on page <FONT STYLE="white-space:nowrap">S-4</FONT> of this prospectus supplement and page 23 of the accompanying prospectus. </I></B></P>
<P STYLE="margin-top:30pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>The date of this prospectus supplement is February 5, 2021. </B></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc"></A>TABLE OF CONTENTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Prospectus Supplement </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="95%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#stoc98473_1">CONVENTIONS THAT APPLY TO THIS PROSPECTUS SUPPLEMENT</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">S-1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#stoc98473_2">WHERE YOU CAN FIND MORE INFORMATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">S-2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#stoc98473_3">FORWARD-LOOKING STATEMENTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">S-3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#stoc98473_4">RISK FACTORS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">S-4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#stoc98473_5">SELECTED CONSOLIDATED FINANCIAL DATA</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">S-9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#stoc98473_6">MANAGEMENT&#146;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF
 OPERATIONS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">S-13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#stoc98473_7">CAPITALIZATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">S-46</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#stoc98473_8">BUSINESS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">S-47</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#stoc98473_10">PRINCIPAL AND SELLING SHAREHOLDERS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">S-50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#stoc98473_12">DESCRIPTION OF SHARE CAPITAL</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">S-57</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#stoc98473_13">INDEX TO CONSOLIDATED FINANCIAL STATEMENTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">F-1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Prospectus </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="95%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Page</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom98473_1">PROSPECTUS SUMMARY</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom98473_2">THE OFFERING</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom98473_3">SUMMARY CONSOLIDATED FINANCIAL DATA</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom98473_4">RISK FACTORS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom98473_5">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">92</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom98473_6">USE OF PROCEEDS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">94</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom98473_7">DIVIDEND POLICY</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">95</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom98473_8">CAPITALIZATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">96</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom98473_9">ENFORCEABILITY OF CIVIL LIABILITIES</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">97</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom98473_10">CORPORATE HISTORY AND STRUCTURE</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">99</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom98473_11">SELECTED CONSOLIDATED FINANCIAL DATA</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">101</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom98473_12">MANAGEMENT&#146;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF
 OPERATIONS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">105</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom98473_13">BUSINESS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">138</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom98473_14">REGULATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">214</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom98473_15">MANAGEMENT</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">246</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom98473_16">PRINCIPAL AND SELLING SHAREHOLDERS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">265</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom98473_17">RELATED PARTY TRANSACTIONS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">272</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom98473_18">DESCRIPTION OF SHARE CAPITAL</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">274</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-i </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="95%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Page</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom98473_19">DESCRIPTION OF AMERICAN DEPOSITARY SHARES</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">290</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom98473_20">SHARES ELIGIBLE FOR FUTURE SALES</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">302</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom98473_21">TAXATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">304</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom98473_22">PLAN OF DISTRIBUTION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">310</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom98473_23">EXPENSES RELATED TO THIS OFFERING</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">313</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom98473_24">LEGAL MATTERS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">314</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom98473_25">EXPERTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">315</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom98473_26">WHERE YOU CAN FIND ADDITIONAL INFORMATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">316</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom98473_27">INDEX TO CONSOLIDATED FINANCIAL STATEMENTS </A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">F-1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:18pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-ii </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="stoc98473_1"></A>CONVENTIONS THAT APPLY TO THIS PROSPECTUS SUPPLEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In this prospectus supplement, unless otherwise indicated or unless the context otherwise requires, </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;ADRs&#148; refer to the American depositary receipts that evidence our ADSs; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;ADSs&#148; refer to our American depositary shares, each ten (10)&nbsp;ADSs represent twenty-three
(23)&nbsp;ordinary shares; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;China&#148; or &#147;the PRC&#148; refers to the People&#146;s Republic of China, excluding, for the
purposes of this prospectus supplement only, Hong Kong, Macau and Taiwan, and &#147;Greater China&#148; does not exclude Hong Kong, Macau and Taiwan; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;China Portfolio&#148; refers to our investigational drugs of which we
<FONT STYLE="white-space:nowrap">in-license</FONT> Greater China rights from reputable global biopharmaceutical companies and rely on our own research and development capabilities to advance into pivotal clinical trials and commercialize in Greater
China with an aim for near-term product launch; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;Global Portfolio&#148; refers to our own proprietary novel or differentiated drug candidates that we are
advancing towards clinical validation in the United States; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT STYLE="white-space:nowrap">&#147;I-Mab,&#148;</FONT> &#147;we,&#148; &#147;us,&#148; &#147;our
company&#148; and &#147;our&#148; refer to I-Mab, a Cayman Islands exempted company, and its subsidiaries; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;RMB&#148; refers to the legal currency of China; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;shares&#148; or &#147;ordinary shares&#148; refer to our ordinary shares, par value US$0.0001 per share;
and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;US$,&#148; &#147;U.S. dollars,&#148; &#147;$,&#148; and &#147;dollars&#148; refer to the legal currency of
the United States. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our reporting currency is RMB. This prospectus supplement also contains translations of certain
foreign currency amounts into U.S. dollars for the convenience of the reader. Unless otherwise stated, all translations from RMB to U.S. dollars were made at a rate of RMB6.7896 to US$1.00, the exchange rate in effect as of September&nbsp;30, 2020
as set forth in the H.10 statistical release of the Board of Governors of the Federal Reserve System. We make no representation that any RMB or U.S. dollar amounts referred to in this prospectus supplement could have been or could be converted into
U.S. dollars or RMB, as the case may be, at any particular rate, or at all. On January 29, 2021, the noon buying rate for RMB was RMB6.4282 to US$1.00. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">All discrepancies in any table between the amounts identified as total amounts and the sum of the amounts listed therein are due to rounding.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="stoc98473_2"></A>WHERE YOU CAN FIND MORE INFORMATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We have filed a registration statement, including relevant exhibits, with the SEC on Form <FONT STYLE="white-space:nowrap">F-1</FONT> under
the Securities Act with respect to the underlying ordinary shares represented by the ADSs being registered by this prospectus supplement and the accompanying prospectus. We have also filed a related registration statement on Form <FONT
STYLE="white-space:nowrap">F-6</FONT> with the SEC to register the ADSs. This prospectus supplement and the accompanying prospectus are part of the registration statement on Form <FONT STYLE="white-space:nowrap">F-1,</FONT> and do not contain all of
the information contained in the registration statement. You should read our registration statements and their exhibits and schedules for further information with respect to us, our ordinary shares and our ADSs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We are subject to periodic reporting and other informational requirements of the Exchange Act as applicable to foreign private issuers.
Accordingly, we are required to file reports, including annual reports on Form <FONT STYLE="white-space:nowrap">20-F,</FONT> and other information with the SEC. The SEC maintains an internet site at http://www.sec.gov that contains reports, proxy
and information statements, and other information regarding issuers that file electronically with the SEC. We maintain our website at <FONT STYLE="white-space:nowrap">http://www.i-mabbiopharma.com/en/.</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">As a foreign private issuer, we are exempt under the Exchange Act from, among other things, the rules prescribing the furnishing and content
of proxy statements, and our executive officers, directors, principal shareholders and selling shareholders are exempt from the reporting and short-swing profit recovery provisions contained in Section&nbsp;16 of the Exchange Act. In addition, we
are not required under the Exchange Act to file periodic reports and financial statements with the SEC as frequently or as promptly as U.S. companies whose securities are registered under the Exchange Act. However, we intend to furnish the
depositary with our annual reports, which will include a review of operations and annual audited consolidated financial statements prepared in conformity with U.S. GAAP, and all notices of shareholders&#146; meetings and other reports and
communications that are made generally available to our shareholders. The depositary will make such notices, reports and communications available to holders of ADSs and, if we so request, will mail to all record holders of ADSs the information
contained in any notice of a shareholders&#146; meeting received by the depositary from us. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="stoc98473_3"></A>FORWARD-LOOKING STATEMENTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">This prospectus supplement and the accompanying prospectus contain forward-looking statements that reflect our current expectations and views
of future events. These statements are made under the &#147;safe harbor&#148; provisions of the U.S. Private Securities Litigation Reform Act of 1995. You can identify these forward-looking statements by terminology such as &#147;may,&#148;
&#147;will,&#148; &#147;expect,&#148; &#147;anticipate,&#148; &#147;aim,&#148; &#147;intend,&#148; &#147;plan,&#148; &#147;believe,&#148; &#147;estimate,&#148; &#147;is/are likely to,&#148; &#147;future,&#148; &#147;potential,&#148;
&#147;continue&#148; or other similar expressions. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our financial condition,
results of operations, business strategy and financial needs. These forward-looking statements include statements relating to, among other things: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the timing of initiation and completion, and the progress of our drug discovery and research programs;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the timing and likelihood of regulatory filings and approvals; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to advance our drug candidates into drugs, and the successful completion of clinical trials;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the approval, pricing and reimbursement of our drug candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the commercialization of our drug candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the market opportunities and competitive landscape of our drug candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the payment, receipt and timing of any milestone payments in relation to the licensing agreements;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">estimates of our costs, expenses, future revenues, capital expenditures and our needs for additional financing;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to attract and retain senior management and key employees; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our future business development, financial condition and results of operations; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">future developments, trends, conditions and competitive landscape in the industry and markets in which we
operate; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our strategies, plans, objectives and goals and our ability to successfully implement these strategies, plans,
objectives and goals; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to continue to maintain our market position in China&#146;s biopharmaceutical and biotechnology
industries; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to identify and integrate suitable acquisition targets; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">changes to regulatory and operating conditions in our industry and markets. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The forward-looking statements included in this prospectus supplement and in the accompanying prospectus are subject to risks, uncertainties
and assumptions about our company. Our actual results of operations may differ materially from the forward-looking statements as a result of the risk factors disclosed in this prospectus supplement and the accompanying prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We would like to caution you not to place undue reliance on these forward-looking statements. You should read these statements in conjunction
with the risk factors disclosed herein and in the accompanying prospectus for a more complete discussion of the risks of an investment in our securities. We operate in a rapidly evolving environment. New risks emerge from time to time and it is
impossible for our management to predict all risk factors, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ from those contained in any
forward-looking statement. We do not undertake any obligation to update or revise the forward-looking statements except as required under applicable law. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="stoc98473_4"></A>RISK FACTORS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">An investment in our ordinary shares or ADSs involves significant risks. The following section sets forth certain risk factors that have been
updated and/or supplemented to reflect changes since the effectiveness of the accompanying prospectus. You should carefully consider the risk factors set forth below together with the other information contained in this prospectus supplement and the
accompanying prospectus before deciding whether to purchase the ordinary shares or ADSs. Any of the following risks and the risks described in the accompanying prospectus, and additional risks and uncertainties not currently known to us or those we
currently view to be immaterial, may also materially and adversely affect our business, financial condition or results of operations. In such case, you may lose all or part of your original investment. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We have incurred net losses in each period since our inception and anticipate that we will continue to incur net losses for the foreseeable future and
may never achieve or maintain profitability. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Investment in the development of biopharmaceutical products is highly speculative as
it entails substantial upfront capital expenditures and significant risks that a drug candidate may fail to demonstrate efficacy and/or safety to gain regulatory or marketing approvals or become commercially viable. To date, we have financed our
activities primarily through private placements. While we have generated revenue from licensing and collaboration deals, we have not generated any revenue from commercial product sales to date, and we continue to incur significant research and
development expenses and other expenses related to our ongoing operations. As a result, we are not profitable and have incurred net losses in each period since our inception. In 2017, 2018, 2019 and the nine months ended September 30, 2020, our net
losses were RMB298.2&nbsp;million, RMB402.8&nbsp;million, RMB1,452.0&nbsp;million (US$213.8 million) and RMB570.6&nbsp;million (US$84.0 million), respectively. Substantially all of our net losses have resulted from costs incurred in connection with
our research and development programs and from general and administrative costs associated with our operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We expect to continue to
incur net losses in the foreseeable future, and that these net losses will increase as we carry out certain activities relating to our development, including, but not limited to, the following: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">conducting clinical trials of our drug candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">manufacturing clinical trial materials through contract manufacturing organizations, or CMOs, in and out of
China; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">seeking regulatory approvals for our drug candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">commercializing our drug candidates for which we have obtained marketing approval; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">completing the construction of and maintaining our manufacturing facilities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">hiring additional clinical, operational, financial, quality control and scientific personnel;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">establishing a sales, marketing and commercialization team for any future products that have obtained regulatory
approval; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">seeking to identify additional drug candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">obtaining, maintaining, expanding and protecting our intellectual property portfolio; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">enforcing and defending any intellectual property-related claims; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">acquiring or <FONT STYLE="white-space:nowrap">in-licensing</FONT> other drug candidates, intellectual property
and technologies. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Typically, it takes many years to develop one new drug from the time it is discovered to when it
becomes available for treating patients. During the process, we may encounter unforeseen expenses, difficulties, complications, delays and other unknown factors that may adversely affect our business. The size of our future net losses will depend
partially on the rate of the future growth of our expenses, our ability to generate revenues </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
and the timing and amount of milestone payments and other payments that we receive from or pay to third parties. If any of our drug candidates fails during clinical trials or does not gain
regulatory approval, or, even if approved, fails to achieve market acceptance, our business may not become profitable. Even if we achieve profitability in the future, we may not be able to sustain profitability in subsequent periods thereafter. Our
prior losses and expected future losses have had, and will continue to have, an adverse effect on our working capital and shareholders&#146; equity. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We recorded net cash outflow from operating activities since our inception. We may need to obtain additional financing to fund our operations. If we are
unable to obtain such financing, we may be unable to complete the development and commercialization of our major drug candidates. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Since our inception, our operations have consumed substantial amounts of cash. We had raised over US$400&nbsp;million in <FONT
STYLE="white-space:nowrap">pre-IPO</FONT> financing in the past three years and received total net proceeds of approximately US$105.3&nbsp;million from our initial public offering. We spent RMB252.2&nbsp;million, RMB280.7&nbsp;million,
RMB868.0&nbsp;million (US$127.8 million) and RMB582.6&nbsp;million (US$85.8 million) in net cash to finance our operations in 2017, 2018, 2019 and the nine months ended September 30, 2020, respectively. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We expect our expenses to increase significantly in connection with our ongoing activities, particularly as we advance the clinical
development of our clinical-stage drug candidates, continue the research and development of our <FONT STYLE="white-space:nowrap">pre-clinical</FONT> stage drug candidates and initiate additional clinical trials of, and seek regulatory approval for,
these and other future drug candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In addition, if we obtain regulatory approvals for any of our drug candidates, we expect to incur
significant commercialization expenses relating to product manufacturing, marketing, sales and distribution and post-approval commitments to continue monitoring the efficacy and safety data of our future products on the market. In particular, costs
that may be required for the manufacture of any drug candidate that has received regulatory approval may be substantial as we may need to modify or increase our production capacity in the future at manufacturing facilities. We may also incur
expenses as we create additional infrastructure to support our operations as a public company. Accordingly, we will need to obtain substantial additional funding in connection with our continuing operations through public or private equity
offerings, debt financing, collaborations or licensing arrangements or other sources. If we are unable to raise capital when needed or on acceptable terms, we could be forced to delay, limit, reduce or terminate our research and development programs
or any future commercialization efforts. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The recent <FONT STYLE="white-space:nowrap">COVID-19</FONT> outbreak has brought uncertainties
and interruptions to global economy and caused significant volatility across the financial markets, which had a cooling effect on the financing and investing activities in general. We believe that our current cash and cash equivalents, together with
our cash generated from operating activities, financing activities, our initial public offering and private placement, will be sufficient to meet our present anticipated working capital requirements and capital expenditures. However, if the impact
of the <FONT STYLE="white-space:nowrap">COVID-19</FONT> and volatility in the financial markets continue, our financing activities in future to raise additional capital may be materially and adversely affected, which may in turn have an adverse
effect on our ability to meet our working capital requirement and our liquidity. For other risks related to the <FONT STYLE="white-space:nowrap">COVID-19,</FONT> see &#147;&#151;Our business and results of operations could be adversely affected by
public health crisis (including the <FONT STYLE="white-space:nowrap">COVID-19</FONT> global pandemic) and natural catastrophes or other disasters outside of our control in the locations in which we, our suppliers, CROs, CMOs and other contractors
operate.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The manufacture of biopharmaceutical products is a complex process which requires significant expertise and capital investment, and
if we encounter problems in establishing our manufacturing capabilities or manufacturing our future products, our business could suffer. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We have limited experience in managing the manufacturing process. The manufacture of biopharmaceutical products is a complex process, in part
due to strict regulatory requirements. As of the date of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
this prospectus supplement, we have no existing manufacturing infrastructure or capabilities. We intend to build a comprehensive biologics manufacturing facility in Hangzhou, China (the
&#147;Hangzhou Facility&#148;) as part of our strategic plan to become a fully integrated biopharma company. We have taken concrete steps to execute this plan. These steps include detailed operational planning for the facility, actions taken to
secure an appropriate site, and negotiations with external financing providers. The Hangzhou Facility targets to have a pilot capacity of 2 production lines (1 line configured with 2&nbsp;x&nbsp;2,000L and another line with 1 x 2,000L) by 2022 and
commercially progressive capacity up to 8&nbsp;x&nbsp;4,000L to begin operation by the end of 2023. Construction is expected to commence in April 2021 and ready for use by the end of 2023. <B><I></I></B>However, the investment for building this new
biologics manufacturing facility that is compliant with cGMP regulations will be a significant upfront cost for us. In turn, this could materially harm our commercialization plans. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In addition, problems may arise during the manufacturing process for a variety of reasons, including equipment malfunction, failure to follow
specific protocols and procedures, problems with raw materials, delays related to the construction of new facilities or expansion of any future manufacturing facilities, including changes in manufacturing production sites and limits to manufacturing
capacity due to regulatory requirements, changes in the types of products produced, increases in the prices of raw materials, physical limitations that could inhibit continuous supply, <FONT STYLE="white-space:nowrap">man-made</FONT> or natural
disasters and environmental factors. If problems arise during the production of a batch of future products, that batch of future products may have to be discarded and we may experience product shortages or incur added expenses. This could, among
other things, lead to increased costs, lost revenue, damage to customer relationships, time and expense spent investigating the cause and, depending on the cause, similar losses with respect to other batches or products. If problems are not
discovered before such product is released to the market, recall and product liability costs may also be incurred. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our auditor, like other
independent registered public accounting firms operating in China, is not permitted to be subject to inspection by Public Company Accounting Oversight Board, and consequently investors may be deprived of the benefits of such inspection. In addition,
the adoption of any rules, legislations or other efforts to increase U.S. regulatory access to audit information could cause uncertainty and we could be delisted if we are unable to meet the PCAOB inspection requirement in time. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our auditor, the independent registered public accounting firm that issued the audit report included elsewhere in this prospectus supplement,
as an auditor of companies that are traded publicly in the United States and a firm registered with the Public Company Accounting Oversight Board (United States), or PCAOB, is subject to laws in the United States pursuant to which the PCAOB conducts
regular inspections to assess its compliance with applicable professional standards. Our auditor is located in, and organized under the laws of, the PRC, which is a jurisdiction where the PCAOB, has been unable to conduct inspections without the
approval of the Chinese authorities. In May 2013, PCAOB announced that it had entered into a Memorandum of Understanding on Enforcement Cooperation with the CSRC and the PRC Ministry of Finance, which establishes a cooperative framework between the
parties for the production and exchange of audit documents relevant to investigations undertaken by PCAOB, the CSRC or the PRC Ministry of Finance in the United States and the PRC, respectively. PCAOB continues to be in discussions with the China
Securities Regulatory Commission, or CSRC, and the PRC Ministry of Finance to permit joint inspections in China of audit firms that are registered with PCAOB and audit Chinese companies that trade on U.S. exchanges. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">On December&nbsp;7, 2018, the SEC and the PCAOB issued a joint statement highlighting continued challenges faced by the U.S. regulators in
their oversight of financial statement audits of U.S.-listed companies with significant operations in China. The joint statement reflects a heightened interest in an issue that has vexed U.S. regulators in recent years. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">On April&nbsp;21, 2020, the SEC and the PCAOB issued another joint statement reiterating the greater risk that disclosures will be
insufficient in many emerging markets, including China, compared to those made by U.S. domestic companies. In discussing the specific issues related to the greater risk, the statement again highlights the PCAOB&#146;s inability to inspect audit work
paper and practices of accounting firms in China, with respect to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
their audit work of U.S. reporting companies. However, it remains unclear what further actions the SEC and PCAOB will take to address the problem. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">On June&nbsp;4, 2020, the U.S. President issued a memorandum ordering the President&#146;s Working Group on Financial Markets, or the PWG, to
submit a report to the President within 60&nbsp;days of the memorandum that includes recommendations for actions that can be taken by the executive branch and by the SEC or PCAOB on Chinese companies listed on U.S. stock exchanges and their audit
firms, in an effort to protect investors in the United States. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">On August&nbsp;6, 2020, the PWG released a report recommending that the
SEC take steps to implement the five recommendations outlined in the report. In particular, to address companies from jurisdictions that do not provide the PCAOB with sufficient access to fulfill its statutory mandate, or NCJs, the PWG recommends
enhanced listing standards on U.S. stock exchanges. This would require, as a condition to initial and continued exchange listing, PCAOB access to work papers of the principal audit firm for the audit of the listed company. Companies unable to
satisfy this standard as a result of governmental restrictions on access to audit work papers and practices in NCJs may satisfy this standard by providing a <FONT STYLE="white-space:nowrap">co-audit</FONT> from an audit firm with comparable
resources and experience where the PCAOB determines it has sufficient access to audit work papers and practices to conduct an appropriate inspection of the <FONT STYLE="white-space:nowrap">co-audit</FONT> firm. The report permits the new listing
standards to provide for a transition period until January&nbsp;1, 2022 for listed companies, but would apply immediately to new listings once the necessary rulemakings and/or standard-setting are effective. If we fail to meet the new listing
standards before the deadline specified thereunder due to factors beyond our control, we could face possible <FONT STYLE="white-space:nowrap">de-listing</FONT> from the Nasdaq Global Market, deregistration from the SEC and/or other risks, which may
materially and adversely affect the market price and liquidity of our ADS, or effectively terminate our ADS trading in the United States. There were recent media reports about the SEC&#146;s proposed rulemaking in this regard. It is uncertain
whether the PWG recommendations will be adopted, in whole or in part, and the impact of any new rule on us cannot be estimated at this time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">This lack of PCAOB inspections in China prevents the PCAOB from fully evaluating audits and quality control procedures of our independent
registered public accounting firm. As a result, we and investors in our ordinary shares are deprived of the benefits of such PCAOB inspections. The inability of the PCAOB to conduct inspections of auditors in China makes it more difficult to
evaluate the effectiveness of our independent registered public accounting firm&#146;s audit procedures or quality control procedures as compared to auditors outside of China that are subject to PCAOB inspections, which could cause investors and
potential investors in our stock to lose confidence in our audit procedures and reported financial information and the quality of our financial statements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">On December&nbsp;7, 2018, the SEC and the PCAOB issued a joint statement highlighting continued challenges faced by the U.S. regulators in
their oversight of financial statement audits of U.S.-listed companies with significant operations in China. As part of a continued regulatory focus in the United States on access to audit and other information currently protected by national law,
in particular the PRC&#146;s, in June 2019, a bipartisan group of lawmakers introduced bills in both houses of the U.S. Congress that would require the SEC to maintain a list of issuers for which PCAOB is not able to inspect or investigate an
auditor report issued by a foreign public accounting firm. The Ensuring Quality Information and Transparency for Abroad-Based Listings on our Exchanges (EQUITABLE) Act prescribes increased disclosure requirements for these issuers and, beginning in
2025, the delisting from U.S. national securities exchanges such as Nasdaq of issuers included on the SEC&#146;s list for three consecutive years. On December 18, 2020, the Holding Foreign Companies Accountable Act, or the HFCA Act, was enacted into
law, which requires the SEC to prohibit any foreign company from listing securities on U.S. securities exchanges if such company retains a foreign accounting firm that cannot be inspected by the PCAOB for three consecutive years, beginning in 2021.
The enactment of the HFCA Act and any additional rulemaking efforts to increase U.S. regulatory access to audit information in China may prohibit our securities from trading on Nasdaq or other U.S. stock exchanges if our auditor is not inspected by
the PCAOB for three consecutive years, and this ultimately could result in our ADSs being delisted. While we </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
understand that there has been dialogue among the CSRC, the SEC and the PCAOB regarding the inspection of PCAOB-registered accounting firms in China, there can be no assurance that our auditor or
us will be able to comply with requirements imposed by U.S. regulators. Delisting of our ADSs would force our U.S.-based shareholders to sell their ADSs or convert them into Class A ordinary shares listed in Hong Kong. Although we are listed in Hong
Kong, investors may face difficulties in migrating their underlying ordinary shares to Hong Kong, or may have to incur increased costs or suffer losses in order to do so. The market prices of our ADSs could be adversely affected as a result of
anticipated negative impacts of the HFCA Act upon, as well as negative investor sentiment towards, China-based companies listed in the United States, regardless of whether the HFCA Act is enacted and regardless of our actual operating performance.
In addition, on June 4, 2020, the U.S. President issued a memorandum ordering the President&#146;s Working Group on Financial Markets, or the PWG, to submit a report to the President within 60 days of the memorandum that includes recommendations for
actions that can be taken by the executive branch and by the SEC or PCAOB on Chinese companies listed on U.S. stock exchanges and their audit firms, in an effort to protect investors in the U.S. On August 6, 2020, the PWG released a report
recommending that the SEC take steps to implement the five recommendations outlined in the report. In particular, to address companies from jurisdictions that do not provide the PCAOB with sufficient access to fulfill its statutory mandate, or NCJs,
the PWG recommends enhanced listing standards on U.S. stock exchanges. This would require, as a condition to initial and continued exchange listing, PCAOB access to work papers of the principal audit firm for the audit of the listed company.
Companies unable to satisfy this standard as a result of governmental restrictions on access to audit work papers and practices in NCJs may satisfy this standard by providing a co-audit from an audit firm with comparable resources and experience
where the PCAOB determines it has sufficient access to audit work papers and practices to conduct an appropriate inspection of the co-audit firm. The report permits the new listing standards to provide for a transition period until January 1, 2022
for listed companies, but would apply immediately to new listings once the necessary rulemakings and/or standard-setting are effective. Any resulting actions, proceedings or new rules could adversely affect the listing and compliance status of
China-based issuers listed in the United States, such as our company, and may have a material and adverse impact on the trading prices of the securities of such issuers, including our ADSs and potentially our Class A ordinary shares, and
substantially reduce or effectively terminate the trading of our ADSs in the United States. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We have granted, and may continue to grant, options and
other types of awards under our share incentive plans, which may result in increased share-based compensation expenses. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We have
adopted the Second Amended and Restated 2017 Employee Stock Option Plan (the &#147;2017 Plan&#148;), the Second Amended and Restated 2018 Employee Stock Option Plan (the &#147;2018 Plan&#148;), the 2019 Share Incentive Plan (the &#147;2019
Plan&#148;) and the 2020 Share Incentive Plan (the &#147;2020 Plan&#148;), for the purpose of granting share-based compensation awards to employees, directors and consultants to incentivize their performance and align their interests with ours. We
recognize expenses in our consolidated financial statements in accordance with U.S. GAAP. As of the date of this prospectus supplement, the awards that had been granted to our directors, officers, employees and consultants and remained outstanding
included (i)&nbsp;options to purchase an aggregate of 7,139,583 ordinary shares, 9,948,512 ordinary shares, 72,000 ordinary shares and 1,052,367 ordinary shares under the 2017 Plan, the 2018 Plan, the 2019 Plan and the 2020 Plan, respectively,
excluding options that were forfeited, cancelled, or exercised after the relevant grant date; and (ii) restricted share units to receive an aggregate of 5,106,138 ordinary shares under the 2020 Plan, excluding restricted share units that were
forfeited, cancelled, or vested after the relevant grant date. See &#147;Management&#151;Share Incentive Plans.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We believe the
granting of share-based compensation is of significant importance to our ability to attract and retain key personnel and employees, and we will continue to grant share-based compensation to employees in the future. As a result, our expenses
associated with share-based compensation may increase, which may have an adverse effect on our results of operations. We may <FONT STYLE="white-space:nowrap">re-evaluate</FONT> the vesting schedules, <FONT STYLE="white-space:nowrap">lock-up</FONT>
period, exercise price or other key terms applicable to the grants under our currently effective share incentive plans from time to time. If we choose to do so, we may experience substantial change in our share-based compensation charges. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="stoc98473_5"></A>SELECTED CONSOLIDATED FINANCIAL DATA </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I>The following section sets forth certain information in the section titled &#147;Selected Consolidated Financial Data&#148; of the
accompanying prospectus that has been updated and/or supplemented to reflect changes since the effectiveness of the accompanying prospectus. </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The following selected consolidated statements of comprehensive loss data for the years ended December&nbsp;31, 2017, 2018 and 2019, selected
consolidated balance sheet data as of December&nbsp;31, 2017, 2018 and 2019 and selected consolidated statements of cash flow data for the years ended December&nbsp;31, 2017, 2018 and 2019 have been derived from our audited consolidated financial
statements included elsewhere in this prospectus supplement. The following selected consolidated statements of comprehensive loss data for the nine months ended September&nbsp;30, 2019 and 2020, selected consolidated balance sheet data as of
September 30, 2020 and selected consolidated statements of cash flow data for the nine months ended September 30, 2019 and 2020 are derived from our unaudited interim condensed consolidated financial statements included elsewhere in this prospectus
supplement. Our consolidated financial statements are prepared and presented in accordance with accounting principles generally accepted in the U.S. GAAP. Our historical results are not necessarily indicative of results expected for future periods.
You should read this Selected Consolidated Financial Data section together with our consolidated financial statements and the related notes and &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations&#148;
included elsewhere in this prospectus supplement. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="31%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>For&nbsp;the&nbsp;Year&nbsp;Ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>For&nbsp;the&nbsp;Nine&nbsp;Months&nbsp;Ended<BR>September 30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>RMB</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>RMB</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>RMB</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>US$</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>RMB</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>RMB</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>US$</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="26" ALIGN="center"><B>(in thousands, except for share and per share data)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Selected Consolidated Statements of Comprehensive Loss Data:</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Revenues</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Licensing and collaboration revenue</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,556</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">53,781</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,419</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Expenses</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development expenses<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>

<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(267,075</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(426,028</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(840,415</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(123,780</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(578,377</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(698,461</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(102,872</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Administrative expenses<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(25,436</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(66,391</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(654,553</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(96,405</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(582,732</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(310,775</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(45,772</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Loss from operations</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(280,955</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(438,638</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(1,464,968</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(215,766</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(1,131,109</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(1,009,236</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(148,644</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest income</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">858</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,597</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30,570</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,502</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,828</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,658</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,748</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest expense</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5,643</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(11,695</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,991</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(441</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,466</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(957</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(141</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other income (expenses), net</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,527</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(16,780</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(20,205</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,976</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,758</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">420,900</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">61,992</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fair value change of warrants</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:10pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:10pt">(14,027</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:10pt">)&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:10pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:10pt">61,405</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:10pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:10pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:10pt">5,644</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:10pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:10pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:10pt">832</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:10pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,609</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Loss before income tax expense</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(298,240</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(401,111</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(1,451,950</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(213,849</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(1,103,380</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(570,635</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(84,045</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income tax expense</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,722</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net loss attributable to <FONT STYLE="white-space:nowrap">I-Mab</FONT></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(298,240</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(402,833</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(1,451,950</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(213,849</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(1,103,380</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(570,635</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(84,045</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="24%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>For&nbsp;the&nbsp;Year&nbsp;Ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>For&nbsp;the&nbsp;Nine&nbsp;Months&nbsp;Ended<BR>September 30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>RMB</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>RMB</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>RMB</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>US$</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>RMB</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>RMB</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>US$</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="26" ALIGN="center"><B>(in thousands, except for share and per share data)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deemed dividend to Series <FONT STYLE="white-space:nowrap">C-1</FONT> preferred shareholders at
extinguishment of Series <FONT STYLE="white-space:nowrap">C-1</FONT> Preferred Shares</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5,283</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(778</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deemed dividend to Series <FONT STYLE="white-space:nowrap">B-1,</FONT> <FONT
STYLE="white-space:nowrap">B-2</FONT> and C preferred shareholders at modification of Series <FONT STYLE="white-space:nowrap">B-1,</FONT> <FONT STYLE="white-space:nowrap">B-2</FONT> and C Preferred Shares</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(27,768</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4,090</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net loss attributable to ordinary shareholders</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(298,240</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(402,833</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(1,485,001</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(218,717</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(1,103,380</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(570,635</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(84,045</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Other comprehensive income</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Foreign currency translation adjustments, net of nil tax</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,918</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">53,689</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,747</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,583</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">66,254</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,530</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,288</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total comprehensive loss attributable to
<FONT STYLE="white-space:nowrap">I-Mab</FONT></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(292,322</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(349,144</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(1,441,203</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(212,266</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(1,037,126</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(555,105</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(81,757</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net loss attributable to ordinary shareholders</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(298,240</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(402,833</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(1,485,001</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(218,717</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(1,103,380</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(570,635</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(84,045</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Weighted-average number of ordinary shares used in calculating net loss per shares</B></P></TD>

<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,742,669</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,529,092</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,381,230</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,381,230</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,184,086</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">126,758,926</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">126,758,926</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net loss per share attributable to ordinary shareholders</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Basic</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(51.93</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(61.70</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(201.19</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(29.63</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(153.59</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4.50</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(0.66</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Diluted</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(51.93</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(61.70</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(201.19</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(29.63</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(153.59</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4.50</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(0.66</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Note: </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Share-based compensation expenses were allocated as follows: </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="50%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>For&nbsp;the&nbsp;Year&nbsp;Ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>For&nbsp;the&nbsp;Nine&nbsp;Months&nbsp;Ended<BR>September&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>RMB</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>RMB</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>RMB</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>US$</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>RMB</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>RMB</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>US$</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="26" ALIGN="center"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,112</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,056</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">470</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">69</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">467</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">224,619</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">33,083</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Administrative expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,927</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,464</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">514,733</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">75,812</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">514,726</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">167,957</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24,737</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>7,039</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>3,520</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>515,203</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>75,881</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>515,193</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>392,576</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>57,820</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The following table presents our selected consolidated statements of balance sheet data as of
December&nbsp;31, 2017, 2018 and 2019 and September&nbsp;30, 2020: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="39%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>As of December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>As of September&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>RMB</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>RMB</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>RMB</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>US$</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>RMB</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>US$</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="22" ALIGN="center"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Selected Consolidated Statements of Balance Sheet Data:</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Current assets:</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">307,930</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,588,278</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,137,473</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">167,532</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,960,017</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">435,963</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Restricted cash</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">104,783</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">92,653</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">55,810</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,220</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Contract assets</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Short-term investments</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">32,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,713</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">28,526</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,201</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepayments and other receivables</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,633</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">88,972</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">136,036</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20,036</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">219,839</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">32,379</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other financial assets</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">266,245</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">255,958</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total current assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">691,591</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,036,861</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,361,319</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">200,501</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,208,382</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">472,543</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Property, equipment and software</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,336</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27,659</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30,069</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,429</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27,058</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,985</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating lease
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT> assets</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,435</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,421</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,061</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,218</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Intangible assets</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">148,844</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">148,844</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">148,844</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21,922</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">122,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17,969</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Goodwill</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">162,574</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">162,574</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">162,574</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23,945</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">162,574</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23,945</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Investment accounted for using the equity method</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">762,997</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">112,377</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other <FONT STYLE="white-space:nowrap">non-current</FONT> assets</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,331</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,699</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1,025,345</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>2,375,938</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1,737,572</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>255,917</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>4,298,072</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>633,037</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total liabilities</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>309,151</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>415,684</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>668,090</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>98,399</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>556,437</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>81,954</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total mezzanine equity</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1,015,989</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>2,915,358</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>3,104,177</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>457,196</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="39%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>As of December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>As of September&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>RMB</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>RMB</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>RMB</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>US$</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>RMB</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>US$</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="22" ALIGN="center"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Shareholders&#146; equity (deficit)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ordinary shares (US$0.0001 par value, 500,000,000 shares authorized as of December&nbsp;31, 2018
and 2019 and 800,000,000 shares authorized as of September&nbsp;30, 2020, respectively; 8,363,719 shares issued and outstanding as of December&nbsp;31, 2018 and 2019 and 153,543,910 shares issued and outstanding September&nbsp;30, 2020,
respectively)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">106</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Treasury stock</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Additional <FONT STYLE="white-space:nowrap">paid-in</FONT> capital</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">52,369</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">389,379</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">57,349</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,720,714</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">989,854</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated other comprehensive income</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,691</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">59,380</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">70,127</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,329</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">85,657</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,616</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated deficit</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(357,860</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,014,489</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,494,207</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(367,357</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,064,842</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(451,403</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total shareholders&#146; equity (deficit)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(299,795</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(955,104</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(2,034,695</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(299,678</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>3,741,635</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>551,083</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total liabilities, mezzanine equity and shareholders&#146; equity (deficit)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1,025,345</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>2,375,938</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1,737,572</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>255,917</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>4,298,072</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>633,037</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The following table presents our selected consolidated statements of cash flow data for the years ended
December&nbsp;31, 2017, 2018 and 2019 and the nine months ended September&nbsp;30, 2019 and 2020: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="34%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>For the Year Ended December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>For the Nine Months Ended<BR>September&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>RMB</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>RMB</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>RMB</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>US$</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>RMB</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>RMB</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>US$</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="26" ALIGN="center"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Selected Consolidated Statements of Cash Flow Data:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash used in operating activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(252,157</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(280,705</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(867,982</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(127,840</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(651,993</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(582,631</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(85,812</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash (used in) generated from investing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(157,665</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">212,462</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">31,292</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">135,128</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(256,381</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(37,760</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash (used in) generated from financing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">758,585</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,479,669</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">152,709</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,493</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">39,413</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,595,692</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">382,304</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Effect of exchange rate changes on cash and cash equivalents and restricted cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(132</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">59,754</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,163</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,233</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">77,581</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,054</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,480</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net increase (decrease) in cash, cash equivalents and restricted cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">348,631</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,268,218</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(487,648</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(71,822</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(399,871</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,766,734</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">260,212</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash, cash equivalents and restricted cash, beginning of the year/period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">64,082</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">412,713</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,680,931</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">247,574</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,680,931</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,193,283</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">175,751</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash, cash equivalents and restricted cash, end of the year/period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">412,713</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,680,931</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,193,283</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">175,752</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,281,060</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,960,017</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">435,963</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="stoc98473_6"></A>MANAGEMENT&#146;S DISCUSSION AND ANALYSIS OF </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FINANCIAL CONDITION AND RESULTS OF OPERATIONS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I>The following section sets forth certain information in the section titled &#147;Management&#146;s Discussion and Analysis of Financial
Condition and Results of Operations&#148; of the accompanying prospectus that has been updated and/or supplemented to reflect changes since the effectiveness of the accompanying prospectus. </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">You should read the following discussion and analysis of our financial condition and results of operations in conjunction with the section
entitled &#147;Selected Consolidated Financial Data&#148; and our consolidated financial statements and the related notes included elsewhere in this prospectus supplement. This discussion contains forward-looking statements that reflect our current
expectations and views of future events, which may involve risks and uncertainties. Our actual results and the timing of selected events could differ materially from those anticipated in these forward-looking statements as a result of various
factors, including those set forth under &#147;Risk Factors&#148; and elsewhere in this prospectus supplement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Overview </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We are a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel or highly
differentiated biologics to treat diseases with significant unmet medical needs, particularly cancers and autoimmune disorders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We were
founded to capture the opportunities presented by the confluence of two major developments&#151;the emergence of an attractive and growing biologics market in China, and the revolutionary scientific breakthroughs in cancer and autoimmune disease
medicines. We believe we are well-positioned to become a biotech leader in China because of our innovative discovery expertise, <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">fit-for-purpose</FONT></FONT> technology platforms,
biomarker-enabled translational medicine capabilities, and clinical development capabilities. These integrated capabilities are further enhanced by our deep understanding of China&#146;s biologics regulatory framework and our direct access to
extensive <FONT STYLE="white-space:nowrap">pre-clinical</FONT> and clinical trial resources in China. To date, we have developed an innovative pipeline of more than 10 clinical and <FONT STYLE="white-space:nowrap">pre-clinical</FONT> stage assets
through our internal research and development efforts and <FONT STYLE="white-space:nowrap">in-licensing</FONT> arrangements with global pharmaceutical and biotech companies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We are fully aware of the competitive and regulatory challenges we face as an innovative clinical stage biotech company based in China,
including need to raise significant capital, significant competition from global and other China-based biopharmaceutical companies, less streamlined regulatory pathway compared to countries with long-established regulatory systems, and potential
implementation challenges and uncertainties of the recent government reform of the drug approval system. However, with these challenges in mind, we have been mitigating the risks through our internal R&amp;D system that integrates multi-functional
aspects of our drug development process to proactively deal with some of the regulatory challenges mentioned above. Furthermore, through our Beijing office which focuses on regulatory matters, we have established an effective communication channel
with the regulatory agencies to discuss and resolve various regulatory issues promptly and effectively. We see vast opportunities for immuno-oncology and autoimmune biologics therapies in China. First, both the incidence and mortality of cancers in
China have been increasing in recent years and are outpacing those in the United States and the rest of the world. Second, many innovative biologics approved to treat cancer and autoimmune diseases in the United States and Europe are not yet
available in China. Third, the Chinese government has implemented new policies and regulations to simplify the review and approval cycle of clinical trials and new drug applications to encourage biologics innovation. Fourth, there has been a
continuous and rapid increase in personal disposable income in China coupled with ongoing improvement in basic national health insurance coverage, making innovative biologics more accessible to more Chinese patients. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We believe we are uniquely positioned as a China-based global player to tap into these vast commercial opportunities. This is best
demonstrated by our short journey in becoming one of the top clinical stage </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
immunology companies in China. For example, in 2018 and 2019, we are the only China-based biotech company recognized by Genetic Engineering&nbsp;&amp; Biotechnology News (GEN) as a top 10
immuno-oncology <FONT STYLE="white-space:nowrap">start-up</FONT> in the world. To date, our research and development capabilities encompass discovery, translational medicine, biologics CMC development,
<FONT STYLE="white-space:nowrap">pre-clinical</FONT> development and clinical development with footprints in Shanghai, Beijing and the United States. We are now at a critical juncture to transition from a clinical stage biotech company into a fully
integrated <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">end-to-end</FONT></FONT> global biopharmaceutical company in the next few years. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Since the commencement of our operation in 2014, we have devoted most of our efforts and financial resources to organize and staff our
operations, business planning, raise capital, establish our intellectual property portfolio and conduct <FONT STYLE="white-space:nowrap">pre-clinical</FONT> and clinical trials of our drug candidates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We have raised in excess of US$940&nbsp;million in the past four years. We have not generated any revenue from product sales, and as a result,
we have never been profitable and have incurred net losses since the commencement of our operations. In 2017, 2018, 2019 and the nine months ended September 30, 2020, our net losses were RMB298.2&nbsp;million, RMB402.8&nbsp;million,
RMB1,452.0&nbsp;million (US$213.8 million) and RMB570.6 million (US$84.0 million), respectively. We do not expect to generate product revenue unless and until we obtain marketing approval for and commercialize a drug candidate, and we cannot assure
you that we will ever generate significant revenue or profits. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Key Factors Affecting Our Results of Operations </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our results of operations, financial condition, and the
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">year-to-year</FONT></FONT> comparability of our financial results have been, and are expected to continue to be, principally affected by the below factors: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Cost and Expenses Structure </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our
results of operations are significantly affected by our cost structure, which primarily consists of research and development expenses and administrative expenses. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Research and development activities are central to our business model. We believe our ability to successfully develop drug candidates will be
the primary factor affecting our long-term competitiveness, as well as our future growth and development. Developing high-quality drug candidates requires a significant investment of resources over a prolonged period of time, and a core part of our
strategy is to continue making sustained investments in this area. Since our inception, we have focused our resources on our research and development activities, including conducting <FONT STYLE="white-space:nowrap">pre-clinical</FONT> studies and
clinical trials, and activities related to regulatory filings for our drug candidates. Our research and development expenses primarily include the following: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">costs related to development of our pipeline assets under all stages including discovery, <FONT
STYLE="white-space:nowrap">pre-clinical</FONT> testing or clinical trials; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">patent license fees and other fees under the licensing, collaboration and development agreements with respect to
our <FONT STYLE="white-space:nowrap">in-licensed</FONT> drug candidates; and </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">employee salaries and related benefit costs, including share-based compensation expenses, for research and
development personnel and key management. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">At this time, we are unable to predict when, if ever, we will be able to
achieve profitability. Even if we achieve profitability in the future, we may not be able to sustain profitability in subsequent periods thereafter. This is due to the numerous risks and uncertainties associated with developing such drug candidates,
including the uncertainty of: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">successful enrollment in and completion of clinical trials; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">establishing an appropriate safety profile; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">establishing commercial manufacturing capabilities or making arrangements with third-party manufacturers;
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">receipt of marketing approvals from applicable regulatory authorities; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">commercializing the drug candidates, if and when approved, whether alone or in collaboration with others;
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">obtaining and maintaining patent and trade secret protection and regulatory exclusivity for our drug candidates;
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">continued acceptable safety profiles of the products following approval; and </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">retention of key research and development personnel. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Any change in the outcome of any of these variables with respect to the development of any of our drug candidates would significantly change
the costs, timing and viability associated with the development of that drug candidate. We expect research and development costs to continue to increase for the foreseeable future as we expand our operations and our development programs progress,
including as we continue to support and advance the clinical trials of our drug candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our administrative expenses consist primarily
of employee salaries and related benefit costs. Other administrative expenses include professional fees for consulting and auditing as well as other direct and allocated expenses for rental expenses for our facilities, travel costs and other
supplies used in administrative activities. We expect our administrative expenses to increase in the future to support our pipeline assets and research and development efforts, and the commercialization of our drug candidates once approval is
obtained. We also anticipate that our administrative expenses will increase as we operate as a public company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Revenue from <FONT
STYLE="white-space:nowrap">Out-Licensing</FONT> Agreements </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We continue to seek
<FONT STYLE="white-space:nowrap">out-licensing</FONT> opportunities for our <FONT STYLE="white-space:nowrap">de-prioritized</FONT> assets to streamline our pipeline. In 2017, 2018 and 2019, our revenue consisted primarily of payments from granting
licenses to use and otherwise exploit certain of our intellectual properties linked to our <FONT STYLE="white-space:nowrap">de-prioritized</FONT> assets. See &#147;Business&#151;Licensing and Collaboration Arrangements&#148; for more information on
the existing <FONT STYLE="white-space:nowrap">out-licensing</FONT> arrangements. In addition, after validating clinical safety and preliminary efficacy of a drug candidate in our Global Portfolio in clinical trials in the United States, we may elect
to <FONT STYLE="white-space:nowrap">out-license</FONT> the global rights (excluding Greater China) of such drug candidate, while retaining the Greater China rights for further development and commercialization. But we may also choose to retain these
rights for the United States or other countries or regions as we may deem fit. Before the commercialization of one or more of our drug candidates, we expect that the majority of our revenue will continue to be generated from <FONT
STYLE="white-space:nowrap">out-licensing</FONT> our intellectual properties. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Funding for Our Operations </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">During the periods presented, we funded our operations primarily from financing through the issuance and sale of preferred shares and
convertible promissory notes in private placement transactions. Going forward, in the event of successful commercialization of one or more of our drug candidates, we expect to fund our operations in part with revenue generated from sales of our
commercialized drug products. However, with the continuing expansion of our business and our product pipeline, we may require further funding through public or private offerings, debt financing, collaboration, and licensing arrangements or other
sources. Any fluctuation in our ability to fund our operations will impact our cash flow plan and our results of operations. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our Ability to Commercialize Our Drug Candidates </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our business and results of operations depend on our ability to commercialize our drug candidates, once and if those candidates are approved
for marketing by the respective health authority. Currently, our pipeline consists of more than ten drug candidates ranging in development status from <FONT STYLE="white-space:nowrap">pre-clinical</FONT> to late-stage clinical programs. Although we
currently do not have any product approved for commercial sale and have not generated any revenue from product sales, we expect to generate revenue from sales of a drug candidate after we complete the clinical development, obtain regulatory
approval, and successfully commercialize such drug candidate. Our late-stage investigational drugs at or potentially near pivotal trials are felzartamab, eftansomatropin, olamkicept and enoblituzumab. See &#147;Business&#151;Our Drug Pipeline&#148;
for more information on the development status of our various drug candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The Effect of Our Acquisition of
<FONT STYLE="white-space:nowrap">I-Mab</FONT> Tianjin </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We acquired a controlling interest in
<FONT STYLE="white-space:nowrap">I-Mab</FONT> Tianjin on July&nbsp;15, 2017 and the remaining interest in <FONT STYLE="white-space:nowrap">I-Mab</FONT> Tianjin in May 2018. Since our acquisition of the controlling interest in <FONT
STYLE="white-space:nowrap">I-Mab</FONT> Tianjin on July&nbsp;15, 2017, <FONT STYLE="white-space:nowrap">I-Mab</FONT> Tianjin has been consolidated into our results of operations. Shortly after we acquired the controlling interest in <FONT
STYLE="white-space:nowrap">I-Mab</FONT> Tianjin, we integrated the operations of <FONT STYLE="white-space:nowrap">I-Mab</FONT> Tianjin into our operations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">I-Mab</FONT> Tianjin did not generate any external revenue from July&nbsp;15, 2017 to September&nbsp;30,
2020. In connection with our acquisition of <FONT STYLE="white-space:nowrap">I-Mab</FONT> Tianjin, we identified RMB148.8&nbsp;million of intangible assets and RMB162.6&nbsp;million of goodwill of <FONT STYLE="white-space:nowrap">I-Mab</FONT>
Tianjin. Goodwill is not amortized, but impairment of goodwill assessment is performed on an least an annual basis on December&nbsp;31 or whenever events or changes in circumstances indicate that the carrying value of the assets may not be
recoverable. No impairment was identified as of December&nbsp;31, 2017, 2018 and 2019 and September&nbsp;30, 2020. Impairment charges could substantially affect our results of operations in the periods of such charges. In addition, impairment
charges would negatively impact our financial ratios and could limit our ability to obtain financing in the future. See &#147;Risk Factors&#151;Risks Related to Our Industry, Business and Operations&#150;&#150;Change in business prospects of
acquisitions may result in impairment to our goodwill, which could negatively affect our reported results of operations.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Impact of the <FONT
STYLE="white-space:nowrap">COVID-19</FONT> Outbreak on Our Business </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">As of the date of this prospectus supplement, the impact of the
ongoing global coronavirus- 19 <FONT STYLE="white-space:nowrap">(COVID-19)</FONT> pandemic to our business has been limited. To date, although <FONT STYLE="white-space:nowrap">COVID-19</FONT> has caused some delays in the initiation of the ongoing
trials of certain clinical-stage drug candidates in early 2020, the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic has not had a material impact on our ongoing clinical activities, in particular, clinical activities related to our
late-stage drug candidates, such as felzartamab, eftansomatropin and olamkicept. See &#147;Our Business&#150;&#150;Our Drug Candidates&#148; for our clinical development plans for our drug candidates. As of the date of this prospectus supplement,
the outbreak of COVID- 19 has not caused any early termination of our clinical trials or necessitated removal of any enrolled patients. We have employed various measures to mitigate impacts of the COVID- 19 outbreak on our currently ongoing trials
in Greater China and the United States. We worked closely with our CROs to monitor the situation and manage the process of our clinical trials. We maintained contact with our patients to ensure that they remain on the trials and that any information
they need will be readily available. In addition, we believe the COVID- 19 outbreak has not significantly impacted our ability to carry out our obligations under existing contracts or disrupted any supply chains that we rely upon. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">As of the date of this prospectus supplement, we have not had any suspected or confirmed <FONT STYLE="white-space:nowrap">COVID-19</FONT>
cases on our premises or among our employees. To prevent any spread of <FONT STYLE="white-space:nowrap">COVID-19</FONT> in our offices and research facilities, we have adopted a thorough disease prevention scheme to protect our employees from
contracting <FONT STYLE="white-space:nowrap">COVID-19.</FONT> The measures we have implemented include, among others, regularly sterilizing and ventilating our offices, checking the body temperature of our employees, keeping track of the travel
history and health </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
conditions of employees and their immediate family members, providing face masks to employees attending the office, minimizing <FONT STYLE="white-space:nowrap">in-person</FONT> meetings to the
extent possible and encouraging employees to wear masks when needed. As of the date of this prospectus supplement, our ongoing clinical trials and CROs had resumed full and normal operations and the COVID- 19 outbreak had not resulted in a major
disruption to our operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Taking into account our past and prospective cash burn rate, including but not limited to future clinical
development and administrative expenses, lease payment, capital expenditure and current financial position, our ability to control the speed and breadth of our clinical development and business development activities and our expansion in headcount,
our current internal resources, we estimate that our financial resources can support our research and development activities and business operations for at least the next 12 months. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Although we believe we have implemented strategies to potentially minimize the impact of the <FONT STYLE="white-space:nowrap">COVID-19</FONT>
pandemic to our business, we expect that we may experience delays with respect to the initiation and patient enrollment of certain additional trials. The extent to which the COVID- 19 pandemic impacts the timing of these additional trials will
depend on future developments, which are highly uncertain and cannot be predicted with confidence, such as the ultimate geographic spread of the disease, the duration of the pandemic, any restrictions on the ability of hospitals and trial sites to
conduct trials that are not designed to address the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic and the perceived effectiveness of actions taken in China and the United States to contain and treat the disease. We will continue to
evaluate the impact of the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic to our business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In addition, there are still
uncertainties with regard to the continued development of <FONT STYLE="white-space:nowrap">COVID-19</FONT> and its implications, and we will continue to assess the situation and seek to put in place relevant mitigating measures where necessary. The
above analyses are made by our management based on currently available information concerning <FONT STYLE="white-space:nowrap">COVID-19.</FONT> We cannot guarantee that the outbreak of COVID- 19 will not further escalate or have a material adverse
effect on our business operations. Please also see &#147;Risk Factors&#151;Risks Related to Our Industry, Business and Operations&#151;Our business, financial condition and results of operations could be adversely affected by the <FONT
STYLE="white-space:nowrap">COVID-19</FONT> outbreak.&#148; and &#147;Risk Factors&#151;Risks Related to Our Industry, Business and Operations&#151;Business disruptions could seriously harm our future revenue and financial condition and increase our
costs and expenses.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Key Components of Results of Operations </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Revenues </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">To date, we have not
generated any revenue from product sales and do not expect to generate any revenue from product sales for the foreseeable future before the successful commercialization of one or more of our drug candidates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We generated substantially all of our revenues for the years ended December&nbsp;31, 2017, 2018 and 2019 from granting licenses to use and
otherwise exploit certain of our intellectual properties in connection with our <FONT STYLE="white-space:nowrap">de-prioritized</FONT> assets. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Research and Development Expenses </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Research and development expenses primarily consist of: (i)&nbsp;payroll and other related expenses of research and development personnel,
(ii)&nbsp;fees associated with the exclusive development rights of our <FONT STYLE="white-space:nowrap">in-licensed</FONT> drug candidates, (iii)&nbsp;fees for services provided by contract research organizations, investigators and clinical trial
sites that conduct our clinical studies, and (iv)&nbsp;expenses relating to the development of our drug candidates, including raw materials and supplies, product testing, depreciation, and facility related expenses. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our current research and development activities primarily relate to the clinical development
of the following investigational drugs: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Felzartamab, a potential highly differentiated CD38 antibody for multiple myeloma and autoimmune diseases, if
approved; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Efineptakin, the first long-acting recombinant human <FONT STYLE="white-space:nowrap">IL-7</FONT> with the
potential for cancer treatment-related lymphopenia and cancer immunotherapy, if approved; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Eftansomatropin, a potential highly differentiated long-acting growth hormone for growth hormone deficiency, if
approved; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Olamkicept, a potential highly differentiated <FONT STYLE="white-space:nowrap">IL-6</FONT> blocker for ulcerative
colitis and other autoimmune diseases, if approved; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Enoblituzumab, the most advanced clinical stage humanized <FONT STYLE="white-space:nowrap">B7-H3</FONT> antibody
as a potential immuno-oncology treatment, if approved; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Lemzoparlimab, a potential highly differentiated CD47 monoclonal antibody with unique <FONT
STYLE="white-space:nowrap">RBC-sparing</FONT> differentiation, if approved; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Uliledlimab, a potential highly differentiated CD73 antibody for immuno-oncology, if approved; and
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Plonmarlimab, a <FONT STYLE="white-space:nowrap">GM-CSF</FONT> monoclonal antibody for rheumatoid arthritis and <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">CAR-T-related</FONT></FONT> therapies, if approved. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We
incurred research and development expenses of RMB267.1&nbsp;million, RMB426.0&nbsp;million and RMB840.4&nbsp;million (US$123.8 million) for the years ended December&nbsp;31, 2017, 2018 and 2019, respectively, representing 91.3%, 86.5% and 56.2% of
our total research and development and administrative expenses for the corresponding periods. We incurred research and development expenses of RMB578.4&nbsp;million and RMB698.5&nbsp;million (US$102.9&nbsp;million) for the nine months ended
September&nbsp;30, 2019 and 2020, respectively. We expect our research and development expenses to continue to increase for the foreseeable future, as we continue to expand our operations and to advance our pipeline and our drug candidates toward
later stages. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Administrative Expenses </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Administrative expenses primarily consist of salaries and related benefit costs, including share-based compensation, for employees engaged in
managerial and administrative positions or involved in general corporate functions, professional fees for consulting and auditing as well as other direct and allocated expenses for rental expenses for our facilities, travel costs and other supplies
used in administrative activities. For the years ended December&nbsp;31, 2017, 2018 and 2019 and the nine months ended September 30, 2020, our administrative expenses amounted to RMB25.4&nbsp;million, RMB66.4&nbsp;million, RMB654.6&nbsp;million
(US$96.4 million) and RMB310.8&nbsp;million (US$45.8 million), respectively. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Interest Expense </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Interest expense consist primarily of interest expenses on our (i)&nbsp;short-term bank borrowings and (ii)&nbsp;convertible promissory notes
issued to certain investors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Interest Income </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Interest income consists primarily of interest income derived from our term deposit and restricted cash pledged as collateral for a working
capital loan. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Other Income (Expenses), Net </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Other income consists primarily of income from the equity transfer of I-Mab Hangzhou and other financial assets. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Other expenses consist primarily of the net loss resulting from the conversion of a portion of our convertible promissory notes and loss on
the termination agreement with Everest. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Fair Value Change of Warrants </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Fair value change of warrants consists primarily of the <FONT STYLE="white-space:nowrap">non-cash</FONT> items incurred in connection with
changes in the fair value of our warrant liabilities that we issued to certain investors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Taxation </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Cayman Islands </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><FONT
STYLE="white-space:nowrap">I-Mab,</FONT> our holding entity, is incorporated in the Cayman Islands. The Cayman Islands currently has no income, corporation or capital gains tax and no estate duty, inheritance tax or gift tax. Additionally, the
Cayman Islands does not impose a withholding tax on payments of dividends to shareholders. I-Mab did business registration in Hong Kong and had a HK tax file number. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Hong Kong </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><FONT
STYLE="white-space:nowrap">I-Mab</FONT> Biopharma Hong Kong Limited is incorporated in Hong Kong. Companies registered in Hong Kong are subject to Hong Kong profits tax on the taxable income as reported in their respective statutory financial
statements adjusted in accordance with the relevant Hong Kong tax laws. Under the current Hong Kong Inland Revenue Ordinance, from the year of assessment 2018/2019 onwards, our subsidiary in Hong Kong is subject to profits tax at the rate of 8.25%
on assessable profits up to HK$2,000,000; and 16.5% on any part of assessable profits over HK$2,000,000. For the years ended December&nbsp;31, 2017, 2018 and 2019 and the nine months ended September 30, 2020,
<FONT STYLE="white-space:nowrap">I-Mab</FONT> Biopharma Hong Kong Limited did not make any provisions for Hong Kong profit tax as there were no assessable profits derived from or earnings in Hong Kong for any of the periods presented. Under the Hong
Kong tax law, <FONT STYLE="white-space:nowrap">I-Mab</FONT> Biopharma Hong Kong Limited is exempted from income tax on its foreign-derived income and there are no withholding taxes in Hong Kong on remittance of dividends. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>United States </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><FONT
STYLE="white-space:nowrap">I-Mab</FONT> Biopharma US Ltd. is incorporated in Maryland and is subject to U.S. federal corporate income tax at a rate of 21%. It is also subject to state income tax in Maryland at a rate of 8.25%. <FONT
STYLE="white-space:nowrap">I-Mab</FONT> Biopharma US Ltd. has no taxable income for all periods presented and therefore no provision for income taxes is required. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>China </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">On March&nbsp;16, 2007,
the National People&#146;s Congress of PRC enacted a new Corporate Income Tax Law (&#147;new CIT law&#148;) (as amended in 2017 and 2018), under which Foreign Investment Enterprises (&#147;FIEs&#148;) and domestic companies would be subject to
corporate income tax at a uniform rate of 25%. The new CIT law became effective on January&nbsp;1, 2008. Under the new CIT law, preferential tax treatments will continue to be granted to entities which conduct businesses in certain encouraged
sectors and to entities otherwise classified as &#147;High and New Technology Enterprises.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">I-Mab</FONT> Shanghai has been qualified as a &#147;High and New Technology Enterprise&#148; and enjoys a
preferential income tax rate of 15% from 2018 to 2020. Our company&#146;s other PRC subsidiaries are subject to the statutory income tax rate of 25%. No provision for income taxes has been accrued because all of our PRC subsidiaries are in
cumulative loss positions for all the periods presented. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">A valuation allowance is provided to reduce the amount of deferred tax assets if it is
considered more likely than not that some portion or all of the deferred tax assets will not be realized in the foreseeable future. In making such determination, we evaluate a variety of positive and negative factors including our operating history,
accumulated deficit, the existence of taxable temporary differences and reversal periods. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We have incurred net accumulated operating
losses for income tax purposes since our inception. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We evaluate each uncertain tax position (including the potential application of
interest and penalties) based on the technical merits, and measure the unrecognized benefits associated with the tax positions. As of December&nbsp;31, 2017, 2018 and 2019 and September 30, 2020, we did not have any significant unrecognized
uncertain tax positions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Results of Operations </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The following table sets forth a summary of our consolidated results of operations for the periods indicated. This information should be read
together with our consolidated financial statements and related notes included elsewhere in this prospectus supplement. The operating results in any period are not necessarily indicative of the results that may be expected for any future period.
</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="24%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>For&nbsp;the&nbsp;Year&nbsp;Ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>For&nbsp;the&nbsp;Nine Months&nbsp;Ended&nbsp;September 30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>RMB</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>RMB</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>RMB</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>US$</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>RMB</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>RMB</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>US$</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="26" ALIGN="center"><B>(in thousands, except for share and per share data)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Revenues</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Licensing and collaboration revenue</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,556</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">53,781</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,419</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Expenses</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development expenses<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>

<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(267,075</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(426,028</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(840,415</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(123,780</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(578,377</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(698,461</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(102,872</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Administrative expenses<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(25,436</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(66,391</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(654,553</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(96,405</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(582,732</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(310,775</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(45,772</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Loss from operations</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(280,955</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(438,638</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(1,464,968</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(215,766</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><B>(1,131,109</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)</B>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B></B><B></B><B></B><B></B><B></B><B></B>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><B></B><B>(1,0</B><B>09</B><B>,</B><B>236</B><B></B></TD>
<TD NOWRAP VALIGN="bottom"><B></B><B></B><B></B><B></B><B></B><B>)</B>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B></B><B></B><B></B><B></B><B></B><B></B>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><B></B><B>(1</B><B>48</B><B>,</B><B>644</B><B></B></TD>
<TD NOWRAP VALIGN="bottom"><B></B><B></B><B></B><B></B><B></B><B>)</B>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest income</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">858</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,597</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30,570</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,502</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,828</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,658</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,748</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest expense</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5,643</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(11,695</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,991</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(441</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,466</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(957</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(141</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other income (expenses), net</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,527</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(16,780</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(20,205</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,976</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,758</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">420,900</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">61,992</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fair value change of warrants</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(14,027</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">61,405</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,644</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">832</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,609</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Loss before income tax expense</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(298,240</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(401,111</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(1,451,950</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(213,849</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><B>(1,103,380</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)</B>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B></B><B></B><B></B><B></B><B></B><B></B><B></B>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><B></B><B>(</B><B>570</B><B>,</B><B>635</B><B></B><B></B></TD>
<TD NOWRAP VALIGN="bottom"><B></B><B></B><B></B><B></B><B></B><B>)</B><B></B>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B></B><B></B><B></B><B></B><B></B><B></B>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><B></B><B>(</B><B>84</B><B>,</B><B>045</B><B></B></TD>
<TD NOWRAP VALIGN="bottom"><B></B><B></B><B></B><B></B><B></B><B>)</B>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income tax expense</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,722</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net loss attributable to <FONT STYLE="white-space:nowrap">I-Mab</FONT></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(298,240</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(402,833</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(1,451,950</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(213,849</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><B>(1,103,380</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)</B>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B></B><B></B><B></B><B></B><B></B><B></B><B></B>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><B></B><B>(</B><B>570</B><B>,</B><B>635</B><B></B><B></B></TD>
<TD NOWRAP VALIGN="bottom"><B></B><B></B><B></B><B></B><B></B><B>)</B><B></B>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B></B><B></B><B></B><B></B><B></B><B></B>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><B></B><B>(</B><B>84</B><B>,</B><B>045</B><B></B></TD>
<TD NOWRAP VALIGN="bottom"><B></B><B></B><B></B><B></B><B></B><B>)</B>&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="24%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>For&nbsp;the&nbsp;Year&nbsp;Ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>For&nbsp;the&nbsp;Nine Months&nbsp;Ended&nbsp;September 30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>RMB</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>RMB</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>RMB</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>US$</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>RMB</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>RMB</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>US$</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="26" ALIGN="center"><B>(in thousands, except for share and per share data)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deemed dividend to Series <FONT STYLE="white-space:nowrap">C-1</FONT> preferred shareholders at
extinguishment of <FONT STYLE="white-space:nowrap">Series&nbsp;C-1</FONT> Preferred Shares</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5,283</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(778</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp; <B></B></TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B></B><B></B>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><B></B>&#151;&nbsp;&nbsp; <B></B></TD>
<TD NOWRAP VALIGN="bottom"><B></B><B></B>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><B></B>&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deemed dividend to Series <FONT STYLE="white-space:nowrap">B-1,</FONT> <FONT
STYLE="white-space:nowrap">B-2</FONT> and C preferred shareholders at modification of Series <FONT STYLE="white-space:nowrap">B-1,</FONT> <FONT STYLE="white-space:nowrap">B-2</FONT> and C Preferred Shares</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(27,768</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4,090</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp; <B></B></TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B></B><B></B>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><B></B>&#151;&nbsp;&nbsp; <B></B></TD>
<TD NOWRAP VALIGN="bottom"><B></B><B></B>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><B></B>&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net loss attributable to ordinary shareholders</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(298,240</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(402,833</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(1,485,001</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(218,717</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><B>(1,103,380</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)</B>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B></B><B></B><B></B><B></B><B></B><B></B><B></B>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><B></B><B>(</B><B>570</B><B>,</B><B>635</B><B></B><B></B></TD>
<TD NOWRAP VALIGN="bottom"><B></B><B></B><B></B><B></B><B></B><B>)</B><B></B>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B></B><B></B><B></B><B></B><B></B><B></B>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><B></B><B>(</B><B>84</B><B>,</B><B>045</B><B></B></TD>
<TD NOWRAP VALIGN="bottom"><B></B><B></B><B></B><B></B><B></B><B>)</B>&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Other comprehensive income</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Foreign currency translation adjustments, net of nil tax</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,918</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">53,689</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,747</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,583</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">66,254</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,530</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,288</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total comprehensive loss attributable to
<FONT STYLE="white-space:nowrap">I-Mab</FONT></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(292,322</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(349,144</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(1,441,203</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(212,266</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><B>(1,037,126</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)</B>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B></B><B></B><B></B><B></B><B></B><B></B><B></B>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><B></B><B>(</B><B>555</B><B>,</B><B>105</B><B></B><B></B></TD>
<TD NOWRAP VALIGN="bottom"><B></B><B></B><B></B><B></B><B></B><B>)</B><B></B>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B></B><B></B><B></B><B></B><B></B><B></B>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><B></B><B>(</B><B>81</B><B>,</B><B>757</B><B></B></TD>
<TD NOWRAP VALIGN="bottom"><B></B><B></B><B></B><B></B><B></B><B>)</B>&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net loss attributable to ordinary shareholders</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(298,240</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(402,833</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(1,485,001</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(218,717</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><B>(1,103,380</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)</B>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B></B><B></B><B></B><B></B><B></B><B></B><B></B>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><B></B><B>(</B><B>570</B><B>,</B><B>635</B><B></B><B></B></TD>
<TD NOWRAP VALIGN="bottom"><B></B><B></B><B></B><B></B><B></B><B>)</B><B></B>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B></B><B></B><B></B><B></B><B></B><B></B>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><B></B><B>(</B><B>84</B><B>,</B><B>045</B><B></B></TD>
<TD NOWRAP VALIGN="bottom"><B></B><B></B><B></B><B></B><B></B><B>)</B>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Weighted-average number of ordinary shares used in calculating net loss per shares</B></P></TD>

<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,742,669</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,529,092</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,381,230</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,381,230</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,184,086</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">126,758,926</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">126,758,926</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net loss per share attributable to ordinary shareholders</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Basic</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(51.93</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(61.70</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(201.19</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(29.63</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(153.59</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4.50</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(0.66</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Diluted</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(51.93</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(61.70</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(201.19</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(29.63</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(153.59</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4.50</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(0.66</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">Non-GAAP</FONT> Measure</B>:<SUP
STYLE="font-size:85%; vertical-align:top">(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Adjusted Net Loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(291,201</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(399,313</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(969,798</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(142,836</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(588,187</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(178,059</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(26,225</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Note: </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Share-based compensation expenses were allocated as follows: </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="50%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>For&nbsp;the&nbsp;Year&nbsp;Ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>For&nbsp;the&nbsp;Nine&nbsp;Months&nbsp;Ended<BR>September&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>RMB</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>RMB</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>RMB</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>US$</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>RMB</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>RMB</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>US$</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="26" ALIGN="center"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,112</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,056</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">470</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">69</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">467</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">224,619</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">33,083</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Administrative expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,927</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,464</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">514,733</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">75,812</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">514,726</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">167,957</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24,737</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>7,039</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>3,520</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>515,203</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>75,881</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>515,193</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>392,576</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>57,820</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">See <FONT STYLE="white-space:nowrap">&#147;&#151;Non-GAAP</FONT> Financial Measure.&#148;
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Comparison of Nine Months Ended September 30, 2020 and 2019 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Revenues </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our revenues generated
from licensing and collaboration decreased from RMB30.0&nbsp;million for the nine months ended September 30, 2019 to nil the nine months ended September 30, 2020. Our revenues generated for the nine months ended September 30, 2019 consisted of CSPC
entity&#146;s upfront payment and first milestone payment to us pursuant to our <FONT STYLE="white-space:nowrap">out-licensing</FONT> arrangement with CSPC entity. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Research and Development Expenses </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The following table sets forth a breakdown of the major components of our research and development expenses in absolute amounts and as a
percentage of our total research and development expenses for the periods indicated: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="64%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="18" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>For the Nine Months Ended September 30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>RMB</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>%</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>RMB</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>US$</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>%</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="18" ALIGN="center"><B>(in thousands, except percentages)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">CRO service fees</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">316,594</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">54.7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">330,266</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">48,643</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">47.3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">In-licensed</FONT> patent right fees</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">160,351</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27.7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,376</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,265</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Employee benefit expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">72,132</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12.5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">315,455</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">46,461</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">45.2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Material costs for drug candidates</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,269</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,197</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,649</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">28,031</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26,167</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,854</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">578,377</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100.0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">698,461</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">102,872</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100.0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our research and development expenses increased by 20.8% from RMB578.4 million for the nine months ended
September 30, 2019 to RMB698.5 million (US$102.9 million) for the nine months ended September 30, 2020, primarily attributable to (i)&nbsp;an increase in the CRO service fees from RMB316.6&nbsp;million for the nine months ended September 30, 2019 to
RMB330.3 million (US$48.6 million) for the nine months ended September 30, 2020, as we advanced some of our existing investigational drugs into more advanced clinical development stages; and (ii)&nbsp;an increase in employee benefit expenses of
employees involved in research and development from RMB72.1&nbsp;million for the nine months ended September 30, 2019 to RMB315.5 million (US$46.5 million) for the nine months ended September 30, 2020, mainly due to an increase in share-based
compensation by RMB224.6 million (US$33.1 million). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In the nine months ended September 30, 2020, 78.8% and 21.2% of our total research
and development expenses were attributable to clinical programs and preclinical programs, respectively. In the nine months ended September 30, 2019, 90.3% and 9.7% of our total research and development expenses were attributable to clinical programs
and preclinical programs, respectively. For the nine months ended September 30, 2020, felzartamab represented approximately 51.2% of our external research and development expenses, which primarily included payments to CROs and CMOs. No other
programs represented a significant amount of research and development expenses in the nine months ended September 30, 2020 and 2019. Though we manage our external research and development expenses by program, we do not allocate our internal research
and development expenses by program because our employees and internal resources may be engaged in projects for multiple programs at any time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Administrative Expenses </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our
administrative expenses decreased from RMB582.7&nbsp;million for the nine months ended September&nbsp;30, 2019 to RMB310.8&nbsp;million (US$45.8 million) for the nine months ended September 30, 2020, primarily attributable to the decrease in
employee benefit expenses by RMB310.6 million (US$45.7 million) due to decrease of share-based compensation expenses. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Interest Income </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We recorded RMB22.8&nbsp;million of interest income for the nine months ended September 30, 2019 and RMB18.7&nbsp;million (US$2.7 million) of
interest income for the nine months ended September 30, 2020. The change was primarily attributable to the interest income derived from bank deposits. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Interest Expense </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We recorded
RMB2.5&nbsp;million of interest expense for the nine months ended September 30, 2019 and RMB1.0&nbsp;million (US$0.1 million) of interest expense for the nine months ended September 30, 2020. The change was primarily attributable to the interest
expense related to our short-term borrowings, which were borrowed in June 2019 and repaid in June 2020. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Other Income (Expenses), Net </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We recorded RMB1.8&nbsp;million of other income for the nine months ended September 30, 2019 and RMB420.9&nbsp;million (US$62.0 million) of
other income for the nine months ended September 30, 2020. The increase was primarily attributable to the RMB407.6 million gain recognized as a result of transfer of equity of <FONT STYLE="white-space:nowrap">I-Mab</FONT> Hangzhou from I-Mab Hong
Kong to a group of domestic investors. The equity transfer realized the fair value appreciation in the pipeline assets as well as the employment of a team of designated management and workforce. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Fair Value Change of Warrants </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We
recorded a loss from change in the fair value of warrant liability of RMB5.6 million for the nine months ended September 30, 2019 and nil for the nine months ended September 30, 2020. The change was primarily attributable to the fact that the
holders of Series B Warrants have unconditionally and irrevocably waived and cancelled the Tranche II of Series B Warrants in July 2019. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Comparison of
Year Ended December&nbsp;31, 2019 and 2018 </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Revenues </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our revenues generated from licensing and collaboration decreased by 44.2% from RMB53.8&nbsp;million for the year ended December&nbsp;31, 2018
to RMB30.0&nbsp;million (US$4.4 million) for the year ended December&nbsp;31, 2019. Our revenues generated for the year ended December&nbsp;31, 2018 consisted of both HDYM&#146;s milestone payment and ABL Bio&#146;s upfront payment to us pursuant to
our <FONT STYLE="white-space:nowrap">out-licensing</FONT> arrangements with them, respectively. Our revenues generated for the year ended December&nbsp;31, 2019 solely consisted of CSPC entity&#146;s upfront and milestone payments to us pursuant to
our <FONT STYLE="white-space:nowrap">out-licensing</FONT> arrangement with CSPC entity. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-23 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Research and Development Expenses </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The following table sets forth a breakdown of the major components of our research and development expenses in absolute amounts and as a
percentage of our total research and development expenses for the periods indicated: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="64%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="18" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>For the Year Ended December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>RMB</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>%</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>RMB</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>US$</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>%</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="18" ALIGN="center"><B>(in thousands, except percentages)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">CRO service fees</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">212,278</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">49.8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">521,920</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">76,871</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">62.1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">In-licensed</FONT> patent right fees</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">108,794</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25.5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">166,844</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24,573</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19.9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Employment benefit expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">56,630</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13.3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">106,313</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,658</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12.7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Material costs for drug candidates</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,652</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,117</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">901</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">28,674</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">39,221</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,777</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">426,028</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100.0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">840,415</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">123,780</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100.0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our research and development expenses increased by 97.3% from RMB426.0&nbsp;million for the year ended
December&nbsp;31, 2018 to RMB840.4&nbsp;million (US$123.8 million) for the year ended December&nbsp;31, 2019, primarily attributable to (i)&nbsp;an increase in the CRO service fees from RMB212.3&nbsp;million for the year ended December&nbsp;31, 2018
to RMB521.9&nbsp;million (US$76.9 million) for the year ended December&nbsp;31, 2019, as we initiated a few more research and development programs and advanced some of our existing investigational drugs into more advanced clinical development
stages; (ii)&nbsp;an increase in <FONT STYLE="white-space:nowrap">in-licensed</FONT> patent right fees from RMB108.8&nbsp;million for the year ended December&nbsp;31, 2018 to RMB166.8&nbsp;million (US$24.6 million) for the year ended
December&nbsp;31, 2019, mainly due to upfront fees paid to MacroGenics; and (iii)&nbsp;an increase in employee benefit expenses of employees involved in research and development from RMB56.6&nbsp;million for the year ended December&nbsp;31, 2018 to
RMB106.3&nbsp;million (US$15.7&nbsp;million) for the year ended December&nbsp;31, 2019, due to an increase in the headcount. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In 2019,
87.3% and 12.7% of our total research and development expenses were attributable to clinical programs and preclinical programs, respectively. In 2018, 72.3% and 27.7% of our total research and development expenses were attributable to clinical
programs and preclinical programs, respectively. In 2019, felzartamab represented approximately 41.4% of our external research and development expenses, which primarily included licensing fees and payments to CROs and CMOs. In 2018, efineptakin and
felzartamab represented approximately 25.0% and 9.9% of our external research and development expenses, which primarily included licensing fees and payments to CROs and CMOs. No other programs represented a significant amount of research and
development expenses in 2019 and 2018. Though we manage our external research and development expenses by program, we do not allocate our internal research and development expenses by program because our employees and internal resources may be
engaged in projects for multiple programs at any time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Administrative Expenses </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our administrative expenses increased from RMB66.4&nbsp;million for the year ended December&nbsp;31, 2018 to RMB654.6&nbsp;million (US$96.4
million) for the year ended December&nbsp;31, 2019, primarily attributable to (i)&nbsp;RMB365.3&nbsp;million (US$53.8 million) in connection with stock options granted to a director of our company under the 2018 Plan which were immediately vested,
(ii)&nbsp;RMB148.3&nbsp;million (US$21.8 million) in connection with repurchase of share awards held by a director of our company, (iii)&nbsp;the increase in employee benefit expenses by RMB7.9&nbsp;million (US$1.2 million) due to headcount
increase, and (iv)&nbsp;the increase in third-party professional expenses by RMB41.4&nbsp;million (US$6.1 million). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Interest Income </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We recorded RMB4.6&nbsp;million of interest income for the year ended December&nbsp;31, 2018 and RMB30.6&nbsp;million (US$4.5 million) of
interest income for the year ended December&nbsp;31, 2019. The change was primarily attributable to the interest income derived from bank deposits. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Interest Expense </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We recorded
RMB11.7&nbsp;million of interest expense for the year ended December&nbsp;31, 2018 and RMB3.0&nbsp;million (US$0.4 million) of interest expense for the year ended December&nbsp;31, 2019. The change was primarily attributable to the interest expense
related to our convertible promissory notes, which were converted in June and July 2018. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Other Income (Expenses), Net </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We recorded RMB16.8&nbsp;million of other expenses for the year ended December&nbsp;31, 2018 and RMB20.2&nbsp;million (US$3.0 million) of
other income for the year ended December&nbsp;31, 2019. The change was primarily attributable to the conversion of our convertible promissory notes and onshore convertible loans and loss on the termination agreement with Everest in 2019. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Fair Value Change of Warrants </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We
recorded a gain from change in the fair value of warrant liability of RMB61.4&nbsp;million for the year ended December&nbsp;31, 2018 and RMB5.6&nbsp;million (US$0.8 million) for the year ended December&nbsp;31, 2019. The change was primarily
attributable to the change in fair value of warrants due to the increase in the valuation of our company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Comparison of Year Ended December&nbsp;31,
2018 and 2017 </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Revenues </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our revenues generated from licensing and collaboration increased by 365.4% from RMB11.6&nbsp;million for the year ended December&nbsp;31,
2017 to RMB53.8&nbsp;million for the year ended December&nbsp;31, 2018. Our revenues generated for the year ended December&nbsp;31, 2017 consisted solely of HDYM&#146;s milestone payment to us pursuant to
<FONT STYLE="white-space:nowrap">our&nbsp;out-licensing&nbsp;arrangement</FONT> with it. Our revenues generated for the year ended December&nbsp;31, 2018 consisted of both HDYM&#146;s milestone payment and ABL Bio&#146;s upfront payment to us
pursuant to <FONT STYLE="white-space:nowrap">our&nbsp;out-licensing&nbsp;arrangements</FONT> with them, respectively. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Research and Development
Expenses </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The following table sets forth a breakdown of the major components of our research and development expenses in absolute
amounts and as a percentage of our total research and development expenses for the periods indicated: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="66%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>For the Year Ended December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>RMB</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>%</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>RMB</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>%</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center"><B>(in thousands, except percentages)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">CRO service fees</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">83,047</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">31.1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">212,278</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">49.8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">In-licensed</FONT> patent right fees</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">134,846</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50.5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">108,794</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25.5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Employment benefit expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26,799</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10.0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">56,630</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13.3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Material costs for drug candidates</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,393</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,652</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,990</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">28,674</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">267,075</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100.0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">426,028</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100.0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-25 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our research and development expenses increased by 59.5% from RMB267.1&nbsp;million for the
year ended December&nbsp;31, 2017 to RMB426.0&nbsp;million for the year ended December&nbsp;31, 2018, primarily attributable to (i)&nbsp;an increase in the CRO service fees from RMB83.0&nbsp;million in 2017 to RMB212.3&nbsp;million in 2018, as we
initiated a few more research and development programs and advanced some of our existing investigational drugs into more advanced clinical development stages; and (ii)&nbsp;an increase in employee benefit expenses of employees involved in research
and development from RMB26.8&nbsp;million in 2017 to RMB56.6&nbsp;million in 2018, due to an increase in the headcount. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In 2018, 72.3%
and 27.7% of our total research and development expenses were attributable to clinical programs <FONT STYLE="white-space:nowrap">and&nbsp;pre-clinical&nbsp;programs,</FONT> respectively. In 2017, 77.5% and 22.5% of our total research and development
expenses were attributable to clinical programs <FONT STYLE="white-space:nowrap">and&nbsp;pre-clinical&nbsp;programs,</FONT> respectively. In 2018, TJ107 and TJ202 represented approximately 25.0% and 9.9% of our external research and development
expenses, which primarily included licensing fees and payments to CROs and CMOs. In 2017, TJ202 represented approximately 59.1% of our external research and development expenses, which primarily included licensing fees and payments to CROs and CMOs.
No other programs represented a significant amount of research and development expenses in 2018 and 2017. Though we manage our external research and development expenses by program we do not allocate our internal research and development expenses by
program because our employees and internal resources may be engaged in projects for multiple programs at any time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Administrative Expenses
</I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our administrative expenses increased from RMB25.4&nbsp;million for the year ended December&nbsp;31, 2017 to RMB66.4&nbsp;million
for the year ended December&nbsp;31, 2018, primarily attributable to (i)&nbsp;the increase in employee benefit expenses due to headcount increase, and (ii)&nbsp;the increase in third-party professional expenses. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Interest Income </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We recorded
RMB0.9&nbsp;million of interest income for the year ended December&nbsp;31, 2017 and RMB4.6&nbsp;million of interest income for the year ended December&nbsp;31, 2018. The change was primarily attributable to the interest income derived from our bank
deposits. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Interest Expense </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We recorded RMB5.6&nbsp;million of interest expense for the year ended December&nbsp;31, 2017 and RMB11.7&nbsp;million of interest expense for
the year ended December&nbsp;31, 2018. The change was primarily attributable to (i)&nbsp;the interest expense accrued on <FONT STYLE="white-space:nowrap">the&nbsp;one-year&nbsp;bank</FONT> borrowing facilities we entered into in the third quarter of
2017 and 2018, respectively; and (ii)&nbsp;the interest expense related to our convertible promissory notes, which were converted in June and July 2018. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Other Income (Expenses), Net </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We
recorded RMB1.5&nbsp;million of other income for the year ended December&nbsp;31, 2017 and RMB16.8&nbsp;million of other expenses for the year ended December&nbsp;31, 2018. The change was primarily attributable to the net loss resulting from the
conversion of a portion of our convertible promissory notes, partially offset by an increase in the income from the other financial assets. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Fair
Value Change of Warrants </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We recorded a loss from change in the fair value of warrant liability of RMB14.0&nbsp;million for the
year ended December&nbsp;31, 2017, and a gain from change in the fair value of warrant liability of RMB61.4&nbsp;million for the year ended December&nbsp;31, 2018. The change was primarily attributable to (i)&nbsp;the change in fair value of
warrants due to the increase in the valuation of our company, and (ii)&nbsp;the modification in 2018 that added certain forfeiture conditions to the warrants, which increased the possibility of forfeiture of the warrants and therefore resulted in a
reduction in our warrant liabilities. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-26 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">Non-GAAP</FONT> Financial Measure </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">To supplement our consolidated financial statements, which are presented in accordance with GAAP, we also use adjusted net loss as an
additional financial measure, which is not required by, or presented in accordance with, GAAP. We believe adjusted net loss facilitates comparisons of operating performance from period to period and company to company by eliminating potential
impacts of items which our management considers <FONT STYLE="white-space:nowrap">non-indicative</FONT> of our operating performance. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We
believe adjusted net loss provides useful information to investors and others in understanding and evaluating our consolidated results of operations in the same manner as they help our management. However, our presentation of adjusted net loss may
not be comparable to similarly titled measures presented by other companies. The use of adjusted net loss has limitations as an analytical tool, and you should not consider it in isolation from, or as a substitute for an analysis of, our results of
operations or financial condition as reported under GAAP. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We define adjusted net loss as net loss for the year/period, excluding
share-based compensation expenses. We exclude share-based compensation expenses because they are not expected to result in future cash payments that are recurring in nature and they are not indicative of our core operating results and business
outlook. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The following table reconciles our adjusted net loss for the periods presented to the most directly comparable financial measure
calculated and presented in accordance with GAAP, which is net loss for the year/period: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="34%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>For the Year Ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>For the Nine Months<BR>Ended&nbsp;September 30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>RMB</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>RMB</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>RMB</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>US$</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>RMB</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>RMB</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>US$</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="26" ALIGN="center"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Reconciliation of net loss to adjusted net loss:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss for the year/period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(298,240</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(402,833</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,451,950</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(213,849</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,103,380</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(570,635</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(84,045</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Add back:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Share-based compensation expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,039</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,520</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">515,203</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">75,881</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">515,193</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">392,576</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">57,820</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Adjusted net loss for the year/period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(291,201</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(399,313</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(936,747</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(137,968</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(588,187</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(178,059</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(26,225</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Liquidity and Capital Resources </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Since inception, we have incurred net losses and negative cash flows from our operations. Substantially all of our losses have resulted from
funding our research and development programs and administrative costs associated with our operations. We incurred net losses of RMB298.2&nbsp;million, RMB402.8&nbsp;million, RMB1,452.0&nbsp;million (US$213.8 million) and RMB570.6&nbsp;million
(US$84.0 million) for the years ended December&nbsp;31, 2017, 2018 and 2019 and the nine months ended September 30, 2020, respectively. Our primary use of cash is to fund our research and development activities. We used RMB252.2&nbsp;million,
RMB280.7&nbsp;million, RMB868.0&nbsp;million (US$127.8 million) and RMB582.6 million (US$85.8&nbsp;million) in cash for our operating activities for the years ended December&nbsp;31, 2017, 2018 and 2019 and the nine months ended September 30, 2020,
respectively. Historically, we have financed our operations principally through proceeds from the issuance and sale of preferred shares and convertible promissory notes in private placement transactions, and we also received total net proceeds of
approximately US$105.3 million from our initial public offering. For more information of our financing, see &#147;Description of Share Capital&#151;History of Securities Issuances.&#148; As of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-27 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
September 30, 2020, we had cash, cash equivalents and restricted cash of RMB2,960&nbsp;million (US$436.0 million). Our cash, cash equivalents and restricted cash consist primarily of cash in bank
and on hand. In September 2020, we entered into definitive subscription agreements with a consortium of institutional investors (the &#147;Investors&#148;) to raise approximately US$418&nbsp;million through a private placement. The private placement
consists of (i)&nbsp;the sale to the Investors of approximately US$418&nbsp;million of our 29,133,502 ordinary shares (equivalent to 12,666,740 ADSs) at a purchase price equivalent to US$33 per ADS, representing a 2.9% premium to the <FONT
STYLE="white-space:nowrap">30-day</FONT> volume weighted average price; and (ii)&nbsp;warrants (the &#147;Warrants&#148;) to subscribe for an aggregate of 5,341,267 ordinary shares (equivalent to 2,322,290 ADSs) at an exercise price equivalent to
US$45 per ADS, representing a 40.3% premium to the <FONT STYLE="white-space:nowrap">30-day</FONT> volume weighted average price, which may further increase the proceeds of approximately US$104.5&nbsp;million if the Warrants are fully exercised. The
Warrants will remain exercisable at the election of the Investors within 12&nbsp;months after the closing of the private placement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The
following table sets forth a summary of our cash flows for the periods presented: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="34%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>For the Year Ended December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>For the Nine Months Ended<BR>September 30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>RMB</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>RMB</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>RMB</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>US$</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>RMB</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>RMB</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>US$</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="26" ALIGN="center"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash used in operating activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(252,157</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(280,705</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(867,982</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(127,840</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(651,993</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(582,631</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(85,812</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash (used in) generated from investing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(157,665</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">212,462</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">31,292</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">135,128</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(256,381</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(37,760</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash (used in) generated from financing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">758,585</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,479,669</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">152,709</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,493</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">39,413</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,595,692</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">382,304</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Effect of exchange rate changes on cash and cash equivalents and restricted cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(132</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">59,754</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,163</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,233</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">77,581</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,054</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,480</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net increase (decrease) in cash, cash equivalents and restricted cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">348,631</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,268,218</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(487,648</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(71,822</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(399,871</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,766,734</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">260,212</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash, cash equivalents and restricted cash, beginning of the year/period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">64,082</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">412,713</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,680,931</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">247,574</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,680,931</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,193,283</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">175,751</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash, cash equivalents and restricted cash, end of the year/period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">412,713</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,680,931</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,193,283</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">175,752</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,281,060</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,960,017</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">435,963</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We do not expect to generate any revenue from product sales unless and until we obtain regulatory approval of
and commercialize one of our current or future drug candidates. We anticipate that we will continue to generate losses for the foreseeable future, and we expect the losses to increase as we continue the development of, and seek regulatory approvals
for, our drug candidates and begin to commercialize any approved products. We also expect to incur additional costs associated with operating as a public company. In addition, subject to obtaining regulatory approval of any of our drug candidates,
we expect to incur significant commercialization expenses for product sales, marketing and manufacturing. Accordingly, we anticipate that we will need substantial additional funding in connection with our continuing operations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Based on our current operating plan, we believe that our current cash and cash equivalents will be sufficient to meet our current and
anticipated working capital requirements and capital expenditures for at least the next 12 months. In that time, we expect that our expenses will increase substantially as we fund new and ongoing research and development activities and working
capital needs. We have based our estimates on </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-28 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
assumptions that may prove to be wrong, and we may use our available capital resources sooner than we currently expect. Because of the numerous risks and uncertainties associated with the
development and commercialization of our drug candidates, we are unable to estimate the amounts of increased capital outlays and operating expenditures necessary to complete the development and commercialization of our drug candidates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We may decide to enhance our liquidity position or increase our cash reserve for future operations and investments through additional
financing. The issuance and sale of additional equity would result in further dilution to our shareholders and ADS holders, and the terms of these securities may include liquidation or other preferences that adversely affect your rights as an ADS
holder. The incurrence of indebtedness would result in increased fixed obligations and could result in operating covenants that would restrict our operations, which could potentially dilute your interest. If we raise additional funds through
collaborations, strategic alliances or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams or research programs or to grant licenses on terms that may not be favorable to
us. If we are unable to raise additional funds through equity or debt financings when needed, we may be required to delay, limit, reduce or terminate our product development or future commercialization efforts or grant rights to develop and market
products or drug candidates that we would otherwise prefer to develop and market ourselves. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">As of September&nbsp;30, 2020, 31% of our
cash and cash equivalents were denominated in RMB and held in China. We may make additional capital contributions to our PRC subsidiaries, establish new PRC subsidiaries and make capital contributions to these new PRC subsidiaries, make loans to our
PRC subsidiaries, or acquire offshore entities with business operations in China in offshore transactions. However, most of these uses are subject to PRC regulations and approvals. See &#147;Risk Factors&#151;Risks Related to Doing Business in
China&#151;PRC regulation of loans to and direct investment in PRC entities by offshore holding companies and governmental control of currency conversion may delay or prevent us from making loans to our PRC subsidiaries or making additional capital
contributions to our wholly foreign-owned subsidiaries in China, which could materially and adversely affect our liquidity and our ability to fund and expand our business&#148;. In addition, the <FONT STYLE="white-space:nowrap">COVID-19</FONT>
outbreaks may materially and adversely affect our ability to raise additional capital in future and our liquidity. See &#147;Risk Factors&#151;Risks Related to Our Business and Our Industry&#151;Our business and results of operations could be
adversely affected by public health crisis (including the <FONT STYLE="white-space:nowrap">COVID-19</FONT> global pandemic) and natural catastrophes or other disasters outside of our control in the locations in which we, our suppliers, CROs, CMOs
and other contractors operate.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We expect that the majority of our future revenues will be denominated in RMB. Under existing PRC
foreign exchange regulations, payments of current account items, including profit distributions, interest payments and trade and service-related foreign exchange transactions, can be made in foreign currencies without prior SAFE approval as long as
certain routine procedural requirements are fulfilled. Therefore, our PRC subsidiaries are allowed to pay dividends in foreign currencies to us without prior SAFE approval by following certain routine procedural requirements. However, approval from
or registration with competent government authorities is required where RMB is to be converted into foreign currency and remitted out of China to pay capital expenses such as the repayment of loans denominated in foreign currencies. The PRC
government may at its discretion restrict access to foreign currencies for current account transactions in the future. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Operating Activities
</I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Net cash used in operating activities for the nine months ended September 30, 2020 was RMB582.6 million (US$85.8 million). Our
net loss was RMB570.6 million (US$84.0 million) for the same period. The difference between our net loss and our net cash used in operating activities was primarily attributable to certain <FONT STYLE="white-space:nowrap">non-cash</FONT> expenses,
including share-based compensation of RMB392.6 million (US$57.8 million) and depreciation of property, equipment and software of RMB7.7 million (US$1.1 million), and changes in certain working capital items, including an increase in the prepayments
and other receivables of RMB3.3 million (US$0.5 million), an increase in the deferred subsidy income of RMB3.7 million (US$0.5 million), an increase in the other <FONT STYLE="white-space:nowrap">non-current</FONT> liabilities of RMB8.4&nbsp;million
(US$1.2 million), partially offset by an decrease in accruals </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-29 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
and other payables of RMB17.6 million (US$2.6 million). The change in share-based compensation was attributable to the grant of stock options to certain directors and employees of our company
under the 2017 Plan, 2018 Plan and 2019 Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Net cash used in operating activities for the year ended December&nbsp;31, 2019 was
RMB868.0&nbsp;million (US$127.8 million). Our net loss was RMB1,452.0&nbsp;million (US$213.9 million) for the same period. The difference between our net loss and our net cash used in operating activities was primarily attributable to certain <FONT
STYLE="white-space:nowrap">non-cash</FONT> expenses, including share-based compensation of RMB366.9&nbsp;million (US$54.0 million) and loss on the termination agreement with Everest of RMB23.0&nbsp;million (US$3.4 million), and changes in certain
working capital items, including an increase in the research and development funding of RMB53.1&nbsp;million (US$7.8 million), an increase in the accruals and other payables of RMB188.4&nbsp;million (US$27.7 million), partially offset by an decrease
in advance from customers of RMB14.2&nbsp;million (US$2.1 million) and an decrease in repayments and other receivables of RMB48.8&nbsp;million (US$7.2 million). The change in share-based compensation was attributable to the grant of stock options to
a director of our company under the 2018 Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Net cash used in operating activities for the year ended December&nbsp;31, 2018 was
RMB280.7&nbsp;million. Our net loss was RMB402.8&nbsp;million for the same period. The difference between our net loss and our net cash used in operating activities was primarily attributable to certain
<FONT STYLE="white-space:nowrap">non-cash</FONT> expenses or gains, including fair value gains of warrants of RMB61.4&nbsp;million, and changes in certain working capital items, including (i)&nbsp;an increase in the research and development funding
of RMB178.7&nbsp;million and (ii)&nbsp;an increase in accruals and other payables of RMB55.6&nbsp;million, partially offset by an increase in prepayments and other receivables of RMB76.3&nbsp;million. The accruals and other payables principally
consist of accrued external research and development activities related expenses and staff salaries and welfare payables. The change in fair value of warrant liabilities was attributable to the exercise of part of the warrants issued in 2017 and the
modification in 2018 that added certain forfeiture conditions to the warrants. Prepayments and other receivables primarily consist of our prepayment to CRO partners and value-added tax recoverable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Net cash used in operating activities for the year ended December&nbsp;31, 2017 was RMB252.2&nbsp;million. Our net loss was
RMB298.2&nbsp;million. The difference between our net loss and our net cash used in operating activities was primarily attributable to <FONT STYLE="white-space:nowrap">certain&nbsp;non-cash&nbsp;expenses</FONT> or gains, including the fair value
loss of warrant liabilities of RMB14.0&nbsp;million, and changes in certain working capital items, including (i)&nbsp;an increase in contract liabilities of RMB15.8&nbsp;million and (ii)&nbsp;a decrease in prepayments and other receivables of
RMB8.8&nbsp;million. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Investing Activities </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Net cash used in investing activities for the nine months ended September&nbsp;30, 2020 was RMB256.4&nbsp;million (US$37.8 million). The net
cash decrease was primarily attributable to RMB270.9&nbsp;million (US$39.9 million) of the cash received from proceeds from purchase of short-term investments and RMB257.7 million (US$37.9 million) of the cash injection of I-Mab Hangzhou, an
affiliate of us, partially offset by RMB276.9&nbsp;million (US$40.8 million) of disposal of short-term investments. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Net cash generated
from investing activities for the year ended December&nbsp;31, 2019 was RMB212.5&nbsp;million (US$31.3 million). The net cash increase was primarily attributable to RMB256.0&nbsp;million (US$37.7 million) of the cash received from disposal of other
financial assets and RMB134.0&nbsp;million (US$19.7 million) of purchase of short-term investments, partially offset by RMB102.0&nbsp;million (US$15.0 million) of proceeds from disposal of short-term investments. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Net cash generated from investing activities for the year ended December&nbsp;31, 2018 was RMB9.5&nbsp;million. The net cash increase was
primarily attributable to RMB40.0&nbsp;million of the cash received from disposal of other financial assets, partially offset by RMB30.0&nbsp;million of the cash used in other financial assets. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Net cash used in investing activities for the year ended December&nbsp;31, 2017 was RMB157.7&nbsp;million. The net cash decrease was primarily
attributable to RMB369.0&nbsp;million of investments in other financial assets, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-30 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
partially offset by RMB133.0&nbsp;million of proceeds from disposal of other financial assets and RMB93.3&nbsp;million of cash acquired from acquisition
<FONT STYLE="white-space:nowrap">of&nbsp;I-Mab&nbsp;Tianjin.</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Financing Activities </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Net cash generated from financing activities for the nine months ended September&nbsp;30, 2020 was RMB2,595.7&nbsp;million (US$382.3 million),
primarily attributable to the proceeds from the initial public offering of our company, net of payment of offering issuance cost of RMB726.3&nbsp;million (US$107.0 million), the proceeds from private placement of our company, net of payment of
issuance cost of RMB1,980.5 million (US$291.7 million), partially offset by the repayment of bank borrowings of RMB50.0&nbsp;million (US$7.4 million). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Net cash generated from financing activities for the year ended December&nbsp;31, 2019 was RMB152.7&nbsp;million (US$22.5 million), primarily
attributable to the proceeds from issuance of convertible preferred shares, net of issuance cost of RMB183.5&nbsp;million (US$27.0 million) and the repayment of bank borrowings of RMB80.0&nbsp;million (US$11.8 million), partially offset by the
proceeds of bank borrowings of RMB50.0&nbsp;million (US$7.4 million). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Net cash generated from financing activities in the year ended
December&nbsp;31, 2018 was RMB1,479.7&nbsp;million, primarily attributable to (i)&nbsp;proceeds from issuance of RMB1,306.6&nbsp;million convertible preferred shares and (ii)&nbsp;receipt of RMB132.3&nbsp;million resulting from the exercise of
warrants by investors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Net cash generated from financing activities in the year ended December&nbsp;31, 2017 was RMB758.6&nbsp;million,
primarily attributable to proceeds of our issuance of RMB346.5&nbsp;million convertible preferred shares, RMB161.2&nbsp;million <FONT STYLE="white-space:nowrap">redeemable&nbsp;non-controlling&nbsp;interest</FONT> and RMB99.0&nbsp;million proceeds
from bank borrowings. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Capital Expenditures </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our capital expenditures were incurred for purposes of purchasing property, equipment and software. Our capital expenditures were
RMB20.3&nbsp;million, RMB14.4&nbsp;million, RMB12.2&nbsp;million (US$1.8 million) and RMB4.8&nbsp;million (US$0.7 million) in the years ended December&nbsp;31, 2017, 2018 and 2019 and nine months ended September 30, 2020, respectively. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Contractual Obligations </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The following
table sets forth our contractual obligations as of December&nbsp;31, 2019: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="49%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Less&nbsp;Than<BR>1&nbsp;Year</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B><FONT STYLE="white-space:nowrap">1-3</FONT> Years</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B><FONT STYLE="white-space:nowrap">3-5</FONT> Years</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>More&nbsp;Than<BR>5 Years</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>RMB</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>US$</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>RMB</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>US$</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>RMB</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>US$</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>RMB</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>US$</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>RMB</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>US$</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="38" ALIGN="center"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating lease commitments</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,437</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,274</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,634</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,124</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,502</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,105</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">120</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">181</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our operating lease commitments relate to leases for our office premises pursuant to <FONT
STYLE="white-space:nowrap">non-cancellable</FONT> operating lease agreements. Other than as shown above, we did not have any significant capital and other commitments, long-term obligations or guarantees as of December&nbsp;31, 2019. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">Off-Balance</FONT> Sheet Commitments and Arrangements </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We have not entered into any financial guarantees or other commitments to guarantee the payment obligations of any third parties. In addition,
we have not entered into any derivative contracts that are indexed to our shares and classified as shareholder&#146;s equity or that are not reflected in our consolidated financial statements. Furthermore, we do not have any retained or contingent
interest in assets transferred to an unconsolidated entity </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-31 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
that serves as credit, liquidity or market risk support to such entity. We do not have any variable interest in any unconsolidated entity that provides financing, liquidity, market risk or credit
support to us or engages in leasing, hedging or product development services with us. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Internal Control Over Financial Reporting </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In connection with the audits of our consolidated financial statements included in this prospectus supplement, we and our independent
registered public accounting firm identified the following material weaknesses and other control deficiencies in our internal control over financial reporting. As defined in the standards established by the U.S. Public Company Accounting Oversight
Board, a &#147;material weakness&#148; is a deficiency, or combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of the company&#146;s annual or interim
financial statements will not be prevented or detected on a timely basis. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The material weaknesses that have been identified relate to
(i)&nbsp;our lack of sufficient and competent financial reporting and accounting personnel with appropriate knowledge of U.S. GAAP and SEC reporting and compliance requirements, to formalize key controls over financial reporting and to prepare
consolidated financial statements and related disclosures; and (ii)&nbsp;our lack of sufficient documented financial closing policies and procedures, specifically those related to (a)&nbsp;accounting for licensing and collaboration agreements and
(b)&nbsp;period end expenses <FONT STYLE="white-space:nowrap">cut-off</FONT> and accruals. These material weaknesses, if not timely remedied, may lead to significant misstatements in our consolidated financial statements in the future. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We have implemented and plan to implement a number of measures to address the material weaknesses that have been identified in connection with
the audits of our consolidated financial statements as of and for the years ended December&nbsp;31, 2017, 2018 and 2019 and the review of the consolidated financial statements as of and for the nine months ended September 30, 2020. We have hired
additional qualified financial and accounting staff with working experience of U.S. GAAP and SEC reporting requirements, and plan to continue such hiring efforts. We intend to conduct regular and continuous U.S. GAAP accounting and financial
reporting training programs for our financial reporting and accounting personnel. We further intend to establish sufficient and formal financial closing policies and procedures, specifically those related to accounting for licensing and
collaboration arrangements and period end <FONT STYLE="white-space:nowrap">cut-off</FONT> and accruals. We plan to, as <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">work-in-progress,</FONT></FONT> engage an external consulting
firm to assist us to assess Sarbanes-Oxley Act compliance requirements and improve our overall internal controls. Furthermore, we plan to prepare more detailed guidance on accounting policies, manuals and closing procedures to improve the quality
and accuracy of our period end financing closing process. We will continue to implement these and other measures to remediate our internal control deficiencies. We may incur significant costs in the implementation of such measures. However, the
implementation of these measures may not fully address the deficiencies in our internal control over financial reporting, and we cannot assure you that all of these measures will be sufficient to remediate our material weakness in time, or at all.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">As a company with less than US$1.07&nbsp;billion in revenue for our last fiscal year, we qualify as an &#147;emerging growth
company&#148; pursuant to the JOBS Act. An emerging growth company may take advantage of specified reduced reporting and other requirements that are otherwise applicable generally to public companies. These provisions include exemption from the
auditor attestation requirement under Section&nbsp;404 of the Sarbanes-Oxley Act of 2002 in the assessment of the emerging growth company&#146;s internal control over financial reporting. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Inflation </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">To date, inflation in China
has not materially impacted our results of operations. According to the National Bureau of Statistics of China, the year-over-year percent changes in the consumer price index for December 2017, 2018 and 2019 were increases of 1.8%, 1.9% and 4.5%,
respectively. Although we have not been materially affected by inflation in the past, we can provide no assurance that we will not be affected by higher rates of inflation in China in the future. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-32 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Holding Company Structure </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We are a holding company with no material operations of its own. We currently conduct our operations primarily through our PRC subsidiaries.
As a result, our ability to pay dividends depends upon dividends paid by our PRC subsidiaries. If our existing PRC subsidiaries or any newly formed ones incur debt on their own behalf in the future, the instruments governing their debt may restrict
their ability to pay dividends to us. In addition, our wholly foreign-owned subsidiaries in China are permitted to pay dividends to us only out of its retained earnings, if any, as determined in accordance with PRC accounting standards and
regulations. Under PRC law, each of our subsidiaries and their subsidiaries in China is required to set aside at least 10% of its <FONT STYLE="white-space:nowrap">after-tax</FONT> profits each year, if any, to fund certain statutory reserve funds
until such reserve funds reach 50% of their registered capital. In addition, our wholly foreign-owned subsidiaries in China may allocate a portion of their <FONT STYLE="white-space:nowrap">after-tax</FONT> profits based on PRC accounting standards
to enterprise expansion funds and staff bonus and welfare funds at their discretion, and their subsidiaries may allocate a portion of their <FONT STYLE="white-space:nowrap">after-tax</FONT> profits based on PRC accounting standards to a surplus fund
at their discretion. The statutory reserve funds and the discretionary funds are not distributable as cash dividends. Remittance of dividends by a wholly foreign-owned company out of China is subject to examination by the banks designated by SAFE.
Our PRC subsidiaries have not paid dividends and will not be able to pay dividends until they generate accumulated profits and meet the requirements for statutory reserve funds. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Quantitative and Qualitative Disclosures about Market Risk </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Interest and Credit Risk </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We had
cash, cash equivalents and restricted cash of RMB412.7&nbsp;million, RMB1,680.9&nbsp;million, RMB1,193.3&nbsp;million (US$175.8 million) and RMB2,960.0 million (US$436.0 million) as of December&nbsp;31, 2017, 2018 and 2019 and September 30, 2020,
respectively. Our exposure to interest rate risk primarily relates to the interest income generated by excess cash, which is mostly held in interest-bearing bank deposits. Interest-earning instruments carry a degree of interest rate risk. We have
not been exposed to material risks due to changes in interest rates, and we have not used any derivative financial instruments to manage our interest risk exposure. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our credit risk is primarily attributable to the carrying amounts of cash and cash equivalents. The carrying amounts of cash and cash
equivalents represent the maximum amount of loss due to credit risk. We mainly place or invest cash and cash equivalents with state-owned or reputable financial institutions in the PRC, and reputable financial institutions outside of the PRC. We do
not believe that our cash and cash equivalents have significant risk of default or illiquidity, and we will continually monitor the credit worthiness of these financial institutions. While we believe our cash and cash equivalents do not contain
excessive risk, future investments may be subject to adverse changes in market value. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Foreign Exchange Risk </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Most of our revenues and expenses are denominated in RMB. We do not believe that we currently have any significant direct foreign exchange
risk and have not used any derivative financial instruments to hedge exposure to such risk. Although our exposure to foreign exchange risks should be limited in general, the value of your investment in our ADSs will be affected by the exchange rate
between U.S. dollar and RMB because the value of our business is effectively denominated in RMB, while our ADSs will be traded in U.S. dollars. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The conversion of RMB into foreign currencies, including U.S. dollars, is based on rates set by the People&#146;s Bank of China. The RMB has
fluctuated against the U.S. dollar, at times significantly and unpredictably. It is difficult to predict how market forces or PRC or U.S. government policy may impact the exchange rate between RMB and the U.S. dollar in the future. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">To the extent that we need to convert U.S. dollars into RMB for our operations, appreciation of the RMB against the U.S. dollar would have an
adverse effect on the RMB amount we receive from the conversion. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-33 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Conversely, if we decide to convert RMB into U.S. dollars for the purpose of making payments for dividends on our ordinary shares or ADSs or for other business purposes, appreciation of the U.S.
dollar against the RMB would have a negative effect on the U.S. dollar amounts available to us. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">As of September 30, 2020, we had <FONT
STYLE="white-space:nowrap">RMB-denominated</FONT> cash and cash equivalents, restricted cash and short-term investments of RMB940&nbsp;million (US$138.4 million). A 10% depreciation of RMB against U.S. dollar based on the foreign exchange rate on
September 30, 2020 would result in a decrease of US$13.8&nbsp;million in cash and cash equivalents. A 10% appreciation of RMB against U.S. dollar based on the foreign exchange rate on September 30, 2020 would result in an increase of US$13.8 million
in cash and cash equivalents. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Critical Accounting Policies and Significant Judgments and Estimates </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our discussion and analysis of our financial condition and results of operations is based on our financial statements, which have been
prepared in accordance with U.S. GAAP. The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the
disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Estimates are used when accounting for amounts recorded in connection
with acquisitions, including initial fair value determinations of assets and liabilities and other intangible assets as well as subsequent fair value measurements. Additionally, estimates are used in determining items such as fair value measurements
of wealth management products, impairment of other receivables, contract assets, long-lived assets, intangible assets and goodwill, useful lives of property, equipment and software, recognition of right-of-use assets and lease liabilities, fair
value measurements of warrant liabilities, variable consideration in collaboration revenue agreements, determination of the standalone compensation arrangement. We base the estimates on historical experience, known trends and various other
assumptions that are believed to be reasonable, the results of which form the basis for making judgments about the carrying values of assets and liabilities. Actual results could differ from those estimates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Revenue Recognition </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We adopted
Accounting Standard Codification (&#147;ASC&#148;) 606, Revenue from Contracts with Customers (Topic 606) (&#147;ASC 606&#148;) for all periods presented. Consistent with the criteria of Topic 606, we recognize revenue to depict the transfer of
promised goods or services to customers in an amount that reflects the consideration to which the entity expects to receive in exchange for those goods or services. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Under ASC 606, an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the
consideration that the entity expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that an entity determines are within the scope of ASC 606, the entity performs the following five steps:
(i)&nbsp;identify the contract(s) with a customer; (ii)&nbsp;identify the performance obligations in the contract; (iii)&nbsp;determine the transaction price, including variable consideration, if any; (iv)&nbsp;allocate the transaction price to the
performance obligations in the contract; and (v)&nbsp;recognize revenue when (or as) the entity satisfies a performance obligation. We only apply the five-step model to contracts when it is probable that the entity will collect substantially all the
consideration to which it is entitled in exchange for the goods or services it transfers to the customer. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Once a contract is determined
to be within the scope of ASC 606 at contract inception, we audit the contract to determine which performance obligations it must deliver and which of these performance obligations are distinct. We recognize as revenue the amount of the transaction
price that is allocated to each performance obligation when that performance obligation is satisfied or as it is satisfied. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Collaboration Revenue
</I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">At contract inception, we analyze its collaboration arrangements to assess whether they are within the scope of ASC 808,
Collaborative Arrangements (&#147;ASC 808&#148;) to determine whether such arrangements involve </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-34 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
joint operating activities performed by parties that are both active participants in the activities and exposed to significant risks and rewards dependent on the commercial success of such
activities. For collaboration arrangements within the scope of ASC 808 that contain multiple elements, we first determine if the collaboration is deemed to be within the scope of ASC 808. For any units of account that are reflective of a
vendor-customer relationship those units of account are accounted for within the scope of ASC 606. For any units of account that are not accounted for under ASC 606 and therefore accounted for pursuant to ASC 808, an appropriate recognition method
is determined and applied consistently. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our collaborative arrangements may contain more than one unit of account, or performance
obligation, including grants of licenses to intellectual property rights, agreement to provide research and development services and other deliverables. The collaborative arrangements do not include a right of return for any deliverable. As part of
the accounting for these arrangements, we must develop assumptions that require judgment to determine the stand-alone selling price for each performance obligation identified in the contract. In developing the stand-alone selling price for a
performance obligation, we consider competitor pricing for a similar or identical product, market awareness of and perception of the product, expected product life and current market trends. In general, the consideration allocated to each
performance obligation is recognized when the respective obligation is satisfied either by delivering a good or providing a service, limited to the consideration that is not constrained. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">When the timing of the delivery of product is different from the timing of payments made by the customers, we recognize either a contract
asset (performance precedes the contractual due date) or a contract liability (customer payment precedes performance). Our contractual payment terms are typically due in no more than 30&nbsp;days from invoicing. In limited situations, certain
customer contractual payment terms require us to bill in arrears; thus, we satisfy some or all of our performance obligations before we are contractually entitled to bill the customer. In these situations, billing occurs subsequent to revenue
recognition, which results in a contract asset. For example, certain of the contractual arrangements do not permit us to bill until the completion of the production of the samples. In other limited situations, certain customer contractual payment
terms allow us to bill in advance; thus, we receive customer cash payment before satisfying some or all of its performance obligations. In these situations, billing occurs in advance of revenue recognition, which results in contract liabilities.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Licenses of Intellectual Property </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Upfront <FONT STYLE="white-space:nowrap">non-refundable</FONT> payments for licensing our intellectual property are evaluated to determine if
the license is distinct from the other performance obligations identified in the arrangement. For licenses determined to be distinct, we recognize revenues from <FONT STYLE="white-space:nowrap">non-refundable,</FONT>
<FONT STYLE="white-space:nowrap">up-front</FONT> fees allocated to the license at a point in time, when the license is transferred to the licensee and the licensee is able to use and benefit from the license. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Research and Development Services </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The portion of the transaction price allocated to research and development services performance obligations is deferred and recognized as
revenue over time as delivery or performance of such services occurs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Milestone Payments </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">At the inception of each arrangement that includes development, commercialization, and regulatory milestone payments, we evaluate whether the
milestones are considered probable of being reached and to the extent that a significant reversal of cumulative revenue would not occur in future periods, estimates the amount to be included in the transaction price using the most likely amount
method. The transaction price is then allocated to each performance obligation on a relative stand-alone selling price basis, for which we recognize revenue as or when the performance obligations under the contract are satisfied. At the end of each
subsequent reporting period, we <FONT STYLE="white-space:nowrap">re-evaluate</FONT> the probability of achieving such development milestones and any related </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-35 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
constraint, and if necessary, adjust our estimate of the overall transaction price. Any such adjustments are recorded on a cumulative <FONT STYLE="white-space:nowrap">catch-up</FONT> basis, which
would affect revenues and earnings in the period of adjustment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Royalties </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and the license is deemed to be
the predominant item to which the royalties or milestone payments based on the level of sales relate, we recognize revenue at the later of (i)&nbsp;when the related sales occur, or (ii)&nbsp;when the performance obligation to which some or all of
the royalty has been allocated has been satisfied (or partially satisfied). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Research and Development Expenses </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Elements of research and development expenses primarily include: (1)&nbsp;payroll and other related expenses of personnel engaged in research
and development activities, <FONT STYLE="white-space:nowrap">(2)&nbsp;in-licensed</FONT> patent rights fee of exclusive development rights of drugs granted to us, (3)&nbsp;expenses related to <FONT STYLE="white-space:nowrap">pre-clinical</FONT>
testing of our technologies under development and clinical trials such as payments to contract research organizations (&#147;CRO&#148;), investigators and clinical trial sites that conduct our clinical studies, (4)&nbsp;expenses to develop the
product candidates, including raw materials and supplies, product testing, depreciation, and facility related expenses, and (5)&nbsp;other research and development expenses. Research and development expenses are charged to expense as incurred when
these expenditures relate to our research and development services and have no alternative future uses. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We have acquired rights to
develop and commercialize product candidates. Upfront payments that relate to the acquisition of a new drug compound, as well as <FONT STYLE="white-space:nowrap">pre-commercial</FONT> milestone payments, are immediately expensed as acquired <FONT
STYLE="white-space:nowrap">in-process</FONT> research and development in the period in which they are incurred, provided that the new drug compound did not also include processes or activities that would constitute a &#147;business&#148; as defined
under U.S. GAAP, the drug has not achieved regulatory approval for marketing and, absent obtaining such approval, has no established alternative future use. Milestone payments made to third parties subsequent to regulatory approval would be
capitalized as intangible assets and amortized over the estimated remaining useful life of the related product. The conditions enabling capitalization of development expenses as an asset have not yet been met and, therefore, all development
expenditures are recognized in profit or loss when incurred. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Share-Based Compensation </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We grant restricted shares and stock options to eligible employees and account for share-based compensation in accordance with ASC 718,
Compensation&#151;Stock Compensation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Employees&#146; share-based compensation awards are measured at the grant date fair value of the
awards and recognized as expenses (i)&nbsp;immediately at the grant date if no vesting conditions are required; (ii)&nbsp;for share-based awards granted with only service conditions, using the graded vesting method net of estimated forfeitures over
the vesting period; or (iii)&nbsp;for share-based awards granted with service conditions and the occurrence of an initial public offering as performance condition cumulative share-based compensation expenses for the options that have satisfied the
service condition should be recorded upon the completion of the initial public offering using the graded vesting method. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">A change in any
of the terms or conditions of share-based awards is accounted for as a modification of the awards. We calculate incremental compensation expense of a modification as the excess of the fair value of the modified awards over the fair value of the
original awards immediately before its terms are modified at the modification date. For vested awards, we recognize incremental compensation cost in the period when the modification occurs. For awards not being fully vested, we recognize the sum of
the incremental compensation expense and the remaining unrecognized compensation expense for the original awards over the remaining requisite service period after modification. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-36 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Share-based compensation in relation to the restricted shares is measured based on the fair
market value of our ordinary shares at the grant date of the award. Prior to the listing, estimation of the fair value of our ordinary shares involves significant assumptions that might not be observable in the market, and a number of complex and
subjective variables, including discount rate, and subjective judgments regarding our projected financial and operating results, its unique business risks, the liquidity of its ordinary shares and its operating history and prospects at the time the
grants are made. Share-based compensation in relation to the share options is estimated using the Binominal Option Pricing Model. The determination of the fair value of share options is affected by the share price of our ordinary shares as well as
the assumptions regarding a number of complex and subjective variables, including the expected share price volatility, risk-free interest rate, exercise multiple and expected dividend yield. The fair value of these awards was determined with the
assistance from an independent valuation firm. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><I>Restricted ordinary shares </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">During the year ended December&nbsp;31, 2016, we issued 4,019,554 ordinary shares to Mr.&nbsp;Zang Jingwu Zhang, Ms.&nbsp;Qian Lili,
Mr.&nbsp;Wang Zhengyi and Mr.&nbsp;Fang Lei (collectively the &#147;Founders&#148;), including the 369,301 shares which represented the equity interests of Third Venture held by the Founders, and we recorded share-based compensation expense of
RMB18.7&nbsp;million for issuance and grant of 3,650,253 ordinary shares to the Founders in June 2016. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In October 2016, the Founders
entered into an arrangement with our other investors, and the 87,441 ordinary shares issued to the Founders in June 2016 were cancelled, and out of the remaining 3,932,113 ordinary shares held by the Founders, 70% became restricted and subject to
service vesting conditions, that shall vest 20%, 20% and 30% over the next three years, respectively. By October 2019, all the restricted shares were vested. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Deferred share-based compensation was measured for the restricted shares using the estimated fair value of our ordinary shares of US$0.77 at
the date of imposition of the restriction in October 2016, and was amortized to the consolidated statements of comprehensive loss by using graded vesting method over the vesting term of 3&nbsp;years. The following table summarizes our Founders&#146;
restricted shares activities for the years ended December&nbsp;31, 2017, 2018 and 2019 and the nine months ended September 30, 2019 and 2020: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="73%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Numbers of<BR>Shares</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Weighted-<BR>Average<BR>Grant<BR>Date&nbsp;Fair</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Value</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outstanding at December&nbsp;31, 2017</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,966,056</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.77</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Vested</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(786,423</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outstanding at December&nbsp;31, 2018 and September&nbsp;30, 2019</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,179,633</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.77</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Vested</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,179,633</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outstanding at December&nbsp;31, 2019 and September&nbsp;30, 2020</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The amounts of share-based compensation expense in relation to the restricted shares recognized in the year
ended December&nbsp;31, 2019 was RMB1,566&nbsp;thousand, of which RMB1,566&nbsp;thousand was recognized in the nine months ended September 30, 2019. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-37 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">No share-based compensation expense was recognized in the nine months ended September 30,
2020. Share-based compensation expenses relating to restricted shares were included in: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="64%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Year Ended December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Nine Months&nbsp;Ended<BR>September&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>RMB</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>RMB</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>RMB</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>US$</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>RMB</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>RMB</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>US$</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="26" ALIGN="center"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,112</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,056</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">470</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">69</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">467</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Administrative expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,927</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,464</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,096</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">161</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,089</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,039</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,520</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,566</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">231</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,556</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><I>Second Amended and Restated 2017 Employee Stock Option Plan (the &#147;2017 Plan&#148;) </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In October 2017, we adopted the 2017 Plan (as last amended and restated on December&nbsp;25, 2019). Under the 2017 Plan, a maximum aggregate
number of 13,376,865 shares that may be issued pursuant to all awards granted were approved. Stock options granted to an employee under the 2017 Plan will be exercisable upon the completion of a listing and the employee renders service to us in
accordance with a stipulated service schedule starting from the employee&#146;s date of employment. Employees are generally subject to a three-year service schedule, under which an employee earns an entitlement to vest in 50% of the option grants on
the second&nbsp;anniversary of the grant date, a vesting of the remaining fifty percent 50% on the third anniversary of the applicable grant date. The stock options under the 2017 Plan, to the extent then vested, shall become exercisable only upon
the earlier of (i)&nbsp;a listing, and (ii)&nbsp;occurrence of a change in control. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">On December&nbsp;25, 2019, the 2017 Plan was approved
by our shareholders and board of directors, pursuant to which, in connection with our initial public offering, the maximum aggregate number of shares that may be granted pursuant to all awards under the 2017 Plan shall be adjusted in accordance with
a formula <FONT STYLE="white-space:nowrap">pre-approved</FONT> by the shareholders. In connection with above amendments to the 2017 Plan, each of our founders, namely, Zheru Zhang, Lili Qian, Zhengyi Wang and Lei Fang, is willing to irrevocably
surrender by him or her, for no consideration, of a portion of the unvested options granted to him or her, which, if vested, would entitle him or her to acquire up to 130,000 ordinary shares of our company, par value US$0.0001 per share, at an
exercise price of US$1.0, respectively, under the 2017 Plan (in respect of each individual, the &#147;Founder&#146;s Surrendered Options&#148;). On December&nbsp;25, 2019, our board of directors approved that our company accepts all Founder&#146;s
Surrendered Options from each of the founders, namely, Zheru Zhang, Lili Qian, Zhengyi Wang and Lei Fang, for no consideration, with effect immediately prior to the completion of the initial public offering and such surrendered options be cancelled
with effect immediately prior to the completion of the initial public offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Prior to our completion of a listing, all stock options
granted to an employee shall be forfeited at the time the employee terminates his employment with us. After we complete a listing, vested options not exercised by an employee shall be exercised until later of: (i) 90 days after the date when the
options become exercisable, or (ii) 30 days after the date of cessation of employment or directorship, or such longer period as the board of directors may otherwise determine. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We granted 11,051,230, 1,470,000, 640,000, 640,000 and nil stock options to employees, all with an exercise price of US$1, for the years ended
December&nbsp;31, 2017, 2018 and 2019 and for the nine months ended September 30, 2019 and 2020, respectively. No options are exercisable as of December&nbsp;31, 2017, 2018 and 2019 and 8,047,548 stock options are exercisable as of September 30,
2020. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-38 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The following table sets forth the stock options activities for the periods presented: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="85.5%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="58%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Number of<BR>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Weighted<BR>Average<BR>Exercise<BR>Price<BR>US$</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Weighted<BR>Average<BR>Remaining<BR>Contractual<BR>Term</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Aggregate<BR>Intrinsic<BR>Value&nbsp;US$&#146;000</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outstanding as of December&nbsp;31, 2017</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,761,596</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.94</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9.50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24,890</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Granted</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,470,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Forfeited</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(226,000</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outstanding as of December&nbsp;31, 2018</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,005,596</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.95</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.61</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">70,129</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Granted</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">640,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Forfeited</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(397,500</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Repurchased</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,435,215</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outstanding as of December&nbsp;31, 2019</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,812,881</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.93</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.76</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">47,671</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercisable as of December&nbsp;31, 2019</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercised</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(115,888</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Forfeited</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(336,377</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Surrendered</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(332,566</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outstanding as of September&nbsp;30, 2020</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,028,050</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.93</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">175,576</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercisable as of September&nbsp;30, 2020</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,047,548</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.92</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.91</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">156,567</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%" VALIGN="top" ALIGN="left">Note:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Other addition represented the modified share options that originally granted to two senior management
employees in October 2016 (see &#147;&#151;other share-based compensation&#148;). </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Stock options granted to the
employees were measured at fair value on the dates of grant using the Binomial Option Pricing Model with the following assumptions: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="61%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Year&nbsp;Ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Nine&nbsp;Months<BR>Ended<BR>September&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected volatility</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">62.34</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">61.32%&#151;62.13</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">54.64</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">54.64</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">N/A</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Risk-free interest rate (per annum)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.32</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2.81%&#151;3.06</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.15</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.15</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">N/A</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercise multiple</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.80</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.80</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.80</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">N/A</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected dividend yield</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">N/A</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Contractual term (in years)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">N/A</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The expected volatility was estimated based on the historical volatility of comparable peer public companies
with a time horizon close to the expected term of our options. The risk-free interest rate was estimated based on the yield to maturity of U.S. treasury bonds denominated in US$ for a term consistent with the expected term of our options in effect
at the option valuation date. The expected exercise multiple was estimated as the average ratio of the stock price to the exercise price when employees would decide to voluntarily exercise their vested options. As we did not have sufficient
information of past employee exercise history, it was estimated by referencing to a widely-accepted academic research publication. Expected dividend yield is zero as we have never declared or paid any cash dividends on its shares, and we do not
anticipate any dividend payments in the foreseeable future. Expected term is the contract life of the option. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">There were no stock options
granted to employees under the 2017 Plan for the nine months ended September&nbsp;30, 2020. On January&nbsp;17, 2020, we completed our initial public offering. After achieving this performance condition, the options continue to vest based only on
service period completed according to the graded vesting schedule. We have begun recognizing share-based compensation expense for the options granted using the graded vesting method with a cumulative <FONT STYLE="white-space:nowrap">catch-up</FONT>
for the service period completed to date during the nine months ended September&nbsp;30, 2020 and recognized RMB56,019 thousand and RMB69,204 thousand share-based compensation expenses in administrative expenses and research and development
expenses, respectively, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-39 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
relating to options vested cumulatively. According to the amendments to the 2017 Plan, the maximum aggregate number of shares which may be granted pursuant to all awards under the 2017 Plan was
changed to 9,609,084. Each of our founders, namely Zheru Zhang, Lili Qian, Zhengyi Wang and Lei Fang surrendered 83,142 unvested stock options that were granted to him or her under the 2017 Plan before, totaling 332,566 unvested options, for no
consideration, and these stock options were cancelled immediately. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><I>Second Amended and Restated 2018 Employee Stock Option Plan (the
&#147;2018 Plan&#148;) </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">On February&nbsp;22, 2019, our company adopted the 2018 Plan, which was subsequently amended and restated on
July&nbsp;22, 2019. Under the amended and restated the 2018 Plan, the maximum aggregate number of ordinary shares which may be issued pursuant to all awards is 14,005,745, and if we successfully list on an internationally recognized securities
exchange for a qualified public offering by December&nbsp;31, 2019, the maximum aggregate number of ordinary shares which may be issued shall be 15,452,620. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">On December&nbsp;25, 2019, the 2018 Plan was approved by the shareholders and board of directors of our company, pursuant to which, in
connection with offering, the maximum aggregate number of shares that may be granted pursuant to all awards under the 2018 Plan may be adjusted in accordance with a formula <FONT STYLE="white-space:nowrap">pre-approved</FONT> by our shareholders. In
connection with above amendments to the 2018 Plan, the director of our company, Dr.&nbsp;Jingwu Zhang Zang is willing to irrevocably surrender by him, for no consideration, of the right to acquire a certain amount of ordinary shares of our company,
par value US$0.0001 per share, at an exercise price of US$1.0 pursuant to the options granted to him under the 2018 Plan (the &#147;Dr.&nbsp;Zang&#146;s Surrendered Options&#148;). On December&nbsp;25, 2019, the board of directors of our company
approved that our company accepts the irrevocable surrender of Dr.&nbsp;Zang&#146;s Surrendered Options for no consideration, with effect immediately prior to the completion of the initial public offering and such surrendered options be cancelled
with effect immediately prior to the completion of the initial public offering. See &#147;Management&#151;Share Incentive Plans&#151;Second Amended and Restated 2018 Employee Stock Option Plan.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Stock options granted to an employee under the 2018 Plan will be generally exercisable when our company completes a listing and the employee
renders service to our company in accordance with a stipulated service schedule starting from the employee&#146;s date of employment. The vesting schedule shall generally be a <FONT STYLE="white-space:nowrap">two-year</FONT> vesting schedule
consisting of a cliff vesting of 50% of the stock options on the first anniversary of the applicable vesting commencement date and a vesting of the remaining 50% on the second anniversary of the applicable vesting commencement date. If a listing
occurs at any time prior to any stock option granted under the 2018 Plan becoming fully vested, to the extent such stock option has been granted and is outstanding, any such stock option shall vest in full with immediate effect upon the listing.
Except as otherwise approved by the Board of Directors, any vested portion of the stock options shall become exercisable upon the earlier of six months after a listing or the occurrence of a change in control; provided, however, that in each case,
no stock option of an employee shall become exercisable until the third anniversary of such employee&#146;s employment commencement date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Pursuant to the board of director&#146;s approval of the 2018 Plan on February&nbsp;22, 2019, the 10,893,028 stock options granted to a
director of our company under the 2018 Plan were fully vested and exercisable upon the adoption of 2018 Plan. Out of these 10,893,028 stock options, 454,940 stock options were repurchased by our company (see Note 14 (d) to our unaudited interim
condensed consolidated financial statements for further details). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The amount of share-based compensation expense in relation to the
aforementioned grant of stock options to a director of our company (except for those repurchased by our company as described in Note 14 (d) to our unaudited interim condensed consolidated financial statements) recognized in the year ended
December&nbsp;31, 2019 was RMB365,329 thousand, which were allocated to our administrative expenses. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-40 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The following table sets forth the stock options activities under the 2018 Plan for the nine
months ended September&nbsp;30, 2020: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="85.5%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="50%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Number&nbsp;of<BR>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Weighted<BR>Average<BR>Exercise<BR>Price<BR>US$</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Weighted<BR>Average<BR>Remaining<BR>Contractual<BR>Term</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Aggregate<BR>Intrinsic<BR>Value<BR>US$</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outstanding as of December&nbsp;31, 2018</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Granted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,991,528</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Repurchased</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(454,940</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outstanding as of December&nbsp;31, 2019</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,536,588</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9.15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">64,840</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercisable as of December&nbsp;31,2019</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,438,088</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.86</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">49,998</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Surrendered</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,544,917</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outstanding as of September&nbsp;30, 2020</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,991,671</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.40</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">213,764</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercisable as of September&nbsp;30, 2020</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,166,671</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.40</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">197,720</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Stock options granted to certain directors and employees of our company were measured at fair value on the
dates of grant using the Binomial Option Pricing Model with the following assumptions: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="85.5%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="38%"></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Year&nbsp;Ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Nine&nbsp;Months&nbsp;Ended&nbsp;September&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected volatility</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">N/A</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">54.64&#151;56.31</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">54.64&#151;56.31</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">N/A</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Risk-free interest rate (per annum)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">N/A</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2.15&#151;2.75</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2.15&#151;2.75</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">N/A</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercise multiple</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">N/A</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.80</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.80</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">N/A</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected dividend yield</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">N/A</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">N/A</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Contractual term (in years)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">N/A</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">N/A</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The expected volatility was estimated based on the historical volatility of comparable peer public companies
with a time horizon close to the expected term of our company&#146;s options. The risk-free interest rate was estimated based on the yield to maturity of U.S. treasury bonds denominated in US$ for a term consistent with the expected term of our
company&#146;s options in effect at the option valuation date. The expected exercise multiple was estimated as the average ratio of the stock price to the exercise price when employees would decide to voluntarily exercise their vested options. As
our company did not have sufficient information of past employee exercise history, it was estimated by referencing to a widely-accepted academic research publication. Expected dividend yield is zero as our company has never declared or paid any cash
dividends on its shares, and our company does not anticipate any dividend payments in the foreseeable future. Expected term is the contract life of the option. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Except for the aforementioned grant of stock options to a director of our company under the 2018 Plan, since the exercisability is dependent
upon the listing, and it is not probable that this performance condition can be achieved until a listing, no share-based compensation expense related to the 2018 Plan was recorded for the year ended December&nbsp;31, 2019. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">On January&nbsp;17, 2020, our Company completed its IPO. After achieving this performance condition, the options continue to vest based only
on service period completed according to the graded vesting schedule. We have begun recognizing share-based compensation expenses for the options granted using the graded vesting method with a cumulative
<FONT STYLE="white-space:nowrap">catch-up</FONT> for the service period completed to date during the nine months ended September&nbsp;30, 2020 and recognized RMB46,312 thousand and RMB66,496 thousand share-based compensation expense in
administrative expenses and research and development expenses, respective, relating to options vested cumulatively. According to the amendments to the 2018 Plan, the maximum aggregate number of shares which
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-41 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
may be granted pursuant to all awards under the 2018 Plan was changed to 11,005,888. Dr.&nbsp;Jingwu Zhang Zang, a director of our Company, surrendered 2,544,917 unvested options that were
granted to him under the 2018 Plan, for no consideration, and these stock options were cancelled immediately. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><I>Repurchase of share
awards held by a director </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">On February&nbsp;22, 2019, the amendment and restated 2017 equity incentive plan was approved by the Board
of Directors of our company, pursuant to which only the 3,435,215 stock options held by a director of our company under the 2017 equity incentive plan became fully vested and exercisable on February&nbsp;22, 2019. As a result of the performance
condition being waived, the shares held by a director of our company were accounted for as a Type III modification where a condition that our company expects will not be satisfied is changed to a condition that our company expects will be satisfied.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Additionally, on the same day, our company repurchased such 3,435,215 stock options under the amendment and restated 2017 equity
incentive plan that was held by a director of our company along with 454,940 of his stock options under the 2018 equity incentive plan for which the share awards also became fully vested and exercisable, at a total consideration of US$21,902
thousand (equivalent to approximately RMB148,308 thousand) at an average share price of US$5.63 per share. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">For the nine months ended
September 30, 2019, our company recorded the total payment of US$21,902 thousand (equivalent to approximately RMB148,308 thousand) as share-based compensation costs (included in administrative expenses) in the condensed consolidated statement of
comprehensive loss. There was no impact to the overall stockholder&#146;s equity balance as the amended shares vested immediately and were repurchased. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><I>2019 Share Incentive Plan (the &#147;2019 Plan&#148;) </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">On October&nbsp;29, 2019, we adopted the 2019 Plan. Under the 2019 Plan, the maximum aggregate number of ordinary shares available for
issuance shall initially be 100,000. The options shall vest when our Company completes a listing and the employee renders service to our Company in accordance with a stipulated service schedule starting from the employee&#146;s date of employment.
Stock options granted to 3 independent directors under the 2019 Plan will be generally exercisable under the following terms: (a)&nbsp;a cliff vesting of 1/3 of the option on the first anniversary of the vesting commencement date (January 17, 2020);
(b) a cliff vesting of 1/3 of the option on the second anniversary of the vesting commencement date (January 17, 2020); (c) a vesting of the remaining 1/3 of the option on the third anniversary of the vesting commencement date (January 7, 2020). In
the last year of the grantee&#146;s service, the options shall vest on a prorated basis to reflect the portion of the year during which the grantee provided services to our Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">For the nine months ended September&nbsp;30, 2020, our Company granted 72,000 stock options to three independent directors (all with an
exercise price of US$6.09) and recognized RMB741 thousand share-based compensation expenses relating to the options vested. No options were exercisable as of September 30, 2020. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The following table sets forth the stock option activities of the 2019 Plan for the periods presented: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="85.5%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="53%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Number&nbsp;of<BR>Shares</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Weighted<BR>Average<BR>Exercise<BR>Price<BR>US$</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Weighted<BR>Average<BR>Remaining<BR>Contractual<BR>Term</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Aggregate<BR>Intrinsic<BR>Value<BR>US$</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outstanding as of December&nbsp;31, 2019</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Granted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">72,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.09</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outstanding as of September 30, 2020</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">72,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.09</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9.59</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,034</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercisable as of September&nbsp;30, 2020</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-42 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Stock options granted to certain directors and employees of our company were measured at
fair value on the dates of grant using the Binomial Option Pricing Model with the following assumptions: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="55.5%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="49%"></TD>

<TD VALIGN="bottom" WIDTH="44%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Nine&nbsp;Months&nbsp;Ended&nbsp;September&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected volatility</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">54.88</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Risk-free interest rate (per annum)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.79</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercise multiple</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected dividend yield</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Contractual term (in years)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The expected volatility was estimated based on the historical volatility of comparable peer public companies
with a time horizon close to the expected term of our company&#146;s options. The risk-free interest rate was estimated based on the yield to maturity of U.S. treasury bonds denominated in US$ for a term consistent with the expected term of our
options in effect at the option valuation date. The expected exercise multiple was estimated as the average ratio of the stock price to the exercise price when employees would decide to voluntarily exercise their vested options. As our Company did
not have sufficient information of past employee exercise history, it was estimated by referencing to a widely-accepted academic research publication. Expected dividend yield is zero as our Company has never declared or paid any cash dividends on
its shares, and our Company does not anticipate any dividend payments in the foreseeable future. Expected term is the contract life of the option. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><I>2020 Share Incentive Plan (the &#147;2020 Plan&#148;) </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In July 2020, we adopted the 2020 Plan. Under the 2020 Plan, the maximum aggregate number of ordinary shares which may be issued pursuant to
all awards shall be 10,760,513, provided that the maximum number of shares may be issued pursuant to awards in the form of restricted share units under this plan shall not exceed 7,686,081 ordinary shares. From August 2020 through September 2020, we
granted 1,068,733 stock options and 4,892,918 restricted share units under the 2020 Plan to employees, respectively. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><I>Other share-based
compensation </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In October 2017, in connection with the adoption of the 2017 Plan, we amended the stock option agreement with the two
aforementioned employees, under which the stock options would become exercisable only upon the earlier of (i)&nbsp;a listing, and (ii)&nbsp;occurrence of a change in control that defined in the stock option agreements. As the modification of terms
and conditions of share-based compensation were not beneficial to its employees, no further accounting impact was resulting from it. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><I>Establishment of Biomaster Trust </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Biomaster Trust was established under the trust deed, dated October&nbsp;23, 2019, between us and TMF Trust (HK) Limited, or TMF Trust, as the
trustee of the Biomaster Trust. Through the Biomaster Trust, our company&#146;s ordinary shares and other rights and interests under awards granted pursuant to the 2017 Plan and the 2018 Plan may be provided to certain recipients of equity awards.
Upon satisfaction of the vesting conditions, TMF Trust will exercise the equity awards and transfer the relevant ordinary shares and other rights and interests under the equity awards to the relevant grant recipients with the consent of the advisory
committee of Biomaster Trust. TMF Trust shall not exercise the voting rights attached to such ordinary shares unless otherwise directed by the advisory committee, whose members shall be appointed by our company. Our company has the power to direct
the relevant activities of Biomaster Trust and has the ability to use its power over Biomaster Trust to affect its exposure to returns. Therefore, the assets and liabilities of Biomaster Trust are included in our consolidated statements of financial
position. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-43 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><I>Surrender of stock options </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">On January&nbsp;17, 2020, our Company completed its IPO. According to the amendments to 2017 Plan, the maximum aggregate number of shares
which may be granted pursuant to all awards under 2017 Plan was changed to 9,609,084. Each of our founders, namely Zheru Zhang, Lili Qian, Zhengyi Wang and Lei Fang surrendered 83,142 unvested stock options that were granted to him or her under 2017
Plan before, totally 332,566 unvested options, for no consideration, and these stock options were cancelled immediately. According to the amendments to 2018 Plan, the maximum aggregate number of shares which may be granted pursuant to all awards
under 2018 Plan was changed to 11,005,888. Dr.&nbsp;Jingwu Zhang Zang, a director of our Company, surrendered 2,544,917 unvested options that were granted to him under 2018 Plan, for no consideration, and these stock options were cancelled
immediately. Upon the completion of our initial public offering in January 2020, we recorded RMB91,051 thousand share-based compensation expense related to these surrendered options. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The stock options surrendered by the founders should be accounted for as capital contribution. As the founders did not get the title of the
options to be surrendered and the number of share options would not be determined until listing, the capital contribution was not accounted for during the year ended December&nbsp;31, 2019. For the nine months ended September&nbsp;30, 2020, our
Company has reclassified RMB91,051 thousand from additional <FONT STYLE="white-space:nowrap">paid-in</FONT> capital&#151;share-based compensation to additional <FONT STYLE="white-space:nowrap">paid-in</FONT> capital&#151;capital contribution
relating to the options surrendered in the condensed consolidated financial statement of comprehensive loss. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><I>Fair Value of Ordinary
Shares </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We are required to estimate the fair value of the ordinary shares on grant dates of share-based compensation awards/share
option to our employees and the issuance of financial instruments to investors. Therefore, our board of directors has estimated the fair value of our ordinary shares on various dates, with inputs from management, considering the third-party
valuations. The valuations of our ordinary shares were performed using methodologies, approaches and assumptions consistent with the American Institute of Certified Public Accountants Audit and Accounting Practice Aid Series: Valuation of
Privately-Held-Company Equity Securities Issued as Compensation, or the AICPA Practice Guide. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In addition, our board of directors
considered various objective and subjective factors, along with inputs from management and the independent third-party valuation firm, to determine the fair value of our ordinary shares, including: external market conditions affecting the
biopharmaceutical industry, trends within the biopharmaceutical industry, the prices at which we sold convertible preferred shares, the superior rights and preference of the convertible preferred shares or other senior securities relative to our
ordinary shares at the time of each grant and the likelihood of achieving a liquidity event such as an initial public offering. The option-pricing method was used to allocate the enterprise&#146;s value to preferred shares or other senior securities
and ordinary shares, taking into account the guidance prescribed by the AICPA Practice Guide. This method treats ordinary shares and convertible preferred shares or other senior securities as call options on the enterprise&#146;s value, with
exercise prices based on their respective payoffs upon a liquidity event. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In determining the enterprise&#146;s value, we applied the
market approach/backsolve method based on pricing from recent transactions in our own securities. The basis for application of this method is our transactions in equity securities with unrelated parties or among unrelated parties themselves. No
evidence is observed to indicate these transactions are not <FONT STYLE="white-space:nowrap">arm&#146;s-length</FONT> transactions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our
board of directors determined the fair value of our share options and the restricted shares as of the dates of grant, taking into consideration the various objective and subjective factors described above, including the conclusion of valuation of
our ordinary shares as of dates close to the grant dates of our share options and the restricted shares. We computed the per share estimated fair value for share options based on the binomial option pricing model and the per share estimated fair
value for restricted shares based on per share estimated fair value of ordinary shares as of the date of grant. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-44 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Once public trading market of the ADSs has been established in connection with the
completion of our initial public offering, it is no longer necessary for our board of directors to estimate the fair value of our ordinary shares in connection with our accounting for granted share options and restricted shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><I>Fair Value Measurements </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our financial assets and liabilities primarily comprise of cash and cash equivalents, restricted cash, short-term investments, other financial
assets, contract assets, other receivables, short-term borrowings, accruals and other payables and warrant liabilities. As of December&nbsp;31, 2017, 2018 and 2019 and September&nbsp;30, 2020, except for short-term investments, other financial
assets and warrants liabilities, the carrying values of these financial assets and liabilities approximated their fair values because of their generally short maturities. We report short-term investments, other financial assets and warrant
liabilities at fair value at each balance sheet date and changes in fair value are reflected in the consolidated statements of comprehensive loss. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We measure our financial assets and liabilities using inputs from the following three levels of the fair value hierarchy. The three levels are
as follows: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Level&nbsp;1 inputs are unadjusted quoted prices in active markets for identical assets that the management has the ability
to access at the measurement date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Level&nbsp;2 inputs include quoted prices for similar assets in active markets, quoted prices for
identical or similar assets in markets that are not active, inputs other than quoted prices that are observable for the asset (i.e., interest rates, yield curves, etc.), and inputs that are derived principally from or corroborated by observable
market data by correlation or other means (market corroborated inputs). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Level&nbsp;3 includes unobservable inputs that reflect the
management&#146;s assumptions about the assumptions that market participants would use in pricing the asset. The management develops these inputs based on the best information available, including the own data. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We measured our short-term investments, other financial assets and warrant liabilities at fair value on a recurring basis. As our short-term
investments, other financial assets and warrant liabilities are not traded in an active market with readily observable prices, we use significant unobservable inputs to measure the fair value of short-term investments, other financial assets and
warrant liabilities. These instruments are categorized in the Level&nbsp;3 valuation hierarchy based on the significance of unobservable factors in the overall fair value measurement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Recent Accounting Pronouncements </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">A list
of recently issued accounting pronouncements that are relevant to us is included in note 2 &#147;Principal Accounting Policies&#151;2.26 Recent Accounting Pronouncements&#148; of our consolidated financial statements included elsewhere in this
prospectus supplement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-45 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="stoc98473_7"></A>CAPITALIZATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I>The following section sets forth certain information in the section titled &#147;Capitalization&#148; of the accompanying prospectus that
has been updated and/or supplemented to reflect changes since the effectiveness of the accompanying prospectus. </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The following table
sets forth our capitalization as of September 30, 2020. You should read this table together with our consolidated financial statements and the related notes included elsewhere in this prospectus supplement and the information under
&#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations.&#148; </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="76%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>As of September&nbsp;30, 2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>RMB</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>US$</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Convertible promissory notes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">64,771</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,540</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Shareholders&#146; equity</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ordinary shares (US$0.0001 par value, 800,000,000 shares authorized as of September 30, 2020;
153,543,910 shares issued and outstanding as of September 30, 2020)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">106</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Additional <FONT STYLE="white-space:nowrap">paid-in</FONT> capital</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,720,714</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">989,854</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated other comprehensive income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">85,657</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,616</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,064,842</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(451,403</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total shareholders&#146; equity</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><B>3,741,635 </B></TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><B>551,083</B></TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total capitalization</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>3,806,406</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>560,623</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-46 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="stoc98473_8"></A>BUSINESS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I>The following section sets forth certain information in the section titled &#147;Business&#148; of the accompanying prospectus that has
been updated and/or supplemented to reflect changes since the effectiveness of the accompanying prospectus. </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Unique Business Model </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Fast-to-Market</FONT></FONT> China Strategy </I></B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">For enoblituzumab, a humanized antibody directed at <FONT STYLE="white-space:nowrap">B7-H3,</FONT> in the first
quarter of 2021, MacroGenics expects to initiate a Phase 2 study of enoblituzumab in a chemo-free regimen in combination with either retifanlimab (an investigational PD-1 antibody) in front-line patients with SCCHN who are PD-L1 positive or with
tebotelimab (an investigational PD-1 x LAG-3 bispecific DART<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> antibody) in SCCHN patients who are PD-L1 negative. We expect to participate in a subsequent Phase 3 global study if and when
initiated, as we deem appropriate. In addition, considering the dynamic regulatory environment and evolving clinical practice, we have been continually refining the development of enoblituzumab in our territory. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">For efineptakin (TJ107), a long-acting interleukin 7, we obtained regulatory clearance from the NMPA in April
2020 to initiate a Phase 2 clinical trial in glioblastoma multiforme (GBM) patients with lymphopenia. We had the first patient in on December 31, 2020 and expect to have the first patient dosed in the first quarter of 2021. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Capabilities </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our Clinical Development
Capabilities </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our clinical development capabilities are best demonstrated by the rapid implementation of 11 clinical trials,
including one completed trial in the United States and ten <FONT STYLE="white-space:nowrap">on-going</FONT> Phase 1/2 or registration trials in the United States and China in the past three years. To ensure regulatory approval and subsequent product
launch as currently planned, we strive to reach the following critical clinical milestones by early 2021: 11 active clinical programs consisting of two Phase 3 or registrational trials in China, three Phase 2 trials and six Phase 1/2 trials in the
United States and China. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Global Strategic Collaborations </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Global Strategic Partnership with AbbVie </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Pursuant to this collaboration, AbbVie has paid us an upfront payment of US$180&nbsp;million. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Strategies </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Build our manufacturing
capabilities </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We believe it is strategically important and advantageous that we own and control our GMP manufacturing process in
order to ensure quality, secure production slots and maximize cost-effectiveness for clinical trial materials and commercial supplies. We intend to build a comprehensive biologics manufacturing facility in Hangzhou, China (the &#147;Hangzhou
Facility&#148;) as part of our strategic plan to become a fully integrated biopharma company. We have taken concrete steps to execute this plan. These steps include detailed operational planning for the facility, actions taken to secure an
appropriate site, and negotiations with external financing providers. The Hangzhou Facility targets to have a pilot capacity of 2 production lines (1 line configured with </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-47 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
2&nbsp;x&nbsp;2,000L and another line with 1 x 2,000L) by 2022 and commercially progressive capacity up to 8 x 4,000L to begin operation by the end of 2023. Construction is expected to commence
in April 2021 and ready for use by the end of 2023. <B><I></I></B>The project will be financed by a combination of internal and external sources. In September 2020, a group of domestic investors in China invested a total of US$120&nbsp;million (in
RMB equivalent) in cash. Upon closing, I-Mab Hangzhou became an affiliate of us. We, through our wholly owned subsidiary and parties acting in concert, remain the majority shareholder of <FONT STYLE="white-space:nowrap">I-Mab</FONT> Biopharma
(Hangzhou) Limited <FONT STYLE="white-space:nowrap">(&#147;I-Mab</FONT> Hangzhou&#148;), the entity holding the Hangzhou Facility, and retain a managing role and take full control to build and operate the manufacturing facility. We plan to
prioritize our therapeutic focus and resources on immuno-oncology in our global ambition to become a leading immuno-oncology company. This goal has been accelerated by our recent global strategic collaboration with AbbVie and its commercialization
plan for the initial oncology products. <FONT STYLE="white-space:nowrap">I-Mab</FONT> Hangzhou is positioned to provide manufacturing capabilities for us, as well as the continued development of selected biologics assets that are <FONT
STYLE="white-space:nowrap">non-essential</FONT> to our immuno-oncology focus, i.e. olamkicept, plonmarlimab (excluding cytokine release syndrome indications) and a few <FONT STYLE="white-space:nowrap">pre-clinical</FONT> <FONT
STYLE="white-space:nowrap">CMC-stage</FONT> programs. We believe that this strategic alignment is necessary to maximize the pipeline value and balance the development risk for us. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Licensing and Collaboration Arrangements </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>A.
In-Licensing Arrangements </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Licensing Agreement with Genexine (GX-I7/TJ107) </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In May 2020, we and Genexine entered into an amendment to this agreement, whereby both parties desire to establish a collaboration on TJ107
GBM Study in Greater China. Under the terms of the expanded collaboration, we will be mainly responsible for using commercially reasonable efforts to conduct the Phase 2 GBM clinical trial in Greater China, and Genexine will share the development
strategies, data and costs for success of this clinical trial. As of September 30, 2020, the costs incurred for the development of this new indication was immaterial and had no material impact to our unaudited interim condensed consolidated
financial statements for the first nine months ended September 30, 2020. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Other In-Licensing Arrangements </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In November 2018, we entered into a license and collaboration agreement with MorphoSys for MorphoSys&#146;s proprietary antibody
(MOR210/TJ210) directed against C5aR (the &#147;C5aR Agreement&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">As of the date of this prospectus supplement, we have made an
upfront payment of US$3.5&nbsp;million and milestone payment of US$1 million to MorphoSys. No other milestone payments or royalties are due under this agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>R&amp;D Governance </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Quality Committees
</I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We have formed two Quality Committees, namely, I-Mab Biopharma Quality Management Review and R&amp;D Quality Council. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">I-Mab Biopharma Quality Management Review (&#147;I-Mab QMR&#148;) is composed of Dr.&nbsp;Joan Huaqiong Shen, Dr.&nbsp;Zheru Zhang, Yuan Meng
and Thomas Song, co-chaired by R&amp;D Quality Assurance officer Yuan Meng and CMC Quality Assurance officer Jack Qin. I-Mab QMR is a company-level cross-functional senior leadership meeting to provide management oversight of our company&#146;s
Quality Management System (&#147;QMS&#148;) and the compliance status of our company&#146;s regulated activities with applicable laws, regulations, policies and procedures, focusing on R&amp;D and CMC GXP activities. To ensure our Corporate Quality
Plan is set, key QMS elements are established and maintained, quality requirements are met, and trends, changes and risks are identified and addressed proactively. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-48 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">R&amp;D Quality Council is composed of representatives from each research and development
function, including Dr.&nbsp;Joan Huaqiong Shen, Sophie Song, Yuan Meng, Michelle Yang, Dr.&nbsp;Claire Xu, Dr.&nbsp;Jane Meng and heads of therapeutic areas (in China and the United States), chaired by Dr.&nbsp;Joan Huaqiong Shen. R&amp;D Quality
Council is a governance body that oversees the performance of the QMS and serves as the final decision-making body for critical quality issues that affect subject and patient safety, data integrity and compliance with global and local regulatory
authorities. The QMS encompasses the structure, responsibilities and procedures that enable the organization to identify, measure, control and enhance core regulated processes and activities. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-49 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="stoc98473_10"></A>PRINCIPAL AND SELLING SHAREHOLDERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I>The following section sets forth certain information in the section titled &#147;Principal and Selling Shareholders&#148; of the
accompanying prospectus that has been updated and/or supplemented to reflect changes since the effectiveness of the accompanying prospectus. </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Except as specifically noted, the following table sets forth information with respect to the beneficial ownership of our ordinary shares as of
the date of this prospectus supplement by: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">each of our directors and executive officers; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">each of our principal shareholders, including all shareholders who own beneficially more than 5% of our total
outstanding shares; and </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">each selling shareholder. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The ordinary shares registered under this prospectus supplement include (i) 20,421,378 ordinary shares (represented by 8,878,860 ADSs) issued
to the selling shareholders identified in this prospectus supplement on September&nbsp;11, 2020, (ii) 3,744,032 ordinary shares (represented by 1,627,840 ADSs) that certain selling shareholders identified in this prospectus supplement have the right
to purchase from our company through the exercise of the warrants issued to them, and (iii) 958,341 ordinary shares (represented by 416,670 ADSs) that certain selling shareholders identified in this prospectus supplement have the right to purchase
pursuant to a call option agreement with certain members of our management team. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The ordinary shares held by the selling shareholders
reflected in the table below may be sold by the selling shareholders from time to time in one or more offerings described in this prospectus supplement and any applicable prospectus supplement. The selling shareholders may sell all, some or none of
these ordinary shares (or the ADSs representing these ordinary shares) beneficially owned by them, and therefore we cannot estimate either the number or the percentage of ordinary shares (or the ADSs representing these ordinary shares) that will be
beneficially owned by the selling shareholders following any offering or sale hereunder. We cannot advise you as to whether the selling shareholders will in fact sell any or all of the ordinary shares (or the ADSs representing these ordinary shares)
that they own. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The selling shareholders listed in the table below may have sold or transferred, or pledged as collateral, in transactions
pursuant to this prospectus supplement or exempt from the registration requirements of the Securities Act, some or all of their ordinary shares (or the ADSs representing their ordinary shares) since the date as of which the information is presented
in the table below. Information concerning the selling shareholders may change from time to time, and any changed information will, if required, be set forth in prospectus supplements or post-effective amendments to the registration statement of
which this prospectus supplement is a part, as may be appropriate. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The calculations in the table below are based on 165,477,620 ordinary
shares outstanding as of the date of this prospectus supplement (excluding 4,036,868 ordinary shares issued to our depositary bank for bulk issuance of ADSs reserved for future issuances upon the exercising or vesting of awards granted under our
share incentive plans). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We intend to use our reasonable efforts to keep the Registration Statement effective for a period of 90 days
after the effectiveness of the Registration Statement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Beneficial ownership is determined in accordance with the rules and regulations of
the SEC. In computing the number of shares beneficially owned by a person and the percentage ownership of that person, we have included shares that the person has the right to acquire within 60 days, including through the exercise of any
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-50 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
option, warrant or other right or the conversion of any other security. These shares, however, are not included in the computation of the percentage ownership of any other person. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="58%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Ordinary Shares</B><br><B>Beneficially Owned</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Ordinary Shares</B><br><B>Being Registered</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Number</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>%</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Number</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>%</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Directors and Executive Officers**:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">All Directors and Executive Officers as a Group</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">47,059,711</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26.5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Wei Fu<SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">31,043,576</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18.8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jingwu Zhang Zang<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,069,136</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Joan Huaqiong Shen</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,921,497</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Zheru Zhang</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,963,257</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jielun Zhu</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Mengjiao Jiang</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jie Yu</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Bing Yuan</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Chun Kwok Alan Au</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Conor Chia-hung Yang</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pamela M. Klein</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weimin Tang</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Yunhan Lin</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Neil Warma</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ivan Yifei Zhu</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gigi Qi Feng</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Principal and Selling Shareholders:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">C-Bridge</FONT> entities<SUP
STYLE="font-size:85%; vertical-align:top">(2) </SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">31,043,576</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18.8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Hillhouse entities<SUP STYLE="font-size:85%; vertical-align:top">(3) </SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,492,602</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13.2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,143,961</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Tasly entities<SUP STYLE="font-size:85%; vertical-align:top">(4)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,664,020</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">GIC Private Limited<SUP STYLE="font-size:85%; vertical-align:top">(5)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,099,770</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,773,253</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Genexine<SUP STYLE="font-size:85%; vertical-align:top">(6)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,572,823</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Hony entity<SUP STYLE="font-size:85%; vertical-align:top">(7)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,465,631</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Avidity entities<SUP STYLE="font-size:85%; vertical-align:top">(8)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,092,833</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,092,833</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Temasek entity<SUP STYLE="font-size:85%; vertical-align:top">(9)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,649,537</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,649,537</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">OrbiMed entities<SUP STYLE="font-size:85%; vertical-align:top">(10)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,649,537</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,649,537</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Octagon Investments Master Fund
LP<SUP STYLE="font-size:85%; vertical-align:top">(11)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,237,147</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,237,147</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Invus Public Equities, L.P.<SUP STYLE="font-size:85%; vertical-align:top">(12)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,072,191</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,072,191</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Lake Bleu Prime Healthcare Master Fund Limited
<SUP STYLE="font-size:85%; vertical-align:top">(13)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">824,780</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">824,780</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Perceptive Life Sciences Master Fund,
Ltd.<SUP STYLE="font-size:85%; vertical-align:top">(14)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">742,279</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">742,279</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cormorant Global Healthcare Master Fund,
LP<SUP STYLE="font-size:85%; vertical-align:top">(15)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">618,585</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">618,585</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sphera entities<SUP STYLE="font-size:85%; vertical-align:top">(16)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">494,868</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">494,868</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Alyeska entities<SUP STYLE="font-size:85%; vertical-align:top">(17)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">412,390</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">412,390</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">CVI Investments, Inc.<SUP STYLE="font-size:85%; vertical-align:top">(18)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">412,390</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">412,390</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Notes: </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Less than 1% of our total ordinary shares on an <FONT STYLE="white-space:nowrap">as-converted</FONT> basis
outstanding as of the date of this prospectus supplement. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">**</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Except as otherwise indicated below, the business address of our directors and executive officers is
Suite&nbsp;802, West Tower, OmniVision, 88 Shangke Road, Pudong District, Shanghai, China. The business address of Wei Fu and Mengjiao Jiang is Suite 3306-3307, Two Exchange Square, 8 Connaught Place, Central, Hong Kong. The business address of Jie
Yu is Tasly Great Health Town, No.&nbsp;2, East Puji River Road, Beichen District, Tianjin, China. The business address of Bing Yuan is Flat B, 31/F BLK 2, The </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-51 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
Hermitage, Mongkok, Hong Kong. The business address of Chun Kwok Alan Au is 22 Pottinger Street, Central, Hong Kong. The business address of Conor Chia-hung Yang is 7th Floor, Building C, Luneng
International Center, No.&nbsp;209 Guoyao Road, Pudong New Area, Shanghai, China. The business address of Dr.&nbsp;Pamela&nbsp;M. Klein is 231 Fort Mason, San Francisco, California 94123, the United States. </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Represents (i) 3,817,113 ordinary shares directly held by Mabcore Limited, a British Virgin Islands company and
(ii) 7,252,023 ordinary shares issuable upon exercise of options exercisable within 60 days after the date of this prospectus supplement held by Dr.&nbsp;Zang through Doctor Zang 2020 Dynasty Trust. Dr.&nbsp;Zang, through himself and The Jingwu
Zhang Zang 2018 Irrevocable Family Trust, owns a 55.6% equity interest in Mabcore Limited. Dr.&nbsp;Lili Qian and two other individuals own the remaining equity interest in Mabcore Limited. Dr.&nbsp;Zang is the sole director of Mabcore Limited. The
Jingwu Zhang Zang 2018 Irrevocable Family Trust was established under the laws of New York and is managed by Ms.&nbsp;Ying Qin Zang, as the trustee and Dr.&nbsp;Zang as the settlor. The Doctor Zang 2020 Dynasty Trust was established under the laws
of the State of California and is managed by Dr.&nbsp;Zang as the settlor and investment trustee and Ms.&nbsp;Ying Qin Zang as the trustee. Pursuant to the currently effective memorandum and articles of association of Mabcore Limited, Dr.&nbsp;Zang,
as the sole director, has the power to direct the actions of Mabcore Limited, including the voting and disposal of Mabcore Limited&#146;s shares in <FONT STYLE="white-space:nowrap">I-Mab.</FONT> Accordingly, Dr.&nbsp;Zang is deemed to indirectly own
all of the 3,817,113 ordinary shares held by Mabcore Limited, while Dr.&nbsp;Qian and the other two individuals are only entitled to their respective <FONT STYLE="white-space:nowrap">pro-rata</FONT> economic interest in Mabcore Limited. The
registered address of Mabcore Limited is Trinity Chambers, P.O. Box 4301, Road Town, Tortola, British Virgin Islands. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Represents (i) 3,931,802 ordinary shares directly held by IBC Investment Seven Limited, a Hong Kong limited
liability company, (ii) 5,574,560 ordinary shares directly held by CBC SPVII LIMITED, a Hong Kong limited liability company, (iii) 12,229,916 ordinary shares directly held by CBC Investment <FONT STYLE="white-space:nowrap">I-Mab</FONT> Limited, a
British Virgin Islands limited liability company, (iv) 2,369,546 ordinary shares directly held by <FONT STYLE="white-space:nowrap">C-Bridge</FONT> II Investment Ten Limited, a British Virgin Islands limited liability company, (v) 6,078,571 ordinary
shares directly held by Everest, and (vi) 373,557ADSs (representing 859,181 ordinary shares) held by <FONT STYLE="white-space:nowrap">C-Bridge</FONT> II Investment Thirteen Limited, a British Virgin Islands limited liability company. IBC Investment
Seven Limited, CBC SPVII LIMITED, CBC Investment <FONT STYLE="white-space:nowrap">I-Mab</FONT> Limited, <FONT STYLE="white-space:nowrap">C-Bridge</FONT> II Investment Ten Limited, Everest, and <FONT STYLE="white-space:nowrap">C-Bridge</FONT> II
Investment Thirteen Limited are collectively referred to as the <FONT STYLE="white-space:nowrap">C-Bridge</FONT> entities. CBC Investment <FONT STYLE="white-space:nowrap">I-Mab</FONT> Limited, <FONT STYLE="white-space:nowrap">C-Bridge</FONT> II
Investment Ten Limited and <FONT STYLE="white-space:nowrap">C-Bridge</FONT> II Investment Thirteen Limited are controlled by <FONT STYLE="white-space:nowrap">C-Bridge</FONT> Healthcare Fund II, L.P., whose general partner is <FONT
STYLE="white-space:nowrap">C-Bridge</FONT> Healthcare Fund GP II, L.P., and its general partner is <FONT STYLE="white-space:nowrap">C-Bridge</FONT> Capital GP, Ltd. CBC SPVII Limited and IBC Investment Seven Limited are controlled by <FONT
STYLE="white-space:nowrap">I-Bridge</FONT> Healthcare Fund, L.P., whose general partner is <FONT STYLE="white-space:nowrap">I-Bridge</FONT> Healthcare GP, L.P., and its general partner is <FONT STYLE="white-space:nowrap">I-Bridge</FONT> Capital GP,
Ltd., which is indirectly controlled by <FONT STYLE="white-space:nowrap">C-Bridge</FONT> Capital GP, Ltd. Mr.&nbsp;Wei Fu is the sole director of <FONT STYLE="white-space:nowrap">C-Bridge</FONT> Capital GP, Ltd. Everest is a public company listed on
the Hong Kong Stock Exchange and controlled by funds which are under common control of the <FONT STYLE="white-space:nowrap">C-Bridge</FONT> group, which, in turn, is controlled by Mr.&nbsp;Wei Fu. The business address of each of <FONT
STYLE="white-space:nowrap">C-Bridge</FONT> entities is Suite 3306-3307, Two Exchange Square, 8 Connaught Place, Central, Hong Kong.<B><I> </I></B> </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Represents (i) 9,614,299 ordinary shares and 2,187,280 ADSs (representing 5,030,744 ordinary shares), 1,229,741
ordinary shares issuable upon exercise of call options and 2,459,482 ordinary shares issuable upon exercise of warrants directly held by Gaoling Fund, L.P., or Gaoling, an exempted limited partnership organized under the laws of the Cayman Islands,
(ii) 375,631 ordinary shares and 85,450 ADSs (representing 196,535 ordinary shares), 48,047 ordinary shares issuable upon exercise of call options and 96,094 ordinary shares issuable upon exercise of warrants directly held by YHG Investment, L.P.,
or YHG, an exempted limited partnership organized under the laws of the Cayman Islands, and (iii) 5 ordinary shares and 1,496,540 ADSs (representing 3,442,042 ordinary shares) directly held by HH IMB Holdings Limited, or HH IMB, an exempted Cayman
Islands company. Hillhouse Capital Advisors, Ltd., or HCA, an exempted Cayman Islands company, acts as sole management company of Gaoling and the sole general </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-52 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
partner of YHG, and is deemed to be the beneficial owner of, and to control the voting power of, the ordinary shares held by Gaoling and YHG. HH IMB is wholly owned by Hillhouse Fund IV, L.P.,
whose sole management company is Hillhouse Capital Management, Ltd., or HCM. HCM is deemed to be the beneficial owner of, and to control the voting power of, the ordinary shares held by HH IMB. HCA and HCM are under common control and share certain
policies, personnel and resources. Accordingly, each of HCA and HCM has shared voting and dispositive power of the ordinary shares beneficially owned by each of HCA and HCM. The business address of each of Gaoling, YHG and HH IMB is Suite 2202, 22nd
Floor, Two International Finance Centre, 8 Finance Street, Central Hong Kong. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Represents (i) 12,942,997 ordinary shares directly held by Tasly Biopharm Limited, a British Virgin Islands
limited liability company, and (ii) 1,721,023 ordinary shares directly held by Tasly International BioInv One Limited. Tasly Biopharm Limited and Tasly International BioInv One Limited are collectively referred to as the Tasly entities. Tasly
Biopharm Limited&#146;s sole shareholder is Tasly Biopharmaceuticals Co., Ltd., which is controlled by Tasly Pharmaceutical Group Co., Ltd., which is in turn controlled by Tasly Holding Group Co., Ltd. Tasly International BioInv One Limited is
wholly-owned by Tasly International Capital Limited, whose sole shareholder is Tasly Holding Group Co., Ltd. Tasly Holding Group Co., Ltd. is controlled by Tianjin Tasly Health Industry Investment Group Co., Ltd., which is in turn controlled by
Tianjin Fuhuade Science&nbsp;&amp; Technology Development Co., Ltd. Kaijing Yan is the controlling shareholder of Tianjin Fuhuade Science&nbsp;&amp; Technology Development Co., Ltd. and the ultimate beneficial owner of Tasly entities. The registered
address of Tasly Biopharm Limited is P.O. Box 957, Offshore Incorporation Centre, Road Town, Tortola, British Virgin Islands. The registered address of Tasly International BioInv One Limited is 4th Floor, Harbour Place, 103 South Church Street, P.O.
Box 10240, Grand Cayman <FONT STYLE="white-space:nowrap">KY1-1002,</FONT> Cayman Islands. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Represents 8,677,996 ordinary shares, 1,098,838 ADSs (representing 2,527,327 ordinary shares) and 894,447
ordinary shares issuable upon exercise of warrants held by GIC Private Limited, a Singapore fund manager. GIC Private Limited only has two clients: the Government of Singapore, or GoS, and the Monetary Authority of Singapore, or MAS. Under the
investment management agreement with GoS, GIC Private Limited has been given the sole discretion to exercise the voting rights attached to, and the disposition of, any shares managed on behalf of GoS. As such, GIC Private Limited has the sole power
to vote and dispose of securities beneficially owned by it. GIC Private Limited shares the power to vote and dispose of securities beneficially owned by it with MAS. The business address of GIC Private Limited is 168 Robinson Road, <FONT
STYLE="white-space:nowrap">#37-01</FONT> Capital Tower, Singapore 068912. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(6)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Represents (i) 9,261,823 ordinary shares directly held by Genexine, Inc. (Genexine), and (ii) 570,000 ADSs
(representing 1,311,000 ordinary shares) purchased by Genexine. Genexine is a Korean public company. The registered address of Genexine is 4th Fl., Bldg. B, Korea Bio Park, 700 Daewangpangyo-ro, Seongnam-si, Gyeonggi-do 13488, Republic of Korea.
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(7)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Represents 9,465,631 ordinary shares directly held by Fortune Eight Jogging Limited, a British Virgin Islands
limited liability company, which we refer to as the Hony entity. Fortune Eight Jogging Limited is wholly-owned by Hony Hongling (Shanghai) Investment Center, a PRC limited partnership, whose general partner is Hony Investment (Shanghai) Limited. The
sole shareholder of Hony Investment (Shanghai) Limited is Beijing Hony Hezhong Enterprise Management Limited. Each of Yonggang Cao, Minsheng Xu and Wen Zhao holds 33.3% equity interests in Beijing Hony Hezhong Enterprise Management Limited. The
registered address of Fortune Eight Jogging Limited is Kingston Chambers, PO Box 173, Road Town, Tortola, British Virgin Islands. Mr.&nbsp;Bing Yuan, our director, is a managing director of the sole director of the Hony entity.
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(8)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Represents (i) 1,018,190 ADSs (representing 2,341,837 ordinary shares) and 429,364 ordinary shares issuable
upon exercise of warrants directly held by Avidity Master Fund LP, or Avidity Master, a Delaware limited partnership, and (ii)&nbsp;118,180 ADSs (representing 271,814 ordinary shares) and 49,818 ordinary shares issuable upon exercise of warrants
directly held by Avidity Capital Fund II LP, or Avidity Capital, a </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-53 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
Delaware limited partnership. Avidity Master and Avidity Capital are collectively referred to as the Avidity entities. The general partner of each of the Avidity entities is Avidity Capital
Partners Fund (GP) LP, a Delaware limited partnership, whose general partner is Avidity Capital Partners (GP) LLC, a Delaware limited liability company. David Witzke and Michael Gregory are the managing members of Avidity Capital Partners (GP) LLC.
The address of David Witzke and Michael Gregory&#146;s principal office is 2828 N Harwood Street, Suite 1220, Dallas, Texas 75201. The registered address of each of Avidity entities is 2828 N. Harwood St., Suite 1220, Dallas, TX 75201.
</TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(9)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Represents 1,393,961 ordinary shares and 255,576 ordinary shares issuable upon exercise of warrants directly
held by ARANDA INVESTMENTS PTE. LTD., a company incorporated under the laws of Singapore. ARANDA INVESTMENTS PTE. LTD. is an indirect wholly-owned subsidiary of Temasek Holdings (Private) Limited. The registered address of ARANDA INVESTMENTS PTE.
LTD. is 60B Orchard Road, <FONT STYLE="white-space:nowrap">#06-18</FONT> Tower 2, The Atrium@Orchard, Singapore 238891. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(10)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Represents (i) 303,040 ADSs (representing 696,992 ordinary shares) and 127,788 ordinary shares issuable upon
exercise of warrants directly held by OrbiMed Partners Master Fund Limited, or OPM, an exempted company organized under the laws of Bermuda, (ii) 166,670 ADSs (representing 383,341 ordinary shares) and 70,288 ordinary shares issuable upon exercise
of warrants directly held by The Biotech Growth Trust PLC, or BIOG, a publicly-listed investment trust organized under the laws of England, (iii) 75,760 ADSs (representing 174,248 ordinary shares) and 31,947 ordinary shares issuable upon exercise of
warrants directly held by OrbiMed Genesis Master Fund, L.P., or OrbiMed Genesis, an exempted limited partnership organized under the laws of the Cayman Islands, and (iv) 60,600 ADSs (representing 139,380 ordinary shares) and 25,553 ordinary shares
issuable upon exercise of warrants directly held by OrbiMed New Horizons Master Fund, L.P., or ONH, an exempted limited partnership organized under the laws of the Cayman Islands. OPM, BIOG, OrbiMed Genesis and ONH are collectively referred to as
the OrbiMed Entities. OrbiMed Capital LLC, or OrbiMed Capital, is the portfolio manager of BIOG and the investment advisor to OPM. OrbiMed Advisors LLC, or OrbiMed Advisors, is the investment manager of OrbiMed Genesis and ONH. OrbiMed Capital and
OrbiMed Advisors exercise voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and Jonathan T. Silverstein, each of whom disclaims beneficial ownership of the shares held by OPM, BIOG, OrbiMed
Genesis, and ONH. The business address of each of OrbiMed Entities is c/o OrbiMed Advisors LLC, 601 Lexington Avenue, 54th Floor, New York, NY 10022. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(11)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Represents 454,550 ADSs (representing 1,045,465 ordinary shares) and 191,682 ordinary shares issuable upon
exercise of warrants directly held by Octagon Investments Master Fund LP, or Octagon, an exempted limited partnership organized under the laws of the Cayman Islands. Octagon&#146;s shareholders are comprised of global institutions such as university
endowments, <FONT STYLE="white-space:nowrap">non-profit</FONT> foundations, family offices, pension funds and established asset managers. The registered address of Octagon Investments Master Fund LP is at c/o Ogier, 89 Nexus Way, Camana Bay, Grand
Cayman, Cayman Islands <FONT STYLE="white-space:nowrap">KY1-9009.</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(12)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Represents 906,062 ordinary shares and 166,129 ordinary shares issuable upon exercise of warrants directly held
by Invus Public Equities, L.P., a Bermuda limited partnership. Invus is a investment firm with source of capital from a European family group. The registered address of Invus Public Equities, L.P. is Clarendon House, 2 Church Street, Hamilton HM 11,
Bermuda. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(13)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Represents 303,040 ADSs (representing 696,992 ordinary shares) and 127,788 ordinary shares issuable upon
exercise of warrants directly held by Lake Bleu Prime Healthcare Master Fund Limited, or Lake Bleu Prime, an exempted limited partnership organized under the laws of the Cayman Islands. LBC Prime Management Limited is the ultimate controlling
shareholder of Lake Bleu Prime. The registered address of Lake Bleu Prime Healthcare Master Fund Limited is Cayman Corporate Centre, 27 Hospital Road, George Town, Grand Cayman <FONT STYLE="white-space:nowrap">KY1-9008,</FONT> Cayman Islands.
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(14)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Represents 627,279 ordinary shares and 115,000 ordinary shares issuable upon exercise of warrants directly held
by Perceptive Life Sciences Master Fund, Ltd., a Cayman Islands limited liability company. The </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-54 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
registered address of Perceptive Life Sciences Master Fund, Ltd. is 190 Elgin Avenue, George Town, Grand Cayman, <FONT STYLE="white-space:nowrap">KY1-9007,</FONT> Cayman Islands.
</TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(15)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Represents 522,744 ordinary shares and 95,841 ordinary shares issuable upon exercise of warrants directly held
by Cormorant Global Healthcare Master Fund, LP, or Cormorant Global, an exempted limited partnership organized under the laws of the Cayman Islands. Cormorant Global is a long-term investment partnership whose beneficial owners include institutional
and other sophisticated investors. The registered address of Cormorant Global Healthcare Master Fund, LP is PO Box 309, Ugland House, Grand Cayman, KY14104, Cayman Islands. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(16)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Represents (i) 136,370 ADSs (representing 313,651 ordinary shares) and 57,500 ordinary shares issuable upon
exercise of warrants directly held by Sphera Global Healthcare Master Fund, or Sphera Global, a Cayman Islands limited liability company, and (ii) 45,450 ADSs (representing 104,535 ordinary shares) and 19,182 ordinary shares issuable upon exercise
of warrants directly held by Sphera Biotech Master Fund L.P., or Sphera Biotech, an exempted limited partnership organized under the laws of the Cayman Islands. Sphera Global and Sphera Biotech are collectively referred to as the Sphera entities.
Both Sphera Global and Sphera Biotech appointed Sphera Global Healthcare Management LP or Sphera Management, as their investment manager. Sphera Management also serves as Sphera Biotech&#146;s general partner, and has
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">day-to-day</FONT></FONT> investment discretion for the Sphera entities. The registered address of each of Sphera entities is at c/o Maples Corporate Services Limited, P.O. Box 309,
Ugland House, Grand Cayman, <FONT STYLE="white-space:nowrap">KY1-1104,</FONT> Cayman Islands. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(17)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Represents (i) 150,310 ADSs (representing 345,713 ordinary shares) and 63,388 ordinary shares issuable upon
exercise of warrants directly held by Alyeska Master Fund, L.P., an exempted limited partnership organized under the laws of the Cayman Islands, and (ii) 1,210 ADSs (representing 2,783 ordinary shares) and 506 ordinary shares issuable upon exercise
of warrants directly held by Alyeska Master Fund 3, L.P., a Delaware limited partnership. Alyeska Master Fund, L.P. and Alyeska Master Fund 3, L.P. are collectively referred to as the Alyeska entities. Alyeska entities are controlled by Alyeska
Investment Group, L.P., a limited partnership incorporated in the United States, whose chief executive officer is Anand Parekh. Mr.&nbsp;Parekh, however, disclaims any beneficial ownership of the shares held by Alyeska entities. The registered
address of Alyeska Master Fund, L.P. is at c/o Maples Corporate Services Limited, P.O. Box 309, Ugland House, South Church Street George Town, Grand Cayman, <FONT STYLE="white-space:nowrap">KY1-1104,</FONT> Cayman Islands. The registered address of
Alyeska Master Fund 3, L.P. is 251 Little Falls Drive, Wilmington, DE 19808. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(18)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Represents 151,520 ADSs (representing 348,496 ordinary shares) and 63,894 ordinary shares issuable upon
exercise of warrants directly held by CVI Investments, Inc., or CVI, a Cayman Islands limited liability company. Heights Capital Management, Inc., the authorized agent of CVI, has discretionary authority to vote and dispose of the shares held by CVI
and may be deemed to be the beneficial owner of these shares. Martin Kobinger, in his capacity as Investment Manager of Heights Capital Management, Inc., may also be deemed to have investment discretion and voting power over the shares held by CVI.
Mr.&nbsp;Kobinger disclaims any such beneficial ownership of the shares. CVI is affiliated with one or more FINRA members. CVI purchased the shares being registered hereunder in the ordinary course of business and at the time of purchase, had no
agreements or understandings, directly or indirectly, with any other person to distribute such shares. The registered address of CVI Investments, Inc. is at c/o Maples Corporate Services Limited, PO Box 309, Ugland House, Grand Cayman, KY <FONT
STYLE="white-space:nowrap">l-1104,</FONT> Cayman Islands. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">As of the date of this prospectus supplement, 53,600,672 of
our ordinary shares are held by one record holder in the United States (including 4,036,868 ordinary shares issued to our depositary bank for bulk issuance of ADSs reserved for future issuances upon the exercising or vesting of awards granted under
our share incentive plans), representing approximately 36.9% of our total outstanding shares. The holder is Citibank, N.A., the depositary of our ADS program. The number of beneficial owners of our ADSs in the United States is likely to be much
larger than the number of record holders of our ordinary shares in the United States. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-55 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">On February 5, 2021, we announced a registered follow-on public offering (the &#147;ADS
Offering&#148;) by certain shareholders identified therein of 3,283,950 ADSs. The underwriters in the ADS Offering will have a <FONT STYLE="white-space:nowrap">30-day</FONT> option to purchase up to 492,590 additional ADSs from certain selling
shareholders identified therein. We will not receive any proceeds from the sale of the ADSs by those selling shareholders in the ADS Offering. The ADS Offering is being made only by means of a prospectus supplement and the accompanying prospectus
included in an automatic shelf registration statement on Form F-3 filed with the SEC on February&nbsp;5, 2021, which automatically became effective upon filing. The registration statement on Form F-3 and the preliminary prospectus supplement dated
February 5, 2021 are available at the SEC website at: http://www.sec.gov. The final prospectus supplement will be filed with the SEC and will be available on the SEC&#146;s website at: http://www.sec.gov. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Upon the completion of the ADS Offering and assuming the underwriters do not exercise their over-allotment option, (i) the beneficial
ownership of the Tasly entities in our company is expected to decrease from 8.9% to 8.3%; (ii) the beneficial ownership of Genexine in our company is expected to decrease from 6.4% to 6.0% and (iii) the beneficial ownership of the Hony entity in our
company is expected to decrease from 5.7% to 5.2%. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We are not aware of any arrangement that may, at a subsequent date, result in a change
of control of our company. See &#147;Description of Share Capital&#151;History of Securities Issuances&#148; for historical changes in our shareholding structure. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-56 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="stoc98473_12"></A>DESCRIPTION OF SHARE CAPITAL </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I>The following section sets forth certain information in the section titled &#147;Description of Share Capital&#148; of the accompanying
prospectus that has been updated and/or supplemented to reflect changes since the effectiveness of the accompanying prospectus. </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">As of
the date of this prospectus supplement, our authorized share capital is US$80,000 divided into 800,000,000 ordinary shares of a par value of US$0.0001 each. As of the date of this prospectus supplement, there are 165,477,620 ordinary shares issued
and outstanding (excluding 4,036,868 ordinary shares issued to our depositary bank for bulk issuance of ADSs reserved for future issuances upon the exercising or vesting of awards granted under our share incentive plans). </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>History of Securities Issuances </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Ordinary Shares
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In September 2020, we entered into definitive subscription agreements (collectively, the &#147;Subscription Agreements,&#148; and
each, a &#147;Subscription Agreement&#148;) with a consortium of institutional investors (including Hillhouse Entities), pursuant to which we agree to issue and sell to these investors (i)&nbsp;a total of 29,133,502 ordinary shares of our company
for an aggregate purchase price of approximately US$418&nbsp;million (equivalent to a price of US$33 per ADS); and (ii)&nbsp;warrants (the &#147;Investor Warrants&#148;) to subscribe for up to 5,341,267 ordinary shares of our company at an exercise
price of US$45 per ADS, subject to the closing conditions set forth in the Subscription Agreements. Each ten ADSs of our company represents twenty-three ordinary shares of our company. On September&nbsp;11, 2020 and December 17, 2020, we issued
20,421,378 ordinary shares and 8,712,124 ordinary shares, respectively, to these investors, pursuant to the Subscription Agreements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The
Subscription Agreement with the Hillhouse Entities contemplates two closings. The first closing occurred on September&nbsp;11, 2020, and the second closing occurred on December 17, 2020. The closings of the Subscription Agreements with investors
other than the Hillhouse Entities have occurred in September 2020. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">On December 17, 2020, we issued 900,000 ordinary shares to Genexine,
Inc. as a result of its full conversion of interest-free convertible promissory notes issued to it on February 5, 2018. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">On December 31,
2020, we issued 115,000 ordinary shares to Biomaster Holding Limited upon exercise of options granted to certain of our employees for an aggregate exercise price of US$115,000. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Convertible Promissory Notes </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">On
February&nbsp;5, 2018, we issued a US$9.0&nbsp;million convertible promissory note due February 2021 to Genexine. Genexine can at any time prior to February&nbsp;5, 2021 convert this note into preferred shares of
<FONT STYLE="white-space:nowrap">I-Mab</FONT> at US$10 per share, subject to certain price adjustments. On December 17, 2020, Genexine converted this note to 900,000 ordinary shares. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Options and Warrants </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Pursuant to
the Subscription Agreements, we agree to issue and sell to the investors thereunder the Investor Warrants, exercisable at the election of the applicable investors within 12 months after the initial or subsequent closing dates set forth in the
applicable Subscription Agreements. On September&nbsp;11, 2020 and December&nbsp;17, 2020, we issued and sold a portion of the Investor Warrants, allowing the applicable investors to purchase 3,744,032 ordinary shares and 1,597,235 ordinary shares,
respectively. As of the date of this Prospectus supplement, none of the Investor Warrants has been exercised. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-57 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Subscription Agreement with Hillhouse Entities </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In September 2020, we entered into a Subscription Agreement with the Hillhouse Entities, as amended by an amendment to Subscription Agreement
entered into between Hillhouse Entities and our company in December 2020. The Subscription Agreement, as amended, provides for (i)&nbsp;certain investors&#146; rights, such as registration rights, board representation rights and anti-dilution rights
and <FONT STYLE="white-space:nowrap">(ii)&nbsp;lock-up</FONT> and other transfer restrictions. Set forth below is a description of certain rights and restrictions thereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I>Mandatory Registration after Initial Closing (September 11, 2020)</I>. We agree to file with the SEC a registration statement to register
the resale of Hillhouse Entities&#146; registrable securities, which include ordinary shares issued and issuable upon exercise of Investor Warrants under the Subscription Agreement, on Form <FONT STYLE="white-space:nowrap">F-3</FONT> or Form <FONT
STYLE="white-space:nowrap">F-1,</FONT> as applicable. We shall have the relevant registration statement declared effective by the SEC no later than ninety (90)&nbsp;calendar days after September&nbsp;11, 2020, which period could be extended to one
hundred and twenty (120)&nbsp;calendar days if the SEC reviews and comments on the registration statement. However, if the SEC prevents inclusion of the registrable securities in the registration statement pursuant to limitations under Rule 415 of
the Securities Act, the number of registrable securities to be registered for each selling shareholder named in the registration statement shall be reduced pro rata among all such selling shareholders. We shall maintain the continuous effectiveness
of the registration statement for a period of ninety (90)&nbsp;days after its effectiveness or such shorter period upon which the Hillhouse Entities have notified us that their registrable securities have actually been sold. We have fulfilled this
obligation. On December 14, 2020, the SEC declared effective a registration statement on Form F-1, under which the selling shareholders identified therein (including the Hillhouse Entities) may offer, from time to time, up to 25,123,751 ordinary
shares, including ordinary shares represented by ADSs of our company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I>Mandatory Registration after Subsequent Closing</I> <I>(December
17, 2020)</I>. With respect to the registrable securities then held by the Hillhouse Entities which have not been previously registered pursuant to an effective registration statement, we agree to file a prospectus supplement or a registration
statement to register the resale of such registrable securities on a Form <FONT STYLE="white-space:nowrap">F-3</FONT> or Form F-3ASR registration statement (or, if Form F-3 or Form F-3ASR is not then available to us, on Form F-1 or such other form
of registration statement as is then available to effect a registration for resale of such registrable securities), and have such registration statement declared effective by the SEC no later than (a)&nbsp;the ten (10)&nbsp;business days after the
later of (i)&nbsp;the first date when we become eligible to use registration statement on <FONT STYLE="white-space:nowrap">F-3,</FONT> or (ii)&nbsp;the expiration of the <FONT STYLE="white-space:nowrap">lock-up</FONT> period with respect to the
subsequent closing, or forty-five (45)&nbsp;calendar days after such <FONT STYLE="white-space:nowrap">lock-up</FONT> period expiration date if the SEC reviews and comments on the registration statement. We shall maintain the effectiveness of such
registration statement for a period ending on the date the registrable securities registered thereon have ceased to be registrable securities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I>Demand Registration Rights</I>. Upon written request from the Hillhouse Entities at any time after we have effected two registration
statements abovementioned, with respect to the registrable securities then held by the Hillhouse Entities, and in no event later than the forty-five (45)&nbsp;calendar days following the delivery of such request, we shall file a prospectus
supplement or a registration statement to register the resale of such registrable securities on a Form <FONT STYLE="white-space:nowrap">F-3</FONT> or Form F-3ASR registration statement (or, if Form F-3 or Form F-3ASR is not then available to us, on
Form F-1 or such other form of registration statement as is then available to effect a registration for resale of such registrable securities), have such registration statement declared effective, and maintain the effectiveness of such registration
statement for a period ending on the date the registrable securities registered thereon have ceased to be registrable securities. If the registrable securities are offered by means of an underwritten offering, and we or the underwriters determine
that marketing factors require a limitation of the number of securities to be underwritten, the number of registrable securities that may be included in the underwriting shall be reduced and allocated (i)&nbsp;first, to us and each holder in
accordance with the terms of the Shareholders Agreement; (ii)&nbsp;second, to investors in the private placements entered into in September 2020 (including the Hillhouse Entities) requesting inclusion of their registrable securities in such
registration statement on a pro rata basis based on the total number of registrable securities then held by each such investor; and (iii)&nbsp;third, to other holders of registrable securities, if any. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-58 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I>Expenses</I>. We will bear all registration expenses, except any (i)&nbsp;portions of
fees and disbursements of counsel for the Hillhouse Entities exceeding US$30,000, (ii) underwriting discounts and selling commissions applicable to sale of registrable securities, and (iii)&nbsp;fees payable pursuant to the deposit agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I>Ranking of Registration Rights</I>. Registration rights granted to the Hillhouse Entities shall not be senior to, or on a parity with,
those granted to holders under the Shareholders Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I>Board Representation Rights</I>. As long as the Hillhouse Entities continue
to jointly beneficially own at least five percent (5.0%) of our total issued and outstanding share capital, it is entitled to nominate and maintain one representative to our board of directors. We shall cause an individual jointly designated by the
Hillhouse Entities to be appointed as the investor director with immediate effect no later than the fifteenth (15<SUP STYLE="font-size:85%; vertical-align:top">th</SUP>) business day after receiving written notice from the Hillhouse Entities or such
later date on which we receive necessary shareholder approval. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I><FONT STYLE="white-space:nowrap">Lock-up</FONT></I>. The Hillhouse
Entities shall not dispose of any of the ordinary shares purchased by Hillhouse Entities on September 11, 2020 or December 17, 2020 within a 90-day period following September 11, 2020 or December 17, 2020, as applicable, to any person other than
affiliates of the Hillhouse Entities, who shall be bound by the Hillhouse Entities&#146; lock-up obligations for the balance of each applicable lock-up period. Each of the Hillhouse Entities and their affiliates may directly or indirectly, place any
charge, mortgage, lien, pledge, restrictions, security interest or other encumbrance in respect of the lock-up securities in connection with such Hillhouse Entity&#146;s (or any of its affiliates&#146;) margin loans, collars, derivative transactions
or other such downside protection transactions to be entered into on or after the date of the subscription agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I>Anti-dilution
rights</I>. We agree not to issue, offer, sell, or grant any option or right to purchase any new securities, without the prior written consent of the Hillhouse Entities, (i)&nbsp;during the <FONT STYLE="white-space:nowrap">90-day</FONT> period
following each closing date; or (ii)&nbsp;at an effective purchase price per share lower than the purchase price under the Subscription Agreement with Hillhouse Entities during the <FONT STYLE="white-space:nowrap">90-day</FONT> period commencing
from the expiration of each <FONT STYLE="white-space:nowrap">lock-up</FONT> period. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Subscription Agreements with Other Investors </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In September 2020, we entered into subscription agreements with various investors other than HillHouse Entities. The subscription agreements
are of the same form and provide for certain investors&#146; rights, such as registration rights and anti-dilution right. Set forth below is a description of certain rights and restrictions thereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I>Mandatory Registration</I>. We agree to file with the SEC a registration statement to register the resale of such investors&#146;
registrable securities, which include ordinary shares issued and issuable upon exercise of Investor Warrants under the Subscription Agreement, on Form <FONT STYLE="white-space:nowrap">F-3</FONT> or Form <FONT STYLE="white-space:nowrap">F-1,</FONT>
as applicable. We shall have the relevant registration statement declared effective by the SEC no later than ninety (90)&nbsp;calendar days after the initial closing date, which period could be extended to one hundred and twenty (120)&nbsp;calendar
days if the SEC reviews and comments on the registration statement. However, if the SEC prevents inclusion of the registrable securities in the registration statement pursuant to limitations under Rule 415 of the Securities Act, the number of
registrable securities to be registered for each selling shareholder named in the registration statement shall be reduced pro rata among all such selling shareholders. We shall maintain the continuous effectiveness of the registration statement for
a period of ninety (90)&nbsp;days after its effectiveness or such shorter period upon which such investors have notified us that their registrable securities have actually been sold. We have fulfilled this obligation. On December 14, 2020, the SEC
declared effective a registration statement on Form F-1, under which the selling shareholders identified therein (including these investors) may offer, from time to time, up to 25,123,751 ordinary shares, including ordinary shares represented by
ADSs of our company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I>Piggyback Registration</I>. We agree to notify such investors at least thirty (30)&nbsp;days prior to filing any
registration statement for purposes of effecting a public offering of ADSs (excluding registration statements </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-59 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
relating to the mandatory registration described above). The Private Placement Investors has 20 days after receiving notice from us to notify us in writing of their desire to include their
registrable securities in the registration statement. However, if the registrable securities in such registration statement are offered by means of an underwritten offering, and we or the underwriters determine that marketing factors require a
limitation of the number of securities to be underwritten, the number of registrable securities that may be included in the underwriting shall be reduced and allocated (i)&nbsp;first, to us and each holder in accordance with the terms of the
Shareholders Agreement; (ii)&nbsp;second, to investors in the private placements entered into in September 2020 requesting inclusion of their registrable securities in such registration statement on a pro rata basis based on the total number of
registrable securities then held by each such investor; and (iii)&nbsp;third, to other holders of registrable securities, if any. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I>Suspension of Registration</I>. We may suspend the use of any registration statement for a period not exceeding thirty
(30)&nbsp;consecutive trading days, if we (i)&nbsp;determine that we would be required to make disclosure of material information in the registration statement that we have a bona fide business purpose for preserving as confidential;
(ii)&nbsp;determine that we must amend or supplement the registration statement so that it shall not include an untrue statement of a material fact or omit to state a material fact; or (iii)&nbsp;have experienced or are experiencing some other
material <FONT STYLE="white-space:nowrap">non-public</FONT> event, the disclosure of which at such time would adversely affect us. However, we cannot exercise the suspension right more than once in any twelve (12)&nbsp;month period and may not
register any other securities during such suspension period. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I>Expenses</I>. We will bear all registration expenses, except any
(i)&nbsp;portions of fees and disbursements of counsel for such investors, and (ii)&nbsp;underwriting discounts and selling commissions applicable to sale of registrable securities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I>Ranking of Registration Rights</I>. Registration rights granted to such investors shall not be senior to, or on a parity with, those
granted to holders under the Shareholders Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-60 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="stoc98473_13"></A>INDEX TO CONSOLIDATED FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Unaudited Interim Condensed Consolidated Financial Statements for the Nine Months Ended September&nbsp;30, 2019 and 2020 </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="95%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Page</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#suppfin98473_1">Consolidated Balance Sheet as of December 31, 2019 and Unaudited Interim Condensed
Consolidated Balance Sheet as of September&nbsp;30, 2020</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">F-2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#suppfin98473_2">Unaudited Interim Condensed Consolidated Statements of Comprehensive Loss for
 the Nine Months Ended September&nbsp;30, 2019 and 2020</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">F-4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#suppfin98473_3">Unaudited Interim Condensed Consolidated Statements of Changes in Shareholders&#146;
 Equity (Deficit) for the Nine Months Ended September&nbsp;30, 2019 and 2020</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">F-5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#suppfin98473_4">Unaudited Interim Condensed Consolidated Statements of Cash Flows for the Nine
 Months Ended September&nbsp;30, 2019 and 2020</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">F-6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#suppfin98473_5">Notes to the Unaudited Interim Condensed Consolidated Financial Statements
</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">F-8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">I-MAB</FONT> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="suppfin98473_1"></A>Consolidated Balance Sheet as of December&nbsp;31, 2019 and </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Unaudited Interim Condensed Consolidated Balance Sheet </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>as of September&nbsp;30, 2020 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(All amounts in thousands, except for share and per share data, unless otherwise noted) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="60%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>As&nbsp;of&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>As of September&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Notes</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>RMB</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>RMB</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>US$<BR>(Note&nbsp;2.5)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD COLSPAN="5" VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Current assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,137,473</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,960,017</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">435,963</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Restricted cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">55,810</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Short-term investments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">32,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">28,526</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,201</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepayments and other receivables</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">136,036</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">219,839</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">32,379</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total current assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,361,319</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,208,382</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">472,543</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Property, equipment and software</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30,069</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27,058</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,985</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating lease
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT> assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,435</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,061</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,218</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Intangible assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">148,844</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">122,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17,969</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Goodwill</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">162,574</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">162,574</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23,945</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Investment accounted for using the equity method</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">762,997</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">112,377</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other <FONT STYLE="white-space:nowrap">non-current</FONT> assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,331</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1,737,572</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>4,298,072</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>633,037</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Liabilities, mezzanine equity and shareholders&#146; equity (deficit)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Current liabilities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Short-term borrowings</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accruals and other payables</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">273,553</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">338,317</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">49,829</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating lease liabilities, current</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,807</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,001</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,178</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred subsidy income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,078</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">453</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ordinary shares to be issued to Everest</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">258,119</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total current liabilities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">588,479</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">349,396</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">51,460</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Convertible promissory notes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">68,199</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">64,771</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,540</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Put right liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">124,100</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,278</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating lease liabilities, <FONT STYLE="white-space:nowrap">non-current</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,492</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,177</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">762</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred subsidy income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,920</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,560</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">672</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other <FONT STYLE="white-space:nowrap">non-current</FONT> liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,433</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,242</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total liabilities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>668,090</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>556,437</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>81,954</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Commitments and contingencies</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">I-MAB</FONT> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Consolidated Balance Sheet as of December&nbsp;31, 2019 and </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Unaudited Interim Condensed Consolidated Balance Sheet </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>as of September&nbsp;30, 2020&nbsp;(Continued) </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(All amounts in thousands, except for share and per share data, unless otherwise noted) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="60%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>As&nbsp;of&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>As of September&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Notes</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>RMB</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>RMB</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>US$<BR>(Note&nbsp;2.5)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Mezzanine equity</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series A convertible preferred shares (US$0.0001 par value, 30,227,056 shares authorized, issued
and outstanding as of December&nbsp;31, 2019, and nil authorized, issued and outstanding as of September&nbsp;30, 2020)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">687,482</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series B convertible preferred shares (US$0.0001 par value, 30,305,212 shares authorized, issued
and outstanding as of December&nbsp;31, 2019, and nil authorized, issued and outstanding as of September&nbsp;30, 2020)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">921,243</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series C convertible preferred shares (US$0.0001 par value, 31,046,360 shares authorized, issued
and outstanding as of December&nbsp;31, 2019, and nil authorized, issued and outstanding as of September&nbsp;30, 2020)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,306,633</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series <FONT STYLE="white-space:nowrap">C-1</FONT> convertible preferred shares (US$0.0001 par
value, 3,857,143 shares authorized, issued and outstanding as of December&nbsp;31, 2019, and nil authorized, issued and outstanding as of September&nbsp;30, 2020)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">188,819</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total mezzanine equity</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>3,104,177</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Shareholders&#146; equity (deficit)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ordinary shares (US$0.0001 par value, 500,000,000 and 800,000,000 shares authorized as of
December&nbsp;31, 2019 and September&nbsp;30, 2020, respectively; 8,363,719 and 153,543,910 shares issued and outstanding as of December&nbsp;31, 2019 and September&nbsp;30, 2020, respectively)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">106</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Additional <FONT STYLE="white-space:nowrap">paid-in</FONT> capital</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">389,379</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,720,714</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">989,854</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated other comprehensive income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">70,127</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">85,657</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,616</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,494,207</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,064,842</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(451,403</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total shareholders&#146; equity (deficit)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(2,034,695</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>3,741,635</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>551,083</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total liabilities, mezzanine equity and shareholders&#146; equity (deficit)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1,737,572</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>4,298,072</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>633,037</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The accompanying notes are an integral part of these unaudited interim condensed consolidated financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">I-MAB</FONT> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="suppfin98473_2"></A>Unaudited Interim Condensed Consolidated Statements of Comprehensive Loss </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>For the Nine Months Ended September&nbsp;30, 2019 and 2020 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(All amounts in thousands, except for share and per share data, unless otherwise noted) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="60%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Nine Months Ended September&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Notes</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>RMB</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>RMB</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>US$</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>(Note 2.5)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Revenues</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Licensing and collaboration revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Expenses</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(578,377</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(698,461</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(102,872</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Administrative expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(582,732</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(310,775</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(45,772</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Loss from operations</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(1,131,109</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(1,009,236</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(148,644</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,828</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,658</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,748</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,466</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(957</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(141</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other income, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,758</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">420,900</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">61,992</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fair value change of warrants</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,609</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Loss before income tax expense</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(1,103,380</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(570,635</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(84,045</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income tax expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net loss attributable to <FONT STYLE="white-space:nowrap">I-MAB</FONT></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(1,103,380</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(570,635</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(84,045</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net loss attributable to ordinary shareholders</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(1,103,380</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(570,635</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(84,045</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net loss attributable to <FONT STYLE="white-space:nowrap">I-MAB</FONT></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(1,103,380</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(570,635</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(84,045</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Other comprehensive income:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Foreign currency translation adjustments, net of nil tax</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">66,254</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,530</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,288</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total comprehensive loss attributable to
<FONT STYLE="white-space:nowrap">I-MAB</FONT></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(1,037,126</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(555,105</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(81,757</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net loss attributable to ordinary shareholders</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(1,103,380</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(570,635</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(84,045</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted-average number of ordinary shares used in calculating net loss per share&#151;basic and
diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,184,086</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">126,758,926</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">126,758,926</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net loss per share attributable to ordinary shareholders</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&#151;Basic</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(153.59</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4.50</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(0.66</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&#151;Diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(153.59</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4.50</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(0.66</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The accompanying notes are an integral part of these unaudited interim condensed consolidated financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">I-MAB</FONT> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="suppfin98473_3"></A>Unaudited Interim Condensed Consolidated Statements of Changes in Shareholders&#146; Equity (Deficit) </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>For the Nine Months Ended September&nbsp;30, 2019 and 2020 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(All amounts in thousands, except for share and per share data, unless otherwise noted) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" ALIGN="center">


<TR>

<TD WIDTH="45%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD ROWSPAN="3" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Ordinary&nbsp;shares&nbsp;(Note&nbsp;11)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="3">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="3" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Treasury<BR>stock</B></TD>
<TD VALIGN="bottom" ROWSPAN="3">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="3">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="3" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Additional<BR><FONT STYLE="white-space:nowrap">paid-in</FONT><BR>capital</B></TD>
<TD VALIGN="bottom" ROWSPAN="3">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="3">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="3" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Accumulated<BR>other<BR>comprehensive<BR>income</B></TD>
<TD VALIGN="bottom" ROWSPAN="3">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="3">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="3" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Accumulated<BR>deficit</B></TD>
<TD VALIGN="bottom" ROWSPAN="3">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="3">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="3" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Total<BR>shareholders&#146;<BR>deficit</B></TD>
<TD VALIGN="bottom" ROWSPAN="3">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>(US$0.001 par value)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Number of</B><br><B>shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:7pt; font-family:Times New Roman; " ALIGN="center"><B>RMB</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:7pt; font-family:Times New Roman; " ALIGN="center"><B>RMB</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:7pt; font-family:Times New Roman; " ALIGN="center"><B>RMB</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:7pt; font-family:Times New Roman; " ALIGN="center"><B>RMB</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:7pt; font-family:Times New Roman; " ALIGN="center"><B>RMB</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:7pt; font-family:Times New Roman; " ALIGN="center"><B>RMB</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><B>Balance as of December&nbsp;31, 2018</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>8,363,719</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>6</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(1</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>59,380</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(1,014,489</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(955,104</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Foreign currency translation adjustments</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">66,254</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">66,254</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,103,380</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,103,380</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Share-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">366,885</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">366,885</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><B>Balance as of September&nbsp;30, 2019</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>8,363,719</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>6</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(1</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>366,885</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>125,634</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(2,117,869</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(1,625,345</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><B>Balance as of December&nbsp;31, 2019</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>8,363,719</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>6</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>389,379</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>70,127</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(2,494,207</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(2,034,695</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Foreign currency translation adjustments</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,530</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,530</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(570,635</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(570,635</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Share-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">301,525</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">301,525</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Exercise of stock options</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">115,888</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">790</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">791</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Capital contribution from stock option surrender (Note 15 (h))</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">91,051</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">91,051</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Conversion of preferred shares to ordinary shares upon the completion of initial public offering
(&#147;IPO&#148;)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">99,760,129</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">69</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,104,108</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,104,177</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Issuance of ordinary shares to Everest</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,078,571</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">254,844</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">254,848</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Issuance of ordinary shares upon IPO and over-allotment, net of issuance cost</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,804,225</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">697,865</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">697,878</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Issuance of ordinary shares upon private placement, net of issuance cost</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20,421,378</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,809,278</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,809,291</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Issuance of warrants</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">71,874</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">71,874</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><B>Balance as of September&nbsp;30, 2020</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>153,543,910</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>106</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>6,720,714</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>85,657</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(3,064,842</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>3,741,635</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The accompanying notes are an integral part of these unaudited interim condensed consolidated financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">I-MAB</FONT> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="suppfin98473_4"></A>Unaudited Interim Condensed Consolidated Statements of Cash Flows </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>For the Nine Months Ended September&nbsp;30, 2019 and 2020 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(All amounts in thousands, except for share and per share data, unless otherwise noted) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="71%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Nine Months Ended September&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>RMB</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>RMB</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>US$</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>(Note&nbsp;2.5)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Cash flows from operating activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,103,380</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(570,635</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(84,045</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Adjustments to reconcile net loss to net cash used in operating activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Depreciation of property, equipment and software</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,835</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,738</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,140</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss on disposal of property, equipment and software</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fair value change of short-term investments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(332</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,557</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(377</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fair value change of warrants</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5,609</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fair value change of other financial assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">145</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Share-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">366,885</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">392,576</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">57,820</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Amortization of <FONT STYLE="white-space:nowrap">right-of</FONT> use assets and interest of lease
liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,427</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,935</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,021</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gains on deconsolidation of a subsidiary</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(407,598</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(60,033</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Changes in operating assets and liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepayments and other receivables</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,310</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,309</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">488</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accruals and other payables</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">32,200</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(17,623</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,596</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Advance from customers</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(14,151</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development funding received</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">52,207</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred subsidy income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,420</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,718</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">548</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other <FONT STYLE="white-space:nowrap">non-current</FONT> liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,433</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,242</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Lease liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4,950</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(6,935</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,021</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net cash used in operating activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(651,993</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(582,631</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(85,812</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Cash flows from investing activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Purchase of property, equipment and software</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4,617</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4,761</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(701</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds from disposal of property, equipment and software</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds from disposal of short-term investments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">35,332</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">276,884</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">40,781</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Purchase of short-term investments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(88,000</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(270,853</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(39,892</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash disposed of resulting from deconsolidation of a subsidiary</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(257,651</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(37,948</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash received from disposal of other financial assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">192,401</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net cash generated from (used in) investing activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>135,128</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(256,381</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(37,760</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">I-MAB</FONT> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Unaudited Interim Condensed Consolidated Statements of Cash Flows&nbsp;(Continued) </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>For the Nine Months Ended September&nbsp;30, 2019 and 2020 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(All amounts in thousands, except for share and per share data, unless otherwise noted) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="71%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Nine Months Ended September&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>RMB</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>RMB</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>US$</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>(Note&nbsp;2.5)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Cash flows from financing activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Consideration received in advance from a preferred shares investor</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">70,729</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds from initial public offering and over-allotment, net of underwriting discounts and
commissions</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">726,300</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">106,972</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Payment of issuance cost for initial public offering and over-allotment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,316</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(27,088</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,990</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds from private placement, net of payment of issuance cost</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,980,548</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">291,703</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds from exercise of stock options</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">791</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">117</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds from bank borrowings</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepayment for stock repurchase program</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(34,859</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5,134</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Repayment of bank borrowings</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(80,000</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(50,000</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(7,364</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net cash generated from financing activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>39,413</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>2,595,692</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>382,304</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Effect of exchange rate changes on cash and cash equivalents and restricted cash</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">77,581</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,054</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,480</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net increase (decrease) in cash and cash equivalents and restricted cash</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(399,871</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1,766,734</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>260,212</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash, cash equivalents, and restricted cash, beginning of period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,680,931</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,193,283</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">175,751</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash, cash equivalents, and restricted cash, end of the period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1,281,060</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>2,960,017</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>435,963</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Additional ASC 842 supplemental disclosures</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash paid for fixed operating lease costs included in the measurement of lease obligations in
operating activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,950</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,935</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,021</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Right-of-use</FONT></FONT>
assets obtained in exchange for operating lease obligations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,952</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,029</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">741</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Other supplemental cash flow disclosures</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest paid</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,466</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">957</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">141</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">Non-cash</FONT> activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued initial public offering costs payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,850</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">508</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">75</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued private placement offering costs payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">96,837</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,263</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ordinary shares issued to Everest</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">254,848</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">37,535</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Conversion of preferred shares to ordinary shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,104,177</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">457,196</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The accompanying notes are an integral part of these unaudited interim condensed consolidated financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">I-MAB</FONT> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="suppfin98473_5"></A>Notes to the Unaudited Interim Condensed Consolidated Financial Statements </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(All amounts in thousands, except for share and per share data, unless otherwise noted) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1. Principal Activities and Organization </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">I-Mab</FONT> (the &#147;Company&#148;) was incorporated in the Cayman Islands on June&nbsp;30, 2016 as an
exempted company with limited liability under the Companies Act of the Cayman Islands. The Company and its subsidiaries (together the &#147;Group&#148;) are principally engaged in discovering and developing transformational biologics in the fields
of immuno-oncology and immuno-inflammation diseases in the People&#146;s Republic of China (the &#147;PRC&#148;) and other countries and regions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Prior to the incorporation of the Company, the Group carried out its operation in the PRC since November 2014 mainly through Third Venture
Biopharma (Nanjing) Co., Ltd. (&#147;Third Venture&#148;), which was incorporated on November&nbsp;17, 2014 in the PRC. For the purpose of introduction of overseas investors and in preparation for a listing of the Company&#146;s shares on the
overseas capital markets, the Group underwent a reorganization (the &#147;Reorganization&#148;) in 2016. The Reorganization was approved by the Board of Directors and a restructuring framework agreement was entered into by Third Venture, the
Company, and the shareholders of the Company based on Reorganization framework agreement, pursuant to which on July&nbsp;7, 2016, Third Venture transferred all of its assets and operations to the Company&#146;s wholly owned subsidiary, <FONT
STYLE="white-space:nowrap">I-Mab</FONT> Biopharma Co., Ltd. <FONT STYLE="white-space:nowrap">(&#147;I-Mab</FONT> Shanghai&#148;), which was a transaction in which shareholders had identical ownership interests before and after the transaction and
was accounted for in a manner similar to a common control transaction. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Reorganization, as described above has been accounted for at
historical cost. That Reorganization was reverse merger of Third Venture and Third Venture is the predecessor of the Company. As such, the assets and liabilities of Third Venture are consolidated in the Company&#146;s financial statements at
historical cost. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">On January&nbsp;17, 2020, the Company consummated its IPO on the Nasdaq Global Market, where 7,407,400 American
Depositary Shares (&#147;ADSs&#148;) were issued at the price of US$14.00 per ADS for total gross proceeds of US$103.7&nbsp;million. On February&nbsp;10, 2020, the underwriters of the IPO have exercised their over-allotment option to purchase an
additional 768,350 ADSs of the Company at the IPO price of US$14.00 per ADS. After giving effect to the exercise of the over-allotment option, the Company has issued and sold a total of 8,175,750 ADSs in the IPO, for total gross proceeds of
US$114.5&nbsp;million. Each ten ADSs represents twenty-three ordinary shares of the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">As of<B> </B>September&nbsp;30, 2020, the
Company&#146;s principal subsidiaries are as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="40%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Subsidiaries</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Place of<BR>incorporation</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Date
of<BR>incorporation&nbsp;or<BR>acquisition</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Percentage<BR>of direct<BR>or
indirect<BR>ownership<BR>by the<BR>Company</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Principal&nbsp;activities</B></P></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">I-Mab</FONT> Biopharma Hong Kong Limited <FONT
STYLE="white-space:nowrap">(&#147;I-Mab</FONT> Hong Kong&#148;)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Hong&nbsp;Kong</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">July&nbsp;8, 2016</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Investment holding</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">I-Mab</FONT> Shanghai</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">PRC</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">August&nbsp;24,&nbsp;2016</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Research&nbsp;and&nbsp;development<BR>of innovative medicines</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">I-Mab</FONT> <FONT STYLE="white-space:nowrap">Bio-tech</FONT>
(Tianjin) Co., Ltd. <FONT STYLE="white-space:nowrap">(&#147;I-Mab</FONT> Tianjin&#148;)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">PRC</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">July&nbsp;15, 2017</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Research and development<BR>of innovative medicines</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">I-Mab</FONT> Biopharma US Ltd.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">U.S.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">February&nbsp;28,&nbsp;2018</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Research and development<BR>of innovative medicines</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">I-MAB</FONT> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to the Unaudited Interim Condensed Consolidated Financial Statements </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(All amounts in thousands, except for share and per share data, unless otherwise noted) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2. Principal Accounting Policies </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>2.1 Basis of presentation </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The
accompanying unaudited interim condensed consolidated financial statements of the Group have been prepared in accordance with the accounting principles generally accepted in the United States of America (&#147;U.S. GAAP&#148;) for interim financial
information. Accordingly, they do not include all of the information and footnotes normally included in the annual financial statements prepared in accordance with U.S. GAAP. Certain information and footnote disclosures normally included in the
annual financial statements prepared in accordance with U.S. GAAP have been condensed or omitted consistent with Article 10 of Regulation <FONT STYLE="white-space:nowrap">S-X.</FONT> In the opinion of management, the Group&#146;s unaudited interim
condensed consolidated financial statements and accompanying notes include all adjustments (consisting of normal recurring adjustments) considered necessary for the fair statement of the Group&#146;s financial position as of September&nbsp;30, 2020,
and results of operations and cash flows for the nine months ended September&nbsp;30, 2019 and 2020. Interim results of operations are not necessarily indicative of the results for the full year or for any future period. These unaudited interim
condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements as of and for the year ended December&nbsp;31, 2019, and related notes included in the Group&#146;s audited consolidated
financial statements. The financial information as of December&nbsp;31, 2019 presented in the unaudited interim condensed consolidated financial statements is derived from the audited consolidated financial statements as of December&nbsp;31, 2019.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Significant accounting policies followed by the Group in the preparation of the accompanying consolidated financial statements are
summarized below. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>2.2 Basis of consolidation </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The accompanying consolidated financial statements reflect the accounts of the Company and all of its subsidiaries in which a controlling
interest is maintained. All inter-company balances and transactions have been eliminated in consolidation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>2.3 Use of estimates </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions
that affect the reported amounts of assets and liabilities and the disclosures of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period.
Estimates are used when accounting for amounts recorded in connection with acquisitions, including initial fair value determinations of assets and liabilities and other intangible assets as well as subsequent fair value measurements. Additionally,
estimates are used in determining items such as fair value measurements of wealth management products, impairment of other receivables, long-lived assets, intangible assets and goodwill, useful lives of property, equipment and software, recognition
of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT> assets and lease liabilities, fair value measurements of warrants, variable consideration in collaboration revenue arrangements, determination of the
standalone selling price of each performance obligation in the Company&#146;s revenue arrangements, valuation of share-based compensation arrangements, deferred tax assets valuation allowances and fair value of put right liabilities. Management
bases the estimates on historical experience, known trends and various other assumptions that are believed to be reasonable, the results of which form the basis for making judgments about the carrying values of assets and liabilities. Actual results
could differ from those estimates. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">I-MAB</FONT> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to the Unaudited Interim Condensed Consolidated Financial Statements </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(All amounts in thousands, except for share and per share data, unless otherwise noted) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2. Principal Accounting Policies&nbsp;(Continued) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>2.4 Fair value measurements </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Financial assets and liabilities of the Group primarily comprise of cash and cash equivalents, restricted cash, short-term investments, other
financial assets, contract assets, other receivables, short-term borrowings, accruals and other payables and put right liabilities. As of December&nbsp;31, 2019, and September&nbsp;30, 2020, except for short-term investments and put right
liabilities, the carrying values of these financial assets and financial liabilities approximated their fair values because of their generally short maturities. The Group reports short-term investments and put right liabilities at fair value at each
balance sheet date and changes in fair value are reflected in the consolidated statements of comprehensive loss. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Group measures its
financial assets and liabilities using inputs from the following three levels of the fair value hierarchy. The three levels are as follows: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Level&nbsp;1 inputs are unadjusted quoted prices in active markets for identical assets that the management has the ability to access at the
measurement date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Level&nbsp;2 inputs include quoted prices for similar assets in active markets, quoted prices for identical or similar
assets in markets that are not active, inputs other than quoted prices that are observable for the asset (i.e., interest rates, yield curves, etc.), and inputs that are derived principally from or corroborated by observable market data by
correlation or other means (market corroborated inputs). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Level&nbsp;3 includes unobservable inputs that reflect the management&#146;s
assumptions about the assumptions that market participants would use in pricing the asset. The management develops these inputs based on the best information available, including the own data.</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><I>Assets and liabilities measured at fair value on a recurring basis </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Group measured its short-term investments and put right liabilities at fair value on a recurring basis. As the Group&#146;s short-term
investments and put right liabilities are not traded in an active market with readily observable prices, the Group uses significant unobservable inputs to measure the fair value of short-term investments and put right liabilities. These instruments
are categorized in the Level&nbsp;3 valuation hierarchy based on the significance of unobservable factors in the overall fair value measurement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The following table summarizes the Group&#146;s financial assets and financial liabilities measured and recorded at fair value on a recurring
basis as of December&nbsp;31, 2019 and September&nbsp;30, 2020: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="85.5%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="34%"></TD>

<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>As of December&nbsp;31, 2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Active&nbsp;market<BR>(Level&nbsp;1)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Observable&nbsp;input<BR>(Level 2)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B><FONT STYLE="white-space:nowrap">Non-observable&nbsp;input</FONT><BR>(Level 3)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>RMB</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>RMB</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>RMB</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>RMB</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Assets:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Short-term investments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">32,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">32,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">I-MAB</FONT> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to the Unaudited Interim Condensed Consolidated Financial Statements </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(All amounts in thousands, except for share and per share data, unless otherwise noted) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2. Principal Accounting Policies&nbsp;(Continued) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>2.4 Fair value measurements&nbsp;(Continued) </I></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="85.5%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="34%"></TD>

<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>As of September&nbsp;30, 2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Active&nbsp;market<BR>(Level&nbsp;1)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Observable&nbsp;input<BR>(Level 2)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B><FONT STYLE="white-space:nowrap">Non-observable&nbsp;input</FONT><BR>(Level 3)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>RMB</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>RMB</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>RMB</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>RMB</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Assets:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Short-term investments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">28,526</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">28,526</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Liabilities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Put right liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">124,100</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">124,100</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The roll forward of major Level&nbsp;3 financial assets and financial liabilities are as follows: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="72%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="57%"></TD>

<TD VALIGN="bottom" WIDTH="12%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="12%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B><FONT STYLE="white-space:nowrap">Short-term&nbsp;investments</FONT></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Put&nbsp;right&nbsp;liabilities</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fair value of Level&nbsp;3 financial assets and financial liabilities as of December&nbsp;31,
2019</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">32,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Purchase of short-term investments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">270,853</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Disposal of short-term investments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(276,884</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Grant of put right liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">124,321</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fair value changes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,557</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Effect of exchange rate changes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(221</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fair value of Level&nbsp;3 financial assets and financial liabilities as of September&nbsp;30,
2020</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">28,526</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">124,100</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Refer to Note 7 for additional information about Level&nbsp;3 put right measured at fair value on a recurring
basis for the nine months ended September&nbsp;30, 2020. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>2.5 Foreign currency translation </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Group uses Chinese Renminbi (&#147;RMB&#148;) as its reporting currency. The United States Dollar (&#147;US$&#148;) is the functional
currency of the Group&#146;s entities incorporated in the Cayman Islands, the United States of America (&#147;U.S.&#148;) and Hong Kong, the Australia Dollar (&#147;AUD&#148;) is the functional currency of the Group&#146;s entity incorporated in
Australia and the RMB is the functional currency of the Company&#146;s PRC subsidiaries. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Transactions denominated in other than the
functional currencies are translated into the functional currency of the entity at the exchange rates prevailing on the transaction dates. Assets and liabilities denominated in other than the functional currencies are translated at the balance sheet
date exchange rate. The resulting exchange differences are recorded in the consolidated statements of comprehensive loss. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The unaudited
interim condensed consolidated financial statements of the Group are translated from the functional currency to the reporting currency, RMB. Assets and liabilities of the subsidiaries are translated into RMB using the exchange rate in effect at each
balance sheet date. Income and expenses are translated at the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">I-MAB</FONT> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to the Unaudited Interim Condensed Consolidated Financial Statements </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(All amounts in thousands, except for share and per share data, unless otherwise noted) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2. Principal Accounting Policies&nbsp;(Continued) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>2.5 Foreign currency translation&nbsp;(Continued) </I></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
average exchange rates prevailing for the year. Foreign currency translation adjustments arising from these are reflected in the accumulated other comprehensive income. The exchange rates used
for translation on December&nbsp;31, 2019 and September&nbsp;30, 2020 were US$1.00 = RMB6.9762 and RMB6.8101 respectively, representing the index rates stipulated by the People&#146;s Bank of China. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Translations of balances in the consolidated balance sheets, consolidated statements of comprehensive loss, consolidated statements of changes
in shareholders&#146; equity (deficit) and consolidated statements of cash flows from RMB into US$ as of and for the nine months ended September&nbsp;30, 2020 are solely for the convenience of the readers and were calculated at the rate of
US$1.00=RMB6.7896, representing the noon buying rate in The City of New York for cable transfers of RMB as certified for customs purposes by the Federal Reserve Bank of New York on September&nbsp;30, 2020. No representation is made that the RMB
amounts could have been, or could be, converted, realized or settled into US$ at that rate on September&nbsp;30, 2020, or at any other rate. The US$ convenience translation is not required under U.S. GAAP and all US$ convenience translation amounts
in the accompanying consolidated financial statements are unaudited. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>2.6 Cash and cash equivalents </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents consist of cash on hand and bank deposits, which are unrestricted as to withdrawal and use. The Company considers
all highly liquid investments with an original maturity date of three months or less at the date of purchase to be cash equivalents. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>2.7 Restricted
cash </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Restricted cash consists of the guarantee deposits held in a designated bank account as security deposits under bank
borrowing agreements. Such restricted cash was released when the Group repaid the related bank borrowings. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>2.8 Short-term investments </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Short-term investments represent the investments issued by commercial banks or other financial institutions with a variable interest rate
indexed to the performance of underlying assets within one year. These investments are stated at fair value. Changes in the fair value are reflected in the consolidated statements of comprehensive loss. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>2.9 Property, equipment and software </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Property, equipment and software are stated at cost less accumulated depreciation and amortization. Depreciation and amortization is computed
using the straight-line method over the following estimated useful lives, taking into account any estimated residual value: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="85.5%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="62%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="35%"></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Laboratory equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3 to 5 years</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Software</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2 to 5 years</P></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Office furniture and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">5 years</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Leasehold improvements</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Lesser&nbsp;of&nbsp;useful life or lease term</P></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">I-MAB</FONT> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to the Unaudited Interim Condensed Consolidated Financial Statements </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(All amounts in thousands, except for share and per share data, unless otherwise noted) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2. Principal Accounting Policies&nbsp;(Continued) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>2.9 Property, equipment and software&nbsp;(Continued) </I></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Group recognized the gain or loss on the disposal of property, equipment and software in
the consolidated statements of comprehensive loss. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>2.10 Intangible assets </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Intangible assets with definite useful lives are amortized to their estimated residual values over their estimated useful lives and reviewed
for impairment if certain events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Amortization is initiated for <FONT STYLE="white-space:nowrap">in-process</FONT> research and development (IPR&amp;D)
intangible assets that are acquired from business combination when their useful lives have been determined. IPR&amp;D intangible assets which are determined to have an impairment in their fair value are adjusted downward and an expense recognized in
research and development in the consolidated statements of comprehensive loss. These IPR&amp;D intangible assets are tested at least on an annual basis on December&nbsp;31 or when a triggering event occurs that could indicate a potential impairment
(see Note 5). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>2.11 Impairment of long-lived assets </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Long-lived assets are reviewed for impairment in accordance with authoritative guidance for impairment or disposal of long-lived assets.
Long-lived assets are reviewed for events or changes in circumstances, which indicate that their carrying value may not be recoverable. Long-lived assets are reported at the lower of carrying amount or fair value less cost to sell. For the year
ended December&nbsp;31, 2019 and nine months ended September&nbsp;30, 2020, there was no impairment of the value of the Group&#146;s long-lived assets. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>2.12 Goodwill </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Goodwill is an
asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized. The Group allocates the cost of an acquired entity to the assets acquired
and liabilities assumed based on their estimated fair values at the date of acquisition. The excess of the purchase price for acquisitions over the fair value of the net assets acquired, including other intangible assets, is recorded as goodwill.
Goodwill is not amortized, but impairment of goodwill assessment is performed on at least an annual basis on December&nbsp;31 or whenever events or changes in circumstances indicate that the carrying value of the asset may not be recoverable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Group has elected to first assess qualitative factors to determine whether it is more likely than not that the fair value of the
Group&#146;s reporting unit is less than its carrying amount, including goodwill. The qualitative assessment includes the Group&#146;s evaluation of relevant events and circumstances affecting the Group&#146;s single reporting unit, including
macroeconomic, industry, market conditions and the Group&#146;s overall financial performance. If qualitative factors indicate that it is more likely than not that the Group&#146;s reporting unit&#146;s fair value is less than its carrying amount,
then the Group will perform the quantitative impairment test by comparing the reporting unit&#146;s carrying amount, including goodwill, to its fair value. If the carrying amount of the reporting unit exceeds its fair value, an impairment loss will
be recognized in an amount equal to that excess. For the year ended December&nbsp;31, 2019 and nine months ended September&nbsp;30, 2020, the Group determined that there were no indicators of impairment of the goodwill. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">I-MAB</FONT> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to the Unaudited Interim Condensed Consolidated Financial Statements </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(All amounts in thousands, except for share and per share data, unless otherwise noted) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2. Principal Accounting Policies&nbsp;(Continued) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>2.13 Long-term investments </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Group&#146;s long-term investments include equity investments in an affiliate in which it does not have a controlling financial interest,
but has the ability to exercise significant influence over the operating and financial policies of the investee. The investment is accounted for using the equity method of accounting in accordance with ASC topic 323, Investments&#151;Equity Method
and Joint Ventures (&#147;ASC 323&#148;). Under the equity method, the Group initially records its investments at fair value. The Group subsequently adjusts the carrying amount of the investment to recognize the Group&#146;s proportionate share of
the equity investee&#146;s net income or loss after the date of investment. The Group evaluates the equity method investment for impairment under ASC 323. An impairment loss on the equity method investments is recognized in losses when the decline
in value is determined to be other-than-temporary. No impairment charge was recognized for the nine months ended September&nbsp;30, 2020. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>2.14
Deferred subsidy income </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Deferred subsidy income consists of deferred income from government grants. Government grants mainly
consist of cash subsidies received by the Group&#146;s subsidiaries in the PRC from local governments as support on expenses relating to certain projects. Grants received with government specified performance obligations are recognized when all the
obligations have been fulfilled. If such obligations are not satisfied, the Group may be required to refund the subsidy. Cash grants of RMB3,920 was recorded in deferred subsidy income as of December&nbsp;31, 2019. As of September&nbsp;30, 2020,
cash grants of RMB7,638 was recorded in deferred subsidy income, which will be recognized when the government specified performance obligation is satisfied. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>2.15 Revenue recognition </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The
Group adopted Accounting Standard Codification (&#147;ASC&#148;) 606, <I>Revenue from Contracts with Customers</I> (Topic 606) (&#147;ASC 606&#148;) for all periods presented. Consistent with the criteria of Topic 606, the Group recognizes revenue
to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to receive in exchange for those goods or services. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Under ASC 606, an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the
consideration that the entity expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that an entity determines are within the scope of ASC 606, the entity performs the following five steps:
(i)&nbsp;identify the contract(s) with a customer; (ii)&nbsp;identify the performance obligations in the contract; (iii)&nbsp;determine the transaction price, including variable consideration, if any; (iv)&nbsp;allocate the transaction price to the
performance obligations in the contract; and (v)&nbsp;recognize revenue when (or as) the entity satisfies a performance obligation. The Group only applies the five-step model to contracts when it is probable that the entity will collect
substantially all the consideration to which it is entitled in exchange for the goods or services it transfers to the customer. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Once a
contract is determined to be within the scope of ASC 606 at contract inception, the Group audits the contract to determine which performance obligations it must deliver and which of these performance obligations are distinct. The Group recognizes as
revenue the amount of the transaction price that is allocated to each performance obligation when that performance obligation is satisfied or as it is satisfied. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">I-MAB</FONT> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to the Unaudited Interim Condensed Consolidated Financial Statements </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(All amounts in thousands, except for share and per share data, unless otherwise noted) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2. Principal Accounting Policies&nbsp;(Continued) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>2.15 Revenue recognition&nbsp;(Continued) </I></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><I>Collaboration revenue </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">At contract inception, the Group analyzes its collaboration arrangements to assess whether they are within the scope of ASC
808,<I>&nbsp;Collaborative Arrangements</I>&nbsp;(&#147;ASC 808&#148;) to determine whether such arrangements involve joint operating activities performed by parties that are both active participants in the activities and exposed to significant
risks and rewards dependent on the commercial success of such activities.&nbsp;For collaboration arrangements within the scope of ASC 808 that contain multiple elements, the Group first determines if the collaboration is deemed to be within the
scope of ASC 808. For any units of account that are reflective of a vendor-customer relationship those units of account are accounted for within the scope of ASC 606. For any units of account that are not accounted for under ASC 606 and therefore
accounted for pursuant to ASC 808, an appropriate recognition method is determined and applied consistently.</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Group&#146;s
collaborative arrangements may contain more than one unit of account, or performance obligation, including grants of licenses to intellectual property rights, agreement to provide research and development services and other deliverables. The
collaborative arrangements do not include a right of return for any deliverable. As part of the accounting for these arrangements, the Group must develop assumptions that require judgment to determine the stand-alone selling price for each
performance obligation identified in the contract.&nbsp;In developing the stand-alone selling price for a performance obligation, the Group considers competitor pricing for a similar or identical product, market awareness of and perception of the
product, expected product life and current market trends. In general, the consideration allocated to each performance obligation is recognized when the respective obligation is satisfied either by delivering a good or providing a service, limited to
the consideration that is not constrained. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">When the timing of the delivery of product is different from the timing of payments made by
the customers, the Group recognizes either a contract asset (performance precedes the contractual due date) or a contract liability (customer payment precedes performance). The Group&#146;s contractual payment terms are typically due in no more than
30 days from invoicing. In limited situations, certain customer contractual payment terms require the Group to bill in arrears; thus, the Group satisfies some or all of the performance obligations before the Group is contractually entitled to bill
the customer. In these situations, billing occurs subsequent to revenue recognition, which results in a contract asset. A receivable is recorded when the Group has an unconditional right to consideration. A right to consideration is unconditional if
only the passage of the time is required before payment of the consideration is due. A contract asset is recorded when the Group has transferred products or services to the customer before payment is received or is due, and the Group&#146;s right to
consideration is conditional on future performance or other factors in the contract. For example, certain of the contractual arrangements do not permit the Group to bill until the completion of the production of the samples. In other limited
situations, certain customer contractual payment terms allow the Group to bill in advance; thus, the Group receives customer cash payment before satisfying some or all of its performance obligations. In these situations, billing occurs in advance of
revenue recognition, which results in contract liabilities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I>Licenses of Intellectual Property:</I> Upfront <FONT
STYLE="white-space:nowrap">non-refundable</FONT> payments for licensing the Group&#146;s intellectual property are evaluated to determine if the license is distinct from the other performance obligations identified in the arrangement. For licenses
determined to be distinct, the Group recognizes revenues from <FONT STYLE="white-space:nowrap">non-refundable,</FONT> <FONT STYLE="white-space:nowrap">up-front</FONT> fees allocated to the license at a point in time, when the license is transferred
to the licensee and the licensee is able to use and benefit from the license. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">I-MAB</FONT> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to the Unaudited Interim Condensed Consolidated Financial Statements </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(All amounts in thousands, except for share and per share data, unless otherwise noted) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2. Principal Accounting Policies&nbsp;(Continued) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>2.15 Revenue recognition&nbsp;(Continued) </I></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I>Research and Development Services: </I>The portion of the transaction price allocated to
research and development services performance obligations is deferred and recognized as revenue over time as delivery or performance of such services provided to the Group&#146;s customers occurs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I>Milestone Payments</I>: At the inception of each arrangement that includes development, commercialization, and regulatory milestone
payments, the Group evaluates whether the milestones are considered probable of being reached and to the extent that a significant reversal of cumulative revenue would not occur in future periods, estimates the amount to be included in the
transaction price using the most likely amount method. The transaction price is then allocated to each performance obligation on a relative stand-alone selling price basis, for which the Group recognizes revenue as or when the performance
obligations under the contract are satisfied. At the end of each subsequent reporting period, the Group <FONT STYLE="white-space:nowrap">re-evaluates</FONT> the probability of achieving such development milestones and any related constraint, and if
necessary, adjust the estimate of the overall transaction price. Any such adjustments are recorded on a cumulative <FONT STYLE="white-space:nowrap">catch-up</FONT> basis, which would affect revenues and earnings in the period of adjustment. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I>Royalties</I>: For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and the
license is deemed to be the predominant item to which the royalties or milestone payments based on the level of sales relate, the Group recognizes revenue at the later of (i)&nbsp;when the related sales occur, or (ii)&nbsp;when the performance
obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>2.16
<FONT STYLE="white-space:nowrap">Value-added-tax</FONT> (&#147;VAT&#148;) recoverable and surcharges </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Value added tax recoverable
represent amounts paid by the Group for purchases. The surcharges (i.e., Urban construction and maintenance tax, educational surtax, local educational surtax), vary from 6% to 17% of
<FONT STYLE="white-space:nowrap">the&nbsp;value-added-tax&nbsp;depending</FONT> on <FONT STYLE="white-space:nowrap">the&nbsp;tax-payer&#146;s&nbsp;location.</FONT> The deductible input VAT balance is reflected in the prepayments and other
receivables, and VAT payable balance is recorded in the accruals and other payables. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>2.17 Research and development expenses </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Elements of research and development expenses primarily include (1)&nbsp;payroll and other related expenses of personnel engaged in research
and development activities, <FONT STYLE="white-space:nowrap">(2)&nbsp;in-licensed</FONT> patent rights fee of exclusive development rights of drugs granted to the Group, (3)&nbsp;expenses related to preclinical testing of the Group&#146;s
technologies under development and clinical trials such as payments to contract research organizations (&#147;CRO&#148;), investigators and clinical trial sites that conduct the clinical studies (4)&nbsp;expenses to develop the product candidates,
including raw materials and supplies, product testing, depreciation, and facility related expenses, (5)&nbsp;other research and development expenses. Research and development expenses are charged to expense as incurred when these expenditures relate
to the Group&#146;s research and development services and have no alternative future uses. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Group has acquired rights to develop and
commercialize product candidates. Upfront payments that relate to the acquisition of a new drug compound, as well as <FONT STYLE="white-space:nowrap">pre-commercial</FONT> milestone payments, are immediately expensed as acquired <FONT
STYLE="white-space:nowrap">in-process</FONT> research and development in the period in which they are incurred, provided that the new drug compound did not also include processes or activities that would constitute a &#147;business&#148; as defined
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">I-MAB</FONT> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to the Unaudited Interim Condensed Consolidated Financial Statements </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(All amounts in thousands, except for share and per share data, unless otherwise noted) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2. Principal Accounting Policies&nbsp;(Continued) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>2.17 Research and development expenses&nbsp;(Continued) </I></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
under U.S. GAAP, the drug has not achieved regulatory approval for marketing and, absent obtaining such approval, has no established alternative future use. Milestone payments made to third
parties subsequent to regulatory approval would be capitalized as intangible assets and amortized over the estimated remaining useful life of the related product. The conditions enabling capitalization of development expenses as an asset have not
yet been met and, therefore, all development expenditures are recognized in profit or loss when incurred. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>2.18 Leases </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In accordance with ASC 842 adopted on January&nbsp;1, 2019, the Group determines if an arrangement is a lease at inception. Operating leases
are included in operating lease <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT> (&#147;ROU&#148;) assets, operating lease liability, and operating lease liability,
<FONT STYLE="white-space:nowrap">non-current</FONT> in the Group&#146;s consolidated balance sheets. The Group does not have any finance leases since the adoption date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">ROU assets represent the Group&#146;s right to use an underlying asset for the lease term and lease liabilities represent the Group&#146;s
obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. When determining the lease term, the Group
includes options to extend or terminate the lease when it is reasonably certain that it will exercise that option, if any. As the Group&#146;s leases do not provide an implicit rate, the Group uses its incremental borrowing rate, which it calculates
based on the credit quality of the Group and by comparing interest rates available in the market for similar borrowings, and adjusting this amount based on the impact of collateral over the term of each lease. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Group has elected to adopt the following lease policies in conjunction with the adoption of ASU
<FONT STYLE="white-space:nowrap">2016-02:</FONT> (i) elect for each lease not to separate <FONT STYLE="white-space:nowrap">non-lease</FONT> components from lease components and instead to account for each separate lease component and the <FONT
STYLE="white-space:nowrap">non-lease</FONT> components associated with that lease component as a single lease component; (ii)&nbsp;for leases that have lease terms of 12 months or less and does not include a purchase option that is reasonably
certain to exercise, the Group elected not to apply ASC 842 recognition requirements; and (iii)&nbsp;the Group elected to apply the package of practical expedients for existing arrangements entered into prior to January&nbsp;1, 2019 to not reassess
(a)&nbsp;whether an arrangement is or contains a lease, (b)&nbsp;the lease classification applied to existing leases, and (c)&nbsp;initial direct costs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In connection with the adoption of ASC 842, on January&nbsp;1, 2019, the Company recorded an impact of RMB13,100 on its assets and RMB11,333
on its liabilities for the recognition of operating lease <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use-assets</FONT></FONT></FONT> and operating lease liabilities, respectively,
which are primarily related to the lease of the Group&#146;s offices and warehouses. The adoption of ASC 842 did not have a material impact on the Company&#146;s results of operations or cash flows. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>2.19 Comprehensive loss </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Comprehensive loss is defined as the changes in equity of the Group during a period from transactions and other events and circumstances
excluding transactions resulting from investments by owners and distributions to owners. Among other disclosures, ASC 220,&nbsp;Comprehensive Income, requires that all items that are required to be recognized under current accounting standards as
components of comprehensive loss be </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">I-MAB</FONT> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to the Unaudited Interim Condensed Consolidated Financial Statements </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(All amounts in thousands, except for share and per share data, unless otherwise noted) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2. Principal Accounting Policies&nbsp;(Continued) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>2.19 Comprehensive loss&nbsp;(Continued) </I></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
reported in a financial statement that is displayed with the same prominence as other financial statements. For each of the periods presented, the Group&#146;s comprehensive loss includes net
loss and foreign currency translation adjustments, which are presented in the consolidated statements of comprehensive loss. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>2.20 Share-based
compensation </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Company grants restricted shares and stock options to eligible employees and accounts for share-based
compensation in accordance with ASC 718, Compensation&#151;Stock Compensation.</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Employees&#146; share-based compensation awards are
measured at the grant date fair value of the awards and recognized as expenses a) immediately at the grant date if no vesting conditions are required; or b) for share based awards granted with only service conditions, using the graded vesting method
net of estimated forfeitures over the vesting period; or c) for share-based awards granted with service conditions and the occurrence of an initial public offering (&#147;IPO&#148;) as performance condition cumulative share-based compensation
expenses for the options that have satisfied the service condition should be recorded upon the completion of the IPO using the graded vesting method.</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">A change in any of the terms or conditions of share-based awards is accounted for as a modification of the awards. The Group calculates
incremental compensation expense of a modification as the excess of the fair value of the modified awards over the fair value of the original awards immediately before its terms are modified at the modification date. For vested awards, the Group
recognizes incremental compensation cost in the period when the modification occurs. For awards not being fully vested, the Group recognizes the sum of the incremental compensation expense and the remaining unrecognized compensation expense for the
original awards over the remaining requisite service period after modification. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Share-based compensation in relation to the restricted
shares is measured based on the fair market value of the Group&#146;s ordinary shares at the grant date of the award. Prior to the listing, estimation of the fair value of the Group&#146;s ordinary shares involves significant assumptions that might
not be observable in the market, and a number of complex and subjective variables, including discount rate, and subjective judgments regarding the Group&#146;s projected financial and operating results, its unique business risks, the liquidity of
its ordinary shares and its operating history and prospects at the time the grants are made. Share-based compensation in relation to the stock options is estimated using the Binominal Option Pricing Model. The determination of the fair value of
stock options is affected by the share price of the Group&#146;s ordinary shares as well as the assumptions regarding a number of complex and subjective variables, including the expected share price volatility, risk-free interest rate, exercise
multiple and expected dividend yield. The fair value of these awards was determined with the assistance from an independent valuation firm. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>2.21
Income taxes </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Group accounts for income taxes under the liability method. Under the liability method, deferred income tax
assets and liabilities are determined based on the differences between the financial reporting and income tax bases of assets and liabilities and are measured using the tax income rates that will be in effect when the differences are expected to
reverse. A valuation allowance is recorded if it is more likely than not that some portion or all of the deferred income tax assets will not be utilized in the foreseeable future. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">I-MAB</FONT> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to the Unaudited Interim Condensed Consolidated Financial Statements </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(All amounts in thousands, except for share and per share data, unless otherwise noted) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2. Principal Accounting Policies&nbsp;(Continued) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>2.21 Income taxes&nbsp;(Continued) </I></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Group evaluates its uncertain tax positions using the provisions of ASC <FONT
STYLE="white-space:nowrap">740-10,&nbsp;Income</FONT> Taxes, which prescribes a recognition threshold that a tax position is required to meet before being recognized in the financial statements. The Group recognizes in the financial statements the
benefit of a tax position which is &#145;&#145;more likely than not&#146;&#146; to be sustained under examination based solely on the technical merits of the position assuming a review by tax authorities having all relevant information. Tax
positions that meet the recognition threshold are measured using a cumulative probability approach, at the largest amount of tax benefit that has a greater than fifty percent likelihood of being realized upon settlement. It is the Group&#146;s
policy to recognize interest and penalties related to unrecognized tax benefits, if any, as a component of income tax expense. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>2.22 Borrowings
</I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Borrowings are recognized initially at fair value, net of transaction costs incurred. Borrowings are subsequently stated at
amortized cost; any difference between the proceeds (net&nbsp;of transaction costs) and the redemption value is recognized in the consolidated statements of comprehensive loss over the period of the borrowings using the effective interest method.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>2.23 Segment information </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In
accordance with ASC 280,&nbsp;Segment Reporting, the Group&#146;s chief operating decision maker, the Chief Executive Officer, reviews the consolidated results when making decisions about allocating resources and assessing performance of the Group
as a whole and hence, the Group has only one reportable segment. The Group does not distinguish between markets or segments for the purpose of internal reporting. As the Group&#146;s long-lived assets are substantially located in and derived from
the PRC, no geographical segments are presented. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>2.24 Loss per share </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Basic loss per share is computed by dividing net loss attributable to ordinary shareholders by the weighted average number of ordinary shares
outstanding during the period using <FONT STYLE="white-space:nowrap">the&nbsp;two-class&nbsp;method.</FONT> Under <FONT STYLE="white-space:nowrap">the&nbsp;two-class&nbsp;method,</FONT> the net loss is allocated between ordinary shares and other
participating securities based on their participating rights. Net loss is not allocated to other participating securities if based on their contractual terms they are not obligated to share in the loss. Diluted loss per share is calculated by
dividing net loss attributable to ordinary shareholders by the weighted average number of ordinary and dilutive ordinary equivalent shares outstanding during the period. Ordinary equivalent shares consist of shares issuable upon the conversion of
the preferred shares using <FONT STYLE="white-space:nowrap">the&nbsp;if-converted&nbsp;method,</FONT> shares issuable upon the exercise of stock options using the treasury stock method, shares issuable upon the conversion of the convertible
promissory notes using <FONT STYLE="white-space:nowrap">the&nbsp;if-converted&nbsp;method,</FONT> and shares issuable upon the exercise of warrants using the treasury stock method. Ordinary equivalent shares are not included in the denominator of
the diluted loss per share calculation when inclusion of such shares would be anti-dilutive. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>2.25 Adopted accounting pronouncements </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In June 2016, the FASB issued ASU <FONT STYLE="white-space:nowrap">2016-13,</FONT> Financial Instruments&#151;Credit Losses (Topic 326):
Measurement of Credit Losses on Financial Instruments (&#147;ASU <FONT STYLE="white-space:nowrap">2016-13&#148;).</FONT> This guidance requires that financial </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">I-MAB</FONT> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to the Unaudited Interim Condensed Consolidated Financial Statements </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(All amounts in thousands, except for share and per share data, unless otherwise noted) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2. Principal Accounting Policies&nbsp;(Continued) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>2.25 Adopted accounting pronouncements&nbsp;(Continued) </I></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
assets measured at amortized cost be presented at the net amount expected to be collected. The measurement of expected credit losses is based on historical experience, current conditions, and
reasonable and supportable forecasts that affect the collectability. In November 2018, the FASB issued ASU <FONT STYLE="white-space:nowrap">2018-19,</FONT> Codification Improvements to Topic 326, Financial Instruments-Credit Losses (&#147;ASU <FONT
STYLE="white-space:nowrap">2018-19&#148;),</FONT> which clarifies certain topics included within ASU <FONT STYLE="white-space:nowrap">2016-13.</FONT> ASU <FONT STYLE="white-space:nowrap">2016-13</FONT> and ASU
<FONT STYLE="white-space:nowrap">2018-19</FONT> are effective for the annual reporting period beginning after December&nbsp;15, 2019, including interim periods within that reporting period. The impact of this ASU to the consolidated financial
statements is immaterial. The Group elected to adopt this ASU and applied this guidance retrospectively to all periods presented. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In
January 2017, the FASB issued ASU <FONT STYLE="white-space:nowrap">2017-04,</FONT> Intangibles&#151;Goodwill and Other (Topic 350), which simplifies the subsequent measurement of goodwill by removing the second step of the <FONT
STYLE="white-space:nowrap">two-step</FONT> impairment test. The amendment requires an entity to perform its annual or interim goodwill impairment test by comparing the fair value of a reporting unit with its carrying amount. A goodwill impairment
will be the amount by which a reporting unit&#146;s carrying value exceeds its fair value, not to exceed the carrying amount of goodwill. The Group adopted this ASU on January&nbsp;1, 2020 and the adoption of this ASU does not have a material impact
to its consolidated financial statements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In August 2018 the FASB issued ASU <FONT STYLE="white-space:nowrap">No.&nbsp;2018-13,</FONT>
Fair Value Measurement (Topic 820): Disclosure Framework&#151;Changes to the Disclosure Requirements for Fair Value Measurement. This standard modifies certain disclosure requirements on fair value measurements. This standard became effective for us
on January&nbsp;1, 2020. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In November 2018 the FASB issued
<FONT STYLE="white-space:nowrap">ASU&nbsp;No.&nbsp;2018-18,&nbsp;Collaborative</FONT> Arrangements (Topic 808): Clarifying the Interaction between Topic 808 and Topic 606. This standard makes targeted improvements for collaborative arrangements as
follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Clarifies that certain transactions between collaborative arrangement participants should be accounted for as
revenue under ASC 606, Revenue from Contracts with Customers, when the collaborative arrangement participant is a customer in the context of a unit of account. In those situations, all the guidance in ASC 606 should be applied, including
recognition, measurement, presentation and disclosure requirements; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
<P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Adds&nbsp;unit-of-account&nbsp;guidance</FONT></FONT> to ASC 808,
Collaborative Arrangements, to align with the guidance in ASC 606 (that is, a distinct good or service) when an entity is assessing whether the collaborative arrangement or a part of the arrangement is within the scope of ASC 606; and
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Precludes a company from presenting transactions with collaborative arrangement participants that are not
directly related to sales to third parties with revenue recognized under ASC 606 if the collaborative arrangement participant is not a customer. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">This standard became effective for the Group on January&nbsp;1, 2020. A retrospective transition approach is required for either all contracts
or only for contracts that are not completed at the date of initial application of ASC 606, with a cumulative adjustment to opening retained earnings. Since the Group&#146;s all relevant units of accounts were accounted for under ASC 606, the
adoption of this ASU does not have a material impact to the Group&#146;s consolidated financial statements, with no adjustment to its opening retained earnings. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">I-MAB</FONT> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to the Unaudited Interim Condensed Consolidated Financial Statements </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(All amounts in thousands, except for share and per share data, unless otherwise noted) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2. Principal Accounting Policies&nbsp;(Continued) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>2.26 Recent accounting pronouncements </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In December 2019, the FASB issued ASU <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">2019-12-Income</FONT></FONT> Taxes
(Topic 740): Simplifying the Accounting for Income Taxes. The amendments in ASU <FONT STYLE="white-space:nowrap">2019-12</FONT> simplify the accounting for income taxes by removing certain exceptions to the general principles in Topic 740. The
amendments also improve consistent application of and simplify GAAP for other areas of Topic 740 by clarifying and amending existing guidance. ASU <FONT STYLE="white-space:nowrap">2019-12</FONT> is effective for the Company beginning on
January&nbsp;1, 2022. Early adoption of the amendments is permitted. The Company is currently evaluating the impact of ASU <FONT STYLE="white-space:nowrap">2019-12</FONT> on its consolidated financial statements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>3. Prepayments and Other Receivables </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="72%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="53%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As&nbsp;of&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As of September&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>RMB</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>RMB</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>US$<BR>(Note&nbsp;2.5)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepayments:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&#151;Prepayments to CRO vendors</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">78,740</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">72,285</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,646</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&#151;Prepayments for stock repurchase program (Note 11)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">34,051</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,015</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&#151;Prepayments for other services</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">880</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,722</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">254</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Receivables due from employees (Note (i))</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,201</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loans to an affiliate (Note 21)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">52,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,659</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Value-added tax recoverable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,517</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25,330</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,731</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Rental deposits</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">546</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">994</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">146</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest receivables</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">764</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Others</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26,388</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">33,457</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,928</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">136,036</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">219,839</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">32,379</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Note: </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(i) The balance mainly represented the receivables due from employees, which were arising from the Group&#146;s obligation to pay the
withholding individual income tax (&#147;IIT&#148;) for those employees&#146; stock option activities and was collected by the Group in January 2020. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">I-MAB</FONT> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to the Unaudited Interim Condensed Consolidated Financial Statements </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(All amounts in thousands, except for share and per share data, unless otherwise noted) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>4. Property, Equipment and Software </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Property, equipment and software consist of the following: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="72%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="54%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>As&nbsp;of&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>As&nbsp;of&nbsp;September&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>RMB</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>RMB</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>US$<BR>(Note&nbsp;2.5)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cost</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Laboratory equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24,265</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27,336</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,026</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Leasehold improvement</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,856</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,605</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,857</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Software</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,220</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,201</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,502</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Office furniture and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,526</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,526</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">225</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total property, equipment and software</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">47,867</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">51,668</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,610</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Less: accumulated depreciation and amortization</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(18,221</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(25,935</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,820</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net book value</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">29,646</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25,733</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,790</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Construction in progress</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">423</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,325</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">195</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total net book value of property, equipment and software</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30,069</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27,058</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,985</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The total amounts charged to the interim condensed consolidated statements of comprehensive loss for
depreciation and amortization expenses amounted to approximately RMB6.8&nbsp;million and RMB7.7&nbsp;million for the nine months ended September&nbsp;30, 2019 and 2020, respectively. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>5. Intangible Assets </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Intangible assets
as of December&nbsp;31, 2019 and September&nbsp;30, 2020 are summarized as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="72%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="47%"></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>As&nbsp;of&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>As of September&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>RMB</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>RMB</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>US$<BR>(Note&nbsp;2.5)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cost</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">IPR&amp;D</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">148,844</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">122,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17,969</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Less: accumulated amortization</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net book value</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">148,844</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">122,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17,969</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">IPR&amp;D represents the fair value assigned to research and development assets that the Group acquired from
business combination of <FONT STYLE="white-space:nowrap">I-Mab</FONT> Tianjin and its subsidiaries including Chengdu Tasgen <FONT STYLE="white-space:nowrap">Bio-Tech</FONT> Co., Ltd. and Shanghai Tianyunjian
<FONT STYLE="white-space:nowrap">Bio-Tech</FONT> Co., Ltd. (together the &#147;Tasgen Group&#148;) in 2017 and had not reached technological feasibility at the date of acquisition. Upon commercialization, the Group will determine the estimated
useful life and amortize these amounts based upon an economic consumption method. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">I-MAB</FONT> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to the Unaudited Interim Condensed Consolidated Financial Statements </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(All amounts in thousands, except for share and per share data, unless otherwise noted) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>5. Intangible Assets&nbsp;(Continued) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The fair value assigned to the IPR&amp;D related to TJ102 was RMB26,844 (US$3,954). On
September 15, 2020, <FONT STYLE="white-space:nowrap">I-Mab</FONT> Hong Kong and Genexine, Inc. entered into amendments to Intellectual Property License Agreement with <FONT STYLE="white-space:nowrap">I-Mab</FONT> Hangzhou to assign and transfer all
the rights and obligations related to TJ102 to <FONT STYLE="white-space:nowrap">I-Mab</FONT> Hangzhou, pursuant to an equity transfer and investment agreement entered into between <FONT STYLE="white-space:nowrap">I-Mab</FONT> Hong Kong and various
parties (Note 7). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2019 and September&nbsp;30, 2020, there was no impairment of the value of the Group&#146;s
intangible assets. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>6. Goodwill </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">On
July&nbsp;15, 2017, the Group acquired 66.67% of the equity interests in the Tasgen Group by issuing convertible preferred shares and controlled the board of directors and business of <FONT STYLE="white-space:nowrap">I-Mab</FONT> Tianjin since then.
Tasgen Group is principally engaged in the research and development of innovative medicines and the Group acquired Tasgen Group for its research team, technical experience, and IPR&amp;D pipeline assets (see Note 5). As of December&nbsp;31, 2019 and
September&nbsp;30, 2020, the goodwill of RMB162,574 (US$23,945) represented the goodwill generated from the aforementioned acquisition of Tasgen Group and the business of Tasgen Group was fully integrated into the Company after the acquisition.
There was no impairment of the value of the Group&#146;s goodwill. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2019 and September&nbsp;30, 2020, the Group
performed a qualitative assessment by evaluating relevant events and circumstances that would affect the Group&#146;s single reporting unit and did not note any indicator that it is more likely than not that the fair value of the Group&#146;s
reporting unit is less than its carrying amount and therefore the Group&#146;s goodwill was not impaired. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>7. Investment Accounted for Using the Equity
Method and Put Right Liabilities </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>(a) Investment accounted for using the equity method </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">I-Mab</FONT> Hangzhou, incorporated on June&nbsp;16, 2019, was a wholly owned subsidiary of <FONT
STYLE="white-space:nowrap">I-Mab</FONT> Hong Kong with registered capital of US$30&nbsp;million, which was paid up by <FONT STYLE="white-space:nowrap">I-Mab</FONT> Hong Kong on September&nbsp;14, 2020. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">On September&nbsp;15, 2020 (the &#147;Closing Date&#148;), <FONT STYLE="white-space:nowrap">I-Mab</FONT> Hong Kong entered into an equity
transfer and investment agreement (the &#147;SPA&#148;) with (i)&nbsp;a limited partnership jointly established by the management of <FONT STYLE="white-space:nowrap">I-Mab</FONT> Hangzhou to hold restricted equity of
<FONT STYLE="white-space:nowrap">I-Mab</FONT> Hangzhou issued to the management (&#147;Management Holdco&#148;), (ii) a limited partnership established to hold the shares of <FONT STYLE="white-space:nowrap">I-Mab</FONT> Hangzhou for future equity
incentive plan (&#147;ESOP Holdco&#148;) and (iii)&nbsp;a group of domestic investors in China (&#147;Domestic Investors&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In
accordance with the terms of the SPA, </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><FONT STYLE="white-space:nowrap">I-Mab</FONT> Hong Kong agreed to assign all rights and obligations/ownership
of certain drug candidates in different stages of development (&#147;Target Pipelines&#148;) to <FONT STYLE="white-space:nowrap">I-Mab</FONT> Hangzhou as of the Closing Date as well as to transfer employment of a team of designated
management/workforce to <FONT STYLE="white-space:nowrap">I-Mab</FONT> Hangzhou. The Target Pipelines were evaluated by an independent valuer, with a total value of US$105&nbsp;million as of the Closing Date; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-23 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">I-MAB</FONT> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to the Unaudited Interim Condensed Consolidated Financial Statements </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(All amounts in thousands, except for share and per share data, unless otherwise noted) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>7. Investment Accounted for Using the Equity Method and Put Right Liabilities&nbsp;(Continued) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>(a) Investment accounted for using the equity method&nbsp;(Continued) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Management Holdco would acquire 10% of the equity of <FONT STYLE="white-space:nowrap">I-Mab</FONT> Hangzhou
from <FONT STYLE="white-space:nowrap">I-Mab</FONT> Hong Kong with no consideration. The 10% equity is represented by <FONT STYLE="white-space:nowrap">I-Mab</FONT> Hangzhou&#146;s registered capital of US$3&nbsp;million, and that after acquiring such
equity, Management Holdco will pay US$3&nbsp;million to <FONT STYLE="white-space:nowrap">I-Mab</FONT> Hangzhou to fulfil its capital contribution obligations in a period of four years starting from the Closing Date; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">ESOP Holdco would acquire 5% of the equity of <FONT STYLE="white-space:nowrap">I-Mab</FONT> Hangzhou from <FONT
STYLE="white-space:nowrap">I-Mab</FONT> Hong Kong with no consideration. The 5% equity is represented by <FONT STYLE="white-space:nowrap">I-Mab</FONT> Hangzhou&#146;s registered capital of US$1.5&nbsp;million. All of such equity will be used to
implement <FONT STYLE="white-space:nowrap">I-Mab</FONT> Hangzhou&#146;s equity incentive plan. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(iv)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Domestic Investors would acquire a total of 40% of the equity of <FONT STYLE="white-space:nowrap">I-Mab</FONT>
Hangzhou from <FONT STYLE="white-space:nowrap">I-Mab</FONT> Hong Kong with no consideration. The 40% equity is represented <FONT STYLE="white-space:nowrap">I-Mab</FONT> Hangzhou&#146;s registered capital of US$12&nbsp;million, and after acquiring
such equity of <FONT STYLE="white-space:nowrap">I-Mab</FONT> Hangzhou, Domestic Investors would pay US$120&nbsp;million collectively to <FONT STYLE="white-space:nowrap">I-Mab</FONT> Hangzhou to fulfil its capital contribution obligations.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">After completion of the equity transfer, the registered capital of <FONT STYLE="white-space:nowrap">I-Mab</FONT>
Hangzhou remained to be US$30&nbsp;million. The equity interest in <FONT STYLE="white-space:nowrap">I-Mab</FONT> Hangzhou held by <FONT STYLE="white-space:nowrap">I-Mab</FONT> Hong Kong, Domestic Investors, Management Holdco and ESOP Holdco are 45%,
40%, 10% and 5% respectively. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">On the same day, <FONT STYLE="white-space:nowrap">I-Mab</FONT> Hong Kong also entered into a shareholders
agreement with the aforementioned investors (the &#147;SHA&#148;). According to the SHA and <FONT STYLE="white-space:nowrap">I-Mab</FONT> Hangzhou&#146;s articles of association, the board of directors of
<FONT STYLE="white-space:nowrap">I-Mab</FONT> Hangzhou shall be composed of seven directors. The directors shall be elected in the following ways: <FONT STYLE="white-space:nowrap">I-Mab</FONT> Hong Kong is entitled to appoint three directors,
including the chairman of the board of directors, as well as nominate one independent director; the Management Holdco is entitled to appoint one director; two <FONT STYLE="white-space:nowrap">non-related</FONT> entities of the Domestic Investors are
entitled to appoint one director respectively (&#147;Investors Directors&#148;). Each director of the board of directors shall have one vote. <FONT STYLE="white-space:nowrap">I-Mab</FONT> Hong Kong, Management Holdco and ESOP Holdco agree to act in
concert, as long as each of Management Holdco and ESOP Holdco respectively holds equity in <FONT STYLE="white-space:nowrap">I-Mab</FONT> Hangzhou, when exercising the rights as a shareholder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">As a result of the above transactions, <FONT STYLE="white-space:nowrap">I-Mab</FONT> Hangzhou became an affiliate of the Group on the Closing
Date in accordance with ASC 810 since <FONT STYLE="white-space:nowrap">I-Mab</FONT> Hangzhou meets the definition of a business under ASC 805. In accordance with ASC 810-10, I-Mab Hangzhou is a variable interest entity, and no shareholder shall
consolidate I-Mab Hangzhou under variable interest entity model as neither party have the power to direct all the activities that most significantly impact the economic performance of I-Mab Hangzhou. Therefore, the Group deconsolidated <FONT
STYLE="white-space:nowrap">I-Mab</FONT> Hangzhou and retained 45% equity interest in <FONT STYLE="white-space:nowrap">I-Mab</FONT> Hangzhou. The investment was accounted for using the equity method. The retained investment in the common stock of <FONT
STYLE="white-space:nowrap">I-Mab</FONT> Hangzhou was initially measured at fair value in accordance with ASC <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">810-10-40.</FONT></FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Group determined the fair value of its retained equity interest with the assistance of an independent third-party valuation firm. The
Group used equity allocation model to estimate the fair value of the investment. The fair value as of the Closing Date was US$112,039 (equivalent to approximately RMB764,352) which reflected the fact that the shares subscribed by Management Holdco
and ESOP Holdco were not issued and outstanding as of the Closing Date. The carrying value of the Group&#146;s long-term investment measured under equity method was RMB762,997 as of September&nbsp;30, 2020. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">I-MAB</FONT> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to the Unaudited Interim Condensed Consolidated Financial Statements </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(All amounts in thousands, except for share and per share data, unless otherwise noted) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>7. Investment Accounted for Using the Equity Method and Put Right Liabilities&nbsp;(Continued) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>(a) Investment accounted for using the equity method&nbsp;(Continued) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">A gain of RMB407,598&nbsp;was recognized as a result of the deconsolidation. The gain
represented the difference between: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The fair value of the retained noncontrolling investment in <FONT STYLE="white-space:nowrap">I-Mab</FONT>
Hangzhou at the Closing Date; and </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The aggregate of all of the following: </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="12%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the carrying amount of transferred intellectual property related to TJ102 at the Closing Date (Note 5);
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="12%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the fair value of the put right liabilities written by <FONT STYLE="white-space:nowrap">I-Mab</FONT> Hong Kong
to Domestic Investors; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="12%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the carrying amount of <FONT STYLE="white-space:nowrap">I-Mab</FONT> Hangzhou&#146;s net assets at the Closing
Date. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>(b) Put right liabilities </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Pursuant to the SHA, if <FONT STYLE="white-space:nowrap">I-Mab</FONT> Hangzhou fails to close a public offering of <FONT
STYLE="white-space:nowrap">I-Mab</FONT> Hangzhou&#146;s shares on the China Stock Exchange&#146;s Science and Technology Innovation Board, Main Board, Small and <FONT STYLE="white-space:nowrap">Medium-Sized</FONT> Enterprise Board, Growth Enterprise
Board, or Hong Kong Stock Exchange, U.S. Stock Exchange, or other stock exchanges approved by the shareholders of <FONT STYLE="white-space:nowrap">I-Mab</FONT> Hangzhou in accordance with provisions of the SHA within 4 years after September&nbsp;15,
2020, <FONT STYLE="white-space:nowrap">I-Mab</FONT> Hong Kong has agreed to repurchase the equity held by Domestic Investors by cash or <FONT STYLE="white-space:nowrap">I-Mab&#146;s</FONT> stock (subject to the approval procedures of <FONT
STYLE="white-space:nowrap">I-Mab)</FONT> within 3 years after the expiration of the <FONT STYLE="white-space:nowrap">4-year</FONT> period after September&nbsp;15, 2020. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The put right written by <FONT STYLE="white-space:nowrap">I-Mab</FONT> Hong Kong to Domestic Investors is a freestanding equity-linked
instrument, which is classified as a put right liability and recorded at fair value with changes in fair value recorded in the income statement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Group determined the fair value of the put right with the assistance of an independent third-party valuation firm. The Group used the
option pricing model (finnerty model) to estimate the fair value of the put right using the following assumptions: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="76%"></TD>

<TD VALIGN="bottom" WIDTH="20%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As&nbsp;of&nbsp;September&nbsp;15,<BR>and September&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected terms (Year)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Estimated volatility</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">55.2</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Spot price</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">US$</TD>
<TD VALIGN="bottom" ALIGN="right">143,401</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Probability of triggering event for redemption option</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">65</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The model requires the input of highly subjective assumptions including the expected terms, estimated
volatility, spot price and probability of triggering event for redemption option. Expected terms is estimated based on the timing of a hypothetical redemption event which is assumed to be the earlier of expected redemption date
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-25 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">I-MAB</FONT> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to the Unaudited Interim Condensed Consolidated Financial Statements </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(All amounts in thousands, except for share and per share data, unless otherwise noted) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>7. Investment Accounted for Using the Equity Method and Put Right Liabilities&nbsp;(Continued) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>(b) Put right liabilities&nbsp;(Continued) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
or expected public offering date. Expected volatility is estimated based on daily stock prices of the comparable company for a period with length commensurate to the expected terms of redemption
event. The spot price was determined with assistance from an independent third-party valuation firm. The Group&#146;s management is ultimately responsible for the determination of the spot price and probability of triggering event for redemption
option. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Significant decreases in interval between valuation date and maturity date, estimated volatility, spot price and probability of
triggering event for redemption option would result in a significantly lower fair value measurement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>8. Short-term Borrowings </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In June 2019, <FONT STYLE="white-space:nowrap">I-Mab</FONT> <FONT STYLE="white-space:nowrap">Bio-tech</FONT> (Tianjin) Co., Ltd. borrowed a
loan of RMB50,000 from China Merchant Bank Co., Ltd. for a term of one year and at the interest rate of 4.15% per annum. To facilitate this borrowing, another subsidiary of the Company in Hong Kong placed cash deposits of US$8,000 (equivalent to
approximately RMB55,810) with the bank. The use of such cash deposits and the interest earned thereon are restricted by the bank during the period of the borrowing. The deposits have a <FONT STYLE="white-space:nowrap">one-year</FONT> term and bear
interest at 2.63% per annum. The borrowing was repaid in June 2020. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>9. Accruals and Other Payables </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="72%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="57%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>As&nbsp;of&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>As of September&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>RMB</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>RMB</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>US$<BR>(Note
2.5)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Staff salaries and welfare payables</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30,166</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,783</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,325</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued external research and development activities related expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">144,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">150,622</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,184</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued initial public offering costs payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17,504</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">508</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">75</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued private placement offering costs payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">96,837</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,263</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Withholding IIT payable related to stock options</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,201</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Non-refundable</FONT> incentive payment from depositary bank
(Note)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,630</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">387</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued traveling expenses, office expenses and others</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">65,682</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">71,937</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,595</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">273,553</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">338,317</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">49,829</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Non-current:</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Non-refundable</FONT> incentive payment from depositary bank
(Note)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,433</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,242</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-26 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">I-MAB</FONT> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to the Unaudited Interim Condensed Consolidated Financial Statements </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(All amounts in thousands, except for share and per share data, unless otherwise noted) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>9. Accruals and Other Payables&nbsp;(Continued) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Note: The Group received a <FONT STYLE="white-space:nowrap">non-refundable</FONT> incentive
payment&nbsp;of US$1,857&nbsp;(equivalent to approximately RMB12,982) from depositary bank in April 2020.&nbsp;The amount was recorded ratably as other gains over a five-year arrangement period. For the nine months ended September&nbsp;30, 2020, the
Group has recorded RMB1,731 as other income in the interim condensed consolidated financial statements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>10. Income Taxes </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Group has incurred net accumulated operating losses for income tax purposes since its inception. The Group believes that it is more likely
than not that these net accumulated operating losses will not be utilized in the future. Therefore, the Group has provided full valuation allowances for the deferred tax assets as of December&nbsp;31, 2019 and September&nbsp;30, 2020. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>11. Ordinary Shares </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">As of
December&nbsp;31, 2019 and September&nbsp;30, 2020, 500,000,000 ordinary shares had been authorized by the Company. Each ordinary share is entitled to one vote. The holders of ordinary shares are also entitled to receive dividends whenever funds are
legally available and when declared by the Board of Directors of the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">On October&nbsp;29, 2019, the Company&#146;s shareholders
and board of directors approved that immediately prior to the completion of initial public offering, the Company&#146;s authorized share capital will be changed into US$80,000 divided into 800,000,000 ordinary shares of a par value of US$0.0001
each. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">On January&nbsp;17, 2020, the Company completed its IPO and became listed on the Nasdaq Global Market by issuing 7,407,400 American
Depositary Shares (&#147;ADSs&#148;) at the price of US$14.00 per ADS for total gross proceeds of US$103.7&nbsp;million. On February&nbsp;10, 2020, the underwriters of the IPO have exercised their over-allotment option to purchase an additional
768,350 ADSs of the Company at the IPO price of US$14.00 per ADS. After giving effect to the exercise of the over-allotment option, the Company has issued and sold a total of 8,175,750 ADSs in the IPO, for total net proceeds of US$101.3&nbsp;million
(equivalent to RMB697,788), netting of issuance cost from total gross proceeds of US$114.5&nbsp;million. Each ten ADSs represent twenty-three ordinary shares of the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">On January&nbsp;17, 2020, the Company also issued 6,078,571 ordinary shares to Everest (see Note 16 for details). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Upon the completion of the IPO, the Company&#146;s then outstanding 30,227,056 Series A Preferred Shares, 23,288,783 Series B Preferred
Shares, 3,714,580 Series <FONT STYLE="white-space:nowrap">B-1</FONT> Preferred Shares, 3,301,849 Series <FONT STYLE="white-space:nowrap">B-2</FONT> Preferred Shares, 31,046,360 Series C Preferred Shares and 3,857,143 Series <FONT
STYLE="white-space:nowrap">C-1</FONT> Preferred Shares were converted into 30,227,056, 23,288,783, 3,714,580, 3,571,427, 34,420,469 and 4,537,814 ordinary shares, respectively. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">On July&nbsp;15, 2020, the Group&#146;s Board of Directors approved a share repurchase program to repurchase in the open market up to
US$20&nbsp;million worth of outstanding ADSs of the Group. The Group paid total prepayment of US$5,000 (equivalent to RMB34,051) for the share repurchase. As of September&nbsp;30, 2020, none of the ordinary shares were repurchased. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">On September&nbsp;3, 2020, the Group entered into definitive subscription agreements with a consortium of institutional investors (the
&#147;Investors&#148;) to raise approximately US$418&nbsp;million through a private placement. The consortium is led by Hillhouse Capital Group (&#147;Hillhouse&#148;), with significant participation by GIC Private Limited, and also includes certain
other leading Asian and U.S. biotech investment funds, Hillhouse is entitled to nominate one representative to <FONT STYLE="white-space:nowrap">I-Mab&#146;s</FONT> Board of Directors. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-27 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">I-MAB</FONT> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to the Unaudited Interim Condensed Consolidated Financial Statements </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(All amounts in thousands, except for share and per share data, unless otherwise noted) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>11. Ordinary Shares&nbsp;(Continued) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The private placement comprises (1)&nbsp;the sale to the Investors of the Group&#146;s
29,133,502 ordinary shares (equivalent to 12,666,740 ADSs) at a purchase price equivalent to US$33 per ADS amounting to approximately US$418&nbsp;million; and (2)&nbsp;warrants (the &#147;Investor Warrants&#148;, see Note 14(b)) to subscribe for an
aggregate of 5,341,267 ordinary shares (equivalent to 2,322,290 ADSs) at an exercise price equivalent to US$45 per ADS, which may further increase the proceeds of approximately US$104.5&nbsp;million if the Investor Warrants are fully exercised. The
Investor Warrants will remain exercisable at the election of the Investors within 12 months after the closing of the private placement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The subscription agreement with the Hillhouse entities contemplates two closings. The first closing occurred on September&nbsp;11, 2020, and
the second closing is conditioned upon an existing director of the Group having resigned to enable the Hillhouse entities to appoint a director to replace such director and the lemzoparlimab <FONT STYLE="white-space:nowrap">out-licensing</FONT>
agreement with AbbVie (see Note 16) being or remaining effective. As of September&nbsp;30, 2020, 20,421,378 ordinary shares and 3,744,032 Investor Warrants were issued to the Investors for total gross proceeds of approximately US$293&nbsp;million.
In December 2020, the Group entered into a written amendment made to the subscription agreement with the Hillhouse entities, which removed one of the two conditions for the second closing that an existing director of the Group having resigned to
enable the Hillhouse entities to appoint a director to replace such director. The second closing occurred as the other condition was satisfied and 8,712,124 ordinary shares as well as 1,597,235 Investor Warrants were issued to the Hillhouse entities
for total gross proceeds of approximately US$125.0&nbsp;million. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">As of September&nbsp;30, 2020, 115,888 stock options under 2017 Employee
Stock Option Plan were exercised. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>12. Convertible Preferred Shares </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">On January&nbsp;17, 2020, immediately prior to the completion of the Company&#146;s IPO, all of the convertible redeemable preferred shares
were converted to ordinary shares. Prior to their conversion, the convertible redeemable preferred shares were entitled to certain privileges over ordinary shares with respect to dividends, conversion, and liquidation. The transactions and impact
are disclosed as below. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">On October&nbsp;18, 2016, the Company issued 5,141,587 shares of Series
<FONT STYLE="white-space:nowrap">A-1</FONT> and <FONT STYLE="white-space:nowrap">A-2</FONT> Preferred Shares with a consideration of US$11,282 (equivalent to approximately RMB74,742). In connection with the Series
<FONT STYLE="white-space:nowrap">A-1</FONT> and <FONT STYLE="white-space:nowrap">A-2</FONT> Preferred Shares issuance, the Company also issued 2,246,744 warrant to purchase its Series <FONT STYLE="white-space:nowrap">A-3</FONT> Preferred Shares
(&#147;Series <FONT STYLE="white-space:nowrap">A-3</FONT> Warrants&#148; and see Note 14). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">On September&nbsp;6, 2017, in connection with
the Group&#146;s acquisition of Tasgen Group, the Company issued 16,723,646 shares of Series <FONT STYLE="white-space:nowrap">A-3</FONT> Preferred Shares at a price of US$2.55 per share with a total consideration of US$42,645 (equivalent to
approximately RMB289,024). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Series <FONT STYLE="white-space:nowrap">A-1</FONT> Preferred Shares, Series
<FONT STYLE="white-space:nowrap">A-2</FONT> Preferred Shares and Series <FONT STYLE="white-space:nowrap">A-3</FONT> Preferred Shares are also referred to as Series A Preferred Shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">On September&nbsp;22, 2017, the Company issued 15,894,594 shares of Series B Preferred Shares with a consideration of US$52,546 (equivalent to
approximately RMB346,515). In connection with the Series B Preferred Shares issuance, the Company also issued convertible promissory notes that are convertible into Series <FONT STYLE="white-space:nowrap">B-1</FONT> Preferred Shares (&#147;2017
Notes&#148; and see Notes 13) and 5,633,780 warrants to purchase its Series <FONT STYLE="white-space:nowrap">B-2</FONT> Preferred Shares (&#147;Series B Warrant&#148; and see Note 14). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-28 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">I-MAB</FONT> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to the Unaudited Interim Condensed Consolidated Financial Statements </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(All amounts in thousands, except for share and per share data, unless otherwise noted) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>12. Convertible Preferred Shares&nbsp;(Continued) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Concurrently with the Company&#146;s issuance of Series B Preferred Shares, the Company also
completed a round of onshore financing with respect to the Group&#146;s subsidiary <FONT STYLE="white-space:nowrap">I-MAB</FONT> Tianjin (&#147;Series B Onshore Financing&#148;). Series B Onshore Financing comprised 1) capital injection to <FONT
STYLE="white-space:nowrap">I-Mab</FONT> Tianjin by a number of investors (&#147;Series B Onshore Investors&#148;) (see Note 13), 2) <FONT STYLE="white-space:nowrap">I-Mab</FONT> Tianjin&#146;s issuance of convertible loans (&#147;Onshore Convertible
Loans&#148; and see Note 13), and 3) the Company&#146;s issuance of 2,620,842 warrants to purchase its Series <FONT STYLE="white-space:nowrap">B-2</FONT> Preferred Shares (&#147;Series B Warrants&#148; and see Note 14). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">On June&nbsp;29, 2018, the Company issued total 8,361,823 shares of Series <FONT STYLE="white-space:nowrap">A-3</FONT> Preferred Shares upon
exercise of Series <FONT STYLE="white-space:nowrap">A-3</FONT> Option held by its holder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">On June&nbsp;29, 2018, the Company issued
2,535,201 shares of Series <FONT STYLE="white-space:nowrap">B-1</FONT> Preferred Shares upon conversion of 2017 Notes and issued 2,253,512 shares of Series <FONT STYLE="white-space:nowrap">B-2</FONT> Preferred Shares upon exercise of Series B
Warrant by Series B preferred shareholders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">On June&nbsp;29, 2018, the Company issued 5,938,640 shares of Series B Preferred Shares upon
exercise of the Series B Option held by a Series B Onshore Investor and issued 947,218 shares of Series <FONT STYLE="white-space:nowrap">B-1</FONT> Preferred Shares upon conversion of Onshore Convertible Loans by a Series B Onshore Investor (see
Note 13), respectively. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">On July&nbsp;6, 2018, the Company issued 1,455,549 shares of Series B Preferred Shares upon exercise of the
Series B Option held by a Series B Onshore Investor, issued 232,161 shares of Series <FONT STYLE="white-space:nowrap">B-1</FONT> Preferred Shares upon conversion of Onshore Convertible Loans by a Series B Onshore Investor (see Note 13) and issued
1,048,337 shares of Series <FONT STYLE="white-space:nowrap">B-2</FONT> Preferred Shares upon exercise of Series B Warrant by Series B Onshore Investors, respectively. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Series B Preferred Shares, Series <FONT STYLE="white-space:nowrap">B-1</FONT> Preferred Shares and Series
<FONT STYLE="white-space:nowrap">B-2</FONT> Preferred Shares are also referred to as Series B Preferred Shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">On July&nbsp;6, 2018, the
Company issued 31,046,360 shares of Series C Preferred Shares at a price of US$6.4419 per share with a total consideration of US$200,000 (equivalent to approximately RMB1,323,363). In connection with the offering of the Series C Preferred Shares,
the Company incurred issuance costs of RMB16,730. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">On July&nbsp;25, 2019, the Group entered into a share purchase agreement with certain
third party investors, under which these investors will subscribe for an aggregate of 3,857,143 Series <FONT STYLE="white-space:nowrap">C-1</FONT> convertible preferred shares of the Company for an aggregate purchase price of US$27.0&nbsp;million.
Out of the aforementioned subscription of 3,857,143 Series <FONT STYLE="white-space:nowrap">C-1</FONT> convertible preferred shares by certain third party investors, 1,428,571 Series <FONT STYLE="white-space:nowrap">C-1</FONT> convertible preferred
shares were issued to an investor on October&nbsp;17, 2019, and the Group also received the cash consideration of US$10,000 (equivalent to approximately RMB70,036). On November&nbsp;6, 2019, the Group received cash consideration of US$17,000
(equivalent to approximately RMB119,387) for the remaining 2,428,572 Series <FONT STYLE="white-space:nowrap">C-1</FONT> convertible preferred shares from the investors and the issuance of such 2,428,572 Series
<FONT STYLE="white-space:nowrap">C-1</FONT> convertible preferred shares were consummated on that day. In connection with the offering of the Series <FONT STYLE="white-space:nowrap">C-1</FONT> convertible preferred shares, the Company incurred
issuance costs of approximately US$840 (equivalent to approximately RMB5,887). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-29 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">I-MAB</FONT> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to the Unaudited Interim Condensed Consolidated Financial Statements </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(All amounts in thousands, except for share and per share data, unless otherwise noted) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>12. Convertible Preferred Shares&nbsp;(Continued) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Upon the completion of the IPO on January&nbsp;17, 2020, all outstanding 30,227,056 Series A
Preferred Shares, 23,288,783 Series B Preferred Shares, 3,714,580 Series <FONT STYLE="white-space:nowrap">B-1</FONT> Preferred Shares, 3,301,849 Series <FONT STYLE="white-space:nowrap">B-2</FONT> Preferred Shares, 31,046,360 Series C Preferred
Shares and 3,857,143 Series <FONT STYLE="white-space:nowrap">C-1</FONT> Preferred Shares were converted into 30,227,056, 23,288,783, 3,714,580, 3,571,427, 34,420,469 and 4,537,814 ordinary shares, respectively. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Series A Preferred Shares, Series B Preferred Shares, Series C Preferred Shares and Series <FONT STYLE="white-space:nowrap">C-1</FONT>
Preferred Shares are collectively referred to as Preferred Shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Key terms of the Preferred Shares are summarized as follows: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><I>Dividends </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The holders
of Preferred Shares are entitled to receive dividends, out of any assets legally available therefore, prior and in preference to any declaration or payment of any dividend on the ordinary shares or any other class or series of shares of the Group at
the rate of eight percent (8%) of the original issue price per share per annum on each Preferred Share, payable in US$ and annually when, as and if declared by the Board of Directors. Such distributions shall not be cumulative. No dividend, whether
in cash, in property or in shares of the capital of the Group, shall be paid on or declared and set aside for any ordinary shares or any other class or series of shares of the Group unless and until all dividends have been paid in full on the
Preferred Shares (on an <FONT STYLE="white-space:nowrap">as-converted</FONT> basis). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><I>Conversion </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Each Preferred Share may be converted at any time into ordinary shares at the option of the preferred shares holders at the then applicable
conversion price. The initial conversion ratio is 1:1, subject to adjustment in the event of (i)&nbsp;share splits, share combinations, share dividends or distribution, other dividends, recapitalizations and similar events, or (ii)&nbsp;issuance of
ordinary shares (excluding certain events such as issuance of ordinary shares pursuant to a public offering) at a price per share less than the conversion price in effect on the date of or immediately prior to such issuance. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Preferred Shares shall be automatically converted into ordinary shares immediately upon the closing of a public offering of the
Company&#146;s shares with an offering price (exclusive of underwriting commissions and expenses) that reflects a market capitalization (immediately prior to the public offering) of not less than US$1,000,000,000 or otherwise approved by all
directors and certain preferred shareholders as specified in the Company&#146;s memorandum and articles of association (the &#147;Qualified Public Offering&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Group determined that there were no beneficial conversion features (&#147;BCF&#148;) identified for any of the Preferred Shares during any
of the periods. In making this determination, the Company compared the fair value of the ordinary shares into which the Preferred Shares are convertible with the respective effective conversion price at the issuance date. In all instances, the
effective conversion price was greater than the fair value of the ordinary shares. To the extent a conversion price adjustment occurs, as described above, the Group will reevaluate whether or not a beneficial conversion feature should be recognized.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-30 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">I-MAB</FONT> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to the Unaudited Interim Condensed Consolidated Financial Statements </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(All amounts in thousands, except for share and per share data, unless otherwise noted) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>12. Convertible Preferred Shares&nbsp;(Continued) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><I>Liquidation </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In the event of any liquidation (unless waived by the preferred shareholders) including deemed liquidation, dissolution or winding up of the
Company, holders of the Preferred Shares shall be entitled to receive a per share amount equal to one hundred percent (100%) of the original issue price on each Preferred Share, plus an amount representing an internal rate of return of twelve
percent (12%) per annum on the original issue price as adjusted for share dividends, share splits, combinations, recapitalizations or similar events, plus all accrued and declared but unpaid dividends thereon, in the sequence of Series C Preferred
Shares, Series B Preferred Shares and Series A Preferred Shares. After such liquidation amounts have been paid in full, any remaining funds or assets of the Company legally available for distribution to shareholders shall be distributed on a pro
rata basis among the holders of the Preferred Shares, on an <FONT STYLE="white-space:nowrap">as-converted</FONT> basis, together with the holders of the ordinary shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Accounting for preferred shares </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The
Preferred Shares are redeemable by the holders upon a liquidation event, including a deemed liquidation event (e.g., change in control), and as such are presented as mezzanine equity on the consolidated balance sheets. In accordance with ASC <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">480-10-S99,</FONT></FONT> each issuance of the convertible preferred shares should be recognized at the date of issuance after deducting fair value allocated to the detachable warrants and
issuance costs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Modification of preferred shares </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Company assesses whether an amendment to the terms of its convertible preferred shares is an extinguishment or a modification using the
fair value model.</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">When convertible redeemable preferred shares are extinguished, the difference between the fair value of the
consideration transferred to the convertible redeemable Preferred Shareholders and the carrying amount of such preferred shares (net of issuance costs) is treated as a deemed dividend to the Preferred Shareholders. When convertible redeemable
preferred shares are modified and such modification results in value transfer between Preferred Shareholders and ordinary shareholders, the change in fair value resulted from the amendment is treated as a deemed dividend to or from the Preferred
Shareholders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">On December&nbsp;25, 2019, the Company&#146;s shareholders and board of directors approved that, where the final offering
price of a Qualified Public Offering is no less than US$4.176 per ordinary share, the agreed provisions related to the number of shares to be converted into the Company&#146;s ordinary shares shall apply with respect to the Series <FONT
STYLE="white-space:nowrap">C-1</FONT> Preferred Shares, Series C Preferred Shares, Series <FONT STYLE="white-space:nowrap">B-2</FONT> Preferred Shares and Series <FONT STYLE="white-space:nowrap">B-1</FONT> Preferred Shares, which will generally give
rise to a one to multiple conversion of the such rounds of Preferred Shares, provided that unanimous consent of the directors on the final offering price needs to be obtained in the event that the final offering price per ordinary share of such IPO
is fixed at a price equal to or higher than US$4.176 per ordinary share but lower than US$5.22 per ordinary share. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Company evaluated
the aforementioned modifications and concluded that they represented modifications, rather than extinguishment, to Series <FONT STYLE="white-space:nowrap">B-1,</FONT> <FONT STYLE="white-space:nowrap">B-2</FONT> and C Preferred Shares, which resulted
in a transfer of value from ordinary shareholders to preferred shareholders. The combined change in fair value of Series <FONT STYLE="white-space:nowrap">B-1,</FONT> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-31 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">I-MAB</FONT> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to the Unaudited Interim Condensed Consolidated Financial Statements </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(All amounts in thousands, except for share and per share data, unless otherwise noted) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>12. Convertible Preferred Shares&nbsp;(Continued) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Modification of preferred shares&nbsp;(Continued) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
<FONT STYLE="white-space:nowrap">B-2</FONT> and C Preferred Shares immediately before and after the modification was US$4.0&nbsp;million (equivalent to approximately RMB27.8 million) on
December&nbsp;25, 2019. This decrease in fair value of the ordinary shares of US$4.0&nbsp;million (equivalent to approximately RMB27.8 million) on December&nbsp;25, 2019 was, in substance, a transfer of wealth mostly from ordinary shareholders to
preferred shareholders, and therefore was recorded as a deemed dividend to the preferred shareholders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Company evaluated the
aforementioned modifications and concluded that they represented extinguishment to Series <FONT STYLE="white-space:nowrap">C-1</FONT> Preferred Shares. The difference between the fair value of the modified Series
<FONT STYLE="white-space:nowrap">C-1</FONT> Preferred Shares and the carrying value of the original Series <FONT STYLE="white-space:nowrap">C-1</FONT> Preferred Shares was amounting US$0.8&nbsp;million on December&nbsp;25, 2019 and represented the
fair value of the consideration transferred, and therefore was recognized as a deemed dividend to the preferred shareholders and adjustment to the carrying amount of Series <FONT STYLE="white-space:nowrap">C-1</FONT> Preferred Shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Company&#146;s convertible preferred shares activities for the nine months ended September&nbsp;30, 2019 and 2020 are summarized below:
</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:7.5pt" ALIGN="center">


<TR>

<TD WIDTH="13%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Series A Preferred</B><br><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Series B Preferred</B><br><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Series C Preferred</B><br><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Series <FONT STYLE="white-space:nowrap">C-1</FONT> Preferred</B><br><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Number&nbsp;of<BR>shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Number&nbsp;of<BR>shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Number&nbsp;of<BR>shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Number&nbsp;of<BR>shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:7pt; font-family:Times New Roman; " ALIGN="center"><B>US$</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:7pt; font-family:Times New Roman; " ALIGN="center"><B>RMB</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:7pt; font-family:Times New Roman; " ALIGN="center"><B>US$</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:7pt; font-family:Times New Roman; " ALIGN="center"><B>RMB</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:7pt; font-family:Times New Roman; " ALIGN="center"><B>US$</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:7pt; font-family:Times New Roman; " ALIGN="center"><B>RMB</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:7pt; font-family:Times New Roman; " ALIGN="center"><B>US$</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:7pt; font-family:Times New Roman; " ALIGN="center"><B>RMB</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7.5pt; font-family:Times New Roman">Balance as of January&nbsp;1, 2019 and September&nbsp;30, 2019</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30,227,056</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">102,852</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">687,482</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30,305,212</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">139,407</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">921,243</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">31,046,360</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">197,478</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,306,633</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7.5pt; font-family:Times New Roman">Balance as of January&nbsp;1, 2020</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30,227,056</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">102,852</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">687,482</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30,305,212</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">139,407</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">921,243</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">31,046,360</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">197,478</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,306,633</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,857,143</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26,914</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">188,819</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7.5pt; font-family:Times New Roman">Conversion to ordinary shares upon IPO</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(30,227,056</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(102,852</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(687,482</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(30,305,212</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(139,407</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(921,243</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(31,046,360</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(197,478</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,306,633</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,857,143</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(26,914</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(188,819</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7.5pt; font-family:Times New Roman">Balance as of September&nbsp;30, 2020</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>13. Convertible Promissory Notes </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">On February&nbsp;3, 2018, the Company issued US$9,000 (equivalent to approximately RMB59,704) convertible promissory notes (&#147;2018
Notes&#148;) to an investor of Series <FONT STYLE="white-space:nowrap">A-3</FONT> Preferred Shares at an annual interest rate of 0%, maturing on 36 months after the issuance date. Under the agreement, the holder of the 2018 Notes may convert the
2018 Notes outstanding principal amount into Series <FONT STYLE="white-space:nowrap">B-1</FONT> Preferred Shares at the conversion price being lower of US$10 per share and fair market value at any time prior to the maturity date. Alternatively, the
2018 Notes shall be automatically converted into the Company&#146;s Series B Preferred Shares upon the maturity. As the fair value of the Company&#146;s ordinary shares on February&nbsp;3, 2018 of US$3.96 was equal to the effective conversion price
(being lower of US$10 per share and fair market value), the Company did not record a BCF. In </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-32 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">I-MAB</FONT> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to the Unaudited Interim Condensed Consolidated Financial Statements </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(All amounts in thousands, except for share and per share data, unless otherwise noted) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>13. Convertible Promissory Notes&nbsp;(Continued) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
December 2020, the Group issued 900,000 ordinary shares to Genexine, Inc. upon the full conversion of the 2018 Notes with the conversion price of US$10 per share. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>14. Warrants </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>(a) Warrants to purchase preferred
shares </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In connection with the issuance of the Series B Preferred Shares on September&nbsp;22, 2017, 5,633,780 Series B Warrants
were issued to Series B preferred shareholders, which provided the holders the right to purchase <FONT STYLE="white-space:nowrap">Series&nbsp;B-2&nbsp;Preferred</FONT> Shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In connection with the Company&#146;s Series B Onshore Financing that took place on September&nbsp;25, 2017, 2,620,842 Series B Warrants were
issued to Series B Onshore Investors, which provided the holders the right to purchase <FONT STYLE="white-space:nowrap">Series&nbsp;B-2&nbsp;Preferred</FONT> Shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">During the period from June&nbsp;29, 2018 to July&nbsp;6, 2018, 3,301,849 Series B Warrants (representing Tranche I of Series B Warrants) were
exercised to purchase 3,301,849 <FONT STYLE="white-space:nowrap">Series&nbsp;B-2&nbsp;Preferred</FONT> Shares with proceeds of US$20,000 (equivalent to approximately RMB132,332). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">On July&nbsp;6, 2018, the Series B Warrants holders agreed that the Series B Warrants shall be divided into two tranches and exercisable in
accordance with different time schedules, such that: (i)&nbsp;the holders have exercised part of the Series B Warrants in the total consideration of US$20,000 (&#147;Tranche I of Series B Warrants&#148;) and 3,301,849
<FONT STYLE="white-space:nowrap">Series&nbsp;B-2&nbsp;Preferred</FONT> Shares of the Company in aggregate have been newly issued to such holders on a pro rata basis; (ii)&nbsp;only when the Company fails to submit a Qualified Public Offering
application at an internationally recognized securities exchange by March&nbsp;31, 2019, the Warrant Holders may exercise the remaining part of Series B Warrants, in the total consideration of US$30,000 (&#147;Tranche II of Series B Warrants&#148;)
and 4,952,773 <FONT STYLE="white-space:nowrap">Series&nbsp;B-2&nbsp;Preferred</FONT> Shares of the Company in aggregate will be issued to such holders on a pro rata basis; (iii)&nbsp;provided that the Company successfully submits a Qualified Public
Offering application at an internationally recognized securities exchange by March&nbsp;31, 2019, the holders shall unconditionally and irrevocably waive and cancel Tranche II of Series B Warrants; and (iv)&nbsp;the Tranche II of Series B Warrants
may only be concurrently exercised by all the Warrant Holders in one lump. This is considered to be a modification to Series B Warrants. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">According to the confirmations issued by the Company&#146;s Series B Warrants holders in July 2019, the holders of Series B Warrants has
unconditionally and irrevocably waived and cancelled the Tranche II of Series B Warrants. The fair value gain of warrants for the nine months ended September&nbsp;30, 2019 and 2020 was amounting to RMB5,609 and nil, respectively. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><I>Accounting of warrants for purchase preferred shares </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The warrant is a freestanding instrument and is recorded as liability in accordance with ASC 480,<I>&nbsp;Distinguishing Liabilities from
Equity</I>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">As the Company&#146;s issuance of warrants were bundled with other instruments (such as convertible preferred shares,
convertible promissory notes, etc.), out of total considerations, the warrants are initially </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-33 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">I-MAB</FONT> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to the Unaudited Interim Condensed Consolidated Financial Statements </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(All amounts in thousands, except for share and per share data, unless otherwise noted) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>14. Warrants&nbsp;(Continued) </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>(a) Warrants to
purchase preferred shares&nbsp;(Continued) </I></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
recognized at fair value and the remaining were allocated to other instruments on a relative fair value basis (if applicable). The fair value changes of the warrants (including the fair value
changes arising from modification of warrants) up to the time of exercise or termination were recognized in earnings. Upon exercise, the total carrying value of the associated warrant liabilities was reclassified into the carrying value of the
Preferred Shares into which it was converted. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Company determined the fair value of the warrants with the assistance of an independent
third-party valuation firm. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>(b) Warrants to purchase ordinary shares </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">As mentioned in Note 11, on September&nbsp;3, 2020, the Group entered into definitive subscription agreements with the Investors to raise
approximately US$418&nbsp;million through a private placement, which comprises the Investor Warrants to subscribe for an aggregate of 5,341,267 ordinary shares (equivalent to 2,322,290 ADSs) at an exercise price equivalent to US$45 per ADS. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Subscription Agreement with the Hillhouse entities contemplates two closings. In the first closing occurred on September&nbsp;11, 2020,
the Investor Warrants were issued with fixed exercise prices of US$45.00 per ADS (equivalent to US$19.57 per share) and lives of one year. The number of common share purchasable upon exercise of the Investor Warrants shall be proportionally adjusted
to reflect any share dividend, share split, combination of shares or reverse share split, or other similar event affecting the number of outstanding common shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><I>Accounting for warrants to purchase ordinary shares </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Investor Warrants are regarded as indexed to the Company&#146;s own stock and were classified as equity and initially measured at fair
value and subsequent changes in fair value are not recognized as long as the Investor Warrants continue to be classified as equity. The estimated fair value of the Investor Warrants was RMB71,874 as shown below, which were used to determine the
allocation of the total proceeds for the sale of ordinary shares between the Investor Warrants and ordinary shares. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="59%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Terms</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Exercise</B><br><B>Price&nbsp;per<BR>share</B><br><B>US$</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Outstanding</B><br><B>Units</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Fair value at</B><br><B>September&nbsp;11,<BR>2020</B><br><B>RMB&#146;000</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Warrants to purchase ordinary shares (first closing)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12&nbsp;months</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19.57</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,744,032</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">71,874</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-34 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">I-MAB</FONT> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to the Unaudited Interim Condensed Consolidated Financial Statements </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(All amounts in thousands, except for share and per share data, unless otherwise noted) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>14. Warrants&nbsp;(Continued) </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>(b) Warrants to
purchase ordinary shares&nbsp;(Continued) </I></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Group determined the fair value of the warrants with the assistance of an independent
third-party valuation firm. The Group used the binomial model to estimate the fair value of the warrant on September&nbsp;11, 2020 when the Investor Warrants were issued using the following assumptions: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="72%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="70%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As of September&nbsp;11,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Risk-free rate of return</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.12</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Maturity date</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">September&nbsp;11,&nbsp;2021</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Estimated volatility rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">60.72</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercise price</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">US$19.57</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The model requires the input of assumptions including the risk-free rate of return, maturity date and
estimated volatility rate. The risk-free rate for periods within the contractual life is based on the US treasury strip bond with maturity similar to the maturity of the warrants as of valuation dates plus a China country risk premium. For expected
volatilities, the Group has made reference to the historical daily stock prices volatilities of ordinary shares of several comparable companies in the same industry as the Group. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>15. Share-based Compensation </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>(a) Restricted
shares </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">During the year ended December&nbsp;31, 2016, the Company issued 4,019,554 ordinary shares to Mr.&nbsp;Zang Jingwu Zhang,
Ms.&nbsp;Qian Lili, Mr.&nbsp;Wang Zhengyi and Mr.&nbsp;Fang Lei (collectively the &#147;Founders&#148;), including the 369,301 shares which represented the equity interests of Third Venture held by the Founders, and the Company recorded share-based
compensation expense of RMB18.7&nbsp;million for issuance and grant of 3,650,253 ordinary shares to the Founders in June 2016. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In October
2016, the Founders entered into an arrangement with other investors of the Company, and the 87,441 ordinary shares issued to the Founders in June 2016 were canceled and out of the remaining 3,932,113 ordinary shares held by the Founders, 70% became
restricted and subject to service vesting conditions, that should vest 20%, 20% and 30% over the next three years, respectively. There shall be no acceleration of the vesting schedule except that, in case of a change of control of the Company or a
Qualified Public Offering, or the termination of the Founder&#146;s employment with the Group without cause. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Deferred share-based
compensation was measured for the restricted shares using the estimated fair value of the Company&#146;s ordinary shares of US$0.77 at the date of imposition of the restriction in October 2016, and was amortized to the interim condensed consolidated
statements of comprehensive loss by using graded vesting method over the vesting term of 3 years. As of December&nbsp;31, 2019, all the restricted shares were fully vested. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The amounts of shared-based compensation expense in relation to the restricted shares recognized in the year ended December&nbsp;31, 2019 was
RMB1,566, of which RMB1,556 was recognized in the nine months ended September&nbsp;30, 2019. No share-based compensation expense was recognized in the nine months ended September&nbsp;30, 2020. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-35 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">I-MAB</FONT> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to the Unaudited Interim Condensed Consolidated Financial Statements </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(All amounts in thousands, except for share and per share data, unless otherwise noted) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>15. Share-based Compensation&nbsp;(Continued) </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>(a)
Restricted shares&nbsp;(Continued) </I></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Share-based compensation expenses related to restricted shares are included in: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="56%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Year&nbsp;Ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Nine&nbsp;Months&nbsp;Ended&nbsp;September&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>&nbsp;&nbsp;2019&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>RMB</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>RMB</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>RMB</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>US$&nbsp;(Note&nbsp;2.5)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">470</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">467</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Administrative expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,096</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,089</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,566</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,556</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>(b) 2017 Employee Stock Option Plan (&#147;2017 Plan&#148;) </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In October 2017, the Company adopted the 2017 Plan. Under the 2017 Plan, a maximum aggregate number of 13,376,865 shares that may be issued
pursuant to all awards granted was approved. Stock options granted to an employee under the 2017 Plan will be exercisable upon the Company completes a listing and the employee renders service to the Company in accordance with a stipulated service
schedule starting from the employee&#146;s date of employment. Employees are generally subject to a three-year service schedule, under which an employee earns an entitlement to vest in 50% of the option grants on the second anniversary of the grant
date, a vesting of the remaining 50% on the third anniversary of the applicable grant date. The stock option under 2017 Plan, to the extent then vested, shall become exercisable only upon the earlier of (i)&nbsp;a listing, and (ii)&nbsp;occurrence
of a change in control. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">On December&nbsp;25, 2019, the Second Amended and Restated 2017 Plan was approved by the shareholders and board
of directors of the Company, pursuant to which, in connection with the Company&#146;s IPO, the maximum aggregate number of shares that may be granted pursuant to all awards under 2017 Plan shall be adjusted in accordance with a formula <FONT
STYLE="white-space:nowrap">pre-approved</FONT> by the shareholders. In connection with above amendments to 2017 Plan, each of the Company&#146;s founders, namely Zheru Zhang, Lili Qian, Zhengyi Wang and Lei Fang, is willing to irrevocably surrender
by him or her, for no consideration, a portion of the unvested options granted to him or her, which, if vested, would entitle him or her to acquire up to 130,000 ordinary shares of the Company, par value US$0.0001 per share, at an exercise price of
US$1.0, respectively, under the Second Amended and Restated 2017 Plan (in respect of each individual, the &#147;Founder&#146;s Surrendered Options&#148;). On December&nbsp;25, 2019, the board of directors of the Company approved that the Company
accepts all Founder&#146;s Surrendered Options from each of the founders, Zheru Zhang, Lili Qian, Zhengyi Wang and Lei Fang, for no consideration, with effect immediately prior to the completion of the IPO and such surrendered options be cancelled
with effect immediately prior to the completion of the IPO. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Prior to the Company completes a listing, all stock options granted to an
employee shall be forfeited at the time the employee terminates his employment with the Group. After the Company completes a listing, vested options not exercised by an employee shall be exercised until later of: (i) 90 days after the date when the
options become exercisable, or (ii) 30 days after the date of cessation of employment or directorship, or such longer period as the Board of Directors may otherwise determine. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Group granted 640,000 stock options to employees for the year ended December 31, 2019 and did not grant any stock options to employees for
the nine months ended September 30, 2020. No options were </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-36 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">I-MAB</FONT> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to the Unaudited Interim Condensed Consolidated Financial Statements </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(All amounts in thousands, except for share and per share data, unless otherwise noted) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>15. Share-based Compensation&nbsp;(Continued) </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>(b)
2017 Employee Stock Option Plan (&#147;2017 Plan&#148;)&nbsp;(Continued) </I></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
exercisable as of December&nbsp;31, 2019 and 8,047,548 stock options were exercisable as of September&nbsp;30, 2020. No options were exercised as of December&nbsp;31, 2019 and 115,888 stock
options were exercised as of September&nbsp;30, 2020. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth the stock options activities of 2017 Plan for the
nine months ended September&nbsp;30, 2020 is presented below: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="85.5%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Number&nbsp;of</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>shares</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Weighted</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>average</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>exercise</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>price</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>US$</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Weighted</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>average</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>remaining</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>contractual</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>term</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Aggregate</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>intrinsic</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>value</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>US$</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outstanding as of December&nbsp;31, 2019</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,812,881</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.93</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.76</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">47,671</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercised</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(115,888</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Forfeited</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(336,377</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Surrendered (Note 15 (h))</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(332,566</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outstanding as of September&nbsp;30, 2020</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,028,050</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.93</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">175,576</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercisable as of September&nbsp;30, 2020</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,047,548</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.92</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.91</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">156,567</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A summary of <FONT STYLE="white-space:nowrap">non-vested</FONT> stock option activities for the nine months
ended September&nbsp;30, 2020 is presented below: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="72%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="56%"></TD>

<TD VALIGN="bottom" WIDTH="12%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="12%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Number&nbsp;of<BR>shares</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Weighted average</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Grant&nbsp;date&nbsp;fair&nbsp;value</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>US$</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Non-vested</FONT> at December&nbsp;31, 2019</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,812,881</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Vested</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(8,047,548</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.74</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercised</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(115,888</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Forfeited</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(336,377</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Surrendered</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(332,566</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.47</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Non-vested</FONT> at September&nbsp;30, 2020</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">980,502</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.02</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Since the exercisability is dependent upon the listing, and it is not probable that this performance condition
can be achieved until a listing, no share-based compensation expense relating to the 2017 Plan was recorded for the year ended December&nbsp;31, 2019. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">On January&nbsp;17, 2020, the Group completed its IPO. After achieving this performance condition, the options continue to vest based only on
service period completed according to the graded vesting schedule. The Group has begun recognizing share-based compensation expense for the options granted using the graded vesting method with a cumulative
<FONT STYLE="white-space:nowrap">catch-up</FONT> for the service period completed to date during the nine months ended September&nbsp;30, 2020 and recognized RMB56,019 and RMB69,204 share-based compensation expenses in administrative expenses and
research and development expenses respectively relating to options vested cumulatively. According to the amendments to 2017 Plan, the maximum aggregate number of shares which may be granted pursuant to all awards under 2017 Plan was changed to
9,609,084. Each of the Group&#146;s founders, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-37 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">I-MAB</FONT> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to the Unaudited Interim Condensed Consolidated Financial Statements </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(All amounts in thousands, except for share and per share data, unless otherwise noted) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>15. Share-based Compensation&nbsp;(Continued) </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>(b)
2017 Employee Stock Option Plan (&#147;2017 Plan&#148;)&nbsp;(Continued) </I></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
namely Zheru Zhang, Lili Qian, Zhengyi Wang and Lei Fang surrendered 83,142 unvested stock options that were granted to him or her under 2017 Plan before, totally 332,566 unvested options, for no
consideration, and these stock options were cancelled immediately. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>(c) 2018 Employee Stock Option Plan (&#147;2018 Plan&#148;) </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">On February&nbsp;22, 2019, the Group adopted the 2018 Plan, which was subsequently amended on July&nbsp;22, 2019. Under the amended and
restated 2018 Plan, the maximum aggregate number of ordinary shares which may be issued pursuant to all awards is 14,005,745, and if the Group successfully lists on an internationally recognized securities exchange for a Qualified Public Offering by
December&nbsp;31, 2019, the maximum aggregate number of ordinary shares which may be issued shall be 15,452,620. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">On December&nbsp;25,
2019, the Second Amended and Restated 2018 Plan were approved by the shareholders and board of directors of the Company, pursuant to which, in connection with the Company&#146;s IPO, the maximum aggregate number of shares that may be granted
pursuant to all awards under 2018 Plan shall be adjusted in accordance with a formula <FONT STYLE="white-space:nowrap">pre-approved</FONT> by the shareholders. In connection with above amendments to 2018 Plan, the director of the Company,
Dr.&nbsp;Jingwu Zhang Zang is willing to irrevocably surrender by him, for no consideration, of the right to acquire a certain amount of ordinary shares of the Company, par value US$0.0001 per share, at an exercise price of US$1.0 pursuant to the
options granted to him under the Second Amended and Restated 2018 Plan (the &#147;Dr.&nbsp;Zang&#146;s Surrendered Options&#148;). On December&nbsp;25, 2019, the board of directors of the Company approved that the Company accepts the irrevocable
surrender of Dr.&nbsp;Zang&#146;s Surrendered Options for no consideration, with effect immediately prior to the completion of the IPO and such surrendered options be cancelled with effect immediately prior to the completion of the IPO. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Stock options granted to an employee under the 2018 Plan will be generally exercisable when the Company completes a listing and the employee
renders service to the Company in accordance with a stipulated service schedule starting from the employee&#146;s date of employment. The vesting schedule shall generally be a <FONT STYLE="white-space:nowrap">two-year</FONT> vesting schedule
consisting of a cliff vesting 50% on the first anniversary of the applicable vesting commencement date, and a vesting of the remaining 50% on the second anniversary of the applicable vesting commencement date. If a listing occurs at anytime prior to
any option granted under the 2018 Plan becoming full vested, and to the extent such option has been granted and outstanding, any such option shall vest in full with immediate effect upon the listing. Except as otherwise approved by the board of
directors, vested portion of option shall become exercisable upon the earlier of six months after a listing or the occurrence of a change in control; provided, however that in each case, no option of an employee shall become exercisable until the
third anniversary of such employee&#146;s employment commencement date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Pursuant to the Board of Director&#146;s approval of 2018 Plan on
February&nbsp;22, 2019, the 10,893,028 stock options granted to a director of the Group under 2018 Plan were fully vested and exercisable upon the adoption of 2018 Plan. Out of aforementioned total 10,893,028 stock options, 454,940 stock options
were repurchased by the Group (see Note15(d) for further details). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The amounts of shared-based compensation expense in relation to the
aforementioned grant of stock options to a director of the Group (except for those repurchased by the Group as described in Note 15(d)) </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-38 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">I-MAB</FONT> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to the Unaudited Interim Condensed Consolidated Financial Statements </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(All amounts in thousands, except for share and per share data, unless otherwise noted) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>15. Share-based Compensation&nbsp;(Continued) </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>(c)
2018 Employee Stock Option Plan (&#147;2018 Plan&#148;)&nbsp;(Continued) </I></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
recognized in the nine months ended September&nbsp;30, 2019 and in the year ended December&nbsp;31, 2019 was RMB365,329, included in administrative expenses. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth the stock options activities of 2018 Plan for the nine months ended September&nbsp;30, 2020 is presented below:
</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="85.5%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="50%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Number&nbsp;of</B><br><B>shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Weighted</B><br><B>average</B><br><B>exercise</B><br><B>price</B><br><B>US$</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Weighted</B><br><B>average</B><br><B>remaining</B><br><B>contractual</B><br><B>term</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Aggregate</B><br><B>intrinsic</B><br><B>value</B><br><B>US$</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outstanding as of December&nbsp;31, 2019</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,536,588</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9.15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">64,840</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Surrendered (Note 15 (h))</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,544,917</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outstanding as of September&nbsp;30, 2020</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,991,671</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.40</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">213.764</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercisable as of September&nbsp;30, 2020</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,166,671</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.40</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">197,720</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A summary of <FONT STYLE="white-space:nowrap">non-vested</FONT> stock option activities for the nine months
ended September&nbsp;30, 2020 is presented below: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="72%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="68%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Number&nbsp;of<BR>shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Weighted<BR>average</B><br><B><FONT STYLE="white-space:nowrap">grant-date</FONT><BR>fair value</B><br><B>US$</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Non-vested</FONT> at December&nbsp;31, 2019</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,098,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.57</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Vested</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,273,500</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.57</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Non-vested</FONT> at September&nbsp;30, 2020</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">825,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.57</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Except for the aforementioned grant of stock options to a director of the Group under 2018 Plan, since the
exercisability is dependent upon the listing, and it is not probable that this performance condition can be achieved until a listing, no share-based compensation expense related to the 2018 Plan was recorded for the year ended December&nbsp;31,
2019. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">On January&nbsp;17, 2020, the Group completed its IPO. After achieving this performance condition, the options continue to vest
based only on service period completed according to the graded vesting schedule. The Group has begun recognizing share-based compensation expense for the options granted using the graded vesting method with a cumulative <FONT
STYLE="white-space:nowrap">catch-up</FONT> for the service period completed to date during the nine months ended September&nbsp;30, 2020 and recognized RMB46,312 and RMB66,496 share-based compensation expense in administrative expenses and research
and development expenses, respectively relating to options vested cumulatively. According to the amendments to 2018 Plan, the maximum aggregate number of shares which may be granted pursuant to all awards under 2018 Plan was changed to 11,005,888.
The director of the Company, Dr.&nbsp;Jingwu Zhang Zang surrendered 2,544,917 unvested options that were granted to him under 2018 Plan, for no consideration, and these stock options were cancelled immediately. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-39 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">I-MAB</FONT> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to the Unaudited Interim Condensed Consolidated Financial Statements </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(All amounts in thousands, except for share and per share data, unless otherwise noted) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>15. Share-based Compensation&nbsp;(Continued) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>(d) Repurchase of share awards held by a director </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">On February&nbsp;22, 2019, the amendment and restated 2017 equity incentive plan was approved by the Board of Directors of the Group, pursuant
to which only the 3,435,215 stock options held by the director under the 2017 equity incentive plan became fully vested and exercisable on February&nbsp;22, 2019. As a result of the performance condition being waived, the stock options held by the
director of the Group were accounted for as a Type III modification where a condition that the Group expects will not be satisfied is changed to a condition that the Group expects will be satisfied. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Additionally, on the same day, the Group repurchased such 3,435,215 stock options under the amendment and restated 2017 equity incentive plan
that was held by the director of the Group along with 454,940 of his stock options under the 2018 equity incentive plan for which the share awards also became fully vested and exercisable, at a total consideration of US$21,902 (equivalent to
approximately RMB148,308) at an average share price of US$5.63 per share. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">For the nine months ended September&nbsp;30, 2019, the Group
recorded the total payment of US$21,902 (equivalent to approximately RMB148,308) as share-based compensation costs (included in administrative expenses) in the condensed consolidated statement of comprehensive loss. There was no impact to the
overall stockholder&#146;s equity balance as the amended shares vested immediately and were repurchased. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>(e) 2019 Share Incentive Plan (&#147;2019
Plan&#148;) </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">On October&nbsp;29, 2019, the Group adopted 2019 Share Incentive Plan (the &#147;2019 Plan&#148;), which will become
effective immediately prior to the completion of the Group&#146;s initial public offering. Under the 2019 Plan, the maximum aggregate number of ordinary shares available for issuance shall initially be 100,000. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The options shall vest when the Group completes a listing and the employee renders service to the Group in accordance with a stipulated
service schedule starting from the employee&#146;s date of employment. Stock options granted to 3 independence directors under the 2019 Plan will be generally exercisable under the following terms:(a) a cliff vesting of 1/3 of the option on the
first anniversary of the vesting commencement date (January 17, 2020);(b) a cliff vesting of 1/3 of the option on the second anniversary of the vesting commencement date (January 17, 2020);(c) a vesting of the remaining 1/3 of the option on the
third anniversary of the vesting commencement date. In the last year of the grantee&#146;s service, the options shall vest on a prorated basis to reflect the portion of the year during which the grantee provided services to the Group. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">For the nine months ended September&nbsp;30, 2020, the Group granted 72,000 stock options to 3 independent directors (all with an exercise
price of US$6.09) and recognized RMB741 share-based compensation expenses according to the options&#146; vesting schedule. No options were exercisable as of September&nbsp;30, 2020. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-40 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">I-MAB</FONT> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to the Unaudited Interim Condensed Consolidated Financial Statements </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(All amounts in thousands, except for share and per share data, unless otherwise noted) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>15. Share-based Compensation&nbsp;(Continued) </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>(e)
2019 Share Incentive Plan (&#147;2019 Plan&#148;)&nbsp;(Continued) </I></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth the stock options activities of 2019 Plan for the nine months
ended September&nbsp;30, 2020 presented: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="85.5%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="53%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Number&nbsp;of</B><br><B>shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Weighted</B><br><B>average</B><br><B>exercise</B><br><B>price</B><br><B>US$</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Weighted</B><br><B>average</B><br><B>remaining</B><br><B>contractual</B><br><B>term</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Aggregate</B><br><B>intrinsic</B><br><B>value</B><br><B>US$</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outstanding as of December&nbsp;31, 2019</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Granted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">72,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.09</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outstanding as of September&nbsp;30, 2020</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">72,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.09</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9.59</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,034</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercisable as of September&nbsp;30, 2020</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A summary of <FONT STYLE="white-space:nowrap">non-vested</FONT> stock options activity for the nine months
ended September&nbsp;30, 2020 is presented below: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="72%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="59%"></TD>

<TD VALIGN="bottom" WIDTH="13%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="13%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Number&nbsp;of<BR>shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Weighted average</B><br><B><FONT STYLE="white-space:nowrap">grant-date&nbsp;fair&nbsp;value</FONT></B><br><B>US$</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Non-vested</FONT> at December&nbsp;31, 2019</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Granted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">72,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.09</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Non-vested</FONT> at September&nbsp;30, 2020</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">72,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.09</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Stock options granted to the 3 independent directors were measured at fair value on the dates of grant using
the Binomial Option Pricing Model with the following assumptions: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="72%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="58%"></TD>

<TD VALIGN="bottom" WIDTH="36%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Nine&nbsp;Months&nbsp;Ended&nbsp;September&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected volatility</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">54.88</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Risk-free interest rate (per annum)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.79</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercise multiple</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.80</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected dividend yield</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Contractual term (in years)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The expected volatility was estimated based on the historical volatility of comparable peer public companies
with a time horizon close to the expected term of the Group&#146;s options. The risk-free interest rate was estimated based on the yield to maturity of U.S. treasury bonds denominated in US$ for a term consistent with the expected term of the
Group&#146;s options in effect at the option valuation date. The expected exercise multiple was estimated as the average ratio of the stock price to the exercise price when employees would decide to voluntarily exercise their vested options. As the
Group did not have sufficient information of past employee exercise history, it was estimated by referencing to a widely-accepted academic research publication. Expected dividend yield is zero as the Group has never declared or paid any cash
dividends on its shares, and the Group does not anticipate any dividend payments in the foreseeable future. Expected term is the contract life of the option. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-41 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">I-MAB</FONT> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to the Unaudited Interim Condensed Consolidated Financial Statements </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(All amounts in thousands, except for share and per share data, unless otherwise noted) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>15. Share-based Compensation&nbsp;(Continued) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>(f) 2020 Share Incentive Plan (&#147;2020 Plan&#148;) </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">On July&nbsp;15, 2020, the Company adopted the 2020 Plan. Under the 2020 Plan, the maximum aggregate number of shares which may be issued
pursuant to all awards shall be 10,760,513 ordinary shares, provided that the maximum number of shares may be issued pursuant to awards in the form of restricted share units under this plan shall not exceed 7,686,081 ordinary shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Stock options granted to employees under the 2020 Plan will be exercisable under the following items: (a)&nbsp;a vesting of 25% the option on
the first anniversary of the applicable vesting commencement date;(b) a vesting of 25% of the option on the second anniversary of the applicable vesting commencement date;(c) a vesting of 25% of the option on the third anniversary of the applicable
vesting commencement date;(d) a vesting of 25% of the option on the fourth anniversary of the applicable vesting commencement date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">For
the nine months ended September&nbsp;30, 2020, the Group granted 1,068,733 stock options to its employees and recognized RMB2,052 and RMB3,606 share-based compensation expense according to the options&#146; vesting schedule in administrative
expenses and research and development expenses respectively. No options were exercisable as of September&nbsp;30, 2020. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following
table sets forth the stock options activities of 2020 Plan for the nine months ended September&nbsp;30, 2020: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="85.5%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="52%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Number&nbsp;of</B><br><B>shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Weighted</B><br><B>average</B><br><B>exercise</B><br><B>price</B><br><B>US$</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Weighted</B><br><B>average</B><br><B>remaining</B><br><B>contractual</B><br><B>term</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Aggregate</B><br><B>intrinsic</B><br><B>value</B><br><B>US$</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outstanding as of December&nbsp;31, 2019</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Granted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,068,733</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.91</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Forfeited</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(18,693</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.91</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outstanding as of September&nbsp;30, 2020</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,050,040</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.91</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9.88</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,265</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercisable as of September&nbsp;30, 2020</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A summary of <FONT STYLE="white-space:nowrap">non-vested</FONT> stock option activities for the nine months
ended September&nbsp;30, 2020 is presented below: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="72%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="57%"></TD>

<TD VALIGN="bottom" WIDTH="12%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="12%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Number&nbsp;of<BR>shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Weighted average</B><br><B><FONT STYLE="white-space:nowrap">grant-date&nbsp;fair&nbsp;value</FONT></B><br><B>US$</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Non-vested</FONT> at December&nbsp;31, 2019</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Granted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,068,733</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.65</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Forfeited</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(18,693</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.65</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Non-vested</FONT> at September&nbsp;30, 2020</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,050,040</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.65</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-42 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">I-MAB</FONT> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to the Unaudited Interim Condensed Consolidated Financial Statements </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(All amounts in thousands, except for share and per share data, unless otherwise noted) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>15. Share-based Compensation&nbsp;(Continued) </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>(f)
2020 Share Incentive Plan (&#147;2020 Plan&#148;)&nbsp;(Continued) </I></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Stock options granted to the employees were measured at fair value on the dates of grant
using the Binomial Option Pricing Model with the following assumptions: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="72%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="58%"></TD>

<TD VALIGN="bottom" WIDTH="31%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Nine&nbsp;Months&nbsp;Ended&nbsp;September&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected volatility</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">56.51</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Risk-free interest rate (per annum)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.86</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercise multiple</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">2.20-2.80</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected dividend yield</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Contractual term (in years)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The expected volatility was estimated based on the historical volatility of comparable peer public companies
with a time horizon close to the expected term of the Group&#146;s options. The risk-free interest rate was estimated based on the yield to maturity of U.S. treasury bonds denominated in US$ for a term consistent with the expected term of the
Group&#146;s options in effect at the option valuation date. The expected exercise multiple was estimated as the average ratio of the stock price to the exercise price when employees would decide to voluntarily exercise their vested options. As the
Group did not have sufficient information of past employee exercise history, it was estimated by referencing to a widely-accepted academic research publication. Expected dividend yield is zero as the Group has never declared or paid any cash
dividends on its shares, and the Group does not anticipate any dividend payments in the foreseeable future. Expected term is the contract life of the option. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Restricted share units granted to employees under the 2020 Plan will be exercisable under the following items: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(a) 1/3 of the awarded restricted share units shall vest based on the following time attribution:(i) a vesting of 25% of the time attribution
based restricted share units on the first anniversary of the applicable adoption date;(ii) a vesting of 25% of the time attribution based restricted share units on the second anniversary of the applicable adoption date;(iii) a vesting of 25% of the
time attribution based restricted share units on the third anniversary of the applicable adoption date;(iv) a vesting of 25% of the time attribution based restricted share units on the fourth anniversary of the applicable adoption date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(b) 1/3 of the awarded restricted share units shall vest based on the Group&#146;s weighted average market value during the last 30 days prior
to the initial vesting date, the terms and conditions of which are set forth in the executed award agreements. In the event that dilution of additional share issuance occurs, the market value targets herein shall be adjusted accordingly with the
proportion of additional share issuance. In the event that the average market value of Standard&nbsp;&amp; Poor&#146;s 500 index falls by more than 20% from the date of grant, it shall be deemed as a decline of the market, and the board of the Group
or a committee that board delegated its powers or authority to shall adjust the vesting schedule as appropriate. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(c) 1/3 of the awarded
restricted share units shall vest based on certain performance conditions:(i) a vesting of 20% of the performance conditions based restricted share units if one of the performance conditions has been met at the initial vesting date;(ii) a vesting of
40% of the performance conditions based restricted share </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-43 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">I-MAB</FONT> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to the Unaudited Interim Condensed Consolidated Financial Statements </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(All amounts in thousands, except for share and per share data, unless otherwise noted) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>15. Share-based Compensation&nbsp;(Continued) </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>(f)
2020 Share Incentive Plan (&#147;2020 Plan&#148;)&nbsp;(Continued) </I></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
units if two of the performance conditions have been met at the initial vesting date;(iii) a vesting of 60% of the performance conditions based restricted share units if three of the performance
conditions have been met at the initial vesting date;(iv) a vesting of 80% of the performance conditions based restricted share units if four of the performance conditions have been met at the initial vesting date; (v)&nbsp;a vesting of all of the
performance conditions based restricted share units if five of the performance conditions have been met at the initial vesting date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Notwithstanding the foregoing, if the Group&#146;s weighted average market value during the last 30 days prior to the initial vesting date
reaches US$2&nbsp;billion or above, and to the extent such restricted share units have been granted and outstanding, any such restricted share unit (except for those are based on time attribution) shall vest in full with immediate effect, inure to
the benefit of the related grantees. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">For the nine months ended September&nbsp;30, 2020, the Group granted 3,564,798 restricted share
units to employees and recognized RMB20,189 and RMB20,054 share-based compensation expense according to the restricted share units&#146; vesting schedule in administrative expenses and research and development expenses respectively. No restricted
share units were exercisable as of September&nbsp;30, 2020. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth the restricted share units of 2020 Plan for
the nine months ended September&nbsp;30, 2020: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="85.5%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="53%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Number&nbsp;of</B><br><B>restricted<BR>share units</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Weighted</B><br><B>average</B><br><B>exercise</B><br><B>price</B><br><B>US$</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Weighted</B><br><B>average</B><br><B>remaining</B><br><B>contractual</B><br><B>term</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Aggregate</B><br><B>intrinsic</B><br><B>value</B><br><B>US$</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outstanding as of December&nbsp;31, 2019</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Granted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,564,798</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Forfeited</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(13,461</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outstanding as of September&nbsp;30, 2020</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,551,337</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9.91</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">72,617</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A summary of <FONT STYLE="white-space:nowrap">non-vested</FONT> restricted share units activities for the nine
months ended September&nbsp;30, 2020 is presented below: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="72%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="58%"></TD>

<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Number&nbsp;of<BR>restricted<BR>share units</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Weighted average</B><br><B><FONT STYLE="white-space:nowrap">grant-date&nbsp;fair&nbsp;value</FONT></B><br><B>US$</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Non-vested</FONT> at December&nbsp;31, 2019</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Granted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,564,798</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13.63</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Forfeited</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(13,461</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11.75</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Non-vested</FONT> at September&nbsp;30, 2020</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,551,337</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13.68</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Besides the aforementioned restricted share units, up to 1,446,875 shares may be issued in the form of
restricted share unit to eligible grantees that the board of the Group or a committee that board delegated its powers or authority determined appropriate with immediate effect of being fully vested, which are defined as special awards and subject to
terms and conditions under 2018 Plan. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-44 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">I-MAB</FONT> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to the Unaudited Interim Condensed Consolidated Financial Statements </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(All amounts in thousands, except for share and per share data, unless otherwise noted) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>15. Share-based Compensation&nbsp;(Continued) </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>(f)
2020 Share Incentive Plan (&#147;2020 Plan&#148;)&nbsp;(Continued) </I></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">For the nine months ended September&nbsp;30, 2020, the Group granted 1,328,120 such
restricted share units to employees and recognized RMB42,644 and RMB65,259 share-based compensation expense according to the restricted share units&#146; vesting schedule in administrative expenses and research and development expenses respectively.
558,200 restricted share units were vested but not issued as ordinary shares as of September&nbsp;30, 2020 as the employees will not be entitled to the rights of ordinary shares from the Group until they settle the individual income tax for the
transaction. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth the restricted share units subject to terms and conditions under 2018 Plan for the nine
months ended September&nbsp;30, 2020: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="85.5%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="53%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Number&nbsp;of</B><br><B>restricted<BR>share units</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Weighted</B><br><B>average</B><br><B>exercise</B><br><B>price</B><br><B>US$</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Weighted</B><br><B>average</B><br><B>remaining</B><br><B>contractual</B><br><B>term</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Aggregate</B><br><B>intrinsic</B><br><B>value</B><br><B>US$</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outstanding as of December&nbsp;31, 2019</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Granted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,328,120</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outstanding as of September&nbsp;30, 2020</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,328,120</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9.90</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25,829</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A summary of <FONT STYLE="white-space:nowrap">non-vested</FONT> restricted share units activities for the nine
months ended September&nbsp;30, 2020 is presented below: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="72%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="58%"></TD>

<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Number&nbsp;of<BR>restricted<BR>share units</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Weighted average</B><br><B><FONT STYLE="white-space:nowrap">grant-date&nbsp;fair&nbsp;value</FONT></B><br><B>US$</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Non-vested</FONT> at December&nbsp;31, 2019</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Granted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,328,120</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13.34</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Vested</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(558,200</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13.98</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Non-vested</FONT> at September&nbsp;30, 2020</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">769,920</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12.88</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>(g) Establishment of Biomaster Trust </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Biomaster Trust was established under the trust deed dated October&nbsp;23, 2019, between the Company and TMF Trust (HK) Limited, or TMF
Trust, as the trustee of the Biomaster Trust. Through the Biomaster Trust, the Company&#146;s ordinary shares and other rights and interests under awards granted pursuant to 2017 Plan and 2018 Plan may be provided to certain recipients of equity
awards. Upon satisfaction of vesting conditions, TMF Trust will exercise the equity awards and transfer the relevant ordinary shares and other rights and interests under the equity awards to the relevant grant recipients with the consent of the
advisory committee of Biomaster Trust. TMF Trust shall not exercise the voting rights attached to such ordinary shares unless otherwise directed by the advisory committee, whose members shall be appointed by
<FONT STYLE="white-space:nowrap">I-Mab.</FONT> The Company has the power to direct the relevant activities of Biomaster Trust and it has the ability to use its power over the Biomaster Trust to affect its exposure to returns. Therefore, the assets
and liabilities of the Biomaster Trust are included in the Group&#146;s consolidated statement of financial position. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-45 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">I-MAB</FONT> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to the Unaudited Interim Condensed Consolidated Financial Statements </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(All amounts in thousands, except for share and per share data, unless otherwise noted) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>15. Share-based Compensation&nbsp;(Continued) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>(h) Surrender of stock options </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">On January&nbsp;17, 2020, the Group completed its IPO. According to the amendments to 2017 Plan, the maximum aggregate number of shares which
may be granted pursuant to all awards under 2017 Plan was changed to 9,609,084. Each of the Company&#146;s founders, namely Zheru Zhang, Lili Qian, Zhengyi Wang and Lei Fang surrendered 83,142 unvested stock options that were granted to him or her
under 2017 Plan before, totally 332,566 unvested options, for no consideration, and these stock options were cancelled immediately. According to the amendments to 2018 Plan, the maximum aggregate number of shares which may be granted pursuant to all
awards under 2018 Plan was changed to 11,005,888. The director of the Company, Dr.&nbsp;Jingwu Zhang Zang surrendered 2,544,917 unvested options that were granted to him under 2018 Plan, for no consideration, and these stock options were cancelled
immediately. Upon the completion of the Company&#146;s IPO in January 2020, the Group has recorded RMB91,051 share-based compensation expense related to these surrendered options. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The stock options surrendered by the founders should be accounted for as capital contribution. As the founders did not get the title of the
stock options to be surrendered and the number of stock options would not be determined until listing, the capital contribution was not accounted for during the year ended December&nbsp;31, 2019. For the nine months ended September&nbsp;30, 2020,
the Group has reclassified RMB91,051 from additional <FONT STYLE="white-space:nowrap">paid-in</FONT> capital &#150; share-based compensation to additional <FONT STYLE="white-space:nowrap">paid-in</FONT> capital &#150; capital contribution relating
to the stock options surrendered in the condensed consolidated financial statement of comprehensive loss. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Share-Based Compensation Expense </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The allocation of share-based compensation expense was as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="53%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Year
Ended<BR>December&nbsp;31,</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Nine Months Ended September&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>US$&nbsp;(Note&nbsp;2.5)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">470</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">467</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">224,619</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">33,083</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Administrative expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">514,733</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">514,726</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">167,957</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24,737</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>515,203</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>515,193</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>392,576</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>57,820</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>16. Licensing and Collaboration Arrangements </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The following is a description of the Group&#146;s significant licensing and collaboration agreements entered into from January&nbsp;1, 2017
to September&nbsp;30, 2020. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>A. <FONT STYLE="white-space:nowrap">In-Licensing</FONT> Arrangements </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><I>Licensing Agreement with MorphoSys AG (&#147;MorphoSys&#148;) </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In November 2017, the Group entered into a license and collaboration agreement with MorphoSys, with respect to the development and
commercialization of MOR202/TJ202, MorphoSys&acute;s proprietary investigational antibody against CD38 (the &#147;CD38 product&#148;). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-46 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">I-MAB</FONT> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to the Unaudited Interim Condensed Consolidated Financial Statements </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(All amounts in thousands, except for share and per share data, unless otherwise noted) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>16. Licensing and Collaboration Arrangements&nbsp;(Continued) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>A. <FONT STYLE="white-space:nowrap">In-Licensing</FONT> Arrangements&nbsp;(Continued) </I></B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Under this agreement, MorphoSys granted to the Group an exclusive, royalty-bearing,
sublicensable license to exploit MOR202/TJ202 for any human therapeutic or diagnostic purpose in the licensed territory, namely mainland China, Hong Kong, Macau and Taiwan (collectively &#147;Greater China&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Pursuant to this agreement, the Group granted to MorphoSys an exclusive license to its rights in any inventions that the Group make while
exploiting the CD38 product under this agreement, solely to exploit the CD38 product outside of Greater China. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Pursuant to this
agreement, the Group paid to MorphoSys an upfront license fee of US$20.0&nbsp;million (equivalent to approximately RMB132.7 million). The Group also agreed to make milestone payments to MorphoSys, conditioned upon the achievement of certain
development, regulatory and commercial milestones, in the aggregate amount of US$98.5&nbsp;million (equivalent to approximately RMB653.5 million). Such milestones include first patient dosed in human clinical trials, marketing approval, and first
annual net sales of CD38 products covered by the agreement in excess of a certain amount. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In addition, the Group is required to pay
tiered <FONT STYLE="white-space:nowrap">low-double-digit</FONT> royalties to MorphoSys on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">country-by-country</FONT></FONT> and <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">product-by-product</FONT></FONT> basis during the term, commencing with the first commercial sale of a relevant licensed product in Greater China. Unless terminated earlier in accordance with the terms thereof, this
agreement will remain in effect until the expiration of the Group&#146;s last payment obligation under the agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In 2017, the Group
paid US$20.0&nbsp;million (equivalent to approximately RMB132.7 million) upfront fee to MorphoSys, which was recorded as research and development expense. No additional payments were made in 2018. Due to the uncertainty involved in meeting these
developments and commercialization based targets, the Group evaluated and concluded that the remaining milestones are still not probable as of December&nbsp;31, 2018. In March and April 2019, the project achieved the first and second milestone and
the Group paid US$8.0&nbsp;million (equivalent to approximately RMB55.7 million) of milestone fees to MorphoSys, which was recorded as research and development expense in the interim condensed consolidated statement of comprehensive loss for the
nine months ended September&nbsp;30, 2019 and for the year ended December&nbsp;31, 2019. No additional payments were made for the nine months ended September&nbsp;30, 2020 as no milestone has been achieved. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><I>Licensing Agreement with Genexine, Inc. (&#147;Genexine&#148;) </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In December 2017, the Group entered into an intellectual property license agreement with Genexine with respect to <FONT
STYLE="white-space:nowrap">GX-I7/TJ107,</FONT> a long-acting <FONT STYLE="white-space:nowrap">IL-7</FONT> cytokine. Under this agreement, the Group obtained an exclusive, sublicensable and transferable license to use and otherwise exploit certain
intellectual property in connection with the <FONT STYLE="white-space:nowrap">pre-clinical</FONT> and clinical development, manufacturing, sale and distribution of GX-I7 to treat cancer in Greater China. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Under the terms of the agreement, the Group made an upfront payment of US$12.0&nbsp;million (equivalent to approximately RMB79.6 million) to
Genexine which was recorded as a research and development expense in January 2018. The Group also agreed to make milestone payments in the aggregate amount of US$23.0&nbsp;million (equivalent to approximately RMB152.6 million), conditioned upon the
achievement of certain development milestones, including completion of Phase 2 and Phase 3 clinical studies and new drug application (&#147;NDA&#148;) or biologic license application (&#147;BLA&#148;) approval in Greater China. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-47 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">I-MAB</FONT> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to the Unaudited Interim Condensed Consolidated Financial Statements </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(All amounts in thousands, except for share and per share data, unless otherwise noted) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>16. Licensing and Collaboration Arrangements&nbsp;(Continued) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>A. <FONT STYLE="white-space:nowrap">In-Licensing</FONT> Arrangements&nbsp;(Continued) </I></B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Further, the Group agreed to make milestone payments in the aggregate amount of
US$525.0&nbsp;million (equivalent to approximately RMB3,482.7 million), conditioned upon the achievement of certain cumulative net sales of GX<I>-I7 </I>up to US$2,000&nbsp;million. The Group also is required to pay Genexine a <FONT
STYLE="white-space:nowrap">low-single-digit</FONT> percentage royalty in respect of the total annual net sales of <FONT STYLE="white-space:nowrap">GX-I7.</FONT> The aforesaid milestones and royalties (other than the upfront payment) will be reduced
by 50% following the entry of a generic version of <FONT STYLE="white-space:nowrap">GX-I7</FONT> in China, Hong Kong, Macau and Taiwan without the consent or authorization of the Group or any of the Group&#146;s sublicensees. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Unless terminated earlier in accordance with the terms thereof, this agreement will remain in effect until the later of (i)&nbsp;the expiry of
the last to expire patent of the licensed intellectual property that includes a valid claim for Greater China and that covers the composition of GX-I7; and (ii) 15 years from the date of the first commercial sale of
<FONT STYLE="white-space:nowrap">GX-I7.</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">No additional payments to Genexine were made in the nine months ended September&nbsp;30,
2019 and 2020. Due to the uncertainty involved in meeting these developments and commercialization based targets, the Group evaluated and concluded that the remaining milestones are still not probable as of December&nbsp;31, 2019 and
September&nbsp;30, 2020. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In May 2020, the Group and Genexine entered into an amendment to this agreement whereby both parties desire to
establish collaboration on TJ107 GBM Study in Greater China Under the terms of the expanded collaboration, the Group will be mainly responsible for using commercially reasonable efforts to conduct the Phase 2 GBM clinical trial in Greater China, and
Genexine will share the development strategies, data and costs for success of this clinical trial. The Group shall undertake to bear <FONT STYLE="white-space:nowrap">two-thirds</FONT> (2/3) proportion of the clinical development costs and Genexine
shall undertake to bear <FONT STYLE="white-space:nowrap">one-third</FONT> (1/3) proportion of these costs. As of September&nbsp;30, 2020, the costs incurred for the development of this new indication was RMB1.4&nbsp;million and thus
RMB0.9&nbsp;million expense was recorded in the unaudited interim condensed consolidated statement of comprehensive loss for the nine months ended September&nbsp;30, 2020. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><I>Licensing Agreement with MorphoSys </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In November 2018, the Group entered into a license and collaboration agreement with MorphoSys for MorphoSys&acute;s proprietary antibody
(MOR210/TJ210) directed against C5aR (the &#147;C5aR Agreement&#148;). Under this agreement, the Group obtained an exclusive, royalty-bearing license to explore, develop and commercialize certain anti-C5aR antibodies in Greater China and South
Korea. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Group will perform and fund all global development activities related to the development of MOR210/TJ210 in Greater China and
South Korea, including all relevant clinical trials (including in the U.S. and China) and all development activities required for IND filing in the US as well as CMC development of manufacturing processes. MorphoSys retains rights in respect of
development and commercialization of MOR210/TJ210 in the rest of the world. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Under the terms of the agreement, the Group also agreed to
make milestone payments conditional upon the achievement of certain development milestones and certain annual net sales of anti-C5aR antibodies. The Group is also required to pay to MorphoSys tiered
<FONT STYLE="white-space:nowrap">mid-single-digit</FONT> royalties on annual net sales of anti-C5aR antibody products within the licensed territory. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-48 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">I-MAB</FONT> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to the Unaudited Interim Condensed Consolidated Financial Statements </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(All amounts in thousands, except for share and per share data, unless otherwise noted) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>16. Licensing and Collaboration Arrangements&nbsp;(Continued) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>A. <FONT STYLE="white-space:nowrap">In-Licensing</FONT> Arrangements&nbsp;(Continued) </I></B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In 2018, the Group paid US$3.5&nbsp;million (equivalent to approximately RMB23.2 million)
upfront fee to MorphoSys, which was recorded as research and development expense. No additional payments were made in the year ended December&nbsp;31, 2019. In August 2020, the project achieved the first milestone and the Group paid
US$1.0&nbsp;million (equivalent to approximately RMB6.8 million) of milestone fees to Morphosys, which was recorded as research and development expenses in the unaudited interim condensed consolidated statement of comprehensive loss for the nine
months ended September&nbsp;30, 2020. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><I>Licensing Agreement with MacroGenics </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In July 2019, the Group entered into a license and collaboration agreement with MacroGenics, Inc. for development and commercialization of an <FONT
STYLE="white-space:nowrap">Fc-optimized</FONT> antibody known as enoblituzumab that targets <FONT STYLE="white-space:nowrap">B7-H3,</FONT> including in combination with other agents, such as the <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">anti-PD-1</FONT></FONT> antibody known as MGA012, in the People&#146;s Republic of China, Hong Kong, Macau and Taiwan(&#147;Greater China&#148;). Under this agreement, the Group obtained an exclusive, sublicenseable,
royalty-bearing license to MacroGenics&#146; patents and <FONT STYLE="white-space:nowrap">know-how</FONT> to develop and commercialize the enoblituzumab product, and a combination regimen of enoblituzumab and MGA012, in Greater China during the term
of the agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In exchange for these rights, in addition to certain financial consideration, the Group will grant to MacroGenics a
royalty-free, sublicenseable, license outside of Greater China, to the patents and <FONT STYLE="white-space:nowrap">know-how</FONT> that are related to the enoblituzumab product or useful or necessary for MacroGenics to develop or commercialize the
enoblituzumab product or a product containing MGA012, and combinations thereof. The license is <FONT STYLE="white-space:nowrap">(i)&nbsp;non-exclusive</FONT> with respect to the enoblituzumab product, and (ii)&nbsp;exclusive with regard to MGA012.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Pursuant to the agreement, the Group paid an upfront fee of US$15.0&nbsp;million (equivalent to approximately RMB104.4 million) to
MacroGenics, which was recorded as research and development expense in the consolidated statement of comprehensive loss for the year ended December&nbsp;31, 2019. No additional payments were made in the nine months ended September&nbsp;30, 2020.
Under the terms of the agreement, the Group also agreed to pay MacroGenics development milestone fees of up to US$75.0&nbsp;million and regulatory milestones fees of up to US$60.0&nbsp;million, respectively, and tiered double-digit royalties
(ranging from <FONT STYLE="white-space:nowrap">mid-teens</FONT> to twenty percent) based on annual net sales in the territories. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The
Group is responsible for all development costs in Greater China. MacroGenics is responsible for all development costs in the rest of the world, except that the Group is responsible for 20% of the costs incurred in (i)&nbsp;activities supporting
global clinical trials in which the Group participates, (ii)&nbsp;certain CMC activities for material intended to be used in clinical trials in Greater China, and (iii)&nbsp;companion diagnostic development and validation for indications being
studied in Greater China. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Due to the uncertainty involved in meeting these developments and commercialization based targets, the Group
evaluated and concluded that no milestones are probable as of December&nbsp;31, 2019 and September&nbsp;30, 2020. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><I>Other <FONT
STYLE="white-space:nowrap">In-Licensing</FONT> Arrangements </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In addition to the above arrangements, the Group has entered into other
various <FONT STYLE="white-space:nowrap">in-licensing</FONT> and collaboration agreements with third party licensors to develop and commercialize drug candidates. Based on the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-49 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">I-MAB</FONT> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to the Unaudited Interim Condensed Consolidated Financial Statements </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(All amounts in thousands, except for share and per share data, unless otherwise noted) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>16. Licensing and Collaboration Arrangements&nbsp;(Continued) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>A. <FONT STYLE="white-space:nowrap">In-Licensing</FONT> Arrangements&nbsp;(Continued) </I></B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
terms of these agreements the Group is contingently obligated to make additional material payments upon the achievement of certain contractually defined milestones. The Group recorded
US$1.2&nbsp;million (equivalent to approximately RMB8.4 million) milestone payment under these agreements during the year ended December&nbsp;31, 2019 and made in total US$1.5&nbsp;million (equivalent to approximately RMB10.5 million) milestone
payment as of December&nbsp;31, 2019, of which US$0.4&nbsp;million (equivalent to approximately RMB2.9 million) milestone payment was recorded during the nine months ended September&nbsp;30, 2019. The Group additionally recorded US$1.2&nbsp;million
(equivalent to approximately RMB8.2 million) milestone payment during the nine months ended September&nbsp;30, 2020. Under the terms of the agreements, the licensors are eligible to receive from the Group up to an aggregate of approximately
US$164.4&nbsp;million (equivalent to approximately RMB1,144.5 million) in milestone payments upon the achievement of contractually specified development milestones and sales milestones, such as regulatory approval for the drug candidates, which may
be before the Group has commercialized the drug or received any revenue from sales of such drug candidate, which may never occur. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>B. <FONT
STYLE="white-space:nowrap">Out-Licensing</FONT> and collaboration Arrangements </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><I>Licensing Agreement among HDYM, <FONT
STYLE="white-space:nowrap">I-Mab</FONT> and Hangzhou HealSun Biopharm Co., Ltd. (&#147;HealSun&#148;) </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In April 2017, one of the
Company&#146;s subsidiaries, <FONT STYLE="white-space:nowrap">I-Mab</FONT> Shanghai, entered into a technology transfer agreement with HDYM and HealSun with respect to
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-L1</FONT></FONT> humanized monoclonal antibodies. Under the agreement, <FONT STYLE="white-space:nowrap">I-Mab</FONT> Shanghai agreed to grant to HDYM exclusive, worldwide and
sublicensable rights to develop, manufacture, have manufactured, use, sell, have sold, import, or otherwise exploit certain <FONT STYLE="white-space:nowrap">PD-L1</FONT> related patents, patent applications, know-hows, data and information of <FONT
STYLE="white-space:nowrap">I-Mab</FONT> Shanghai, relevant cell lines as well as any <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-L1</FONT></FONT> monoclonal antibody arising from such cell lines for the treatment of
diseases. Further, <FONT STYLE="white-space:nowrap">I-Mab</FONT> Shanghai and its cooperative party, HealSun agreed to provide subsequent research and development services on such intellectual property to HDYM, including the selection and
examination of innovative <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-L1</FONT></FONT> humanized monoclonal antibodies, cultivation and selection of stable cell lines, establishment of cell bank, research and
development of manufacturing processes and preparation of samples, toxicological and pharmacological testing, <FONT STYLE="white-space:nowrap">pre-clinical</FONT> pharmaceutical experiment report drafting, and application for and registration of
clinical trials. HDYM agreed to make milestone payments conditioned upon achieving certain contractually defined milestones. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Group
determined that this collaboration is reflective of a vendor-customer relationship and therefore within the scope of ASC 606. Under this agreement, due to the early stage nature of the development, in which the underlying intellectual property is
significantly modified by the development activities being performed, the Group determined the license to the intellectual property and research and development services are not distinct and thus were accounted for as a single performance obligation
that is satisfied over time. The Group would receive RMB51.0&nbsp;million (inclusive of VAT) milestone payments under this agreement, and considered that the achievements of milestone II, III, IV are constrained such that the transaction price shall
initially only include the milestones payment which have been achieved (that means when uncertainty associated with the variable consideration is subsequently resolved), the additional milestone payment shall be included in the total transaction
price when it is no longer probable that a significant reversal of cumulative revenue would occur in future periods. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-50 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">I-MAB</FONT> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to the Unaudited Interim Condensed Consolidated Financial Statements </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(All amounts in thousands, except for share and per share data, unless otherwise noted) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>16. Licensing and Collaboration Arrangements&nbsp;(Continued) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>B. <FONT STYLE="white-space:nowrap">Out-Licensing</FONT> and collaboration Arrangements&nbsp;(Continued) </I></B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">All the revenue has been recognized before the year ended December&nbsp;31, 2019 and all the
milestone payments were received by the Group as of December&nbsp;31, 2019. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><I>Collaboration Agreement with Everest (&#147;Everest&#148;)
</I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In January 2018, the Group entered into a collaboration agreement with Everest, which is controlled by the ultimate controlling party
of a principal shareholder of the Group. Under the agreement, both parties agreed to collaborate on programs to <FONT STYLE="white-space:nowrap">co-develop</FONT> MorphoSys&#146; proprietary anti-CD38 antibody for all indications in hematologic
oncology and commercialize of MOR202/TJ202 in Greater China. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">A joint steering committee with equal representation from each party was
established to coordinate and oversee the development and commercialization of the CD38 product. All decisions of the joint steering committee shall be made by unanimous vote. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Under the agreement, the Group is primarily responsible for carrying out the development, manufacture and supply of the CD38 product, as well
as seeking regulatory approval of the CD38 product. Everest is primarily responsible for sharing the development costs of the CD38 product, including payments due to MorphoSys under the Licensing Agreement, dated November&nbsp;30, 2017, in the
proportion of 75% by Everest and 25% by the Group. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The joint steering committee will decide which party shall be responsible for
conducting the commercialization of the CD38 product pursuant to the commercialization plan approved by the committee. If Everest is selected to be responsible for commercialization, the Group shall grant an exclusive royalty-free license to Everest
to commercialize the CD38 product for all indications in hematologic oncology in Greater China. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Group and Everest will share the
profit and loss and <FONT STYLE="white-space:nowrap">out-licensing</FONT> revenue derived from the CD 38 product in proportion to the costs that each party incur in developing the product. The parties will also split
<FONT STYLE="white-space:nowrap">out-license</FONT> revenue according to the proportion of development costs incurred, with the Group getting an additional five percent (5%) share and Everest receiving five percent (5%) less. Everest cannot share in
any profit from the commercialization of CD38 product until it has fulfilled its payment obligations under this agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Upon any
termination of this arrangement, the terminating party has the right to continue the development and commercialization of CD38 product. If Everest is the rightful terminating party, the Group shall reasonably cooperate with Everest to facilitate the
following: (i)&nbsp;assign the MorphoSys license to Everest (subject to the terms and conditions of such license); (ii) grant to Everest an exclusive license to all intellectual property rights that the Group owns or controls to further develop,
manufacture, and commercialize the CD38 product; (iii)&nbsp;transfer the development, manufacture and commercialization of the CD38 product to Everest. The terminating party shall be solely responsible for the cost and expense of such development
and commercialization after termination. In the event that such continuing party successfully develops and commercializes the CD38 product, it shall pay to the other party a percentage of the product profit and
<FONT STYLE="white-space:nowrap">out-license</FONT> revenue generated therefrom in accordance with the terms of this agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-51 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">I-MAB</FONT> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to the Unaudited Interim Condensed Consolidated Financial Statements </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(All amounts in thousands, except for share and per share data, unless otherwise noted) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>16. Licensing and Collaboration Arrangements&nbsp;(Continued) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>B. <FONT STYLE="white-space:nowrap">Out-Licensing</FONT> and collaboration Arrangements&nbsp;(Continued) </I></B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">During the year ended December&nbsp;31, 2018, the US$26.0&nbsp;million in aggregate proceeds
from Everest under the agreement represented the funding available under the agreement and was recorded as a research and development funding received liability (equivalent to approximately RMB178.7 million) on the consolidated balance sheet as of
December&nbsp;31, 2018, in accordance with ASC 730, Research and Development. Because there is a significant related party relationship between the Group and Everest, the Group is treating its obligation to make payments under the commercialization
stage as an implicit obligation to repay the funds advanced by Everest (see Note 21). During the nine months ended September&nbsp;30, 2019, an additional US$7.6&nbsp;million (equivalent to approximately RMB51.6 million) of funding was received and
recorded as a research and development funding received liability, no further funding received from July&nbsp;1, 2019 to the date of termination agreement entered into with Everest. No additional milestone has been achieved in the year ended
December&nbsp;31, 2019. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><I>Termination Agreement with Everest </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">On November&nbsp;4, 2019, the Group and Everest have terminated the collaboration agreement with respect to the
<FONT STYLE="white-space:nowrap">co-development</FONT> and commercialization of TJ202 in Greater China. Upon the termination, Everest will not retain any rights or entitlements to develop or commercialize TJ202 or any economic interest in its
commercialization. All intellectual property rights in respect of TJ202 arising from its development under the collaboration agreement are vested and owned by <FONT STYLE="white-space:nowrap">I-Mab,</FONT> and the Group holds all intellectual
property rights and have maximum flexibility to further develop, manufacture and commercialize TJ202 in Greater China. In consideration of the above arrangements, the board of directors of the Group has approved the issuance of a total value of
US$37.0&nbsp;million (equivalent to approximately RMB258.1 million) of ordinary shares (the &#147;CPP Shares&#148;) to Everest, representing Everest&#146;s historical contribution to the collaboration and the associated time cost. The CPP Shares
will be issued concurrently with, and subject to, the completion of the Company&#146;s initial public offering within 180 days from termination of the collaboration agreement. The total value of US$37.0&nbsp;million was calculated based on the sum
of (1)&nbsp;US$33.7&nbsp;million, which equals cumulative <FONT STYLE="white-space:nowrap">paid-in</FONT> contributions historically made by Everest under the collaboration agreement; and (2)&nbsp;a negotiated US$3.3&nbsp;million time cost of the
foregoing historical contribution in light of <FONT STYLE="white-space:nowrap">I-Mab&#146;s</FONT> exclusive rights over the commercialization of TJ202 after this termination. The issuance of the CPP Shares was approved by <FONT
STYLE="white-space:nowrap">I-Mab&#146;s</FONT> existing shareholders on December&nbsp;25, 2019. In the event that the initial public offering has not been completed within 180 days from the termination of the collaboration agreement, the Company
will issue 4,762,751 ordinary shares (the &#147;Subject Shares&#148;) to Everest on the 181st day. As a result of the aforementioned termination of the collaboration agreement with Everest, the Group derecognized the research and development funding
received from Everest and recognized a liability that represented the ordinary shares to be issued to Everest, which was measured at fair value in accordance with ASC 480, and the difference of US$3.3&nbsp;million (equivalent to approximately
RMB23.0 million) between the initial fair value of the liability and the carrying amount of research and development funding received was recognized as other expenses in the consolidated statements of comprehensive loss for the year ended
December&nbsp;31, 2019. Upon the completion of the IPO in January 2020, the Group issued 6,078,571 ordinary shares to Everest. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-52 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">I-MAB</FONT> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to the Unaudited Interim Condensed Consolidated Financial Statements </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(All amounts in thousands, except for share and per share data, unless otherwise noted) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>16. Licensing and Collaboration Arrangements&nbsp;(Continued) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>B. <FONT STYLE="white-space:nowrap">Out-Licensing</FONT> and collaboration Arrangements&nbsp;(Continued) </I></B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><I>Licensing Agreement with ABL Bio </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In July 2018, the Group entered into a license and collaboration agreement with ABL Bio, under which the Group granted to ABL Bio exclusive,
worldwide (excluding Greater China), royalty-bearing rights to develop and commercialize a bispecific antibody (&#147;BsAb&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The
Group agreed to share costs fifty-fifty (50:50) with ABL Bio through the completion of in vivo studies, with ABL Bio responsible for all costs and activities following that time. As of December&nbsp;31, 2019, in total US$0.2&nbsp;million (equivalent
to approximately RMB1.4 million) expenses were incurred by ABL Bio, of which US$0.1&nbsp;million (equivalent to approximately RMB0.7 million) were incurred for the nine months ended September&nbsp;30, 2019. In the nine months ended
September&nbsp;30, 2020, US$0.04&nbsp;million (equivalent to approximately RMB0.3 million) expenses were incurred by ABL Bio. Accordingly, the Group recorded US$0.02&nbsp;million (equivalent to approximately RMB0.15 million) (50% cost sharing) of
expenses in the Group&#146;s consolidated statement of comprehensive loss for the nine months ended September&nbsp;30, 2020. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Pursuant to
the license and collaboration agreement that signed in July 2018 and memorandum of understanding that subsequently entered into with ABL Bio in January 2020, ABL Bio agreed to pay the Group an upfront fee of US$2.5&nbsp;million (equivalent to
approximately RMB17.2 million), and milestone payments in the aggregate amount of US$97.5&nbsp;million (equivalent to approximately RMB690.3 million) conditioned upon achieving certain research, clinical development and sales milestones. These
include clinical milestones of up to US$32.5&nbsp;million (equivalent to approximately RMB230.1 million) and sales milestones of up to US$65&nbsp;million (equivalent to approximately RMB460.2 million). Further, ABL Bio agreed to pay the Group
royalties at <FONT STYLE="white-space:nowrap">mid-single-digit</FONT> percentages in respect of the total annual net sales of the licensed BsAb product. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In addition, ABL Bio granted to the Group an exclusive, royalty-free, sublicensable license to use the BsAb technology solely to exploit the
licensed BsAb product for all indications in Greater China. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Group determined that this collaboration is reflective of a
vendor-customer relationship and therefore within the scope of ASC 606. Under this agreement, the only one performance obligation was to grant the BsAb license to ABL Bio. If it is probable that a significant revenue reversal would not occur, the
associated milestone value is included in the transaction price. Achievement of milestones that are not within the control of the Group or the licensee, such as regulatory approvals, are not considered probable until the approvals are achieved. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Group recognized revenue of US$2.5&nbsp;million (equivalent to RMB17.2 million) of revenue in the consolidated statements of comprehensive
loss for the year ended December&nbsp;31, 2018, which was the upfront fee related to the grant of the rights of BsAb to ABL Bio as mentioned above. As of December&nbsp;31, 2019 and September&nbsp;30, 2020, no other milestone has been achieved. No
revenue was recognized for the nine months ended September&nbsp;30, 2020 and 2019. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><I>Collaboration Agreement with ABL Bio </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In July 2018, the Group and ABL Bio entered into a collaboration agreement (the &#147;ABL Bio Collaboration&#148;) whereby both parties agreed
to collaborate to develop three <FONT STYLE="white-space:nowrap">PD-L1</FONT> based bispecific antibodies by </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-53 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">I-MAB</FONT> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to the Unaudited Interim Condensed Consolidated Financial Statements </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(All amounts in thousands, except for share and per share data, unless otherwise noted) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>16. Licensing and Collaboration Arrangements&nbsp;(Continued) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>B. <FONT STYLE="white-space:nowrap">Out-Licensing</FONT> and collaboration Arrangements&nbsp;(Continued) </I></B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
using ABL Bio&#146;s proprietary BsAb technology and commercialize them in their respective territories, which, collectively, include Greater China and South Korea, and other territories
throughout the rest of the world if both parties agree to do so in such other territories during the performance of the agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">At
contract inception, as both <FONT STYLE="white-space:nowrap">I-Mab</FONT> and ABL Bio participate actively in the research and development activity. Also, the parties share the risk of failure of the BsAb products and share the income of licensing,
so this contract meet the criteria of the definition of a collaborative arrangement, the Group categorized this agreement within the scope ASC 808. Prior to commercialization, the Group recorded the share of the expenses incurred by the
collaboration for the development of three <FONT STYLE="white-space:nowrap">PD-L1</FONT> based bispecific antibodies products in research and development expense in the interim condensed consolidated statements of comprehensive loss. As of
December&nbsp;31, 2019, in total RMB12.2&nbsp;million expenses were incurred by the Group and RMB8.0&nbsp;million expenses were incurred by ABL, of which, RMB6.0&nbsp;million expenses were incurred by the Group and RMB6.6&nbsp;million expenses were
incurred by ABL for the nine months ended September&nbsp;30, 2019. According to the terms set out in the agreement, the Group recorded RMB6.3&nbsp;million (50% cost sharing) of expenses in the Group&#146;s interim condensed consolidated statements
of comprehensive loss for the nine months ended September&nbsp;30, 2019. For the nine months ended September&nbsp;30, 2020, RMB12.4&nbsp;million expenses were incurred by the Group and RMB39.6&nbsp;million expenses were incurred by ABL. According to
the terms set out in the agreement, the Group recorded RMB26.0&nbsp;million (50% cost sharing) of expenses in the Group&#146;s interim condensed consolidated statements of comprehensive loss for the nine months ended September&nbsp;30, 2020. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><I>Collaboration Agreements with Tracon Pharmaceuticals, Inc. (&#147;Tracon&#148;) </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In November 2018, the Group entered into collaboration agreements with Tracon, under which both parties agreed to <FONT
STYLE="white-space:nowrap">co-develop</FONT> the Group&#146;s proprietary CD73 antibody, TJD5 (the &#147;TJD5 Agreement&#148;) and <FONT STYLE="white-space:nowrap">co-develop</FONT> up to five BsAbs (the &#147;BsAbs Agreement&#148;). Both agreements
may be terminated by either party for the other party&#146;s uncured material breach, bankruptcy or insolvency or for safety reasons. In addition, the agreement in respect of TJD5 may be terminated by the Group: (i)&nbsp;for convenience within a
certain period upon completing different clinical stages subject to certain payments and royalties, based on the clinical stage, that would be owed to Tracon upon the exercise of such termination for convenience; (ii)&nbsp;in the event that Tracon
causes the Phase 1 study timeline to be delayed beyond the agreed extension periods; or (iii)&nbsp;if the Group decides to end the development of the collaborative product prior to its first commercial sale. Further, prior to the first commercial
sale, Tracon may deem this agreement to be terminated by the Group if it reasonably believes that the Group has discontinued all meaningful development of the collaborative product for at least 12 months and certain other conditions are met.
Additionally, in March 2019, the Group agreed with Tracon and F. <FONT STYLE="white-space:nowrap">Hoffmann-La</FONT> Roche Ltd (&#147;Roche&#148;) on a clinical supply agreement for Roche to supply atezolizumab for use in clinical studies under the
collaboration agreement with Tracon. As of December&nbsp;31, 2019, the Group has recorded US$4.0&nbsp;million (equivalent to approximately RMB27.8 million) of research and development costs in the consolidated statement of comprehensive loss for the
year ended December&nbsp;31, 2019, of which US$3.4&nbsp;million (equivalent to approximately RMB24.3 million) was recorded in the nine months ended September&nbsp;30, 2019. As of September&nbsp;30, 2020, no payments or royalties are due under this
agreement. For the nine months ended September&nbsp;30, 2020, the Group has recorded US$0.03&nbsp;million (equivalent to approximately RMB0.2 million) of research and development costs in the interim condensed consolidated statements of
comprehensive loss. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-54 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">I-MAB</FONT> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to the Unaudited Interim Condensed Consolidated Financial Statements </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(All amounts in thousands, except for share and per share data, unless otherwise noted) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>16. Licensing and Collaboration Arrangements&nbsp;(Continued) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>B. <FONT STYLE="white-space:nowrap">Out-Licensing</FONT> and collaboration Arrangements&nbsp;(Continued) </I></B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><I>Licensing Agreement with CSPC Pharmaceutical Group Limited (&#147;CSPC&#148;) </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In December 2018, the Group entered into a product development agreement with CSPC. The Group granted to CSPC exclusive, <FONT
STYLE="white-space:nowrap">non-transferable,</FONT> <FONT STYLE="white-space:nowrap">non-irrevocable</FONT> and sublicensable rights in the PRC (excluding Hong Kong, Macau and Taiwan) to develop and commercialize TJ103 for treating type 2 diabetes.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">CSPC is responsible for developing, obtaining market approval and commercializing the licensed products. The Group is responsible for
transferring the manufacturing technology of the licensed products to CSPC and assisting CSPC in the continued optimization of such manufacturing technology thereafter. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In consideration of the license, CSPC agreed to pay the Group an upfront fee of RMB15.0&nbsp;million and milestone payments in an aggregate
amount of RMB135.0&nbsp;million conditioned upon achieving certain clinical development and regulatory approval milestones. In addition, the Group is also entitled to royalties of up to <FONT STYLE="white-space:nowrap">low-double-digit</FONT>
percentages in respect of the total annual net sales of the products after its commercialization in the PRC. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Group determined that
this collaboration is reflective of a vendor-customer relationship and therefore within the scope of ASC 606. Under this agreement, the only one performance obligation was to grant TJ103 license to CSPC. considering that the achievements of
milestones are constrained such that the transaction price shall initially only include upfront payment and subsequently, once another milestone was achieved (that means when uncertainty associated with the variable consideration is subsequently
resolved), the additional milestone payment shall be included in the total transaction price when it is no longer probable that a significant reversal of cumulative revenue would occur in future periods. As of December&nbsp;31, 2018, the amount
received of RMB14.2&nbsp;million (net of VAT) was recorded as advance from customers in the consolidated balance sheet. In February 2019, an additional amount of RMB0.8&nbsp;million (net of VAT) was received, and the license was also approved by
China intellectual property office in May 2019. The first milestone was achieved in September 2019 and the amount of RMB15.0&nbsp;million (net of VAT) was received according to the terms of the agreement. Accordingly, RMB30.0&nbsp;million was
recognized as revenue in the consolidated statements of comprehensive loss for the year ended December&nbsp;31, 2019, of which RMB15.0&nbsp;million of upfront payment and RMB15.0&nbsp;million milestone payment were recognized for the nine months
ended September&nbsp;30, 2019. No additional revenue was recognized in the nine months ended September&nbsp;30, 2020 as no further milestone has been achieved. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><I>Strategic Alliance Agreement with PT Kalbe Genexine Biologics (&#147;KG Bio&#148;) </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In March 2020, the Group entered into a strategic partnership with Kalbe Genexine Biologics (&#147;KG Bio&#148;) to grant a right of first
negotiation for an exclusive license for the development and commercialization of two <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">I-Mab-discovered</FONT></FONT> product candidates: uliledlimab, a highly differentiated anti-CD73
antibody in Phase 1 development for advanced solid tumors (&#147;First Program&#148;), and an <FONT STYLE="white-space:nowrap">I-Mab</FONT> product candidate (&#147;Second Program&#148;) to be agreed upon by both parties in certain regions. Through
this agreement, both parties intend to negotiate the terms that will be reflected in definitive agreements for each prospective program covered under this agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">If and when the Group and KG Bio enter into the definitive licensing agreement, the Group will be eligible to receive from KG Bio an aggregate
amount of up to approximately US$340&nbsp;million, including an </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-55 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">I-MAB</FONT> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to the Unaudited Interim Condensed Consolidated Financial Statements </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(All amounts in thousands, except for share and per share data, unless otherwise noted) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>16. Licensing and Collaboration Arrangements&nbsp;(Continued) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>B. <FONT STYLE="white-space:nowrap">Out-Licensing</FONT> and collaboration Arrangements&nbsp;(Continued) </I></B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
upfront payment and subsequent payments conditional upon achieving certain development and commercial milestones. KG Bio will pay the Group tiered royalties in the low to <FONT
STYLE="white-space:nowrap">mid-teen</FONT> percentages on net sales from certain regions. As the right of first negotiation has not been exercised and the definitive agreement has not been entered into as of September&nbsp;30, 2020, no revenue was
recognized during the nine months ended September&nbsp;30, 2020. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><I>Global Strategic Partnership with AbbVie </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">On September&nbsp;3, 2020, the Group, through <FONT STYLE="white-space:nowrap">I-Mab</FONT> Biopharma (Shanghai) Co., Ltd. and <FONT
STYLE="white-space:nowrap">I-Mab</FONT> Biopharma US Limited, each a wholly-owned subsidiary of the Group, entered into a broad global strategic partnership with AbbVie Ireland Unlimited Group (&#147;AbbVie&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Pursuant to this collaboration, the Group will grant AbbVie a global license, excluding Mainland China, Macau, and Hong Kong, to develop and
commercialize lemzoparlimab (also known as TJC4), an innovative anti-CD47 monoclonal antibody internally discovered and developed by <FONT STYLE="white-space:nowrap">I-Mab</FONT> for the treatment of multiple cancers. The Group will retain all
rights to develop and commercialize lemzoparlimab (as well as certain other compounds directed against CD47) in Mainland China, Macau, and Hong Kong. AbbVie will conduct further global clinical trials (which the Group may elect to <FONT
STYLE="white-space:nowrap">co-fund)</FONT> to evaluate lemzoparlimab in multiple cancers. This deal also allows for potential collaboration on future CD47-related therapeutic agents, including CD47-based bispecific antibodies and combination
therapies with lemzoparlimab and AbbVie&#146;s venetoclax (Venclexta<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>). Each party will have the opportunity, subject to rights of first negotiation to further licenses, to explore certain of
each other&#146;s related CD47-antibody programs in their respective territories. In addition, the Group and AbbVie will share manufacturing responsibilities, with AbbVie being the primary manufacturer supply outside of Mainland China, Hong Kong and
Macau and the Group being the primary manufacturer for supply for Mainland China, Hong Kong and Macau. The Group believes that this collaboration will accelerate its establishment of commercial production operations in China. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">AbbVie will pay the Group an upfront payment of US$180&nbsp;million. Additionally, in connection with the recently released clinical data from
the Phase 1 trial of lemzoparlimab in the United States, the Group expects to be paid a first milestone payment of US$20&nbsp;million. The Group will also be eligible to receive up to US$1.74&nbsp;billion in further success-based development,
regulatory and sales milestone payments for lemzoparlimab, of which US$840&nbsp;million are based on clinical development and regulatory approval milestones, with the remainder based on commercial milestones. Upon commercialization of lemzoparlimab,
AbbVie will also pay tiered royalties from low double-digit percentages on global net sales outside of Mainland China, Macau, and Hong Kong. In addition, AbbVie has a license and right of first negotiation to further develop and commercialize two
additional lemzoparlimab-based bispecific antibodies discovered and currently being developed by the Group and the Group cannot commercialize products containing these two additional lemzoparlimab-based bispecific antibodies outside of Mainland
China, Macau and Hong Kong even if AbbVie does not exercise its right of first negotiation or both parties are unable to come to an agreement of financial terms on such products. The potential value of each such license is minimum
US$500&nbsp;million in upfront and milestone payments, for a combined total of no less than US$1&nbsp;billion. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">As of September&nbsp;30,
2020, certain contractual obligations and regulatory approval were not obtained to bring the contract into effect. Thus, there was no financial impact in the interim condensed consolidated </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-56 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">I-MAB</FONT> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to the Unaudited Interim Condensed Consolidated Financial Statements </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(All amounts in thousands, except for share and per share data, unless otherwise noted) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>16. Licensing and Collaboration Arrangements&nbsp;(Continued) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>B. <FONT STYLE="white-space:nowrap">Out-Licensing</FONT> and collaboration Arrangements&nbsp;(Continued) </I></B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
statement of comprehensive loss for the nine months ended September&nbsp;30, 2020. Subsequently, it has become effective on December&nbsp;10, 2020. The Group received the upfront payment of
US$180&nbsp;million in December 2020. Additionally, the first milestone event was achieved before the end of 2020 and the Group is entitled to receive the first milestone payment of US$20 million. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>17. Other Income, Net </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following
table summarizes other income and expenses, recognized for the nine months ended September&nbsp;30, 2019 and 2020: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="85.5%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="66%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Nine Months Ended September&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>RMB</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>RMB</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>US$&nbsp;(Note&nbsp;2.5)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fair value change of short-term investments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">332</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,557</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">377</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income of incentive payment from depository bank<BR>(Note 9)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,731</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">255</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net foreign exchange gains</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,489</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,760</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(260</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Subsidy income (Note (i))</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">180</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,658</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,570</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fair value change of other financial assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(145</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gains on deconsolidation of a subsidiary (Note 7)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">407,598</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">60,033</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Others</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(98</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">116</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,758</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">420,900</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">61,992</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Note: </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(i) For the nine months ended September&nbsp;30, 2020, subsidy income consists primarily of the government grant of RMB10&nbsp;million. The
government grant was granted by the project management office of Shanghai Zhangjiang Science City to support the research and development activities in the local region. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>18. Net Loss Per Share </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Basic and
diluted net loss per share for each of the periods presented are calculated as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="85.5%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="54%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Nine Months Ended September&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>RMB</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>RMB</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>US$ (Note 2.5)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Numerator:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss attributable to ordinary shareholders</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,103,380</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(570,635</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(84,045</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Denominator:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted average number of ordinary shares outstanding&#151;basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,184,086</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">126,758,926</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">126,758,926</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss per share&#151;basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(153.59</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4.50</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(0.66</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-57 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">I-MAB</FONT> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to the Unaudited Interim Condensed Consolidated Financial Statements </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(All amounts in thousands, except for share and per share data, unless otherwise noted) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>18. Net Loss Per Share&nbsp;(Continued) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">For the nine months ended September&nbsp;30, 2019 and 2020, the effects of all outstanding
convertible preferred shares, restricted shares, warrants and certain restricted share units and stock options have been excluded from the computation of diluted loss per share for the nine months ended September&nbsp;30, 2019 and 2020 as their
effects would be anti-dilutive. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">For the nine months ended September&nbsp;30, 2019 and 2020, the Group also has certain dilutive potential
stock options. These stock options which cannot be exercised until the Company completed its listing are not included in the computation of diluted earnings per shares as such contingent event had not taken place. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The potentially dilutive securities that have not been included in the calculation of diluted net loss per share as their inclusion would be
anti-dilutive are as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="72%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="64%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Nine Months Ended<BR>September&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Convertible preferred shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">95,222,315</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,593,305</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Restricted shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,179,634</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Restricted share units</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,071,194</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stock options</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,445,457</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17,321,232</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>19. Employee Benefits </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Full time employees of the Group in the PRC participate in a government mandated defined contribution plan, pursuant to which certain pension
benefits, medical care, employee housing fund and other welfare benefits are provided to the employees. Chinese labor regulations require that the PRC subsidiaries of the Group make contributions to the government for these benefits based on certain
percentage of the employees&#146; salaries, up to a maximum amount specified by the government. The Group has no legal obligation for the benefits beyond the contribution made. The total amounts charged to the interim condensed consolidated
statements of comprehensive loss for such employee benefits amounted to approximately RMB9,987 and RMB8,815 for the nine months ended September&nbsp;30, 2019 and 2020, respectively. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>20. Commitments and Contingencies </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Contingencies
</I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Group is a party to or an assignee of license and collaboration agreements that may require it to make future payments
relating to milestone fees and royalties on future sales of licensed products (Note 16). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Group did not have significant capital and
other commitments, long-term obligations, or guarantees as of December&nbsp;31, 2019 and September&nbsp;30, 2020. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-58 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">I-MAB</FONT> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to the Unaudited Interim Condensed Consolidated Financial Statements </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(All amounts in thousands, except for share and per share data, unless otherwise noted) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>21. Related Party Balances and Transactions </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The table below sets forth the major related parties and their relationships with the Group as of December&nbsp;31, 2019 and
September&nbsp;30, 2020: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="50%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name of related parties</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Relationship with the Group</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Everest</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Controlled by the ultimate controlling party of a principal shareholder of the Group</P></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Tasly Pharmaceutical Group Co., Ltd.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Controlled by the ultimate controlling party of a principal shareholder of the Group</P></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">CMAB Biopharma (Suzhou) Inc.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Controlled by the ultimate controlling party of a principal shareholder of the Group</P></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><FONT STYLE="white-space:nowrap">I-Mab</FONT> Biopharma (Hangzhou) Co., Limited</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Subsidiary of the Group before September&nbsp;15, 2020; Affiliate of the Group after
September&nbsp;15, 2020</P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Details of related party balance as of December&nbsp;31, 2019 and September&nbsp;30, 2020 are as follows: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><I>Ordinary Shares to be issued to Everest* </I></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="72%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="47%"></TD>

<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>As&nbsp;of&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>As&nbsp;of&nbsp;September&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>RMB</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>RMB</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>US$&nbsp;(Note&nbsp;2.5)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Everest (Note 16)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">258,119</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><I>Loans to an affiliate </I></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="72%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="43%"></TD>

<TD VALIGN="bottom" WIDTH="12%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="12%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="12%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>As&nbsp;of&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>As&nbsp;of&nbsp;September&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>RMB</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>RMB</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>US$&nbsp;(Note&nbsp;2.5)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">I-Mab Hangzhou (Note(i))</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">52,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,659</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Note(i): In July 2019 and July 2020, <FONT STYLE="white-space:nowrap">I-Mab</FONT> Shanghai provided an
interest free loan to <FONT STYLE="white-space:nowrap">I-Mab</FONT> Hangzhou of RMB2,000 and RMB50,000 respectively to finance <FONT STYLE="white-space:nowrap">I-Mab</FONT> Hangzhou&#146;s operation. These loans were repaid in November 2020. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Details of related party transactions for the nine months ended September&nbsp;30, 2019 and 2020 are as follows: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><I>Receipt of CRO services&#151;recognized in research and development expenses </I></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="72%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="59%"></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Nine Months Ended September&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>RMB</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>RMB</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>US$&nbsp;(Note&nbsp;2.5)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Tasly Pharmaceutical Group Co., Ltd.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,590</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-59 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">I-MAB</FONT> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to the Unaudited Interim Condensed Consolidated Financial Statements </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(All amounts in thousands, except for share and per share data, unless otherwise noted) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>21. Related Party Balances and Transactions&nbsp;(Continued) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><I>Receipt of research and development funding </I></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="72%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="60%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Nine Months Ended September&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>RMB</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>RMB</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>US$&nbsp;(Note&nbsp;2.5)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Everest (Note 16)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">52,207</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><I>Project development fee &#150; recognized in research and development expenses </I></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="67%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Nine&nbsp;Months&nbsp;Ended&nbsp;September&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>RMB</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>US$&nbsp;(Note&nbsp;2.5)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">CMAB Biopharma (Suzhou) Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">690</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">102</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>22. Concentration of Credit Risk </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Financial instruments that are potentially subject to significant concentration of credit risk consist of cash and cash equivalents,
restricted cash, short-term investments and other receivables. The carrying amounts of cash and cash equivalents, restricted cash, and short-term investments represent the maximum amount of loss due to credit risk. As of December&nbsp;31, 2019 and
September&nbsp;30, 2020, all of the Group&#146;s cash and cash equivalents, restricted cash and short-term investments were held by major financial institutions located in the PRC and international financial institutions outside of the PRC which
management believes are of high credit quality and continually monitors the credit worthiness of these financial institutions. With respect to the contract assets, other receivables and other financial assets, the Group performs <FONT
STYLE="white-space:nowrap">on-going</FONT> credit evaluations of the financial condition of its customers and counterparties. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>23. Subsequent Events
</B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">In December 2020, the Group issued 900,000 ordinary shares to Genexine, Inc. upon the full conversion of the
2018 Notes with the conversion price of US$10 per share. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">In December 2020, the broad global strategic partnership with AbbVie became effective as the conditions of the
effective date were satisfied. The Group received the upfront payment of US$180&nbsp;million in December 2020. Additionally, the first milestone event was achieved before the end of 2020 and the Group is entitled to receive the first milestone
payment of US$20 million. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">In December 2020, the Group entered into a written amendment made to the subscription agreement with the
Hillhouse entities, which removed one of the two conditions for the second closing that an existing director of the Group having resigned to enable the Hillhouse entities to appoint a director to replace such director. The second closing occurred as
the other condition was satisfied and 8,712,124 ordinary shares as well as 1,597,235 Investor Warrants were issued to the Hillhouse entities for total gross proceeds of approximately US$125.0&nbsp;million. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-60 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#cc062a">The information in this preliminary prospectus is not complete and may be changed.
These securities may not be sold until the registration statement filed with the Securities and Exchange Commission is effective. This preliminary prospectus is not an offer to sell nor does it seek an offer to buy these securities in any
jurisdiction where the offer or sale is not permitted. </FONT></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT
 COLOR="#c21128">Subject to Completion </FONT></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#c21128">Preliminary Prospectus dated December 1, 2020. </FONT></P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>Up to 10,923,370 American Depositary Shares </B></P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g98473g25k48.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">I-MAB</FONT> </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Representing Up to 25,123,751 Ordinary Shares </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The selling shareholders identified in this prospectus may offer, from time to time, up to 25,123,751 ordinary shares, including ordinary
shares represented by American depositary shares (&#147;ADSs&#148;) of <FONT STYLE="white-space:nowrap">I-Mab.</FONT> Each ten (10)&nbsp;ADSs represent twenty-three (23)&nbsp;of our ordinary shares, par value US$0.0001 per share. The selling
shareholders identified in this prospectus are party to the subscription agreements we entered into with them in September 2020. We are not selling any ordinary shares or ADSs. We will not receive any of the proceeds from the sale of the ordinary
shares or ADSs by the selling shareholders. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our ADSs are listed on the Nasdaq Global Market under the symbol &#147;IMAB.&#148; On
November&nbsp;30, 2020, the closing trading price for our ADSs, as reported on the Nasdaq Global Market, was US$39.14 per ADS. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">At the
time the selling shareholders offer ordinary shares or ADSs under this prospectus, we will provide a prospectus supplement, if required, that will contain specific information about the terms of the offering and that may add to or update the
information in this prospectus. You should read this prospectus and any applicable prospectus supplement carefully before you invest. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The
selling shareholders may offer ordinary shares or ADSs in amounts, at prices and on terms determined by market conditions at the time of the offering. The selling shareholders may sell ordinary shares or ADSs through agents it selects or through
underwriters and dealers it selects. The selling shareholders also may sell ordinary shares or ADSs directly to investors. If the selling shareholders use agents, underwriters or dealers to sell ordinary shares or ADSs, we will name them and
describe their compensation in a prospectus supplement. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We are an &#147;emerging growth company&#148; under applicable U.S. federal
securities laws and are eligible for reduced public company reporting requirements. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:8%; font-size:12pt; font-family:Times New Roman"><B>Investing in our ordinary shares or ADSs involves
risks. See &#147;<A HREF="#rom98473_4">Risk Factors</A>&#148; beginning on page 23 for factors you should consider before buying our ordinary shares or ADSs. </B></P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:20%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>Neither the
United States Securities and Exchange Commission nor any other regulatory body has approved or disapproved of these securities, or determined if this prospectus is truthful or complete. Any representation to the contrary is a criminal offense.
</B></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Prospectus dated&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2020. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">This prospectus is part of a registration statement we filed with the Securities and
Exchange Commission (the &#147;SEC&#148;) using a &#147;shelf&#148; registration process. Under this shelf registration process, the selling shareholders may, from time to time, offer and sell, in one or more offerings, ordinary shares or ADSs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">At the time the selling shareholders offer ordinary shares or ADSs under this prospectus, if required, we will provide a prospectus supplement
that will contain specific information about the terms of the offering and that may add to or update the information in this prospectus. If the information in this prospectus is inconsistent with a prospectus supplement, you should rely on the
information in that prospectus supplement. You should read this prospectus and any applicable prospectus supplement as well as any post-effective amendments to the registration statement of which this prospectus forms a part before you make any
investment decision. You should read both this prospectus and any applicable prospectus supplement together with additional information described under the heading &#147;Where You Can Find Additional Information.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We are responsible for the information contained in this prospectus, any applicable prospectus supplement or in any free writing prospectus
prepared by or on behalf of us that we have referred to you. Neither we nor the selling shareholders have authorized anyone to provide you with additional information or information different from that contained in this prospectus or in any free
writing prospectus filed with the SEC and we take no responsibility for any other information that others may give you. The selling shareholders are offering to sell, and seeking offers to buy, ordinary shares or ADSs only in jurisdictions where
offers and sales are permitted. The information contained in this prospectus is accurate only as of the date of this prospectus, regardless of the time of delivery of this prospectus or of any sale of ordinary shares or ADSs. Our business, operating
results or financial condition may have changed since such date. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc"></A>TABLE OF CONTENTS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="95%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Page</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom98473_1">PROSPECTUS SUMMARY</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom98473_2">THE OFFERING</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom98473_3">SUMMARY CONSOLIDATED FINANCIAL DATA</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom98473_4">RISK FACTORS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom98473_5">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">92</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom98473_6">USE OF PROCEEDS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">94</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom98473_7">DIVIDEND POLICY</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">95</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom98473_8">CAPITALIZATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">96</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom98473_9">ENFORCEABILITY OF CIVIL LIABILITIES</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">97</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom98473_10">CORPORATE HISTORY AND STRUCTURE</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">99</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom98473_11">SELECTED CONSOLIDATED FINANCIAL DATA</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">101</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom98473_12">MANAGEMENT&#146;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF
 OPERATIONS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">105</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom98473_13">BUSINESS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">138</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom98473_14">REGULATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">214</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom98473_15">MANAGEMENT</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">246</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom98473_16">PRINCIPAL AND SELLING SHAREHOLDERS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">265</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom98473_17">RELATED PARTY TRANSACTIONS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">272</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom98473_18">DESCRIPTION OF SHARE CAPITAL</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">274</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom98473_19">DESCRIPTION OF AMERICAN DEPOSITARY SHARES</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">290</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom98473_20">SHARES ELIGIBLE FOR FUTURE SALES</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">302</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom98473_21">TAXATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">304</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom98473_22">PLAN OF DISTRIBUTION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">310</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom98473_23">EXPENSES RELATED TO THIS OFFERING</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">313</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom98473_24">LEGAL MATTERS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">314</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom98473_25">EXPERTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">315</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom98473_26">WHERE YOU CAN FIND ADDITIONAL INFORMATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">316</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom98473_27">INDEX TO CONSOLIDATED FINANCIAL STATEMENTS </A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">F-1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">i </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom98473_1"></A>PROSPECTUS SUMMARY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The following summary is qualified in its entirety by, and should be read in conjunction with, the more detailed information and financial
statements appearing elsewhere in this prospectus. In addition to this summary, we urge you to read the entire prospectus carefully, especially the risks of investing in our ordinary shares or ADSs discussed under &#147;Risk Factors,&#148; before
deciding whether to invest in our ordinary shares or ADSs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Overview </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We are a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel or highly
differentiated biologics to treat diseases with significant unmet medical needs, particularly cancers and autoimmune disorders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We were
founded to capture the opportunities presented by the confluence of two major developments&#151;the emergence of an attractive and growing biologics market in China, and the revolutionary scientific breakthroughs in cancer and autoimmune disease
medicines. We believe we are well-positioned to become a biotech leader in China because of our innovative discovery expertise, <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">fit-for-purpose</FONT></FONT> technology platforms,
biomarker-enabled translational medicine capabilities, and clinical development capabilities. These integrated capabilities are further enhanced by our deep understanding of China&#146;s biologics regulatory framework and our direct access to
extensive <FONT STYLE="white-space:nowrap">pre-clinical</FONT> and clinical trial resources in China. To date, we have developed an innovative pipeline of more than 10 clinical and <FONT STYLE="white-space:nowrap">pre-clinical</FONT> stage assets
through our internal research and development efforts and <FONT STYLE="white-space:nowrap">in-licensing</FONT> arrangements with global pharmaceutical and biotech companies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Commercial Opportunities in China and Our Unique Position </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We are fully aware of the competitive and regulatory challenges we face as an innovative clinical stage biotech company based in China,
including need to raise significant capital, significant competition from global and other China-based biopharmaceutical companies, less streamlined regulatory pathway compared to countries with long-established regulatory systems, and potential
implementation challenges and uncertainties of the recent government reform of the drug approval system. However, with these challenges in mind, we have been mitigating the risks through our internal R&amp;D system that integrates multi-functional
aspects of our drug development process to proactively deal with some of the regulatory challenges mentioned above. Furthermore, through our Beijing office which focuses on regulatory matters, we have established an effective communication channel
with the regulatory agencies to discuss and resolve various regulatory issues promptly and effectively. We see vast opportunities for immuno-oncology and autoimmune biologics therapies in China. First, both the incidence and mortality of cancers in
China have been increasing in recent years and are outpacing those in the United States and the rest of the world. Second, many innovative biologics approved to treat cancer and autoimmune diseases in the United States and Europe are not yet
available in China. Third, the Chinese government has implemented new policies and regulations to simplify the review and approval cycle of clinical trials and new drug applications to encourage biologics innovation. Fourth, there has been a
continuous and rapid increase in personal disposable income in China coupled with ongoing improvement in basic national health insurance coverage, making innovative biologics more accessible to more Chinese patients. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We believe we are uniquely positioned as a China-based global player to tap into these vast commercial opportunities. This is best
demonstrated by our short journey in becoming one of the top clinical stage immunology companies in China. For example, in 2018 and 2019, we are the only China-based biotech company recognized by Genetic Engineering&nbsp;&amp; Biotechnology News
(GEN) as a top 10 immuno-oncology <FONT STYLE="white-space:nowrap">start-up</FONT> in the world. To date, our research and development capabilities encompass discovery, translational medicine, biologics
</P>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
CMC development, <FONT STYLE="white-space:nowrap">pre-clinical</FONT> development and clinical development with footprints in Shanghai, Beijing and the United States. We are now at a critical
juncture to transition from a clinical stage biotech company into a fully integrated <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">end-to-end</FONT></FONT> global biopharmaceutical company in the next few years. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Unique Business Model </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">To achieve
our mission and capitalize on these commercial opportunities, we have developed a business model built on two pillars: a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">fast-to-market</FONT></FONT> China strategy and a <FONT
STYLE="white-space:nowrap">fast-to-PoC</FONT> (proof of concept) global strategy. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Fast-to-Market</FONT></FONT> China Strategy </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">fast-to-market</FONT></FONT> China strategy focuses on seeking
opportunities to <FONT STYLE="white-space:nowrap">in-license</FONT> the development and commercialization rights of investigational drugs from global biopharmaceutical companies for Greater China. We only select investigational drugs that have the
potential to become novel or highly differentiated medicines. Through our substantial <FONT STYLE="white-space:nowrap">in-house</FONT> research and development efforts, we build additional data packages to meet the requirements of the National
Medical Products Administration (the &#147;NMPA&#148;) to ensure programs are ready for late-stage or registrational clinical development. Our internal development capabilities combined with our deep insight into China&#146;s regulatory framework
and our clinical network enable us to efficiently navigate through the drug development process to registration. To date, we have built an innovative China Portfolio consisting of five investigational drugs with an aim for near-term product launch.
All of these investigational drugs have met the related <FONT STYLE="white-space:nowrap">pre-set</FONT> safety and preliminary efficacy endpoints in Phase 1 or Phase 2 clinical trials in Europe, the United States or elsewhere and are either in or
ready for Phase 2 or Phase 3 clinical trials in China. Set forth below is a summary of the latest development status of the anchor assets in our China Portfolio: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">For felzartamab (TJ202), a differentiated anti-CD38, we are conducting two parallel registrational trials as a
third-line monotherapy and as a second line combination therapy with lenalidomide, both in patients with multiple myeloma in Greater China. The recruitment progress for these two trials remains on track, and we expect to submit an NDA to the NMPA in
2021. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">For eftansomatropin (TJ101), a differentiated long-acting growth hormone, in September 2020, the NMPA approved
our IND application for a registrational Phase 3 trial in pediatric growth hormone deficiency (PGHD). We expect to initiate this trial in the first quarter of 2021. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">For enoblituzumab, a humanized antibody directed at <FONT STYLE="white-space:nowrap">B7-H3,</FONT> in the first
quarter of 2021, MacroGenics expects to initiate a Phase 2 study of enoblituzumab in a chemo-free regimen in combination with either retifanlimab (an investigational <FONT STYLE="white-space:nowrap">PD-1</FONT> antibody) in front-line patients with
SCCHN who are <FONT STYLE="white-space:nowrap">PD-L1</FONT> positive or with tebotelimab (an investigational <FONT STYLE="white-space:nowrap">PD-1</FONT> x <FONT STYLE="white-space:nowrap">LAG-3</FONT> bispecific DART<SUP
STYLE="font-size:85%; vertical-align:top">&reg;</SUP> antibody) in SCCHN patients who are <FONT STYLE="white-space:nowrap">PD-L1</FONT> negative. We expect to participate in any subsequent Phase 3 global study if and when initiated. In addition,
considering the dynamic regulatory environment and evolving clinical practice, we have been continually refining the development of enoblituzumab in our territory. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">For efineptakin (TJ107), a long-acting interleukin 7, we obtained regulatory clearance from the NMPA in April
2020 to initiate a Phase 2 clinical trial in glioblastoma multiforme (GBM) patients with lymphopenia. We expect to initiate this trial in the fourth quarter of 2020. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">As a result, the investigational drugs in our China Portfolio are positioned for a series of new drug applications (NDAs) in China with the
submission of the first NDA expected in 2021. </P>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I><FONT STYLE="white-space:nowrap">Fast-to-PoC</FONT> Global Strategy </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our <FONT STYLE="white-space:nowrap">fast-to-PoC</FONT> global strategy focuses on advancing our own novel or differentiated biologics towards
clinical validation in the United States. First, we seek PoC of these drug candidates in the United States by conducting early phase clinical trials with a set of safety and efficacy endpoints and leveraging the FDA&#146;s streamlined regulatory
system for innovative drug development, including a predictable timeline towards IND approval. Second, we will use the data generated to advance clinical development in China, which we believe confers several advantages, including access to
China&#146;s large patient pool, extensive clinical trial resources through collaborations with leading hospitals in China, and a regulatory pathway for fast-track approval of drugs supported by solid overseas clinical data. Building on this
approach, we may <FONT STYLE="white-space:nowrap">out-license</FONT> the global rights (excluding Greater China) of these investigational drugs following clinical validation in the United States, while retaining the Greater China rights for further
development and commercialization. We believe this approach will allow Chinese patients to benefit from our most advanced treatments concurrently or soon after their market approvals elsewhere. To date, we have created a Global Portfolio that
consists of two molecular classes&#151; monoclonal antibodies and <FONT STYLE="white-space:nowrap">bi-specific</FONT> antibodies, which are internally generated. They are highly innovative molecules compared to global competitor assets in the same
or related classes of drug candidates. Set forth below is a summary of the latest development status of the anchor assets in our Global Portfolio: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">For lemzoparlimab (TJC4), a differentiated anti-CD47, the topline results of the recently completed Phase 1a dose
escalation monotherapy trial in the United States have demonstrated the differentiated profile of lemzoparlimab in drug safety and favorable pharmacokinetics in cancer patients. The key findings include: (i)&nbsp;lemzoparlimab was well tolerated up
to 30 mg/kg on a weekly basis without priming dosing strategy, and no dose-limiting toxicity and no clinical or laboratory evidence of hemolytic anemia were observed throughout; (ii)&nbsp;lemzoparlimab PK appears to be linear at mid to high dose
levels following a single dose with no significant &#147;sink effect&#148; and (iii)&nbsp;one confirmed Partial Response (PR) was observed in the 30 mg/kg monotherapy cohort (N=3), and this patient had failed prior treatments with checkpoint
inhibitors. In September 2020, we received the NMPA approval for a Phase 1 clinical trial of lemzoparlimab in relapsed or refractory advanced lymphoma in China as part of the ongoing international multi-center trial. In addition, lemzoparlimab is
being evaluated in a Phase 1/2a clinical trial in China in patients with relapsed or refractory acute myeloid leukemia (r/r AML) or myelodysplastic syndrome (MDS), and we anticipate reporting <FONT STYLE="white-space:nowrap">top-line</FONT> results
in early 2021. We have also entered into a clinical trial collaboration and supply agreement with Merck Sharp&nbsp;&amp; Dohme Corp, or MSD, through a subsidiary, under which we will sponsor a Phase 1 clinical trial in the United States evaluating
lemzoparlimab in combination with KEYTRUDA<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> (pembrolizumab), MSD&#146;s <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-1</FONT></FONT> therapy, in patients with
multiple types of solid tumors. In September 2020, we granted AbbVie a global license, excluding Mainland China, Hong Kong and Macau, to develop and commercialize lemzoparlimab (as well as certain other compounds directed against CD47), and we will
retain all rights to develop and commercialize lemzoparlimab in Mainland China, Hong Kong and Macau. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">For uliledlimab (TJD5), a differentiated anti-CD73, we are conducting a Phase 1 clinical trial in the United
States as a single agent and in combination with atezolizumab (TECENTRIQ<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>), a <FONT STYLE="white-space:nowrap">PD-L1</FONT> antibody marketed by Roche, in patients with advanced solid tumors.
The preliminary data of this trial in the United States are expected by mid-2021. In China, we are conducting a Phase 1/2 clinical trial to evaluate uliledlimab in patients with advanced solid tumors. The first patient was dosed in May 2020. This
Phase 1/2 study is a multicenter, open-label, dose escalation and cohort expansion study, which will evaluate safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy of uliledlimab, and determine a recommended dose for further planned
clinical studies of its efficacy and safety as a single agent and in combination with standard dose of toripalimab (TUOYI<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>) in patients with advanced or metastatic cancers who are refractory
to or intolerant of all </P></TD></TR></TABLE>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="12%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
available therapies; for the combination therapy. We have been able to accelerate the Phase 1/2 trial in China by leveraging data from the ongoing Phase 1 clinical study of uliledlimab in the
United States, which is a testament to our global clinical development capabilities and well-executed pipeline strategies. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">For plonmarlimab (TJM2), an
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-GM-CSF,</FONT></FONT> we have completed a single-dose <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-human</FONT></FONT> study in healthy volunteers
in the United States. It is the first antibody of its class entering clinical development in China. We dosed the first patient in a Phase 1b study of plonmarlimab in August 2020 in patients with rheumatoid arthritis (RA). We may expand plonmarlimab
to other autoimmune and inflammatory indications with high unmet medical need, where <FONT STYLE="white-space:nowrap">GM-CSF</FONT> is known as a pathogenic cytokine in disease activity and progression. If approved, plonmarlimab is expected to
provide an effective treatment option as a disease-modifying anti-rheumatic drug (&#147;DMARD&#148;) therapy. In addition, since the <FONT STYLE="white-space:nowrap">COVID-19</FONT> outbreak, we have sprung into action to prioritize plonmarlimab in
response to the urgent medical needs. In May 2020, we announced preliminary results from part 1 of a clinical study in the United States of plonmarlimab in patients with cytokine release syndrome (CRS) associated with severe <FONT
STYLE="white-space:nowrap">COVID-19,</FONT> in which plonmarlimab was found to be well tolerated. We are currently conducting part 2 of this clinical trial to evaluate the efficacy, safety and cytokine levels following a single dose of 6 mg/kg
plonmarlimab or placebo (standard care) in patients with severe <FONT STYLE="white-space:nowrap">COVID-19.</FONT> We are currently in discussion with the FDA to finalize the plan for plonmarlimab in relation to clinical development and potential
registration in the United States. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">These two strategies and the resulting two portfolios complement each other. This
enables us to achieve a balance among our ambition to develop novel or highly differentiated drugs, our goal to efficiently advance our pipeline assets towards commercialization and the inherent development risks. With this goal in mind, we are also
aware that the intended novelty and key differentiation of our investigational drugs or drug candidates are subject to pivotal clinical validation and approval by the relevant regulatory authorities. There is no assurance that any such
investigational drug or drug candidate will receive regulatory approval. See &#147;Risk Factors&#148; for a detailed description of the risks related to the development and commercialization of our drug candidates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Capabilities </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our Innovative Discovery
Expertise </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Built by an elite group of seasoned immunologists with extensive academic research and drug development experience, our
discovery engine has generated a panel of internally developed innovative drug molecules in a short span of five years. Among them, 12 innovative drug molecules have met our standard of novelty or high differentiation and have advanced toward
further development. This achievement is a testament to our discovery team&#146;s acumen and technical prowess in translating target biology into points of innovation or differentiation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The discovery of lemzoparlimab showcases our innovative research capabilities. Not settling on performing routine or traditional antibody
screening, we set a specific goal to identify and select a unique CD47 antibody that is free from binding to red blood cells (RBC) from all CD47 antibody leads. As a result, we selected by design, our proprietary CD47 antibody (TJC4) with a rare
epitope that spares binding to RBCs as a differentiation point from other CD47 antibodies that typically cause inherent hematologic side effects. The topline results of the recently completed Phase 1a dose escalation monotherapy trial in the United
States have demonstrated the differentiated profile of lemzoparlimab in drug safety and favorable pharmacokinetics in cancer patients. The key findings include: (i)&nbsp;lemzoparlimab was well tolerated up to 30 mg/kg on a weekly basis without
priming dosing strategy, and no dose-limiting toxicity and no clinical or laboratory evidence of </P>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
hemolytic anemia were observed throughout; (ii)&nbsp;lemzoparlimab PK appears to be linear at mid to high dose levels following a single dose with no significant &#147;sink effect&#148; and
(iii)&nbsp;one confirmed Partial Response (PR) was observed in the 30 mg/kg cohort (N=3), and this patient had failed prior treatments with checkpoint inhibitors. Three patients achieved Stable Disease (SD). Therefore, we believe that lemzoparlimab,
if approved, will be a potentially highly differentiated antitumor CD47 antibody with the advantage of minimizing hematologic side effects. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Another example of our R&amp;D capability relates to our novel <FONT STYLE="white-space:nowrap">bi-specific</FONT> antibody panel that
represents a new wave of oncology drug candidates. We created novel biological properties of these <FONT STYLE="white-space:nowrap">bi-specific</FONT> antibodies that are capable of enriching immune cells in tumors through dual targeting of <FONT
STYLE="white-space:nowrap">PD-L1</FONT> and immune cells for a synergistic anti-tumor effect. These <FONT STYLE="white-space:nowrap">bi-specific</FONT> drug candidates have been shown to exhibit unique properties that render tumors more responsive
to treatment. Our discovery expertise, when combined with our <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">&#147;fit-for-purpose&#148;</FONT></FONT> antibody engineering technology platforms, becomes a powerful engine of
innovation to create novel molecules. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Fit-for-Purpose</FONT></FONT>
Technology Platforms </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our proprietary antibody engineering platforms enable us to accurately capture the biological properties of <FONT
STYLE="white-space:nowrap">bi-specific</FONT> antibodies and retain good manufacturability and druggability of the molecules. To date, we have eight novel <FONT STYLE="white-space:nowrap">pre-clinical</FONT> stage
<FONT STYLE="white-space:nowrap">bi-specific</FONT> drug molecules. In addition to our own <FONT STYLE="white-space:nowrap">bi-specific</FONT> antibody platform, we partnered with ABL Bio and WuXi Biologics to access their antibody engineering
platforms in order to increase the probability of success, as different molecular configurations require different technologies. Furthermore, our proprietary antibody-cytokine technology has enabled another form of
<FONT STYLE="white-space:nowrap">bi-specific</FONT> antibodies such as <FONT STYLE="white-space:nowrap">TJ-L1I7</FONT> and <FONT STYLE="white-space:nowrap">TJ-C4GM</FONT> that link a tumor-engaging antibody with an immuno-modulatory cytokine.
Superior to monoclonal antibodies or cytokines alone, this class of <FONT STYLE="white-space:nowrap">bi-specific</FONT> antibodies has demonstrated unique properties of concentrating the drug molecules in tumors for a desired target effect with
reduced systemic toxicity of cytokines or creating biologic synergy that can potentially translate into better treatment outcome. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our
Biomarker-Enabled Translational Medicine Capabilities </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">As we focus on developing innovative drug molecules, the ability to apply
relevant biomarkers that link a drug response to treatment effects is critical for early-stage clinical trials of our investigational drugs. This translational medicine capability requires cross-functional knowledge and unique skills to link the
target biology of an investigational drug to clinical responses. We have been developing tailor-made biomarkers for each of our investigational drugs, which are used to select potential responders, predict and measure target engagement, support dose
determination and enable timely informed decisions on advancing our assets to the next phase of clinical development. For example, for the development of uliledlimab, we intend to use CD73 in tumor tissue in combination with other tumor biomarkers
to stratify potential target patient populations in our clinical trial. To that end, we have developed assays to measure CD73 expression and activity in tumor tissues. Furthermore, we have developed specialized assays to measure uliledlimab drug
concentrations in tumor tissues. By linking drug concentration with its activity in the same tumor location, these data help us determine appropriate dose selection for further clinical studies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our Clinical Development Capabilities </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our clinical development is led by a global team of clinical scientists, industry physicians and experts in portfolio management, quantitative
science, clinical operations, drug safety and quality control. Our clinical team accounts for approximately 80% of our entire R&amp;D organization&#146;s headcount and 80% of our budget allocation. The skillset of our clinical development team is
highlighted by a combination of extensive global pharma, local drug development and operation experiences with clinical networks in China and the United States. The team is driven by high ethical standards, with passion for improving the lives of
patients. </P>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our team has the ability to integrate internal core development functions to conduct global
and local clinical trials. We also effectively leverage external resources, including clinical contract research organizations, academic clinical centers and/or networks, and global pharmaceutical or biotech partnerships. Furthermore, we have
established and implemented a robust internal clinical governance system and processes to safeguard patient safety and data integrity. Our current clinical development functions and teams are strategically based in Shanghai, Beijing, and the United
States to cover Phase 1 through Phase 3 clinical trials in China and early-stage clinical trials in the United States. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our clinical
development capabilities are best demonstrated by the rapid implementation of 11 clinical trials, including one completed trial in the United States and ten <FONT STYLE="white-space:nowrap">on-going</FONT> Phase 1/2 or registration trials in the
United States and China in the past three years. To ensure regulatory approval and subsequent product launch as currently planned, we strive to reach the following critical clinical milestones by the end of 2020: 11 active clinical programs
consisting of two Phase 3 or registrational trials in China, three Phase 2 trials and six Phase 1/2 trials in the United States and China. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Global
Strategic Collaborations </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We have established an excellent track record of <FONT STYLE="white-space:nowrap">in-licensing</FONT> and <FONT
STYLE="white-space:nowrap">out-licensing</FONT> deals with our global and regional partners. These <FONT STYLE="white-space:nowrap">in-licensing</FONT> deals enable us to acquire multiple innovative clinical stage assets with favorable clinical data
packages. We have quickly built our China Portfolio through <FONT STYLE="white-space:nowrap">in-licensing</FONT> deals with global biotech partners, including MorphoSys, Genexine, MacroGenics and Ferring (as the sublicensee under our agreement with
Ferring related to olamkicept). Over the past three years, we have established more than 10 global and regional partnerships with reputable pharma or biotech companies. Our partners selected us among many China-based companies with the belief that
we are an ideal partner in China given our strength in science and drug development capability, our outstanding track record of execution demonstrated by rapidly progressing drug development programs in China and the United States, and our vision
and network to tap into business opportunities and China&#146;s growing pharmaceutical market. For example, MorphoSys, MacroGenics and Genexine all stated that we are an ideal or the best partner in China in their press releases or public
announcements. The <FONT STYLE="white-space:nowrap">out-licensing</FONT> deals enable us to streamline our pipeline, focus our resources on the most valuable assets in the most desirable territories and build strategic alliances with leading global
biopharmaceutical companies. In addition, we seek <FONT STYLE="white-space:nowrap">co-development</FONT> opportunities to share development costs, risks and territorial commercial rights with our partners. In the past several years, we have <FONT
STYLE="white-space:nowrap">out-licensed</FONT> four assets and initiated multiple <FONT STYLE="white-space:nowrap">co-development</FONT> programs with partners such as ABL Bio, MSD, Roche and Junshi and WuXi Biologics. The revenue from <FONT
STYLE="white-space:nowrap">out-licensing</FONT> and <FONT STYLE="white-space:nowrap">co-development</FONT> deals is expected to continue to grow as our pipeline progresses. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Global Strategic Partnership with AbbVie </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In September 2020, we, through <FONT STYLE="white-space:nowrap">I-Mab</FONT> Biopharma Co., Ltd. and
<FONT STYLE="white-space:nowrap">I-Mab</FONT> Biopharma US Limited, each a wholly-owned subsidiary of our company, entered into a broad global strategic collaboration with AbbVie Ireland Unlimited Company (&#147;AbbVie&#148;), a leading global,
research-based biopharmaceutical company. Pursuant to this collaboration, we grant AbbVie a global license, excluding Mainland China, Hong Kong and Macau, to develop and commercialize lemzoparlimab. We retain all rights to develop and commercialize
lemzoparlimab (as well as certain other compounds directed against CD47) in Mainland China, Hong Kong and Macau. AbbVie will conduct further global clinical trials (which we may elect to <FONT STYLE="white-space:nowrap">co-fund)</FONT> to evaluate
lemzoparlimab in multiple cancers. This deal also allows for potential collaboration on future CD47-related therapeutic agents, including CD47-based bispecific antibodies and combination therapies with lemzoparlimab and AbbVie&#146;s venetoclax
(Venclexta<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>). Each party will have the opportunity, subject to rights of first negotiation to further licenses, to explore certain of each other&#146;s related CD47-antibody programs in their
respective territories. In addition, we and AbbVie will share manufacturing responsibilities, with AbbVie being the primary manufacturer for supply </P>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
outside of Mainland China, Hong Kong and Macau and us being the primary manufacturer for supply in Mainland China, Hong Kong and Macau. We believe that this collaboration will accelerate the
establishment of our commercial production operations in China. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Pursuant to this collaboration, AbbVie will pay us an upfront payment of
US$180&nbsp;million. Additionally, in connection with the recently released clinical data from the Phase 1 trial of lemzoparlimab in the United States, we expect to be paid a first milestone payment of US$20&nbsp;million. We will also be eligible to
receive up to US$1.74&nbsp;billion in further success-based development, regulatory and sales milestone payments for lemzoparlimab, of which US$840&nbsp;million are based on clinical development and regulatory approval milestones, with the remainder
based on commercial milestones. Upon commercialization of lemzoparlimab, AbbVie will also pay tiered royalties from low double-digit percentages on global net sales outside of Mainland China, Hong Kong and Macau. In addition, AbbVie has a license
and right of first negotiation to further develop and commercialize two additional lemzoparlimab-based bispecific antibodies discovered and currently being developed by us and we cannot commercialize products containing these two additional
lemzoparlimab-based bispecific antibodies outside of Mainland China, Hong Kong and Macau even if AbbVie does not exercise its right of first negotiation or we are unable to come to financial terms on such products. The potential value of each such
license is minimum US$500&nbsp;million in upfront and milestone payments, for a combined total of no less than US$1&nbsp;billion. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">This
strategic collaboration with AbbVie reinforces our internal research and development capabilities and our leading position in immuno-oncology and enables us to realize the full potential of our innovation. By leveraging the combined development
strength of our company and AbbVie, we aim to speed lemzoparlimab to market for patients in need around the world. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Drug Pipeline </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The chart below summarizes the development status of our drug pipeline. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g98473g46b24.jpg" ALT="LOGO">
 </P>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:26%">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">Notes: </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">(i) for felzartamab (TJ202), we are conducting two parallel registrational trials with felzartamab as a
third-line monotherapy and as a second line combination therapy with lenalidomide, both in patients with multiple myeloma in Greater China. The recruitment progress for these two trials remains on track, and we expect to submit an NDA to the NMPA in
2021. In addition, we submitted an IND application to the NMPA in October 2019 for a Phase 1b trial for felzartamab in SLE; (ii)&nbsp;for eftansomatropin (TJ101), in September 2020, the NMPA approved our IND application for a registrational Phase 3
trial of eftansomatropin in pediatric growth hormone deficiency (PGHD). We expect to initiate this trial in the first quarter of 2021; (iii) for enoblituzumab, we expect to submit an IND application in 2021 for a Phase 2 trial; (iv)&nbsp;for
efineptakin (TJ107), we have obtained regulatory clearance from the NMPA to initiate a phase 2 clinical trial in GBM patients with lymphopenia. We expect to initiate this trial in the fourth quarter of 2020; and (v)&nbsp;for olamkicept (TJ301), we
are conducting an ongoing Phase 2 clinical trial in patients with active ulcerative colitis. The enrollment of this trial is complete and topline data are expected to be released by early 2021. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">**</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">We were collaborating with Everest Medicines Limited (&#147;Everest&#148;) to
<FONT STYLE="white-space:nowrap">co-develop</FONT> and commercialize felzartamab in Greater China for all indications in hematologic oncology. Everest was primarily responsible for sharing with us, by the proportion of 75% for Everest and 25% for
us, the development costs of felzartamab. On November&nbsp;4, 2019, we and Everest terminated the collaboration agreement (including all the supplements and amendments thereto) with respect to the
<FONT STYLE="white-space:nowrap">co-development</FONT> and commercialization of felzartamab in Greater China. Upon the termination, Everest will not retain any rights or entitlements to develop or commercialize felzartamab or any economic interest
in its commercialization. All intellectual property rights in respect of felzartamab arising from its development under the collaboration agreement are vested and owned by us, and we hold all intellectual property rights and have maximum flexibility
to further develop, manufacture and commercialize felzartamab in Greater China. In consideration of the above arrangements, we issued a total value of US$37.0&nbsp;million of ordinary shares (the &#147;CPP Shares&#148;) to Everest, representing
Everest&#146;s historical contribution to our collaboration and the associated time cost. The CPP Shares were issued concurrently with the completion of our initial public offering in January 2020, at a per share price equal to the initial public
offering price adjusted to reflect the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">ADS-to-ordinary</FONT></FONT> share ratio. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">***</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Our <FONT STYLE="white-space:nowrap">bi-specific</FONT> antibody panel consists of (i)&nbsp;six <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">PD-L1-based</FONT></FONT> <FONT STYLE="white-space:nowrap">bi-specific</FONT> antibodies, including <FONT STYLE="white-space:nowrap">TJ-L1C4</FONT>
<FONT STYLE="white-space:nowrap">(PD-L1</FONT> &times; CD47), <FONT STYLE="white-space:nowrap">TJ-L1A3</FONT> <FONT STYLE="white-space:nowrap">(PD-L1</FONT> &times; LAG3), <FONT STYLE="white-space:nowrap">TJ-L1H3</FONT> <FONT
STYLE="white-space:nowrap">(PD-L1</FONT> &times; <FONT STYLE="white-space:nowrap">B7-H3),</FONT> <FONT STYLE="white-space:nowrap">TJ-L14B</FONT> <FONT STYLE="white-space:nowrap">(PD-L1</FONT> &times; <FONT STYLE="white-space:nowrap">4-1BB),</FONT> <FONT
STYLE="white-space:nowrap">TJ-L1T6</FONT> <FONT STYLE="white-space:nowrap">(PD-L1</FONT> &times; T1G1T) and <FONT STYLE="white-space:nowrap">TJ-L1I7</FONT> <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">(anti-PD-L1</FONT></FONT>
&times; <FONT STYLE="white-space:nowrap">IL-7</FONT> cytokine), (ii) <FONT STYLE="white-space:nowrap">TJ-C4GM</FONT> (anti-CD47 &times; <FONT STYLE="white-space:nowrap">GM-CSF</FONT> cytokine), and
<FONT STYLE="white-space:nowrap">(iii)&nbsp;TJ-CLDN4B</FONT> (Claudin 18.2 &times; <FONT STYLE="white-space:nowrap">4-1BB).</FONT> </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Highlights of Our <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Fast-to-Market</FONT></FONT> China Portfolio </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">fast-to-market</FONT></FONT> China strategy is demonstrated by our China
Portfolio, which consists of novel or highly differentiated investigational drugs. Felzartamab, efineptakin, enoblituzumab and eftansomatropin are the four anchor assets in our China Portfolio. While we have been diligently pursuing our <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">fast-to-market</FONT></FONT> China strategy, we are aware that there is no assurance that we will always be successful in commercializing any of our product candidates in our China
Portfolio in an accelerated manner. See &#147;Risk Factors&#148; for a detailed description of the risks related to the development and commercialization of our drug candidates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Felzartamab is a differentiated CD38 antibody originally developed by MorphoSys that meets the <FONT STYLE="white-space:nowrap">pre-set</FONT>
clinical safety and preliminary efficacy endpoints from a clinical trial conducted in the European Union (EU). <FONT STYLE="white-space:nowrap">In-licensed</FONT> from MorphoSys, felzartamab is being developed to address the current unmet needs and
commercial opportunities in China for multiple myeloma and potentially autoimmune diseases, such as SLE. We own an exclusive license to develop felzartamab in Greater China. We believe felzartamab, if approved, is potentially highly differentiated
compared with the currently marketed CD38 antibody. First, under a similar <FONT STYLE="white-space:nowrap">pre-medication</FONT> condition with dexamethasone, anti-pyretics and anti-histamines, felzartamab has demonstrated a
</P>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
significantly shorter infusion time and lower infusion reaction rate. Second, unlike the currently marketed CD38 antibody, felzartamab does not down-regulate CD38 expression on the surface of
bone marrow myeloma cells in vitro, maintaining sensitivity of myeloma cells to felzartamab for repeated treatments. We are conducting two parallel registrational trials with felzartamab as a third-line monotherapy and as a second line combination
therapy with lenalidomide, both in patients with multiple myeloma in Greater China. The recruitment progress for these two trials remains on track. We aim to submit an NDA for felzartamab as a third-line monotherapy in 2021, followed by another NDA
submission for felzartamab as a second-line combination therapy. Moreover, we believe felzartamab has great market potential in the treatment of pathogenic antibody-mediated autoimmune diseases, such as SLE, where there is a significant unmet need
for more effective therapies. Additionally, we submitted an IND application to the NMPA in October 2019 for a Phase 1b trial for felzartamab in SLE. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Efineptakin is the first long-acting recombinant human <FONT STYLE="white-space:nowrap">IL-7</FONT> known to boost cancer-fighting T
lymphocytes by increasing their number and function and is being developed as a potential oncology investigational drug. The clinical safety and effect of efineptakin on T cells have been investigated in multiple previous and ongoing clinical trials
in South Korea and the United States. Efineptakin is being positioned to address a huge unmet medical need in oncology. First, efineptakin can be an oncology-care agent to treat cancer treatment-related lymphopenia (low blood lymphocyte levels), a
common condition that occurs in cancer patients who have received chemotherapy or radiation therapy, and there is no approved treatment for this condition. This condition causes further damage to patients&#146; already compromised immune system and
weakens its ability to fight cancers. Second, efineptakin has been shown to synergize with a <FONT STYLE="white-space:nowrap">PD-1</FONT> antibody in a tumor animal model potentially through increased T lymphocyte activation and proliferation. In
May 2020, we obtained regulatory clearance from the NMPA to initiate a phase 2 clinical trial with efineptakin in GBM patients with lymphopenia. We expect to initiate this trial in the fourth quarter of 2020. We are coordinating our study globally
with Genexine, which is conducting a Phase 2 clinical trial in South Korea and parallel clinical trials in the United States towards clinical PoC. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Enoblituzumab is a humanized antibody directed at <FONT STYLE="white-space:nowrap">B7-H3,</FONT> a member of the B7 family of T cell
checkpoint regulators that is widely expressed across multiple tumor types and plays a key role in the regulation of immune response against cancers. Similar to other inhibitors of the B7 family such as <FONT STYLE="white-space:nowrap">PD-L1,</FONT>
targeting <FONT STYLE="white-space:nowrap">B7-H3</FONT> potentially provides a treatment option for a variety of cancers expressing <FONT STYLE="white-space:nowrap">B7-H3.</FONT> Enoblituzumab was originally developed by MacroGenics, and we own the
Greater China rights of this investigational drug. In multiple clinical trials conducted by MacroGenics, when combined with pembrolizumab in recurrent or metastatic squamous cell carcinoma of the head and neck (&#147;SCCHN&#148;) and <FONT
STYLE="white-space:nowrap">non-small</FONT> cell lung cancer (&#147;NSCLC&#148;), enoblituzumab has shown favorable clinical results that warrant further investigation. In the first quarter of 2021, MacroGenics expects to initiate a Phase 2 study of
enoblituzumab in a chemo-free regimen in combination with either retifanlimab (an investigational <FONT STYLE="white-space:nowrap">PD-1</FONT> antibody) in front-line patients with SCCHN who are <FONT STYLE="white-space:nowrap">PD-L1</FONT> positive
or with tebotelimab (an investigational <FONT STYLE="white-space:nowrap">PD-1</FONT> x <FONT STYLE="white-space:nowrap">LAG-3</FONT> bispecific DART<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> antibody) in SCCHN patients who are <FONT
STYLE="white-space:nowrap">PD-L1</FONT> negative. We expect to participate in any subsequent Phase 3 global study if and when initiated. In addition, considering the dynamic regulatory environment and evolving clinical practice, we have been
continually refining the development of enoblituzumab in our territory. Further clinical development may be planned together with MacroGenics to extend to other cancer indications in China and/or globally. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Eftansomatropin is a potentially highly differentiated long-acting human growth hormone that is being developed as a weekly treatment for
pediatric growth hormone deficiency as compared to currently available daily regimens of recombinant human growth hormone (&#147;rhGH&#148;). Eftansomatropin was originally developed by Genexine, and we own the Greater China rights of this product,
which has the potential to address an important clinical need and to cover a significant market gap in pediatric growth hormone deficiency. In a previous Phase 2 trial conducted by Genexine in South Korea and the EU, both weekly and <FONT
STYLE="white-space:nowrap">bi-weekly</FONT> administration of Eftansomatropin demonstrated similar therapeutic effects to daily injection of Genotropin, a short-acting rhGH. </P>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In September 2020, the NMPA approved our IND application for a registrational Phase 3 trial
of eftansomatropin in pediatric growth hormone deficiency (PGHD). We expect to initiate this trial in the first quarter of 2021. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Highlights of Our <FONT
STYLE="white-space:nowrap">Fast-to-PoC</FONT> Global Portfolio </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our <FONT STYLE="white-space:nowrap">fast-to-PoC</FONT> global
strategy is demonstrated by our Global Portfolio, which mainly consists of our internally developed novel or differentiated biologics. Our Global Portfolio focuses on two molecular classes&#151; monoclonal antibodies and <FONT
STYLE="white-space:nowrap">bi-specific</FONT> antibodies. While we have been diligently pursuing our <FONT STYLE="white-space:nowrap">fast-to-PoC</FONT> global strategy, we are aware that there is no assurance that we will always be successful in
achieving PoC or pivotal development milestones for any of our product candidates in our Global Portfolio in an accelerated manner. See &#147;Risk Factors&#148; for a detailed description of the risks related to the development and commercialization
of our drug candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I>Monoclonal antibodies</I>&#151;Among the five monoclonal antibody drug candidates, lemzoparlimab (TJC4),
uliledlimab (TJD5) and plonmarlimab (TJM2) are in clinical development. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Lemzoparlimab is an internally discovered, fully human monoclonal
antibody targeting CD47, which is one of the most promising immuno-oncology targets after <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">PD-1/PD-L1.</FONT></FONT> Blocking CD47 activates tumor-engulfing macrophages, a component of
the innate immune system as an important cancer-fighting mechanism. CD47 antibodies are being actively pursued in clinical trials by a few global companies. However, current development efforts on CD47 antibody drugs are hampered by hematologic side
effects (such as anemia) due to binding to human RBCs. For example, at least two clinical trials conducted by other companies have been suspended. Unlike competitor investigational drugs, lemzoparlimab is a rare antibody originally selected, by
design, to purposefully avoid or minimize binding to RBCs while maintaining a high antibody affinity and tumor killing properties. Lemzoparlimab&#146;s unique property of minimal RBC binding and no significant hematologic changes has been
extensively validated in a whole series of robust in vitro assays and <FONT STYLE="white-space:nowrap">non-human</FONT> primate studies. In a GLP toxicology study involving 40 monkeys, no hematologic side-effects were seen even with repeated
injections of 100 mg/kg doses. This unique property may enable lemzoparlimab to be used safely in a broader patient population to explore its treatment potential in cancers, differentiating it from other clinical stage lemzoparlimab investigational
antibody drugs. Notably, the topline results of the recently completed Phase 1a dose escalation monotherapy trial in the United States have demonstrated the differentiated profile of lemzoparlimab in drug safety and favorable pharmacokinetics in
cancer patients. The key findings include: (i)&nbsp;lemzoparlimab was well tolerated up to 30 mg/kg on a weekly basis without priming dosing strategy, and no dose-limiting toxicity and no clinical or laboratory evidence of hemolytic anemia were
observed throughout; (ii)&nbsp;lemzoparlimab PK appears to be linear at mid to high dose levels following a single dose with no significant &#147;sink effect&#148; and (iii)&nbsp;one confirmed Partial Response (PR) was observed in the 30 mg/kg
cohort (N=3), and this patient had failed prior treatments with checkpoint inhibitors. Three patients achieved Stable Disease (SD). Therefore, we believe that lemzoparlimab, if approved, will be a potentially highly differentiated anti-tumor CD47
antibody with the advantage of minimizing hematologic side effects. In September 2020, we received the NMPA approval for a Phase 1 clinical trial of lemzoparlimab in relapsed or refractory advanced lymphoma in China as part of the ongoing
international multi-center trial. In addition, lemzoparlimab is being evaluated in a Phase 1/2a clinical trial in China in patients with relapsed or refractory acute myeloid leukemia (r/r AML) or myelodysplastic syndrome (MDS), and we anticipate
reporting <FONT STYLE="white-space:nowrap">top-line</FONT> results in early 2021. We have also entered into a clinical trial collaboration and supply agreement with Merck Sharp&nbsp;&amp; Dohme Corp, or MSD, through a subsidiary, under which we will
sponsor a Phase 1 clinical trial in the United States evaluating lemzoparlimab in combination with KEYTRUDA<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> (pembrolizumab), MSD&#146;s <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">anti-PD-1</FONT></FONT> therapy, in patients with multiple types of solid tumors. In September 2020, we granted AbbVie a global license, excluding Mainland China, Hong Kong and Macau, to develop and commercialize
lemzoparlimab (as well as certain other </P>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
compounds directed against CD47), and we will retain all rights to develop and commercialize lemzoparlimab in Mainland China, Hong Kong and Macau. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Uliledlimab is an internally developed, humanized inhibitory antibody against human CD73. CD73 is a homodimeric enzyme expressed in tumors and
plays a critical role in suppressing immune cells in tumor micro-environment. Uliledlimab displays sub-nanomolar binding affinity to CD73 and inhibits its nucleotidase activity. In vitro, uliledlimab completely reversed the <FONT
STYLE="white-space:nowrap">AMP-</FONT> or tumor cell-mediated suppression of T cells. In vivo, when combined with a <FONT STYLE="white-space:nowrap">PD-L1</FONT> antibody, uliledlimab exhibited a superior or synergistic inhibitory effect on tumor
growth. The key differentiation of uliledlimab when compared to some of the other clinical stage antibodies of the same class, is related to its novel epitope, which works through a unique intra-dimer binding mode, resulting in a complete inhibition
of the enzymatic activity and avoiding the aberrant pharmacological property known as the &#147;hook effect.&#148; With this particular mode of action, uliledlimab, if approved, has the potential to become a highly differentiated CD73 antibody. In
the United States, uliledlimab is in a Phase 1 clinical trial as a single agent and in combination with atezolizumab (TECENTRIQ<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>), a <FONT STYLE="white-space:nowrap">PD-L1</FONT> antibody
marketed by Roche, in patients with advanced solid tumors. Twenty patients have been enrolled and nineteen of them have been dosed so far. The preliminary data of this trial in the United States are expected by mid-2021. In China, we are conducting
a Phase 1/2 clinical trial in China to evaluate uliledlimab in patients with advanced solid tumors. The first patient was dosed in May 2020. This Phase 1/2 study is a multicenter, open-label, dose escalation and cohort expansion study, which will
evaluate safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy of uliledlimab, and determine a recommended dose for further planned clinical studies of its efficacy and safety as a single agent and in combination with standard dose
of toripalimab (TUOYI<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>) in patients with advanced or metastatic cancers who are refractory to or intolerant of all available therapies. We have been able to accelerate the Phase 1/2 trial in
China by leveraging data from the ongoing Phase 1 clinical study of uliledlimab in the United States, which is a testament to our global clinical development capabilities and well-executed pipeline strategies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Plonmarlimab is an internally discovered neutralizing antibody against human granulocyte-macrophage colony-stimulating factor <FONT
STYLE="white-space:nowrap">(&#147;GM-CSF&#148;),</FONT> an important cytokine that plays a critical role in chronic inflammation and destruction in autoimmune diseases such as rheumatoid arthritis (&#147;RA&#148;). Plonmarlimab is a humanized IgG1
that displays high affinity binding to <FONT STYLE="white-space:nowrap">GM-CSF</FONT> and blocks its signaling and downstream effects. Plonmarlimab is being developed for the treatment of autoimmune and inflammatory diseases, including RA and
cytokine release syndrome (&#147;CRS&#148;). We have completed a single-dose <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-human</FONT></FONT> study in healthy volunteers in the United States. In China, plonmarlimab is
the first antibody of its class entering clinical development. We dosed the first patient in a Phase 1b study of plonmarlimab in August 2020 in patients with rheumatoid arthritis (RA) in China. We may expand plonmarlimab to other autoimmune and
inflammatory indications with high unmet medical need, where <FONT STYLE="white-space:nowrap">GM-CSF</FONT> is known as a pathogenic cytokine in disease activity and progression. If approved, plonmarlimab is expected to provide an effective
treatment option as a disease-modifying anti-rheumatic drug (&#147;DMARD&#148;) therapy. In addition, since the <FONT STYLE="white-space:nowrap">COVID-19</FONT> outbreak, we have sprung into action to prioritize plonmarlimab in response to the
urgent medical needs. In May 2020, we announced preliminary results from part 1 of a clinical study in the United States of plonmarlimab in patients with cytokine release syndrome (CRS) associated with severe
<FONT STYLE="white-space:nowrap">COVID-19,</FONT> in which plonmarlimab was found to be well tolerated. We are currently conducting part 2 of this clinical trial to evaluate the efficacy, safety and cytokine levels following a single dose of 6 mg/kg
plonmarlimab or placebo (standard care) in patients with severe <FONT STYLE="white-space:nowrap">COVID-19.</FONT> We are currently in discussion with the FDA to finalize the plan for plonmarlimab in relation to clinical development and potential
registration in the United States. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">TJ210 is a novel monoclonal antibody directed at C5aR for cancers through a partnership with
MorphoSys. In September 2020, the FDA has cleared the IND application for TJ210 to initiate a Phase 1 clinical trial. The trial is designed to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of TJ210 and is expected to
commence by early 2021. We plan to work jointly with MorphoSys to develop this asset. </P>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I><FONT STYLE="white-space:nowrap">Bi-specific</FONT> antibody panel</I>&#151;This novel
antibody class represents an emerging and fast-moving area of new drug discovery. <FONT STYLE="white-space:nowrap">Bi-specific</FONT> antibodies are typically constructed to have a dual specificity of two selected antibodies or combined properties
of an antibody linked with a cytokine, previously called an immuno-cytokine. However, despite the recent success of checkpoint inhibitors, clinical efficacy of these drugs has been unsatisfactory. It is estimated that over 60% of cancer patients,
including those with melanoma, renal cell cancer, colorectal cancer, <FONT STYLE="white-space:nowrap">non-small</FONT> cell lung cancer, urothelial cancer and head and neck squamous cell carcinoma, do not respond to <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">PD-1/PD-L1</FONT></FONT> monotherapies. In addition, some patients develop resistance after initial treatment with these therapies. As a result, the standard of care today leaves many cancer patients underserved. There is
consensus among cancer immunologists that tumors that do not respond to <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">PD-1/PD-L1</FONT></FONT> treatment have poor immunologic features, such as an absence or paucity of
tumor-fighting immune cells or the presence of dysfunctional immune cells within the tumors, collectively known as &#147;cold tumors.&#148; We believe that <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">PD-1/PD-L1</FONT></FONT> <FONT
STYLE="white-space:nowrap">non-responders</FONT> can be better treated with novel <FONT STYLE="white-space:nowrap">bi-specific</FONT> antibodies. The unique and superior properties of these <FONT STYLE="white-space:nowrap">bi-specific</FONT>
antibodies over <FONT STYLE="white-space:nowrap">PD-L1</FONT> inhibitors alone stem from a second targeting component attached to the <FONT STYLE="white-space:nowrap">PD-L1</FONT> antibody moiety of the
<FONT STYLE="white-space:nowrap">bi-specific</FONT> molecules, thereby enabling them to elicit a sufficient immune response and converting a &#147;cold tumor&#148; to an immune-active &#147;hot tumor.&#148; Such unique properties of <FONT
STYLE="white-space:nowrap">bi-specific</FONT> antibodies cannot be substituted by a combination of the <FONT STYLE="white-space:nowrap">PD-L1</FONT> antibody with a selected second component (either cytokine or antibody) in a free form. The
underlying mechanism is such that the second component must be structurally integrated with the tumor-engaging <FONT STYLE="white-space:nowrap">PD-L1</FONT> antibody in order to concentrate and function inside the tumor, which cannot be readily
achieved by the two free agents used in combination. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We have successfully generated a panel of
<FONT STYLE="white-space:nowrap">bi-specific</FONT> antibodies in which our proprietary <FONT STYLE="white-space:nowrap">PD-L1</FONT> antibody acts as the backbone (the first signal) and is linked with various second components (the second signal),
including, but not limited to, a <FONT STYLE="white-space:nowrap">4-1BB</FONT> agonist antibody <FONT STYLE="white-space:nowrap">(TJ-L14B),</FONT> a <FONT STYLE="white-space:nowrap">B7-H3</FONT> antibody
<FONT STYLE="white-space:nowrap">(TJ-L1H3),</FONT> a CD47 antibody <FONT STYLE="white-space:nowrap">(TJ-L1C4)</FONT> and an <FONT STYLE="white-space:nowrap">IL-7</FONT> cytokine <FONT STYLE="white-space:nowrap">(TJ-L1I7),</FONT> which are shown to
work with the <FONT STYLE="white-space:nowrap">PD-L1</FONT> backbone in various assays and cancer animal models. This unique panel of <FONT STYLE="white-space:nowrap">bi-specific</FONT> antibodies is only made possible by our proprietary and
partnered antibody engineering technologies and the availability of our proprietary monoclonal antibodies. Furthermore, we have generated two other <FONT STYLE="white-space:nowrap">bi-specific</FONT> antibodies
<FONT STYLE="white-space:nowrap">(TJ-C4GM</FONT> and <FONT STYLE="white-space:nowrap">TJ-CLDN4B)</FONT> that are tailor-made to function as novel fortified antibodies by linking lemzoparlimab with an engineered
<FONT STYLE="white-space:nowrap">GM-CSF</FONT> cytokine for the treatment of solid tumors and by linking our Claudin 18.2 antibody with a <FONT STYLE="white-space:nowrap">4-1BB</FONT> antibody as a unique gastric cancer treatment agent that only
activates T cells conditionally upon tumor engagement. All <FONT STYLE="white-space:nowrap">bi-specific</FONT> antibodies have been validated in a series of robust in vitro and in vivo studies for biology <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">proof-of-concept,</FONT></FONT> providing a solid basis for clinical validation in cancer patients. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Strategies </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We plan to achieve our goal by pursuing the following strategies: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Rapidly advance our China Portfolio towards commercialization. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Expand our research and development capabilities and footprint in the United States to advance our Global
Portfolio. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Build our manufacturing capabilities. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Maximize the value of our pipeline. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Summary of Risk Factors </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Investing in
our ordinary shares or ADSs involves significant risks. You should carefully consider all of the information in this prospectus before making an investment in our ordinary shares or ADSs. Below please
</P>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
find a summary of the principal risks we face, organized under relevant headings. These risks are discussed more fully in the section titled &#147;Risk factors.&#148; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Risks Related to Our Financial Position and Need for Additional Capital </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Risks and uncertainties related to our financial position and need for additional capital include, but are not limited to, the following: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We have a limited operating history, which may make it difficult to evaluate our current business and predict our
future performance; and </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We recorded net cash outflow from operating activities since inception, and we may need to obtain additional
financing to fund our operations, otherwise we may be unable to complete the development and commercialization of our major drug candidates. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Risks Related to Clinical Development, Obtaining Regulatory Approval and Commercialization of Our Drug Candidates and Our Reliance on Third Parties
</I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Risks and uncertainties related to clinical development, obtaining regulatory approval and commercialization of our drug
candidates include, but are not limited to, the following: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Clinical development involves a lengthy and expensive process with an uncertain outcome, and results of earlier
studies and trials may not be predictive of future trial results; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We depend substantially on the success of our drug candidates, all of which are in
<FONT STYLE="white-space:nowrap">pre-clinical</FONT> or clinical development, and our ability to identify additional drug candidates. If we are unable to identify new drug candidates, complete clinical development, obtain regulatory approval and
commercialize our drug candidates, or experience significant delays in doing so, our business will be materially harmed; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We may not be able to identify, discover or <FONT STYLE="white-space:nowrap">in-license</FONT> new drug
candidates, and may allocate our limited resources to pursue a particular drug candidate or indication and fail to capitalize on drug candidates or indications that may later prove to be more profitable, or for which there is a greater likelihood of
success; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The regulatory approval processes of the NMPA, the FDA and other comparable regulatory authorities are
time-consuming and may evolve overtime, and if we are ultimately unable to obtain regulatory approval for our drug candidates, our business will be substantially harmed; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Our drug candidates may fail to achieve the degree of market acceptance by physicians, patients, third-party
payors and others in the medical community necessary for commercial success; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We face intense competition and rapid technological change and the possibility that our competitors may develop
therapies that are similar, more advanced, or more effective than ours, which may adversely affect our financial condition and our ability to successfully commercialize our drug candidates; and </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">As we rely on third parties to conduct our <FONT STYLE="white-space:nowrap">pre-clinical</FONT> studies and
clinical trials, if we lose our relationships with these third parties or if they do not successfully carry out their contractual duties or meet expected deadlines, we may not be able to obtain regulatory approval for or commercialize our drug
candidates and our business could be substantially harmed. </P></TD></TR></TABLE>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Risks Related to Our Intellectual Property </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Risks and uncertainties related to our intellectual property include, but are not limited to, the following: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">If we are unable to obtain and maintain patent and other intellectual property protection for our drug
candidates, or if the scope of such intellectual property rights obtained is not sufficiently broad, third parties could develop and commercialize products and technologies similar or identical to ours and compete directly against us, adversely
affecting our ability to successfully commercialize any product or technology; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We enjoy only limited geographical protection with respect to certain patents and may not be able to protect our
intellectual property rights throughout the world, including in the PRC; and </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We have identified two material weaknesses in our internal controls, and if we fail to implement and maintain an
effective system of internal controls to remediate our material weaknesses over financial reporting, we may be unable to accurately report our results of operations, meet our reporting obligations or prevent fraud. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Risks Related to Our Industry, Business and Operations and Doing Business in China </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We are also subject to risks and uncertainties related to our industry, business and operations, and doing business in China in general,
including, but not limited to, the following: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Our future success depends on our ability to attract, retain and motivate senior management and qualified
scientific employees; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Our business and results of operations could be adversely affected by public health crisis (including the <FONT
STYLE="white-space:nowrap">COVID-19</FONT> global pandemic) and natural catastrophes or other disasters outside of our control in the locations in which we, our suppliers, CROs, CMOs and other contractors operate; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The adoption of any rules, legislations or other efforts to increase U.S. regulatory access to audit information
could cause uncertainty and we could be delisted if we are unable to meet the PCAOB inspection requirement in time; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Changes in international trade policies and rising political tensions, particularly between the United States and
China, may adversely impact our business and operating results; and </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Changes in the political and economic policies of the PRC government may materially and adversely affect our
business, financial condition and results of operations and may result in our inability to sustain our growth and expansion strategies. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>General Risks Related to Our ADSs and the Offering </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In addition to the risks described above, we are subject to general risks related to the ADSs, including, but not limited to, the following:
</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The trading price of our ADSs may be volatile; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Because we do not expect to pay dividends in the foreseeable future, you must rely on price appreciation of our
ADSs for return on your investment; and </P></TD></TR></TABLE>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The voting rights of holders of ADSs are limited by the terms of the deposit agreement, and you may not be able
to exercise the same rights as our shareholders. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Corporate History and Structure </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We commenced our operations in November 2014, when our predecessor Third Venture Biopharma (Nanjing) Co., Ltd (&#147;Third Venture&#148;) was
established. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">I-Mab</FONT> was established in June 2016 under the laws of the Cayman Islands as our
offshore holding company. In July 2016, <FONT STYLE="white-space:nowrap">I-Mab</FONT> established <FONT STYLE="white-space:nowrap">I-Mab</FONT> Biopharma Hong Kong Limited <FONT STYLE="white-space:nowrap">(&#147;I-Mab</FONT> Hong Kong&#148;), as its
intermediary holding company. In August 2016, <FONT STYLE="white-space:nowrap">I-Mab</FONT> Hong Kong established a wholly-owned PRC subsidiary, <FONT STYLE="white-space:nowrap">I-Mab</FONT> Biopharma Co., Ltd.
<FONT STYLE="white-space:nowrap">(&#147;I-Mab</FONT> Shanghai&#148;). In September 2016, the assets and operations of Third Venture were consolidated into <FONT STYLE="white-space:nowrap">I-Mab</FONT> Shanghai. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In July 2017, <FONT STYLE="white-space:nowrap">I-Mab</FONT> Hong Kong acquired a controlling interest in
<FONT STYLE="white-space:nowrap">I-Mab</FONT> <FONT STYLE="white-space:nowrap">Bio-tech</FONT> (Tianjin) Co., Ltd. <FONT STYLE="white-space:nowrap">(&#147;I-Mab</FONT> Tianjin&#148;), formerly known as Tasgen
<FONT STYLE="white-space:nowrap">Bio-tech</FONT> (Tianjin) Co., Ltd., a company focused on CMC management of biologics in China. Through an internal corporate restructuring, <FONT STYLE="white-space:nowrap">I-Mab</FONT> Tianjin became the 100% owner
of <FONT STYLE="white-space:nowrap">I-Mab</FONT> Shanghai in September 2017 and <FONT STYLE="white-space:nowrap">I-Mab</FONT> Hong Kong acquired the remaining interest in <FONT STYLE="white-space:nowrap">I-Mab</FONT> Tianjin in May 2018, becoming
the 100% owner of <FONT STYLE="white-space:nowrap">I-Mab</FONT> Tianjin. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In February 2018, <FONT STYLE="white-space:nowrap">I-Mab</FONT>
Hong Kong established in Maryland, United States, a wholly-owned subsidiary <FONT STYLE="white-space:nowrap">I-Mab</FONT> Biopharma US Limited <FONT STYLE="white-space:nowrap">(&#147;I-Mab</FONT> US&#148;), as the hub for the discovery and
development of the drug candidates in our Global Portfolio. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">On January&nbsp;17, 2020, our ADSs commenced trading on the Nasdaq Global
Market under the symbol &#147;IMAB.&#148; We raised from our initial public offering approximately US$103.7&nbsp;million in net proceeds, after the underwriters exercise in part their over-allotment option to purchase additional ADSs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In June 2019, with intention to build a comprehensive biologics manufacturing facility as part of our strategic plan to become a fully
integrated biopharma company, <FONT STYLE="white-space:nowrap">I-Mab</FONT> Hong Kong established <FONT STYLE="white-space:nowrap">I-Mab</FONT> Biopharma (Hangzhou) Co. Ltd <FONT STYLE="white-space:nowrap">(&#147;I-Mab</FONT> Hangzhou&#148;) in
Hangzhou, China. <FONT STYLE="white-space:nowrap">I-Mab</FONT> Hangzhou targets to have a pilot capacity of 2 x 2,000L by the end of 2021 and commercially progressive capacity up to 8 x 2,000L to begin operation by the end of 2023. In September
2020, a group of domestic investors in China invested a total of US$120&nbsp;million (in RMB equivalent) in cash. We and parties acting in concert remain the majority shareholder of <FONT STYLE="white-space:nowrap">I-Mab</FONT> Hangzhou, retain a
managing role and take full control to build and operate the manufacturing facility. </P>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The following diagram illustrates our corporate structure, including our principal
subsidiaries, as of the date of this prospectus: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g98473g36k00.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Implication of Being an Emerging Growth Company </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">As a company with less than US$1.07&nbsp;billion in revenue for our last fiscal year, we qualify as an &#147;emerging growth company&#148;
pursuant to the Jumpstart Our Business Startups Act of 2012, as amended (the &#147;JOBS Act&#148;). An emerging growth company may take advantage of specified reduced reporting and other requirements compared to those that are otherwise applicable
generally to public companies. These provisions include an exemption from the auditor attestation requirement under Section&nbsp;404 of the Sarbanes-Oxley Act of 2002 in the assessment of the emerging growth company&#146;s internal control over
financial reporting. The JOBS Act also provides that an emerging growth company does not need to comply with any new or revised financial accounting standards until such date that a private company is otherwise required to comply with such new or
revised accounting standards. However, we have elected to &#147;opt out&#148; of this provision and, as a result, we will comply with new or revised accounting standards as required when they are adopted for public companies. This decision to opt
out of the extended transition period under the JOBS Act is irrevocable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We will remain an emerging growth company until the earliest of
(a)&nbsp;the last day of the fiscal year during which we have total annual gross revenues of at least US$1.07&nbsp;billion; (b)&nbsp;the last day of our fiscal year following the fifth anniversary of the completion of our initial public offering;
(c)&nbsp;the date on which we have, during the preceding three-year period, issued more than US$1.0&nbsp;billion in <FONT STYLE="white-space:nowrap">non-convertible</FONT> debt; or (d)&nbsp;the date on which we are deemed to be a &#147;large
accelerated filer&#148; under the United States Securities Exchange Act of 1934, as amended, (the &#147;Exchange Act&#148;), which would occur if the market value of our ADSs that are held by <FONT STYLE="white-space:nowrap">non-affiliates</FONT>
exceeds US$700&nbsp;million as of the last business day of our most recently completed second fiscal quarter. Once we cease to be an emerging growth company, we will not be entitled to the exemptions provided in the JOBS Act discussed above. </P>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Corporate Information </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our principal executive offices are located at Suite 802, West Tower, OmniVision, 88 Shangke Road, Pudong District, Shanghai, People&#146;s
Republic of China. Our telephone number at this address is +86 <FONT STYLE="white-space:nowrap">21-60578000.</FONT> Our registered office in the Cayman Islands is located at Vistra (Cayman) Limited, P.O. Box 31119 Grand Pavilion, Hibiscus Way, 802
West Bay Road, Grand Cayman, <FONT STYLE="white-space:nowrap">KY1-1205,</FONT> Cayman Islands. Our agent for service of process in the United States is Cogency Global Inc., located at 122 East 42nd Street, 18th Floor, New York, NY 10168. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Investors should submit any inquiries to the address or through the telephone number of our principal executive offices. Our main website is <FONT
STYLE="white-space:nowrap">http://www.i-mabbiopharma.com/en/.</FONT> The information contained on our website is not a part of this prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Conventions that Apply to this Prospectus </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Unless otherwise indicated or the context otherwise requires, and for purposes of this prospectus only: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;ADRs&#148; refer to the American depositary receipts that evidence our ADSs; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;ADSs&#148; refer to our American depositary shares, each ten (10)&nbsp;ADSs represent twenty-three
(23)&nbsp;ordinary shares; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;China&#148; or &#147;the PRC&#148; refers to the People&#146;s Republic of China, excluding, for the
purposes of this prospectus only, Hong Kong, Macau and Taiwan, and &#147;Greater China&#148; does not exclude Hong Kong, Macau and Taiwan; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;China Portfolio&#148; refers to our investigational drugs of which we
<FONT STYLE="white-space:nowrap">in-license</FONT> Greater China rights from reputable global biopharmaceutical companies and rely on our own research and development capabilities to advance into pivotal clinical trials and commercialize in Greater
China with an aim for near-term product launch; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;Global Portfolio&#148; refers to our own proprietary novel or differentiated drug candidates that we are
advancing towards clinical validation in the United States; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT STYLE="white-space:nowrap">&#147;I-Mab,&#148;</FONT> &#147;we,&#148; &#147;us,&#148; &#147;our
company&#148; and &#147;our&#148; refer to <FONT STYLE="white-space:nowrap">I-Mab,</FONT> a Cayman Islands exempted company, and its subsidiaries; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;RMB&#148; refers to the legal currency of China; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;shares&#148; or &#147;ordinary shares&#148; refer to our ordinary shares, par value US$0.0001 per share;
and </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;US$,&#148; &#147;U.S. dollars,&#148; &#147;$,&#148; and &#147;dollars&#148; refer to the legal currency of
the United States. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our reporting currency is RMB. This prospectus also contains translations of certain foreign
currency amounts into U.S. dollars for the convenience of the reader. Unless otherwise stated, all translations from RMB to U.S. dollars were made at a rate of RMB7.0651 to US$1.00, the exchange rate in effect as of June&nbsp;30, 2020 as set forth
in the H.10 statistical release of the Board of Governors of the Federal Reserve System. We make no representation that any RMB or U.S. dollar amounts referred to in this prospectus could have been or could be converted into U.S. dollars or RMB, as
the case may be, at any particular rate, or at all. On November 25, 2020, the noon buying rate for RMB was RMB6.5750 to US$1.00. </P>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom98473_2"></A>THE OFFERING </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman"><B>Ordinary shares offered by the selling shareholders </B></P></TD>
<TD>Up to 25,123,751 ordinary shares, including ordinary shares represented by ADSs. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman"><B>The ADSs </B></P></TD>
<TD>Each ten (10)&nbsp;ADSs represent twenty-three (23)&nbsp;ordinary shares, par value US$0.0001 per share. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD>The depositary or its nominee will hold ordinary shares underlying your ADSs. You will have rights as provided in the deposit agreement among us, the depositary and all holders and beneficial owners of ADSs issued thereunder. </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD>We do not expect to pay dividends in the foreseeable future. If, however, we declare dividends on our ordinary shares, the depositary will pay you the cash dividends and other distributions it receives on our ordinary shares after deducting its
fees and expenses in accordance with the terms set forth in the deposit agreement. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD>You may surrender your ADSs to the depositary in exchange for ordinary shares. The depositary will charge you fees for any such exchange. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD>We may amend or terminate the deposit agreement without your consent. If you continue to hold your ADSs after an amendment to the deposit agreement, you agree to be bound by the deposit agreement as amended. </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD>To better understand the terms of the ADSs, you should carefully read the &#147;Description of American Depositary Shares&#148; section of this prospectus. You should also read the deposit agreement, which is filed as an exhibit to the
registration statement that includes this prospectus. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman"><B>Use of proceeds </B></P></TD>
<TD>We will not receive any of the proceeds from the sale of our ordinary shares or ADSs by the selling shareholders. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">Lock-up</FONT> </B></P></TD>
<TD> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Gaoling Fund, L.P. and YHG Investment, L.P (both controlled by Hillhouse) (collectively &#147;the Hillhouse Entities&#148;), is subject to certain <FONT
STYLE="white-space:nowrap">lock-up</FONT> obligations pursuant to the subscription agreement with us. Each of the Hillhouse Entities shall not dispose of any of the ordinary shares purchased by Hillhouse Entities on September&nbsp;11, 2020 or a
subsequent closing date within a <FONT STYLE="white-space:nowrap">90-day</FONT> period following September&nbsp;11, 2020 or a subsequent closing date set forth in the subscription agreement to any person other than affiliates of the Hillhouse
Entities, who shall be bound by the Hillhouse Entities&#146; <FONT STYLE="white-space:nowrap">lock-up</FONT> obligations for the balance of each applicable <FONT STYLE="white-space:nowrap">lock-up</FONT> period. Each of the Hillhouse Entities and
their affiliates may directly or indirectly, place any charge, mortgage, lien, pledge, restrictions, </P></TD></TR></TABLE>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="38%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:0%; font-size:10pt; font-family:Times New Roman">
security interest or other encumbrance in respect of the <FONT STYLE="white-space:nowrap">lock-up</FONT> securities in connection with such Hillhouse Entity&#146;s (or any of its
affiliates&#146;) margin loans, collars, derivative transactions or other such downside protection transactions to be entered into on or after the date of the subscription agreement. See &#147;Shares Eligible for Future <FONT
STYLE="white-space:nowrap">Sale&#151;Lock-up</FONT> Agreements&#148; and Exhibit 10.15 to this registration statement on Form <FONT STYLE="white-space:nowrap">F-1</FONT> for more information on the related
<FONT STYLE="white-space:nowrap">lock-up</FONT> obligations. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman"><B>Listing </B></P></TD>
<TD>Our ADSs are listed on the Nasdaq Global Market under the symbol &#147;IMAB.&#148; Our ADSs and shares are not listed on any other stock exchange or traded on any automated quotation system. </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman"><B>Depositary </B></P></TD>
<TD>Citibank, N.A. </TD></TR></TABLE>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom98473_3"></A>SUMMARY CONSOLIDATED FINANCIAL DATA </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The following summary consolidated statements of comprehensive loss data for the years ended December&nbsp;31, 2017, 2018 and 2019, summary
consolidated statements of balance sheet data as of December&nbsp;31, 2017, 2018 and 2019 and summary consolidated statements of cash flow data for the years ended December&nbsp;31, 2017, 2018 and 2019 have been derived from our audited consolidated
financial statements included elsewhere in this prospectus. The following summary consolidated statements of comprehensive loss data for the six months ended June&nbsp;30, 2019 and 2020, summary consolidated balance sheet data as of June&nbsp;30,
2020 and summary consolidated statements of cash flow data for the six months ended June&nbsp;30, 2019 and 2020 are derived from our unaudited interim condensed consolidated financial statements included elsewhere in this prospectus. Our
consolidated financial statements are prepared and presented in accordance with accounting principles generally accepted in the United States of America (&#147;U.S. GAAP&#148;). Our historical results are not necessarily indicative of results
expected for future periods. You should read this Summary Consolidated Financial Data section together with our consolidated financial statements and the related notes and &#147;Management&#146;s Discussion and Analysis of Financial Condition and
Results of Operations&#148; included elsewhere in this prospectus. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="39%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>For the Year Ended December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>For&nbsp;the&nbsp;Six&nbsp;Months<BR>Ended&nbsp;June&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>RMB</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>RMB</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>RMB</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>US$</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>RMB</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>RMB</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>US$</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="26" ALIGN="center"><B>(in thousands, except for share and per share data)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><B>Summary Consolidated Statements of Comprehensive Loss Data:</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><B>Revenues</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Licensing and collaboration revenue</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,556</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">53,781</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,246</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><B>Expenses</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Research and development expenses<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(267,075</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(426,028</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(840,415</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(118,953</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(265,084</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(442,291</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(62,602</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Administrative expenses<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(25,436</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(66,391</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(654,553</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(92,646</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(574,584</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(171,384</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(24,258</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><B>Loss from operations</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(280,955</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(438,638</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(1,464,968</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(207,353</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(824,668</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(613,675</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(86,860</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Interest income</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">858</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,597</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30,570</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,327</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,818</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,955</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,683</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Interest expense</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5,643</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(11,695</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,991</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(423</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,936</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(957</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(135</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Other income (expenses), net</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,527</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(16,780</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(20,205</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,860</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">303</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,824</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,815</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Fair value change of warrants</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(14,027</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">61,405</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,644</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">799</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(43,854</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><B>Loss before income tax expense</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(298,240</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(401,111</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(1,451,950</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(205,510</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(857,337</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(582,853</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(82,497</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Income tax expense</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,722</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><B>Net loss attributable to <FONT STYLE="white-space:nowrap">I-Mab</FONT></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(298,240</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(402,833</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(1,451,950</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(205,510</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(857,337</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(582,853</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(82,497</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Deemed dividend to Series <FONT STYLE="white-space:nowrap">C-1</FONT> preferred shareholders at
extinguishment of Series <FONT STYLE="white-space:nowrap">C-1</FONT> Preferred Shares</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5,283</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(748</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Deemed dividend to Series <FONT STYLE="white-space:nowrap">B-1,</FONT> <FONT
STYLE="white-space:nowrap">B-2</FONT> and C preferred shareholders at modification of Series <FONT STYLE="white-space:nowrap">B-1,</FONT> <FONT STYLE="white-space:nowrap">B-2</FONT> and C Preferred Shares</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(27,768</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,930</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><B>Net loss attributable to ordinary shareholders</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(298,240</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(402,833</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(1,485,001</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(210,188</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(857,337</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(582,853</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(82,497</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><B>Other comprehensive income</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Foreign currency translation adjustments, net of nil tax</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,918</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">53,689</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,747</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,521</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4,972</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">34,726</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,915</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><B>Total comprehensive loss attributable to
<FONT STYLE="white-space:nowrap">I-Mab</FONT></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(292,322</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(349,144</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(1,441,203</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(203,989</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(862,309</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(548,127</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(77,582</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><B>Net loss attributable to ordinary shareholders</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(298,240</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(402,833</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(1,485,001</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(210,188</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(857,337</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(582,853</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(82,497</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><B>Weighted-average number of ordinary shares used in calculating net loss per shares</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,742,669</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,529,092</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,381,230</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,381,230</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,184,086</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">121,815,986</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">121,815,986</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><B>Net loss per share attributable to ordinary shareholders</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Basic</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(51.93</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(61.70</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(201.19</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(28.48</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(119.34</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4.78</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(0.68</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Diluted</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(51.93</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(61.70</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(201.19</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(28.48</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(119.34</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4.78</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(0.68</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
</TABLE>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">Note: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left">Share-based compensation expenses were allocated as follows: </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="55%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>For&nbsp;the&nbsp;Year&nbsp;Ended&nbsp;December&nbsp;31,</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>For the Six Months Ended
June&nbsp;30,</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>2017</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>2018</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>2019</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>2019</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>2020</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>RMB</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>RMB</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>RMB</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>US$</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>RMB</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>RMB</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>US$</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="26" ALIGN="center"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Research and Development expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,112</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,056</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">470</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">67</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">308</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">132,724</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,786</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Administrative expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,927</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,464</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">514,733</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">72,856</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">514,356</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">97,071</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,739</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><B>Total</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>&nbsp;&nbsp;7,039</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>&nbsp;&nbsp;3,520</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>515,203</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>72,922</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>514,664</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>229,795</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>32,525</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The following table presents our summary consolidated balance sheet data as of December&nbsp;31, 2017, 2018
and 2019 and June&nbsp;30, 2020: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" ALIGN="center">


<TR>

<TD WIDTH="45%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>As of
December&nbsp;31,</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>As of June&nbsp;30,</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>2017</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>2018</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>2019</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>2020</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>RMB</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>RMB</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>RMB</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>US$</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>RMB</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>US$</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="22" ALIGN="center"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><B>Summary Consolidated Statements of Balance Sheet Data:</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><B>Current assets:</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">307,930</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,588,278</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,137,473</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">160,999</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,560,031</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">220,808</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Restricted cash</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">104,783</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">92,653</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">55,810</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,899</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Contract assets</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Short-term investments</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">32,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,529</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,926</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">273</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Prepayments and other receivables</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,633</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">88,972</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">136,036</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,255</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">131,130</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,560</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Other financial assets</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">266,245</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">255,958</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><B>Total current assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">691,591</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,036,861</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,361,319</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">192,682</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,693,087</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">239,641</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Property, equipment and software</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,336</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27,659</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30,069</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,256</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26,625</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,769</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Operating lease
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT> assets</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,435</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,326</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17,592</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,490</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Intangible assets</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">148,844</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">148,844</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">148,844</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21,068</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">148,844</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21,068</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Goodwill</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">162,574</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">162,574</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">162,574</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23,011</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">162,574</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23,011</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Other <FONT STYLE="white-space:nowrap">non-current</FONT> assets</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,331</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,594</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><B>Total assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1,025,345</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>2,375,938</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1,737,572</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>245,937</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>2,048,722</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>289,979</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><B>Total liabilities</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>309,151</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>415,684</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>668,090</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>94,561</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>344,846</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>48,811</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><B>Total mezzanine equity</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1,015,989</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>2,915,358</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>3,104,177</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>439,368</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><B>Shareholders&#146; equity (deficit)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Ordinary shares (US$0.0001 par value, 500,000,000 shares authorized as of December&nbsp;31, 2018
and 2019 and 800,000,000 shares authorized as of June&nbsp;30, 2020, respectively; 8,363,719 shares issued and outstanding as of December&nbsp;31, 2018 and 2019 and 133,006,644 shares issued and outstanding June&nbsp;30, 2020, respectively)</P></TD>

<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">92</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Treasury stock</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Additional <FONT STYLE="white-space:nowrap">paid-in</FONT> capital</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">52,369</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">389,379</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">55,113</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,675,991</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">661,844</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Accumulated other comprehensive income</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,691</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">59,380</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">70,127</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,926</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">104,853</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,841</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Accumulated deficit</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(357,860</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,014,489</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,494,207</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(353,032</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,077,060</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(435,530</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><B>Total shareholders&#146; equity (deficit)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(299,795</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(955,104</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(2,034,695</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(287,992</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1,703,876</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>241,168</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><B>Total liabilities, mezzanine equity and shareholders&#146; equity (deficit)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1,025,345</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>2,375,938</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1,737,572</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>245,937</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>2,048,722</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>289,979</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The following table presents our summary consolidated statements of cash flow data for the
years ended December&nbsp;31, 2017, 2018 and 2019 and the six months ended June&nbsp;30, 2019 and 2020: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="34%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>For the Year Ended
December&nbsp;31,</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>For the Six Months Ended
June&nbsp;30,</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>2017</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>2018</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>2019</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>2019</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>2020</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>RMB</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>RMB</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>RMB</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>US$</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>RMB</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>RMB</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>US$</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="26" ALIGN="center"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Summary Consolidated Statements of Cash Flow Data:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash used in operating activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(252,157</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(280,705</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(867,982</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(122,855</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(389,034</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(349,793</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(49,510</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash (used in) generated from investing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(157,665</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">212,462</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30,072</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">158,056</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30,354</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,298</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash (used in) generated from financing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">758,585</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,479,669</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">152,709</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21,615</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(30,000</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">653,798</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">92,539</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Effect of exchange rate changes on cash and cash equivalents and restricted cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(132</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">59,754</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,163</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,146</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,093</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">32,389</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,584</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net increase (decrease) in cash, cash equivalents and restricted cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">348,631</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,268,218</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(487,648</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(69,022</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(264,071</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">366,748</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">51,911</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash, cash equivalents and restricted cash, beginning of the year/period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">64,082</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">412,713</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,680,931</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">237,920</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,680,931</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,193,283</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">168,897</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash, cash equivalents and restricted cash, end of the year/period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">412,713</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,680,931</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,193,283</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">168,898</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,416,860</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,560,031</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">220,808</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom98473_4"></A>RISK FACTORS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">An investment in our ordinary shares or ADSs involves significant risks. You should carefully consider all of the information in this
prospectus, including the risks and uncertainties described below, before making an investment in our ordinary shares or ADSs. Any of the following risks could have a material adverse effect on our business, financial condition and results of
operations. In any such case, the market price of our ordinary shares or ADSs could decline, and you may lose all or part of your investment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks
Related to Our Financial Position and Need for Additional Capital </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We have a limited operating history, which may make it difficult to evaluate
our current business and predict our future performance. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We are a clinical stage biopharmaceutical company with a limited
operating history. Our operations to date have focused on organizing and staffing our operations, business planning, raising capital, establishing our intellectual property portfolio and conducting
<FONT STYLE="white-space:nowrap">pre-clinical</FONT> and clinical trials of our drug candidates. We have not yet demonstrated an ability to successfully manufacture, obtain marketing approvals for or commercialize our drug candidates. We have no
products approved for commercial sale and have not generated any revenue from product sales. Consequently, any predictions about our future success or viability may not be as accurate as they could be if we had a longer operating history. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We are focused on the discovery and development of innovative drugs for the treatment of various immuno-oncological and immuno-inflammatory
diseases. Our limited operating history, particularly in light of the rapidly evolving drug research and development industry in which we operate and the changing regulatory and market environments we encounter, may make it difficult to evaluate our
prospects for future performance. As a result, any assessment of our future performance or viability is subject to significant uncertainty. We will encounter risks and difficulties frequently experienced by early-stage companies in rapidly evolving
fields as we seek to transition to a company capable of supporting commercial activities. If we do not address these risks and difficulties successfully, our business will suffer. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We have incurred net losses in each period since our inception and anticipate that we will continue to incur net losses for the foreseeable future and
may never achieve or maintain profitability. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Investment in the development of biopharmaceutical products is highly speculative as
it entails substantial upfront capital expenditures and significant risks that a drug candidate may fail to demonstrate efficacy and/or safety to gain regulatory or marketing approvals or become commercially viable. To date, we have financed our
activities primarily through private placements. While we have generated revenue from licensing and collaboration deals, we have not generated any revenue from commercial product sales to date, and we continue to incur significant research and
development expenses and other expenses related to our ongoing operations. As a result, we are not profitable and have incurred net losses in each period since our inception. In 2017, 2018, 2019 and the six months ended June&nbsp;30, 2020, our net
losses were RMB298.2&nbsp;million, </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">RMB402.8&nbsp;million, RMB1,452.0&nbsp;million (US$205.5 million) and RMB582.9&nbsp;million (US$82.5
million), respectively. Substantially all of our net losses have resulted from costs incurred in connection with our research and development programs and from general and administrative costs associated with our operations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We expect to continue to incur net losses in the foreseeable future, and that these net losses will increase as we carry out certain
activities relating to our development, including, but not limited to, the following: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">conducting clinical trials of our drug candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">manufacturing clinical trial materials through contract manufacturing organizations, or CMOs, in and out of
China; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">seeking regulatory approvals for our drug candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">commercializing our drug candidates for which we have obtained marketing approval; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">completing the construction of and maintaining our manufacturing facilities; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">hiring additional clinical, operational, financial, quality control and scientific personnel;
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">establishing a sales, marketing and commercialization team for any future products that have obtained regulatory
approval; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">seeking to identify additional drug candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">obtaining, maintaining, expanding and protecting our intellectual property portfolio; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">enforcing and defending any intellectual property-related claims; and </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">acquiring or <FONT STYLE="white-space:nowrap">in-licensing</FONT> other drug candidates, intellectual property
and technologies. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Typically, it takes many years to develop one new drug from the time it is discovered to when it
becomes available for treating patients. During the process, we may encounter unforeseen expenses, difficulties, complications, delays and other unknown factors that may adversely affect our business. The size of our future net losses will depend
partially on the rate of the future growth of our expenses, our ability to generate revenues and the timing and amount of milestone payments and other payments that we receive from or pay to third parties. If any of our drug candidates fails during
clinical trials or does not gain regulatory approval, or, even if approved, fails to achieve market acceptance, our business may not become profitable. Even if we achieve profitability in the future, we may not be able to sustain profitability in
subsequent periods thereafter. Our prior losses and expected future losses have had, and will continue to have, an adverse effect on our working capital and shareholders&#146; equity. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We recorded net cash outflow from operating activities since our inception. We may need to obtain additional financing to fund our operations. If we are
unable to obtain such financing, we may be unable to complete the development and commercialization of our major drug candidates. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Since our inception, our operations have consumed substantial amounts of cash. We had raised over US$400&nbsp;million in <FONT
STYLE="white-space:nowrap">pre-IPO</FONT> financing in the past three years and received total net proceeds of approximately US$105.3&nbsp;million from our initial public offering. We spent RMB252.2&nbsp;million, RMB280.7&nbsp;million,
RMB868.0&nbsp;million (US$122.9 million) and RMB349.8&nbsp;million (US$49.5 million) in net cash to finance our operations in 2017, 2018, 2019 and the six months ended June&nbsp;30, 2020, respectively. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We expect our expenses to increase significantly in connection with our ongoing activities, particularly as we advance the clinical
development of our clinical-stage drug candidates, continue the research and development of our <FONT STYLE="white-space:nowrap">pre-clinical</FONT> stage drug candidates and initiate additional clinical trials of, and seek regulatory approval for,
these and other future drug candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In addition, if we obtain regulatory approvals for any of our drug candidates, we expect to incur
significant commercialization expenses relating to product manufacturing, marketing, sales and distribution and post-approval commitments to continue monitoring the efficacy and safety data of our future products on the market. In particular, costs
that may be required for the manufacture of any drug candidate that has received regulatory approval may be substantial as we may need to modify or increase our production capacity in the future at manufacturing facilities. We may also incur
expenses as we create additional infrastructure to support our operations as a public company. Accordingly, we will need to obtain substantial additional funding in </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
connection with our continuing operations through public or private equity offerings, debt financing, collaborations or licensing arrangements or other sources. If we are unable to raise capital
when needed or on acceptable terms, we could be forced to delay, limit, reduce or terminate our research and development programs or any future commercialization efforts. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The recent <FONT STYLE="white-space:nowrap">COVID-19</FONT> outbreak has brought uncertainties and interruptions to global economy and caused
significant volatility across the financial markets, which had a cooling effect on the financing and investing activities in general. We believe that our current cash and cash equivalents, together with our cash generated from operating activities,
financing activities, our initial public offering and private placement, will be sufficient to meet our present anticipated working capital requirements and capital expenditures. However, if the impact of the
<FONT STYLE="white-space:nowrap">COVID-19</FONT> and volatility in the financial markets continue, our financing activities in future to raise additional capital may be materially and adversely affected, which may in turn have an adverse effect on
our ability to meet our working capital requirement and our liquidity. For other risks related to the <FONT STYLE="white-space:nowrap">COVID-19,</FONT> see &#147;&#151;Our business and results of operations could be adversely affected by public
health crisis (including the <FONT STYLE="white-space:nowrap">COVID-19</FONT> global pandemic) and natural catastrophes or other disasters outside of our control in the locations in which we, our suppliers, CROs, CMOs and other contractors
operate.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Raising additional capital may cause dilution to the interests to the holders of our ADSs and our shareholders, restrict our
operations or require us to relinquish rights to our technologies or drug candidates. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We may seek additional funding through a
combination of equity offerings, debt financings, collaborations, licensing arrangements, strategic alliances or partnerships and government grants or subsidies. To the extent that we raise additional capital through the sale of equity or
convertible debt securities, your ownership interest will be diluted, and the terms may include liquidation or other preferences that adversely affect your rights as a holder of our ADSs. The incurrence of additional indebtedness or the issuance of
certain equity securities could give rise to increased fixed payment obligations and also result in certain additional restrictive covenants, such as limitations on our ability to incur additional debt or issue additional equity, limitations on our
ability to acquire or license intellectual property rights and other operating restrictions that could adversely impact our ability to conduct our business. In addition, the issuance of additional equity securities, or the possibility of such
issuance, may cause the market price of our ADSs to decline. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In the event we enter into collaborations or licensing arrangements in order
to raise capital, we may be required to accept unfavorable terms, including relinquishing or licensing to a third party our rights to technologies or drug candidates on unfavorable terms, which we would have otherwise sought to develop or
commercialize on our own or reserve for future potential arrangements when we are more likely to achieve more favorable terms. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to
Clinical Development of Our Drug Candidates </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Clinical development involves a lengthy and expensive process with an uncertain outcome, and
results of earlier studies and trials may not be predictive of future trial results. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Clinical testing is expensive and can take
many years to complete, and its outcome is inherently uncertain. While our exclusive focus is to develop drug candidates with potential to become novel or highly differentiated drugs in China and globally, we cannot guarantee that we are able to
achieve this for any of our drug candidates. Failure can occur at any time during the clinical development process. The results of <FONT STYLE="white-space:nowrap">pre-clinical</FONT> studies and early clinical trials of our drug candidates may not
be predictive of the results of later-stage clinical trials. Drug candidates during later stages of clinical trials may fail to show the desired results in safety and efficacy despite having progressed through
<FONT STYLE="white-space:nowrap">pre-clinical</FONT> studies and initial clinical trials and despite the level of scientific rigor in the study, design and adequacy of execution. In some instances, there can be significant variability in safety
and/or efficacy results among different trials of the same drug candidate due to numerous factors, including, but not limited to, differences in individual patient conditions, including genetic differences, and other compounding factors, such as
other medications or <FONT STYLE="white-space:nowrap">pre-existing</FONT> medical conditions. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">25 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In the case of any trials we conduct, results may differ from earlier trials due to the
larger number of clinical trial sites and additional countries and languages involved in such trials. A number of companies in the biopharmaceutical industry have suffered significant setbacks in advanced clinical trials due to a lack of efficacy or
adverse safety profiles, notwithstanding promising results in earlier trials. We cannot guarantee that our future clinical trial results will be favorable based on currently available clinical and <FONT STYLE="white-space:nowrap">pre-clinical</FONT>
data. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We depend substantially on the success of our drug candidates, all of which are in <FONT STYLE="white-space:nowrap">pre-clinical</FONT> or
clinical development, and our ability to identify additional drug candidates. If we are unable to successfully identify new drug candidates, complete clinical development, obtain regulatory approval and commercialize our drug candidates, or
experience significant delays in doing so, our business will be materially harmed. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our business will depend on the successful
development, regulatory approval and commercialization of our drug candidates for the treatment of patients with our targeted indications, all of which are still in <FONT STYLE="white-space:nowrap">pre-clinical</FONT> or clinical development, and
other new drug candidates that we may identify and develop. As of the date of this prospectus, we have obtained IND approvals from the NMPA for seven of our drug candidates, felzartamab, olamkicept, efineptakin, lemzoparlimab, uliledlimab,
plonmarlimab and eftansomatropin. In addition, we have obtained IND approvals from the FDA for four of our drug candidates, lemzoparlimab, uliledlimab, plonmarlimab and TJ210; from the Taiwan Food and Drug Administration (the &#147;TFDA&#148;) for
two of our drug candidates, felzartamab and olamkicept; and from the Korea Ministry of Food and Drug Safety (the &#147;MFDS&#148;) for olamkicept. However, we cannot guarantee that we are able to obtain regulatory approvals for our other existing
drug candidates in a timely manner, or at all. In addition, none of our drug candidates has been approved for marketing in China or any other jurisdiction. Each of our drug candidates will require additional
<FONT STYLE="white-space:nowrap">pre-clinical</FONT> and/ or clinical development, regulatory approvals in multiple jurisdictions, development of manufacturing supply and capacity, substantial investment and significant marketing efforts before we
generate any revenue from product sales. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The success of our drug candidates will depend on several factors, including but not limited to
the successful completion of <FONT STYLE="white-space:nowrap">pre-clinical</FONT> and/or clinical trials or studies, receipt of regulatory approvals from applicable regulatory authorities for planned clinical trials, future clinical trials or drug
registrations, establishing adequate manufacturing capabilities and capacities, commercialization of our existing drug candidates, hiring sufficient technical experts to oversee all development and regulatory activities and license renewal and
meeting of the safety requirements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">If we do not achieve one or more of these in a timely manner or at all, we could experience
significant delays in our ability to obtain approval for our drug candidates, which would materially harm our business and we may not be able to generate sufficient revenues and cash flows to continue our operations. As a result, our financial
condition, results of operations and prospects will be materially and adversely harmed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may not be able to identify, discover or <FONT
STYLE="white-space:nowrap">in-license</FONT> new drug candidates, and may allocate our limited resources to pursue a particular drug candidate or indication and fail to capitalize on drug candidates or indications that may later prove to be more
profitable, or for which there is a greater likelihood of success. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Although a substantial amount of our effort will focus on the
continued clinical testing, potential approval, and commercialization of our existing drug candidates, the success of our business depends in part upon our ability to identify, license, discover, develop, or commercialize additional drug candidates.
Research programs to identify new drug candidates require substantial technical, financial, and human resources. We may focus our efforts and resources on potential programs or drug candidates that ultimately prove to be unsuccessful. Our research
programs or licensing efforts may fail to identify, discover or <FONT STYLE="white-space:nowrap">in-license</FONT> new drug candidates for clinical development and commercialization for a number of reasons, including, without limitation, the
following: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our research or business development methodology or search criteria and process may be unsuccessful in
identifying potential drug candidates; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">26 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our potential drug candidates may be shown to have harmful side effects or may have other characteristics that
may make the products unmarketable or unlikely to receive marketing approval; and </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">it may take greater human and financial resources to identify additional therapeutic opportunities for our drug
candidates or to develop suitable potential drug candidates through internal research programs than we possess, thereby limiting our ability to diversify and expand our drug portfolio. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Because we have limited financial and managerial resources, we focus on research programs and drug candidates for specific indications. As a
result, we may forgo or delay pursuit of opportunities with other drug candidates or for other indications that later may prove to have greater commercial potential or a greater likelihood of success. Our resource allocation decisions may cause us
to fail to capitalize on viable commercial products or profitable market opportunities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Accordingly, there can be no assurance that we
will ever be able to identify additional therapeutic opportunities for our drug candidates or to develop suitable potential drug candidates through internal research programs, which could materially adversely affect our future growth and prospects.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we encounter delays or difficulties enrolling patients in our clinical trials, our clinical development progress could be delayed or otherwise
adversely affected. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We may not be able to initiate or continue clinical trials for our drug candidates if we are unable to locate
and enroll a sufficient number of eligible patients to participate in these trials as required by the NMPA, the FDA, or similar regulatory authorities, or if there are delays in the enrollment of eligible patients as a result of the competitive
clinical enrollment environment. The inability to enroll a sufficient number of patients who meet the applicable criteria for our clinical trials would result in significant delays. As of the date of this prospectus, we have initiated clinical
trials for olamkicept in South Korea and Greater China, for efineptakin in China, for felzartamab in Greater China, for lemzoparlimab, plonmarlimab and uliledlimab in China and the United States. In addition, we expect to initiate clinical trials
for TJ210 by early 2021 in the United States. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In addition, some of our competitors have ongoing clinical trials for drug candidates that
treat the same indications as our drug candidates, and patients who would otherwise be eligible for our clinical trials may instead enroll in the clinical trials of our competitors&#146; drug candidates, which may further delay our clinical trial
enrollments. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Patient enrollment for our clinical trials may be affected by other factors, including but not limited to the following:
</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">severity of the disease under investigation; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">total size and nature of the relevant patient population; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">design and eligibility criteria for the clinical trial in question; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">perceived risks and benefits of the drug candidate under study; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our resources to facilitate timely enrollment in clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">patient referral practices of physicians; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">availability of competing therapies also undergoing clinical trials; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">27 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our investigators&#146; or clinical trial sites&#146; efforts to screen and recruit eligible patients; and
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">proximity and availability of clinical trial sites for prospective patients. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Even if we are able to enroll a sufficient number of patients in our clinical trials, delays in patient enrollment may result in increased
costs or may affect the timing or outcome of the planned clinical trials, which could prevent completion of these trials and adversely affect our ability to advance the development of our drug candidates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If clinical trials of our drug candidates fail to demonstrate safety and efficacy to the satisfaction of regulatory authorities or do not otherwise
produce positive results, we may incur additional costs or experience delays in completing, or ultimately be unable to complete, the development and commercialization of our drug candidates. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Before obtaining regulatory approval for the sale of our drug candidates, we must conduct extensive clinical trials to demonstrate the safety
and efficacy of our drug candidates in humans. We may experience numerous unexpected events during, or as a result of, clinical trials that could delay or prevent our ability to receive regulatory approval or commercialize our drug candidates,
including, without limitation: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">regulators, institutional review boards, or IRBs, or ethics committees may not authorize us or our investigators
to commence a clinical trial or conduct a clinical trial at a prospective trial site; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our inability to reach agreements on acceptable terms with prospective CROs and trial sites, the terms of which
can be subject to extensive negotiation and may vary significantly among different CROs and trial sites; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">manufacturing issues, including problems with manufacturing, supply quality, compliance with good manufacturing
practice, or GMP, or obtaining sufficient quantities of a drug candidate from third parties for use in a clinical trial; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">clinical trials of our drug candidates may produce negative or inconclusive results, and we may decide to conduct
additional clinical trials or abandon drug development programs, or regulators may require us to do so; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the number of patients required for clinical trials of our drug candidates may be larger than we anticipate,
enrollment may be insufficient or slower than we anticipate or patients may drop out at a higher rate than we anticipate; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our third-party contractors, including clinical investigators, may fail to comply with regulatory requirements or
meet their contractual obligations to us in a timely manner, or at all; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we might have to suspend or terminate clinical trials of our drug candidates for various reasons, including a
finding of a lack of clinical response or other unexpected characteristics or a finding that participants are being exposed to unacceptable health risks; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">regulators, IRBs or ethics committees may require that we or our investigators suspend or terminate clinical
research or not rely on the results of clinical research for various reasons, including <FONT STYLE="white-space:nowrap">non-compliance</FONT> with regulatory requirements; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the cost of clinical trials of our drug candidates may be greater than we anticipate; and </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the supply or quality of our drug candidates, companion diagnostics or other materials necessary to conduct
clinical trials of our drug candidates may be insufficient or inadequate. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">28 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">If we are required to conduct additional clinical trials or other testing of our drug
candidates beyond those that we currently plan, if we are unable to successfully complete clinical trials of our drug candidates or other testing, if the results of these trials or tests are not positive or are only modestly positive or if they
raise safety concerns, we may (i)&nbsp;be delayed in obtaining regulatory approval for our drug candidates; (ii)&nbsp;obtain approval for indications that are not as broad as intended; (iii)&nbsp;not obtain regulatory approval at all; (iv)&nbsp;have
the drug removed from the market after obtaining regulatory approval; (v)&nbsp;be subject to additional post-marketing testing requirements; (vi)&nbsp;be subject to restrictions on how the drug is distributed or used; or (vii)&nbsp;be unable to
obtain reimbursement for use of the drug. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Significant clinical trial delays may also increase our development costs and could shorten any
periods during which we have the exclusive right to commercialize our drug candidates or allow our competitors to bring drugs to market before we do. This could impair our ability to commercialize our drug candidates and may harm our business and
results of operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Obtaining Regulatory Approval for Our Drug Candidates </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>All material aspects of the research, development and commercialization of pharmaceutical products are heavily regulated. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">All jurisdictions in which we intend to conduct our pharmaceutical-industry activities regulate these activities in great depth and detail. We
intend to focus our activities in the major markets of China and the United States. These jurisdictions strictly regulate the pharmaceutical industry, and in doing so they employ broadly similar regulatory strategies, including regulation of product
development and approval, manufacturing, and marketing, sales and distribution of products. However, there are differences in the regulatory regimes that make for a more complex and costly regulatory compliance burden for a company like us that
plans to operate in these regions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The process of obtaining regulatory approvals and compliance with appropriate laws and regulations
requires the expenditure of substantial time and financial resources. Failure to comply with the applicable requirements at any time during the product development process and approval process, or after approval, may subject an applicant to
administrative or judicial sanctions. These sanctions could include: refusal to approve pending applications; withdrawal of an approval; license revocation; clinical hold; voluntary or mandatory product recalls; product seizures; total or partial
suspension of production or distribution; injunctions; fines; refusals of government contracts; providing restitution; undergoing disgorgement; or other civil or criminal penalties. Failure to comply with these regulations could have a material
adverse effect on our business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The regulatory approval processes of the NMPA, the FDA and other comparable regulatory authorities are
time-consuming and may evolve over time, and if we are ultimately unable to obtain regulatory approval for our drug candidates, our business will be substantially harmed. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The time required to obtain the approval of the NMPA, the FDA and other comparable regulatory authorities is inherently uncertain and depends
on numerous factors, including the substantial discretion of the regulatory authorities. Generally, such approvals take many years to obtain following the commencement of <FONT STYLE="white-space:nowrap">pre-clinical</FONT> studies and clinical
trials, although they are typically provided within 12 to 18 months after clinical trials are completed. In addition, approval policies, regulations or the type and amount of clinical data necessary to gain approval may change during the course of a
drug candidate&#146;s clinical development and may vary among jurisdictions. As of the date of this prospectus, we have obtained IND approvals from the NMPA for seven of our drug candidates, felzartamab, olamkicept, efineptakin, lemzoparlimab,
uliledlimab, plonmarlimab and eftansomatropin.<B><I> </I></B>In addition, we have obtained IND approvals from the FDA for four of our drug candidates, lemzoparlimab, uliledlimab, plonmarlimab and TJ210; from the TFDA for two of our drug candidates,
felzartamab and olamkicept; and from the MFDS for olamkicept. However, we cannot guarantee that we are able to obtain regulatory approvals for our other existing drug candidates or any drug candidates we may discover,
<FONT STYLE="white-space:nowrap">in-license</FONT> or acquire and seek to develop in the future. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">29 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our drug candidates could fail to receive the regulatory approval of the NMPA, the FDA or a
comparable regulatory authority for many reasons, including, without limitation: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">disagreement with the design or implementation of our clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">failure to demonstrate that a drug candidate is safe and effective and potent for its proposed indication;
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">failure of our clinical trial results to meet the level of statistical significance required for approval;
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">failure of our clinical trial process to pass relevant good clinical practice (&#147;GCP&#148;) inspections;
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">failure to demonstrate that a drug candidate&#146;s clinical and other benefits outweigh its safety risks;
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">disagreement with our interpretation of data from <FONT STYLE="white-space:nowrap">pre-clinical</FONT> studies or
clinical trials; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">insufficient data collected from the clinical trials of our drug candidates to support the submission and filing
of a new drug application, or NDA, or other submissions or to obtain regulatory approval; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">failure of our drug candidates to pass current Good Manufacturing Practice (&#147;cGMP&#148;), inspections during
the regulatory review process or across the production cycle of our drug; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">failure of our clinical sites to pass audits carried out by the NMPA, the FDA or comparable regulatory
authorities, resulting in a potential invalidation of our research data; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">findings by the NMPA, the FDA or comparable regulatory authorities of deficiencies related to our manufacturing
processes or the facilities of third-party manufacturers with whom we contract for clinical and commercial supplies; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">changes in approval policies or regulations that render our <FONT STYLE="white-space:nowrap">pre-clinical</FONT>
and clinical data insufficient for approval; and </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">failure of our clinical trial process to keep up with any scientific or technological advancements required by
approval policies or regulations. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The NMPA, the FDA or a comparable regulatory authority may require more information,
including additional <FONT STYLE="white-space:nowrap">pre-clinical</FONT> or clinical data, to support approval, which may delay or prevent approval and our commercialization plans. Even if we were to obtain approval, regulatory authorities may
approve any of our drug candidates for fewer or more limited indications than we request, grant approval contingent on the performance of costly post-marketing clinical trials, or approve a drug candidate with an indication that is not desirable for
the successful commercialization of that drug candidate. Any of the foregoing scenarios could materially harm the commercial prospects of our drug candidates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The absence of patent linkage, patent term extension and data and market exclusivity for NMPA-approved pharmaceutical products could increase the risk
of early generic competition with our products in China. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In the United States, the Federal Food, Drug and Cosmetic Act, as
amended by the law generally referred to as &#147;Hatch-Waxman,&#148; provides the opportunity for patent-term restoration, meaning a patent term extension of up to five years to reflect patent term lost during certain portions of product
development and the FDA regulatory review process. Hatch-Waxman also has a process for patent linkage, pursuant to which the FDA will stay approval of certain <FONT STYLE="white-space:nowrap">follow-on</FONT> applications during the pendency of
litigation between the <FONT STYLE="white-space:nowrap">follow-on</FONT> applicant and the patent holder or licensee, generally for a period of 30 months. Finally, Hatch-Waxman provides </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">30 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
for statutory exclusivities that can prevent submission or approval of certain <FONT STYLE="white-space:nowrap">follow-on</FONT> marketing applications. For example, federal law provides a
five-year period of exclusivity within the United States to the first applicant to obtain approval of a new chemical entity and three years of exclusivity protecting certain innovations to previously approved active ingredients where the applicant
was required to conduct new clinical investigations to obtain approval for the modification. Similarly, the United States Orphan Drug Act provides seven years of market exclusivity for certain drugs to treat rare diseases, where the FDA designates
the drug candidate as an orphan drug and the drug is approved for the designated orphan indication. These provisions, designed to promote innovation, can prevent competing products from entering the market for a certain period of time after the FDA
grants marketing approval for the innovative product. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Depending upon the timing, duration and specifics of any FDA marketing approval
process for any drug candidates we may develop, one or more of our U.S. patents, if issued, may be eligible for limited patent term extension under Hatch-Waxman. Hatch-Waxman permits a patent extension term of up to five years as compensation for
patent term lost during clinical trials and the FDA regulatory review process. A patent term extension cannot extend the remaining term of a patent beyond a total of 14 years from the date of drug approval, only one patent may be extended and only
those claims covering the approved drug, a method for using it, or a method for manufacturing it may be extended. However, we may not be granted an extension because of, for example, failing to exercise due diligence during the testing phase or
regulatory review process, failing to apply within applicable deadlines, failing to apply prior to expiration of relevant patents, or otherwise failing to satisfy applicable requirements. Furthermore, the applicable time period or the scope of
patent protection afforded could be less than we request. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In China, however, there is no currently effective law or regulation providing
for patent term extension, patent linkage, or data exclusivity (referred to as regulatory data protection). Therefore, a lower-cost generic drug can emerge onto the market much more quickly. Chinese regulators have set forth a framework for
integrating patent linkage and data exclusivity into the Chinese regulatory regime, as well as for establishing a pilot program for patent term extension. To be implemented, this framework will require adoption of regulations. To date, no
regulations have been issued. These factors result in weaker protection for us against generic competition in China than could be available to us in the United States. For instance, the patents we have in China are not yet eligible to be extended
for patent term lost during clinical trials and the regulatory review process. If we are unable to obtain patent term extension or the term of any such extension is less than we request, our competitors may obtain approval of competing products
following our patent expiration, and our business, financial condition, results of operations, and prospects could be materially harmed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our drug
candidates may cause undesirable adverse events or have other properties that could delay or prevent their regulatory approval, limit the commercial profile of an approved label, or result in significant negative consequences following regulatory
approval. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Undesirable adverse events caused by our drug candidates could cause us or regulatory authorities to interrupt, delay
or halt clinical trials and may result in a more restrictive label, a delay or denial of regulatory approval by the NMPA, the FDA or other comparable regulatory authorities, or a significant change in our clinical protocol or even our development
plan. In particular, as is the case with drugs treating cancers and auto-immune diseases, it is likely that there may be side effects, such as nausea, fatigue and infusion-related reactions, associated with the use of certain of our drug candidates.
Results of our trials could reveal a high and unacceptable severity or prevalence of certain adverse events. In such an event, our trials could be suspended or terminated and the NMPA, the FDA or other comparable regulatory authorities could order
us to cease further development of, or deny approval of, our drug candidates for any or all targeted indications. Adverse events related to our drug candidates may affect patient recruitment or the ability of enrolled subjects to complete the trial,
and could result in potential liability claims. Any of these occurrences may significantly harm our reputation, business, financial condition and prospects. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">31 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Additionally, if we or others identify undesirable side effects caused by those of our
existing drug candidates that have received regulatory approval, or our other drug candidates after having received regulatory approval, this may lead to potentially significant negative consequences which include, but are not limited to, the
following: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may suspend marketing of the drug candidate; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">regulatory authorities may withdraw their approvals of or revoke the licenses for the drug candidate;
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">regulatory authorities may require additional warnings on the label; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the FDA may require the establishment of a Risk Evaluation and Mitigation Strategy, or REMS, or the NMPA or a
comparable regulatory authority may require the establishment of a similar strategy that may, for instance, restrict distribution of our drugs and impose burdensome implementation requirements on us; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may be required to conduct specific post-marketing studies; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we could be subjected to litigation proceedings and held liable for harm caused to subjects or patients; and
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our reputation may suffer. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Any of these events could prevent us from achieving or maintaining market acceptance of any particular drug candidate that is approved and
could significantly harm our business, results of operations and prospects. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Further, combination therapy, such as using our wholly-owned
drug candidates as well as third-party agents, may involve unique adverse events that could be exacerbated compared with adverse events from monotherapies. Results of our trials could reveal a high and unacceptable severity or prevalence of adverse
events. These types of adverse events could be caused by our drug candidates and could cause us or regulatory authorities to interrupt, delay or halt clinical trials and may result in a more restrictive indication or the delay or denial of
regulatory approval by the NMPA, the FDA or other comparable regulatory authority. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we are unable to obtain the NMPA approval for our drug
candidates to be eligible for an expedited registration pathway as innovative drug candidates, the time and cost we incur to obtain regulatory approvals may increase. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The NMPA has mechanisms in place for expedited review and approval for drug candidates that are innovative drug applications, provided such
drug or drug candidate has a new and clearly defined structure, pharmacological property and apparent clinical value and has not been marketed anywhere in the world. However, there is no assurance that an innovative drug designation will be granted
by the NMPA for any of our drug candidates. Moreover, an innovative drug designation, which is typically granted only towards the end of a drug&#146;s developmental stage, does not increase the likelihood that our drug candidates will receive
regulatory approval on a fast-track basis, or at all. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Further, there have been recent regulatory initiatives in China in relation to
clinical trial approvals, the evaluation and approval of certain drugs and medical devices and the simplification and acceleration of the clinical trial process. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">As a result, the regulatory process in China is evolving and subject to change. Any future policies, or changes to current polices might
require us to change our planned clinical study design or otherwise spend additional resources and effort to obtain approval of our drug candidates. In addition, policy changes may contain significant limitations related to use restrictions for
certain age groups, warnings, precautions or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">32 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
contraindications, or may be subject to burdensome post-approval study or risk management requirements. If we are unable to obtain regulatory approval for our drug candidates in the PRC, or any
approval contains significant limitations, we may not be able to obtain sufficient funding or generate sufficient revenue to continue the development of our drug candidates or any other drug candidate that we may
<FONT STYLE="white-space:nowrap">in-license,</FONT> acquire or develop in the future. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Even if we receive regulatory approval for our drug
candidates, we will be subject to ongoing regulatory obligations and continued regulatory review, which may result in significant additional expenses and we may be subject to penalties if we fail to comply with regulatory requirements or experience
unanticipated problems with our drug candidates. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">If the NMPA, the FDA or a comparable regulatory authority approves any of our
drug candidates, the manufacturing processes, labeling, packaging, distribution, adverse event reporting, storage, advertising, promotion and recordkeeping for the drug will be subject to extensive and ongoing regulatory requirements on
pharmacovigilance. These requirements include submissions of safety and other post-marketing information and reports, registration, random quality control testing, adherence to any chemistry, manufacturing, and controls (&#147;CMC&#148;),
variations, continued compliance with current cGMPs, and GCPs and potential post-approval studies for the purposes of license renewal. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Any regulatory approvals that we receive for our drug candidates may also be subject to limitations on the approved indicated uses for which
the drug may be marketed or to the conditions of approval, or contain requirements for potentially costly post-marketing studies, including Phase 4 studies for the surveillance and monitoring of the safety and efficacy of the drug. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In addition, once a drug is approved by the NMPA, the FDA or a comparable regulatory authority for marketing, it is possible that there could
be a subsequent discovery of previously unknown problems with the drug, including problems with third-party manufacturers or manufacturing processes, or failure to comply with regulatory requirements. If any of the foregoing occurs with respect to
our drug products, it may result in, among other things: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">restrictions on the marketing or manufacturing of the drug, withdrawal of the drug from the market, or voluntary
or mandatory drug recalls; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">fines, warning letters or holds on our clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">refusal by the NMPA, the FDA or comparable regulatory authorities to approve pending applications or supplements
to approved applications filed by us, or suspension or revocation of drug license approvals; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">refusal by the NMPA, the FDA or comparable regulatory authorities to accept any of our other IND approvals, NDAs
or BLAs; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">drug seizure or detention, or refusal to permit the import or export of drugs; and </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">injunctions or the imposition of civil, administrative or criminal penalties. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Any government investigation of alleged violations of law could require us to expend significant time and resources and could generate
negative publicity. Moreover, regulatory policies may change or additional government regulations may be enacted that could prevent, limit or delay regulatory approval of our drug candidates. If we are not able to maintain regulatory compliance, we
may lose the regulatory approvals that we have already obtained and may not achieve or sustain profitability, which in turn could significantly harm our business, financial condition and prospects. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">33 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Illegal and/or parallel imports and counterfeit pharmaceutical products may reduce demand for our
future approved drug candidates and could have a negative impact on our reputation and business. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The illegal importation of
competing products from countries where government price controls or other market dynamics result in lower prices may adversely affect the demand for our future approved drug candidates and, in turn, may adversely affect our sales and profitability
in China and other countries where we commercialize our products. Unapproved foreign imports of prescription drugs are illegal under the current laws of China. However, illegal imports may continue to occur or even increase as the ability of
patients and other customers to obtain these lower priced imports continues to grow. Furthermore, cross-border imports from lower-priced markets (which are known as parallel imports) into higher-priced markets could harm sales of our future drug
products and exert commercial pressure on pricing within one or more markets. In addition, competent government authorities may expand consumers&#146; ability to import lower priced versions of our future approved products or competing products from
outside China or other countries where we operate. Any future legislation or regulations that increase consumer access to lower priced medicines from outside China or other countries where we operate could have a material adverse effect on our
business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Certain products distributed or sold in the pharmaceutical market may be manufactured without proper licenses or approvals, or
be fraudulently mislabeled with respect to their content or manufacturers. These products are generally referred to as counterfeit pharmaceutical products. The counterfeit pharmaceutical product control and enforcement system, particularly in
developing markets such as China, may be inadequate to discourage or eliminate the manufacturing and sale of counterfeit pharmaceutical products imitating our products. Since counterfeit pharmaceutical products in many cases have very similar
appearances compared with the authentic pharmaceutical products but are generally sold at lower prices, counterfeits of our products could quickly erode the demand for our future approved drug candidates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In addition, counterfeit pharmaceutical products are not expected to meet our or our collaborators&#146; rigorous manufacturing and testing
standards. A patient who receives a counterfeit pharmaceutical product may be at risk for a number of dangerous health consequences. Our reputation and business could suffer harm as a result of counterfeit pharmaceutical products sold under our or
our collaborators&#146; brand name(s). In addition, thefts of inventory at warehouses, plants or while <FONT STYLE="white-space:nowrap">in-transit,</FONT> which are not properly stored and which are sold through unauthorized channels, could
adversely impact patient safety, our reputation and our business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Commercialization of Our Drug Candidates </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our drug candidates may fail to achieve the degree of market acceptance by physicians, patients, third-party payors and others in the medical community
necessary for commercial success. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Even if our drug candidates receive regulatory approval, they may nonetheless fail to gain
sufficient market acceptance by physicians and patients and others in the medical community. Physicians and patients may prefer other drugs or drug candidates to ours. If our drug candidates do not achieve an adequate level of acceptance, we may not
generate significant revenue from sales of our drugs or drug candidates and may not become profitable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The degree of market acceptance of
our drug candidates, if and only when they are approved for commercial sale, will depend on a number of factors, including, but not limited to: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the clinical indications for which our drug candidates are approved; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">physicians, hospitals and patients considering our drug candidates as a safe and effective treatment;
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">whether our drug candidates have achieved the perceived advantages of our drug candidates over alternative
treatments; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">34 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the prevalence and severity of any side effects; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">product labeling or package insert requirements of the NMPA, the FDA or other comparable regulatory authorities;
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">limitations or warnings contained in the labeling approved by the NMPA, the FDA or other comparable regulatory
authorities; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">timing of market introduction of our drug candidates as well as competitive drugs; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">cost of treatment in relation to alternative treatments; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">availability of adequate coverage and reimbursement under the national and provincial reimbursement drug lists in
the PRC, or from third-party payors and government authorities in the United States or any other jurisdictions; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">willingness of patients to pay any
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> expenses in the absence of coverage and reimbursement by third-party payors and government authorities; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">relative convenience and ease of administration, including as compared with alternative treatments and
competitive therapies; and </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the effectiveness of our sales and marketing efforts. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">If our drug candidates are approved but fail to achieve market acceptance among physicians, patients, hospitals or others in the medical
community, we will not be able to generate significant revenue or become profitable. Even if our drugs achieve market acceptance, we may not be able to maintain such market acceptance over time if new products or technologies are introduced which
are more favorably received than our drugs, are more cost effective or render our drugs obsolete. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We face intense competition and rapid
technological change and the possibility that our competitors may develop therapies that are similar, more advanced, or more effective than ours, which may adversely affect our financial condition and our ability to successfully commercialize our
drug candidates. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The biotechnology and pharmaceutical industries are intensely competitive and subject to rapid and significant
technological change. While our exclusive focus is to develop drug candidates with potential to become novel or highly differentiated drugs, we continue to face competition with respect to our current drug candidates, and will face competition with
respect to any drug candidates that we may seek to develop or commercialize in the future. Our competitors include major pharmaceutical companies, specialty pharmaceutical companies and biotechnology companies worldwide. We are developing our drug
candidates for the treatment of cancer in competition with a number of large biopharmaceutical companies that currently market and sell drugs or are pursuing the development of drugs also for the treatment of cancer. Some of these competitive drugs
and therapies are based on scientific approaches that are the same as or similar to our approach, and others are based on entirely different approaches. For details, see &#147;Business&#151;Our Drug Pipeline.&#148; Potential competitors further
include academic institutions, government agencies and other public and private research organizations that conduct research, seek patent protection and establish collaborative arrangements for research, development, manufacturing and
commercialization. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Many of our competitors have substantially greater financial, technical, and other resources, such as larger research
and development staff and experienced marketing and manufacturing organizations. Additional mergers and acquisitions in the biotechnology and pharmaceutical industries may result in even more resources being concentrated in our competitors. As a
result, these companies may obtain regulatory approval from the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">35 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
NMPA, the FDA or other comparable regulatory authorities more rapidly than we are able to and may be more effective in selling and marketing their products as well. For example, the NMPA has
recently accelerated market approval of drugs for diseases with high unmet medical need. In particular, the NMPA may review and approve drugs that have gained regulatory market approval in the United States, the European Union or Japan in the recent
ten years without requiring further clinical trials in China. This may lead to potential increased competition from drugs which have already obtained approval in other jurisdictions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large,
established companies. Competition may increase further as a result of advances in the commercial applicability of technologies and greater availability of capital for investment in these industries. Our competitors may succeed in developing,
acquiring, or licensing on an exclusive basis, products that are more effective or less costly than any drug candidate that we may develop, or achieve earlier patent protection, regulatory approval, product commercialization, and market penetration
than we do. Additionally, technologies developed by our competitors may render our potential drug candidates uneconomical or obsolete, and we may not be successful in marketing our drug candidates against competitors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The manufacture of biopharmaceutical products is a complex process which requires significant expertise and capital investment, and if we encounter
problems in establishing our manufacturing capabilities or manufacturing our future products, our business could suffer. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We have
limited experience in managing the manufacturing process. The manufacture of biopharmaceutical products is a complex process, in part due to strict regulatory requirements. As of the date of this prospectus, we have no existing manufacturing
infrastructure or capabilities. We intend to build a comprehensive biologics manufacturing facility in Hangzhou, China (the &#147;Hangzhou Facility&#148;) as part of our strategic plan to become a fully integrated biopharma company. We have taken
concrete steps to execute this plan. These steps include detailed operational planning for the facility, actions taken to secure an appropriate site, and negotiations with external financing providers. The Hangzhou Facility targets to have a pilot
capacity of 2&nbsp;x&nbsp;2,000L by the end of 2021 and commercially progressive capacity up to 8 x 2,000L to begin operation by the end of 2023. Construction is expected to commence in late 2020. However, the investment for building this new
biologics manufacturing facility that is compliant with cGMP regulations will be a significant upfront cost for us. In turn, this could materially harm our commercialization plans. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In addition, problems may arise during the manufacturing process for a variety of reasons, including equipment malfunction, failure to follow
specific protocols and procedures, problems with raw materials, delays related to the construction of new facilities or expansion of any future manufacturing facilities, including changes in manufacturing production sites and limits to manufacturing
capacity due to regulatory requirements, changes in the types of products produced, increases in the prices of raw materials, physical limitations that could inhibit continuous supply, <FONT STYLE="white-space:nowrap">man-made</FONT> or natural
disasters and environmental factors. If problems arise during the production of a batch of future products, that batch of future products may have to be discarded and we may experience product shortages or incur added expenses. This could, among
other things, lead to increased costs, lost revenue, damage to customer relationships, time and expense spent investigating the cause and, depending on the cause, similar losses with respect to other batches or products. If problems are not
discovered before such product is released to the market, recall and product liability costs may also be incurred. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We have no experience in
launching and marketing drug candidates. We may not be able to effectively build and manage our sales network, or benefit from third-party collaborators&#146; sales network. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We currently have no sales, marketing or commercial product distribution capabilities and have no experience in marketing drugs. We intend to
develop an <FONT STYLE="white-space:nowrap">in-house</FONT> marketing organization and sales force, which will require significant capital expenditures, management resources and time. We will have to compete with other biopharmaceutical companies to
recruit, hire, train and retain marketing and sales personnel. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">36 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">If we are unable or decide not to establish internal sales, marketing and commercial
distribution capabilities for any or all of the drugs we develop, we will likely pursue collaborative arrangements regarding the sales and marketing of our drugs. However, there can be no assurance that we will be able to establish or maintain such
collaborative arrangements, or, if we are able to do so, that they will have effective sales forces. Any revenue we receive will depend on the efforts of such third parties, which may not be successful. We may have little or no control over the
marketing and sales efforts of such third parties, and our revenue from product sales may be lower than if we had commercialized our drug candidates ourselves. We will also face competition in our search for third parties to assist us with the sales
and marketing efforts of our drug candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">There can be no assurance that we will be able to develop
<FONT STYLE="white-space:nowrap">in-house</FONT> sales and commercial distribution capabilities or establish or maintain relationships with third-party collaborators to successfully commercialize any product, and as a result, we may not be able to
generate product sales revenue. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Even if we are able to commercialize any approved drug candidates, reimbursement may be limited or unavailable in
certain market segments for our drug candidates, and we may be subject to unfavorable pricing regulations, which could harm our business. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The regulations that govern regulatory approvals, pricing and reimbursement for new therapeutic products vary widely from country to country.
Some countries require approval of the sale price of a drug before it can be marketed. In many countries, the pricing review period begins after marketing or licensing approval is granted. In some <FONT STYLE="white-space:nowrap">non-U.S.</FONT>
markets, prescription pharmaceutical pricing remains subject to continuing governmental control even after initial approval is granted. As a result, we might obtain regulatory approval for a drug in a particular country, but then be subject to price
regulations that delay our commercial launch of the drug and negatively impact the revenues we are able to generate from the sale of the drug in that country. Adverse pricing limitations may hinder our ability to recoup our investment in one or more
drug candidates, even if our drug candidates obtain regulatory approval. For example, according to a statement, Opinions on Reforming the Review and Approval Process for Pharmaceutical Products and Medical Devices, issued by the PRC State Council in
August 2015, the enterprises applying for new drug approval will be required to undertake that the selling price of new drug on PRC mainland market shall not be higher than the comparable market prices of the product in its country of origin or
PRC&#146;s neighboring markets, as applicable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our ability to commercialize any drugs successfully also will depend in part on the extent
to which reimbursement for these drugs and related treatments will be available from government health administration authorities, private health insurers and other organizations. Government authorities and third-party payors, such as private health
insurers and health maintenance organizations, decide which medications they will pay for and establish reimbursement levels. A primary trend in the global healthcare industry is cost containment. Government authorities and these third-party payors
have attempted to control costs by limiting coverage and the amount of reimbursement for particular medications. Increasingly, third-party payors are requiring that companies provide them with predetermined discounts from list prices and are
challenging the prices charged for medical products. We cannot be sure that reimbursement will be available for any drug that we commercialize and, if reimbursement is available, what the level of reimbursement will be. Reimbursement may impact the
demand for, or the price of, any drug for which we obtain regulatory approval. Obtaining reimbursement for our drugs may be particularly difficult because of the higher prices often associated with drugs administered under the supervision of a
physician. If reimbursement is not available or is available only to limited levels, we may not be able to successfully commercialize any drug candidate that we successfully develop. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">There may be significant delays in obtaining reimbursement for approved drug candidates, and coverage may be more limited than the purposes
for which the drug candidates are approved by the NMPA, the FDA or other comparable regulatory authorities. Moreover, eligibility for reimbursement does not imply that any drug will be paid for in all cases or at a rate that covers our costs,
including research, development, manufacture, sale and distribution. Interim payments for new drugs, if applicable, may also not be sufficient to cover our costs and may not be made permanent. Payment rates may vary according to the use of the drug
and the clinical setting in </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">37 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
which it is used, may be based on payments allowed for lower cost drugs that are already reimbursed, and may be incorporated into existing payments for other services. Net prices for drugs may be
reduced by mandatory discounts or rebates required by government healthcare programs or private payors and by any future weakening of laws that presently restrict imports of drugs from countries where they may be sold at lower prices than in the
United States. Our inability to promptly obtain coverage and profitable payment rates from both government-funded and private payors for any future approved drug candidates and any new drugs that we develop could have a material adverse effect on
our business, our operating results, and our overall financial condition. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Current and future legislation may increase the difficulty and cost for
us to obtain marketing approval of and commercialize our drug candidates and affect the prices we may obtain. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In the United
States and certain other jurisdictions, there have been a number of legislative and regulatory changes and proposed changes regarding the healthcare system that could prevent or delay marketing approval of our drug candidates, restrict post-approval
activities and affect our ability to sell profitably any drug candidates for which we obtain marketing approval. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Patient Protection
and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act of 2010, or collectively the ACA, became law. The ACA is a sweeping law intended to broaden access to health insurance, reduce or constrain the growth of
healthcare spending, enhance remedies against fraud and abuse, add new transparency requirements for the healthcare and health insurance industries, impose new taxes and fees on the health industry and impose additional health policy reforms. Among
the provisions of the ACA of importance to our drug candidates are the following: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an annual, nondeductible fee on any entity that manufactures or imports specified branded prescription drugs and
biologic products; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an increase in the statutory minimum rebates a manufacturer must pay under the Medicaid Drug Rebate Program;
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">expansion of healthcare fraud and abuse laws, including the False Claims Act and the Anti-Kickback Statute, new
government investigative powers, and enhanced penalties for noncompliance; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a new Medicare Part D coverage gap discount program, in which manufacturers must agree to offer 50% <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">point-of-sale</FONT></FONT> discounts off negotiated prices; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">extension of manufacturers&#146; Medicaid rebate liability; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">expansion of eligibility criteria for Medicaid programs; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">expansion of the entities eligible for discounts under the Public Health Service Act&#146;s pharmaceutical
pricing program; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">new requirements to report to CMS financial arrangements with physicians and teaching hospitals;
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a new requirement to annually report to the FDA drug samples that manufacturers and distributors provide to
physicians; and </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a new Patient-Centered Outcomes Research Institute to oversee, identify priorities in, and conduct comparative
clinical effectiveness research, along with funding for such research. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Legislative and regulatory proposals have been
made to expand post-approval requirements and restrict sales and promotional activities for pharmaceutical products. We cannot be sure whether additional legislative </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">38 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
changes will be enacted, or whether the FDA regulations, guidance or interpretations will be changed, or what the impact of such changes on the marketing approvals, if any, of our drug candidates
may be. In addition, increased scrutiny by the U.S. Congress of the FDA&#146;s approval process may significantly delay or prevent marketing approval, as well as subject us to more stringent product labeling and post-marketing conditions and other
requirements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>As we <FONT STYLE="white-space:nowrap">out-license</FONT> some of our commercialization rights and engage in other forms of
collaboration worldwide, including conducting clinical trials abroad, we may be exposed to specific risks of conducting our business and operations in international markets. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Markets outside of China form an important component of our growth strategy, as we <FONT STYLE="white-space:nowrap">out-license</FONT> some of
our commercialization rights to third parties outside the PRC and conduct certain of our clinical trials abroad. If we fail to obtain applicable licenses or fail to enter into strategic collaboration arrangements with third parties in these markets,
or if these collaboration arrangements turn out unsuccessful, our revenue-generating growth potential will be adversely affected. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Moreover, international business relationships subject us to additional risks that may materially adversely affect our ability to attain or
sustain profitable operations, including: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">efforts to enter into collaboration or licensing arrangements with third parties in connection with our
international sales, marketing and distribution efforts may increase our expenses or divert our management&#146;s attention from the acquisition or development of drug candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">changes in a specific country&#146;s or region&#146;s political and cultural climate or economic condition;
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">differing regulatory requirements for drug approvals and marketing internationally; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">difficulty of effective enforcement of contractual provisions in local jurisdictions; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">potentially reduced protection for intellectual property rights; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">potential third-party patent rights; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">unexpected changes in tariffs, trade barriers and regulatory requirements; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">economic weakness, including inflation or political instability; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">compliance with tax, employment, immigration and labor laws for employees traveling abroad;
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the effects of applicable <FONT STYLE="white-space:nowrap">non-PRC</FONT> tax structures and potentially adverse
tax consequences; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">currency fluctuations, which could result in increased operating expenses and reduced revenue, and other
obligations incidental to doing business in another country; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">workforce uncertainty and labor unrest; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the potential for <FONT STYLE="white-space:nowrap">so-called</FONT> parallel importing, which is what happens
when a local seller, faced with high or higher local prices, opts to import goods from an international market with low or lower prices rather than buying them locally; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">failure of our employees and contracted third parties to comply with Office of Foreign Assets Control rules and
regulations and the Foreign Corrupt Practices Act of the United States, and other applicable rules and regulations; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">39 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">production shortages resulting from any events affecting raw material supply or manufacturing capabilities
abroad; and </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">business interruptions resulting from <FONT STYLE="white-space:nowrap">geo-political</FONT> actions, including
war and terrorism, or natural disasters, including earthquakes, volcanoes, typhoons, floods, hurricanes and fires. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">These and other risks may materially adversely affect our ability to attain or sustain revenue from international markets. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If safety, efficacy, or other issues arise with any medical product that is used in combination with our drug candidates, we may be unable to market
such drug candidate or may experience significant regulatory delays or supply shortages, and our business could be materially harmed. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We plan to develop certain of our drug candidates for use as a combination therapy. If the NMPA, the FDA or another comparable regulatory
agency revokes its approval of another therapeutic we use in combination with our drug candidates, we will not be able to market our drug candidates in combination with such revoked therapeutic. If safety or efficacy issues arise with these or other
therapeutics that we seek to combine with our drug candidates in the future, we may experience significant regulatory delays, and we may be required to redesign or terminate the applicable clinical trials. In addition, if manufacturing or other
issues result in a supply shortage of any component of our combination drug candidates or if we cannot secure supply of any component of our drug candidates at commercially reasonable or acceptable prices, we may not be able to complete clinical
development of our drug candidates on our current timeline or within our current budget, or at all. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Lack of third-party combination drugs may
materially and adversely affect demand for our drugs. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our drug candidates may be administered in combination with drugs of other
pharmaceutical companies as one regimen. In addition, we often use such third-party drugs in our development and clinical trials as controls for our studies. As a result, both the results of our clinical trials and the sales of our drugs may be
affected by the availability of these third-party drugs. If other pharmaceutical companies discontinue these combination drugs, regimens that use these combination drugs may no longer be prescribed, and we may not be able to introduce or find an
alternative drug to be used in combination with our drugs at all or in a timely manner and on a cost-effective basis. As a result, demand for our drugs may be lowered, which would in turn materially and adversely affect our business and results of
operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Our Reliance on Third Parties </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>As we rely on third parties to conduct our <FONT STYLE="white-space:nowrap">pre-clinical</FONT> studies and clinical trials, if we lose our
relationships with these third parties or if they do not successfully carry out their contractual duties or meet expected deadlines, we may not be able to obtain regulatory approval for or commercialize our drug candidates and our business could be
substantially harmed. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We have relied on and plan to continue to rely on third-party contract research organization
(&#147;CROs&#148;) to monitor and manage data for some of our ongoing <FONT STYLE="white-space:nowrap">pre-clinical</FONT> and clinical programs. We rely on these parties for the execution of our <FONT STYLE="white-space:nowrap">pre-clinical</FONT>
and clinical trials, and control only certain aspects of their activities. Nevertheless, we are responsible for ensuring that each of our studies is conducted in accordance with the applicable protocol and legal, regulatory and scientific standards,
and our reliance on the CROs does not relieve us of our regulatory responsibilities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We also rely on third parties to assist in
conducting our <FONT STYLE="white-space:nowrap">pre-clinical</FONT> studies in accordance with Good Laboratory Practices (&#147;GLP&#148;). We and our CROs are required to comply with GCP, GLP and other regulatory regulations and guidelines enforced
by the NMPA, the FDA and comparable foreign regulatory authorities for all of our drug candidates in clinical development. Regulatory authorities enforce these GCP, GLP or other </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">40 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
regulatory requirements through periodic inspections of trial sponsors, investigators and trial sites. If we or any of our CROs fail to comply with applicable GCP, GLP or other regulatory
requirements, the relevant data generated in our clinical trials may be deemed unreliable and the NMPA, the FDA or other comparable regulatory authorities may require us to perform additional clinical studies before approving our marketing
applications. There can be no assurance that upon inspection by a given regulatory authority, such regulatory authority will determine that any of our clinical trials complies with GCP requirements. In addition, our clinical trials must be conducted
with drug candidates or products produced under cGMP requirements. Failure to comply with these regulations may require us to repeat <FONT STYLE="white-space:nowrap">pre-clinical</FONT> and clinical trials, which would delay the regulatory approval
process. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our CROs have the right to terminate their agreements with us in the event of an unrectified material breach. If any of our
relationships with our third-party CROs is terminated, we may not be able to (i)&nbsp;enter into arrangements with alternative CROs or do so on commercially reasonable terms or (ii)&nbsp;meet our desired clinical development timelines. In addition,
there is a natural transition period when a new CRO commences work, and the new CRO may not provide the same type or level of services as the original provider and data from our clinical trials may be compromised as a result. There is also a need
for relevant technology to be transferred to the new CRO, which may take time and further delay our development timelines. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Except for
remedies available to us under our agreements with our CROs, we cannot control whether or not our CROs devote sufficient time and resources to our ongoing clinical, nonclinical and <FONT STYLE="white-space:nowrap">pre-clinical</FONT> programs. If
our CROs do not successfully carry out their contractual duties or obligations or meet expected deadlines or if the quality or accuracy of the clinical data they obtain is compromised due to their failure to adhere to our clinical protocols,
regulatory requirements or for other reasons, our clinical trials may be extended, delayed or terminated and we may not be able to obtain regulatory approval for or successfully commercialize our drug candidates. As a result, our results of
operations and the commercial prospects for our drug candidates would be harmed and our costs could increase. In turn, our ability to generate revenues could be delayed or compromised. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Because we rely on third parties, our internal capacity to perform these functions is limited. Outsourcing these functions involves certain
risks that third parties may not perform to our standards, may not produce results in a timely manner or may fail to perform at all. In addition, the use of third-party service providers requires us to disclose our proprietary information to these
third parties, which could increase the risk that such information will be misappropriated. We currently have a small number of employees, which limits the internal resources we have available to identify and monitor our third-party service
providers. To the extent we are unable to identify and successfully manage the performance of third-party service providers in the future, our business may be adversely affected. Though we carefully manage our relationships with our CROs, there can
be no assurance that we will not encounter similar challenges or delays in the future or that these delays or challenges will not have a material adverse impact on our business, financial condition and prospects. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We expect to rely on third parties to manufacture at least a portion of our drug candidate supplies, and we intend to rely on third parties for at least
a portion of the manufacturing process of our drug candidates, if approved. Our business could be harmed if those third parties fail to provide us with sufficient quantities of product or fail to do so at acceptable quality levels or prices.
</I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Although we plan to either construct or acquire a facility that will be used as our clinical-scale manufacturing and processing
facility, we intend to also partially rely on third-party vendors to manufacture supplies and process our drug candidates. We have not yet manufactured or processed our drug candidates on a commercial scale and may not be able to do so for any of
our drug candidates. We have limited experience in managing the manufacturing process, and our process may be more difficult or expensive than the approaches currently in use. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">41 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our anticipated reliance on third-party manufacturers exposes us to certain risks,
including, but not limited to, the following: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may be unable to identify manufacturers on acceptable terms or at all because the number of potential
manufacturers is limited and the NMPA, the FDA or other comparable regulatory authorities must approve any manufacturers as part of their regulatory oversight of our drug candidates. This approval would require new testing and cGMP-compliance
inspections by the NMPA, the FDA or other comparable regulatory authorities. In addition, a new manufacturer would have to be educated in, or develop substantially equivalent processes for, production of our drugs; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our contract manufacturers may have little or no experience with manufacturing our drug candidates, and therefore
may require a significant amount of support from us in order to implement and maintain the infrastructure and processes required to manufacture our drug candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our contract manufacturers may have limited capacity or limited manufacturing slots, which may affect the
timeline for the production of our drugs; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our contract manufacturers might be unable to timely manufacture our drug candidates or produce the quantity and
quality required to meet our clinical and commercial needs, if any; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">contract manufacturers may not be able to execute our manufacturing procedures and other logistical support
requirements appropriately; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our future contract manufacturers may not perform as agreed, may not devote sufficient resources to our drugs, or
may not remain in the contract manufacturing business for the time required to supply our clinical trials or to successfully produce, store and distribute our drugs; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our contract manufacturers are subject to ongoing periodic unannounced inspections by the NMPA and the FDA to
ensure strict compliance with cGMP and other government regulations in the PRC and the United States, respectively, and by other comparable regulatory authorities for corresponding regulatory requirements. We do not have control over third-party
manufacturers&#146; compliance with these regulations and requirements; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may not own, or may have to share, the intellectual property rights to any improvements made by our
third-party manufacturers in the manufacturing process for our drugs; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our contract manufacturers could breach or terminate their agreements with us; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our contract manufacturers may be unable to sustain their business and become bankrupt as a result;
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">raw materials and components used in the manufacturing process, particularly those for which we have no other
source or supplier, may not be available or may not be suitable or acceptable for use due to material or component defects; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">products and components from our third-party manufacturers may be subject to additional customs and import
charges, which may cause us to incur delays or additional costs as a result; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our contract manufacturers and critical reagent suppliers may be subject to inclement weather, as well as natural
or <FONT STYLE="white-space:nowrap">man-made</FONT> disasters; and </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our contract manufacturers may have unacceptable or inconsistent product quality success rates and yields.
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">42 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Each of these risks could delay or prevent the completion of our clinical trials or the
approval of any of our drug candidates by the NMPA, the FDA or other comparable regulatory authorities, result in higher costs or adversely impact the commercialization of our drug candidates. In addition, we will rely on third parties to perform
certain specification tests on our drug candidates prior to delivery to patients. If these tests are not appropriately done and test data is not reliable, patients could be put at risk of serious harm and the NMPA, the FDA or other comparable
regulatory authorities could place significant restrictions on our company until deficiencies are remedied. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The manufacture of
biopharmaceutical products is complex and requires significant expertise and capital investment, including the development of advanced manufacturing techniques and process controls. Currently, our drug raw materials for our manufacturing activities
are supplied by multiple source suppliers. We have agreements for the supply of drug materials with manufacturers or suppliers that we believe have sufficient capacity to meet our demands. In addition, we believe that adequate alternative sources
for such supplies exist. However, there is a risk that, if supplies are interrupted, our business would be materially harmed. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Manufacturers of biopharmaceutical products often encounter difficulties in production, particularly in scaling up or out, validating the
production process, and assuring high reliability of the manufacturing process, including the absence of contamination. These problems include logistics and shipping, difficulties with production costs and yields, quality control, including
stability of the product, product testing, operator error and availability of qualified personnel, as well as compliance with strictly enforced regulations in the PRC, the United States and other applicable jurisdictions. Further, if contaminants
are discovered in the supply of our drug candidates or in the manufacturing facilities, such manufacturing facilities may need to be closed for an extended period of time for us to investigate and remedy the contamination. There can be no assurance
that any stability failures or other issues relating to the manufacture of our drug candidates will not occur in the future. Additionally, our contract manufacturers may experience manufacturing difficulties due to resource constraints or as a
result of labor disputes or unstable political environment. If our contract manufacturers were to encounter any of these difficulties, or otherwise fail to comply with their contractual obligations, our ability to provide our drug candidate to
patients in clinical trials would be jeopardized. Any delay or interruption in the supply of clinical trial supplies could delay the completion of our clinical trials, increase the costs associated with maintaining clinical trial programs and,
depending upon the period of delay, require us to begin new clinical trials at additional expense or terminate clinical trials completely. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We have
entered into collaborations and may form or seek collaborations or strategic alliances or enter into additional licensing arrangements in the future, and we may not realize the benefits of such alliances or licensing arrangements. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We may form or seek strategic alliances, create joint ventures or collaborations, or enter into additional licensing arrangements with third
parties that we believe will complement or augment our development and commercialization efforts with respect to our drug candidates and any future drug candidates that we may develop. Any of these relationships may require us to incur recurring or <FONT
STYLE="white-space:nowrap">non-recurring</FONT> expenses and other charges, increase our near and long-term expenditures, issue securities that dilute the value of our ADSs, or disrupt our management and business. For example, we have entered into a
license and collaboration agreement with MorphoSys AG (&#147;MorphoSys&#148;), pursuant to which we <FONT STYLE="white-space:nowrap">in-licensed</FONT> from MorphoSys the development and commercialization rights of felzartamab in Greater China.
Another example is our collaboration with AbbVie. In September 2020, we granted AbbVie a global license, excluding Mainland China, Hong Kong and Macau, to develop and commercialize lemzoparlimab (as well as certain other compounds directed against
CD47), and we will retain all rights to develop and commercialize lemzoparlimab in Mainland China, Hong Kong and Macau. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The effectiveness
of the contract with AbbVie is subject to our performance of certain contractual obligations and regulatory approval; such approval may not be obtained or may be delayed, which could result in a detrimental effect on our collaboration. For a more
detailed discussion, please see &#147;Business&#151;Our Global Strategic Collaborations&#151;Global Strategic Partnership with AbbVie.&#148; In addition, we face significant </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">43 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
competition in seeking appropriate strategic partners and the negotiation process is time-consuming and complex. Moreover, we may not be successful in our efforts to establish a strategic
partnership or other alternative arrangements for our drug candidates because they may be deemed to be at too early a stage of development for collaborative effort and third parties may not view our drug candidates as having the requisite potential
to demonstrate safety and efficacy. If and when we collaborate with a third party for the development and commercialization of a drug candidate, we can expect to relinquish some or all of the control over the future success of that drug candidate to
the third party. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Further, collaborations involving our drug candidates are subject to specific risks, which include, but are not limited
to, the following: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">collaborators have significant discretion in determining the efforts and resources that they will apply to a
collaboration; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">collaborators may not pursue the development and commercialization of our drug candidates or may elect not to
continue or renew the development or commercialization programs based on clinical trial results, change in their strategic focus due to the acquisition of competitive drugs, availability of funding, or other external factors, such as a business
combination that diverts resources or creates competing priorities; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">collaborators may delay clinical trials, provide insufficient funding for a clinical trial, discontinue a
clinical trial, repeat or conduct new clinical trials, or require a new formulation of a drug candidate for clinical testing; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">collaborators could independently develop, or develop with third parties, drugs that compete directly or
indirectly with our drug candidates or future drugs; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">collaborators with marketing and distribution rights to one or more of our drug candidates or future drugs may
not commit sufficient resources to their marketing and distribution; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">collaborators may not properly maintain or defend our intellectual property rights or may use our intellectual
property or proprietary information in a way that gives rise to actual or threatened litigation that could jeopardize or invalidate our intellectual property or proprietary information or expose us to potential liability; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">collaborators may not always be cooperative or responsive in providing their services in a clinical trial;
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">disputes may arise between us and a collaborator that cause a delay or termination of the research, development
or commercialization of our drug candidates, or that result in costly litigation or arbitration that diverts management attention and resources; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">collaborations may be terminated and, if terminated, may result in a need for additional capital to pursue
further development or commercialization of the applicable drug candidates; and </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">collaborators may own or <FONT STYLE="white-space:nowrap">co-own</FONT> intellectual property covering our drug
candidates or future drugs that results from our collaborating with them, and in such cases, we would not have the exclusive right to commercialize such intellectual property. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">As a result, if we enter into collaboration agreements and strategic partnerships or license our drugs, we may not be able to realize the
benefit of such transactions if we are unable to successfully integrate these agreements or partnerships with our existing operations and company culture, which could delay our timelines or otherwise adversely affect our business. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">44 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Neither can we be certain that, following a strategic transaction or license, we will be
able to achieve the revenue or specific net income that justifies such transaction. If we are unable to reach agreements with suitable collaborators on a timely basis, on acceptable terms, or at all, we may have to curtail the development of a drug
candidate, reduce or delay its development program or one or more of our other development programs, delay its potential commercialization or reduce the scope of any sales or marketing activities, or increase our expenditures and undertake
development or commercialization activities at our own expense. If we elect to fund and undertake development or commercialization activities on our own, we may need to obtain additional expertise and additional capital, which may not be available
to us on acceptable terms or at all. If we fail to enter into collaborations and do not have sufficient funds or expertise to undertake the necessary development and commercialization activities, we may not be able to further develop our drug
candidates or bring them to market and generate product sales revenue, which would harm our business, financial condition, results of operations and prospects. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Our Intellectual Property </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we
are unable to obtain and maintain patent and other intellectual property protection for our drug candidates, or if the scope of such intellectual property rights obtained is not sufficiently broad, third parties could develop and commercialize
products and technologies similar or identical to ours and compete directly against us, and our ability to successfully commercialize any product or technology may be adversely affected. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our success depends in large part on our ability to protect our proprietary technology and drug candidates from competition by obtaining,
maintaining, defending and enforcing our intellectual property rights, including patent rights. As of September&nbsp;30, 2020, our owned patent portfolio consists of 11 issued patents and 223 patent applications primarily in connection with the drug
candidates in our Global Portfolio, including 12&nbsp;Patent Cooperation Treaty (&#147;PCT&#148;) patent applications, 16 U.S. patent applications, 18 PRC patent applications and 177 patent applications in other jurisdictions. In addition, as of
September&nbsp;30, 2020, we <FONT STYLE="white-space:nowrap">in-licensed</FONT> the Greater China and Korea rights relating to 22 issued patents and 34 pending patent applications primarily in connection with felzartamab, eftansomatropin,
olamkicept, enoblituzumab and efineptakin. We seek to protect the drug candidates and technology that we consider commercially important by filing patent applications in China, the United States and other countries or regions, relying on trade
secrets or pharmaceutical regulatory protection or employing a combination of these methods. This process is expensive and time-consuming, and we or our licensors may not be able to file and prosecute all necessary or desirable patent applications
in all jurisdictions at a reasonable cost or in a timely manner. It is also possible that we or our licensors will fail to identify patentable aspects of our research and development output before it is too late to obtain patent protection. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The patent position of biotechnology and pharmaceutical companies generally is highly uncertain, involves complex legal and factual questions
and has in recent years been the subject of much litigation. As a result, the issuance, scope, validity, enforceability and commercial value of our patent rights are highly uncertain. Our pending and future patent applications may not result in
patents being issued which protect our technology or drug candidates or which effectively prevent others from commercializing competitive technologies and drug candidates. The patent examination process may require us or our licensors to narrow the
scope of the claims of our or our licensors&#146; pending and future patent applications, which may limit the scope of patent protection that may be obtained. We cannot assure that all of the potentially relevant prior art relating to our patents
and patent applications has been found. If such prior art exists, it can invalidate a patent or prevent a patent application from being issued as a patent. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Even if patents do issue on any of these applications, there can be no assurance that a third party will not challenge their validity,
enforceability, or scope, which may result in the patent claims being narrowed or invalidated, or that we will obtain sufficient claim scope in those patents to prevent a third party from competing successfully with our drug candidates. We may
become involved in interference, inter partes review, post grant review, ex parte reexamination, derivation, opposition or similar other proceedings challenging our patent rights </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">45 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
or the patent rights of others. An adverse determination in any such proceeding could reduce the scope of, or invalidate, our patent rights, allow third parties to commercialize our technology or
drug candidates and compete directly with us, or result in our inability to manufacture or commercialize drug candidates without infringing third-party patent rights. Thus, even if our patent applications issue as patents, they may not issue in a
form that will provide us with any meaningful protection, prevent competitors from competing with us or otherwise provide us with any competitive advantage. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our competitors may be able to circumvent our patents by developing similar or alternative technologies or drug candidates in a <FONT
STYLE="white-space:nowrap">non-infringing</FONT> manner. The issuance of a patent is not conclusive as to its scope, validity or enforceability, and our owned and licensed patents may be challenged in the courts or patent offices in the United
States and other countries. Such challenges may result in patent claims being narrowed, invalidated or held unenforceable, which could limit our ability to stop or prevent us from stopping others from using or commercializing similar or identical
technology and drug candidates, or limit the duration of the patent protection of our technology and drug candidates. Given the amount of time required for the development, testing and regulatory review of new drug candidates, patents protecting
such assets might expire before or shortly after such assets are commercialized. As a result, our patent portfolio may not provide us with sufficient rights to exclude others from commercializing drug candidates similar or identical to ours. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Changes in either the patent laws or interpretation of the patent laws in the United States and other countries may diminish the value of our
patents or narrow the scope of our patent protection. Under the America Invents Act (&#147;AIA&#148;) enacted in 2011, the United States moved to this <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-to-file</FONT></FONT>
system in early 2013 from the previous system under which the first to make the claimed invention was entitled to the patent. Assuming the other requirements for patentability are met, the first to file a patent application is entitled to the
patent. Publications of discoveries in the scientific literature often lag behind the actual discoveries, and patent applications in the United States and other jurisdictions are typically not published until 18 months after filing, or in some cases
not at all. Therefore, we cannot be certain that we were the first to make the inventions claimed in our patents or pending patent applications, or that we were the first to file for patent protection of such inventions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We enjoy only limited geographical protection with respect to certain patents and may not be able to protect our intellectual property rights throughout
the world, including in the PRC. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Filing and prosecuting patent applications and defending patents covering our drug candidates in
all countries throughout the world could be prohibitively expensive. Competitors may use our and our licensors&#146; technologies in jurisdictions where we have not obtained patent protection to develop their own drug candidates and, further, may
export otherwise infringing drug candidates to territories, including the PRC, where we and our licensors have patent protection, but enforcement rights are not as strong as that in the United States or Europe. These drug candidates may compete with
our drug candidates, and our and our licensors&#146; patents or other intellectual property rights may not be effective or sufficient to prevent them from competing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The laws of some jurisdictions, including the PRC, do not protect intellectual property rights to the same extent as the laws or rules and
regulations in the United States and Europe, and many companies have encountered significant difficulties in protecting and defending such rights in such jurisdictions. The legal systems of certain countries, particularly certain developing
countries, do not favor the enforcement of patents, trade secrets and other intellectual property protection, which could make it difficult for us to stop the infringement of our patents or marketing of competing drug candidates in violation of our
proprietary rights generally. Proceedings to enforce our patent rights in other jurisdictions, whether or not successful, could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our
patents at risk of being invalidated or interpreted narrowly and our patent applications at risk of not issuing as patents, and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate and the
damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">46 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
commercial advantage from the intellectual property that we develop or license. Furthermore, while we intend to protect our intellectual property rights in our expected significant markets, we
cannot ensure that we will be able to initiate or maintain similar efforts in all jurisdictions in which we may wish to market our drug candidates. Accordingly, our efforts to protect our intellectual property rights in such countries may be
inadequate, which may have an adverse effect on our ability to successfully commercialize our drug candidates in all of our expected significant foreign markets. If we or our licensors encounter difficulties in protecting, or are otherwise precluded
from effectively protecting, the intellectual property rights important for our business in such jurisdictions, the value of these rights may be diminished and we may face additional competition from others in those jurisdictions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Some countries also have compulsory licensing laws under which a patent owner may be compelled to grant licenses to third parties. In
addition, some countries limit the enforceability of patents against government agencies or government contractors. In those countries, the patent owner may have limited remedies, which could materially diminish the value of such patents. If we or
any of our licensors is forced to grant a license to third parties with respect to any patents relevant to our business, our competitive position may be impaired. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment, and other requirements
imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for <FONT STYLE="white-space:nowrap">non-compliance</FONT> with these requirements. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Periodic maintenance and annuity fees on any issued patent are due to be paid to the United States Patent and Trademark Office
(&#147;USPTO&#148;) and foreign patent agencies over the lifetime of a patent. In addition, the USPTO and other foreign patent agencies require compliance with a number of procedural, documentary, fee payment, and other similar provisions during the
patent application process. While an inadvertent failure to make payment of such fees or to comply with such provisions can in many cases be cured by payment of a late fee or by other means in accordance with the applicable rules, there are
situations in which such <FONT STYLE="white-space:nowrap">non-compliance</FONT> will result in the abandonment or lapse of the patent or patent application, and the partial or complete loss of patent rights in the relevant jurisdiction. <FONT
STYLE="white-space:nowrap">Non-compliance</FONT> events that could result in abandonment or lapse of a patent or patent application include failure to respond to official actions within prescribed time limits, and
<FONT STYLE="white-space:nowrap">non-payment</FONT> of fees and failure to properly legalize and submit formal documents within prescribed time limits. If we or our licensors fail to maintain the patents and patent applications covering our drug
candidates or if we or our licensors otherwise allow our patents or patent applications to be abandoned or lapse, our competitors might be able to enter the market, which would hurt our competitive position and could impair our ability to
successfully commercialize our drug candidates in any indication for which they are approved. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our owned and
<FONT STYLE="white-space:nowrap">in-licensed</FONT> patents and other intellectual property may be subject to further priority disputes or to inventorship disputes and similar proceedings. If we or our licensors are unsuccessful in any of these
proceedings, we may be required to obtain licenses from third parties, which may not be available on commercially reasonable terms or at all, or to modify or cease the development, manufacture and commercialization of one or more of the drug
candidates we may develop, which could have a material adverse impact on our business. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We or our licensors may be subject to
claims that former employees, collaborators or other third parties have an interest in our owned or <FONT STYLE="white-space:nowrap">in-licensed</FONT> patents or other intellectual property as an inventor or
<FONT STYLE="white-space:nowrap">co-inventor.</FONT> If we or our licensors are unsuccessful in any interference proceedings or other priority or validity disputes (including any patent oppositions) to which we or they are subject, we may lose
valuable intellectual property rights through the loss of one or more patents owned or licensed or our owned or licensed patent claims may be narrowed, invalidated, or held unenforceable. In addition, if we or our licensors are unsuccessful in any
inventorship disputes to which we or they are subject, we may lose valuable intellectual property rights, such as exclusive ownership of, or the exclusive right to use, our owned or <FONT STYLE="white-space:nowrap">in-licensed</FONT> patents. If we
or our licensors are unsuccessful in any interference proceeding or other priority or inventorship dispute, we may be required to obtain and maintain licenses from third parties, including parties involved in any such interference proceedings
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">47 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
or other priority or inventorship disputes. Such licenses may not be available on commercially reasonable terms or at all, or may be <FONT STYLE="white-space:nowrap">non-exclusive.</FONT> If we
are unable to obtain and maintain such licenses, we may need to modify or cease the development, manufacture, and commercialization of one or more of our drug candidates. The loss of exclusivity or the narrowing of our owned and licensed patent
claims could limit our ability to stop others from using or commercializing similar or identical drug products. Any of the foregoing could result in a material adverse effect on our business, financial condition, results of operations, or prospects.
Even if we are successful in an interference proceeding or other similar priority or inventorship disputes, it could result in substantial costs and be a distraction to our management and other employees. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Claims that our drug candidates or the sale or use of our future products infringe, misappropriate or otherwise violate the patents or other
intellectual property rights of third parties could result in costly litigation or could require substantial time and money to resolve, even if litigation is avoided. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We cannot guarantee that our drug candidates or the sale or use of our future products do not and will not in the future infringe,
misappropriate or otherwise violate third-party patents or other intellectual property rights. Third parties might allege that we are infringing their patent rights or that we have misappropriated their trade secrets, or that we are otherwise
violating their intellectual property rights, whether with respect to the manner in which we have conducted our research, or with respect to the use or manufacture of the compounds we have developed or are developing. Litigation relating to patents
and other intellectual property rights in the biopharmaceutical and pharmaceutical industries is common, including patent infringement lawsuits. The various markets in which we plan to operate are subject to frequent and extensive litigation
regarding patents and other intellectual property rights. Some claimants may have substantially greater resources than we have and may be able to sustain the costs of complex intellectual property litigation to a greater degree and for longer
periods of time than we could. Third parties might resort to litigation against us or other parties we have agreed to indemnify, which litigation could be based on either existing intellectual property or intellectual property that arises in the
future. For example, we are aware of a third-party U.S. patent and its counterpart European patents that relate to the use of antibodies having specificity to <FONT STYLE="white-space:nowrap">PD-L1</FONT> to treat cancer. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">It is also possible that we failed to identify, or may in the future fail to identify, relevant patents or patent applications held by third
parties that cover our drug candidates. Publication of discoveries in the scientific or patent literature often lags behind actual discoveries. Therefore, we cannot be certain that we were the first to invent, or the first to file patent
applications on, our drug candidates or for their uses, or that our drug candidates will not infringe patents that are currently issued or that are issued in the future. In the event that a third party has also filed a patent application covering
one of our drug candidates or a similar invention, our patent application may be regarded as a competing application and may not be approved in the end. Additionally, pending patent applications that have been published can, subject to certain
limitations, be later amended in a manner that could cover our products or their use. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">If a third party were to assert claims of patent
infringement against us, even if we believe such third-party claims are without merit, a court of competent jurisdiction could hold that these third-party patents are valid, enforceable and infringed, and the holders of any such patents may be able
to block our ability to commercialize the applicable product unless we obtained a license under the applicable patents, or until such patents expire or are finally determined to be invalid or unenforceable. Similarly, if any third-party patents were
held by a court of competent jurisdiction to cover aspects of our compositions, formulations, or methods of treatment, prevention, or use, the holders of any such patents may be able to block our ability to develop and commercialize the applicable
product unless we obtained a license or until such patent expires or is finally determined to be invalid or unenforceable. In addition, defending such claims would cause us to incur substantial expenses and could cause us to pay substantial damages,
if we are found to be infringing a third party&#146;s patent rights. These damages potentially include increased damages and attorneys&#146; fees if we are found to have infringed such rights willfully. In order to avoid or settle potential claims
with respect to any patent or other intellectual property rights of third parties, we may choose or be required to seek a license from a third party and be required to pay license fees or royalties or both, which could be substantial. These licenses
may not be </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">48 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
available on acceptable terms, or at all. Even if we were able to obtain a license, the rights may be nonexclusive, which could result in our competitors gaining access to the same intellectual
property. Ultimately, we could be prevented from commercializing a drug candidate, or be forced, by court order or otherwise, to modify or cease some or all aspects of our business operations, if, as a result of actual or threatened patent or other
intellectual property claims, we are unable to enter into licenses on acceptable terms. Further, we could be found liable for significant monetary damages as a result of claims of intellectual property infringement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Defending against claims of patent infringement, misappropriation of trade secrets or other violations of intellectual property rights could
be costly and time-consuming, regardless of the outcome. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be
compromised by disclosure during this type of litigation. Thus, even if we were to ultimately prevail, or to settle at an early stage, such litigation could burden us with substantial unanticipated costs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Issued patents covering one or more of our drug candidates could be found invalid or unenforceable if challenged in court. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Despite measures we take to obtain and maintain patent and other intellectual property rights with respect to our drug candidates, our
intellectual property rights could be challenged or invalidated. For example, if we were to initiate legal proceedings against a third party to enforce a patent covering one of our drug candidates, the defendant could counterclaim that our patent is
invalid and/or unenforceable. Grounds for a validity challenge could be an alleged failure to meet any of several statutory requirements, for example, lack of novelty, obviousness or <FONT STYLE="white-space:nowrap">non-enablement.</FONT> Grounds
for an unenforceability assertion could be an allegation that someone connected with prosecution of the patent withheld relevant information from the USPTO, SIPO, or the applicable foreign counterpart, or made a misleading statement, during
prosecution. Although we believe that we have conducted our patent prosecution in accordance with a duty of candor and in good faith, the outcome following legal assertions of invalidity and unenforceability during patent litigation is
unpredictable. If a defendant were to prevail on a legal assertion of invalidity and/or unenforceability, we would lose at least part, and perhaps all, of the patent protection on a drug candidate. Even if a defendant does not prevail on a legal
assertion of invalidity and/or unenforceability, our patent claims may be construed in a manner that would limit our ability to enforce such claims against the defendant and others. Even if we establish infringement, the court may decide not to
grant an injunction against further infringing activity and instead award only monetary damages, which may not be an adequate remedy. In addition, if the breadth or strength of protection provided by our patents is threatened, it could dissuade
companies from collaborating with us to license, develop, or commercialize our current or future drug candidates. Any loss of patent protection could have a material adverse impact on one or more of our drug candidates and our business. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Enforcing our intellectual property rights against third parties may also cause such third parties to file other counterclaims against us,
which could be costly to defend and could require us to pay substantial damages, cease the sale of certain drugs or enter into a license agreement and pay royalties (which may not be possible on commercially reasonable terms or at all). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Intellectual property litigation may lead to unfavorable publicity which may harm our reputation and cause the market price of our ADSs to decline, and
any unfavorable outcome from such litigation could limit our research and development activities and/or our ability to commercialize our drug candidates. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">During the course of any intellectual property litigation, there could be public announcements of the results of hearings, rulings on motions,
and other interim proceedings in the litigation. If securities analysts or investors regard these announcements as negative, the perceived value of our drug candidates, future drugs, programs or intellectual property could be diminished.
Accordingly, the market price of our ADSs may decline. Such announcements could also harm our reputation or the market for our drug candidates, which could have a material adverse effect on our business. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">49 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In the event of intellectual property litigation, there can be no assurance that we would
prevail, even if the case against us is weak or flawed. If third parties successfully assert their intellectual property rights against us, prohibitions against using certain technologies, or prohibitions against commercializing our drug candidates,
could be imposed by a court or by a settlement agreement between us and a plaintiff. In addition, if we are unsuccessful in defending against allegations that we have infringed, misappropriated or otherwise violated the patent or other intellectual
property rights of others, we may be forced to pay substantial damage awards to the plaintiff. Additionally, we may be required to obtain a license from the intellectual property owner in order to continue our research and development programs or to
commercialize any resulting product. It is possible that the necessary license will not be available to us on commercially acceptable terms, or at all. This may not be technically or commercially feasible, may render our products less competitive,
or may delay or prevent the launch of our products to the market. Any of the foregoing could limit our research and development activities, our ability to commercialize one or more drug candidates, or both. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Most of our competitors are larger than we are and have substantially greater resources. They are, therefore, likely to be able to sustain the
costs of complex intellectual property litigation longer than we could. In addition, the uncertainties associated with litigation could have a material adverse effect on our ability to raise the funds necessary to conduct our clinical trials,
continue our internal research programs, <FONT STYLE="white-space:nowrap">in-license</FONT> needed technology, or enter into strategic partnerships that would help us bring our drug candidates to market. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In addition, any future intellectual property litigation, interference or other administrative proceedings will result in additional expense
and distraction of our personnel. An adverse outcome in such litigation or proceedings may expose us or any future strategic partners to loss of our proprietary position, expose us to significant liabilities, or require us to seek licenses that may
not be available on commercially acceptable terms, if at all, each of which could have a material adverse effect on our business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Changes in patent
law could diminish the value of patents in general, thereby impairing our ability to protect our drug candidates. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">As is the case
with other biopharmaceutical companies, our success is heavily dependent on intellectual property, particularly patent rights. Obtaining and enforcing patents in the biopharmaceutical industry involves both technological and legal complexity, and is
therefore costly, time-consuming, and inherently uncertain. In addition, the United States has recently enacted and is implementing wide-ranging patent reform legislation. Recent U.S. Supreme Court rulings have narrowed the scope of patent
protection available in certain circumstances and weakened the rights of patent owners in certain situations. In addition to increasing uncertainty with regard to our ability to obtain patents in the future, this combination of events has created
uncertainty with respect to the value of patents once obtained, if any. Depending on decisions by the U.S. Congress, the federal courts and the USPTO, the laws and regulations governing patents could change in unpredictable ways that would weaken
our ability to obtain new patents or to enforce our existing patents and patents that we might obtain in the future. For example, in a recent case, <I>Assoc. for Molecular Pathology v.&nbsp;Myriad Genetics, Inc.</I>, the U.S. Supreme Court held that
certain claims to naturally-occurring substances are not patentable. Although we do not believe that our currently issued patents and any patents that may issue from our pending patent applications directed to our drug candidates if issued in their
currently pending forms, as well as patent rights licensed by us, will be found invalid based on this decision, we cannot predict how future decisions by the courts, the U.S. Congress or the USPTO may impact the value of our patent rights. There
could be similar changes in the laws of foreign jurisdictions that may impact the value of our patent rights or our other intellectual property rights. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">50 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we are unable to protect the confidentiality of our trade secrets, our business and competitive
position would be harmed. We also may be subject to claims that our employees, consultants, or advisers have wrongfully used or disclosed alleged trade secrets of their former employers or claims asserting ownership of what we regard as our own
intellectual property. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In addition to our issued patents and pending patent applications, we rely on trade secret and
confidential information, including unpatented <FONT STYLE="white-space:nowrap">know-how,</FONT> technology and other proprietary information, to maintain our competitive position and to protect our drug candidates. We seek to protect this trade
secret and confidential information, in part, by entering into <FONT STYLE="white-space:nowrap">non-disclosure</FONT> and confidentiality agreements with parties that have access to them, such as our employees, corporate collaborators, outside
scientific collaborators, sponsored researchers, contract manufacturers, consultants, advisers and other third parties. We also enter into confidentiality and invention or patent assignment agreements with our employees and consultants. However, any
of these parties may breach such agreements and disclose our proprietary information, and we may not be able to obtain adequate remedies for such breaches. Enforcing a claim that a party illegally disclosed or misappropriated a trade secret can be
difficult, expensive and time-consuming, and the outcome is unpredictable. If any of our trade secrets were to be lawfully obtained or independently developed by a competitor or other third party, we would have no right to prevent them from using
that technology or information to compete with us and our competitive position would be harmed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Furthermore, many of our employees,
consultants, and advisers, including our senior management, were previously employed at other biotechnology or pharmaceutical companies, including our competitors or potential competitors. Some of these employees, consultants, and advisers,
including members of our senior management, executed proprietary rights, <FONT STYLE="white-space:nowrap">non-disclosure</FONT> and <FONT STYLE="white-space:nowrap">non-competition</FONT> agreements in connection with such previous employment.
Although we try to ensure that our employees do not use the proprietary information or <FONT STYLE="white-space:nowrap">know-how</FONT> of others in their work for us, we may be subject to claims that we or these employees have used or disclosed
intellectual property, including trade secrets or other proprietary information, of any such individual&#146;s former employer. We are not aware of any threatened or pending claims related to these matters or concerning the agreements with our
senior management, but in the future litigation may be necessary to defend against such claims. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel. Even if
we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management. In addition, while we typically require our employees, consultants and contractors who may be involved in the
development of intellectual property to execute agreements assigning such intellectual property to us, we may be unsuccessful in executing such an agreement with each party who in fact develops intellectual property that we regard as our own, and
furthermore, the assignment of intellectual property rights may not be self-executing, or the assignment agreements may be breached, each of which may result in claims by or against us related to the ownership of such intellectual property. If we
fail in prosecuting or defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights. Even if we are successful in prosecuting or defending against such claims, litigation could result in
substantial costs, be a distraction to our management and scientific personnel and have a material adverse effect on our business, financial condition, results of operations and prospects. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may not be successful in obtaining or maintaining necessary rights for our development pipeline through acquisitions and <FONT
STYLE="white-space:nowrap">in-licenses.</FONT> </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Because our programs may involve additional drug candidates that may require the
use of proprietary rights held by third parties, the growth of our business may depend in part on our ability to acquire and maintain licenses or other rights to use these proprietary rights. We may be unable to acquire or <FONT
STYLE="white-space:nowrap">in-license</FONT> any compositions, methods of use, or other intellectual property rights from third parties that we identify. The licensing and acquisition of third-party intellectual property rights is a competitive
area, and a number of more established companies are also pursuing strategies to license or acquire third-party intellectual property rights that we may consider attractive or necessary. These established companies may have a competitive advantage
over us due to their size, cash resources and greater clinical development and commercialization capabilities. In </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">51 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
addition, companies that perceive us to be a competitor may be unwilling to assign or license rights to us. We also may be unable to license or acquire third-party intellectual property rights on
terms that would allow us to make an appropriate return on our investment or at all. If we are unable to successfully obtain rights to required third-party intellectual property rights or maintain the existing intellectual property rights we have,
we may have to abandon development of the relevant program or drug candidate, which could have a material adverse effect on our business, financial condition, results of operations and prospects for growth. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our rights to develop and commercialize our drug candidates are subject, in part, to the terms and conditions of licenses granted to us by others.
</I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We rely on licenses to certain patent rights and other intellectual property from third parties that are important or necessary
to the development of our drug candidates. These and other licenses may not provide exclusive rights to use such intellectual property in all relevant fields of use and in all territories in which we may wish to develop or commercialize our drug
products. As a result, we may not be able to prevent competitors from developing and commercializing competitive drug products in territories included in all of our licenses. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We may not have the right to control the preparation, filing, prosecution, maintenance, enforcement, and defense of patents and patent
applications covering the drug candidates that we license from third parties. Moreover, we have not had and do not have primary control over these activities for certain of our patents or patent applications and other intellectual property rights
that we jointly own with certain of our licensors and <FONT STYLE="white-space:nowrap">sub-licensors.</FONT> Therefore, we cannot be certain that these patents and patent applications will be prepared, filed, prosecuted, maintained, enforced, and
defended in a manner consistent with the best interests of our business. If our licensors fail to prosecute, maintain, enforce and defend such patents, or lose rights to those patents or patent applications, the rights we have licensed may be
reduced or eliminated, and our right to develop and commercialize any of our drugs that are subject of such licensed rights could be adversely affected. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Pursuant to the terms of the license agreements with some of our licensors, the licensors may have the right to control enforcement of our
licensed patents or defense of any claims asserting the invalidity or unenforceability of these patents. Even if we are permitted to pursue the enforcement or defense of our licensed patents, we will require the cooperation of our licensors and any
applicable patent owners and such cooperation may not be provided to us. We cannot be certain that our licensors will allocate sufficient resources or prioritize their or our enforcement of such patents or defense of such claims to protect our
interests in the licensed patents. Even if we are not a party to these legal actions, an adverse outcome could harm our business because it might prevent us from continuing to license intellectual property that we may need to operate our business.
If we lose any of our licensed intellectual property, our right to develop and commercialize any of our drug candidates that are subject of such licensed rights could be adversely affected. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In addition, our licensors may have relied on third party consultants or collaborators or on funds from third parties such that our licensors
are not the sole and exclusive owners of the patents we <FONT STYLE="white-space:nowrap">in-license.</FONT> This could have a material adverse effect on our competitive position, business, financial conditions, results of operations, and prospects.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In spite of our best efforts, our licensors might conclude that we have materially breached our license agreements and might therefore
terminate the license agreements, thereby removing our ability to develop and commercialize drug products covered by these license agreements. If such licenses are terminated, we may be required seek alternative
<FONT STYLE="white-space:nowrap">in-license</FONT> arrangements, which may not be available on commercially reasonable terms or at all, or may be <FONT STYLE="white-space:nowrap">non-exclusive.</FONT> If these
<FONT STYLE="white-space:nowrap">in-licenses</FONT> are terminated, or if the underlying patents fail to provide the intended exclusivity, we may need to modify or cease the development, manufacture, and commercialization of one or more of our drug
candidates and competitors would have the freedom to seek regulatory approval of, and to market, products identical to ours. In addition, we may seek to obtain additional licenses from our licensors and, in connection with obtaining such licenses,
we may agree to amend our existing licenses in a manner that may be more favorable to the licensors, including by agreeing to terms that could enable third parties </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">52 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
(potentially including our competitors) to receive licenses to a portion of the intellectual property that is subject to our existing licenses. Any of these events could have a material adverse
effect on our competitive position, business, financial conditions, results of operations, and prospects. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we fail to comply with our obligations
in the agreements under which we license intellectual property rights from third parties or otherwise experience disruptions to our business relationships with our licensors, we could be required to pay monetary damages or could lose license rights
that are important to our business. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our business relies, in large part, on our ability to develop and commercialize drug
candidates we have licensed from third parties, and we have entered into license agreements with third parties providing us with rights to various third-party intellectual property, including rights in patents and patent applications. Our licenses
may not encumber all intellectual property rights owned or controlled by the affiliates of our licensors and relevant to our drug candidates, and we may need to obtain additional licenses from our existing licensors and others to advance our
research or allow commercialization of drug candidates we may develop. In such case, we may need to obtain additional licenses which may not be available on an exclusive basis, on commercially reasonable terms or at a reasonable cost, if at all. In
that event, we may be required to expend significant time and resources to redesign our drug candidates or the methods for manufacturing them or to develop or license replacement technology, all of which may not be feasible on a technical or
commercial basis. If we are unable to do so, we may be unable to develop or commercialize the affected drug candidates, which could harm our business, financial condition, results of operations, and prospects significantly. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In addition, if our licensors breach the license agreements, we may not be able to enforce such agreements against our licensors&#146; parent
entity or affiliates. Under each of our license and intellectual property-related agreements, in exchange for licensing or sublicensing us the right to develop and commercialize the applicable drug candidates, our licensors will be eligible to
receive from us milestone payments, tiered royalties from commercial sales of such drug candidates, assuming relevant approvals from government authorities are obtained, or other payments. Our license and intellectual property-related agreements
also require us to comply with other obligations including development and diligence obligations, providing certain information regarding our activities with respect to such drug candidates and/or maintaining the confidentiality of information we
receive from our licensors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">If we fail to comply with our obligations under our current or future license agreements, our counterparties
may have the right to terminate these agreements and, upon the effective date of such termination, have the right to <FONT STYLE="white-space:nowrap">re-obtain</FONT> the licensed and <FONT STYLE="white-space:nowrap">sub-licensed</FONT> technology
and intellectual property. If any of our licensors terminate any of our licenses, we might not be able to develop, manufacture or market any drug or drug candidate that is covered by the licenses provided for under these agreements and other third
parties may be able to market drug candidates similar or identical to ours. In such case, we may have to negotiate new or reinstated agreements with less favorable terms, and may be required to provide a grant back license to the licensors under our
own intellectual property with respect to the terminated products. We may also face claims for monetary damages or other penalties under these agreements. While we would expect to exercise all rights and remedies available to us, including seeking
to cure any breach by us, and otherwise seek to preserve our rights under the intellectual property rights licensed and sublicensed to us, we may not be able to do so in a timely manner, at an acceptable cost or at all. In particular, some of the
milestone payments are payable upon our drug candidates reaching development milestones before we have commercialized, or received any revenue from, sales of such drug candidate, and we cannot guarantee that we will have sufficient resources to make
such milestone payments. Any uncured, material breach under the license agreements could result in our loss of exclusive rights and may lead to a complete termination of our rights to the applicable drug candidate. Any of the foregoing could have a
material adverse effect on our business, financial conditions, results of operations, and prospects. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">It is possible that we may be unable
to obtain any additional licenses at a reasonable cost or on reasonable terms, if at all. Certain of our license agreements also require us to meet development thresholds to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">53 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
maintain the license, including establishing a set timeline for developing and commercializing products. Disputes may arise regarding intellectual property subject to a license agreement,
including: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the scope of rights granted under the license agreement and other interpretation-related issues;
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the extent to which our technology and processes infringe, misappropriate or violate intellectual property of the
licensor that is not subject to the license agreement; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the sublicensing of patent and other rights under our collaborative development relationships;
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our diligence obligations under the license agreement and what activities satisfy those diligence obligations;
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the inventorship and ownership of inventions and <FONT STYLE="white-space:nowrap">know-how</FONT> resulting from
the joint creation or use of intellectual property by our licensors and us and our partners; and </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the priority of invention of patented technology. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In addition, the agreements under which we license intellectual property or technology from third parties are complex, and certain provisions
in such agreements may be susceptible to multiple interpretations. The resolution of any contract interpretation disagreement that may arise could narrow what we believe to be the scope of our rights to the relevant intellectual property or
technology, or increase what we believe to be our financial or other obligations under the relevant agreement, either of which could have a material adverse effect on our business, financial condition, results of operations, and prospects. Moreover,
if disputes over intellectual property that we have licensed prevent or impair our ability to maintain our current licensing arrangements on commercially acceptable terms, we may be unable to successfully develop and commercialize the affected drug
candidates, which could have a material adverse effect on our business, financial condition, results of operations and prospects. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Intellectual
property rights do not necessarily protect us from all potential threats to our competitive advantage. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The degree of future
protection afforded by our intellectual property rights is uncertain because intellectual property rights have limitations, and may not adequately protect our business, or permit us to maintain our competitive advantage. The following examples are
illustrative: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">others may be able to make compounds that are similar to our drug candidates but that are not covered by the
claims of the patents that we own or have exclusively licensed; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we might not have been the first to make the inventions covered by the issued patents or pending patent
applications that we own or may in the future exclusively license, which could result in the patents applied for not being issued or being invalidated after issuing; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we might not have been the first to file patent applications covering certain of our inventions, which could
result in the patents applied for not being issued or being invalidated after issuing; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">others may independently develop similar or alternative technologies or duplicate any of our technologies without
infringing our intellectual property rights; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">it is possible that our pending patent applications will not lead to issued patents; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">issued patents that we own or have exclusively licensed may not provide us with any competitive advantages, or
may be held invalid or unenforceable, as a result of legal challenges by our competitors or other third parties; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">54 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may obtain patents for certain compounds many years before we receive regulatory approval for drugs containing
such compounds, and because patents have a limited life, which may begin to run prior to the commercial sale of the related drugs, the commercial value of our patents may be limited; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our competitors might conduct research and development activities in countries where we do not have patent rights
and then use the information learned from such activities to develop competitive drugs for commercialization in our major markets; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may fail to develop additional proprietary technologies that are patentable; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may fail to apply for or obtain adequate intellectual property protection in all the jurisdictions in which we
operate; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">third parties may gain unauthorized access to our intellectual property due to potential lapses in our
information systems; and </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the patents of others may have an adverse effect on our business, for example by preventing us from
commercializing one or more of our drug candidates for one or more indications. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Any of the aforementioned threats to
our competitive advantage could have a material adverse effect on our business and future prospects. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If our trademarks and trade names are not
adequately protected, we may not be able to build name recognition in our markets of interest and our competitive position may be adversely affected. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We own registered trademarks. We may not be able to obtain trademark protection in territories that we consider of significant importance to
us. In addition, any of our trademarks or trade names, whether registered or unregistered, may be challenged, opposed, infringed, cancelled, circumvented or declared generic, or determined to be infringing on other marks, as applicable. We may not
be able to protect our rights to these trademarks and trade names, which we will need to build name recognition by potential collaborators or customers in our markets of interest. Over the long term, if we are unable to establish name recognition
based on our trademarks and trade names, we may not be able to compete effectively and our business may be adversely affected. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Terms of our future
patents may not be sufficient to effectively protect our drug candidates and business. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In many countries where we file
applications for patents, the term of an issued patent is generally 20&nbsp;years from the earliest claimed filing date of a <FONT STYLE="white-space:nowrap">non-provisional</FONT> patent application in the applicable country. Although various
extensions may be available, the life of a patent and the protection it affords are limited. Even if we obtain patents covering our drug candidates, we may still be open to competition from other companies, as well as generic medications once the
patent life has expired for a drug. While there are patent regulations in the PRC in respect of regulatory data protection of new drugs containing new chemical components, there are currently no other clear mechanisms providing patent term extension
or patent linkages for other drugs in the PRC. Therefore, it is possible that a lower-cost generic drug can emerge onto the market much more quickly. PRC regulators have set out a framework for integrating patent linkage and data exclusivity into
the PRC regulatory regime, as well as for establishing a pilot program for patent term extension. This framework will require adoption of regulations to be implemented, although no such regulations have been issued to date. These factors may result
in weaker protection for us against generic competition in the PRC than could be available to us in other jurisdictions, such as the United States. In addition, patents which we expect to obtain in the PRC may not be eligible to be extended for
patent terms lost during clinical trials and the regulatory review process. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">If we are unable to obtain patent term extensions or if such
extensions are less than requested for, our competitors may obtain approval of competing products following our patent expirations and our business, financial condition, results of operations and prospects could be materially harmed as a result.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">55 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we do not obtain additional protection under the Hatch-Waxman Amendments and similar legislation in
other countries extending the terms of our patents, if issued, relating to our drug candidates, our business may be materially harmed. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Depending upon the timing, duration and specifics of FDA regulatory approval for our drug candidates, one or more of our U.S. patents, if
issued, may be eligible for limited patent term restoration under the Drug Price Competition and Patent Term Restoration Act of 1984 (the &#147;Hatch-Waxman Amendments&#148;). The Hatch-Waxman Amendments permit a patent term extension of up to five
years as compensation for patent term lost during drug development and the FDA regulatory review process. Patent term extensions, however, cannot extend the remaining term of a patent beyond a total of 14 years from the date of drug approval by the
FDA, and only one patent can be extended for a particular drug. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The application for patent term extension is subject to approval by the
USPTO, in conjunction with the FDA. We may not be granted an extension because of, for example, failing to apply within applicable deadlines, failing to apply prior to expiration of relevant patents or otherwise failing to satisfy applicable
requirements. Moreover, the applicable time period or the scope of patent protection afforded could be less than we request. If we are unable to obtain a patent term extension for a given patent or the term of any such extension is less than we
request, the period during which we will have the right to exclusively market our drug will be shortened and our competitors may obtain earlier approval of competing drugs, and our ability to generate revenues could be materially adversely affected.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Our Industry, Business and Operations </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our future success depends on our ability to attract, retain and motivate senior management and qualified scientific employees. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We are highly dependent on the expertise of the members of our research and development team, as well as the principal members of our
management. We have entered into employment agreements with our executive officers, but each of them may terminate their employment with us at any time with prior written notice. In addition, we currently do not have
<FONT STYLE="white-space:nowrap">&#147;key-man&#148;</FONT> insurance for any of our executive officers or other key personnel. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Recruiting, retaining and motivating qualified management, scientific, clinical, manufacturing and sales and marketing personnel will also be
critical to our success. The loss of the services of our executive officers or other key employees could impede the achievement of our research, development and commercialization objectives and seriously harm our ability to successfully implement
our business strategy. Further, replacing executive officers and key employees may be difficult and may take an extended period of time because of the limited number of individuals in our industry with the breadth of skills and experience required
to successfully develop, gain regulatory approval of and commercialize drugs. Competition to hire from this limited pool is intense, and we may be unable to hire, train, retain or motivate these key personnel on acceptable terms given the
competition among numerous biopharmaceutical companies for similar personnel. We also experience competition for the hiring of scientific and clinical personnel from universities and research institutions. In addition, our management will be
required to devote significant time to new compliance initiatives from our status as a public company, which may require us to recruit more management personnel. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We will need to increase the size and capabilities of our organization, and we may experience difficulties in managing our growth. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We expect to experience significant growth in the number of our employees and consultants and the scope of our operations, particularly in the
areas of clinical development, regulatory affairs and business development. To manage our anticipated future growth, we must continue to implement and improve our managerial, operational and financial systems, expand our facilities and continue to
recruit and train additional </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">56 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
qualified personnel. Due to our limited financial resources, we may not be able to effectively manage the expansion of our operations or recruit and train additional qualified personnel. The
expansion of our operations may lead to significant costs and may divert our management and business development resources. Any inability to manage growth could delay the execution of our business plans or disrupt our operations, and have a material
adverse effect on our business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The data and information that we gather in our research and development process could be inaccurate or incomplete,
which could harm our business, reputation, financial condition and results of operations. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We collect, aggregate, process, and
analyze data and information from our <FONT STYLE="white-space:nowrap">pre-clinical</FONT> studies, manufacturing technology development programs and clinical programs. We also engage in substantial information gathering following the identification
of a promising drug candidate. Because data in the healthcare industry is fragmented in origin, inconsistent in format, and often incomplete, the overall quality of data collected or accessed in the healthcare industry is often subject to challenge,
the degree or amount of data which is knowingly or unknowingly absent or omitted can be material, and we often discover data issues and errors when monitoring and auditing the quality of our data. If we make mistakes in the capture, input, or
analysis of these data, our ability to advance the development of our drug candidates may be materially harmed and our business, prospects and reputation may suffer. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We also engage in the procurement of regulatory approvals necessary for the development and commercialization of our products under
development, for which we manage and submit data to governmental entities. These processes and submissions are governed by complex data processing and validation policies and regulations. Notwithstanding such policies and regulations, interim, <FONT
STYLE="white-space:nowrap">top-line</FONT> or preliminary data from our clinical trials that we announce or publish from time to time may change as more patient data become available and are subject to audit and verification procedures that could
result in material changes in the final data, in which case we may be exposed to liability to a customer, court or government agency that concludes that our storage, handling, submission, delivery, or display of health information or other data was
wrongful or erroneous. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Although we maintain insurance coverage for clinical trials, this coverage may prove to be inadequate or could
cease to be available to us on acceptable terms, if at all. Even unsuccessful claims could result in substantial costs and diversion of management time, attention, and resources. A claim brought against us that is uninsured or under-insured could
harm our business, financial condition and results of operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In addition, we rely on CROs, our partners and other third parties to
monitor and manage data for some of our ongoing <FONT STYLE="white-space:nowrap">pre-clinical</FONT> and clinical programs and control only certain aspects of their activities. If any of our CROs, our partners or other third parties do not perform
to our standards in terms of data accuracy or completeness, data from those <FONT STYLE="white-space:nowrap">pre-clinical</FONT> and clinical trials may be compromised as a result, and our reliance on these parties does not relieve us of our
regulatory responsibilities. For a detailed discussion, see &#147;&#151;Risks Related to Our Reliance on Third Parties&#151;As we rely on third parties to conduct our <FONT STYLE="white-space:nowrap">pre-clinical</FONT> studies and clinical trials,
if we lose our relationships with these third parties or if they do not successfully carry out their contractual duties or meet expected deadlines, we may not be able to obtain regulatory approval for or commercialize our drug candidates and our
business could be substantially harmed&#148; above. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may be subject to liability lawsuits arising from our clinical trials. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We currently carry liability insurance covering our clinical trials. Although we maintain such insurance, any claim that may be brought
against us could result in a court judgment or settlement in an amount that is not covered, in whole or in part, by our insurance or which is in excess of the limits of our insurance coverage. Our insurance policies also contain various exclusions,
and we may be subject to particular liability claims for which we have no coverage. We will have to pay any amount awarded by a court or negotiated in a settlement that exceed our coverage limitations or that are not covered by our insurance, and we
may not have, or be able to obtain, sufficient capital to pay such amounts. In addition, if we cannot successfully defend ourselves against </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">57 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
such claims, we may incur substantial liabilities and be required to suspend or delay our ongoing clinical trials. Even a successful defense would require significant financial and management
resources. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Regardless of the merits or eventual outcome, liability claims may result in significant negative consequences to our business
and prospects, including, but not limited to: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">decreased demand for our drug candidates or any resulting products; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">injury to our reputation; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">withdrawal of other clinical trial participants; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">costs to defend the related litigation; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a diversion of our management&#146;s time and resources; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">substantial monetary awards to trial participants or patients; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">inability to commercialize our drug candidates; and </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a decline in the market price of our ADSs. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We have limited insurance coverage, and any claims beyond our insurance coverage may result in our incurring substantial costs and a diversion of
resources. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We maintain insurance policies that are required under PRC laws and regulations as well as insurance based on our
assessment of our operational needs and industry practice. We also maintain liability insurance covering our clinical trials. In line with industry practice in the PRC, we have elected not to maintain certain types of insurances, such as business
interruption insurance or <FONT STYLE="white-space:nowrap">key-man</FONT> insurance. Our insurance coverage may be insufficient to cover any claim for product liability, damage to our fixed assets or employee injuries. Any liability or damage to, or
caused by, our facilities or our personnel beyond our insurance coverage may result in our incurring substantial costs and a diversion of resources. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Disruptions in the financial markets and economic conditions could affect our ability to raise capital. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Global economies could suffer dramatic downturns as the result of a deterioration in the credit markets and related financial crisis as well
as a variety of other factors including, extreme volatility in security prices, severely diminished liquidity and credit availability, ratings downgrades of certain investments and declining valuations of others. In the past, governments have taken
unprecedented actions in an attempt to address and rectify these extreme market and economic conditions by providing liquidity and stability to the financial markets. If these actions are not successful, the return of adverse economic conditions may
cause a significant impact on our ability to raise capital, if needed, on a timely basis and on acceptable terms or at all. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In addition,
there is considerable uncertainty over the long-term effects of the expansionary monetary and fiscal policies adopted by the central banks and financial authorities of some of the world&#146;s leading economies, including the United States and
China. There have been concerns over unrest and terrorist threats in the Middle East, Europe and Africa and over the conflicts involving Ukraine, Syria and North Korea. There have also been concerns on the relationship among China and other Asian
countries, which may result in or intensify potential conflicts in relation to territorial disputes or the trade related disputes between the United States and China. In addition, the impact of the decision by the United Kingdom to withdraw from the
European Union, commonly referred to as &#147;Brexit&#148;, and the resulting effect on the political and economic future of the U.K. and the European Union is uncertain. Brexit could adversely affect European and worldwide economic and market
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">58 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
conditions and could contribute to instability in global financial and foreign exchange markets. It is unclear whether these challenges and uncertainties will be contained or resolved, and what
effects they may have on the global political and economic conditions in the long term. It is unclear whether these challenges and uncertainties will be contained or resolved, and what effects they may have on the global political and economic
conditions in the long term. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our employees, independent contractors, consultants, commercial partners and vendors may engage in misconduct or other
improper activities, including <FONT STYLE="white-space:nowrap">non-compliance</FONT> with regulatory standards and requirements. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We are exposed to the risk of fraud, misconduct or other illegal activities by our employees, independent contractors, consultants, commercial
partners and vendors. Misconduct by these parties could include intentional, reckless and negligent conduct that fails to: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">comply with the laws of the NMPA, the FDA and other comparable regulatory authorities; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">provide true, complete and accurate information to the NMPA, the FDA and other comparable regulatory authorities;
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">comply with manufacturing standards we have established; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">comply with healthcare fraud and abuse laws in the PRC, the United States and similar fraudulent misconduct laws
in other applicable jurisdictions; or </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">report financial information or data accurately or to disclose unauthorized activities to us.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">For example, our founder, Dr.&nbsp;Jingwu Zhang Zang, was the corresponding author of a research paper prepared by
scientists at GSK China&#146;s research center and published in Nature Medicine in 2010. The paper was retracted in 2013 as a result of misrepresentation of certain data for which Dr.&nbsp;Zang admitted his management oversight, accepted the
responsibility as the corresponding author and coordinated the retraction of the paper. In addition, Dr.&nbsp;Zang received a warning letter from the FDA in March 1999 relating to the lack of IND approval before the initiation of a clinical research
study in human subjects. For details, please see &#147;Management&#151;Certain Past Incidents.&#148; We cannot assure you that there will not be any inquiries, investigations or other actions against Dr.&nbsp;Zang by any regulatory or government
authorities or any negative publicity against Dr.&nbsp;Zang or us regarding these incidents, any of which could distract Dr.&nbsp;Zang and our management&#146;s attention and negatively affect our business and results of operations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">If we obtain approval of any of our drug candidates and begin commercializing those drugs in the PRC, the United States or other applicable
jurisdictions, our potential exposure under the laws of such jurisdictions will increase significantly and our costs associated with compliance with such laws are also likely to increase. These laws may impact, among other things, our current
activities with principal investigators and research patients, as well as future sales, marketing and education programs. In particular, the promotion, sales and marketing of healthcare items and services, as well as certain business arrangements in
the healthcare industry, are subject to extensive laws designed to prevent fraud, kickbacks, self-dealing and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion,
structuring and commission(s), certain customer incentive programs and other business arrangements generally. Activities subject to these laws also involve the improper use of information obtained in the course of patient recruitment for clinical
trials, which could result in regulatory sanctions and cause serious harm to our reputation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">It is not always possible to identify and
deter misconduct by employees and other parties, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other
actions or lawsuits stemming from a </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">59 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
failure to comply with these laws or regulations. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have
a significant impact on our business, including the imposition of significant fines or other sanctions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we engage in future acquisitions or
strategic partnerships, this may increase our capital requirements, dilute the value of your investment in our ADSs, cause us to incur debt or assume contingent liabilities, and subject us to other risks. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We may evaluate various acquisitions and strategic partnerships, including licensing or acquiring complementary products, intellectual
property rights, technologies or businesses. Any potential acquisition or strategic partnership may entail numerous risks, including, but not limited to: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">increased operating expenses and cash requirements; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the assumption of additional indebtedness or contingent liabilities; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the issuance of our equity securities; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">assimilation of operations, intellectual property and products of an acquired company, including difficulties
associated with integrating new personnel; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the diversion of our management&#146;s attention from our existing product programs and initiatives in pursuing
such a strategic merger or acquisition; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">retention of key employees, the loss of key personnel, and uncertainties in our ability to maintain key business
relationships; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">risks and uncertainties associated with the assimilation of operations, corporate culture and personnel of the
acquired business; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">risks and uncertainties associated with the other party to such a transaction, including the prospects of that
party and its existing drugs or drug candidates and regulatory approvals; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our inability to generate revenue from acquired technology and/or products sufficient to meet our objectives in
undertaking the acquisition or even to offset the associated acquisition and maintenance costs; and </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">changes in accounting principles relating to recognition and measurement of our investments that may have a
significant impact on our financial results. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In addition, if we undertake acquisitions, we may issue dilutive
securities, assume or incur debt obligations, incur large <FONT STYLE="white-space:nowrap">one-time</FONT> expenses and acquire intangible assets that could result in significant future amortization expense. Moreover, we may not be able to locate
suitable acquisition opportunities and this inability could impair our ability to grow or obtain access to technology or products that may be important to the development of our business. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we fail to comply with applicable anti-bribery laws, our reputation may be harmed and we could be subject to penalties and significant expenses that
have a material adverse effect on our business, financial condition and results of operations. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We are subject to anti-bribery
laws in China that generally prohibit companies and their intermediaries from making payments to government officials for the purpose of obtaining or retaining business or securing any </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">60 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
other improper advantage. In addition, although currently our primary operating business is in China, we are subject to the Foreign Corrupt Practices Act (the &#147;FCPA&#148;). The FCPA
generally prohibits us from making improper payments to <FONT STYLE="white-space:nowrap">non-U.S.</FONT> officials for the purpose of obtaining or retaining business. Although we have policies and procedures designed to ensure that we, our employees
and our agents comply with anti-bribery laws, there is no assurance that such policies or procedures will prevent our agents, employees and intermediaries from engaging in bribery activities. Failure to comply with anti-bribery laws could disrupt
our business and lead to severe criminal and civil penalties, including imprisonment, criminal and civil fines, loss of our export licenses, suspension of our ability to do business with the government, denial of government reimbursement for our
products and/or exclusion from participation in government healthcare programs. Other remedial measures could include further changes or enhancements to our procedures, policies, and controls and potential personnel changes and/or disciplinary
actions, any of which could have a material adverse effect on our business, financial condition, results of operations and liquidity. We could also be adversely affected by any allegation that we violated such laws. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Any failure to comply with applicable regulations and industry standards or obtain various licenses and permits could harm our reputation and our
business, results of operations and prospects. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">A number of governmental agencies or industry regulatory bodies in the PRC, the
United States and other applicable jurisdictions impose strict rules, regulations and industry standards governing biopharmaceutical research and development activities, which apply to us. Our or our CROs&#146; failure to comply with such
regulations could result in the termination of ongoing research, administrative penalties imposed by regulatory bodies or the disqualification of data for submission to regulatory authorities. This could harm our business, reputation, prospects for
future work and results of operations. For example, if we or our CROs were to treat research animals inhumanely or in violation of international standards set out by the Association for Assessment and Accreditation of Laboratory Animal Care, it
could revoke any such accreditation and the accuracy of our animal research data could be questioned. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we or our CROs or other contractors or
consultants fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur costs that could have a material adverse effect on the success of our business. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We and third parties, such as our CROs or other contractors or consultants, are subject to numerous environmental, health and safety laws and
regulations, including those governing laboratory procedures and the handling, use, storage, treatment and disposal of hazardous materials and wastes. Our operations involve the use of hazardous and flammable materials, including chemicals and
radioactive and biological materials. Our operations also produce hazardous waste products. We generally contract with third parties for the disposal of these materials and wastes. We cannot eliminate the risk of contamination or injury from these
materials. In the event of contamination or injury resulting from our use of hazardous materials, we could be held liable for any resulting damages, and any liability could exceed our resources. We also could incur significant costs associated with
civil or criminal fines and penalties. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Although we maintain workers&#146; compensation insurance to cover us for costs and expenses we
may incur due to injuries to our employees resulting from the use of or exposure to hazardous materials, this insurance may not provide adequate coverage against potential liabilities. We do not maintain insurance for environmental liability or
toxic tort claims that may be asserted against us in connection with our storage, use or disposal of biological, hazardous or radioactive materials. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In addition, we may be required to incur substantial costs to comply with current or future environmental, health and safety laws and
regulations. These current or future laws and regulations may impair our research, development or production efforts. Failure to comply with these laws and regulations also may result in substantial fines, penalties or other sanctions. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">61 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we face allegations of <FONT STYLE="white-space:nowrap">non-compliance</FONT> with laws and
encounter sanctions, our reputation, revenues and liquidity may suffer, and our drug candidates and future drugs could be subject to restrictions or withdrawal from the market. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Any government investigation of alleged violations of laws could require us to expend significant time and resources in response, and could
generate negative publicity. Any failure to comply with ongoing regulatory requirements may significantly and adversely affect our ability to commercialize and generate revenues from our drugs. If regulatory sanctions are applied or if regulatory
approval is withdrawn, the value of our company and our operating results will be adversely affected. Additionally, if we are unable to generate revenues from our product sales, our potential for achieving profitability will be diminished and the
capital necessary to fund our operations will be increased. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our internal computer systems, or those used by our CROs or other contractors or
consultants, may fail or suffer security breaches. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Although to our knowledge we have not experienced any material system failure
or security breach to date, if such an event were to occur and cause interruptions in our operations, it could result in a material disruption of our development programs and our business operations. For example, the loss of clinical trial data from
completed or future clinical trials could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. Likewise, we partially rely on our third-party research institution collaborators
for research and development of our drug candidates and other third parties for the manufacture of our drug candidates and to conduct clinical trials, and similar events relating to their computer systems could also have a material adverse effect on
our business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">To the extent that any disruption or security breach were to result in a loss of, or damage to, our data or applications,
or inappropriate disclosure of confidential or proprietary information, we could incur liability and the further development and commercialization of our drug candidates could be delayed. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Failure to comply with existing or future laws and regulations related to privacy or data security could lead to government enforcement actions, which
could include civil or criminal fines or penalties, private litigation, other liabilities, and/or adverse publicity. Compliance or the failure to comply with such laws could increase the costs of our products and services, could limit their use or
adoption, and could otherwise negatively affect our operating results and business. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The regulatory framework for the collection,
use, safeguarding, sharing, transfer and other processing of personal information worldwide is rapidly evolving and is likely to remain uncertain for the foreseeable future. Regulatory authorities in virtually every jurisdiction in which we operate
have implemented and are considering a number of legislative and regulatory proposals concerning personal data protection. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Regulatory
authorities in China have implemented and are considering a number of legislative and regulatory proposals concerning data protection. For example, China&#146;s Cyber Security Law, which became effective in June 2017, created China&#146;s first
national-level data protection for &#147;network operators,&#148; which may include all organizations in China that provide services over the internet or another information network. Numerous regulations, guidelines and other measures are expected
to be adopted under the umbrella of the Cyber Security Law. Drafts of some of these measures have now been published, including the draft rules on cross-border transfers published by the China Cyberspace Administration in 2017, which may, upon
enactment, require security review before transferring human health-related data out of China. In addition, certain industry-specific laws and regulations affect the collection and transfer of personal data in China. For example, the PRC State
Council promulgated Regulations on the Administration of Human Genetic Resources (effective in July 2019), which require approval from the Science and Technology Administration Department of the State Council where human genetic resources, or HGR,
are involved in any international collaborative project and additional approval for any export or cross-border transfer of the HGR samples or associated data. It is possible that these laws may </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">62 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
be interpreted and applied in a manner that is inconsistent with our practices, potentially resulting in confiscation of HGR samples and associated data, administrative fines and criminal
liabilities. In addition, the interpretation and application of data protection laws in China and elsewhere are often uncertain and in flux. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In the United States, we are subject to laws and regulations that address privacy, personal information protection and data security at both
the federal and state levels. Numerous laws and regulations, including security breach notification laws, health information privacy laws, and consumer protection laws, govern the collection, use, disclosure and protection of health-related and
other personal information. Given the variability and evolving state of these laws, we face uncertainty as to the exact interpretation of the new requirements, and we may be unsuccessful in implementing all measures required by regulators or courts
in their interpretation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Regulatory authorities in Europe have implemented and are considering a number of legislative and regulatory
proposals concerning data protection. For example, the General Data Protection Regulation (EU) 2016/679, or GDPR, which became effective in May 2018, imposes a broad range of strict requirements on companies subject to the GDPR, such as us,
including, but not limited to, requirements relating to having legal bases for processing personal information relating to identifiable individuals and transferring such information outside the European Economic Area (including to the United
States), providing details to those individuals regarding the processing of their personal information, keeping personal information secure, having data processing agreements with third parties who process personal information, responding to
individuals&#146; requests to exercise their rights in respect of their personal information, reporting security breaches involving personal data to the competent national data protection authority and affected individuals, and recordkeeping. The
GDPR substantially increases the penalties to which we could be subject in the event of any <FONT STYLE="white-space:nowrap">non-compliance,</FONT> including fines of up to 10,000,000 Euros or up to 2% of our total worldwide annual turnover for
certain comparatively minor offenses, or up to 20,000,000 Euros or up to 4% of our total worldwide annual turnover for more serious offenses. Given the new law, we face uncertainty as to the exact interpretation of the new requirements, and we may
be unsuccessful in implementing all measures required by data protection authorities or courts in interpretation of the new law. National laws of member states of the European Union are in the process of being adapted to the requirements under the
GDPR. Because the GDPR specifically gives member states flexibility with respect to certain matters, national laws may partially deviate from the GDPR and impose different obligations from country to country, leading to additional complexity and
uncertainty. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We expect that we will continue to face uncertainty as to whether our efforts to comply with evolving obligations under
global data protection, privacy and security laws will be sufficient. Any failure or perceived failure by us to comply with applicable laws and regulations could result in reputational damage or proceedings or actions against us by governmental
entities, individuals or others. These proceedings or actions could subject us to significant civil or criminal penalties and negative publicity, result in the delayed or halted transfer or confiscation of certain personal information, require us to
change our business practices, increase our costs and materially harm our business, prospects, financial condition and results of operations. In addition, our current and future relationships with customers, vendors, pharmaceutical partners and
other third parties could be negatively affected by any proceedings or actions against us or current or future data protection obligations imposed on them under applicable law, including the GDPR. In addition, a data breach affecting personal
information, including health information, could result in significant legal and financial exposure and reputational damage that could potentially have an adverse effect on our business. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our operating results for fiscal year 2020, our China operations and our worldwide operations could be adversely affected by the outbreak of and
response to the coronavirus or other health crises. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our business, financial condition and results of operations could be
adversely affected by the <FONT STYLE="white-space:nowrap">COVID-19</FONT> outbreak. The global outbreak of <FONT STYLE="white-space:nowrap">COVID-19,</FONT> the disease caused by a novel strain of coronavirus, has created significant business
disruption which could materially and adversely affect our business and operations. The outbreak has resulted in governments implementing numerous measures to contain <FONT STYLE="white-space:nowrap">COVID-19,</FONT> such as travel bans and
restrictions, quarantines, <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">shelter-in-place,</FONT></FONT> temporary shutdown of factories, business limitations, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">63 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
or total lock-down orders. These containment measures are subject to change and may be further tightened. This outbreak has led to temporary closure of our offices in the first quarter of 2020,
causing cancellation of physical participation in meetings, restrictions on employee travels, and a significant portion of our employees working from home, which resulted in lower work efficiency and productivity, and the disruption to our business
operations and clinical trials. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The outbreak of <FONT STYLE="white-space:nowrap">COVID-19</FONT> and the resulting government measures
may materially and adversely impact our planned and ongoing clinical trials and development. Clinical site initiation, including recruiting clinical site investigators and clinical site staff, and patient enrollment may be delayed due to
prioritization of hospital resources toward the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic. The diversion of healthcare resources away from the conduct of clinical trials to focus on pandemic concerns, including the attention of
physicians serving as our clinical trial investigators and hospitals serving as our clinical trial sites, or other staff supporting the conduct of our clinical trials may significantly disrupt our research activities. Hospitals have also had reduced
patient flow in general during the outbreak period. As a result, the expected timeline for data readouts of our clinical trials and potential submission and filings will likely be negatively impacted, which would adversely affect and delay our
ability to obtain certain regulatory approvals, increase our operating expenses and have a material adverse effect on our financial condition. Furthermore, we could face the interruption of key clinical activities such as trial site data monitoring,
which may impact the integrity of clinical data. Similarly, our ability to recruit and retain patients and principal investigators and site staff who, as healthcare providers, may have heightened exposure to
<FONT STYLE="white-space:nowrap">COVID-19,</FONT> may be impeded, which would also materially and adversely impact our clinical trial operations. As a result of disruptions caused by the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic, we
may require additional capital to continue our research activities, which we may be unable to secure on favorable terms, if at all. In addition, we believe that our business partners, such as our licensing partners, CROs, CMOs or suppliers, have
also experienced and may continue to experience similar or more severe disruptions to their business operations. Any disruption to the business operations of us and our business partners could materially and adversely affect the development of our
drug candidates, our business, financial condition and results of operations. To the extent the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic adversely affects our business and financial results, it may also have the effect of
heightening many of the other risks described in this &#147;Risk Factors&#148; section. See also &#147;Management&#146;s Discussion And Analysis Of Financial Condition And Results Of Operations&#150;&#150;Impact of the
<FONT STYLE="white-space:nowrap">COVID-19</FONT> Outbreak on Our Business&#148; for a detailed description of the impact of the <FONT STYLE="white-space:nowrap">COVID-19</FONT> outbreak on our business. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Business disruptions could seriously harm our future revenue and financial condition and increase our costs and expenses. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Natural disasters, acts of war or terrorism, health epidemics, or other factors beyond our control may adversely affect the economy,
infrastructure and livelihood of the people in the regions where we conduct our business. Our operations may be under the threat of floods, earthquakes, sandstorms, snowstorms, fire or drought, power, water or fuel shortages, failures, malfunction
and breakdown of information management systems, unexpected maintenance or technical problems, or may be susceptible to potential wars or terrorist attacks. Serious natural disasters may result in loss of lives, injury, destruction of assets and
disruption of our business and operations. Acts of war or terrorism may also injure our employees, cause loss of lives, disrupt our business network and destroy our markets. Any of these factors and other factors beyond our control could have an
adverse effect on the overall business sentiment and environment, cause uncertainties in the regions where we conduct business, cause our business to suffer in ways that we cannot predict and materially and adversely impact our business, financial
conditions and results of operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our business and results of operations could be adversely affected by public health crisis (including the <FONT
STYLE="white-space:nowrap">COVID-19</FONT> global pandemic) and natural catastrophes or other disasters outside of our control in the locations in which we, our suppliers, CROs, CMOs and other contractors operate. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our business could be adversely affected by the effects of epidemics, including <FONT STYLE="white-space:nowrap">COVID-19,</FONT> avian
influenza, severe acute respiratory syndrome, (SARS), influenza A (H1N1), Ebola or another epidemic. Any such </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">64 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
occurrences could cause severe disruption to our daily operations and may even require a temporary closure of our offices and laboratories. For example, in early 2020, in response to intensifying
efforts to contain the spread of <FONT STYLE="white-space:nowrap">COVID-19,</FONT> the Chinese government took a number of actions, which included extending the Chinese New Year holiday, quarantining individuals infected with or suspected of having <FONT
STYLE="white-space:nowrap">COVID-19,</FONT> prohibiting residents from free travel, encouraging employees of enterprises to work remotely from home and cancelling public activities, among others. The <FONT STYLE="white-space:nowrap">COVID-19</FONT>
pandemic has also resulted in temporary closure of many corporate offices, retail stores, manufacturing facilities and factories. As research hospitals and government agencies focus clinical resources on the pandemic, we believe that there could be
some delay in regulatory interactions and inspections and patient recruitment and participation, particularly in the first quarter of 2020. Meanwhile, the outbreak of <FONT STYLE="white-space:nowrap">COVID-19</FONT> continues in the United States
and other countries, and related government and private sector responsive actions may cause some delay in our ongoing clinical trials in the United States. We have taken a series of measures in response to the outbreak, including, among others,
remote working arrangement for our employees. These measures could reduce the capacity and efficiency of our operations, which in turn could negatively affect our results of operations. The extent to which
<FONT STYLE="white-space:nowrap">COVID-19</FONT> impacts our results of operations will depend on the future developments of the outbreak, including new information concerning the global severity of and actions taken to contain the outbreak, which
are highly uncertain and unpredictable. These uncertain and unpredictable factors include, but are not limited to, potential adverse effects of the pandemic on the economy, our suppliers, CROs, CMOs and other contractors. In addition, our results of
operations could be adversely affected to the extent that the outbreak harms the Chinese economy in general. To the extent the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic adversely affects our business and financial results, it may
also have the effect of heightening many of the other risks described in this prospectus, including those relating to our ability to initiate or continue clinical trials for our drug candidates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We have identified two material weaknesses in our internal controls, and if we fail to implement and maintain an effective system of internal controls
to remediate our material weaknesses over financial reporting, we may be unable to accurately report our results of operations, meet our reporting obligations or prevent fraud. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Prior to the initial public offering of our ADSs on NASDAQ in January 2020, we were a private company with limited accounting personnel and
other resources with which to address our internal controls and procedures. Effective internal control over financial reporting is necessary for us to provide reliable financial reports and, together with adequate disclosure controls and procedures,
are designed to prevent fraud. In the course of auditing our consolidated financial statements as of and for the year ended December&nbsp;31, 2019, we and our independent registered public accounting firm identified two material weaknesses and
control deficiencies in our internal control over financial reporting. As defined in the standards established by the U.S. Public Company Accounting Oversight Board, a &#147;material weakness&#148; is a deficiency, or combination of deficiencies, in
internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of the company&#146;s annual or interim financial statements will not be prevented or detected on a timely basis. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The material weaknesses that have been identified relate to (i)&nbsp;our lack of sufficient and competent financial reporting and accounting
personnel with appropriate knowledge of U.S. GAAP and the reporting and compliance requirements of the United States Securities and Exchange Commission, or the SEC, to formalize key controls over financial reporting and to prepare consolidated
financial statements and related disclosures; and (ii)&nbsp;our lack of sufficient documented financial closing policies and procedures, specifically those related to (a)&nbsp;accounting for licensing and collaboration agreements and (b)&nbsp;period
end expenses <FONT STYLE="white-space:nowrap">cut-off</FONT> and accruals. These material weaknesses, if not timely remedied, may lead to significant misstatements in our consolidated financial statements in the future. Following the identification
of the material weaknesses and other control deficiencies, we have taken measures and plan to continue to take measures to remediate these deficiencies. See &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of
Operations&#151;Internal Control over Financial Reporting.&#148; However, the implementation of those measures may not fully remediate the material weaknesses in a timely manner. Our failure to correct these deficiencies or our failure to discover
and address any other deficiencies could result in inaccuracies in our financial statements and impair our ability to comply </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">65 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
with applicable financial reporting requirements and related regulatory filings on a timely basis. Moreover, ineffective internal control over financial reporting could significantly hinder our
ability to prevent fraud. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">As required by Section&nbsp;404 of the Sarbanes-Oxley Act, or Section&nbsp;404, we will include a report from
management on the effectiveness of our internal control over financial reporting in our annual report on <FONT STYLE="white-space:nowrap">Form&nbsp;20-F</FONT> beginning with our annual report for the fiscal year ending December&nbsp;31, 2020. In
addition, once we cease to be an &#147;emerging growth company&#148; as defined in the JOBS Act, our independent registered public accounting firm must attest to and report on the effectiveness of our internal control over financial reporting. Our
management may conclude that our internal control over financial reporting is not effective. Moreover, even if our management concludes that our internal control over financial reporting is effective, our independent registered public accounting
firm, after conducting its own independent testing, may issue an adverse report if it is not satisfied with our internal controls or the level at which our controls are documented, designed, operated or reviewed, or if it interprets the relevant
requirements differently from us. In addition, as a public company, our reporting obligations may place a significant strain on our management, operational and financial resources and systems for the foreseeable future. We may be unable to timely
complete our evaluation testing and any required remediation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">During the course of documenting and testing our internal control
procedures, in order to satisfy the requirements of Section&nbsp;404, we may identify other weaknesses and deficiencies in our internal control over financial reporting. In addition, if we fail to maintain the adequacy of our internal control over
financial reporting, as these standards are modified, supplemented or amended from time to time, we may not be able to conclude on an ongoing basis that we have effective internal control over financial reporting in accordance with Section&nbsp;404.
If we fail to establish and maintain adequate internal controls, we could suffer material misstatements in our financial statements and fail to meet our reporting obligations, which would likely cause investors to lose confidence in our reported
financial information. This could limit our access to capital markets, adversely affect our results of operations and lead to a decline in the trading price of the ADSs. Additionally, ineffective internal controls could expose us to an increased
risk of fraud or misuse of corporate assets and subject us to potential delisting from the stock exchange on which we list or to other regulatory investigations and civil or criminal sanctions. We could also be required to restate our historical
financial statements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our auditor, like other independent registered public accounting firms operating in China, is not permitted to be subject to
inspection by Public Company Accounting Oversight Board, and consequently investors may be deprived of the benefits of such inspection. In addition, the adoption of any rules, legislations or other efforts to increase U.S. regulatory access to audit
information could cause uncertainty and we could be delisted if we are unable to meet the PCAOB inspection requirement in time. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our auditor, the independent registered public accounting firm that issued the audit report included elsewhere in this prospectus, as an
auditor of companies that are traded publicly in the United States and a firm registered with the Public Company Accounting Oversight Board (United States), or PCAOB, is subject to laws in the United States pursuant to which the PCAOB conducts
regular inspections to assess its compliance with applicable professional standards. Our auditor is located in, and organized under the laws of, the PRC, which is a jurisdiction where the PCAOB, has been unable to conduct inspections without the
approval of the Chinese authorities. In May 2013, PCAOB announced that it had entered into a Memorandum of Understanding on Enforcement Cooperation with the CSRC and the PRC Ministry of Finance, which establishes a cooperative framework between the
parties for the production and exchange of audit documents relevant to investigations undertaken by PCAOB, the CSRC or the PRC Ministry of Finance in the United States and the PRC, respectively. PCAOB continues to be in discussions with the China
Securities Regulatory Commission, or CSRC, and the PRC Ministry of Finance to permit joint inspections in China of audit firms that are registered with PCAOB and audit Chinese companies that trade on U.S. exchanges. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">On December&nbsp;7, 2018, the SEC and the PCAOB issued a joint statement highlighting continued challenges faced by the U.S. regulators in
their oversight of financial statement audits of U.S.-listed companies </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">66 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
with significant operations in China. The joint statement reflects a heightened interest in an issue that has vexed U.S. regulators in recent years. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">On April&nbsp;21, 2020, the SEC and the PCAOB issued another joint statement reiterating the greater risk that disclosures will be
insufficient in many emerging markets, including China, compared to those made by U.S. domestic companies. In discussing the specific issues related to the greater risk, the statement again highlights the PCAOB&#146;s inability to inspect audit work
paper and practices of accounting firms in China, with respect to their audit work of U.S. reporting companies. However, it remains unclear what further actions the SEC and PCAOB will take to address the problem. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">On June&nbsp;4, 2020, the U.S. President issued a memorandum ordering the President&#146;s Working Group on Financial Markets, or the PWG, to
submit a report to the President within 60 days of the memorandum that includes recommendations for actions that can be taken by the executive branch and by the SEC or PCAOB on Chinese companies listed on U.S. stock exchanges and their audit firms,
in an effort to protect investors in the United States. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">On August&nbsp;6, 2020, the PWG released a report recommending that the SEC take
steps to implement the five recommendations outlined in the report. In particular, to address companies from jurisdictions that do not provide the PCAOB with sufficient access to fulfill its statutory mandate, or NCJs, the PWG recommends enhanced
listing standards on U.S. stock exchanges. This would require, as a condition to initial and continued exchange listing, PCAOB access to work papers of the principal audit firm for the audit of the listed company. Companies unable to satisfy this
standard as a result of governmental restrictions on access to audit work papers and practices in NCJs may satisfy this standard by providing a <FONT STYLE="white-space:nowrap">co-audit</FONT> from an audit firm with comparable resources and
experience where the PCAOB determines it has sufficient access to audit work papers and practices to conduct an appropriate inspection of the <FONT STYLE="white-space:nowrap">co-audit</FONT> firm. The report permits the new listing standards to
provide for a transition period until January&nbsp;1, 2022 for listed companies, but would apply immediately to new listings once the necessary rulemakings and/or standard-setting are effective. The measures in the PWG Report are presumably subject
to the standard SEC rulemaking process before becoming effective. On August&nbsp;10, 2020, the SEC announced that SEC Chairman had directed the SEC staff to prepare proposals in response to the PWG Report, and that the SEC was soliciting public
comments and information with respect to these proposals. If we fail to meet the new listing standards before the deadline specified thereunder due to factors beyond our control, we could face possible
<FONT STYLE="white-space:nowrap">de-listing</FONT> from the Nasdaq Global Market, deregistration from the SEC and/or other risks, which may materially and adversely affect the market price and liquidity of our ADS, or effectively terminate our ADS
trading in the United States. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">This lack of PCAOB inspections in China prevents the PCAOB from fully evaluating audits and quality control
procedures of our independent registered public accounting firm. As a result, we and investors in our ordinary shares are deprived of the benefits of such PCAOB inspections. The inability of the PCAOB to conduct inspections of auditors in China
makes it more difficult to evaluate the effectiveness of our independent registered public accounting firm&#146;s audit procedures or quality control procedures as compared to auditors outside of China that are subject to PCAOB inspections, which
could cause investors and potential investors in our stock to lose confidence in our audit procedures and reported financial information and the quality of our financial statements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">As part of a continued regulatory focus in the United States on access to audit and other information currently protected by national law, in
particular China&#146;s, in June 2019, a bipartisan group of lawmakers introduced bills in both houses of the U.S. Congress, which if passed, would require the SEC to maintain a list of issuers for which PCAOB is not able to inspect or investigate
an auditor report issued by a foreign public accounting firm. The proposed Ensuring Quality Information and Transparency for Abroad-Based Listings on our Exchanges (EQUITABLE) Act prescribes increased disclosure requirements for these issuers and,
beginning in 2025, the delisting from U.S. national securities exchanges of issuers included on the SEC&#146;s list for three consecutive years. On May&nbsp;20, 2020, the U.S. Senate passed S. 945, the Holding Foreign Companies
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">67 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Accountable Act, or the Kennedy Bill. On July&nbsp;21, 2020, the U.S. House of Representatives approved its version of the National Defense Authorization Act for Fiscal Year 2021, which contains
provisions comparable to the Kennedy Bill. If either of these bills is enacted into law, it would amend the Sarbanes-Oxley Act of 2002 to direct the SEC to prohibit securities of any registrant from being listed on any of the U.S. securities
exchanges or traded <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">&#147;over-the-counter&#148;</FONT></FONT> if the auditor of the registrant&#146;s financial statements is not subject to PCAOB inspection for three consecutive
years after the law becomes effective. Enactment of any of such legislations or other efforts to increase U.S. regulatory access to audit information could cause investor uncertainty for affected issuers, including us, the market price of our ADSs
could be adversely affected, and we could be delisted if we are unable to cure the situation to meet the PCAOB inspection requirement in time. It is unclear if and when any of such proposed legislations will be enacted. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Furthermore, there has been recent media reports on deliberations within the U.S. government regarding potentially limiting or restricting
China-based companies from accessing U.S. capital markets. If any such deliberations were to materialize, the resulting legislation may have material and adverse impact on the stock performance of China-based issuers listed in the United States.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Proceedings instituted by the SEC against &#147;big four&#148; <FONT STYLE="white-space:nowrap">PRC-based</FONT> accounting firms, including our
independent registered public accounting firm, could result in financial statements being determined to not be in compliance with the requirements of the Exchange Act. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Starting in 2011 &#147;big four&#148; <FONT STYLE="white-space:nowrap">PRC-based</FONT> accounting firms, including our independent registered
public accounting firm, were affected by a conflict between U.S. and Chinese law. Specifically, for certain U.S.-listed companies operating and audited in mainland China, the SEC and the PCAOB sought to obtain from the Chinese firms access to their
audit work papers and related documents. The firms were, however, advised and directed that under Chinese law, they could not respond directly to the U.S. regulators on those requests, and that requests by foreign regulators for access to such
papers in China had to be channeled through the CSRC. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In late 2012, this impasse led the SEC to commence administrative proceedings under
Rule 102(e) of its Rules of Practice and also under the Sarbanes-Oxley Act of 2002 against the Chinese accounting firms, including our independent registered public accounting firm. A first instance trial of the proceedings in July 2013 in the
SEC&#146;s internal administrative court resulted in an adverse judgment against the firms. The administrative law judge proposed penalties on the firms including a temporary suspension of their right to practice before the SEC, although that
proposed penalty did not take effect pending review by the Commissioners of the SEC. On February&nbsp;6, 2015, before a review by the Commissioner had taken place, the firms reached a settlement with the SEC. Under the settlement, the SEC accepted
that future requests by the SEC for the production of documents will normally be made to the CSRC. The firms were to receive matching Section&nbsp;106 requests, and were required to abide by a detailed set of procedures with respect to such
requests, which in substance require them to facilitate production via the CSRC. If they failed to meet specified criteria, the SEC retained authority to impose a variety of additional remedial measures on the firms depending on the nature of the
failure. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Under the terms of the settlement, the underlying proceeding against the four China-based accounting firms was deemed dismissed
with prejudice four years after entry of the settlement. The four-year mark occurred on February&nbsp;6, 2019. While we cannot predict if the SEC will further challenge the four China-based accounting firms&#146; compliance with U.S. law in
connection with U.S. regulatory requests for audit work papers or if the results of such a challenge would result in the SEC imposing penalties such as suspensions. If additional remedial measures are imposed on the &#147;big four&#148; <FONT
STYLE="white-space:nowrap">PRC-based</FONT> accounting firms, including our independent registered public accounting firm, we could be unable to timely file future financial statements in compliance with the requirements of the Exchange Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In the event the &#147;big four&#148; <FONT STYLE="white-space:nowrap">PRC-based</FONT> accounting firms become subject to additional legal
challenges by the SEC or PCAOB, depending upon the final outcome, listed companies in the United States with major PRC operations may find it difficult or impossible to retain auditors in respect of their operations in China, which
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">68 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
could result in financial statements being determined to not be in compliance with the requirements of the Exchange Act, including possible delisting. Moreover, any negative news about any such
future proceedings against these audit firms may cause investor uncertainty regarding China-based, U.S.-listed companies and the market price of our common stock may be adversely affected. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">If our independent registered public accounting firm was denied, even temporarily, the ability to practice before the SEC and we were unable
to timely find another registered public accounting firm to audit and issue an opinion on our financial statements, our financial statements could be determined not to be in compliance with the requirements of the Exchange Act. Such a determination
could ultimately lead to the delisting of the ADSs from the Nasdaq Global Market or deregistration from the SEC, or both, which would substantially reduce or effectively terminate the trading of the ADSs in the United States. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our reputation is important to our business success. Negative publicity may adversely affect our reputation and business prospects. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Any negative publicity concerning us, our affiliates or any entity that shares the <FONT STYLE="white-space:nowrap">&#147;I-Mab&#148;</FONT>
name, even if untrue, could adversely affect our reputation and business prospects. There can be no assurance that negative publicity about us or any of our affiliates or any entity that shares the
<FONT STYLE="white-space:nowrap">&#147;I-Mab&#148;</FONT> name would not damage our brand image or have a material adverse effect on our business, results of operations and financial condition. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may be subject to material litigation and regulatory proceedings. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We may be subject to litigation in China and outside China relating to securities law class actions, third-party and principal intellectual
property infringement claims, claims relating to data and privacy protection, employment related cases and other matters in the ordinary course of our business. Laws, rules and regulations may vary in their scope and overseas laws and regulations
may impose requirements that are more stringent than, or which conflict with, those in China. We have acquired and may acquire companies that may become subject to litigation, as well as regulatory proceedings. In addition, in connection with
litigation or regulatory proceedings we may be subject to in various jurisdictions, we may be prohibited by laws, regulations or government authorities in one jurisdiction from complying with subpoenas, orders or other requests from courts or
regulators of other jurisdictions, including those relating to data held in or with respect to persons in these jurisdictions. Our failure or inability to comply with the subpoenas, orders or requests could subject us to fines, penalties or other
legal liability, which could have a material adverse effect on our reputation, business, results of operations and the trading price of our ADSs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">As a publicly-listed company, we and certain of our subsidiaries face additional exposure to claims and lawsuits inside and outside China. We
will need to defend against these lawsuits, including any appeals should our initial defense be successful. The litigation process may utilize a material portion of our cash resources and divert management&#146;s attention away from the <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">day-to-day</FONT></FONT> operations of our company, all of which could harm our business. There can be no assurance that we will prevail in any of these cases, and any adverse outcome of
these cases could have a material adverse effect on our reputation, business and results of operations. In addition, although we have obtained directors&#146; and officers&#146; liability insurance, the insurance coverage may not be adequate to
cover our obligations to indemnify our directors and officers, fund a settlement of litigation in excess of insurance coverage or pay an adverse judgment in litigation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The existence of litigation, claims, investigations and proceedings may harm our reputation, limit our ability to conduct our business in the
affected areas and adversely affect the trading price of our ADSs. The outcome of any claims, investigations and proceedings is inherently uncertain, and in any event defending against these claims could be both costly and time-consuming, and could
significantly divert the efforts and resources of our management and other personnel. An adverse determination in any litigation, investigation or proceeding could cause us to pay damages, incur legal and other costs, limit our ability to conduct
business or require us to change the manner in which we operate. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">69 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Negative publicity with respect to us, our management, employees, business partners, affiliates, or
our industry, may materially and adversely affect our reputation, business, results of operations and prospect. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our reputation is
vulnerable to many threats that can be difficult or impossible to control, and costly or impossible to remediate. Negative publicity about us, such as alleged misconduct or improper activities, or negative rumors relating to us, our management,
employees, business partners or affiliates, can harm our business and results of operations, even if they are unsubstantiated or are satisfactorily addressed. For example, a number of media reported that our founder, Dr.&nbsp;Jingwu Zhang Zang, was
involved in misrepresentation of certain data in a research paper prepared by scientists at GSK China&#146;s research center and published in Nature Medicine in 2010, for which Dr.&nbsp;Zang was the corresponding author, and consequently
Dr.&nbsp;Zang was dismissed by GSK in 2013. In addition, Dr.&nbsp;Zang received a warning letter from the FDA in March 1999 relating to the lack of IND approval before the initiation of a clinical research study in human subjects. For details,
please see &#147;Management&#151;Certain Past Incidents.&#148; To the best of our knowledge, Dr.&nbsp;Zang was not and is not subject to any legal or regulatory charges, proceedings or disciplinary actions in connection with these incidents or by
relevant parties involved in the incidents. However, we cannot assure you that there will not be any inquiries, investigations or other actions against Dr.&nbsp;Zang by any regulatory or government authorities in the future. Any regulatory inquiries
or investigations or other actions against our management, any perceived unethical, fraudulent, or inappropriate business conduct by us or perceived wrong doing by any key member of our management team or other employees, our business partners or
our affiliates, could harm our reputation and materially adversely affect our business. Regardless of the merits or final outcome of any such regulatory inquiries or investigations or other actions, our reputation may be substantially damaged, which
may impede our ability to attract and retain talents and business partners and grow our business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Moreover, any negative media publicity
about the biopharmaceutical industry in general or product or service quality problems of other companies in the industry, including our peers, may also negatively impact our reputation. If we are unable to maintain a good reputation, our ability to
attract and retain key employees and business partners could be harmed which in turn may materially and adversely affect our business, results of operations and prospect. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Change in business prospects of acquisitions may result in impairment to our goodwill, which could negatively affect our reported results of operations.
</I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We acquired a controlling interest in <FONT STYLE="white-space:nowrap">I-Mab</FONT> Tianjin in July 2017 and the remaining
interest in <FONT STYLE="white-space:nowrap">I-Mab</FONT> Tianjin in May 2018. In connection with our acquisition of <FONT STYLE="white-space:nowrap">I-Mab</FONT> Tianjin, we identified RMB148.8&nbsp;million of intangible assets and
RMB162.6&nbsp;million of goodwill of <FONT STYLE="white-space:nowrap">I-Mab</FONT> Tianjin attributable to core technology and synergy effects expected from combining the operations of the discovery and development of innovative biologics and the
development of clinical stage biologics. We are required to test our goodwill annually, or more frequently if events or changes in circumstances indicate that it might be impaired. Goodwill is allocated to cash-generating units or groups of
cash-generating units for the purpose of impairment testing. An impairment loss of goodwill is recognized for the amount by which the relevant cash-generating unit&#146;s or group of cash-generating unit&#146;s carrying amount exceeds its
recoverable amount, and we would be required to write down the carrying value of our goodwill during the period in which it is determined to be impaired, which would materially and adversely affect our results of operations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We are subject to changing law and regulations regarding regulatory matters, corporate governance and public disclosure that have increased both our
costs and the risk of <FONT STYLE="white-space:nowrap">non-compliance.</FONT> </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We are or will be subject to rules and regulations
by various governing bodies, including, for example, the SEC, which is charged with the protection of investors and the oversight of companies whose securities are publicly traded, and the various regulatory authorities in China and the Cayman
Islands, and to new and evolving regulatory measures under applicable law. Our efforts to comply with new and changing laws and regulations have resulted in and are likely to continue to result in, increased general and administrative expenses and a
diversion of management time and attention from revenue-generating activities to compliance activities. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">70 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Moreover, because these laws, regulations and standards are subject to varying
interpretations, their application in practice may evolve over time as new guidance becomes available. This evolution may result in continuing uncertainty regarding compliance matters and additional costs necessitated by ongoing revisions to our
disclosure and governance practices. If we fail to address and comply with these regulations and any subsequent changes, we may be subject to penalty and our business may be harmed. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Doing Business in China </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The
pharmaceutical industry in China is highly regulated and such regulations are subject to change which may affect approval and commercialization of our drugs. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our research and development operations and manufacturing facilities are in China, which we believe confers clinical, commercial and
regulatory advantages. The pharmaceutical industry in China is subject to comprehensive government regulation and supervision, encompassing the approval, registration, manufacturing, packaging, licensing and marketing of new drugs. See
&#147;Regulation&#148; for a discussion of the regulatory requirements that are applicable to our current and planned business activities in China. In recent years, the regulatory framework in China regarding the pharmaceutical industry has
undergone significant changes, and we expect that it will continue to undergo significant changes. Any such changes or amendments may result in increased compliance costs on our business or cause delays in or prevent the successful development or
commercialization of our drug candidates in China and reduce the current benefits we believe are available to us from developing and manufacturing drugs in China. PRC authorities have become increasingly vigilant in enforcing laws in the
pharmaceutical industry and any failure by us or our partners to maintain compliance with applicable laws and regulations or obtain and maintain required licenses and permits may result in the suspension or termination of our business activities in
China. We believe our strategy and approach are aligned with the PRC government&#146;s regulatory policies, but we cannot ensure that our strategy and approach will continue to be aligned. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Changes in the political and economic policies of the PRC government may materially and adversely affect our business, financial condition and results
of operations and may result in our inability to sustain our growth and expansion strategies. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">A significant portion of our
operations are in China. Our financial condition and results of operations are affected to a large extent by economic, political and legal developments in China. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The PRC economy differs from the economies of most developed countries in many respects, including the extent of government involvement, level
of development, growth rate, control of foreign exchange and allocation of resources. Although the PRC government has implemented measures emphasizing the utilization of market forces for economic reform, the reduction of state ownership of
productive assets, and the establishment of improved corporate governance in business enterprises, a substantial portion of productive assets in China is still owned by the government. In addition, the PRC government continues to play a significant
role in regulating industrial development by imposing industrial policies. The PRC government also exercises significant control over China&#146;s economic growth by allocating resources, controlling payment of foreign currency-denominated
obligations, setting monetary policy, regulating financial services and institutions and providing preferential treatment to particular industries or companies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">While the PRC economy has experienced significant growth in the past four decades, growth has been uneven, both geographically and among
various sectors of the economy. The PRC government has implemented various measures to encourage economic growth and guide the allocation of resources. Some of these measures may benefit the overall PRC economy, but may also have a negative effect
on us. Our business, financial condition and results of operations could be materially and adversely affected by government control over capital investments or changes in tax regulations that are applicable to us. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">71 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In addition, the PRC government had, in the past, implemented certain measures, including
interest rate increases, to control the pace of economic growth. These measures may cause decreased economic activity in China, which may adversely affect our business and results of operations. More generally, if the business environment in China
deteriorates from the perspective of domestic or international investment, our business in China may also be adversely affected. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>There are
uncertainties regarding the interpretation and enforcement of PRC laws, rules and regulations. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our primary business is governed
by PRC laws and regulations. Our primary business operation is supervised by relevant regulatory authorities in China. The PRC legal system is a civil law system based on written statutes and, unlike the common law system, prior court decisions can
only be cited as reference and have limited precedential value. Additionally, written statutes in the PRC are often principle-oriented and require detailed interpretations by the enforcement bodies to further apply and enforce such laws. Since 1979,
the PRC government has developed a comprehensive system of laws, rules and regulations in relation to economic matters, such as foreign investment, corporate organization and governance, commerce, taxation and trade. However, the interpretation and
enforcement of these laws, rules and regulations involve uncertainties and may not be as consistent or predictable as in other more developed jurisdictions. As these laws and regulations are continually evolving in response to changing economic and
other conditions, and because of the limited volume of published cases and their <FONT STYLE="white-space:nowrap">non-binding</FONT> nature, any particular interpretation of PRC laws and regulations may not be definitive. Moreover, we cannot predict
the effect of future developments in the PRC legal system and regulatory structure. Such unpredictability towards our contractual, property and procedural rights as well as our rights licensed, approved or granted by the competent regulatory
authority could adversely affect our business and impede our ability to continue our operations. In addition, the PRC legal system is based in part on government policies and internal rules, some of which are not published on a timely basis, if at
all, and which may have a retroactive effect. Hence, we may not be aware of violation of these policies and rules until after such violation has occurred. Further, the legal protections available to us and our investors under these laws, rules and
regulations may be limited. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In addition, any administrative or court proceedings in China may be protracted, resulting in substantial
costs and diversion of resources and management attention. Since PRC administrative and court authorities have significant discretion in interpreting and implementing statutory and contractual terms, it may be more difficult to evaluate the outcome
of administrative and court proceedings and the level of legal protection we enjoy than in more developed legal systems. These uncertainties may impede our ability to enforce various contracts we have entered into and could materially and adversely
affect our business, financial condition and results of operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>You may experience difficulties in effecting service of legal process,
enforcing foreign judgments or bringing actions in China against us or our management named in the prospectus based on foreign laws. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We are a company incorporated under the laws of the Cayman Islands, we conduct substantially all of our operations in China and substantially
all of our assets are located in China. In addition, all our senior executive officers reside within China for a significant portion of the time and some of them are PRC nationals. As a result, it may be difficult for you to effect service of
process upon us or those persons inside China. It may also be difficult for you to enforce in U.S. courts judgments obtained in U.S. courts based on the civil liability provisions of the U.S. federal securities laws against us and our officers and
directors as none of them currently resides in the United States or has substantial assets located in the United States. In addition, there is uncertainty as to whether the courts of the Cayman Islands or the PRC would recognize or enforce judgments
of U.S. courts against us or such persons predicated upon the civil liability provisions of the securities laws of the United States or any state. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The recognition and enforcement of foreign judgments are provided for under the PRC Civil Procedures Law. PRC courts may recognize and enforce
foreign judgments in accordance with the requirements of the PRC Civil Procedures Law based either on treaties between China and the country where the judgment is made or on </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">72 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
principles of reciprocity between jurisdictions. China does not have any treaties or other forms of written arrangement with the United States that provide for the reciprocal recognition and
enforcement of foreign judgments. In addition, according to the PRC Civil Procedures Law, the PRC courts will not enforce a foreign judgment against us or our directors and officers if they decide that the judgment violates the basic principles of
PRC laws or national sovereignty, security or the public interest. As a result, it is uncertain whether and on what basis a PRC court would enforce a judgment rendered by a court in the United States. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>It may be difficult for overseas regulators to conduct investigation or collect evidence within China. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Shareholder claims or regulatory investigation that are common in the United States generally are difficult to pursue as a matter of law or
practicality in China. For example, in China, there are significant legal and other obstacles to providing information needed for regulatory investigations or litigations initiated outside China. Although the authorities in China may establish a
regulatory cooperation mechanism with the securities regulatory authorities of another country or region to implement cross-border supervision and administration, such cooperation with the securities regulatory authorities in the Unities States may
not be efficient in the absence of mutual and practical cooperation mechanism. Furthermore, according to Article 177 of the PRC Securities Law, which became effective in March 2020, no overseas securities regulator is allowed to directly conduct
investigation or evidence collection activities within the PRC territory. While detailed interpretation of or implementation rules under Article 177 have yet to be promulgated, the inability for an overseas securities regulator to directly conduct
investigation or evidence collection activities within China may further increase the difficulties you face in protecting your interests. See also &#147;&#151;Risks Related to Our ADSs and the Offering&#151; You may face difficulties in protecting
your interests, and your ability to protect your rights through U.S. courts may be limited, because we are incorporated under Cayman Islands law.&#148; for risks associated with investing in us as a Cayman Islands company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may be restricted from transferring our scientific data abroad. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">On March&nbsp;17, 2018, the General Office of the PRC State Council promulgated the Measures for the Management of Scientific Data, or the
Scientific Data Measures, which provide a broad definition of scientific data and relevant rules for the management of scientific data. According to the Scientific Data Measures, enterprises in China must seek governmental approval before any
scientific data involving a state secret may be transferred abroad or to foreign parties. Further, any researcher conducting research funded, at least in part, by the PRC government is required to submit relevant scientific data for management by
the entity to which such researcher is affiliated before such data may be published in any foreign academic journal. Currently, as the term &#147;state secret&#148; is not clearly defined, there is no assurance that we can always obtain relevant
approvals for sending scientific data (such as the results of our <FONT STYLE="white-space:nowrap">pre-clinical</FONT> studies or clinical trials conducted within China) abroad, or to our foreign partners in China. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">If we are unable to obtain the necessary approvals in a timely manner, or at all, our research and development of drug candidates may be
hindered, which may materially and adversely affect our business, results of operations, financial conditions and prospects. If relevant government authorities consider the transmission of our scientific data to be in violation of the requirements
under the Scientific Data Measures, we may be subject to specific administrative penalties imposed by those government authorities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Changes in
international trade policies and rising political tensions, particularly between the U.S. and China, may adversely impact our business and operating results. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The U.S. government has made statements and taken certain actions that may lead to potential changes to U.S. and international trade policies
towards China. While the &#147;Phase One&#148; agreement was signed between the United States and China on trade matters, it remains unclear what additional actions, if any, will be taken by the U.S. or other governments with respect to
international trade, tax policy related to international commerce, or other trade matters. The situation is further complicated by the political tensions between the United States and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">73 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
China that escalated during the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic and in the wake of the PRC National People&#146;s Congress&#146; decision on Hong Kong national security
legislation, sanctions imposed by the U.S. Department of Treasury on certain officials of the Hong Kong Special Administrative Region and the central government of the PRC and the executive orders issued by U.S. President in August 2020 that
prohibit certain transactions with certain China-based companies and their respective subsidiaries. Rising trade and political tensions could reduce levels of trades, investments, technological exchanges and other economic activities between China
and other countries, which would have an adverse effect on global economic conditions, the stability of global financial markets, and international trade policies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">While we have not started commercialization of drug candidates, any rising trade and political tensions or unfavorable government policies on
international trade, such as capital controls or tariffs, may affect the demand for our drug products, the competitive position of our drug products, the hiring of scientists and other research and development personnel, and import or export of raw
materials in relation to drug development, or prevent us from selling our drug products in certain countries. In particular, if any new tariffs, legislation and/or regulations are implemented, or if existing trade agreements are renegotiated or,
especially, if the U.S. government takes retaliatory trade actions due to the recent U.S.-China trade and political tension, such changes could have an adverse effect on our business, financial condition and results of operations. In addition, our
results of operations could be adversely affected if any such tensions or unfavorable government trade policies harm the Chinese economy or the global economy in general. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we are classified as a PRC resident enterprise for PRC income tax purposes, such classification could result in unfavorable tax consequences to us
and our <FONT STYLE="white-space:nowrap">non-PRC</FONT> shareholders or ADS holders. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Under the PRC Enterprise Income Tax Law and
its implementation rules, an enterprise established outside of the PRC with &#147;de facto management body&#148; within China is considered a &#147;resident enterprise&#148; and will be subject to the enterprise income tax on its global income at
the rate of 25%. The implementation rules define the term &#147;de facto management body&#148; as the body that exercises full and substantial control and overall management over the business, productions, personnel, accounts and properties of an
enterprise. In 2009, the SAT issued the Circular of the State Administration of Taxation on Issues Relating to Identification of <FONT STYLE="white-space:nowrap">PRC-Controlled</FONT> Overseas Registered Enterprises as Resident Enterprises in
Accordance With the De Facto Standards of Organizational Management, or Circular 82, which provides certain specific criteria for determining whether the &#147;de facto management body&#148; of a
<FONT STYLE="white-space:nowrap">PRC-controlled</FONT> enterprise that is incorporated offshore is located in China. Although this Circular only applies to offshore enterprises controlled by PRC enterprises or PRC enterprise groups, not those
controlled by PRC individuals or foreigners, the criteria set forth in the circular may reflect the SAT&#146;s general position on how the &#147;de facto management body&#148; text should be applied in determining the tax resident status of all
offshore enterprises. According to Circular 82, an offshore incorporated enterprise controlled by a PRC enterprise or a PRC enterprise group will be regarded as a PRC tax resident by virtue of having its &#147;de facto management body&#148; in China
and will be subject to PRC enterprise income tax on its global income if all of the following conditions are met: (i)&nbsp;the primary location of the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">day-to-day</FONT></FONT>
operational management is in China; (ii)&nbsp;decisions relating to the enterprise&#146;s financial and human resource matters are made or are subject to approval by organizations or personnel in China; (iii)&nbsp;the enterprise&#146;s primary
assets, accounting books and records, company seals, and board and shareholder resolutions, are located or maintained in China; and (iv)&nbsp;at least 50% of voting board members or senior executives habitually reside in China. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our PRC counsel, JunHe LLP, has advised us that, based on its understanding of the current PRC Laws and Regulations, <FONT
STYLE="white-space:nowrap">I-Mab</FONT> should not be considered as a PRC resident enterprise for PRC tax income purposes. However, the tax resident status of an enterprise is subject to determination by the PRC tax authorities and uncertainties
remain with respect to the interpretation of the term &#147;de facto management body.&#148; If the PRC tax authorities determine that we are a PRC resident enterprise for enterprise income tax purposes, we could be subject to PRC tax at a rate of
25% on our worldwide income, which could materially reduce our net income, and we may be required to withhold a 10% withholding tax from dividends we pay to our shareholders that are <FONT STYLE="white-space:nowrap">non-resident</FONT> enterprises
(including the holders of our ADSs). In addition, <FONT STYLE="white-space:nowrap">non-resident</FONT> enterprise shareholders </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">74 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
(including our ADS holders) may be subject to PRC tax at a rate of 10% on gains realized on the sale or other disposition of ADSs or ordinary shares, if such income is treated as sourced from
within China. Furthermore, if we are deemed a PRC resident enterprise, dividends payable to our <FONT STYLE="white-space:nowrap">non-PRC</FONT> individual shareholders (including our ADS holders) and any gain realized on the transfer of ADSs or
ordinary shares by such shareholders may be subject to PRC tax at a rate of 20% in the case of <FONT STYLE="white-space:nowrap">non-PRC</FONT> individuals (which in the case of dividends may be withheld at source) unless a reduced rate is available
under an applicable tax treaty. It is unclear whether <FONT STYLE="white-space:nowrap">non-PRC</FONT> shareholders of our company would be able to claim the benefits of any tax treaties between their country of tax residence and the PRC in the event
that we are treated as a PRC resident enterprise. Any such tax may reduce the returns on your investment in the ADSs or ordinary shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Failure to
renew our current leases or locate desirable alternatives for our leased properties could materially and adversely affect our business. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We lease properties for our offices and laboratories. We may not be able to successfully extend or renew such leases upon expiration of the
current term on commercially reasonable terms or at all, and may therefore be forced to relocate our affected operations. This could disrupt our operations and result in significant relocation expenses, which could adversely affect our business,
financial condition and results of operations. In addition, we compete with other businesses for premises at certain locations or of desirable sizes. As a result, even though we could extend or renew our leases, rental payments may significantly
increase as a result of the high demand for the leased properties. In addition, we may not be able to locate desirable alternative sites for our current leased properties as our business continues to grow and failure in relocating our affected
operations could adversely affect our business and operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Certain of our leasehold interests in leased properties have not been registered
with the relevant PRC governmental authorities as required by relevant PRC laws. The failure to register leasehold interests may expose us to potential fines. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We have not registered certain of our lease agreements with the relevant government authorities. Under the relevant PRC laws and regulations,
we may be required to register and file with the relevant government authority executed leases. The failure to register the lease agreements for our leased properties will not affect the validity of these lease agreements, but the competent housing
authorities may order us to register the lease agreements in a prescribed period of time and impose a fine ranging from RMB1,000 to RMB10,000 for each <FONT STYLE="white-space:nowrap">non-registered</FONT> lease if we fail to complete the
registration within the prescribed timeframe. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We have granted, and may continue to grant, options and other types of awards under our share
incentive plans, which may result in increased share-based compensation expenses. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We have adopted the Second Amended and Restated
2017 Employee Stock Option Plan (the &#147;2017 Plan&#148;), the Second Amended and Restated 2018 Employee Stock Option Plan (the &#147;2018 Plan&#148;), the 2019 Share Incentive Plan (the &#147;2019 Plan&#148;) and the 2020 Share Incentive Plan
(the &#147;2020 Plan&#148;), for the purpose of granting share-based compensation awards to employees, directors and consultants to incentivize their performance and align their interests with ours. We recognize expenses in our consolidated
financial statements in accordance with U.S. GAAP. As of the date of this prospectus, the awards that had been granted to our directors, officers, employees and consultants and remained outstanding included (i)&nbsp;options to purchase an aggregate
of 7,895,607 ordinary shares, 10,589,660 ordinary shares, 72,000 ordinary shares and 1,046,919 ordinary shares under the 2017 Plan, the 2018 Plan, the 2019 Plan and the 2020 Plan, respectively, excluding options that were forfeited, cancelled, or
exercised after the relevant grant date; and (ii)&nbsp;restricted share units to receive an aggregate of 4,321,257 ordinary shares under the 2020 Plan, excluding restricted share units that were forfeited, cancelled, or vested after the relevant
grant date. See &#147;Management&#151;Share Incentive Plans.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We believe the granting of share-based compensation is of significant
importance to our ability to attract and retain key personnel and employees, and we will continue to grant share-based compensation to employees </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">75 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
in the future. As a result, our expenses associated with share-based compensation may increase, which may have an adverse effect on our results of operations. We may <FONT
STYLE="white-space:nowrap">re-evaluate</FONT> the vesting schedules, <FONT STYLE="white-space:nowrap">lock-up</FONT> period, exercise price or other key terms applicable to the grants under our currently effective share incentive plans from time to
time. If we choose to do so, we may experience substantial change in our share-based compensation charges. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Fluctuations in exchange rates could
have a material and adverse effect on our results of operations and the value of your investment. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The conversion of RMB into
foreign currencies, including U.S. dollars, is based on rates set by the People&#146;s Bank of China. The RMB has fluctuated against the U.S. dollar, at times significantly and unpredictably. The value of RMB against the U.S. dollar and other
currencies is affected by changes in China&#146;s political and economic conditions and by China&#146;s foreign exchange policies, among other things. We cannot assure you that RMB will not appreciate or depreciate significantly in value against the
U.S. dollar in the future. It is difficult to predict how market forces or PRC or U.S. government policy may impact the exchange rate between RMB and the U.S. dollar in the future. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Any significant appreciation or depreciation of RMB may materially and adversely affect our revenues, earnings and financial position, and the
value of, and any dividends payable on, our ADSs in U.S. dollars. For example, to the extent that we need to convert U.S. dollars we receive into RMB to pay our operating expenses, appreciation of RMB against the U.S. dollar would have an adverse
effect on the RMB amount we would receive from the conversion. Conversely, a significant depreciation of RMB against the U.S. dollar may significantly reduce the U.S. dollar equivalent of our earnings, which in turn could adversely affect the price
of our ADSs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Very limited hedging options are available in China to reduce our exposure to exchange rate fluctuations. To date, we have
not entered into any hedging transactions in an effort to reduce our exposure to foreign currency exchange risk. While we may decide to enter into hedging transactions in the future, the availability and effectiveness of these hedges may be limited
and we may not be able to adequately hedge our exposure or at all. In addition, our currency exchange losses may be magnified by PRC exchange control regulations that restrict our ability to convert RMB into foreign currency. As a result,
fluctuations in exchange rates may have a material adverse effect on your investment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Certain PRC regulations may make it more difficult for us to
pursue growth through acquisitions. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Regulations on Mergers and Acquisitions of Domestic Enterprises by Foreign Investors, or
the M&amp;A Rules, adopted by six PRC regulatory agencies in 2006 and amended in 2009, established additional procedures and requirements that could make merger and acquisition activities by foreign investors more time-consuming and complex. Such
regulation requires, among other things, that the Ministry of Commerce, or MOFCOM, be notified in advance of any change of control transaction in which a foreign investor acquires control of a PRC domestic enterprise and involves any of the
following circumstances: (i)&nbsp;any important industry is concerned; (ii)&nbsp;such transaction involves factors that impact or may impact national economic security; or (iii)&nbsp;such transaction will lead to a change in control of a domestic
enterprise which holds a famous trademark or PRC time-honored brand. We do not expect that this offering will trigger MOFCOM <FONT STYLE="white-space:nowrap">pre-notification</FONT> under each of the above-mentioned circumstances or any review by
other PRC government authorities, except as disclosed below in &#147;&#151;The approval of the CSRC may be required in connection with this offering, and, if required, we cannot predict whether we will be able to obtain such approval.&#148;
Moreover, the Anti-Monopoly Law promulgated by the Standing Committee of National People&#146;s Congress which became effective in 2008 requires that transactions which are deemed concentrations and involve parties with specified turnover thresholds
must be cleared by State Administration for Market Regulation (the &#147;SAMR&#148;), the successive authority of MOFCOM, before they can be completed. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">76 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may rely on dividends and other distributions on equity paid by our PRC subsidiaries to fund any
cash and financing requirements we may have, and any limitation on the ability of our PRC subsidiaries to make payments to us could have a material and adverse effect on our ability to conduct our business. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We are a Cayman Islands holding company and we may rely on dividends and other distributions on equity paid by our PRC subsidiaries for our
cash and financing requirements, including the funds necessary to pay dividends and other cash distributions to our shareholders and service any debt we may incur. If any of our PRC subsidiaries incur debt on its own behalf in the future, the
instruments governing the debt may restrict their ability to pay dividends or make other distributions to us. Under PRC laws and regulations, our PRC subsidiaries, each of which is a wholly foreign-owned enterprise may pay dividends only out of its
respective accumulated profits as determined in accordance with PRC accounting standards and regulations. In addition, a wholly foreign-owned enterprise is required to set aside at least 10% of its <FONT STYLE="white-space:nowrap">after-tax</FONT>
profits each year, if any, to fund a certain statutory reserve fund, until the aggregate amount of such fund reaches 50% of its registered capital. At its discretion, a wholly foreign-owned enterprise may allocate a portion of its <FONT
STYLE="white-space:nowrap">after-tax</FONT> profits based on PRC accounting standards to a staff welfare and bonus fund. The reserve fund and staff welfare and bonus fund cannot be distributed to us as dividends. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our PRC subsidiaries generate primarily all of their revenue in RMB, which is not freely convertible into other currencies. As result, any
restriction on currency exchange may limit the ability of our PRC subsidiaries to use their RMB revenues to pay dividends to us. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The PRC
government may continue to strengthen its capital controls, and more restrictions and a substantial vetting process may be put forward by SAFE for cross-border transactions falling under both the current account and the capital account. Any
limitation on the ability of our PRC subsidiaries to pay dividends or make other kinds of payments to us could materially and adversely limit our ability to grow, make investments or acquisitions that could be beneficial to our business, pay
dividends, or otherwise fund and conduct our business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In addition, the PRC Enterprise Income Tax Law and its implementation rules
provide that a withholding tax rate of up to 10% will be applicable to dividends payable by PRC companies to <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">non-PRC-resident</FONT></FONT> enterprises unless otherwise exempted or
reduced according to treaties or arrangements between the PRC central government and governments of other countries or regions where the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">non-PRC-resident</FONT></FONT> enterprises are
incorporated. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>PRC regulations relating to offshore investment activities by PRC residents may limit our PRC subsidiaries&#146; ability to change
their registered capital or distribute profits to us or otherwise expose us or our PRC resident beneficial owners to liability and penalties under PRC laws. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In July 2014, SAFE promulgated the Circular on Relevant Issues Concerning Foreign Exchange Control on Domestic Residents&#146; Offshore
Investment and Financing and Roundtrip Investment Through Special Purpose Vehicles, or SAFE Circular 37. SAFE Circular 37 requires PRC residents (including PRC individuals and PRC corporate entities as well as foreign individuals that are deemed as
PRC residents for foreign exchange administration purpose) to register with SAFE or its local branches in connection with their direct or indirect offshore investment activities. SAFE Circular 37 further requires amendment to the SAFE registrations
in the event of any changes with respect to the basic information of the offshore special purpose vehicle, such as changes of a PRC individual shareholder, name and operation term, or any significant changes with respect to the offshore special
purpose vehicle, such as increase or decrease of capital contribution, share transfer or exchange, or mergers or divisions. SAFE Circular 37 is applicable to our shareholders who are PRC residents. If our shareholders who are PRC residents fail to
make the required registration or to update the previously filed registration, our PRC subsidiaries may be prohibited from distributing their profits or the proceeds from any capital reduction, share transfer or liquidation to us, and we may also be
prohibited from making additional capital contributions into our PRC subsidiaries. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">77 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In February 2015, SAFE promulgated a Notice on Further Simplifying and Improving Foreign
Exchange Administration Policy on Direct Investment, or SAFE Notice 13, effective June 2015. Under SAFE Notice 13, applications for foreign exchange registration of inbound foreign direct investments and outbound overseas direct investments,
including those required under SAFE Circular 37, will be filed with qualified banks instead of SAFE. The qualified banks will directly examine the applications and accept registrations under the supervision of SAFE. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">All of our shareholders who we are aware of being subject to the SAFE regulations have completed the initial registrations with the local SAFE
branch or qualified banks as required by SAFE Circular 37. However, we may not be informed of the identities of all the PRC residents holding direct or indirect interests in our company, and we cannot provide any assurance that these PRC residents
will comply with our request to make or obtain any applicable registrations or continuously comply with all requirements under SAFE Circular 37 or other related rules. The failure or inability of the relevant shareholders to comply with the
registration procedures set forth in these regulations may subject us to fines and legal sanctions, such as restrictions on our cross-border investment activities, on the ability of our wholly foreign-owned subsidiaries in China to distribute
dividends and the proceeds from any reduction in capital, share transfer or liquidation to us. Moreover, failure to comply with the various foreign exchange registration requirements described above could result in liability under PRC law for
circumventing applicable foreign exchange restrictions. As a result, our business operations and our ability to distribute profits could be materially and adversely affected. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Any failure to comply with PRC regulations regarding our employee equity incentive plans may subject the PRC plan participants or us to fines and other
legal or administrative sanctions. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We and our directors, executive officers and other employees who are PRC citizens or who have
resided in China for a continuous period of not less than one year and who will be granted restricted shares or options are subject to the Notice on Issues Concerning the Foreign Exchange Administration for Domestic Individuals Participating in
Stock Incentive Plan of Overseas Publicly Listed Company, issued by SAFE in February 2012, according to which, employees, directors, supervisors and other management members participating in any share incentive plan of an overseas publicly listed
company who are PRC citizens or who are <FONT STYLE="white-space:nowrap">non-PRC</FONT> citizens residing in China for a continuous period of not less than one year, subject to limited exceptions, are required to register with SAFE through a
domestic qualified agent, which could be a PRC subsidiary of such overseas listed company, and complete certain other procedures. In addition, an overseas entrusted institution must be retained to handle matters in connection with the exercise or
sale of stock options and the purchase or sale of shares and interests. Failure to complete the SAFE registrations may subject them to fines and legal sanctions and may also limit our ability to make payments under our equity incentive plans or
receive dividends or sales proceeds related thereto, or our ability to contribute additional capital into our wholly foreign-owned enterprises in China and limit our wholly foreign-owned enterprises&#146; ability to distribute dividends to us. We
also face regulatory uncertainties that could restrict our ability to adopt additional equity incentive plans for our directors and employees under PRC law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In addition, the SAT has issued circulars concerning employee share options or restricted shares. Under these circulars, employees working in
China who exercise share options, or whose restricted shares vest, will be subject to PRC individual income tax. The PRC subsidiaries of an overseas listed company have obligations to file documents related to employee share options or restricted
shares with relevant tax authorities and to withhold individual income taxes of those employees related to their share options or restricted shares. If the employees fail to pay, or the PRC subsidiaries fail to withhold applicable income taxes, the
PRC subsidiaries may face sanctions imposed by the tax authorities or other PRC government authorities. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">78 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>PRC regulation of loans to and direct investment in PRC entities by offshore holding companies and
governmental control of currency conversion may delay or prevent us from making loans to our PRC subsidiaries or making additional capital contributions to our wholly foreign-owned subsidiaries in China, which could materially and adversely affect
our liquidity and our ability to fund and expand our business. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We are an offshore holding company conducting our operations in
China through our PRC subsidiaries. We may make loans to our PRC subsidiaries subject to the approval from governmental authorities and limitation on the available loan amount, or we may make additional capital contributions to our wholly
foreign-owned subsidiaries in China. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Any loans to our wholly foreign-owned subsidiaries in China, which are treated as foreign-invested
enterprises under PRC law, are subject to PRC regulations and foreign exchange loan registrations. For example, loans by us to our wholly foreign-owned subsidiaries in China to finance their activities cannot exceed statutory limits and must be
registered with the local counterpart of SAFE. In addition, a foreign-invested enterprise shall use its capital pursuant to the principle of authenticity and <FONT STYLE="white-space:nowrap">self-use</FONT> within its business scope. The capital of
a foreign-invested enterprise shall not be used for the following purposes: (i)&nbsp;directly or indirectly used for payment beyond the business scope of the enterprises or the payment prohibited by relevant laws and regulations; (ii)&nbsp;directly
or indirectly used for investment in securities or investments other than banks&#146; principal-secured products unless otherwise provided by relevant laws and regulations; (iii)&nbsp;the granting of loans to
<FONT STYLE="white-space:nowrap">non-affiliated</FONT> enterprises, except where it is expressly permitted in the business license; and (iv)&nbsp;paying the expenses related to the purchase of real estate that is not for <FONT
STYLE="white-space:nowrap">self-use</FONT> (except for the foreign-invested real estate enterprises). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">SAFE promulgated the Notice of the
State Administration of Foreign Exchange on Reforming the Administration of Foreign Exchange Settlement of Capital of Foreign-invested Enterprises, or SAFE Circular 19, effective June 2015, in replacement of the Circular on the Relevant Operating
Issues Concerning the Improvement of the Administration of the Payment and Settlement of Foreign Currency Capital of Foreign-Invested Enterprises, the Notice from the State Administration of Foreign Exchange on Relevant Issues Concerning
Strengthening the Administration of Foreign Exchange Businesses, and the Circular on Further Clarification and Regulation of the Issues Concerning the Administration of Certain Capital Account Foreign Exchange Businesses. According to SAFE Circular
19, the flow and use of RMB capital converted from foreign currency-denominated registered capital of a foreign-invested company is regulated such that RMB capital may not be used for the issuance of RMB entrusted loans, the repayment of
inter-enterprise loans or the repayment of banks loans that have been transferred to a third party. Although SAFE Circular 19 allows RMB capital converted from foreign currency-denominated registered capital of a foreign-invested enterprise to be
used for equity investments within China, it also reiterates the principle that RMB converted from the foreign currency-denominated capital of a foreign-invested company may not be directly or indirectly used for purposes beyond its business scope.
Thus, it is unclear whether SAFE will permit such capital to be used for equity investments in China in actual practice. SAFE promulgated the Notice of the State Administration of Foreign Exchange on Reforming and Standardizing the Foreign Exchange
Settlement Management Policy of Capital Account, or SAFE Circular 16, effective on June&nbsp;9, 2016, which reiterates some of the rules set forth in SAFE Circular 19, but changes the prohibition against using RMB capital converted from foreign
currency-denominated registered capital of a foreign-invested company to issue RMB entrusted loans to a prohibition against using such capital to issue loans to <FONT STYLE="white-space:nowrap">non-associated</FONT> enterprises. Violations of SAFE
Circular 19 and SAFE Circular 16 could result in administrative penalties. SAFE Circular 19 and SAFE Circular 16&nbsp;may significantly limit our ability to transfer any foreign currency we hold, including the net proceeds from our initial public
offering, to our PRC subsidiaries, which may adversely affect our liquidity and our ability to fund and expand our business in China. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In
light of the various requirements imposed by PRC regulations on loans to and direct investment in PRC entities by offshore holding companies, we cannot assure you that we will be able to complete the necessary government registrations or obtain the
necessary government approvals on a timely basis, if at all, with respect to future loans to our PRC subsidiaries or future capital contributions by us to our wholly foreign-owned subsidiaries in China. As a result, uncertainties exist as to our
ability to provide prompt financial support to our </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">79 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
PRC subsidiaries when needed. If we fail to complete such registrations or obtain such approvals, our ability to use foreign currency, including the proceeds we received from our initial public
offering, to capitalize or otherwise fund our PRC operations may be negatively affected, which could materially and adversely affect our liquidity and our ability to fund and expand our business. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We and our shareholders face uncertainties with respect to indirect transfers of equity interests in PRC resident enterprises or other assets
attributable to a PRC establishment of a <FONT STYLE="white-space:nowrap">non-PRC</FONT> company. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">On February&nbsp;3, 2015, the
SAT issued the Bulletin on Issues of Enterprise Income Tax and Indirect Transfers of Assets by <FONT STYLE="white-space:nowrap">Non-PRC</FONT> Resident Enterprises, or Bulletin 7. Pursuant to this Bulletin, an &#147;indirect transfer&#148; of
&#147;PRC taxable assets,&#148; including equity interests in a PRC resident enterprise, by <FONT STYLE="white-space:nowrap">non-PRC</FONT> resident enterprises may be recharacterized and treated as a direct transfer of PRC taxable assets, if such
arrangement does not have a reasonable commercial purpose and was established for the purpose of avoiding payment of PRC enterprise income tax. As a result, gains derived from such indirect transfer may be subject to PRC enterprise income tax. When
determining whether there is a &#147;reasonable commercial purpose&#148; of the transaction arrangement, factors to be taken into consideration include: whether the main value of the equity interest of the relevant offshore enterprise derives from
PRC taxable assets; whether the assets of the relevant offshore enterprise mainly consist of direct or indirect investment in China or if its income mainly derives from China; whether the offshore enterprise and its subsidiaries directly or
indirectly holding PRC taxable assets have real commercial nature which is evidenced by their actual function and risk exposure; the duration of existence of the business model and organizational structure; the replicability of the transaction by
direct transfer of PRC taxable assets; and the tax situation of such indirect transfer and applicable tax treaties or similar arrangements. On October&nbsp;17, 2017, the SAT issued the Announcement of the State Administration of Taxation on Issues
Concerning the Withholding of <FONT STYLE="white-space:nowrap">Non-resident</FONT> Enterprise Income Tax at Source, or Bulletin 37, which came into effect on December&nbsp;1, 2017. Bulletin 37 further clarifies the practice and procedure of the
withholding of <FONT STYLE="white-space:nowrap">non-resident</FONT> enterprise income tax. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Late payment of applicable tax will subject
the transferor to default interest. Gains derived from the sale of shares by investors are not subject to the PRC enterprise income tax pursuant to Bulletin 7 where such shares were acquired in a transaction through a public stock exchange. However,
the sale of ADSs or ordinary shares by a <FONT STYLE="white-space:nowrap">non-PRC</FONT> resident enterprise outside a public stock exchange may be subject to PRC enterprise income tax under Bulletin 7. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">There are uncertainties as to the application of Bulletin 7. Bulletin 7&nbsp;may be determined by the tax authorities to be applicable to the
sale of the shares of our offshore subsidiaries or investments where PRC taxable assets are involved. The transferors and transferees may be subject to the tax filing and withholding or tax payment obligation, while our PRC subsidiaries may be
requested to assist in the filing. Furthermore, we, our <FONT STYLE="white-space:nowrap">non-resident</FONT> enterprises and PRC subsidiaries may be required to spend valuable resources to comply with Bulletin 7 or to establish that we and our <FONT
STYLE="white-space:nowrap">non-resident</FONT> enterprises should not be taxed under Bulletin 7, for our previous and future restructuring or disposal of shares of our offshore subsidiaries, which may have a material adverse effect on our financial
condition and results of operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The PRC tax authorities have the discretion under Bulletin 7 to make adjustments to the taxable
capital gains based on the difference between the fair value of the taxable assets transferred and the cost of investment. If the PRC tax authorities make adjustments to the taxable income of the transactions under Bulletin 7 / Bulletin&nbsp;37, our
income tax costs associated with such potential acquisitions or disposals will increase, which may have an adverse effect on our financial condition and results of operations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The approval of the CSRC may be required in connection with this offering, and, if required, we cannot predict whether we will be able to obtain such
approval. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The M&amp;A Rules require overseas special purpose vehicles that are controlled by PRC companies or individuals and
formed for the purpose of seeking a public listing on an overseas stock exchange through </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">80 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
acquisitions of PRC domestic companies using shares of such special purpose vehicles or held by its shareholders as consideration to obtain the approval of the CSRC, prior to the listing and
trading of such special purpose vehicle&#146;s securities on an overseas stock exchange. However, the application of the M&amp;A Rules remains unclear. If CSRC approval is required, it is uncertain whether it would be possible for us to obtain the
approval, and any failure to obtain or delay in obtaining CSRC approval for this offering would subject us to sanctions imposed by the CSRC and other PRC regulatory agencies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our PRC counsel has advised us based on their understanding of the current PRC laws, rules and regulations that the CSRC&#146;s approval may
not be required for the listing and trading of our ADSs on the Nasdaq Stock Market in the context of this offering, given that: (i)&nbsp;the CSRC currently has not issued any definitive rule or interpretation concerning whether offerings like ours
in this prospectus are subject to this regulation, <FONT STYLE="white-space:nowrap">(ii)&nbsp;I-Mab</FONT> Tianjin was not acquired by a connected merger or by acquisition of equity interest or assets of a PRC domestic company owned by PRC companies
or individuals as defined under the M&amp;A Rules, <FONT STYLE="white-space:nowrap">(iii)&nbsp;I-Mab</FONT> Shanghai and <FONT STYLE="white-space:nowrap">I-Mab</FONT> Hangzhou were incorporated as wholly foreign-owned enterprises by means of direct
investment, and (iv)&nbsp;our other three PRC subsidiaries, including Tasgen (Chengdu) <FONT STYLE="white-space:nowrap">Bio-Tech</FONT> Co., Ltd. (&#147;<B>Tasgen Chengdu</B>&#148;), Shanghai Tianyunjian
<FONT STYLE="white-space:nowrap">Bio-Tech</FONT> Co., Ltd. (&#147;<B>Shanghai Tianyunjian</B>&#148;) and Sanjing (Beijing) Biotechnology Co., Ltd. (&#147;<B>Sanjing Beijing</B>&#148;), belong to the reinvestment enterprises of foreign investment
enterprises. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">However, our PRC counsel has further advised us that there remain some uncertainties as to how the M&amp;A Rules will be
interpreted or implemented in the context of an overseas offering and its opinions summarized above are subject to any new laws, rules and regulations or detailed implementations and interpretations in any form relating to the M&amp;A Rules. We
cannot assure you that relevant PRC government agencies, including the CSRC, would reach the same conclusion as our PRC counsel. If it is determined that CSRC approval is required for this offering, we may face sanctions by the CSRC or other PRC
regulatory agencies for failure to seek CSRC approval for this offering. These sanctions may include fines and penalties on our operations in China, limitations on our operating privileges in China, restrictions on or prohibition of the payments or
remittance of dividends by our subsidiaries in China, or other actions that could have a material and adverse effect on our business, financial condition, results of operations, reputation and prospects, as well as the trading price of our ADSs. The
CSRC or other PRC regulatory agencies may also take actions requiring us, or making it advisable for us, to halt this offering before the settlement and delivery of the ADSs in this offering. Consequently, if you engage in market trading or other
activities in anticipation of and prior to the settlement and delivery of the ADSs in this offering, you would be doing so at the risk that the settlement and delivery may not occur. In addition, if the CSRC or other regulatory agencies later
promulgate new rules or explanations requiring that we obtain their approvals for this offering, we may be unable to obtain a waiver of such approval requirements, if and when procedures are established to obtain such a waiver. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Recent litigation and negative publicity surrounding China-based companies listed in the U.S. may result in increased regulatory scrutiny of us and
negatively impact the trading price of the ADSs and could have a material adverse effect upon our business, including our results of operations, financial condition, cash flows and prospects. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We believe that litigation and negative publicity surrounding companies with operations in China that are listed in the U.S. have negatively
impacted stock prices for such companies. Various equity-based research organizations have published reports on China-based companies after examining, among other things, their corporate governance practices, related party transactions, sales
practices and financial statements that have led to special investigations and stock suspensions on national exchanges. Any similar scrutiny of us, regardless of its lack of merit, could result in a diversion of management resources and energy,
potential costs to defend ourselves against rumors, decreases and volatility in the ADS trading price, and increased directors and officers insurance premiums and could have a material adverse effect upon our business, including our results of
operations, financial condition, cash flows and prospects. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">81 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>General Risks Related to Our ADSs and the Offering </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The trading price of our ADSs may be volatile, which could result in substantial losses to you. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The trading price of our ADSs ranged from US$9.30 to US$47.46 per ADS since the listing of ADSs on Nasdaq. The trading price of our ADSs can
be volatile and fluctuate widely in response to a variety of factors, many of which are beyond our control. In addition, the performance and fluctuation of the market prices of other companies with business operations located mainly in the PRC that
have listed their securities in the United States may affect the volatility in the price of and trading volumes for our ADSs. Some of these companies have experienced significant volatility. The trading performances of these PRC companies&#146;
securities may affect the overall investor sentiment towards other PRC companies listed in the United States and consequently may impact the trading performance of our ADSs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In addition to market and industry factors, the price and trading volume for our ADSs may be highly volatile for specific business reasons,
including: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">announcements of regulatory approval or a complete response letter, or specific label indications or patient
populations for a drug&#146;s use, or changes or delays in the regulatory review process; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">announcements of therapeutic innovations, new products, acquisitions, strategic relationships, joint ventures or
capital commitments by us or our competitors; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">adverse actions taken by regulatory agencies with respect to our clinical trials, manufacturing supply chain or
sales and marketing activities; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any adverse changes to our relationship with manufacturers or suppliers; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the results of our testing and clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the results of our efforts to acquire or license additional drug candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">variations in the level of expenses related to our existing drugs and drug candidates or <FONT
STYLE="white-space:nowrap">pre-clinical,</FONT> clinical development and commercialization programs; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any intellectual property infringement actions in which we may become involved; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">announcements concerning our competitors or the pharmaceutical industry in general; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">fluctuations in product revenue, sales and marketing expenses and profitability; manufacture, supply or
distribution shortages; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">variations in our results of operations; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">announcements about our results of operations that are not in line with analyst expectations, the risk of which
is enhanced because it is our policy not to give guidance on results of operations; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">publication of operating or industry metrics by third parties, including government statistical agencies, that
differ from expectations of industry or financial analysts; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">changes in financial estimates by securities research analysts; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">media reports, whether or not true, about our business, our competitors or our industry; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">82 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">additions to or departures of our management; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">fluctuations of exchange rates between the RMB and the U.S. dollar; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">release or expiry of <FONT STYLE="white-space:nowrap">lock-up</FONT> or other transfer restrictions on our
outstanding ordinary shares or ADSs; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">sales or perceived potential sales of additional ordinary shares or ADSs by us, our executive officers and
directors or our shareholders; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any share repurchase program; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">general economic and market conditions and overall fluctuations in the U.S. equity markets;
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">changes in accounting principles; and </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">changes or developments in the PRC or global regulatory environment. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In addition, the stock market, in general, and pharmaceutical and biotechnology companies have experienced extreme price and volume
fluctuations that have often been unrelated or disproportionate to the operating performance of these companies. Broad market and industry factors may negatively affect the market price of our ADSs, regardless of our actual operating performance.
Further, the current volatility in the financial markets and related factors beyond our control may cause the market price of our ADSs to decline rapidly and unexpectedly. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may face an increased risk of securities class action litigation. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Historically, securities class action litigation has often been brought against a company following a significant decline in the market price
of its securities. This risk is especially relevant for us because biotechnology and biopharmaceutical companies have experienced significant share price volatilities in recent years. If we were to face lawsuits, it could lead to substantial costs
and a distraction of management&#146;s attention and resources, which could harm our business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We cannot guarantee that any share repurchase
program will be fully consummated or that any share repurchase program will enhance long-term shareholder value, and share repurchases could increase the volatility of the price of our ADSs and could diminish our cash reserves. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">On July&nbsp;15, 2020, we announced that our board of directors has authorized a share repurchase program, pursuant to which we were
authorized to repurchase our own ordinary shares, in the form of ADSs, with an aggregate value of up to US$20.0&nbsp;million during a twelve-month period effective upon and from the date on which a formal stock repurchase plan engagement agreement
is signed with a qualified broker-dealer(s). From July&nbsp;15, 2020 to the date of this prospectus, we didn&#146;t repurchase any ADSs. Our share repurchase program could affect the price of our ADSs and increase volatility and may be suspended or
terminated at any time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If securities or industry analysts do not publish research or publish inaccurate or unfavorable research about our
business, or if they adversely change their recommendations regarding our ADSs, the market price for our ADSs and trading volume could decline. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The trading market for our ADSs will depend in part on the research and reports that securities or industry analysts publish about us or our
business. If research analysts do not establish and maintain adequate research coverage or if one or more of the analysts who covers us downgrades our ADSs or publishes inaccurate or unfavorable research about our business, the market price for our
ADSs would likely decline. If one or more of these analysts cease coverage of our company or fail to publish reports on us regularly, we could lose visibility in the financial markets, which, in turn, could cause the market price or trading volume
for our ADSs to decline. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">83 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Because we do not expect to pay dividends in the foreseeable future, you must rely on price
appreciation of our ADSs for return on your investment. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We currently intend to retain most, if not all, of our available funds
and any future earnings to fund the development and growth of our business. As a result, we do not expect to pay any cash dividends in the foreseeable future. Therefore, you should not rely on an investment in our ADSs as a source for any future
dividend income. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our board of directors has complete discretion as to whether to distribute dividends, subject to our memorandum and
articles of association and certain requirements of Cayman Islands law. In addition, our shareholders may by ordinary resolution declare a dividend, but no dividend may exceed the amount recommended by our directors. Under Cayman Islands law, a
Cayman Islands company may pay a dividend out of either profit or share premium account of the company, provided that in no circumstances may a dividend be paid out of share premium if this would result in the company being unable to pay its debts
as they fall due in the ordinary course of business. Even if our board of directors decides to declare and pay dividends, the timing, amount and form of future dividends, if any, will depend on our future results of operations and cash flow, our
capital requirements and surplus, the amount of distributions, if any, received by us from our subsidiaries, our financial condition, contractual restrictions and other factors deemed relevant by our board of directors. Accordingly, the return on
your investment in our ADSs will likely depend entirely upon any future price appreciation of our ADSs. There is no guarantee that our ADSs will appreciate in value or even maintain the price at which you purchased the ADSs. You may not realize a
return on your investment in our ADSs and you may even lose your entire investment in our ADSs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Substantial future sales or perceived potential
sales of our ADSs in the public market could cause the price of our ADSs to decline. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Sales of substantial amounts of our ADSs in
the public market or the perception that these sales could occur, could adversely affect the market price of our ADSs and could materially impair our ability to raise capital through equity offerings in the future. The ADSs sold in this offering
will be freely tradable without restriction or further registration under the Securities Act, and ordinary shares held by our existing shareholders may also be sold in the public market subject to the restrictions in Rule 144 and Rule 701 under the
Securities Act and the applicable <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements. We cannot predict what effect, if any, market sales of securities held by our significant shareholders or any other shareholder or the availability of
these securities for future sale will have on the market price of our ADSs. See &#147;Shares Eligible for Future Sales&#148; for a more detailed description of the restrictions on selling our securities after this offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The voting rights of holders of ADSs are limited by the terms of the deposit agreement, and you may not be able to exercise the same rights as our
shareholders. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Holders of ADSs do not have the same rights as our shareholders. As a holder of our ADSs, you will not have any
direct right to attend general meetings of our shareholders or to cast any votes at such meetings. As an ADS holder, you will only be able to exercise the voting rights carried by the underlying ordinary shares indirectly by giving voting
instructions to the depositary in accordance with the provisions of the deposit agreement. Under the deposit agreement, you may vote only by giving voting instructions to the depositary. Upon receipt of your voting instructions, the depositary will
try, as far as is practicable, to vote the ordinary shares underlying your ADSs in accordance with your instructions. If we ask for your instructions, then upon receipt of your voting instructions, the depositary will try to vote the underlying
ordinary shares in accordance with these instructions. If we do not instruct the depositary to ask for your instructions, the depositary may still vote in accordance with instructions you give, but it is not required to do so. You will not be able
to directly exercise your right to vote with respect to the underlying ordinary shares unless you withdraw the shares, and become the registered holder of such shares prior to the record date for the general meeting. When a general meeting is
convened, you may not receive sufficient advance notice of the meeting to withdraw the shares </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">84 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
underlying your ADSs and become the registered holder of such shares to allow you to attend the general meeting and to vote directly with respect to any specific matter or resolution to be
considered and voted upon at the general meeting. In addition, under our memorandum and articles of association, for the purposes of determining those shareholders who are entitled to attend and vote at any general meeting, our directors may close
our register of members and/or fix in advance a record date for such meeting, and such closure of our register of members or the setting of such a record date may prevent you from withdrawing the ordinary shares underlying your ADSs and becoming the
registered holder of such shares prior to the record date, so that you would not be able to attend the general meeting or to vote directly. If we ask for your instructions, the depositary will notify you of the upcoming vote and will arrange to
deliver our voting materials to you. We have agreed to give the depositary notice of shareholder meetings sufficiently in advance of such meetings. Nevertheless, we cannot assure you that you will receive the voting materials in time to ensure that
you can instruct the depositary to vote the underlying ordinary shares represented by your ADSs. In addition, the depositary and its agents are not responsible for failing to carry out voting instructions or for their manner of carrying out your
voting instructions. This means that you may not be able to exercise your right to direct how the shares underlying your ADSs are voted and you may have no legal remedy if the shares underlying your ADSs are not voted as you requested. In addition,
in your capacity as an ADS holder, you will not be able to call a shareholders&#146; meeting. Except in limited circumstances, the depositary for our ADSs will give us a discretionary proxy to vote the ordinary shares underlying your ADSs if you do
not vote at shareholders&#146; meetings, which could adversely affect your interests. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Under the deposit agreement for the ADSs, if you do
not vote, the depositary will give us a discretionary proxy to vote the ordinary shares underlying your ADSs at shareholders&#146; meetings unless: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we have instructed the depositary that we do not wish a discretionary proxy to be given; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we have informed the depositary that there is substantial opposition as to a matter to be voted on at the
meeting; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a matter to be voted on at the meeting would have an adverse impact on shareholders; or </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the voting at the meeting is to be made on a show of hands. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The effect of this discretionary proxy is that you cannot prevent our ordinary shares underlying your ADSs from being voted, except under the
circumstances described above. This may make it more difficult for shareholders to influence the management of our company. Holders of our ordinary shares are not subject to this discretionary proxy. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Your right to participate in any future rights offerings may be limited, which may cause dilution to your holdings. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We may from time to time distribute rights to our shareholders, including rights to acquire our securities. However, we cannot make rights
available to you in the United States unless we register both the rights and the securities to which the rights relate under the Securities Act or an exemption from the registration requirements is available. Under the deposit agreement, the
depositary will not make rights available to you unless both the rights and the underlying securities to be distributed to ADS holders are either registered under the Securities Act or exempt from registration under the Securities Act. We are under
no obligation to file a registration statement with respect to any such rights or securities or to endeavor to cause such a registration statement to be declared effective and we may not be able to establish a necessary exemption from registration
under the Securities Act. Accordingly, you may be unable to participate in our rights offerings and may experience dilution in your holdings. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">85 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>You may not receive cash dividends if the depositary decides it is impractical to make them available
to you. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The depositary will pay cash dividends on the ADSs only to the extent that we decide to distribute dividends on our
ordinary shares or other deposited securities, and we do not have any present plan to pay any cash dividends on our ordinary shares in the foreseeable future. To the extent that there is a distribution, the depositary of our ADSs has agreed to pay
to you the cash dividends or other distributions it or the custodian receives on our ordinary shares or other deposited securities after deducting its fees and expenses pursuant to the deposit agreement. You will receive these distributions in
proportion to the number of ordinary shares your ADSs represent. However, the depositary may, at its discretion, decide that it is inequitable or impractical to make a distribution available to any holders of ADSs. For example, the depositary may
determine that it is not practicable to distribute certain property through the mail, or that the value of certain distributions may be less than the cost of mailing them. In these cases, the depositary may decide not to distribute such property to
you. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>You may be subject to limitations on transfer of your ADSs. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Your ADSs are transferable on the books of the depositary. However, the depositary may close its transfer books at any time or from time to
time when it deems expedient in connection with the performance of its duties. The depositary may close its books from time to time for a number of reasons, including in connection with corporate events such as a rights offering, during which time
the depositary needs to maintain an exact number of ADS holders on its books for a specified period. The depositary may also close its books in emergencies, and on weekends and public holidays. In addition, the depositary may refuse to deliver,
transfer or register transfers of ADSs generally when our books or the books of the depositary are closed, or at any time if we or the depositary deems it advisable to do so because of any requirement of law or of any government or governmental
body, or under any provision of the deposit agreement, or for any other reason. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Certain judgments obtained against us by our shareholders may not
be enforceable. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We are an exempted company incorporated under the laws of the Cayman Islands. We conduct our operations in China
and substantially all of our assets are located in China. In addition, our directors and executive officers, and some of the experts named in this prospectus, reside within China, and most of the assets of these persons are located within China. As
a result, it may be difficult or impossible for you to bring an action against us or against these individuals in the United States in the event that you believe that your rights have been infringed under the U.S. federal securities laws or
otherwise. Even if you are successful in bringing an action of this kind, the laws of the Cayman Islands and of the PRC may render you unable to enforce a judgment against our assets or the assets of our directors and officers. For more information
regarding the relevant laws of the Cayman Islands and China, see &#147;Enforceability of Civil Liabilities.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>ADSs holders may not be entitled
to a jury trial with respect to claims arising under the deposit agreement, which could result in less favorable outcomes to the plaintiff(s) in any such action. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The deposit agreement governing the ADSs representing our ordinary shares provides that, subject to the depositary&#146;s right to require a
claim to be submitted to the federal or state courts in the City of New York have jurisdiction to hear and determine claims arising under the deposit agreement and in that regard, to the fullest extent permitted by law, ADS holders waive the right
to a jury trial of any claim they may have against us or the depositary arising out of or relating to our shares, the ADSs or the deposit agreement, including any claim under the U.S. federal securities laws. Also, we may amend or terminate the
deposit agreement without your consent. If you continue to hold your ADSs after an amendment to the deposit agreement, you agree to be bound by the deposit agreement as amended. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">If we or the depositary were to oppose a jury trial demand based on such waiver, the court would determine whether the waiver was enforceable
in the facts and circumstances of that case in accordance with applicable state and federal law, including whether a party knowingly, intelligently and voluntarily waived the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">86 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
right to a jury trial. The waiver to right to a jury trial of the deposit agreement is not intended to be deemed a waiver by any holder or beneficial owner of ADSs of our or the depositary&#146;s
compliance with the U.S. federal securities laws and the rules and regulations promulgated thereunder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">If you or any other holders or
beneficial owners of ADSs bring a claim against us or the depositary in connection with matters arising under the deposit agreement or the ADSs, including claims under U.S. federal securities laws, you or such other holder or beneficial owner may
not be entitled to a jury trial with respect to such claims, which may have the effect of limiting and discouraging lawsuits against us and/or the depositary. If a lawsuit is brought against us and/or the depositary under the deposit agreement, it
may be heard only by a judge or justice of the applicable trial court, in which the trial would be conducted according to different civil procedures and may result in different outcomes than a trial by jury would have had, including results that
could be less favorable to the plaintiff(s) in any such action. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Nevertheless, if this jury trial waiver provision is not enforced, to the
extent a court action proceeds, it would proceed under the terms of the deposit agreement with a jury trial. No condition, stipulation or provision of the deposit agreement or ADSs serves as a waiver by any holder or beneficial owner of ADSs or by
us or the depositary of compliance with any substantive provision of the U.S. federal securities laws and the rules and regulations promulgated thereunder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>You may face difficulties in protecting your interests, and your ability to protect your rights through U.S. courts may be limited, because we are
incorporated under Cayman Islands law. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We are an exempted company incorporated under the laws of the Cayman Islands with limited
liability. Our corporate affairs are governed by our memorandum and articles of association, the Companies Law (2020 Revision) of the Cayman Islands, which we refer to as the Companies Law, and the common law of the Cayman Islands. The rights of
shareholders to take action against our directors, actions by our minority shareholders and the fiduciary duties of our directors to us under Cayman Islands law are to a large extent governed by the common law of the Cayman Islands. The common law
of the Cayman Islands is derived in part from comparatively limited judicial precedent in the Cayman Islands as well as from the common law of England, the decisions of whose courts are of persuasive authority, but are not binding, on a court in the
Cayman Islands. The rights of our shareholders and the fiduciary duties of our directors under Cayman Islands law are not as clearly established as they would be under statutes or judicial precedent in some jurisdictions in the United States. In
particular, the Cayman Islands has a less developed body of securities laws than the United States. Some U.S. states, such as Delaware, have more fully developed and judicially interpreted bodies of corporate law than the Cayman Islands. In
addition, Cayman Islands companies may not have standing to initiate a shareholder derivative action in a federal court of the United States. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Shareholders of Cayman Islands exempted companies like us have no general rights under Cayman Islands law to inspect corporate records or to
obtain copies of lists of shareholders of these companies. Our directors have discretion under our articles of association to determine whether or not, and under what conditions, our corporate records may be inspected by our shareholders, but are
not obliged to make them available to our shareholders. This may make it more difficult for you to obtain the information needed to establish any facts necessary for a shareholder motion or to solicit proxies from other shareholders in connection
with a proxy contest. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">As a result of all of the above, our public shareholders may have more difficulty in protecting their interests in
the face of actions taken by management, members of the board of directors or controlling shareholders than they would as public shareholders of a company incorporated in the United States. For a discussion of significant differences between the
provisions of the Companies Law and the laws applicable to companies incorporated in the United States and their shareholders, see &#147;Description of Share Capital&#151;Differences in Corporate Law.&#148; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">87 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We will not receive any proceeds from this offering. However, we continue to retain broad discretion
in the use of the net proceeds from our initial public offering. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We will not receive any proceeds from this offering. However, we
will continue to retain broad discretion in the application of the net proceeds from our initial public offering and could spend the proceeds in ways that do not produce income or increase our ADS price. We have not determined a specific use for a
portion of the net proceeds of our initial public offering, and our management will have considerable discretion in deciding how to apply these proceeds. You will not have the opportunity to assess whether the net proceeds from our initial public
offering are being used appropriately before you make your investment decision. You must rely on the judgment of our management regarding the application of the net proceeds of our initial public offering. We cannot assure you that the net proceeds
from our initial public offering will be used in a manner that would improve our results of operations or increase our ADS price, nor that these net proceeds will be placed only in investments that generate income or appreciate in value. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our memorandum and articles of association contains anti-takeover provisions that could discourage a third party from acquiring us and adversely affect
the rights of holders of our ordinary shares and the ADSs. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our memorandum and articles of association contains provisions to
limit the ability of others to acquire control of our company or cause us to engage in change of control transactions. These provisions could have the effect of depriving our shareholders of an opportunity to sell their shares at a premium over
prevailing market prices by discouraging third parties from seeking to obtain control of our company in a tender offer or similar transaction. Our board of directors has the authority to issue preferred shares in one or more series and to fix their
designations, powers, preferences, privileges, and relative participating, optional or special rights and the qualifications, limitations or restrictions, including dividend rights, conversion rights, voting rights, terms of redemption and
liquidation preferences, any or all of which may be greater than the rights associated with our ordinary shares, in the form of ADS or otherwise. Preferred shares could be issued with terms calculated to delay or prevent a change in control of our
company or make removal of management more difficult. If our board of directors decides to issue preferred shares, the price of our ADSs may fall and the voting and other rights of the holders of our ordinary shares and ADSs may be materially and
adversely affected. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We are an emerging growth company within the meaning of the Securities Act and may take advantage of certain reduced reporting
requirements. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We are an &#147;emerging growth company,&#148; as defined in the U.S. Jumpstart Our Business Startups Act of 2012,
or the JOBS Act, and we may take advantage of certain exemptions from various requirements applicable to other public companies that are not emerging growth companies including, most significantly, not being required to comply with the auditor
attestation requirements of Section&nbsp;404 of Sarbanes-Oxley Act of 2002 for so long as we are an emerging growth company. As a result, if we elect not to comply with such auditor attestation requirements, our investors may not have access to
certain information they may deem important. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The JOBS Act also provides that an emerging growth company does not need to comply with any
new or revised financial accounting standards until such date that a private company is otherwise required to comply with such new or revised accounting standards. However, we have elected to &#147;opt out&#148; of this provision and, as a result,
we will comply with new or revised accounting standards as required when they are adopted for public companies. This decision to opt out of the extended transition period under the JOBS Act is irrevocable. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">88 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We are a foreign private issuer within the meaning of the rules under the Exchange Act, and as such we
are exempt from certain provisions applicable to U.S. domestic public companies. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Because we qualify as a foreign private issuer
under the Exchange Act, we are exempt from certain provisions of the securities rules and regulations in the United States that are applicable to U.S. domestic issuers, including: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the rules under the Exchange Act requiring the filing with the SEC of quarterly reports on <FONT
STYLE="white-space:nowrap">Form&nbsp;10-Q</FONT> or current reports on Form <FONT STYLE="white-space:nowrap">8-K;</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the sections of the Exchange Act regulating the solicitation of proxies, consents, or authorizations in respect
of a security registered under the Exchange Act; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the sections of the Exchange Act requiring insiders to file public reports of their stock ownership and trading
activities and liability for insiders who profit from trades made in a short period of time; and </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the selective disclosure rules by issuers of material nonpublic information under Regulation FD promulgated by
SEC. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We are required to file an annual report on Form <FONT STYLE="white-space:nowrap">20-F</FONT> within four months
of the end of each fiscal year. In addition, we intend to publish our results on a quarterly basis as press releases, distributed pursuant to the rules and regulations of the Nasdaq Stock Market. Press releases relating to financial results and
material events will also be furnished to the SEC on Form <FONT STYLE="white-space:nowrap">6-K.</FONT> However, the information we are required to file with or furnish to the SEC will be less extensive and less timely compared to that required to be
filed with the SEC by U.S. domestic issuers. As a result, you may not be afforded the same protections or information that would be made available to you were you investing in a U.S. domestic issuer. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>As an exempted company incorporated in the Cayman Islands, we are permitted to adopt certain home country practices in relation to corporate governance
matters that differ significantly from the Nasdaq Stock Market&#146;s corporate governance requirements; these practices may afford less protection to shareholders than they would enjoy if we complied fully with the Nasdaq Stock Market&#146;s
corporate governance requirements. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">As a Cayman Islands company listed on the Nasdaq Stock Market, we are subject to the Nasdaq
Stock Market&#146;s corporate governance requirements. However, the Nasdaq Stock Market rules permit a foreign private issuer like us to follow the corporate governance practices of its home country. Certain corporate governance practices in the
Cayman Islands, which is our home country, may differ significantly from the Nasdaq Stock Market&#146;s corporate governance requirements. For example, neither the Companies Law nor our memorandum and articles of association requires a majority of
our directors to be independent and we could include <FONT STYLE="white-space:nowrap">non-independent</FONT> directors as members of our compensation committee and nominating committee, and our independent directors would not necessarily hold
regularly scheduled meetings at which only independent directors are present. We follow home country practice with respect to adoption of the 2020 Plan. However, if we choose to follow home country practice in the future, our shareholders may be
afforded less protection than they otherwise would under the Nasdaq Stock Market&#146;s corporate governance requirements applicable to U.S. domestic issuers. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>There can be no assurance that we will not be classified as a passive foreign investment company, or PFIC, for U.S. federal income tax purposes for any
taxable year, which could subject U.S. investors in our ADSs or ordinary shares to significant adverse U.S. income tax consequences. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We will be a passive foreign investment company, or PFIC, for any taxable year if either (i) 75% or more of our gross income for such year
consists of certain types of &#147;passive&#148; income or (ii) 50% or more of the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">89 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
average quarterly value of our assets (generally determined on the basis of fair market value) during such year produce or are held for the production of passive income (the &#147;asset
test&#148;). No assurance can be given with respect to our PFIC status for the current taxable year or any future taxable year. The determination of whether we are or will become a PFIC is uncertain because it is a fact-intensive inquiry made on an
annual basis that will depend, in part, on the composition of our income and assets. Fluctuations in the market price of our ADSs may cause us to be a PFIC for the current or subsequent taxable years because the value of our assets for purposes of
the asset test may be determined by reference to the market price of our ADSs from time to time (which may be volatile for biopharmaceutical companies, such as ours, that have not yet achieved commercialization with respect to any of their
products). The composition of our income and assets may also be affected by how, and how quickly, we use our liquid assets. Under circumstances where our revenue from activities that produce passive income increases relative to our revenue from
activities that produce <FONT STYLE="white-space:nowrap">non-passive</FONT> income, or where we determine not to deploy cash for active purposes, our risk of being a PFIC will substantially increase. Furthermore, prior to the commercialization of
any of our drug candidates, interest and other passive income could constitute more than 75% of gross income for any taxable year. Because there are uncertainties in the application of the relevant rules, it is possible that the IRS may challenge
our classification or valuation of certain income and assets, each of which may result in our being or becoming a PFIC for the current or subsequent taxable years. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">If we are a PFIC in any taxable year, a U.S. Holder (as defined in &#147;Taxation&#151;United States Federal Income Tax Considerations&#148;)
may incur significantly increased U.S. income tax on gain recognized on the sale or other disposition of the ADSs or ordinary shares and on the receipt of distributions on the ADSs or ordinary shares to the extent such gain or distribution is
treated as an &#147;excess distribution&#148; under the U.S. federal income tax rules and such holder may be subject to burdensome reporting requirements. Further, if we are a PFIC for any year during which a U.S. Holder holds our ADSs or ordinary
shares, we generally will continue to be treated as a PFIC for all succeeding years during which such U.S. Holder holds our ADSs or ordinary shares. For more information see &#147;Taxation&#151;United States Federal Income Tax
Considerations&#151;Passive Foreign Investment Company Considerations.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We expect to incur increased costs and become subject to additional
rules and regulations as a result of being a public company, particularly after we cease to qualify as an &#147;emerging growth company.&#148; </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">As a public company, we expect to incur significant legal, accounting and other expenses that we did not incur as a private company. The
Sarbanes-Oxley Act of 2002, as well as rules subsequently implemented by the SEC and the Nasdaq Global Market, impose various requirements on the corporate governance practices of public companies. As a company with less than US$1.07&nbsp;billion in
net revenues for our last fiscal year, we qualify as an &#147;emerging growth company&#148; pursuant to the JOBS Act. An emerging growth company may take advantage of specified reduced reporting and other requirements that are otherwise applicable
generally to public companies. These provisions include exemption from the auditor attestation requirement under Section&nbsp;404 of the Sarbanes-Oxley Act of 2002 in the assessment of the emerging growth company&#146;s internal control over
financial reporting and permission to delay adopting new or revised accounting standards until such time as those standards apply to private companies. However, we have elected to &#147;opt out&#148; of the provision that allows us to delay adopting
new or revised accounting standards and, as a result, we will comply with new or revised accounting standards as required when they are adopted for public companies. This decision to opt out of the extended transition period under the JOBS Act is
irrevocable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We expect these rules and regulations to increase our legal and financial compliance costs and to make some corporate
activities more time-consuming and costly. After we are no longer an &#147;emerging growth company,&#148; we expect to incur significant expenses and devote substantial management effort toward ensuring compliance with the requirements of
Section&nbsp;404 of the Sarbanes-Oxley Act of 2002 and the other rules and regulations of the SEC. We also expect that operating as a public company will make it more difficult and more expensive for us to obtain director and officer liability
insurance, and we may be required to accept reduced policy limits and coverage or incur substantially higher costs to obtain the same or similar coverage. In addition, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">90 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
we will incur additional costs associated with our public company reporting requirements. It may also be more difficult for us to find qualified persons to serve on our board of directors or as
executive officers. We are currently evaluating and monitoring developments with respect to these rules and regulations, and we cannot predict or estimate with any degree of certainty the amount of additional costs we may incur or the timing of such
costs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In the past, shareholders of a public company often brought securities class action suits against the company following periods of
instability in the market price of that company&#146;s securities. If we were involved in a class action suit, it could divert a significant amount of our management&#146;s attention and other resources from our business and operations, which could
harm our results of operations and require us to incur significant expenses to defend the suit. Any such class action suit, whether or not successful, could harm our reputation and restrict our ability to raise capital in the future. In addition, if
a claim is successfully made against us, we may be required to pay significant damages, which could have a material adverse effect on our financial condition and results of operations. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">91 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom98473_5"></A>SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">This prospectus contains forward-looking statements that reflect our current expectations and views of future events. The forward-looking
statements are contained principally in the sections entitled &#147;Prospectus Summary,&#148; &#147;Risk Factors,&#148; &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations&#148; and &#147;Business.&#148;
Known and unknown risks, uncertainties and other factors, including those listed under &#147;Risk Factors,&#148; may cause our actual results, performance or achievements to be materially different from those expressed or implied by the
forward-looking statements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">You can identify some of these forward-looking statements by words or phrases such as &#147;may,&#148;
&#147;will,&#148; &#147;expect,&#148; &#147;anticipate,&#148; &#147;aim,&#148; &#147;estimate,&#148; &#147;intend,&#148; &#147;plan,&#148; &#147;believe,&#148; &#147;is/are likely to,&#148; &#147;potential,&#148; &#147;continue&#148; or other
similar expressions. We have based these forward-looking statements largely on our current expectations and projections about future events that we believe may affect our financial condition, results of operations, business strategy and financial
needs. These forward-looking statements include statements relating to: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the timing of initiation and completion, and the progress of our drug discovery and research programs;
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the timing and likelihood of regulatory filings and approvals; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to advance our drug candidates into drugs, and the successful completion of clinical trials;
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the approval, pricing and reimbursement of our drug candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the commercialization of our drug candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the market opportunities and competitive landscape of our drug candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the payment, receipt and timing of any milestone payments in relation to the licensing agreements;
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">estimates of our costs, expenses, future revenues, capital expenditures and our needs for additional financing;
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to attract and retain senior management and key employees; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our future business development, financial condition and results of operations; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">future developments, trends, conditions and competitive landscape in the industry and markets in which we
operate; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our strategies, plans, objectives and goals and our ability to successfully implement these strategies, plans,
objectives and goals; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to continue to maintain our market position in China&#146;s biopharmaceutical and biotechnology
industries; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to identify and integrate suitable acquisition targets; and </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">changes to regulatory and operating conditions in our industry and markets. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">These forward-looking statements involve various risks and uncertainties. Although we believe that our expectations expressed in these
forward-looking statements are reasonable, our expectations may later be found </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">92 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
to be incorrect. Our actual results could be materially different from our expectations. Important risks and factors that could cause our actual results to be materially different from our
expectations are generally set forth in &#147;Prospectus Summary&#151;Our Challenges,&#148; &#147;Risk Factors,&#148; &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations,&#148; &#147;Business,&#148;
&#147;Regulation&#148; and other sections in this prospectus. You should read thoroughly this prospectus and the documents that we refer to with the understanding that our actual future results may be materially different from and worse than what we
expect. We qualify all of our forward-looking statements by these cautionary statements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">This prospectus contains certain data and
information that we obtained from various government and private publications. Statistical data in these publications also include projections based on a number of assumptions. The biopharmaceutical industry may not grow at the rate projected by
market data, or at all. Failure of this market to grow at the projected rate may have a material and adverse effect on our business and the market price of our ADSs. In addition, the rapidly evolving nature of the biopharmaceutical industry results
in significant uncertainties for any projections or estimates relating to the growth prospects or future condition of our market. Furthermore, if any one or more of the assumptions underlying the market data are later found to be incorrect, actual
results may differ from the projections based on these assumptions. You should not place undue reliance on these forward-looking statements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The forward-looking statements made in this prospectus relate only to events or information as of the date on which the statements are made in
this prospectus. Except as required by law, we undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made
or to reflect the occurrence of unanticipated events. You should read this prospectus and the documents that we refer to in this prospectus and have filed as exhibits to the registration statement, of which this prospectus is apart, completely and
with the understanding that our actual future results may be materially different from what we expect. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">93 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom98473_6"></A>USE OF PROCEEDS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">All the ordinary shares or ADSs sold pursuant to this prospectus will be offered and sold by the selling shareholders. We will not receive any
proceeds from such sales. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">94 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom98473_7"></A>DIVIDEND POLICY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our board of directors has complete discretion on whether to pay dividends, subject to certain requirements of Cayman Islands law. Even if our
board of directors decides to pay dividends on our ordinary shares, the form, frequency and amount will depend upon our future operations and earnings, capital requirements and surplus, general financial condition, contractual restrictions and other
factors that our board of directors may deem relevant. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We do not have any present plan to pay any cash dividends on our ordinary shares
in the foreseeable future after this offering. We currently intend to retain most, if not all, of our available funds and any future earnings to operate and expand our business. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We are a holding company incorporated in the Cayman Islands. We may rely on dividends from our subsidiaries in China for our cash
requirements, including any payment of dividends to our shareholders. PRC regulations may restrict the ability of our PRC subsidiaries to pay dividends to us. See &#147;Regulation&#151;PRC Regulation&#151;Regulations Relating to Foreign Exchange and
the Dividend Distribution.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">If we pay any dividends on our ordinary shares, we will pay those dividends which are payable in respect
of the ordinary shares underlying our ADSs to the depositary, as the registered holder of such ordinary shares, and the depositary then will pay such amounts to our ADS holders in proportion to the ordinary shares underlying the ADSs held by such
ADS holders, subject to the terms of the deposit agreement, including the fees and expenses payable thereunder. See &#147;Description of American Depositary Shares.&#148; Cash dividends on our ordinary shares, if any, will be paid in U.S. dollars.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">95 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom98473_8"></A>CAPITALIZATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The following table sets forth our capitalization as of June&nbsp;30, 2020. You should read this table together with our consolidated
financial statements and the related notes included elsewhere in this prospectus and the information under &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations.&#148; </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="85.5%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="74%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>As of June&nbsp;30, 2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>RMB</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>US$</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Convertible promissory notes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">69,138</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,787</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Shareholders&#146; equity</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ordinary shares (US$0.0001 par value, 800,000,000 shares <BR>authorized as of June&nbsp;30, 2020;
133,006,644 shares issued <BR>and outstanding as of June&nbsp;30, 2020)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">92</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Additional <FONT STYLE="white-space:nowrap">paid-in</FONT> capital</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,675,991</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">661,844</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated other comprehensive income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">104,853</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,841</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,077,060</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(435,530</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total shareholders&#146; equity</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,703,876</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">241,168</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total capitalization</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,048,722</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">289,979</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">96 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom98473_9"></A>ENFORCEABILITY OF CIVIL LIABILITIES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We are incorporated under the laws of the Cayman Islands as an exempted company with limited liability. We are incorporated in the Cayman
Islands because of certain benefits associated with being a Cayman Islands exempted company, such as political and economic stability, an effective judicial system, a favorable tax system, the absence of foreign exchange control or currency
restrictions and the availability of professional and support services. However, the Cayman Islands has a less developed body of securities laws than the United States and provides less protection for investors. In addition, Cayman Islands companies
do not have standing to sue before the federal courts of the United States. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Most of our assets are located outside the United States. In
addition, most of our directors and officers are nationals or residents of jurisdictions other than the United States and all or a substantial portion of their assets are located outside the United States. As a result, it may be difficult for
investors to effect service of process within the United States upon us or these persons, or to enforce judgments obtained in U.S. courts against us or them, including judgments predicated upon the civil liability provisions of the securities laws
of the United States or any state in the United States. It may also be difficult for you to enforce judgments obtained in U.S. courts based on the civil liability provisions of the U.S. federal securities laws against us and our officers and
directors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We have appointed Cogency Global Inc. as our agent to receive service of process with respect to any action brought against us
in the U.S. District Court for the Southern District of New York in connection with this offering under the federal securities laws of the United States or the securities laws of any state in the United States or any action brought against us in the
Supreme Court of the State of New York in the County of New York in connection with this offering under the securities laws of the State of New York. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Conyers Dill&nbsp;&amp; Pearman, our counsel as to Cayman Islands law, has advised us that there is uncertainty as to whether the courts of
the Cayman Islands would (1)&nbsp;recognize or enforce judgments of U.S. courts obtained against us or our directors or officers that are predicated upon the civil liability provisions of the federal securities laws of the United States or the
securities laws of any state in the United States, or (2)&nbsp;entertain original actions brought in the Cayman Islands against us or our directors or officers that are predicated upon the federal securities laws of the United States or the
securities laws of any state in the United States. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Conyers Dill&nbsp;&amp; Pearman has informed us that the uncertainty with regard to
Cayman Islands law relates to whether a judgment obtained from the U.S. courts under civil liability provisions of the securities law will be determined by the courts of the Cayman Islands as penal or punitive in nature. The courts of the Cayman
Islands may not recognize or enforce such judgments against a Cayman company, and because such a determination has not yet been made by a court of the Cayman Islands, it is uncertain whether such civil liability judgments from U.S. courts would be
enforceable in the Cayman Islands. Conyers Dill&nbsp;&amp; Pearman has further advised us that the courts of the Cayman Islands would recognize as a valid judgment, a final and conclusive judgment in personam obtained in the federal or state courts
of the United States under which a sum of money is payable (other than a sum of money payable in respect of multiple damages, taxes or other charges of a like nature or in respect of a fine or other penalty) or, in certain circumstances, an in
personam judgment for <FONT STYLE="white-space:nowrap">non-monetary</FONT> relief, and would give a judgment based thereon provided that (a)&nbsp;such courts had proper jurisdiction over the parties subject to such judgment; (b)&nbsp;such courts did
not contravene the rules of natural justice of the Cayman Islands; (c)&nbsp;such judgment was not obtained by fraud; (d)&nbsp;the enforcement of the judgment would not be contrary to the public policy of the Cayman Islands; (e)&nbsp;no new
admissible evidence relevant to the action is submitted prior to the rendering of the judgment by the courts of the Cayman Islands; and (f)&nbsp;there is due compliance with the correct procedures under the laws of the Cayman Islands. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">JunHe LLP, our counsel as to PRC law, has advised us that there is uncertainty as to whether the courts of China would (1)&nbsp;recognize or
enforce judgments of United States courts obtained against us or our directors or officers predicated upon the civil liability provisions of the securities laws of the United States or any state in the
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">97 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
United States, or (2)&nbsp;entertain original actions brought in each respective jurisdiction against us or our directors or officers predicated upon the securities laws of the United States or
any state in the United States. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">JunHe LLP has further advised us that the recognition and enforcement of foreign judgments are provided
for under the PRC Civil Procedures Law. The PRC courts may recognize and enforce foreign judgments in accordance with the requirements of the PRC Civil Procedures Law based either on treaties between China and the country where the judgment is made
or on principles of reciprocity between jurisdictions. China does not have any treaties or other form of reciprocal arrangements with the United States or the Cayman Islands that provide for the reciprocal recognition and enforcement of foreign
judgments. In addition, according to the PRC Civil Procedures Law, courts in China will not enforce a foreign judgment against us or our directors and officers if they decide that the judgment violates the basic principles of PRC law or national
sovereignty, security or public interest. As a result, it is uncertain whether and on what basis a PRC court would enforce a judgment rendered by a court in the United States or in the Cayman Islands. Under the PRC Civil Procedures Law, foreign
shareholders may initiate actions based on PRC law before a PRC court against a company for disputes, if the plaintiff can establish a sufficient contact with China for a PRC court to exercise jurisdiction and has a direct interest, cause of action
and a concrete claim. The action may be initiated by a shareholder through filing a complaint with the PRC court. The PRC court will determine whether to accept the complaint in accordance with the PRC Civil Procedures Law. The shareholder may
participate in the action by itself or entrust any other person or PRC legal counsel to participate on behalf of such shareholder. In addition, it will be difficult for U.S. shareholders to originate actions against us in China in accordance with
PRC laws because we are incorporated under the laws of the Cayman Islands and it will be difficult for U.S. shareholders, by virtue only of holding our ADSs or ordinary shares, to establish a connection to China for a PRC court to have jurisdiction
as required under the PRC Civil Procedures Law. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">98 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom98473_10"></A>CORPORATE HISTORY AND STRUCTURE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We commenced our operations in November 2014, when our predecessor Third Venture Biopharma (Nanjing) Co., Ltd (&#147;Third Venture&#148;) was
established. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">I-Mab</FONT> was established in June 2016 under the laws of the Cayman Islands as our
offshore holding company. In July 2016, <FONT STYLE="white-space:nowrap">I-Mab</FONT> established <FONT STYLE="white-space:nowrap">I-Mab</FONT> Biopharma Hong Kong Limited <FONT STYLE="white-space:nowrap">(&#147;I-Mab</FONT> Hong Kong&#148;), as its
intermediary holding company. In August 2016, <FONT STYLE="white-space:nowrap">I-Mab</FONT> Hong Kong established a wholly-owned PRC subsidiary, <FONT STYLE="white-space:nowrap">I-Mab</FONT> Biopharma Co., Ltd.
<FONT STYLE="white-space:nowrap">(&#147;I-Mab</FONT> Shanghai&#148;). In September 2016, the assets and operations of Third Venture were consolidated into <FONT STYLE="white-space:nowrap">I-Mab</FONT> Shanghai. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In July 2017, <FONT STYLE="white-space:nowrap">I-Mab</FONT> Hong Kong acquired a controlling interest in
<FONT STYLE="white-space:nowrap">I-Mab</FONT> <FONT STYLE="white-space:nowrap">Bio-tech</FONT> (Tianjin) Co., Ltd. <FONT STYLE="white-space:nowrap">(&#147;I-Mab</FONT> Tianjin&#148;), formerly known as Tasgen
<FONT STYLE="white-space:nowrap">Bio-tech</FONT> (Tianjin) Co., Ltd., a company focused on CMC management of biologics in China. Through an internal corporate restructuring, <FONT STYLE="white-space:nowrap">I-Mab</FONT> Tianjin became the 100% owner
of <FONT STYLE="white-space:nowrap">I-Mab</FONT> Shanghai in September 2017 and <FONT STYLE="white-space:nowrap">I-Mab</FONT> Hong Kong acquired the remaining interest in <FONT STYLE="white-space:nowrap">I-Mab</FONT> Tianjin in May 2018, becoming
the 100% owner of <FONT STYLE="white-space:nowrap">I-Mab</FONT> Tianjin. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In February 2018, <FONT STYLE="white-space:nowrap">I-Mab</FONT>
Hong Kong established in Maryland, United States, a wholly-owned subsidiary <FONT STYLE="white-space:nowrap">I-Mab</FONT> Biopharma US Limited <FONT STYLE="white-space:nowrap">(&#147;I-Mab</FONT> US&#148;), as the hub for the discovery and
development of the drug candidates in our Global Portfolio. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">On January&nbsp;17, 2020, our ADSs commenced trading on the Nasdaq Global
Market under the symbol &#147;IMAB.&#148; We raised from our initial public offering approximately US$103.7&nbsp;million in net proceeds, after the underwriters exercise in part their over-allotment option to purchase additional ADSs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In June 2019, with intention to build a comprehensive biologics manufacturing facility as part of our strategic plan to become a fully
integrated biopharma company, <FONT STYLE="white-space:nowrap">I-Mab</FONT> Hong Kong established <FONT STYLE="white-space:nowrap">I-Mab</FONT> Biopharma (Hangzhou) Co. Ltd <FONT STYLE="white-space:nowrap">(&#147;I-Mab</FONT> Hangzhou&#148;) in
Hangzhou, China. <FONT STYLE="white-space:nowrap">I-Mab</FONT> Hangzhou targets to have a pilot capacity of 2 x 2,000L by the end of 2021 and commercially progressive capacity up to 8 x 2,000L to begin operation by the end of 2023. In September
2020, a group of domestic investors in China invested a total of US$120&nbsp;million (in RMB equivalent) in cash. We and parties acting in concert remain the majority shareholder of <FONT STYLE="white-space:nowrap">I-Mab</FONT> Hangzhou, retain a
managing role and take full control to build and operate the manufacturing facility. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">99 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The following diagram illustrates our corporate structure, including our principal
subsidiaries, as of the date of this prospectus: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g98473g36k00.jpg" ALT="LOGO">
 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">100 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom98473_11"></A>SELECTED CONSOLIDATED FINANCIAL DATA </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The following selected consolidated statements of comprehensive loss data for the years ended December&nbsp;31, 2017, 2018 and 2019, selected
consolidated balance sheet data as of December&nbsp;31, 2017, 2018 and 2019 and selected consolidated statements of cash flow data for the years ended December&nbsp;31, 2017, 2018 and 2019 have been derived from our audited consolidated financial
statements included elsewhere in this prospectus. The following selected consolidated statements of comprehensive loss data for the six months ended June&nbsp;30, 2019 and 2020, selected consolidated balance sheet data as of June&nbsp;30, 2020 and
selected consolidated statements of cash flow data for the six months ended June&nbsp;30, 2019 and 2020 are derived from our unaudited interim condensed consolidated financial statements included elsewhere in this prospectus. Our consolidated
financial statements are prepared and presented in accordance with accounting principles generally accepted in the U.S. GAAP. Our historical results are not necessarily indicative of results expected for future periods. You should read this Selected
Consolidated Financial Data section together with our consolidated financial statements and the related notes and &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations&#148; included elsewhere in this
prospectus. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="25%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>For the Year Ended December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>For the Six Months Ended June&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>RMB</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>RMB</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>RMB</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>US$</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>RMB</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>RMB</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>US$</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="26" ALIGN="center"><B>(in thousands, except for share and per share data)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Selected Consolidated Statements of Comprehensive Loss Data:</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Revenues</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Licensing and collaboration revenue</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,556</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">53,781</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,246</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Expenses</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development expenses<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>

<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(267,075</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(426,028</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(840,415</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(118,953</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(265,084</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(442,291</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(62,602</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Administrative expenses<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(25,436</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(66,391</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(654,553</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(92,646</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(574,584</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(171,384</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(24,258</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Loss from operations</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(280,955</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(438,638</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(1,464,968</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(207,353</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(824,668</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(613,675</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(86,860</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest income</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">858</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,597</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30,570</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,327</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,818</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,955</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,683</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest expense</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5,643</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(11,695</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,991</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(423</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,936</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(957</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(135</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other income (expenses), net</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,527</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(16,780</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(20,205</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,860</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">303</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,824</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,815</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fair value change of warrants</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(14,027</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">61,405</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,644</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">799</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(43,854</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Loss before income tax expense</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(298,240</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(401,111</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(1,451,950</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(205,510</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(857,337</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(582,853</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(82,497</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income tax expense</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,722</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net loss attributable to <FONT STYLE="white-space:nowrap">I-Mab</FONT></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(298,240</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(402,833</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(1,451,950</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(205,510</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(857,337</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(582,853</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(82,497</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deemed dividend to Series <FONT STYLE="white-space:nowrap">C-1</FONT> preferred shareholders at
extinguishment of Series <FONT STYLE="white-space:nowrap">C-1</FONT> Preferred Shares</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5,283</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(748</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">101 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="25%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>For the Year Ended December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>For the Six Months Ended June&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>RMB</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>RMB</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>RMB</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>US$</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>RMB</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>RMB</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>US$</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="26" ALIGN="center"><B>(in thousands, except for share and per share data)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deemed dividend to Series <FONT STYLE="white-space:nowrap">B-1,</FONT> <FONT
STYLE="white-space:nowrap">B-2</FONT> and C preferred shareholders at modification of Series <FONT STYLE="white-space:nowrap">B-1,</FONT> <FONT STYLE="white-space:nowrap">B-2</FONT> and C Preferred Shares</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(27,768</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,930</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net loss attributable to ordinary shareholders</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(298,240</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(402,833</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(1,485,001</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(210,188</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(857,337</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(582,853</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(82,497</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Other comprehensive income</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Foreign currency translation adjustments, net of nil tax</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,918</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">53,689</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,747</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,521</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4,972</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">34,726</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,915</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total comprehensive loss attributable to
<FONT STYLE="white-space:nowrap">I-Mab</FONT></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(292,322</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(349,144</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(1,441,203</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(203,989</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(862,309</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(548,127</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(77,582</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net loss attributable to ordinary shareholders</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(298,240</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(402,833</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(1,485,001</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(210,188</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(857,337</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(582,853</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(82,497</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Weighted-average number of ordinary shares used in calculating net loss per shares</B></P></TD>

<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,742,669</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,529,092</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,381,230</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,381,230</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,184,086</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">121,815,986</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">121,815,986</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net loss per share attributable to ordinary shareholders</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Basic</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(51.93</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(61.70</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(201.19</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(28.48</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(119.34</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4.78</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(0.68</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Diluted</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(51.93</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(61.70</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(201.19</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(28.48</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(119.34</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4.78</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(0.68</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Note: </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Share-based compensation expenses were allocated as follows: </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="50%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>For the Year Ended December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>For the Six Months</B><br><B>Ended June&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>RMB</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>RMB</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>RMB</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>US$</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>RMB</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>RMB</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>US$</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="26" ALIGN="center"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,112</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,056</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">470</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">67</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">308</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">132,724</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,786</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Administrative expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,927</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,464</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">514,733</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">72,856</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">514,356</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">97,071</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,739</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>7,039</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>3,520</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>515,203</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>72,922</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>514,664</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>229,795</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>32,525</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">102 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The following table presents our selected consolidated statements of balance sheet data as
of December&nbsp;31, 2017, 2018 and 2019 and June&nbsp;30, 2020: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="39%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>As of December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>As of June&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>RMB</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>RMB</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>RMB</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>US$</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>RMB</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>US$</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="22" ALIGN="center"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Selected Consolidated Statements of Balance Sheet Data:</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Current assets:</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">307,930</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,588,278</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,137,473</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">160,999</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,560,031</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">220,808</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Restricted cash</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">104,783</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">92,653</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">55,810</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,899</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Contract assets</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Short-term investments</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">32,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,529</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,926</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">273</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepayments and other receivables</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,633</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">88,972</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">136,036</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,255</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">131,130</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,560</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other financial assets</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">266,245</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">255,958</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total current assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">691,591</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,036,861</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,361,319</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">192,682</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,693,087</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">239,641</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Property, equipment and software</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,336</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27,659</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30,069</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,256</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26,625</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,769</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating lease
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT> assets</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,435</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,326</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17,592</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,490</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Intangible assets</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">148,844</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">148,844</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">148,844</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21,068</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">148,844</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21,068</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Goodwill</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">162,574</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">162,574</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">162,574</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23,011</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">162,574</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23,011</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other <FONT STYLE="white-space:nowrap">non-current</FONT> assets</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,331</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,594</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1,025,345</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>2,375,938</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1,737,572</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>245,937</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>2,048,722</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>289,979</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total liabilities</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>309,151</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>415,684</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>668,090</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>94,561</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>344,846</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>48,811</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total mezzanine equity</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1,015,989</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>2,915,358</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>3,104,177</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>439,368</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Shareholders&#146; equity (deficit)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ordinary shares (US$0.0001 par value, 500,000,000 shares authorized as of December&nbsp;31, 2018
and 2019 and 800,000,000 shares authorized as of June&nbsp;30, 2020, respectively; 8,363,719 shares issued and outstanding as of December&nbsp;31, 2018 and 2019 and 133,006,644 shares issued and outstanding June&nbsp;30, 2020, respectively)</P></TD>

<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">92</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Treasury stock</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Additional <FONT STYLE="white-space:nowrap">paid-in</FONT> capital</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">52,369</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">389,379</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">55,113</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,675,991</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">661,844</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated other comprehensive income</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,691</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">59,380</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">70,127</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,926</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">104,853</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,841</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated deficit</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(357,860</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,014,489</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,494,207</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(353,032</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,077,060</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(435,530</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total shareholders&#146; equity (deficit)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(299,795</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(955,104</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(2,034,695</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(287,992</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1,703,876</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>241,168</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total liabilities, mezzanine equity and shareholders&#146; equity (deficit)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1,025,345</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>2,375,938</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1,737,572</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>245,937</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>2,048,722</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>289,979</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">103 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The following table presents our selected consolidated statements of cash flow data for the
years ended December&nbsp;31, 2017, 2018 and 2019 and the six months ended June&nbsp;30, 2019 and 2020: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="34%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>For the Year Ended December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>For the Six Months</B><br><B>Ended June 30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>RMB</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>RMB</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>RMB</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>US$</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>RMB</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>RMB</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>US$</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="26" ALIGN="center"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Selected Consolidated Statements of Cash Flow Data:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash used in operating activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(252,157</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(280,705</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(867,982</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(122,855</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(389,034</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(349,793</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(49,510</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash (used in) generated from investing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(157,665</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">212,462</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30,072</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">158,056</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30,354</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,298</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash (used in) generated from financing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">758,585</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,479,669</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">152,709</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21,615</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(30,000</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">653,798</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">92,539</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Effect of exchange rate changes on cash and cash equivalents and restricted cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(132</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">59,754</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,163</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,146</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,093</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">32,389</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,584</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net increase (decrease) in cash, cash equivalents and restricted cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">348,631</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,268,218</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(487,648</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(69,022</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(264,071</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">366,748</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">51,911</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash, cash equivalents and restricted cash, beginning of the year/period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">64,082</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">412,713</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,680,931</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">237,920</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,680,931</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,193,283</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">168,897</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash, cash equivalents and restricted cash, end of the year/period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">412,713</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,680,931</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,193,283</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">168,898</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,416,860</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,560,031</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">220,808</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">104 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom98473_12"></A>MANAGEMENT&#146;S DISCUSSION AND ANALYSIS OF </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FINANCIAL CONDITION AND RESULTS OF OPERATIONS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">You should read the following discussion and analysis of our financial condition and results of operations in conjunction with the section
entitled &#147;Selected Consolidated Financial Data&#148; and our consolidated financial statements and the related notes included elsewhere in this prospectus. This discussion contains forward-looking statements that reflect our current
expectations and views of future events, which may involve risks and uncertainties. Our actual results and the timing of selected events could differ materially from those anticipated in these forward-looking statements as a result of various
factors, including those set forth under &#147;Risk Factors&#148; and elsewhere in this prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Overview </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We are a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel or highly
differentiated biologics to treat diseases with significant unmet medical needs, particularly cancers and autoimmune disorders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We were
founded to capture the opportunities presented by the confluence of two major developments&#151;the emergence of an attractive and growing biologics market in China, and the revolutionary scientific breakthroughs in cancer and autoimmune disease
medicines. We believe we are well-positioned to become a biotech leader in China because of our innovative discovery expertise, <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">fit-for-purpose</FONT></FONT> technology platforms,
biomarker-enabled translational medicine capabilities, and clinical development capabilities. These integrated capabilities are further enhanced by our deep understanding of China&#146;s biologics regulatory framework and our direct access to
extensive <FONT STYLE="white-space:nowrap">pre-clinical</FONT> and clinical trial resources in China. To date, we have developed an innovative pipeline of more than 10 clinical and <FONT STYLE="white-space:nowrap">pre-clinical</FONT> stage assets
through our internal research and development efforts and <FONT STYLE="white-space:nowrap">in-licensing</FONT> arrangements with global pharmaceutical and biotech companies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We are fully aware of the competitive and regulatory challenges we face as an innovative clinical stage biotech company based in China,
including need to raise significant capital, significant competition from global and other China-based biopharmaceutical companies, less streamlined regulatory pathway compared to countries with long-established regulatory systems, and potential
implementation challenges and uncertainties of the recent government reform of the drug approval system. However, with these challenges in mind, we have been mitigating the risks through our internal R&amp;D system that integrates multi-functional
aspects of our drug development process to proactively deal with some of the regulatory challenges mentioned above. Furthermore, through our Beijing office which focuses on regulatory matters, we have established an effective communication channel
with the regulatory agencies to discuss and resolve various regulatory issues promptly and effectively. We see vast opportunities for immuno-oncology and autoimmune biologics therapies in China. First, both the incidence and mortality of cancers in
China have been increasing in recent years and are outpacing those in the United States and the rest of the world. Second, many innovative biologics approved to treat cancer and autoimmune diseases in the United States and Europe are not yet
available in China. Third, the Chinese government has implemented new policies and regulations to simplify the review and approval cycle of clinical trials and new drug applications to encourage biologics innovation. Fourth, there has been a
continuous and rapid increase in personal disposable income in China coupled with ongoing improvement in basic national health insurance coverage, making innovative biologics more accessible to more Chinese patients. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We believe we are uniquely positioned as a China-based global player to tap into these vast commercial opportunities. This is best
demonstrated by our short journey in becoming one of the top clinical stage immunology companies in China. For example, in 2018 and 2019, we are the only China-based biotech company recognized by Genetic Engineering&nbsp;&amp; Biotechnology News
(GEN) as a top 10 immuno-oncology <FONT STYLE="white-space:nowrap">start-up</FONT> in the world. To date, our research and development capabilities encompass discovery, translational medicine, biologics CMC development, <FONT
STYLE="white-space:nowrap">pre-clinical</FONT> development and clinical development with footprints in Shanghai, Beijing and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">105 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the United States. We are now at a critical juncture to transition from a clinical stage biotech company into a fully integrated
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">end-to-end</FONT></FONT> global biopharmaceutical company in the next few years. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Since the commencement of our operation in 2014, we have devoted most of our efforts and financial resources to organize and staff our
operations, business planning, raise capital, establish our intellectual property portfolio and conduct <FONT STYLE="white-space:nowrap">pre-clinical</FONT> and clinical trials of our drug candidates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We have raised in excess of US$940&nbsp;million in the past four years. We have not generated any revenue from product sales, and as a result,
we have never been profitable and have incurred net losses since the commencement of our operations. In 2017, 2018, 2019 and the six months ended June&nbsp;30, 2020, our net losses were RMB298.2&nbsp;million, RMB402.8&nbsp;million,
RMB1,452.0&nbsp;million (US$205.5 million) and RMB582.9&nbsp;million (US$82.5 million), respectively. We do not expect to generate product revenue unless and until we obtain marketing approval for and commercialize a drug candidate, and we cannot
assure you that we will ever generate significant revenue or profits. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Key Factors Affecting Our Results of Operations </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our results of operations, financial condition, and the
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">year-to-year</FONT></FONT> comparability of our financial results have been, and are expected to continue to be, principally affected by the below factors: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Cost and Expenses Structure </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our
results of operations are significantly affected by our cost structure, which primarily consists of research and development expenses and administrative expenses. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Research and development activities are central to our business model. We believe our ability to successfully develop drug candidates will be
the primary factor affecting our long-term competitiveness, as well as our future growth and development. Developing high-quality drug candidates requires a significant investment of resources over a prolonged period of time, and a core part of our
strategy is to continue making sustained investments in this area. Since our inception, we have focused our resources on our research and development activities, including conducting <FONT STYLE="white-space:nowrap">pre-clinical</FONT> studies and
clinical trials, and activities related to regulatory filings for our drug candidates. Our research and development expenses primarily include the following: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">costs related to development of our pipeline assets under all stages including discovery, <FONT
STYLE="white-space:nowrap">pre-clinical</FONT> testing or clinical trials; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">patent license fees and other fees under the licensing, collaboration and development agreements with respect to
our <FONT STYLE="white-space:nowrap">in-licensed</FONT> drug candidates; and </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">employee salaries and related benefit costs, including share-based compensation expenses, for research and
development personnel and key management. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">At this time, we are unable to predict when, if ever, we will be able to
achieve profitability. Even if we achieve profitability in the future, we may not be able to sustain profitability in subsequent periods thereafter. This is due to the numerous risks and uncertainties associated with developing such drug candidates,
including the uncertainty of: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">successful enrollment in and completion of clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">establishing an appropriate safety profile; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">establishing commercial manufacturing capabilities or making arrangements with third-party manufacturers;
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">106 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">receipt of marketing approvals from applicable regulatory authorities; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">commercializing the drug candidates, if and when approved, whether alone or in collaboration with others;
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">obtaining and maintaining patent and trade secret protection and regulatory exclusivity for our drug candidates;
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">continued acceptable safety profiles of the products following approval; and </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">retention of key research and development personnel. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Any change in the outcome of any of these variables with respect to the development of any of our drug candidates would significantly change
the costs, timing and viability associated with the development of that drug candidate. We expect research and development costs to continue to increase for the foreseeable future as we expand our operations and our development programs progress,
including as we continue to support and advance the clinical trials of our drug candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our administrative expenses consist primarily
of employee salaries and related benefit costs. Other administrative expenses include professional fees for consulting and auditing as well as other direct and allocated expenses for rental expenses for our facilities, travel costs and other
supplies used in administrative activities. We expect our administrative expenses to increase in the future to support our pipeline assets and research and development efforts, and the commercialization of our drug candidates once approval is
obtained. We also anticipate that our administrative expenses will increase as we operate as a public company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Revenue from <FONT
STYLE="white-space:nowrap">Out-Licensing</FONT> Agreements </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We continue to seek
<FONT STYLE="white-space:nowrap">out-licensing</FONT> opportunities for our <FONT STYLE="white-space:nowrap">de-prioritized</FONT> assets to streamline our pipeline. In 2017, 2018 and 2019, our revenue consisted primarily of payments from granting
licenses to use and otherwise exploit certain of our intellectual properties linked to our <FONT STYLE="white-space:nowrap">de-prioritized</FONT> assets. See &#147;Business&#151;Licensing and Collaboration Arrangements&#148; for more information on
the existing <FONT STYLE="white-space:nowrap">out-licensing</FONT> arrangements. In addition, after validating clinical safety and preliminary efficacy of a drug candidate in our Global Portfolio in clinical trials in the United States, we may elect
to <FONT STYLE="white-space:nowrap">out-license</FONT> the global rights (excluding Greater China) of such drug candidate, while retaining the Greater China rights for further development and commercialization. But we may also choose to retain these
rights for the United States or other countries or regions as we may deem fit. Before the commercialization of one or more of our drug candidates, we expect that the majority of our revenue will continue to be generated from <FONT
STYLE="white-space:nowrap">out-licensing</FONT> our intellectual properties. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Funding for Our Operations </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">During the periods presented, we funded our operations primarily from financing through the issuance and sale of preferred shares and
convertible promissory notes in private placement transactions. Going forward, in the event of successful commercialization of one or more of our drug candidates, we expect to fund our operations in part with revenue generated from sales of our
commercialized drug products. However, with the continuing expansion of our business and our product pipeline, we may require further funding through public or private offerings, debt financing, collaboration, and licensing arrangements or other
sources. Any fluctuation in our ability to fund our operations will impact our cash flow plan and our results of operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our Ability to
Commercialize Our Drug Candidates </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our business and results of operations depend on our ability to commercialize our drug
candidates, once and if those candidates are approved for marketing by the respective health authority. Currently, our pipeline </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">107 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
consists of more than ten drug candidates ranging in development status from <FONT STYLE="white-space:nowrap">pre-clinical</FONT> to late-stage clinical programs. Although we currently do not
have any product approved for commercial sale and have not generated any revenue from product sales, we expect to generate revenue from sales of a drug candidate after we complete the clinical development, obtain regulatory approval, and
successfully commercialize such drug candidate. Our late-stage investigational drugs at or potentially near pivotal trials are felzartamab, eftansomatropin, olamkicept and enoblituzumab. See &#147;Business&#151;Our Drug Pipeline&#148; for more
information on the development status of our various drug candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The Effect of Our Acquisition of
<FONT STYLE="white-space:nowrap">I-Mab</FONT> Tianjin </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We acquired a controlling interest in
<FONT STYLE="white-space:nowrap">I-Mab</FONT> Tianjin on July&nbsp;15, 2017 and the remaining interest in <FONT STYLE="white-space:nowrap">I-Mab</FONT> Tianjin in May 2018. Since our acquisition of the controlling interest in <FONT
STYLE="white-space:nowrap">I-Mab</FONT> Tianjin on July&nbsp;15, 2017, <FONT STYLE="white-space:nowrap">I-Mab</FONT> Tianjin has been consolidated into our results of operations. Shortly after we acquired the controlling interest in <FONT
STYLE="white-space:nowrap">I-Mab</FONT> Tianjin, we integrated the operations of <FONT STYLE="white-space:nowrap">I-Mab</FONT> Tianjin into our operations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">I-Mab</FONT> Tianjin did not generate any external revenue from July&nbsp;15, 2017 to June&nbsp;30, 2020. In
connection with our acquisition of <FONT STYLE="white-space:nowrap">I-Mab</FONT> Tianjin, we identified RMB148.8&nbsp;million of intangible assets and RMB162.6&nbsp;million of goodwill of <FONT STYLE="white-space:nowrap">I-Mab</FONT> Tianjin.
Goodwill is not amortized, but impairment of goodwill assessment is performed on an least an annual basis on December&nbsp;31 or whenever events or changes in circumstances indicate that the carrying value of the assets may not be recoverable. No
impairment was identified as of December&nbsp;31, 2017, 2018 and 2019 and June&nbsp;30, 2020. Impairment charges could substantially affect our results of operations in the periods of such charges. In addition, impairment charges would negatively
impact our financial ratios and could limit our ability to obtain financing in the future. See &#147;Risk Factors&#151;Risks Related to Our Industry, Business and Operations&#150;&#150;Change in business prospects of acquisitions may result in
impairment to our goodwill, which could negatively affect our reported results of operations.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Impact of the
<FONT STYLE="white-space:nowrap">COVID-19</FONT> Outbreak on Our Business </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">As of the date of this prospectus, the impact of the
ongoing global coronavirus- 19 <FONT STYLE="white-space:nowrap">(COVID-19)</FONT> pandemic to our business has been limited. To date, although <FONT STYLE="white-space:nowrap">COVID-19</FONT> has caused some delays in the initiation of the ongoing
trials of certain clinical-stage drug candidates in early 2020, the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic has not had a material impact on our ongoing clinical activities, in particular, clinical activities related to our
late-stage drug candidates, such as felzartamab, eftansomatropin and olamkicept. See &#147;Our Business&#150;&#150;Our Drug Candidates&#148; for our clinical development plans for our drug candidates. As of the date of this prospectus, the outbreak
of COVID- 19 has not caused any early termination of our clinical trials or necessitated removal of any enrolled patients. We have employed various measures to mitigate impacts of the COVID- 19 outbreak on our currently ongoing trials in Greater
China and the United States. We worked closely with our CROs to monitor the situation and manage the process of our clinical trials. We maintained contact with our patients to ensure that they remain on the trials and that any information they need
will be readily available. In addition, we believe the COVID- 19 outbreak has not significantly impacted our ability to carry out our obligations under existing contracts or disrupted any supply chains that we rely upon. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">As of the date of this prospectus, we have not had any suspected or confirmed <FONT STYLE="white-space:nowrap">COVID-19</FONT> cases on our
premises or among our employees. To prevent any spread of <FONT STYLE="white-space:nowrap">COVID-19</FONT> in our offices and research facilities, we have adopted a thorough disease prevention scheme to protect our employees from contracting <FONT
STYLE="white-space:nowrap">COVID-19.</FONT> The measures we have implemented include, among others, regularly sterilizing and ventilating our offices, checking the body temperature of our employees, keeping track of the travel history and health
conditions of employees and their immediate family members, providing face masks to employees attending the office, minimizing <FONT STYLE="white-space:nowrap">in-person</FONT> meetings to the extent possible and encouraging employees to wear masks
when needed. As of the date of this prospectus, our ongoing clinical trials and CROs had resumed full and normal operations and the <FONT STYLE="white-space:nowrap">COVID-19</FONT> outbreak had not resulted in a major disruption to our operations.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">108 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Taking into account our past and prospective cash burn rate, including but not limited to
future clinical development and administrative expenses, lease payment, capital expenditure and current financial position, our ability to control the speed and breadth of our clinical development and business development activities and our
expansion in headcount, our current internal resources, we estimate that our financial resources can support our research and development activities and business operations for at least the next 12 months. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Although we believe we have implemented strategies to potentially minimize the impact of the <FONT STYLE="white-space:nowrap">COVID-19</FONT>
pandemic to our business, we expect that we may experience delays with respect to the initiation and patient enrollment of certain additional trials. The extent to which the COVID- 19 pandemic impacts the timing of these additional trials will
depend on future developments, which are highly uncertain and cannot be predicted with confidence, such as the ultimate geographic spread of the disease, the duration of the pandemic, any restrictions on the ability of hospitals and trial sites to
conduct trials that are not designed to address the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic and the perceived effectiveness of actions taken in China and the United States to contain and treat the disease. We will continue to
evaluate the impact of the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic to our business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In addition, there are still
uncertainties with regard to the continued development of <FONT STYLE="white-space:nowrap">COVID-19</FONT> and its implications, and we will continue to assess the situation and seek to put in place relevant mitigating measures where necessary. The
above analyses are made by our management based on currently available information concerning <FONT STYLE="white-space:nowrap">COVID-19.</FONT> We cannot guarantee that the outbreak of COVID- 19 will not further escalate or have a material adverse
effect on our business operations. Please also see &#147;Risk Factors&#151;Risks Related to Our Industry, Business and Operations&#151;Our business, financial condition and results of operations could be adversely affected by the <FONT
STYLE="white-space:nowrap">COVID-19</FONT> outbreak.&#148; and &#147;Risk Factors&#151;Risks Related to Our Industry, Business and Operations&#151; Business disruptions could seriously harm our future revenue and financial condition and increase our
costs and expenses.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Key Components of Results of Operations </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Revenues </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">To date, we have not
generated any revenue from product sales and do not expect to generate any revenue from product sales for the foreseeable future before the successful commercialization of one or more of our drug candidates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We generated substantially all of our revenues for the years ended December&nbsp;31, 2017, 2018 and 2019 from granting licenses to use and
otherwise exploit certain of our intellectual properties in connection with our <FONT STYLE="white-space:nowrap">de-prioritized</FONT> assets. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Research and Development Expenses </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Research and development expenses primarily consist of: (i)&nbsp;payroll and other related expenses of research and development personnel,
(ii)&nbsp;fees associated with the exclusive development rights of our <FONT STYLE="white-space:nowrap">in-licensed</FONT> drug candidates, (iii)&nbsp;fees for services provided by contract research organizations, investigators and clinical trial
sites that conduct our clinical studies, and (iv)&nbsp;expenses relating to the development of our drug candidates, including raw materials and supplies, product testing, depreciation, and facility related expenses. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our current research and development activities primarily relate to the clinical development of the following investigational drugs: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Felzartamab, a potential highly differentiated CD38 antibody for multiple myeloma and autoimmune diseases, if
approved; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Efineptakin, the first long-acting recombinant human <FONT STYLE="white-space:nowrap">IL-7</FONT> with the
potential for cancer treatment-related lymphopenia and cancer immunotherapy, if approved; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">109 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Eftansomatropin, a potential highly differentiated long-acting growth hormone for growth hormone deficiency, if
approved; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Olamkicept, a potential highly differentiated <FONT STYLE="white-space:nowrap">IL-6</FONT> blocker for ulcerative
colitis and other autoimmune diseases, if approved; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Enoblituzumab, the most advanced clinical stage humanized <FONT STYLE="white-space:nowrap">B7-H3</FONT> antibody
as a potential immuno-oncology treatment, if approved; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Lemzoparlimab, a potential highly differentiated CD47 monoclonal antibody with unique <FONT
STYLE="white-space:nowrap">RBC-sparing</FONT> differentiation, if approved; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Uliledlimab, a potential highly differentiated CD73 antibody for immuno-oncology, if approved; and
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Plonmarlimab, a <FONT STYLE="white-space:nowrap">GM-CSF</FONT> monoclonal antibody for rheumatoid arthritis and <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">CAR-T-related</FONT></FONT> therapies, if approved. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We
incurred research and development expenses of RMB267.1&nbsp;million, RMB426.0&nbsp;million and RMB840.4&nbsp;million (US$119.0 million) for the years ended December&nbsp;31, 2017, 2018 and 2019, respectively, representing 91.3%, 86.5% and 56.2% of
our total research and development and administrative expenses for the corresponding periods. We incurred research and development expenses of RMB265.1&nbsp;million and RMB442.3&nbsp;million (US$62.6 million) for the six months ended June&nbsp;30,
2019 and 2020, respectively. We expect our research and development expenses to continue to increase for the foreseeable future, as we continue to expand our operations and to advance our pipeline and our drug candidates toward later stages. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Administrative Expenses </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Administrative expenses primarily consist of salaries and related benefit costs, including share-based compensation, for employees engaged in
managerial and administrative positions or involved in general corporate functions, professional fees for consulting and auditing as well as other direct and allocated expenses for rental expenses for our facilities, travel costs and other supplies
used in administrative activities. For the years ended December&nbsp;31, 2017, 2018 and 2019 and the six months ended June&nbsp;30, 2020, our administrative expenses amounted to RMB25.4&nbsp;million, RMB66.4&nbsp;million, RMB654.6&nbsp;million
(US$92.7 million) and RMB171.4&nbsp;million (US$24.3 million), respectively. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Interest Expense </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Interest expense consist primarily of interest expenses on our (i)&nbsp;short-term bank borrowings and (ii)&nbsp;convertible promissory notes
issued to certain investors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Interest Income </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Interest income consists primarily of interest income derived from our term deposit and restricted cash pledged as collateral for a working
capital loan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Other Income (Expenses), Net </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Other income consists primarily of income from other financial assets. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Other expenses consist primarily of the net loss resulting from the conversion of a portion of our convertible promissory notes and loss on
the termination agreement with Everest. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">110 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Fair Value Change of Warrants </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Fair value change of warrants consists primarily of the <FONT STYLE="white-space:nowrap">non-cash</FONT> items incurred in connection with
changes in the fair value of our warrant liabilities that we issued to certain investors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Taxation </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Cayman Islands </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><FONT
STYLE="white-space:nowrap">I-Mab,</FONT> our holding entity, is incorporated in the Cayman Islands. The Cayman Islands currently has no income, corporation or capital gains tax and no estate duty, inheritance tax or gift tax. Additionally, the
Cayman Islands does not impose a withholding tax on payments of dividends to shareholders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Hong Kong </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">I-Mab</FONT> Biopharma Hong Kong Limited is incorporated in Hong Kong. Companies registered in Hong Kong are
subject to Hong Kong profits tax on the taxable income as reported in their respective statutory financial statements adjusted in accordance with the relevant Hong Kong tax laws. Under the current Hong Kong Inland Revenue Ordinance, from the year of
assessment 2018/2019 onwards, our subsidiary in Hong Kong is subject to profits tax at the rate of 8.25% on assessable profits up to HK$2,000,000; and 16.5% on any part of assessable profits over HK$2,000,000. For the years ended December&nbsp;31,
2017, 2018 and 2019 and the six months ended June&nbsp;30, 2020, <FONT STYLE="white-space:nowrap">I-Mab</FONT> Biopharma Hong Kong Limited did not make any provisions for Hong Kong profit tax as there were no assessable profits derived from or
earnings in Hong Kong for any of the periods presented. Under the Hong Kong tax law, <FONT STYLE="white-space:nowrap">I-Mab</FONT> Biopharma Hong Kong Limited is exempted from income tax on its foreign-derived income and there are no withholding
taxes in Hong Kong on remittance of dividends. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>United States </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">I-Mab</FONT> Biopharma US Ltd. is incorporated in Maryland and is subject to U.S. federal corporate income
tax at a rate of 21%. It is also subject to state income tax in Maryland at a rate of 8.25%. <FONT STYLE="white-space:nowrap">I-Mab</FONT> Biopharma US Ltd. has no taxable income for all periods presented and therefore no provision for income taxes
is required. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>China </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">On
March&nbsp;16, 2007, the National People&#146;s Congress of PRC enacted a new Corporate Income Tax Law (&#147;new CIT law&#148;) (as amended in 2017 and 2018), under which Foreign Investment Enterprises (&#147;FIEs&#148;) and domestic companies
would be subject to corporate income tax at a uniform rate of 25%. The new CIT law became effective on January&nbsp;1, 2008. Under the new CIT law, preferential tax treatments will continue to be granted to entities which conduct businesses in
certain encouraged sectors and to entities otherwise classified as &#147;High and New Technology Enterprises.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><FONT
STYLE="white-space:nowrap">I-Mab</FONT> Shanghai has been qualified as a &#147;High and New Technology Enterprise&#148; and enjoys a preferential income tax rate of 15% from 2018 to 2020. Our company&#146;s other PRC subsidiaries are subject to the
statutory income tax rate of 25%. No provision for income taxes has been accrued because all of our PRC subsidiaries are in cumulative loss positions for all the periods presented. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">A valuation allowance is provided to reduce the amount of deferred tax assets if it is considered more likely than not that some portion or
all of the deferred tax assets will not be realized in the foreseeable future. In making such determination, we evaluate a variety of positive and negative factors including our operating history, accumulated deficit, the existence of taxable
temporary differences and reversal periods. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">111 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We have incurred net accumulated operating losses for income tax purposes since our
inception. We believe that it is more likely than not that these net accumulated operating losses will not be utilized in the future based on the assessment as of June&nbsp;30, 2020. Therefore, we have provided full valuation allowances for the
deferred tax assets as of December&nbsp;31, 2017, 2018 and 2019 and June&nbsp;30, 2020. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We evaluate each uncertain tax position
(including the potential application of interest and penalties) based on the technical merits, and measure the unrecognized benefits associated with the tax positions. As of December&nbsp;31, 2017, 2018 and 2019 and June&nbsp;30, 2020, we did not
have any significant unrecognized uncertain tax positions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Results of Operations </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The following table sets forth a summary of our consolidated results of operations for the periods indicated. This information should be read
together with our consolidated financial statements and related notes included elsewhere in this prospectus. The operating results in any period are not necessarily indicative of the results that may be expected for any future period. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="25%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>For the Year Ended December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>For&nbsp;the&nbsp;Six&nbsp;Months&nbsp;Ended&nbsp;June&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>RMB</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>RMB</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>RMB</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>US$</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>RMB</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>RMB</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>US$</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="26" ALIGN="center"><B>(in thousands, except for share and per share data)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Revenues</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Licensing and collaboration revenue</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,556</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">53,781</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,246</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Expenses</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development expenses<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>

<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(267,075</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(426,028</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(840,415</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(118,953</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(265,084</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(442,291</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(62,602</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Administrative expenses<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(25,436</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(66,391</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(654,553</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(92,646</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(574,584</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(171,384</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(24,258</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Loss from operations</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(280,955</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(438,638</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(1,464,968</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(207,353</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(824,668</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(613,675</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(86,860</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest income</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">858</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,597</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30,570</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,327</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,818</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,955</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,683</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest expense</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5,643</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(11,695</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,991</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(423</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,936</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(957</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(135</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other income (expenses), net</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,527</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(16,780</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(20,205</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,860</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">303</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,824</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,815</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fair value change of warrants</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(14,027</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">61,405</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,644</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">799</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(43,854</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Loss before income tax expense</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(298,240</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(401,111</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(1,451,950</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(205,510</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(857,337</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(582,853</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(82,497</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income tax expense</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,722</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net loss attributable to <BR><FONT STYLE="white-space:nowrap">I-Mab</FONT></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(298,240</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(402,833</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(1,451,950</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(205,510</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(857,337</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(582,853</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(82,497</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">112 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="25%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>For the Year Ended December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>For&nbsp;the&nbsp;Six&nbsp;Months&nbsp;Ended&nbsp;June&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>RMB</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>RMB</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>RMB</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>US$</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>RMB</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>RMB</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>US$</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="26" ALIGN="center"><B>(in thousands, except for share and per share data)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deemed dividend to Series <FONT STYLE="white-space:nowrap">C-1</FONT> preferred shareholders at
extinguishment of Series <FONT STYLE="white-space:nowrap">C-1</FONT> Preferred Shares</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5,283</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(748</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deemed dividend to Series <FONT STYLE="white-space:nowrap">B-1,</FONT> <FONT
STYLE="white-space:nowrap">B-2</FONT> and C preferred shareholders at modification of Series <FONT STYLE="white-space:nowrap">B-1,</FONT> <FONT STYLE="white-space:nowrap">B-2</FONT> and C Preferred Shares</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(27,768</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,930</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net loss attributable to ordinary shareholders</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(298,240</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(402,833</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(1,485,001</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(210,188</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(857,337</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(582,853</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(82,497</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Other comprehensive income</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Foreign currency translation adjustments, net of nil tax</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,918</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">53,689</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,747</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,521</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4,972</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">34,726</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,915</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total comprehensive loss attributable to
<FONT STYLE="white-space:nowrap">I-Mab</FONT></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(292,322</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(349,144</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(1,441,203</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(203,989</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(862,309</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(548,127</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(77,582</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net loss attributable to ordinary shareholders</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(298,240</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(402,833</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(1,485,001</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(210,188</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(857,337</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(582,853</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(82,497</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Weighted-average number of ordinary shares used in calculating net loss per shares</B></P></TD>

<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,742,669</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,529,092</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,381,230</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,381,230</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,184,086</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">121,815,986</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">121,815,986</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net loss per share attributable to ordinary shareholders</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Basic</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(51.93</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(61.70</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(201.19</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(28.48</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(119.34</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4.78</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(0.68</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Diluted</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(51.93</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(61.70</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(201.19</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(28.48</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(119.34</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4.78</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(0.68</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">Non-GAAP</FONT> Measure</B>:<SUP
STYLE="font-size:85%; vertical-align:top">(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Adjusted Net Loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(291,201</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(399,313</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(969,798</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(137,266</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(342,673</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(353,058</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(49,972</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">113 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Note: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Share-based compensation expenses were allocated as follows: </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="50%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>For the Year Ended December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>For the Six Months&nbsp;Ended June&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>RMB</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>RMB</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>RMB</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>US$</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>RMB</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>RMB</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>US$</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="26" ALIGN="center"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,112</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,056</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">470</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">67</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">308</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">132,724</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,786</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Administrative expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,927</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,464</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">514,733</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">72,856</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">514,356</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">97,071</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,739</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>7,039</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>3,520</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>515,203</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>72,922</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>514,664</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>229,795</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>32,525</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">See <FONT STYLE="white-space:nowrap">&#147;&#151;Non-GAAP</FONT> Financial Measure.&#148;
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Comparison of Six Months Ended June&nbsp;30, 2020 and 2019 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Revenues </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our revenues generated
from licensing and collaboration decreased from RMB15.0&nbsp;million for the six months ended June&nbsp;30, 2019 to nil for the six months ended June&nbsp;30, 2020. Our revenues generated for the six months ended June&nbsp;30, 2019 solely consisted
of CSPC entity&#146;s upfront payment to us pursuant to our <FONT STYLE="white-space:nowrap">out-licensing</FONT> arrangement with CSPC entity. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Research and Development Expenses </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The following table sets forth a breakdown of the major components of our research and development expenses in absolute amounts and as a
percentage of our total research and development expenses for the periods indicated: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="65%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="18" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>For the Six Months Ended June&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>RMB</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>%</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>RMB</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>US$</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>%</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="18" ALIGN="center"><B>(in thousands, except percentages)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">CRO service fees</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">144,765</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">54.6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">226,805</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">32,102</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">51.3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">In-licensed</FONT> patent right fees</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">55,525</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20.9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,408</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">199</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Employee benefit expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">44,764</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16.9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">191,919</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27,164</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">43.4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Material costs for drug candidates</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,895</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,489</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,202</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,135</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,670</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,935</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">265,084</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100.0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">442,291</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">62,602</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100.0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our research and development expenses increased by 66.8% from RMB265.1&nbsp;million for the six months ended
June&nbsp;30, 2019 to RMB442.3&nbsp;million (US$62.6 million) for the six months ended June&nbsp;30, 2020, primarily attributable to (i)&nbsp;an increase in the CRO service fees from RMB144.8&nbsp;million for the six months ended June&nbsp;30, 2019
to RMB226.8&nbsp;million (US$32.1 million) for the six months ended June&nbsp;30, 2020, as we advanced some of our existing investigational drugs into more advanced clinical development stages; and (ii)&nbsp;an increase in employee benefit expenses
of employees involved in research and development from RMB44.8&nbsp;million for the six months ended June&nbsp;30, 2019 to RMB191.9&nbsp;million (US$27.2 million) for the six months ended June&nbsp;30, 2020, mainly due to an increase in share-based
compensation by RMB132.4&nbsp;million (US$18.7 million). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In the six months ended June&nbsp;30, 2020, 79.9% and 20.1% of our total
research and development expenses were attributable to clinical programs and preclinical programs, respectively. In the six months ended June&nbsp;30, 2019, 81.7% and 18.3% of our total research and development expenses were attributable to clinical
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">114 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
programs and preclinical programs, respectively. For the six months ended June&nbsp;30, 2020, felzartamab represented approximately 54.2% of our external research and development expenses, which
primarily included payments to CROs and CMOs. For the six months ended June&nbsp;30, 2019, felzartamab represented approximately 63.8% of our external research and development expenses, which primarily included licensing fees and payments to CROs
and CMOs. No other programs represented a significant amount of research and development expenses in the six months ended June&nbsp;30, 2020 and 2019. Though we manage our external research and development expenses by program, we do not allocate our
internal research and development expenses by program because our employees and internal resources may be engaged in projects for multiple programs at any time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Administrative Expenses </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our
administrative expenses decreased from RMB574.6&nbsp;million for the six months ended June&nbsp;30, 2019 to RMB171.4&nbsp;million (US$24.3 million) for the six months ended June&nbsp;30, 2020, primarily attributable to (i)&nbsp;the decrease in
employee benefit expenses by RMB 385.8&nbsp;million (US$54.6 million) due to decrease of share-based compensation expenses, and (ii)&nbsp;the decrease in third-party professional expenses by RMB22.7&nbsp;million (US$5.9 million). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Interest Income </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We recorded
RMB12.8&nbsp;million of interest income for the six months ended June&nbsp;30, 2019 and RMB19.0&nbsp;million (US$2.7 million) of interest income for the six months ended June&nbsp;30, 2020. The change was primarily attributable to the interest
income derived from bank deposits and an increase in bank balance. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Interest Expense </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We recorded RMB1.9&nbsp;million of interest expense for the six months ended June&nbsp;30, 2019 and RMB1.0&nbsp;million (US$0.1 million) of
interest expense for the six months ended June&nbsp;30, 2020. The change was primarily attributable to the interest expense related to our short-term borrowings, which were borrowed in June 2019 and repaid in June 2020. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Other Income (Expenses), Net </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We
recorded RMB0.3&nbsp;million of other income for the six months ended June&nbsp;30, 2019 and RMB12.8&nbsp;million (US$1.8 million) of other income for the six months ended June&nbsp;30, 2020. The change was primarily attributable to the subsidy
income from PRC local government and income of incentive payment from depository banks. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Fair Value Change of Warrants </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We recorded a loss from change in the fair value of warrant liability of RMB43.9&nbsp;million for the six months ended June&nbsp;30, 2019 and
nil for the six months ended June&nbsp;30, 2020. The change was primarily attributable to the fact that the holders of Series B Warrants have unconditionally and irrevocably waived and cancelled the Tranche II of Series B Warrants in July 2019. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Comparison of Year Ended December&nbsp;31, 2019 and 2018 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Revenues </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our revenues generated
from licensing and collaboration decreased by 44.2% from RMB53.8&nbsp;million for the year ended December&nbsp;31, 2018 to RMB30.0&nbsp;million (US$4.2 million) for the year ended December&nbsp;31, 2019. Our revenues generated for the year ended
December&nbsp;31, 2018 consisted of both HDYM&#146;s milestone payment and ABL Bio&#146;s upfront payment to us pursuant to our <FONT STYLE="white-space:nowrap">out-licensing</FONT> arrangements with them, respectively. Our revenues generated for
the year ended December&nbsp;31, 2019 solely consisted of CSPC entity&#146;s upfront and milestone payments to us pursuant to our <FONT STYLE="white-space:nowrap">out-licensing</FONT> arrangement with CSPC entity. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">115 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Research and Development Expenses </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The following table sets forth a breakdown of the major components of our research and development expenses in absolute amounts and as a
percentage of our total research and development expenses for the periods indicated: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="64%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="18" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>For the Year Ended December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>RMB</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>%</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>RMB</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>US$</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>%</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="18" ALIGN="center"><B>(in thousands, except percentages)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">CRO service fees</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">212,278</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">49.8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">521,920</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">73,873</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">62.1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">In-licensed</FONT> patent right fees</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">108,794</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25.5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">166,844</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23,615</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19.9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Employee benefit expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">56,630</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13.3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">106,313</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,048</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12.7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Material costs for drug candidates</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,652</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,117</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">866</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">28,674</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">39,221</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,551</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">426,028</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100.0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">840,415</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">118,953</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100.0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our research and development expenses increased by 97.3% from RMB426.0&nbsp;million for the year ended
December&nbsp;31, 2018 to RMB840.4&nbsp;million (US$119.0 million) for the year ended December&nbsp;31, 2019, primarily attributable to (i)&nbsp;an increase in the CRO service fees from RMB212.3&nbsp;million for the year ended December&nbsp;31, 2018
to RMB521.9&nbsp;million (US$73.9 million) for the year ended December&nbsp;31, 2019, as we initiated a few more research and development programs and advanced some of our existing investigational drugs into more advanced clinical development
stages; (ii)&nbsp;an increase in <FONT STYLE="white-space:nowrap">in-licensed</FONT> patent right fees from RMB108.8&nbsp;million for the year ended December&nbsp;31, 2018 to RMB166.8&nbsp;million (US$23.6 million) for the year ended
December&nbsp;31, 2019, mainly due to upfront fees paid to MacroGenics; and (iii)&nbsp;an increase in employee benefit expenses of employees involved in research and development from RMB56.6&nbsp;million for the year ended December&nbsp;31, 2018 to
RMB106.3&nbsp;million (US$15.0 million) for the year ended December&nbsp;31, 2019, due to an increase in the headcount. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In 2019, 87.3%
and 12.7% of our total research and development expenses were attributable to clinical programs and preclinical programs, respectively. In 2018, 72.3% and 27.7% of our total research and development expenses were attributable to clinical programs
and preclinical programs, respectively. In 2019, felzartamab represented approximately 41.4% of our external research and development expenses, which primarily included licensing fees and payments to CROs and CMOs. In 2018, efineptakin and
felzartamab represented approximately 25.0% and 9.9% of our external research and development expenses, which primarily included licensing fees and payments to CROs and CMOs. No other programs represented a significant amount of research and
development expenses in 2019 and 2018. Though we manage our external research and development expenses by program, we do not allocate our internal research and development expenses by program because our employees and internal resources may be
engaged in projects for multiple programs at any time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Administrative Expenses </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our administrative expenses increased from RMB66.4&nbsp;million for the year ended December&nbsp;31, 2018 to RMB654.6&nbsp;million (US$92.7
million) for the year ended December&nbsp;31, 2019, primarily attributable to (i)&nbsp;RMB365.3&nbsp;million (US$51.7 million) in connection with stock options granted to a director of our company under the 2018 Plan which were immediately vested,
(ii)&nbsp;RMB148.3&nbsp;million (US$21.0 million) in connection with repurchase of share awards held by a director of our company, (iii)&nbsp;the increase in employee benefit expenses by RMB7.9&nbsp;million (US$1.1 million) due to headcount
increase, and (iv)&nbsp;the increase in third-party professional expenses by RMB41.4&nbsp;million (US$5.9 million). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">116 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Interest Income </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We recorded RMB4.6&nbsp;million of interest income for the year ended December&nbsp;31, 2018 and RMB30.6&nbsp;million (US$4.3 million) of
interest income for the year ended December&nbsp;31, 2019. The change was primarily attributable to the interest income derived from bank deposits. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Interest Expense </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We recorded
RMB11.7&nbsp;million of interest expense for the year ended December&nbsp;31, 2018 and RMB3.0&nbsp;million (US$0.4 million) of interest expense for the year ended December&nbsp;31, 2019. The change was primarily attributable to the interest expense
related to our convertible promissory notes, which were converted in June and July 2018. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Other Income (Expenses), Net </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We recorded RMB16.8&nbsp;million of other expenses for the year ended December&nbsp;31, 2018 and RMB20.2&nbsp;million (US$2.9 million) of
other income for the year ended December&nbsp;31, 2019. The change was primarily attributable to the conversion of our convertible promissory notes and onshore convertible loans and loss on the termination agreement with Everest in 2019. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Fair Value Change of Warrants </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We
recorded a gain from change in the fair value of warrant liability of RMB61.4&nbsp;million for the year ended December&nbsp;31, 2018 and RMB5.6&nbsp;million (US$0.8 million) for the year ended December&nbsp;31, 2019. The change was primarily
attributable to the change in fair value of warrants due to the increase in the valuation of our company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Comparison of Year Ended December&nbsp;31,
2018 and 2017 </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Revenues </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our revenues generated from licensing and collaboration increased by 365.4% from RMB11.6&nbsp;million for the year ended December&nbsp;31,
2017 to RMB53.8&nbsp;million for the year ended December&nbsp;31, 2018. Our revenues generated for the year ended December&nbsp;31, 2017 consisted solely of HDYM&#146;s milestone payment to us pursuant to our
<FONT STYLE="white-space:nowrap">out-licensing</FONT> arrangement with it. Our revenues generated for the year ended December&nbsp;31, 2018 consisted of both HDYM&#146;s milestone payment and ABL Bio&#146;s upfront payment to us pursuant to our <FONT
STYLE="white-space:nowrap">out-licensing</FONT> arrangements with them, respectively. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Research and Development Expenses </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The following table sets forth a breakdown of the major components of our research and development expenses in absolute amounts and as a
percentage of our total research and development expenses for the periods indicated: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="85.5%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="60%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>For the Year Ended December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>RMB</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>%</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>RMB</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>%</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center"><B>(in thousands, except percentages)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">CRO service fees</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">83,047</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">31.1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">212,278</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">49.8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">In-licensed</FONT> patent right fees</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">134,846</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50.5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">108,794</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25.5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Employment benefit expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26,799</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10.0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">56,630</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13.3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Material costs for drug candidates</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,393</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,652</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,990</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">28,674</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">267,075</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100.0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">426,028</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100.0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">117 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our research and development expenses increased by 59.5% from RMB267.1&nbsp;million for the
year ended December&nbsp;31, 2017 to RMB426.0&nbsp;million for the year ended December&nbsp;31, 2018, primarily attributable to (i)&nbsp;an increase in the CRO service fees from RMB83.0&nbsp;million in 2017 to RMB212.3&nbsp;million in 2018, as we
initiated a few more research and development programs and advanced some of our existing investigational drugs into more advanced clinical development stages; and (ii)&nbsp;an increase in employee benefit expenses of employees involved in research
and development from RMB26.8&nbsp;million in 2017 to RMB56.6&nbsp;million in 2018, due to an increase in the headcount. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In 2018, 72.3%
and 27.7% of our total research and development expenses were attributable to clinical programs and <FONT STYLE="white-space:nowrap">pre-clinical</FONT> programs, respectively. In 2017, 77.5% and 22.5% of our total research and development expenses
were attributable to clinical programs and <FONT STYLE="white-space:nowrap">pre-clinical</FONT> programs, respectively. In 2018, TJ107 and TJ202 represented approximately 25.0% and 9.9% of our external research and development expenses, which
primarily included licensing fees and payments to CROs and CMOs. In 2017, TJ202 represented approximately 59.1% of our external research and development expenses, which primarily included licensing fees and payments to CROs and CMOs. No other
programs represented a significant amount of research and development expenses in 2018 and 2017. Though we manage our external research and development expenses by program we do not allocate our internal research and development expenses by program
because our employees and internal resources may be engaged in projects for multiple programs at any time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Administrative Expenses </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our administrative expenses increased from RMB25.4&nbsp;million for the year ended December&nbsp;31, 2017 to RMB66.4&nbsp;million for the year
ended December&nbsp;31, 2018, primarily attributable to (i)&nbsp;the increase in employee benefit expenses due to headcount increase, and (ii)&nbsp;the increase in third-party professional expenses. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Interest Income </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We recorded
RMB0.9&nbsp;million of interest income for the year ended December&nbsp;31, 2017 and RMB4.6&nbsp;million of interest income for the year ended December&nbsp;31, 2018. The change was primarily attributable to the interest income derived from our bank
deposits. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Interest Expense </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We recorded RMB5.6&nbsp;million of interest expense for the year ended December&nbsp;31, 2017 and RMB11.7&nbsp;million of interest expense for
the year ended December&nbsp;31, 2018. The change was primarily attributable to (i)&nbsp;the interest expense accrued on the <FONT STYLE="white-space:nowrap">one-year</FONT> bank borrowing facilities we entered into in the third quarter of 2017 and
2018, respectively; and (ii)&nbsp;the interest expense related to our convertible promissory notes, which were converted in June and July 2018. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Other Income (Expenses), Net </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We
recorded RMB1.5&nbsp;million of other income for the year ended December&nbsp;31, 2017 and RMB16.8&nbsp;million of other expenses for the year ended December&nbsp;31, 2018. The change was primarily attributable to the net loss resulting from the
conversion of a portion of our convertible promissory notes, partially offset by an increase in the income from the other financial assets. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Fair
Value Change of Warrants </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We recorded a loss from change in the fair value of warrant liability of RMB14.0&nbsp;million for the
year ended December&nbsp;31, 2017, and a gain from change in the fair value of warrant liability of RMB61.4&nbsp;million for the year ended December&nbsp;31, 2018. The change was primarily attributable to (i)&nbsp;the change in fair value of
warrants due to the increase in the valuation of our company, and (ii)&nbsp;the modification in 2018 that added certain forfeiture conditions to the warrants, which increased the possibility of forfeiture of the warrants and therefore resulted in a
reduction in our warrant liabilities. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">118 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">Non-GAAP</FONT> Financial Measure </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">To supplement our consolidated financial statements, which are presented in accordance with GAAP, we also use adjusted net loss as an
additional financial measure, which is not required by, or presented in accordance with, GAAP. We believe adjusted net loss facilitates comparisons of operating performance from period to period and company to company by eliminating potential
impacts of items which our management considers <FONT STYLE="white-space:nowrap">non-indicative</FONT> of our operating performance. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We
believe adjusted net loss provides useful information to investors and others in understanding and evaluating our consolidated results of operations in the same manner as they help our management. However, our presentation of adjusted net loss may
not be comparable to similarly titled measures presented by other companies. The use of adjusted net loss has limitations as an analytical tool, and you should not consider it in isolation from, or as a substitute for an analysis of, our results of
operations or financial condition as reported under GAAP. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We define adjusted net loss as net loss for the year/period, excluding
share-based compensation expenses. We exclude share-based compensation expenses because they are not expected to result in future cash payments that are recurring in nature and they are not indicative of our core operating results and business
outlook. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The following table reconciles our adjusted net loss for the periods presented to the most directly comparable financial measure
calculated and presented in accordance with GAAP, which is net loss for the year/ period: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="36%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>For the Year Ended December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>For the Six Months Ended June&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>RMB</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>RMB</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>RMB</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>US$</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>RMB</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>RMB</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>US$</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="26" ALIGN="center"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Reconciliation of net loss to adjusted net loss:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss for the year/period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(298,240</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(402,833</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,451,950</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(205,510</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(857,337</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(582,853</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(82,497</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Add back:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Share-based compensation expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,039</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,520</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">515,203</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">72,922</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">514,664</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">229,795</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">32,525</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Adjusted net loss for the year/ period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(291,201</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(399,313</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(936,747</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(132,588</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(342,673</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(353,058</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(49,972</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Liquidity and Capital Resources </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Since inception, we have incurred net losses and negative cash flows from our operations. Substantially all of our losses have resulted from
funding our research and development programs and administrative costs associated with our operations. We incurred net losses of RMB298.2&nbsp;million, RMB402.8&nbsp;million, RMB1,452.0&nbsp;million (US$205.5 million) and RMB582.9&nbsp;million
(US$82.5 million) for the years ended December&nbsp;31, 2017, 2018 and 2019 and the six months ended June&nbsp;30, 2020, respectively. Our primary use of cash is to fund our research and development activities. We used RMB252.2&nbsp;million,
RMB280.7&nbsp;million, RMB868.0&nbsp;million (US$122.9 million) and RMB349.8&nbsp;million (US$49.5 million) in cash for our operating activities for the years ended December&nbsp;31, 2017, 2018 and 2019 and the six months ended June&nbsp;30, 2020,
respectively. Historically, we have financed our operations principally through proceeds from the issuance and sale of preferred shares and convertible promissory notes in private placement transactions, and we also received total net proceeds of
approximately US$105.3&nbsp;million from our initial public offering. For more information of our financing, see &#147;Description of Share Capital&#151;History of Securities Issuances.&#148; As of June&nbsp;30, 2020, we had cash, cash equivalents
and restricted cash of RMB1,560.0&nbsp;million (US$220.8 million). Our cash, cash equivalents </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">119 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
and restricted cash consist primarily of cash in bank and on hand. In September 2020, we entered into definitive subscription agreements with a consortium of institutional investors (the
&#147;Investors&#148;) to raise approximately US$418&nbsp;million through a private placement. The private placement consists of (i)&nbsp;the sale to the Investors of approximately US$418&nbsp;million of our 29,133,502 ordinary shares (equivalent to
12,666,740 ADSs) at a purchase price equivalent to US$33 per ADS, representing a 2.9% premium to the <FONT STYLE="white-space:nowrap">30-day</FONT> volume weighted average price; and (ii)&nbsp;warrants (the &#147;Warrants&#148;) to subscribe for an
aggregate of 5,341,267 ordinary shares (equivalent to 2,322,290 ADSs) at an exercise price equivalent to US$45 per ADS, representing a 40.3% premium to the <FONT STYLE="white-space:nowrap">30-day</FONT> volume weighted average price, which may
further increase the proceeds of approximately US$104.5&nbsp;million if the Warrants are fully exercised. The Warrants will remain exercisable at the election of the Investors within 12 months after the closing of the private placement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The following table sets forth a summary of our cash flows for the periods presented: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="34%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>For the Year Ended December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>For the Six Months Ended June&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>RMB</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>RMB</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>RMB</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>US$</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>RMB</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>RMB</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>US$</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="26" ALIGN="center"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash used in operating activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(252,157</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(280,705</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(867,982</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(122,855</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(389,034</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(349,793</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(49,510</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash generated from investing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(157,665</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">212,462</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30,072</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">158,056</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30,354</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,298</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash (used in) generated from financing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">758,585</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,479,669</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">152,709</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21,615</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(30,000</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">653,798</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">92,539</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Effect of exchange rate changes on cash and cash equivalents and restricted cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(132</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">59,754</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,163</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,146</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,093</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">32,389</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,584</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net increase (decrease) in cash, cash equivalents and restricted cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">348,631</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,268,218</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(487,648</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(69,022</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(264,071</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">366,748</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">51,911</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash, cash equivalents and restricted cash, beginning of the year/period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">64,082</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">412,713</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,680,931</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">237,920</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,680,931</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,193,283</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">168,897</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash, cash equivalents and restricted cash, end of the year/period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">412,713</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,680,931</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,193,283</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">168,898</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,416,860</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,560,031</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">220,808</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We do not expect to generate any revenue from product sales unless and until we obtain regulatory approval of
and commercialize one of our current or future drug candidates. We anticipate that we will continue to generate losses for the foreseeable future, and we expect the losses to increase as we continue the development of, and seek regulatory approvals
for, our drug candidates and begin to commercialize any approved products. We also expect to incur additional costs associated with operating as a public company. In addition, subject to obtaining regulatory approval of any of our drug candidates,
we expect to incur significant commercialization expenses for product sales, marketing and manufacturing. Accordingly, we anticipate that we will need substantial additional funding in connection with our continuing operations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Based on our current operating plan, we believe that our current cash and cash equivalents will be sufficient to meet our current and
anticipated working capital requirements and capital expenditures for at least the next 12 months. In that time, we expect that our expenses will increase substantially as we fund new and ongoing research and development activities and working
capital needs. We have based our estimates on </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">120 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
assumptions that may prove to be wrong, and we may use our available capital resources sooner than we currently expect. Because of the numerous risks and uncertainties associated with the
development and commercialization of our drug candidates, we are unable to estimate the amounts of increased capital outlays and operating expenditures necessary to complete the development and commercialization of our drug candidates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We may decide to enhance our liquidity position or increase our cash reserve for future operations and investments through additional
financing. The issuance and sale of additional equity would result in further dilution to our shareholders and ADS holders, and the terms of these securities may include liquidation or other preferences that adversely affect your rights as an ADS
holder. The incurrence of indebtedness would result in increased fixed obligations and could result in operating covenants that would restrict our operations, which could potentially dilute your interest. If we raise additional funds through
collaborations, strategic alliances or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams or research programs or to grant licenses on terms that may not be favorable to
us. If we are unable to raise additional funds through equity or debt financings when needed, we may be required to delay, limit, reduce or terminate our product development or future commercialization efforts or grant rights to develop and market
products or drug candidates that we would otherwise prefer to develop and market ourselves. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">As of June&nbsp;30, 2020, 7% of our cash and
cash equivalents were denominated in RMB and held in China. We may make additional capital contributions to our PRC subsidiaries, establish new PRC subsidiaries and make capital contributions to these new PRC subsidiaries, make loans to our PRC
subsidiaries, or acquire offshore entities with business operations in China in offshore transactions. However, most of these uses are subject to PRC regulations and approvals. See &#147;Risk Factors&#151;Risks Related to Doing Business in
China&#151;PRC regulation of loans to and direct investment in PRC entities by offshore holding companies and governmental control of currency conversion may delay or prevent us from making loans to our PRC subsidiaries or making additional capital
contributions to our wholly foreign-owned subsidiaries in China, which could materially and adversely affect our liquidity and our ability to fund and expand our business&#148;. In addition, the <FONT STYLE="white-space:nowrap">COVID-19</FONT>
outbreaks may materially and adversely affect our ability to raise additional capital in future and our liquidity. See &#147;Risk Factors&#151;Risks Related to Our Business and Our Industry&#151;Our business and results of operations could be
adversely affected by public health crisis (including the <FONT STYLE="white-space:nowrap">COVID-19</FONT> global pandemic) and natural catastrophes or other disasters outside of our control in the locations in which we, our suppliers, CROs, CMOs
and other contractors operate.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We expect that the majority of our future revenues will be denominated in RMB. Under existing PRC
foreign exchange regulations, payments of current account items, including profit distributions, interest payments and trade and service-related foreign exchange transactions, can be made in foreign currencies without prior SAFE approval as long as
certain routine procedural requirements are fulfilled. Therefore, our PRC subsidiaries are allowed to pay dividends in foreign currencies to us without prior SAFE approval by following certain routine procedural requirements. However, approval from
or registration with competent government authorities is required where RMB is to be converted into foreign currency and remitted out of China to pay capital expenses such as the repayment of loans denominated in foreign currencies. The PRC
government may at its discretion restrict access to foreign currencies for current account transactions in the future. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Operating Activities
</I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Net cash used in operating activities for the six months ended June&nbsp;30, 2020 was RMB349.8&nbsp;million (US$49.5 million).
Our net loss was RMB582.9&nbsp;million (US$82.5 million) for the same period. The difference between our net loss and our net cash used in operating activities was primarily attributable to certain <FONT STYLE="white-space:nowrap">non-cash</FONT>
expenses, including share-based compensation of RMB229.8&nbsp;million (US$32.5 million) and depreciation of property, equipment and software of RMB5.1&nbsp;million (US$0.7 million), and changes in certain working capital items, including an increase
in the prepayments and other receivables of RMB4.9&nbsp;million (US$0.7 million), an increase in the deferred subsidy income of RMB3.8&nbsp;million (US$0.5 million), an increase in the other <FONT STYLE="white-space:nowrap">non-current</FONT>
liabilities of RMB9.4&nbsp;million (US$1.3million), partially offset by an decrease in accruals and other </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">121 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
payables of RMB19.6&nbsp;million (US$2.8 million). The change in share-based compensation was attributable to the grant of stock options to certain directors and employees of our company under
the 2017 Plan, 2018 Plan and 2019 Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Net cash used in operating activities for the year ended December&nbsp;31, 2019 was
RMB868.0&nbsp;million (US$122.9 million). Our net loss was RMB1,452.0&nbsp;million (US$205.5 million) for the same period. The difference between our net loss and our net cash used in operating activities was primarily attributable to certain <FONT
STYLE="white-space:nowrap">non-cash</FONT> expenses, including share-based compensation of RMB366.9&nbsp;million (US$51.9 million) and loss on the termination agreement with Everest of RMB23.0&nbsp;million (US$3.3 million), and changes in certain
working capital items, including an increase in the research and development funding of RMB53.1&nbsp;million (US$7.5 million), an increase in the accruals and other payables of RMB188.4&nbsp;million (US$26.7 million), partially offset by an decrease
in advance from customers of RMB14.2&nbsp;million (US$2.0 million) and an decrease in repayments and other receivables of RMB48.8&nbsp;million (US$6.9 million). The change in share-based compensation was attributable to the grant of stock options to
a director of our company under the 2018 Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Net cash used in operating activities for the year ended December&nbsp;31, 2018 was
RMB280.7&nbsp;million. Our net loss was RMB402.8&nbsp;million for the same period. The difference between our net loss and our net cash used in operating activities was primarily attributable to certain
<FONT STYLE="white-space:nowrap">non-cash</FONT> expenses or gains, including fair value gains of warrants of RMB61.4&nbsp;million, and changes in certain working capital items, including (i)&nbsp;an increase in the research and development funding
of RMB178.7&nbsp;million and (ii)&nbsp;an increase in accruals and other payables of RMB55.6&nbsp;million, partially offset by an increase in prepayments and other receivables of RMB76.3&nbsp;million. The accruals and other payables principally
consist of accrued external research and development activities related expenses and staff salaries and welfare payables. The change in fair value of warrant liabilities was attributable to the exercise of part of the warrants issued in 2017 and the
modification in 2018 that added certain forfeiture conditions to the warrants. Prepayments and other receivables primarily consist of our prepayment to CRO partners and value-added tax recoverable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Net cash used in operating activities for the year ended December&nbsp;31, 2017 was RMB252.2&nbsp;million. Our net loss was
RMB298.2&nbsp;million. The difference between our net loss and our net cash used in operating activities was primarily attributable to certain <FONT STYLE="white-space:nowrap">non-cash</FONT> expenses or gains, including the fair value loss of
warrant liabilities of RMB14.0&nbsp;million, and changes in certain working capital items, including (i)&nbsp;an increase in contract liabilities of RMB15.8&nbsp;million and (ii)&nbsp;a decrease in prepayments and other receivables of
RMB8.8&nbsp;million. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Investing Activities </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Net cash generated from investing activities for the six months ended June&nbsp;30, 2020 was RMB30.4&nbsp;million (US$4.3 million). The net
cash increase was primarily attributable to RMB143.5&nbsp;million (US$20.3 million) of the cash received from proceeds from disposal of short-term investments, partially offset by RMB113.0&nbsp;million (US$16.0 million) of purchase of short-term
investments. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Net cash generated from investing activities for the year ended December&nbsp;31, 2019 was RMB212.5&nbsp;million (US$30.1
million). The net cash increase was primarily attributable to RMB256.0&nbsp;million (US$36.2 million) of the cash received from disposal of other financial assets and RMB134.0&nbsp;million (US$ 19.0 million) of purchase of short-term investments,
partially offset by RMB102.0&nbsp;million (US$14.4 million) of proceeds from disposal of short-term investments. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Net cash generated from
investing activities for the year ended December&nbsp;31, 2018 was RMB9.5&nbsp;million. The net cash increase was primarily attributable to RMB40.0&nbsp;million of the cash received from disposal of other financial assets, partially offset by
RMB30.0&nbsp;million of the cash used in other financial assets. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Net cash used in investing activities for the year ended
December&nbsp;31, 2017 was RMB157.7&nbsp;million. The net cash decrease was primarily attributable to RMB369.0&nbsp;million of investments in other financial assets, partially offset by RMB133.0&nbsp;million of proceeds from disposal of other
financial assets and RMB93.3&nbsp;million of cash acquired from acquisition of <FONT STYLE="white-space:nowrap">I-Mab</FONT> Tianjin. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">122 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Financing Activities </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Net cash generated from financing activities for the six months ended June&nbsp;30, 2020 was RMB653.8&nbsp;million (US$92.5 million),
primarily attributable to the proceeds from the initial public offering of our company, net of payment of offering issuance cost of RMB703.8&nbsp;million (US$99.6 million), partially offset by the repayment of bank borrowings of RMB50.0&nbsp;million
(US$7.1 million). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Net cash generated from financing activities for the year ended December&nbsp;31, 2019 was RMB152.7&nbsp;million
(US$21.6 million), primarily attributable to the proceeds from issuance of convertible preferred shares, net of issuance cost of RMB183.5&nbsp;million (US$26.0 million) and the repayment of bank borrowings of RMB80.0&nbsp;million (US$11.3 million),
partially offset by the proceeds of bank borrowings of RMB50.0&nbsp;million (US$7.1 million). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Net cash generated from financing
activities in the year ended December&nbsp;31, 2018 was RMB1,479.7&nbsp;million, primarily attributable to (i)&nbsp;proceeds from issuance of RMB1,306.6&nbsp;million convertible preferred shares and (ii)&nbsp;receipt of RMB132.3&nbsp;million
resulting from the exercise of warrants by investors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Net cash generated from financing activities in the year ended December&nbsp;31,
2017 was RMB758.6&nbsp;million, primarily attributable to proceeds of our issuance of RMB346.5&nbsp;million convertible preferred shares, RMB161.2&nbsp;million redeemable <FONT STYLE="white-space:nowrap">non-controlling</FONT> interest and
RMB99.0&nbsp;million proceeds from bank borrowings. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Capital Expenditures </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our capital expenditures were incurred for purposes of purchasing property, equipment and software. Our capital expenditures were
RMB20.3&nbsp;million, RMB14.4&nbsp;million, RMB12.2&nbsp;million (US$1.7 million) and RMB0.1&nbsp;million (US$0.02 million) in the years ended December&nbsp;31, 2017, 2018 and 2019 and six months ended June&nbsp;30, 2020, respectively. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Contractual Obligations </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The following
table sets forth our contractual obligations as of December&nbsp;31, 2019: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="49%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Less Than<BR>1&nbsp;Year</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B><FONT STYLE="white-space:nowrap">1-3</FONT> Years</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B><FONT STYLE="white-space:nowrap">3-5</FONT> Years</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>More Than<BR>5&nbsp;Years</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>RMB</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>US$</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>RMB</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>US$</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>RMB</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>US$</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>RMB</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>US$</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>RMB</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>US$</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="38" ALIGN="center"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating lease commitments</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,437</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,185</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,634</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,081</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,502</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,062</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">120</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">181</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our operating lease commitments relate to leases for our office premises pursuant to <FONT
STYLE="white-space:nowrap">non-cancellable</FONT> operating lease agreements. Other than as shown above, we did not have any significant capital and other commitments, long-term obligations or guarantees as of December&nbsp;31, 2019. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">Off-Balance</FONT> Sheet Commitments and Arrangements </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We have not entered into any financial guarantees or other commitments to guarantee the payment obligations of any third parties. In addition,
we have not entered into any derivative contracts that are indexed to our shares and classified as shareholder&#146;s equity or that are not reflected in our consolidated financial statements. Furthermore, we do not have any retained or contingent
interest in assets transferred to an unconsolidated entity that serves as credit, liquidity or market risk support to such entity. We do not have any variable interest in any unconsolidated entity that provides financing, liquidity, market risk or
credit support to us or engages in leasing, hedging or product development services with us. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">123 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Internal Control Over Financial Reporting </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In connection with the audits of our consolidated financial statements included in this prospectus, we and our independent registered public
accounting firm identified the following material weaknesses and other control deficiencies in our internal control over financial reporting. As defined in the standards established by the U.S. Public Company Accounting Oversight Board, a
&#147;material weakness&#148; is a deficiency, or combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of the company&#146;s annual or interim financial
statements will not be prevented or detected on a timely basis. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The material weaknesses that have been identified relate to (i)&nbsp;our
lack of sufficient and competent financial reporting and accounting personnel with appropriate knowledge of U.S. GAAP and SEC reporting and compliance requirements, to formalize key controls over financial reporting and to prepare consolidated
financial statements and related disclosures; and (ii)&nbsp;our lack of sufficient documented financial closing policies and procedures, specifically those related to (a)&nbsp;accounting for licensing and collaboration agreements and (b)&nbsp;period
end expenses <FONT STYLE="white-space:nowrap">cut-off</FONT> and accruals. These material weaknesses, if not timely remedied, may lead to significant misstatements in our consolidated financial statements in the future. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We have implemented and plan to implement a number of measures to address the material weaknesses that have been identified in connection with
the audits of our consolidated financial statements as of and for the years ended December&nbsp;31, 2017, 2018 and 2019 and the review of the consolidated financial statements as of and for the six months ended June&nbsp;30, 2020. We have hired
additional qualified financial and accounting staff with working experience of U.S. GAAP and SEC reporting requirements, and plan to continue such hiring efforts. We intend to conduct regular and continuous U.S. GAAP accounting and financial
reporting training programs for our financial reporting and accounting personnel. We further intend to establish sufficient and formal financial closing policies and procedures, specifically those related to accounting for licensing and
collaboration arrangements and period end <FONT STYLE="white-space:nowrap">cut-off</FONT> and accruals. We plan to, as <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">work-in-progress,</FONT></FONT> engage an external consulting
firm to assist us to assess Sarbanes-Oxley Act compliance requirements and improve our overall internal controls. Furthermore, we plan to prepare more detailed guidance on accounting policies, manuals and closing procedures to improve the quality
and accuracy of our period end financing closing process. We will continue to implement these and other measures to remediate our internal control deficiencies. We may incur significant costs in the implementation of such measures. However, the
implementation of these measures may not fully address the deficiencies in our internal control over financial reporting, and we cannot assure you that all of these measures will be sufficient to remediate our material weakness in time, or at all.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">As a company with less than US$1.07&nbsp;billion in revenue for our last fiscal year, we qualify as an &#147;emerging growth
company&#148; pursuant to the JOBS Act. An emerging growth company may take advantage of specified reduced reporting and other requirements that are otherwise applicable generally to public companies. These provisions include exemption from the
auditor attestation requirement under Section&nbsp;404 of the Sarbanes-Oxley Act of 2002 in the assessment of the emerging growth company&#146;s internal control over financial reporting. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Inflation </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">To date, inflation in China
has not materially impacted our results of operations. According to the National Bureau of Statistics of China, the year-over-year percent changes in the consumer price index for December 2017, 2018 and 2019 were increases of 1.8%, 1.9% and 4.5%,
respectively. Although we have not been materially affected by inflation in the past, we can provide no assurance that we will not be affected by higher rates of inflation in China in the future. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Holding Company Structure </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We are a
holding company with no material operations of its own. We currently conduct our operations primarily through our PRC subsidiaries. As a result, our ability to pay dividends depends upon dividends paid by
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">124 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
our PRC subsidiaries. If our existing PRC subsidiaries or any newly formed ones incur debt on their own behalf in the future, the instruments governing their debt may restrict their ability to
pay dividends to us. In addition, our wholly foreign-owned subsidiaries in China are permitted to pay dividends to us only out of its retained earnings, if any, as determined in accordance with PRC accounting standards and regulations. Under PRC
law, each of our subsidiaries and their subsidiaries in China is required to set aside at least 10% of its <FONT STYLE="white-space:nowrap">after-tax</FONT> profits each year, if any, to fund certain statutory reserve funds until such reserve funds
reach 50% of their registered capital. In addition, our wholly foreign-owned subsidiaries in China may allocate a portion of their <FONT STYLE="white-space:nowrap">after-tax</FONT> profits based on PRC accounting standards to enterprise expansion
funds and staff bonus and welfare funds at their discretion, and their subsidiaries may allocate a portion of their <FONT STYLE="white-space:nowrap">after-tax</FONT> profits based on PRC accounting standards to a surplus fund at their discretion.
The statutory reserve funds and the discretionary funds are not distributable as cash dividends. Remittance of dividends by a wholly foreign-owned company out of China is subject to examination by the banks designated by SAFE. Our PRC subsidiaries
have not paid dividends and will not be able to pay dividends until they generate accumulated profits and meet the requirements for statutory reserve funds. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Quantitative and Qualitative Disclosures about Market Risk </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Interest and Credit Risk </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We had
cash, cash equivalents and restricted cash of RMB412.7&nbsp;million, RMB1,680.9&nbsp;million, RMB1,193.3&nbsp;million (US$168.9 million) and RMB1,560.0&nbsp;million (US$220.8 million) as of December&nbsp;31, 2017, 2018 and 2019 and June&nbsp;30,
2020, respectively. Our exposure to interest rate risk primarily relates to the interest income generated by excess cash, which is mostly held in interest-bearing bank deposits. Interest-earning instruments carry a degree of interest rate risk. We
have not been exposed to material risks due to changes in interest rates, and we have not used any derivative financial instruments to manage our interest risk exposure. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our credit risk is primarily attributable to the carrying amounts of cash and cash equivalents. The carrying amounts of cash and cash
equivalents represent the maximum amount of loss due to credit risk. We mainly place or invest cash and cash equivalents with state-owned or reputable financial institutions in the PRC, and reputable financial institutions outside of the PRC. We do
not believe that our cash and cash equivalents have significant risk of default or illiquidity, and we will continually monitor the credit worthiness of these financial institutions. While we believe our cash and cash equivalents do not contain
excessive risk, future investments may be subject to adverse changes in market value. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Foreign Exchange Risk </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Most of our revenues and expenses are denominated in RMB. We do not believe that we currently have any significant direct foreign exchange
risk and have not used any derivative financial instruments to hedge exposure to such risk. Although our exposure to foreign exchange risks should be limited in general, the value of your investment in our ADSs will be affected by the exchange rate
between U.S. dollar and RMB because the value of our business is effectively denominated in RMB, while our ADSs will be traded in U.S. dollars. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The conversion of RMB into foreign currencies, including U.S. dollars, is based on rates set by the People&#146;s Bank of China. The RMB has
fluctuated against the U.S. dollar, at times significantly and unpredictably. It is difficult to predict how market forces or PRC or U.S. government policy may impact the exchange rate between RMB and the U.S. dollar in the future. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">To the extent that we need to convert U.S. dollars into RMB for our operations, appreciation of the RMB against the U.S. dollar would have an
adverse effect on the RMB amount we receive from the conversion. Conversely, if we decide to convert RMB into U.S. dollars for the purpose of making payments for dividends on our ordinary shares or ADSs or for other business purposes, appreciation
of the U.S. dollar against the RMB would have a negative effect on the U.S. dollar amounts available to us. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">125 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">As of June&nbsp;30, 2020, we had <FONT STYLE="white-space:nowrap">RMB-denominated</FONT>
cash and cash equivalents, restricted cash and short-term investments of RMB111.2&nbsp;million (US$15.7 million). A 10% depreciation of RMB against U.S. dollar based on the foreign exchange rate on June&nbsp;30, 2020 would result in a decrease of
US$1.6&nbsp;million in cash and cash equivalents. A 10% appreciation of RMB against U.S. dollar based on the foreign exchange rate on June&nbsp;30, 2020 would result in an increase of US$1.6&nbsp;million in cash and cash equivalents. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Critical Accounting Policies and Significant Judgments and Estimates </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our discussion and analysis of our financial condition and results of operations is based on our financial statements, which have been
prepared in accordance with U.S. GAAP. The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the
disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Estimates are used when accounting for amounts recorded in connection
with acquisitions, including initial fair value determinations of assets and liabilities and other intangible assets as well as subsequent fair value measurements. Additionally, estimates are used in determining items such as fair value measurements
of wealth management products, impairment of other receivables, contract assets, long-lived assets, intangible assets and goodwill, useful lives of property, equipment and software, recognition of <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">right-of-use</FONT></FONT> assets and lease liabilities, fair value measurements of warrant liabilities, variable consideration in collaboration revenue agreements, determination of the standalone compensation arrangement.
We base the estimates on historical experience, known trends and various other assumptions that are believed to be reasonable, the results of which form the basis for making judgments about the carrying values of assets and liabilities. Actual
results could differ from those estimates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Revenue Recognition </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We adopted Accounting Standard Codification (&#147;ASC&#148;) 606, Revenue from Contracts with Customers (Topic 606) (&#147;ASC 606&#148;) for
all periods presented. Consistent with the criteria of Topic 606, we recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to receive in exchange
for those goods or services. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Under ASC 606, an entity recognizes revenue when its customer obtains control of promised goods or services,
in an amount that reflects the consideration that the entity expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that an entity determines are within the scope of ASC 606, the entity performs
the following five steps: (i)&nbsp;identify the contract(s) with a customer; (ii)&nbsp;identify the performance obligations in the contract; (iii)&nbsp;determine the transaction price, including variable consideration, if any; (iv)&nbsp;allocate the
transaction price to the performance obligations in the contract; and (v)&nbsp;recognize revenue when (or as) the entity satisfies a performance obligation. We only apply the five-step model to contracts when it is probable that the entity will
collect substantially all the consideration to which it is entitled in exchange for the goods or services it transfers to the customer. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Once a contract is determined to be within the scope of ASC 606 at contract inception, we audit the contract to determine which performance
obligations it must deliver and which of these performance obligations are distinct. We recognize as revenue the amount of the transaction price that is allocated to each performance obligation when that performance obligation is satisfied or as it
is satisfied. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Collaboration Revenue </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">At contract inception, we analyze its collaboration arrangements to assess whether they are within the scope of ASC 808, Collaborative
Arrangements (&#147;ASC 808&#148;) to determine whether such arrangements involve joint operating activities performed by parties that are both active participants in the activities and exposed to significant risks and rewards dependent on the
commercial success of such activities. For collaboration </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">126 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
arrangements within the scope of ASC 808 that contain multiple elements, we first determine if the collaboration is deemed to be within the scope of ASC 808. For any units of account that are
reflective of a vendor-customer relationship those units of account are accounted for within the scope of ASC 606. For any units of account that are not accounted for under ASC 606 and therefore accounted for pursuant to ASC 808, an appropriate
recognition method is determined and applied consistently. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our collaborative arrangements may contain more than one unit of account, or
performance obligation, including grants of licenses to intellectual property rights, agreement to provide research and development services and other deliverables. The collaborative arrangements do not include a right of return for any deliverable.
As part of the accounting for these arrangements, we must develop assumptions that require judgment to determine the stand-alone selling price for each performance obligation identified in the contract. In developing the stand-alone selling price
for a performance obligation, we consider competitor pricing for a similar or identical product, market awareness of and perception of the product, expected product life and current market trends. In general, the consideration allocated to each
performance obligation is recognized when the respective obligation is satisfied either by delivering a good or providing a service, limited to the consideration that is not constrained. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">When the timing of the delivery of product is different from the timing of payments made by the customers, we recognize either a contract
asset (performance precedes the contractual due date) or a contract liability (customer payment precedes performance). Our contractual payment terms are typically due in no more than 30 days from invoicing. In limited situations, certain customer
contractual payment terms require us to bill in arrears; thus, we satisfy some or all of our performance obligations before we are contractually entitled to bill the customer. In these situations, billing occurs subsequent to revenue recognition,
which results in a contract asset. For example, certain of the contractual arrangements do not permit us to bill until the completion of the production of the samples. In other limited situations, certain customer contractual payment terms allow us
to bill in advance; thus, we receive customer cash payment before satisfying some or all of its performance obligations. In these situations, billing occurs in advance of revenue recognition, which results in contract liabilities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Licenses of Intellectual Property </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Upfront <FONT STYLE="white-space:nowrap">non-refundable</FONT> payments for licensing our intellectual property are evaluated to determine if
the license is distinct from the other performance obligations identified in the arrangement. For licenses determined to be distinct, we recognize revenues from <FONT STYLE="white-space:nowrap">non-refundable,</FONT>
<FONT STYLE="white-space:nowrap">up-front</FONT> fees allocated to the license at a point in time, when the license is transferred to the licensee and the licensee is able to use and benefit from the license. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Research and Development Services </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The portion of the transaction price allocated to research and development services performance obligations is deferred and recognized as
revenue over time as delivery or performance of such services occurs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Milestone Payments </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">At the inception of each arrangement that includes development, commercialization, and regulatory milestone payments, we evaluate whether the
milestones are considered probable of being reached and to the extent that a significant reversal of cumulative revenue would not occur in future periods, estimates the amount to be included in the transaction price using the most likely amount
method. The transaction price is then allocated to each performance obligation on a relative stand-alone selling price basis, for which we recognize revenue as or when the performance obligations under the contract are satisfied. At the end of each
subsequent reporting period, we <FONT STYLE="white-space:nowrap">re-evaluate</FONT> the probability of achieving such development milestones and any related constraint, and if necessary, adjust our estimate of the overall transaction price. Any such
adjustments are recorded on a cumulative <FONT STYLE="white-space:nowrap">catch-up</FONT> basis, which would affect revenues and earnings in the period of adjustment. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">127 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Royalties </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and the license is deemed to be
the predominant item to which the royalties or milestone payments based on the level of sales relate, we recognize revenue at the later of (i)&nbsp;when the related sales occur, or (ii)&nbsp;when the performance obligation to which some or all of
the royalty has been allocated has been satisfied (or partially satisfied). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Research and Development Expenses </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Elements of research and development expenses primarily include: (1)&nbsp;payroll and other related expenses of personnel engaged in research
and development activities, <FONT STYLE="white-space:nowrap">(2)&nbsp;in-licensed</FONT> patent rights fee of exclusive development rights of drugs granted to us, (3)&nbsp;expenses related to <FONT STYLE="white-space:nowrap">pre-clinical</FONT>
testing of our technologies under development and clinical trials such as payments to contract research organizations (&#147;CRO&#148;), investigators and clinical trial sites that conduct our clinical studies, (4)&nbsp;expenses to develop the
product candidates, including raw materials and supplies, product testing, depreciation, and facility related expenses, and (5)&nbsp;other research and development expenses. Research and development expenses are charged to expense as incurred when
these expenditures relate to our research and development services and have no alternative future uses. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We have acquired rights to
develop and commercialize product candidates. Upfront payments that relate to the acquisition of a new drug compound, as well as <FONT STYLE="white-space:nowrap">pre-commercial</FONT> milestone payments, are immediately expensed as acquired <FONT
STYLE="white-space:nowrap">in-process</FONT> research and development in the period in which they are incurred, provided that the new drug compound did not also include processes or activities that would constitute a &#147;business&#148; as defined
under U.S. GAAP, the drug has not achieved regulatory approval for marketing and, absent obtaining such approval, has no established alternative future use. Milestone payments made to third parties subsequent to regulatory approval would be
capitalized as intangible assets and amortized over the estimated remaining useful life of the related product. The conditions enabling capitalization of development expenses as an asset have not yet been met and, therefore, all development
expenditures are recognized in profit or loss when incurred. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Share-Based Compensation </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We grant restricted shares and stock options to eligible employees and account for share-based compensation in accordance with ASC 718,
Compensation&#151;Stock Compensation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Employees&#146; share-based compensation awards are measured at the grant date fair value of the
awards and recognized as expenses (i)&nbsp;immediately at the grant date if no vesting conditions are required; (ii)&nbsp;for share-based awards granted with only service conditions, using the graded vesting method net of estimated forfeitures over
the vesting period; or (iii)&nbsp;for share-based awards granted with service conditions and the occurrence of an initial public offering as performance condition cumulative share-based compensation expenses for the options that have satisfied the
service condition should be recorded upon the completion of the initial public offering using the graded vesting method. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">A change in any
of the terms or conditions of share-based awards is accounted for as a modification of the awards. We calculate incremental compensation expense of a modification as the excess of the fair value of the modified awards over the fair value of the
original awards immediately before its terms are modified at the modification date. For vested awards, we recognize incremental compensation cost in the period when the modification occurs. For awards not being fully vested, we recognize the sum of
the incremental compensation expense and the remaining unrecognized compensation expense for the original awards over the remaining requisite service period after modification. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Share-based compensation in relation to the restricted shares is measured based on the fair market value of our ordinary shares at the grant
date of the award. Prior to the listing, estimation of the fair value of our </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">128 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
ordinary shares involves significant assumptions that might not be observable in the market, and a number of complex and subjective variables, including discount rate, and subjective judgments
regarding our projected financial and operating results, its unique business risks, the liquidity of its ordinary shares and its operating history and prospects at the time the grants are made. Share-based compensation in relation to the share
options is estimated using the Binominal Option Pricing Model. The determination of the fair value of share options is affected by the share price of our ordinary shares as well as the assumptions regarding a number of complex and subjective
variables, including the expected share price volatility, risk-free interest rate, exercise multiple and expected dividend yield. The fair value of these awards was determined with the assistance from an independent valuation firm. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><I>Restricted ordinary shares </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">During the year ended December&nbsp;31, 2016, we issued 4,019,554 ordinary shares to Mr.&nbsp;Zang Jingwu Zhang, Ms.&nbsp;Qian Lili,
Mr.&nbsp;Wang Zhengyi and Mr.&nbsp;Fang Lei (collectively the &#147;Founders&#148;), including the 369,301 shares which represented the equity interests of Third Venture held by the Founders, and we recorded share-based compensation expense of
RMB18.7&nbsp;million for issuance and grant of 3,650,253 ordinary shares to the Founders in June 2016. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In October 2016, the Founders
entered into an arrangement with our other investors, and the 87,441 ordinary shares issued to the Founders in June 2016 were cancelled, and out of the remaining 3,932,113 ordinary shares held by the Founders, 70% became restricted and subject to
service vesting conditions, that shall vest 20%, 20% and 30% over the next three years, respectively. By October 2019, all the restricted shares were vested. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Deferred share-based compensation was measured for the restricted shares using the estimated fair value of our ordinary shares of US$0.77 at
the date of imposition of the restriction in October 2016, and was amortized to the consolidated statements of comprehensive loss by using graded vesting method over the vesting term of 3 years. The following table summarizes our Founders&#146;
restricted shares activities for the years ended </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">December&nbsp;31, 2017, 2018 and 2019 and the six months ended June&nbsp;30, 2019 and
2020: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="72%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="62%"></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Numbers&nbsp;of</B><br><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B><FONT STYLE="white-space:nowrap">Weighted-</FONT></B><br><B>Average&nbsp;Grant</B><br><B>Date&nbsp;Fair</B><br><B>Value</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outstanding at December&nbsp;31, 2017</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,966,056</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.77</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Vested</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(786,423</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outstanding at December&nbsp;31, 2018 and June&nbsp;30, 2019</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,179,633</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.77</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Vested</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,179,633</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outstanding at December&nbsp;31, 2019 and June&nbsp;30, 2020</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The amounts of share-based compensation expense in relation to the restricted shares recognized in the year
ended December&nbsp;31, 2019 was RMB1,566&nbsp;thousand, of which RMB1,026&nbsp;thousand was recognized in the six months ended June&nbsp;30, 2019. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">129 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">No share-based compensation expense was recognized in the six months ended June&nbsp;30,
2020. Share-based compensation expenses relating to restricted shares were included in: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="64%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Year Ended December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Six&nbsp;Months&nbsp;Ended&nbsp;June&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>RMB</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>RMB</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>RMB</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>US$</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>RMB</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>RMB</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>US$</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="26" ALIGN="center"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,112</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,056</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">470</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">67</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">308</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Administrative expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,927</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,464</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,096</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">155</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">718</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>7,039</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>3,520</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1,566</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>222</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1,026</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><I>Second Amended and Restated 2017 Employee Stock Option Plan (the &#147;2017 Plan&#148;) </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In October 2017, we adopted the 2017 Plan (as last amended and restated on December&nbsp;25, 2019). Under the 2017 Plan, a maximum aggregate
number of 13,376,865 shares that may be issued pursuant to all awards granted were approved. Stock options granted to an employee under the 2017 Plan will be exercisable upon the completion of a listing and the employee renders service to us in
accordance with a stipulated service schedule starting from the employee&#146;s date of employment. Employees are generally subject to a three-year service schedule, under which an employee earns an entitlement to vest in 50% of the option grants on
the second anniversary of the grant date, a vesting of the remaining fifty percent 50% on the third anniversary of the applicable grant date. The stock options under the 2017 Plan, to the extent then vested, shall become exercisable only upon the
earlier of (i)&nbsp;a listing, and (ii)&nbsp;occurrence of a change in control. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">On December&nbsp;25, 2019, the 2017 Plan was approved by
our shareholders and board of directors, pursuant to which, in connection with our initial public offering, the maximum aggregate number of shares that may be granted pursuant to all awards under the 2017 Plan shall be adjusted in accordance with a
formula <FONT STYLE="white-space:nowrap">pre-approved</FONT> by the shareholders. In connection with above amendments to the 2017 Plan, each of our founders, namely, Zheru Zhang, Lili Qian, Zhengyi Wang and Lei Fang, is willing to irrevocably
surrender by him or her, for no consideration, of a portion of the unvested options granted to him or her, which, if vested, would entitle him or her to acquire up to 130,000 ordinary shares of our company, par value US$0.0001 per share, at an
exercise price of US$1.0, respectively, under the 2017 Plan (in respect of each individual, the &#147;Founder&#146;s Surrendered Options&#148;). On December&nbsp;25, 2019, our board of directors approved that our company accepts all Founder&#146;s
Surrendered Options from each of the founders, namely, Zheru Zhang, Lili Qian, Zhengyi Wang and Lei Fang, for no consideration, with effect immediately prior to the completion of the initial public offering and such surrendered options be cancelled
with effect immediately prior to the completion of the initial public offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Prior to our completion of a listing, all stock options
granted to an employee shall be forfeited at the time the employee terminates his employment with us. After we complete a listing, vested options not exercised by an employee shall be exercised until later of: (i) 90 days after the date when the
options become exercisable, or (ii) 30 days after the date of cessation of employment or directorship, or such longer period as the board of directors may otherwise determine. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We granted 11,051,230, 1,470,000, 640,000, 640,000 and nil stock options to employees, all with an exercise price of US$1, for the years ended
December&nbsp;31, 2017, 2018 and 2019 and for the six months ended June&nbsp;30, 2019 and 2020, respectively. No options are exercisable as of December&nbsp;31, 2017, 2018 and 2019 and 4,063,676 stock options are exercisable as of June&nbsp;30,
2020. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">130 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The following table sets forth the stock options activities for the periods presented: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="85.5%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="46%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Number of<BR>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Weighted<BR>Average<BR>Exercise<BR>Price&nbsp;US$</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Weighted<BR>Average<BR>Remaining<BR>Contractual<BR>Term</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Aggregate<BR>Intrinsic&nbsp;Value</B><br><B>US$&#146;000</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outstanding as of December&nbsp;31, 2017</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,761,596</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.94</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9.50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24,890</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Granted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,470,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Forfeited</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(226,000</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outstanding as of December&nbsp;31, 2018</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,005,596</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.95</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.61</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">70,129</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Granted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">640,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Forfeited</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(397,500</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Repurchased</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,435,215</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outstanding as of December&nbsp;31, 2019</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,812,881</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.93</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.76</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">47,671</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercisable&nbsp;as&nbsp;of&nbsp;December&nbsp;31,&nbsp;2019</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Forfeited</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(329,377</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Surrendered</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(332,566</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outstanding as of June&nbsp;30, 2020</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,150,938</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.93</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">110,598</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercisable as of June&nbsp;30, 2020</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,061,176</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">48,787</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">Note:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Other addition represented the modified share options that originally granted to two senior management
employees in October 2016 (see &#147;&#151;other share-based compensation&#148;). </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Stock options granted to the
employees were measured at fair value on the dates of grant using the Binomial Option Pricing Model with the following assumptions: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="50%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Year&nbsp;Ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Six&nbsp;Months&nbsp;Ended&nbsp;June&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected volatility</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">62.34</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">61.32%&#151;62.13</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">54.64</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">N/A</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">N/A</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Risk-free interest rate (per annum)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.32</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2.81%&#151;3.06</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.15</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">N/A</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">N/A</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercise multiple</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.80</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.80</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.80</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">N/A</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">N/A</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected dividend yield</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">N/A</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">N/A</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Contractual term (in years)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">N/A</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">N/A</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The expected volatility was estimated based on the historical volatility of comparable peer public companies
with a time horizon close to the expected term of our options. The risk-free interest rate was estimated based on the yield to maturity of U.S. treasury bonds denominated in US$ for a term consistent with the expected term of our options in effect
at the option valuation date. The expected exercise multiple was estimated as the average ratio of the stock price to the exercise price when employees would decide to voluntarily exercise their vested options. As we did not have sufficient
information of past employee exercise history, it was estimated by referencing to a widely-accepted academic research publication. Expected dividend yield is zero as we have never declared or paid any cash dividends on its shares, and we do not
anticipate any dividend payments in the foreseeable future. Expected term is the contract life of the option. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">There were no stock options
granted to employees under the 2017 Plan for the six months ended June&nbsp;30, 2020. On January&nbsp;17, 2020, we completed our initial public offering. After achieving this performance condition, the options continue to vest based only on service
period completed according to the graded vesting schedule. We have begun recognizing share-based compensation expense for the options granted using the graded vesting method with a cumulative <FONT STYLE="white-space:nowrap">catch-up</FONT> for the
service period completed to date during the six months ended June&nbsp;30, 2020 and recognized RMB53,362&nbsp;thousand and RMB66,837&nbsp;thousand share-based compensation </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">131 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
expenses in administrative expenses and research and development expenses, respectively, relating to options vested cumulatively. According to the amendments to the 2017 Plan, the maximum
aggregate number of shares which may be granted pursuant to all awards under the 2017 Plan was changed to 9,609,084. Each of our founders, namely Zheru Zhang, Lili Qian, Zhengyi Wang and Lei Fang surrendered 83,142 unvested stock options that were
granted to him or her under the 2017 Plan before, totaling 332,566 unvested options, for no consideration, and these stock options were cancelled immediately. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><I>Second Amended and Restated 2018 Employee Stock Option Plan (the &#147;2018 Plan&#148;) </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">On February&nbsp;22, 2019, our company adopted the 2018 Plan, which was subsequently amended and restated on July&nbsp;22, 2019. Under the
amended and restated the 2018 Plan, the maximum aggregate number of ordinary shares which may be issued pursuant to all awards is 14,005,745, and if we successfully list on an internationally recognized securities exchange for a qualified public
offering by December&nbsp;31, 2019, the maximum aggregate number of ordinary shares which may be issued shall be 15,452,620. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">On
December&nbsp;25, 2019, the 2018 Plan was approved by the shareholders and board of directors of our company, pursuant to which, in connection with offering, the maximum aggregate number of shares that may be granted pursuant to all awards under the
2018 Plan may be adjusted in accordance with a formula <FONT STYLE="white-space:nowrap">pre-approved</FONT> by our shareholders. In connection with above amendments to the 2018 Plan, the director of our company, Dr.&nbsp;Jingwu Zhang Zang is willing
to irrevocably surrender by him, for no consideration, of the right to acquire a certain amount of ordinary shares of our company, par value US$0.0001 per share, at an exercise price of US$1.0 pursuant to the options granted to him under the 2018
Plan (the &#147;Dr.&nbsp;Zang&#146;s Surrendered Options&#148;). On December&nbsp;25, 2019, the board of directors of our company approved that our company accepts the irrevocable surrender of Dr.&nbsp;Zang&#146;s Surrendered Options for no
consideration, with effect immediately prior to the completion of the initial public offering and such surrendered options be cancelled with effect immediately prior to the completion of the initial public offering. See &#147;Management&#151;Share
Incentive Plans&#151;Second Amended and Restated 2018 Employee Stock Option Plan.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Stock options granted to an employee under the
2018 Plan will be generally exercisable when our company completes a listing and the employee renders service to our company in accordance with a stipulated service schedule starting from the employee&#146;s date of employment. The vesting schedule
shall generally be a <FONT STYLE="white-space:nowrap">two-year</FONT> vesting schedule consisting of a cliff vesting of 50% of the stock options on the first anniversary of the applicable vesting commencement date and a vesting of the remaining 50%
on the second anniversary of the applicable vesting commencement date. If a listing occurs at any time prior to any stock option granted under the 2018 Plan becoming fully vested, to the extent such stock option has been granted and is outstanding,
any such stock option shall vest in full with immediate effect upon the listing. Except as otherwise approved by the Board of Directors, any vested portion of the stock options shall become exercisable upon the earlier of six months after a listing
or the occurrence of a change in control; provided, however, that in each case, no stock option of an employee shall become exercisable until the third anniversary of such employee&#146;s employment commencement date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Pursuant to the board of director&#146;s approval of the 2018 Plan on February&nbsp;22, 2019, the 10,893,028 stock options granted to a
director of our company under the 2018 Plan were fully vested and exercisable upon the adoption of 2018 Plan. Out of these 10,893,028 stock options, 454,940 stock options were repurchased by our company (see Note 14 (d) to our unaudited interim
condensed consolidated financial statements for further details). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The amount of share-based compensation expense in relation to the
aforementioned grant of stock options to a director of our company (except for those repurchased by our company as described in Note 14 (d) to our unaudited interim condensed consolidated financial statements) recognized in the year ended
December&nbsp;31, 2019 was RMB365,329&nbsp;thousand, which were allocated to our administrative expenses. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">132 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The following table sets forth the stock options activities under the 2018 Plan for the six
months ended June&nbsp;30, 2020: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="85.5%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="50%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Number of<BR>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Weighted<BR>Average<BR>Exercise<BR>Price</B><br><B>US$</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Weighted<BR>Average<BR>Remaining<BR>Contractual<BR>Term</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Aggregate<BR>Intrinsic<BR>Value</B><br><B>US$</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outstanding as of December&nbsp;31, 2018</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Granted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,991,528</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Repurchased</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(454,940</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outstanding as of December&nbsp;31, 2019</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,536,588</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.86</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">64,840</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercisable as of December&nbsp;31,2019</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,438,088</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9.15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">49,998</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Surrendered</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,544,917</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outstanding as of June&nbsp;30, 2020</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,991,671</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.65</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">132,043</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercisable as of June&nbsp;30, 2020</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,565,171</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.65</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">114,907</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Stock options granted to certain directors and employees of our company were measured at fair value on the
dates of grant using the Binomial Option Pricing Model with the following assumptions: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="85.5%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="52%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Year&nbsp;Ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Six&nbsp;Months&nbsp;Ended&nbsp;June&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>&nbsp;&nbsp;2018&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected volatility</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">N/A</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">54.64&#151;56.31</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">56.31</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">N/A</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Risk-free interest rate (per annum)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">N/A</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.15&#151;2.75</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.75</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">N/A</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercise multiple</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">N/A</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.80</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.80</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">N/A</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected dividend yield</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">N/A</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">N/A</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Contractual term (in years)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">N/A</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">N/A</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The expected volatility was estimated based on the historical volatility of comparable peer public companies
with a time horizon close to the expected term of our company&#146;s options. The risk-free interest rate was estimated based on the yield to maturity of U.S. treasury bonds denominated in US$ for a term consistent with the expected term of our
company&#146;s options in effect at the option valuation date. The expected exercise multiple was estimated as the average ratio of the stock price to the exercise price when employees would decide to voluntarily exercise their vested options. As
our company did not have sufficient information of past employee exercise history, it was estimated by referencing to a widely-accepted academic research publication. Expected dividend yield is zero as our company has never declared or paid any cash
dividends on its shares, and our company does not anticipate any dividend payments in the foreseeable future. Expected term is the contract life of the option. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Except for the aforementioned grant of stock options to a director of our company under the 2018 Plan, since the exercisability is dependent
upon the listing, and it is not probable that this performance condition can be achieved until a listing, no share-based compensation expense related to the 2018 Plan was recorded for the year ended December&nbsp;31, 2019. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">On January&nbsp;17, 2020, our Company completed its IPO. After achieving this performance condition, the options continue to vest based only
on service period completed according to the graded vesting schedule. We have begun recognizing share-based compensation expenses for the options granted using the graded vesting method with a cumulative
<FONT STYLE="white-space:nowrap">catch-up</FONT> for the service period completed to date during the six months ended June&nbsp;30, 2020 and recognized RMB43,410&nbsp;thousand and RMB65,887&nbsp;thousand share-based compensation expense in
administrative expenses and research and development expenses, respective, relating to options vested cumulatively. According to the amendments to the 2018 Plan, the maximum aggregate number of shares which may be granted pursuant to all awards
under the 2018 Plan was changed to 11,005,888. Dr.&nbsp;Jingwu Zhang Zang, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">133 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
a director of our Company, surrendered 2,544,917 unvested options that were granted to him under the 2018 Plan, for no consideration, and these stock options were cancelled immediately. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><I>Repurchase of share awards held by a director </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">On February&nbsp;22, 2019, the amendment and restated 2017 equity incentive plan was approved by the Board of Directors of our company,
pursuant to which only the 3,435,215 stock options held by a director of our company under the 2017 equity incentive plan became fully vested and exercisable on February&nbsp;22, 2019. As a result of the performance condition being waived, the
shares held by a director of our company were accounted for as a Type III modification where a condition that our company expects will not be satisfied is changed to a condition that our company expects will be satisfied. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Additionally, on the same day, our company repurchased such 3,435,215 stock options under the amendment and restated 2017 equity incentive
plan that was held by a director of our company along with 454,940 of his stock options under the 2018 equity incentive plan for which the share awards also became fully vested and exercisable, at a total consideration of US$21,902&nbsp;thousand
(equivalent to approximately RMB148,308 thousand) at an average share price of US$5.63 per share. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">For the six months ended June&nbsp;30,
2019, our company recorded the total payment of US$21,902&nbsp;thousand (equivalent to approximately RMB148,308 thousand) as share-based compensation costs (included in administrative expenses) in the condensed consolidated statement of
comprehensive loss. There was no impact to the overall stockholder&#146;s equity balance as the amended shares vested immediately and were repurchased. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><I>2019 Share Incentive Plan (the &#147;2019 Plan&#148;) </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">On October&nbsp;29, 2019, we adopted the 2019 Plan. Under the 2019 Plan, the maximum aggregate number of ordinary shares available for
issuance shall initially be 100,000. The options shall vest when our Company completes a listing and the employee renders service to our Company in accordance with a stipulated service schedule starting from the employee&#146;s date of employment.
Stock options granted to 3 independent directors under the 2019 Plan will be generally exercisable under the following terms: (a)&nbsp;a cliff vesting of 1/3 of the option on the first anniversary of the vesting commencement date (January 17, 2020);
(b) a cliff vesting of 1/3 of the option on the second anniversary of the vesting commencement date (January 17, 2020); (c) a vesting of the remaining 1/3 of the option on the third anniversary of the vesting commencement date (January 7, 2020). In
the last year of the grantee&#146;s service, the options shall vest on a prorated basis to reflect the portion of the year during which the grantee provided services to our Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">For the six months ended June&nbsp;30, 2020, our Company granted 72,000 stock options to 3 independent directors (all with an exercise price
of US$6.09) and recognized RMB299&nbsp;thousand share-based compensation expenses relating to the options vested. No options were exercisable as of June&nbsp;30, 2020. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The following table sets forth the stock option activities of the 2019 Plan for the periods presented: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="85.5%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Number&nbsp;of<BR>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Weighted<BR>Average<BR>Exercise<BR>Price</B><br><B>US$</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Weighted<BR>Average<BR>Remaining<BR>Contractual<BR>Term</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Aggregate<BR>Intrinsic<BR>Value</B><br><B>US$</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outstanding as of December&nbsp;31, 2019</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Granted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">72,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.09</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outstanding as of June&nbsp;30, 2020</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">72,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.09</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9.84</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">498</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercisable as of June&nbsp;30, 2020</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">134 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Stock options granted to certain directors and employees of our company were measured at
fair value on the dates of grant using the Binomial Option Pricing Model with the following assumptions: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="55.5%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="56%"></TD>

<TD VALIGN="bottom" WIDTH="37%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Six&nbsp;Months&nbsp;Ended&nbsp;June&nbsp;30,</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>2020</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected volatility</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">54.88</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Risk-free interest rate (per annum)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.79</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercise multiple</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.80</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected dividend yield</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Contractual term (in years)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The expected volatility was estimated based on the historical volatility of comparable peer public companies
with a time horizon close to the expected term of our company&#146;s options. The risk-free interest rate was estimated based on the yield to maturity of U.S. treasury bonds denominated in US$ for a term consistent with the expected term of our
options in effect at the option valuation date. The expected exercise multiple was estimated as the average ratio of the stock price to the exercise price when employees would decide to voluntarily exercise their vested options. As our Company did
not have sufficient information of past employee exercise history, it was estimated by referencing to a widely-accepted academic research publication. Expected dividend yield is zero as our Company has never declared or paid any cash dividends on
its shares, and our Company does not anticipate any dividend payments in the foreseeable future. Expected term is the contract life of the option. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><I>2020 Share Incentive Plan (the &#147;2020 Plan&#148;) </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In July 2020, we adopted the 2020 Plan. Under the 2020 Plan, the maximum aggregate number of ordinary shares which may be issued pursuant to
all awards shall be 10,760,513, provided that the maximum number of shares may be issued pursuant to awards in the form of restricted share units under this plan shall not exceed 7,686,081 ordinary shares. From August 2020 through September 2020, we
granted 1,068,733 stock options and 4,892,918 restricted share units under the 2020 Plan to employees, respectively. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><I>Other share-based
compensation </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In October 2017, in connection with the adoption of the 2017 Plan, we amended the stock option agreement with the two
aforementioned employees, under which the stock options would become exercisable only upon the earlier of (i)&nbsp;a listing, and (ii)&nbsp;occurrence of a change in control that defined in the stock option agreements. As the modification of terms
and conditions of share-based compensation were not beneficial to its employees, no further accounting impact was resulting from it. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><I>Establishment of Biomaster Trust </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Biomaster Trust was established under the trust deed, dated October&nbsp;23, 2019, between us and TMF Trust (HK) Limited, or TMF Trust, as the
trustee of the Biomaster Trust. Through the Biomaster Trust, our company&#146;s ordinary shares and other rights and interests under awards granted pursuant to the 2017 Plan and the 2018 Plan may be provided to certain recipients of equity awards.
Upon satisfaction of the vesting conditions, TMF Trust will exercise the equity awards and transfer the relevant ordinary shares and other rights and interests under the equity awards to the relevant grant recipients with the consent of the advisory
committee of Biomaster Trust. TMF Trust shall not exercise the voting rights attached to such ordinary shares unless otherwise directed by the advisory committee, whose members shall be appointed by our company. Our company has the power to direct
the relevant activities of Biomaster Trust and has the ability to use its power over Biomaster Trust to affect its exposure to returns. Therefore, the assets and liabilities of Biomaster Trust are included in our consolidated statements of financial
position. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">135 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><I>Surrender of stock options </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">On January&nbsp;17, 2020, our Company completed its IPO. According to the amendments to 2017 Plan, the maximum aggregate number of shares which
may be granted pursuant to all awards under 2017 Plan was changed to 9,609,084. Each of our founders, namely Zheru Zhang, Lili Qian, Zhengyi Wang and Lei Fang surrendered 83,142 unvested stock options that were granted to him or her under 2017 Plan
before, totally 332,566 unvested options, for no consideration, and these stock options were cancelled immediately. According to the amendments to 2018 Plan, the maximum aggregate number of shares which may be granted pursuant to all awards under
2018 Plan was changed to 11,005,888. Dr.&nbsp;Jingwu Zhang Zang, a director of our Company, surrendered 2,544,917 unvested options that were granted to him under 2018 Plan, for no consideration, and these stock options were cancelled immediately.
Upon the completion of our initial public offering in January 2020, we recorded RMB91,051&nbsp;thousand share-based compensation expense related to these surrendered options. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The stock options surrendered by the founders should be accounted for as capital contribution. As the founders did not get the title of the
options to be surrendered and the number of share options would not be determined until listing, the capital contribution was not accounted for during the year ended December&nbsp;31, 2019. For the six months ended June&nbsp;30, 2020, our Company
has reclassified RMB91,051&nbsp;thousand from additional <FONT STYLE="white-space:nowrap">paid-in</FONT> capital&#151;share-based compensation to additional <FONT STYLE="white-space:nowrap">paid-in</FONT> capital&#151;capital contribution relating
to the options surrendered in the condensed consolidated financial statement of comprehensive loss. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><I>Fair Value of Ordinary Shares
</I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We are required to estimate the fair value of the ordinary shares on grant dates of share-based compensation awards/share option to
our employees and the issuance of financial instruments to investors. Therefore, our board of directors has estimated the fair value of our ordinary shares on various dates, with inputs from management, considering the third-party valuations. The
valuations of our ordinary shares were performed using methodologies, approaches and assumptions consistent with the American Institute of Certified Public Accountants Audit and Accounting Practice Aid Series: Valuation of Privately-Held-Company
Equity Securities Issued as Compensation, or the AICPA Practice Guide. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In addition, our board of directors considered various objective
and subjective factors, along with inputs from management and the independent third-party valuation firm, to determine the fair value of our ordinary shares, including: external market conditions affecting the biopharmaceutical industry, trends
within the biopharmaceutical industry, the prices at which we sold convertible preferred shares, the superior rights and preference of the convertible preferred shares or other senior securities relative to our ordinary shares at the time of each
grant and the likelihood of achieving a liquidity event such as an initial public offering. The option-pricing method was used to allocate the enterprise&#146;s value to preferred shares or other senior securities and ordinary shares, taking into
account the guidance prescribed by the AICPA Practice Guide. This method treats ordinary shares and convertible preferred shares or other senior securities as call options on the enterprise&#146;s value, with exercise prices based on their
respective payoffs upon a liquidity event. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In determining the enterprise&#146;s value, we applied the market approach/backsolve method
based on pricing from recent transactions in our own securities. The basis for application of this method is our transactions in equity securities with unrelated parties or among unrelated parties themselves. No evidence is observed to indicate
these transactions are not <FONT STYLE="white-space:nowrap">arm&#146;s-length</FONT> transactions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our board of directors determined the
fair value of our share options and the restricted shares as of the dates of grant, taking into consideration the various objective and subjective factors described above, including the conclusion of valuation of our ordinary shares as of dates
close to the grant dates of our share options and the restricted shares. We computed the per share estimated fair value for share options based on the binomial option pricing model and the per share estimated fair value for restricted shares based
on per share estimated fair value of ordinary shares as of the date of grant. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">136 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Once public trading market of the ADSs has been established in connection with the
completion of our initial public offering, it is no longer necessary for our board of directors to estimate the fair value of our ordinary shares in connection with our accounting for granted share options and restricted shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><I>Fair Value Measurements </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our financial assets and liabilities primarily comprise of cash and cash equivalents, restricted cash, short-term investments, other financial
assets, contract assets, other receivables, short-term borrowings, accruals and other payables and warrant liabilities. As of December&nbsp;31, 2017, 2018 and 2019 and June&nbsp;30, 2020, except for short-term investments, other financial assets and
warrants liabilities, the carrying values of these financial assets and liabilities approximated their fair values because of their generally short maturities. We report short-term investments, other financial assets and warrant liabilities at fair
value at each balance sheet date and changes in fair value are reflected in the consolidated statements of comprehensive loss. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We measure
our financial assets and liabilities using inputs from the following three levels of the fair value hierarchy. The three levels are as follows: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Level&nbsp;1 inputs are unadjusted quoted prices in active markets for identical assets that the management has the ability to access at the
measurement date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Level&nbsp;2 inputs include quoted prices for similar assets in active markets, quoted prices for identical or similar
assets in markets that are not active, inputs other than quoted prices that are observable for the asset (i.e., interest rates, yield curves, etc.), and inputs that are derived principally from or corroborated by observable market data by
correlation or other means (market corroborated inputs). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Level&nbsp;3 includes unobservable inputs that reflect the management&#146;s
assumptions about the assumptions that market participants would use in pricing the asset. The management develops these inputs based on the best information available, including the own data. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We measured our short-term investments, other financial assets and warrant liabilities at fair value on a recurring basis. As our short-term
investments, other financial assets and warrant liabilities are not traded in an active market with readily observable prices, we use significant unobservable inputs to measure the fair value of short-term investments, other financial assets and
warrant liabilities. These instruments are categorized in the Level&nbsp;3 valuation hierarchy based on the significance of unobservable factors in the overall fair value measurement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Recent Accounting Pronouncements </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">A list
of recently issued accounting pronouncements that are relevant to us is included in note 2 &#147;Principal Accounting Policies&#151;2.26 Recent Accounting Pronouncements&#148; of our consolidated financial statements included elsewhere in this
prospectus. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">137 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom98473_13"></A>BUSINESS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Overview </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We are a clinical stage
biopharmaceutical company committed to the discovery, development and commercialization of novel or highly differentiated biologics to treat diseases with significant unmet medical needs, particularly cancers and autoimmune disorders. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We were founded to capture the opportunities presented by the confluence of two major developments&#151;the emergence of an attractive and
growing biologics market in China, and the revolutionary scientific breakthroughs in cancer and autoimmune disease medicines. We believe we are well-positioned to become a biotech leader in China because of our innovative discovery expertise, <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">fit-for-purpose</FONT></FONT> technology platforms, biomarker-enabled translational medicine capabilities, and clinical development capabilities. These integrated capabilities are further
enhanced by our deep understanding of China&#146;s biologics regulatory framework and our direct access to extensive <FONT STYLE="white-space:nowrap">pre-clinical</FONT> and clinical trial resources in China. To date, we have developed an innovative
pipeline of more than 10 clinical and <FONT STYLE="white-space:nowrap">pre-clinical</FONT> stage assets through our internal research and development efforts and <FONT STYLE="white-space:nowrap">in-licensing</FONT> arrangements with global
pharmaceutical and biotech companies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Commercial Opportunities in China and Our Unique Position </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We are fully aware of the competitive and regulatory challenges we face as an innovative clinical stage biotech company based in China,
including need to raise significant capital, significant competition from global and other China-based biopharmaceutical companies, less streamlined regulatory pathway compared to countries with long-established regulatory systems, and potential
implementation challenges and uncertainties of the recent government reform of the drug approval system. However, with these challenges in mind, we have been mitigating the risks through our internal R&amp;D system that integrates multi-functional
aspects of our drug development process to proactively deal with some of the regulatory challenges mentioned above. Furthermore, through our Beijing office which focuses on regulatory matters, we have established an effective communication channel
with the regulatory agencies to discuss and resolve various regulatory issues promptly and effectively. We see vast opportunities for immuno-oncology and autoimmune biologics therapies in China. First, both the incidence and mortality of cancers in
China have been increasing in recent years and are outpacing those in the United States and the rest of the world. Second, many innovative biologics approved to treat cancer and autoimmune diseases in the United States and Europe are not yet
available in China. Third, the Chinese government has implemented new policies and regulations to simplify the review and approval cycle of clinical trials and new drug applications to encourage biologics innovation. Fourth, there has been a
continuous and rapid increase in personal disposable income in China coupled with ongoing improvement in basic national health insurance coverage, making innovative biologics more accessible to more Chinese patients. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We believe we are uniquely positioned as a China-based global player to tap into these vast commercial opportunities. This is best
demonstrated by our short journey in becoming one of the top clinical stage immunology companies in China. For example, in 2018 and 2019, we are the only China-based biotech company recognized by Genetic Engineering&nbsp;&amp; Biotechnology News
(GEN) as a top 10 immuno-oncology <FONT STYLE="white-space:nowrap">start-up</FONT> in the world. To date, our research and development capabilities encompass discovery, translational medicine, biologics CMC development, <FONT
STYLE="white-space:nowrap">pre-clinical</FONT> development and clinical development with footprints in Shanghai, Beijing and the United States. We are now at a critical juncture to transition from a clinical stage biotech company into a fully
integrated <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">end-to-end</FONT></FONT> global biopharmaceutical company in the next few years. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Unique Business Model </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">To achieve
our mission and capitalize on these commercial opportunities, we have developed a business model built on two pillars: a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">fast-to-market</FONT></FONT> China strategy and a <FONT
STYLE="white-space:nowrap">fast-to-PoC</FONT> (proof of concept) global strategy. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">138 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Fast-to-Market</FONT></FONT> China
Strategy </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">fast-to-market</FONT></FONT> China strategy
focuses on seeking opportunities to <FONT STYLE="white-space:nowrap">in-license</FONT> the development and commercialization rights of investigational drugs from global biopharmaceutical companies for Greater China. We only select investigational
drugs that have the potential to become novel or highly differentiated medicines. Through our substantial <FONT STYLE="white-space:nowrap">in-house</FONT> research and development efforts, we build additional data packages to meet the requirements
of the National Medical Products Administration (the &#147;NMPA&#148;) to ensure programs are ready for late-stage or registrational clinical development. Our internal development capabilities combined with our deep insight into China&#146;s
regulatory framework and our clinical network enable us to efficiently navigate through the drug development process to registration. To date, we have built an innovative China Portfolio consisting of five investigational drugs with an aim for
near-term product launch. All of these investigational drugs have met the related <FONT STYLE="white-space:nowrap">pre-set</FONT> safety and preliminary efficacy endpoints in Phase 1 or Phase 2 clinical trials in Europe, the United States or
elsewhere and are either in or ready for Phase 2 or Phase 3 clinical trials in China. Set forth below is a summary of the latest development status of the anchor assets in our China Portfolio: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">For felzartamab (TJ202), a differentiated anti-CD38, we are conducting two parallel registrational trials as a
third-line monotherapy and as a second line combination therapy with lenalidomide, both in patients with multiple myeloma in Greater China. The recruitment progress for these two trials remains on track, and we expect to submit an NDA to the NMPA in
2021. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">For eftansomatropin (TJ101), a differentiated long-acting growth hormone, in September 2020, the NMPA approved
our IND application for a registrational Phase 3 trial in pediatric growth hormone deficiency (PGHD). We expect to initiate this trial in the first quarter of 2021. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">For enoblituzumab, a humanized antibody directed at <FONT STYLE="white-space:nowrap">B7-H3,</FONT> in the first
quarter of 2021, MacroGenics expects to initiate a Phase 2 study of enoblituzumab in a chemo-free regimen in combination with either retifanlimab (an investigational <FONT STYLE="white-space:nowrap">PD-1</FONT> antibody) in front-line patients with
SCCHN who are <FONT STYLE="white-space:nowrap">PD-L1</FONT> positive or with tebotelimab (an investigational <FONT STYLE="white-space:nowrap">PD-1</FONT> x <FONT STYLE="white-space:nowrap">LAG-3</FONT> bispecific DART<SUP
STYLE="font-size:85%; vertical-align:top">&reg;</SUP> antibody) in SCCHN patients who are <FONT STYLE="white-space:nowrap">PD-L1</FONT> negative. We expect to participate in any subsequent Phase 3 global study if and when initiated. In addition,
considering the dynamic regulatory environment and evolving clinical practice, we have been continually refining the development of enoblituzumab in our territory. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">For efineptakin (TJ107), a long-acting interleukin 7, we obtained regulatory clearance from the NMPA in April
2020 to initiate a Phase 2 clinical trial in glioblastoma multiforme (GBM) patients with lymphopenia. We expect to initiate this trial in the fourth quarter of 2020. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">As a result, the investigational drugs in our China Portfolio are positioned for a series of new drug applications (NDAs) in China with the
submission of the first NDA expected in 2021. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I><FONT STYLE="white-space:nowrap">Fast-to-PoC</FONT> Global Strategy </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our <FONT STYLE="white-space:nowrap">fast-to-PoC</FONT> global strategy focuses on advancing our own novel or differentiated biologics towards
clinical validation in the United States. First, we seek PoC of these drug candidates in the United States by conducting early phase clinical trials with a set of safety and efficacy endpoints and leveraging the FDA&#146;s streamlined regulatory
system for innovative drug development, including a predictable timeline towards IND approval. Second, we will use the data generated to advance clinical development in China, which we believe confers several advantages, including access to
China&#146;s large patient pool, extensive clinical trial resources through collaborations with leading hospitals in China, and a regulatory pathway for fast-track approval of drugs supported by solid overseas clinical data. Building on this
approach, we may <FONT STYLE="white-space:nowrap">out-license</FONT> the global rights (excluding Greater China) of these investigational drugs following clinical validation in the United States, while retaining the Greater China rights for further
development and commercialization. We believe this approach will </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">139 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
allow Chinese patients to benefit from our most advanced treatments concurrently or soon after their market approvals elsewhere. To date, we have created a Global Portfolio that consists of two
molecular classes&#151;monoclonal antibodies and <FONT STYLE="white-space:nowrap">bi-specific</FONT> antibodies, which are internally generated. They are highly innovative molecules compared to global competitor assets in the same or related classes
of drug candidates. Set forth below is a summary of the latest development status of the anchor assets in our Global Portfolio: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">For lemzoparlimab (TJC4), a differentiated anti-CD47, the topline results of the recently completed Phase 1a dose
escalation monotherapy trial in the United States have demonstrated the differentiated profile of lemzoparlimab in drug safety and favorable pharmacokinetics in cancer patients. The key findings include: (i)&nbsp;lemzoparlimab was well tolerated up
to 30 mg/kg on a weekly basis without priming dosing strategy, and no dose-limiting toxicity and no clinical or laboratory evidence of hemolytic anemia were observed throughout; (ii)&nbsp;lemzoparlimab PK appears to be linear at mid to high dose
levels following a single dose with no significant &#147;sink effect&#148; and (iii)&nbsp;one confirmed Partial Response (PR) was observed in the 30 mg/kg cohort (N=3), and this patient had failed prior treatments with checkpoint inhibitors. Three
patients achieved Stable Disease (SD). In September 2020, we received the NMPA approval for a Phase 1 clinical trial of lemzoparlimab in relapsed or refractory advanced lymphoma in China as part of the ongoing international multi-center trial. In
addition, lemzoparlimab is being evaluated in a Phase 1/2a clinical trial in China in patients with relapsed or refractory acute myeloid leukemia (r/r AML) or myelodysplastic syndrome (MDS), and we anticipate reporting
<FONT STYLE="white-space:nowrap">top-line</FONT> results in early 2021. We have also entered into a clinical trial collaboration and supply agreement with Merck Sharp&nbsp;&amp; Dohme Corp, or MSD, through a subsidiary, under which we will sponsor a
Phase 1 clinical trial in the United States evaluating lemzoparlimab in combination with KEYTRUDA<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> (pembrolizumab), MSD&#146;s
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-1</FONT></FONT> therapy, in patients with multiple types of solid tumors. In September 2020, we granted AbbVie a global license, excluding Mainland China, Hong Kong and Macau,
to develop and commercialize lemzoparlimab (as well as certain other compounds directed against CD47), and we will retain all rights to develop and commercialize lemzoparlimab in Mainland China, Hong&nbsp;Kong and Macau. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">For uliledlimab (TJD5), a differentiated anti-CD73, we are conducting a Phase 1 clinical trial in the United
States as a single agent and in combination with atezolizumab (TECENTRIQ<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>), a <FONT STYLE="white-space:nowrap">PD-L1</FONT> antibody marketed by Roche, in patients with advanced solid tumors.
The preliminary data of this trial in the United States are expected by mid-2021. In China, we are conducting a Phase 1/2 clinical trial to evaluate uliledlimab in patients with advanced solid tumors. The first patient was dosed in May 2020. This
Phase 1/2 study is a multicenter, open-label, dose escalation and cohort expansion study, which will evaluate safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy of uliledlimab, and determine a recommended dose for further planned
clinical studies of its efficacy and safety as a single agent and in combination with standard dose of toripalimab (TUOYI<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>) in patients with advanced or metastatic cancers who are refractory
to or intolerant of all available therapies. We have been able to accelerate the Phase 1/2 trial in China by leveraging data from the ongoing Phase 1 clinical study of uliledlimab in the United States, which is a testament to our global clinical
development capabilities and well-executed pipeline strategies. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">For plonmarlimab (TJM2), an
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-GM-CSF,</FONT></FONT> we have completed a single-dose <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-human</FONT></FONT> study in healthy volunteers
in the United States. It is the first antibody of its class entering clinical development in China. We dosed the first patient in a Phase 1b study of plonmarlimab in August 2020 in patients with rheumatoid arthritis (RA). We may expand plonmarlimab
to other autoimmune and inflammatory indications with high unmet medical need, where <FONT STYLE="white-space:nowrap">GM-CSF</FONT> is known as a pathogenic cytokine in disease activity and progression. If approved, plonmarlimab is expected to
provide an effective treatment option as a disease-modifying anti-rheumatic drug (&#147;DMARD&#148;) therapy. In addition, since the <FONT STYLE="white-space:nowrap">COVID-19</FONT> outbreak, we have sprung into action to
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">140 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="12%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
prioritize plonmarlimab in response to the urgent medical needs. In May 2020, we announced preliminary results from part 1 of a clinical study in the United States of plonmarlimab in patients
with cytokine release syndrome (CRS) associated with severe <FONT STYLE="white-space:nowrap">COVID-19,</FONT> in which plonmarlimab was found to be well tolerated. We are currently conducting part 2 of this clinical trial to evaluate the efficacy,
safety and cytokine levels following a single dose of 6 mg/kg plonmarlimab or placebo (standard care) in patients with severe <FONT STYLE="white-space:nowrap">COVID-19.</FONT> We are currently in discussion with the FDA to finalize the plan for
plonmarlimab in relation to clinical development and potential registration in the United States. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">These two strategies
and the resulting two portfolios complement each other. This enables us to achieve a balance among our ambition to develop novel or highly differentiated drugs, our goal to efficiently advance our pipeline assets towards commercialization and the
inherent development risks. With this goal in mind, we are also aware that the intended novelty and key differentiation of our investigational drugs or drug candidates are subject to pivotal clinical validation and approval by the relevant
regulatory authorities. There is no assurance that any such investigational drug or drug candidate will receive regulatory approval. See &#147;Risk Factors&#148; for a detailed description of the risks related to the development and
commercialization of our drug candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Capabilities </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our Innovative Discovery Expertise </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Built by an elite group of seasoned immunologists with extensive academic research and drug development experience, our discovery engine has
generated a panel of internally developed innovative drug molecules in a short span of five years. Among them, 12 innovative drug molecules have met our standard of novelty or high differentiation and have advanced toward further development. This
achievement is a testament to our discovery team&#146;s acumen and technical prowess in translating target biology into points of innovation or differentiation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The discovery of lemzoparlimab showcases our innovative research capabilities. Not settling on performing routine or traditional antibody
screening, we set a specific goal to identify and select a unique CD47 antibody that is free from binding to red blood cells (RBC) from all CD47 antibody leads. As a result, we selected by design, our proprietary CD47 antibody (TJC4) with a rare
epitope that spares binding to RBCs as a differentiation point from other CD47 antibodies that typically cause inherent hematologic side effects. The topline results of the recently completed Phase 1a dose escalation monotherapy trial in the United
States have demonstrated the differentiated profile of lemzoparlimab in drug safety and favorable pharmacokinetics in cancer patients. The key findings include: (i)&nbsp;lemzoparlimab was well tolerated up to 30 mg/kg on a weekly basis without
priming dosing strategy, and no dose-limiting toxicity and no clinical or laboratory evidence of hemolytic anemia were observed throughout; (ii)&nbsp;lemzoparlimab PK appears to be linear at mid to high dose levels following a single dose with no
significant &#147;sink effect&#148; and (iii)&nbsp;one confirmed Partial Response (PR) was observed in the 30 mg/kg cohort (N=3), and this patient had failed prior treatments with checkpoint inhibitors. Three patients achieved Stable Disease (SD).
Therefore, we believe that lemzoparlimab, if approved, will be a potentially highly differentiated antitumor CD47 antibody with the advantage of minimizing hematologic side effects. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Another example of our R&amp;D capability relates to our novel <FONT STYLE="white-space:nowrap">bi-specific</FONT> antibody panel that
represents a new wave of oncology drug candidates. We created novel biological properties of these <FONT STYLE="white-space:nowrap">bi-specific</FONT> antibodies that are capable of enriching immune cells in tumors through dual targeting of <FONT
STYLE="white-space:nowrap">PD-L1</FONT> and immune cells for a synergistic anti-tumor effect. These <FONT STYLE="white-space:nowrap">bi-specific</FONT> drug candidates have been shown to exhibit unique properties that render tumors more responsive
to treatment. Our discovery expertise, when combined with our <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">&#147;fit-for-purpose&#148;</FONT></FONT> antibody engineering technology platforms, becomes a powerful engine of
innovation to create novel molecules. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">141 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Fit-for-Purpose</FONT></FONT>
Technology Platforms </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our proprietary antibody engineering platforms enable us to accurately capture the biological properties of <FONT
STYLE="white-space:nowrap">bi-specific</FONT> antibodies and retain good manufacturability and druggability of the molecules. To date, we have eight novel <FONT STYLE="white-space:nowrap">pre-clinical</FONT> stage
<FONT STYLE="white-space:nowrap">bi-specific</FONT> drug molecules. In addition to our own <FONT STYLE="white-space:nowrap">bi-specific</FONT> antibody platform, we partnered with ABL Bio and WuXi Biologics to access their antibody engineering
platforms in order to increase the probability of success, as different molecular configurations require different technologies. Furthermore, our proprietary antibody-cytokine technology has enabled another form of
<FONT STYLE="white-space:nowrap">bi-specific</FONT> antibodies such as <FONT STYLE="white-space:nowrap">TJ-L1I7</FONT> and <FONT STYLE="white-space:nowrap">TJ-C4GM</FONT> that link a tumor-engaging antibody with an immune-modulatory cytokine.
Superior to monoclonal antibodies or cytokines alone, this class of <FONT STYLE="white-space:nowrap">bi-specific</FONT> antibodies has demonstrated unique properties of concentrating the drug molecules in tumors for a desired target effect with
reduced systemic toxicity of cytokines or creating biologic synergy that can potentially translate into better treatment outcome. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our
Biomarker-Enabled Translational Medicine Capabilities </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">As we focus on developing innovative drug molecules, the ability to apply
relevant biomarkers that link a drug response to treatment effects is critical for early-stage clinical trials of our investigational drugs. This translational medicine capability requires cross-functional knowledge and unique skills to link the
target biology of an investigational drug to clinical responses. We have been developing tailor-made biomarkers for each of our investigational drugs, which are used to select potential responders, predict and measure target engagement, support dose
determination and enable timely informed decisions on advancing our assets to the next phase of clinical development. For example, for the development of uliledlimab, we intend to use CD73 in tumor tissue in combination with other tumor biomarkers
to stratify potential target patient populations in our clinical trial. To that end, we have developed assays to measure CD73 expression and activity in tumor tissues. Furthermore, we have developed specialized assays to measure uliledlimab drug
concentrations in tumor tissues. By linking drug concentration with its activity in the same tumor location, these data help us determine appropriate dose selection for further clinical studies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our Clinical Development Capabilities </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our clinical development is led by a global team of clinical scientists, industry physicians and experts in portfolio management, quantitative
science, clinical operations, drug safety and quality control. Our clinical team accounts for approximately 80% of our entire R&amp;D organization&#146;s headcount and 80% of our budget allocation. The skillset of our clinical development team is
highlighted by a combination of extensive global pharma, local drug development and operation experiences with clinical networks in China and the United States. The team is driven by high ethical standards, with passion for improving the lives of
patients. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our team has the ability to integrate internal core development functions to conduct global and local clinical trials. We also
effectively leverage external resources, including clinical contract research organizations, academic clinical centers and/or networks, and global pharmaceutical or biotech partnerships. Furthermore, we have established and implemented a robust
internal clinical governance system and processes to safeguard patient safety and data integrity. Our current clinical development functions and teams are strategically based in Shanghai, Beijing, and the United States to cover Phase 1 through Phase
3 clinical trials in China and early-stage clinical trials in the United States. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our clinical development capabilities are best
demonstrated by the rapid implementation of 11 clinical trials, including one completed trial in the United States and ten <FONT STYLE="white-space:nowrap">on-going</FONT> Phase 1/2 or registration trials in the United States and China in the past
three years. To ensure regulatory approval and subsequent product launch as currently planned, we strive to reach the following critical clinical milestones by the end of 2020: 11 active clinical programs consisting of two Phase 3 or registrational
trials in China, three Phase 2 trials and six Phase 1/2 trials in the United States and China. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">142 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Global Strategic Collaborations </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We have established an excellent track record of <FONT STYLE="white-space:nowrap">in-licensing</FONT> and
<FONT STYLE="white-space:nowrap">out-licensing</FONT> deals with our global and regional partners. These <FONT STYLE="white-space:nowrap">in-licensing</FONT> deals enable us to acquire multiple innovative clinical stage assets with favorable
clinical data packages. We have quickly built our China Portfolio through <FONT STYLE="white-space:nowrap">in-licensing</FONT> deals with global biotech partners, including MorphoSys, Genexine, MacroGenics and Ferring (as the sublicensee under our
agreement with Ferring related to olamkicept). Over the past three years, we have established more than 10&nbsp;global and regional partnerships with reputable pharma or biotech companies. Our partners selected us among many China-based companies
with the belief that we are an ideal partner in China given our strength in science and drug development capability, our outstanding track record of execution demonstrated by rapidly progressing drug development programs in China and the United
States, and our vision and network to tap into business opportunities and China&#146;s growing pharmaceutical market. For example, MorphoSys, MacroGenics and Genexine all stated that we are an ideal or the best partner in China in their press
releases or public announcements. The <FONT STYLE="white-space:nowrap">out-licensing</FONT> deals enable us to streamline our pipeline, focus our resources on the most valuable assets in the most desirable territories and build strategic alliances
with leading global biopharmaceutical companies. In addition, we seek <FONT STYLE="white-space:nowrap">co-development</FONT> opportunities to share development costs, risks and territorial commercial rights with our partners. In the past several
years, we have <FONT STYLE="white-space:nowrap">out-licensed</FONT> four assets and initiated multiple <FONT STYLE="white-space:nowrap">co-development</FONT> programs with partners such as ABL Bio, MSD, Roche and Junshi and WuXi Biologics. The
revenue from <FONT STYLE="white-space:nowrap">out-licensing</FONT> and <FONT STYLE="white-space:nowrap">co-development</FONT> deals is expected to continue to grow as our pipeline progresses. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Global Strategic Partnership with AbbVie </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In September 2020, we, through <FONT STYLE="white-space:nowrap">I-Mab</FONT> Biopharma Co., Ltd. and
<FONT STYLE="white-space:nowrap">I-Mab</FONT> Biopharma US Limited, each a wholly-owned subsidiary of our company, entered into a broad global strategic collaboration with AbbVie Ireland Unlimited Company (&#147;AbbVie&#148;), a leading global,
research-based biopharmaceutical company. Pursuant to this collaboration, we grant AbbVie a global license, excluding Mainland China, Hong Kong and Macau, to develop and commercialize lemzoparlimab. We retain all rights to develop and commercialize
lemzoparlimab (as well as certain other compounds directed against CD47) in Mainland China, Hong Kong and Macau. AbbVie will conduct further global clinical trials (which we may elect to <FONT STYLE="white-space:nowrap">co-fund)</FONT> to evaluate
lemzoparlimab in multiple cancers. This deal also allows for potential collaboration on future CD47-related therapeutic agents, including CD47-based bispecific antibodies and combination therapies with lemzoparlimab and AbbVie&#146;s venetoclax
(Venclexta<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>). Each party will have the opportunity, subject to rights of first negotiation to further licenses, to explore certain of each other&#146;s related CD47-antibody programs in their
respective territories. In addition, we and AbbVie will share manufacturing responsibilities, with AbbVie being the primary manufacturer for supply outside of Mainland China, Hong Kong and Macau and us being the primary manufacturer for supply in
Mainland China, Hong Kong and Macau. We believe that this collaboration will accelerate the establishment of our commercial production operations in China. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Pursuant to this collaboration, AbbVie will pay us an upfront payment of US$180&nbsp;million. Additionally, in connection with the recently
released clinical data from the Phase 1 trial of lemzoparlimab in the United States, we expect to be paid a first milestone payment of US$20&nbsp;million. We will also be eligible to receive up to US$1.74&nbsp;billion in further success-based
development, regulatory and sales milestone payments for lemzoparlimab, of which US$840&nbsp;million are based on clinical development and regulatory approval milestones, with the remainder based on commercial milestones. Upon commercialization of
lemzoparlimab, AbbVie will also pay tiered royalties from low double-digit percentages on global net sales outside of Mainland China, Hong&nbsp;Kong and Macau. In addition, AbbVie has a license and right of first negotiation to further develop and
commercialize two additional lemzoparlimab-based bispecific antibodies discovered and currently being developed by us and we cannot commercialize products containing these two additional lemzoparlimab-based bispecific antibodies outside of Mainland
China, Hong Kong and Macau even if AbbVie does not exercise its right of first negotiation or we are unable to come to financial terms on such products. The potential value of each such license is minimum US$500&nbsp;million in upfront and milestone
payments, for a combined total of no less than US$1&nbsp;billion. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">143 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">This strategic collaboration with AbbVie reinforces our internal research and development
capabilities and our leading position in immuno-oncology and enables us to realize the full potential of our innovation. By leveraging the combined development strength of our company and AbbVie, we aim to speed lemzoparlimab to market for patients
in need around the world. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Drug Pipeline </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The chart below summarizes the development status of our drug pipeline. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g98473g46b24.jpg" ALT="LOGO">
 </P> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Notes:
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">(i) for felzartamab (TJ202), we are conducting two parallel registrational trials with felzartamab as a
third-line monotherapy and as a second line combination therapy with lenalidomide, both in patients with multiple myeloma in Greater China. The recruitment progress for these two trials remains on track, and we expect to submit an NDA to the NMPA in
2021. In addition, we submitted an IND application to the NMPA in October 2019 for a Phase 1b trial for felzartamab in SLE; (ii)&nbsp;for eftansomatropin (TJ101), in September 2020, the NMPA approved our IND application for a registrational Phase 3
trial of eftansomatropin in pediatric growth hormone deficiency (PGHD). We expect to initiate this trial in the first quarter of 2021; (iii) for enoblituzumab, we expect to submit an IND application in 2021 for a Phase 2 trial; (iv)&nbsp;for
efineptakin (TJ107), we have obtained regulatory clearance from the NMPA to initiate a phase 2 clinical trial in GBM patients with lymphopenia. We expect to initiate this trial in the fourth quarter of 2020; and (v)&nbsp;for olamkicept (TJ301), we
are conducting an ongoing Phase 2 clinical trial in patients with active ulcerative colitis. The enrollment of this trial is complete and topline data are expected to be released by early 2021. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">**</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">We were collaborating with Everest Medicines Limited (&#147;Everest&#148;) to
<FONT STYLE="white-space:nowrap">co-develop</FONT> and commercialize felzartamab in Greater China for all indications in hematologic oncology. Everest was primarily responsible for sharing with us, by the proportion of 75% for Everest and 25% for
us, the development costs of felzartamab. On November&nbsp;4, 2019, we and Everest terminated the collaboration agreement (including all the supplements and amendments thereto) with respect to the
<FONT STYLE="white-space:nowrap">co-development</FONT> and commercialization of </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">144 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
felzartamab in Greater China. Upon the termination, Everest will not retain any rights or entitlements to develop or commercialize felzartamab or any economic interest in its commercialization.
All intellectual property rights in respect of felzartamab arising from its development under the collaboration agreement are vested and owned by us, and we hold all intellectual property rights and have maximum flexibility to further develop,
manufacture and commercialize felzartamab in Greater China. In consideration of the above arrangements, we issued a total value of US$37.0&nbsp;million of ordinary shares (the &#147;CPP Shares&#148;) to Everest, representing Everest&#146;s
historical contribution to our collaboration and the associated time cost. The CPP Shares were issued concurrently with the completion of our initial public offering in January 2020, at a per share price equal to the initial public offering price
adjusted to reflect the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">ADS-to-ordinary</FONT></FONT> share ratio. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">***</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Our <FONT STYLE="white-space:nowrap">bi-specific</FONT> antibody panel consists of (i)&nbsp;six <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">PD-L1-based</FONT></FONT> <FONT STYLE="white-space:nowrap">bi-specific</FONT> antibodies, including <FONT STYLE="white-space:nowrap">TJ-L1C4</FONT>
<FONT STYLE="white-space:nowrap">(PD-L1</FONT> &times; CD47), <FONT STYLE="white-space:nowrap">TJ-L1A3</FONT> <FONT STYLE="white-space:nowrap">(PD-L1</FONT> &times; LAG3), <FONT STYLE="white-space:nowrap">TJ-L1H3</FONT> <FONT
STYLE="white-space:nowrap">(PD-L1</FONT> &times; <FONT STYLE="white-space:nowrap">B7-H3),</FONT> <FONT STYLE="white-space:nowrap">TJ-L14B</FONT> <FONT STYLE="white-space:nowrap">(PD-L1</FONT> &times; <FONT STYLE="white-space:nowrap">4-1BB),</FONT> <FONT
STYLE="white-space:nowrap">TJ-L1T6</FONT> <FONT STYLE="white-space:nowrap">(PD-L1</FONT> &times; T1G1T) and <FONT STYLE="white-space:nowrap">TJ-L1I7</FONT> <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">(anti-PD-L1</FONT></FONT>
&times; <FONT STYLE="white-space:nowrap">IL-7</FONT> cytokine), (ii) <FONT STYLE="white-space:nowrap">TJ-C4GM</FONT> (anti-CD47 &times; <FONT STYLE="white-space:nowrap">GM-CSF</FONT> cytokine), and
<FONT STYLE="white-space:nowrap">(iii)&nbsp;TJ-CLDN4B</FONT> (Claudin 18.2 &times; <FONT STYLE="white-space:nowrap">4-1BB).</FONT> </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Highlights of Our <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Fast-to-Market</FONT></FONT> China Portfolio </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">fast-to-market</FONT></FONT> China strategy is demonstrated by our China
Portfolio, which consists of novel or highly differentiated investigational drugs. Felzartamab, efineptakin, enoblituzumab and eftansomatropin are the four anchor assets in our China Portfolio. While we have been diligently pursuing our <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">fast-to-market</FONT></FONT> China strategy, we are aware that there is no assurance that we will always be successful in commercializing any of our product candidates in our China
Portfolio in an accelerated manner. See &#147;Risk Factors&#148; for a detailed description of the risks related to the development and commercialization of our drug candidates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Felzartamab is a differentiated CD38 antibody originally developed by MorphoSys that meets the <FONT STYLE="white-space:nowrap">pre-set</FONT>
clinical safety and preliminary efficacy endpoints from a clinical trial conducted in the European Union (EU). <FONT STYLE="white-space:nowrap">In-licensed</FONT> from MorphoSys, felzartamab is being developed to address the current unmet needs and
commercial opportunities in China for multiple myeloma and potentially autoimmune diseases, such as SLE. We own an exclusive license to develop felzartamab in Greater China. We believe felzartamab, if approved, is potentially highly differentiated
compared with the currently marketed CD38 antibody. First, under a similar <FONT STYLE="white-space:nowrap">pre-medication</FONT> condition with dexamethasone, anti-pyretics and anti-histamines, felzartamab has demonstrated a significantly shorter
infusion time and lower infusion reaction rate. Second, unlike the currently marketed CD38 antibody, felzartamab does not down-regulate CD38 expression on the surface of bone marrow myeloma cells in vitro, maintaining sensitivity of myeloma cells to
felzartamab for repeated treatments. We are conducting two parallel registrational trials with felzartamab as a third-line monotherapy and as a second line combination therapy with lenalidomide, both in patients with multiple myeloma in Greater
China. The recruitment progress for these two trials remains on track. We aim to submit an NDA for felzartamab as a third-line monotherapy in 2021, followed by another NDA submission for felzartamab as a second-line combination therapy. Moreover, we
believe felzartamab has great market potential in the treatment of pathogenic antibody-mediated autoimmune diseases, such as SLE, where there is a significant unmet need for more effective therapies. We submitted an IND application to the NMPA in
October 2019 for a Phase 1b trial for felzartamab in SLE. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Efineptakin is the first long-acting recombinant human <FONT
STYLE="white-space:nowrap">IL-7</FONT> known to boost cancer-fighting T lymphocytes by increasing their number and function and is being developed as a potential oncology investigational drug. The clinical safety and effect of efineptakin on T cells
have been investigated in multiple previous and ongoing clinical trials in South Korea and the United States. Efineptakin is being positioned to address a huge unmet medical need in oncology. First, efineptakin can be an oncology-care agent to treat
cancer treatment-related lymphopenia (low blood lymphocyte levels), a common condition that occurs in cancer patients who have received chemotherapy or radiation therapy, and there is no approved treatment for this condition. This condition causes
further damage to patients&#146; already compromised immune system and weakens its ability to fight cancers. Second, efineptakin has been shown to synergize with a <FONT STYLE="white-space:nowrap">PD-1</FONT> antibody in a tumor animal model
potentially through increased T lymphocyte activation and proliferation. In May 2020, we obtained regulatory clearance from the NMPA to initiate a phase 2 clinical trial with efineptakin in GBM patients with lymphopenia. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">145 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We expect to initiate this trial in the fourth quarter of 2020. We are coordinating our
study globally with Genexine, which is conducting a Phase 2 clinical trial in South Korea and parallel clinical trials in the United States towards clinical PoC. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Enoblituzumab is a humanized antibody directed at <FONT STYLE="white-space:nowrap">B7-H3,</FONT> a member of the B7 family of T cell
checkpoint regulators that is widely expressed across multiple tumor types and plays a key role in the regulation of immune response against cancers. Similar to other inhibitors of the B7 family such as <FONT STYLE="white-space:nowrap">PD-L1,</FONT>
targeting <FONT STYLE="white-space:nowrap">B7-H3</FONT> potentially provides a treatment option for a variety of cancers expressing <FONT STYLE="white-space:nowrap">B7-H3.</FONT> Enoblituzumab was originally developed by MacroGenics, and we own the
Greater China rights of this investigational drug. In multiple clinical trials conducted by MacroGenics, when combined with pembrolizumab in recurrent or metastatic squamous cell carcinoma of the head and neck (&#147;SCCHN&#148;) and <FONT
STYLE="white-space:nowrap">non-small</FONT> cell lung cancer (&#147;NSCLC&#148;), enoblituzumab has shown favorable clinical results that warrant further investigation. In the first quarter of 2021, MacroGenics expects to initiate a Phase 2 study of
enoblituzumab in a chemo-free regimen in combination with either retifanlimab (an investigational <FONT STYLE="white-space:nowrap">PD-1</FONT> antibody) in front-line patients with SCCHN who are <FONT STYLE="white-space:nowrap">PD-L1</FONT> positive
or with tebotelimab (an investigational <FONT STYLE="white-space:nowrap">PD-1</FONT> x <FONT STYLE="white-space:nowrap">LAG-3</FONT> bispecific DART<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> antibody) in SCCHN patients who are <FONT
STYLE="white-space:nowrap">PD-L1</FONT> negative. We expect to participate in any subsequent Phase 3 global study if and when initiated. In addition, considering the dynamic regulatory environment and evolving clinical practice, we have been
continually refining the development of enoblituzumab in our territory. Further clinical development may be planned together with MacroGenics to extend to other cancer indications in China and/or globally. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Eftansomatropin is a potentially highly differentiated long-acting human growth hormone that is being developed as a weekly treatment for
pediatric growth hormone deficiency as compared to currently available daily regimens of recombinant human growth hormone (&#147;rhGH&#148;). Eftansomatropin was originally developed by Genexine, and we own the Greater China rights of this product,
which has the potential to address an important clinical need and to cover a significant market gap in pediatric growth hormone deficiency. In a previous Phase 2 trial conducted by Genexine in South Korea and the EU, both weekly and <FONT
STYLE="white-space:nowrap">bi-weekly</FONT> administration of Eftansomatropin demonstrated similar therapeutic effects to daily injection of Genotropin, a short-acting rhGH. In September 2020, the NMPA approved our IND application for a
registrational Phase 3 trial of eftansomatropin in pediatric growth hormone deficiency (PGHD). We expect to initiate this trial in the first quarter of 2021. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Highlights of Our <FONT STYLE="white-space:nowrap">Fast-to-PoC</FONT> Global Portfolio </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our <FONT STYLE="white-space:nowrap">fast-to-PoC</FONT> global strategy is demonstrated by our Global Portfolio, which mainly consists of our
internally developed novel or differentiated biologics. Our Global Portfolio focuses on two molecular classes&#151;monoclonal antibodies and <FONT STYLE="white-space:nowrap">bi-specific</FONT> antibodies. While we have been diligently pursuing our <FONT
STYLE="white-space:nowrap">fast-to-PoC</FONT> global strategy, we are aware that there is no assurance that we will always be successful in achieving PoC or pivotal development milestones for any of our product candidates in our Global Portfolio in
an accelerated manner. See &#147;Risk Factors&#148; for a detailed description of the risks related to the development and commercialization of our drug candidates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Monoclonal antibodies&#151;Among the five monoclonal antibody drug candidates, lemzoparlimab (TJC4), uliledlimab (TJD5) and plonmarlimab
(TJM2) are in clinical development. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Lemzoparlimab is an internally discovered, fully human monoclonal antibody targeting CD47, which is
one of the most promising immuno-oncology targets after <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">PD-1/PD-L1.</FONT></FONT> Blocking CD47 activates tumor-engulfing macrophages, a component of the innate immune system as an
important cancer-fighting mechanism. CD47 antibodies are being actively pursued in clinical trials by a few global companies. However, current development efforts on CD47 antibody drugs are hampered by hematologic side effects (such as anemia) due
to binding to human RBCs. For example, at least two clinical trials conducted by other companies have been suspended. Unlike competitor investigational drugs, lemzoparlimab is a rare antibody originally selected, by design, to purposefully avoid or
minimize binding to RBCs while maintaining a high antibody affinity and tumor killing properties. Lemzoparlimab&#146;s unique property of minimal RBC binding and no significant hematologic </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">146 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
changes has been extensively validated in a whole series of robust in vitro assays and <FONT STYLE="white-space:nowrap">non-human</FONT> primate studies. In a GLP toxicology study involving 40
monkeys, no hematologic side-effects were seen even with repeated injections of 100 mg/kg doses. This unique property may enable lemzoparlimab to be used safely in a broader patient population to explore its treatment potential in cancers,
differentiating it from other clinical stage lemzoparlimab investigational antibody drugs. Notably, the topline results of the recently completed Phase 1a dose escalation monotherapy trial in the United States have demonstrated the differentiated
profile of lemzoparlimab in drug safety and favorable pharmacokinetics in cancer patients. The key findings include: (i)&nbsp;lemzoparlimab was well tolerated up to 30 mg/kg on a weekly basis without priming dosing strategy, and no dose-limiting
toxicity and no clinical or laboratory evidence of hemolytic anemia were observed throughout; (ii)&nbsp;lemzoparlimab PK appears to be linear at mid to high dose levels following a single dose with no significant &#147;sink effect&#148; and
(iii)&nbsp;one confirmed partial response (PR) was observed in the 30 mg/kg monotherapy cohort (N=3), and this patient had failed prior treatments with checkpoint inhibitors. Therefore, we believe that lemzoparlimab, if approved, will be a
potentially highly differentiated anti-tumor CD47 antibody with the advantage of minimizing hematologic side effects. In September 2020, we received the NMPA approval for a Phase 1 clinical trial of lemzoparlimab in relapsed or refractory advanced
lymphoma in China as part of the ongoing international multi-center trial. In addition, lemzoparlimab is being evaluated in a Phase 1/2a clinical trial in China in patients with relapsed or refractory acute myeloid leukemia (r/r AML) or
myelodysplastic syndrome (MDS), and we anticipate reporting <FONT STYLE="white-space:nowrap">top-line</FONT> results in early 2021. We have also entered into a clinical trial collaboration and supply agreement with Merck Sharp&nbsp;&amp; Dohme Corp,
or MSD, through a subsidiary, under which we will sponsor a Phase 1 clinical trial in the United States evaluating lemzoparlimab in combination with KEYTRUDA<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> (pembrolizumab), MSD&#146;s <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-1</FONT></FONT> therapy, in patients with multiple types of solid tumors. In September 2020, we granted AbbVie a global license, excluding Mainland China, Hong Kong and Macau, to
develop and commercialize lemzoparlimab (as well as certain other compounds directed against CD47), and we will retain all rights to develop and commercialize lemzoparlimab in Mainland China, Hong Kong and Macau. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Uliledlimab is an internally developed, humanized inhibitory antibody against human CD73. CD73 is a homodimeric enzyme expressed in tumors and
plays a critical role in suppressing immune cells in tumor micro-environment. Uliledlimab displays sub-nanomolar binding affinity to CD73 and inhibits its nucleotidase activity. In vitro, uliledlimab completely reversed the <FONT
STYLE="white-space:nowrap">AMP-</FONT> or tumor cell-mediated suppression of T cells. In vivo, when combined with a <FONT STYLE="white-space:nowrap">PD-L1</FONT> antibody, uliledlimab exhibited a superior or synergistic inhibitory effect on tumor
growth. The key differentiation of uliledlimab when compared to some of the other clinical stage antibodies of the same class, is related to its novel epitope, which works through a unique intra-dimer binding mode, resulting in a complete inhibition
of the enzymatic activity and avoiding the aberrant pharmacological property known as the &#147;hook effect.&#148; With this particular mode of action, uliledlimab, if approved, has the potential to become a highly differentiated CD73 antibody. In
the United States, uliledlimab is in a Phase 1 clinical trial as a single agent and in combination with atezolizumab (TECENTRIQ<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>), a <FONT STYLE="white-space:nowrap">PD-L1</FONT> antibody
marketed by Roche, in patients with advanced solid tumors. 20 patients have been enrolled and nineteen of them have been dosed so far. The preliminary data of this trial in the United States are expected by mid-2021. In China, we are conducting a
Phase 1/2 clinical trial in China to evaluate uliledlimab in patients with advanced solid tumors. The first patient was dosed in May 2020. This Phase 1/2 study is a multicenter, open-label, dose escalation and cohort expansion study, which will
evaluate safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy of uliledlimab, and determine a recommended dose for further planned clinical studies of its efficacy and safety as a single agent and in combination with standard dose
of toripalimab (TUOYI<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>) in patients with advanced or metastatic cancers who are refractory to or intolerant of all available therapies. We have been able to accelerate the Phase 1/2 trial in
China by leveraging data from the ongoing Phase 1 clinical study of uliledlimab in the United States, which is a testament to our global clinical development capabilities and well-executed pipeline strategies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Plonmarlimab is an internally discovered neutralizing antibody against human granulocyte-macrophage colony-stimulating factor <FONT
STYLE="white-space:nowrap">(&#147;GM-CSF&#148;),</FONT> an important cytokine that plays a critical role in chronic inflammation and destruction in autoimmune diseases such as rheumatoid arthritis (&#147;RA&#148;). Plonmarlimab is a humanized IgG1
that displays high affinity binding to <FONT STYLE="white-space:nowrap">GM-CSF</FONT> and blocks its signaling and downstream effects. Plonmarlimab is </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">147 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
being developed for the treatment of autoimmune and inflammatory diseases, including RA and cytokine release syndrome (&#147;CRS&#148;). We have completed a single-dose <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-human</FONT></FONT> study in healthy volunteers in the United States. In China, plonmarlimab is the first antibody of its class entering clinical development. We dosed the first
patient in a Phase 1b study of plonmarlimab in August 2020 in patients with rheumatoid arthritis (RA) in China. We may expand plonmarlimab to other autoimmune and inflammatory indications with high unmet medical need, where <FONT
STYLE="white-space:nowrap">GM-CSF</FONT> is known as a pathogenic cytokine in disease activity and progression. If approved, plonmarlimab is expected to provide an effective treatment option as a disease-modifying anti-rheumatic drug
(&#147;DMARD&#148;) therapy. In addition, since the <FONT STYLE="white-space:nowrap">COVID-19</FONT> outbreak, we have sprung into action to prioritize plonmarlimab in response to the urgent medical needs. In May 2020, we announced preliminary
results from part&nbsp;1 of a clinical study in the United States of plonmarlimab in patients with cytokine release syndrome (CRS) associated with severe <FONT STYLE="white-space:nowrap">COVID-19,</FONT> in which plonmarlimab was found to be well
tolerated. We are currently conducting part 2 of this clinical trial to evaluate the efficacy, safety and cytokine levels following a single dose of 6 mg/kg plonmarlimab or placebo (standard care) in patients with severe <FONT
STYLE="white-space:nowrap">COVID-19.</FONT> We are currently in discussion with the FDA to finalize the plan for plonmarlimab in relation to clinical development and potential registration in the United States. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">TJ210 is a novel monoclonal antibody directed at C5aR for cancers through a partnership with MorphoSys. In September 2020, the FDA has cleared
the IND application for TJ210 to initiate a Phase 1 clinical trial. The trial is designed to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of TJ210 and is expected to commence by early 2021. We plan to work jointly with
MorphoSys to develop this asset. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Bi-specific</FONT> antibody panel&#151;This novel antibody class
represents an emerging and fast-moving area of new drug discovery. <FONT STYLE="white-space:nowrap">Bi-specific</FONT> antibodies are typically constructed to have a dual specificity of two selected antibodies or combined properties of an antibody
linked with a cytokine, previously called an immune-cytokine. However, despite the recent success of checkpoint inhibitors, clinical efficacy of these drugs has been unsatisfactory. It is estimated that over 60% of cancer patients, including those
with melanoma, renal cell cancer, colorectal cancer, <FONT STYLE="white-space:nowrap">non-small</FONT> cell lung cancer, urothelial cancer and head and neck squamous cell carcinoma, do not respond to <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">PD-1/PD-L1</FONT></FONT> monotherapies. In addition, some patients develop resistance after initial treatment with these therapies. As a result, the standard of care today leaves many cancer patients underserved. There is
consensus among cancer immunologists that tumors that do not respond to <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">PD-1/PD-L1</FONT></FONT> treatment have poor immunologic features, such as an absence or paucity of
tumor-fighting immune cells or the presence of dysfunctional immune cells within the tumors, collectively known as &#147;cold tumors.&#148; We believe that <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">PD-1/PD-L1</FONT></FONT> <FONT
STYLE="white-space:nowrap">non-responders</FONT> can be better treated with novel <FONT STYLE="white-space:nowrap">bi-specific</FONT> antibodies. The unique and superior properties of these <FONT STYLE="white-space:nowrap">bi-specific</FONT>
antibodies over <FONT STYLE="white-space:nowrap">PD-L1</FONT> inhibitors alone stem from a second targeting component attached to the <FONT STYLE="white-space:nowrap">PD-L1</FONT> antibody moiety of the
<FONT STYLE="white-space:nowrap">bi-specific</FONT> molecules, thereby enabling them to elicit a sufficient immune response and converting a &#147;cold tumor&#148; to an immune-active &#147;hot tumor.&#148; Such unique properties of <FONT
STYLE="white-space:nowrap">bi-specific</FONT> antibodies cannot be substituted by a combination of the <FONT STYLE="white-space:nowrap">PD-L1</FONT> antibody with a selected second component (either cytokine or antibody) in a free form. The
underlying mechanism is such that the second component must be structurally integrated with the tumor-engaging <FONT STYLE="white-space:nowrap">PD-L1</FONT> antibody in order to concentrate and function inside the tumor, which cannot be readily
achieved by the two free agents used in combination. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We have successfully generated a panel of
<FONT STYLE="white-space:nowrap">bi-specific</FONT> antibodies in which our proprietary <FONT STYLE="white-space:nowrap">PD-L1</FONT> antibody acts as the backbone (the first signal) and is linked with various second components (the second signal),
including, but not limited to, a <FONT STYLE="white-space:nowrap">4-1BB</FONT> agonist antibody <FONT STYLE="white-space:nowrap">(TJ-L14B),</FONT> a <FONT STYLE="white-space:nowrap">B7-H3</FONT> antibody
<FONT STYLE="white-space:nowrap">(TJ-L1H3),</FONT> a CD47 antibody <FONT STYLE="white-space:nowrap">(TJ-L1C4)</FONT> and an <FONT STYLE="white-space:nowrap">IL-7</FONT> cytokine <FONT STYLE="white-space:nowrap">(TJ-L1I7),</FONT> which are shown to
work with the <FONT STYLE="white-space:nowrap">PD-L1</FONT> backbone in various assays and cancer animal models. This unique panel of <FONT STYLE="white-space:nowrap">bi-specific</FONT> antibodies is only made possible by our proprietary and
partnered antibody engineering technologies and the availability of our proprietary monoclonal antibodies. Furthermore, we have generated two other <FONT STYLE="white-space:nowrap">bi-specific</FONT> antibodies
<FONT STYLE="white-space:nowrap">(TJ-C4GM</FONT> and <FONT STYLE="white-space:nowrap">TJ-CLDN4B)</FONT> that are tailor-made to function as novel fortified antibodies by linking lemzoparlimab with an engineered
<FONT STYLE="white-space:nowrap">GM-CSF</FONT> cytokine for the treatment of solid tumors and by linking our Claudin 18.2 antibody with a <FONT STYLE="white-space:nowrap">4-1BB</FONT> antibody as a unique gastric cancer treatment agent that only
activates T cells conditionally upon tumor </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">148 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
engagement. All <FONT STYLE="white-space:nowrap">bi-specific</FONT> antibodies have been validated in a series of robust in vitro and in vivo studies for biology <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">proof-of-concept,</FONT></FONT> providing a solid basis for clinical validation in cancer patients. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Strategies </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Moving forward, we strive to become a fully integrated
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">end-to-end</FONT></FONT> global biopharmaceutical company whose capabilities encompass drug discovery, GMP manufacturing, <FONT STYLE="white-space:nowrap">pre-clinical</FONT> and
clinical development and commercialization. To achieve this goal, we intend to pursue the following strategies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Rapidly advance our China Portfolio
towards commercialization </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We intend to pursue the most efficient pathway to NDA approval for the investigational drugs in our
China Portfolio. In the next 12 months, we expect to make significant advances with our China Portfolio. Most of the clinical assets of our China Portfolio are expected to undergo Phase 2, Phase 3 or registrational clinical trials in 2021. We plan
to submit NDAs to the NMPA for our China Portfolio products in sequence from 2021 to 2024. With respect to commercialization capabilities, we plan to initially partner with a specialty pharmaceutical company that has existing commercial capabilities
and infrastructure in China to jointly market our leading products. Once we have acquired commercial experience and developed a distribution network, we plan to build a robust internal sales and marketing platform. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Expand our research and development capabilities and footprint in the United States to advance our Global Portfolio </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">As part of our global strategy, we plan to expand our research and development capabilities in the United States to include regulatory
affairs, translational medicine, drug formulation and clinical operations. These specific research and development functions in the United States are complementary to and an integral part of our overall research and development capabilities to
support clinical development of our Global Portfolio. Currently, three of our investigational antibody drugs (lemzoparlimab, uliledlimab and plonmarlimab) are in clinical trials in the United States. We aim to continue advancing the ongoing clinical
trials to Phase 2 for clinical validation and to initiate multiple new clinical programs by the end of 2021 in the United States. In addition, we intend to expand our operational footprint in the United States to create an independent
multi-functional business entity covering global business development, investor relations and corporate communications and other operational capabilities. We are in the process of assembling an integrated management team with global experience and
extensive track record dedicated to overseeing our operations in the United States. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Build our manufacturing capabilities </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We believe it is strategically important and advantageous that we own and control our GMP manufacturing process in order to ensure quality,
secure production slots and maximize cost-effectiveness for clinical trial materials and commercial supplies. We intend to build a comprehensive biologics manufacturing facility in Hangzhou, China (the &#147;Hangzhou Facility&#148;) as part of our
strategic plan to become a fully integrated biopharma company. We have taken concrete steps to execute this plan. These steps include detailed operational planning for the facility, actions taken to secure an appropriate site, and negotiations with
external financing providers. The Hangzhou Facility targets to have a pilot capacity of 2 x 2,000L by the end of 2021 and commercially progressive capacity up to 8 x 2,000L to begin operation by the end of 2023. Construction is expected to commence
in late 2020. The project will be financed by a combination of internal and external sources. A group of domestic investors in China have agreed to invest a total of US$120&nbsp;million (in RMB equivalent) in cash. Upon closing, we, through our
wholly owned subsidiary and parties acting in concert, will remain the majority shareholder of <FONT STYLE="white-space:nowrap">I-Mab</FONT> Biopharma (Hangzhou) Limited <FONT STYLE="white-space:nowrap">(&#147;I-Mab</FONT> Hangzhou&#148;), the
entity holding the Hangzhou Facility, and retain a managing role and take full control to build and operate the manufacturing facility. We plan to prioritize our therapeutic focus and resources on immuno-oncology in our global ambition to become a
leading immuno-oncology company. This goal has been accelerated by our recent </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">149 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
global strategic collaboration with AbbVie and its commercialization plan for the initial oncology products. <FONT STYLE="white-space:nowrap">I-Mab</FONT> Hangzhou is positioned to provide
manufacturing capabilities for us, as well as the continued development of selected biologics assets that are <FONT STYLE="white-space:nowrap">non-essential</FONT> to our immuno-oncology focus, i.e. olamkicept, plonmarlimab (excluding cytokine
release syndrome indications) and a few <FONT STYLE="white-space:nowrap">pre-clinical</FONT> <FONT STYLE="white-space:nowrap">CMC-stage</FONT> programs. We believe that this strategic alignment is necessary to maximize the pipeline value and balance
the development risk for us. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Maximize the value of our pipeline </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In addition to our successful <FONT STYLE="white-space:nowrap">in-licensing</FONT> efforts, we have established a good track record of <FONT
STYLE="white-space:nowrap">out-licensing</FONT> collaborations and <FONT STYLE="white-space:nowrap">co-development</FONT> partnerships. For the years ended December&nbsp;31, 2017, 2018 and 2019, we recorded revenues of RMB11.6&nbsp;million,
RMB53.8&nbsp;million and RMB30.0&nbsp;million from upfront and milestone payments through three <FONT STYLE="white-space:nowrap">out-licensing</FONT> deals, respectively. We have reached cost-sharing
<FONT STYLE="white-space:nowrap">co-development</FONT> deals for some of our drug candidates with multiple global and regional partners. In September 2020, we, through <FONT STYLE="white-space:nowrap">I-Mab</FONT> Biopharma Co., Ltd. and <FONT
STYLE="white-space:nowrap">I-Mab</FONT> Biopharma US Limited, each a wholly-owned subsidiary of our company, entered into a broad global strategic collaboration with AbbVie Ireland Unlimited Company (&#147;AbbVie&#148;), a leading global,
research-based biopharmaceutical company. Pursuant to this collaboration, we grant AbbVie an exclusive global license, excluding Mainland China, Hong Kong and Macau, to develop and commercialize lemzoparlimab (as well as certain other compounds
directed against CD47). We retain all rights to develop and commercialize lemzoparlimab in Mainland China, Hong Kong and Macau. Pursuant to this collaboration, AbbVie will pay us an upfront payment of US$180&nbsp;million. Additionally, in connection
with the recently released clinical data from the Phase 1 trial of lemzoparlimab in the United States, we expect to be paid a first milestone payment of US$20&nbsp;million. We will also be eligible to receive up to US$1.74&nbsp;billion in further
success-based development, regulatory and sales milestone payments for lemzoparlimab, of which US$840&nbsp;million are based on clinical development and regulatory approval milestones, with the remainder based on commercial milestones. Upon
commercialization of lemzoparlimab, AbbVie will also pay tiered royalties consisting of low double-digit percentages on global net sales outside of Mainland China, Hong Kong and Macau. In addition, AbbVie has a license and a right of first
negotiation to further develop and commercialize two additional lemzoparlimab-based bispecific antibodies discovered and currently being developed by us, and we cannot commercialize products containing these two additional lemzoparlimab-based
bispecific antibodies outside of Mainland China, Hong Kong and Macau even if AbbVie does not exercise its right of first negotiation or we are unable to come to financial terms on such products. The potential value of each such license is minimum
US$500&nbsp;million in upfront and milestone payments, for a combined total of no less than US$1&nbsp;billion. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">These achievements, in
particular our collaboration with AbbVie, have not only demonstrated our ability to optimize our pipeline but also provided a sustainable revenue stream. Going forward, we plan to enhance our <FONT STYLE="white-space:nowrap">out-licensing</FONT>
efforts. We expect that the revenue generated from <FONT STYLE="white-space:nowrap">out-licensing</FONT> opportunities will continue to increase and will account for the majority of our net revenue before the commercialization of our marketed
products. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Drug Pipeline </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>China Portfolio
</I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><B><I>Felzartamab (TJ202): A Potential Highly Differentiated CD38 Antibody for Multiple Myeloma and Autoimmune Diseases
</I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><B><I>Summary </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Felzartamab is a fully human, highly differentiated monoclonal antibody directed against CD38. Felzartamab, if approved, is positioned as a
potential highly differentiated anti-CD38 therapy for multiple myeloma (&#147;MM&#148;), either as a monotherapy or as a combination therapy with other anti-cancer agents. We aim to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">150 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
demonstrate the advantages of felzartamab, including its short infusion time, low infusion related reaction (&#147;IRR&#148;) and potentially sustained efficacy, in our ongoing clinical trials in
China. Additionally, as pathogenic CD38-positive B cells and plasma cells are strongly implicated in the disease progression of pathogenic antibody-mediated autoimmune diseases, we believe the therapeutic value of felzartamab can be extended to
these diseases that have significant unmet medical needs. We have begun to explore its therapeutic application in systemic lupus erythematosus (&#147;SLE&#148;) and later in other autoimmune diseases. In November 2017, we obtained an exclusive
license from MorphoSys to develop felzartamab in Greater China. The development of felzartamab is driven by a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">fast-to-market</FONT></FONT> strategy. We are conducting two parallel
registrational trials with felzartamab as a third-line monotherapy and as a second line combination therapy with lenalidomide, both in patients with multiple myeloma in Greater China. The recruitment progress for these two trials remains on track,
and we expect to submit an NDA to the NMPA in 2021. Additionally, we submitted an IND application to the NMPA in October 2019 for a Phase 1b trial for felzartamab in SLE. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><B><I>Therapeutic Options and Current Development </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><I>Multiple Myeloma (MM) </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The treatment options and investigational drugs under development in China include: (i)&nbsp;for small molecule drugs, two or three approved
drugs known as doublets or triplets are used. VRD triplet (Velcade (bortezomib), Revlimid (lenalidomide) and dexamethasone) has been approved for overseas frontline treatment and is recommended in China in the 2017 version of treatment guideline.
VCD triplet (Velcade, cyclophosphamide and dexamethasone) is the most widely adopted first-line treatment in China due to its lower cost. In 2017, lenalidomide and bortezomib were included in the National Reimbursement Drug List in China;
(ii)&nbsp;with respect to CD38 antibody therapy, daratumumab (from Johnson&nbsp;&amp; Johnson) received conditional NDA approval from the NMPA in July 2019, and isatuximab (from Sanofi) is in a Phase 3 trial in China; and (iii)&nbsp;for <FONT
STYLE="white-space:nowrap">CAR-T</FONT> therapy, several Phase 1 or 2 clinical trials are ongoing in China. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">However, there is no curative
treatment for MM. Although the currently marketed CD38 antibody (daratumumab) in China is efficacious, it takes a long time to be administered by IV infusion (up to six hours) and causes a high infusion reaction rate (&#147;IRR&#148;). In clinical
trials, approximately half of all patients experience an infusion reaction, symptoms of which may include fever, chills, nausea, bronchospasm, hypoxia, dyspnea, hypertension, laryngeal edema and pulmonary edema. Thus, there is a need for a safer and
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">convenient-to-use</FONT></FONT> drug. Such a drug may be combined with other therapeutic agents for better treatment effects in MM. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><I>Systemic Lupus Erythematosus (SLE) </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Patients with mild SLE are often given <FONT STYLE="white-space:nowrap">non-steroidal</FONT> anti-inflammatory drugs, while more severe
patients may need corticosteroids or immunosuppressants. Approved by the FDA in 2011 and by the NMPA in July 2019, Benlysta (belimumab), a <FONT STYLE="white-space:nowrap">B-lymphocyte</FONT> stimulator (BLyS)-specific inhibitor developed by GSK, is
currently the world&#146;s only biologic approved to treat SLE. However, there remains a significant unmet medical need beyond belimumab for SLE in China and the rest of the world. As dysregulated CD38-positive B cells and auto-antibodies produced
by CD38-positive plasma cells and resulting immune complexes are at the core of the pathogenesis of SLE, direct inhibition and selective depletion of pathogenic B cells and plasma cells are believed to offer better treatment options. Our felzartamab
has the potential to offer such a disease-modifying treatment option. In addition, as described below, the advantages of our felzartamab include convenience of use and a lower IRR, making it a more favorable treatment agent in the long-term clinical
management of SLE if approved. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><B><I>Advantages of Felzartamab </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Felzartamab, if approved, is a potentially highly differentiated CD38 monoclonal antibody and could be the second antibody therapy for MM to
launch in China. A Phase 2a trial of felzartamab in MM showed a level of treatment effects comparable to that observed in trials of the currently marketed CD38 antibody. However, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">151 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
available trial data from MorphoSys and Johnson&nbsp;&amp; Johnson indicate that with similar <FONT STYLE="white-space:nowrap">pre-medications</FONT> of dexamethasone, anti-pyretics and
anti-histamines, Felzartamab required only a short infusion time of 0.5 to 2 hours, compared to 3.5 to 6.5 hours for the currently marketed CD38 antibody at the first infusion. Moreover, the IRR was as low as 7% for felzartamab, compared to 48% for
the currently marketed CD38 antibody. The advantages of felzartamab associated with infusion may be attributed to its lack of antibody CDC activity and are likely to translate into clinical benefits in terms of tolerability and convenience of use as
well as economic benefits due to the cost and length of hospital stay. In addition, unlike the currently marketed CD38 antibody, felzartamab treatment does not down-regulate CD38 expression on the surface of bone marrow myeloma cells in vitro,
maintaining sensitivity of malignant myeloma cells to repeated felzartamab treatments. As felzartamab is being considered for long-term treatment management of autoimmune diseases, we believe such clinical differentiation is critical. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">For autoimmune diseases, felzartamab has advantages over other B cell-targeting therapies such as CD20 antibodies, as it specifically targets
malfunctioned CD38<SUP STYLE="font-size:85%; vertical-align:top">high</SUP> B cells and pathogenic plasma cells involved in autoimmune diseases while CD20 antibodies target most B cells, including those involved in normal immune functions and
regulatory functions, but not plasma cells producing pathogenic antibodies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><B><I>Mechanism ofAction </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Felzartamab binds to CD38 overexpressed on the surface of target cells and kills them by inducing antibody-dependent cellular cytotoxicity
(&#147;ADCC&#148;) and antibody-dependent cellular phagocytosis (&#147;ADCP&#148;). The target cells are the malignant plasma cells in MM and a group of dysregulated CD38<SUP STYLE="font-size:85%; vertical-align:top">high</SUP> B cells and plasma
cells that produce pathogenic antibodies in autoimmune conditions such as SLE. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g98473g63r89.jpg" ALT="LOGO">
 </P> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><I>Figure:</I></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>Felzartamab kills CD38-bearing tumor cells by inducing ADCC and ADCP.</I> </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><I></I><B><I>Summary of Clinical Results</I></B><I> </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">MorphoSys has conducted a Phase 1/2a study in adult patients with relapsed or refractory MM in Austria and Germany. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I>Study Design</I>. The open-label, multicenter, dose-escalation study was designed to characterize the safety profile and preliminary
efficacy of felzartamab in adults with relapsed or refractory MM. A 3+3 dose escalation design was used to establish the maximum tolerated dose (&#147;MTD&#148;), recommended dose and dosing regimen of felzartamab as monotherapy, weekly or <FONT
STYLE="white-space:nowrap">bi-weekly,</FONT> with or without dexamethasone (&#147;DEX&#148;), and in combination with pomalidomide (&#147;POM&#148;) and DEX or lenalidomide (&#147;LEN&#148;) and DEX standard regimens. The MTD and recommended dose
and dosing regimens were to be confirmed in three confirmation cohorts of at least six evaluable subjects each. Felzartamab dose levels in this study ranged from 0.01 mg/kg to 16.0 mg/kg, administered by intravenous (&#147;IV&#148;) infusion. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">152 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The clinical study results as of the data cutoff date, December&nbsp;31, 2017, are
summarized as follows. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I>Safety</I>. Felzartamab was well tolerated in patients with RRMM, as a single agent and in combination with
DEX, or with POM/DEX, or with LEN/DEX. The MTD of felzartamab was not reached. In the 56 patients from three groups receiving combination regimens, grade &sup3; 3 adverse events (&#147;AEs&#148;) were mainly in the hematological system reflected by
a decrease of various blood cells. This was as expected, because of decreased bone marrow function due to the presence of myeloma as well as the expression of CD38 on various cell lineages of the myeloid and lymphoid compartments. Most of the
hematological adverse events were transient and generally manageable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Felzartamab was administered as a
<FONT STYLE="white-space:nowrap">two-hour</FONT> IV infusion at first dose and infusion time could be reduced to as short as 30 minutes at subsequent doses without obvious safety concerns. Among all cohorts, infusion-related reactions, including
tachycardia, pyrexia and hypersensitivity, occurred in 18 of 91 patients (19.8%) and were mostly mild to moderate. In the combination cohorts containing DEX, a very low IRR (4 out of 56 patients (7%)) was observed. These results compared favorably
with the historical data of the currently marketed CD38 antibody. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I>Clinical Efficacy</I>. Preliminary efficacy results were based on 56
patients from three groups treated with felzartamab combination therapies. No responses were observed for the monotherapy groups which were primarily serving for dose escalation. Felzartamab in combination with low dose DEX, POM/DEX or LEN/DEX
demonstrated an overall response rate (&#147;ORR&#148;) of 28%, 48% and 65%, respectively. Durable responses were observed as median progression-free survival (&#147;PFS&#148;) was of 8.4 months and 17.5 months for the DEX and the POM/DEX
combination groups, respectively, and PFS levels were not reached for the LEN/DEX combination group, as there were not sufficient events of progression recorded. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g98473g95p44.jpg" ALT="LOGO">
 </P> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><I>Figure:</I></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>Best overall response and ORR. Patients were treated with felzartamab in combination with low dose ofDEX (40
mgfor 75 years old and younger, or 20 mgfor older than 75 years old), POM (4 mg) /Dex or LEN (25 mg)/Dex. Dex: dexamethasone; POM: pomalidomide; LEN: lenalidomide; ITT: intent to treat; NE: not evaluable; PD: progressive disease; SD: stable disease;
MR: minimal response; PR:</I> </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">153 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
<I>partial response; VGPR: very good partial response; CR: complete response; sCR: stringent complete response; ORR: overall response rate. (Source: MorphoSys)</I> </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The definitions of PD, SD, MR, PR, VGPR, CR and sCR and how these responses were measured for multiple myeloma are set forth in the table
below. (Source: International Myeloma Working Group Uniform Response Criteria (2006)&nbsp;and European Group for Blood and Marrow Transplantation Criteria) </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="23%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="75%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>RESPONSE&nbsp;SUBCATEGORY</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>CRITERIA <SUP
STYLE="font-size:85%; vertical-align:top">A</SUP></B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">sCR</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&#149;&#8194;&#8202;CR as defined below plus</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; font-size:10pt; font-family:Times New Roman">Normal free light chain ratio (FLC) and</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; font-size:10pt; font-family:Times New Roman">Absence of clonal cells in bone marrow<SUP STYLE="font-size:85%; vertical-align:top">b</SUP> by immunohistochemistry or immunofluorescence<SUP
STYLE="font-size:85%; vertical-align:top">c</SUP></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">CR</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&#149;&#8194;&#8202;Negative immunofixation on the serum and urine and</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&#149;&#8194;&#8202;Disappearance of any soft tissue plasmacytomas and</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&#149;&#8194;&#8202;&lt;5% plasma cells in bone
marrow<SUP STYLE="font-size:85%; vertical-align:top">b</SUP></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">VGPR</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&#149;&#8194;&#8202;Serum and urine <FONT STYLE="white-space:nowrap">M-protein</FONT> detectable
by immunofixation but not electrophoresis or</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&#149;&#8194;&#8202;<FONT STYLE="FONT-FAMILY:SYMBOL">&#179;</FONT>90%
reduction in serum <FONT STYLE="white-space:nowrap">M-protein</FONT> plus urine <FONT STYLE="white-space:nowrap">M-protein</FONT> level &lt;100 mg/ 24&nbsp;hours</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">PR</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&#149;&#8194;&#8202;<FONT STYLE="FONT-FAMILY:SYMBOL">&#179;</FONT>50% reduction of serum <FONT
STYLE="white-space:nowrap">M-protein</FONT> and reduction in <FONT STYLE="white-space:nowrap">24-hour</FONT> urinary <FONT STYLE="white-space:nowrap">M-protein</FONT> by &sup3;90% or to &lt;200 mg/24 hours</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&#149;&#8194;&#8202;If the serum and urine <FONT STYLE="white-space:nowrap">M-protein</FONT> were unmeasurable, a <FONT
STYLE="FONT-FAMILY:SYMBOL">&#179;</FONT>50% decrease in the difference between levels of involved and uninvolved free-light-chains instead of the <FONT STYLE="white-space:nowrap">M-protein</FONT> criteria</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&#149;&#8194;&#8202;In addition to the above-listed criteria, if present at baseline, a <FONT
STYLE="FONT-FAMILY:SYMBOL">&#179;</FONT>50% reduction in the size of soft tissue plasmacytomas was also required</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">MR <SUP STYLE="font-size:85%; vertical-align:top">d,e</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&#149;&#8194;&#8202;25&#150;49% reduction in level of serum
<FONT STYLE="white-space:nowrap">M-protein</FONT></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&#149;&#8194;&#8202;50&#150;89% reduction in <FONT
STYLE="white-space:nowrap">24-hour</FONT> urinary <FONT STYLE="white-space:nowrap">M-protein,</FONT> which still exceeds 200 mg/24&nbsp;hours. If present at baseline, 25&#150;49% reduction in the size of soft tissue plasmacytomas (by radiography or
clinical examination)</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&#149;&#8194;&#8202;No increase in the size or number of lytic bone lesions (development of
a compression fracture did not exclude response)</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SD <SUP STYLE="font-size:85%; vertical-align:top">f</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&#149;&#8194;&#8202;Not meeting criteria for CR, VGPR, PR, MR, or PD</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">PD</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:0.00em; font-size:10pt; font-family:Times New Roman">NOTE: Required any 1 or more of the following:</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:0.00em; font-size:10pt; font-family:Times New Roman">Increase of <FONT STYLE="FONT-FAMILY:SYMBOL">&#179;</FONT>25% from nadir in</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&#149;&#8194;&#8202;Serum <FONT STYLE="white-space:nowrap">M-component</FONT> and/or (absolute increase <FONT
STYLE="FONT-FAMILY:SYMBOL">&#179;</FONT>0.5 g/dL)g</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&#149;&#8194;&#8202;Urine
<FONT STYLE="white-space:nowrap">M-component</FONT> and/or (absolute increase <FONT STYLE="FONT-FAMILY:SYMBOL">&#179;</FONT>200 mg/24 hours)</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&#149;&#8194;&#8202;Only in subjects without measurable serum and urine
<FONT STYLE="white-space:nowrap">M-protein</FONT> levels: the difference between involved and uninvolved FLC levels. Absolute increase &gt;10&nbsp;mg/dL.</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&#149;&#8194;&#8202;Bone marrow plasma cell percentage: absolute % <FONT STYLE="FONT-FAMILY:SYMBOL">&#179;</FONT>10%<SUP
STYLE="font-size:85%; vertical-align:top">h</SUP></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&#149;&#8194;&#8202;Definite development of new bone lesions or
soft tissue plasmacytomas or definite increase in the size of existing bone lesions or soft tissue plasmacytomas</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&#149;&#8194;&#8202;Development of hypercalcemia (corrected serum calcium &gt;11.5 mg/dL or 2.65&nbsp;mmol/L) that
could be attributed solely to the plasma cell proliferative disorder</P></TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">Notes:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">a</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">All response categories required 2 consecutive assessments made at any time before the institution of any new
therapy; all categories also required no known evidence of progressive or new bone lesions if radiographic studies were performed. Radiographic studies were not required to satisfy these response requirements. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">b</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Confirmation with repeat bone marrow biopsy not needed. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">154 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">c</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Presence/absence of clonal cells was based upon the <FONT STYLE="FONT-FAMILY:SYMBOL">&#107;</FONT>/<FONT
STYLE="FONT-FAMILY:SYMBOL">&#108;</FONT> ratio. An abnormal k/? ratio by immunohistochemistry and/or immunofluorescence required a minimum of 100 plasma cells for analysis. An abnormal ratio reflecting presence of an abnormal clone is <FONT
STYLE="FONT-FAMILY:SYMBOL">&#107;</FONT>/<FONT STYLE="FONT-FAMILY:SYMBOL">&#108;</FONT> of &gt;4:1 or &lt;1:2. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">d</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">MR also included subjects in whom some, but not all, the criteria for PR were fulfilled, provided the remaining
criteria satisfied the requirements for MR. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">e</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The response criterion MR did not apply to subjects who presented with serum FLCs only. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">f</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Per the International Myeloma Working Group Uniform Response Criteria, stable disease was not recommended for
use as an indicator of response; stability of disease is best described by providing the time to progression estimates. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">g</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">For progressive disease, serum <FONT STYLE="white-space:nowrap">M-component</FONT> increases of <FONT
STYLE="FONT-FAMILY:SYMBOL">&#179;</FONT>1 g/dL were sufficient to define relapse if starting <FONT STYLE="white-space:nowrap">M-component</FONT> was <FONT STYLE="FONT-FAMILY:SYMBOL">&#179;</FONT>5 g/dL. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">h</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Relapse from CR has the 5% <FONT STYLE="white-space:nowrap">cut-off</FONT> versus 10% for other categories of
relapse. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I>Pharmacodynamics. </I>As a pharmacodynamic marker, serum myeloma (M)&nbsp;protein levels were used to
evaluate severity and clinical response. The median relative change in M protein levels from baseline to post-baseline nadir for felzartamab in combination with low doses of DEX, POM/DEX or LEN/DEX was <FONT STYLE="white-space:nowrap">-13%,</FONT> <FONT
STYLE="white-space:nowrap">-58%</FONT> and <FONT STYLE="white-space:nowrap">-81%,</FONT> respectively. The data below show strong effects of felzartamab in reducing M protein levels. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g98473g36d33.jpg" ALT="LOGO">
 </P> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><I>Figure:</I></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>The relative change in M protein levels from baseline to post-baseline nadir. Patients were treated with
felzartamab in combination with low doses ofDEX, POM/DEX or LEN/DEX. S: serum sample; U: urine sample. (Source: MorphoSys)</I> </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I>Pharmacokinetics (&#147;PK&#148;)</I>. The PK of felzartamab in humans was well characterized by a
<FONT STYLE="white-space:nowrap">two-compartment</FONT> model at dose levels greater than 4 mg/kg. At these doses, stable or even increasing trough levels could be observed over time suggesting the potential for full target occupancy, especially at
the highest dose level (16 mg/kg). For most subjects, steady state at 16 mg/kg was observed after the fourth infusion. Terminal half-life at high-dose levels (<FONT STYLE="FONT-FAMILY:SYMBOL">&#179;</FONT>4 mg/kg) was at approximately two weeks.
Pharmacokinetics of felzartamab were generally consistent across different individuals and dosing days and not affected by the <FONT STYLE="white-space:nowrap">co-medications.</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I>Immunogenicity</I>. No anti-drug antibody (&#147;ADA&#148;) against felzartamab was observed as of the
<FONT STYLE="white-space:nowrap">cut-off</FONT> date. Thus, risk of ADA induction for felzartamab in humans is considered low. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><B><I>Clinical Development Plan </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Immediately after <FONT STYLE="white-space:nowrap">in-licensing</FONT> felzartamab, we formulated a robust clinical development strategy with
an aim for an NDA submission in 2021. With an approved IND, we have started a <FONT STYLE="white-space:nowrap">single-arm</FONT> registrational trial with felzartamab and DEX as a third-line therapy for MM patients in Greater China using ORR as the
primary endpoint (NCT03860038). Dosing of the first patient took place in March 2019. Data from this study are expected to be the major package supporting registrational filing in 2021 for conditional approval. In parallel, we started a
registrational trial combining felzartamab with LEN and DEX as a second-line combination therapy in </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">155 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
MM patients (NCT03952091). We plan to enroll 291 patients for full approval. Dosing of the first patient took place in Taiwan in April 2019. As of September&nbsp;30, 2020, we had enrolled a total
of 159 patients for these two registrational trials. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our clinical development plan for SLE starts with a Phase 1b clinical trial to
explore dose range, clinical safety and tolerability as well as felzartamab&#146;s profiles of PK and pharmacodynamics (&#147;PD&#148;) in SLE patients. For this, we submitted an IND application to the NMPA in October 2019. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><B><I>Efineptakin (TJ107): The First Long-acting Recombinant Human <FONT STYLE="white-space:nowrap">IL-7</FONT> with the Potential for Cancer
Treatment-related Lymphopenia and Cancer Immunotherapy </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><B><I>Summary </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Efineptakin is the world&#146;s first and only long-acting recombinant human <FONT STYLE="white-space:nowrap">interleukin-7</FONT> <FONT
STYLE="white-space:nowrap">(&#147;rhIL-7&#148;),</FONT> which is being developed as a T lymphocyte-booster for cancer-related immunotherapy. Due to its advantages in terms of selective immune functions, improved stability, developability, and
extended half-life, efineptakin is differentiated from an earlier generation of short-acting <FONT STYLE="white-space:nowrap">rhIL-7</FONT> and T cell growth factor <FONT STYLE="white-space:nowrap">(interleukin-2).</FONT> In December 2017, we
acquired exclusive rights from Genexine to develop and commercialize efineptakin in Greater China. We plan to position efineptakin first as a monotherapy or an oncology care product for cancer patients with cancer treatment-related lymphopenia (low
blood lymphocyte levels) induced by chemotherapy or radiation therapy. This target indication covers a large population of cancer patients who develop cancer treatment-related lymphopenia, a condition that weakens the ability to receive continued
chemotherapy or radiation therapy and leads to worsened disease prognosis and clinical outcome. Currently, there is no treatment available for this condition. Second, efineptakin is expected to show a therapeutic effect as a combination therapy with
immune checkpoint inhibitors, i.e., <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">PD-1/PD-L1</FONT></FONT> therapies, due to its inherent selective T cell-boosting properties. <FONT STYLE="white-space:nowrap">Pre-clinical</FONT>
studies have indicated that efineptakin exerted additional anti-tumor effect when combined with <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">PD-1/PD-L1</FONT></FONT> therapies. If proven efficacious in clinical studies, we
believe such a combination therapy, can potentially treat a large population of cancer patients who do not respond or respond poorly to <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">PD-1/PD-L1</FONT></FONT> therapies. In May
2020, we obtained regulatory clearance from the NMPA to initiate a Phase 2 clinical trial in GBM patients with lymphopenia. We expect to initiate this trial in the fourth quarter of 2020. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><B><I>Therapeutic Options and Current Development </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">One of the target therapeutic indications of efineptakin is cancer treatment-related lymphopenia. Cancer patients who undergo chemotherapy
and/or radiation therapy often develop cancer treatment-related lymphopenia, which further damages their already compromised immune systems and their ability to fight against cancers. Advanced solid tumor is another indication of efineptakin as a
combination therapy with <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">PD-1/PD-L1</FONT></FONT> treatments. As more than 60% cancer patients either do not respond or respond poorly to current <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">PD-1/PD-L1</FONT></FONT> therapies, there are intense attempts to identify an effective agent that can work synergistically with <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">PD-1/PD-L1</FONT></FONT>
therapies to increase the probability of treatment success. Efineptakin is believed to provide such a treatment option, which is supported by <FONT STYLE="white-space:nowrap">pre-clinical</FONT> reports that
<FONT STYLE="white-space:nowrap">IL-7</FONT> exhibits a synergistic effect with <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">PD-1/PD-L1</FONT></FONT> antibodies in the treatment of cancers. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><B><I>Advantages of Efineptakin </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Efineptakin has an advantage over other T lymphocyte cytokines with therapeutic potential in oncology.
<FONT STYLE="white-space:nowrap">Pre-clinical</FONT> and clinical results generated so far indicate that efineptakin has a favorable immune function profile over recombinant human <FONT STYLE="white-space:nowrap">interleukin-2</FONT> <FONT
STYLE="white-space:nowrap">(&#147;rhIL-2&#148;)</FONT> in that efineptakin activates and expands tumor-fighting CD4, </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">CD8 and natural
killer T cells but spares tumor-protecting Treg cells. By contrast, <FONT STYLE="white-space:nowrap">rhIL-2</FONT> is a well-known inducer of Tregs, which suppresses tumor-fighting effector T cells. Furthermore,
<FONT STYLE="white-space:nowrap">rhIL-2</FONT> has a narrow therapeutic window and causes serious side effects such as capillary leak syndrome, breathing problems, serious </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">156 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
infections, and seizures. A polyethylene glycol (PEG)-conjugated <FONT STYLE="white-space:nowrap">IL-2</FONT> variant developed by Nektar Therapeutics has yielded mixed results, indicating the
complexity associated with using <FONT STYLE="white-space:nowrap">IL-2</FONT> as a cancer treatment. Owing to its preferred immune function and molecular profiles demonstrated in <FONT STYLE="white-space:nowrap">pre-clinical</FONT> and Phase 1/2
clinical trials, we believe that efineptakin is a superior T cell cytokine investigational drug for cancer treatment-related lymphopenia and cancer immunotherapy. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Efineptakin, as an engineered <FONT STYLE="white-space:nowrap">rhIL-7,</FONT> has the advantages of improved stability and half-life extension
through Genexine&#146;s proprietary hybrid fragment crystallizable region (&#147;hyFc&#148;). Introducing a few hydrophilic amino acid residues to the <FONT STYLE="white-space:nowrap">N-terminus</FONT> of <FONT STYLE="white-space:nowrap">IL-7</FONT>
overcomes stability issues that hampered the development of previous <FONT STYLE="white-space:nowrap">rhIL-7</FONT> drug candidates. Furthermore, application of the hyFc technology enhances <FONT STYLE="white-space:nowrap">IL-7&#146;s</FONT>
function, increases its half-life (from 48 to 112 hours after a single subcutaneous (&#147;SC&#148;) dose in clinical studies), and allows for a robust purification process. By contrast, the half-life of first-generation <FONT
STYLE="white-space:nowrap">rhIL-7</FONT> was reported to be about 12 hours after SC dosing in human subjects. The hyFc in efineptakin is also non-cytolytic, so it will not damage the T cells to which it binds. Unlike efineptakin, the previous <FONT
STYLE="white-space:nowrap">rhIL-7</FONT> drug candidates adopt <FONT STYLE="white-space:nowrap">non-glycosylated</FONT> (CYT <FONT STYLE="white-space:nowrap">99-007)</FONT> or glycosylated <FONT STYLE="white-space:nowrap">(CYT-107)</FONT> forms of
short-acting <FONT STYLE="white-space:nowrap">rhIL-7</FONT> and were developed by Revimmune Inc (formerly known as Cytheris SA). These molecules had low stability, low production yield, and a short half-life because
<FONT STYLE="white-space:nowrap">IL-7</FONT> protein is intrinsically unstable and prone to aggregation. However, the preliminary clinical results from Phase 1 and Phase 2 trials in patients with AIDS did show an increase of T lymphocytes following
treatment with <FONT STYLE="white-space:nowrap">CYT-107</FONT> (Thiebaut R et al., PLoS Comput Biol., 2014). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><B><I>Mechanism of Action
</I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">IL-7</FONT> is a cytokine essential for the survival and homeostatic proliferation of naive and
memory T cells (see figure below). <FONT STYLE="white-space:nowrap">IL-7</FONT> is critically involved in restoring T cells to normal levels in the event of lymphopenia by stimulating T cell proliferation.
<FONT STYLE="white-space:nowrap">IL-7</FONT> exerts its functions by binding to and activating the <FONT STYLE="white-space:nowrap">IL-7</FONT> receptor, which is expressed primarily on lymphocytes, including the lymphoid precursors, developing T
and B cells, naive T cells, and memory T cells, but not on tumor-protecting Tregs. Efineptakin as a monotherapy may enhance anti-tumor immunity by augmenting the number and functionality of T cells, whereas efineptakin in combination with an immune
checkpoint inhibitor, cancer vaccine or <FONT STYLE="white-space:nowrap">CAR-T</FONT> may improve the anti-tumor response by restoring T cell numbers, reconstituting T cell pools and reinvigorating exhausted T cells. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g98473g59k87.jpg" ALT="LOGO">
 </P> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><I>Figure:</I></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>Role of <FONT STYLE="white-space:nowrap">IL-7</FONT> in T cell maintenance and proliferation.</I>
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">157 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><B><I>Summary of Clinical Results </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">A <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-human</FONT></FONT> Phase 1 trial has been conducted by Genexine
in South Korea. This was a randomized, double-blind, placebo-controlled, single ascending dose study, to evaluate the safety, tolerability, pharmacokinetic and pharmacodynamic properties of 20 or 60 &micro;g/kg efineptakin via SC or intramuscular
(&#147;IM&#148;) administration in healthy volunteers. Each dose group consisted of 10 subjects, eight of whom were administered efineptakin and two were given placebo via the same route of administration. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I>Safety</I>. Efineptakin was well-tolerated in all 30 subjects without serious adverse events. The most common adverse events were transient
Grade 1 or 2 injection site skin reactions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I>Pharmacodynamics (&#147;PD&#148;)</I>. Because
<FONT STYLE="white-space:nowrap">IL-7</FONT> promotes the survival and proliferation of T cells, absolute lymphocyte count (&#147;ALC&#148;) in the peripheral blood was used as a reliable and convenient PD marker for efineptakin (see figure below).
ALC initially decreased transiently in all efineptakin groups. This effect is often termed margination, which is a physiological phenomenon common to many cytokines as a result of increased adherence of cytokine-stimulated white blood cells to the
blood vessels and subsequent trafficking to tissues and lymphoid organs. ALC recovered in approximately seven days, reaching a maximum value at close to 21 days, before gradually declining. This result indicated that a single dose of efineptakin had
a long-lasting effect of increasing lymphocyte levels. Overall, a greater increase in ALC was observed in Cohort 2 compared with Cohort 1, demonstrating a dose-dependent response. Additionally, a higher increase in ALC was observed in Cohort 3
compared with Cohort 2, which was consistent with the results of an animal study, where IM injection induced a more effective increase in lymphocytes than SC injection. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g98473g27s64.jpg" ALT="LOGO">
 </P> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><I>Figure:</I></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>Median fold changes of ALC following a single dose of efineptakin in humans. Cohort 1: 20 ,ug/kg, SC; Cohort
2: 60 ,ug/kg, SC; and Cohort 3: 60 ,ug/kg, IM. (Source: Genexine)</I> </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Efineptakin treatment resulted in a substantial
increase in the number of CD4 and CD8 T cells, natural killer T cells, naive T cells, central memory, effector memory, and terminally differentiated effector memory T&nbsp;cells, without affecting the number of B cells, natural killer cells,
monocytes or Tregs. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g98473g95b62.jpg" ALT="LOGO">
 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">158 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g98473g99a02.jpg" ALT="LOGO">
 </P> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><I>Figure:</I></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>Median fold changes of T cells and subsets following a single dose of efineptakin in human subjects. Cohort
1: 20 ,ug/kg, SC; Cohort 2: 60 ,ug/kg, SC; Cohort 3: 60 ,ug/kg, IM. (A)&nbsp;CD3+T cells, (B)&nbsp;CD4+T cells, (C)CD8 + T cells, (D)&nbsp;Natural Killer T cells, and (E)&nbsp;regulatory T cells (Treg). (Source: Genexine) </I></P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I>Pharmacokinetics</I>. Efineptakin was slowly absorbed, particularly after SC administration, and was slowly removed, resulting in a
half-life of 48 to 112 hours, longer than that reported for the first generation <FONT STYLE="white-space:nowrap">rhIL-7</FONT> (about 12 hours). Intramuscular efineptakin showed approximately <FONT STYLE="white-space:nowrap">two-fold</FONT> greater
exposure than SC administration at the same dose level of 60 &micro;g/kg. The higher plasma exposure of efineptakin after IM administration was well-correlated with a more robust PD effect on ALC in Cohort 3. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I>Immunogenicity</I>. ADAs were detected in 22 of 24 subjects treated with efineptakin. One subject in Cohort 3 was positive for ADAs before
treatment. Neutralizing antibodies were observed in 42% and 46% of the subjects within one to two months following administration, respectively, but only one person still harbored neutralizing ADAs five months after administration. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The clinical relevance of ADA was evaluated during long-term <FONT STYLE="white-space:nowrap">follow-up</FONT> monitoring. ALC levels were
maintained above the baseline values, endogenous <FONT STYLE="white-space:nowrap">IL-7</FONT> was maintained at normal levels, and no specific adverse events associated with ADAs were observed. These results are consistent with well-documented
reports that a normal individual can harbor <FONT STYLE="white-space:nowrap">pre-existing</FONT> auto-antibodies for cytokines such as <FONT STYLE="white-space:nowrap">IL-2,</FONT> <FONT STYLE="white-space:nowrap">IL-3,</FONT> <FONT
STYLE="white-space:nowrap">IL-4,</FONT> and <FONT STYLE="white-space:nowrap">IL-7,</FONT> and that these anti-cytokine antibodies tend to serve as a reservoir and carrier of the cytokines in the blood, extending the half-life of these cytokines and
preserving their functions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><B><I>Clinical Development Plan </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">By leveraging the results of Genexine&#146;s ongoing clinical trials in South Korea and the United States, we aim to rapidly advance the
clinical development of efineptakin for approval in Greater China. Currently, a Phase 1b trial in China is ongoing to investigate the safety, tolerability and PK/PD response of efineptakin in patients with advanced solid cancers. The clinical trial
(NCT04001075) is designed to include: (i)&nbsp;dose escalation of efineptakin using a conventional &#147;3 + 3&#148; study design to identify a safe and active dose range and (ii)&nbsp;dose expansion to confirm the safety and obtain preliminary
evidence of efficacy. We have finished dose escalation for the four dose cohorts, and the safety and tolerability profile as well as the PK/PD response are consistent with other ongoing studies of efineptakin. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We have obtained regulatory clearance from the NMPA to initiate a Phase 2 clinical trial in GBM patients with lymphopenia. We expect to
initiate this trial in the fourth quarter of 2020. In addition, Genexine and we intend to expand our collaboration, where we will be mainly responsible for conducting the Phase 2 clinical trial in China, and Genexine will share the development
strategies, data and costs for success of this clinical trial. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Genexine has initiated a dose-finding trial in combination with checkpoint
inhibitors in patients with solid tumors. Meanwhile, Genexine is also sponsoring additional early-stage clinical trials in advanced solid </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">159 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
tumors, including glioblastoma and high-risk skin cancer, in the United States and South Korea. The safety, pharmacology and preliminary efficacy data from these ongoing studies are expected to
significantly facilitate our clinical development of efineptakin in Greater China. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><B><I>Eftansomatropin (TJ101): A Potential Highly
Differentiated Long-Acting Growth Hormone for Growth Hormone Deficiency </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><B><I>Summary </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Eftansomatropin, if approved, is a potential highly differentiated long-acting recombinant human growth hormone (&#147;rhGH&#148;) being
developed as a more convenient and effective therapy for growth hormone deficiency (&#147;GHD&#148;), for which there is substantial unmet medical need in China. Eftansomatropin met the <FONT STYLE="white-space:nowrap">pre-set</FONT> safety
endpoints in three multi-regional clinical trials conducted in Europe and Asia and preliminary efficacy endpoints in <FONT STYLE="white-space:nowrap">pre-pubertal</FONT> growth hormone naive pediatric growth hormone deficient (&#147;PGHD&#148;)
patients. In contrast to marketed short-acting rhGH such as Genotropin, eftansomatropin showed similar efficacy results in a weekly (vs. daily) regimen. Furthermore, eftansomatropin has not shown the safety concerns typically associated with
approved pegylated drugs. We <FONT STYLE="white-space:nowrap">in-licensed</FONT> the China rights to eftansomatropin from Genexine and are positioning eftansomatropin as a highly differentiated growth hormone replacement therapy because of its
advantages over a daily regimen in terms of injection frequency (weekly vs. daily) and safety profile (natural protein-based vs. pegylated long-acting rhGH), especially in pediatric patients. In September 2020, the NMPA approved our IND application
for a registrational Phase 3 trial of eftansomatropin in pediatric growth hormone deficiency (PGHD). We expect to initiate this trial in the first quarter of 2021. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><B><I>Therapeutic Options and Current Development </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our current therapeutic indication is PGHD. The widely adopted treatment for PGHD is patient-specific growth hormone replacement therapy,
which is given in a calculated weight-based dosing regimen. Currently, short-acting recombinant human growth hormone (&#147;rhGH&#148;) is commonly used for the long-term treatment of children and adults with inadequate endogenous growth hormone
secretion. There are certain safety concerns related to long-term use of pegylated drugs, such as potential renal toxicity, cellular vacuolation and formation of anti-polyethylene glycol antibodies. Approved by the NMPA in 2014, Jintrolong
(developed by GeneScience) is currently the only marketed long-acting pegylated rhGH in China. Other companies in China currently developing long-acting rhGH include Anhui Anke Biotechnology, Xiamen Amoytop Biotech, Generon Pharmaceutical Technology
and Visen Pharmaceuticals. Our eftansomatropin is the only <FONT STYLE="white-space:nowrap">Fc-based</FONT> long-acting rhGH ready for a Phase 3 clinical trial in China. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Only a very small portion of all PGHD patients in China were receiving growth hormone replacement therapy in 2018, which primarily consists of
daily injections of rhGH before sleep. This dosing regimen puts a substantial burden on pediatric patients and their families because it requires drug preparation and needle injection every day, which is painful and extremely inconvenient, often
resulting in poor patient compliance. More importantly, studies have shown that skipping just one or two doses in a week can markedly reduce the efficacy of the treatment. Therefore, there is a substantial unmet medical need for long-acting growth
hormone therapies that are similarly efficacious but with reduced injection frequency, and the market potential for such a long-acting rhGH in China is largely untapped. In addition, recombinant human growth hormone therapy has been included in the
National Reimbursement Drug List (NRDL) in China. Inclusion of a drug in the NRDL typically results in a much higher sales volume and significant sales growth despite a reduction in price. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><B><I>Advantages of Eftansomatropin </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We believe that eftansomatropin has the following advantages: (i)&nbsp;when compared to the daily regimen of rhGH, eftansomatropin is expected
to be a more convenient therapy with better patient compliance due to a reduced dosing frequency to either weekly or twice-monthly administration, while maintaining similar efficacy; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">160 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
and (ii)&nbsp;eftansomatropin has not shown safety concerns typically associated with pegylated drugs, such as potential renal toxicity, <FONT STYLE="white-space:nowrap">pre-existing</FONT> or
treatment-induced <FONT STYLE="white-space:nowrap">anti-PEG</FONT> antibodies, and cellular vacuolation in macrophages, renal tubule cells and the choroid plexus epithelial cells. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><B><I>Mechanism of Action </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Like endogenous growth hormone, eftansomatropin stimulates the production of insulin-like growth factor 1
<FONT STYLE="white-space:nowrap">(&#147;IGF-1&#148;)</FONT> in the liver, which has growth-stimulating effects on a variety of tissues, including osteoblast and chondrocyte activities that stimulate bone growth. Thus,
<FONT STYLE="white-space:nowrap">IGF-1</FONT> is a reliable pharmacodynamic marker and more importantly, the key mediator of eftansomatropin&#146;s growth-promoting activity. Eftansomatropin is based on Genexine&#146;s patented hyFc technology. The
hyFc part consists of a portion of human immunoglobulin D (&#147;IgD&#148;) and G4 (&#147;IgG4&#148;). The former contains a flexible hinge, and the latter is responsible for half-life extension through neonatal Fc receptor
(&#147;FcRn&#148;)-mediated recycling. Additionally, eftansomatropin&#146;s increased molecular weight (103 kilodalton) is expected to reduce renal clearance. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g98473g31j43.jpg" ALT="LOGO">
 </P> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><I>Figure:</I></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>Schematic presentation of the structure of eftansomatropin. CH2 &amp; CH3: Constant regions 2 &amp; 3 of
antibody heavy chains, respectively; hGH: human growth hormone. (Source: Genexine)</I> </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><B><I>Summary of Clinical
Results </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Genexine has completed three clinical trials with eftansomatropin, including one Phase 1 trial in healthy adult
volunteers, one Phase 1b/2 multi-regional trial in adults with GHD, and one Phase 2 multi-regional trial in PGHD in Europe, altogether involving 32 healthy subjects and 99 patients with GHD and PGHD. Overall, eftansomatropin was shown to be
well-tolerated, and clinical efficacy endpoint achieved by weekly or twice-monthly eftansomatropin administration was comparable to that of daily administration of Genotropin. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><I>Phase 1 Clinical Trial </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-human</FONT></FONT> trial of eftansomatropin was a randomized,
double-blind, placebo-controlled single dose-ascending study in four groups of healthy subjects. A total of 32 subjects were enrolled, and 31 completed the study. Eftansomatropin was shown to be well-tolerated at all dose levels studied
(0.2&#150;1.6 mg/kg). Eftansomatropin was detectable in the blood until Day 7 for the 0.2 mg/kg dose group, Day 14 for the 0.4 and 0.8&nbsp;mg/kg dose groups, and Day 21 for the 1.6 mg/kg dose group. A single subcutaneous (&#147;SC&#148;) injection
of eftansomatropin at dose levels of 0.4 mg/kg and higher increased <FONT STYLE="white-space:nowrap">IGF-1</FONT> and <FONT STYLE="white-space:nowrap">IGF-binding</FONT> <FONT STYLE="white-space:nowrap">protein-3</FONT> <FONT
STYLE="white-space:nowrap">(&#147;IGFBP-3&#148;)</FONT> levels for at least one week. No safety concerns were identified. Eftansomatropin showed a half-life ranging from 69.2 to 138 hours. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><I>Phase 2 Clinical Trial in PGHD </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Study Design. The Phase 2 trial in PGHD was a randomized, open-label, active-controlled study to assess the safety, tolerability, efficacy,
pharmacokinetics, and pharmacodynamics of weekly and twice-monthly doses of eftansomatropin, as compared to a daily injection of Genotropin, which is currently the standard of care for PGHD. Subjects were randomly assigned to receive one of three
doses of eftansomatropin (0.8 mg/kg/ weekly, 1.2 mg/kg/weekly or 2.4 mg/kg/twice monthly) or 0.03 mg/kg/daily of Genotropin for up to 24 months. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">161 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The primary clinical endpoint was annualized height velocity (aHV) in centimeters
(cm)&nbsp;per year (equivalent to annual growth rate), measured at six months. A total of 56 subjects were randomized at 27 centers in nine European countries and South Korea. <FONT STYLE="white-space:nowrap">Fifty-two</FONT> subjects completed the <FONT
STYLE="white-space:nowrap">six-month</FONT> treatment (through Visit 7), meeting the primary endpoint. Two subjects withdrew from the study before first drug administration, and two subjects discontinued due to treatment-related adverse events
(&#147;AEs&#148;). Genexine and its <FONT STYLE="white-space:nowrap">co-developer</FONT> Handok presented the latest interim results of the Phase 2 clinical trial for PGHD in March 2018 at the Endocrine Society&#146;s annual meeting. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Safety. No study drug-related serious adverse events (&#147;SAEs&#148;) or death were observed. The tolerability of eftansomatropin was
consistent with known properties of marketed products. The AE incidence rate was generally similar across the eftansomatropin cohorts treated with three different dose levels (ranging between 69.2% and 84.6%) and the Genotropin cohort (57.1%). A
total of two (14.3%), three (23.1%), two (15.4%), and zero subjects experienced treatment-related AEs in the 0.8 mg/kg/week, 1.2 mg/kg/week, and 2.4 mg/kg/twice monthly eftansomatropin groups, and the 0.03 mg/kg/daily Genotropin group, respectively.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Two subjects withdrew from the study due to treatment-related AEs. One subject from Cohort 2 (1.2&nbsp;mg/kg/week of eftansomatropin)
discontinued due to retinal vascular disorder. The Data and Safety Monitoring Board (&#147;DSMB&#148;) reviewed this case independently, concluding that the retinal finding was more likely to be of completely different etiology than
treatment-induced intracranial hypertension. One subject from Cohort 3 (2.4 mg/kg/twice monthly of eftansomatropin) discontinued due to pseudopapilloedema (optic disc drusen), which was assessed by the principal investigator to be mild with
continuous frequency and possibly related to the study drug. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Injection site reactions (&#147;ISRs&#148;) were reported by 13 out of 40
subjects (32.5%) in the eftansomatropin cohorts. Pain was the most prominent and common symptom observed in 10 subjects. Also, six subjects reported redness, four reported itching, and one reported bruising, swelling and warmness. With respect to
the Genotropin cohort, pain was the only ISR reported in 683 cases by 11 out of 14 subjects (78.5%). None of the ISRs led to discontinuation of treatment, and most of the reported ISRs posed no issue for the subjects and were resolved quickly. No
safety signal was detected in laboratory parameters or vital signs for either eftansomatropin or Genotropin. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Pharmacokinetics. Half-life
of eftansomatropin was 77.75&#150;141.95 hours after a single dose and 43.92&#150;55.66 hours (compared to 5.27 hours for Genotropin) after three months of multiple-dose administration. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Immunogenicity. Formation of treatment-emergent ADA with neutralizing property was reported in two subjects (one from Cohort 2 and one from
Cohort 3) out of a total of 40 subjects randomized and dosed with eftansomatropin. With respect to the Genotropin cohort, the presence of treatment-emergent ADA with neutralizing property was not observed in any subject. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">162 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Clinical Efficacy. Subcutaneous administration of eftansomatropin over the dose range of 0.8
mg/kg/ week&#150;2.4 mg/kg/twice monthly resulted in an increase in aHV over the <FONT STYLE="white-space:nowrap">six-month</FONT> study period. Subjects who received eftansomatropin at 0.8 mg/kg weekly, 1.2 mg/kg weekly, and 2.4 mg/kg twice monthly
showed growth rates of 11.50, 11.54, and 11.86 cm/year, respectively, while the growth rate in the control group treated with Genotropin was approximately 11.24 cm/year. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g98473g29v69.jpg" ALT="LOGO">
 </P> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><I>Figure:</I></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>The aHV at six months indicated comparable growth rates between all doses of eftansomatropin (both weekly
and twice-monthly treatment) and the active comparator, Genotropin. (Source: Genexine)</I> </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In an extension study in
which all patients were put on eftansomatropin, greater than <FONT STYLE="white-space:nowrap">two-digit</FONT> growth velocity remained until 12 months in all eftansomatropin cohorts, while the Genotropin cohort showed 9.14 cm/ year at 12 months.
Moreover, no remarkable slow-down of the growth velocity was observed in the second year in either patients who received eftansomatropin throughout, or in subjects who switched from Genotropin cohort. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Pharmacodynamics. The growth-promoting effect of eftansomatropin was accompanied by elevated serum
<FONT STYLE="white-space:nowrap">IGF-1</FONT> levels. This hormone is an important biomarker, which mediates growth hormone&#146;s biological effects. The Standard Deviation Score (&#147;SDS&#148;), which is a calculated score with reference to the
normal <FONT STYLE="white-space:nowrap">age-</FONT> and <FONT STYLE="white-space:nowrap">sex-matched</FONT> <FONT STYLE="white-space:nowrap">IGF-1</FONT> levels, is a standardized parameter to compare <FONT STYLE="white-space:nowrap">IGF-1</FONT>
levels across laboratories and populations. Mean <FONT STYLE="white-space:nowrap">IGF-1</FONT> SDS at the beginning of the study was below the lower limit of the normal range in all treatment arms. Following initiation of treatment, the <FONT
STYLE="white-space:nowrap">IGF-1</FONT> SDS values quickly normalized by five days (Visit&nbsp;2) and three weeks (Visit 3) after the initial treatment, respectively, for the eftansomatropin treatment arms and the Genotropin treatment arm. <FONT
STYLE="white-space:nowrap">IGF-1</FONT> responses were maintained throughout the intended dosing interval, supporting both the weekly and twice monthly treatment regimens. <FONT STYLE="white-space:nowrap">IGF-1</FONT> mean peak levels were mostly
within the upper limit of the physiologic range, which is considered safe in clinical practice. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><B><I>Clinical Development Plan
</I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In September 2020, the NMPA approved our IND application for a registrational Phase 3 trial of eftansomatropin in pediatric
growth hormone deficiency (PGHD) in China. We expect to initiate this trial in the first quarter of 2021. This Phase 3 trial will be a multi-center, randomized, open-label, active-controlled clinical study designed to assess the safety, efficacy and
pharmacokinetics of eftansomatropin in PGHD. The primary objective is to demonstrate <FONT STYLE="white-space:nowrap">non-inferiority</FONT> of 1.2 mg/kg/week of eftansomatropin administered SC, compared to the active control Norditropin, a daily
rhGH marketed in China. About 165 subjects will be enrolled and treated in the study. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">163 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><B><I>Olamkicept (TJ301): A Potential Highly Differentiated
<FONT STYLE="white-space:nowrap">IL-6</FONT> Blocker for Ulcerative Colitis and other Autoimmune Diseases </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><B><I>Summary
</I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Olamkicept is the only clinical stage selective <FONT STYLE="white-space:nowrap">interleukin-6</FONT> <FONT
STYLE="white-space:nowrap">(&#147;IL-6&#148;)</FONT> inhibitor that works through the trans-signaling mechanism. <FONT STYLE="white-space:nowrap">IL-6</FONT> is an important cytokine driver in the propagation and maintenance of chronic inflammation
in autoimmune diseases. Compared to the approved antibody drugs that directly block <FONT STYLE="white-space:nowrap">IL-6</FONT> or <FONT STYLE="white-space:nowrap">IL-6&nbsp;receptor</FONT>
<FONT STYLE="white-space:nowrap">(&#147;IL-6R&#148;),</FONT> olamkicept is expected to provide a novel alternative for the treatment of <FONT STYLE="white-space:nowrap">IL-6</FONT> mediated inflammation without affecting some of the normal
physiological functions of <FONT STYLE="white-space:nowrap">IL-6,</FONT> e.g., acute immune response against infection and metabolic regulation. Olamkicept demonstrated therapeutic effects in <FONT STYLE="white-space:nowrap">pre-clinical</FONT>
animal models of autoimmune diseases, including inflammatory colitis. Moreover, the safety and tolerability profile of olamkicept was studied in three clinical trials in Germany involving 128 subjects. We believe that olamkicept has the potential to
become a highly differentiated therapy to target autoimmune diseases. We acquired an exclusive license from Ferring Pharmaceuticals to develop and commercialize olamkicept in Greater China and South Korea with an option of licensing worldwide
rights. As part of our <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">fast-to-market</FONT></FONT> strategy for olamkicept, we selected ulcerative colitis (&#147;UC&#148;) as the first indication for the following reasons:
(i)&nbsp;olamkicept was shown to be effective in animal models of colitis; (ii)&nbsp;an exploratory Phase 2a biomarker trial showed promising interim treatment effects of olamkicept in UC patients; and (iii)&nbsp;even though UC incidence is
increasing rapidly, innovative biologic treatments for this disease are lacking in China. We are conducting an ongoing Phase 2 clinical trial in patients with active ulcerative colitis. The enrollment of this trial is complete with a total of
91&nbsp;patients recruited. Topline data of this trial are expected to be released by early 2021. After clinical efficacy and differentiation are validated for UC, we plan to develop olamkicept in other inflammatory indications, in which <FONT
STYLE="white-space:nowrap">IL-6</FONT> plays a role. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><B><I>Therapeutic Options and Current Development </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our current therapeutic indication for development is UC. UC and Crohn&#146;s disease (&#147;CD&#148;) are the main types of inflammatory
bowel disease (&#147;IBD&#148;), which cause chronic and often relapsing inflammation of the large and small intestines, respectively. Anti-inflammatory drugs, such as <FONT STYLE="white-space:nowrap">5-aminosalicylic</FONT> acids <FONT
STYLE="white-space:nowrap">(&#147;5-ASAs&#148;)</FONT> and corticosteroids, are often used as initial treatment for UC. Immune system suppressors are also used to control inflammation in patients with UC, including azathioprine, mercaptopurine, and
cyclosporine. Biologics that inhibit tumor necrosis factor alpha <FONT STYLE="white-space:nowrap">(TNF-a),</FONT> including infliximab (Remicade), adalimumab (Humira), and golimumab (Simponi), are efficacious in some UC patients who fail to respond
to conventional therapies. Entyvio, an integrin a4&szlig;7 antibody that blocks lymphocytes from accumulating in the intestinal wall, was the first
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">non-anti-TNF-a</FONT></FONT></FONT> biologics approved for UC STELARA<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> (ustekinumab), an <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-IL-12/IL-23</FONT></FONT></FONT> antibody was approved for the treatment of adult patients with moderately to severely active ulcerative colitis in
June 2020. In China, Remicade and Entyvio are currently the only two biologics approved for treatment of UC. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">There is a substantial unmet
medical need in UC for a treatment agent(s) that is efficacious and safe through pathways beyond the traditional drug targets. The incidence of UC is increasing rapidly, but UC patients, especially those with a <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">moderate-to-severe</FONT></FONT> disease, have few treatment options, which have limited efficacy and considerable side-effects. For example, Jak1/3 kinase inhibitors can carry the risk of serious infections and
malignancies. <FONT STYLE="white-space:nowrap">TNF-a</FONT> inhibitors also have inherent side effects and do not work in all patients. Thus, as the only clinical stage selective <FONT STYLE="white-space:nowrap">interleukin-6</FONT> <FONT
STYLE="white-space:nowrap">(&#147;IL-6&#148;)</FONT> inhibitor that works through the trans-signaling mechanism, we believe olamkicept has the potential to become a highly differentiated <FONT STYLE="white-space:nowrap">IL-6</FONT> blocker for UC,
if approved. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><B><I>Advantages of Olamkicept </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The existing <FONT STYLE="white-space:nowrap">IL-6</FONT> or <FONT STYLE="white-space:nowrap">IL-6R</FONT> blockers cause total inhibition of <FONT
STYLE="white-space:nowrap">IL-6</FONT> signaling and are associated with significant adverse events in the clinic, such as infection, gastrointestinal perforation, metabolic disturbances, and insulin resistance. Olamkicept is expected to provide a
novel alternative as it works through a different </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">164 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
mechanism, the trans-signaling pathway. This key advantage has been demonstrated in <FONT STYLE="white-space:nowrap">pre-clinical</FONT> studies and three clinical trials conducted in Germany.
The results indicated that olamkicept has no side effects on lipid, glucose or bone metabolism, and it has no agonistic activities that could activate receptors or trigger detrimental immune cascades. We expect that selective inhibition of <FONT
STYLE="white-space:nowrap">IL-6</FONT> trans-signaling is an effective and safer approach to the treatment of chronic inflammation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><B><I>Mechanism ofAction </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Olamkicept is a homodimer of a fusion protein consisting of the extracellular domains of human glycoprotein130 (&#147;gp130&#148;) and the
fragment crystallizable (Fc) domain of human IgG1. Mimicking the function of endogenous soluble gp130, olamkicept works as a decoy by binding to a complex consisting of <FONT STYLE="white-space:nowrap">IL-6</FONT> and soluble <FONT
STYLE="white-space:nowrap">IL-6</FONT> receptor <FONT STYLE="white-space:nowrap">(&#147;sIL-6R&#148;),</FONT> thereby preventing olamkicept from stimulating the trans-signaling pathway in cells that do not express
<FONT STYLE="white-space:nowrap">IL-6R.</FONT> The gp130 part selectively binds the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">IL-6/sIL-6R</FONT></FONT> complex with high affinity (Kd=130 pM), whereas the Fc part initiates
dimerization and offers longer half-life for the molecule. Olamkicept is not expected to affect the beneficial effects of <FONT STYLE="white-space:nowrap">IL-6,</FONT> such as the acute immune response against infection mediated by the classical
pathway. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">


<IMG SRC="g98473g75i90.jpg" ALT="LOGO">
.. </P> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><I>Figure:</I></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>Classical signaling and trans-signaling pathways <FONT STYLE="white-space:nowrap">ofIL-6.</FONT> <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Anti-IL-6R</FONT></FONT> and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-IL-6</FONT></FONT> block both pathways, whereas olamkicept blocks only trans-signaling. <FONT
STYLE="white-space:nowrap">IL-6R:</FONT> <FONT STYLE="white-space:nowrap">IL-6</FONT> receptor; <FONT STYLE="white-space:nowrap">sIL-6R:</FONT> Soluble <FONT STYLE="white-space:nowrap">IL-6</FONT> receptor.</I> </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><B><I>Summary of Clinical Results </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Ferring Pharmaceuticals has completed two Phase 1 trials to evaluate olamkicept&#146;s preliminary safety and clinical pharmacology.
Olamkicept was shown to be well-tolerated based on the clinical results collected from a total of 112 subjects exposed to the drug. In addition, a Phase 2a biomarker study in active IBD (known as the FUTURE study) has been completed in Germany with
promising pharmacodynamic and clinical responses observed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><I>Phase 1 Clinical Trial: Single Dose Ascending Trial </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I>Study Design</I>. The <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-human</FONT></FONT> trial of olamkicept
was a single dose, placebo-controlled, single-blind, randomized within dose, and parallel group dose-escalating trial. The trial recruited both healthy subjects and patients with Crohn&#146;s Disease (&#147;CD&#148;) in clinical remission. The
primary objective was to examine the safety, tolerability and pharmacokinetics after a single dose of olamkicept. Several dose levels were tested, ranging from 0.75 mg to 750 mg, with each dose level including six subjects receiving olamkicept and
two receiving placebo. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I>Pharmacokinetics</I>. In healthy subjects and CD patients, olamkicept showed similar terminal half-life of 4.3
to 5.1 days. The maximum concentration (Cmax) in plasma and the area under curve (&#147;AUC&#148;) of the plasma </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">165 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
drug concentration-time curve were dose proportional. For SC administration of olamkicept (60 mg), the Cmax was approximately 1.0 &micro;g/mL at 2.3 days, and the bioavailability was
approximately 48%. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g98473g19d04.jpg" ALT="LOGO">
 </P> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><I>Figure:</I></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>Single dose pharmacokinetic profile of olamkicept. Left, healthy subjects (colored lines) and IBD patients
in remission (gray lines) received a single IV infusion at 75 mg (blue lines), 300 mg (magenta lines) or 600 mg (red lines) fixed doses. Right, healthy subjects received a single SC injection at 60 mg. LLOQ: lower limit of quantitation. (Source:
Ferring Pharmaceuticals)</I> </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I>Safety</I>. Olamkicept was well-tolerated when administered as a single IV dose at up
to 750 mg and as a single SC dose at 60 mg. No apparent dose-related AE was observed. Infusion was discontinued in two subjects due to mild to moderate infusion-related reactions, with skin symptoms such as urticaria and swelling, which were rapidly
resolved. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Only one healthy subject in the 300 mg group showed <FONT STYLE="white-space:nowrap">non-neutralizing</FONT> treatment-emergent
ADAs at the <FONT STYLE="white-space:nowrap">follow-up</FONT> visit five to six weeks after administration. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><I>Phase 1 Clinical Trial:
Multiple Dose Ascending Trial </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I>Study Design</I>. This trial was a placebo-controlled, double-blind, and randomized dose-escalating
trial in healthy subjects. A total of 24 healthy subjects were randomized into three dose groups and received four weekly infusions of olamkicept at 75 mg, 300 mg or 600 mg. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I>Pharmacokinetics</I>. PK characteristics were similar on the first and last treatment days of the multiple dose-ascending trial and were
similar to results in the single dose-ascending study. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g98473g61j34.jpg" ALT="LOGO">
 </P> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><I>Figure:</I></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>Multiple dose pharmacokinetic profile of olamkicept. Healthy subjects received weekly IV infusions at 75 mg
(blue lines), 300 mg (magenta lines) or 600 mg (gray lines) fixed doses. LLOQ, lower limit of quantitation. (Source: Ferring Pharmaceuticals)</I> </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">166 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I>Safety</I>. There were only a few mild or moderate AEs reported across all treatment
groups. One subject from the 600 mg group withdrew due to mild infusion-related reactions with urticaria and pruritus 30 minutes after administrating the first dose. No apparent dose-related trends or treatment-related change in vital signs,
electrocardiogram or clinical chemistry parameters were observed. No ADAs were reported by any subject. Overall, olamkicept was well-tolerated when administered by IV at up to 600 mg once weekly for four weeks. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Overall Summary of Treatment-Emergent Adverse Events </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="54%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>75 mg</B><br><B>(N=6)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>300 mg<BR>(N=6)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>600 mg<BR>(N=6)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Placebo<BR>(N=6)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Total&nbsp;Active<BR>(N=18)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">n&nbsp;(%)&nbsp;E</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">n&nbsp;(%)&nbsp;E</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">n&nbsp;(%)&nbsp;E</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">n&nbsp;(%)&nbsp;E</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">n&nbsp;(%)&nbsp;E</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Any TEAE <SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6&nbsp;(100)&nbsp;13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2&nbsp;(33)&nbsp;5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4&nbsp;(67)&nbsp;6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6&nbsp;(100)&nbsp;14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12&nbsp;(67)&nbsp;24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Serious TEAEs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Adverse Drug Reactions <SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6&nbsp;(100) 11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2&nbsp;(33) 2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3&nbsp;(50) 5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4&nbsp;(67) 6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11&nbsp;(61) 18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">TEAEs Leading to Withdrawal</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1 (17) 1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1 (6) 1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deaths</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Source:
Ferring Pharmaceuticals </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Note: </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Reasonably possibly related to treatment; N: number of subjects exposed; n: number of subjects with AE; %:
n/N*100; E: number of AEs </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><I>Phase 2a Biomarker Study in Active IBD (FUTURE Study) </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I>Study Design</I>. This was an open-label exploratory study to assess the mechanisms of molecular activity (effects on biomarkers), safety
and tolerability of olamkicept in adult patients with active IBD. Nine UC patients and seven CD patients were dosed with olamkicept (600 mg, IV, q2w) for up to 12 weeks followed by 42 days of safety <FONT STYLE="white-space:nowrap">follow-up.</FONT>
Patients enrolled had moderately to severe active UC or ileocolonic CD with median disease duration of 5.3 (UC) and 6.9 (CD) years and with immunologically active inflammation <FONT STYLE="white-space:nowrap">(C-reactive</FONT> protein
&gt;5&nbsp;mg/l), who had failed conventional therapies and had no prior biologics treatment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The primary endpoint was the proportion of
patients with reduced mucosal expression of a predefined set of inflammation-relevant genes (TNFA, IL1A, REG1A, IL8, IL1B and LILRA) as a composite score. Objective assessments included centrally read endoscopies, histology readings, and various
explorative molecular parameters and inflammatory biomarkers. The trial was sponsored and conducted by the University Hospital Schleswig Holstein and Paul-Ehrlich Institute <FONT STYLE="white-space:nowrap">(EUDRA-CT</FONT> <FONT
STYLE="white-space:nowrap">2016-000205-36),</FONT> with financial and material support from Ferring Pharmaceuticals. The study has been completed, and the abstract of the results was presented at the United European Gastroenterology Week meeting in
October 2019. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I>Safety</I>. Olamkicept was well-tolerated. Reported AEs were unspecific in nature and showed no signs of immune
suppression. Five SAEs were observed, none of which were life-threatening or deemed to be related to olamkicept. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">167 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I>Pharmacokinetics</I>. After single and repeated IV administration of olamkicept (600 mg,
Q2W) to patients with UC and CD, similar serum exposure was observed after the first and last dosing events, with respect to Cmax and total exposure over 14 days. Maximal serum drug concentration after each dosing was reached at the end of infusion.
The mean terminal half-life of olamkicept after the last administration was approximately 5.1 days. Circulating biological activity of olamkicept was confirmed by whole-blood STAT3 phosphorylation assays in all patients. A minimal and transient ADA
production was observed in three patients. ADAs were only detected at week 12 and week 15, but no longer detectable at week 18. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g98473g37e21.jpg" ALT="LOGO">
 </P> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><I>Figure:</I></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>Time course of the mean serum concentration of olamkicept.</I> </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I>Pharmacodynamics</I>. In the assessment of the primary endpoint, it was observed that clinical remission was associated with a significant
reduction of <FONT STYLE="white-space:nowrap">IL-1B,</FONT> <FONT STYLE="white-space:nowrap">IL-8</FONT> and REG1A gene expression in the intestinal mucosa. Pathway analysis of blood transcriptome signatures showed an early molecular
anti-inflammatory signature as early as four hours after treatment in all patients, irrespective of treatment outcome, which indicated a thorough inhibitory effect of <FONT STYLE="white-space:nowrap">IL-6</FONT> trans-signaling blockade on
inflammatory pathways. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I>Clinical Efficacy</I>. A preliminary clinical response was observed in both UC and CD patients, which appeared
to be stronger in patients with UC than those with CD. Overall, 55% of UC patients (5/9) responded to olamkicept, with 22% (2/9) reaching clinical remission, whereas 29% of CD patients (2/7) responded to olamkicept, with 14% (1/7) reaching clinical
remission. All three patients in clinical remission showed a fast and thorough induction of clinical, endoscopic, and immunologic remission within the first four weeks. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><B><I>Clinical Development Plan </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We are positioning olamkicept as a differentiated <FONT STYLE="white-space:nowrap">IL-6</FONT> blocker for a number of autoimmune diseases.
The first target indication is active stage UC that is not well-controlled by conventional therapies such as mesalazine. We are conducting multi-regional Phase 2 clinical trial in Greater China and South Korea to assess the pharmacokinetics, safety,
and efficacy of olamkicept in patients with active UC (NCT03235752). This is a randomized, double-blind, and placebo-controlled clinical trial with three treatment arms. The enrollment of this trial is complete with a total of 91 patients recruited.
Topline data of this trial are expected to be released by early 2021. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Besides UC, we are evaluating the possibility of extending
olamkicept to other autoimmune conditions where there is significant unmet medical need in China. We expect to initiate a second clinical trial for a chronic inflammatory disorder, such as systemic sclerosis or Castleman&#146;s disease, in which <FONT
STYLE="white-space:nowrap">IL-6</FONT> is implicated as a key pathogenic cytokine. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">168 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><B><I>Enoblituzumab: The Most Advanced Clinical Stage Humanized <FONT
STYLE="white-space:nowrap">B7-H3</FONT> Antibody as a Potential Immuno-oncology Treatment </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><B><I>Summary </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Enoblituzumab is a humanized antibody directed at <FONT STYLE="white-space:nowrap">B7-H3,</FONT> a member of the B7 family of T cell
checkpoint regulators. <FONT STYLE="white-space:nowrap">B7-H3</FONT> is a promising immuno-oncology drug target as it is widely expressed across multiple tumor types and plays a key role in regulating immune response against cancers. Increasing <FONT
STYLE="white-space:nowrap">pre-clinical</FONT> and clinical evidence suggests that antibodies targeting the two T cell checkpoint <FONT STYLE="white-space:nowrap">molecules&#151;B7-H3</FONT> and <FONT STYLE="white-space:nowrap">PD-1&#151;work</FONT>
synergistically in treating cancer. Given <FONT STYLE="white-space:nowrap">B7-H3&#146;s</FONT> critical role, enoblituzumab has a wide range of cancer applications as either a monotherapy or in combination with
<FONT STYLE="white-space:nowrap">PD-1</FONT> therapies. At the molecular level, enoblituzumab is engineered to possess an enhanced anti-tumor ADCC function and is at the forefront in global clinical development. Originally developed by MacroGenics,
enoblituzumab has been evaluated in multiple clinical trials as a monotherapy or in combination with <FONT STYLE="white-space:nowrap">CTLA-4</FONT> or <FONT STYLE="white-space:nowrap">PD-1</FONT> therapies in patients with <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">B7-H3-expressing</FONT></FONT> cancers. Enoblituzumab is also being evaluated in a neoadjuvant Phase 2 study as a single agent in patients with intermediate and high-risk localized prostate
cancer. The clinical studies so far have shown that enoblituzumab is well-tolerated, and it increased CD8 T cell infiltration in tumors with more focused T cell repertoires in patients treated with enoblituzumab as a monotherapy. Recent clinical
studies conducted by MacroGenics indicate that combination therapy with enoblituzumab and pembrolizumab correlates with preliminary anti-tumor effects in recurrent or metastatic squamous cell carcinoma of the head and neck (&#147;SCCHN&#148;) and <FONT
STYLE="white-space:nowrap">non-small</FONT> cell lung cancer (&#147;NSCLC&#148;). We acquired the development and commercial rights of enoblituzumab from MacroGenics for Greater China. In the first quarter of 2021, MacroGenics expects to initiate a
Phase 2 study of enoblituzumab in a chemo-free regimen in combination with either retifanlimab (an investigational <FONT STYLE="white-space:nowrap">PD-1</FONT> antibody) in front-line patients with SCCHN who are
<FONT STYLE="white-space:nowrap">PD-L1</FONT> positive or with tebotelimab (an investigational <FONT STYLE="white-space:nowrap">PD-1</FONT> x <FONT STYLE="white-space:nowrap">LAG-3</FONT> bispecific
DART<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> antibody) in SCCHN patients who are <FONT STYLE="white-space:nowrap">PD-L1</FONT> negative. We expect to participate in any subsequent Phase 3 global study if and when initiated. In
addition, considering the dynamic regulatory environment and evolving clinical practice, we have been continually refining the development of enoblituzumab in our territory. As more clinical and <FONT STYLE="white-space:nowrap">pre-clinical</FONT>
data become available, further clinical trials may be planned together with MacroGenics to extend enoblituzumab to other cancer indications in China and/or globally. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><B><I>Therapeutic Options and Current Development </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our initial therapeutic indication is head and neck cancer. Head and neck cancers occur in various parts of the head and neck, including the
mouth, nose, throat and salivary glands. More than 90% of head and neck cancers are classified as SCCHN, which begin in the squamous cells that line the moist, mucosal surfaces inside the head and neck. The treatment principles and regimens for head
and neck cancer in China are similar to those in the rest of the world. Treatment strategies often depend on the location and stage of the cancer, the patient&#146;s physical status, and response to prior treatments. Early-stage disease is primarily
treated with surgical resection, while patients with locally advanced, recurrent or metastatic disease are typically treated with drug therapy. The combination of surgery and drug therapy, with or without radiation therapy, is the current standard
of care for Stage 3 SCCHN patients with locally advanced disease. Platinum-based chemotherapy regimens are widely used as first-line therapies for Stage 4 and distant relapse patients. Erbitux (cetuximab from Eli Lilly and Merck KGaA) was approved
in 2006 as a first-line treatment of locally advanced SCCHN in combination with radiation therapy. Regimens containing Erbitux, platinum-based chemotherapy, and <FONT STYLE="white-space:nowrap">5-fluorouracil,</FONT> known as EXTREME, are often
considered as the standard of care for first-line treatment of distant relapse SCCHN. However, only about 35% of patients respond to EXTREME, and the resulting overall median survival is only 10.1 months. Furthermore, about half of the patients on
first-line therapies need later-line therapies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In addition, even second-line therapy is highly varied, including single-agent docetaxel
or paclitaxel, Erbitux monotherapy, and Erbitux and paclitaxel combination therapy. In 2016, <FONT STYLE="white-space:nowrap">PD-1</FONT> inhibitors were approved globally as second-line therapies. In 2019, Keytruda (pembrolizumab from
Merck&nbsp;&amp; Co), used as a single agent </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">169 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
or in combination with chemotherapy, was approved by the FDA as first-line therapy for patients with metastatic or unresectable recurrent SCCHN. The average ORR for second-line therapies has been
less than 15%. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">As such, we believe that SCCHN patients, especially those with late stage or relapsed disease, need more efficacious
treatments with fewer side effects, which represents a significant unmet medical need for immunotherapy and targeted therapy. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><B><I>Advantages of Enoblituzumab </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Enoblituzumab is the most advanced clinical stage humanized <FONT STYLE="white-space:nowrap">B7-H3</FONT> antibody as a potential
immuno-oncology treatment. The foregoing statement applies only to conventional therapeutic <FONT STYLE="white-space:nowrap">B7-H3</FONT> antibodies and does not include radio-labeled <FONT STYLE="white-space:nowrap">B7-H3</FONT> antibodies in
development by <FONT STYLE="white-space:nowrap">Y-mabs</FONT> Therapeutics. Targeting <FONT STYLE="white-space:nowrap">B7-H3</FONT> offers several advantages over other target options within the class of T cell checkpoint molecules. First, <FONT
STYLE="white-space:nowrap">B7-H3</FONT> is a tumor-associated antigen that is over-expressed in a variety of solid tumors while its expression in normal tissues is rather limited, enabling the tumor killing mechanism of enoblituzumab. Second, <FONT
STYLE="white-space:nowrap">B7-H3</FONT> is a unique checkpoint whose expression in tumors is associated with disease prognosis. For example, biomarker analysis of more than 400 NSCLC patients revealed that among all the elevated immune checkpoint
inhibitors, including <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">PD-1/PD-L1,</FONT></FONT> <FONT STYLE="white-space:nowrap">PD-L2,</FONT> <FONT STYLE="white-space:nowrap">B7-H3,</FONT>
<FONT STYLE="white-space:nowrap">TIM-3,</FONT> BTLA and CTLA4, only <FONT STYLE="white-space:nowrap">B7-H3</FONT> is negatively correlated with clinical efficacies of neoadjuvant treatments (Lou et al., Clinical Cancer Research, 2016). Furthermore,
recent studies have shown that when combined with a <FONT STYLE="white-space:nowrap">PD-1</FONT> antibody, a blockade of <FONT STYLE="white-space:nowrap">B7-H3</FONT> results in superior treatment effects in relevant cancer animal models while
another study indicates that <FONT STYLE="white-space:nowrap">B7-H3</FONT> expression correlates with a lack of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-1</FONT></FONT> response (Yonesaka et al., Clinical Cancer
Research, 2018). The advantages summarized above make <FONT STYLE="white-space:nowrap">B7-H3</FONT> a favorable tumor target for immuno-therapeutic intervention. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><B><I>Mechanism of Action </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Enoblituzumab (MGA271) is an investigational humanized immunoglobulin (IgG1/kappa monoclonal antibody) that binds to B7 homolog 3 <FONT
STYLE="white-space:nowrap">(B7-H3).</FONT> This antibody consists of an engineered human IgG1 fragment crystallizable (Fc) domain that imparts increased affinity for the human activating Fc gamma receptor FcgRIIIA (CD16A) and decreased affinity for
the human inhibitory FcgRIIB (CD32B). The engineered Fc domain confers enoblituzumab with enhanced target-specific antibody-dependent cellular cytotoxicity (&#147;ADCC&#148;) in vitro and anti-tumor activity in preclinical studies. Therefore,
enhanced cytolysis of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">B7-H3-expressing</FONT></FONT> tumor cells is a mechanism that supports the development of this molecule as an antineoplastic agent. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In addition, data suggest that enoblituzumab impacts <FONT STYLE="white-space:nowrap">T-cell</FONT> homeostasis in vivo. Cancer patients
display a more narrowly focused <FONT STYLE="white-space:nowrap">T-cell</FONT> repertoire following enoblituzumab treatment compared to their baseline repertoire distribution. Moreover, enhanced local <FONT STYLE="white-space:nowrap">T-cell</FONT>
infiltration has been observed in prostate cancer patients treated with enoblituzumab. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">170 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">These data are consistent with the notion that enoblituzumab is capable of engaging both
innate and adaptive immunity as mediators of its anti-tumor activity. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g98473g93a29.jpg" ALT="LOGO">
 </P> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><I>Figure:</I></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>Enoblituzumab contributes to the coordination and engagement of innate and adaptive immunity to mediate
tumor regression. Enoblituzumab binds to tumor cells, activates innate immune cells such as</I> <I>natural killer cells (NK cells) to kill cancer cells through ADCC. The released tumor antigens may then be presented by antigen-presenting cells, such
as macrophages, which, in concert with <FONT STYLE="white-space:nowrap">PD-1</FONT> blockade, can promote tumor-specific <FONT STYLE="white-space:nowrap">T-cell</FONT> immunity. (Source: MacroGenics)</I> </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><I>Summary of Clinical Results </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><B><I>Phase 1 Study of Enoblituzumab Monotherapy </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I>Study Design</I>. This was an open-label, multi-dose, <FONT STYLE="white-space:nowrap">single-arm,</FONT> multi-center, and dose-escalation
study to define safety, tolerability, maximum tolerated dose (&#147;MTD&#148;), PK, immunogenicity, and potential anti-tumor activity of enoblituzumab in patients with refractory cancers that express <FONT STYLE="white-space:nowrap">B7-H3</FONT>
conducted by MacroGenics. In the dose escalation segment of the study, six doses (0.15&#150;15 mg/kg QW) were evaluated in a conventional &#147;3+3&#148; design. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">No MTD or dose-limiting toxicity (&#147;DLT&#148;) was observed in the dose escalation phase, so the highest administered dose, 15 mg/kg, was
used in the cohort expansion, in which patients received weekly infusions of enoblituzumab in eight-week cycles for up to 12 cycles. Tumor evaluation was carried out by both Response Evaluation Criteria in Solid Tumors (&#147;RECIST&#148;) and
immune-related response criteria (&#147;irRC&#148;) with an initial response assessment after eight weeks. This entailed seven tumor-specific cohorts, including melanoma (post-checkpoint inhibitor failure, n=31), head and neck cancer (n=19),
prostate cancer (n=34), triple-negative breast cancer (n=17), renal cell carcinoma (n=16), NSCLC (n=8), and bladder cancer (n=12). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I>Safety.</I> Interim data analysis as of the data <FONT STYLE="white-space:nowrap">cut-off</FONT> date of April&nbsp;13, 2017, indicates
that enoblituzumab is well-tolerated. Treatment-related AEs (per investigator assessment) were experienced by 134 out of 170 (78.8%) patients, most of which were infusion-related reactions (n=62, 36.5%), fatigue (n=54, 31.8%), nausea (n=32, 18.8%),
and chills (n=24, 14.1%). Only three out of 179 patients (1.7%) had a treatment-related discontinuation, and 13 (7.3%) patients experienced treatment-related Grade 3 or higher AEs (fatigue, infusion-related reactions, and nausea), assessed based on
Common Terminology Criteria for Adverse Events (CTCAE) criteria version 4.0. Mild to moderate infusion-related reactions were managed with low dose steroids or a decrease of the infusion rate. No severe immune-mediated toxicity was observed. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">171 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I>Pharmacokinetics</I>. Preliminary analysis and population PK modeling based on 18
patients dosed at 15&nbsp;mg/kg indicate that PK of enoblituzumab was characterized primarily by target-mediated drug disposition and was consistent with a typical human IgG1 with near-linear PK. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I>Efficacy</I>. Evidence of decreased size of target and <FONT STYLE="white-space:nowrap">non-target</FONT> lesions as well as extended time
to progression were observed across a broad range of tumors, including heavily pretreated cancers. Three patients achieved PR (partial responses) by RECIST out of a total of approximately 71 patients being evaluated. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><B><I>Phase 1 Study of Enoblituzumab in Combination with Pembrolizumab </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I>Study Design</I>. This is an open-label, dose escalation, cohort expansion, and efficacy <FONT STYLE="white-space:nowrap">follow-up</FONT>
study of enoblituzumab in combination with pembrolizumab conducted by MacroGenics. The dose escalation phase is designed to characterize the safety and tolerability of the combination and to define the maximum tolerated or maximum administered dose.
Three dose levels of enoblituzumab (3, 10, 15 mg/kg, IV, QW) have been evaluated in combination with pembrolizumab (2 mg/kg, IV, Q3W). No MTD has been identified, and so the maximum administered dose of enoblituzumab (15 mg/kg) in combination with
pembrolizumab was given to additional cohorts of patients enrolled during the cohort expansion phase. The efficacy <FONT STYLE="white-space:nowrap">follow-up</FONT> period consists of the <FONT STYLE="white-space:nowrap">two-year</FONT> period after
administering the final dose of the study drug. All tumor evaluations are carried out by both RECIST and irRC. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">A total of 133 patients
with <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">B7-H3-expressing</FONT></FONT> melanoma, squamous cell carcinoma of the head and neck (SCCHN), <FONT STYLE="white-space:nowrap">non-small</FONT> cell lung cancer
(&#147;NSCLC&#148;), and urothelial cancer have been treated in the study. The interim results as of the data <FONT STYLE="white-space:nowrap">cut-off</FONT> date, October&nbsp;12, 2018, were presented at the 2018 Annual Meeting of the Society for
Immunotherapy of Cancer (SITC), which showed an ORR (overall response rate) that compared favorably with historical experience with <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-1</FONT></FONT> monotherapy in <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-1/PD-L1</FONT></FONT></FONT> naive patients. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I>Safety</I>. The combination of enoblituzumab and pembrolizumab demonstrated acceptable tolerability in patients treated to date. Grade 3 or
higher AEs, assessed based on Common Terminology Criteria for Adverse Events (CTCAE) criteria version 4.0, occurred in 27.1% of all patients. Drug-related AEs of all grades included infusion-related reactions (n=73, 54.9%), fatigue (n=37, 27.8%),
rash (n=14, 10.5%), and nausea (n=12, 9.0%). The incidence of immune-related AEs in the study was comparable to that observed in patients who received anti <FONT STYLE="white-space:nowrap">PD-1</FONT> monotherapy. Nine patients experienced
drug-related AEs leading to treatment discontinuation. Drug-related AEs and immune-related AEs of special interest are summarized in the table below. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Drug-Related and Immune-Related Adverse Events </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>During Combination Treatment with Enoblituzumab and Pembrolizumab </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="72%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="53%"></TD>

<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>NO.&nbsp;(%)&nbsp;OF&nbsp;PATIENTS</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>DRUG-RELATED AES (&sup3; 5% OF<BR>PATIENTS)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>ALL&nbsp;GRADES&nbsp;TOTAL</B><br><B>(N=133)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B></B><FONT STYLE="FONT-FAMILY:SYMBOL">&#179;</FONT><B></B><B>&nbsp;GRADE&nbsp;3<BR>(N=133)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Any adverse event</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">115&nbsp;(86.5)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">36&nbsp;(27.1)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Infusion-related reaction</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">73 (54.9)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9 (6.8)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fatigue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">37 (27.8)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2 (1.5)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Rash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14 (10.5)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1 (0.8)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Nausea</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12 (9.0)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pyrexia</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12 (9.0)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Lipase increased</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11 (8.3)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8 (6.0)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Arthralgia</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10 (7.5)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Decreased appetite</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9 (6.8)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2 (1.5)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Diarrhea</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9 (6.8)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1 (0.8)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Hypothyroidism</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8 (6.0)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Anemia</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7 (5.3)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1 (0.8)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pneumonitis</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7 (5.3)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2 (1.5)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Chills</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7 (5.3)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">172 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="72%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="54%"></TD>

<TD VALIGN="bottom" WIDTH="14%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="14%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>NO.&nbsp;(%)&nbsp;OF&nbsp;PATIENTS</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>IMMUNE-RELATED ADVERSE EVENTS<BR>OF SPECIAL INTEREST
(AESI)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>ALL&nbsp;GRADES&nbsp;TOTAL</B><br><B>(N=133)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B></B><FONT STYLE="FONT-FAMILY:SYMBOL">&#179;</FONT><B></B><B>&nbsp;GRADE&nbsp;3<BR>(N=133)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pneumonitis</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5&nbsp;(3.8)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2&nbsp;(1.5)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Myocarditis</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2 (1.5)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1 (0.8)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Diarrhea</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1 (0.8)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1 (0.8)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Adrenal insufficiency</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1 (0.8)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1 (0.8)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Colitis</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1 (0.8)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Drug-related AEs:</I> </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="12%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Leading to treatment discontinuation: 6.8% (9 patients) </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="12%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Leading to death: 0.8% (1 patient with pneumonitis) </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Nature of events consistent with enoblituzumab or pembrolizumab alone </I> </P></TD></TR></TABLE>
<P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><I>Source:</I></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>MacroGenics. </I></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I>Clinical Efficacy</I>. As of October&nbsp;12, 2018, the <FONT STYLE="white-space:nowrap">cut-off</FONT> date of the most recent data
analysis, preliminary results indicated that among the 18 response-evaluable SCCHN patients who had not previously received <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">PD-1/PD-L1</FONT></FONT> therapies, six patients (33.3%)
had confirmed partial responses (&#147;PRs&#148;). Among the subset of patients with 10% or higher <FONT STYLE="white-space:nowrap">B7-H3</FONT> tumor expression, six out of 15 (40.0%) had confirmed PRs (see figure below) compared to previously
reported SCCHN patients treated with <FONT STYLE="white-space:nowrap">PD-1</FONT> monotherapy, which achieved ORRs ranging from 13% to 16%. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Anti-tumor Activity in <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">Anti-PD-1/PD-L1-Naive</FONT></FONT></FONT></FONT> SCCHN Patients </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g98473g27e81.jpg" ALT="LOGO">
 </P> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><I>Source:</I></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>MacroGenics </I></P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Among 14 response-evaluable NSCLC patients who had not previously received
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">PD-1/PD-L1</FONT></FONT> therapies and were <FONT STYLE="white-space:nowrap">PD-L1</FONT> negative, i.e., <FONT STYLE="white-space:nowrap">PD-L1</FONT> less or equal to 1%, five
patients (35.7%) had confirmed PRs (see figure below). Objective response rates ranging from 8% to 17% were reported in <FONT STYLE="white-space:nowrap">PD-L1</FONT> negative NSCLC patients treated with <FONT STYLE="white-space:nowrap">PD-1</FONT>
monotherapy. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">173 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Anti-tumor Activity in
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">PD-1-Naive</FONT></FONT> NSCLC Patients Who are <FONT STYLE="white-space:nowrap">PD-L1</FONT> Negative <FONT STYLE="white-space:nowrap">(PD-L1</FONT> &lt; 1%) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Tumor Volume Change from Baseline (%) </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g98473g05c03.jpg" ALT="LOGO">
 </P> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><I>Source:</I></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>MacroGenics </I></P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In the two figures above, CR (complete response) means the disappearance of all target lesions, with the reduction of all pathological lymph
nodes to &lt;10 mm; PR (partial response) means at least a 30% decrease in the sum of the target lesions, in comparison to the baseline sum diameter; PD (progressive disease) means a 20% increase in the sum of the diameters in comparison to the
smallest sum of diameters with an absolute increase of at least 5 mm, provided that any new lesion is considered progressive disease; and SD (stable disease) means meeting neither the criteria for partial response nor for progressive disease, in
comparison to the smallest sum of diameters. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><I>Clinical Development Plan </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We acquired the development and commercial rights of enoblituzumab from MacroGenics for Greater China. In the first quarter of 2021,
MacroGenics expects to initiate a Phase 2 study of enoblituzumab in a chemo-free regimen in combination with either retifanlimab (an investigational <FONT STYLE="white-space:nowrap">PD-1</FONT> antibody) in front-line patients with SCCHN who are <FONT
STYLE="white-space:nowrap">PD-L1</FONT> positive or with tebotelimab (an investigational <FONT STYLE="white-space:nowrap">PD-1</FONT> x <FONT STYLE="white-space:nowrap">LAG-3</FONT> bispecific
DART<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> antibody) in SCCHN patients who are <FONT STYLE="white-space:nowrap">PD-L1</FONT> negative. We expect to participate in any subsequent Phase 3 global study if and when initiated. In
addition, considering the dynamic regulatory environment and evolving clinical practice, we have been continually refining the development of enoblituzumab in our territory. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Global Portfolio </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><I>Plonmarlimab
(TJM2): A <FONT STYLE="white-space:nowrap">GM-CSF</FONT> Monoclonal Antibody for Rheumatoid Arthritis and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">CAR-T-related</FONT></FONT> Therapies </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><B><I>Summary </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Plonmarlimab is an internally discovered neutralizing antibody against human granulocyte-macrophage colony-stimulating factor <FONT
STYLE="white-space:nowrap">(&#147;GM-CSF&#148;),</FONT> an important cytokine that plays a critical role in chronic inflammation and destruction in autoimmune diseases such as rheumatoid arthritis (&#147;RA&#148;). Plonmarlimab is a humanized IgG1
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">174 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
that displays high affinity binding to <FONT STYLE="white-space:nowrap">GM-CSF</FONT> and blocks its signaling and downstream effects. Plonmarlimab is being developed for the treatment of
autoimmune and inflammatory diseases, including RA and cytokine release syndrome (&#147;CRS&#148;). We have completed a single-dose <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-human</FONT></FONT> study in healthy
volunteers in the United States. In China, plonmarlimab is the first antibody of its class entering clinical development. We dosed the first patient in a Phase 1b study of plonmarlimab in August 2020 in China. We may expand plonmarlimab to other
autoimmune and inflammatory indications with high unmet medical need, where <FONT STYLE="white-space:nowrap">GM-CSF</FONT> is known as a pathogenic cytokine in disease activity and progression. If approved, plonmarlimab is expected to provide an
effective treatment option as a disease-modifying anti-rheumatic drug (&#147;DMARD&#148;) therapy. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In addition, since the <FONT
STYLE="white-space:nowrap">COVID-19</FONT> outbreak, we have sprung into action to prioritize plonmarlimab in response to the urgent medical needs. In May 2020, we announced preliminary results from part 1 of a clinical study in the United States of
plonmarlimab in patients with cytokine release syndrome (CRS) associated with severe <FONT STYLE="white-space:nowrap">COVID-19,</FONT> in which plonmarlimab was found to be well tolerated. We are currently conducting part 2 of this clinical trial to
evaluate the efficacy, safety and cytokine levels following a single dose of 6 mg/kg plonmarlimab or placebo (standard care) in patients with severe <FONT STYLE="white-space:nowrap">COVID-19.</FONT> We are currently in discussion with the FDA to
finalize the plan for plonmarlimab in relation to clinical development and potential registration in the United States. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><B><I>Therapeutic
Options and Current Development </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our current therapeutic indication is RA, a systemic chronic inflammatory disease considered to
be one of the most prevalent immune-mediated inflammatory diseases. RA is nearly always polyarticular and causes joint destruction, deformity, and loss of function. Extra-articular manifestations include cardiopulmonary diseases, eye diseases,
Sjogren&#146;s syndrome, rheumatoid vasculitis and neurological diseases. Current therapies for RA in China include traditional Chinese medicine, corticosteroids, and DMARDs, including immunosuppressants and targeted therapies such as TNF
inhibitors. Although the market for RA has become more competitive in China, new medicines targeting different pathways with greater clinical efficacy and safety remain a significant unmet need. Our <FONT STYLE="white-space:nowrap">GM-CSF</FONT>
antibody targets an entirely different disease pathway and has these desired characteristics to treat RA. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Clinical evidence supporting
the role of a <FONT STYLE="white-space:nowrap">GM-CSF</FONT> antibody in RA is highlighted in a few recent global studies. For example, both otilimab (MOR103), a <FONT STYLE="white-space:nowrap">GM-CSF</FONT> antibody from MorphoSys and GSK, and
mavrilimumab, a GM-CSF receptor antibody from Medimmune, have shown an early onset of clinical responses in Phase 2 <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">proof-of-concept</FONT></FONT> trials with RA patients. In addition
to RA, attempts to develop a <FONT STYLE="white-space:nowrap">GM-CSF</FONT> antibody for treating other autoimmune diseases, such as ankylosing spondylitis, are being studied by Amgen and Takeda. These autoimmune conditions involve the same
autoimmune cell types, including macrophages, and neutrophils and the same connective tissues such as bones, joints, and tendons. Given the large patient population affected and the burden of these diseases, we are keen to explore the therapeutic
role of plonmarlimab in treating these diseases, if initial studies in RA patients meet primary <FONT STYLE="white-space:nowrap">end-points.</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The therapeutic role of plonmarlimab goes beyond autoimmune diseases. A recent study indicates that
<FONT STYLE="white-space:nowrap">GM-CSF</FONT> plays a critical role in serious side effects associated with chimeric antigen receptor <FONT STYLE="white-space:nowrap">(CAR)-T</FONT> therapy, such as cytokine release syndrome (&#147;CRS&#148;) and
neurotoxicity. As <FONT STYLE="white-space:nowrap">CAR-T</FONT> therapy has become an effective treatment option for certain cancer types, finding a treatment solution for
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">CAR-T-related</FONT></FONT> toxicities that occur frequently and can turn into a serious and potentially fatal condition becomes an urgent need. These severe toxicities add to the
morbidity and mortality of <FONT STYLE="white-space:nowrap">CAR-T</FONT> therapy. CRS is caused by a massive release of circulating cytokines by expanding <FONT STYLE="white-space:nowrap">CAR-T</FONT> cells, and
<FONT STYLE="white-space:nowrap">GM-CSF</FONT> is one of the key cytokines of CRS. Currently, there are no effective therapies to prevent CRS or neurotoxicity. Tocilizumab, an <FONT STYLE="white-space:nowrap">IL-6</FONT> receptor antagonist, is
approved for severe CRS with limited therapeutic coverage. Recent studies indicate that neutralizing <FONT STYLE="white-space:nowrap">GM-CSF</FONT> in vivo may ameliorate and potentially prevent CRS and neuroinflammation without affecting <FONT
STYLE="white-space:nowrap">CAR-T</FONT> cell activity. Humanigen has teamed up with Kite to evaluate lenzilumab, a <FONT STYLE="white-space:nowrap">GM-CSF</FONT> antibody, as a preventive or treatment
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">175 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
agent in association with Yescarta, an approved CD19-directed <FONT STYLE="white-space:nowrap">CAR-T</FONT> therapy. In parallel with an RA clinical trial, we are seeking opportunities to <FONT
STYLE="white-space:nowrap">co-develop</FONT> plonmarlimab as a treatment option for CRS associated with <FONT STYLE="white-space:nowrap">CAR-T</FONT> therapy. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Furthermore, emerging data indicate that the common features among <FONT STYLE="white-space:nowrap">COVID-19</FONT> patients particularly
those severely or critically ill include lymphopenia and significantly elevated serum levels of <FONT STYLE="white-space:nowrap">pro-inflammatory</FONT> cytokines including <FONT STYLE="white-space:nowrap">GM-CSF</FONT> and <FONT
STYLE="white-space:nowrap">IL-6,</FONT> <FONT STYLE="white-space:nowrap">IFN-gamma.</FONT> Moreover, recently published data indicate that <FONT STYLE="white-space:nowrap">COVID-19</FONT> can induce a cytokine storm instigated by extensive immune
cell infiltration and the release of <FONT STYLE="white-space:nowrap">GM-CSF</FONT> and <FONT STYLE="white-space:nowrap">IL-6.</FONT> These inflammatory cytokines drive aberrant activation of monocytes and lymphocytes which in turn provoke increased
production of more cytokines and chemokines in a feed forward cycle, resulting in the cytokine storm, or CRS, severe pulmonary complications and mortality. Therefore, blocking of <FONT STYLE="white-space:nowrap">GM-CSF</FONT> by plonmarlimab may
impact the upstream of cytokine storm network to prevent or curb the hyperinflammation and immunopathology which may be responsible for the complications associated with severe <FONT STYLE="white-space:nowrap">COVID-19.</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><B><I>Advantages of Plonmarlimab </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Based on reported clinical findings with front-runner <FONT STYLE="white-space:nowrap">GM-CSF</FONT> antibodies compared to other RA biologics
that are clinically used, we have the following expectations: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Fast onset of therapeutic effect. <I>Because <FONT STYLE="white-space:nowrap">GM-CSF</FONT> acts at a relatively
early stage in the inflammatory cascade, <FONT STYLE="white-space:nowrap">GM-CSF</FONT> blockade is expected to take effect after just a few initial doses and provide quick symptomatic relief to patients. This fast onset of clinical responses in RA
has been shown in Phase 2 clinical trials on otilimab and mavrilimumab (NCT01023256 and NCT01050998);</I> </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Convenience and increased patient compliance. <I>Given the favorable development profile (high affinity,
excellent PK, clean immunogenicity and concentrated formulation) exhibited by plonmarlimab thus far, the clinically active dose for plonmarlimab is expected to be low, which is advantageous for chronic maintenance of the disease by subcutaneous
administration. This provides convenience to the patients and will likely increase patient compliance; and</I> </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Analgesic effect on inflammatory pain. <I>Because the <FONT STYLE="white-space:nowrap">GM-CSF</FONT> receptor is
also expressed on sensory neurons and is involved in <FONT STYLE="white-space:nowrap">RA-associated</FONT> inflammatory pain, <FONT STYLE="white-space:nowrap">GM-CSF</FONT> blockade is expected to provide relieffor inflammatory pain, which provides
additional clinical benefits to patients. This analgesic effect has been shown in a Phase 2 clinical trial on mavrilimumab (NCT01706926).</I> </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><B><I>Mechanism of Action </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">GM-CSF</FONT> is a central driver cytokine in orchestrating an innate immune response during inflammation. It
is responsible for myeloid cell proliferation and functions, such as chemotaxis, adhesion, phagocytosis, and microbial killing. Importantly, <FONT STYLE="white-space:nowrap">GM-CSF</FONT> can polarize macrophages into a <FONT
STYLE="white-space:nowrap">pro-inflammatory</FONT> M1 phenotype and is known to induce an inflammatory cascade involving other <FONT STYLE="white-space:nowrap">pro-inflammatory</FONT> cytokines such as TNF,
<FONT STYLE="white-space:nowrap">IL-1,</FONT> <FONT STYLE="white-space:nowrap">IL-6,</FONT> <FONT STYLE="white-space:nowrap">IL-12,</FONT> and <FONT STYLE="white-space:nowrap">IL-23.</FONT> It is evident that
<FONT STYLE="white-space:nowrap">GM-CSF</FONT> plays a crucial role in the pathogenesis and disease progression of multiple autoimmune conditions. The action of <FONT STYLE="white-space:nowrap">GM-CSF</FONT> is mediated by binding of its cognate
receptor on target cells and subsequent phosphorylation of signal transducer and activator of transcription 5 (&#147;STAT5&#148;). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">176 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Plonmarlimab specifically binds to human <FONT STYLE="white-space:nowrap">GM-CSF</FONT> with
high affinity and can block <FONT STYLE="white-space:nowrap">GM-CSF</FONT> from binding to its receptor, thereby preventing downstream signaling and target cell activation. As a result, it can effectively inhibit inflammatory responses mediated by
macrophages, neutrophils, and dendritic cells, leading to reduced tissue inflammation and damage. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g98473g93q99.jpg" ALT="LOGO">
 </P> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><I>Figure:</I></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>Role of <FONT STYLE="white-space:nowrap">GM-CSF</FONT> in orchestrating coordinated immune response.
</I></P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><B><I>Summary of <FONT STYLE="white-space:nowrap">Pre-clinical</FONT> Results </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">A series of nonclinical studies have been conducted to evaluate the pharmacology, PK, and toxicology profiles of plonmarlimab. Plonmarlimab
could potently bind to human and monkey <FONT STYLE="white-space:nowrap">GM-CSF</FONT> but not rodent <FONT STYLE="white-space:nowrap">GM-CSF.</FONT> Plonmarlimab neutralized <FONT STYLE="white-space:nowrap">GM-CSF</FONT> in a number of
pharmacological studies in vitro and in vivo. Plonmarlimab demonstrated linear PK behavior in single dose IV and SC studies in monkeys with a half-life characteristic of IgG and a low ADA potential. Weekly plonmarlimab treatment significantly
reduced arthritis score and clinical symptoms in monkeys with established collagen-induced arthritis (a model of RA). Both <FONT STYLE="white-space:nowrap">4-week</FONT> and <FONT STYLE="white-space:nowrap">13-week</FONT> repeat-dose GLP general
toxicology studies in <FONT STYLE="white-space:nowrap">non-human</FONT> primates have been completed with sufficient safety margin. The nonclinical studies performed to date continue to support plonmarlimab in clinical studies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><B><I>Summary of Clinical Results </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><I>Completed single-dose <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-human</FONT></FONT> study in healthy
volunteers in the United States </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Based on the <FONT STYLE="white-space:nowrap">pre-clinical</FONT> results, we initiated a <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-human</FONT></FONT> study in healthy volunteers in the United States (NCT03794180). This study has now been completed with a clinical study report (CSR) available. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Study design. This randomized, double-blind, placebo-controlled, and single dose-ascending study was designed to assess the safety,
tolerability, PK/PD, and immunogenicity of plonmarlimab (referred to as TJ003234) in healthy volunteers. We have enrolled and completed dosing of four planned cohorts at 0.3, 1, 3 and 10 mg/kg dose levels, with each cohort consisting of eight
subjects randomized into six receiving plonmarlimab and two receiving placebo IV infusions. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">177 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I>Safety</I>. Plonmarlimab was well tolerated following a single IV dose up to 10 mg/kg in
healthy subjects with no MTD reached. There were no interruptions in dosing or early withdrawals. Fourteen males and 18&nbsp;females participated in the study. The majority of AEs were mild to moderate in nature. No serious adverse events were
reported during the study. Overall, 8 of the 24 subjects who received plonmarlimab and 3 of the 8&nbsp;subjects on placebo reported treatment-related treatment-emergent adverse events (TEAEs). The most common AEs experienced by subjects dosed with
plonmarlimab were headache (25%) and protein urine (25%). These AEs were also the most common AEs reported by subjects receiving placebo (37.5% and 37.5%, respectively). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I>Pharmacokinetics</I>. Serum concentrations of plonmarlimab (TJ003234) were determined by anti-idiotypic antibody capture immunoassay and PK
parameters were analyzed by noncompartmental analysis. Results showed that over the dose range of 0.3 mg/kg to 10 mg/kg, both C<SUB STYLE="font-size:85%; vertical-align:bottom">max</SUB> and exposure increased in an approximately dose-proportional
manner, with C<SUB STYLE="font-size:85%; vertical-align:bottom">max</SUB> increased from 5.75 j.tg/mL to 260 j.tg/mL and AUC0-last increased from 90.5 day*j.tg/mL to 3780 day*j.tg/mL (see Figure below). In addition, t<SUB
STYLE="font-size:85%; vertical-align:bottom">1/2</SUB> was approximately 3&nbsp;weeks across the tested dose range. Clearance of plonmarlimab decreased with increasing dose. Volume of distribution decreased slightly with increasing dose. In terms of
immunogenicity, two subjects in the 3 mg/kg plonmarlimab cohort and 1 placebo subject were positive for ADA. No subject in the 10 mg/kg dose level was positive for ADA. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g98473g02s93.jpg" ALT="LOGO">
 </P> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><I>Figure:</I></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>Mean&plusmn;SD concentration-time plots of serum plonmarlimab (TJ003234) levels. Linear scale, left; <FONT
STYLE="white-space:nowrap">semi-log</FONT> scale, right. LLOQ, lower limit of quantitation. </I></P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I>Pharmacodynamics</I>. Four hours after dosing, the induction of STAT5 phosphorylation by ex vivo
<FONT STYLE="white-space:nowrap">GM-CSF</FONT> in circulating monocytes was inhibited by at least 70% compared to the placebo following a single dose of plonmarlimab for all dose groups. Plonmarlimab inhibited <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">GM-CSF-stimulated</FONT></FONT> STAT5 phosphorylation levels by more than 90% in subjects in the 3 mg/kg and 10 mg/kg cohorts at 4 h to up to 2 weeks after dosing, suggesting the saturation of STAT5 inhibition by the
treatment at doses of 3 mg/kg and above. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><I>Ongoing study for plonmarlimab to treat <FONT STYLE="white-space:nowrap">COVID-19</FONT>
patients with cytokine release syndrome </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We are conducting a study of plonmarlimab in the United States in patients with CRS
associated with severe <FONT STYLE="white-space:nowrap">COVID-19.</FONT> This study adopts a robust clinical trial design and represents one of the first double-blind, placebo-controlled and randomized studies to evaluate the therapeutic role of <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-GM-CSF</FONT></FONT> antibody in severe <FONT STYLE="white-space:nowrap">COVID-19</FONT> patients. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Part 1 of the study evaluated the safety and tolerability of plonmarlimab in a total of 24 patients who were randomized at a ratio of 1:1:1 to
receive either a single dose of 3 mg/kg plonmarlimab, a single dose of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">178 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
6&nbsp;mg/kg plonmarlimab or placebo (standard care), administered by intravenous (IV)&nbsp;infusion. Data from part 1 of the study were reviewed by a data monitoring committee (DMC) to assess
patient safety and overall conduct of the study. After comprehensive review and analysis, the DMC concluded that we could commence part 2 of the study as planned, indicating that plonmarlimab was safe and well-tolerated in severe <FONT
STYLE="white-space:nowrap">COVID-19</FONT> patients in the study. The DMC also endorsed recommended protocol changes, including broadening the inclusion criteria and dosing all patients at 6 mg/kg of plonmarlimab or placebo. Part 2 of the study with
a design similar to part 1 will target the same patient population and is enrolling patients. It will evaluate the efficacy, safety and cytokine levels following a single dose of 6mg/kg plonmarlimab or placebo in patients with severe <FONT
STYLE="white-space:nowrap">COVID-19.</FONT> To preserve the original clinical trial design with blinding and data integrity, the clinical efficacy data will be revealed upon completing part 2 of this study. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">DMC&#146;s assessment and positive recommendation is a testament to our science-focused clinical development capabilities. We believe we have
the most advanced <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-GM-CSF</FONT></FONT> study in <FONT STYLE="white-space:nowrap">COVID-19</FONT> that could potentially lead to registration of plonmarlimab in the United States.
The DMC&#146;s confirmation of plonmarlimab&#146;s safety profile bolsters the drug&#146;s potential to address the complications among the severe and critically ill and could ultimately save lives. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><B><I>Clinical Development Plan </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Data from this <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-human</FONT></FONT> study support continued
development of plonmarlimab. In August 2020, we announced that the first patient has been dosed in a Phase 1b study to evaluate plonmarlimab in patients with RA in China. This trial is a multi-center, double-blind, placebo-controlled study of about
63 patients who will receive a single dose or multiple doses of the treatment for up to eight weeks. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In addition, we are developing
plonmarlimab to treat cytokine storm in severe and critically ill patients caused by <FONT STYLE="white-space:nowrap">COVID-19.</FONT> We are currently conducting part 2 of the clinical trial in the United States to evaluate the efficacy, safety and
cytokine levels following a single dose of 6 mg/kg plonmarlimab or placebo (standard care) in patients with severe <FONT STYLE="white-space:nowrap">COVID-19.</FONT> We are currently in discussion with the FDA to finalize the plan for plonmarlimab in
relation to clinical development and potential registration in the United States. The results from these planned <FONT STYLE="white-space:nowrap">COVID-19</FONT> studies will also be used to further evaluate the potential therapeutic role of
plonmarlimab in reducing or preventing cytokine storm and neurotoxicity associated with <FONT STYLE="white-space:nowrap">CAR-T</FONT> therapy through collaborations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Lemzoparlimab (TJC4): A Potential Highly Differentiated CD47 Antibody for Immuno-Oncology </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><I>Summary </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Lemzoparlimab
is a fully human CD47 monoclonal antibody that we have discovered and developed internally for cancer immunotherapy. CD47 has emerged as one of the most promising immuno-oncology targets. Unlike other immuno-oncology targets being explored, the
CD47-SIRPa pathway is involved in tumor progression by delivering a &#147;don&#146;t eat me&#148; signal to tumor-engulfing macrophages, thereby protecting tumors from natural attacks by macrophages. Blockade of this pathway by CD47 antibody
represents one of the most effective tumor killing mechanisms. However, due to the inherent epitope sharing between tumor cells and normal red blood cells (&#147;RBCs&#148;), the first-wave of clinical stage CD47 antibodies were found in clinical
trials to bind to RBCs and cause significant hematologic adverse effects, such as severe anemia, which has hampered the development of these CD47 antibodies as a potential cancer therapy. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We developed lemzoparlimab by design to possess a unique property or differentiation, to minimize binding to RBCs while retaining anti-tumor
activities in line with other antibodies of the same class. This key differentiation is achieved through additional RBC counter-screening to select rare antibody clones that bind to CD47 with high affinity but do not bind to or bind minimally to
RBCs. Lemzoparlimab has been validated in a series of in vitro and in vivo <FONT STYLE="white-space:nowrap">pre-clinical</FONT> studies, which have consistently shown a unique <FONT STYLE="white-space:nowrap">RBC-sparing</FONT> profile
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">179 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
comprised of minimal RBC binding, lack of hemagglutination and no significant adverse hematologic changes in cynomolgus monkeys even when used at a high dose (100 mg/kg). In addition, the topline
results of the completed Phase 1a dose escalation monotherapy trial in the United States have demonstrated the differentiated profile of lemzoparlimab in drug safety and favorable pharmacokinetics in cancer patients. The key findings include:
(i)&nbsp;lemzoparlimab was well tolerated up to 30 mg/kg on a weekly basis without priming dosing strategy, and no dose-limiting toxicity and no clinical or laboratory evidence of hemolytic anemia were observed throughout; (ii)&nbsp;lemzoparlimab PK
appears to be linear at mid to high dose levels following a single dose with no significant &#147;sink effect&#148; and (iii)&nbsp;one confirmed partial response (PR) was observed in the 30 mg/kg monotherapy cohort (N=3), and this patient had failed
prior treatments with checkpoint inhibitors. Therefore, we believe that lemzoparlimab, if approved, will be a potentially highly differentiated anti-tumor CD47 antibody with the advantage of minimizing hematologic side effects. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In September 2020, we received the NMPA approval for a Phase 1 clinical trial of lemzoparlimab in relapsed or refractory advanced lymphoma in
China as part of the ongoing international multi-center trial. In addition, lemzoparlimab is being evaluated in a Phase 1/2a clinical trial in China in patients with relapsed or refractory acute myeloid leukemia (r/r AML) or myelodysplastic syndrome
(MDS), and we anticipate reporting <FONT STYLE="white-space:nowrap">top-line</FONT> results in early 2021. We have also entered into a clinical trial collaboration and supply agreement with Merck Sharp&nbsp;&amp; Dohme Corp, or MSD, through a
subsidiary, under which we will sponsor a Phase 1 clinical trial in the United States evaluating lemzoparlimab in combination with KEYTRUDA<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> (pembrolizumab), MSD&#146;s <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-1</FONT></FONT> therapy, in patients with multiple types of solid tumors. In September 2020, we granted AbbVie a global license, excluding Mainland China, Hong Kong and Macau, to
develop and commercialize lemzoparlimab (as well as certain other compounds directed against CD47), and we will retain all rights to develop and commercialize lemzoparlimab in Mainland China, Hong Kong and Macau. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><I>Therapeutic Options and Current Development </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We plan to evaluate the therapeutic role of lemzoparlimab in a variety of solid tumors, such as cancers of the ovary, lung, liver, pancreas,
breast and colon, and hematological malignancies such as AML/MDS, lymphoblastic leukemia, and NHL. Although <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">PD-1/PD-L1</FONT></FONT> therapies represent a new paradigm in cancer
treatment, less than 40% of cancer patients have a clinically meaningful response to <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">PD-1/PD-L1</FONT></FONT> treatment. As a result, targeting other immune components or cells
involved in the immune system&#146;s anti-tumor mechanism has become an area of active pursuit in the field of immuno-oncology. Lemzoparlimab is one such innovative and promising therapeutic antibody, which is capable of mobilizing macrophage
functions for effective and direct tumor-killing. Currently, a number of CD47 antibodies are in clinical development by biotech companies including Gilead/Forty-Seven, Inc., Surface Oncology and Arch Oncology. The most advanced asset, magrolimab,
orginally developed by from Forty-Seven, Inc., is in Phase 3 clinical studies for multiple cancer indications. However, almost all clinical trials with CD47 antibodies so far have shown significant hematologic adverse effects, likely due to inherent
<FONT STYLE="white-space:nowrap">RBC-binding</FONT> properties of generic CD47 antibodies, and as a result, some clinical studies had to be either terminated or managed with extra cautions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><I>Advantages of Lemzoparlimab </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Lemzoparlimab has similar <FONT STYLE="white-space:nowrap">sub-nanomolar</FONT> binding affinity as other CD47 antibodies and exhibits
comparable anti-tumor activity. The key advantage of lemzoparlimab is its minimal binding to RBCs, thus potentially avoiding or minimizing inherent hematologic adverse effects typically seen in other CD47 antibodies in clinical trials. This
differentiated property of lemzoparlimab is, at least in part, due to its unique epitope interaction as revealed by crystallography, which is different from those recognized by other CD47 antibodies currently in clinical development based on
publicly available information. The differentiation of lemzoparlimab is highlighted in a series of <FONT STYLE="white-space:nowrap">pre-clinical</FONT> studies summarized as the following: (i)&nbsp;lemzoparlimab displays only minimal <FONT
STYLE="white-space:nowrap">RBC-binding</FONT> even at high antibody concentrations by flow cytometry; (ii)&nbsp;lemzoparlimab does not induce RBC agglutination even in a high concentration range; and (iii)&nbsp;most importantly, lemzoparlimab does
not cause significant hematologic changes or systemic toxicologic effects even at high doses in multiple cynomolgus </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">180 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
monkey studies, including a pivotal <FONT STYLE="white-space:nowrap">4-week</FONT> GLP toxicity study. Taken together, lemzoparlimab has a potentially better clinical safety profile and may be
used in a broader patient population to explore its anti-tumor potential compared to other clinical stage competitor molecules. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g98473g57c81.jpg" ALT="LOGO">
 </P> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><I>Table:</I></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>Differentiated product profile of lemzoparlimab. (Sources for comparator antibodies: American Society
ofHematology publication, PLOS One publication, World Intellectual Property Organization and company data) </I></P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">181 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><I>Mechanism of Action </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Lemzoparlimab blocks the interaction between CD47 expressed on cancer cells and SIRPa expressed on macrophages, leading to increased
phagocytosis of cancer cells by macrophages. Blockade of CD47 by lemzoparlimab may also promote the development of anti-tumor T cell responses, resulting from increased tumor antigen presentation by professional antigen-presenting cells such as
macrophages and dendritic cells. In addition to stimulating the phagocytosis of cancer cells, CD47 blockade was shown to involve other anti-tumor mechanisms, such as the enhancement of ADCC, direct induction of apoptosis (programmed cell death) of
cancer cells, induction of differentiation of cancer stem cells, and inhibition of metastasis. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g98473g21v73.jpg" ALT="LOGO">
 </P> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><I>Figure:</I></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>Targeting the CD47/SIRPa myeloid-specific immune checkpoint. CD47 is highly expressed on many different
types of cancers. SIRPa is an inhibitory receptor expressed on macrophages and other myeloid immune cells. When CD47 binds to SIRPa, it causes the inhibition ofphagocytosis. CD47 antibodies disrupt the CD47/SIRPa axis and enable the phagocytosis of
cancer cells. </I></P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><I>Summary of Clinical Results </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The ongoing phase 1 study of lemzoparlimab in the US is an open-label, multi-center, multiple dose study conducted in two parts to determine
safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and efficacy of lemzoparlimab administered alone and in combination (NCT03934814). The first part is comprised of a single agent dose escalation followed by two separate combination
regimens in an escalating dose range (Part 1b with pembrolizumab; Part 1c with rituximab). The second part is a dose expansion study in the combination therapies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The monotherapy dose escalation (Part 1a) has been completed and the initial data from the monotherapy were presented at Society for
Immunotherapy of Cancer (SITC) in November 2020 (poster #385). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Lemzoparlimab was well tolerated up to 30 mg/kg on a weekly infusion
schedule without priming dosing strategy. No dose-limiting toxicity and no clinical or laboratory evidence of hemolytic anemia were observed throughout. Maximal tolerable dose (MTD) was not reached. Lemzoparlimab PK appeared to be linear at mid to
high dose levels following a single dose with no significant &#147;sink effect&#148;. One confirmed Partial Response (PR) was observed in the 30 mg/kg cohort (n=3). This patient had failed prior treatments with checkpoint inhibitors. Three patients
achieved Stable Disease (SD). Recruitment of patients for the dose escalation study of lemzoparlimab in combination with pembrolizumab or rituximab is ongoing. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">182 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><I>Part 1a of Phase 1 Clinical Trial: Single Agent Dose Escalation <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">First-in-patient</FONT></FONT> Trial </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I>Study Design</I>. NCT03934814 is
an open label, Phase 1 study to evaluate the safety, tolerability, maximal tolerable dose (MTD) or maximum administered dose (MAD), PK, PD, and recommended phase 2 dose (RP2D) of lemzoparlimab in subjects with advanced relapsed or refractory solid
tumors and lymphoma. Part 1 of the study comprises a single agent dose escalation in a standard 3+3 design (1a) and 2 separate dose escalations in combination with pembrolizumab (1b) or rituximab (1c). Part 2 is a dose expansion study. Lemzoparlimab
was administered as weekly IV infusions in successive dose cohorts (1, 3, 10, 20 and 30 mg/kg) without any priming dose. Twenty patients were enrolled. Clinical data from the Part 1a study were reported as of November 2020. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I>Safety</I>. No dose limited toxicities (DLTs) or drug-related severe adverse event (SAE) were reported throughout the study. All
treatment-related adverse events (TRAEs) were either Grade 1 or Grade 2 except one Grade 3 lipase increase was reported. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g98473g97t57.jpg" ALT="LOGO">
 </P> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><I>Table.</I></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>Treatment-related adverse events (TRAE) by cohort. </I></P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">A transient reduction in the hemoglobin levels during the first cycle was observed across all cohorts. The average drop was ~10% and was not
dose dependent. This finding is consistent with the results of <FONT STYLE="white-space:nowrap">pre-clinical</FONT> GLP toxicity studies. None of the drug-related anemia reported was considered to be severe or hemolytic in nature. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g98473g78e43.jpg" ALT="LOGO">
 </P> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><I>Figure.</I></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>Time course of hemoglobulin and reticulocyte counts following lemzoparlimab treatment (all groups). Each
cycle (C)&nbsp;is 21 days (D). Mean&plusmn;SD is shown. </I></P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">183 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I>Pharmacokinetics</I>. The PK profile of lemzoparlimab appeared linear at doses higher
than 10 mg/kg following a single dose administration, while its exposure was greater than dose proportional over the dose range of 1 to 10 mg/kg, suggesting that at higher doses, lemzoparlimab could overcome the CD47 &#147;sink effect&#148;. Five
subjects were confirmed positive for anti-drug antibodies (ADA) following the first treatment: 3 were from 1&nbsp;mg/kg, 1 from 3 mg/kg and 1 from 10 mg/kg. No impact of ADA was seen on safety or PK profiles. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I>Pharmacodynamics. </I>Maximal saturation of CD47 receptor occupancy (RO) on peripheral T cells was achieved at 20 and 30 mg/kg following
weekly administration of lemzoparlimab. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I>Preliminary Efficacy</I>. One confirmed Partial Response (PR) was observed in the 30 mg/kg
monotherapy cohort (1/3) with 6 cycles completed so far. The patient who had metastatic melanoma had failed prior systemic treatment of nivolumab and ipilimumab. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><I>Summary of <FONT STYLE="white-space:nowrap">Pre-clinical</FONT> Results </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><B><I>CD47-related In Vitro and In Vivo Anti-tumor Activities </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Lemzoparlimab exhibits high-affinity binding to human CD47 protein and CD47-expressing tumor cells at the nanomolar level and effectively
blocks interaction of CD47 with its receptor SIRPa. As compared with other CD47 antibodies currently under clinical development, lemzoparlimab (TJC4) demonstrated comparable potency in the enhanced macrophage-mediated phagocytosis of Raji tumor
cells (see Figure A below) and comparable anti-tumor activity in the <FONT STYLE="white-space:nowrap">HL-60</FONT> leukemia and Raji xenograft models (see Figure B below). Moreover, when combined with rituximab, lemzoparlimab exhibited a markedly
enhanced inhibition on tumor growth in a diffuse large B cell lymphoma (DLBCL) animal model, through the synergistic effect of both agents (see Figure C below). </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g98473g30a67.jpg" ALT="LOGO">
 </P> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><I>Figure:</I></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>In vitro and in vivo anti-tumor activity of lemzoparlimab (TJC4). (A) In vitro phagocytosis of Raji cells by
primary human macrophages in the presence of different doses of lemzoparlimab or comparator CD47 antibodies. (B)&nbsp;In vivo anti-tumor activity of lemzoparlimab mono-treatment in Raji xenograft model. (C)&nbsp;In vivo anti-tumor activity of
lemzoparlimab (5 mg/kg, BIW) in combination with Rituximab (5 mg/kg, BIW) in the DLBCL model. </I></P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">184 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><B><I>Assessment of Potential CD47-related In Vitro and In Vivo Hematologic Effects
</I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">First, in a representative flow cytometric analysis (see Figure A below), lemzoparlimab showed minimal binding to human RBCs
compared to comparator CD47 antibodies used at the same concentration (1 j.tg/ml). The minimal binding of lemzoparlimab to RBCs was confirmed when compared with other CD47 antibodies across multiple concentrations in another flow cytometric
experiment (see Figure B below). </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g98473g99f98.jpg" ALT="LOGO">
 </P> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><I>Figure:</I></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>Binding of CD47 monoclonal antibodies to RBCs. (A)&nbsp;Representative graph of the staining of human RBCs
with CD47 monoclonal antibodies or control IgG (1 &micro;g/ml); (B) Dose dependent binding of CD47 monoclonal antibodies with human RBCs from different healthy donors (n = 3). MFI: mean fluorescence intensity. </I></P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Second, as CD47 is expressed on normal RBCs, binding of CD47 antibodies to the surface of RBCs could cross-link the RBCs into lattices and
prevent them from precipitating into compact pellets, which is a phenomenon termed hemagglutination. Our results showed that lemzoparlimab did not induce RBC agglutination across a wide range of antibody concentrations, while a comparator antibody
caused significant hemagglutination starting at a concentration of 0.3 j.tg/ml. Results from a representative experiment are shown below. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g98473g11b01.jpg" ALT="LOGO">
 </P> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><I>Figure:</I></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>Hemagglutination by CD47 monoclonal antibodies. Left: representative graph of hemagglutination (haze
appearance) or lack thereof (precipitate) by different concentrations of control IgG, lemzoparlimab (TJC4), and comparator antibodies. Right: quantification through an index determined by the area of RBC occupation in the presence of the test
antibodies, normalized to that of IgG control. </I></P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">185 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Thirdly, <I>in vivo </I>safety studies were performed in cynomolgus monkeys to assess the
effects of lemzoparlimab on the hematology parameters. Whereas a single bolus IV injection of the comparator antibody caused a significant drop in the number of RBCs and hemoglobin (&#147;HGB&#148;) levels, treatment with lemzoparlimab at a dose of
10 mg/kg did not significantly affect the number of RBCs, HGB levels or reticulocyte or platelet counts (see figure below). </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g98473g61p76.jpg" ALT="LOGO">
 </P> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><I>Figure:</I></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>Hematological parameters in <FONT STYLE="white-space:nowrap">non-human</FONT> primates treated with a single
dose of CD47 antibodies. On Day 0, naive cynomolgus monkeys were IV injected with PBS control (n=2), lemzoparlimab (TJC4) (n=2, 10 mg/kg) or a comparator antibody (n=2, 10 mg/kg). Blood cells were counted, twice before drug injection (baseline) and
at 3, 6, 10, 14 and 21 days post-injection. </I></P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Moreover, in a four-week GLP toxicology study, lemzoparlimab treatment
did not induce significant overall toxicologic changes. Only mild decreases in the number of RBCs, HGB and hematocrit were found, which reached nadir at Day 4 post-first administration and then gradually recovered to the normal range following
administration. The changes were not dose-dependent. Compared with the placebo control, the average decrease of RBCs in the treated animals was approximately 6% to 9% with only one animal showing an 18% drop at a dose of 30 mg/kg. No <FONT
STYLE="white-space:nowrap">RBC-associated</FONT> changes were noted in histopathologic examinations or in bone marrow smears (including erythrocytic series). Therefore, NOAEL was defined at 100 mg/kg. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Four-week GLP Toxicology Study in Monkeys </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g98473g61w04.jpg" ALT="LOGO">
 </P> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><I>Figure:</I></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>RBC counts in male cynomolgus monkeys treated with five consecutive weekly dose of lemzoparlimab (TJC4) at <FONT
STYLE="white-space:nowrap">0-100</FONT> mg/kg in a <FONT STYLE="white-space:nowrap">4-week</FONT> GLP toxicology study. </I></P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">186 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Key preclinical data described above have been published as a poster presentation (#4063) at
American Society of Hematology 2019 Annual Meeting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><B><I>Clinical Development Plan </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The goal of our global and China clinical development plans is to explore the potential in both hematologic malignancies and solid tumor
indications, including but not limited to AML/MDS, ovarian cancer and gastric cancer, in both the United States and China. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In September
2020, we received the NMPA approval for a Phase 1 clinical trial of lemzoparlimab in relapsed or refractory advanced lymphoma in China as part of the ongoing international multi-center trial. In addition, lemzoparlimab is being evaluated in a Phase
1/2a clinical trial in China in patients with relapsed or refractory (r/r) AML or MDS, and we anticipate reporting <FONT STYLE="white-space:nowrap">top-line</FONT> results in early 2021. We have also entered into a clinical trial collaboration and
supply agreement with Merck Sharp&nbsp;&amp; Dohme Corp, or MSD, through a subsidiary, under which we will sponsor a Phase 1 clinical trial in the United States evaluating lemzoparlimab in combination with KEYTRUDA<SUP
STYLE="font-size:85%; vertical-align:top">&reg;</SUP> (pembrolizumab), MSD&#146;s <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-1</FONT></FONT> therapy, in patients with multiple types of solid tumors. In September 2020,
we granted AbbVie a global license, excluding Mainland China, Hong Kong and Macau, to develop and commercialize lemzoparlimab (as well as certain other compounds directed against CD47), and we will retain all rights to develop and commercialize
lemzoparlimab in Mainland China, Hong Kong and Macau. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Uliledlimab (TJD5): A Potential Highly Differentiated CD73 Antibody for Cancer Treatment
</I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><I>Summary </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Uliledlimab is an internally developed, humanized inhibitory antibody against human CD73. CD73 is a homodimeric enzyme expressed in tumors and
plays a critical role in suppressing immune cells in tumor micro-environment. Uliledlimab displays <FONT STYLE="white-space:nowrap">sub-nanomolar</FONT> binding affinity to CD73 and inhibits its nucleotidase activity. <I>In vitro</I>, uliledlimab
completely reversed the <FONT STYLE="white-space:nowrap">AMP-</FONT> or tumor cell-mediated suppression of T cells. <I>In vivo</I>, when combined with a <FONT STYLE="white-space:nowrap">PD-L1</FONT> antibody, uliledlimab exhibited a superior or
synergistic inhibitory effect on tumor growth. The key differentiation of uliledlimab when compared to some of the other clinical stage antibodies of the same class, is related to its novel epitope, which works through a unique intra-dimer binding
mode, resulting in a complete inhibition of the enzymatic activity and avoiding the aberrant pharmacological property known as the &#147;hook effect.&#148; With this particular mode of action, uliledlimab, if approved, has the potential to become a
highly differentiated CD73 antibody. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In the United States, uliledlimab is in a Phase 1 clinical trial as a single agent and in
combination with atezolizumab (TECENTRIQ<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>), a <FONT STYLE="white-space:nowrap">PD-L1</FONT> antibody marketed by Roche, in patients with advanced solid tumors. 20&nbsp;patients have been
enrolled and nineteen of them have been dosed so far. The preliminary data of this trial in the United States are expected by mid-2021. In China, we are conducting a Phase 1/2 clinical trial in China to evaluate uliledlimab in patients with advanced
solid tumors. The first patient was dosed in May 2020. We have been able to accelerate the Phase 1/2 trial in China by leveraging data from the ongoing Phase 1 clinical study of uliledlimab in the United States, which is a testament to our global
clinical development capabilities and well-executed pipeline strategies. In China, we will also collaborate with Shanghai Junshi Biosciences Co., Ltd, or Junshi, for the combination therapy of uliledlimab with Junshi&#146;s <FONT
STYLE="white-space:nowrap">PD-1</FONT> monoclonal antibody toripalimab in cancer patients with various types of solid tumors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><I>Therapeutic Options and Current Development </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Despite recent breakthroughs with <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">PD-1/PD-L1</FONT></FONT> therapies,
clinical <FONT STYLE="white-space:nowrap">non-response</FONT> rates to such treatments remains high in cancer patients (exceeding 60%). This <FONT STYLE="white-space:nowrap">non-responsiveness</FONT> to these standard treatments is partly due to the
fact that T cells within an inhibitory tumor environment are suppressed and fail to respond to stimulation induced by <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">PD-1/PD-L1</FONT></FONT> therapies. CD73, which converts
extracellular adenosine monophosphate </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">187 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
(&#147;AMP&#148;) to adenosine, is implicated in one of the protective mechanisms of tumors that evade immune attack by creating an adenosine-rich microenvironment inhibitory to immune cells. <FONT
STYLE="white-space:nowrap">Pre-clinical</FONT> studies have indicated that the inhibition of CD73 renders T cells more responsive to <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">PD-1/PD-L1</FONT></FONT> therapies by altering the
tumor micro-environment, resulting in a superior anti-tumor effect. As CD73 is widely expressed in various cancers, a combination therapy of uliledlimab with a
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">PD-1/PD-L1</FONT></FONT> antibody may increase the likelihood of treatment success in cancer patients who do not respond to standard <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">PD-1/PD-L1</FONT></FONT> therapies. The potential cancer indications of uliledlimab include thyroid cancer, lung cancer, colorectal cancer, stomach cancer, urothelial cancer, endometrial cancer, head and neck cancer,
breast cancer, ovarian cancer, and melanoma, in which CD73 is widely expressed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">A number of global companies are running active clinical
development programs with CD73 antibodies. Oleclumab (MEDI-9447) from Medimmune and <FONT STYLE="white-space:nowrap">BMS-986179</FONT> from Bristol-Myers Squibb are the two most advanced CD73 antibodies, which are in Phase 2 clinical trials. <FONT
STYLE="white-space:nowrap">BMS-986179</FONT> is being studied as a single agent and in combination with nivolumab (a <FONT STYLE="white-space:nowrap">PD-1</FONT> antibody) for the treatment of advanced colorectal, esophageal, gastric, ovarian, and
pancreatic cancers. MedImmune is testing MEDI-9447 for the treatment of solid tumors as a single agent or in combination with durvalumab (a <FONT STYLE="white-space:nowrap">PD-L1</FONT> antibody) or chemotherapy.
<FONT STYLE="white-space:nowrap">NZV-930</FONT> (from Novartis) and <FONT STYLE="white-space:nowrap">CPI-006</FONT> (from Corvus) have entered Phase 1 clinical trials for the treatment of solid tumors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><I>Advantages of Uliledlimab </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Extracellular AMP can be generated from ATP, cyclic AMP and nicotinamide adenine dinucleotide (&#147;NAD&#148;) through separate biochemical
pathways, all of which converge to CD73 to generate adenosine. Thus, CD73 antibody is expected to block adenosine generation more completely than other related targets. Further, CD73 antibody works through a substrate
<FONT STYLE="white-space:nowrap">non-competitive</FONT> fashion and has advantages over small molecule inhibitors targeting the adenosine pathway through a substrate competing fashion. More importantly, uliledlimab, if approved, is potentially
highly differentiated among the clinical stage CD73 antibodies as it binds to a novel epitope in the <FONT STYLE="white-space:nowrap">C-terminal</FONT> domain of CD73 without causing a &#147;hook effect.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Uliledlimab has the following key advantages: (i)&nbsp;uliledlimab exhibits a typical dose-response curve without the &#147;hook effect&#148;
and with a complete inhibition of both soluble and surface-bound CD73 and (ii)&nbsp;uliledlimab has a <FONT STYLE="white-space:nowrap">non-competitive</FONT> inhibitory effect that is not blunted by high levels of CD73 enzyme substrates, which would
be expected for small-molecule competitive blockers. These pharmacological properties may translate into efficient target inhibition in tumors and superior anti-tumor activity, especially in an adenosine-rich micro-environment. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">188 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><I>Mechanism of Action </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Adenosine is a potent immunosuppressive signaling molecule abundant in the tumor microenvironment. CD73 is the rate-limiting enzyme that
generates adenosine from extracellular AMP. Uliledlimab allosterically inhibits the CD73 enzyme by preventing the inactive CD73 dimer from changing into the active conformation in a substrate <FONT STYLE="white-space:nowrap">non-competitive</FONT>
manner. This results in a decrease in adenosine production in the tumor micro-environment, increasing T cell anti-tumor activity. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g98473g53f99.jpg" ALT="LOGO">
 </P> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><I>Figure:</I></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>Schematic diagram of CD73-catalyzed adenosine (Ado) generation and immunosuppression by Ado in the tumor
microenvironment. </I></P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><I>Summary of <FONT STYLE="white-space:nowrap">Pre-clinical</FONT> Results </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I>Inhibition of CD73 by Uliledlimab. </I>As shown in the figure below, uliledlimab displayed complete inhibition of soluble CD73 enzymatic
activity (IC50= 0.22 n<I>M</I>) without the &#147;hook effect&#148; in contrast to the comparator molecule, which at higher concentrations caused a paradoxical rebound of enzymatic activity presumably due to its inter-dimer binding mode. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g98473g00i34.jpg" ALT="LOGO">
 </P> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><I>Figure:</I></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>Inhibition of soluble CD73 enzymatic activity by CD73 antibodies. </I></P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I>Restoration of T Cell Activity by Uliledlimab In Vitro. </I>We observed that AMP inhibited interferon gamma
<FONT STYLE="white-space:nowrap">(IFN-g)</FONT> production by CD4 or CD8 T cells through adenosine generation, mimicking the suppressive tumor microenvironment where AMP is abundantly produced. However, this suppression could be reversed by
uliledlimab in a concentration-dependent manner. Moreover, in an experimental system where CD73 high human ovarian cell line <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">SK-OV-3</FONT></FONT> and human T cells were <FONT
STYLE="white-space:nowrap">co-cultured,</FONT> addition of uliledlimab restored T cell activity as measured by <FONT STYLE="white-space:nowrap">IFN-g</FONT> production in a concentration-dependent manner. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I>In Vivo Anti-tumor Activity of Uliledlimab. </I>Uliledlimab monotherapy showed a moderate anti-tumor effect in a mouse xenograft model
bearing A375 melanoma cells. To examine whether uliledlimab can enhance </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">189 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the anti-tumor activity of the <FONT STYLE="white-space:nowrap">PD-L1</FONT> antibody, we evaluated the therapeutic effects of uliledlimab used as a single agent and in combination with a <FONT
STYLE="white-space:nowrap">PD-L1</FONT> antibody in the same A375 melanoma model. The combination treatment group resulted in 68% inhibition of tumor growth which is significantly better than the vehicle and uliledlimab monotherapy. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g98473g01c14.jpg" ALT="LOGO">
 </P> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><I>Figure:</I></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>In vivo anti-tumor activity of uliledlimab and <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">anti-PD-L1</FONT></FONT> in A375 melanoma xenograft model. Mice were treated with PBS control, <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-L1</FONT></FONT> (10 mg/kg), uliledlimab (5 mg/kg) or
a combination of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-L1</FONT></FONT> and uliledlimab twice a week for three weeks. Tumor volumes as percentages relative to baseline (day 0) for each treated group (n=7 per
group) (left) and for each individual mouse (right) were plotted. </I></P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I>Pharmacokinetics of Uliledlimab in Cynomolgus
Monkeys</I>. Following a single IV injection of uliledlimab at 5, 25 and 50 mg/kg, the mean C<SUB STYLE="font-size:85%; vertical-align:bottom">max</SUB> ranged dose-proportionally from 136 to 1430 &micro;g/mL, and the systemic exposure indicated by
the AUC0-last increased in a <FONT STYLE="white-space:nowrap">non-linear</FONT> manner, ranging from 4020 to 135000 hr*&micro;g/mL. Mean half-life was 44.9 hours, 61.5 hours and 104 hours, respectively, reflecting decreased clearance of uliledlimab
with increasing dose. No apparent sex difference was observed in the main PK parameters. Positive ADAs against uliledlimab were detected in the majority of the animals, without an apparent impact on systemic exposure. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g98473g93m30.jpg" ALT="LOGO">
 </P> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><I>Figure:</I></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>Concentration-time profile of uliledlimab in cynomolgus monkeys. </I></P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Repeat-dose Toxicology Study of Uliledlimab in Cynomolgus Monkeys. A four-week GLP toxicity study was conducted in cynomolgus monkeys followed
by a <FONT STYLE="white-space:nowrap">six-week</FONT> recovery period to evaluate the potential </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">190 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
toxicity of uliledlimab. Forty cynomolgus monkeys were randomly assigned into four groups (5/sex/group) and given five weekly doses of uliledlimab at 20, 60 or 200 mg/kg via IV injection.
Systemic exposures (C<SUB STYLE="font-size:85%; vertical-align:bottom">max</SUB> and <FONT STYLE="white-space:nowrap">AUC0-t)</FONT> generally increased dose-proportionally, and the Day 22 values were generally higher than those on Day 1, with mean
accumulation ratios (AR) ranging between 1.65 and 2.19. No apparent sex difference was observed. Positive uliledlimab antibodies were detected in the majority of animals following repeat administration at all doses, while no significant impact was
observed on the TK profiles. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The only uliledlimab-related effect was decreased monocyte chemoattractant protein 1 <FONT
STYLE="white-space:nowrap">(MCP-1)</FONT> on Day 1 (24 or 48 hours post-dosing) in treated animals. Due to a lack of corresponding findings or impact on the wellbeing of the animals, this effect was not considered adverse. No abnormality was
observed in other study endpoints, including safety pharmacology parameters and immunotoxicity. The no observed adverse effect level (NOAEL) was defined at 200 mg/kg. This dose level corresponded to the mean C<SUB
STYLE="font-size:85%; vertical-align:bottom">max</SUB> and AUC values of 6890 j.tg/ mL and 594000 j.tg*hr/mL in males, respectively, and 6450 j.tg/mL and 501000 j.tg*hr/mL in females, respectively, on Day 22 of the dosing phase. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><I>Clinical Development Plan </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We will develop uliledlimab in the United States and China in parallel. In the United States, uliledlimab is in a Phase 1 clinical trial as a
single agent and in combination with atezolizumab (TECENTRIQ<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>), a <FONT STYLE="white-space:nowrap">PD-L1</FONT> antibody marketed by Roche, in patients with advanced solid tumors. 20 patients
have been enrolled and nineteen of them have been dosed so far. The preliminary data of this trial in the United States are expected by mid-2021. In China, we are conducting a Phase 1/2 clinical trial in China to evaluate uliledlimab in patients
with advanced solid tumors. The first patient was dosed in May 2020. This Phase 1/2 study is a multicenter, open-label, dose escalation and cohort expansion study, which will evaluate safety, tolerability, pharmacokinetics, pharmacodynamics and
efficacy of uliledlimab, and determine a recommended dose for further planned clinical studies of its efficacy and safety as a single agent and in combination with standard dose of toripalimab
(TUOYI<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>) in patients with advanced or metastatic cancers who are refractory to or intolerant of all available therapies. We have been able to accelerate the Phase 1/2 trial in China by
leveraging data from the ongoing Phase 1 clinical study of uliledlimab in the United States, which is a testament to our global clinical development capabilities and well-executed pipeline strategies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><I><FONT STYLE="white-space:nowrap">Pre-clinical</FONT> Assets (Monoclonal antibodies) </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">TJ210 and TJX7 are monoclonal antibodies currently at the <FONT STYLE="white-space:nowrap">pre-clinical</FONT> stage. The FDA clearance for
the IND application of TJ210 was obtained in September 2020. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><I>TJ210: A Potential Highly Differentiated Antibody Targeting Myeloid
Derived Suppressor Cells in Cancers and Autoimmune Diseases </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">TJ210 is a fully human, high affinity antibody against human C5aR1 for
the treatment of cancers and potentially autoimmune diseases. Tumors produce large amounts of complement factor C5a to attract C5aR1-expressing myeloid derived suppressor cells (&#147;MDSCs&#148;), M2 macrophages and neutrophils. These myeloid cells
critically contribute to an immunosuppressive microenvironment as part of the evading mechanism of tumors and are associated with poor prognosis and resistance to
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">PD-1/PD-L1</FONT></FONT> therapies in many cancers. Inhibition of C5a or its receptor C5aR in mice leads to markedly reduced MDSCs and has an inhibitory effect on tumor growth in
various tumor-bearing animal models. The C5aR-blocking antibody has been shown to have significant therapeutic activity when combined with <FONT STYLE="white-space:nowrap">PD-1</FONT> therapies in <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">PD-1-resistant</FONT></FONT> tumor models. TJ210 exerts strong anti-tumor activity by blocking the activation and migration of C5aR1-expressing myeloid cells and has a highly differentiated potential, if approved, as it
binds to a novel epitope and possesses superior functional properties. Compared to the only competitor antibody from Innate Pharma, TJ210 shows a more potent anti-tumor effect, especially when C5a concentrations are high, and binds to C5a receptors
in both humans and monkeys, making <FONT STYLE="white-space:nowrap">pre-clinical</FONT> safety assessment possible. In addition, TJ210 has therapeutic potential in multiple inflammatory and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">191 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
autoimmune indications, in which the role of the C5a/C5aR axis has been validated. We partnered with the original developer of TJ210, MorphoSys, for Greater China rights and shared global rights.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In September 2020, the FDA has cleared the IND application for TJ210 to initiate a Phase 1 clinical trial. The trial is designed to
evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of TJ210 and is expected to commence by early 2021. We plan to work jointly with MorphoSys to develop this asset. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><I>TJX7: A Novel CXCL13 Antibody for Autoimmune Diseases </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">TJX7 is an internally discovered novel humanized neutralizing antibody targeting the CXCL13 chemokine. CXCL13, through its receptor CXCR5,
plays a key role in forming germinal centers, which are critical for immune response. The role of CXCL13 in forming germinal centers is to guide the migration of germinal center B cells and follicular T cells within the lymphoid organs and
facilitate their interaction, maturation and function. One of the key pathogenic features in autoimmune diseases is related to the aberrant formation of ectopic germinal centers formed in affected organs, contributing to chronic inflammation and
tissue destruction. Elevated serum CXCL13 levels, CXCR5-expressing T cells and pathogenic germinal center B cells and even ectopic germinal center formation are found in multiple autoimmune diseases, including Sj&ouml;gren&#146;s syndrome, RA,
multiple sclerosis, and SLE. TJX7 is being developed for the treatment of autoimmune disorders and has been shown to bind to CXCL13 with <FONT STYLE="white-space:nowrap">sub-nanomolar</FONT> affinity, effectively blocking the interaction between
CXCL13 and CXCR5 and the downstream signaling. TJX7 has been shown to completely inhibit the migration of primary human tonsil B cells. Pharmacodynamic studies in mice and cynomolgus monkeys have confirmed TJX7&#146;s inhibitory effects on germinal
center formation and antibody production. Results generated so far indicate that TJX7 may provide a new therapeutic angle in the treatment of autoimmune diseases as it acts uniquely at the core of tissue pathologies. TJX7 is currently under CMC and <FONT
STYLE="white-space:nowrap">pre-clinical</FONT> development. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><I><FONT STYLE="white-space:nowrap">Pre-clinical</FONT> Assets <FONT
STYLE="white-space:nowrap">(Bi-Specific</FONT> Antibody Panel) </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">PD-L1-based</FONT></FONT>
<FONT STYLE="white-space:nowrap">Bi-specific</FONT> Antibodies</I>. As previously discussed, this panel of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">PD-L1-based</FONT></FONT>
<FONT STYLE="white-space:nowrap">bi-specific</FONT> antibodies is designed according to the scientific rationale that a <FONT STYLE="white-space:nowrap">PD-L1</FONT> antibody, when engineered with a selected second immune component such as a
cytokine or another antibody, is able to convert &#147;cold tumors,&#148; which typically do not respond to <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">PD-1/PD-L1</FONT></FONT> inhibitors, to &#147;hot tumors,&#148; which are
more sensitive to <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">PD-1/PD-L1</FONT></FONT> therapies. Such <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">PD-L1-based</FONT></FONT>
<FONT STYLE="white-space:nowrap">bi-specific</FONT> antibodies are expected to increase the probability of treatment success in patients who do not respond to <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">PD-1/PD-L1</FONT></FONT>
treatment. Based on this concept, we have generated a panel of <FONT STYLE="white-space:nowrap">bi-specific</FONT> antibodies using our proprietary <FONT STYLE="white-space:nowrap">PD-L1</FONT> antibody sequence as the backbone (the first signal),
linked to a second component (the second signal) of selected immune properties. Representative examples of the second signals for this panel of <FONT STYLE="white-space:nowrap">bi-specific</FONT> antibodies include
<FONT STYLE="white-space:nowrap">IL-7</FONT> cytokine (expanding T effector cells), <FONT STYLE="white-space:nowrap">4-1BB</FONT> and <FONT STYLE="white-space:nowrap">B7-H3</FONT> antibodies (activating T cells synergistically with <FONT
STYLE="white-space:nowrap">PD-L1)</FONT> and CD47 antibody (adding the macrophage killing mechanism). We strive to validate all <FONT STYLE="white-space:nowrap">bi-specific</FONT> antibodies through a series of robust <I>in vitro </I>and <I>in vivo
</I>studies for <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">proof-of-concept,</FONT></FONT> thus providing a solid basis for further development. Collectively, we have demonstrated that the second paired component must be
structurally integrated with the tumor-engaging <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-L1</FONT></FONT> backbone to concentrate and function effectively inside tumors, which cannot be achieved by simply combining
two free agents. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I>&#147;Fortified&#148; <FONT STYLE="white-space:nowrap">Bi-specific</FONT> Antibodies for Specific Cancer Therapeutic
Purposes. </I><FONT STYLE="white-space:nowrap">TJ-C4GM</FONT> is a &#147;fortified&#148; version of the CD47 antibody, which is specifically designed for the treatment of solid tumors through the CD47-mediated macrophage killing mechanism. As the
majority of tumor-associated macrophages adopt an anti-inflammatory and tumor-promoting M2 phenotype rather than a <FONT STYLE="white-space:nowrap">pro-inflammatory</FONT> M1 phenotype, they are less efficient in phagocytosis in response to CD47
blockade. Thus, treatment of solid tumors with the CD47 antibody may exhibit limited efficacy. <FONT STYLE="white-space:nowrap">TJ-C4GM</FONT> is a novel molecule composed of lemzoparlimab with an engineered
<FONT STYLE="white-space:nowrap">GM-CSF</FONT> moiety fused at the <FONT STYLE="white-space:nowrap">C-terminus</FONT> of the antibody heavy chain. <FONT STYLE="white-space:nowrap">GM-CSF</FONT> is a potent cytokine known to convert tumor-resident M2
macrophages into tumor-engulfing M1 macrophages, which enables <FONT STYLE="white-space:nowrap">TJ-C4GM</FONT> to exert a better phagocytic effect in solid tumors. These unique functional properties of <FONT STYLE="white-space:nowrap">TJ-C4GM</FONT>
are confirmed in </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">192 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
a series of <I>in vitro </I>and <I>in vivo </I>tumor animal models, in which <FONT STYLE="white-space:nowrap">TJ-C4GM</FONT> exerts superior anti-tumor activity against solid tumors, which cannot
be achieved by lemzoparlimab or <FONT STYLE="white-space:nowrap">GM-CSF</FONT> used either alone or in combination. <FONT STYLE="white-space:nowrap">TJ-C4GM</FONT> is currently at the CMC and <FONT STYLE="white-space:nowrap">pre-clinical</FONT>
development stage. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">TJ-CLDN4B</FONT> is a <FONT STYLE="white-space:nowrap">bi-specific</FONT> antibody
targeting both Claudin18.2 (CLDN18.2), a tumor antigen preferentially expressed in gastric and pancreatic cancers, and <FONT STYLE="white-space:nowrap">4-1BB,</FONT> a <FONT STYLE="white-space:nowrap">co-stimulatory</FONT> molecule on T cells.
CLDN18.2 is a tight junction molecule normally expressed only on epithelial cells of the gastric mucosa, which is inaccessible by antibodies under normal conditions, making it a highly attractive tumor target. Although a CLDN18.2 monoclonal antibody
(claudiximab) was active in a Phase 2 trial, only the CLDN18.2 high-expressing tumors seemed to be susceptible. In collaboration with ABL Bio, we developed a <FONT STYLE="white-space:nowrap">bi-specific</FONT> antibody, <FONT
STYLE="white-space:nowrap">TJ-CLDN4B,</FONT> which provides two key advantages over current CLDN18.2 antibodies and <FONT STYLE="white-space:nowrap">4-1BB</FONT> agonistic antibodies. First, <FONT STYLE="white-space:nowrap">TJ-CLDN4B</FONT> is
capable of binding to tumor cells even with low levels of CLDN18.2 expression, making it more suitable for a broader patient population. Second, only upon tumor cell engagement by <FONT STYLE="white-space:nowrap">TJ-CLDN4B</FONT> are T cells
activated. In contrast, other <FONT STYLE="white-space:nowrap">pan-activating</FONT> <FONT STYLE="white-space:nowrap">4-1BB</FONT> antibodies that activate T cells regardless of tumor engagement are prone to liver toxicity as seen in clinical
studies. In a humanized mouse model, <FONT STYLE="white-space:nowrap">TJ-CLDN4B</FONT> suppressed tumor growth to a greater extent than anti-CLDN18.2 or <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-4-1BB</FONT></FONT> alone
or in combination. <FONT STYLE="white-space:nowrap">TJ-CLDN4B</FONT> is currently at the CMC and <FONT STYLE="white-space:nowrap">pre-clinical</FONT> development stage. We expect to file an IND for a <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">first-in-human</FONT></FONT> clinical study with the FDA in the first quarter of 2021. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Licensing and Collaboration
Arrangements </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>A. <FONT STYLE="white-space:nowrap">In-Licensing</FONT> Arrangements </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><I>Licensing Agreement with MorphoSys (Felzartamab) </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In November 2017, we entered into a license and collaboration agreement with MorphoSys AG (&#147;MorphoSys&#148;) with respect to the
development and commercialization of felzartamab (MOR202/TJ202), MorphoSys&acute;s proprietary investigational antibody against CD38 (the &#147;CD38 product&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Under this agreement, MorphoSys granted to us an exclusive, royalty-bearing, sublicensable license to exploit MOR202/TJ202 for any human
therapeutic or diagnostic purpose in the licensed territory, namely Greater China. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Pursuant to this agreement, we granted to MorphoSys an
exclusive license to our rights in any inventions that we make while exploiting MOR202/TJ202 under this agreement, solely to exploit MOR202/TJ202 outside of Greater China. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We also received the right to sublicense to affiliates and third parties acting as contract manufacturers, contract research organizations,
distributors or wholesalers without prior written consent, as well as the right to sublicense to other third parties with the prior written consent of MorphoSys, not to be unreasonably withheld, delayed or conditioned. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We are solely responsible for the development and commercialization of MOR202/TJ202 in Greater China, and must use commercially reasonable
efforts as we develop and commercialize MOR202/TJ202. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Pursuant to this agreement, we paid to MorphoSys an upfront license fee of
US$20.0&nbsp;million. We also agreed to make milestone payments to MorphoSys, conditioned upon the achievement of certain development, regulatory and commercial milestones, in the aggregate amount of US$98.5&nbsp;million. Such milestones include
first patient dosed in human clinical trials, marketing approval, and first annual net sales of CD38 products covered by the agreement in excess of a certain amount. As of the date of this prospectus, we have made milestone payments of
US$8.0&nbsp;million to MorphoSys. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">193 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In addition, we are required to pay tiered <FONT STYLE="white-space:nowrap">low-teens</FONT>
royalties to MorphoSys on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">country-by-country</FONT></FONT> and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">product-by-product</FONT></FONT> basis during the
term, commencing with the first commercial sale of a relevant licensed product in Greater China. The end of the royalty term is linked to (i)&nbsp;the expiration, invalidation or abandonment of relevant patent claims, (ii) 10 years from the date of
first commercial sale of such CD38 product, and (iii)&nbsp;marketing exclusivity for such relevant licensed product. To date, we have not paid any royalties to MorphoSys. Unless terminated earlier in accordance with the terms thereof, this agreement
will remain in effect until the expiration of our last payment obligation under the agreement. This agreement may be terminated by either party for the other party&#146;s uncured material breach, bankruptcy or insolvency. In addition, we have the
right to terminate the agreement for convenience at any time after a certain specified time period upon a notice period that varies based upon the stage of development. MorphoSys has the right to terminate the agreement if we challenge its patents.
To the extent that we terminate for convenience or MorphoSys terminates for our material breach, bankruptcy, insolvency or patent challenge, among other things, all licenses and rights granted by MorphoSys to us will automatically terminate and the
licenses and rights granted by us to MorphoSys will survive. In the event of such termination, we must also grant to MorphoSys an exclusive, royalty-bearing, sublicensable license under certain of our intellectual property relating to the licensed
product to exploit MOR202/TJ202 for any human therapeutic or diagnostic purpose in Greater China. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><I>Assignment and License Agreement
with Genexine (Eftansomatropin) </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In October 2015, <FONT STYLE="white-space:nowrap">I-Mab</FONT>
<FONT STYLE="white-space:nowrap">Bio-tech</FONT> Tianjin Co., Ltd., known as Tasgen <FONT STYLE="white-space:nowrap">Bio-tech</FONT> (Tianjin) Co., Ltd. at the time (which subsequently became our subsidiary following the Acquisition) <FONT
STYLE="white-space:nowrap">(&#147;I-Mab</FONT> Tianjin&#148;), entered into an intellectual property assignment and license agreement with Genexine, Inc. (&#147;Genexine&#148;), further amended in December 2017, with respect to four licensed
products, namely <FONT STYLE="white-space:nowrap">GX-H9</FONT> (TJ101), <FONT STYLE="white-space:nowrap">GX-G3</FONT> (TJ102), <FONT STYLE="white-space:nowrap">GX-G8</FONT> and <FONT STYLE="white-space:nowrap">GX-P2</FONT> and one assigned product, <FONT
STYLE="white-space:nowrap">GX-G6</FONT> (TJ103). Under this agreement, Genexine (i)&nbsp;granted to <FONT STYLE="white-space:nowrap">I-Mab</FONT> Tianjin an exclusive, <FONT STYLE="white-space:nowrap">non-transferable,</FONT> sublicensable license
to use and otherwise exploit certain intellectual property to engage in <FONT STYLE="white-space:nowrap">pre-clinical</FONT> and clinical development, manufacturing, sale and distribution of the above-mentioned licensed products for (A)&nbsp;the
treatment of any disease with respect to <FONT STYLE="white-space:nowrap">GX-H9</FONT> and <FONT STYLE="white-space:nowrap">GX-G3</FONT> in China (which, for clarity excludes, Hong Kong, Macau and Taiwan), (B) the treatment of chemically induced
diarrhea, with respect to <FONT STYLE="white-space:nowrap">GX-G8</FONT> anywhere in the world and (C)&nbsp;the treatment of rheumatoid arthritis and lupus (not including psoriasis) with respect to <FONT STYLE="white-space:nowrap">GX-P2</FONT>
anywhere in the world and further (ii)&nbsp;assigned to <FONT STYLE="white-space:nowrap">I-Mab</FONT> Tianjin a certain Chinese patent and related <FONT STYLE="white-space:nowrap">know-how</FONT> related to the assigned product (TJ103) and granted <FONT
STYLE="white-space:nowrap">I-Mab</FONT> Tianjin an exclusive license to exploit the assigned intellectual property to engage in <FONT STYLE="white-space:nowrap">pre-clinical</FONT> and clinical development, manufacturing, sale and distribution of
the assigned product (TJ103) for the treatment of any disease in China (which, for clarity, excludes Hong Kong, Macau and Taiwan). <FONT STYLE="white-space:nowrap">I-Mab</FONT> Tianjin will also receive an exclusive license to any improvements that
Genexine develops or acquires related to any of the aforementioned products. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Under this agreement,
<FONT STYLE="white-space:nowrap">I-Mab</FONT> Tianjin paid an aggregate upfront license fee of US$13.0&nbsp;million in relation to the patents, patent applications, <FONT STYLE="white-space:nowrap">know-how,</FONT> data and information in connection
with the four licensed products and a purchase fee of US$7.0&nbsp;million in connection with the assigned product (TJ103). <FONT STYLE="white-space:nowrap">I-Mab</FONT> Tianjin also agreed to make certain milestone payments, including milestone
payments in the aggregate amount of US$40.0&nbsp;million for <FONT STYLE="white-space:nowrap">GX-H9,</FONT> US$25.0&nbsp;million for TJ103 and US$15.0&nbsp;million for <FONT STYLE="white-space:nowrap">GX-G3,</FONT> conditioned upon the achievement
of certain net sales targets. As of the date of this prospectus, we have made upfront license payment of US$0.1&nbsp;million and milestone payments of US$0.9&nbsp;million to Genexine. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The term of this agreement is 30 years unless terminated earlier in accordance with the terms thereof. This agreement may be terminated by
either party for the other party&#146;s uncured material breach, bankruptcy or insolvency, in the event of force majeure or a PRC regulatory requirement to make material alteration or modification to the contractual rights or obligations of this
agreement which has the effect of preventing the parties from achieving their business objectives, or upon the termination of a certain subscription agreement or a certain joint venture agreement entered into by
<FONT STYLE="white-space:nowrap">I-Mab</FONT> Tianjin and Genexine in October 2015 (provided that the termination of such subscription agreement or joint venture agreement was not due to the material breach of the party electing to terminate this
agreement). Genexine has the right to terminate the agreement if we fail to use </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">194 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
commercially reasonable efforts to obtain regulatory approvals for commercializing the licensed product in the agreed period due to our own fault or if we cease to pursue clinical development or
product registration or to conduct licensed activities on a reasonable scale as approved by our board of directors. During the term of this agreement, if <FONT STYLE="white-space:nowrap">I-Mab</FONT> Tianjin develops or acquires any improvement,
modification or alteration to the licensed products, <FONT STYLE="white-space:nowrap">I-Mab</FONT> Tianjin will become the sole legal owner of such improvements, modifications and alterations and has full power, right and authority to grant licenses
or transfer ownership of the same. <FONT STYLE="white-space:nowrap">I-Mab</FONT> Tianjin is required to promptly notify Genexine in writing giving details of any such improvements, modifications or alterations and provide Genexine with such
explanations or trainings to enable Genexine to legally and effectively use the same. Additionally, <FONT STYLE="white-space:nowrap">I-Mab</FONT> Tianjin shall grant to Genexine a fully paid up, royalty-free, exclusive license to use any such
improvements, modifications and alterations anywhere outside of the territory for which <FONT STYLE="white-space:nowrap">I-Mab</FONT> Tianjin is licensed under this agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><I>Licensing Agreement with Genexine <FONT STYLE="white-space:nowrap">(GX-I7/TJ107)</FONT> </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In December 2017, we entered into an intellectual property license agreement with Genexine with respect to
<FONT STYLE="white-space:nowrap">GX-I7,</FONT> a long-acting <FONT STYLE="white-space:nowrap">IL-7</FONT> cytokine. Under this agreement, Genexine granted to us an exclusive, sublicensable and transferable license to use and otherwise exploit
certain intellectual property (including improvements subsequently developed or acquired by Genexine) in connection with the <FONT STYLE="white-space:nowrap">pre-clinical</FONT> and clinical development, manufacturing, sale and distribution of <FONT
STYLE="white-space:nowrap">GX-I7</FONT> to treat cancers in the field of oncology in China, Hong Kong, Macau and Taiwan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Under this
agreement, we paid an upfront license fee of US$12.0&nbsp;million to Genexine. We also agreed to make milestone payments in the aggregate amount of US$23.0&nbsp;million, conditioned upon the achievement of certain development milestones, including
completion of Phase 2 and Phase 3 clinical studies and NDA or BLA approval in any of China, Hong Kong, Macau or Taiwan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Further, we
agreed to make milestone payments in the aggregate amount of US$525.0&nbsp;million, conditioned upon the achievement of certain cumulative net sales of <FONT STYLE="white-space:nowrap">GX-I7</FONT> up to US$2,000&nbsp;million. We also are required
to pay Genexine a <FONT STYLE="white-space:nowrap">low-single-digit</FONT> percentage royalty in respect of the total annual net sales of <FONT STYLE="white-space:nowrap">GX-I7.</FONT> The aforesaid milestones and royalties (other than the upfront
payment) will be reduced by 50% following the entry of a generic version of <FONT STYLE="white-space:nowrap">GX-I7</FONT> in China, Hong Kong, Macau and Taiwan without the consent or authorization of us or any of our sublicensees. As of the date of
this prospectus, no milestone payments or royalties are due under this agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Unless terminated earlier in accordance with the terms
thereof, this agreement will remain in effect until the later of (i)&nbsp;the expiry of the last to expire patent of the licensed intellectual property that includes a valid claim for China, Hong Kong, Macau or Taiwan and that covers the composition
of <FONT STYLE="white-space:nowrap">GX-I7;</FONT> and (ii) 15 years from the date of the first commercial sale of <FONT STYLE="white-space:nowrap">GX-I7.</FONT> This agreement may be terminated by either party for the other party&#146;s uncured
material breach, bankruptcy or insolvency, in the event of force majeure or regulatory requirement to make material alteration or modification to the contractual rights or obligations of this agreement which has the effect of preventing the parties
from achieving their business objectives, or by mutual agreement of both parties. Genexine has the right to terminate the agreement if we fail to use commercially reasonable efforts to obtain regulatory approvals or other registrations necessary for
commercializing the licensed product in the agreed period due to our fault or if we cease to pursue clinical development or product registration or to conduct licensed activities on a reasonable scale as agreed (&#147;Development and
Commercialization Termination Events&#148;). Such Development and Commercialization Termination Events expressly include our failure to reach certain development milestones or commercially launch the licensed product in the agreed period. To the
extent that we terminate as a result of a regulatory requirement to make material alteration or modification to the contractual rights or obligations of this agreement or Genexine terminates for our material breach, bankruptcy or insolvency, force
majeure, or the Development and Commercialization Termination Events, we cannot develop, manufacture, market, promote, sell, offer for sale, distribute or otherwise make available any competing product for a certain period after such termination.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">195 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">During the term of this agreement, if we develop or acquire any improvement, modification or
alteration to the licensed product, we will own such improvements, modifications or alterations and provide Genexine details thereof, whether patentable or not. Additionally, we shall grant to Genexine a fully paid up, royalty-free, exclusive
license (with a right to sublicense) to use any such improvements, modifications or alterations anywhere outside of China, Hong Kong, Macau and Taiwan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In May 2020, we and Genexine entered into an amendment to this agreement, whereby both parties desire to establish a collaboration on TJ107
GBM Study in Greater China. Under the terms of the expanded collaboration, we will be mainly responsible for using commercially reasonable efforts to conduct the Phase 2 GBM clinical trial in Greater China, and Genexine will share the development
strategies, data and costs for success of this clinical trial. As of June&nbsp;30, 2020, the costs incurred for the development of this new indication was immaterial and had no material impact to our unaudited interim condensed consolidated
financial statements for the first six months ended June&nbsp;30, 2020. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><I>Licensing Agreement with Ferring (Olamkicept) </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In November 2016, we entered into a license and sublicense agreement with Ferring International Center SA (&#147;Ferring&#148;) with respect
to (i)&nbsp;FE301, an <FONT STYLE="white-space:nowrap">interleukin-6</FONT> inhibitor, and (ii)&nbsp;all pharmaceutical formulations in finished packaged form containing FE301 covered by certain patents or patent applications. Under this agreement,
Ferring granted to us an exclusive, sublicensable license (excluding any <FONT STYLE="white-space:nowrap">non-exclusive</FONT> license that Ferring granted to Conaris Research Institute AG under a licensing agreement entered into in November 2008)
under certain Ferring intellectual property to research, develop, make, have made, import, use, sell and offer to sell FE301 (and the licensed products containing FE301) in China, Hong Kong, Macau, Taiwan and South Korea. We also have an option to
receive an exclusive, sublicensable license under certain Ferring intellectual property to research, develop, make, have made, import, use, sell and offer to sell FE301 (and the licensed products containing FE301) in the countries in North America,
the European Union and Japan that are mutually agreed upon by the parties. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We are required to use commercially reasonable efforts to
obtain approval of FE301 and to promote, market, distribute and sell it in China, Hong Kong, Macau, Taiwan, and South Korea. Such activities are to be at our own cost and expense. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Under this agreement, we paid to Ferring an upfront license fee of US$2.0&nbsp;million. We also agreed to make milestone payments to Ferring,
in the aggregate amount of US$14.5&nbsp;million, conditioned on the achievement of certain development milestones in the licensed territory, including completion of Phase 1b and Phase 2a clinical studies and the submission and approval of the new
drug application. Further, if we exercise our option to receive a license in any of the mutually agreed upon countries in North America, the European Union and Japan, we are required to pay to Ferring an additional US$3.0&nbsp;million as an upfront
license fee (upon the exercise of the option), and milestone fees up to the aggregate amount of US$30.0&nbsp;million, conditioned upon the licensed product achieving certain development milestones in certain countries in the option territory. As of
the date of this prospectus, no milestone payments are due under this agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In addition, we agreed to pay Ferring tiered royalties
ranging from the <FONT STYLE="white-space:nowrap">mid-single-digit</FONT> to high-single-digit percentages of annual net sales for countries in China, Hong Kong, Macau, Taiwan, and South Korea, and from the high-single-digits to 10% of annual net
sales for the mutually agreed upon countries in North America, the European Union and Japan. To date, we have not paid any royalties to Ferring. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The royalty term commences with the first commercial sale of the licensed product in the relevant country and ends upon the later of (i) 15
years from the date of launch, and (ii)&nbsp;the expiry of the last to expire patent of Ferring that includes a valid claim covering the development, making, using or selling of the licensed compound or licensed product in the licensed territory
and/or option territory. Unless terminated earlier in accordance with the terms thereof, this agreement will remain in effect until the later of the expiry of the royalty </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">196 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
term, and the first date on which we are not conducting any necessary and outstanding clinical study with respect to the licensed product or seeking to obtain any necessary and pending regulatory
approval for the licensed product, if applicable. This agreement may be terminated by either party for the other party&#146;s uncured material breach, bankruptcy or insolvency. In addition, in the event that the original licensor terminates its
license to Ferring governing any of the intellectual property sublicensed to us under this agreement, Ferring has the right to terminate this agreement with respect to such sublicenses in which case both parties will discuss in good faith how to
resolve and mitigate to mutual satisfaction. To the extent that Ferring terminates for our material breach, bankruptcy or insolvency, among other things, all licenses and rights granted by Ferring to us will automatically terminate and the licenses
and rights we granted to Ferring will survive and automatically become irrevocable with the right to sublicense. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">During the term of the
licensing agreement, if we develop or acquire any improvement, modification, enhancement or addition to the licensed product, we will own and retain all rights, title and interest therein, and grant to Ferring a
<FONT STYLE="white-space:nowrap">non-exclusive,</FONT> fully paid, royalty-free, worldwide license thereto. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><I>License and Collaboration
Agreement with MacroGenics (enoblituzumab) </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In July 2019, we entered into a license and collaboration agreement with MacroGenics, Inc.
for development and commercialization of an <FONT STYLE="white-space:nowrap">Fc-optimized</FONT> antibody known as enoblituzumab that targets <FONT STYLE="white-space:nowrap">B7-H3,</FONT> including in combination with other agents, such as the <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-1</FONT></FONT> antibody known as MGA012, in the People&#146;s Republic of China, Hong Kong, Macau and Taiwan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Under this agreement, MacroGenics granted to us an exclusive, sublicensable, royalty-bearing license to MacroGenics&#146; patents and <FONT
STYLE="white-space:nowrap">know-how</FONT> to develop and commercialize the enoblituzumab product, and a combination regimen of enoblituzumab and MGA012, in Greater China during the term of the agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In exchange for these rights, in addition to certain financial consideration, we grant to MacroGenics a royalty-free, sublicensable, license
outside of Greater China, to our patents and <FONT STYLE="white-space:nowrap">know-how</FONT> that are related to the enoblituzumab product or useful or necessary for MacroGenics to develop or commercialize the enoblituzumab product or a product
containing MGA012, and combinations thereof. The license is <FONT STYLE="white-space:nowrap">(i)&nbsp;non-exclusive</FONT> with respect to the enoblituzumab product, and (ii)&nbsp;exclusive with regard to MGA012. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Unless prohibited by applicable laws and regulations, which include all international, national, federal, state, regional, provincial,
municipal and local government laws, rules, and regulations that apply to either us or MacroGenics or to the conduct of the collaboration under this agreement (including Good Manufacturing Practice, Good Clinical Practices, General Biological
Products Standards, and the laws, rules and regulations of the International Conference on Harmonisation, the United States, China, Hong Kong, Macau, and Taiwan, each as may be then in effect, as applicable and amended from time to time), we will <FONT
STYLE="white-space:nowrap">co-own</FONT> all clinical data generated pursuant to this agreement in any clinical trial conducted solely in Greater China, and, to the extent that such joint ownership is not legally permitted, MacroGenics will be the
sole and exclusive owner of such clinical data. MacroGenics will solely and exclusively own all other clinical data generated pursuant to this agreement. We are not aware of any applicable laws or regulations that would prohibit us from jointly
owning such clinical data and, to our knowledge, we currently qualify for such joint ownership with MacroGenics under this agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Pursuant to this agreement, we paid MacroGenics an upfront payment of US$15.0&nbsp;million. We also agreed to pay MacroGenics development and
regulatory milestone fees of up to US$135.0&nbsp;million and tiered double-digit royalties (ranging from <FONT STYLE="white-space:nowrap">mid-teens</FONT> to twenty percent) based on annual net sales in the territories. As of the date of this
prospectus, no milestone payments or royalties are due under this agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We are responsible for, and must use commercially reasonable
efforts, to develop and commercialize the enoblituzumab product (which includes the enoblituzumab product in combination with MGA012) in Greater </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">197 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
China. This includes conducting all clinical studies required for approval, participating in a planned, global Phase 3 trial (or another mutually agreeable global clinical trial) of the
enoblituzumab combination product, the conduct of at least two Phase 2 or Phase 3 trials each targeting <FONT STYLE="white-space:nowrap">B7-H3</FONT> expressing patient populations, and submissions to regulatory authorities in Greater China.
MacroGenics is responsible for, and must use commercially reasonable efforts to, develop and commercialize the enoblituzumab product (which includes the enoblituzumab product in combination with MGA012) in the rest of the world. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We are responsible for all development costs in Greater China. MacroGenics is responsible for all development costs in the rest of the world,
except that we are responsible for 20% of the costs incurred in (i)&nbsp;activities supporting global clinical trials in which we participate, (ii)&nbsp;certain CMC activities for material intended to be used in clinical trials in Greater China, and
(iii)&nbsp;companion diagnostic development and validation for indications being studied in Greater China. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Unless terminated earlier in
accordance with the terms thereof, this agreement will remain in effect, on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">country-by-country</FONT></FONT> and
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">region-by-region</FONT></FONT> basis, until the later of (i)&nbsp;the twelfth (12th) anniversary of the first commercial sale of an enoblituzumab product in such country or region,
(ii)&nbsp;the expiration of the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">last-to-expire</FONT></FONT> MacroGenics patent licensed under this agreement, which will occur in October 2036, and (iii)&nbsp;the expiration of the
latest data exclusivity period for the enoblituzumab product in such country or region. Since there is currently no data exclusivity protection period in China, Hong Kong, Macau or Taiwan, this agreement will remain in effect until the later of
clauses (i)&nbsp;and (ii). This agreement may be terminated by either party for the other party&#146;s uncured material breach, safety reasons or force majeure. In addition, we have the right to terminate the agreement for convenience at any time
after a certain specified time period upon advance notice to MacroGenics. MacroGenics has the right to terminate the agreement if we challenge its patents. To the extent that we terminate for convenience or MacroGenics terminates for our material
breach, patent challenge or safety reasons, all licenses and rights granted by MacroGenics to us will automatically terminate and the licenses and rights granted by us to MacroGenics will survive and automatically become exclusive and worldwide. To
the extent that we terminate for MacroGenics&#146; material breach or safety reasons, among other things, all licenses and rights granted by MacroGenics to us will automatically terminate. The licenses and rights granted by us to MacroGenics will
also automatically terminate to the extent we terminate for MacroGenics&#146; material breach. To the extent we terminate for safety reasons, such licenses and rights will terminate only with respect to the licensed territory and will otherwise
survive outside the licensed territory. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><I>Other <FONT STYLE="white-space:nowrap">In-Licensing</FONT> Arrangements </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In November 2018, we entered into a license and collaboration agreement with MorphoSys for MorphoSys&#146;s proprietary antibody
(MOR210/TJ210) directed against C5aR (the &#147;C5aR Agreement&#148;). Under this agreement, MorphoSys granted to us an exclusive, royalty-bearing license to explore, develop and commercialize MOR210/TJ210 in Greater China and South Korea. <FONT
STYLE="white-space:nowrap">I-Mab</FONT> will perform and fund all global development activities related to the development of MOR210/TJ210 in Greater China and South Korea, including all relevant clinical trials (including in the U.S. and China) and
all development activities required for IND filing in the U.S. as well as CMC development of manufacturing processes. As of the date of this prospectus, we have made an upfront payment of US$3.5&nbsp;million to MorphoSys. No milestone payments or
royalties are due under this agreement. MorphoSys retains rights in respect of development and commercialization of MOR210/TJ210 in the rest of the world. Additionally, MorphoSys maintains the right to conduct activities in Greater China and South
Korea that enable MorphoSys to exploit MOR210/TJ210 outside of those countries. Pursuant to the C5aR Agreement, we are required to use commercially reasonable efforts as we develop and commercialize MOR210/TJ210 in Greater China and South Korea.
This agreement may be terminated by either party for the other party&#146;s uncured material breach, bankruptcy or insolvency. In addition, we have the right to terminate the agreement for convenience at any time after a certain specified time
period upon a notice period that varies based upon the stage of development and for safety reasons. MorphoSys has the right to terminate the agreement if we challenge its patents. To the extent that we terminate for convenience or MorphoSys
terminates for our material breach, bankruptcy, insolvency or patent challenge, among other things, all licenses and rights granted by </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">198 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
MorphoSys to us will automatically terminate and the licenses and rights granted by us to MorphoSys will survive. In the event of such termination, in addition to other obligations, we must grant
to MorphoSys an exclusive, royalty-bearing, sublicensable license under certain of our intellectual property relating to the licensed product to exploit MOR210/TJ210 in Greater China and South Korea. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>B. <FONT STYLE="white-space:nowrap">Out-Licensing</FONT> Arrangements </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><I>License and Collaboration Agreement with AbbVie </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In September 2020, we, through our subsidiaries <FONT STYLE="white-space:nowrap">I-Mab</FONT> Biopharma Co., Ltd. and <FONT
STYLE="white-space:nowrap">I-Mab</FONT> Biopharma US Limited, entered into a license and collaboration agreement with AbbVie Ireland Unlimited Company (&#147;AbbVie&#148;) for the development and commercialization of certain compounds and products
that target CD47, including lemzoparlimab (which targets a unique epitope of CD47). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Under this agreement, we grant AbbVie an exclusive,
royalty-bearing, sublicensable license to develop, manufacture and commercialize the licensed compounds and products (but excluding products that are directed to both a CD47 epitope that is not the same or substantially similar to the epitope
targeted by lemzoparlimab and a <FONT STYLE="white-space:nowrap">non-CD47</FONT> target) anywhere in the world outside of Mainland China, Hong Kong and Macau, and to conduct development and manufacturing activities in Mainland China, Hong Kong and
Macau to further AbbVie&#146;s commercialization of the licensed products outside of Mainland China, Hong Kong and Macau, except that, with respect to products containing either our preclinical CD47-PDL1 compound or our preclinical CD47-GMCSF
compound, AbbVie will not develop, manufacture or commercialize such products until the parties come to financial terms on such products following AbbVie&#146;s exercise of its rights of first negotiation. We have granted AbbVie a license and cannot
commercialize products containing our preclinical CD47-PDL1 compound or our preclinical CD47-GMCSF compound outside of Mainland China, Hong Kong and Macau even if AbbVie does not exercise its right of first negotiation or we are unable to come to
financial terms on such products. We also grant AbbVie a <FONT STYLE="white-space:nowrap">co-exclusive,</FONT> royalty-bearing, sublicensable license to develop, manufacture and commercialize licensed compounds and products that are directed to both
a CD47 epitope that is not the same or substantially similar to the epitope targeted by lemzoparlimab and a <FONT STYLE="white-space:nowrap">non-CD47</FONT> target (excluding such compounds and products that have been developed by us) anywhere in
the world. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Under this agreement, AbbVie grants us an exclusive, royalty-free, sublicensable license under its technology and any joint
technology developed under this agreement to clinically develop and commercialize in Mainland China, Hong Kong and Macau certain of the licensed compounds and products that (1)&nbsp;only target CD47, including lemzoparlimab, and (2)&nbsp;to the
extent AbbVie exercises its rights of first negotiation for such licensed compounds and products, consist of our preclinical CD47-PDL1 compound or our preclinical CD47-GMCSF compound. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We are responsible for conducting certain initial development activities, at our cost and expense, following which AbbVie assumes the
responsibility and costs for all development, manufacture and commercialization activities of the licensed compounds and products outside of Mainland China, Hong Kong and Macau. Under this agreement, AbbVie is required to use commercially reasonable
efforts to develop, seek and obtain approval of, and commercialize at least one licensed product in at least two indications in the United States and at least three of the United Kingdom, France, Germany, Italy and Spain. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We are responsible for the development and commercialization of the licensed compounds and products in Mainland China, Hong Kong and Macau. We
are required to use commercially reasonable efforts to develop, seek and obtain approval of, and commercialize at least one licensed product in at least two indications in the PRC. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">During the term of the Agreement, we are not permitted to develop, manufacture or commercialize a compound or product that is directed
(1)&nbsp;solely to CD47 or (2)&nbsp;to an epitope that is the same or substantially </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">199 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
similar to the epitope targeted by lemzoparlimab, and AbbVie is not permitted to market a monoclonal antibody that is solely directed to a CD47 epitope that is the same or substantially similar
to the epitope targeted by lemzoparlimab for an indication in any country where the licensed product has received regulatory approval for such indication. Additionally, during the first five (5)&nbsp;years after the first commercial sale of a
licensed product outside of Mainland China, Hong Kong and Macau, AbbVie will not market any monoclonal antibody solely directed to CD47 for an indication in any country where the licensed product has received regulatory approval for such indication
in such country. AbbVie&#146;s exclusivity restrictions will not prevent it from marketing an antibody that demonstrates additive or synergistic effects in combination with a licensed product, or an improvement on a licensed product based on
improved efficacy or safety data. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Under this agreement, we and AbbVie formed a joint governance committee that consists of three
representatives from each of us. The joint governance committee will oversee and coordinate the development of the licensed compounds and products in both of our territories, including the review and approval of each of our respective development
plans, the review and approval of clinical trials and commercialization in Mainland China, Hong Kong and Macau, and discussing commercialization strategies in each of our territories. The joint governance committee may create working groups as it
deems appropriate. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Under this agreement, AbbVie will pay us an upfront payment of US$180&nbsp;million and, in connection with recently
released clinical data from our Phase 1 trial of lemzoparlimab in the United States, we expect to be paid a first milestone payment of US$20&nbsp;million. Based on the achievement of certain clinical development and regulatory milestones, including
first commercial sales in various markets, we may earn additional milestone payments of up to US$840&nbsp;million. Further, based on the achievement of certain sales-related milestones, we may earn additional milestone payments of up to
US$900&nbsp;million. In addition to the upfront and milestone payments that we may earn, we may also earn tiered royalties consisting of low double-digit percentages of global net sales. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We will not owe any milestone payments for our development or commercialization in Mainland China, Hong Kong and Macau, but we are required to
pay AbbVie tiered royalties in the <FONT STYLE="white-space:nowrap">mid-</FONT> single-digit percentages of net sales of licensed products in those countries. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Under this agreement, we grant AbbVie several rights of first negotiation with respect to our products, including a right of first negotiation
to exercise its right to products containing either our preclinical CD47-PDL1 compound or our preclinical CD47-GMCSF compound outside of Mainland China, Hong Kong and Macau. This right of first negotiation is exercisable following completion of
preclinical activities sufficient to initiate <FONT STYLE="white-space:nowrap">IND-enabling,</FONT> <FONT STYLE="white-space:nowrap">GLP-conforming</FONT> animal toxicology studies, and if AbbVie exercises this right, the parties shall negotiate an
amendment to allow AbbVie to develop, manufacture and commercialize that product in exchange for additional regulatory and sales milestones that could equal or exceed US$500&nbsp;million plus royalty payments. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We also grant AbbVie other rights of first negotiation for rights to commercialize: (1)&nbsp;our preclinical CD47-PDL1 compound or our
preclinical CD47-GMCSF compound in Mainland China, Hong Kong and Macau; (2)&nbsp;our multi-specific or <FONT STYLE="white-space:nowrap">bi-specific</FONT> licensed compounds that contain a targeting moiety that is directed to both an epitope on CD47
that is not the same or substantially similar to the epitope targeted by lemzoparlimab and a <FONT STYLE="white-space:nowrap">non-CD47</FONT> target, as well as any products containing such compounds anywhere in the world; and (3)&nbsp;each licensed
product that contains a licensed compound as its sole active ingredient that is directed solely to CD47 in Mainland China, Hong Kong and Macau. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">AbbVie grants us a right of first negotiation for rights to: (1)&nbsp;commercialize its multi-specific or
<FONT STYLE="white-space:nowrap">bi-specific</FONT> compounds that contain a targeting moiety that is directed to both an epitope on CD47 that is not the same or substantially similar to the epitope targeted by lemzoparlimab and a <FONT
STYLE="white-space:nowrap">non-CD47</FONT> target, as well as any products containing such compounds in Mainland China, Hong Kong and Macau; and (2)&nbsp;develop and commercialize licensed compounds as part of combination products (other than
products that contain a licensed compound directed against both an epitope on CD47 that is not the same or substantially similar to the epitope targeted by lemzoparlimab and a <FONT STYLE="white-space:nowrap">non-CD47</FONT> target) in Mainland
China, Hong Kong and Macau. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">200 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">This agreement may be terminated by either party in the event of an uncured material breach.
If the material breach and failure to cure is by AbbVie with respect to some countries, but not others, we have the right to terminate this agreement solely with respect to the countries to which the breach relates. If the material breach and
failure to cure is by us with respect to our obligations in Mainland China, Hong Kong and Macau, AbbVie will have the right to reduce payments to us by a certain percentage. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">AbbVie has certain termination rights if it determines not to continue development and commercialization based on documented safety concerns.
AbbVie may also terminate this agreement in part or in whole for convenience following prior written notice of a certain period. AbbVie may also terminate this agreement immediately following certain breaches by us of anti-bribery and
anti-corruption laws. AbbVie also has termination rights related to the approval process under the Hart-Scott-Rodino Antitrust Improvements Act. If we stop material clinical development and commercialization activities in Mainland China, Hong Kong
and Macau without justification, AbbVie may reduce any royalties that would have been due to us by a certain percentage. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">If AbbVie stops
material clinical development and commercialization activities without justification for a period of time, we may terminate this agreement. We also have certain termination rights if AbbVie or its affiliates challenge our patents related to the
licensed products. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><I>Licensing Agreement with ABL Bio </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In July 2018, we entered into a license and collaboration agreement with ABL Bio (the &#147;ABL Bio License&#148;), as amended from time to
time. Under the ABL Bio License, we granted to ABL Bio exclusive, worldwide (excluding Greater China), royalty-bearing rights to develop and commercialize a bispecific antibody (the &#147;BsAb&#148;) using certain of our monoclonal antibody
sequences. ABL Bio has developed expertise in the area of bispecific antibodies for cancer treatment and has developed proprietary intellectual property around the BsAb technology, and the license allows ABL Bio to further develop and commercialize
the BsAb based on monoclonal antibodies licensed from us under the ABL Bio License. ABL Bio granted to us an exclusive, royalty-free, sublicensable license under its interest in the BsAb and related <FONT STYLE="white-space:nowrap">know-how</FONT>
(including improvements thereto) to exploit the licensed BsAb in Greater China. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Under the ABL Bio License, we and ABL Bio each are
responsible for using commercially reasonable efforts to develop the licensed products through the completion of in vivo studies, and ABL Bio is responsible for using commercially reasonable efforts thereafter. We agreed to split costs fifty-fifty
(50:50) with ABL Bio through the completion of in vivo studies, with ABL Bio responsible for all costs and activities following that time. ABL Bio is responsible for all development and commercialization activities, subject to our input through a
joint committee comprised of an equal number of our and ABL Bio&#146;s representatives (though ABL Bio has final decision-making authority). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In consideration of the license, ABL Bio paid us an upfront fee of US$2.5&nbsp;million and agrees to make milestone payments in the aggregate
amount of US$97.5&nbsp;million conditioned upon achieving certain clinical development and sales milestones. Further, ABL Bio agreed to pay us royalties at <FONT STYLE="white-space:nowrap">mid-single-digit</FONT> percentages in respect of the total
annual net sales of the licensed BsAb product. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In addition, ABL Bio granted to us an exclusive, royalty-free, sublicensable license to
use its BsAb technology solely to exploit the licensed BsAb product for all indications in Greater China. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We also agreed that, during the
term of the ABL Bio License, neither we nor ABL Bio would develop independently from the other a bispecific antibody that uses the same pair of antibodies as the bispecific antibody molecules created under the ABL Bio License. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The ABL Bio License will continue to be in effect until expiration of the last payment obligation thereunder, unless earlier terminated
according to its terms. The ABL Bio License may be terminated by either </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">201 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
party for the other party&#146;s uncured material breach or in the event that the other party challenges its patents. In addition, after a certain specified time period, ABL Bio may terminate the
ABL Bio License upon a notice period that varies based upon the stage of development. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Upon expiration (but not termination) of the ABL
Bio License, we and ABL Bio will each retain our respective licenses granted under the ABL Bio License. If the ABL Bio License is terminated pursuant to ABL Bio&#146;s right to terminate at will or due to ABL Bio&#146;s material breach, all rights
and obligations (including all licenses granted) shall terminate and upon our request, we and ABL Bio will negotiate in good faith regarding our takeover of the exploitation of the BsAb product outside of Greater China in exchange for reasonable
compensation. Such negotiation will include, among other things, ABL Bio&#146;s assignment of assets related to the licensed BsAb product and the continuation of the licenses granted to us under the ABL Bio License. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><I>Licensing Agreement with CSPC Entity </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In December 2018, we entered into a product development agreement (the &#147;CSPC Agreement&#148;) with an entity controlled by CSPC
Pharmaceutical Group Limited (01093.HK) (&#147;CSPC entity&#148;). Under the CSPC Agreement, we granted to CSPC entity exclusive, <FONT STYLE="white-space:nowrap">non-transferable,</FONT> <FONT STYLE="white-space:nowrap">non-irrevocable</FONT> and
sublicensable rights under our patent rights in China to develop and commercialize TJ103 for treating type 2 diabetes mellitus and any other potential therapeutic applications. CSPC entity&#146;s right to sublicense is conditioned on our prior
written consent, which we cannot unreasonably withhold, other than sublicense to CSPC entity&#146;s affiliates. CSPC entity is a comprehensive pharmaceutical and drug manufacturing company, with an increasing focus on its research and development of
new products focusing the therapeutic area of oncology, among others. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Under the CSPC Agreement, CSPC entity is responsible for using
commercially reasonable efforts to develop, obtain market approval and commercialize the licensed products, while we are responsible for using commercially reasonable efforts to transfer the manufacturing technology of the licensed products to CSPC
entity and assist or guide CSPC entity in the continued optimization of such manufacturing technology thereafter. CSPC entity has final decision-making authority with respect to product development (though the research plan shall be jointly
developed by both parties and any changes to the plan shall be discussed and approved by the joint development committee) and commercialization. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We also agreed that, during the term of the CSPC Agreement, we shall not develop, either for ourselves or for third parties, any other hyFc
platform technology-based long-acting recombinant <FONT STYLE="white-space:nowrap">GLP-1</FONT> Fc fusion proteins that may be in a competitive position with TJ103. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In consideration of the license, CSPC entity paid us an upfront fee of RMB15.0&nbsp;million and agreed to make milestone payments in an
aggregate amount of RMB135.0&nbsp;million conditioned upon achieving certain clinical development and regulatory approval milestones, including completion of Phase 2 and Phase 3 clinical studies and obtaining NDA approval or market approval.
Further, we will also be entitled to tiered royalties ranging from <FONT STYLE="white-space:nowrap">mid-single-digit</FONT> percentages to 10&nbsp;percent in respect of the total annual net sales of the products after their commercialization in
China. The royalty term shall terminate at the later of: (i)&nbsp;the expiry date of the underlying patents of the licensed products with application numbers 201410851771.1 and 201580071643.8 (final grant of rights requested relating to <FONT
STYLE="white-space:nowrap">GLP-1)</FONT> in China, whichever is later; and (ii)&nbsp;the <FONT STYLE="white-space:nowrap">ten-year</FONT> anniversary of the initial commercialization of the product developed under the CSPC Agreement. We expect any
patents that may issue under the aforementioned patent application numbers 201410851771.1 and 201580071643.8 will expire between 2034 and 2035, before taking into account any extension that may be obtained through patent term extensions or
adjustments, or term reduction due to filing of terminal disclaimers. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Unless terminated earlier in accordance with the terms thereof, the
CSPC Agreement will remain in effect until the termination of the royalty term. This agreement may be terminated by either party for the other party&#146;s uncured material breach, bankruptcy or insolvency or force majeure. We have the right to
terminate the agreement if CSPC entity fails to use commercially reasonable efforts to obtain regulatory approvals for </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">202 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
commercializing the licensed product in the period stipulated by its board of directors due to its own fault or if CSPC entity ceases to pursue clinical development or product registration as
determined by its board of directors. CSPC entity has the right to terminate the agreement if we fail to resolve certain intellectual property disputes relating to TJ103 within six months after signing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">During the term of the CSPC Agreement, CSPC entity shall have exclusive, royalty-free rights in China to any work product generated by us, and
be responsible for any patent application and maintenance costs of such work product. CSPC entity shall have all rights to any work product generated by itself under the CSPC Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><B><I>Other <FONT STYLE="white-space:nowrap">Out-Licensing</FONT> Arrangements </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In April 2017, our subsidiary <FONT STYLE="white-space:nowrap">I-Mab</FONT> Shanghai entered into a technology transfer agreement (the
&#147;HDYM License&#148;) with Ningbo Hou De Yi Min Information Technology Co., Ltd. (&#147;HDYM&#148;) and Hangzhou HealSun Biopharm Co., Ltd. (&#147;HealSun&#148;) with respect to <FONT STYLE="white-space:nowrap">PD-L1</FONT> humanized monoclonal
antibodies. HealSun is a portfolio company of Lepu Biotech (<FONT STYLE="font-family:pmingliu">&#20048;&#26222;&#29983;&#29289;</FONT><FONT STYLE="font-family:Times New Roman">). Under the HDYM License, <FONT STYLE="white-space:nowrap">I-Mab</FONT>
Shanghai agreed to grant to HDYM exclusive (even to <FONT STYLE="white-space:nowrap">I-Mab</FONT> Shanghai itself), worldwide and sublicensable rights to develop, manufacture, have manufactured, use, sell, have sold, import, or otherwise exploit
certain <FONT STYLE="white-space:nowrap">PD-L1</FONT> related patents, patent applications, know-hows, data and information of <FONT STYLE="white-space:nowrap">I-Mab</FONT> Shanghai, relevant cell lines as well as any
<FONT STYLE="white-space:nowrap">PD-L1</FONT> monoclonal antibody arising from such cell lines for the treatment of diseases. Further, <FONT STYLE="white-space:nowrap">I-Mab</FONT> Shanghai and its cooperative party HealSun agreed to provide
subsequent research and development services on such intellectual property to HDYM, including the selection and examination of innovative <FONT STYLE="white-space:nowrap">PD-L1</FONT> humanized monoclonal antibodies, cultivation and selection of
stable cell lines, establishment of cell bank, research and development of manufacturing processes and preparation of samples, toxicological and pharmacological testing, <FONT STYLE="white-space:nowrap">pre-clinical</FONT> pharmaceutical experiment
report drafting, and application for and registration of clinical trials. If any party breaches the agreement and fails to cure, the <FONT STYLE="white-space:nowrap">non-breaching</FONT> parties may terminate this agreement. In addition, in the
event that the development of the licensed product encounters insurmountable technical difficulties, this agreement may be terminated by mutual agreement of all parties. To the extent that the agreement is terminated for HDYM&#146;s breach, all
licenses and rights granted by us to HDYM will automatically terminate and be reassigned to us. To the extent that the agreement is terminated due to material difficulty, HDYM will have all rights to dispose of any development data and technology
held by HealSun and us under this agreement and neither HealSun or us may use such development data and technology without HDYM&#146;s consent. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In March 2020, we entered into a strategic partnership with Kalbe Genexine Biologics (&#147;KG&#148;), a joint venture of Kalbe Farma Tbk
(&#147;Kalbe&#148;) and Genexine. Under the terms of the agreement, KG will receive a right of first negotiation for an exclusive license for the commercialization of two
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">I-Mab-discovered</FONT></FONT> product candidates: uliledlimab, a highly differentiated anti-CD73 antibody in Phase 1 development for advanced solid tumors, and an <FONT
STYLE="white-space:nowrap">I-Mab</FONT> product candidate to be agreed upon by both parties. With the agreement, KG will have a right of first negotiation for exclusive rights to commercialize these two product candidates in the ASEAN (Brunei
Darussalam, Cambodia, Indonesia, Laos, Malaysia, Myanmar, Philippines, Singapore, Thailand and Vietnam) and MENA (Algeria, Bahrain, Djibouti, Egypt, Iran, Iraq, Israel, Jordan, Kuwait, Lebanon, Libya, Malta, Morocco, Oman, Qatar, Saudi Arabia,
Syria, Tunisia, United Arab Emirates, Palestine, and Yemen) regions, as well as Sri Lanka. If and when we and KG enter into the definitive licensing agreement for uliledlimab, we will be eligible to receive from KG an aggregate amount of up to
approximately $340&nbsp;million, including an upfront payment and subsequent payments conditional upon achieving certain development and commercial milestones. KG will pay us tiered royalties in the low to
<FONT STYLE="white-space:nowrap">mid-teen</FONT> percentages on net sales from the ASEAN and MENA regions, as well as Sri Lanka. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>C. Collaboration
Arrangements </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In July 2018, we entered into a collaboration agreement with ABL Bio whereby both parties agreed to collaborate to
develop three <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">PD-L1-based</FONT></FONT> bispecific antibodies by using ABL Bio&#146;s proprietary BsAb technology </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">203 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
and commercialize them in their respective territories, which, collectively, include the PRC, Hong Kong, Macau, Taiwan and South Korea, and other territories throughout the rest of the world if
both parties agree to do so in such other territories during the performance of the agreement. This agreement may be terminated by either party for the other party&#146;s uncured material breach or in the event that the other party challenges its
patents. Also, if a party encounters insurmountable technical difficulties and risks, which cannot be resolved by such party within a certain period thereafter despite all reasonable efforts, such party will have the right to terminate this
agreement and will no longer have the right to develop the licensed product. As of the date of this prospectus, ABL Bio has paid US$2.5&nbsp;million upfront payment to us. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In September 2018, we entered into a collaboration and platform technology license agreement with WuXi Biologics Ireland Limited (&#147;WuXi
Biologics&#148;), whereby both parties agreed to collaborate in the research and development of at least three bispecific antibodies for our company to commercialize them worldwide. Such bispecific antibodies shall be created using our proprietary
monoclonal antibodies and WuXi Biologics&#146; proprietary WuXiBody platform technology for generating bispecific antibodies, shall be developed and manufactured through the exclusive service of WuXi Biologics. This agreement may be terminated by
either party for the other party&#146;s uncured material breach, bankruptcy or insolvency. WuXi Biologics has the right to terminate this agreement if we challenge its patents. We have the right to terminate this agreement if we decide to end the
development and commercialization of the licensed product in the licensed territory due to scientific, technical, or commercial reasons. As of the date of this prospectus, we have made an <FONT STYLE="white-space:nowrap">up-front</FONT> payment of
US$1.0&nbsp;million to Wuxi Biologics and no milestone payments or royalties are due under this agreement. In April 2019, we extended our existing partnership with WuXi Biologics (Shanghai) Co., Ltd. (&#147;WuXi Biologics Shanghai&#148;). We entered
into a long-term, strategic collaboration agreement with WuXi Biologics Shanghai to facilitate the CMC development and GMP manufacturing of both clinical and commercial supplies of certain of our monoclonal and bispecific antibodies and fusion
products, leveraging WuXi Biologics&#146; and its affiliates&#146; expertise in this area and supporting our <FONT STYLE="white-space:nowrap">pre-existing</FONT> collaboration and platform technology license agreement with WuXi Biologics. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Competition </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our industry is highly
competitive and subject to rapid and significant change. While we believe that our management&#146;s research, development and commercialization experience provide us with competitive advantages, we face competition from global and China-based
biopharmaceutical companies, including specialty pharmaceutical companies, generic drug companies, biologics drug companies, academic institutions, government agencies and research institutions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">For our Global Portfolio drug candidates, we expect to face competition from a broad range of global and local pharmaceutical companies. Many
of our competitors have significantly greater financial, technical and human resources than we have, and mergers and acquisitions in the biopharmaceutical industry may result in even more resources being concentrated among a smaller number of our
competitors. Our commercial opportunity could be reduced or eliminated if our competitors develop or market products or other novel therapies that are more effective, safer or less costly than our current or future drug candidates, or obtain
regulatory approval for their products more rapidly than we may obtain approval for our drug candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Intellectual Property </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our success will depend significantly on our ability to obtain and maintain patent and other proprietary protection for our drug candidates
and other commercially important products, technologies, inventions and <FONT STYLE="white-space:nowrap">know-how,</FONT> as well as on our ability to defend and enforce our patents including any patent that we have or may issue from our patent
applications, preserve the confidentiality of our trade secrets and operate without infringing the valid and enforceable patents and proprietary rights of other parties. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">As of September&nbsp;30, 2020, our owned patent portfolio consists of (i) 11 issued patents, including four issued in the U.S., one issued in
the PRC, three issued in Korea and three other jurisdictions; and (ii) 223 pending </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">204 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
patent applications, including 12 PCT patent applications, 16 U.S. patent applications, 18 PRC patent applications and 177 patent applications in other jurisdictions. Our owned patents and patent
applications primarily relate to the drug candidates in our Global Portfolio. Furthermore, as of September&nbsp;30, 2020, we <FONT STYLE="white-space:nowrap">in-licensed</FONT> the Greater China and Korea rights relating to (i) 22 issued patents,
including 13 issued in the PRC, one issued in Korea, six issued in Hong Kong and two issued in Taiwan; and (ii) 34 pending patent applications, including five PCT patent applications, 10 PRC patent applications, 10 Hong Kong patent applications, six
Taiwan patent applications, two Korean patent applications and one Macau patent application. The <FONT STYLE="white-space:nowrap">in-licensed</FONT> patents and patent applications primarily relate to felzartamab, eftansomatropin, olamkicept,
enoblituzumab and efineptakin alfa. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="15%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="83%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><U>Felzartamab</U></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">As of September&nbsp;30, 2020, we exclusively licensed from MorphoSys nine issued patents (including six issued in the PRC, two issued in Hong Kong and one issued in Taiwan) and 11 pending patent applications (including two PCT
applications, two in the PRC and four in Hong Kong, two in Taiwan and one in Macau) relating to felzartamab. The licensed patents include composition of matter patents in China, Hong Kong and Taiwan. The patents (including patent applications if
issued) in this portfolio are expected to expire between 2025 and 2040, before taking into account any extension that may be obtained through patent term extension or adjustment, or term reduction due to filing of terminal disclaimers.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><U>Eftansomatropin</U></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">As of September&nbsp;30, 2020, we (i)&nbsp;exclusively licensed from Genexine two pending PRC patent applications directly relating to eftansomatropin and (ii)&nbsp;exclusively licensed from Genexine three issued patents in the PRC
relating to a hyFc platform that develops eftansomatropin. The licensed patents include composition of matter patents in China. The patents (including patent applications if issued) in this portfolio are expected to expire between 2028 and 2037,
before taking into account any extension that may be obtained through patent term extension or adjustment, or term reduction due to filing of terminal disclaimers.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><U>Olamkicept</U></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">As of September&nbsp;30, 2020, we exclusively licensed from Ferring two issued patents in the PRC and Korea relating to olamkicept and six patient applications in the PRC, Hong Kong and Korea relating to olamkicept. The licensed
patents include composition of matter patents. These patents are expected to expire between 2027 and 2035, before taking into account any extension that may be obtained through patent term extension or adjustment, or term reduction due to filing of
terminal disclaimers.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><U>Enoblituzumab</U></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">As of September&nbsp;30, 2020, we exclusively licensed from MacroGenics six issued patents (including two issued in the PRC, three issued in Hong Kong and one issued in Taiwan) and eight pending patent applications (including two in
the PRC, four in Hong Kong and two in Taiwan) relating to enoblituzumab. The patents (including patent applications if issued) in this portfolio are expected to expire between 2023 and 2036, before taking into account any extension that may be
obtained through patent term extension or adjustment, or term reduction due to filing of terminal disclaimers.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><U>Efineptakin</U></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">As of September&nbsp;30, 2020, we (i)&nbsp;exclusively licensed from Genexine one pending PRC patent application directly relating to efineptakin and (ii)&nbsp;exclusively license from Genexine three issued patents in the PRC
relating to a hyFc platform that develops efineptakin. The patents (including patent applications if issued) in this portfolio are expected to expire between 2028 and 2036, before taking into account any extension that may be obtained through patent
term extension or adjustment, or term reduction due to filing of terminal disclaimers.</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">205 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="15%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="83%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><U>Plonmarlimab</U></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">As of September&nbsp;30, 2020, we owned one PCT patent application that relates to plonmarlimab and it has entered national phases in China, the United States and 22 other jurisdictions. We expect that any patent that may issue
under this application will expire in 2037, before taking into account any extension that may be obtained through patent term extension or adjustment, or term reduction due to filing of terminal disclaimers.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><U>Lemzoparlimab</U></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">As of September&nbsp;30, 2020, we owned two PCT patent application, one of which has entered national phases in the PRC, the United States and 24 other jurisdictions, and the other has entered national phase in the PRC. We expect
that any patents that may issue under these applications will expire between 2037 and 2039, before taking into account any extension that may be obtained through patent term extension or adjustment, or term reduction due to filing of terminal
disclaimers.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><U>Uliledlimab</U></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">As of September&nbsp;30, 2020, we owned one PCT patent application and it has entered national phases in the PRC, the United States, and 23 other jurisdictions. We expect that any patent that may issue under this application will
expire in 2038, before taking into account any extension that may be obtained through patent term extension or adjustment, or term reduction due to filing of terminal disclaimers.</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The term of a patent depends upon the laws of the country in which it is issued. In most jurisdictions, a
patent term is 20 years from the earliest filing date of a <FONT STYLE="white-space:nowrap">non-provisional</FONT> patent application. Under the PRC Patent Law, the term of patent protection starts from the date of application. Patents relating to
inventions are effective for twenty years, and utility models and designs are effective for ten years from the date of application. There are no patent term adjustments or patent term extensions available in the PRC for issued patents. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In addition to patents, we rely upon unpatented trade secrets and <FONT STYLE="white-space:nowrap">know-how</FONT> and continuing
technological innovation to develop and maintain our competitive position. However, trade secrets and <FONT STYLE="white-space:nowrap">know-how</FONT> can be difficult to protect. We seek to protect our proprietary information, in part, by executing
confidentiality agreements with our partners, collaborators, scientific advisors, employees, consultants and other third parties, and invention assignment agreements with our consultants and employees. We have also executed agreements requiring
assignment of inventions with selected scientific advisors and collaborators. The confidentiality agreements we enter into are designed to protect our proprietary information and the agreements or clauses requiring assignment of inventions to us are
designed to grant us ownership of technologies that are developed through our relationship with the respective counterparty. We cannot guarantee that we have entered into such agreements with each party that may have or have had access to our trade
secrets or proprietary technology and processes or that these agreements will afford us adequate protection of our intellectual property and proprietary information rights. If any of the partners, collaborators, scientific advisors, employees and
consultants who are parties to these agreements breaches or violates the terms of any of these agreements or otherwise discloses our proprietary information, we may not have adequate remedies for any such breach or violation, and we could lose our
trade secrets as a result. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Additionally, as of September&nbsp;30, 2020, we had (i)&nbsp;three registered trademarks in Hong Kong, 12
registered trademarks in the PRC, two registered trademarks in the United States, 45 trademark applications in the PRC and six trademark applications in the United States; (ii) 12 domain names in the PRC, including
<U><FONT STYLE="white-space:nowrap">www.i-mabbiopharma.com</FONT></U>, four domain names in Hong Kong and two domain names in the United States and (iii) 12 software copyrights in the PRC. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">For more information on these and other risks related to intellectual property, see &#147;Risk Factors&#151;Risks Related to Our Intellectual
Property.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Enterprise Social Responsibility </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Having a positive impact on the communities in which we operate is an integral part of our business, and we maintain that as our core values.
We aim to make a significant positive contribution to society around the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">206 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
world, through the transformational medicines that we research, develop, manufacture and sell. We are committed to reflecting ethical, social and environmental concerns in our business decisions.
Our products must improve people&#146;s lives and ensure a profitable and sustainable future for our business. We also understand that stakeholders, including employees, need to be reassured of the sound ethical basis for our business. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our focus on making a contribution to improving healthcare and alleviating suffering is evidenced by our efforts on coping with the <FONT
STYLE="white-space:nowrap">COVID-19</FONT> outbreak. We are initiating the development of plonmarlimab to treat cytokine storm in severe and critically ill patients caused by <FONT STYLE="white-space:nowrap">COVID-19.</FONT> Cytokine storm is
characterized by surge of high levels of circulating inflammatory cytokines and is an overreaction of the immune system in patients infected with <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">SARS-CoV-2.</FONT></FONT> Recent
studies revealed that high levels of <FONT STYLE="white-space:nowrap">GM-CSF,</FONT> along with a few other cytokines, are critically associated with severe clinical complications in <FONT STYLE="white-space:nowrap">COVID-19</FONT> patients.
Research data provide the rationale to use plonmarlimab as a potential treatment for cytokine storm associated with <FONT STYLE="white-space:nowrap">COVID-19,</FONT> because the antibody effectively neutralizes circulating <FONT
STYLE="white-space:nowrap">GM-CSF</FONT> to control acute inflammatory responses, and it may also exhibit potential advantages over conventional <FONT STYLE="white-space:nowrap">IL-6</FONT> antibodies. We received IND clearance from the FDA in April
2020, and our study commenced initially in the United States with plans to expand into other <FONT STYLE="white-space:nowrap">hardest-hit</FONT> countries. Predefined safety assessment of the first part of the study was performed and the study is
currently ongoing as a Phase 2 trial with potential to be a Phase 3 trial in patients with cytokine release syndrome associated with severe <FONT STYLE="white-space:nowrap">COVID-19.</FONT> Data from part 1 of the study and review results of a data
monitoring committee indicated that plonmarlimab is safe and well-tolerated in the severe <FONT STYLE="white-space:nowrap">COVID-19</FONT> patients in the study. Part 2 of the study will evaluate the efficacy, safety and cytokine levels is <FONT
STYLE="white-space:nowrap">on-going.</FONT> In addition, at the peak of the <FONT STYLE="white-space:nowrap">COVID-19</FONT> outbreak, we donated personal protective equipment and funds worth a total of RMB800&nbsp;thousand to support medical
personnel and hospitals in Wuhan. We also donated US$50&nbsp;thousand to BayHelix, a nonprofit organization focused on global life sciences and healthcare community, for the purpose of supporting relief of
<FONT STYLE="white-space:nowrap">COVID-19</FONT> in the United States. Meanwhile, we took the health and safety of our employees as our top priority and have implemented company-wide self-protection policies for employees to either working remotely
or onsite with protective masks and sanitization. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Manufacturing and Supply </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our manufacturing strategy for our drug candidates consists of two progressive steps, involving (i)&nbsp;using contract development and
manufacturing organizations (&#147;CDMOs&#148;) and (ii)&nbsp;establishing our own capabilities and infrastructure, including a manufacturing facility. We believe that development of our own manufacturing facility will provide us with enhanced
control of material supply for both clinical trials and the commercial market, enable the more rapid implementation of process changes and help us achieve better long-term margins. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We currently outsource the manufacturing of clinical trial material for our internally developed, IND enabling projects to leading CDMOs in
China such as WuXi Biologics, and the manufacturing of clinical trial material for clinical stage projects which were <FONT STYLE="white-space:nowrap">in-licensed</FONT> from our global partners to reputable global CDMOs, which have established
track records for both clinical trial material supply and commercial material supply. We have assembled a seasoned internal team with deep experience in this area to drive and monitor this process. For contingency planning purposes, we have also
established relationships with other CDMOs. We expect to continue our outsourcing relationships with contract manufacturers to meet the ongoing needs for the development of our drug candidates. We have framework agreements with these external
service providers, under which they provide services to us on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">project-by-project</FONT></FONT> basis. We also monitor the manufacturing activities of clinical trial material at CDMO
to ensure the compliance with local and international cGMP and applicable regulations. Currently, our contract manufacturers obtain raw materials and supplies for the manufacturing activities from multiple suppliers who we believe have sufficient
capacity to meet our demands. We typically order materials and services on a purchase order basis. We also enter into long-term capacity or minimum supply arrangements with them. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We believe it is strategically important and advantageous that we own and control our GMP manufacturing process in order to ensure quality,
secure production slots and maximize cost-effectiveness for </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">207 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
clinical trial materials and commercial supplies. We intend to build a comprehensive biologics manufacturing facility in Hangzhou, China (the &#147;Hangzhou Facility&#148;) as part of our
strategic plan to become a fully integrated biopharma company. We have taken concrete steps to execute this plan. These steps include detailed operational planning for the facility, actions taken to secure an appropriate site, and negotiations with
external financing providers. The Hangzhou Facility targets to have a pilot capacity of 2 x 2,000L by the end of 2021 and commercially progressive capacity up to 8 x 2,000L to begin operation by the end of 2023. Construction is expected to commence
in late 2020. The project will be financed by a combination of internal and external sources. A group of domestic investors in China have agreed to invest a total of US$120&nbsp;million (in RMB equivalent) in cash. Upon closing, we, through our
wholly owned subsidiary and parties acting in concert, will remain the majority shareholder of <FONT STYLE="white-space:nowrap">I-Mab</FONT> Biopharma (Hangzhou) Limited <FONT STYLE="white-space:nowrap">(&#147;I-Mab</FONT> Hangzhou&#148;), the
entity holding the Hangzhou Facility, and retain a managing role and take full control to build and operate the manufacturing facility. We plan to prioritize our therapeutic focus and resources on immuno-oncology in our global ambition to become a
leading immuno-oncology company. This goal has been accelerated by our recent global strategic partnership with AbbVie and its commercialization plan for the initial oncology products. <FONT STYLE="white-space:nowrap">I-Mab</FONT> Hangzhou is
positioned to provide manufacturing capabilities for us, as well as the continued development of selected biologics assets that are unessential to our immuno-oncology focus, i.e. olamkicept, plonmarlimab (excluding cytokine release syndrome
indications) and a few <FONT STYLE="white-space:nowrap">pre-clinical</FONT> <FONT STYLE="white-space:nowrap">CMC-stage</FONT> programs. We believe that this strategic alignment is necessary to maximize the pipeline value and balance the development
risk for us. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>R&amp;D Governance </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We
have established robust governance regime for all stages of our research and development activities, through our internal discovery, CMC, <FONT STYLE="white-space:nowrap">pre-clinical</FONT> and clinical development programs, and through product
acquisition and <FONT STYLE="white-space:nowrap">in-licensing</FONT> strategies. The research and development governance regime has enabled our senior management to continuously oversee and monitor our company&#146;s research and development
activities for complying with applicable laws, regulations, rules, guidelines and internal policies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We have established various
governance and decision-making committees, composed of senior representatives from the respective functional units to review, discuss and determine, for instance, whether a drug candidate molecule is qualified to move forward into the next stage or
not, what data package is considered appropriate and compliant to be submitted to regulatory agencies and how clinical safety of our investigational drugs will be monitored and reported. These committees make decisions over the critical
&#147;checkpoints&#148; of our research and development activities and include our (i)&nbsp;Science Committee, (ii)&nbsp;IND Scientific Advisory Committee, (iii)&nbsp;R&amp;D Project/Program/Portfolio Governance, (iv)&nbsp;Medical Safety Council,
(v)&nbsp;Safety Management Team, and (vi)&nbsp;Quality Committees. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Science Committee for Early Stage Research of Drug Candidates </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our Science Committee is composed of selected functional heads and members of the leadership, including Dr.&nbsp;Taylor&nbsp;B. Guo,
Dr.&nbsp;Zheru Zhang, Dr.&nbsp;Joan Huaqiong Shen, Dr.&nbsp;Jane Meng, Yuan Meng, Dr.&nbsp;Weimin Tang, Dr.&nbsp;Chao Zhang and Dr.&nbsp;Zhengyi Wang, chaired by Dr.&nbsp;Taylor&nbsp;B. Guo. The Science Committee will collaborate with the management
team to enhance our company&#146;s research practices and assist management in evaluating scientific aspects of potential <FONT STYLE="white-space:nowrap">in-licensing</FONT> opportunities, collaborations and new technologies that may bolster our
pipeline and research and development capabilities. The Science Committee&#146;s responsibilities include: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">approving the target review package submitted by our discovery group; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">providing governance on the quality and integrity of drug candidates, before entering into CMC process
development; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">examining the experimental data and scientific evidence supporting the drug candidate; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">208 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing and making recommendations on our company&#146;s resource allocation in further development; and
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">setting the direction for scientific and technical review of potential
<FONT STYLE="white-space:nowrap">in-licensing</FONT> opportunities. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Furthermore, our Corporate Compliance Function led
by Mr.&nbsp;Thomas Song has taken a number of steps to review the integrity and reliability of the experimental data submitted with the selected drug candidate. The design, operation and monitoring of this data integrity program is integral to our
quality control and assurance system, and is independent with respect to our research and development unit and Science Committee, to ensure the compliance with the principles of scientific data integrity, including controls over changes to, and
deletions of source of data. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>IND Scientific Advisory Committee for Drug Candidates Entering into Clinical Development Stage </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our IND Scientific Advisory Committee is composed of Dr.&nbsp;Joan Huaqiong Shen, Dr.&nbsp;Zheru Zhang and Dr.&nbsp;Jane Meng. The IND
Scientific Advisory Committee is accountable for our IND application strategy and the data quality of our IND registration dossier before submission to the FDA, the NMPA and other comparable authorities. Our IND Scientific Advisory Committee advises
the project team on policy matters and provides overall direction of new drug studies, and to that extent serves as a standing modality committee. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>R&amp;D Project/Program/Portfolio Governance (&#147;IP3 Governance&#148;) </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our IP3 Governance is composed of Dr.&nbsp;Joan Huaqiong Shen, Dr.&nbsp;Zheru Zhang and Dr.&nbsp;Chao Zhang, with Dr.&nbsp;Joan Huaqiong Shen
serving as the chair. Our IP3 Governance is a decision-making body that assesses and approves research and development portfolio strategy and execution proposals from a multi-discipline perspective, with an integrated approach incorporating
scientific, clinical and commercial considerations. Our IP3 Governance aims to ensure that the project, program and/or portfolio-related decisions are logical, robust and repeatable and that our investments in research and development activities is
aligned with our vision and strategy. The IP3 Governance responsibilities include: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing and determining the <FONT STYLE="white-space:nowrap">in-licensing</FONT> and <FONT
STYLE="white-space:nowrap">out-licensing</FONT> strategic plan; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">performing reviews on critical research and development stage gates, including clinical asset selection, GLP
pharmacology and toxicology studies, FIH studies, clinical development and regulatory submission; and </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing product development strategy and monitoring project timeline and costs. <B><I>Medical Safety Council
(&#147;MSC&#148;)</I></B> </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our MSC is composed of selected research and development functional heads and Subject Matter
Experts, including Yuan Meng, Dr.&nbsp;Joan Huaqiong Shen, Michelle Yang, Dr.&nbsp;Taylor&nbsp;B. Guo, Dr.&nbsp;Jane Meng, Dr.&nbsp;Claire Xu and Zhengsong Zhang, chaired by Yuan Meng, Head of Medical Office. Our MSC is the highest medical safety
governance body engaged in setting standards for protecting the medical safety of patients and users of our products, and providing strategic direction in product vigilance and patient or user safety. The MSC&#146;s responsibilities include: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">establishing standards and policies, and identifying best practices related to medical safety;
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">providing oversight of all medical safety relevant activities, and overseeing the implementation of our
company&#146;s medical safety standard, as well as the outcomes of the periodic audits; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">addressing safety information that could result in a significant change in the benefit-risk profile of our
products; and </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">209 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing and approving FIH studies and any other issues with respect to the safety of human exposure during
early development stage. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Safety Management Teams (&#147;SMT&#148;) for Product-Related Safety System </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our SMT is composed of representatives from each research and development function, including Yuan Meng, program lead, clinical physician (on
program level), representatives of regulatory affairs (on program level), representatives of project management (on project level), external business partner (if applicable) and representatives of medical affairs (if applicable), chaired by Yuan
Meng. The SMT is a product-based, cross-functional collaborative team responsible for the review and evaluation of medical safety data arising from any source throughout the product lifecycle. Our SMT performs assessments to identify changes in
safety profiles or potential safety signals. Based on these safety evaluations, the SMT will determine the appropriate safety-related actions to be taken with respect to the product based on its benefit-risk profile for subjects in clinical trials
and for patients treated with the marketed product. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our SMT works closely with and escalates safety issues, as appropriate, to the MSC to
fulfill our medical safety obligations. Our SMT is responsible for reviewing available safety information from multiple sources on a regular basis and make final decisions on safety in a timely manner with appropriate cross-functional input. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Quality Committees </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We have
formed two Quality Committees, namely, <FONT STYLE="white-space:nowrap">I-Mab</FONT> Biopharma Quality Management Review and R&amp;D Quality Council. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">I-Mab</FONT> Biopharma Quality Management Review <FONT STYLE="white-space:nowrap">(&#147;I-Mab</FONT>
QMR&#148;) is composed of Dr.&nbsp;Joan Huaqiong Shen, Dr.&nbsp;Zheru Zhang, Yuan Meng and Thomas Song, <FONT STYLE="white-space:nowrap">co-chaired</FONT> by R&amp;D Quality Assurance officer Yuan Meng and CMC Quality Assurance officer Jack Qin. <FONT
STYLE="white-space:nowrap">I-Mab</FONT> QMR is a company-level cross-functional senior leadership meeting to provide management oversight of our company&#146;s Quality Management System (&#147;QMS&#148;) and the compliance status of our
company&#146;s regulated activities with applicable laws, regulations, policies and procedures, focusing on R&amp;D and CMC GXP activities. To ensure our Corporate Quality Plan is set, key QMS elements are established and maintained, quality
requirements are met, and trends, changes and risks are identified and addressed proactively. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">R&amp;D Quality Council is composed of
representatives from each research and development function, including Dr.&nbsp;Joan Huaqiong Shen, Niri Wu, Yuan Meng, Michelle Yang, Dr.&nbsp;Claire Xu, Dr.&nbsp;Jane Meng and heads of therapeutic areas (in China and the United States), chaired by
Dr.&nbsp;Joan Huaqiong Shen. R&amp;D Quality Council is a governance body that oversees the performance of the QMS and serves as the final decision-making body for critical quality issues that affect subject and patient safety, data integrity and
compliance with global and local regulatory authorities. The QMS encompasses the structure, responsibilities and procedures that enable the organization to identify, measure, control and enhance core regulated processes and activities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Code of Conduct </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We have adopted
a Code of Conduct that is applicable to many aspects of our business operation, such as business ethics, responsible research and development activities, IP and data protection, workplace ethics and other corporate governance topics, as well as
implementing high ethical standards that are mandatory for our employees. In addition, we have adopted an employee handbook which describes the compliance management system implemented at <FONT STYLE="white-space:nowrap">I-Mab</FONT> to ensure
compliance with applicable legal and regulatory requirements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Quality Control and Assurance </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In addition to the research and development governance regime described above, we have established an independent quality control and
assurance system and devote significant attention to quality control for the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">210 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
designing, manufacturing and testing of our drug candidates. Our Assurance Board is composed of Dr.&nbsp;Joan Huaqiong Shen, Dr.&nbsp;Zheru Zhang and Thomas Song. Our senior management is firmly
committed to delivering our quality performance, actively involved in allocating sufficient resources to quality management system and setting quality governance mechanism. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">For <FONT STYLE="white-space:nowrap">pre-clinical</FONT> and clinical trials, the overall quality management outlines the implementation of
our business policies and procedures in order to consistently comply with the regulatory requirements, including Good Laboratory Practices, or GLP; Good Clinical Practices, or GCP; Good Pharmacovigilance Practice, or GVP and other applicable
regulatory requirements in the performance of the trials. This includes: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">predefined policies and procedures to manage <FONT STYLE="white-space:nowrap">pre-clinical</FONT> and clinical
studies; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">dedicated resources and personnel with well delineated roles and responsibilities; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">quality risk management across the product lifecycle; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">continuous quality management system improvement; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT STYLE="white-space:nowrap">non-conformance</FONT> management via quality issue management process;
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">development and execution of quality audit program; and </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">regulatory inspection readiness. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">For CMC, we have established a quality management system to oversee the process development and API and drug production at the CDMOs. This
system takes a holistic approach bringing senior management, quality assurance team and company policies together to create an efficient and agile quality culture. Our CMC quality commitment includes, but not limited to: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">ensure that the product manufacturing, releasing, packaging, storage, and shipment meets all specifications and
the requirements of the FDA and/or NMPA&#146;s quality system regulations, cGMP or other applicable laws and regulations; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">review of process deviations and changes, root cause analysis, impact assessment, corrective and preventative
actions, and validation; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">ensure the consistency of key quality practices with our CDMOs; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">proactive quality system review based on audits, process data analysis, equipment condition, and periodic review
of internal and external sources of data; and </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">assessment of regulatory guidance and ensure readiness for regulatory inspections. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">211 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Employees </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We had 59, 134, 185 and 229 employees as of December&nbsp;31, 2017, 2018 and 2019 and September&nbsp;30, 2020, respectively. As of
September&nbsp;30, 2020, 203 employees were located in China and 26 were located outside China. The table below sets forth our employees by function as of September&nbsp;30, 2020: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="85.5%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="90%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Number</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Management</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">123</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Chemistry, manufacturing and controls</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">40</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">47</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Business and corporate development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Commercial</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>229</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We recruit our employees primarily through recruitment websites, recruiters, internal referrals and job fairs.
We recruit our employees based on their qualification and potential. We promote culture diversity, and our employees come from the United States, Taiwan and South Korea, in addition to China. The remuneration package of our employees includes
salary, benefits and bonus. Our compensation programs are designed to remunerate our employees based on their performance, measured against specified objective criteria. We are required to make contributions to social insurance and housing provident
funds in accordance with PRC laws and regulations from time to time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We provide new hire training to our employees and periodic <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">on-the-job</FONT></FONT> training to enhance the skills and knowledge of our employees. We have not established a labor union. We have not experienced any material labor disputes or strikes
that may have a material and adverse effect on our business, financial condition or results of operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We enter into standard
confidentiality and employment agreements with all of our key management and research staff. The contracts with our key personnel typically include a standard <FONT STYLE="white-space:nowrap">non-compete</FONT> agreement that prohibits the employee
from competing with us, directly or indirectly, during his or her employment and for one year after the termination of his or her employment. The contracts also typically include undertakings regarding assignment of innovations and discoveries made
during the course of his or her employment. For further details regarding the terms of confidentiality and employment agreements with our key management, see &#147;Management.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Facilities </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our headquarter is located
in Shanghai, China, where we lease and occupy approximately 2,851 square meters as office space and laboratories. We currently lease approximately 435 square meters of office space in Beijing, approximately 54 square meters of office space in
Tianjin, approximately 14,495 square meters of office space and manufacturing space in Hangzhou, approximately 187 square meters of office space in Hong Kong, and approximately 441 square meters of office space and laboratories in Maryland. The
terms of these leases range from one year to five years. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Legal Proceedings </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">From time to time we may become involved in legal proceedings or be subject to claims arising in the ordinary course of our business. We are
not presently a party to any legal proceedings that, if determined adversely to us, would individually or taken together have a material adverse effect on our business, results of operations, financial condition or cash flows. Regardless of the
outcome, litigation can have an adverse impact on us because of defense and settlement costs, diversion of management resources and other factors. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">212 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Internal Control and Risk Management </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We have implemented various risk management policies and measures to identify, assess and manage risks arising from our operations. In
addition, we have codified risk categories identified by our management, internal and external reporting mechanisms, remedial measures and contingency management as part of our policies. For details on major risks identified by our management, see
&#147;Risk Factors&#148; in this prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">To monitor the ongoing implementation of our risk management policies and corporate
governance measures, we have adopted or will adopt, among other things, the following risk management and internal control measures: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the establishment of an audit committee responsible for overseeing our financial records, internal control
procedures and risk management systems. See &#147;Management&#151;Committees of the Board of Directors&#148; in this prospectus for information of our audit committee members and detailed description of the responsibility of our audit committee;
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the establishment of an internal audit function for identifying and assessing operational risks, reviewing our
internal control over financial reporting and facilitating the remediation actions; and </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the engagement of external legal advisors to advise us on compliance with relevant regulatory requirements and
applicable laws to which we will be subject to as a public company, where necessary. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Further, we have adopted or will
adopt, various internal regulations against corrupt and fraudulent activities, including measures against bribery and the misuse of company assets. Key measures and procedures to implement such regulations include: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">authorizing our compliance department to assume responsibility for our anti-corruption and anti-fraud measures,
including handling complaints, conducting internal investigations and ensuring protection for whistleblowers; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">providing anti-corruption compliance training to our senior management and employees on a periodic basis to
enhance their knowledge and compliance with applicable laws and regulations, including relevant policies and prohibitions against <FONT STYLE="white-space:nowrap">non-compliance</FONT> set out in our employee handbook; and </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">evaluating and undertaking rectification measures with respect to any identified corrupt or fraudulent activity,
including proposing and establishing preventative measures to avoid future <FONT STYLE="white-space:nowrap">non-compliance.</FONT> </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We will continue to implement and enforce these measures and procedures to ensure ongoing compliance with all applicable laws and regulations,
including the prevention of our employees from engaging in corruption, bribery or other improper conduct. During the periods presented, we were not subject to any government investigation or litigation with respect to claims or allegations relating
to monetary and <FONT STYLE="white-space:nowrap">non-monetary</FONT> bribery activities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We have also designated responsible personnel to
monitor our ongoing compliance with relevant laws and regulations that govern our business operations, and to oversee the implementation of any necessary measures. Meanwhile, we plan to provide our directors, senior management and relevant employees
with continuing training programs and updates regarding relevant laws and regulations on a regular basis, with a view to proactively identifying concerns or issues relating to any potential <FONT STYLE="white-space:nowrap">non-compliance.</FONT>
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">213 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom98473_14"></A>REGULATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>PRC Regulation </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We are subject to a
variety of PRC laws, rules and regulations affecting many aspects of our business. This section summarizes the principal PRC laws, rules and regulations that we believe are relevant to our business and operations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Regulations on Company Establishment and Foreign Investment </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><B><I>Company Law </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The
establishment, operation and management of companies in China is governed by the PRC Company Law, which was passed by the Standing Committee of the National People&#146;s Congress (the &#147;NPC&#148;), on December&nbsp;29, 1993 and came into effect
on July&nbsp;1, 1994 and was latest revised or amended on October&nbsp;26, 2018, respectively. In light of the PRC Company Law, companies established in the PRC are either in the form of a limited liability company or a joint stock company. The PRC
Company Law applies to both PRC domestic companies and foreign-invested companies, unless otherwise provided in the relevant foreign investment laws and regulations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><B><I>Foreign Investment Law </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">On March&nbsp;15, 2019, the NPC approved the PRC Foreign Investment Law, which became effective on January&nbsp;1, 2020 and replaced the three
old rules on foreign investment in China, namely, the PRC Equity Joint Venture Law, the PRC Cooperation Joint Venture Law and the Wholly Foreign-Owned Enterprise Law, together with their implementation rules and ancillary regulations. The Foreign
Investment Law establishes the basic framework for the access to, and the promotion, protection and administration of foreign investments in view of investment protection and fair competition. According to the Foreign Investment Law, &#147;foreign
investment&#148; refer to investment activities directly or indirectly conducted by one or more natural persons, business entities, or other organizations of a foreign country (collectively referred to as &#147;foreign investor&#148;) within China,
and &#147;investment activities&#148; include the following activities: (i)&nbsp;a foreign investor, individually or together with other investors, establishes a foreign-invested enterprise within China; (ii)&nbsp;a foreign investor acquires stock
shares, equity shares, shares in assets, or other similar rights and interests of an enterprise within China; (iii)&nbsp;a foreign investor, individually or together with other investors, invests in a new construction project within China; and
(iv)&nbsp;investments in other means as provided by the laws, administrative regulations or the State Council. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><B><I>Regulations Relating
to Foreign Investment </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">On December&nbsp;26, 2019, the State Council promulgated the Implementation Rules to the Foreign Investment
Law, which became effective on January&nbsp;1, 2020. The implementation rules further clarified that the state encourages and promotes foreign investment, protects the lawful rights and interests of foreign investors, regulates foreign investment
administration, continues to optimize foreign investment environment, and advances a higher-level opening. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Furthermore, <FONT
STYLE="white-space:nowrap">PRC-based</FONT> investments by foreign investors have historically been regulated by the Catalogue for the Guidance of Foreign Investment Industries (2017 Revision) issued on June&nbsp;28, 2017 and effective from
July&nbsp;28, 2017, the Special Management Measures (Negative List) for the Access of Foreign Investment (2018)&nbsp;issued on June&nbsp;28, 2018 and effective from July&nbsp;28, 2018, and the Special Management Measures (Negative List) for the
Access of Foreign Investment (2019)&nbsp;issued on June&nbsp;30, 2019 and effective from July&nbsp;30, 2019. According to the aforesaid catalogue and management measures, foreign-invested industries fall into four categories, namely,
&#147;encouraged&#148; &#147;permitted&#148; &#147;restricted&#148; and &#147;prohibited&#148; and certain ownership requirements, requirements for senior executives and other special management measures shall apply to foreign
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">214 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
investors with regard to the access of foreign investments in certain categories. Currently, the Catalogue for the Guidance of Foreign Investment Industries (2017 Revision), the Special
Management Measures (Negative List) for the Access of Foreign Investment (2018)&nbsp;and the Special Management Measures (Negative List) for the Access of Foreign Investment (2018)&nbsp;have all been replaced. The currently effective industry entry
clearance requirements governing investment activities in the PRC by foreign investors are set out in two categories, namely the Special Management Measures (Negative List) for the Access of Foreign Investment (2020), and the Catalogue of Industries
for Encouraging Foreign Investment (2019 Version), which were promulgated by the National Development and Reform Commission (the &#147;NDRC&#148;), and the MOFCOM, and took effect on July&nbsp;23, 2020 and on July&nbsp;30, 2019, respectively. The
Catalogue of Industries for Encouraging Foreign Investment (2019 Version) and the Special Management Measures (Negative List) for the Access of Foreign Investment (2020)&nbsp;further reduce restrictions on the foreign investment. Industries not
listed in these two catalogues are generally deemed &#147;permitted&#148; for foreign investment unless specifically restricted by other PRC laws. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">On December&nbsp;30, 2019, the MOFCOM and SAMR jointly promulgated Measures for Information Reporting on Foreign Investment, which became
effective on January&nbsp;1, 2020. Pursuant to the Measures for Information Reporting on Foreign Investment, where a foreign investor carries out investment activities in China directly or indirectly, the foreign investor or the foreign-invested
enterprise shall submit the investment information to the competent commerce department. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><B><I>M&amp;A Rules </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">According to the Provisions on the Merger or Acquisition of Domestic Enterprises by Foreign Investors jointly issued by the MOFCOM, the State
Assets Supervision and Administration Commission of the State Council, the State Administration of Taxation (the &#147;SAT&#148;), the State Administration for Industry and Commerce (now known as the State Administration for Market Regulation), the
China Securities Regulatory Commission and the State Administration of Foreign Exchange (the &#147;SAFE&#148;), on August&nbsp;8, 2006 and amended by the MOFCOM on June&nbsp;22, 2009, among other things, (i)&nbsp;the purchase of an equity interest
or subscription to the increase in the registered capital of <FONT STYLE="white-space:nowrap">non-foreign-invested</FONT> enterprises, (ii)&nbsp;the establishment of foreign-invested enterprises to purchase and operate the assets of <FONT
STYLE="white-space:nowrap">non-foreign-invested</FONT> enterprises, or (iii)&nbsp;the purchase of the assets of <FONT STYLE="white-space:nowrap">non-foreign-invested</FONT> enterprises and the use of such assets to establish foreign-invested
enterprises to operate such assets, in each case, by foreign investors shall be subject to the Provisions on the Merger or Acquisition of Domestic Enterprises by Foreign Investors. Particularly, application shall be made for examination and approval
of the acquisition of any company in China affiliating to a domestic company, enterprise or natural person, which is made in the name of an oversea company established or controlled by such domestic company, enterprise or natural person. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><B><I>PRC Drug Regulation </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Drug Administration Law of the PRC promulgated by the Standing Committee of the NPC on September&nbsp;20, 1984 and effective from
July&nbsp;1, 1985 and amended on February&nbsp;28, 2001, December&nbsp;28, 2013, April&nbsp;24, 2015 and August&nbsp;26, 2019, respectively, and the Implementing Measures of the Drug Administration Law promulgated by the State Council on
August&nbsp;4, 2002 and effective from September&nbsp;15, 2002 and amended on February&nbsp;6, 2016 and March&nbsp;2, 2019, respectively, have jointly established the legal framework for the administration of pharmaceutical products in China,
including the research, development and manufacturing of new drugs. The Drug Administration Law applies to entities and individuals engaged in the development, production, trade, application, supervision and administration of pharmaceutical
products, which regulates and provides for a framework for the administration of pharmaceutical manufacturers, pharmaceutical trading companies and medicinal preparations of medical institutions, and the development, research, manufacturing,
distribution, packaging, pricing and advertisements of pharmaceutical products. The Implementing Measures of the Drug Administration Law, on the other hand, provides detailed implementation regulations for the Drug Administration Law. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">215 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The newly amended Drug Administration Law, which became effective on December&nbsp;1, 2019,
brought a series of changes to the drug supervision and administration system, including but not limited to the clarification of the drug marketing authorization holder system, pursuant to which the marketing authorization holder shall assume
responsibilities for <FONT STYLE="white-space:nowrap">non-clinical</FONT> studies, clinical trials, manufacturing and marketing, post-marketing studies, monitoring, reporting and handling of adverse reactions of the drug. The amendment also
stipulates that the State supports the innovation of drugs with clinical value and specific or special effects on human diseases, encourages the development of drugs with new therapeutic mechanisms and have multi-targeted, systematic regulatory and
intervention functions on human body and promotes the technological advancement of drugs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We are required to follow the above-mentioned
regulations in respect of our <FONT STYLE="white-space:nowrap">non-clinical</FONT> research, clinical trials and production of new drugs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><B><I>Regulatory Authorities and Recent Government Reorganization </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Pharmaceutical products and medical devices and equipment in China are monitored and supervised on a national scale by the NMPA (formerly
known as the China Food and Drug Administration, or the &#147;CFDA&#148;), while the local provincial medical products administrative authorities are responsible for the supervision and administration of drugs within their respective administrative
regions. Pursuant to the Decision of the First Session of the Thirteenth National People&#146;s Congress on the State Council Institutional Reform Proposal made by the NPC on March&nbsp;17, 2018, the NMPA is no longer an independent agency and its
duties shall be performed by the newly established State Administration for Market Regulation, into which the various agencies responsible for, among other areas, consumer protection, advertising, anticorruption, pricing, fair competition and
intellectual property, have been merged. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The NMPA is still the chief drug regulatory agency and implements the same laws, regulations,
rules, and guidelines as the CFDA, and the NMPA regulates almost all of the key stages of the life cycle of pharmaceutical products, including <FONT STYLE="white-space:nowrap">non-clinical</FONT> studies, clinical trials, marketing approvals,
manufacturing, advertising and promotion, distribution, and pharmacovigilance (i.e., post-marketing safety reporting obligations). The Center for Drug Evaluation (the &#147;CDE&#148;), which remains under the NMPA, conducts the technical evaluation
of each drug and biologic application for safety and effectiveness. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Formed on March 2018, the National Health Commission (the
&#147;NHC&#148;) (formerly known as the Ministry of Health (&#147;MOH&#148;) and the National Health and Family Planning Commission (&#147;NHFPC&#148;)) is China&#146;s chief healthcare regulator. It is primarily responsible for overseeing the
operation of medical institutions, which also serve as clinical trial sites, and regulating the licensure of hospitals and medical personnel. The NHC plays a significant role in drug reimbursement. Furthermore, the NHC and its local counterparts at
or below provincial-level local governments also oversee and organize public medical institutions&#146; centralized bidding and procurement process for pharmaceutical products, which is the chief means through which public hospitals and their
internal pharmacies acquire drugs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Also, as part of its 2018 reorganization, the PRC government formed a new State Medical Insurance
Bureau (the &#147;SMIB&#148;), which focuses on regulating reimbursement under the state-sponsored insurance plans. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><B><I><FONT
STYLE="white-space:nowrap">Non-Clinical</FONT> Research </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">On August&nbsp;4, 2003, the NMPA promulgated the Administrative Measures
for Good Laboratories Practice of <FONT STYLE="white-space:nowrap">Non-clinical</FONT> Laboratory, which was revised on July&nbsp;27, 2017, to improve the quality of <FONT STYLE="white-space:nowrap">non-clinical</FONT> research, and began to conduct
the Good Laboratories Practice. Pursuant to the Circular on Administrative Measures for Certification of Good Laboratory Practice for <FONT STYLE="white-space:nowrap">Non-clinical</FONT> Laboratory issued by the NMPA on April&nbsp;16, 2007, the NMPA
is responsible for the certification of <FONT STYLE="white-space:nowrap">non-clinical</FONT> research institutions nationwide and local provincial medical products administrative authorities is in charge of the daily supervision of <FONT
STYLE="white-space:nowrap">non-clinical</FONT> research institution. The NMPA decides whether an institution is qualified for undertaking pharmaceutical </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">216 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
<FONT STYLE="white-space:nowrap">non-clinical</FONT> research by evaluating such institution&#146;s organizational administration, its research personnel, its equipment and facilities, and its
operation and management of <FONT STYLE="white-space:nowrap">non-clinical</FONT> pharmaceutical projects. A Good Laboratory Practice Certification will be issued by the NMPA if all the relevant requirements are satisfied, which will also be
published on the NMPA&#146;s website. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Pursuant to the Regulations for the Administration of Affairs Concerning Experimental Animals
promulgated by the State Science and Technology Commission on November&nbsp;14, 1988 and amended on January&nbsp;8, 2011, July&nbsp;18, 2013 and March&nbsp;1, 2017, respectively, by the State Council, the Administrative Measures on Good Practice of
Experimental Animals jointly promulgated by the State Science and Technology Commission and the State Bureau of Quality and Technical Supervision on December&nbsp;11, 1997, and the Administrative Measures on the Certificate for Experimental Animals
(Trial) promulgated by the State Science and Technology Commission and other regulatory authorities on December&nbsp;5, 2001, a Certificate for Use of Laboratory Animals is required for performing experimentation on animals. Applicants must satisfy
the following conditions: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Laboratory animals must be qualified and sourced from institutions that have Certificates for Production of
Laboratory Animals; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The environment and facilities for the animals&#146; living and propagating must meet national requirements;
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The animals&#146; feed and water must meet national requirements; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The animals&#146; feeding and experimentation must be conducted by professionals, specialized and skilled
workers, or other trained personnel; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The management systems must be effective and efficient; and </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The applicable entity must follow other requirements as stipulated by Chinese laws and regulations.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><B><I><FONT STYLE="white-space:nowrap">Pre-clinical</FONT> and Clinical Development </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The NMPA requires supporting <FONT STYLE="white-space:nowrap">pre-clinical</FONT> data for the registration applications for imported and
domestic drugs. <FONT STYLE="white-space:nowrap">Pre-clinical</FONT> work, including pharmacology and toxicology studies, must satisfy the requirements of the Administrative Measures for Good Laboratories Practice of
<FONT STYLE="white-space:nowrap">Non-clinical</FONT> Laboratory. No approval is required from the NMPA to conduct <FONT STYLE="white-space:nowrap">pre-clinical</FONT> studies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><B><I>Clinical Trials and Registration of New Drugs </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><I>Categories </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Pursuant to
the Administrative Measures for Drug Registration promulgated by the NMPA on July&nbsp;10, 2007 and effective from October&nbsp;1, 2007, which provides the standards and requirements for clinical trials and drug registration applications, drug
registration applications are divided into three different types, namely, New Drug Application, Generic Drug Application, and Imported Drug Application. Drugs are categorized based on their working mechanism, including chemical medicine, biological
product or traditional Chinese or natural medicine. On January&nbsp;22, 2020, the SAMR promulgated the new Administrative Measures for Drug Registration (the &#147;New Measures for Registration&#148;), which became effective from July&nbsp;1, 2020.
According to the New Measures for Registration, drug registration applications are divided into three different types, namely, traditional Chinese medicine, chemical medicine, and biological products, and each type is further divided into several <FONT
STYLE="white-space:nowrap">sub-types.</FONT> The category and corresponding application requirements will be promulgated by the NMPA based on a drug&#146;s working mechanism, degree of innovation, and the need of review management. As provided in
the New </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">217 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Administrative Measures for Registration, the Drug Administration Law and Implementing Measures of the Drug Administration Law, upon completion of
<FONT STYLE="white-space:nowrap">non-clinical</FONT> research, clinical trials shall be conducted for the application of new drug registration. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><I>Clinical Trial Approval </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">All clinical trials conducted in China for new drug development must be approved and conducted at pharmaceutical clinical trial institution
which shall be under filing administration. For imported drugs, proof of foreign approval is required prior to the trial, unless the drug has never been approved anywhere in the world. In addition to a standalone trial in China, imported drug
applicants may establish a site in China as part of an international multi-center trial (the &#147;IMCT&#148;) at the outset of the global trial. Domestically manufactured drugs are not subject to foreign approval requirements, and by contrast to
prior practice, the NMPA has recently decided to also permit such drugs to be tested and developed through an IMCT. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In addition, the NMPA
has adopted a notification system for clinical trials of new drugs. Pursuant to the newly amended Drug Administration Law and the New Measures for Registration, effective from July&nbsp;1, 2020, clinical trials may be commenced as long as the
applicant has not received any objections from the CDE within 60 business days of application filing after acceptance of the application, and such application will be deemed as approved. Bioequivalence test may only be conducted after the completion
of record-filing on the website of the CDE. All clinical trials that have been approved but not initiated within three years since the execution of the Informed Consent Forms will become invalid. As provided in the New Measures for Registration, a
new application of clinical trial must be submitted if an applicant of an approved clinical trial decides to add new indications or drug combinations into the trial. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><I>Drug Clinical Trial Registration </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Pursuant to the Administrative Measures for Drug Registration, upon obtaining the clinical trial approval and before commencing a clinical
trial, the applicant shall file a registration with the NMPA containing various details of the clinical trial, including the clinical study protocol, the name of the principal researcher of the leading institution, names of participating
institutions and researchers, an approval letter from the ethics committee, and a sample of the Informed Consent Form, with a copy sent to the competent provincial administration departments where the trial institutions will be located. On
September&nbsp;6, 2013, the NMPA released the Announcement on Drug Clinical Trial Information Platform, providing that for all clinical trials approved by the NMPA and conducted in China, instead of the aforementioned registration filed with the
NMPA, clinical trial registration shall be completed and trial information shall be published through the Drug Clinical Trial Information Platform. The applicant shall complete trial <FONT STYLE="white-space:nowrap">pre-registration</FONT> within
one month after obtaining the clinical trial approval to obtain the trial&#146;s unique registration number and shall complete registration of certain <FONT STYLE="white-space:nowrap">follow-up</FONT> information before the first subject&#146;s
enrollment in the trial. If approval of the foregoing <FONT STYLE="white-space:nowrap">pre-registration</FONT> and registration is not obtained within one year after obtaining the clinical trial approval, the applicant shall submit an explanation,
and if the procedure is not completed within three years, the clinical trial approval shall automatically expire. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Pursuant to the New
Measures for Registration, during the period of clinical trial, the applicant must continuously update the registration information and the trial results after completion of each clinical trial on the Drug Clinical Trial Information Platform.
Applicants are responsible for the authenticity of the registration information. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><I>Human Genetic Resources Approval </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">On June&nbsp;10, 1998, the Ministry of Science and Technology and the MOH jointly established the rules for protecting and utilizing human
genetic resources in China. On July&nbsp;2, 2015, the Ministry of Science and Technology issued the Service Guide for Administrative Licensing Items concerning Examination and Approval </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">218 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
of Sampling, Collecting, Trading, Exporting Human Genetic Resources, or Taking Such Resources out of the PRC, which provides that foreign-invested sponsors that sample and collect human genetic
resources in clinical trials shall be required to file with the China Human Genetic Resources Management Office through its online system. On October&nbsp;26, 2017, the Ministry of Science and Technology issued the Circular on Optimizing the
Administrative Examination and Approval of Human Genetic Resources, which simplified the approval for sampling and collecting human genetic resources for the purpose of commercializing a drug in the PRC. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">On June&nbsp;10, 2019, the State Council of the PRC issued the PRC Administrational Rules on the Management of Human Genetic Resources
(effective from July&nbsp;1, 2019) (&#147;Genetic Rules&#148;), which formalized the approval requirements pertinent to research collaborations between Chinese and foreign-owned entities. Pursuant to this new rule, a new notification system (as
opposed to the advance approval approach originally in place) is put in place for clinical trials using China&#146;s human genetic resources at clinical institutions without involving the export of human genetic resources outside of China. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">On October&nbsp;17, 2020, the Standing Committee of the NPC promulgated the Biosecurity Law of the PRC, which will become effective from
April&nbsp;15, 2021. The new law restates the approval and notification requirements of human genetic resources sampling, collecting, utilizing and exporting, as provided in the Genetic Rules. Moreover, the promulgation of the new law, which takes
the form of national law, further demonstrates the commitments of protecting China&#146;s human genetic resources and safeguarding state biosecurity by the PRC government. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><I>Trial Exemptions and Acceptance of Foreign Data </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The NMPA may reduce its requirements for clinical trials and data, depending on the drug and the existing data. The NMPA has granted waivers
for all or part of trials and has stated that it will accept data generated abroad (even if not as part of a global study), including early phase data, that meets its requirements. On July&nbsp;6, 2018, the NMPA issued the Technical Guidance
Principles on Accepting Foreign Drug Clinical Trial Data (the &#147;Guidance Principles&#148;) as one of the implementing rules for the Innovation Opinion. According to the Guidance Principles, the data of foreign clinical trials must meet the
authenticity, completeness, accuracy and traceability requirements, and such data must be obtained in consistency with the relevant requirements under the Good Clinical Trial Practice (GCP) of the International Conference on Harmonization of
Technical Requirements for Registration of Pharmaceuticals for Human Use (the &#147;ICH&#148;). Clinical trial sponsors must be attentive to potentially meaningful ethnic differences in the subject population. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The NMPA now officially permits, and its predecessor agencies have permitted on a <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">case-by-case</FONT></FONT> basis in the past, drugs approved outside of China to be approved in China on a conditional basis without <FONT STYLE="white-space:nowrap">pre-approval</FONT> clinical trials being conducted in
China. Specifically, in 2018, the NMPA issued the Procedures for Reviewing and Approval of Clinical Urgently Needed Overseas New Drugs, permitting drugs that have been approved within the last ten years in the United States, the European Union or
Japan and that prevent or treat orphan diseases or prevent or treat serious life-threatening illnesses for which there is either no effective therapy in China or for which the foreign-approved drug would have clear clinical advantages. Applicants
will be required to establish a risk mitigation plan and may be required to complete trials in China after the drug has been marketed. The CDE has developed a list of qualifying drugs that meet the foregoing criteria. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><I>Clinical Trial Process and Good Clinical Practices </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Typically, drug clinical trials in China have four phases. Phase 1 refers to the initial clinical pharmacology and human safety evaluation
studies. Phase 2 refers to the preliminary evaluation of a drug candidate&#146;s therapeutic efficacy and safety for target indication(s) in patients. Phase 3 (often the pivotal study) refers to clinical trials that further verify the drug
candidate&#146;s therapeutic efficacy and safety on patients with target indication(s) and ultimately provide sufficient evidence for the review of a drug registration application. Phase 4 refers to a new drug&#146;s post-marketing study to assess
therapeutic effectiveness and adverse reactions </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">219 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
when the drug is widely used, to evaluate overall benefit-risk relationships of the drug when used among the general population or specific groups and to adjust the administration dose, etc. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">On August&nbsp;6, 2003, the NMPA promulgated the Administration of Quality of Drug Clinical Practice (the &#147;GCP&#148;) to improve the
quality of clinical trials. Pursuant to the newly amended Drug Administrative Law, and the Regulations on the Administration of Drug Clinical Trial Institution jointly promulgated by NMPA and NHC on November&nbsp;29, 2019 and effective from
December&nbsp;1, 2019, drug clinical trial institutions shall be under filing administration. Clinical trial institutions that only conduct analysis of biological samples related to clinical trials of drugs do not need to be filed. Pursuant to the
Circular on Measures for Certification of Good Laboratory Practice for <FONT STYLE="white-space:nowrap">Non-clinical</FONT> Laboratory, a Good Laboratory Practice Certification will be issued by the NMPA if all the relevant requirements are
satisfied, which will also be published on the NMPA&#146;s website. Pursuant to the Opinions on Deepening the Reform of the Evaluation and Approval System and Inspiring Innovation of Drugs and Medical Devices and Equipment, the accreditation of the
institutions for drug clinical trials shall be subject to record-filing administration. The conduct of clinical trials must adhere to the Good Laboratory Practice, and the protocols must be approved by the ethics committees of each study site. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><B><I>Reform of Evaluation and Approval System for Drugs </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">On August&nbsp;9, 2015, the State Council promulgated the Opinions on the Reform of Evaluation and Approval System for Drugs and Medical
Devices and Equipment, which establishes the reform framework of the evaluation and approval system for drugs, medical devices and equipment, indicating the enhancement of the standard of approval for drug registration and accelerating the
evaluation and approval process for innovative drugs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">On November&nbsp;11, 2015, the NMPA issued the Circular Concerning Several Policies
on Drug Registration Review and Approval, which further clarifies the measures and policies with regard to the simplification and acceleration of the approval process for drugs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">According to the Decision of the NMPA on Adjusting the Approval Procedures under the Administrative Approval Items for Certain Drugs made on
March&nbsp;17, 2017 and effective from May&nbsp;1, 2017, the approval for a clinical trial application can be directly issued by the CDE under the NMPA on behalf of the NMPA. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">On October&nbsp;8, 2017, the General Office of the State Council promulgated the Innovation Opinions, which further promotes the structural
adjustment to and technical innovations of drugs, medical devices and equipment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">On May&nbsp;17, 2018, the NMPA and the NHC jointly
issued the Circular on Issues Concerning Optimizing Drug Registration Review and Approval, which further simplifies and accelerates the clinical trial approval process. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">On January&nbsp;22, 2020, the SAMR promulgated the New Measures for Registration, effective from July&nbsp;1, 2020, which deploys several
mechanisms to simplify and accelerate the drug registration process, including the Priority Review Procedure and the Special Review Procedure. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">On July&nbsp;7, 2020, the NMPA promulgated the Evaluation and Approval Working Process for Revolutionary Therapeutic Drugs (Trial), the
Evaluation and Approval Working Process for the Conditional Approval Application of Drugs (Trial) and the Priority Evaluation and Approval Working Process for Drugs (Trial), repealing the Opinions on Encouraging the Prioritized Evaluation and
Approval for Drug Innovations, which provide for fast track clinical trial approval, drug registration pathway or conditional approval to innovative drugs or drugs with revolutionary therapeutic effects. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">220 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><B><I>Special Examination and Fast Track Approval for Innovative Drugs under Current Reform
Frame </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Pursuant to the Provisions on the Administration of Special Examination and Approval of Registration of New Drugs
promulgated by the NMPA on January&nbsp;7, 2009, the NMPA conducts special examination and approval for new drug registration applications when, among others, (1)&nbsp;the effective constituent of a drug extracted from plants, animals, minerals,
etc., as well as the preparations thereof, have never been marketed in China, or the material medicines and the preparations thereof are newly discovered; (2)&nbsp;the chemical raw material medicines as well as the preparations thereof and the
biological product have not been approved for marketing anywhere in the world; (3)&nbsp;the new drugs are for treating AIDS, malignant tumors and rare diseases, etc., and have obvious advantages in clinical treatment; or (4)&nbsp;the new drugs are
for treating diseases with no effective methods of treatment. The Provisions on the Administration of Special Examination and Approval of Registration of New Drugs provides that the applicant may file for special examination and approval at the
clinical trial application stage if the drug candidate falls within items (1)&nbsp;or (2). The provisions provide that for drug candidates that fall within items (3)&nbsp;or (4), the application for special examination and approval cannot be made
until filing for production. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Circular Concerning Several Policies on Drug Registration Review and Approval issued on
November&nbsp;11, 2015 further clarifies the above-mentioned policy, potentially simplifying and accelerating the approval process of clinical trials: (x)&nbsp;a <FONT STYLE="white-space:nowrap">one-time</FONT> umbrella approval procedure allowing
the overall approval of all phases of a new drug&#146;s clinical trials, replacing the current <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">phase-by-phase</FONT></FONT> application and approval procedure, will be adopted for new
drugs&#146; clinical trial applications; and (y)&nbsp;a fast track drug registration or clinical trial approval pathway for the following applications: (i)&nbsp;registration of innovative new drugs treating AIDS, malignant tumors, serious infectious
diseases and rare diseases; (ii)&nbsp;registration of pediatric drugs; (iii)&nbsp;registration of drugs treating specific or prevalent diseases in elders; (iv)&nbsp;registration of drugs listed in national major science and technology projects or
national key research and development plan; (v)&nbsp;registration of innovative drugs using advanced technology, using innovative treatment methods, or having distinctive clinical benefits; (vi)&nbsp;registration of foreign innovative drugs to be
manufactured locally in China; (vii)&nbsp;concurrent applications for new drug clinical trials which are already approved in the United States or the European Union or concurrent drug registration applications for drugs which have applied to the
competent drug approval authorities for marketing authorization and passed such authorities&#146; onsite inspections in the United States or European Union and are manufactured using the same production line in China; and (viii)&nbsp;clinical trial
approval for drugs with urgent clinical need and patent expiry within three years, and manufacturing authorization applications for drugs with urgent clinical need and patent expiry within one year. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Opinions on Encouraging the Prioritized Evaluation and Approval for Drug Innovations promulgated on December&nbsp;21, 2017 provides that a
fast track clinical trial approval or drug registration pathway will be available to both innovative drugs with distinctive clinical benefits, which have not been sold within or outside China, and drugs using advanced technology, innovative
treatment methods or having distinctive treatment advantages. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Opinions on the Reform of Evaluation and Approval System for Drugs and
Medical Devices and Equipment promulgated on August&nbsp;9, 2015 provides that the composition of the examiner team of the CDE shall be strengthened by, among other actions, (1)&nbsp;recruiting professional evaluation talent from the public,
(2)&nbsp;engaging relevant experts to participate in technological examination and evaluation, and (3)&nbsp;establishing a system of chief professional positions. Additionally, the Opinions on Encouraging the Prioritized Evaluation and Approval for
Drug Innovations emphasizes the improvement of the examination and evaluation system, which requires the establishment of a new drug examination and evaluation team comprising professionals specialized in clinical medicine, pharmaceutical sciences,
pharmacology, toxicology and statistics. As a result, since 2015, the NMPA and the CDE have started a large-scale expansion of examiners, which could greatly accelerate the new drug approval process in China. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Pursuant to the New Measures for Registration, at the stage of clinical trial application, depending on the characteristics of the drug and
the corresponding conditions, applicants may apply for adoption of the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">221 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Breakthrough Drug Procedure or the Conditioned Approval Procedure. Such procedures may be applied for eligible drugs, including drugs for fatal diseases without any effective treatment and
breakthrough drugs, and extra policy support, including communication with the CDE at the critical stage of clinical trials and suggestions from the CDE may be given to applicants in such special procedures. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><B><I>Manufacturing and Distribution </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">According to the Drug Administration Law, all facilities that manufacture drugs in China must receive a drug manufacturing license from the
local drug regulatory authority. Each drug manufacturing license issued to a pharmaceutical manufacturing enterprise is effective for a period of five years. Any enterprise holding a drug manufacturing license is subject to review by the relevant
regulatory authorities on an annual basis. A separate certification of compliance with Good Manufacturing Practice (the &#147;GMP&#148;) is also required. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Similarly, to conduct sales, importation, shipping and storage (collectively, the &#147;distribution activities&#148;), a company must obtain
a Drug Distribution License from the local drug regulatory authority, subject to renewal every five years. A separate certification of compliance with the NMPA&#146;s drug good supply practice (the &#147;GSP&#148;), is also required. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">China has implemented a <FONT STYLE="white-space:nowrap">&#147;Two-Invoice</FONT> System&#148; to control the distribution of prescription
drugs. The <FONT STYLE="white-space:nowrap">&#147;Two-Invoice</FONT> System&#148; generally requires that no more than two invoices be issued throughout the distribution chain: one from the manufacturer to a distributor and another from the
distributor to the <FONT STYLE="white-space:nowrap">end-user</FONT> hospital. This excludes the sale of products invoiced from the manufacturer to its wholly-owned or controlled distributors, or for imported drugs, to its exclusive distributor, or
from a distributor to its wholly-owned or controlled subsidiary (or between its wholly-owned or controlled subsidiaries). However, the system still significantly limits the options for companies to use multiple distributors to reach a larger
geographic area in China. Compliance with the <FONT STYLE="white-space:nowrap">Two-Invoice</FONT> System is a prerequisite for pharmaceutical companies to participate in the procurement processes of public hospitals, which currently provide most of
China&#146;s healthcare services. Manufacturers and distributors that fail to implement the <FONT STYLE="white-space:nowrap">Two-Invoice</FONT> System may lose their qualifications to participate in the bidding process. <FONT
STYLE="white-space:nowrap">Non-compliant</FONT> manufacturers may also be blacklisted from engaging in drug sales to public hospitals in a locality. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The <FONT STYLE="white-space:nowrap">Two-Invoice</FONT> System was first implemented in 11 provinces involved in pilot comprehensive medical
reforms, and the program has been expanded to nearly all provinces, each with its own individual rules for the program. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><B><I>New Drug
Application </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Pursuant to the Administrative Measures for Drug Registration, when Phases 1, 2 and 3 clinical trials have been
completed, the applicant may apply to the NMPA for approval of a new drug application. The NMPA shall then determine whether to approve the application according to the comprehensive evaluation opinion provided by the CDE of the NMPA. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Pursuant to the New Measures for Registration, at the stage of new drug application, depending on the characteristics of the drug and the
corresponding conditions, applicants may apply for adoption of special procedures, including the Priority Review Procedure and the Special Review Procedure. Such procedures may be applied for innovative drugs for severe infectious diseases or rare
diseases, breakthrough drugs and other eligible drugs stipulated in the New Measures for Registration. Extra policy support, including less review period, may be given to applicants in such special procedures. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><B><I>International Multi-center Clinical Trials Regulations </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">On January&nbsp;30, 2015, the NMPA promulgated the Notice on Issuing the International Multi-Center Clinical Trial Guidelines (Trial),
effective as of March&nbsp;1, 2015, to provide guidance on the regulation of the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">222 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
application, implementation and administration of international multi-center clinical trials in China. Pursuant to the Notice on Issuing the International Multi-Center Clinical Trial Guidelines
(Trial), international multi-center clinical trial applicants may simultaneously perform clinical trials in different centers using the same clinical trial protocol. Where the applicant plans to make use of the data derived from the international
multi-center clinical trials for its application to the NMPA for approval of a new drug application, such international multi-center clinical trials shall satisfy, in addition to the requirements set forth in the Drug Administration Law and its
implementation measures, the Administrative Measures for Drug Registration and other relevant laws and regulations, the following requirements: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The applicant shall first conduct an overall evaluation on the global clinical trial data and further make trend
analysis of the Asian and Chinese clinical trial data. In the analysis of Chinese clinical trial data, the applicant shall consider the representativeness of the research subjects, i.e., the participating patients; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The applicant shall analyze whether the amount of Chinese research subjects is sufficient to assess and
adjudicate the safety and effectiveness of the drug under clinical trial, and satisfy the statistical and relevant legal requirements; and </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The onshore and offshore international multi-center clinical trial research centers shall be subject to <FONT
STYLE="white-space:nowrap">on-site</FONT> inspections by competent PRC governmental agencies. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">International
multi-center clinical trials shall follow international prevailing GCP principles and ethics requirements. Applications shall ensure the truthfulness, reliability and trustworthiness of clinical trials results; the researchers shall have the
qualification and capability to perform relevant clinical trials; and an ethics committee shall continuously review the trials and protect the subjects&#146; interests, benefits and safety. Before the performance of the international multi-center
clinical trial, applicants shall obtain clinical trial approvals or complete filings pursuant to requirements under the local regulations where clinical trials are conducted, and register and disclose the information of all major researchers and
clinical trial organizations on the NMPA drug clinical trial information platform. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Pursuant to the Opinions on Deepening the Reform of
the Evaluation and Approval System and Inspiring Innovation of Drugs and Medical Devices and Equipment, clinical trial data obtained from foreign centers may be used to apply for registration in China as long as such data meet the relevant
requirements for the registration of drugs and medical devices in China. When using international multi-center clinical trial data to support new drug applications in China, applicants shall submit the completed global clinical trial report,
statistical analysis report and database, along with relevant supporting data in accordance with <FONT STYLE="white-space:nowrap">ICH-CTD</FONT> (International Conference on Harmonization-Common Technical Document) content and format requirements;
subgroup research results summary and comparative analysis shall also be conducted concurrently. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><B><I>Marketing Authorization Holder
System </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Pursuant to the Opinions on the Reform of Evaluation and Approval System for Drugs and Medical Devices and Equipment
promulgated on August&nbsp;9, 2015, the State Council published the policy for carrying out a pilot plan for the drug marketing authorization holder mechanism. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Pursuant to the newly amended Drug Administrative Law, under the drug marketing authorization holder mechanism, an enterprise obtained drug
registration certificate and a research and development institution are eligible to be a pharmaceutical marketing authorization holder and the drug marketing authorization holder shall be responsible for nonclinical laboratory studies, clinical
trials, production and distribution, post-market studies, and the monitoring, reporting, and handling of adverse reactions in connection with pharmaceuticals in accordance with the provisions of the Drug Administrative Law. The pharmaceutical
marketing authorization holder may engage contract manufacturers for manufacturing, provided that the contract manufacturers are </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">223 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
licensed and may engage pharmaceutical distribution enterprises with drug distribution license for the distribution activities. Upon the approval of the medical products administrative department
under the State Council, a drug marketing authorization holder may transfer the drug marketing license and the transferee shall have the capability of quality management, risk prevention and control, and liability compensation to ensure the safety,
effectiveness and quality controllability of drugs, and fulfill the obligations of the drug marketing license holder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><B><I>Administrative Observation Periods for New Drugs </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">According to the Implementing Measures of the Drug Administration Law, the NMPA may, for the purposes of protecting public health, set an
administrative observation period of not more than five years for a new drug produced by a drug manufacturer. During the administrative observation period, no approval shall be given to any other manufacturer to produce or import the said drug. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><B><I><FONT STYLE="white-space:nowrap">Non-Inferiority</FONT> Standard </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In China, a drug may receive regulatory approval without showing superiority in its primary endpoint. Rather, a drug may be approved for use
if it shows <FONT STYLE="white-space:nowrap">non-inferiority</FONT> in its primary endpoint and superiority in one of its secondary endpoints. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><B><I>Packaging of Pharmaceutical Products </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Pursuant to the Administration of Quality of Drug Clinical Practice, the applicant shall be responsible for proper packaging and labeling of
drugs for clinical trials, and in double-blinded clinical trials, the test drug shall be consistent with the control drug or placebo in appearance, odor, packaging, labeling, and certain other features. According to the Measures for the
Administration of Pharmaceutical Packaging promulgated on February&nbsp;12, 1988 and effective from September&nbsp;1, 1988, pharmaceutical packaging must comply with national and professional standards. If there is no national or professional
standard available, an applicant may formulate and implement its own standards after obtaining the approval of the provincial administration or bureau of standards. The applicant must reapply if it needs to change its own packaging standards. Drugs
that have not been developed and approved for packaging standards must not be sold or marketed in the PRC (except for drugs for the military). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><B><I>National List of Essential Drugs </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">On August&nbsp;18, 2009, the MOH and eight other ministries and commissions in the PRC issued the Provisional Measures on the Administration
of the National List of Essential Drugs which was revised on February&nbsp;13, 2015 aim to promote essential medicines sold to consumers at fair prices in the PRC and ensure that the general public in the PRC has equal access to the drugs contained
in the National List of Essential Drugs. The MOH promulgated the National List of Essential Drugs on March&nbsp;13, 2013 and on September&nbsp;30, 2018. According to these regulations, basic healthcare institutions funded by the government shall
store up and use drugs listed in the National List of Essential Drugs. The drugs listed in the National List of Essential Drugs shall be purchased by centralized tender process and shall be subject to the price control by the National Development
and Reform Commission (the &#147;NDRC&#148;). Remedial drugs in the National List of Essential Drugs are all listed in the NRDL and the purchase price of such drugs is entitled to reimbursement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><B><I>Government Price Controls </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Chinese government has abolished the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">15-year-old</FONT></FONT> <FONT
STYLE="white-space:nowrap">government-led</FONT> pricing system for drugs. On May&nbsp;4, 2015, the NDRC and six other ministries and commissions in the PRC issued the Opinion on Promoting Drug Pricing Reform, which lifted the government-prescribed
maximum retail price for most drugs, except for narcotic drugs and Class&nbsp;I psychotropic drugs. The government regulates drug prices mainly by establishing a consolidated procurement mechanism, restructuring medical insurance reimbursement
standards and strengthening the regulation of medical and pricing practices as discussed below. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">224 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><B><I>Centralized Procurement and Tenders </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Under the current regulations, public medical institutions owned by the government or owned by State-owned or controlled enterprises are
required to purchase pharmaceutical products through centralized online procurement processes. There are exceptions for drugs on the National List of Essential Drugs, which have their own procurement rules, and for certain drugs subject to the
central government&#146;s special control, such as toxic, radioactive and narcotic drugs and traditional Chinese medicines. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The
centralized procurement process takes the form of public tenders operated by provincial or municipal-level government agencies. The centralized tender process is typically conducted once every year. The bids are assessed by a committee randomly
selected from a database of experts. The committee members assess the bids based on a number of factors, including, but not limited to, bid price, product quality, clinical effectiveness, product safety, level of technology, qualifications and
reputation of the manufacturer, after-sale services and innovation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The State Council approved
<FONT STYLE="white-space:nowrap">state-run</FONT> centralized medicine procurement and 11 pilot cities for the program in a circular issued on January&nbsp;17, 2019. It is an effort to deepen reform of the medical and health sector and optimize the
pricing system of drugs. According to the circular, in the 11 pilot cities drugs will be selected from generic brands for centralized medicine procurement. The selected drugs must pass the consistency evaluation on quality and effectiveness. The
policy is aimed at lowering drug costs for patients, reducing transaction costs for enterprises, regulating drug use of institutions, and improving the centralized medicine procurement and pricing system. The centralized procurement is open to all
approved enterprises that can produce drugs on the procurement list in China. Clinical effects, adverse reactions, and batch stability of the drugs will be considered, and their consistency will be the main criteria for evaluation, while production
capacity and stability of the supplier will also be considered. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><B><I>Commercial Insurance </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">On October&nbsp;25, 2016, the State Council issued the Plan for Healthy China 2030. According to the Plan, the country will establish a
multi-level medical security system built around basic medical insurance, with other forms of insurance supplementing the basic medical insurance, including serious illness insurance for urban and rural residents, commercial health insurance and
medical assistance. Furthermore, the Plan encourages enterprises and individuals to participate in commercial health insurance and various forms of supplementary insurance. The evolving medical insurance system makes innovative drugs more affordable
and universally available to the Chinese population, which renders greater opportunities to drug manufacturers that focus on the research and development of innovative drugs, such as high-cost cancer therapeutics. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><B><I>Healthcare System Reform </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The PRC government recently promulgated several healthcare reform policies and regulations to reform the healthcare system. On March&nbsp;17,
2009, the State Council issued the Guidelines on Strengthening the Reform of Healthcare System. On December&nbsp;27, 2016, the State Council issued the Notice on the Issuance of the 13th Five-year Plan on Strengthening the Reform of Healthcare
System. On May&nbsp;23, 2019, the General Office of the State Council issued the Notice on the Main Tasks of Strengthening the Reform of Healthcare System in 2019, which specified the key legislative work of the national medical and health system
and the key tasks to promote its implementation. <FONT STYLE="white-space:nowrap">Twenty-one</FONT> specific tasks have been proposed to address the difficulty and high cost of getting medical services and to strengthen hospital management. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><B><I>Chronic Diseases Prevention and Treatment </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Pursuant to the Guiding Opinion of the General Office of the State Council on Promoting the Construction of the Hierarchical Healthcare System
issued by the General Office of the State Council on </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">225 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
September&nbsp;8, 2015 and the Notice on Promoting Pilot Work for Hierarchical Healthcare System jointly promulgated by the NHFPC and the State Administration of Traditional Chinese Medicine on
August&nbsp;19, 2016, the hierarchical healthcare system is expected to be gradually improved, and the framework for division and coordination among medical and health institutions shall be substantially established by 2017, and a diagnosis and
treatment model featuring objectives, such as initial diagnosis of common diseases and frequent diseases at primary hospitals and separate treatment of acute and chronic diseases, are expected to be gradually established. According to the Guiding
Opinion of the General Office of the State Council on Promoting the Construction of the Hierarchical Healthcare System, several chronic diseases, including hypertension, diabetes, cancer and cardiovascular and cerebrovascular diseases, are pilot
diseases under the hierarchical healthcare system. Primary healthcare institutions, rehabilitation hospitals and nursing institutions may provide treatment, rehabilitation and nursing services for patients with chronic diseases, patients in stable
conditions, elderly patients, and advanced cancer patients who have clear diagnosis and stable disease conditions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">On January&nbsp;22,
2017, the General Office of the State Council issued the Notice on the Medium and Long-Term Plan for Chronic Disease Prevention and Treatment in China (2017-2025), which sets up the objectives of the management of diabetes patients, targeting the
involvement of 35&nbsp;million diabetic patients by 2020 and 40&nbsp;million by 2025 in chronic disease management. The Notice on the Medium and Long-Term Plan for Chronic Disease Prevention and Treatment in China (2017-2025) reaffirms that the
hierarchical healthcare system of chronic diseases such as diabetes shall be promoted and encourages the initial diagnosis of common diseases and frequent diseases at primary hospitals. In addition, social participation in regional medical services,
health management and chronic disease prevention services, as well as investments in the field of chronic disease prevention by social capital, are encouraged. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><B><I>Intellectual Property Rights </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">China became a member of the World Trade Organization and a party to the Agreement on Trade-Related Aspects of Intellectual Property Rights on
December&nbsp;11, 2001. China has also entered into several international conventions on intellectual property rights, including, but not limited to, the Paris Convention for the Protection of Industrial Property, the Madrid Agreement Concerning the
International Registration of Marks, and the Patent Cooperation Treaty. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><B><I>Patents </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Pursuant to the PRC Patent Law promulgated by the Standing Committee of the NPC on March&nbsp;12, 1984 and amended on September&nbsp;4, 1992,
August&nbsp;25, 2000 and December&nbsp;27, 2008, respectively, and effective from October&nbsp;1, 2009, and the Implementation Rules of the Patent Law of the PRC promulgated by the State Council on June&nbsp;15, 2001 and amended on December&nbsp;28,
2002 and January&nbsp;9, 2010, respectively, patents in China fall into three categories: invention, utility model and design. An invention patent is granted to a new technical solution proposed in respect of a product or method or an improvement of
a product or method. A utility model is granted to a new technical solution that is practicable for application and proposed in respect of the shape, structure or a combination of both of a product. A design patent is granted to the new design of a
certain product in shape, pattern or a combination of both and in color, shape and pattern combinations aesthetically suitable for industrial application. Under the PRC Patent Law, the term of patent protection starts from the date of application.
Patents relating to invention are effective for twenty years, and utility models and designs are effective for ten years from the date of application. The PRC Patent Law adopts the principle of <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">&#147;first-to-file&#148;</FONT></FONT> system, which provides that where more than one person files a patent application for the same invention, a patent will be granted to the person who files the application first. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Existing patents can become narrowed, invalid or unenforceable due to a variety of grounds, including lack of novelty, creativity, and
deficiencies in patent application. In China, a patent must have novelty, creativity and practical applicability. Under the PRC Patent Law, novelty means that before a patent application is filed, no identical invention or utility model has been
publicly disclosed in any publication in China or overseas or has </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">226 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
been publicly used or made known to the public by any other means, whether in or outside of China, nor has any other person filed with the patent authority an application that describes an
identical invention or utility model and is recorded in patent application documents or patent documents published after the filing date. Creativity means that, compared with existing technology, an invention has prominent substantial features and
represents notable progress, and a utility model has substantial features and represents any progress. Practical applicability means an invention or utility model can be manufactured or used and may produce positive results. Patents in China are
filed with the State Intellectual Property Office (the &#147;SIPO&#148;). Normally, the SIPO publishes an application for an invention patent within 18 months after the filing date, which may be shortened at the request of applicant. The applicant
must apply to the SIPO for a substantive examination within three years from the date of application. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Article 20 of the PRC Patent Law
provides that, for an invention or utility model completed in China, any applicant (not just Chinese companies and individuals), before filing a patent application outside of China, must first submit it to the SIPO for a confidential examination.
Failure to comply with this requirement will result in the denial of any Chinese patent for the relevant invention. This added requirement of confidential examination by the SIPO has raised concerns by foreign companies who conduct research and
development activities in China or outsource research and development activities to service providers in China. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">On October&nbsp;17, 2020,
the Standing Committee of the NPC promulgated the Amendment to the Patent Law. The Amendment to the Patent Law, which will become effective from June&nbsp;1, 2021, extends the validity period for design and the time limitation of actions for
infringement of patent rights, and increases the maximum amount of infringement compensation. Meanwhile, the Amendment to the Patent Law implements a &#147;compensation for patent term&#148; (the &#147;Term Compensation&#148;) measure. In the event
that an invention patent is granted after the forth (4th) anniversary of the date of application and the third (3rd) anniversary of the date of the request for substantive examination, the Patent Administration Department of the State Council shall,
at the request of the patentee, provide the Term Compensation for the unreasonable delay in the process of granting the patent, except for the unreasonable delay caused by the applicant. In particular, in order to compensate the time taken for the
review and approval of new drugs, if the new drug-related invention patents are approved for marketing in China, the Patent Administration Department of the State Council shall provide the Term Compensation to the patentee, for the duration of
patent rights at the request of the patentee. The Term Compensation shall not exceed five (5)&nbsp;years, and the total effective patent right period after the new drug is approved for marketing shall not exceed fourteen (14)&nbsp;years. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><B><I>Patent Enforcement </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Unauthorized use of patents without consent from owners of patents, forgery of the patents belonging to other persons, or engagement in other
patent infringement acts, will subject the infringers to infringement liability. Serious offenses such as forgery of patents may be subject to criminal penalties. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">When a dispute arises out of infringement of the patent owner&#146;s patent right, Chinese law requires that the parties first attempt to
settle the dispute through mutual consultation. However, if the dispute cannot be settled through mutual consultation, the patent owner, or an interested party who believes the patent is being infringed, may either file a civil legal suit or file an
administrative complaint with the relevant patent administration authority. A Chinese court may issue a preliminary injunction upon the patent owner&#146;s or an interested party&#146;s request before instituting any legal proceedings or during the
proceedings. Damages for infringement are calculated as the loss suffered by the patent holder arising from the infringement, and if the loss suffered by the patent holder arising from the infringement cannot be determined, the damages for
infringement shall be calculated as the benefit gained by the infringer from the infringement. If it is difficult to ascertain damages in this manner, damages may be determined by using a reasonable multiple of the license fee under a contractual
license. Statutory damages may be awarded in the circumstances where the damages cannot be determined by the above-mentioned calculation standards. The damage calculation methods shall be applied in the aforementioned order. Generally, the patent
owner has the burden of proving that the patent is being </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">227 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
infringed. However, if the owner of an invention patent for manufacturing process of a new product alleges infringement of its patent, the alleged infringer has the burden of proof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><B><I>Medical Patent Compulsory License </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">According to the PRC Patent Law, for the purpose of public health, the SIPO may grant a compulsory license for manufacturing patented drugs
and exporting them to countries or regions covered under relevant international treaties to which the PRC has acceded. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><B><I>Trade
Secrets </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Pursuant to the PRC Anti-Unfair Competition Law promulgated by the Standing Committee of the NPC on September&nbsp;2,
1993 and amended on November&nbsp;4, 2017 and April&nbsp;23, 2019, respectively, the term &#147;trade secrets&#148; refers to technical and business information that is unknown to the public, has utility, may create business interests or profits for
its legal owners or holders, and is maintained as a secret by its legal owners or holders. Under the PRC Anti-Unfair Competition Law, business persons are prohibited from infringing others&#146; trade secrets by (1)&nbsp;obtaining the trade secrets
from the legal owners or holders by any unfair methods, such as theft, bribery, fraud, coercion, electronic intrusion, or any other illicit means; (2)&nbsp;disclosing, using or permitting others to use the trade secrets obtained illegally under item
(1)&nbsp;above; (3) disclosing, using or permitting others to use the trade secrets, in violation of any contractual agreements or any requirements of the legal owners or holders to keep such trade secrets in confidence; or (4)&nbsp;instigating,
inducing or assisting others to disclose, use or permit others to use the trade secrets, in violation of any contractual agreements or any requirement of the legal owners or holders to keep such trade secret in confidence. If a third party knows or
should have known of the above-mentioned illegal conduct but nevertheless obtains, uses or discloses trade secrets of others, the third party may be deemed to have committed a misappropriation of the others&#146; trade secrets. The parties whose
trade secrets are being misappropriated may petition for administrative corrections, and regulatory authorities may terminate any illegal activities and impose fines on the infringing parties. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><B><I>Trademarks </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Pursuant to the Trademark Law of the PRC promulgated by the Standing Committee of the NPC on August&nbsp;23, 1982 and amended on
February&nbsp;22, 1993, October&nbsp;27, 2001 and August&nbsp;30, 2013, respectively, and effective from May&nbsp;1, 2014, which has been amended on April&nbsp;23, 2019 and became effective from November&nbsp;1, 2019, the period of validity for a
registered trademark is ten years, commencing from the date of registration. The registrant shall go through the formalities for renewal within twelve months prior to the expiry date of the trademark if continued use is intended. Where the
registrant fails to do so, a grace period of six months may be granted. The validity period for each renewal of registration is ten years, commencing from the day immediately after the expiry of the preceding period of validity for the trademark. In
the absence of a renewal upon expiry, the registered trademark shall be cancelled. Industrial and commercial administrative authorities have the authority to investigate any behavior in infringement of the exclusive right under a registered
trademark in accordance with the law. In case of a suspected criminal offense, the case shall be timely referred to a judicial authority and decided according to the law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><B><I>Domain Names </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Domain names are protected under the Measures on Administration of Domain Names for the Chinese Internet promulgated by the Ministry of
Industry and Information Technology, on November&nbsp;5, 2004 and effective from December&nbsp;20, 2004, which was replaced by the Administrative Measures on the Internet Domain Names issued by the Ministry of Industry and Information Technology on
August&nbsp;24, 2017 and effective from November&nbsp;1, 2017, and the Implementing Rules on Registration of Domain Names issued by China Internet Network Information Center on May&nbsp;28, 2012, which became effective on May&nbsp;29, 2012. The
Ministry of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">228 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Industry and Information Technology is the main regulatory body responsible for the administration of PRC internet domain names. Domain name registrations are handled through domain name service
agencies established under the relevant regulations, and the applicants become domain name holders upon successful registration. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><B><I>Product Liability </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Product Quality Law of the PRC promulgated by the Standing Committee of the NPC on February&nbsp;22, 1993 and amended on July&nbsp;8,
2000, August&nbsp;27, 2009 and December&nbsp;29, 2018, respectively, is the principal governing law relating to the supervision and administration of product quality. According to the Product Quality Law, manufacturers shall be liable for the
quality of products produced by them, and sellers shall take measures to ensure the quality of the products sold by them. A manufacturer shall be liable for compensating for any bodily injuries or property damages, other than the defective product
itself, resulting from the defects in the product, unless the manufacturer is able to prove that: (1)&nbsp;the product has never been distributed; (2)&nbsp;the defects causing injuries or damages did not exist at the time when the product was
distributed; or (3)&nbsp;the science and technology at the time when the product was distributed was at a level incapable of detecting the defects. A seller shall be liable for compensating for any bodily injuries or property damages of others
caused by the defects in the product if such defects are attributable to the seller. A seller shall pay compensation if it fails to indicate either the manufacturer or the supplier of the defective product. A person who is injured or whose property
is damaged by the defects in the product may claim for compensation from the manufacturer or the seller. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Pursuant to the General
Principles of the Civil Law of the PRC promulgated by the NPC on April&nbsp;12, 1986 and amended on August&nbsp;27, 2009, both manufacturers and sellers shall be held liable where the defective products result in property damages or bodily injuries
to others. Pursuant to the Tort Liability Law of the PRC promulgated by the Standing Committee of the NPC on December&nbsp;26, 2009 and effective from July&nbsp;1, 2010, manufacturers shall assume tort liabilities where the defects in products cause
damages to others. Sellers shall assume tort liabilities where the defects in products that have caused damages to others are attributable to the sellers. The aggrieved party may claim for compensation from the manufacturer or the seller of the
defected product that has caused damage. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Regulation of Commercial Bribery </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Pharmaceutical companies involved in a criminal investigation or administrative proceedings related to bribery are listed in the Adverse
Records of Commercial Briberies by their respective provincial health and family planning administrative department. Pursuant to the Provisions on the Establishment of Adverse Records of Commercial Briberies in the Medicine Purchase and Sales
Industry which became effective on March&nbsp;1, 2014, provincial health and family planning administrative departments formulate the implementing measures for establishment of Adverse Records of Commercial Briberies. Where a pharmaceutical company
or its agent is listed in the Adverse Records of Commercial Briberies on one occasion, it will be prohibited from participating in the procurement bidding process or selling its products to public medical institutions located in the local
provincial-level region for two years from the publication of the adverse records. The evaluation points of such pharmaceutical company or agent in respect of the procurement bidding process and procurement by public medical institutions must be
credited by public medical institutions in the other provincial-level regions for two years from the publication of the adverse records. Where a pharmaceutical company or its agent is listed in the Adverse Records of Commercial Briberies on two or
more occasions within five years, it will be prohibited from participating in the procurement bidding process or selling its products to all public medical institutions in the PRC for two years from the publication of these adverse records. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Regulations Relating to Employee Stock Incentive Plan </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In February 2012, the SAFE promulgated the Notices on Issues Concerning the Foreign Exchange Administration for Domestic Individuals
Participating in Stock Incentive Plans of Overseas Publicly Listed </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">229 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Companies (the &#147;Stock Option Rules&#148;), which replaced the Application Procedures of Foreign Exchange Administration for Domestic Individuals Participating in Employee Stock Ownership
Plans or Stock Option Plans of Overseas Publicly Listed Companies issued by the SAFE on March&nbsp;28, 2007. In accordance with the Stock Option Rules and relevant rules and regulations, PRC citizens or
<FONT STYLE="white-space:nowrap">non-PRC</FONT> citizens residing in China for a continuous period of not less than one year, who participate in any stock incentive plan of an overseas publicly listed company, subject to a few exceptions, are
required to register with the SAFE through a domestic qualified agent, which could be a PRC subsidiary of such overseas listed company, and complete certain procedures. We and our employees who are PRC citizens or who reside in China for a
continuous period of not less than one year and who participate in our stock incentive plan will be subject to such regulation. In addition, the SAT has issued circulars concerning employee share options or restricted shares. Under these circulars,
employees working in the PRC who exercise share options, or whose restricted shares vest, will be subject to PRC individual income tax (the &#147;IIT&#148;). The PRC subsidiaries of an overseas listed company have obligations to file documents
related to employee share options or restricted shares with relevant tax authorities and to withhold IIT of those employees related to their share options or restricted shares. If the employees fail to pay, or the PRC subsidiaries fail to withhold,
their IIT according to relevant laws, rules and regulations, the PRC subsidiaries may face sanctions imposed by the tax authorities or other PRC government authorities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Regulations Relating to Foreign Exchange and the Dividend Distribution </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><B><I>Foreign Exchange Control </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The State Council promulgated the PRC Regulation for the Foreign Exchange on January&nbsp;29, 1996, which was amended on January&nbsp;14, 1997
and August&nbsp;5, 2008, respectively. On June&nbsp;20, 1996, the People&#146;s Bank of China promulgated the Regulation on the Administration of the Foreign Exchange Settlement, Sales and Payment, which came into effect on July&nbsp;1, 1996.
Pursuant to the above-mentioned regulations, foreign exchanges required for distribution of profits and payment of dividends may be purchased from designated foreign exchange banks in the PRC upon presentation of a board resolution authorizing the
distribution of profits or payment of dividends. The Regulation on the Administration of the Foreign Exchange Settlement, Sales and Payment removed the previous restrictions on convertibility of foreign exchange in respect of current account items,
including the distribution of dividends, interest and royalty payments, trade and service-related foreign exchange transactions, while foreign exchange transactions in respect of capital account items, such as direct investment, loan, securities
investment and repatriation of investment, remain subject to the approval of the SAFE. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">On November&nbsp;19, 2012, the SAFE issued the
Operating Rules for Foreign Exchange Issues with Regard to Direct Investment under Capital Account as an appendix to the Circular of the SAFE on Further Improving and Adjusting the Foreign Exchange Policies on Direct Investment, which was issued on
November&nbsp;19, 2012 and amended on May&nbsp;4, 2015. According to the Circular of the SAFE on Further Improving and Adjusting the Foreign Exchange Policies on Direct Investment, (i)&nbsp;the opening of and payment into foreign exchange accounts
under direct investment accounts are no longer subject to approval by the SAFE; (ii)&nbsp;reinvestment with the legal income of foreign investors in China is no longer subject to approval by the SAFE; (iii)&nbsp;the procedures for capital
verification and confirmation that foreign-funded enterprises need to go through are simplified; (iv)&nbsp;the purchase and external payment of foreign exchange under direct investment accounts are no longer subject to approval by the SAFE;
(v)&nbsp;domestic transfer of foreign exchange under direct investment accounts is no longer subject to approval by the SAFE; and (vi)&nbsp;the administration over the conversion of foreign exchange capital of foreign-funded enterprises is improved.
On February&nbsp;13, 2015, the SAFE issued the Circular on Further Simplifying and Improving Foreign Exchange Administration Policies in Respect of Direct Investment, which came into effect on June&nbsp;1, 2015, providing that the banks, instead of
the SAFE, can directly handle the foreign exchange registration and approval under foreign direct investment, while the SAFE and its branches indirectly supervise the foreign exchange registration and approval under foreign direct investment through
the banks. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">230 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">On May&nbsp;11, 2013, the SAFE promulgated the Provisions on the Administration of Foreign
Exchange in Foreign Direct Investments by Foreign Investors, which became effective on May&nbsp;13, 2013, and relevant supporting documents that regulate and clarify the administration over foreign exchange administration in foreign direct
investments. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">On March&nbsp;30, 2015, the SAFE released the Circular on the Reform of the Management Method for the Settlement of Foreign
Exchange Capital of Foreign-invested Enterprises, which came into effect on June&nbsp;1, 2015 and superseded the Notice on the Relevant Operating Issues Concerning the Improvement of the Administration of Payment and Settlement of Foreign Currency
Capital of Foreign-funded Enterprises issued by the SAFE on August&nbsp;29, 2008. The Circular on the Reform of the Management Method for the Settlement of Foreign Exchange Capital of Foreign-invested Enterprises has made certain adjustments to some
regulatory requirements on the settlement of foreign exchange capital of foreign-invested enterprises, and some foreign exchange restrictions provided in the Notice on the Relevant Operating Issues Concerning the Improvement of the Administration of
Payment and Settlement of Foreign Currency Capital of Foreign-funded Enterprises. On June&nbsp;9, 2016, the SAFE issued the Circular on the Reform and Standardization of the Management Policy of the Settlement of Capital Projects. Under the Circular
on the Reform and Standardization of the Management Policy of the Settlement of Capital Projects and the Circular on the Reform of the Management Method for the Settlement of Foreign Exchange Capital of Foreign-invested Enterprises, the settlement
of foreign exchange by foreign-invested enterprises shall be governed by the policy of foreign exchange settlement on a discretionary basis. However, the aforementioned circulars also reiterate that the settlement of foreign exchange shall only be
used for its own operation purposes within the business scope of the foreign-invested enterprises and following the principles of authenticity. Considering that these circulars are relatively new, it is unclear how they will be implemented, and
there exist great uncertainties with respect to their interpretation and implementation by the authorities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The SAFE promulgated the
Circular on Relevant Issues Concerning Foreign Exchange Control on Domestic Residents&#146; Offshore Investment and Financing and Roundtrip Investment through Special Purpose Vehicles on July&nbsp;4, 2014, which requires PRC residents to register
with local branches of the SAFE in connection with their direct establishment or indirect control of an offshore entity for the purpose of overseas investment and financing, with such PRC residents&#146; legally owned assets or equity interests in
domestic enterprises or offshore assets or interests as a &#147;special purpose vehicle&#148; as defined therein. The aforesaid circular further requires amendment to the registration in the event of any significant changes with respect to the
special purpose vehicle. Failure to comply with the SAFE registration requirements under the Circular on Relevant Issues Concerning Foreign Exchange Control on Domestic Residents&#146; Offshore Investment and Financing and Roundtrip Investment
through Special Purpose Vehicles could result in liabilities under PRC law for evasion of foreign exchange controls. The Circular on Further Simplifying and Improving Foreign Exchange Administration Policies in Respect of Direct Investment, provides
that local banks, instead of the SAFE, can directly handle the initial foreign exchange registration and amendment registration under the Circular on Relevant Issues Concerning Foreign Exchange Control on Domestic Residents&#146; Offshore Investment
and Financing and Roundtrip Investment through Special Purpose Vehicles. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">On April&nbsp;10, 2020, SAFE promulgated the Circular on
Optimizing Administration of Foreign Exchange to Support the Development of Foreign-related Business, which allows eligible enterprises to make domestic payments using their capital funds, foreign credits and the income under capital accounts of
overseas listing, without providing evidentiary materials concerning authenticity of such capital for banks in advance, provided that their capital use shall be authentic and in line with provisions, and conform to the prevailing administrative
regulations on the use of income under capital accounts. The administering bank shall perform <FONT STYLE="white-space:nowrap">ex-post</FONT> sampling in accordance with the relevant requirements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><B><I>Dividend Distribution </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Pursuant to the PRC Company Law and Foreign Investment Law of the PRC, foreign-invested enterprises in the PRC may pay dividends only out of
their accumulated profits as determined in accordance with </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">231 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
PRC accounting standards and regulations. In addition, a foreign-invested enterprise is required to set aside at least 10% of its accumulated profits each year to fund certain reserve funds,
until the accumulative amount of such fund reaches 50% of its registered capital. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">On January&nbsp;26, 2017, the SAFE issued the Notice on
Improving the Check of Authenticity and Compliance to Further Promote Foreign Exchange Control, which stipulates several capital control measures with respect to outbound remittance of profits from domestic entities to offshore entities, including
the following: (i)&nbsp;under the principle of genuine transaction, banks shall check board resolutions regarding profit distribution, the original version of tax filing records and audited financial statements; and (ii)&nbsp;domestic entities shall
hold income to account for previous years&#146; losses before remitting the profits. Moreover, domestic entities shall provide detailed explanations of the sources of capital and the utilization arrangements and board resolutions, contracts and
other proof when completing the registration procedures in connection with an outbound investment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Regulations Relating to Labor </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><B><I>Labor Law and Labor Contract Law </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Pursuant to the PRC Labor Law promulgated by the Standing Committee of the NPC on July&nbsp;5, 1994 and effective from January&nbsp;1, 1995
and amended on August&nbsp;27, 2009 and December&nbsp;29, 2018, respectively, the PRC Labor Contract Law promulgated by the Standing Committee of the NPC on June&nbsp;29, 2007 and effective from January&nbsp;1, 2008 and amended on December&nbsp;28,
2012 and effective from July&nbsp;1, 2013, and the Implementing Regulations of the Employment Contracts Law of the PRC promulgated by the State Council on September&nbsp;18, 2008, labor contracts in written form shall be executed to establish labor
relationships between employers and employees. Wages cannot be lower than the local minimum wage. The employer must establish a system for labor safety and sanitation, strictly abide by the state rules and standards, provide education regarding
labor safety and sanitation to its employees, provide employees with labor safety and sanitary conditions and necessary protection materials in compliance with the state rules and standards, and carry out regular health examinations for employees
engaged in work involving occupational hazards. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><B><I>Social Insurance and Housing Provident Funds </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Under applicable PRC laws, including the Social Insurance Law of the PRC which became effective on July&nbsp;1, 2011 and was amended on
December&nbsp;19, 2018, the Interim Regulations on the Collection and Payment of Social Security Funds promulgated by the State Council on January&nbsp;22, 1999 and amended on March&nbsp;24, 2019, and the Regulations on the Administration of Housing
Provident Funds promulgated by the State Council on April&nbsp;3, 1999 and amended on March&nbsp;24, 2002 and March&nbsp;24, 2019, respectively, employers are required to contribute, on behalf of their employees, to a number of social security
funds, including funds for basic pension insurance, unemployment insurance, basic medical insurance, occupational injury insurance, maternity insurance and housing provident funds. These payments are made to local administrative authorities, and any
employer who fails to contribute may be fined and ordered to pay the deficit amount within a stipulated time limit. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Regulations Relating to
Enterprise Income Tax </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Pursuant to the Enterprise Income Tax Law of the PRC effective as of January&nbsp;1, 2008 and as amended on
February&nbsp;24, 2017 and December&nbsp;29, 2018, respectively, the income tax rate for both domestic and foreign-invested enterprises is 25% with certain exceptions. To clarify certain provisions in the Enterprise Income Tax Law, the State Council
promulgated the Implementation Rules of the Enterprise Income Tax Law on December&nbsp;6, 2007, which was amended and became effective on April&nbsp;23, 2019. Under the Enterprise Income Tax Law and the Implementation Rules of the Enterprise Income
Tax Law, enterprises are classified as either &#147;resident enterprises&#148; or <FONT STYLE="white-space:nowrap">&#147;non-resident</FONT> enterprises.&#148; Besides enterprises established within the PRC, enterprises established outside of China
whose &#147;de facto management bodies&#148; are located in China are considered &#147;resident </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">232 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
enterprises&#148; and subject to the uniform 25% enterprise income tax rate for their global income. In addition, the Enterprise Income Tax Law provides that a
<FONT STYLE="white-space:nowrap">non-resident</FONT> enterprise refers to an entity established under foreign law whose &#147;de facto management bodies&#148; are not within the PRC, but has an establishment or place of business in the PRC, or does
not have an establishment or place of business in the PRC but has income sourced within the PRC. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Implementation Rules of the
Enterprise Income Tax Law provide that since January&nbsp;1, 2008, an income tax rate of 10% shall normally be applicable to dividends declared to <FONT STYLE="white-space:nowrap">non-PRC</FONT> resident enterprise investors that do not have an
establishment or place of business in the PRC, or have such establishment or place of business but the relevant income is not effectively connected with the establishment or place of business, to the extent such dividends are derived from sources
within the PRC. The income tax on the dividends may be reduced pursuant to a tax treaty between China and the jurisdictions in which the <FONT STYLE="white-space:nowrap">non-PRC</FONT> shareholders reside. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Other PRC National- and Provincial-Level Laws and Regulations </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We are subject to changing regulations under many other laws and regulations administered by governmental authorities at the national,
provincial and municipal levels, some of which are or may become applicable to our business. For example, regulations control the confidentiality of patients&#146; medical information and the circumstances under which patient medical information may
be released for inclusion in our databases, or released by us to third parties. These laws and regulations governing both the disclosure and the use of confidential patient medical information may become more restrictive in the future. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We also comply with numerous additional national and provincial laws relating to matters such as safe working conditions, manufacturing
practices, environmental protection and fire hazard control. We believe that we are currently in compliance with these laws and regulations; however, we may be required to incur significant costs to comply with these laws and regulations in the
future. Unanticipated changes in existing regulatory requirements or adoption of new requirements could therefore have a material adverse effect on our business, results of operations and financial condition. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>U.S. Regulation </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Government Regulation and Product
Approval in the United States </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The FDA and other regulatory authorities in the United States at federal, state and local levels,
as well as in foreign countries, extensively regulate, among other things, the research, development, testing, manufacture, quality control, import, export, safety, effectiveness, labeling, packaging, storage, distribution, recordkeeping, approval,
advertising, promotion, marketing, post-approval monitoring and post-approval reporting of biological products. Along with third-party contractors, we will be required to navigate the various <FONT STYLE="white-space:nowrap">pre-clinical,</FONT>
clinical and commercial approval requirements of the governing regulatory agencies of the countries in which we wish to conduct studies or seek approval or licensure of our drug candidates. The processes for obtaining regulatory approvals in the
United States and in foreign jurisdictions, along with subsequent compliance with applicable laws and regulations and other regulatory authorities, require the expenditure of substantial time and financial resources. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Government policies may change and additional government regulations may be enacted that could prevent or delay further development or
regulatory approval of any of our drug candidates, or anticipated manufacturing processes, disease indications, or labeling. We cannot predict the likelihood, nature or extent of government regulation that might arise from future legislative or
administrative action. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Review and Approval for Licensing Biologics in the United States </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In the United States, the FDA regulates our current drug candidates as biological products, or biologics, under the Federal Food, Drug, and
Cosmetic Act (the &#147;FDCA&#148;), the Public Health Service Act and associated </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">233 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
implementing regulations. Biologics, like other drugs, are used for the treatment, prevention or cure of disease in humans. In contrast to chemically synthesized small molecular weight drugs,
which have a well-defined structure and can be thoroughly characterized, biologics are generally derived from living material (human, animal, or microorganism) and are complex in structure, and thus are usually not fully characterized. Biologics
include immunomedicines for cancer and other diseases. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Biologics are also subject to other federal, state and local statutes and
regulations. The failure to comply with applicable statutory and regulatory requirements at any time during the product development process, approval process or after approval may subject a sponsor or applicant to administrative or judicial
enforcement actions. These actions could include the suspension or termination of clinical trials by the FDA, the FDA&#146;s refusal to approve pending applications or supplemental applications, withdrawal of an approval, &#147;Warning Letters&#148;
(official messages from the FDA to a manufacturer or other organization that it has violated some rule in a federally regulated activity) or &#147;Untitled Letters&#148; (initial correspondences from the FDA with a regulated industry that cite
violations that do not meet the threshold of regulatory significance for a Warning Letter and request correction of the violation), product recalls, product seizures, total or partial suspension of production or distribution, import detention,
injunctions, fines, refusals of government contracts, restitution, disgorgement of profits, or civil or criminal investigations and penalties brought by the FDA, the Department of Justice (the &#147;DOJ&#148;), or other governmental entities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">An applicant seeking approval to market and distribute a biologic in the United States typically must undertake the following: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">completion of <FONT STYLE="white-space:nowrap">non-clinical</FONT> laboratory tests and animal studies performed
in accordance with the FDA&#146;s good laboratory practice (the &#147;GLP&#148;), regulations; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">submission to the FDA of an application for an Investigational New Drug (&#147;IND&#148;), which must become
effective before clinical trials may begin and must be updated annually or when significant changes are made; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">manufacture, labeling and distribution of an investigational drug in compliance with current good manufacturing
practice (the &#147;cGMP&#148;); </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">approval by an independent institutional review board (the &#147;IRB&#148;), or ethics committee at each clinical
site before each clinical trial may be initiated; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">performance of adequate and well-controlled human clinical trials in accordance with the FDA&#146;s current Good
Clinical Practices requirements (the &#147;cGCP&#148;), to establish the safety, purity and potency of the proposed biological drug candidate for its intended purpose; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">preparation of and submission to the FDA of a biologics license application (&#147;BLA&#148;), after completion
of all pivotal clinical trials requesting marketing approval for one or more proposed indications; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">satisfactory completion of an FDA Advisory Committee review, where appropriate or if applicable, as may be
requested by the FDA to assist with its review; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">satisfactory completion of one or more FDA inspections of the manufacturing facility or facilities at which the
proposed product, or components thereof, are produced to assess compliance with cGMP and data integrity requirements to assure that the facilities, methods and controls are adequate to preserve the biologic&#146;s identity, safety, quality, purity
and potency; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">satisfactory completion of FDA audits of selected clinical investigation sites to assure compliance with cGCP
requirements and the integrity of the clinical data; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">234 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">payment of user fees under the Prescription Drug User Fee Act (the &#147;PDUFA&#148;), for the relevant year;
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">obtaining FDA review and approval of the BLA to permit commercial marketing of the licensed biologic for
particular indications for use in the United States; and </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">compliance with any post-approval requirements, including the potential requirement to implement a Risk
Evaluation and Mitigation Strategy (the &#147;REMS&#148;), and the potential requirement to conduct post-approval studies. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The testing and approval process requires substantial time, effort and financial resources and we cannot be certain that any approvals for our
drug candidates will be granted on a timely basis, if at all. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">From time to time, legislation is drafted, introduced and passed in the
Congress of the United States that could significantly change the statutory provisions governing the testing, approval, manufacturing and marketing of products regulated by the FDA. In addition to new legislation, FDA regulations and policies are
often revised or interpreted by the agency in ways that may significantly affect our business and our drug candidates. It is impossible to predict whether further legislative changes will be enacted or whether FDA regulations, guidance, policies or
interpretations will be changed or what the effect of such changes, if any, may be. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I><FONT STYLE="white-space:nowrap">Pre-clinical</FONT> and
Clinical Development in the United States </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Before a BLA applicant can begin testing the potential asset in human subjects, the
applicant must first conduct <FONT STYLE="white-space:nowrap">pre-clinical</FONT> studies. <FONT STYLE="white-space:nowrap">Pre-clinical</FONT> studies include laboratory evaluations of product chemistry, toxicity and formulation, as well as in
vitro and animal studies to assess the potential safety and activity of the biologic for initial testing in humans and to establish a rationale for therapeutic use. <FONT STYLE="white-space:nowrap">Pre-clinical</FONT> studies are subject to federal
regulations and requirements, including GLP regulations. The results of an applicant&#146;s <FONT STYLE="white-space:nowrap">pre-clinical</FONT> studies are submitted to the FDA as part of an IND. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">An IND is a request for authorization from the FDA to administer an investigational new drug product to humans. An IND is an exemption from
the FDCA that allows an unapproved drug to be shipped in interstate commerce for use in an investigational clinical trial. Such authorization must be secured prior to interstate shipment. In support of a request for an IND, applicants must submit a
range of information, including <FONT STYLE="white-space:nowrap">pre-clinical</FONT> data, manufacturing information and a detailed protocol for each clinical trial. Any subsequent protocol amendments must be submitted to the FDA as part of the IND.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Human clinical trials may not begin until an IND is effective. The IND automatically becomes effective 30 days after receipt by the FDA,
unless the FDA raises safety concerns or questions about the proposed clinical trial within the <FONT STYLE="white-space:nowrap">30-day</FONT> time period. In such a case, the IND may be placed on clinical hold and the IND sponsor and the FDA must
resolve any outstanding concerns or questions before the clinical trial can begin. Submission of an IND therefore may or may not result in FDA authorization to begin a clinical trial. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The FDA may also place a clinical hold or partial clinical hold on such trial following commencement of a clinical trial under an IND. A
clinical hold is an order issued by the FDA to the sponsor to delay a proposed clinical investigation or to suspend an ongoing investigation. A partial clinical hold is a delay or suspension of only part of the clinical work requested under the IND.
For example, a specific protocol or part of a protocol is not allowed to proceed, while other protocols may do so. No more than 30 days after the imposition of a clinical hold or partial clinical hold, the FDA will provide the sponsor with a written
explanation of the basis for the hold. Following issuance of a clinical hold or partial clinical hold, an investigation may only resume after the FDA has notified the sponsor that the investigation may proceed. The FDA will base that determination
on information provided by the sponsor correcting the deficiencies previously cited or otherwise satisfying the FDA that the investigation can proceed. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">235 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Clinical trials involve the administration of the investigational product to human subjects
under the supervision of qualified investigators in accordance with cGCP regulations, which include the requirement that all research subjects provide their informed consent for their participation in any clinical study. Clinical trials are
conducted under protocols detailing, among other things, the objectives of the study, the parameters to be used in monitoring safety and the effectiveness criteria to be evaluated. A separate submission to the existing IND must be made for each
successive clinical trial conducted during product development and for any subsequent protocol amendments. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">A sponsor may choose, but is
not required, to conduct a foreign clinical study under an IND. When a foreign clinical study is conducted under an IND, all FDA IND requirements must be met unless waived. When the foreign clinical study is not conducted under an IND, the sponsor
must ensure that the study complies with cGCP regulations in order to use the study as support for an IND or application for marketing approval, including review and approval by an independent ethics committee and informed consent from subjects.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Furthermore, an independent IRB for each site proposing to conduct the clinical trial must review and approve the plan for any clinical
trial and its informed consent form before the clinical trial begins at that site, and must monitor the study until completed. Regulatory authorities, the IRB or the sponsor may suspend a clinical trial at any time on various grounds, including a
finding that the subjects are being exposed to an unacceptable health risk or that the trial is unlikely to meet its stated objectives. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Some trials also include oversight by an independent group of qualified experts organized by the clinical trial sponsor, known as a data
safety monitoring board (the &#147;DSMB&#148;). DSMBs provide authorization for whether or not a trial may move forward at designated check points based on access to certain data from the trial and may halt the clinical trial if a DSMB determines
that there is an unacceptable safety risk for subjects or based on other grounds, such as no demonstration of efficacy. Other grounds for suspension or termination may be made based on evolving business objectives and/or competitive climate. There
are also requirements governing the reporting of ongoing clinical trials and clinical trial results to public registries. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Clinical Trials
</I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">For purposes of BLA approval, clinical trials are typically conducted in the following sequential phases that may overlap or be
combined: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Phase 1: The investigational product is initially introduced into a small number of healthy human subjects or
patients with the target disease or condition. These trials are designed to test the safety, dosage tolerance, absorption, metabolism and distribution of the investigational product in humans and the side effects associated with increasing doses.
These trials may also yield early evidence of effectiveness. In the case of some products for severe or life-threatening diseases, especially when the product is suspected or known to be unavoidably toxic, the initial human testing may be conducted
in patients. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Phase 2: The investigational product is administered to a limited patient population with a specified disease or
condition to evaluate the preliminary efficacy, optimal dosages and dosing schedule and to identify possible adverse side effects and safety risks. Multiple Phase 2 clinical trials may be conducted to obtain information prior to beginning larger and
more expensive Phase 3 clinical trials. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Phase 3: The investigational product is administered to an expanded patient population generally at multiple
geographically dispersed clinical trial sites to further evaluate dosage, to provide statistically significant evidence of clinical efficacy and to further test for safety. These clinical trials are intended to generate sufficient data to
statistically evaluate the efficacy and safety of the product for approval, to establish the overall risk/benefit ratio of the investigational product and to provide an adequate basis for product approval by the FDA. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">236 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In some cases, the FDA may require, or companies may voluntarily pursue, additional clinical
trials after a product is approved to gain more information about the product, referred to as Phase 4 trials. Such post-approval trials, when applicable, are conducted following initial approval, typically to develop additional data and information
relating to the biological characteristics of the product and treatment of patients in the intended therapeutic indication. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Progress
reports detailing the results of the clinical trials must be submitted at least annually to the FDA and more frequently if serious adverse events occur. In addition, IND safety reports must be submitted to the FDA for any of the following: suspected
serious and unexpected adverse reactions; findings from epidemiological studies, pooled analysis of multiple studies, animal or in vitro testing, or other clinical studies, whether or not conducted under an IND, and whether or not conducted by the
sponsor, that suggest a significant risk in humans exposed to the drug; and any clinically important increase in the rate of a serious suspected adverse reaction over such rate listed in the protocol or investigator brochure, which is a
comprehensive document summarizing the body of information about an investigational product obtained during clinical and <FONT STYLE="white-space:nowrap">non-clinical</FONT> trials. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Each of Phase 1, Phase 2 and Phase 3 clinical trials may not be completed successfully within any specified period, or at all. Furthermore,
the FDA or the sponsor may suspend or terminate a clinical trial at any time on various grounds, including a finding that the research patients are being exposed to an unacceptable health risk. Similarly, an IRB can suspend or terminate approval of
a clinical trial at its institution, or an institution it represents, if the clinical trial is not being conducted in accordance with the IRB&#146;s requirements or if the drug has been associated with unexpected serious harm to patients. The FDA
will typically inspect one or more clinical sites to assure compliance with cGCP and the integrity of the clinical data submitted. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">During
clinical development, the sponsor often refines the indication and endpoints on which the BLA will be based. For endpoints based on patient-reported outcomes (the &#147;PROs&#148;), and observer-reported outcomes (the &#147;OROs&#148;), the process
typically is an iterative one. The FDA has issued guidance on the framework it uses to evaluate PRO instruments. Although the agency may offer advice on optimizing PRO and ORO instruments during the clinical development process, the FDA usually
reserves final judgment until it reviews the BLA. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Concurrent with clinical trials, companies often complete additional animal studies,
and develop additional information about the chemistry and physical characteristics of the drug and finalize a process for manufacturing the product in commercial quantities in accordance with cGMP requirements. The manufacturing process must be
capable of consistently producing quality batches of the drug candidate and, among other things, must develop methods for testing the identity, strength, quality, purity and potency of the final drug. Additionally, appropriate packaging must be
selected and tested and stability studies must be conducted to demonstrate that the drug candidate does not undergo unacceptable deterioration over its shelf life. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>BLA Submission and Review </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Assuming successful completion of all required clinical testing in accordance with all applicable regulatory requirements, an applicant may
submit a BLA requesting licensing to market the biologic for one or more indications in the United States. The BLA must include the results of product development, <FONT STYLE="white-space:nowrap">non-clinical</FONT> studies and clinical trials;
detailed information on the product&#146;s chemistry, manufacture and controls; and proposed labeling. Under the Prescription Drug User Fee Amendments, a BLA submission is subject to an application user fee, unless a waiver or exemption applies.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The FDA will initially review the BLA for completeness before accepting it for filing. Under the FDA&#146;s procedures, the agency has 60
days from its receipt of a BLA to determine whether the application will be accepted for filing and substantive review. If the agency determines that the application does not meet this initial threshold standard, the FDA may refuse to file the
application and request additional information, in which case the application must be resubmitted with the requested information and review of the application delayed. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">237 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">With certain exceptions, BLAs must include a pediatric assessment, generally based on
clinical trial data, of the safety and effectiveness of the biologic in relevant pediatric populations. Under certain circumstances, the FDA may waive or defer the requirement for a pediatric assessment, either at the sponsor&#146;s request or by
the agency&#146;s initiative. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">After the BLA is accepted for filing, the FDA reviews the BLA to determine, among other things, whether a
product is safe, pure and potent and if the facility in which it is manufactured, processed, packed or held meets standards designed to assure the product&#146;s continued identity, strength, quality, safety, purity and potency. The FDA may convene
an advisory committee to provide clinical insight on application review questions. Before approving a BLA, the FDA will typically inspect the facility or facilities where the product is manufactured. The FDA will not approve an application unless it
determines that the manufacturing processes and facilities comply with cGMP and are adequate to assure consistent production of the product within required specifications. In addition, the FDA expects that all data be reliable and accurate, and
requires sponsors to implement meaningful and effective strategies to manage data integrity risks. Data integrity is an important component of the sponsor&#146;s responsibility to ensure the safety, efficacy and quality of its product or products.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The FDA will typically inspect one or more clinical sites to assure compliance with cGCP regulations before approving a BLA. If the FDA
determines that the application, manufacturing process or manufacturing facilities are not acceptable, it will outline the deficiencies in the submission and often will request additional testing or information. Notwithstanding the submission of any
requested additional information, the FDA ultimately may decide that the application does not satisfy the regulatory criteria for approval. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">FDA performance goals generally provide for action on a BLA within ten months of filing, which (as discussed above) typically occurs within 60
days of submission, but that deadline is extended in certain circumstances. Furthermore, the review process is often significantly extended by FDA requests for additional information or clarification. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The FDA may refer applications for novel products or products that present difficult questions of safety or efficacy to an advisory committee.
Typically, an advisory committee consists of a panel that includes clinicians and other experts who will review, evaluate and provide a recommendation as to whether the application should be approved and, if so, under what conditions. The FDA is not
bound by the recommendations of an advisory committee, but it considers such recommendations carefully when making decisions and usually has followed such recommendations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">After the FDA evaluates a BLA and conducts inspections of manufacturing facilities where the investigational product and/or its components
will be produced, the FDA may issue an approval letter or a Complete Response Letter (the &#147;CRL&#148;). An approval letter authorizes commercial marketing of the biologic with specific prescribing information for specific indications. A CRL will
describe all of the deficiencies that the FDA has identified in the BLA, except that where the FDA determines that the data supporting the application are inadequate to support approval, the FDA may issue the CRL without first conducting required
inspections, testing submitted product lots and/or reviewing proposed labeling. If and when the deficiencies have been addressed to the FDA&#146;s satisfaction in a resubmission of the BLA, the FDA will issue an approval letter. In issuing the CRL,
the FDA may recommend actions that the applicant might take to place the BLA in condition for approval, including requests for additional data, information or clarification. The FDA may delay or refuse approval of a BLA if applicable regulatory
criteria are not satisfied, and may require additional testing or information and/or require post-marketing studies and clinical trials. Even with submission of this additional information, the FDA ultimately may decide that the application does not
satisfy the regulatory criteria for approval. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">During the approval process, the FDA will determine whether a REMS is necessary to assure
the safe use of the biologic. A REMS is a safety strategy to manage a known or potential serious risk associated with a product and to enable patients to have continued access to such medicines by managing their safe use, and could
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">238 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
include medication guides, physician communication plans or elements to assure safe use, such as restricted distribution methods, patient registries and other risk minimization tools. If the FDA
concludes that a REMS is needed, the BLA sponsor must submit a proposed REMS and the FDA will not approve the BLA without a REMS that the agency has determined is acceptable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In addition, under the Pediatric Research Equity Act of 2003 (the &#147;PREA&#148;), as amended and reauthorized, certain applications or
supplements must contain data that are adequate to assess the safety and effectiveness of the drug for the claimed indications in all relevant pediatric subpopulations, and to support dosing and administration for each pediatric subpopulation for
which the product is safe and effective. The FDA may, on its own initiative or at the request of the applicant, grant deferrals for submission of some or all pediatric data until after approval of the product for use in adults, or full or partial
waivers from the pediatric data requirements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">If the FDA approves a product, it may limit the approved indications for use for the
product, or require that contraindications, warnings or precautions be included in the product labeling. The FDA may also require that post-approval studies, including Phase 4 clinical trials, be conducted to further assess the drug&#146;s safety
after approval. The FDA may prevent or limit further marketing of a product based on the results of post-marketing studies or surveillance programs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The FDA may also require testing and surveillance programs to monitor the product after commercialization. For biologics, such testing may
include official lot release, which requires the manufacturer to perform certain tests on each lot of the product before it is released for distribution. The manufacturer then typically must submit samples of each lot of product to the FDA, together
with a release protocol showing a summary of the history of manufacture of the lot and the results of all of the manufacturer&#146;s tests performed on the lot. The FDA may also perform certain confirmatory tests on lots of some products itself,
before releasing the lots for distribution by the manufacturer. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">After approval, many types of changes to the approved product, such as
adding new indications, manufacturing changes and additional labeling claims, are often subject to further testing requirements and FDA review and approval, depending on the nature of the post-approval change. The FDA may withdraw the product
approval if compliance with <FONT STYLE="white-space:nowrap">pre-</FONT> and post-marketing requirements is not maintained or if problems occur after the product reaches the marketplace. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Post-Approval Requirements </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Any
products manufactured or distributed pursuant to FDA approvals are subject to pervasive and continuing regulation by the FDA, including, among other things, requirements relating to recordkeeping, periodic reporting, reporting of certain deviations
and adverse experiences, product sampling and distribution and advertising and promotion of the product. After approval, most changes to the approved product, such as adding new indications or other labeling claims, are subject to FDA review and
approval. There also are continuing user fee requirements, under which the FDA assesses an annual program fee for each product identified in an approved BLA. Biologic manufacturers and their third-party contractors are required to register their
establishments with the FDA and certain state agencies. These establishments are subject to routine and periodic unannounced inspections by the FDA and certain state agencies for compliance with cGMP and data integrity requirements, which impose
certain procedural and documentation requirements to assure quality of manufacturing and product. The FDA has increasingly observed cGMP violations involving data integrity during site inspections and investigating compliance with data integrity
requirements is a significant focus of its oversight. Requirements with respect to data integrity include, among other things, controls to ensure data are complete and secure; activities documented at the time of performance; audit trail
functionality; authorized access and limitations; validated computer systems; and review of records for accuracy, completeness and compliance with established standards. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">239 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Post-approval changes to the manufacturing process are strictly regulated, and, depending on
the significance of the change, may require FDA approval before being implemented. FDA regulations also require investigation and correction of any deviations from cGMP and impose reporting requirements upon us and any third-party manufacturers that
we may decide to use. Accordingly, manufacturers must continue to expend time, money and effort in the area of production and quality control to maintain compliance with cGMP, data integrity, pharmacovigilance (i.e., post-marketing safety reporting
obligations) and other aspects of regulatory compliance. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The FDA may withdraw a product approval if compliance with regulatory
requirements and standards is not maintained or if problems occur after the product reaches the market. Later discovery of previously unknown problems with a product, including adverse events of unanticipated severity or frequency, or with
manufacturing processes, or failure to comply with regulatory requirements, may result in revisions to the approved labeling to add new safety information; imposition of post-approval studies or clinical trials to assess new safety risks; or
imposition of distribution or other restrictions under a REMS. Other potential consequences include: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">restrictions on the marketing or manufacturing of a product, complete withdrawal of the product from the market
or product recalls; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">fines, Warning Letters, Untitled Letters or holds on post-approval clinical studies; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">refusal of the FDA to approve pending applications or supplements to approved applications, or suspension or
revocation of existing product approvals; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">product seizure or detention, or refusal of the FDA to permit the import or export of products that it believes
present safety problems by issuing an Import Alert; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">permanent injunctions and consent decrees, including the imposition of civil or criminal penalties; or
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">voluntary product recall. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The FDA strictly regulates the marketing, labeling, advertising and promotion of prescription drug products placed on the market. A company
can make only those claims relating to safety and efficacy, purity and potency that are approved by the FDA and in accordance with the provisions of the approved label. The FDA&#146;s regulation includes, among other things, standards and
regulations for <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">direct-to-consumer</FONT></FONT> advertising, communications regarding unapproved uses, industry-sponsored scientific and educational activities and promotional
activities involving the Internet and social media. Promotional claims relating to a product&#146;s safety or effectiveness are prohibited before the drug is approved. After approval, a product generally may not be promoted for uses that are not
approved by the FDA, as reflected in the product&#146;s prescribing information. In the United States, healthcare professionals are generally permitted to prescribe drugs for such uses not described in the drug&#146;s labeling, known as <FONT
STYLE="white-space:nowrap">off-label</FONT> uses, because the FDA does not regulate the practice of medicine. However, FDA regulations impose rigorous restrictions on manufacturers&#146; communications, prohibiting the promotion of <FONT
STYLE="white-space:nowrap">off-label</FONT> uses. It may be permissible, under very specific, narrow conditions, for a manufacturer to engage in <FONT STYLE="white-space:nowrap">non-promotional,</FONT>
<FONT STYLE="white-space:nowrap">non-misleading</FONT> communication regarding <FONT STYLE="white-space:nowrap">off-label</FONT> information, such as distributing scientific or medical journal information. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">If a company is found to have promoted <FONT STYLE="white-space:nowrap">off-label</FONT> uses, it may become subject to adverse public
relations and administrative and judicial enforcement by the FDA, the DOJ or the Office of the Inspector General of the Department of Health and Human Services, as well as other federal and state authorities. This could subject a company to a range
of penalties that could have a significant commercial impact, including civil and criminal fines and agreements that materially restrict the manner in which a company promotes or distributes products. The federal government has levied large civil
and criminal fines against companies for alleged improper promotion, and has also requested that companies enter into consent decrees and permanent injunctions under which specified promotional conduct is changed or curtailed. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">240 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The distribution of prescription drugs and biologics are subject to the Drug Supply Chain
Security Act (the &#147;DSCSA&#148;), which requires manufacturers and other stakeholders to comply with product identification, tracing, verification, detection and response, notification and licensing requirements. In addition, the Prescription
Drug Marketing Act (the &#147;PDMA&#148;), and its implementing regulations, and state laws limit the distribution of prescription pharmaceutical product samples, and the DSCSA imposes requirements to ensure accountability in distribution and to
identify and remove prescription drug and biological products that may be counterfeit, stolen, contaminated, or otherwise harmful from the market. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Patent Term Restoration and Marketing Exclusivity </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">After approval, owners of relevant drug or biological product patents may apply for up to a five-year patent extension to restore a portion of
patent term lost during product development and FDA review of a BLA if approval of the application is the first permitted commercial marketing or use of a biologic containing the active ingredient under the Drug Price Competition and Patent Term
Restoration Act of 1984, referred to as the Hatch-Waxman Act. The allowable patent term extension is calculated as <FONT STYLE="white-space:nowrap">one-half</FONT> of the product&#146;s testing phase, which is the time between IND and BLA
submission, and all of the review phase, which is the time between BLA submission and approval, up to a maximum of five years. The time can be shortened if the FDA determines that the applicant did not pursue approval with due diligence. The total
patent term after the extension may not exceed more than 14 years from the date of FDA approval of the product. Only one patent claiming each approved product is eligible for restoration and the patent holder must apply for restoration within 60
days of approval. The United States Patent and Trademark Office (the &#147;USPTO&#148;), in consultation with the FDA, reviews and approves the application for patent term restoration. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">For patents that might expire during the application phase, the patent owner may request an interim patent extension. An interim patent
extension increases the patent term by one year and may be renewed up to four times. For each interim patent extension granted, the post-approval patent extension is reduced by one year. The director of the USPTO must determine that approval of the
drug candidate covered by the patent for which a patent extension is being sought is likely. Interim patent extensions are not available for a drug candidate for which a BLA has not been submitted. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Expedited Development and Review Programs </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The FDA is required to facilitate the development and expedite the review of pharmaceutical products that are intended for the treatment of a
serious or life-threatening condition for which there is no effective treatment and which demonstrate the potential to address unmet medical need for the condition. Under the fast track program, the sponsor of a new drug candidate may request the
FDA to designate the product for a specific indication as a fast track product concurrent with or after the filing of the IND for the drug candidate. The FDA must determine if the drug candidate qualifies for fast track designation within 60 days
after receipt of the sponsor&#146;s request. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In addition to other benefits, such as the ability to have more frequent interactions with
the FDA, the agency may initiate review of sections of a fast track product&#146;s BLA before the application is complete. This rolling review is available if the applicant provides and the FDA approves a schedule for the submission of the remaining
information and the applicant pays applicable user fees. However, the FDA&#146;s PDUFA review period for a fast track application does not begin until the last section of the BLA is submitted. In addition, the fast track designation may be withdrawn
by the FDA if the agency believes that the designation is no longer supported by data emerging in the clinical trial process. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Healthcare Regulation
</I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><B><I>Pharmaceutical Coverage and Reimbursement </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Significant uncertainty exists as to the coverage and reimbursement status of any products for which we may obtain regulatory approval. In the
United States, sales of any products for which we may receive regulatory </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">241 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
approval for commercial sale will depend in part on the availability of coverage and reimbursement from third-party payors. Third-party payors include government authorities, managed care
providers, private health insurers and other organizations. Third-party payors establish the coverage and reimbursement policies for pharmaceutical products, and the marketability of any products for which we may receive regulatory approval for
commercial sale depends on those payors&#146; coverage policies and reimbursement rates. Third-party payors may limit coverage to specific products on an approved list, or formulary, which might not include one or more of our drug candidates, if
approved. Third-party payors, together with regulators and others, are increasingly challenging the prices charged for pharmaceutical products and health services, in addition to their cost-effectiveness, safety and efficacy. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In addition, no uniform policy for coverage and reimbursement exists in the United States. Third-party payors often rely upon Medicare
coverage policy and payment limitations in setting their own coverage and reimbursement policies, but also have their own methods and approval process apart from Medicare determinations. Therefore, coverage and reimbursement rates can vary
significantly from payor to payor. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Moreover, obtaining coverage and adequate reimbursement is a time-consuming and costly process. We may
be required to provide scientific and clinical support for the use of any product to each third-party payor separately with no assurance that approval will be obtained, and we may need to conduct expensive pharmacoeconomic studies in order to
demonstrate the cost-effectiveness of our products. We cannot be certain that our drug candidates will be considered cost-effective by third-party payors. This process could delay the market acceptance of any drug candidates for which we may receive
approval and could have a negative effect on our future revenues and operating results. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><B><I>Other U.S. Healthcare Laws and Compliance
Requirements </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In the United States, our business may be subject to healthcare fraud and abuse regulation and enforcement by both
the federal government and the states in which we conduct our business, particularly once third-party reimbursement becomes available for one or more of our products. The healthcare fraud and abuse laws and regulations that may affect our ability to
operate include, but are not limited to: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The federal Anti-Kickback Statute, which prohibits, among other things, knowingly and willfully soliciting,
receiving, offering or paying any remuneration (including any kickback, bribe or rebate), directly or indirectly, overtly or covertly, in cash or in kind, to induce, or in return for, either the referral of an individual, or the purchase, lease,
order or recommendation of any good, facility, item or service for which payment may be made, in whole or in part, under the Medicare and Medicaid programs, or other federal healthcare programs; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The federal civil and criminal false claims laws and civil monetary penalty laws, including the civil False
Claims Act, or FCA, which prohibits, among other things, knowingly presenting, or causing to be presented, claims for payment of government funds that are false or fraudulent, or knowingly making, or using or causing to be made or used, a false
record or statement material to a false or fraudulent claim to avoid, decrease, or conceal an obligation to pay money to the federal government; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The federal Health Insurance Portability and Accountability Act of 1996 (the &#147;HIPAA&#148;), which, among
other things, prohibits executing a scheme to defraud any healthcare benefit program, including private third-party payors, and prohibits (i)&nbsp;knowingly and willfully falsifying, concealing or covering up a material fact or making any materially
false, fictitious or fraudulent statement or representation and (ii)&nbsp;making or using any false writing or document knowing the same to contain any materially false, fictitious or fraudulent statement or entry in connection with the delivery of
or payment for healthcare benefits, items or services; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act of 2009 (the
&#147;HITECH&#148;), and their respective implementing regulations, which impose </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">242 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="12%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
requirements relating to the privacy, security and transmission of individually identifiable health information held by covered entities, including health plans, healthcare clearinghouses and
certain healthcare providers, and their business associates, individuals or entities that perform certain services on behalf of a covered entity that involve the use or disclosure of individually identifiable health information. HITECH also created
new tiers of civil monetary penalties, amended HIPAA to make civil and criminal penalties directly applicable to business associates and gave state attorneys general new authority to file civil actions for damages or injunctions in federal courts to
enforce HIPAA and seek attorneys&#146; fees and costs associated with pursuing federal civil actions; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The federal Physician Payments Sunshine Act, being implemented as the Open Payments Program, which requires
manufacturers of drugs, devices, biologics and medical supplies for which payment is available under Medicare, Medicaid or the Children&#146;s Health Insurance Program (with certain exceptions) to report annually to the Centers for Medicare and
Medicaid Services (the &#147;CMS&#148;), information related to direct or indirect payments and other transfers of value to physicians and teaching hospitals, as well as ownership and investment interests held in a company by physicians and their
immediate family members. Beginning in 2022, applicable manufacturers will also be required to report information regarding payments and transfers of value provided to physician assistants, nurse practitioners, clinical nurse specialists, certified
nurse anesthetists and certified nurse-midwives; and </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">U.S. state and local laws and regulations, such as state anti-kickback and false claims laws, which may apply to
sales or marketing arrangements and claims involving healthcare items or services reimbursed by non-governmental third-party payors, including private insurers; state laws that require pharmaceutical companies to comply with the pharmaceutical
industry&#146;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government or otherwise restrict payments that may be made to healthcare providers; state laws that restrict the ability of manufacturers
to offer <FONT STYLE="white-space:nowrap">co-pay</FONT> support to patients for certain prescription drugs; state laws that require drug manufacturers to report information related to clinical trials, or information related to payments and other
transfers of value to physicians and other healthcare providers or marketing expenditures; state laws that require drug manufacturers to report information on the pricing of certain drugs; state laws and local ordinances that require identification
or licensing of sales representatives; and state laws governing the privacy and security of health information in certain circumstances, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating
compliance efforts. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We will be required to spend substantial time and money to ensure that our business arrangements
with third parties comply with applicable healthcare laws and regulations. Even then, governmental authorities may conclude that our business practices do not comply with current or future statutes, regulations or case law involving applicable fraud
and abuse or other healthcare laws and regulations. If governmental authorities find that our operations violate any of these laws or any other governmental regulations that may apply to us, we may be subject to significant civil, criminal and
administrative penalties, damages, fines, disgorgement, individual imprisonment, exclusion from government funded healthcare programs, such as Medicare and Medicaid, and additional reporting obligations and oversight if we become subject to a
corporate integrity agreement or other agreement to resolve allegations of <FONT STYLE="white-space:nowrap">non-compliance</FONT> with these laws, and we may be required to curtail or restructure our operations. Moreover, we expect that there will
continue to be federal and state laws and regulations, proposed and implemented, that could impact our operations and business. In addition, the approval and commercialization of any drug candidate we develop outside the United States will also
likely subject us to foreign equivalents of the healthcare laws mentioned above, among other foreign laws. The extent to which future legislation or regulations, if any, relating to health care fraud and abuse laws or enforcement, may be enacted or
what effect such legislation or regulation would have on our business remains uncertain. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">243 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><B><I>Healthcare Reform </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In the United States there have been, and continue to be, several legislative and regulatory changes and proposed reforms of the healthcare
system to contain costs, improve quality and expand access to care. In the United States, there have been and continue to be a number of healthcare-related legislative initiatives that have significantly affected the pharmaceutical industry. For
example, the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act of 2010 (collectively, the &#147;ACA&#148;), was passed in March 2010, substantially changing the way healthcare is financed by
both governmental and private insurers and significantly impacting the U.S. pharmaceutical industry. Among other things, the ACA subjects biologics to potential competition by lower-cost biosimilars; addresses a new methodology by which rebates owed
by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs that are inhaled, infused, instilled, implanted or injected; increases the minimum Medicaid rebates owed by manufacturers under the Medicaid Drug Rebate Program and
extends the rebate program to individuals enrolled in Medicaid managed care organizations; establishes annual fees and taxes on manufacturers of certain branded prescription drugs; and creates a new Medicare Part D coverage gap discount program in
which, as a condition of coverage of its products under Medicare Part D, manufacturers must now agree to offer 70% <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">point-of-sale</FONT></FONT> discounts off negotiated prices of
applicable brand drugs to eligible beneficiaries during their coverage gap period. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Some of the provisions of the ACA have yet to be fully
implemented, while certain provisions have been subject to judicial and Congressional challenges. In addition, there have been efforts by the Trump Administration to repeal or replace certain aspects of the ACA and to alter the implementation of the
ACA and related laws. For example, Congress has considered legislation that would repeal or repeal and replace all or part of the ACA. While Congress has not passed comprehensive repeal legislation, bills affecting the implementation of certain
taxes under the ACA have been signed into law. The Tax Cuts and Jobs Act of 2017 (the &#147;Tax Act&#148;), includes a provision repealing, effective January&nbsp;1, 2019, the <FONT STYLE="white-space:nowrap">tax-based</FONT> shared responsibility
payment imposed by the ACA on certain individuals who fail to maintain qualifying health coverage for all or part of a year commonly referred to as the &#147;individual mandate.&#148; On January&nbsp;22, 2018, President Trump signed a continuing
resolution on appropriations for fiscal year 2018 that delayed the implementation of certain <FONT STYLE="white-space:nowrap">ACA-mandated</FONT> fees, including the <FONT STYLE="white-space:nowrap">so-called</FONT> &#147;Cadillac&#148; tax on
certain high cost employer-sponsored insurance plans, the annual fee imposed on certain high cost employer-sponsored insurance plans, the annual fee imposed on certain health insurance providers based on market share and the medical device excise
tax on <FONT STYLE="white-space:nowrap">non-exempt</FONT> medical devices. The Bipartisan Budget Act of 2018 (the &#147;BBA&#148;), among other things, amends the ACA, effective January&nbsp;1, 2019, to reduce the coverage gap in most Medicare drug
plans, commonly referred to as the &#147;donut hole.&#148; In addition, in July 2018, the CMS issued a final rule permitting further collections and payments to and from certain ACA qualified health plans and health insurance issuers under the ACA
risk adjustment program in response to the outcome of federal district court litigation regarding the method CMS uses to determine this risk adjustment. Additional legislative changes or regulatory changes related to the ACA remain possible. In
December 2018, a United States District Court Judge for the Northern District of Texas ruled that the entire ACA is unconstitutional because the tax penalty associated with the &#147;individual mandate&#148; was repealed by Congress as part of the
Tax Act. This ruling is under appeal and stayed pending appeal. While the United States District Court Judge for the Northern District of Texas, as well as the Trump Administration and the CMS, have stated that the ruling will have no effect while
this appeal is pending, it is unclear how this decision, subsequent appeals and other efforts to invalidate the ACA, regulations promulgated under the ACA or portions thereof, will impact the ACA and its implementation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Additionally, there has been increasing legislative and enforcement interest in the United States with respect to specialty drug pricing
practices. Specifically, there have been several recent U.S. Congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to drug pricing; reduce the cost of prescription
drugs under Medicare; review the relationship between pricing and manufacturer patient programs; and reform government program reimbursement methodologies for drugs. For example, the Trump Administration released a &#147;Blueprint&#148; to lower
drug prices and reduce <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> costs of drugs that contains additional proposals to increase manufacturer competition,
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">244 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
increase the negotiating power of certain federal healthcare programs, incentivize manufacturers to lower the list price of their products and reduce the <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> costs of drug products paid by consumers. On January&nbsp;31, 2019, Office of the Inspector General of the Department of Health and Human Services proposed modifications to the federal
Anti-Kickback Statute discount safe harbor for the purpose of reducing the cost of drug products to consumers which, among other things, if finalized, will remove safe harbor protection from rebates paid by manufacturers to Medicare Part D plans,
Medicaid managed care organizations and pharmacy benefit managers working with these organizations. Although a number of these, and other proposed measures may require additional authorization to become effective, Congress and the Trump
Administration have each indicated that they will continue to seek new legislative and/or administrative measures to control drug costs. Individual states in the United States have also increasingly passed legislation and implemented regulations
designed to control pharmaceutical and biological product pricing, including price or patient reimbursement limitations, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases,
designed to encourage importation from other countries and bulk purchasing. In addition, regional healthcare authorities and individual hospitals are increasingly using bidding procedures to determine what pharmaceutical products and which suppliers
will be included in their prescription drug and other healthcare programs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Moreover, on May&nbsp;30, 2018, the Right to Try Act was
signed into law. The law, among other things, provides a federal framework for certain patients to access certain investigational new drug products that have completed a Phase 1 clinical trial and that are undergoing investigation for FDA approval.
Under certain circumstances, eligible patients can seek treatment without enrolling in clinical trials and without obtaining FDA permission under the FDA expanded access program. There is no obligation for a pharmaceutical manufacturer to make its
drug products available to eligible patients as a result of the Right to Try Act. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">245 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom98473_15"></A>MANAGEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Directors and Executive Officers </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The
following table sets forth information regarding our directors and executive officers as of the date of this prospectus. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="37%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="55%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Directors and Executive Officers</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Age</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-bottom:1.00px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman"><B>Position/Title</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jingwu Zhang Zang, M.D., Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">64</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Founder, Honorary Chairman and Director</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Joan Huaqiong Shen, M.D., Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">58</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Director and Chief Executive Officer</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Zheru Zhang, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">57</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Director and President</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jielun Zhu</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">44</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Director and Chief Financial Officer</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Wei Fu</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">38</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Director</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Mengjiao Jiang</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">39</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Director</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jie Yu</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">45</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Director</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Bing Yuan</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">52</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Director</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Chun Kwok Alan Au</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">48</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Independent Director</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Conor Chia-hung Yang</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">57</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Independent Director</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pamela M. Klein</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">59</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Independent Director</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Lili Qian, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">38</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Vice President of Operations</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weimin Tang, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">55</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Executive Vice President of Global Business Development</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Yunhan Lin, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">43</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Vice President of Corporate Development</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Neil Warma</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">57</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General Manager of <FONT STYLE="white-space:nowrap">I-Mab</FONT> US</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ivan Yifei Zhu</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">51</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Chief Commercial Officer</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gigi Qi Feng</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">39</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Chief Communications Officer</P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I>Jingwu Zhang Zang</I>, M.D., Ph.D., is our founder, honorary chairman and director. Dr.&nbsp;Zang served as
our chief executive officer from our inception to October 2019. Prior to founding our company, Dr.&nbsp;Zang served as the chief scientific officer and president of Simcere Pharmaceutical Group and Bioscikin Co., Ltd. from September 2013 to April
2016. Dr.&nbsp;Zang held senior management positions at GlaxoSmithKline (GSK), as the global senior vice president and head of GSK&#146;s Research and Development in China from April 2007 to June 2013. The academic career of Dr.&nbsp;Zang started in
Dr.&nbsp;Willems Institute and University of Limburg in Belgium. Dr.&nbsp;Zang became a professor at Baylor College of Medicine in Houston and later joined the Chinese Academy of Sciences as the founding director of the Institute of Health Sciences
and as a <FONT STYLE="white-space:nowrap">co-director</FONT> of Institute Pasteur Shanghai, an independent <FONT STYLE="white-space:nowrap">non-profit</FONT> life science institute to address public health problems in China, where he served as its
director from October 2004 to September 2006. Dr.&nbsp;Zang also served as a director of Shanghai Institute of Immunology from June 2002 to April 2007. Dr.&nbsp;Zang received his M.D. from Shanghai Second Medical University (now part of Shanghai
Jiaotong University) in 1984, and his Ph.D. in neuroimmunology from the University of Brussels in 1990. Dr.&nbsp;Zang conducted his post-doctoral work at Harvard Medical School in 1992, and obtained his U.S. medical license from the Texas Medical
Board through a clinical residency at Baylor College of Medicine in Houston. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I>Joan Huaqiong Shen</I>, M.D., Ph.D., has served as our
head of discovery and clinical development since September 2017, as our director since July 2019 and as our chief executive officer since October 2019. Prior to joining our company, Dr.&nbsp;Shen served as the vice president and development head of
Janssen Pharmaceutical Companies of Johnson&nbsp;&amp; Johnson from September 2015 to September 2017. Dr.&nbsp;Shen was the chief medical officer and vice president in Jiangsu Hengrui Medicine, Co., Ltd. (SHA: 600276) from May 2013 to August 2015.
Dr.&nbsp;Shen served as the head of the China clinical department and a senior director at Pfizer (China) Research and Development Co., Ltd. from August 2011 to May 2013. Prior to that, Dr.&nbsp;Shen worked as a senior medical director at Pfizer
Inc. (NYSE: PFE) from November 2009 to August 2011. From August 2005 to November 2009, Dr.&nbsp;Shen was the medical director at Wyeth Research, a leading pharmaceutical company. Dr.&nbsp;Shen worked as a clinical research physician at Eli Lilly and
Company (NYSE: LLY) from September 2003 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">246 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
to August 2005. Dr.&nbsp;Shen served as an adjunctive assistant professor in the department of psychiatry of the Indiana University School of Medicine from October 2003 to October 2005. She has
also been a guest professor of Beijing University Clinical Research Institute since March 2018. Dr.&nbsp;Shen completed three fellowships in the Indiana University School of Medicine, one in endocrinology from August 1996 to July 1998, one in
psychopharmacology and one in clinical pharmacology, both from January 2002 to September 2003. Dr.&nbsp;Shen obtained her U.S. medical license from the Indiana University School of Medicine through a clinical residency. Dr.&nbsp;Shen received her
M.D. from Southeast University Medical College in 1983, master&#146;s degree in anatomy from West China University of Medical Sciences, currently Sichuan University School of Medicine in 1989, and her Ph.D. in anatomy/neuroscience from the Indiana
University School of Medicine in 1996. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I>Zheru Zhang</I>, Ph.D., has served as our director and president since September 2017. Prior to
joining our company, Dr.&nbsp;Zhang served as the president at Tasgen <FONT STYLE="white-space:nowrap">Bio-tech</FONT> (Tianjin) Co., Ltd. from November 2015 to April 2017, as the chief executive officer at Shanghai
<FONT STYLE="white-space:nowrap">JMT-Bio</FONT> Co., Ltd. from October 2012 to October 2015, as a vice president, research and development at Celltrion Inc. from March 2008 to October 2012, as a group leader for the development of analytics and drug
products at Johnson&nbsp;&amp; Johnson (NYSE: JNJ) from January 2006 to March 2008, and as a research investigator at Bristol-Myers Squibb Company from May 2000 to January 2006, focusing on bioanalytical development and protein therapeutics
development, respectively. Dr.&nbsp;Zhang received his master&#146;s degree in chemistry from Suzhou University in 1991, and his Ph.D. in chemistry from University of Alberta in Canada in 2000. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I>Jielun Zhu </I>has served as our chief financial officer since August 2018 and as our director since July 2019. Prior to joining our
company, Mr.&nbsp;Zhu held positions as a managing director and the head of healthcare investment banking, Asia, at Jefferies Hong Kong Limited from December 2015 to July 2018, advising biotechnology and healthcare clients globally on initial public
offerings, mergers and acquisitions and other strategic transactions. From August 2008 to December 2015, Mr.&nbsp;Zhu worked at the Deutsche Bank Group in its Hong Kong branch, with his last position being a director in the corporate finance
division. He worked as an investment banker at UBS Investment Bank in Hong Kong from July 2007 to July 2008. Mr.&nbsp;Zhu received his bachelor&#146;s degree of arts with honors in mathematics-economics from Wesleyan University in May 2000 and
master&#146;s degree in business administration from the Harvard Business School with Distinction in June 2007. Mr.&nbsp;Zhu was awarded the Chartered Financial Analyst (CFA) charter by the CFA Institute in January 2012. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I>Wei Fu </I>has served as our director since June 2018. Mr.&nbsp;Fu was appointed by the <FONT STYLE="white-space:nowrap">C-Bridge</FONT>
entities pursuant to our shareholders agreement dated July&nbsp;6, 2018. Mr.&nbsp;Fu has served as the chief executive officer and a managing partner of <FONT STYLE="white-space:nowrap">C-Bridge</FONT> Capital Investment Management, Ltd. since April
2014. Mr.&nbsp;Fu currently also serves on the board of several private companies. From August 2011 to December 2013, Mr.&nbsp;Fu served as the general manager of the investment department at Far East Horizon International, a financial services
organization. Mr.&nbsp;Fu served as a partner and the head of the Beijing office of Themes Investment Management Ltd, a private equity firm specializing in healthcare and environmental businesses, from July 2010 to July 2011. From March 2008 to
April 2010, Mr.&nbsp;Fu worked as an associate director of the private equity department at Standard Chartered Business Consulting (Beijing) Co., Ltd, where he was mainly responsible for private equity investment in relation to infrastructure
projects. Mr.&nbsp;Fu received his bachelor&#146;s degree in electrical engineering and business administration from Nanyang Technological University in Singapore in February 2005. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I>Mengjiao Jiang </I>has served as our director since September 2017. Ms.&nbsp;Jiang was appointed by the
<FONT STYLE="white-space:nowrap">C-Bridge</FONT> entities pursuant to our shareholders agreement dated July&nbsp;6, 2018. Ms.&nbsp;Jiang is a managing director of <FONT STYLE="white-space:nowrap">C-Bridge</FONT> Capital Investment Management, Ltd.,
a healthcare-dedicated private equity firm, and has served as a partner and a managing director since January 2014. Ms.&nbsp;Jiang currently also serves on the board of several private companies. Ms.&nbsp;Jiang served as a director at International
Far East Horizon International, a financial services organization, from March 2012 to December 2013. Prior to that, Ms.&nbsp;Jiang served at ARC China Inc. as a managing director from May 2008 to June 2011. Ms.&nbsp;Jiang received her
bachelor&#146;s degree in economics with a political science double major from Wellesley College in Massachusetts in May 2003. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">247 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I>Jie Yu </I>has served as our director since July 2019. Mr.&nbsp;Yu was appointed by the
Tasly entities pursuant to our shareholders agreement dated July&nbsp;6, 2018. Mr.&nbsp;Yu has served as the secretary of the board at Tasly Pharmaceutical Group Co., Ltd. since November 2016. Prior to that, Mr.&nbsp;Yu was a director of brand
management office at China Minsheng Investment Co., Ltd., an international private capital investment group, from March 2015 to October 2016. Mr.&nbsp;Yu worked as the head of the brand management department and the head of Chinese media affairs
department at Huawei Technologies Co., Ltd. from April 2001 to March 2015. Mr.&nbsp;Yu received his bachelor&#146;s degree in management from Harbin Normal University in 1998 and master&#146;s degree in management from Northeast Forestry University
in 2001. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I>Bing Yuan </I>has served as our director since April 2020. Mr.&nbsp;Yuan is a managing director of Hony Capital and a member
of Hony Capital&#146;s executive committee, responsible for its equity investment operations. Mr.&nbsp;Yuan joined Hony Capital in April 2009 and has served as a managing director of the private equity department since January 2010. Prior to joining
Hony Capital, Mr.&nbsp;Yuan served as a managing director of the direct investment department of Morgan Stanley Asia Limited from 2008 to 2009. Before that, Mr.&nbsp;Yuan served as a managing director of the investment banking division of Morgan
Stanley Asia Limited from April 2004 to June 2008. Prior to that, Mr.&nbsp;Yuan served as a vice president with Credit Suisse First Boston in Hong Kong and New York from August 1998 to March 2004, focusing on corporate finance and merger&nbsp;&amp;
acquisitions transactions in the technology, media and telecom industry. During his investment banking time, Mr.&nbsp;Yuan assisted numerous prominent Chinese state-owned enterprises and private sector companies in completing their initial public
offerings, corporate finance and merger&nbsp;&amp; acquisition transactions. Mr.&nbsp;Yuan also worked as a financial analyst in project finance with Fieldstone Private Equity LLP in New York from 1993 to 1995. Mr.&nbsp;Yuan received his
bachelor&#146;s degree in English from Nanjing University in July 1990 and received his master&#146;s degree in international relations in June 1993 and his Juris Doctor degree in June 1998 from Yale University. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I>Mr.</I><I></I><I>&nbsp;Chun Kwok Alan Au </I>has served as our director since January 2020. Mr.&nbsp;Au is the founder of GT Healthcare
Group, a private equity platform focusing on cross border healthcare investments, and has served as the managing partner of GT Healthcare Group since September 2015. Mr.&nbsp;Au has served as a director of Cellular BioMedicine Group (Nasdaq: CBMG),
a clinical-stage biopharmaceutical firm engaged in the development of immunotherapies for cancer and stem cell therapies for degenerative diseases, since November 2014. Mr.&nbsp;Au also has served as a panel member for the Entrepreneur Support
Scheme (ESS Program) of the Innovation and Technology Fund of the Hong Kong SAR Government since 2014. Mr.&nbsp;Au was an advisor to Simcere Pharmaceutical Group, a leading pharmaceutical company in China (previously listed on NYSE: SCR, privatized
in December 2013, when Mr.&nbsp;Au served as chairman of the special committee on the board of directors). Mr.&nbsp;Au was also a member of the board of China Nepstar Chain Drugstore Ltd. (NYSE: NPD, privatized in September 2016) from March 2013 to
August 2016. Mr.&nbsp;Au served as the head of the Asia Healthcare Investment Banking of Deutsche Bank Group, advising healthcare IPOs and M&amp;A in the region from April 2011 to December 2012. Prior to that, Mr.&nbsp;Au served as the executive
director at JAFCO Asia Investment Group, responsible for healthcare investments in China from 2008 to 2010. Mr.&nbsp;Au worked at Morningside Group as a director in charge of healthcare investments in Asia from 2000 to 2005. Mr.&nbsp;Au received his
bachelor&#146;s degree in psychology from Chinese University of Hong Kong in 1995 and his master&#146;s degree in management from Columbia Business School in New York in 2007. Mr.&nbsp;Au is a certified public accountant (CPA) in the U.S. and a
chartered financial analyst (CFA). He is an associate member of the Hong Kong Institute of Financial Analysts and member of the American Institute of Certified Public Accountants. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I>Mr.</I><I></I><I>&nbsp;Conor Chia-hung Yang </I>has served as our director since January 2020. Mr.&nbsp;Yang is a <FONT
STYLE="white-space:nowrap">co-founder</FONT> of Black Fish Group Limited and has served as the president of Black Fish Group Limited since November 2017. Prior to that, Mr.&nbsp;Yang was the chief financial officer of Tuniu Corporation (Nasdaq:
TOUR) from January 2013 to November 2017, the chief financial officer of <FONT STYLE="white-space:nowrap">E-Commerce</FONT> China Dangdang Inc. from March 2010 to July 2012 and the chief financial officer of AirMedia Group Inc., currently known as
AirNet Technology Inc., (Nasdaq: ANTE) from March 2007 to March 2010. Mr.&nbsp;Yang was the chief executive officer of Rock Mobile Corporation from 2004 to February 2007. From 1999 to 2004, Mr.&nbsp;Yang served as the chief financial officer of the
Asia Pacific region for CellStar Asia Corporation. Mr.&nbsp;Yang was an executive director of Goldman Sachs </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">248 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
(Asia) L.L.C. from 1997 to 1999. Prior to that, Mr.&nbsp;Yang was a vice president of Lehman Brothers Asia Limited from 1994 to 1996 and an associate at Morgan Stanley Asia Limited from 1992 to
1994. Mr.&nbsp;Yang currently serves as an independent director and chairman of the audit committee of each of China Online Education Group (NYSE: COE) and Ehang Holdings Limited (Nasdaq: EH). Mr.&nbsp;Yang received a master&#146;s degree of
business administration from University of California, Los Angeles in 1992. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I>Dr.</I><I></I><I>&nbsp;Pamela</I><I></I><I>&nbsp;M. Klein
</I>has served as our director since January 2020. Dr.&nbsp;Klein currently serves a director of Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH) since July 2019, a director of argenx SE (Nasdaq: ARGX) since April 2016 and a director of Patrys
Limited (ASX: PAB) since October 2019. In addition, Dr.&nbsp;Klein has served as the president at PMK BioResearch since 2008, offering consultancy in Oncology Drug Development to Biotech, Pharma and the Investment Community. Dr.&nbsp;Klein has also
served as the consulting chief medical officer at Olema Oncology since 2018. Previously, Dr.&nbsp;Klein served as Chief Medical Officer for successful biotech <FONT STYLE="white-space:nowrap">start-ups</FONT> and prior to that, Vice President,
Genentech, Development. Dr.&nbsp;Klein received her bachelor&#146;s degree in cell and molecular biology from California State University in 1985 and an M.D. from Stritch School of Medicine, Loyola University Chicago in 1992 followed by an internal
medicine residency at Cedars Sinai, Los Angeles. Dr.&nbsp;Klein spent seven years at the National Cancer Institute of the NIH in Bethesda, Maryland in medical oncology. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I>Lili Qian</I>, Ph.D., has served as the vice president of operations since June 2016 and our director from September 2017 to July 2019.
Dr.&nbsp;Qian worked at Bioscikin Biopharma Technology Co., Ltd. from January 2016 to May 2016, serving as the secretary to the board of directors and president office manager. Prior to that, Dr.&nbsp;Qian held various positions at Simcere
Pharmaceutical Group as the president assistant and a project management manager from October 2013 to December 2015, and as a business development manager from July 2013 to October 2013. She was the project leader of the national key laboratory of
protein and plant genetic engineering at Peking University from September 2007 to June 2013. Dr.&nbsp;Qian received her bachelor&#146;s degree in biochemistry from University of British Columbia in 2005 and her Ph.D. in biochemistry and molecular
biology from Peking University in 2013. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I>Weimin Tang</I>, Ph.D., has served as our executive vice president of global business
development since April 2018. Prior to joining our company, Dr.&nbsp;Tang served as an executive director and a business director at Hengrui Therapeutics, Inc. from July 2015 to April 2018. Dr.&nbsp;Tang served as the vice president and a business
director at Crown Bioscience Inc., a <FONT STYLE="white-space:nowrap">pre-clinical</FONT> contract research organization, from July 2011 to July 2015. Prior to that, Dr.&nbsp;Tang served as the vice president and a business director at ShanghaiBio
Corporation Shanghai Biotechnology Cooperation, a biotech company based in Shanghai, from October 2010 to July 2011. Dr.&nbsp;Tang received his bachelor&#146;s degree in plant pathology from Zhejiang University in 1986, master&#146;s degree in
microbiology from Chinese Academy of Sciences in 1989, and Ph.D. in biochemistry from Rutgers University, New Jersey in 1997. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I>Yunhan
Lin</I>, Ph.D., has served as our vice president of corporate development since September 2017. Prior to joining our company, Dr.&nbsp;Lin served as the head of business development at Mycenax Biotech Inc., a Taiwan-based public pharmaceutical
company, from January 2016 to September 2017. Prior to that, Dr.&nbsp;Lin served as the head of business development at SynCore Biotechnology Co., Ltd, a Taiwan-based public biopharmaceutical company, from February 2012 to December 2015.
Dr.&nbsp;Lin worked as a science project deputy manager at Sinphar Pharmaceutical Co, Ltd., a Taiwan-based pharmaceutical company, from September 2001 to January 2012. Dr.&nbsp;Lin received his bachelor&#146;s degree in applied chemistry from
Providence University, Taiwan in 2000, master&#146;s degree in chemistry from Fu Jen Catholic University, Taiwan in 2003, and Ph.D. in chemistry from Tamkang University, Taiwan in 2008. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I>Neil Warma </I>has served as the general manager of <FONT STYLE="white-space:nowrap">I-Mab</FONT> US since September 2019. Mr.&nbsp;Warma
is currently an advisor to several companies and serves on the board of directors of several biotechnology companies and BioHouston, a <FONT STYLE="white-space:nowrap">non-profit</FONT> <FONT STYLE="white-space:nowrap">tax-exempt</FONT> 501(c)(3)
corporation founded by Houston area academic/ research institutions. Prior to joining our company, Mr.&nbsp;Warma served as the president and chief executive </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">249 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
officer of Opexa Therapeutics, currently Acer Therapeutics Inc. (Nasdaq: OPXA), from June 2008 to September 2017, and as its director from September 2008 to September 2017. At Opexa Therapeutics,
he also served as acting chief financial officer from March 2016 to September 2017, and previously served in such role from March 2009 to August 2012. From July 2004 to September 2007, Mr.&nbsp;Warma served as president and chief executive officer
of Viron Therapeutics Inc., a privately-held clinical stage biopharmaceutical company. Mr.&nbsp;Warma <FONT STYLE="white-space:nowrap">co-founded</FONT> MedExact USA, Inc., an Internet company providing clinical information and services to
physicians and pharmaceutical companies in 2000 and served as president until 2003. From 1992 to 2000, Mr.&nbsp;Warma held senior positions of increasing responsibility at Novartis Pharmaceuticals (previously Ciba-Geigy Ltd.) at its corporate
headquarters in Basel, Switzerland. While at Novartis, Mr.&nbsp;Warma served as the Head of International Pharma Policy&nbsp;&amp; Advocacy and in senior management within global marketing where he worked on the international launch of a
gastrointestinal product. Mr.&nbsp;Warma obtained an honors degree specializing in neuroscience from the University of Toronto in 1984 and an International M.B.A. from the Schulich School of Management at York University in Toronto in 1992. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I>Ivan Yifei Zhu </I>has served as our chief commercial officer since August 2020. Mr.&nbsp;Zhu has more than 20 years of successful
commercialization experience at global and domestic pharma and biotech companies. Prior to joining us, Mr.&nbsp;Zhu served as vice president and general manager of the sales division of Qilu Pharmaceutical Group where he managed the company&#146;s
sales and marketing team. From April 2018 to March 2019, Mr.&nbsp;Zhu served as the chief commercial officer of BeiGene (HKEX: 6160) where he played an instrumental role in the expansion of BeiGene&#146;s commercialization team and the
implementation of its commercialization strategies. Mr.&nbsp;Zhu also worked for Xi&#146;an Janssen for more than 20 years where he held various senior management positions. During this period, he built and managed numerous business units, covering
a wide range of therapeutic areas including oncology, immunotherapy, skin diseases, infectious diseases and the central nervous system. Mr.&nbsp;Zhu received his bachelor&#146;s degree in medicine from Zhejiang University in 1992. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I>Gigi Qi Feng </I>has served as our chief communications officer since October 2020 and served as our vice president and global head of
corporate communications from April 2020 to October 2020. Prior to joining us, Ms.&nbsp;Feng served as Amgen&#146;s Japan Asia Pacific regional head of corporate affairs from March 2018 to March 2020, where she led communications efforts including
executive communications, media relations, employee engagement and philanthropy to build the Amgen brand across 14 markets in the Asia Pacific region. Prior to joining Amgen, Ms.&nbsp;Feng held progressive China, Asia Pacific and global
communications leadership roles at Sanofi from November 2013 to March 2018, positioning the company as a scientific partner of choice. Prior to that, Ms.&nbsp;Feng led the strategic communications group at an international public affairs consultancy
from December 2009 to November 2013 with a focus on the healthcare industry. She also worked at the U.S. Consulate General in Shanghai from 2005 to 2009, where she managed consulate-wide communications and large-scale events. Ms.&nbsp;Feng received
her bachelor&#146;s degree in Government and Asian studies from Cornell University in 2003 and completed an EMBA program in business strategy from Harvard Business School in 2015. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Scientific Advisory Board </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The
members of our scientific advisory board provide scientific, portfolio and project strategy advice to us, including the evaluation of research and development strategies. The members of our scientific advisory board receive cash compensation for
their services. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I>Howard Weiner</I>, M.D., has served on our scientific advisory board since July 2019. Dr.&nbsp;Weiner is the Robert L.
Kroc Professor of Neurology at the Harvard Medical School, Director of the Partners Multiple Sclerosis (&#147;MS&#148;) Center and <FONT STYLE="white-space:nowrap">Co-Director</FONT> of Center for Neurologic Diseases at Brigham&nbsp;&amp;
Women&#146;s Hospital in Boston. The Partners MS Center is the first integrated MS Center that combines clinical care, MRI imaging and immune monitoring to the MS patient as part of the 2000 patient CLIMB cohort study. Dr.&nbsp;Weiner has pioneered
immunotherapy in MS and has investigated immune mechanisms in nervous system diseases including MS, Alzheimer&#146;s disease, amyotrophic lateral sclerosis, stroke and brain tumors. Dr.&nbsp;Weiner has also pioneered the
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">250 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
investigation of the mucosal immune system for the treatment of autoimmune and other diseases and the use of <FONT STYLE="white-space:nowrap">anti-CD3</FONT> to induce regulatory T cells for the
treatment of these diseases. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I>Eric K. Rowinsky</I>, M.D., has served on our scientific advisory board since June 2019.
Dr.&nbsp;Rowinsky is an independent consultant and/or board member of various public and private companies and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">not-for-profit</FONT></FONT> efforts. Since 2017, Dr.&nbsp;Rowinsky has
served as an advisor to <FONT STYLE="white-space:nowrap">C-Bridge</FONT> Capital and the U.S. Chief Medical Officer for Everest Medicines, Inc. Since 2015, Dr.&nbsp;Rowinsky has served as an Executive Director and President at Rgenix Inc. and as the
Chief Scientific Officer of Clearpath Development Co. From 2005 to 2015, Dr.&nbsp;Rowinsky held various positions with various biotechnology companies. At ImClone Systems (now a wholly-owned subsidiary of Eli Lilly), Dr.&nbsp;Rowinsky and his team
developed and registered cetuximab (Erbitux) and ramucirumab in five indications and two other monoclonal antibodies in North America and elsewhere. Dr.&nbsp;Rowinsky has been an Adjunct Professor of Medicine at New York University School of
Medicine since 2005. From 1987 to 2005, Dr.&nbsp;Rowinsky held various academic and research positions with various universities and research institutions including the Institute for Drug Development of the Cancer Therapy and Research Center in San
Antonio, where he held the SBC Endowed Chair for Early Drug Development, and the Johns Hopkins University School of Medicine. Dr.&nbsp;Rowinsky received his B.A. degree from New York University and his M.D. from the Vanderbilt University School of
Medicine and completed fellowship training at the Johns Hopkins University School of Medicine. Dr.&nbsp;Rowinsky received the career development award of the American Cancer Society and the 6th Annual Emil J. Freireich Award. He has also served on
the Board of Scientific Counselors of the NCI. Dr.&nbsp;Rowinsky is the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Editor-in-Chief</FONT></FONT> of Investigational New Drugs, an Editorial Board Member of Cancer Research and
several other oncology journals. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I>Patricia LoRusso</I>, D.O., M.A., Ph.D., has served on our scientific advisory board since July 2019.
Dr.&nbsp;LoRusso is currently a professor of medicine and a clinical scholar in medical oncology and Associate Director of Innovative Medicine at Yale Cancer Center in New Haven, Connecticut, USA, where she is also Director of Early Therapeutics
Disease-Aligned Team. Dr.&nbsp;LoRusso&#146;s expertise is in testing new treatments on patient volunteers with advanced-stage cancer. She heads the early clinical trials program at Yale Cancer Center. She has served as the <FONT
STYLE="white-space:nowrap">co-leader</FONT> of the Stand Up To Cancer/Melanoma Research Alliance&#150;funded Melanoma Dream Team, a Komen Promise grant <FONT STYLE="white-space:nowrap">co-Principal</FONT> Investigator, and has been a Principal
Investigator of the National Cancer Institute Phase 1/early phase clinical trials program grant in excess of 20 years. She is currently primary investigator or <FONT STYLE="white-space:nowrap">co-investigator</FONT> of numerous clinical trials.
Prior to joining Yale in August 2014, Dr.&nbsp;LoRusso served in numerous leadership roles at Wayne State University&#146;s Barbara Karmanos Cancer Institute for more than 25 years, most recently as director of the Phase 1 Clinical Trials Program
and of the Eisenberg Center for Experimental Therapeutics. Dr.&nbsp;LoRusso also worked as a director in Karmanos Cancer Institute, a cancer research and provider network, from 1997 to 2014. Dr.&nbsp;LoRusso received her B.A. degree of science in
religion/religious studies and biology, her master&#146;s degree at Yale University, her D.O. and Ph.D. from Michigan State University, and completed fellowship training at Wayne State University. Dr.&nbsp;LuRosso served as <FONT
STYLE="white-space:nowrap">co-chair</FONT> of the National Cancer Institute Cancer Therapy Evaluation Program (NCI CTEP) Investigational Drug Steering Committee, a prior parent member of the NCI&#146;s Quick Trials Clinical Subcommittee, and has
served as either an ad hoc or an appointed member on multiple study sections and has reviewed for Komen Promise grants, numerous SPORE and P01 study sections, and translational research grants. She has served on the education and scientific
committees of the American Society of Clinical Oncology, the Scientific Committee of the American Association for Cancer Research as well as a Vice-Chair for the 2019 AACR annual meeting. She is a member of the NCI Board of Scientific Council and
has served on the Board of Directors for the American Association for Cancer Research. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I><FONT STYLE="white-space:nowrap">Yi-Long</FONT>
Wu</I>, M.D., FACS, has served on our scientific advisory board since August 2019. <FONT STYLE="white-space:nowrap">Yi-Long</FONT> Wu is a tenured professor of Guangdong General Hospital, Guangdong Academy of Medical Sciences and Guangdong Lung
Cancer Institute. He is the former President of Chinese Society of Clinical Oncology (CSCO), the Chief of the WUJIEPING Oncology Medical Foundation, the vice-director of the Precision Medicine of the Chinese Medical Doctor Association, the President
of Chinese Thoracic Oncology Group <FONT STYLE="white-space:nowrap">(C-TONG),</FONT> the President of International Chinese Society of Thoracic Surgery (ICSTS), a Fellow of the American College of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">251 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Surgeons, a Member of Board of Directors of the International Association Study of Lung Cancer (IASLC), the Chairman of European Society for Medical Oncology (ESMO) in China, the Chairman of
Federation of Asia Clinical Oncology (FACO), a past Member of the International Affairs Committee of American Society of Clinical Oncology (ASCO), and a former Member of staging committee of the IASLC. He graduated from Sun <FONT
STYLE="white-space:nowrap">Yat-sen</FONT> University of Medical Sciences in 1982 and completed his thoracic surgery training in Germany in 1989. His main research interests are the multidisciplinary synthetic therapy on lung cancer in translation
medicine and evidence-based medicine in oncology. He is leading the Chinese lung cancer research field and has been the Principal Investigator or <FONT STYLE="white-space:nowrap">Co-PI</FONT> of more than 120 international or national multicenter
clinical trials. He has contributed 20 books on cancer and has published more than 300 articles in peer-reviewed journals including <I>J Clin Oncol, Lancet Oncol, New Engl J Med, Cancer Cell and J Thorac Oncol</I>. He also serves on the editorial
boards of <I>Cancer Letters, Annals of Surgical Oncology, Lung Cancer Management, International Journal of Biological Marker and General Thoracic and Cardiovascular Surgery</I>. He is
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Editor-in-Chief</FONT></FONT> of <I>Journal of Evidence-based Medicine, Journal of Thoracic Oncology (Chinese Edition), and The Oncologist (Chinese Edition) </I>etc. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I>Timothy Yap</I>, M.D., Ph.D., has served on our scientific advisory board since August 2019. Dr.&nbsp;Yap is a medical oncologist and
physician-scientist based at the University of Texas MD Anderson Cancer Center. He is an Associate Professor in the Department for Investigational Cancer Therapeutics (Phase I Program), and the Department of Thoracic/Head and Neck Medical Oncology.
Dr.&nbsp;Yap is the Medical Director of the Institute for Applied Cancer Science, a drug discovery biopharmaceutical unit where drug discovery and clinical translation are seamlessly integrated. He is also the Associate Director of Translational
Research in the Institute for Personalized Cancer Therapy, which is an integrated research and clinical trials program aimed at implementing personalized cancer therapy and improving patient outcomes. Prior to his current position, Dr.&nbsp;Yap was
a Consultant Medical Oncologist at The Royal Marsden Hospital in London, UK and National Institute for Health Research BRC Clinician Scientist at The Institute of Cancer Research, London, UK. Dr.&nbsp;Yap gained his BSc degree with First
Class&nbsp;Honors in Immunology and Infectious Diseases at Imperial College London, UK, and was awarded the Huggett Memorial Prize. His BSc laboratory research involved an immunogenetics study under the supervision of Professor Charles Bangham. He
subsequently went on to attain his Medical degree from Imperial College London, UK, before completing general medical training in Oxford. Dr.&nbsp;Yap&#146;s main research focuses on the <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">first-in-human</FONT></FONT> and combinatorial development of molecularly targeted agents and immunotherapies, and their acceleration through clinical studies using novel predictive and pharmacodynamic biomarkers.
Dr.&nbsp;Yap leads immuno-oncology clinical and associated translational studies, including novel agents targeting <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">PD-1/PD-L1,</FONT></FONT> ICOS, IDO, LAG3, TIM3, STING, TGFbeta,
adenosine A2A receptor and fucosylation. He was previously the UK Chief Investigator for the CheckMate 331 Phase III trial in relapsed small cell lung cancer and the <FONT STYLE="white-space:nowrap">KEYNOTE-158</FONT> Phase II biomarker study in
advanced solid tumors and multiple novel immunotherapy combination phase I trials. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I>Roy S. Herbst, MD, PhD</I>, has served on our
scientific advisory board since July 2019. Dr.&nbsp;Roy&nbsp;S. Herbst is an Ensign Professor of Medicine (Medical Oncology) and Professor of Pharmacology, the Chief of Medical Oncology at Yale Cancer Center and Smilow Cancer Hospital, and an
Associate Cancer Center Director for Translational Research, Yale Cancer Center in New Haven, CT. Dr.&nbsp;Herbst is nationally recognized for his leadership and expertise in lung cancer treatment and research. He is best known for his work in
developmental therapeutics and the personalized therapy of <FONT STYLE="white-space:nowrap">non-small</FONT> cell lung cancer, in particular the process of linking genetic abnormalities of cancer cells to novel therapies. Prior to his appointment at
Yale, Dr.&nbsp;Herbst was the Barnhart Distinguished Professor and Chief of the Section of Thoracic Medical Oncology in the Department of Thoracic/Head and Neck Medical Oncology, at The University of Texas M.D. Anderson Cancer Center <FONT
STYLE="white-space:nowrap">(UT-MDACC)</FONT> in Houston, Texas. He also served as Professor in the Department of Cancer Biology and <FONT STYLE="white-space:nowrap">Co-Director</FONT> of the Phase I Clinical Trials Program. He has led the Phase I
development of several of the new generation of targeted agents for <FONT STYLE="white-space:nowrap">non-small</FONT> cell lung cancer (NSCLC), including gefitinib, erlotinib, cetuximab, and bevacizumab. More recently, he participated in the
successful registration of pembrolizumab for the treatment of advanced <FONT STYLE="white-space:nowrap">non-small</FONT> cell lung cancer, following the successful <FONT STYLE="white-space:nowrap">Yale-led</FONT> KEYNOTE 10 study of the immune
therapy drug commonly used to treat other cancers. He was <FONT STYLE="white-space:nowrap">co-leader</FONT> for the <FONT STYLE="white-space:nowrap">BATTLE-1</FONT> clinical trial </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">252 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
program, <FONT STYLE="white-space:nowrap">co-leads</FONT> the subsequent <FONT STYLE="white-space:nowrap">BATTLE-2</FONT> clinical trial program, and served as a
<FONT STYLE="white-space:nowrap">Co-program</FONT> Leader of the Developmental Therapeutics Program for the YCC Support Grant. Dr.&nbsp;Herbst&#146;s laboratory work is focused on immunotherapy angiogenesis; dual epidermal growth factor receptor
(EGFR)/vascular endothelial growth factor receptor (VEGFR) inhibition in NSCLC, and targeting KRAS-activated pathways. More recently, he has explored predictive biomarkers for the use of immunotherapy agents. This work has been translated from the
preclinical to clinical setting in multiple Phase II and III studies which he has led. After earning a B.S. and M.S. degree from Yale University, Dr.&nbsp;Herbst earned his M.D. at Cornell University Medical College and his Ph.D. in molecular cell
biology at The Rockefeller University in New York City, New York. His postgraduate training included an internship and residency in medicine at Brigham and Women&#146;s Hospital in Boston, Massachusetts. His clinical fellowships in medicine and
hematology were completed at the Dana-Farber Cancer Institute and Brigham and Women&#146;s Hospital, respectively. Subsequently, Dr.&nbsp;Herbst completed a M.S. degree in clinical translational research at Harvard University in Cambridge,
Massachusetts. Dr.&nbsp;Herbst is an author or <FONT STYLE="white-space:nowrap">co-author</FONT> of more than 275 publications, including peer-reviewed journal articles, abstracts, and book chapters. His work has been published in many prominent
journals, such as the Journal of Clinical Oncology, Clinical Cancer Research, Lancet, the New England Journal of Medicine, and Nature. Dr.&nbsp;Herbst was a member of the National Cancer Policy Forum (1998-2014) for which he organized an Institute
of Medicine meeting focused on policy issues in personalized medicine. He is a member of ASCO and, as a member of AACR, he chairs the Tobacco Task Force. He is a fellow of the American College of Physicians and an elected member of the Association
of American Physicians. Dr.&nbsp;Herbst is also a member of the medical advisory committee for the Lung Cancer Research Foundation and chair of the communications committee for ASCO and the International Association for the Study of Lung Cancer. He
is currently the Vice Chair for Developmental Therapeutics for the Southwestern Oncology Group (SWOG) Lung Committee, Principal Investigator of the SWOG 0819 trial, and steering committee chair for the Lung Master Protocol (Lung MAP). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I>Chen Dong</I>, Ph.D., has served on our scientific advisory board since September 2020. Dr.&nbsp;Dong is a professor and the director of
the Institute for Immunology at Tsinghua University. Prior to joining Tsinghua University in 2013, Dr.&nbsp;Dong served as a professor of immunology and the director of the Center for inflammation and Cancer at the University of Texas MD Anderson
Cancer Center from 2004 to 2013. Dr.&nbsp;Dong&#146;s research focuses on understanding the molecular mechanisms whereby immune and inflammatory responses are normally regulated, and applying this knowledge to the understanding and treatment of
autoimmunity and allergy disorders as well as cancer. The work from Dr.&nbsp;Dong&#146;s group has led to the discoveries of Th17 and T follicular helper (Tfh) cell subsets in the immune system and elucidation of their biological and pathological
functions. Dr.&nbsp;Dong has over 200 publications and was rated highly cited researcher for six years from 2014 to 2019. The honors he has received include the 2009 American Association of <FONT STYLE="white-space:nowrap">Immunologists-BD</FONT>
Bioscience Investigator Award and 2019 International Cytokine and Interferon Society Biolegend-William E. Paul Award. He is a fellow of the American Association for the advancement of Science and a member of the Chinese Academy of Sciences.
Dr.&nbsp;Dong is currently an Editor for Immunity, <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Editor-in-chief</FONT></FONT> for Frontiers in Immunology- T Cell Biology and Associate Editor for China Sciences- Life Sciences.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I>Jun Ma</I>, has served on our scientific advisory board since December 2020. Dr.&nbsp;Ma is Chief Physician, Professor, Doctoral
Supervisor, Director of Harbin Institute of Hematology&nbsp;&amp; Oncology, Chief Supervisor of Supervisory Committee, Chinese Society of Clinical Oncology (CSCO), Vice Chairman of ACOS, Chairman of Union for China Leukemia Investigators of CSCO,
Past-Vice Chairman of Chinese Society of Hematology, Vice Chairman of CMDA for Hematologist Committee, Vice Chairman of CMDA for Oncology Committee and Past-Chairman of Union for China Lymphoma Investigators of CSCO. Dr.&nbsp;Ma studied in the
University of Tokyo Hospital since 1979. He was devoted to giving the treatment for benign and malignant diseases of hematological system. He earns the fame for treating Leukemia and lymphoma. In 1982, he built the very first multiple hematopoietic
progenitor cells culture system in vitro in China. Since 1983, he used the sequential therapy of ATRA and ATO to treat APL for 1200 cases or so. And disease free survival ( DFS ) were 85% in 10 years, which achieved international advanced level. He
has published about 200 articles in Journals from home and abroad, with over 40 monographs and has earned 20 national, provincial and municipal Science&nbsp;&amp; Technology </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">253 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
awards. He has taken 8 programs from National R&amp;D Program (863 Program) and 25 projects from provincial, municipal scientific research project. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Certain Past Incidents </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">From June 2007
to June 2013, Dr.&nbsp;Jingwu Zhang Zang worked and held senior management positions at GlaxoSmithKline (&#147;GSK&#148;), as a global senior vice president, and head of GSK&#146;s Research and Development in China. Dr.&nbsp;Zang was dismissed by
GSK in June 2013 after GSK became aware of misrepresentation of certain data in a research paper entitled &#147;Crucial role of <FONT STYLE="white-space:nowrap">interleukin-7</FONT> in T helper type 17 survival and expansion in autoimmune
disease,&#148; which was prepared by scientists at GSK China&#146;s research center and published in Nature Medicine in 2010. Dr.&nbsp;Zang was the corresponding author of the paper, primarily handling manuscript editing and communications with
editors and reviewers of the paper, which are the general responsibility of a corresponding author. According to Dr.&nbsp;Zang and the first author of the paper, Dr.&nbsp;Zang, as the head of GSK China&#146;s research center and a member of
GSK&#146;s global senior management, was neither involved in nor aware of the mislabeled samples relating to the misrepresented data referenced in the paper at the time when the paper was prepared and published. Nonetheless, Dr.&nbsp;Zang admitted
his management oversight and accepted the responsibility as the corresponding author. He later coordinated the retraction of the paper in September 2013. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">From 1996 to 2002, Dr.&nbsp;Zang was employed by Baylor College of Medicine in Houston, Texas initially as an associate professor and was
later promoted to full professor. At that time, Dr.&nbsp;Zang&#146;s team was conducting a clinical study on <FONT STYLE="white-space:nowrap">T-cell</FONT> vaccination for the treatment of multiple sclerosis after approval by Baylor&#146;s
Institutional Review Board (&#147;IRB&#148;). Dr.&nbsp;Zang was led to believe that such clinical research would not require FDA approval. In March 1999, the Food and Drug Administration, or the FDA, issued a warning letter to Dr.&nbsp;Zang stating
that the clinical study did require IND approval from the FDA in addition to the approval from the IRB and requested the study to be suspended. The study was suspended and later <FONT STYLE="white-space:nowrap">re-initiated</FONT> and successfully
completed after the IND approval was obtained. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">To the best of our knowledge, Dr.&nbsp;Zang was not and is not subject to any legal or
regulatory charges, proceedings or disciplinary actions in connection with the above incidents or by relevant parties involved in the incidents. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Since the incident, Dr.&nbsp;Zang continues to be recognized by his peers and institutions, given his longstanding scientific achievements.
For example, he was approved by the Ministry of Science and Technology of PRC in 2015 through a peer review process, to serve as the director of China National Key Laboratory of Translational Medicine and Innovative Medicine. Since 2016,
Dr.&nbsp;Zang has successfully led all financing rounds of our company from high caliber investors, including the initial public offering of our company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">For risks related to the above incidents, please see &#147;Risk Factors&#151;Risks Related to Our Industry, Business and
Operations&#151;Negative publicity with respect to us, our management, employees, business partners, affiliates, or our industry, may materially and adversely affect our reputation, business, results of operations and prospect.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">For the measures and systems we have in place to ensure the integrity and legal compliance of our R&amp;D process and business operations,
please see &#147;Business&#151;R&amp;D Governance&#148; and &#147;Business&#151;Quality Control and Assurance.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Board of Directors </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our board of directors consists of 11 directors. A director is not required to hold any shares in our company by way of qualification. Subject
to the Nasdaq Global Market rules and disqualification by the chairman of the relevant board meeting, a director may vote with respect to any contract, proposed contract or arrangement in which he is interested. A director who is interested in a
contract, proposed contract or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">254 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
arrangement shall declare the nature of his or her interest at the earliest meeting of the board at which it is practicable for him or her to do so, either specifically or by way of a general
notice. The directors may exercise all the powers of our company to borrow money, mortgage its undertaking, property and uncalled capital, and issue debentures or other securities whenever money is borrowed or as security for any obligation of our
company or of any third party. None of our directors who are not our executive officers has a service contract with us that provides for benefits upon termination of service. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Committees of the Board of Directors </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We
have established three committees under the board of directors: an audit committee, a compensation committee and a nominating and corporate governance committee. We have adopted a charter for each of the three committees. Each committee&#146;s
members and functions are described below. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I>Audit Committee</I>. Our audit committee consists of Mr.&nbsp;Conor Chia-hung Yang,
Mr.&nbsp;Chun Kwok Alan Au and Mr.&nbsp;Bing Yuan. Mr.&nbsp;Conor Chia-hung Yang is the chairman of our audit committee. We have determined that each of Mr.&nbsp;Conor Chia-hung Yang, Mr.&nbsp;Chun Kwok Alan Au and Mr.&nbsp;Bing Yuan satisfies the
&#147;independence&#148; requirements of Rule 5605(c)(2) of the Nasdaq Stock Market Rules and meets the independence standards under Rule <FONT STYLE="white-space:nowrap">10A-3</FONT> under the Exchange Act. We have determined that Mr.&nbsp;Conor
Chia-hung Yang qualifies as an &#147;audit committee financial expert.&#148; The audit committee will oversee our accounting and financial reporting processes and the audits of the financial statements of our company. The audit committee is
responsible for, among other things: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">appointing the independent auditors and <FONT STYLE="white-space:nowrap">pre-approving</FONT> all auditing and <FONT
STYLE="white-space:nowrap">non-auditing</FONT> services permitted to be performed by the independent auditors; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing with the independent auditors any audit problems or difficulties and management&#146;s response;
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">discussing the annual audited financial statements with management and the independent auditors;
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing the adequacy and effectiveness of our accounting and internal control policies and procedures and any
steps taken to monitor and control major financial risk exposures; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing and approving all proposed related party transactions; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">meeting separately and periodically with management and the independent auditors; and </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">monitoring compliance with our code of business conduct and ethics, including reviewing the adequacy and
effectiveness of our procedures to ensure proper compliance. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I>Compensation Committee</I>. Our compensation committee
consists of Dr.&nbsp;Jingwu Zhang Zang, Mr.&nbsp;Chun Kwok Alan Au and Dr.&nbsp;Pamela&nbsp;M. Klein. Dr.&nbsp;Jingwu Zhang Zang is the chairman of our compensation committee. We have determined that each of Mr.&nbsp;Chun Kwok Alan Au and
Dr.&nbsp;Pamela&nbsp;M. Klein satisfies the &#147;independence&#148; requirements of Rule 5605(a)(2) of the Nasdaq Stock Market Rules. The compensation committee will assist the board in reviewing and approving the compensation structure, including
all forms of compensation, relating to our directors and executive officers. Our chief executive officer may not be present at any committee meeting during which his compensation is deliberated. The compensation committee is responsible for, among
other things: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing and approving, or recommending to the board for its approval, the compensation for our chief executive
officer and other executive officers; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">255 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing and recommending to the board for determination with respect to the compensation of our directors who
are not our employees; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing periodically and approving any incentive compensation or equity plans, programs or similar
arrangements; and </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">selecting compensation consultant, legal counsel or other adviser only after taking into consideration all
factors relevant to that person&#146;s independence from management. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I>Nominating and Corporate Governance
Committee</I>. Our nominating and corporate governance committee consists of Mr.&nbsp;Wei Fu, Mr.&nbsp;Chun Kwok Alan Au and Mr.&nbsp;Conor Chia-hung Yang. Mr.&nbsp;Wei Fu is the chairman of our nominating and corporate governance committee. We have
determined that each of Mr.&nbsp;Chun Kwok Alan Au and Mr.&nbsp;Conor Chia-hung Yang satisfies the &#147;independence&#148; requirements of Rule 5605(a)(2) of the Nasdaq Stock Market Rules. The nominating and corporate governance committee will
assist the board of directors in selecting individuals qualified to become our directors and in determining the composition of the board and its committees. The nominating and corporate governance committee is responsible for, among other things:
</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">selecting and recommending to the board nominees for election by the shareholders or appointment by the board;
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing annually with the board the current composition of the board with regards to characteristics such as
independence, knowledge, skills, experience and diversity; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">making recommendations on the frequency and structure of board meetings and monitoring the functioning of the
committees of the board; and </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">advising the board periodically with regards to significant developments in the law and practice of corporate
governance as well as our compliance with applicable laws and regulations, and making recommendations to the board on all matters of corporate governance and on any corrective action to be taken. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Duties of Directors </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Under Cayman
Islands law, our directors owe fiduciary duties to our company, including a duty of loyalty, a duty to act honestly, and a duty to act in what they consider in good faith to be in our best interests. Our directors must also exercise their powers
only for a proper purpose. A director must exercise the skill and care of a reasonably diligent person having both&#151;(a) the general knowledge, skill and experience that may reasonably be expected of a person in the same position (an objective
test), and (b)&nbsp;if greater, the general knowledge, skill and experience that that director actually possesses (a subjective test). In fulfilling their duty of care to us, our directors must ensure compliance with our memorandum and articles of
association, as amended from time to time, and the class rights vested thereunder in the holders of the shares. Our company has the right to seek damages if a duty owed by our directors is breached. A shareholder may in certain limited circumstances
have the right to seek damages in our name if a duty owed by the directors is breached. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our board of directors has all the powers
necessary for managing, and for directing and supervising, our business affairs. The functions and powers of our board of directors include: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">convening shareholders&#146; annual general meetings and reporting its work to shareholders at such meetings;
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">declaring dividends and other distributions; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">256 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">appointing officers and determining the term of office of the officers; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">exercising the borrowing powers of our company and mortgaging the property of our company; and
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">approving the transfer of shares in our company, including the registration of such shares in our share register.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Terms of Directors and Officers </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our directors may be elected by an ordinary resolution of our shareholders. Alternatively, our board of directors may, by the affirmative vote
of a simple majority of the directors present and voting at a board meeting appoint any person as a director to fill a casual vacancy on our board or as an addition to the existing board. Our directors (other than independent directors) are not
automatically subject to a term of office and hold office until such time as they are removed from office by an ordinary resolution of our shareholders. Our independent directors hold office until the earlier of (i)&nbsp;the date on which the
independent director ceases to be a member of the board for any reason; (ii)&nbsp;the date of termination of an independent director&#146;s director agreement, which may be terminated by either the independent director or by us with a <FONT
STYLE="white-space:nowrap">30-day</FONT> advance written notice or such other shorter period as mutually agreed; or (iii)&nbsp;three years from the effective date of the director agreement, subject to the terms of our current memorandum and articles
of association of our company. In addition, a director will cease to be a director if he or she (i)&nbsp;becomes bankrupt or makes any arrangement or composition with his or her creditors; (ii)&nbsp;dies or is found to be or becomes of unsound mind;
(iii)&nbsp;resigns his or her office by notice in writing; (iv)&nbsp;without special leave of absence from our board, is absent from meetings of our board for three consecutive meetings and our board resolves that his or her office be vacated; or
(v)&nbsp;is removed from office pursuant to any other provision of our articles of association. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our officers are appointed by and serve
at the discretion of the board of directors, and may be removed by our board of directors. Under our articles of association, the board of directors may appoint one or more of their number to the office of managing director upon like terms, but any
such appointment shall ipso facto terminate if any managing director ceases for any cause to be a director, or if our company by ordinary resolution of shareholders resolves that his tenure of office be terminated. In addition, the board of
directors may appoint any natural person or corporation to be a secretary (and if need be an assistant secretary or assistant secretaries) who shall hold office for such term, at such remuneration and upon such conditions and with such powers as
they think fit. Any secretary or assistant secretary so appointed by the board of directors may be removed by the board of directors or by ordinary resolution of shareholders. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Employment Agreements and Indemnification Agreements </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We have entered into employment agreements with all of our executive officers. Under these agreements, each of our executive officers is
employed for a specified time period. We may terminate employment for cause, at any time, for certain acts of the executive officer, such as continued failure to satisfactorily perform, willful misconduct or gross negligence in the performance of
agreed duties, conviction or nolo contendere plea of guilty to any felony or any misdemeanor involving moral turpitude, or dishonest act that result in material harm to our detriment, or material breach by the executive officer of the employment
agreement. We may also terminate an executive officer&#146;s employment without cause upon a <FONT STYLE="white-space:nowrap">60-day</FONT> prior written notice. In such case of termination by us, we will provide severance payments to the executive
officer as may be agreed between the executive officer and us. The executive officer may resign at any time with a <FONT STYLE="white-space:nowrap">60-day</FONT> prior written notice. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Under these agreements, each executive officer has agreed to hold, both during and after the termination or expiry of his or her employment
agreement, in strict confidence and not to use, except as required in the performance of his or her duties in connection with the employment or pursuant to applicable law, any of our confidential information or trade secrets, any confidential
information or trade secrets of our clients or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">257 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
prospective clients, or the confidential or proprietary information of any third party received by us and for which we have confidential obligations. The executive officers have also agreed to
disclose in confidence to us all inventions, designs and trade secrets which they conceive, develop or reduce to practice during the executive officer&#146;s employment with us and to assign all right, title and interest in them to us, and assist us
in obtaining and enforcing patents, copyrights and other legal rights for these inventions, designs and trade secrets. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In addition, under
these agreements, each executive officer has agreed to be bound by <FONT STYLE="white-space:nowrap">non-competition</FONT> and <FONT STYLE="white-space:nowrap">non-solicitation</FONT> restrictions during the term of his or her employment and
typically for one year following the last date of employment. Specifically, each executive officer has agreed not to (i)&nbsp;approach our suppliers, clients, direct or end customers or contacts or other persons or entities introduced to the
executive officer in his or her capacity as a representative of us for the purpose of doing business with such persons or entities that will harm our business relationships with these persons or entities; (ii)&nbsp;assume employment with or provide
services to any of our competitors, or engage, whether as principal, partner, licensor or otherwise, any of our competitors, without our express consent; or (iii)&nbsp;seek directly or indirectly, to solicit the services of any of our employees who
is employed by us on or after the date of the executive officer&#146;s termination, or in the year preceding such termination, without our express consent. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We have also entered into indemnification agreements with each of our directors and executive officers. Under these agreements, we agree to
indemnify our directors and executive officers against certain liabilities and expenses incurred by such persons in connection with claims made by reason of their being a director or officer of our company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Compensation of Directors and Executive Officers </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">For the fiscal year ended December&nbsp;31, 2019, we paid an aggregate of approximately US$2.7&nbsp;million for salaries and benefits in cash
to our executive officers. We also completed a repurchase of 3,890,155 options held by a director of our company at the total consideration of US$21.9&nbsp;million. We did not pay any compensation to our directors who are not our executive officers.
We have not set aside or accrued any amount to provide pension, retirement or other similar benefits to our executive officers and directors. Our PRC subsidiaries are required by law to make contributions equal to certain percentages of each
employee&#146;s salary for his or her pension insurance, medical insurance, unemployment insurance and other statutory benefits and a housing provident fund. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Share Incentive Plans </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Second Amended and Restated
2017 Employee Stock Option Plan </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In October 2017, we adopted an equity incentive plan (as last amended and restated in December
2019), which we refer to as the 2017 Plan, to secure and retain the services of valuable employees, directors or consultants, and provide incentives for such persons to exert their best efforts for the success of our business. The maximum aggregate
number of ordinary shares which may be issued pursuant to all awards under the 2017 Plan is 9,609,084, subject to certain adjustments. As of the date of this prospectus, options to purchase an aggregate of 7,895,607 ordinary shares under the 2017
Plan had been granted and remained outstanding, excluding options that were forfeited, cancelled or exercised after the relevant grant date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The following paragraphs describe the principal terms of the 2017 Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I>Types of awards</I>. The 2017 Plan permits the awards of options. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I>Plan administration</I>. Our board of directors will administer the 2017 Plan. The board of directors will determine, among other things,
the participants to receive options, the number and subscription price of options to be granted to each participant, and the terms and conditions of each option granted. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">258 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I>Offer letter</I>. Options granted under the 2017 Plan are evidenced by an offer letter
that sets forth terms, conditions and limitations for each option, which may include the term of the option, and the provisions applicable in the event that the grantee&#146;s employment or service terminates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I>Eligible participants</I>. We may grant awards to employees, officers, directors, contractors, advisors and consultants of our company.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I>Vesting schedule</I>. Unless otherwise approved by the board of directors and set forth in an offer letter, the vesting schedule shall
be a three-year vesting schedule consisting of a cliff vesting 50% on the second anniversary of the applicable vesting commencement date, and a vesting of the remaining 50% on the third anniversary of the applicable vesting commencement date. Except
as otherwise approved by the board of directors, vested portion of option shall become exercisable upon the earlier of a listing or the occurrence of a change in control. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I>Exercise of options</I>. The board of directors determines the subscription price for each option, which is stated in the offer letter. The
vested portion of each option will expire if not exercised prior to the time as the board of directors determines at the time of its grant. However, the maximum exercisable term is ten years from the applicable vesting commencement date or such
shorter period specified in the award agreement. Further, an option will lapse upon the earliest of, among other circumstances, two years after the date when the option becomes exercisable upon the listing or the occurrence of a change in control,
and a violation in transfer restrictions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I>Transfer restrictions</I>. Options may not be transferred in any manner by the participant
other than in accordance with the exceptions provided in the 2017 Plan or the relevant offer letter or otherwise determined by the board of directors, such as transfers by will or the laws of descent and distribution. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I>Termination and amendment of the 2017 Plan</I>. Unless terminated earlier, the 2017 Plan has a term of ten years. The board of directors
has the authority to amend, suspend or terminate the plan, subject to the limitations of applicable laws. No amendment, suspension or termination may adversely affect in any material way any awards previously granted pursuant to the 2017 Plan unless
agreed to by the participant. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The following table summarizes, as of the date of this prospectus, the number of ordinary shares underlying
outstanding options that we granted under the 2017 Plan, excluding options that were forfeited, cancelled or exercised after the relevant grant date. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="39%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Ordinary&nbsp;Shares</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Underlying</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Outstanding<BR>Options</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Exercise&nbsp;Price<BR>(US$/Share)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Date&nbsp;of&nbsp;Grant</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Date&nbsp;of&nbsp;Expiration</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Zheru Zhang</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">1.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">October&nbsp;1,&nbsp;2017</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">October&nbsp;1,&nbsp;2027</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Joan Huaqiong Shen</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">1.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">October&nbsp;1, 2017</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">October&nbsp;1, 2027</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jielun Zhu</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">1.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">August&nbsp;1, 2018</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">October&nbsp;1, 2027</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weimin Tang</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">1.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">April&nbsp;2, 2018</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">October&nbsp;1, 2027</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Yunhan Lin</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">1.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">October&nbsp;1, 2017</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">October&nbsp;1, 2027</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Lili Qian</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">1.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">October&nbsp;1, 2017</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">October&nbsp;1, 2027</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other grantees</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,115,887</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">1.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;<BR></TD>
<TD VALIGN="bottom">October&nbsp;1, 2017<BR>to July&nbsp;25, 2019</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;<BR>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">October&nbsp;1, 2027</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>7,895,607</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Note: </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Less than 1% of our total outstanding shares. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">259 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Second Amended and Restated 2018 Employee Stock Option Plan </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In February 2019, we adopted an equity incentive plan (as last amended and restated in December 2019), which we refer to as the 2018 Plan, to
secure and retain the services of valuable employees, directors or consultants, and provide incentives for such persons to exert their best efforts for the success of our business. The maximum aggregate number of ordinary shares which may be issued
pursuant to all awards under the 2018 Plan is 11,005,888, subject to certain adjustments. As of the date of this prospectus, options to purchase an aggregate of 10,589,660 ordinary shares under the 2018 Plan had been granted and remained
outstanding, excluding options that were forfeited, cancelled or exercised after the relevant grant date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The following paragraphs
describe the principal terms of the 2018 Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I>Types of awards</I>. The 2018 Plan permits the awards of options. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I>Plan administration</I>. Our board of directors will administer the 2018 Plan. The board of directors will determine, among other things,
the participants to receive options, the number and subscription price of options to be granted to each participant, and the terms and conditions of each option granted. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I>Offer letter</I>. Options granted under the 2018 Plan are evidenced by an offer letter that sets forth terms, conditions and limitations
for each option, which may include the term of the option, and the provisions applicable in the event that the grantee&#146;s employment or service terminates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I>Eligible participants</I>. We may grant awards to employees or if approved by the board, designee of any employee. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I>Vesting schedule</I>. Unless otherwise approved by the board of directors and set forth in an offer letter, the vesting schedule shall be a
<FONT STYLE="white-space:nowrap">two-year</FONT> vesting schedule consisting of a cliff vesting 50% on the first anniversary of the applicable vesting commencement date, and a vesting of the remaining 50% on the second anniversary of the applicable
vesting commencement date. Notwithstanding the foregoing, if a listing occurs at any time prior to any option granted under the 2018 Plan becoming full vested, and to the extent such option has been granted and outstanding, any such option shall
vest in full with immediate effect upon the listing. Except as otherwise approved by the board of directors, vested portion of option shall become exercisable upon the earlier of six months after a listing or the occurrence of a change in control;
provided, however that in each case, no option of an employee shall become exercisable until the third anniversary of such employee&#146;s employment commencement date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I>Exercise of options</I>. The board of directors determines the subscription price for each option, which is stated in the offer letter. The
vested portion of each option will expire if not exercised prior to the time as the board of directors determines at the time of its grant. However, the maximum exercisable term is ten years from the applicable vesting commencement date or such
shorter period specified in the award agreement. Further, an option will lapse upon the earliest of, among other circumstances, two years after the date when the option becomes exercisable upon the listing or the occurrence of a change in control,
and a violation in transfer restrictions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I>Transfer restrictions</I>. Options may not be transferred in any manner by the participant
other than in accordance with the exceptions provided in the 2018 Plan or the relevant offer letter or otherwise determined by the board of directors, such as transfers by will or the laws of descent and distribution. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I>Termination and amendment of the 2018 Plan</I>. Unless terminated earlier, the 2018 Plan has a term often years. The board of directors has
the authority to amend, suspend or terminate the plan, subject to the limitations of applicable laws. No amendment, suspension or termination may adversely affect in any material way any awards previously granted pursuant to the 2018 Plan unless
agreed to by the participant. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">260 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The following table summarizes, as of the date of this prospectus, the number of ordinary
shares underlying outstanding options that we granted under the 2018 Plan, excluding options that were forfeited, cancelled, exercised after the relevant grant date. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="42%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Ordinary&nbsp;Shares<BR>Underlying<BR>Outstanding<BR>Options</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Exercise&nbsp;Price<BR>(US$/Share)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Date of Grant</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Date of Expiration</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jingwu Zhang Zang</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,893,171</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">1.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">February&nbsp;22,&nbsp;2019</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">February&nbsp;22,&nbsp;2029</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Zheru Zhang</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">1.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">July&nbsp;25, 2019</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">February&nbsp;22, 2029</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Joan Huaqiong Shen</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">1.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">July&nbsp;25, 2019</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">February&nbsp;22, 2029</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jielun Zhu</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">1.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">July&nbsp;25, 2019</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">February&nbsp;22, 2029</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weimin Tang</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">1.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">July&nbsp;25, 2019</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">February&nbsp;22, 2029</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Yunhan Lin</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">1.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">July&nbsp;25, 2019</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">February&nbsp;22, 2029</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Lili Qian</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">1.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">July&nbsp;25, 2019</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">February&nbsp;22, 2029</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other grantees</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">1.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">July&nbsp;25, 2019</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">February&nbsp;22, 2029</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; font-size:10pt; font-family:Times New Roman"><B>Total</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>10,589,660</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Note: </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Less than 1% of our total outstanding shares. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>2019 Share Incentive Plan </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In
October 2019, we adopted an equity incentive plan, which we refer to as 2019 Plan, to promote the success and enhance the value of our company. Under the 2019 Plan, the maximum aggregate number of ordinary shares available for issuance is 100,000.
As of the date of this prospectus, options to purchase an aggregate of 72,000 ordinary shares under the 2019 Plan had been granted and remained outstanding, excluding options that were forfeited, cancelled or exercised after the relevant grant date.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The following paragraphs describe the principal terms of the 2019 Plan: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I>Type of Awards</I>. The plan permits the awards of options, restricted shares, restricted share units or other types of awards approved by
the board of directors or a committee of one or more members of the board of directors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I>Plan Administration</I>. Our board of
directors or a committee of one or more members of the board of directors will administer the plan. The committee or the board of directors, as applicable, will determine the participants to receive awards, the type and number of awards to be
granted to each participant, and the terms and conditions of each grant. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I>Award Agreement</I>. Awards granted under the plan are
evidenced by an award agreement that sets forth the terms, conditions and limitations for each award, which may include the term of the award, the provisions applicable in the event that the grantee&#146;s employment or service terminates, and our
authority to unilaterally or bilaterally amend, modify, suspend, cancel or rescind the award. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I>Eligibility</I>. We may grant awards to
our independent directors, as determined by a committee of one or more members of the board of directors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I>Vesting Schedule. </I>In
general, the plan administrator determines the vesting schedule, which is specified in the relevant award agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">261 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I>Exercise of Options</I>. The plan administrator determines the exercise price for each
award, which is stated in the relevant award agreement. Options that are vested and exercisable will terminate if they are not exercised prior to the time as the plan administrator determines at the time of grant. However, the maximum exercisable
term is ten years from the date of grant. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I>Transfer Restrictions</I>. Awards may not be transferred in any manner by the participant
other than in accordance with the exceptions provided in the plan or the relevant award agreement or otherwise determined by the plan administrator, such as transfers by will or the laws of descent and distribution. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I>Termination and Amendment of the Plan</I>. Our board of directors has the authority to terminate, amend, suspend or modify the plan in
accordance with our articles of association. However, without the prior written consent of the participant, no such action may adversely affect in any material way any award previously granted pursuant to the plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The following table summarizes, as of the date of this prospectus, the number of ordinary shares underlying outstanding options that we
granted under the 2019 Plan, excluding options that were forfeited, cancelled or exercised after the relevant grant date. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="48%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Ordinary&nbsp;Shares<BR>Underlying<BR>Outstanding<BR>Options</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Exercise<BR>Price<BR>(US$/<BR>Share)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Date&nbsp;of&nbsp;Grant</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Date&nbsp;of&nbsp;Expiration</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Chun Kwok Alan Au</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">6.09</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">April&nbsp;30, 2020</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">April&nbsp;30,&nbsp;2030</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Conor Chia-hung Yang</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">6.09</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">April&nbsp;30, 2020</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">April&nbsp;30, 2030</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pamela M. Klein</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">6.09</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">April&nbsp;30,&nbsp;2020</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">April&nbsp;30, 2030</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; font-size:10pt; font-family:Times New Roman"><B>Total</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>72,000</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Note: </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Less than 1% of our total outstanding shares. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>2020 Share Incentive Plan </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In
July 2020, we adopted 2020 Share Incentive Plan, which we refer to as the 2020 Plan, to promote the success and enhance the value of our company. Under the 2020 Plan, the maximum aggregate number of ordinary shares which may be issued pursuant to
all awards shall be 10,760,513 ordinary shares; provided that the maximum number of ordinary shares may be issued pursuant to awards in the form of restricted share units under the 2020 Plan shall not exceed 7,686,081 ordinary shares. As of the date
of this prospectus, options to purchase an aggregate of 1,046,919 ordinary shares and restricted share units to receive an aggregate of 4,321,257 ordinary shares under the 2020 Plan had been granted and remained outstanding, excluding awards that
were forfeited, cancelled, exercised or vested after the relevant grant date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The following paragraphs describe the principal terms of
the 2020 Plan: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I>Type of Awards</I>. The plan permits the awards of options, restricted shares, restricted share units or other
share-based awards. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I>Plan Administration</I>. Our board of directors or one or more committees or subcommittees of the board of
directors, or the Committee, will administer the plan. The Committee or the board of directors, as applicable, will determine the participants to receive awards, the type and number of awards to be granted to each participant, and the terms and
conditions of each grant. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I>Award Agreement</I>. Awards granted under the plan are evidenced by an award agreement that sets forth the
terms, conditions and restrictions for each award, which may include the term of the award, the provisions applicable in the event that the grantee&#146;s employment or service terminates, and our authority to unilaterally or bilaterally amend,
modify, suspend, cancel or rescind the award. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">262 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I>Eligibility</I>. We may grant awards to our employees, directors and consultants of our
company. However, we may grant options that are intended to qualify as incentive share options only to our employees and employees of our subsidiaries. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I>Vesting Schedule. </I>The options and restricted share units shall vest according to the schedules specified in the plan, unless otherwise
determined by the plan administrator. The vesting schedule of other share-based awards shall be determined by the plan administrator, which is specified in the relevant award agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I>Exercise of Options</I>. The plan administrator determines the exercise price for each award, which is stated in the relevant award
agreement. Options that are vested and exercisable will terminate if they are not exercised prior to the time as the plan administrator determines at the time of grant. However, the maximum exercisable term is ten years from the date of grant. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I>Transfer Restrictions</I>. Awards may not be transferred in any manner by the participant other than in accordance with the exceptions
provided in the plan or the relevant award agreement or otherwise determined by the plan administrator, such as transfers by will or the laws of descent and distribution. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I>Termination and Amendment of the Plan</I>. Our board of directors has the authority to terminate, amend or modify the plan in accordance
with our articles of association. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The following table summarizes, as of the date of this prospectus, the number of ordinary shares
underlying outstanding options and restricted share units that we granted under the 2020 Plan, excluding awards that were forfeited, cancelled, exercised or vested after the relevant grant date. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="28%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD WIDTH="17%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Ordinary&nbsp;Shares&nbsp;Underlying</B><br><B>Options and Restricted</B><br><B>Share Units</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Exercise&nbsp;Price<BR>(US$/
Share)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Date of Grant</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Date of Expiration</B></P></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jingwu Zhang Zang</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">N/A</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">September&nbsp;4,&nbsp;2020</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#151;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Zheru Zhang</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">N/A</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">September&nbsp;4, 2020</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#151;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Joan Huaqiong Shen</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">N/A</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">September&nbsp;4, 2020</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#151;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jielun Zhu</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">5.91</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">August&nbsp;14, 2020</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">August&nbsp;14, 2030</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">N/A</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">August&nbsp;14, 2020</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#151;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">1.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">August&nbsp;14, 2020</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#151;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weimin Tang</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">N/A</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">September&nbsp;4, 2020</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#151;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">1.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">September&nbsp;4, 2020</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#151;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Yunhan Lin</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">5.91</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">August&nbsp;14, 2020</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">August&nbsp;14, 2030</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">N/A</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">August&nbsp;14, 2020</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#151;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Lili Qian</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">5.91</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">August&nbsp;14, 2020</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">August&nbsp;14, 2030</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">N/A</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">August&nbsp;14, 2020</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#151;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gigi Qi Feng</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">N/A</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">September&nbsp;4, 2020</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#151;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other grantees</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">5.91</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">August&nbsp;14, 2020</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">August&nbsp;14, 2030</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top"> (1)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">N/A</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;<BR><BR></TD>
<TD VALIGN="bottom">August&nbsp;14, 2020<BR>to September&nbsp;4,<BR>2020</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;<BR>&nbsp;<BR>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#151;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">1.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;<BR><BR></TD>
<TD VALIGN="bottom">August 14, 2020<BR>to September&nbsp;4,<BR>2020</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;<BR>&nbsp;<BR>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#151;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.50em; font-size:10pt; font-family:Times New Roman"><B>Total</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>5,368,176</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">263 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Note: </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Less than 1% of our total outstanding shares. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Represents restricted share units. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Biomaster Trust </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Biomaster Trust was
established under the trust deed dated October&nbsp;23, 2019, between us and TMF Trust (HK) Limited, or TMF Trust, as the trustee of the Biomaster Trust. As of the date of this prospectus, all participants in Biomaster Trust are our employees or
former employees. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Participants in Biomaster Trust transfer their equity awards granted under the 2017 Plan and the 2018 Plan to TMF Trust
for their benefit. Upon satisfaction of vesting conditions, TMF Trust will exercise the equity awards and transfer the relevant ordinary shares and other rights and interests under the equity awards to the relevant grant recipients with the consent
of the advisory committee. TMF Trust shall not exercise the voting rights attached to such ordinary shares unless otherwise directed by the advisory committee, whose members shall be appointed by our company. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">264 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom98473_16"></A>PRINCIPAL AND SELLING SHAREHOLDERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Except as specifically noted, the following table sets forth information with respect to the beneficial ownership of our ordinary shares as of
the date of this prospectus by: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">each of our directors and executive officers; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">each of our principal shareholders, including all shareholders who own beneficially more than 5% of our total
outstanding shares; and </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">each selling shareholder. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The ordinary shares registered under this prospectus include (i) 20,421,378 ordinary shares (represented by 8,878,860 ADSs) issued to the
selling shareholders identified in this prospectus on September&nbsp;11, 2020, (ii) 3,744,032 ordinary shares (represented by 1,627,840 ADSs) that certain selling shareholders identified in this prospectus have the right to purchase from our company
through the exercise of the warrants issued to them, and (iii) 958,341 ordinary shares (represented by 416,670 ADSs) that certain selling shareholders identified in this prospectus have the right to purchase pursuant to a call option agreement with
certain members of our management team. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The ordinary shares held by the selling shareholders reflected in the table below may be sold by
the selling shareholders from time to time in one or more offerings described in this prospectus and any applicable prospectus supplement. The selling shareholders may sell all, some or none of these ordinary shares (or the ADSs representing these
ordinary shares) beneficially owned by them, and therefore we cannot estimate either the number or the percentage of ordinary shares (or the ADSs representing these ordinary shares) that will be beneficially owned by the selling shareholders
following any offering or sale hereunder. We cannot advise you as to whether the selling shareholders will in fact sell any or all of the ordinary shares (or the ADSs representing these ordinary shares) that they own. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The selling shareholders listed in the table below may have sold or transferred, or pledged as collateral, in transactions pursuant to this
prospectus or exempt from the registration requirements of the Securities Act, some or all of their ordinary shares (or the ADSs representing their ordinary shares) since the date as of which the information is presented in the table below.
Information concerning the selling shareholders may change from time to time, and any changed information will, if required, be set forth in prospectus supplements or post-effective amendments to the registration statement of which this prospectus
is a part, as may be appropriate. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The calculations in the table below are based on 154,310,098 ordinary shares outstanding as of the date
of this prospectus (excluding 4,036,868 ordinary shares issued to our depositary bank for bulk issuance of ADSs reserved for future issuances upon the exercising or vesting of awards granted under our share incentive plans). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We intend to use our reasonable efforts to keep the Registration Statement effective for a period of 90 days after the effectiveness of the
Registration Statement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">265 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Beneficial ownership is determined in accordance with the rules and regulations of the SEC.
In computing the number of shares beneficially owned by a person and the percentage ownership of that person, we have included shares that the person has the right to acquire within 60 days, including through the exercise of any option, warrant or
other right or the conversion of any other security. These shares, however, are not included in the computation of the percentage ownership of any other person. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="58%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Ordinary Shares</B><br><B>Beneficially Owned</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Ordinary Shares</B><br><B>Being Registered</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Number</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>%</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Number</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>%</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Directors and Executive Officers**:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jingwu Zhang Zang<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,825,284</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Joan Huaqiong Shen</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,055,128</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Zheru Zhang</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,030,186</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jielun Zhu</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Wei Fu<SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">36,430,941</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23.6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Mengjiao Jiang</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jie Yu</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Bing Yuan</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Chun Kwok Alan Au</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Conor Chia-hung Yang</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pamela M. Klein</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Lili Qian</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weimin Tang</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Yunhan Lin</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Neil Warma</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ivan Yifei Zhu</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gigi Qi Feng</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">All Directors and Executive Officers as a Group</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">54,420,936</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">32.4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Principal and Selling Shareholders:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">C-Bridge</FONT> entities<SUP
STYLE="font-size:85%; vertical-align:top">(2) </SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">36,430,941</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23.6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Tasly entities<SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,664,020</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9.5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">GIC Private Limited<SUP STYLE="font-size:85%; vertical-align:top">(4)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,099,770</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,773,253</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Hillhouse entities<SUP STYLE="font-size:85%; vertical-align:top">(5) </SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,586,008</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,143,961</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Genexine<SUP STYLE="font-size:85%; vertical-align:top">(6)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,572,823</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Hony entity<SUP STYLE="font-size:85%; vertical-align:top">(7)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,465,631</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Avidity entities<SUP STYLE="font-size:85%; vertical-align:top">(8)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,092,833</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,092,833</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Temasek entity<SUP STYLE="font-size:85%; vertical-align:top">(9)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,649,537</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,649,537</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Octagon Investments Master Fund
LP<SUP STYLE="font-size:85%; vertical-align:top">(10)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,237,147</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,237,147</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">OrbiMed entities<SUP STYLE="font-size:85%; vertical-align:top">(11)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,649,537</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,649,537</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Invus Public Equities, L.P.<SUP STYLE="font-size:85%; vertical-align:top">(12)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,072,191</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,072,191</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Lake Bleu Prime Healthcare Master Fund Limited
<SUP STYLE="font-size:85%; vertical-align:top">(13)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">824,780</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">824,780</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Perceptive Life Sciences Master Fund,
Ltd.<SUP STYLE="font-size:85%; vertical-align:top">(14)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">742,279</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">742,279</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cormorant Global Healthcare Master Fund,
LP<SUP STYLE="font-size:85%; vertical-align:top">(15)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">618,585</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">618,585</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sphera entities<SUP STYLE="font-size:85%; vertical-align:top">(16)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">494,868</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">494,868</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Alyeska entities<SUP STYLE="font-size:85%; vertical-align:top">(17)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">412,390</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">412,390</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">CVI Investments, Inc.<SUP STYLE="font-size:85%; vertical-align:top">(18)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">412,390</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">412,390</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Notes: </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Less than 1% of our total ordinary shares on an <FONT STYLE="white-space:nowrap">as-converted</FONT> basis
outstanding as of the date of this prospectus. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">**</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Except as otherwise indicated below, the business address of our directors and executive officers is
Suite&nbsp;802, West Tower, OmniVision, 88 Shangke Road, Pudong District, Shanghai, China. The business </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">266 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
address of Wei Fu and Mengjiao Jiang is Suite 3306-3307, Two Exchange Square, 8 Connaught Place, Central, Hong Kong. The business address of Jie Yu is Tasly Great Health Town, No.&nbsp;2, East
Puji River Road, Beichen District, Tianjin, China. The business address of Bing Yuan is Flat B, 31/F BLK 2, The Hermitage, Mongkok, Hong Kong. The business address of Chun Kwok Alan Au is 22 Pottinger Street, Central, Hong Kong. The business address
of Conor Chia-hung Yang is 7th Floor, Building C, Luneng International Center, No.&nbsp;209 Guoyao Road, Pudong New Area, Shanghai, China. The business address of Dr.&nbsp;Pamela&nbsp;M. Klein is 231 Fort Mason, San Francisco, California 94123, the
United States. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Represents (i) 3,932,113 ordinary shares directly held by Mabcore Limited, a British Virgin Islands company and
(ii) 7,893,171 ordinary shares issuable upon exercise of options exercisable within 60 days after the date of this prospectus held by Dr.&nbsp;Zang through Doctor Zang 2020 Dynasty Trust. Dr.&nbsp;Zang, through himself and The Jingwu Zhang Zang 2018
Irrevocable Family Trust, owns a 55.6% equity interest in Mabcore Limited. Dr.&nbsp;Lili Qian and two other individuals own the remaining equity interest in Mabcore Limited. Dr.&nbsp;Zang is the sole director of Mabcore Limited. The Jingwu Zhang
Zang 2018 Irrevocable Family Trust was established under the laws of New York and is managed by Ms.&nbsp;Ying Qin Zang, as the trustee and Dr.&nbsp;Zang as the settlor. The Doctor Zang 2020 Dynasty Trust was established under the laws of the State
of California and is managed by Dr.&nbsp;Zang as the settlor and investment trustee and Ms.&nbsp;Ying Qin Zang as the trustee. Pursuant to the currently effective memorandum and articles of association of Mabcore Limited, Dr.&nbsp;Zang, as the sole
director, has the power to direct the actions of Mabcore Limited, including the voting and disposal of Mabcore Limited&#146;s shares in <FONT STYLE="white-space:nowrap">I-Mab.</FONT> Accordingly, Dr.&nbsp;Zang is deemed to indirectly own all of the
3,932,113 ordinary shares held by Mabcore Limited, while Dr.&nbsp;Qian and the other two individuals are only entitled to their respective <FONT STYLE="white-space:nowrap">pro-rata</FONT> economic interest in Mabcore Limited. The registered address
of Mabcore Limited is Trinity Chambers, P.O. Box 4301, Road Town, Tortola, British Virgin Islands. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Represents (i) 5,141,587 ordinary shares directly held by IBC Investment Seven Limited, a Hong Kong limited
liability company, (ii) 7,051,804 ordinary shares directly held by CBC SPVII LIMITED, a Hong Kong limited liability company, (iii) 14,930,252 ordinary shares directly held by CBC Investment <FONT STYLE="white-space:nowrap">I-Mab</FONT> Limited, a
British Virgin Islands limited liability company, (iv) 2,369,546 ordinary shares directly held by <FONT STYLE="white-space:nowrap">C-Bridge</FONT> II Investment Ten Limited, a British Virgin Islands limited liability company, (v) 6,078,571 ordinary
shares directly held by Everest, and (vi) 373,557 ADSs (representing 859,181 ordinary shares) held by <FONT STYLE="white-space:nowrap">C-Bridge</FONT> II Investment Thirteen Limited, a British Virgin Islands limited liability company. IBC Investment
Seven Limited, CBC SPVII LIMITED, CBC Investment <FONT STYLE="white-space:nowrap">I-Mab</FONT> Limited, <FONT STYLE="white-space:nowrap">C-Bridge</FONT> II Investment Ten Limited, Everest, and <FONT STYLE="white-space:nowrap">C-Bridge</FONT> II
Investment Thirteen Limited are collectively referred to as the <FONT STYLE="white-space:nowrap">C-Bridge</FONT> entities. CBC Investment <FONT STYLE="white-space:nowrap">I-Mab</FONT> Limited, <FONT STYLE="white-space:nowrap">C-Bridge</FONT> II
Investment Ten Limited and <FONT STYLE="white-space:nowrap">C-Bridge</FONT> II Investment Thirteen Limited are controlled by <FONT STYLE="white-space:nowrap">C-Bridge</FONT> Healthcare Fund II, L.P., whose general partner is <FONT
STYLE="white-space:nowrap">C-Bridge</FONT> Healthcare Fund GP II, L.P., and its general partner is <FONT STYLE="white-space:nowrap">C-Bridge</FONT> Capital GP, Ltd. CBC SPVII Limited and IBC Investment Seven Limited are controlled by <FONT
STYLE="white-space:nowrap">I-Bridge</FONT> Healthcare Fund, L.P., whose general partner is <FONT STYLE="white-space:nowrap">I-Bridge</FONT> Healthcare GP, L.P., and its general partner is <FONT STYLE="white-space:nowrap">I-Bridge</FONT> Capital GP,
Ltd., which is indirectly controlled by <FONT STYLE="white-space:nowrap">C-Bridge</FONT> Capital GP, Ltd. Mr.&nbsp;Wei Fu is the sole director of <FONT STYLE="white-space:nowrap">C-Bridge</FONT> Capital GP, Ltd. Everest is a public company listed on
the Hong Kong Stock Exchange and controlled by funds which are under common control of the <FONT STYLE="white-space:nowrap">C-Bridge</FONT> group, which, in turn, is controlled by Mr.&nbsp;Wei Fu. The business address of each of <FONT
STYLE="white-space:nowrap">C-Bridge</FONT> entities is Suite 3306-3307, Two Exchange Square, 8 Connaught Place, Central, Hong Kong. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Represents (i) 12,942,997 ordinary shares directly held by Tasly Biopharm Limited, a British Virgin Islands
limited liability company, and (ii) 1,721,023 ordinary shares directly held by Tasly International BioInv One Limited. Tasly Biopharm Limited and Tasly International BioInv One Limited are collectively referred to as the Tasly entities. Tasly
Biopharm Limited&#146;s sole shareholder is Tasly Biopharmaceuticals Co., Ltd., which is controlled by Tasly Pharmaceutical Group Co., Ltd., which is in turn controlled by Tasly Holding Group Co., Ltd. Tasly International BioInv One Limited is
wholly-owned by Tasly International Capital Limited, whose sole shareholder is Tasly Holding Group Co., Ltd. Tasly Holding Group Co., Ltd. is controlled by </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">267 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
Tianjin Tasly Health Industry Investment Group Co., Ltd., which is in turn controlled by Tianjin Fuhuade Science&nbsp;&amp; Technology Development Co., Ltd. Kaijing Yan is the controlling
shareholder of Tianjin Fuhuade Science&nbsp;&amp; Technology Development Co., Ltd. and the ultimate beneficial owner of Tasly entities. The registered address of Tasly Biopharm Limited is P.O. Box 957, Offshore Incorporation Centre, Road Town,
Tortola, British Virgin Islands. The registered address of Tasly International BioInv One Limited is 4th Floor, Harbour Place, 103 South Church Street, P.O. Box 10240, Grand Cayman <FONT STYLE="white-space:nowrap">KY1-1002,</FONT> Cayman Islands.
</TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Represents 8,677,996 ordinary shares, 1,098,838 ADSs (representing 2,527,327 ordinary shares) and 894,447
ordinary shares issuable upon exercise of warrants held by GIC Private Limited, a Singapore fund manager. GIC Private Limited only has two clients: the Government of Singapore, or GoS, and the Monetary Authority of Singapore, or MAS. Under the
investment management agreement with GoS, GIC Private Limited has been given the sole discretion to exercise the voting rights attached to, and the disposition of, any shares managed on behalf of GoS. As such, GIC Private Limited has the sole power
to vote and dispose of securities beneficially owned by it. GIC Private Limited shares the power to vote and dispose of securities beneficially owned by it with MAS. The business address of GIC Private Limited is 168 Robinson Road, <FONT
STYLE="white-space:nowrap">#37-01</FONT> Capital Tower, Singapore 068912. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Represents (i) 5,030,744 ordinary shares, 922,300 ordinary shares that Gaoling Fund, L.P., or Gaoling, has the
right to purchase pursuant to a call option agreement with certain members of our management team, and 922,300 ordinary shares issuable upon exercise of warrants directly held by Gaoling, an exempted limited partnership organized under the laws of
the Cayman Islands, (ii) 196,535 ordinary shares, 36,041 ordinary shares that YHG Investment, L.P., or YHG, has the right to purchase pursuant to a call option agreement with certain members of our management team, and 36,041 ordinary shares
issuable upon exercise of warrants directly held by YHG, an exempted limited partnership organized under the laws of the Cayman Islands, and (iii) 5 ordinary shares and 1,496,540 ADSs (representing 3,442,042 ordinary shares) directly held by HH IMB
Holdings Limited, or HH IMB, an exempted Cayman Islands company. Hillhouse Capital Advisors, Ltd., or HCA, an exempted Cayman Islands company, acts as sole management company of Gaoling and the sole general partner of YHG, and is deemed to be the
beneficial owner of, and to control the voting power of, the ordinary shares held by Gaoling and YHG. HH IMB is wholly owned by Hillhouse Fund IV, L.P., whose sole management company is Hillhouse Capital Management, Ltd., or HCM. HCM is deemed to be
the beneficial owner of, and to control the voting power of, the ordinary shares held by HH IMB. HCA and HCM are under common control and share certain policies, personnel and resources. Accordingly, each of HCA and HCM has shared voting and
dispositive power of the ordinary shares beneficially owned by each of HCA and HCM. The business address of each of Gaoling, YHG and HH IMB is Suite 2202, 22nd Floor, Two International Finance Centre, 8 Finance Street, Central Hong Kong.
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(6)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Represents (i) 8,361,823 ordinary shares directly held by Genexine, Inc. (Genexine), (ii)&nbsp;900,000 ordinary
shares issuable to Genexine upon the full conversion of the US$9.0 million interest free convertible promissory note based on a conversion price of US$10 per share and (iii)&nbsp;570,000 ADSs (representing 1,311,000 ordinary shares) purchased by
Genexine. Genexine is a Korean public company. The registered address of Genexine is 700 <FONT STYLE="white-space:nowrap">Daewangpangyo-ro,</FONT> Korea <FONT STYLE="white-space:nowrap">Bio-Park,</FONT> Bldg. B4D,
<FONT STYLE="white-space:nowrap">Bundang-gu,</FONT> <FONT STYLE="white-space:nowrap">Seongnam-si,</FONT> <FONT STYLE="white-space:nowrap">Gyeonggi-do,</FONT> Korea. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(7)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Represents 9,465,631 ordinary shares directly held by Fortune Eight Jogging Limited, a British Virgin Islands
limited liability company, which we refer to as the Hony entity. Fortune Eight Jogging Limited is wholly-owned by Hony Hongling (Shanghai) Investment Center, a PRC limited partnership, whose general partner is Hony Investment (Shanghai) Limited. The
sole shareholder of Hony Investment (Shanghai) Limited is Beijing Hony Hezhong Enterprise Management Limited. Each of Yonggang Cao, Minsheng Xu and Wen Zhao holds 33.3% equity interests in Beijing Hony Hezhong Enterprise Management Limited. The
registered address of Fortune Eight Jogging Limited is Kingston Chambers, PO Box 173, Road Town, Tortola, British Virgin Islands. Mr.&nbsp;Bing Yuan, our director, is a managing director of the sole director of the Hony entity.
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">268 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(8)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Represents (i) 2,341,837 ordinary shares and 429,364 ordinary shares issuable upon exercise of warrants
directly held by Avidity Master Fund LP, or Avidity Master, a Delaware limited partnership, and (ii)&nbsp;271,814 ordinary shares and 49,818 ordinary shares issuable upon exercise of warrants directly held by Avidity Capital Fund II LP, or Avidity
Capital, a Delaware limited partnership. Avidity Master and Avidity Capital are collectively referred to as the Avidity entities. The general partner of each of the Avidity entities is Avidity Capital Partners Fund (GP) LP, a Delaware limited
partnership, whose general partner is Avidity Capital Partners (GP) LLC, a Delaware limited liability company. David Witzke and Michael Gregory are the managing members of Avidity Capital Partners (GP) LLC. The address of David Witzke and Michael
Gregory&#146;s principal office is 2828 N Harwood Street, Suite 1220, Dallas, Texas 75201. The registered address of each of Avidity entities is 2828 N. Harwood St., Suite 1220, Dallas, TX 75201. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(9)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Represents 1,393,961 ordinary shares and 255,576 ordinary shares issuable upon exercise of warrants directly
held by ARANDA INVESTMENTS PTE. LTD., a company incorporated under the laws of Singapore. ARANDA INVESTMENTS PTE. LTD. is an indirect wholly-owned subsidiary of Temasek Holdings (Private) Limited. The registered address of ARANDA INVESTMENTS PTE.
LTD. is 60B Orchard Road, <FONT STYLE="white-space:nowrap">#06-18</FONT> Tower 2, The Atrium@Orchard, Singapore 238891. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(10)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Represents 1,045,465 ordinary shares and 191,682 ordinary shares issuable upon exercise of warrants directly
held by Octagon Investments Master Fund LP, or Octagon, an exempted limited partnership organized under the laws of the Cayman Islands. Octagon&#146;s shareholders are comprised of global institutions such as university endowments, <FONT
STYLE="white-space:nowrap">non-profit</FONT> foundations, family offices, pension funds and established asset managers. The registered address of Octagon Investments Master Fund LP is at c/o Ogier, 89 Nexus Way, Camana Bay, Grand Cayman, Cayman
Islands <FONT STYLE="white-space:nowrap">KY1-9009.</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(11)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Represents (i) 696,992 ordinary shares and 127,788 ordinary shares issuable upon exercise of warrants directly
held by OrbiMed Partners Master Fund Limited, or OPM, an exempted company organized under the laws of Bermuda, (ii) 383,341 ordinary shares and 70,288 ordinary shares issuable upon exercise of warrants directly held by The Biotech Growth Trust PLC,
or BIOG, a publicly-listed investment trust organized under the laws of England, (iii) 174,248 ordinary shares and 31,947 ordinary shares issuable upon exercise of warrants directly held by OrbiMed Genesis Master Fund, L.P., or OrbiMed Genesis, an
exempted limited partnership organized under the laws of the Cayman Islands, and (iv) 139,380 ordinary shares and 25,553 ordinary shares issuable upon exercise of warrants directly held by OrbiMed New Horizons Master Fund, L.P., or ONH, an exempted
limited partnership organized under the laws of the Cayman Islands. OPM, BIOG, OrbiMed Genesis and ONH are collectively referred to as the OrbiMed Entities. OrbiMed Capital LLC, or OrbiMed Capital, is the portfolio manager of BIOG and the investment
advisor to OPM. OrbiMed Advisors LLC, or OrbiMed Advisors, is the investment manager of OrbiMed Genesis and ONH. OrbiMed Capital and OrbiMed Advisors exercise voting and investment power through a management committee comprised of Carl L. Gordon,
Sven H. Borho, and Jonathan T. Silverstein, each of whom disclaims beneficial ownership of the shares held by OPM, BIOG, OrbiMed Genesis, and ONH. The business address of each of OrbiMed Entities is c/o OrbiMed Advisors LLC, 601 Lexington Avenue,
54th Floor, New York, NY 10022. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(12)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Represents 906,062 ordinary shares and 166,129 ordinary shares issuable upon exercise of warrants directly held
by Invus Public Equities, L.P., a Bermuda limited partnership. Invus is a investment firm with source of capital from a European family group. The registered address of Invus Public Equities, L.P. is Clarendon House, 2 Church Street, Hamilton HM 11,
Bermuda. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(13)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Represents 696,992 ordinary shares and 127,788 ordinary shares issuable upon exercise of warrants directly held
by Lake Bleu Prime Healthcare Master Fund Limited, or Lake Bleu Prime, an exempted limited partnership organized under the laws of the Cayman Islands. LBC Prime Management Limited is the ultimate controlling shareholder of Lake Bleu Prime. The
registered address of Lake Bleu Prime Healthcare Master Fund Limited is Cayman Corporate Centre, 27 Hospital Road, George Town, Grand Cayman <FONT STYLE="white-space:nowrap">KY1-9008,</FONT> Cayman Islands. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">269 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(14)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Represents 627,279 ordinary shares and 115,000 ordinary shares issuable upon exercise of warrants directly held
by Perceptive Life Sciences Master Fund, Ltd., a Cayman Islands limited liability company. The registered address of Perceptive Life Sciences Master Fund, Ltd. is 190 Elgin Avenue, George Town, Grand Cayman,
<FONT STYLE="white-space:nowrap">KY1-9007,</FONT> Cayman Islands. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(15)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Represents 522,744 ordinary shares and 95,841 ordinary shares issuable upon exercise of warrants directly held
by Cormorant Global Healthcare Master Fund, LP, or Cormorant Global, an exempted limited partnership organized under the laws of the Cayman Islands. Cormorant Global is a long-term investment partnership whose beneficial owners include institutional
and other sophisticated investors. The registered address of Cormorant Global Healthcare Master Fund, LP is PO Box 309, Ugland House, Grand Cayman, KY14104, Cayman Islands. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(16)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Represents (i) 313,651 ordinary shares and 57,500 ordinary shares issuable upon exercise of warrants directly
held by Sphera Global Healthcare Master Fund, or Sphera Global, a Cayman Islands limited liability company, and (ii) 104,535 ordinary shares and 19,182 ordinary shares issuable upon exercise of warrants directly held by Sphera Biotech Master Fund
L.P., or Sphera Biotech, an exempted limited partnership organized under the laws of the Cayman Islands. Sphera Global and Sphera Biotech are collectively referred to as the Sphera entities. Both Sphera Global and Sphera Biotech appointed Sphera
Global Healthcare Management LP or Sphera Management, as their investment manager. Sphera Management also serves as Sphera Biotech&#146;s general partner, and has
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">day-to-day</FONT></FONT> investment discretion for the Sphera entities. The registered address of each of Sphera entities is at c/o Maples Corporate Services Limited, P.O. Box 309,
Ugland House, Grand Cayman, <FONT STYLE="white-space:nowrap">KY1-1104,</FONT> Cayman Islands. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(17)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Represents (i) 345,713 ordinary shares and 63,388 ordinary shares issuable upon exercise of warrants directly
held by Alyeska Master Fund, L.P., an exempted limited partnership organized under the laws of the Cayman Islands, and (ii) 2,783 ordinary shares and 506 ordinary shares issuable upon exercise of warrants directly held by Alyeska Master Fund 3,
L.P., a Delaware limited partnership. Alyeska Master Fund, L.P. and Alyeska Master Fund 3, L.P. are collectively referred to as the Alyeska entities. Alyeska entities are controlled by Alyeska Investment Group, L.P., a limited partnership
incorporated in the United States, whose chief executive officer is Anand Parekh. Mr.&nbsp;Parekh, however, disclaims any beneficial ownership of the shares held by Alyeska entities. The registered address of Alyeska Master Fund, L.P. is at c/o
Maples Corporate Services Limited, P.O. Box 309, Ugland House, South Church Street George Town, Grand Cayman, <FONT STYLE="white-space:nowrap">KY1-1104,</FONT> Cayman Islands. The registered address of Alyeska Master Fund 3, L.P. is 251 Little Falls
Drive, Wilmington, DE 19808. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(18)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Represents 348,496 ordinary shares and 63,894 ordinary shares issuable upon exercise of warrants directly held
by CVI Investments, Inc., or CVI, a Cayman Islands limited liability company. Heights Capital Management, Inc., the authorized agent of CVI, has discretionary authority to vote and dispose of the shares held by CVI and may be deemed to be the
beneficial owner of these shares. Martin Kobinger, in his capacity as Investment Manager of Heights Capital Management, Inc., may also be deemed to have investment discretion and voting power over the shares held by CVI. Mr.&nbsp;Kobinger disclaims
any such beneficial ownership of the shares. CVI is affiliated with one or more FINRA members. CVI purchased the shares being registered hereunder in the ordinary course of business and at the time of purchase, had no agreements or understandings,
directly or indirectly, with any other person to distribute such shares. The registered address of CVI Investments, Inc. is at c/o Maples Corporate Services Limited, PO Box 309, Ugland House, Grand Cayman, KY
<FONT STYLE="white-space:nowrap">l-1104,</FONT> Cayman Islands. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">As of the date of this prospectus, 37,636,418 of our
ordinary shares are held by one record holder in the United States (including 4,036,868 ordinary shares issued to our depositary bank for bulk issuance of ADSs reserved for future issuances upon the exercising or vesting of awards granted under our
share incentive plans), representing approximately 23.8% of our total outstanding shares. The holder is Citibank, N.A., the depositary of our ADS program. The number of beneficial owners of our ADSs in the United States is likely to be much larger
than the number of record holders of our ordinary shares in the United States. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">270 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We are not aware of any arrangement that may, at a subsequent date, result in a change of
control of our company. See &#147;Description of Share Capital&#151;History of Securities Issuances&#148; for historical changes in our shareholding structure. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">271 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom98473_17"></A>RELATED PARTY TRANSACTIONS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Private Placements </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">See
&#147;Description of Share Capital&#151;History of Securities Issuances.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Shareholders Agreement </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">See &#147;Description of Share Capital&#151;History of Securities Issuances&#151;Shareholders Agreement.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Employment Agreements and Indemnification Agreements </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">See &#147;Management&#151;Employment Agreements and Indemnification Agreements.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Share Incentive Plans </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">See
&#147;Management&#151;Share Incentive Plans.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Other Related Party Transactions with Our Shareholders and Affiliates </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">On September&nbsp;25, 2017, <FONT STYLE="white-space:nowrap">I-Mab</FONT> Tianjin and <FONT STYLE="white-space:nowrap">I-Mab</FONT> Shanghai
entered into a loan agreement with each of Qianhai Equity Investment Fund (Limited Partnership) (&#147;Qianhai Fund&#148;), Shanghai Tasly Pharmaceutical Co., Ltd. (&#147;Shanghai Tasly&#148;), and Tianjin Kangshijing Biopharmaceutical Technology
Partnership (Limited Partnership) (&#147;CBC RMB Fund&#148;), pursuant to which each of Qianhai Fund, Shanghai Tasly and CBC RMB Fund made a loan to <FONT STYLE="white-space:nowrap">I-Mab</FONT> Tianjin to fund its business operations in an
aggregate principal amount in RMB equivalent to US$1.3&nbsp;million, US$5.1&nbsp;million and US$1.6&nbsp;million, respectively. Each of these loans bears an annual compound interest rate of 8%. Pursuant to these loan agreements, each of Qianhai
Fund, Shanghai Tasly and CBC RMB Fund has the right to contribute its interest in the respective loan to <FONT STYLE="white-space:nowrap">I-Mab</FONT> Tianjin in exchange for <FONT STYLE="white-space:nowrap">I-Mab</FONT> Tianjin&#146;s equity
interests. We fully repaid the loans made by Qianhai Fund and Shanghai Tasly in 2018, and neither of these lenders exercised such right. The loan agreement with CBC RMB Fund was not performed by CBC RMB Fund and was mutually terminated on
September&nbsp;25, 2017. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In January 2018, we entered into a collaboration agreement with Everest, an affiliate of <FONT
STYLE="white-space:nowrap">C-Bridge</FONT> Capital Investment Management, Ltd., whereby both parties agreed to collaborate on programs to <FONT STYLE="white-space:nowrap">co-develop</FONT> MorphoSys&#146; proprietary CD38 antibody for all
indications in hematologic oncology and commercialize the CD38 product in China, Hong Kong, Macau and Taiwan. For a detailed description of this collaboration agreement, see &#147;Business&#151;Licensing and Collaboration Arrangements&#151;(c)
Collaboration Arrangements.&#148; Everest had paid us prepayments of RMB178.7&nbsp;million, RMB53.1&nbsp;million (US$7.5 million) and nil for the year ended December&nbsp;31, 2018 and 2019 and the six months ended June&nbsp;30, 2020, respectively.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">On November&nbsp;4, 2019, we and Everest Medicines Limited, or Everest, terminated the collaboration agreement (including all the
supplements and amendments thereto) with respect to the <FONT STYLE="white-space:nowrap">co-development</FONT> and commercialization of felzartamab in Greater China. Upon the termination, Everest will not retain any rights or entitlements to develop
or commercialize felzartamab or any economic interest in its commercialization. All intellectual property rights in respect of felzartamab arising from its development under the collaboration agreement are vested and owned by us, and we hold all
intellectual property rights and have maximum flexibility to further develop, manufacture and commercialize felzartamab in Greater China. In consideration of the above arrangements, we issued a total value of US$37.0&nbsp;million of ordinary shares
(the &#147;CPP Shares&#148;) to Everest, representing Everest&#146;s historical contribution to our collaboration and the associated time cost. The CPP Shares were issued concurrently with the completion of our initial public offering, at a per
share price equal to the initial public offering price adjusted to reflect the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">ADS-to-ordinary</FONT></FONT> share ratio. The total value of US$37.0&nbsp;million was calculated based
on the sum of (1)&nbsp;US$33.7&nbsp;million, which equals cumulative <FONT STYLE="white-space:nowrap">paid-in</FONT> contributions historically </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">272 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
made by Everest under the collaboration agreement; and (2)&nbsp;a negotiated US$3.3&nbsp;million time cost of the foregoing historical contribution in light of our exclusive rights over the
commercialization of felzartamab after this termination. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Based on the initial public offering price of US$14.00 per ADS (or US$6.09 per
ordinary share), Everest was issued 6,078,571 ordinary shares and became a minority shareholder of our company upon the completion of our initial public offering. Our issuance of ordinary shares to Everest is being made pursuant to an exemption from
registration with the U.S. Securities and Exchange Commission under Regulation S of the U.S. Securities Act of 1933, as amended, or the Securities Act. Everest has agreed not to, directly or indirectly, sell, transfer or dispose of any CPP Shares
for a period of 180 days after the date of the prospectus of our initial public offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In June 2018, we entered into a biologics
master services agreement with CMAB Biopharma (Suzhou) Inc. (&#147;CMAB&#148;), an affiliate of Bridge Capital Partners LLC. In July 2018, we entered into Service Proposal: CMC Development of A Monoclonal Antibody with this entity. Pursuant to these
two agreements, CMAB will provide us with CMC services in connection with the preparation of the IND filings to the FDA and the NMPA in a period of 18 to 22 months for US$3.6&nbsp;million. We had paid CMAB RMB2.8&nbsp;million for the year ended
December&nbsp;31, 2018 and RMB0.7&nbsp;million (US$0.1 million) for the six months ended June&nbsp;30, 2020. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In September 2016, <FONT
STYLE="white-space:nowrap">I-Mab</FONT> Tianjin entered into a CRO agreement with Tasly Pharmaceutical Group Co., Ltd. (&#147;Tasly&#148;) and three ancillary agreements to this CRO agreement in November 2016, May 2017 and June 2017, respectively.
Pursuant to these agreements, Tasly Pharmaceutical Group Co., Ltd. will provide <FONT STYLE="white-space:nowrap">I-Mab</FONT> Tianjin with CRO services in connection with <FONT STYLE="white-space:nowrap">pre-clinical</FONT> studies for <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">G-CSF-HyFc</FONT></FONT> fusion protein. All of these agreements were terminated on December&nbsp;10, 2018. We had paid Tasly RMB0.8&nbsp;million, nil, RMB5.6&nbsp;million (US$0.8 million)
and nil for the year ended December&nbsp;31, 2017, 2018 and 2019 and six months ended June&nbsp;30, 2020, respectively. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">273 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom98473_18"></A>DESCRIPTION OF SHARE CAPITAL </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We are a Cayman Islands exempted company with limited liability and our affairs are governed by our memorandum and articles of association,
the Companies Law, Cap. 22 (Law 3 of 1961, as consolidated and revised), as amended, of the Cayman Islands, which is referred to as the Companies Law below, and the common law of the Cayman Islands. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">As of the date of this prospectus, our authorized share capital is US$80,000 divided into 800,000,000 ordinary shares of a par value of
US$0.0001 each. As of the date of this prospectus, there are 154,310,098 ordinary shares issued and outstanding (excluding 4,036,868 ordinary shares issued to our depositary bank for bulk issuance of ADSs reserved for future issuances upon the
exercising or vesting of awards granted under our share incentive plans). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Sixth Amended and Restated Memorandum and Articles of Association
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The following is a summary of the material provisions of the sixth memorandum and articles of association of our company and of the
Companies Law (2020 Revision), insofar as they relate to the material terms of our ordinary shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I>Objects of Our Company</I>. Under
our current memorandum and articles of association, the objects of our company are unrestricted and we have the full power and authority to carry out any object not prohibited by the Companies Law or any other law of the Cayman Islands. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I>Ordinary Shares</I>. Certificates representing the ordinary shares are issued in registered form and our ordinary shares are issued when
registered in our register of members. We may not issue shares to bearers. Our shareholders who are <FONT STYLE="white-space:nowrap">non-residents</FONT> of the Cayman Islands may freely hold and vote their shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I>Dividends</I>. Our directors may from time to time declare dividends (including interim dividends) and other distributions on our shares in
issue and authorize payment of the same out of the funds of our company lawfully available therefor. In addition, our company may declare dividends by ordinary resolution, but no dividend shall exceed the amount recommended by our directors. Our
current memorandum and articles of association provide that dividends may be declared and paid out of the funds of our company lawfully available therefor. Under the laws of the Cayman Islands, our company may pay a dividend out of either profit or
the credit standing in our share premium account; provided that in no circumstances may a dividend be paid out of the share premium account if this would result in our company being unable to pay its debts as they fall due in the ordinary course of
business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I>Voting Rights</I>. Voting at any meeting of shareholders is by show of hands unless a poll is demanded. A poll may be
demanded by the chairman of such meeting or any one shareholder or shareholders collectively holding not less than 5% of the votes attaching to the shares present in person or by proxy. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">An ordinary resolution to be passed at a meeting by the shareholders requires the affirmative vote of a simple majority of the votes attaching
to the ordinary shares cast at a meeting, while a special resolution requires the affirmative vote of not less than <FONT STYLE="white-space:nowrap">two-thirds</FONT> of the votes attaching to the ordinary shares cast at a meeting. A special
resolution will be required for important matters such as a change of name or making changes to our current memorandum and articles of association. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Alternation of Share Capital </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We
may from time to time by ordinary resolution: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">increase our share capital by such sum, to be divided into shares of such classes and amount, as the resolution
shall prescribe; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">274 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">consolidate and divide all or any of our share capital into shares of a larger amount than its existing shares;
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">subdivide our shares, or any of them, into shares of an amount smaller than that fixed by the memorandum of
association, provided that in the subdivision the proportion between the amount paid and the amount, if any, unpaid on each reduced share shall be the same as it was in case of the share from which the reduced share is derived; and
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">cancel any shares that, at the date of the passing of the resolution, have not been taken or agreed to be taken
by any person and diminish the amount of its share capital by the amount of the shares so cancelled. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We may by special
resolution, subject to any confirmation or consent required by the Companies Law, reduce our share capital and any capital redemption reserve in any manner authorized by law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I>General Meetings of Shareholders</I>. As a Cayman Islands exempted company, we are not obliged by the Companies Law to call
shareholders&#146; annual general meetings. Our current memorandum and articles of association provide that we may (but are not obliged to) in each year hold a general meeting as our annual general meeting in which case we shall specify the meeting
as such in the notices calling it, and the annual general meeting shall be held at such time and place as may be determined by our directors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Shareholders&#146; general meetings may be convened by our directors (acting by a resolution of our board). Advance notice of at least 14
calendar days is required for any general shareholders&#146; meeting. A quorum required for any general meeting of shareholders consists of, at the time when the meeting proceeds to business, one or more of our shareholders holding shares which
carry in aggregate (or representing by proxy) not less than <FONT STYLE="white-space:nowrap">one-third</FONT> of all votes attaching to all of our shares in issue and entitled to vote at such general meeting. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Companies Law does not provide shareholders with any right to requisition a general meeting, nor any right to put any proposal before a
general meeting. However, these rights may be provided in a company&#146;s articles of association. Our current articles of association allow our shareholders holding in aggregate not less than <FONT STYLE="white-space:nowrap">one-tenth</FONT> of
all votes attaching to all issued and outstanding shares of our company that as at the date of the deposit carry the right to vote at general meetings of the company to requisition an extraordinary general meeting of our shareholders, in which case
our board is obliged to convene an extraordinary general meeting and to put the resolutions so requisitioned to a vote at such meeting. However, our current memorandum and articles of association do not provide our shareholders with any right to put
any proposals before annual general meetings or extraordinary general meetings not called by such shareholders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I>Transfer of Ordinary
Shares</I>. Subject to the restrictions set out below, any of our shareholders may transfer all or any of his or her ordinary shares by an instrument of transfer in the usual or common form or any other form approved by our board of directors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our board of directors may, in its absolute discretion, decline to register any transfer of any ordinary share which is not fully paid up or
on which we have a lien. Our board of directors may also decline to register any transfer of any ordinary share unless: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the instrument of transfer is lodged with us, accompanied by the certificate for the ordinary shares to which it
relates and such other evidence as our board of directors may reasonably require to show the right of the transferor to make the transfer; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the instrument of transfer is in respect of only one class of shares; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the instrument of transfer is properly stamped, if required; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">275 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">in the case of a transfer to joint holders, the number of joint holders to whom the ordinary share is to be
transferred does not exceed four; and </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a fee of such maximum sum as the Nasdaq Global Market may determine to be payable or such lesser sum as our
directors may from time to time require is paid to us in respect thereof. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">If our directors refuse to register a
transfer, they shall, within three calendar months after the date on which the instrument of transfer was lodged with our company, send to each of the transferor and the transferee notice of such refusal. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The registration of transfers may, on ten calendar days&#146; notice being given by advertisement in such one or more newspapers, by
electronic means or by any other means in accordance with the rules of the Nasdaq Global Market be suspended and the register closed at such times and for such periods as our board of directors may from time to time determine; provided, however,
that the registration of transfers shall not be suspended nor the register closed for more than 30 calendar days in any year. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I>Liquidation</I>. On the winding up of our company, if the assets available for distribution amongst our shareholders shall be more than
sufficient to repay the whole of the share capital at the commencement of the winding up, the surplus shall be distributed amongst our shareholders in proportion to the par value of the shares held by them at the commencement of the winding up,
subject to a deduction from those shares in respect of which there are monies due, of all monies payable to our company for unpaid calls or otherwise. If our assets available for distribution are insufficient to repay the whole of the share capital,
such assets will be distributed so that, as nearly as may be, the losses are borne by our shareholders in proportion to the par value of the shares held by them. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I>Calls on Shares and Forfeiture of Shares</I>. Our board of directors may from time to time make calls upon shareholders in respect of any
moneys unpaid on their shares in a notice served to such shareholders at least 14 calendar days prior to the specified time or times of payment. The shares that have been called upon and remain unpaid are subject to forfeiture. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I>Redemption, Repurchase and Surrender of Shares</I>. We may issue shares on terms that such shares are subject to redemption, at our option
or at the option of the holders of these shares, on such terms and in such manner as may be determined, before the issue of such shares, by our board of directors or by our shareholders by a special resolution. Our company may also repurchase any of
our shares on such terms and in such manner as have been approved by our board of directors or by an ordinary resolution of our shareholders or are otherwise authorized by the articles of association. Under Cayman Islands law, any redemption or
repurchase of shares by our company may be made out of profits of our company, out of our company&#146;s share premium account or out of the proceeds of a fresh issue of shares made for the purpose of the repurchase or, if so authorized by the
articles of association and subject to provisions of the Companies Law, out of capital. Any premium payable on a redemption or repurchase over the par value of the shares to be repurchased or redeemed must be provided for out of profits of our
company or from sums standing to the credit of the share premium account of our company or, if authorized by the articles of association and subject to the provisions of the Companies Law, out of capital. At no time may a company redeem or
repurchase its shares unless they are fully paid. A company may not redeem or repurchase any of its shares if, as a result of the redemption or repurchase, there would no longer be any issued shares of the company other than shares held as treasury
shares. In addition, our company may accept the surrender of any fully paid share for no consideration. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I>Variations of Rights of
Shares</I>. Whenever the capital of our company is divided into different classes the rights attached to any such class may, subject to any rights or restrictions for the time being attached to any class, only be varied with the consent in writing
of the holders of all of the issued shares of that class or with the sanction of a special resolution passed at a separate meeting of the holders of the shares of that class. The rights conferred upon the holders of the shares of any class issued
with preferred or other rights shall not, subject to any </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">276 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
rights or restrictions for the time being attached to the shares of that class, be deemed to be varied by the creation, allotment or issue of further shares ranking <I>pari passu </I>with or
subsequent to them or the redemption or purchase of any shares of any class by our company. The rights of the holders of shares shall not be deemed to be varied by the creation or issue of shares with preferred or other rights including, without
limitation, the creation of shares with enhanced or weighted voting rights. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I>Issuance of Additional Shares</I>. Our current memorandum
and articles of association authorize our board of directors to issue additional ordinary shares from time to time as our board of directors shall determine. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our current memorandum and articles of association also authorize our board of directors to issue from time to time one or more series of
preference shares and to determine, with respect to any series of preference shares, the terms and rights of that series, including: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the designation of the series; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the number of preferred shares to constitute such series; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the dividend rights, dividend rates, conversion rights, voting rights; and </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the rights and terms of redemption and liquidation preferences. Issuance of these shares may dilute the voting
power of holders of ordinary shares. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I>Inspection of Books and Records</I>. The notice of registered office is a
matter of public record. A list of the names of the current directors and alternate directors (if applicable) are made available by the Registrar of Companies of the Cayman Islands for inspection by any person on payment of a fee. The register of
mortgages is open to inspection by creditors and shareholders. Shareholders have no general right under Cayman Islands law to inspect or obtain copies of our list of shareholders or our corporate records. However, we intend to provide our
shareholders with annual audited financial statements. See &#147;Where You Can Find Additional Information.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I>Anti-Takeover
Provisions</I>. Some provisions of our current memorandum and articles of association may discourage, delay or prevent a change of control of our company or management that shareholders may consider favorable, including provisions that authorize our
board of directors to issue preference shares in one or more series and to designate the price, rights, preferences, privileges and restrictions of such preference shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">However, under Cayman Islands law, our directors may only exercise the rights and powers granted to them under our current memorandum and
articles of association for a proper purpose and for what they believe in good faith to be in the best interests of our company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I>Exempted Company.</I> We are an exempted company with limited liability incorporated under the Companies Law. The Companies Law
distinguishes between ordinary resident companies and exempted companies. Any company that is registered in the Cayman Islands but conducts business mainly outside of the Cayman Islands may apply to be registered as an exempted company. The
requirements for an exempted company are essentially the same as for an ordinary company except that an exempted company: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">does not have to file an annual return of its shareholders with the Registrar of Companies;
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">is not required to open its register of members for inspection; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">does not have to hold an annual general meeting; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">may issue shares with no par value; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">277 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">may obtain an undertaking against the imposition of any future taxation (such undertakings are usually given for
20 years in the first instance); </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">may register by way of continuation in another jurisdiction and be deregistered in the Cayman Islands;
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">may register as a limited duration company; and </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">may register as a segregated portfolio company. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">&#147;Limited liability&#148; means that the liability of each shareholder is limited to the amount unpaid by the shareholder on the shares of
the company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Differences in Corporate Law </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Companies Law is modeled after that of England but does not follow recent English statutory enactments and differs from laws applicable to
U.S. corporations and their shareholders. Set forth below is a summary of the significant differences between the provisions of the Companies Law applicable to us and the laws applicable to companies incorporated in the United States and their
shareholders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I>Mergers and Similar Arrangements</I>. The Companies Law permits mergers and consolidations between Cayman Islands
companies and between Cayman Islands companies and <FONT STYLE="white-space:nowrap">non-Cayman</FONT> Islands companies. For these purposes, (a) &#147;merger&#148; means the merging of two or more constituent companies and the vesting of their
undertaking, property and liabilities in one of such companies as the surviving company, and (b)&nbsp;a &#147;consolidation&#148; means the combination of two or more constituent companies into a consolidated company and the vesting of the
undertaking, property and liabilities of such companies to the consolidated company. In order to effect such a merger or consolidation, the directors of each constituent company must approve a written plan of merger or consolidation, which must then
be authorized by (a)&nbsp;a special resolution of the shareholders of each constituent company, and (b)&nbsp;such other authorization, if any, as may be specified in such constituent company&#146;s articles of association. The plan of merger or
consolidation must be filed with the Registrar of Companies of the Cayman Islands together with a declaration as to the solvency of the consolidated or surviving company, a statement of the assets and liabilities of each constituent company and an
undertaking that a copy of the certificate of merger or consolidation will be given to the members and creditors of each constituent company and that notification of the merger or consolidation will be published in the Cayman Islands Gazette. Court
approval is not required for a merger or consolidation which is effected in compliance with these statutory procedures. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">A merger between
a Cayman parent company and its Cayman subsidiary or subsidiaries does not require authorization by a resolution of shareholders if a copy of the plan of merger is given to every member of that Cayman subsidiary to be merged unless that member
agrees otherwise. For this purpose a company is a &#147;parent&#148; of a subsidiary if it holds issued shares that together represent at least ninety percent (90%) of the votes at a general meeting of the subsidiary. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The consent of each holder of a fixed or floating security interest over a constituent company is required unless this requirement is waived
by a court in the Cayman Islands. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Save in certain limited circumstances, a shareholder of a Cayman constituent company who dissents from
the merger or consolidation is entitled to payment of the fair value of his or her shares (which, if not agreed between the parties, will be determined by the Cayman Islands court) upon dissenting to the merger or consolidation, provided that the
dissenting shareholder complies strictly with the procedures set out in the Companies Law. The exercise of dissenter rights will preclude the exercise by the dissenting shareholder of any other rights to which he or she might otherwise be entitled
by virtue of holding shares, save for the right to seek relief on the grounds that the merger or consolidation is void or unlawful. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">278 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Separate from the statutory provisions relating to mergers and consolidations, the Companies
Law also contains statutory provisions that facilitate the reconstruction and amalgamation of companies by way of schemes of arrangement, provided that the arrangement is approved by a majority in number of each class of shareholders and creditors
with whom the arrangement is to be made, and who must in addition represent three-fourths in value of each such class of shareholders or creditors, as the case may be, that are present and voting either in person or by proxy at a meeting, or
meetings, convened for that purpose. The convening of the meetings and subsequently the arrangement must be sanctioned by the Grand Court of the Cayman Islands. While a dissenting shareholder has the right to express to the court the view that the
transaction ought not to be approved, the court can be expected to approve the arrangement if it determines that: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the statutory provisions as to the required majority vote have been met; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the shareholders have been fairly represented at the meeting in question and the statutory majority are acting
bona fide without coercion of the minority to promote interests adverse to those of the class; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the arrangement is such that may be reasonably approved by an intelligent and honest man or woman of that class
acting in respect of his interest; and </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the arrangement is not one that would more properly be sanctioned under some other provision of the Companies
Law. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">When a takeover offer is made and accepted by holders of 90% of the shares within four months, the offeror may,
within a <FONT STYLE="white-space:nowrap">two-month</FONT> period commencing on the expiration of such four-month period, require the holders of the remaining shares to transfer such shares to the offeror on the terms of the offer. An objection can
be made to the Grand Court of the Cayman Islands but this is unlikely to succeed in the case of an offer which has been so approved unless there is evidence of fraud, bad faith or collusion. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">If an arrangement and reconstruction is thus approved, or if a takeover offer is made and accepted, a dissenting shareholder would have no
rights comparable to appraisal rights, which would otherwise ordinarily be available to dissenting shareholders of Delaware corporations, providing rights to receive payment in cash for the judicially determined value of the shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I>Shareholders&#146; Suits</I>. In principle, we will normally be the proper plaintiff and as a general rule a derivative action may not be
brought by a minority shareholder. However, based on English authorities, which would in all likelihood be of persuasive authority in the Cayman Islands, the Cayman Islands courts can be expected to follow and apply the common law principles (namely
the rule in Foss v. Harbottle and the exceptions thereto) which may permit a minority shareholder to commence a class action against, or derivative actions in the name of, our company to challenge: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an act which is ultra vires or illegal and is therefore incapable of ratification by the shareholders;
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an act which constitutes a fraud against the minority where the wrongdoers are themselves in control of the
company; and </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an act which requires a resolution with a qualified (or special) majority (i.e., more than a simple majority)
which has not been obtained. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I>Indemnification of Directors and Executive Officers and Limitation of Liability</I>.
Cayman Islands law does not limit the extent to which a company&#146;s memorandum and articles of association may provide for indemnification of officers and directors, except to the extent any such provision may be held by the Cayman Islands courts
to be contrary to public policy, such as to provide indemnification against civil fraud or the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">279 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
consequences of committing a crime. Our current memorandum and articles of association permit indemnification of officers and directors for losses, damages, costs and expenses incurred in their
capacities as such unless such losses, damages, costs and expenses arise from dishonesty, willful default or fraud of such directors or officers. This standard of conduct is generally the same as permitted under the Delaware General Corporation Law
for a Delaware corporation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In addition, we have entered into indemnification agreements with our directors and executive officers that
provide such persons with additional indemnification beyond that provided in our current memorandum and articles of association. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Insofar
as indemnification for liabilities arising under the Securities Act may be permitted to our directors, officers or persons controlling us under the foregoing provisions, we have been informed that in the opinion of the SEC, such indemnification is
against public policy as expressed in the Securities Act and is therefore unenforceable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I>Directors&#146; Fiduciary Duties</I>. Under
Delaware corporate law, a director of a Delaware corporation has a fiduciary duty to the corporation and its shareholders. This duty has two components: the duty of care and the duty of loyalty. The duty of care requires that a director act in good
faith, with the care that an ordinarily prudent person would exercise under similar circumstances. Under this duty, a director must inform himself of, and disclose to shareholders, all material information reasonably available regarding a
significant transaction. The duty of loyalty requires that a director acts in a manner he or she reasonably believes to be in the best interests of the corporation. He or she must not use his or her corporate position for personal gain or advantage.
This duty prohibits self-dealing by a director and mandates that the best interests of the corporation and its shareholders take precedence over any interest possessed by a director, officer or controlling shareholder and not shared by the
shareholders generally. In general, actions of a director are presumed to have been made on an informed basis, in good faith and in the honest belief that the action taken was in the best interests of the corporation. However, this presumption may
be rebutted by evidence of a breach of one of the fiduciary duties. Should such evidence be presented concerning a transaction by a director, the director must prove the procedural fairness of the transaction, and that the transaction was of fair
value to the corporation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">As a matter of Cayman Islands law, a director of a Cayman Islands company is in the position of a fiduciary
with respect to the company and therefore it is considered that he or she owes the following duties to the company&#151;a duty to act in good faith in the best interests of the company, a duty not to make a personal profit based on his or her
position as director (unless the company permits him or her to do so), a duty not to put himself or herself in a position where the interests of the company conflict with his or her personal interest or his or her duty to a third party and a duty to
exercise powers for the purpose for which such powers were intended. A director of a Cayman Islands company owes to the company a duty to act with skill and care. It was previously considered that a director need not exhibit in the performance of
his or her duties a greater degree of skill than may reasonably be expected from a person of his or her knowledge and experience. However, English and Commonwealth courts have moved towards an objective standard with regard to the required skill and
care and these authorities are likely to be followed in the Cayman Islands. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I>Shareholder Action by Written Consent</I>. Under the
Delaware General Corporation Law, a corporation may eliminate the right of shareholders to act by written consent by amendment to its certificate of incorporation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Cayman Islands law and our current articles of association provide that shareholders may approve corporate matters by way of a unanimous
written resolution signed by or on behalf of each shareholder who would have been entitled to vote on such matter at a general meeting without a meeting being held. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I>Shareholder Proposals</I>. Under the Delaware General Corporation Law, a shareholder has the right to put any proposal before the annual
meeting of shareholders, provided it complies with the notice provisions in the governing documents. A special meeting may be called by the board of directors or any other person authorized to do so in the governing documents, but shareholders may
be precluded from calling special meetings. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">280 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Companies Law does not provide shareholders with any right to requisition a general
meeting, nor any right to put any proposal before a general meeting. However, these rights may be provided in a company&#146;s articles of association. Our current articles of association allow our shareholders holding in aggregate not less than <FONT
STYLE="white-space:nowrap">one-tenth</FONT> of all votes attaching to the issued and outstanding shares of our company entitled to vote at general meetings to requisition an extraordinary general meeting of our shareholders, in which case our board
is obliged to convene an extraordinary general meeting and to put the resolutions so requisitioned to a vote at such meeting. Other than this right to requisition a shareholders&#146; meeting, our current articles of association do not provide our
shareholders with any other right to put proposals before annual general meetings or extraordinary general meetings. As an exempted Cayman Islands company, we are not obliged by law to call shareholders&#146; annual general meetings. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I>Cumulative Voting</I>. Under the Delaware General Corporation Law, cumulative voting for elections of directors is not permitted unless the
corporation&#146;s certificate of incorporation specifically provides for it. Cumulative voting potentially facilitates the representation of minority shareholders on a board of directors since it permits the minority shareholder to cast all the
votes to which the shareholder is entitled on a single director, which increases the shareholder&#146;s voting power with respect to electing such director. There are no prohibitions in relation to cumulative voting under the laws of the Cayman
Islands but our current articles of association do not provide for cumulative voting. As a result, our shareholders are not afforded any less protections or rights on this issue than shareholders of a Delaware corporation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I>Removal of Directors</I>. Under the Delaware General Corporation Law, a director of a corporation with a classified board may be removed
only for cause with the approval of a majority of the outstanding shares entitled to vote, unless the certificate of incorporation provides otherwise. Under our current articles of association, subject to certain restrictions as contained therein,
directors may be removed with or without cause, by an ordinary resolution of our shareholders. A director shall hold office until the expiration of his or her term or his or her successor shall have been elected and qualified, or until his or her
office is otherwise vacated. In addition, a director&#146;s office shall be vacated if the director (i)&nbsp;becomes bankrupt or makes any arrangement or composition with his or her creditors; (ii)&nbsp;is found to be or becomes of unsound mind or
dies; (iii)&nbsp;resigns his or her office by notice in writing to the company; (iv)&nbsp;without special leave of absence from our board of directors, is absent from three consecutive meetings of the board and the board resolves that his or her
office be vacated; (v)&nbsp;is prohibited by law from being a director; or (vi)&nbsp;is removed from office pursuant to any other provisions of our current memorandum and articles of association. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I>Transactions with Interested Shareholders</I>. The Delaware General Corporation Law contains a business combination statute applicable to
Delaware corporations whereby, unless the corporation has specifically elected not to be governed by such statute by amendment to its certificate of incorporation, it is prohibited from engaging in certain business combinations with an
&#147;interested shareholder&#148; for three years following the date that such person becomes an interested shareholder. An interested shareholder generally is a person or a group who or which owns or owned 15% or more of the target&#146;s
outstanding voting share within the past three years. This has the effect of limiting the ability of a potential acquirer to make a <FONT STYLE="white-space:nowrap">two-tiered</FONT> bid for the target in which all shareholders would not be treated
equally. The statute does not apply if, among other things, prior to the date on which such shareholder becomes an interested shareholder, the board of directors approves either the business combination or the transaction which resulted in the
person becoming an interested shareholder. This encourages any potential acquirer of a Delaware corporation to negotiate the terms of any acquisition transaction with the target&#146;s board of directors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Cayman Islands law has no comparable statute. As a result, we cannot avail ourselves of the types of protections afforded by the Delaware
business combination statute. However, although Cayman Islands law does not regulate transactions between a company and its significant shareholders, it does provide that such transactions must be entered into bona fide in the best interests of the
company and not with the effect of constituting a fraud on the minority shareholders. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">281 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I>Dissolution; Winding up</I>. Under the Delaware General Corporation Law, unless the board
of directors approves the proposal to dissolve, dissolution must be approved by shareholders holding 100% of the total voting power of the corporation. Only if the dissolution is initiated by the board of directors may it be approved by a simple
majority of the corporation&#146;s outstanding shares. Delaware law allows a Delaware corporation to include in its certificate of incorporation a supermajority voting requirement in connection with dissolutions initiated by the board. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Under Cayman Islands law, a company may be wound up by either an order of the courts of the Cayman Islands or by a special resolution of its
members or, if the company is unable to pay its debts as they fall due, by an ordinary resolution of its members. The court has authority to order winding up in a number of specified circumstances including where it is, in the opinion of the court,
just and equitable to do so. Under the Companies Law and our current articles of association, our company may be dissolved, liquidated or wound up by a special resolution of our shareholders. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I>Variation of Rights of Shares</I>. Under the Delaware General Corporation Law, a corporation may vary the rights of a class of shares with
the approval of a majority of the outstanding shares of such class, unless the certificate of incorporation provides otherwise. Under our current articles of association, if our share capital is divided into more than one class of shares, we may
vary the rights attached to any class with the written consent of the holders of all of the issued shares of that class or with the sanction of a special resolution passed at a general meeting of the holders of the shares of that class. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I>Amendment of Governing Documents</I>. Under the Delaware General Corporation Law, a corporation&#146;s governing documents may be amended
with the approval of a majority of the outstanding shares entitled to vote, unless the certificate of incorporation provides otherwise. As permitted by Cayman Islands law, our current memorandum and articles of association may only be amended with a
special resolution of our shareholders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>History of Securities Issuances </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The following is a summary of our securities issuances in the past three years. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Ordinary Shares </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">On
January&nbsp;22, 2020, at the closing of our initial public offering, we issued and sold a total of 17,037,020 ordinary shares, represented by ADSs at a public offering price of US$14.00 per ADS. On February&nbsp;10, 2020, we issued and sold a total
of 1,767,205 ordinary shares, represented by ADSs at the initial public offering price pursuant to the partial exercise by the underwriters in our initial public offering of their option to purchase additional ADSs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">On January&nbsp;22, 2020, we issued 6,078,571 ordinary shares to Everest Medicines Limited concurrently with the completion of our initial
public offering, at a per share price equal to the initial public offering price adjusted to reflect the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">ADS-to-ordinary</FONT></FONT> share ratio, at a total value of
US$37.0&nbsp;million, with respect to Everest&#146;s historical contribution to our <FONT STYLE="white-space:nowrap">co-development</FONT> and commercialization of felzartamab in Greater China. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">On August&nbsp;12, 2020, we issued 4,036,868 ordinary shares to Citi (Nominees) Limited, the nominee of Citibank, N.A., the depositary of our
ADS program, for bulk issuance of ordinary shares reserved and issuable under our share incentive plans. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In September 2020, we entered
into definitive subscription agreements (collectively, the &#147;Subscription Agreements,&#148; and each, a &#147;Subscription Agreement&#148;) with a consortium of institutional investors, pursuant to which we agree to issue and sell to these
investors (i)&nbsp;a total of 29,133,502 ordinary shares of our company for an aggregate purchase price of approximately US$418&nbsp;million (equivalent to a price of US$33 per ADS); and (ii)&nbsp;warrants (the &#147;Investor Warrants&#148;) to
subscribe for up to 5,341,267 ordinary shares of our company at an </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">282 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
exercise price of US$45 per ADS, subject to the closing conditions set forth in the Subscription Agreements. Each ten ADSs of our company represents twenty-three ordinary shares of our company.
On September&nbsp;11, 2020, we issued 20,421,378 ordinary shares to these investors pursuant to the Subscription Agreements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The
Subscription Agreement with the Hillhouse Entities contemplates two closings. The first closing occurred on September&nbsp;11, 2020, and the second closing is conditioned upon an existing director of our company having resigned to enable the
Hillhouse Entities to appoint a director to replace such director and the lemzoparlimab <FONT STYLE="white-space:nowrap">out-licensing</FONT> agreement with AbbVie being or remaining effective. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The closings of the Subscription Agreements with investors other than the Hillhouse Entities have occurred in September 2020. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">On November&nbsp;9, 2020, we issued 100,000 ordinary shares to Biomaster Holding Limited upon exercise of options granted to certain of our
employees for an aggregate exercise price of US$100,000. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">On November&nbsp;19, 2020, we issued 200,000 ordinary shares to Biomaster
Holding Limited upon exercise of options granted to certain of our employees for an aggregate exercise price of US$200,000. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">On
November&nbsp;30, 2020, we issued 582,076 ordinary shares to Biomaster Holding Limited upon exercise of options granted to certain of our employees for an aggregate exercise price of US$452,020 and RMB56,028. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Preferred Shares </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">On
September&nbsp;6, 2017, we issued an aggregate of 16,723,646 Series <FONT STYLE="white-space:nowrap">A-3</FONT> preferred shares to CBC SPVII LIMITED and Genexine for an aggregate purchase price of US$30.0&nbsp;million. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">On September&nbsp;22, 2017, we issued 14,089,714 Series B preferred shares to CBC Investment <FONT STYLE="white-space:nowrap">I-Mab</FONT>
Limited for an aggregate purchase price of US$48.4&nbsp;million. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">On February&nbsp;9, 2018, we issued 1,804,880 Series B preferred shares
to <FONT STYLE="white-space:nowrap">C-Bridge</FONT> II Investment Ten Limited for an aggregate purchase price of US$6.2&nbsp;million. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">On
June&nbsp;29, 2018, we issued an aggregate of 2,535,201 Series <FONT STYLE="white-space:nowrap">B-1</FONT> preferred shares to CBC Investment <FONT STYLE="white-space:nowrap">I-MAB</FONT> Limited and <FONT STYLE="white-space:nowrap">C-Bridge</FONT>
II Investment Ten Limited for an aggregate purchase price of approximately US$13.7&nbsp;million as a result of the conversion by these two entities of the convertible promissory notes issued to them on September&nbsp;25, 2017 and February&nbsp;9,
2018, respectively. On the same date, we issued an aggregate of 2,253,512 Series <FONT STYLE="white-space:nowrap">B-2</FONT> preferred shares to CBC Investment <FONT STYLE="white-space:nowrap">I-MAB</FONT> Limited and
<FONT STYLE="white-space:nowrap">C-Bridge</FONT> II Investment Ten Limited for an aggregate purchase price of approximately US$13.7&nbsp;million as a result of the exercise of the warrants granted to them on September&nbsp;25, 2017. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">On June&nbsp;29, 2018, we issued 8,361,823 Series <FONT STYLE="white-space:nowrap">A-3</FONT> preferred shares, 5,938,640 Series B preferred
shares, and 947,218 Series <FONT STYLE="white-space:nowrap">B-1</FONT> preferred shares to Tasly Biopharma Limited in exchange for Tasly Biopharma Limited&#146;s equity interests in <FONT STYLE="white-space:nowrap">I-Mab</FONT> Hong Kong. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">On July&nbsp;6, 2018, Tasly Biopharma Limited transferred to Rainbow Horizon Limited 947,218 Series
<FONT STYLE="white-space:nowrap">B-1</FONT> preferred shares and the warrant in part to purchase 841,971 Series <FONT STYLE="white-space:nowrap">B-2</FONT> preferred shares for a total purchase price of US$6.0&nbsp;million. On the same date, we
issued 841,971 Series <FONT STYLE="white-space:nowrap">B-2</FONT> preferred shares to Rainbow Horizon Limited as a result of the exercise of the warrant by Rainbow Horizon for an aggregate purchase price of US$5.1&nbsp;million. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">283 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">On July&nbsp;6, 2018, we issued to Qianhai Ark (Cayman) Investment Co. Limited
(&#147;Qianhai Ark Cayman&#148;), (i) 1,455,549 Series B preferred shares for a purchase price of approximately US$2.0&nbsp;million, (ii) 232,161 Series <FONT STYLE="white-space:nowrap">B-1</FONT> preferred shares for an aggregate purchase price of
US$1.25&nbsp;million as a result of the conversion of a convertible promissory note issued to Qianhai Ark Cayman on July&nbsp;6, 2018, and (iii) 206,366 Series <FONT STYLE="white-space:nowrap">B-2</FONT> preferred shares for an aggregate purchase
price of US$1.25&nbsp;million as a result of the exercise of warrant granted to Qianhai Ark Cayman on September&nbsp;25, 2017. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">On
July&nbsp;6, 2018, we issued an aggregate of 31,046,360 Series C preferred shares to Fortune Eight Jogging Limited, <FONT STYLE="white-space:nowrap">C-Bridge</FONT> II Investment Seven Limited, HH IMB Holdings Limited, Ally Bridge LB Precision
Limited, Marvey Investment Company Limited, Mab Health Limited, Casiority H Limited, Southern Creation Limited (formerly known as Ally Bridge <FONT STYLE="white-space:nowrap">LB-Sunshine</FONT> Limited), Tasly International Capital Limited, and
Parkway Limited for an aggregate purchase price of US$200.0&nbsp;million. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">On July&nbsp;25, 2019, we entered into a share purchase
agreement with Caesar Pro Holdings Limited, WuXi Biologics HealthCare Venture, and Hongkong Tigermed Co., Limited. Pursuant to the share purchase agreement, these investors will subscribe for an aggregate of 3,857,143 Series <FONT
STYLE="white-space:nowrap">C-1</FONT> preferred shares of <FONT STYLE="white-space:nowrap">I-Mab</FONT> for an aggregate purchase price of US$27.0&nbsp;million. On October&nbsp;17, 2019, we issued 1,428,571 Series
<FONT STYLE="white-space:nowrap">C-1</FONT> preferred shares to Wuxi Biologics HealthCare Venture. On November&nbsp;6, 2019, we issued an aggregate of 2,428,572 Series <FONT STYLE="white-space:nowrap">C-1</FONT> preferred shares to Hong Kong
Tigermed Co., Limited and Caesar Pro Holdings Limited. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">All the preferred shares outstanding were converted into ordinary shares
immediately upon the closing of the initial public offering of our company&#146;s ordinary shares in January 2020. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Convertible Promissory Notes
</I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">On September&nbsp;25, 2017, we issued a US$12.1&nbsp;million convertible promissory note due September 2020 to CBC Investment <FONT
STYLE="white-space:nowrap">I-Mab</FONT> Limited. On June&nbsp;29, 2018, CBC Investment <FONT STYLE="white-space:nowrap">I-Mab</FONT> Limited converted this note to 2,247,321 Series <FONT STYLE="white-space:nowrap">B-1</FONT> preferred shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">On February&nbsp;5, 2018, we issued a US$9.0&nbsp;million convertible promissory note due February 2021 to Genexine. Genexine can at any time
prior to February&nbsp;5, 2021 convert this note into preferred shares of <FONT STYLE="white-space:nowrap">I-Mab</FONT> at US$10 per share, subject to certain price adjustments. As of the date of this prospectus, Genexine has not converted this
note. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">On February&nbsp;9, 2018, we issued a US$1.6&nbsp;million convertible promissory note due September 2020 to <FONT
STYLE="white-space:nowrap">C-Bridge</FONT> II Investment Ten Limited. On June&nbsp;29, 2018, <FONT STYLE="white-space:nowrap">C-Bridge</FONT> II Investment Ten Limited converted this note into 287,880 Series
<FONT STYLE="white-space:nowrap">B-1</FONT> preferred shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">On July&nbsp;6, 2018, we issued a US$1.3&nbsp;million convertible
promissory note due July 2021 to Qianhai Ark Cayman. On July&nbsp;6, 2018, Qianhai Ark Cayman converted this note into 232,161 Series <FONT STYLE="white-space:nowrap">B-1</FONT> preferred shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Options and Warrants </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">On
September&nbsp;6, 2017, we granted Shanghai Tasly an option to purchase up to 8,361,823 Series <FONT STYLE="white-space:nowrap">A-3</FONT> preferred shares. On September&nbsp;25, 2017, we granted Shanghai Tasly an additional option to purchase up to
5,938,640 Series B preferred shares and 947,218 Series <FONT STYLE="white-space:nowrap">B-1</FONT> preferred shares. On June&nbsp;29, 2018, Tasly Biopharma Limited, as Shanghai Tasly&#146;s permitted assign, exercised these options in full. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">On September&nbsp;25, 2017, we granted (i)&nbsp;Qianhai Fund an option to purchase up to 1,455,549 Series B preferred shares and up to 232,161
Series <FONT STYLE="white-space:nowrap">B-1</FONT> preferred shares, and (ii)&nbsp;CBC RMB Fund an option to purchase up to 1,804,880 Series B preferred shares and up to 287,880 additional Series <FONT STYLE="white-space:nowrap">B-1</FONT> preferred
Shares. The option granted to Qianhai Fund was exercised in full on July&nbsp;6, 2018. The option granted to CMC RMB Fund was terminated on February&nbsp;9, 2018. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">284 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">On September&nbsp;25, 2017, we granted a warrant to each of CBC Investment <FONT
STYLE="white-space:nowrap">I-Mab</FONT> Limited, Shanghai Tasly, Qianhai Fund and <FONT STYLE="white-space:nowrap">C-Bridge</FONT> II Investment Ten Limited to purchase up to 4,994,046 Series <FONT STYLE="white-space:nowrap">B-2</FONT> preferred
shares, up to 2,104,928 Series <FONT STYLE="white-space:nowrap">B-2</FONT> preferred shares, up to 515,914 Series <FONT STYLE="white-space:nowrap">B-2</FONT> preferred shares and up to 639,734 Series <FONT STYLE="white-space:nowrap">B-2</FONT>
preferred shares, respectively. On July&nbsp;6, 2018, these investors exercised their warrants in part and purchased 1,997,618 Series <FONT STYLE="white-space:nowrap">B-2</FONT> preferred shares, 841,971 Series
<FONT STYLE="white-space:nowrap">B-2</FONT> preferred shares, 206,366 Series <FONT STYLE="white-space:nowrap">B-2</FONT> preferred shares and 255,894 Series <FONT STYLE="white-space:nowrap">B-2</FONT> preferred shares, for an aggregate purchase
price of US$20.0&nbsp;million. These investors have waived and cancelled their rights under the rest of the warrants. On September&nbsp;25, 2017, we also granted a warrant to CBC RMB Fund to purchase up to 639,734 Series <FONT
STYLE="white-space:nowrap">B-2</FONT> preferred shares, which was terminated on the same date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">On July&nbsp;6, 2018, Tasly Biopharm
Limited, as Shanghai Tasly&#146;s permitted assign, transferred to Rainbow Horizon Limited the warrant in part to purchase 841,971 Series <FONT STYLE="white-space:nowrap">B-2</FONT> preferred shares. On the same date, Rainbow Horizon Limited
exercised this warrant. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Pursuant to the Subscription Agreements, we agree to issue and sell to the investors thereunder the Investor
Warrants, exercisable at the election of the applicable investors within 12 months after the initial or subsequent closing dates set forth in the applicable Subscription Agreements. On September&nbsp;11, 2020, we issued and sold a portion of the
Investor Warrants, allowing the applicable investors to purchase 3,744,032 ordinary shares. As of the date of this Prospectus, none of the Investor Warrants has been exercised. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We have granted options to purchase our ordinary shares to certain of our directors, executive officers and employees. See
&#147;Management&#151;Share Incentive Plans.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Shareholders Agreement </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In July 2019, we entered into our fourth amended and restated shareholders agreement with our shareholders. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The shareholders agreement provides for certain special rights, including right of first refusal,
<FONT STYLE="white-space:nowrap">co-sale</FONT> rights, preemptive rights and contains provisions governing the board of directors and other corporate governance matters. Those special rights, as well as the corporate governance provisions,
automatically terminated upon the completion of our initial public offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><I>Deed of Undertaking </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In December 2019, a deed of undertaking was made by our company and a few shareholders of our company, each as a warrantor, to the other
shareholders of our company (other than the shareholder warrantors), each as a warrantee, pursuant to which each warrantor represents and warrants to each warrantee that it has provided each warrantee with all information and documents in connection
with the initial public offering of our company that has the effect of establishing rights or otherwise benefiting any shareholder in a manner more favorable than the corresponding terms applicable to the relevant warrantee in relation to the
initial public offering of our company (collectively, the &#147;More Favorable Arrangements&#148;). Pursuant to the deed of undertaking, until the fifth anniversary of the completion of our initial public offering, we will not directly or indirectly
enter into any agreements or arrangements or modify, amend or waive any existing agreements or arrangements of any kind that would have the effect of establishing the More Favorable Arrangements; provided that it shall be allowed to adopt or modify
any employee incentive plans and grant options to the management or any employee of our company after our initial public offering pursuant to such plans and in accordance with the then effective memorandum and articles of association and the
applicable listing rules for the purpose of rewarding their bona fide services. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><I>Registration Rights </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Pursuant to our shareholders agreement, we have granted certain registration rights to our shareholders. Set forth below is a description of
the registration rights granted under the agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">285 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I>Demand Registration Rights</I>. At any time after the earlier of
(i)&nbsp;December&nbsp;31, 2020, or (ii)&nbsp;six months following the effectiveness of a registration statement for a firm underwritten public offering of our ordinary shares on The Stock Exchange of Hong Kong Limited, the New York Stock Exchange,
the Nasdaq Stock Market or other internationally recognized securities exchange, with an offering price (exclusive of underwriting commissions and expenses) that reflects a market capitalization (immediately prior to the public offering) of not less
than US$1.0&nbsp;billion, the holders of a majority of the registrable securities then issued and outstanding may request in writing that we file a registration statement covering the registration of at least 20% of the registrable securities (or
any lesser percentage if the anticipated gross receipts from the offering are to exceed US$5.0 million). Upon such a request, we shall, within ten business days of the receipt of such written request, give written notice of such request to all
holders, and use our best efforts to effect, as soon as practicable, the registration of all registrable securities that the holders request to be registered and included in such registration by written notice given by such holders to us within 20
days after receipt of the request notice. We have the right to defer filing of a registration statement for a period of not more than 90 days after receipt of the request of the initiating holders if our board of directors determines in good faith
that filing of such registration statement at such time will be materially detrimental to us or our shareholders, but we cannot exercise the deferral right more than once during any twelve-month period and cannot register any other securities during
such twelve-month period. We are not obligated to effect any such registration if we have, within the <FONT STYLE="white-space:nowrap">six-month</FONT> period preceding the date of such request, already effected a registration. We are not obligated
to effect more than three demand registrations. This demand registration right is subject to the customary exclusion right of the underwriters. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I>Registration on Form <FONT STYLE="white-space:nowrap">F-3</FONT></I>. If we qualify for registration on Form
<FONT STYLE="white-space:nowrap">F-3,</FONT> any holder or holders of a majority of all registrable securities then issued and outstanding may request in writing that we effect a registration on Form <FONT STYLE="white-space:nowrap">F-3</FONT> (or
an equivalent registration in a jurisdiction outside of the U.S.). We shall promptly give written notice of the proposed registration and as soon as practicable, effect such registration within 20 days after we provide the aforesaid written notice.
The holders are entitled to an unlimited number of registrations on Form <FONT STYLE="white-space:nowrap">F-3</FONT> so long as such registration offerings are in excess of US$500,000. We are not obligated to effect any such registration if we have,
within the <FONT STYLE="white-space:nowrap">six-month</FONT> period preceding the date of such request, already effected a registration other than a registration from which registrable securities of the holders have been excluded, or if we would be
required to qualify to do business or to execute a general consent to service of process in effecting such registration in any particular jurisdiction. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I>Piggyback Registration Rights</I>. If we propose to register for a public offering of our securities (other than registration statements
relating to demand registration, Form <FONT STYLE="white-space:nowrap">F-3</FONT> registration, any employee benefit plan or a corporate reorganization), we shall give written notice of such registration to all holders of registrable securities at
least 30 days prior to filing any registration statement and afford each such holder an opportunity to be included in such registration. If a holder decides not to include all of its registrable securities in any registration statement thereafter
filed by us, such holder shall nevertheless continue to have the right to include any registrable securities in any subsequent registration statement or registration statements as may be filed by us, subject to certain limitations. This piggyback
registration right is subject to the customary exclusion right of the underwriters. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I>Expenses of Registration</I>. We will bear all
registration expenses. Each holder, however, should bear its proportionate share of all of the underwriting discounts and selling commissions applicable to the sale of registrable securities or other amounts payable to underwriter(s) or brokers in
connection with such offering by the holders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I>Termination of Obligations</I>. Our obligations to effect any demand, Form <FONT
STYLE="white-space:nowrap">F-3</FONT> or piggyback registration shall terminate upon the earlier of (i)&nbsp;the tenth anniversary of the initial public offering (ii)&nbsp;after the initial public offering, the date on which such shareholder is
eligible to sell all of the registrable securities held by it under Rule 144 within any <FONT STYLE="white-space:nowrap">90-day</FONT> period without volume limitations. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">286 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Subscription Agreement with Hillhouse Entities </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In September 2020, we entered into a Subscription Agreement with the Hillhouse Entities. The Subscription Agreement provides for
(i)&nbsp;certain investors&#146; rights, such as registration rights, board representation rights and anti-dilution rights and <FONT STYLE="white-space:nowrap">(ii)&nbsp;lock-up</FONT> and other transfer restrictions. Set forth below is a
description of certain rights and restrictions thereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I>Mandatory Registration after Initial Closing (September 11, 2020)</I>. We
agree to file with the SEC a registration statement to register the resale of Hillhouse Entities&#146; registrable securities, which include ordinary shares issued and issuable upon exercise of Investor Warrants under the Subscription Agreement, on
Form <FONT STYLE="white-space:nowrap">F-3</FONT> or Form <FONT STYLE="white-space:nowrap">F-1,</FONT> as applicable. We shall have the relevant registration statement declared effective by the SEC no later than ninety (90)&nbsp;calendar days after
September&nbsp;11, 2020, which period could be extended to one hundred and twenty (120)&nbsp;calendar days if the SEC reviews and comments on the registration statement. However, if the SEC prevents inclusion of the registrable securities in the
registration statement pursuant to limitations under Rule 415 of the Securities Act, the number of registrable securities to be registered for each selling shareholder named in the registration statement shall be reduced pro rata among all such
selling shareholders. We shall maintain the continuous effectiveness of the registration statement for a period of ninety (90)&nbsp;days after its effectiveness or such shorter period upon which the Hillhouse Entities have notified us that their
registrable securities have actually been sold. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I>Mandatory Registration after Subsequent Closing</I>. With respect to the registrable
securities then held by the Hillhouse Entities which have not been previously registered and sold, we agree to file a prospectus supplement or a registration statement to register the resale of such registrable securities on a Form <FONT
STYLE="white-space:nowrap">F-3</FONT> or Form <FONT STYLE="white-space:nowrap">F-3ASR</FONT> registration statement (or, if Form <FONT STYLE="white-space:nowrap">F-3</FONT> or Form <FONT STYLE="white-space:nowrap">F-3ASR</FONT> is not then available
to us, on Form <FONT STYLE="white-space:nowrap">F-1</FONT> or such other form of registration statement as is then available to effect a registration for resale of such registrable securities), and have such registration statement declared effective
by the SEC no later than (a)&nbsp;the ten (10)&nbsp;business days after the later of (i)&nbsp;the first date when we become eligible to use registration statement on <FONT STYLE="white-space:nowrap">F-3,</FONT> or (ii)&nbsp;the expiration of the <FONT
STYLE="white-space:nowrap">lock-up</FONT> period with respect to the subsequent closing, or forty-five (45)&nbsp;calendar days after such <FONT STYLE="white-space:nowrap">lock-up</FONT> period expiration date if the SEC reviews and comments on the
registration statement. We shall maintain the effectiveness of such registration statement for a period ending on the date the registrable securities registered thereon have ceased to be registrable securities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I>Demand Registration Rights</I>. Upon written request from the Hillhouse Entities at any time after we have effected two registration
statements abovementioned, with respect to the registrable securities then held by the Hillhouse Entities, and in no event later than the forty-five (45)&nbsp;calendar days following the delivery of such request, we shall file a prospectus
supplement or a registration statement to register the resale of such registrable securities on a Form <FONT STYLE="white-space:nowrap">F-3</FONT> or Form <FONT STYLE="white-space:nowrap">F-3ASR</FONT> registration statement (or, if Form <FONT
STYLE="white-space:nowrap">F-3</FONT> or Form <FONT STYLE="white-space:nowrap">F-3ASR</FONT> is not then available to us, on Form <FONT STYLE="white-space:nowrap">F-1</FONT> or such other form of registration statement as is then available to effect
a registration for resale of such registrable securities), have such registration statement declared effective, and maintain the effectiveness of such registration statement for a period ending on the date the registrable securities registered
thereon have ceased to be registrable securities. If the registrable securities are offered by means of an underwritten offering, and we or the underwriters determine that marketing factors require a limitation of the number of securities to be
underwritten, the number of registrable securities that may be included in the underwriting shall be r educed and allocated (i)&nbsp;first, to us and each holder in accordance with the terms of the Shareholders Agreement; (ii)&nbsp;second, to
investors in the private placements entered into in September 2020 (including the Hillhouse Entities) requesting inclusion of their registrable securities in such registration statement on a pro rata basis based on the total number of registrable
securities then held by each such investor; and (iii)&nbsp;third, to other holders of registrable securities, if any. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I>Suspension of
Registration</I>. We may suspend the use of any registration statement for a period not exceeding thirty (30)&nbsp;consecutive trading days, if we (i)&nbsp;determine that we would be required to make disclosure of material information in the
registration statement that we have a bona fide business purpose for preserving as </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">287 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
confidential; (ii)&nbsp;determine that we must amend or supplement the registration statement so that it shall not include an untrue statement of a material fact or omit to state a material fact;
or (iii)&nbsp;have experienced or are experiencing some other material <FONT STYLE="white-space:nowrap">non-public</FONT> event, the disclosure of which at such time would adversely affect us. However, we cannot exercise the suspension right more
than once in any twelve (12)&nbsp;month period and may not register any other securities during such suspension period. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I>Expenses</I>.
We will bear all registration expenses, except any (i)&nbsp;portions of fees and disbursements of counsel for the Hillhouse Entities exceeding US$30,000, (ii) underwriting discounts and selling commissions applicable to sale of registrable
securities, and (iii)&nbsp;fees payable pursuant to the deposit agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I>Ranking of Registration Rights</I>. Registration rights
granted to the Hillhouse Entities shall not be senior to, or on a parity with, those granted to holders under the Shareholders Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I>Board Representation Rights</I>. As long as the Hillhouse Entities continue to jointly beneficially own at least five percent (5.0%) of our
total issued and outstanding share capital, it is entitled to nominate and maintain one representative to our board of directors. We shall (i)&nbsp;cause an existing director to duly resign from our board of directors prior to the second closing
date; and (ii)&nbsp;cause an individual jointly designated by the Hillhouse Entities to be appointed as the investor director with immediate effect no later than the tenth (10<SUP STYLE="font-size:85%; vertical-align:top">th</SUP>) business day
after the resignation of the departing director. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I><FONT STYLE="white-space:nowrap">Lock-up</FONT></I>. The Hillhouse Entities shall not
dispose of any of the ordinary shares purchased by Hillhouse Entities on the applicable initial or subsequent closing date within a <FONT STYLE="white-space:nowrap">90-day</FONT> period following September&nbsp;11, 2020 or a subsequent closing date
set forth in the subscription agreement to any person other than affiliates of the Hillhouse Entities, who shall be bound by the Hillhouse Entities&#146; <FONT STYLE="white-space:nowrap">lock-up</FONT> obligations for the balance of each applicable <FONT
STYLE="white-space:nowrap">lock-up</FONT> period. Each of the Hillhouse Entities and their affiliates may directly or indirectly, place any charge, mortgage, lien, pledge, restrictions, security interest or other encumbrance in respect of the <FONT
STYLE="white-space:nowrap">lock-up</FONT> securities in connection with such Hillhouse Entity&#146;s (or any of its affiliates&#146;) margin loans, collars, derivative transactions or other such downside protection transactions to be entered into on
or after the date of the subscription agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I>Anti-dilution rights</I>. We agree not to issue, offer, sell, or grant any option or
right to purchase any new securities, without the prior written consent of the Hillhouse Entities, (i)&nbsp;during the <FONT STYLE="white-space:nowrap">90-day</FONT> period following each closing date; or (ii)&nbsp;at an effective purchase price per
share lower than the purchase price under the Subscription Agreement with Hillhouse Entities during the <FONT STYLE="white-space:nowrap">90-day</FONT> period commencing from the expiration of each <FONT STYLE="white-space:nowrap">lock-up</FONT>
period. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Subscription Agreements with Other Investors </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In September 2020, we entered into subscription agreements with various investors other than HillHouse Entities. The subscription agreements
are of the same form and provide for certain investors&#146; rights, such as registration rights and anti-dilution right. Set forth below is a description of certain rights and restrictions thereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I>Mandatory Registration</I>. We agree to file with the SEC a registration statement to register the resale of such investors&#146;
registrable securities, which include ordinary shares issued and issuable upon exercise of Investor Warrants under the Subscription Agreement, on Form <FONT STYLE="white-space:nowrap">F-3</FONT> or Form <FONT STYLE="white-space:nowrap">F-1,</FONT>
as applicable. We shall have the relevant registration statement declared effective by the SEC no later than ninety (90)&nbsp;calendar days after the initial closing date, which period could be extended to one hundred and twenty (120)&nbsp;calendar
days if the SEC reviews and comments on the registration statement. However, if the SEC prevents inclusion of the registrable securities in the registration statement pursuant to limitations under Rule 415 of the Securities Act, the number of
registrable securities to be registered for each selling shareholder named in the registration statement shall be reduced pro rata among all such selling shareholders. We shall maintain the continuous effectiveness of the
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">288 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
registration statement for a period of ninety (90)&nbsp;days after its effectiveness or such shorter period upon which such investors have notified us that their registrable securities have
actually been sold. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I>Piggyback Registration</I>. We agree to notify such investors at least thirty (30)&nbsp;days prior to filing any
registration statement for purposes of effecting a public offering of ADSs (excluding registration statements relating to the mandatory registration described above). The Private Placement Investors has 20 days after receiving notice from us to
notify us in writing of their desire to include their registrable securities in the registration statement. However, if the registrable securities in such registration statement are offered by means of an underwritten offering, and we or the
underwriters determine that marketing factors require a limitation of the number of securities to be underwritten, the number of registrable securities that may be included in the underwriting shall be reduced and allocated (i)&nbsp;first, to us and
each holder in accordance with the terms of the Shareholders Agreement; (ii)&nbsp;second, to investors in the private placements entered into in September 2020 requesting inclusion of their registrable securities in such registration statement on a
pro rata basis based on the total number of registrable securities then held by each such investor; and (iii)&nbsp;third, to other holders of registrable securities, if any. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I>Suspension of Registration</I>. We may suspend the use of any registration statement for a period not exceeding thirty
(30)&nbsp;consecutive trading days, if we (i)&nbsp;determine that we would be required to make disclosure of material information in the registration statement that we have a bona fide business purpose for preserving as confidential;
(ii)&nbsp;determine that we must amend or supplement the registration statement so that it shall not include an untrue statement of a material fact or omit to state a material fact; or (iii)&nbsp;have experienced or are experiencing some other
material <FONT STYLE="white-space:nowrap">non-public</FONT> event, the disclosure of which at such time would adversely affect us. However, we cannot exercise the suspension right more than once in any twelve (12)&nbsp;month period and may not
register any other securities during such suspension period. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I>Expenses</I>. We will bear all registration expenses, except any
(i)&nbsp;portions of fees and disbursements of counsel for such investors, and (ii)&nbsp;underwriting discounts and selling commissions applicable to sale of registrable securities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I>Ranking of Registration Rights</I>. Registration rights granted to such investors shall not be senior to, or on a parity with, those
granted to holders under the Shareholders Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">289 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom98473_19"></A>DESCRIPTION OF AMERICAN DEPOSITARY SHARES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Citibank, N.A. has agreed to act as the depositary for the American Depositary Shares. Citibank&#146;s depositary offices are located at 388
Greenwich Street, New York, New York 10013. American Depositary Shares are frequently referred to as &#147;ADSs&#148; and represent ownership interests in securities that are on deposit with the depositary. ADSs may be represented by certificates
that are commonly known as &#147;American Depositary Receipts&#148; or &#147;ADRs.&#148; The depositary typically appoints a custodian to safekeep the securities on deposit. In this case, the custodian is Citibank, N.A.&#151;Hong Kong, located at
9/F, Citi Tower, One Bay East, 83 Hon Hai Road, Kwun Tong, Kowloon, Hong Kong. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We have appointed Citibank as depositary pursuant to a
deposit agreement. A copy of the deposit agreement is on file with the SEC under cover of a Registration Statement on Form <FONT STYLE="white-space:nowrap">F-6.</FONT> You may obtain a copy of the deposit agreement from the SEC&#146;s Public
Reference Room at 100 F Street, N.E., Washington, D.C. 20549 and from the SEC&#146;s website (<U>www.sec.gov</U>). Please refer to Registration Number <FONT STYLE="white-space:nowrap">333-234363</FONT> when retrieving such copy. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We are providing you with a summary description of the material terms of the ADSs and of your material rights as an owner of ADSs. Please
remember that summaries by their nature lack the precision of the information summarized and that the rights and obligations of an owner of ADSs will be determined by reference to the terms of the deposit agreement and not by this summary. We urge
you to review the deposit agreement in its entirety. The portions of this summary description that are italicized describe matters that may be relevant to the ownership of ADSs but that may not be contained in the deposit agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Each ten (10)&nbsp;ADSs represent the right to receive, and to exercise the beneficial ownership interests in, twenty-three (23)&nbsp;ordinary
shares that are on deposit with the depositary and/or the custodian. An ADS also represents the right to receive, and to exercise the beneficial interests in, any other property received by the depositary or the custodian on behalf of the owner of
the ADS but that has not been distributed to the owners of ADSs because of legal restrictions or practical considerations. We and the depositary may agree to change the
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">ADS-to-ordinary</FONT></FONT> shares ratio by amending the deposit agreement. This amendment may give rise to, or change, the depositary fees payable by ADS owners. The custodian, the
depositary and their respective nominees will hold all deposited property for the benefit of the holders and beneficial owners of ADSs. The deposited property does not constitute the proprietary assets of the depositary, the custodian or their
nominees. Beneficial ownership in the deposited property will under the terms of the deposit agreement be vested in the beneficial owners of the ADSs. The depositary, the custodian and their respective nominees will be the record holders of the
deposited property represented by the ADSs for the benefit of the holders and beneficial owners of the corresponding ADSs. A beneficial owner of ADSs may or may not be the holder of ADSs. Beneficial owners of ADSs will be able to receive, and to
exercise beneficial ownership interests in, the deposited property only through the registered holders of the ADSs, the registered holders of the ADSs (on behalf of the applicable ADS owners) only through the depositary, and the depositary (on
behalf of the owners of the corresponding ADSs) directly, or indirectly, through the custodian or their respective nominees, in each case upon the terms of the deposit agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">If you become an owner of ADSs, you will become a party to the deposit agreement and therefore will be bound to its terms and to the terms of
any ADR that represents your ADSs. The deposit agreement and the ADR specify our rights and obligations as well as your rights and obligations as owner of ADSs and those of the depositary. As an ADS holder you appoint the depositary to act on your
behalf in certain circumstances. The deposit agreement and the ADRs are governed by New York law. However, our obligations to the holders of ordinary shares will continue to be governed by the laws of the Cayman Islands, which may be different from
the laws in the United States. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In addition, applicable laws and regulations may require you to satisfy reporting requirements and obtain
regulatory approvals in certain circumstances. You are solely responsible for complying with such </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">290 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
reporting requirements and obtaining such approvals. Neither the depositary, the custodian, us or any of their or our respective agents or affiliates shall be required to take any actions
whatsoever on your behalf to satisfy such reporting requirements or obtain such regulatory approvals under applicable laws and regulations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">As an owner of ADSs, we will not treat you as one of our shareholders and you will not have direct shareholder rights. The depositary will
hold on your behalf the shareholder rights attached to the ordinary shares underlying your ADSs. As an owner of ADSs you will be able to exercise the shareholders rights for the ordinary shares represented by your ADSs through the depositary only to
the extent contemplated in the deposit agreement. To exercise any shareholder rights not contemplated in the deposit agreement you will, as an ADS owner, need to arrange for the cancellation of your ADSs and become a direct shareholder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The manner in which you own the ADSs (e.g., in a brokerage account vs. as registered holder, or as holder of certificated vs. uncertificated
ADSs) may affect your rights and obligations, and the manner in which, and extent to which, the depositary&#146;s services are made available to you. As an owner of ADSs, you may hold your ADSs either by means of an ADR registered in your name,
through a brokerage or safekeeping account, or through an account established by the depositary in your name reflecting the registration of uncertificated ADSs directly on the books of the depositary (commonly referred to as the &#147;direct
registration system&#148; or &#147;DRS&#148;). The direct registration system reflects the uncertificated (book-entry) registration of ownership of ADSs by the depositary. Under the direct registration system, ownership of ADSs is evidenced by
periodic statements issued by the depositary to the holders of the ADSs. The direct registration system includes automated transfers between the depositary and The Depository Trust Company (&#147;DTC&#148;), the central book-entry clearing and
settlement system for equity securities in the United States. If you decide to hold your ADSs through your brokerage or safekeeping account, you must rely on the procedures of your broker or bank to assert your rights as ADS owner. Banks and brokers
typically hold securities such as the ADSs through clearing and settlement systems such as DTC. The procedures of such clearing and settlement systems may limit your ability to exercise your rights as an owner of ADSs. Please consult with your
broker or bank if you have any questions concerning these limitations and procedures. All ADSs held through DTC will be registered in the name of a nominee of DTC. This summary description assumes you have opted to own the ADSs directly by means of
an ADS registered in your name and, as such, we will refer to you as the &#147;holder.&#148; When we refer to &#147;you,&#148; we assume the reader owns ADSs and will own ADSs at the relevant time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The registration of the ordinary shares in the name of the depositary or the custodian shall, to the maximum extent permitted by applicable
law, vest in the depositary or the custodian the record ownership in the applicable ordinary shares with the beneficial ownership rights and interests in such ordinary shares being at all times vested with the beneficial owners of the ADSs
representing the ordinary shares. The depositary or the custodian shall at all times be entitled to exercise the beneficial ownership rights in all deposited property, in each case only on behalf of the holders and beneficial owners of the ADSs
representing the deposited property. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Dividends and Distributions </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">As a holder of ADSs, you generally have the right to receive the distributions we make on the securities deposited with the custodian. Your
receipt of these distributions may be limited, however, by practical considerations and legal limitations. Holders of ADSs will receive such distributions under the terms of the deposit agreement in proportion to the number of ADSs held as of the
specified record date, after deduction of the applicable fees, taxes and expenses. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Distributions of Cash </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Whenever we make a cash distribution for the securities on deposit with the custodian, we will deposit the funds with the custodian. Upon
receipt of confirmation of the deposit of the requisite funds, the depositary will arrange for the funds received in a currency other than U.S. dollars to be converted into U.S. dollars and for the distribution of the U.S. dollars to the holders,
subject to the laws and regulations of the Cayman Islands. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">291 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The conversion into U.S. dollars will take place only if practicable and if the U.S. dollars
are transferable to the United States. The depositary will apply the same method for distributing the proceeds of the sale of any property (such as undistributed rights) held by the custodian in respect of securities on deposit. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The distribution of cash will be made net of the fees, expenses, taxes and governmental charges payable by holders under the terms of the
deposit agreement. The depositary will hold any cash amounts it is unable to distribute in a <FONT STYLE="white-space:nowrap">non-interest</FONT> bearing account for the benefit of the applicable holders and beneficial owners of ADSs until the
distribution can be effected or the funds that the depositary holds must be escheated as unclaimed property in accordance with the laws of the relevant states of the United States. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Distributions of Shares </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Whenever we
make a free distribution of ordinary shares for the securities on deposit with the custodian, we will deposit the applicable number of ordinary shares with the custodian. Upon receipt of confirmation of such deposit, the depositary will either
distribute to holders new ADSs representing the ordinary shares deposited or modify the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">ADS-to-ordinary</FONT></FONT> shares ratio, in which case each ADS you hold will represent
rights and interests in the additional ordinary shares so deposited. Only whole new ADSs will be distributed. Fractional entitlements will be sold and the proceeds of such sale will be distributed as in the case of a cash distribution. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The distribution of new ADSs or the modification of the
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">ADS-to-ordinary</FONT></FONT> shares ratio upon a distribution of ordinary shares will be made net of the fees, expenses, taxes and governmental charges payable by holders under the
terms of the deposit agreement. In order to pay such taxes or governmental charges, the depositary may sell all or a portion of the new ordinary shares so distributed. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">No such distribution of new ADSs will be made if it would violate a law (<I>e.g.</I>, the U.S. securities laws) or if it is not operationally
practicable. If the depositary does not distribute new ADSs as described above, it may sell the ordinary shares received upon the terms described in the deposit agreement and will distribute the proceeds of the sale as in the case of a distribution
of cash. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>Distributions of Rights </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Whenever we intend to distribute rights to subscribe for additional ordinary shares, we will give prior notice to the depositary and we will
assist the depositary in determining whether it is lawful and reasonably practicable to distribute rights to subscribe for additional ADSs to holders. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The depositary will establish procedures to distribute rights to subscribe for additional ADSs to holders and to enable such holders to
exercise such rights if it is lawful and reasonably practicable to make the rights available to holders of ADSs, and if we provide all of the documentation contemplated in the deposit agreement (such as opinions to address the lawfulness of the
transaction). You may have to pay fees, expenses, taxes and other governmental charges to subscribe for the new ADSs upon the exercise of your rights. The depositary is not obligated to establish procedures to facilitate the distribution and
exercise by holders of rights to subscribe for new ordinary shares other than in the form of ADSs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The depositary will <I>not
</I>distribute the rights to you if: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We do not timely request that the rights be distributed to you or we request that the rights not be distributed
to you; or </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We fail to deliver satisfactory documents to the depositary; or </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">It is not reasonably practicable to distribute the rights. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">292 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The depositary will sell the rights that are not exercised or not distributed if such sale
is lawful and reasonably practicable. The proceeds of such sale will be distributed to holders as in the case of a cash distribution. If the depositary is unable to sell the rights, it will allow the rights to lapse. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Elective Distributions </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Whenever we
intend to distribute a dividend payable at the election of shareholders either in cash or in additional shares, we will give prior notice thereof to the depositary and will indicate whether we wish the elective distribution to be made available to
you. In such case, we will assist the depositary in determining whether such distribution is lawful and reasonably practicable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The
depositary will make the election available to you only if it is reasonably practicable and if we have provided all of the documentation contemplated in the deposit agreement. In such case, the depositary will establish procedures to enable you to
elect to receive either cash or additional ADSs, in each case as described in the deposit agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">If the election is not made
available to you, you will receive either cash or additional ADSs, depending on what a shareholder in the Cayman Islands would receive upon failing to make an election, as more fully described in the deposit agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Other Distributions </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Whenever we intend
to distribute property other than cash, ordinary shares or rights to subscribe for additional ordinary shares, we will notify the depositary in advance and will indicate whether we wish such distribution to be made to you. If so, we will assist the
depositary in determining whether such distribution to holders is lawful and reasonably practicable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">If it is reasonably practicable to
distribute such property to you and if we provide to the depositary all of the documentation contemplated in the deposit agreement, the depositary will distribute the property to the holders in a manner it deems practicable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The distribution will be made net of fees, expenses, taxes and governmental charges payable by holders under the terms of the deposit
agreement. In order to pay such taxes and governmental charges, the depositary may sell all or a portion of the property received. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The
depositary will <I>not </I>distribute the property to you and will sell the property if: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We do not request that the property be distributed to you or if we request that the property not be distributed
to you; or </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We do not deliver satisfactory documents to the depositary; or </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The depositary determines that all or a portion of the distribution to you is not reasonably practicable.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The proceeds of such a sale will be distributed to holders as in the case of a cash distribution. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Redemption </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Whenever we decide to redeem
any of the securities on deposit with the custodian, we will notify the depositary in advance. If it is practicable and if we provide all of the documentation contemplated in the deposit agreement, the depositary will provide notice of the
redemption to the holders. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">293 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The custodian will be instructed to surrender the shares being redeemed against payment of
the applicable redemption price. The depositary will convert into U.S. dollars upon the terms of the deposit agreement the redemption funds received in a currency other than U.S. dollars and will establish procedures to enable holders to receive the
net proceeds from the redemption upon surrender of their ADSs to the depositary. You may have to pay fees, expenses, taxes and other governmental charges upon the redemption of your ADSs. If less than all ADSs are being redeemed, the ADSs to be
retired will be selected by lot or on a <I>pro rata </I>basis, as the depositary may determine. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>Changes Affecting Ordinary Shares </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The ordinary shares held on deposit for your ADSs may change from time to time. For example, there may be a change in nominal or par value, <FONT
STYLE="white-space:nowrap">split-up,</FONT> cancellation, consolidation or any other reclassification of such ordinary shares or a recapitalization, reorganization, merger, consolidation or sale of assets of our company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">If any such change were to occur, your ADSs would, to the extent permitted by law and the deposit agreement, represent the right to receive
the property received or exchanged in respect of the ordinary shares held on deposit. The depositary may in such circumstances deliver new ADSs to you, amend the deposit agreement, the ADRs and the applicable Registration Statement(s) on Form <FONT
STYLE="white-space:nowrap">F-6,</FONT> call for the exchange of your existing ADSs for new ADSs and take any other actions that are appropriate to reflect as to the ADSs the change affecting the ordinary shares. If the depositary may not lawfully
distribute such property to you, the depositary may sell such property and distribute the net proceeds to you as in the case of a cash distribution. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>Issuance of ADSs upon Deposit of Ordinary Shares </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Each time a selling stockholder sells ordinary shares registered by this prospectus, such ordinary shares will be deposited by the selling
shareholder with the custodian. Upon receipt of confirmation of such deposit, the depositary will issue ADSs to the purchasers named in this prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The depositary may create ADSs on your behalf if you or your broker deposit ordinary shares with the custodian. The depositary will deliver
these ADSs to the person you indicate only after you pay any applicable issuance fees and any charges and taxes payable for the transfer of the ordinary shares to the custodian. Your ability to deposit ordinary shares and receive ADSs may be limited
by U.S. and Cayman Islands legal considerations applicable at the time of deposit. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The issuance of ADSs may be delayed until the
depositary or the custodian receives confirmation that all required approvals have been given and that the ordinary shares have been duly transferred to the custodian. The depositary will only issue ADSs in a denomination often (10)&nbsp;ADSs or any
whole multiple often (10)&nbsp;ADSs. No fractional ADSs will be issued and no fractional share will be accepted for deposit. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">When you
make a deposit of ordinary shares, you will be responsible for transferring good and valid title to the depositary. As such, you will be deemed to represent and warrant that: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The ordinary shares are duly authorized, validly issued, fully paid,
<FONT STYLE="white-space:nowrap">non-assessable</FONT> and legally obtained. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">All preemptive (and similar) rights, if any, with respect to such ordinary shares have been validly waived or
exercised. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">You are duly authorized to deposit the ordinary shares. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The ordinary shares presented for deposit are free and clear of any lien, encumbrance, security interest, charge,
mortgage or adverse claim, and are not, and the ADSs issuable upon such deposit will not be, &#147;restricted securities&#148; (as defined in the deposit agreement). </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The ordinary shares presented for deposit have not been stripped of any rights or entitlements.
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">294 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">If any of the representations or warranties are incorrect in any way, we and the depositary
may, at your cost and expense, take any and all actions necessary to correct the consequences of the misrepresentations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>Transfer, Combination and
Split Up of ADRs </U></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">As an ADR holder, you will be entitled to transfer, combine or split up your ADRs and the ADSs evidenced
thereby. For transfers of ADRs, you will have to surrender the ADRs to be transferred to the depositary and also must: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">ensure that the surrendered ADR is properly endorsed or otherwise in proper form for transfer;
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">provide such proof of identity and genuineness of signatures as the depositary deems appropriate;
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">provide any transfer stamps required by the State of New York or the United States; and </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">pay all applicable fees, charges, expenses, taxes and other government charges payable by ADR holders pursuant to
the terms of the deposit agreement, upon the transfer of ADRs. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">To have your ADRs either combined or split up, you must
surrender the ADRs in question to the depositary with your request to have them combined or split up, and you must pay all applicable fees, charges and expenses payable by ADR holders, pursuant to the terms of the deposit agreement, upon a
combination or split up of ADRs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>Withdrawal of Ordinary Shares Upon Cancellation of ADSs </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">As a holder, you will be entitled to present your ADSs to the depositary for cancellation and then receive the corresponding number of
underlying ordinary shares at the custodian&#146;s offices. Your ability to withdraw the ordinary shares held in respect of the ADSs may be limited by U.S. and Cayman Islands law considerations applicable at the time of withdrawal. In order to
withdraw the ordinary shares represented by your ADSs, you will be required to pay to the depositary the fees for cancellation of ADSs and any charges and taxes payable upon the transfer of the ordinary shares. You assume the risk for delivery of
all funds and securities upon withdrawal. Once canceled, the ADSs will not have any rights under the deposit agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">If you hold ADSs
registered in your name, the depositary may ask you to provide proof of identity and genuineness of any signature and such other documents as the depositary may deem appropriate before it will cancel your ADSs. The withdrawal of the ordinary shares
represented by your ADSs may be delayed until the depositary receives satisfactory evidence of compliance with all applicable laws and regulations. Please keep in mind that the depositary will only accept a number of ADSs for cancellation that
represent a whole number of securities on deposit. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">You will have the right to withdraw the securities represented by your ADSs at any
time except for: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Temporary delays that may arise because (i)&nbsp;the transfer books for the ordinary shares or ADSs are closed,
or (ii)&nbsp;ordinary shares are immobilized on account of a shareholders&#146; meeting or a payment of dividends. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Obligations to pay fees, taxes and similar charges. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Restrictions imposed because of laws or regulations applicable to ADSs or the withdrawal of securities on
deposit. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The deposit agreement may not be modified to impair your right to withdraw the securities represented by your
ADSs except to comply with mandatory provisions of law. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">295 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>Voting Rights </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">As a holder, you generally have the right under the deposit agreement to instruct the depositary to exercise the voting rights for the
ordinary shares represented by your ADSs. The voting rights of holders of ordinary shares are described in &#147;Description of Share Capital.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">At our request, the depositary will distribute to you any notice of shareholders&#146; meeting received from us together with information
explaining how to instruct the depositary to exercise the voting rights of the securities represented by ADSs. In lieu of distributing such materials, the depositary may distribute to holders of ADSs instructions on how to retrieve such materials
upon request. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">If the depositary timely receives voting instructions from a holder of ADSs, it will endeavor to vote the securities (in
person or by proxy) represented by the holder&#146;s ADSs as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>In the event of voting by show of hands</I>, the depositary will vote (or cause the custodian to vote) all
ordinary shares held on deposit at that time in accordance with the voting instructions received from a majority of holders of ADSs who provide timely voting instructions. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>In the event of voting by poll</I>, the depositary will vote (or cause the Custodian to vote) the ordinary
shares held on deposit in accordance with the voting instructions received from the holders of ADSs. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Securities for
which no voting instructions have been received will not be voted (except as otherwise contemplated in the deposit agreement). Please note that the ability of the depositary to carry out voting instructions may be limited by practical and legal
limitations and the terms of the securities on deposit. We cannot assure you that you will receive voting materials in time to enable you to return voting instructions to the depositary in a timely manner. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">296 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Fees and Charges </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">As an ADS holder, you will be required to pay the following fees under the terms of the deposit agreement: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="63%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="35%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Service</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Fees</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Issuance of ADSs (e.g., an issuance of ADS upon a deposit of ordinary shares, upon a change in the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">ADS(s)-to-ordinary</FONT></FONT> shares ratio, or for any other
reason), excluding ADS issuances as a result of distributions of ordinary shares)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Up to U.S. 5&#162; per ADS issued</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Cancellation of ADSs (e.g., a cancellation of ADSs for delivery of deposited property, upon a change in the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">ADS(s)-to-ordinary</FONT></FONT> shares ratio, or for any
other reason)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Up to U.S. 5&#162; per ADS cancelled</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Distribution of cash dividends or other cash distributions (e.g., upon a sale of rights and other entitlements)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Up to U.S. 5&#162; per ADS held</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Distribution of ADSs pursuant to (i)&nbsp;stock dividends or other free stock distributions, or (ii)&nbsp;exercise of rights to purchase additional ADSs</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Up to U.S. 5&#162; per ADS held</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Distribution of securities other than ADSs or rights to purchase additional ADSs (e.g., upon a <FONT STYLE="white-space:nowrap">spin-off)</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Up to U.S. 5&#162; per ADS held</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">ADS Services</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Up to U.S. 5&#162; per ADS held on the applicable record date(s) established by the depositary</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Registration of ADS transfers (e.g., upon a registration of the transfer of registered ownership of ADSs, upon a transfer of ADSs into DTC and vice versa, or for any other reason)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Up to U.S. 5&#162; per ADS (or fraction thereof) transferred</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Conversion of ADSs of one series for ADSs of another series (e.g., upon conversion of Partial Entitlement ADSs for Full Entitlement ADSs, or upon conversion of Restricted ADSs (each as defined in the Deposit Agreement) into freely
transferable ADSs, and vice versa).</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Up to U.S. 5&#162; per ADS (or fraction thereof) converted</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">As an ADS holder you will also be responsible to pay certain charges such as: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">taxes (including applicable interest and penalties) and other governmental charges; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the registration fees as may from time to time be in effect for the registration of ordinary shares on the share
register and applicable to transfers of ordinary shares to or from the name of the custodian, the depositary or any nominees upon the making of deposits and withdrawals, respectively; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">certain cable, telex and facsimile transmission and delivery expenses; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">297 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the fees, expenses, spreads, taxes and other charges of the depositary and/or service providers (which may be a
division, branch or affiliate of the depositary) in the conversion of foreign currency; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the reasonable and customary
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> expenses incurred by the depositary in connection with compliance with exchange control regulations and other regulatory requirements applicable to
ordinary shares, ADSs and ADRs; and </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the fees, charges, costs and expenses incurred by the depositary, the custodian, or any nominee in connection
with the ADR program. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">ADS fees and charges for (i)&nbsp;the issuance of ADSs, and (ii)&nbsp;the cancellation of ADSs
are charged to the person for whom the ADSs are issued (in the case of ADS issuances) and to the person for whom ADSs are cancelled (in the case of ADS cancellations). In the case of ADSs issued by the depositary into DTC, the ADS issuance and
cancellation fees and charges may be deducted from distributions made through DTC, and may be charged to the DTC participant(s) receiving the ADSs being issued or the DTC participant(s) holding the ADSs being cancelled, as the case may be, on behalf
of the beneficial owner(s) and will be charged by the DTC participant(s) to the account of the applicable beneficial owner(s) in accordance with the procedures and practices of the DTC participants as in effect at the time. ADS fees and charges in
respect of distributions and the ADS service fee are charged to the holders as of the applicable ADS record date. In the case of distributions of cash, the amount of the applicable ADS fees and charges is deducted from the funds being distributed.
In the case of (i)&nbsp;distributions other than cash and (ii)&nbsp;the ADS service fee, holders as of the ADS record date will be invoiced for the amount of the ADS fees and charges and such ADS fees and charges may be deducted from distributions
made to holders of ADSs. For ADSs held through DTC, the ADS fees and charges for distributions other than cash and the ADS service fee may be deducted from distributions made through DTC, and may be charged to the DTC participants in accordance with
the procedures and practices prescribed by DTC and the DTC participants in turn charge the amount of such ADS fees and charges to the beneficial owners for whom they hold ADSs. In the case of (i)&nbsp;registration of ADS transfers, the ADS transfer
fee will be payable by the ADS Holder whose ADSs are being transferred or by the person to whom the ADSs are transferred, and (ii)&nbsp;conversion of ADSs of one series for ADSs of another series, the ADS conversion fee will be payable by the Holder
whose ADSs are converted or by the person to whom the converted ADSs are delivered. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In the event of refusal to pay the depositary fees,
the depositary may, under the terms of the deposit agreement, refuse the requested service until payment is received or may set off the amount of the depositary fees from any distribution to be made to the ADS holder. Certain depositary fees and
charges (such as the ADS services fee) may become payable shortly after the closing of the ADS offering. Note that the fees and charges you may be required to pay may vary over time and may be changed by us and by the depositary. You will receive
prior notice of such changes. The depositary may reimburse us for certain expenses incurred by us in respect of the ADR program, by making available a portion of the ADS fees charged in respect of the ADR program or otherwise, upon such terms and
conditions as we and the depositary agree from time to time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Amendments and Termination </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We may agree with the depositary to modify the deposit agreement at any time without your consent. We undertake to give holders 30 days&#146;
prior notice of any modifications that would materially prejudice any of their substantial rights under the deposit agreement. We will not consider to be materially prejudicial to your substantial rights any modifications or supplements that are
reasonably necessary for the ADSs to be registered under the Securities Act or to be eligible for book-entry settlement, in each case without imposing or increasing the fees and charges you are required to pay. In addition, we may not be able to
provide you with prior notice of any modifications or supplements that are required to accommodate compliance with applicable provisions of law. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">298 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">You will be bound by the modifications to the deposit agreement if you continue to hold your
ADSs after the modifications to the deposit agreement become effective. The deposit agreement cannot be amended to prevent you from withdrawing the ordinary shares represented by your ADSs (except as permitted by law). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We have the right to direct the depositary to terminate the deposit agreement. Similarly, the depositary may in certain circumstances on its
own initiative terminate the deposit agreement. In either case, the depositary must give notice to the holders at least 30 days before termination. Until termination, your rights under the deposit agreement will be unaffected. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">After termination, the depositary will continue to collect distributions received (but will not distribute any such property until you request
the cancellation of your ADSs) and may sell the securities held on deposit. After the sale, the depositary will hold the proceeds from such sale and any other funds then held for the holders of ADSs in a non-interest bearing account. At that point,
the depositary will have no further obligations to holders other than to account for the funds then held for the holders of ADSs still outstanding (after deduction of applicable fees, taxes and expenses). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In connection with any termination of the deposit agreement, the depositary may make available to owners of ADSs a means to withdraw the
ordinary shares represented by ADSs and to direct the depositary of such ordinary shares into an unsponsored American depositary share program established by the depositary. The ability to receive unsponsored American depositary shares upon
termination of the deposit agreement would be subject to satisfaction of certain U.S. regulatory requirements applicable to the creation of unsponsored American depositary shares and the payment of applicable depositary fees. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>Books of Depositary </U></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The
depositary will maintain ADS holder records at its depositary office. You may inspect such records at such office during regular business hours but solely for the purpose of communicating with other holders in the interest of business matters
relating to the ADSs and the deposit agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The depositary will maintain in New York facilities to record and process the issuance,
cancellation, combination, <FONT STYLE="white-space:nowrap">split-up</FONT> and transfer of ADSs. These facilities may be closed from time to time, to the extent not prohibited by law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>Limitations on Obligations and Liabilities </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The deposit agreement limits our obligations and the depositary&#146;s obligations to you. Please note the following: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We and the depositary are obligated only to take the actions specifically stated in the deposit agreement without
negligence or bad faith. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The depositary disclaims any liability for any failure to carry out voting instructions, for any manner in which
a vote is cast or for the effect of any vote, provided it acts in good faith and in accordance with the terms of the deposit agreement. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The depositary disclaims any liability for any failure to determine the lawfulness or practicality of any action,
for the content of any document forwarded to you on our behalf or for the accuracy of any translation of such a document, for the investment risks associated with investing in ordinary shares, for the validity or worth of the ordinary shares, for
any tax consequences that result from the ownership of ADSs, for the credit-worthiness of any third party, for allowing any rights to lapse under the terms of the deposit agreement, for the timeliness of any of our notices or for our failure to give
notice. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">299 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We and the depositary will not be obligated to perform any act that is inconsistent with the terms of the deposit
agreement. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We and the depositary disclaim any liability if we or the depositary are prevented or forbidden from or subject
to any civil or criminal penalty or restraint on account of, or delayed in, doing or performing any act or thing required by the terms of the deposit agreement, by reason of any provision, present or future of any law or regulation, or by reason of
present or future provision of any provision of our current memorandum and articles of association, or any provision of or governing the securities on deposit, or by reason of any act of God or war or other circumstances beyond our control.
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We and the depositary disclaim any liability by reason of any exercise of, or failure to exercise, any discretion
provided for in the deposit agreement or in our current memorandum and articles of association or in any provisions of or governing the securities on deposit. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We and the depositary further disclaim any liability for any action or inaction in reliance on the advice or
information received from legal counsel, accountants, any person presenting Shares for deposit, any holder of ADSs or authorized representatives thereof, or any other person believed by either of us in good faith to be competent to give such advice
or information. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We and the depositary also disclaim liability for the inability by a holder to benefit from any distribution,
offering, right or other benefit that is made available to holders of ordinary shares but is not, under the terms of the deposit agreement, made available to you. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We and the depositary may rely without any liability upon any written notice, request or other document believed
to be genuine and to have been signed or presented by the proper parties. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We and the depositary also disclaim liability for any consequential or punitive damages for any breach of the
terms of the deposit agreement. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">No disclaimer of any Securities Act liability is intended by any provision of the deposit agreement.
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Nothing in the deposit agreement gives rise to a partnership or joint venture, or establishes a fiduciary
relationship, among us, the depositary and you as ADS holder. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Nothing in the deposit agreement precludes Citibank (or its affiliates) from engaging in transactions in which
parties adverse to us or the ADS owners have interests, and nothing in the deposit agreement obligates Citibank to disclose those transactions, or any information obtained in the course of those transactions, to us or to the ADS owners, or to
account for any payment received as part of those transactions. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Taxes </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">You will be responsible for the taxes and other governmental charges payable on the ADSs and the securities represented by the ADSs. We, the
depositary and the custodian may deduct from any distribution the taxes and governmental charges payable by holders and may sell any and all property on deposit to pay the taxes and governmental charges payable by holders. You will be liable for any
deficiency if the sale proceeds do not cover the taxes that are due. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The depositary may refuse to issue ADSs, to deliver, transfer, split
and combine ADRs or to release securities on deposit until all taxes and charges are paid by the applicable holder. The depositary and the custodian may take reasonable administrative actions to obtain tax refunds and reduced tax withholding for any
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">300 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
distributions on your behalf. However, you may be required to provide to the depositary and to the custodian proof of taxpayer status and residence and such other information as the depositary
and the custodian may require to fulfill legal obligations. You are required to indemnify us, the depositary and the custodian for any claims with respect to taxes based on any tax benefit obtained for you. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Foreign Currency Conversion </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The
depositary will arrange for the conversion of all foreign currency received into U.S. dollars if such conversion is practical, and it will distribute the U.S. dollars in accordance with the terms of the deposit agreement. You may have to pay fees
and expenses incurred in converting foreign currency, such as fees and expenses incurred in complying with currency exchange controls and other governmental requirements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">If the conversion of foreign currency is not practical or lawful, or if any required approvals are denied or not obtainable at a reasonable
cost or within a reasonable period, the depositary may take the following actions in its discretion: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Convert the foreign currency to the extent practical and lawful and distribute the U.S. dollars to the holders
for whom the conversion and distribution is lawful and practical. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Distribute the foreign currency to holders for whom the distribution is lawful and practical.
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Hold the foreign currency (without liability for interest) for the applicable holders. <U>
</U></P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>Governing Law/Waiver of Jury Trial </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The deposit agreement, the ADRs and the ADSs will be interpreted in accordance with the laws of the State of New York. The rights of holders
of ordinary shares (including ordinary shares represented by ADSs) are governed by the laws of the Cayman Islands. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">AS A PARTY TO THE
DEPOSIT AGREEMENT, YOU IRREVOCABLY WAIVE, TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW, YOUR RIGHT TO TRIAL BY JURY IN ANY LEGAL PROCEEDING ARISING OUT OF THE DEPOSIT AGREEMENT OR THE ADRs AGAINST US AND/OR THE DEPOSITARY. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The deposit agreement provides that, to the extent permitted by law, ADS holders waive the right to a jury trial of any claim they may have
against us or the depositary arising out of or relating to our ordinary shares, the ADSs or the deposit agreement, including any claim under U.S. federal securities laws. If we or the depositary opposed a jury trial demand based on the waiver, the
court would determine whether the waiver was enforceable in the facts and circumstances of that case in accordance with applicable case law. However, you will not be deemed, by agreeing to the terms of the deposit agreement, to have waived our or
the depositary&#146;s compliance with U.S. federal securities laws and the rules and regulations promulgated thereunder. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">301 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom98473_20"></A>SHARES ELIGIBLE FOR FUTURE SALES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">All of the ordinary shares or ADSs sold in this offering will be freely transferable by persons other than by our &#147;affiliates&#148;
without restriction or further registration under the Securities Act. Future sales of substantial amounts of our ADSs in the public market could adversely affect prevailing market prices of our ADSs. Although ADSs are listed on the Nasdaq Global
Market, we cannot assure you that a regular trading market for our ADSs will sustain or continue to exist. We do not expect that a trading market will develop for our ordinary shares not represented by the ADSs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">Lock-up</FONT> Agreements </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Each of Gaoling Fund, L.P. and YHG Investment, L.P (both controlled by Hillhouse) (collectively &#147;the Hillhouse Entities&#148;), is
subject to certain <FONT STYLE="white-space:nowrap">lock-up</FONT> obligations pursuant to the subscription agreement with us. Each of the Hillhouse Entities shall not dispose of any of the ordinary shares purchased by Hillhouse Entities on
September&nbsp;11, 2020 or a subsequent closing date within a <FONT STYLE="white-space:nowrap">90-day</FONT> period following September&nbsp;11, 2020 or a subsequent closing date set forth in the subscription agreement to any person other than
affiliates of the Hillhouse Entities, who shall be bound by the Hillhouse Entities&#146; <FONT STYLE="white-space:nowrap">lock-up</FONT> obligations for the balance of each applicable <FONT STYLE="white-space:nowrap">lock-up</FONT> period. Each of
the Hillhouse Entities and their affiliates may directly or indirectly, place any charge, mortgage, lien, pledge, restrictions, security interest or other encumbrance in respect of the <FONT STYLE="white-space:nowrap">lock-up</FONT> securities in
connection with such Hillhouse Entity&#146;s (or any of its affiliates&#146;) margin loans, collars, derivative transactions or other such downside protection transactions to be entered into on or after the date of the subscription agreement. See
Exhibit 10.15 to this registration statement on Form <FONT STYLE="white-space:nowrap">F-1</FONT> for more information on the related <FONT STYLE="white-space:nowrap">lock-up</FONT> obligations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Other than this offering, we are not aware of any plans by any significant shareholders to dispose of significant numbers of our ADSs or
ordinary shares. However, one or more existing shareholders or owners of securities convertible or exchangeable into or exercisable for our ADSs or ordinary shares may dispose of significant numbers of our ADSs or ordinary shares in the future. We
cannot predict what effect, if any, future sales of our ADSs or ordinary shares, or the availability of ADSs or ordinary shares for future sale, will have on the trading price of our ADSs from time to time. Sales of substantial amounts of our ADSs
or ordinary shares in the public market, or the perception that these sales could occur, could adversely affect the trading price of our ADSs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Rule
144 </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">&#147;Restricted securities&#148; as that term is defined in Rule 144 under the Securities Act, may be sold publicly in the
United States only if they are subject to an effective registration statement under the Securities Act or pursuant to an exemption from the registration requirement such as those provided by Rule 144 and Rule 701 promulgated under the Securities
Act. In general, under Rule 144 as currently in effect, beginning 90 days after we became a reporting company, a person (or persons whose shares are aggregated) who at the time of a sale is not, and has not been during the three months preceding the
sale, an affiliate of ours and has beneficially owned our restricted securities for at least six months will be entitled to sell the restricted securities without registration under the Securities Act, subject only to the availability of current
public information about us, and will be entitled to sell restricted securities beneficially owned for at least one year without restriction. Persons who are our affiliates and have beneficially owned our restricted securities for at least six
months may sell a number of restricted securities within any three-month period that does not exceed the greater of the following: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">1% of the then outstanding ordinary shares of the same class, represented by ADSs or otherwise, which immediately
after this offering will equal 1,583,469 ordinary shares; or </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the average weekly trading volume of our ordinary shares of the same class, represented by ADSs or otherwise,
during the four calendar weeks preceding the date on which notice of the sale is filed with the SEC. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">302 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Sales by our affiliates under Rule 144 are also subject to certain requirements relating to
manner of sale, notice and the availability of current public information about us. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Rule 701 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In general, under Rule 701 of the Securities Act as currently in effect, each of our employees, consultants or advisors who purchases our
ordinary shares from us in connection with a compensatory stock or option plan or other written agreement relating to compensation is eligible to resell such ordinary shares 90 days after we became a reporting company under the Exchange Act in
reliance on Rule 144, but without compliance with some of the restrictions, including the holding period, contained in Rule 144. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">303 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom98473_21"></A>TAXATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The following summary of the material Cayman Islands, PRC and U.S. federal income tax consequences of an investment in the ADSs or ordinary
shares is based upon laws and relevant interpretations thereof in effect as of the date of this prospectus, all of which are subject to change. This summary does not deal with all possible tax consequences relating to an investment in the ADSs or
ordinary shares, such as the tax consequences under U.S. state and local tax laws or under the tax laws of jurisdictions other than the Cayman Islands, China and the United States. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Cayman Islands Taxation </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Cayman
Islands currently levies no taxes on individuals or corporations based upon profits, income, gains or appreciation and there is no taxation in the nature of inheritance tax or estate duty. There are no other taxes likely to be material to us levied
by the government of the Cayman Islands except for stamp duties which may be applicable on instruments executed in, or brought within the jurisdiction of the Cayman Islands. The Cayman Islands are a party to a double tax treaty entered into with the
United Kingdom in 2010 but otherwise is not party to any double tax treaties. There are no exchange control regulations or currency restrictions in the Cayman Islands. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Payments of dividends and capital in respect of our shares will not be subject to taxation in the Cayman Islands and no withholding will be
required on the payment of a dividend or capital to any holder of the shares, nor will gains derived from the disposal of our shares be subject to Cayman Islands income or corporation tax. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">No stamp duty is payable in respect of the issue of shares by our Company and no stamp duty is payable on transfers of shares of our Company
provided our Company does not hold any interest in land in the Cayman Islands. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>PRC Taxation </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Under the PRC Enterprise Income Tax Law and its implementation rules, an enterprise established outside China with &#147;de facto management
body&#148; within China is considered as a Tax Resident Enterprise for PRC enterprise income tax purposes and is generally subject to a uniform 25% enterprise income tax rate on its worldwide income. The implementation rules define the term &#147;de
facto management body&#148; as the body that exercises full and substantial control and overall management over the business, productions, personnel, accounts and properties of an enterprise. In April 2009, the State Administration of Taxation
issued Circular 82, which provides certain specific criteria for determining whether the &#147;de facto management body&#148; of a <FONT STYLE="white-space:nowrap">PRC-controlled</FONT> enterprise that is incorporated offshore is located in China.
Although this circular only applies to offshore enterprises controlled by PRC enterprises or PRC enterprise groups, not those controlled by PRC individuals or foreigners, the criteria set forth in the circular may reflect the State Administration of
Taxation&#146;s general position on how the &#147;de facto management body&#148; text should be applied in determining the tax resident status of all offshore enterprises. According to Circular 82, an offshore incorporated enterprise controlled by a
PRC enterprise or a PRC enterprise group will be regarded as a PRC tax resident by virtue of having its &#147;de facto management body&#148; in China if all of the following conditions are met: (i)&nbsp;the primary location of the <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">day-to-day</FONT></FONT> operational management is in China; (ii)&nbsp;decisions relating to the enterprise&#146;s financial and human resource matters are made or are subject to approval
by organizations or personnel located in China; (iii)&nbsp;the enterprise&#146;s primary assets, accounting books and records, company seals, and board and shareholder resolutions, are located or maintained in China; and (iv)&nbsp;at least 50% of
voting board members or senior executives habitually reside in China. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our PRC counsel, JunHe LLP, is of the opinion that, based on its
understanding of the current PRC Laws and Regulations, <FONT STYLE="white-space:nowrap">I-Mab</FONT> should not be considered as a PRC resident enterprise for PRC income tax purposes because <FONT STYLE="white-space:nowrap">I-Mab</FONT> does not
meet all of the above conditions. <FONT STYLE="white-space:nowrap">I-Mab</FONT> is incorporated outside of China and it </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">304 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
is not controlled by a PRC enterprise or PRC enterprise group. We have structured a clear management guideline in place to segregate the policy set up and business operating execution
responsibilities in order to differentiate the effective control from our headquarter office and subsidiaries including record keeping and offshore work location plan. <FONT STYLE="white-space:nowrap">I-Mab</FONT> is a company incorporated outside
the PRC. As a holding company, its key assets are its ownership interests in its subsidiaries, and its key assets are located, and its records (including the resolutions of its board of directors and the resolutions of its shareholders) are
maintained, outside China. However, the tax resident status of an enterprise is subject to determination by the PRC tax authorities and uncertainties remain with respect to the interpretation of the term &#147;de facto management body.&#148;
However, we cannot guarantee you that PRC tax authorities will not take a different view. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">If the PRC tax authorities determine that <FONT
STYLE="white-space:nowrap">I-Mab</FONT> is a PRC resident enterprise for enterprise income tax purposes, our worldwide income could be subject to 25% enterprise income tax; and any dividends payable to
<FONT STYLE="white-space:nowrap">non-resident</FONT> enterprise holders of our common shares or ADSs may be treated as income derived from sources within China and therefore, subject to a 10% withholding tax (or 20% in the case of <FONT
STYLE="white-space:nowrap">non-resident</FONT> individual holders) unless an applicable income tax treaty provides otherwise. In addition, capital gains realized by <FONT STYLE="white-space:nowrap">non-resident</FONT> enterprise shareholders
(including our ADS holders) upon the disposition of our common shares or ADSs may be treated as income derived from sources within PRC and therefore, subject to 10% income tax (or 20% in the case of
<FONT STYLE="white-space:nowrap">non-resident</FONT> individual shareholders or ADS holders) unless an applicable income tax treaty provides otherwise. It is unclear whether <FONT STYLE="white-space:nowrap">non-PRC</FONT> shareholders of our company
would be able to claim the benefits of any tax treaties between their country of tax residence and the PRC in the event that we are treated as a PRC resident enterprise. See &#147;Risk Factors&#151;Risks Related to Doing Business in China&#151;If we
are classified as a PRC resident enterprise for PRC income tax purposes, such classification could result in unfavorable tax consequences to us and our <FONT STYLE="white-space:nowrap">non-PRC</FONT> shareholders or ADS holders.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>United States Federal Income Tax Considerations </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The following discussion is a summary of U.S. federal income tax considerations relating to the ownership and disposition of our ADSs or
ordinary shares by a U.S. Holder (as defined below) that acquires our ADSs in this offering and holds our ADSs as &#147;capital assets&#148; (generally, property held for investment) under the U.S. Internal Revenue Code of 1986, as amended, or the
Code. This discussion is based upon existing U.S. federal tax law, which is subject to differing interpretations or change, possibly with retroactive effect. No ruling has been sought from the U.S. Internal Revenue Service, or the IRS, with respect
to any U.S. federal income tax consequences described below, and there can be no assurance that the IRS or a court will not take a contrary position. This discussion does not address the U.S. federal estate, gift, Medicare, and alternative minimum
tax considerations, certain information reporting requirements pursuant to section 1471 through 1474 of the Code, or any state, local, and <FONT STYLE="white-space:nowrap">non-U.S.</FONT> tax considerations, relating to the ownership or disposition
of our ADSs or ordinary shares. This discussion, moreover, does not discuss all aspects of U.S. federal income taxation that may be important to particular investors in light of their individual investment circumstances or to investors subject to
special tax situations such as: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">banks and other financial institutions; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">insurance companies; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">pension plans; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">cooperatives; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">regulated investment companies; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">real estate investment trusts; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">broker-dealers; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">305 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">traders in securities that elect to use a
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">mark-to-market</FONT></FONT> method of accounting; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">certain former U.S. citizens or long-term residents; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT STYLE="white-space:nowrap">tax-exempt</FONT> entities (including private foundations);
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">investors who are not U.S. Holders; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">investors who own (directly, indirectly or constructively) 10% or more of our stock (by vote or value);
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">investors who acquire their ADSs or ordinary shares pursuant to any employee share option or otherwise as
compensation; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">investors that will hold their ADSs or ordinary shares as part of a straddle, hedge, conversion, constructive
sale or other integrated transaction for U.S. federal income tax purposes; or </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">investors that have a functional currency other than the U.S. dollar; </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">all of whom may be subject to tax rules that differ significantly from those discussed below. Each U.S. Holder is urged to consult its tax advisor regarding
the U.S. federal, state, local and <FONT STYLE="white-space:nowrap">non-U.S.</FONT> income and other tax considerations of an investment in our ADSs or ordinary shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>General </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">For purposes of this
discussion, a &#147;U.S. Holder&#148; is a beneficial owner of our ADSs or ordinary shares that is, for U.S. federal income tax purposes, (i)&nbsp;an individual who is a citizen or resident of the United States, (ii)&nbsp;a corporation (or other
entity treated as a corporation for U.S. federal income tax purposes) created in, or organized under the law of, the United States or any state thereof or the District of Columbia, (iii)&nbsp;an estate the income of which is includible in gross
income for U.S. federal income tax purposes regardless of its source, or (iv)&nbsp;a trust (A)&nbsp;the administration of which is subject to the primary supervision of a U.S. court and which has one or more U.S. persons who have the authority to
control all substantial decisions of the trust or (B)&nbsp;that has otherwise validly elected to be treated as a U.S. person under the Code. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">If a partnership (or other entity treated as a partnership for U.S. federal income tax purposes) is a beneficial owner of our ADSs or ordinary
shares, the tax treatment of a partner in the partnership will generally depend upon the status of the partner and the activities of the partner and the partnership. Partnerships holding our ADSs or ordinary shares and their partners are urged to
consult their tax advisors regarding an investment in our ADSs or ordinary shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">For U.S. federal income tax purposes, it is generally
expected that a U.S. Holder of ADSs will be treated as the beneficial owner of the underlying shares represented by the ADSs. The remainder of this discussion assumes that a U.S. Holder of our ADSs will be treated as the beneficial owner of the
underlying shares represented by the ADSs. Accordingly, deposits or withdrawals of ordinary shares for ADSs will generally not be subject to U.S. federal income tax. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Passive Foreign Investment Company Considerations </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">A <FONT STYLE="white-space:nowrap">non-U.S.</FONT> corporation, such as our company, will be classified as a passive foreign investment
company, or, or PFIC, for U.S. federal income tax purposes for any taxable year if either (i) 75% or more of its gross income for such year consists of certain types of &#147;passive&#148; income or (ii) 50% or more of the value of its assets
(generally determined on the basis of a quarterly average) during such year is attributable to assets that </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">306 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
produce or are held for the production of passive income. For this purpose, cash and assets readily convertible into cash are each categorized as a passive asset and the company&#146;s goodwill
and other unbooked intangibles are taken into account. Passive income generally includes, among other things, dividends, interest, rents, royalties, and gains from the disposition of passive assets. We will be treated as owning a proportionate share
of the assets and earning a proportionate share of the income of any other corporation in which we own, directly or indirectly, 25% or more (by value) of the stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">No assurance can be given with respect to our PFIC status for the current taxable year or any future taxable year. The determination of
whether we are or will become a PFIC is uncertain, because it is a fact-intensive inquiry made on an annual basis that depends, in part, on the composition of our income and assets. Fluctuations in the market price of our ADSs may cause us to become
a PFIC for the current or subsequent taxable years because the value of our assets for the purpose of the asset test may be determined by reference to the market price of our ADSs from time to time (which may be volatile for biopharmaceutical
companies, such as ours, that have not yet achieved commercialization with respect to any of their products). The composition of our income and assets may also be affected by how, and how quickly, we use our liquid assets. Under circumstances where
our revenue from activities that produce passive income increases relative to our revenue from activities that produce <FONT STYLE="white-space:nowrap">non-passive</FONT> income, or where we determine not to deploy cash for active purposes, our risk
of becoming classified as a PFIC will substantially increase. In addition, because there are uncertainties in the application of the relevant rules, it is possible that the IRS may challenge our classification of certain income and assets as <FONT
STYLE="white-space:nowrap">non-passive</FONT> or our valuation of our tangible and intangible assets, each of which may result in our being or becoming a PFIC for the current or subsequent taxable years. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The discussion below under &#147;&#151;Dividends&#148; and &#147;&#151;Sale or Other Disposition of ADSs or Ordinary Shares&#148; is written
on the basis that we will not be classified as a PFIC for U.S. federal income tax purposes. The U.S. federal income tax rules that apply if we are treated as a PFIC are generally discussed below under &#147;&#151;Passive Foreign Investment Company
Rules.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Dividends </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Subject to the discussion below under &#147;&#151;Passive Foreign Investment Company Rules,&#148; any cash distributions (including the amount
of any tax withheld) paid on our ADSs or ordinary shares out of our current or accumulated earnings and profits, as determined under U.S. federal income tax principles, will generally be includible in the gross income of a U.S. Holder as dividend
income on the day actually or constructively received by the U.S. Holder. Because we do not intend to determine our earnings and profits on the basis of U.S. federal income tax principles, any distribution we pay will generally be reported as a
&#147;dividend&#148; for U.S. federal income tax purposes. Dividends received on our ADSs or ordinary shares will not be eligible for the dividends received deduction allowed to corporations in respect of dividends received from U.S. corporations.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">A <FONT STYLE="white-space:nowrap">non-corporate</FONT> U.S. Holder will generally be subject to tax on dividend income from a
&#147;qualified foreign corporation&#148; at a lower applicable capital gains rate rather than the marginal tax rates generally applicable to ordinary income provided that certain conditions are satisfied, including that (1)&nbsp;our ADSs or
ordinary shares on which the dividends are paid are readily tradable on an established securities market in the United States, or in the event that we are deemed to be a PRC resident enterprise under the PRC tax law, we are eligible for the benefits
of the United <FONT STYLE="white-space:nowrap">States-PRC</FONT> income tax treaty (the &#147;Treaty&#148;); (2) we are neither a PFIC nor treated as such with respect to a U.S. Holder for the taxable year in which the dividend is paid and the
preceding taxable year, and (3)&nbsp;certain holding period requirements are met. The ADSs are listed on the Nasdaq Global Market. We believe that the ADSs are readily tradable on an established securities market in the United States, and that we
will be a qualified foreign corporation with respect to dividends paid on the ADSs. Since we do not expect that our ordinary shares will be listed on an established securities market, we do not believe that dividends that we pay on our ordinary
shares that are not represented by ADSs will meet the conditions required for the reduced tax rate. There can be no assurance, however, that our ADSs will continue to be considered readily tradable on an established securities market in later years.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">307 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In the event that we are deemed to be a PRC resident enterprise under the PRC Enterprise
Income Tax Law, we may be eligible for the benefits of Treaty and in that case we would be treated as a qualified foreign corporation with respect to dividends paid on our ordinary shares or ADSs. Each
<FONT STYLE="white-space:nowrap">non-corporate</FONT> U.S. Holder is advised to consult its tax advisors regarding the availability of the reduced tax rate applicable to qualified dividend income for any dividends we pay with respect to our ADSs or
ordinary shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Dividends will generally be treated as income from foreign sources for U.S. foreign tax credit purposes and will
generally constitute passive category income. In the event that we are deemed to be a PRC resident enterprise under the PRC Enterprise Income Tax Law, a U.S. Holder may be subject to PRC withholding taxes on dividends paid on our ADSs or ordinary
shares. See &#147;&#151;PRC Taxation&#148; above. In that case, depending on the U.S. Holder&#146;s individual facts and circumstances, a U.S. Holder may be eligible, subject to a number of complex limitations, to claim a foreign tax credit not in
excess of any applicable treaty rate in respect of any foreign withholding taxes imposed on dividends received on our ADSs or ordinary shares. A U.S. Holder who does not elect to claim a foreign tax credit for foreign tax withheld may instead claim
a deduction, for U.S. federal income tax purposes, in respect of such withholding, but only for a year in which such holder elects to do so for all creditable foreign income taxes. The rules governing the foreign tax credit are complex and their
outcome depends in large part on the U.S. Holder&#146;s individual facts and circumstances. Accordingly, U.S. Holders are urged to consult their tax advisors regarding the availability of the foreign tax credit under their particular circumstances.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Sale or Other Disposition of ADSs or Ordinary Shares </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Subject to the discussion below under &#147;&#150;&#150;Passive Foreign Investment Company Rules,&#148; a U.S. Holder will generally recognize
capital gain or loss upon the sale or other disposition of ADSs or ordinary shares in an amount equal to the difference between the amount realized upon the disposition and the holder&#146;s adjusted tax basis in such ADSs or ordinary shares. Any
capital gain or loss will be long-term if the ADSs or ordinary shares have been held for more than one year and will generally be U.S. source gain or loss for U.S. foreign tax credit purposes. Long-term capital gain of
<FONT STYLE="white-space:nowrap">non-corporate</FONT> U.S. Holders is generally eligible for a reduced rate of taxation. The deductibility of a capital loss may be subject to limitations. In the event that we are treated as a PRC resident enterprise
under the Enterprise Income Tax Law and gain from the disposition of the ADSs or ordinary shares is subject to tax in China, a U.S. Holder that is eligible for the benefits of the Treaty may elect to treat the gain as PRC source income. If a U.S.
Holder is not eligible for the benefits of the Treaty or fails to make the election to treat any gain as foreign source, then such U.S. Holder may not be able to use the foreign tax credit arising from any PRC tax imposed on the disposition of the
ADSs or ordinary shares unless such credit can be applied (subject to applicable limitations) against U.S. federal income tax due on other income derived from foreign sources in the same income category (generally, the passive category). U.S.
Holders are urged to consult their tax advisors regarding the tax consequences if a foreign tax is imposed on a disposition of our ADSs or ordinary shares, including the availability of the foreign tax credit under their particular circumstances and
the election to treat any gain as PRC source income. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Passive Foreign Investment Company Rules </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">If we are classified as a PFIC for any taxable year during which a U.S. Holder holds our ADSs or ordinary shares, and unless the U.S. Holder
makes a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">mark-to-market</FONT></FONT> election (as described below), the U.S. Holder will generally be subject to special tax rules that have a penalizing effect, regardless of whether
we remain a PFIC, on (i)&nbsp;any excess distribution that we make to the U.S. Holder (which generally means any distribution paid during a taxable year to a U.S. Holder that is greater than 125&nbsp;percent of the average annual distributions paid
in the three preceding taxable years or, if shorter, the U.S. Holder&#146;s holding period for the ADSs or ordinary shares), and (ii)&nbsp;any gain realized on the sale or other disposition (including, under certain circumstances, a pledge) of ADSs
or ordinary shares. Under the PFIC rules: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the excess distribution or gain will be allocated ratably over the U.S. Holder&#146;s holding period for the ADSs
or ordinary shares; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">308 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the amount allocated to the current taxable year and any taxable years in the U.S. Holder&#146;s holding period
prior to the first taxable year in which we are classified as a PFIC (each, a <FONT STYLE="white-space:nowrap">&#147;pre-PFIC</FONT> year&#148;), will be taxable as ordinary income; and </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the amount allocated to each prior taxable year, other than a <FONT STYLE="white-space:nowrap">pre-PFIC</FONT>
year, will be subject to tax at the highest tax rate in effect for individuals or corporations, as appropriate, for that year, increased by an additional tax equal to the interest on the resulting tax deemed deferred with respect to each such
taxable year </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">If we are a PFIC for any taxable year during which a U.S. Holder holds our ADSs or ordinary shares and any
of our subsidiaries is also a PFIC, such U.S. Holder would be treated as owning a proportionate amount (by value) of the shares of the lower-tier PFIC for purposes of the application of these rules. U.S. Holders are urged to consult their tax
advisors regarding the application of the PFIC rules to any of our subsidiaries. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">As an alternative to the foregoing rules, a U.S. Holder
of &#147;marketable stock&#148; (as defined below) in a PFIC may make a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">mark-to-market</FONT></FONT> election with respect to such stock. If a U.S. Holder makes this election, the
holder will generally (i)&nbsp;include as ordinary income for each taxable year that we are a PFIC the excess, if any, of the fair market value of ADSs held at the end of the taxable year over the adjusted tax basis of such ADSs and (ii)&nbsp;deduct
as an ordinary loss the excess, if any, of the adjusted tax basis of the ADSs over the fair market value of such ADSs held at the end of the taxable year, but such deduction will only be allowed to the extent of the amount previously included in
income as a result of the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">mark-to-market</FONT></FONT> election. The U.S. Holder&#146;s adjusted tax basis in the ADSs would be adjusted to reflect any income or loss resulting from
the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">mark-to-market</FONT></FONT> election. If a U.S. Holder makes a <FONT STYLE="white-space:nowrap">mark-to-market</FONT> election in respect of a corporation classified as a PFIC
and such corporation ceases to be classified as a PFIC, the holder will not be required to take into account the gain or loss described above during any period that such corporation is not classified as a PFIC. If a U.S. Holder makes a <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">mark-to-market</FONT></FONT> election, any gain such U.S. Holder recognizes upon the sale or other disposition of our ADSs in a year when we are a PFIC will be treated as ordinary income
and any loss will be treated as ordinary loss, but such loss will only be treated as ordinary loss to the extent of the net amount previously included in income as a result of the
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">mark-to-market</FONT></FONT> election. If a U.S. Holder makes a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">mark-to-market</FONT></FONT> election it will be
effective for the taxable year for which the election is made and all subsequent taxable years unless the ADSs are no longer treated as marketable stock or the IRS consents to the revocation of the election. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">mark-to-market</FONT></FONT> election is available only for
&#147;marketable stock,&#148; which is stock that is regularly traded on a qualified exchange or other market, as defined in applicable United States Treasury Regulations. We believe that the ADSs, but not our ordinary shares, will be treated as
marketable stock because the ADSs are listed on the Nasdaq Global Market. However, we cannot guarantee that our ADSs will continue to be listed and traded on the Nasdaq Global Market. Furthermore, while we anticipate that our ADSs should qualify as
being regularly traded, but no assurances may be given in this regard. Because a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">mark-to-market</FONT></FONT> election cannot be made for any lower-tier PFICs that we may own, a U.S.
Holder may continue to be subject to the PFIC rules with respect to such U.S. Holder&#146;s indirect interest in any investments held by us that are treated as an equity interest in a PFIC for U.S. federal income tax purposes. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We do not intend to provide information necessary for U.S. Holders to make qualified electing fund elections which, if available, would result
in tax treatment different from the general tax treatment for PFICs described above. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">If a U.S. Holder owns our ADSs or ordinary shares
during any taxable year that we are a PFIC, the holder must generally file an annual IRS Form 8621. Each U.S. Holder is urged to consult its tax advisor concerning the U.S. federal income tax consequences of purchasing, holding and disposing ADSs or
ordinary shares if we are or become a PFIC, including the possibility of making a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">mark-to-market</FONT></FONT> election. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">309 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom98473_22"></A>PLAN OF DISTRIBUTION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The selling shareholders identified in this prospectus may offer, from time to time, up to 25,123,751 ordinary shares, including ordinary
shares represented by ADSs. Each ten (10)&nbsp;ADSs represent twenty-three (23)&nbsp;of our ordinary shares, par value US$0.0001 per share. The selling shareholders identified in this prospectus are party to the subscription agreements we entered
into with them in September 2020. Registration of such ordinary shares covered by this prospectus does not mean, however, that such ordinary shares or the ADSs representing such ordinary shares necessarily will be offered or sold. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The selling shareholders and their successors, including their transferees, may sell all or a portion of our ordinary shares or ADSs directly
to purchasers or through underwriters, broker-dealers or agents, who may receive compensation in the form of discounts, concessions or commissions from the selling shareholders or the purchasers of our ordinary shares or ADSs. These discounts,
concessions or commissions as to any particular underwriter, broker-dealer or agent may be in excess of those customary in the types of transactions involved. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our ordinary shares or ADSs may be sold in one or more transactions on any national securities exchange or quotation service on which our
ordinary shares or ADSs may be listed or quoted at the time of sale, in the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">over-the-counter</FONT></FONT> market or in transactions otherwise than on these exchanges or systems or in
the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">over-the-counter</FONT></FONT> market and in one or more transactions at fixed prices, at prevailing market prices at the time of sale, at varying prices determined at the time of
sale or at negotiated prices. These sales may be effected in transactions, which may involve crosses or block transactions. Additionally, the selling shareholders may enter into derivative transactions with third parties, or sell securities not
covered by this prospectus to third parties in privately negotiated transactions. The selling shareholders may use any one or more of the following methods when selling our ordinary shares or ADSs: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">on any national securities exchange or quotation service on which our ordinary shares or ADSs may be listed or
quoted at the time of sale, including Nasdaq; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">in the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">over-the-counter</FONT></FONT> market;
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">in transactions otherwise than on these exchanges or services or in the <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">over-the-counter</FONT></FONT> market; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">through the writing or settlement of options or other hedging transactions, whether the options are listed on an
options exchange or otherwise; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">ordinary brokerage transactions and transactions in which the broker-dealer solicits purchasers;
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">block trades in which the broker-dealer will attempt to sell our ordinary shares or ADSs as agent but may
position and resell a portion of the block as principal to facilitate the transaction; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">purchases by a broker-dealer as principal and resale by the broker-dealer for its account; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an exchange distribution in accordance with the rules of the applicable exchange; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">debt-for-equity</FONT></FONT> exchange;
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">privately negotiated transactions; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">settlement of short sales entered into after the effective date of the registration statement of which this
prospectus forms a part; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">310 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">broker-dealers may agree with the selling shareholders to sell a specified number of such ordinary shares or ADSs
at a stipulated price per share; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a combination of any such methods of sale; and </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any other method permitted pursuant to applicable law. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The selling shareholders may offer our ordinary shares or ADSs to the public through underwriting syndicates represented by managing
underwriters or through underwriters without an underwriting syndicate. If underwriters are used for the sale of our ordinary shares or ADSs, the securities will be acquired by the underwriters for their own account. The underwriters may resell our
ordinary shares or ADSs in one or more transactions, including in negotiated transactions at a fixed public offering price or at varying prices determined at the time of sale. In connection with any such underwritten sale of our ordinary shares or
ADSs, underwriters may receive compensation from the selling shareholders, for whom they may act as agents, in the form of discounts, concessions or commissions. Underwriters may sell our ordinary shares or ADSs to or through dealers, and the
dealers may receive compensation in the form of discounts, concessions or commissions from the underwriters or commissions from the purchasers for whom they may act as agents. Such compensation may be in excess of customary discounts, concessions or
commissions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">If underwriters are used for the sale of our ordinary shares or ADSs, to the extent required by law, the names of the
underwriters will be set forth in the prospectus or prospectus supplement used by the underwriters to sell those securities. The selling shareholders may use underwriters with whom we or the selling shareholders have a material relationship. We will
describe the nature of such relationship in any applicable prospectus supplement naming the underwriter or underwriters. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">If underwriters
are used for the sale of our ordinary shares or ADSs, unless otherwise indicated in the prospectus or prospectus supplement relating to a particular offering of our ordinary shares or ADSs, the obligations of any underwriters to purchase the
securities will be subject to customary conditions precedent, and the underwriters will be obligated to purchase all of the securities offered if any of the securities are purchased. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">If underwriters are used for the sale of our ordinary shares or ADSs, in connection with such offering, the underwriters may advise us that
they may engage in stabilizing transactions, which involves making bids for, purchasing and selling our ADSs in the open market for the purpose of preventing or retarding a decline in the market price of our ADSs while this offering is in progress.
These stabilizing transactions may include making short sales of our ADSs, which involves the sale by the underwriters of a greater number of ADSs than they are required to purchase in this offering, and purchasing ADSs on the open market to cover
positions created by short sales. Short sales may be &#147;covered&#148; shorts, which are short positions in an amount not greater than the underwriters&#146; option to purchase additional ADSs referred to above, or may be &#147;naked&#148; shorts,
which are short positions in excess of that amount. The underwriters may close out any covered short position either by exercising their option to purchase additional ADSs, in whole or in part, or by purchasing our ADSs in the open market. In making
this determination, the underwriters will consider, among other things, the price of our ADSs available for purchase in the open market compared to the price at which the underwriters may purchase our ADSs through the option to purchase additional
ADSs. A naked short position is more likely to be created if the underwriters are concerned that there may be downward pressure on the price of our ADSs in the open market that could adversely affect investors who purchase in this offering. To the
extent that the underwriters create a naked short position, they will purchase our ADSs in the open market to cover the position. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The
anti-manipulation rules of Regulation M under the Exchange Act may apply to sales of our ADSs pursuant to this prospectus and any applicable prospectus supplement and to the activities of the selling shareholders. In addition, we will make copies of
this prospectus and any applicable prospectus supplement available to the selling shareholders for the purpose of satisfying the prospectus delivery requirements of the Securities Act. To the extent applicable, Regulation M may also restrict the
ability of any person engaged in the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">311 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
distribution of our ADSs to engage in market-making activities with respect to the common stock. All of the foregoing may affect the marketability of our ADSs and the ability of any person or
entity to engage in market-making activities with respect to our ADSs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In addition, any securities that qualify for sale pursuant to Rule
144 or Regulation S under the Securities Act or under Section&nbsp;4(1) under the Securities Act may be sold under such rules rather than pursuant to this prospectus or a prospectus supplement. The selling shareholders may enter into hedging
transactions with broker-dealers, which may in turn engage in short sales of our ordinary shares or ADSs in the course of hedging the positions they assume. The selling shareholders may also sell short our ordinary shares or ADSs and deliver our
ordinary shares or ADSs to close out short positions, or loan or pledge our ordinary shares or ADSs to broker-dealers that in turn may sell these ordinary shares or ADSs. The selling shareholders may also enter into option or other transactions with
broker-dealers or other financial institutions or the creation of one or more derivative securities that require the delivery to such broker-dealer or other financial institution of our ordinary shares or ADSs offered by this prospectus and any
applicable prospectus supplement, which our ordinary shares or ADSs such broker-dealer or other financial institution may resell pursuant to this prospectus and any applicable prospectus supplement. The selling shareholders also may transfer and
donate our ordinary shares or ADSs in other circumstances in which case the transferees, donees, pledgees or other successors in interest will be the selling beneficial owners for purposes of this prospectus and any applicable prospectus supplement.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The aggregate proceeds to the selling shareholders from the sale of our ordinary shares or ADSs will be the purchase price of our
ordinary shares or ADSs less discounts and commissions, if any. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In offering our ordinary shares or ADSs covered by this prospectus and
any applicable prospectus supplement, the selling shareholders and any broker-dealers who execute sales for the selling shareholders may be deemed to be &#147;underwriters&#148; within the meaning of Section&nbsp;2(a)(11) of the Securities Act in
connection with such sales. Any profits realized by the selling shareholders and the compensation of any broker-dealer may be deemed to be underwriting discounts and commissions. Selling shareholders who are &#147;underwriters&#148; within the
meaning of Section&nbsp;2(a)(11) of the Securities Act will be subject to the prospectus delivery requirements of the Securities Act and may be subject to certain statutory and regulatory liabilities, including liabilities imposed pursuant to
Sections 11, 12 and 17 of the Securities Act and Rule <FONT STYLE="white-space:nowrap">10b-5</FONT> under the Exchange Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In order to
comply with the securities laws of certain states, if applicable, our ordinary shares or ADSs must be sold in such jurisdictions only through registered or licensed brokers or dealers. In addition, in certain states our ordinary shares or ADSs may
not be sold unless the ordinary shares or ADSs are registered or qualified for sale in the applicable state or an exemption from the registration or qualification requirement is available and is complied with. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">There can be no assurance that the selling shareholders will sell any or all of our ordinary shares or ADSs registered pursuant to the
registration statement of which this prospectus forms a part. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">At the time a particular offering of our ordinary shares or ADSs is made, a
prospectus supplement, if required, will be distributed, which will set forth the names of the selling shareholders, the aggregate amount of our ordinary shares or ADSs being offered by the selling shareholders and the terms of the offering,
including, to the extent required, (1)&nbsp;the name or names of any underwriters, broker-dealers or agents, (2)&nbsp;any discounts, commissions and other terms constituting compensation from the selling shareholders and (3)&nbsp;any discounts,
commissions or concessions allowed or reallowed to be paid to broker-dealers. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Agents and underwriters and their respective affiliates may
engage in transactions with, or perform services for us in the ordinary course of business for which they may receive customary fees and reimbursement of expenses. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The estimated offering expenses payable by the selling shareholders, in addition to any underwriting discounts and commissions that will be
paid by the selling shareholders, will be described in any applicable prospectus supplement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">312 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom98473_23"></A>EXPENSES RELATED TO THIS OFFERING </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Set forth below is an itemization of the total expenses, excluding underwriting discounts and commissions, that we expect to incur in
connection with this offering. With the exception of the SEC registration fee, all amounts are&nbsp;estimates. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="87%"></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SEC Registration Fee</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">US$</TD>
<TD VALIGN="bottom" ALIGN="right">45,375</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Legal Fees and Expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">US$</TD>
<TD VALIGN="bottom" ALIGN="right">440,364</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounting Fees and Expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">US$</TD>
<TD VALIGN="bottom" ALIGN="right">76,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Miscellaneous</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">US$</TD>
<TD VALIGN="bottom" ALIGN="right">15,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>US$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>577,239</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">313 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom98473_24"></A>LEGAL MATTERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We are being represented by Skadden, Arps, Slate, Meagher&nbsp;&amp; Flom LLP with respect to certain legal matters as to United States
federal securities and New York State law. The validity of the ordinary shares represented by the ADSs to be sold in this offering will be passed upon for us by Conyers Dill&nbsp;&amp; Pearman. Certain legal matters as to PRC law will be passed upon
for us by JunHe LLP. Skadden, Arps, Slate, Meagher&nbsp;&amp; Flom LLP may rely upon Conyers Dill&nbsp;&amp; Pearman with respect to matters governed by Cayman Islands law and JunHe LLP with respect to matters governed by PRC law. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">314 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom98473_25"></A>EXPERTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The financial statements as of December&nbsp;31, 2017, 2018 and 2019 and for each of the three years in the period ended December&nbsp;31,
2019 included in this prospectus have been so included in reliance on the report of PricewaterhouseCoopers Zhong Tian LLP, an independent registered public accounting firm, given on the authority of said firm as experts in auditing and accounting.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The office of PricewaterhouseCoopers Zhong Tian LLP is located at 11th Floor, PricewaterhouseCoopers Center, Link Square 2, 202 Hu Bin
Road, Shanghai, the People&#146;s Republic of China. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">315 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom98473_26"></A>WHERE YOU CAN FIND ADDITIONAL INFORMATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We have filed a registration statement, including relevant exhibits, with the SEC on Form <FONT STYLE="white-space:nowrap">F-1</FONT> under
the Securities Act with respect to the underlying ordinary shares represented by the ADSs being registered by this prospectus. We have also filed a related registration statement on Form <FONT STYLE="white-space:nowrap">F-6</FONT> with the SEC to
register the ADSs. This prospectus, which constitutes a part of the registration statement on Form <FONT STYLE="white-space:nowrap">F-1,</FONT> does not contain all of the information contained in the registration statement. You should read our
registration statements and their exhibits and schedules for further information with respect to us, our ordinary shares and our ADSs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We
are subject to periodic reporting and other informational requirements of the Exchange Act as applicable to foreign private issuers. Accordingly, we are required to file reports, including annual reports on Form
<FONT STYLE="white-space:nowrap">20-F,</FONT> and other information with the SEC. The SEC maintains an internet site at <U>http://www.sec.gov</U> that contains reports, proxy and information statements, and other information regarding issuers that
file electronically with the SEC. We maintain our website at <U><FONT STYLE="white-space:nowrap">http://www.i-mabbiopharma.com/en/</FONT></U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">As a foreign private issuer, we are exempt under the Exchange Act from, among other things, the rules prescribing the furnishing and content
of proxy statements, and our executive officers, directors, principal shareholders and selling shareholders are exempt from the reporting and short-swing profit recovery provisions contained in Section&nbsp;16 of the Exchange Act. In addition, we
are not required under the Exchange Act to file periodic reports and financial statements with the SEC as frequently or as promptly as U.S. companies whose securities are registered under the Exchange Act. However, we intend to furnish the
depositary with our annual reports, which will include a review of operations and annual audited consolidated financial statements prepared in conformity with U.S. GAAP, and all notices of shareholders&#146; meetings and other reports and
communications that are made generally available to our shareholders. The depositary will make such notices, reports and communications available to holders of ADSs and, if we so request, will mail to all record holders of ADSs the information
contained in any notice of a shareholders&#146; meeting received by the depositary from us. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">316 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>I-Mab </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="index"></A><A NAME="rom98473_27"></A>INDEX TO CONSOLIDATED FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Consolidated Financial Statements for the Years Ended December 31, 2018 and 2019 </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="95%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Page</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin98473_1">Report of Independent Registered Public Accounting Firm</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">F-2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin98473_2">Consolidated Balance Sheets as of December&nbsp;31, 2018 and
2019</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">F-3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin98473_3">Consolidated Statements of Comprehensive Loss for the Years Ended December&nbsp;31,
 2017, 2018 and 2019</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">F-5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin98473_4">Consolidated Statements of Changes in Shareholders&#146; Deficit for the Years
 Ended December&nbsp;31, 2017, 2018 and 2019</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">F-6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin98473_5">Consolidated Statements of Cash Flows for the Years Ended December&nbsp;
31, 2017, 2018 and 2019</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">F-7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin98473_6">Notes to the Consolidated Financial Statements</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">F-9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Unaudited Interim Condensed Consolidated Financial Statements for the Six Months Ended June&nbsp;30, 2019 and 2020 </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="95%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Page</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin98473_7">Consolidated Balance Sheet as of December 31, 2019 and Unaudited Interim Condensed
 Consolidated Balance Sheet as of June 30, 2020</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">F-68</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin98473_8">Unaudited Interim Condensed Consolidated Statements of Comprehensive Loss for the
 Six Months Ended June&nbsp;30, 2019 and 2020</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">F-70</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin98473_9">Unaudited Interim Condensed Consolidated Statements of Changes in Shareholders&#146;
 Equity (Deficit) for the Six Months Ended June&nbsp;30, 2019 and 2020</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">F-71</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin98473_10">Unaudited Interim Condensed Consolidated Statements of Cash Flows for the Six
 Months Ended June&nbsp;30, 2019 and 2020</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">F-72</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin98473_11">Notes to the Unaudited Interim Condensed Consolidated Financial
Statements</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">F-74</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin98473_1"></A>REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To the<B> </B>Board of Directors and Shareholders of I-Mab </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Opinion on the Financial Statements </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We
have audited the accompanying consolidated balance sheets of I-Mab and its subsidiaries (the &#147;Company&#148;) as of December 31, 2019 and 2018, and the related consolidated statements of comprehensive loss, of changes in shareholders&#146;
deficit and of cash flows for each of the three years in the period ended December 31, 2019, including the related notes (collectively referred to as the &#147;consolidated financial statements&#148;). In our opinion, the consolidated financial
statements present fairly, in all material respects, the financial position of the Company as of December 31, 2019 and 2018, and the results of its operations and its cash flows for each of the three years in the period ended December 31, 2019 in
conformity with accounting principles generally accepted in the United States of America. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Basis for Opinion </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">These consolidated financial statements are the responsibility of the Company&#146;s management. Our responsibility is to express an opinion
on the Company&#146;s consolidated financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (&#147;PCAOB&#148;) and are required to be independent with
respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We conducted our audits of these consolidated financial statements in accordance with the standards of the PCAOB. Those standards require that
we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our audits included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due
to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included
evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that our audits provide a reasonable basis for our opinion.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">/s/PricewaterhouseCoopers Zhong Tian LLP </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Shanghai, the
People&#146;s Republic of China </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">April 29, 2020 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have
served as the Company&#146;s auditor since 2018. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">I-MAB</FONT> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin98473_2"></A>Consolidated Balance Sheets </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>As of December&nbsp;31, 2018 and 2019 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(All amounts in thousands, except for share and per share data, unless otherwise noted) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" ALIGN="center">


<TR>

<TD WIDTH="69%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>As&nbsp;of&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Notes</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>RMB</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>RMB</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>US$</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>(Note&nbsp;2.5)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><B>Assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD COLSPAN="5" VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><B>Current&nbsp;assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,588,278</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,137,473</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">160,999</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Restricted cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">9</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">92,653</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">55,810</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,899</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Contract assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">18</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Short-term investments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">2.8</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">32,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,529</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Prepayments and other receivables</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">3</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">88,972</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">136,036</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,255</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Other financial assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">2.4,&nbsp;4</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">255,958</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><B>Total current assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,036,861</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,361,319</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">192,682</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Property, equipment and software</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">5</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27,659</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30,069</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,256</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Operating lease
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT> assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">6</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,435</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,326</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Intangible assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">7</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">148,844</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">148,844</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21,068</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Goodwill</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">8</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">162,574</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">162,574</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23,011</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Other <FONT STYLE="white-space:nowrap">non-current</FONT> assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,331</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,594</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><B>Total assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>2,375,938</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1,737,572</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>245,937</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><B>Liabilities, mezzanine equity and shareholders&#146; equity (deficit)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><B>Current liabilities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Short-term borrowings</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">9</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">80,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,078</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Accruals and other payables</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">10</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">67,674</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">273,553</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">38,719</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Advance from customers</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">18</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,151</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Operating lease liabilities, current</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">6</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,807</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">963</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Research and development funding received</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">23</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">178,715</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Ordinary shares to be issued to Everest</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">23</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">258,119</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">36,534</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Warrant liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">2.4,&nbsp;15</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,618</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><B>Total current liabilities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">346,158</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">588,479</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">83,294</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Convertible promissory notes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">14</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">67,026</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">68,199</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,652</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Operating lease liabilities, <FONT STYLE="white-space:nowrap">non-current</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">6</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,492</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,060</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Deferred subsidy income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">2.13</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,920</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">555</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><B>Total liabilities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>415,684</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>668,090</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>94,561</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Commitments and contingencies</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">22</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">I-MAB</FONT> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Consolidated Balance Sheets&nbsp;(Continued) </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>As of December&nbsp;31, 2018 and 2019 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(All amounts in thousands, except for share and per share data, unless otherwise noted) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" ALIGN="center">


<TR>

<TD WIDTH="69%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>As&nbsp;of&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Notes</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>RMB</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>RMB</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>US$</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>(Note&nbsp;2.5)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><B>Mezzanine equity</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Series A convertible preferred shares (US$0.0001 par value, 30,227,056 shares authorized, issued
and outstanding on an actual basis as of December&nbsp;31, 2018 and 2019)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">13</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">687,482</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">687,482</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">97,307</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Series B convertible preferred shares (US$0.0001 par value, 30,305,212 shares authorized, issued
and outstanding on an actual basis as of December 31, 2018 and 2019)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">13</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">921,243</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">921,243</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">130,393</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Series C convertible preferred shares (US$0.0001 par value, 31,046,360 shares authorized, issued
and outstanding on an actual basis as of December&nbsp;31, 2018 and 2019)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">13</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,306,633</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,306,633</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">184,942</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Series <FONT STYLE="white-space:nowrap">C-1</FONT> convertible preferred shares (US$0.0001 par
value, nil and 3,857,143 shares authorized, issued and outstanding on an actual basis as of December&nbsp;31, 2018 and 2019, respectively)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">13</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">188,819</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26,726</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><B>Total mezzanine equity</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>2,915,358</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>3,104,177</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>439,368</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><B>Shareholders&#146;&nbsp;equity (deficit)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Ordinary shares (US$0.0001 par value, 500,000,000 shares authorized as of December&nbsp;31, 2018
and 2019; 8,363,719 shares issued and outstanding as of December&nbsp;31, 2018 and 2019 </P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-size:9pt">12</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9pt">6</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9pt">6</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9pt">1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Treasury stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9pt">(1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9pt">)&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9pt">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9pt">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Additional <FONT STYLE="white-space:nowrap">paid-in</FONT> capital</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9pt">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9pt">389,379</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9pt">55,113</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Accumulated other comprehensive income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9pt">59,380</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9pt">70,127</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9pt">9,926</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Accumulated deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9pt">(1,014,489</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9pt">)&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9pt">(2,494,207</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9pt">)&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9pt">(353,032</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9pt">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><B>Total shareholders&#146; equity (deficit)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9pt"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9pt"><B>(955,104</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9pt"><B>)&nbsp;</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9pt"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9pt"><B>(2,034,695</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9pt"><B>)&nbsp;</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9pt"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9pt"><B>(287,992</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9pt"><B>)&nbsp;</B></FONT></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><B>Total liabilities, mezzanine equity and shareholders&#146; equity (deficit)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9pt"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9pt"><B>2,375,938</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9pt"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9pt"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9pt"><B>1,737,572</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9pt"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9pt"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9pt"><B>245,937</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9pt"><B>&nbsp;</B></FONT></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">The accompanying notes are an integral part of these consolidated financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">I-MAB</FONT> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin98473_3"></A>Consolidated Statements of Comprehensive Loss </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>For the Years Ended December&nbsp;31, 2017, 2018 and 2019 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(All amounts in thousands, except for share and per share data, unless otherwise noted) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="54%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Year&nbsp;Ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Notes</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>RMB</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>RMB</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>RMB</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>US$</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>(Note&nbsp;2.5)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Revenues</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Licensing and collaboration revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">18</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,556</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">53,781</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,246</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Expenses</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">2.16</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(267,075</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(426,028</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(840,415</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(118,953</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Administrative expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(25,436</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(66,391</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(654,553</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(92,646</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Loss from operations</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(280,955</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(438,638</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(1,464,968</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(207,353</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">858</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,597</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30,570</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,327</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5,643</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(11,695</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,991</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(423</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other income (expenses), net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">19</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,527</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(16,780</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(20,205</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,860</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fair value change of warrants</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">2.4</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(14,027</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">61,405</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,644</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">799</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Loss before income tax expense</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(298,240</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(401,111</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(1,451,950</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(205,510</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income tax expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">11</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,722</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net loss attributable to <FONT STYLE="white-space:nowrap">I-MAB</FONT></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(298,240</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(402,833</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(1,451,950</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(205,510</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deemed dividend to Series C-1 preferred shareholders at extinguishment of Series <FONT
STYLE="white-space:nowrap">C-1</FONT> Preferred Shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">20</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5,283</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(748</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deemed dividend to Series B-1, B-2 and C preferred shareholders at modification of
Series&nbsp;B-1, <FONT STYLE="white-space:nowrap">B-2</FONT> and C Preferred Shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">20</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(27,768</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,930</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net loss attributable to ordinary shareholders</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(298,240</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(402,833</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(1,485,001</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(210,188</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"><B>Net loss attributable to <FONT STYLE="white-space:nowrap">I-MAB</FONT></B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(298,240</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(402,833</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(1,451,950</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(205,510</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Other comprehensive income:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Foreign currency translation adjustments, net of nil tax</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,918</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">53,689</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,747</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,521</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total comprehensive loss attributable to
<FONT STYLE="white-space:nowrap">I-MAB</FONT></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(292,322</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(349,144</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(1,441,203</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(203,989</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net loss attributable to ordinary shareholders</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(298,240</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(402,833</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(1,485,001</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(210,188</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted-average number of ordinary shares used in calculating net loss per share&#151;basic and
diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">20</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,742,669</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,529,092</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,381,230</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,381,230</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net loss per share attributable to ordinary shareholders</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>&#151;Basic</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">20</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(51.93</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(61.70</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(201.19</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(28.48</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>&#151;Diluted</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">20</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(51.93</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(61.70</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(201.19</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(28.48</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">The accompanying notes are an integral part of these consolidated financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">I-MAB</FONT> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin98473_4"></A>Consolidated Statements of Changes in Shareholders&#146; Deficit </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>For the Years Ended December&nbsp;31, 2017, 2018 and 2019 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(All amounts in thousands, except for share and per share data, unless otherwise noted) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" ALIGN="center">


<TR>

<TD WIDTH="41%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD ROWSPAN="3" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Ordinary&nbsp;share&nbsp;(Note&nbsp;12)</B><br><B>(US$0.001&nbsp;par&nbsp;value)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Treasury<BR>stock</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Additional<BR><FONT STYLE="white-space:nowrap">paid-in</FONT><BR>capital</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Accumulated<BR>other<BR>comprehensive<BR>income</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Accumulated<BR>deficit</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Total<BR>shareholders&#146;<BR>deficit</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Number&nbsp;of</B><br><B>shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>RMB</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>RMB</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>RMB</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>RMB</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>RMB</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>RMB</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><B>Balance as of December&nbsp;31, 2016</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>8,363,719</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>6</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(2</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>45,331</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(227</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(59,620</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(14,512</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Foreign currency translation adjustments</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,918</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,918</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(298,240</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(298,240</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Share-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,038</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,039</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><B>Balance as of December&nbsp;31, 2017</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>8,363,719</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>6</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(1</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>52,369</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>5,691</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(357,860</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(299,795</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Foreign currency translation adjustments</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">53,689</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">53,689</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(402,833</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(402,833</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Share-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,520</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,520</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Transaction with redeemable <FONT STYLE="white-space:nowrap">non-</FONT> controlling interests
(Note 16)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(55,889</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(253,796</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(309,685</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><B>Balance as of December&nbsp;31, 2018</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>8,363,719</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>6</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(1</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>59,380</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(1,014,489</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(955,104</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Foreign currency translation adjustments</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,747</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,747</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,451,950</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,451,950</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Share-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">366,894</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">366,895</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Deemed dividend to <FONT STYLE="white-space:nowrap">Series&nbsp;C-1</FONT> preferred shareholders at
extinguishment of <FONT STYLE="white-space:nowrap">Series&nbsp;C-1</FONT> Preferred Shares</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5,283</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5,283</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Deemed dividend to <FONT STYLE="white-space:nowrap">Series&nbsp;B-1,</FONT> <FONT
STYLE="white-space:nowrap">B-2</FONT> and C preferred shareholders at modification of Series <FONT STYLE="white-space:nowrap">B-1,</FONT> <FONT STYLE="white-space:nowrap">B-2</FONT> and C Preferred Shares</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27,768</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(27,768</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><B>Balance as of December&nbsp;31, 2019</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>8,363,719</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>6</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>389,379</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>70,127</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(2,494,207</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(2,034,695</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">The accompanying notes are an integral part of these consolidated financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">I-MAB</FONT> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin98473_5"></A>Consolidated Statements of Cash Flows </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>For the Years Ended December&nbsp;31, 2017, 2018 and 2019 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(All amounts in thousands, except for share and per share data, unless otherwise noted) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="62%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Year&nbsp;Ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>RMB</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>RMB</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>RMB</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>US$</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>(Note&nbsp;2.5)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Cash&nbsp;flows&nbsp;from&nbsp;operating&nbsp;activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(298,240</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(402,833</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,451,950</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(205,510</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Adjustments to reconcile net loss to net cash used in operating activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Depreciation of property, equipment and software</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,634</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,740</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,831</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,391</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss on disposal of property, equipment and software</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">79</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest expenses of convertible promissory notes and onshore convertible loans</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,835</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,963</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fair value change of warrants</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,027</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(61,405</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5,644</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(799</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fair value change of other financial assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(42</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(6</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income from other financial assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5,572</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(13,622</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Share-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,039</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,520</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">366,895</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">51,931</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss from conversion of 2017 Notes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,375</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss from conversion of onshore convertible loans</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,548</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss from issuance of 2018 Notes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,081</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss on termination agreement with Everest</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23,039</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,261</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Amortization of <FONT STYLE="white-space:nowrap">right-of</FONT> use assets and interest of lease
liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,803</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">821</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fair value change of short-term investments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(703</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(100</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Changes in operating assets and liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Contract assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(11,000</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,557</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepayments and other receivables</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,830</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(76,276</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(48,831</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(6,912</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accruals and other payables</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">408</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">55,641</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">188,375</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26,664</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Contract liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,803</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(15,803</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Advance from customers</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,151</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(14,151</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,003</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development funding received</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">178,715</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">53,148</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,523</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred subsidy income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,420</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">201</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Lease liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(6,172</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(874</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net cash used in operating activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(252,157</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(280,705</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(867,982</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(122,855</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Cash flows from investing activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash acquired from acquisition of a subsidiary</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">93,335</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Purchase of property, equipment and software</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(20,327</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(14,409</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(12,241</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,733</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds from disposal of short-term investments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">102,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,437</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Purchase of short-term investments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(134,000</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(18,966</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash paid for investments in other financial assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(369,000</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(30,000</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash received from disposal of other financial assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">133,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">40,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">256,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">36,234</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash received on income from short-term investments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">703</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash received on income from other financial assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,327</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,909</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net cash (used in) generated from investing activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(157,665</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>9,500</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>212,462</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>30,072</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">I-MAB</FONT> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Consolidated Statements of Cash Flows&nbsp;(Continued) </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>For the Years Ended December&nbsp;31, 2017, 2018 and 2019 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(All amounts in thousands, except for share and per share data, unless otherwise noted) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="64%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Year&nbsp;Ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>RMB</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>RMB</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>RMB</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>US$</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>(Note&nbsp;2.5)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Cash&nbsp;flows&nbsp;from&nbsp;financing&nbsp;activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds from issuance of convertible preferred shares, net of issuance cost</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">346,515</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,306,633</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">183,536</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25,978</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds from issuance of redeemable <FONT STYLE="white-space:nowrap">non-controlling</FONT>
interest</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">161,196</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds from issuance of convertible promissory notes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">75,970</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">59,704</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds from issuance of onshore convertible loans</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">35,341</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds from issuance of warrants</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">40,563</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds from exercise of warrants</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">132,332</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds from bank borrowings</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">99,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">80,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,077</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Repayment of bank borrowings</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(99,000</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(80,000</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(11,323</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Payment of initial public offering costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(827</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(117</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net cash generated from financing activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>758,585</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1,479,669</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>152,709</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>21,615</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Effect of exchange rate changes on cash and cash equivalents and restricted cash</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(132</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">59,754</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,163</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,146</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net increase (decrease) in cash and cash equivalents and restricted cash</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">348,631</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,268,218</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(487,648</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(69,022</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash, cash equivalents, and restricted cash, beginning of year</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">64,082</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">412,713</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,680,931</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">237,920</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash, cash equivalents, and restricted cash, end of the year</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>412,713</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1,680,931</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1,193,283</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>168,898</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Additional ASC 842 supplemental disclosures</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash paid for fixed operating lease costs included in the measurement of lease obligations in
operating activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,172</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">874</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Right-of-use</FONT></FONT>
assets obtained in exchange for operating lease obligations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,595</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,217</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Other supplemental cash flow disclosures</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest paid</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,677</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,862</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,991</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">423</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">Non-cash</FONT> activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercise of warrants</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,314</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Payables for purchase of property, equipment and software</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,346</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Payables for <FONT STYLE="white-space:nowrap">in-licensed</FONT> patent rights</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,970</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Convertible preferred shares issued for business combination</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">289,024</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued initial public offering costs payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17,504</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,478</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deemed dividend to Series C-1 preferred shareholders at extinguishment of Series C-1 Preferred
Shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,283</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">748</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deemed dividend to Series B-1, B-2 and C preferred shareholders at modification of Series B-1, B-2
and C Preferred Shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27,768</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,930</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">The accompanying notes are an integral part of these consolidated financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>I-MAB </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin98473_6"></A>Notes to the Consolidated Financial Statements </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(All amounts in thousands, except for share and per share data, unless otherwise noted) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1. Principal Activities and Organization </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">I-Mab</FONT> (the &#147;Company&#148;) was incorporated in the Cayman Islands on June&nbsp;30, 2016 as an
exempted company with limited liability under the Companies Law of the Cayman Islands. The Company and its subsidiaries (together the &#147;Group&#148;) are principally engaged in discovering and developing transformational biologics in the fields
of immuno-oncology and immuno-inflammation diseases in the People&#146;s Republic of China (the &#147;PRC&#148;) and other countries and regions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Prior to the incorporation of the Company, the Group carried out its operation in the PRC since November 2014 mainly through Third Venture
Biopharma (Nanjing) Co., Ltd. (&#147;Third Venture&#148;), which was incorporated on November&nbsp;17, 2014 in the PRC. For the purpose of introduction of overseas investors and in preparation for a listing of the Company&#146;s shares on the
overseas capital markets, the Group underwent a reorganization (the &#147;Reorganization&#148;) in 2016. The Reorganization was approved by the Board of Directors and a restructuring framework agreement was entered into by Third Venture, the
Company, and the shareholders of the Company based on Reorganization framework agreement, pursuant to which on July&nbsp;7, 2016, Third Venture transferred all of its assets and operations to the Company&#146;s wholly owned subsidiary, <FONT
STYLE="white-space:nowrap">I-Mab</FONT> Biopharma Co., Ltd. <FONT STYLE="white-space:nowrap">(&#147;I-Mab</FONT> Shanghai&#148;), which was a transaction in which shareholders had identical ownership interests before and after the transaction and
was accounted for in a manner similar to a common control transaction. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Reorganization, as described above has been accounted for at
historical cost. That Reorganization was reverse merger of Third Venture and Third Venture is the predecessor of the Company. As such, the assets and liabilities of Third Venture are consolidated in the Company&#146;s financial statements at
historical cost. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2019, the Company&#146;s principal subsidiaries are as follows: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="85.5%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Subsidiaries</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Place&nbsp;of<BR>incorporation</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Date&nbsp;of<BR>incorporation&nbsp;or<BR>acquisition</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Percentage<BR>of&nbsp;direct<BR>or&nbsp;indirect<BR>ownership<BR>by&nbsp;
the<BR>Company</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Principal&nbsp;activities</B></P></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">I-Mab</FONT> Biopharma Hong Kong Limited</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Hong&nbsp;Kong</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">July&nbsp;8, 2016</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Investment&nbsp;holding</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">I-Mab</FONT> Shanghai</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">PRC</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">August&nbsp;24,&nbsp;2016</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">100</TD>
<TD NOWRAP VALIGN="top">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Research and<BR>development of<BR>innovative medicines</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">I-Mab</FONT> <FONT STYLE="white-space:nowrap">Bio-tech</FONT>
(Tianjin) Co., Ltd. <FONT STYLE="white-space:nowrap">(&#147;I-Mab</FONT> Tianjin&#148;)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">PRC</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">July&nbsp;15, 2017</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">100</TD>
<TD NOWRAP VALIGN="top">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Research and<BR>development of<BR>innovative medicines</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">I-Mab</FONT> Biopharma US Ltd.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">U.S.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">February&nbsp;28,&nbsp;2018</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">100</TD>
<TD NOWRAP VALIGN="top">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Research and<BR>development of<BR>innovative&nbsp;medicines</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">On January 17, 2020, the Company completed its Initial Public Offering and became listed on the Nasdaq Global
Market (see Note 25 for details). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>I-MAB </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to the Consolidated Financial Statements </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(All amounts in thousands, except for share and per share data, unless otherwise noted) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2. Principal Accounting Policies </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>2.1 Basis of presentation </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The
accompanying consolidated financial statements of the Group have been prepared in accordance with the accounting principles generally accepted in the United States of America (&#147;U.S. GAAP&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Significant accounting policies followed by the Group in the preparation of the accompanying consolidated financial statements are summarized
below. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>2.2 Basis of consolidation </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The accompanying consolidated financial statements reflect the accounts of the Company and all of its subsidiaries in which a controlling
interest is maintained. All inter-company balances and transactions have been eliminated in consolidation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>2.3 Use of estimates </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions
that affect the reported amounts of assets and liabilities and the disclosures of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period.
Estimates are used when accounting for amounts recorded in connection with acquisitions, including initial fair value determinations of assets and liabilities and other intangible assets as well as subsequent fair value measurements. Additionally,
estimates are used in determining items such as useful lives of property, equipment and software, impairment of contract assets and other receivables, impairment of long-lived assets and goodwill, share-based compensation, leases, tax valuation
allowances and revenues from licensing and collaboration arrangements. Management bases the estimates on historical experience, known trends and various other assumptions that are believed to be reasonable, the results of which form the basis for
making judgments about the carrying values of assets and liabilities. Actual results could differ from those estimates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>2.4 Fair value measurements
</I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Financial assets and liabilities of the Group primarily comprise of cash and cash equivalents, restricted cash, short-term
investments, other financial assets, contract assets, other receivables, short-term borrowings, accruals and other payables and warrants liabilities. As of December&nbsp;31, 2018 and 2019, except for short-term investments, other financial assets
and warrant liabilities, the carrying values of these financial assets and liabilities approximated their fair values because of their generally short maturities. The Group reports short-term investments, other financial assets and warrant
liabilities at fair value at each balance sheet date and changes in fair value are reflected in the consolidated statements of comprehensive loss. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Group measures its financial assets and liabilities using inputs from the following three levels of the fair value hierarchy. The three
levels are as follows: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Level&nbsp;1 inputs are unadjusted quoted prices in active markets for identical assets that the management has
the ability to access at the measurement date. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>I-MAB </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to the Consolidated Financial Statements </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(All amounts in thousands, except for share and per share data, unless otherwise noted) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2. Principal Accounting Policies&nbsp;(Continued) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>2.4 Fair value measurements&nbsp;(Continued) </I></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Level&nbsp;2 inputs include quoted prices for similar assets in active markets, quoted prices
for identical or similar assets in markets that are not active, inputs other than quoted prices that are observable for the asset (i.e., interest rates, yield curves, etc.), and inputs that are derived principally from or corroborated by observable
market data by correlation or other means (market corroborated inputs). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Level&nbsp;3 includes unobservable inputs that reflect the
management&#146;s assumptions about the assumptions that market participants would use in pricing the asset. The management develops these inputs based on the best information available, including the own data.</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><I>Assets and liabilities measured at fair value on a recurring basis </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Group measured its short-term investments, other financial assets and warrant liabilities at fair value on a recurring basis. As the
Group&#146;s short-term investments, other financial assets and warrants liabilities are not traded in an active market with readily observable prices, the Group uses significant unobservable inputs to measure the fair value of short-term
investments, other financial assets and warrant liabilities. These instruments are categorized in the Level&nbsp;3 valuation hierarchy based on the significance of unobservable factors in the overall fair value measurement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The following table summarizes the Group&#146;s financial assets and liabilities measured and recorded at fair value on a recurring basis as
of December&nbsp;31, 2018 and 2019: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="85.5%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="40%"></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>As&nbsp;of&nbsp;December&nbsp;31,&nbsp;2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Active&nbsp;market<BR>(Level&nbsp;1)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Observable&nbsp;input<BR>(Level&nbsp;2)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B><FONT STYLE="white-space:nowrap">Non-</FONT></B><br><B>observable&nbsp;input<BR>(Level&nbsp;3)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>&nbsp;&nbsp;RMB&nbsp;&nbsp;</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>RMB</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>RMB</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>RMB</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Assets:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other financial assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">255,958</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">255,958</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Liabilities:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Warrant liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,618</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,618</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>As of December&nbsp;31, 2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Active&nbsp;market<BR>(Level&nbsp;1)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Observable&nbsp;input<BR>(Level 2)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B><FONT STYLE="white-space:nowrap">Non-</FONT></B><br><B>observable&nbsp;input<BR>(Level 3)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>RMB</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>RMB</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>RMB</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>RMB</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Assets:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Short-term investments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">32,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">32,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>I-MAB </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to the Consolidated Financial Statements </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(All amounts in thousands, except for share and per share data, unless otherwise noted) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2. Principal Accounting Policies&nbsp;(Continued) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>2.4 Fair value measurements&nbsp;(Continued) </I></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The roll forward of major Level&nbsp;3 financial assets and financial liability are as
follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="72%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="52%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Short-term<BR>investments</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Other&nbsp;financial<BR>assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Warrant<BR>liabilities</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fair value of Level&nbsp;3 financial asset and liability as of December&nbsp;31, 2017</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">266,245</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(65,832</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Investment in other financial assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Disposal of other financial assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(40,000</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fair value change</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,622</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">61,405</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercise of warrants</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,314</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income received from other financial assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(13,909</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Currency translation differences</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,505</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fair value of Level&nbsp;3 financial asset and liability as of December&nbsp;31, 2018</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">255,958</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5,618</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Purchase of short-term investments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">134,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Disposal of short-term investments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(102,703</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Disposal of other financial assets due to Termination Agreement (Note&nbsp;4)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(256,000</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fair value changes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">703</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">42</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,644</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Currency translation differences</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(26</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fair value of Level&nbsp;3 financial assets and liability as of December&nbsp;31, 2019</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>32,000</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Refer to Note 15 for additional information about Level&nbsp;3 warrant liabilities measured at fair value on a
recurring basis for the year ended December&nbsp;31, 2018. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>2.5 Foreign currency translation </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Group uses Chinese Renminbi (&#147;RMB&#148;) as its reporting currency. The United States Dollar (&#147;US$&#148;) is the functional
currency of the Group&#146;s entities incorporated in the Cayman Islands, the United States of America (&#147;U.S.&#148;) and Hong Kong, the Australia Dollar (&#147;AUD&#148;) is the functional currency of the Group&#146;s entity incorporated in
Australia and the RMB is the functional currency of the Company&#146;s PRC subsidiaries. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>I-MAB </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to the Consolidated Financial Statements </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(All amounts in thousands, except for share and per share data, unless otherwise noted) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2. Principal Accounting Policies&nbsp;(Continued) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>2.5 Foreign currency translation&nbsp;(Continued) </I></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Transactions denominated in other than the functional currencies are translated into the
functional currency of the entity at the exchange rates prevailing on the transaction dates. Assets and liabilities denominated in other than the functional currencies are translated at the balance sheet date exchange rate. The resulting exchange
differences are recorded in the consolidated statements of comprehensive loss. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The consolidated financial statements of the Group are
translated from the functional currency to the reporting currency, RMB. Assets and liabilities of the subsidiaries are translated into RMB using the exchange rate in effect at each balance sheet date. Income and expenses are translated at the
average exchange rates prevailing for the year. Foreign currency translation adjustments arising from these are reflected in the accumulated other comprehensive income. The exchange rates used for translation on December&nbsp;31, 2018 and 2019 were
US$1.00 = RMB6.8632 and RMB6.9762 respectively, representing the index rates stipulated by the People&#146;s Bank of China. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Translations
of balances in the consolidated balance sheets, consolidated statements of comprehensive loss, consolidated statements of changes in shareholders&#146; equity (deficit) and consolidated statements of cash flows from RMB into US$ as of and for the
year ended December&nbsp;31, 2019 are solely for the convenience of the readers and were calculated at the rate of US$1.00=RMB7.0651, representing the noon buying rate in The City of New York for cable transfers of RMB as certified for customs
purposes by the Federal Reserve Bank of New York on June 30, 2020. No representation is made that the RMB amounts could have been, or could be, converted, realized or settled into US$ at that rate on June 30, 2020, or at any other rate. The US$
convenience translation is not required under U.S. GAAP and all US$ convenience translation amounts in the accompanying consolidated financial statements are unaudited. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>2.6 Cash and cash equivalents </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents consist of cash on hand and bank deposits, which are unrestricted as to withdrawal and use. The Company considers
all highly liquid investments with an original maturity date of three months or less at the date of purchase to be cash equivalents. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>2.7 Restricted
cash </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Restricted cash consists of the guarantee deposits held in a designated bank account as security deposits under bank
borrowing agreements. Such restricted cash will be released when the Group repays the related bank borrowings. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>2.8 Short-term investments
</I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Short-term investments represent the investments issued by commercial banks or other financial institutions with a variable
interest rate indexed to the performance of underlying assets within one year. These investments are stated at fair value. Changes in the fair value are reflected in the consolidated statements of comprehensive loss. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>I-MAB </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to the Consolidated Financial Statements </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(All amounts in thousands, except for share and per share data, unless otherwise noted) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2. Principal Accounting Policies&nbsp;(Continued) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>2.9 Property, equipment and software </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Property, equipment and software are stated at cost less accumulated depreciation and amortization. Depreciation and amortization is computed
using the straight-line method over the following estimated useful lives, taking into account any estimated residual value: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Laboratory&nbsp;equipment</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">3&nbsp;to&nbsp;5&nbsp;years</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Software</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">2 to 5 years</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Office&nbsp;furniture&nbsp;and&nbsp;equipment</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">5 years</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Leasehold improvements</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Lesser&nbsp;of&nbsp;useful&nbsp;life&nbsp;or&nbsp;lease&nbsp;term</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Group recognized the gain or loss on the disposal of property, equipment and software in the consolidated
statements of comprehensive loss. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>2.10 Intangible assets </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Intangible assets with definite useful lives are amortized to their estimated residual values over their estimated useful lives and reviewed
for impairment if certain events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Amortization is initiated for <FONT STYLE="white-space:nowrap">in-process</FONT> research and development (IPR&amp;D)
intangible assets that are acquired from business combination when their useful lives have been determined. IPR&amp;D intangible assets which are determined to have an impairment in their fair value are adjusted downward and an expense recognized in
research and development in the consolidated statements of comprehensive loss. These IPR&amp;D intangible assets are tested at least an annual basis on December&nbsp;31 or when a triggering event occurs that could indicate a potential impairment.
(see Note 7). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>2.11 Impairment of long-lived assets </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Long-lived assets are reviewed for impairment in accordance with authoritative guidance for impairment or disposal of long-lived assets.
Long-lived assets are reviewed for events or changes in circumstances, which indicate that their carrying value may not be recoverable. Long-lived assets are reported at the lower of carrying amount or fair value less cost to sell. For the years
ended December&nbsp;31, 2018 and 2019, there was no impairment of the value of the Group&#146;s long-lived assets. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>2.12 Goodwill </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Goodwill is an asset representing the future economic benefits arising from other assets acquired in a business combination that are not
individually identified and separately recognized. The Group allocates the cost of an acquired entity to the assets acquired and liabilities assumed based on their estimated fair values at the date of acquisition. The excess of the purchase price
for acquisitions over the fair value of the net assets acquired, including other intangible assets, is recorded as goodwill. Goodwill is not amortized, but impairment of goodwill assessment is performed on at least an annual basis on
December&nbsp;31 or whenever events or changes in circumstances indicate that the carrying value of the asset may not be recoverable. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>I-MAB </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to the Consolidated Financial Statements </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(All amounts in thousands, except for share and per share data, unless otherwise noted) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2. Principal Accounting Policies&nbsp;(Continued) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>2.12 Goodwill&nbsp;(Continued) </I></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Group has elected to first assess qualitative factors to determine whether it is more
likely than not that the fair value of the Group&#146;s reporting unit is less than its carrying amount, including goodwill. The qualitative assessment includes the Group&#146;s evaluation of relevant events and circumstances affecting the
Group&#146;s single reporting unit, including macroeconomic, industry, market conditions and the Group&#146;s overall financial performance. If qualitative factors indicate that it is more likely than not that the Group&#146;s reporting unit&#146;s
fair value is less than its carrying amount, then the Group will perform the quantitative impairment test by comparing the reporting unit&#146;s carrying amount, including goodwill, to its fair value. If the carrying amount of the reporting unit
exceeds its fair value, an impairment loss will be recognized in an amount equal to that excess. For the years ended December&nbsp;31, 2018 and 2019, the Group determined that there were no indicators of impairment of the goodwill. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>2.13 Deferred subsidy income </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Deferred subsidy income consists of deferred income from government grants. Government grants consist of cash subsidies received by the
Group&#146;s subsidiaries in the PRC from local governments as support on expenses relating to certain projects. Grants received with government specified performance obligations are recognized when all the obligations have been fulfilled. If such
obligations are not satisfied, the Group may be required to refund the subsidy. Cash grants of RMB3,920 was recorded in deferred subsidy income as of December&nbsp;31, 2019, which will be recognized when the government specified performance
obligation is satisfied, which is expected to be more than 12 months after December&nbsp;31, 2019. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>2.14 Revenue recognition </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Group adopted Accounting Standard Codification (&#147;ASC&#148;) 606, <I>Revenue from Contracts with Customers</I> (Topic 606) (&#147;ASC
606&#148;) for all periods presented. Consistent with the criteria of Topic 606, the Group recognizes revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects
to receive in exchange for those goods or services. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Under ASC 606, an entity recognizes revenue when its customer obtains control of
promised goods or services, in an amount that reflects the consideration that the entity expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that an entity determines are within the scope of
ASC 606, the entity performs the following five steps: (i)&nbsp;identify the contract(s) with a customer; (ii)&nbsp;identify the performance obligations in the contract; (iii)&nbsp;determine the transaction price, including variable consideration,
if any; (iv)&nbsp;allocate the transaction price to the performance obligations in the contract; and (v)&nbsp;recognize revenue when (or as) the entity satisfies a performance obligation. The Group only applies the five-step model to contracts when
it is probable that the entity will collect the consideration to which it is entitled in exchange for the goods or services it transfers to the customer. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Once a contract is determined to be within the scope of ASC 606 at contract inception, the Group audits the contract to determine which
performance obligations it must deliver and which of these performance obligations are distinct. The Group recognizes as revenue the amount of the transaction price that is allocated to each performance obligation when that performance obligation is
satisfied or as it is satisfied. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>I-MAB </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to the Consolidated Financial Statements </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(All amounts in thousands, except for share and per share data, unless otherwise noted) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2. Principal Accounting Policies&nbsp;(Continued) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>2.14 Revenue recognition&nbsp;(Continued) </I></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><I>Collaboration revenue </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">At contract inception, the Group analyzes its collaboration arrangements to assess whether they are within the scope of ASC
808,<I>&nbsp;Collaborative Arrangements</I>&nbsp;(&#147;ASC 808&#148;) to determine whether such arrangements involve joint operating activities performed by parties that are both active participants in the activities and exposed to significant
risks and rewards dependent on the commercial success of such activities.&nbsp;For collaboration arrangements within the scope of ASC 808 that contain multiple elements, the Group first determines if the collaboration is deemed to be within the
scope of ASC 808 and those that are more reflective of a vendor-customer relationship and therefore within the scope of ASC 606. For the collaboration arrangements that are accounted for pursuant to ASC 808, an appropriate recognition method is
determined and applied consistently.</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Group&#146;s collaborative arrangements may contain more than one unit of account, or performance
obligation, including grants of licenses to intellectual property rights, agreement to provide research and development services and other deliverables. The collaborative arrangements do not include a right of return for any deliverable. As part of
the accounting for these arrangements, the Group must develop assumptions that require judgment to determine the stand-alone selling price for each performance obligation identified in the contract.&nbsp;In developing the stand-alone selling price
for a performance obligation, the Group considers competitor pricing for a similar or identical product, market awareness of and perception of the product, expected product life and current market trends. In general, the consideration allocated to
each performance obligation is recognized when the respective obligation is satisfied either by delivering a good or providing a service, limited to the consideration that is not constrained. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">When the timing of the delivery of product is different from the timing of payments made by the customers, the Group recognizes either a
contract asset (performance precedes the contractual due date) or a contract liability (customer payment precedes performance). The Group&#146;s contractual payment terms are typically due in no more than 30 days from invoicing. In limited
situations, certain customer contractual payment terms require the Group to bill in arrears; thus, the Group satisfies some or all of the performance obligations before the Group is contractually entitled to bill the customer. In these situations,
billing occurs subsequent to revenue recognition, which results in a contract asset. For example, certain of the contractual arrangements do not permit the Group to bill until the completion of the production of the samples. In other limited
situations, certain customer contractual payment terms allow the Group to bill in advance; thus, the Group receives customer cash payment before satisfying some or all of its performance obligations. In these situations, billing occurs in advance of
revenue recognition, which results in contract liabilities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I>Licenses of Intellectual Property:</I> Upfront <FONT
STYLE="white-space:nowrap">non-refundable</FONT> payments for licensing the Group&#146;s intellectual property are evaluated to determine if the license is distinct from the other performance obligations identified in the arrangement. For licenses
determined to be distinct, the Group recognizes revenues from <FONT STYLE="white-space:nowrap">non-refundable,</FONT> <FONT STYLE="white-space:nowrap">up-front</FONT> fees allocated to the license at a point in time, when the license is transferred
to the licensee and the licensee is able to use and benefit from the license. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I>Research and Development Services: </I>The portion of
the transaction price allocated to research and development services performance obligations is deferred and recognized as collaboration revenue over time as delivery or performance of such services occurs. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>I-MAB </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to the Consolidated Financial Statements </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(All amounts in thousands, except for share and per share data, unless otherwise noted) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2. Principal Accounting Policies&nbsp;(Continued) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>2.14 Revenue recognition&nbsp;(Continued) </I></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I>Milestone Payments</I>: At the inception of each arrangement that includes development,
commercialization, and regulatory milestone payments, the Group evaluates whether the milestones are considered probable of being reached and to the extent that a significant reversal of cumulative revenue would not occur in future periods,
estimates the amount to be included in the transaction price using the most likely amount method. The transaction price is then allocated to each performance obligation on a relative stand-alone selling price basis, for which the Group recognizes
revenue as or when the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, the Group <FONT STYLE="white-space:nowrap">re-evaluates</FONT> the probability of achieving such development milestones
and any related constraint, and if necessary, adjust the estimate of the overall transaction price. Any such adjustments are recorded on a cumulative <FONT STYLE="white-space:nowrap">catch-up</FONT> basis, which would affect revenues and earnings in
the period of adjustment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I>Royalties</I>: For arrangements that include sales-based royalties, including milestone payments based on
the level of sales, and the license is deemed to be the predominant item to which the royalties relate, the Group recognizes revenue at the later of (i)&nbsp;when the related sales occur, or (ii)&nbsp;when the performance obligation to which some or
all of the royalty has been allocated has been satisfied (or partially satisfied). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>2.15 <FONT STYLE="white-space:nowrap">Value-added-tax</FONT>
(&#147;VAT&#148;) recoverable and surcharges </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Value added tax recoverable represent amounts paid by the Group for purchases. The
surcharges (i.e., Urban construction and maintenance tax, educational surtax, local educational surtax), vary from 6% to 17% of <FONT STYLE="white-space:nowrap">the&nbsp;value-added-tax&nbsp;depending</FONT> on
<FONT STYLE="white-space:nowrap">the&nbsp;tax-payer&#146;s&nbsp;location.</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>2.16 Research and development expenses </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Elements of research and development expenses primarily include (1)&nbsp;payroll and other related expenses of personnel engaged in research
and development activities, <FONT STYLE="white-space:nowrap">(2)&nbsp;in-licensed</FONT> patent rights fee of exclusive development rights of drugs granted to the Group, (3)&nbsp;expenses related to preclinical testing of the Group&#146;s
technologies under development and clinical trials such as payments to contract research organizations (&#147;CRO&#148;), investigators and clinical trial sites that conduct the clinical studies (4)&nbsp;expenses to develop the product candidates,
including raw materials and supplies, product testing, depreciation, and facility related expenses, (5)&nbsp;other research and development expenses. Research and development expenses are charged to expense as incurred when these expenditures relate
to the Group&#146;s research and development services and have no alternative future uses. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Group has acquired rights to develop and
commercialize product candidates. Upfront payments that relate to the acquisition of a new drug compound, as well as <FONT STYLE="white-space:nowrap">pre-commercial</FONT> milestone payments, are immediately expensed as acquired <FONT
STYLE="white-space:nowrap">in-process</FONT> research and development in the period in which they are incurred, provided that the new drug compound did not also include processes or activities that would constitute a &#147;business&#148; as defined
under U.S. GAAP, the drug has not achieved regulatory approval for marketing and, absent obtaining such approval, has no established alternative future use. Milestone payments made to third parties subsequent to regulatory approval would be
capitalized as intangible assets and amortized over the estimated remaining useful life of the related product. The conditions enabling capitalization of development expenses as an asset have not yet been met and, therefore, all development
expenditures are recognized in profit or loss when incurred. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>I-MAB </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to the Consolidated Financial Statements </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(All amounts in thousands, except for share and per share data, unless otherwise noted) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2. Principal Accounting Policies&nbsp;(Continued) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>2.17 Leases </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Prior to the adoption of ASC 842 on January&nbsp;1, 2019: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Leases, mainly leases of offices, where substantially all the rewards and risks of ownership of assets remain with the lessor are accounted
for as operating leases. Payments made under operating leases are recognized as an expense on a straight-line basis over the lease term. The Group had no capital leases for any of the years stated herein. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Upon and hereafter the adoption of ASC 842 on January&nbsp;1, 2019: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Group determines if an arrangement is a lease at inception. Operating leases are included in operating lease <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT> (&#147;ROU&#148;) assets, operating lease liability, and operating lease liability, <FONT STYLE="white-space:nowrap">non-current</FONT> in the Group&#146;s
consolidated balance sheets. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">ROU assets represent the Group&#146;s right to use an underlying asset for the lease term and lease
liabilities represent the Group&#146;s obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. When
determining the lease term, the Group includes options to extend or terminate the lease when it is reasonably certain that it will exercise that option, if any. As the Group&#146;s leases do not provide an implicit rate, the Group uses its
incremental borrowing rate, which it calculates based on the credit quality of the Group and by comparing interest rates available in the market for similar borrowings, and adjusting this amount based on the impact of collateral over the term of
each lease. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Group has elected to adopt the following lease policies in conjunction with the adoption of ASU <FONT
STYLE="white-space:nowrap">2016-02:</FONT> (i) elect for each lease not to separate <FONT STYLE="white-space:nowrap">non-lease</FONT> components from lease components and instead to account for each separate lease component and the <FONT
STYLE="white-space:nowrap">non-lease</FONT> components associated with that lease component as a single lease component; (ii)&nbsp;for leases that have lease terms of 12 months or less and does not include a purchase option that is reasonably
certain to exercise, the Group elected not to apply ASC 842 recognition requirements; and (iii)&nbsp;the Group elected to apply the package of practical expedients for existing arrangements entered into prior to January&nbsp;1, 2019 to not reassess
(a)&nbsp;whether an arrangement is or contains a lease, (b)&nbsp;the lease classification applied to existing leases, and(c) initial direct costs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In connection with the adoption of ASC 842, on January 1, 2019, the Company recorded an impact of RMB13,100 on its assets and RMB11,333 on its
liabilities for the recognition of operating lease right-of-use-assets and operating lease liabilities, respectively, which are primarily related to the lease of the Group&#146;s offices and warehouses. The adoption of ASC 842 did not have a
material impact on the Company&#146;s results of operations or cash flows. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>2.18 Comprehensive loss </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Comprehensive loss is defined as the changes in equity of the Group during a period from transactions and other events and circumstances
excluding transactions resulting from investments by owners and distributions to owners. Among other disclosures, ASC 220,&nbsp;Comprehensive Income, requires that all items that are required to be recognized under current accounting standards as
components of comprehensive loss be </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>I-MAB </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to the Consolidated Financial Statements </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(All amounts in thousands, except for share and per share data, unless otherwise noted) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2. Principal Accounting Policies&nbsp;(Continued) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>2.18 Comprehensive loss&nbsp;(Continued) </I></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
reported in a financial statement that is displayed with the same prominence as other financial statements. For each of the periods presented, the Group&#146;s comprehensive loss includes net
loss and foreign currency translation adjustments, which are presented in the consolidated statements of comprehensive loss. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>2.19 Share-based
compensation </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Company grants restricted shares and stock options to eligible employees and accounts for share-based
compensation in accordance with ASC 718, Compensation&#151;Stock Compensation.</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Employees&#146; share-based compensation awards are
measured at the grant date fair value of the awards and recognized as expenses a) immediately at the grant date if no vesting conditions are required; or b) for share based awards granted with only service conditions, using the graded vesting method
net of estimated forfeitures over the vesting period; or c) for share-based awards granted with service conditions and the occurrence of an initial public offering (&#147;IPO&#148;) as performance condition cumulative share-based compensation
expenses for the options that have satisfied the service condition should be recorded upon the completion of the IPO using the graded vesting method.</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">A change in any of the terms or conditions of share-based awards is accounted for as a modification of the awards. The Group calculates
incremental compensation expense of a modification as the excess of the fair value of the modified awards over the fair value of the original awards immediately before its terms are modified at the modification date. For vested awards, the Group
recognizes incremental compensation cost in the period when the modification occurs. For awards not being fully vested, the Group recognizes the sum of the incremental compensation expense and the remaining unrecognized compensation expense for the
original awards over the remaining requisite service period after modification. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Share-based compensation in relation to the restricted
shares is measured based on the fair market value of the Group&#146;s ordinary shares at the grant date of the award. Prior to the listing, estimation of the fair value of the Group&#146;s ordinary shares involves significant assumptions that might
not be observable in the market, and a number of complex and subjective variables, including discount rate, and subjective judgments regarding the Group&#146;s projected financial and operating results, its unique business risks, the liquidity of
its ordinary shares and its operating history and prospects at the time the grants are made. Share-based compensation in relation to the share options is estimated using the Binominal Option Pricing Model. The determination of the fair value of
share options is affected by the share price of the Group&#146;s ordinary shares as well as the assumptions regarding a number of complex and subjective variables, including the expected share price volatility, risk-free interest rate, exercise
multiple and expected dividend yield. The fair value of these awards was determined with the assistance from an independent valuation firm. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>2.20
Income taxes </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Group accounts for income taxes under the liability method. Under the liability method, deferred income tax
assets and liabilities are determined based on the differences between the financial reporting and income tax bases of assets and liabilities and are measured using the tax income rates that will be in effect when the differences are expected to
reverse. A valuation allowance is recorded if it is more likely than not that some portion or all of the deferred income tax assets will not be utilized in the foreseeable future. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>I-MAB </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to the Consolidated Financial Statements </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(All amounts in thousands, except for share and per share data, unless otherwise noted) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2. Principal Accounting Policies&nbsp;(Continued) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>2.20 Income taxes&nbsp;(Continued) </I></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Group evaluates its uncertain tax positions using the provisions of ASC <FONT
STYLE="white-space:nowrap">740-10,&nbsp;Income</FONT> Taxes, which prescribes a recognition threshold that a tax position is required to meet before being recognized in the financial statements. The Group recognizes in the financial statements the
benefit of a tax position which is &#145;&#145;more likely than not&#146;&#146; to be sustained under examination based solely on the technical merits of the position assuming a review by tax authorities having all relevant information. Tax
positions that meet the recognition threshold are measured using a cumulative probability approach, at the largest amount of tax benefit that has a greater than fifty percent likelihood of being realized upon settlement. It is the Group&#146;s
policy to recognize interest and penalties related to unrecognized tax benefits, if any, as a component of income tax expense. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>2.21 Borrowings
</I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Borrowings are recognized initially at fair value, net of transaction costs incurred. Borrowings are subsequently stated at
amortized cost; any difference between the proceeds (net&nbsp;of transaction costs) and the redemption value is recognized in the consolidated statements of comprehensive loss over the period of the borrowings using the effective interest method.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>2.22 Business combination </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Group accounts for its business combinations using the acquisition method of accounting in accordance with ASC topic 805,&nbsp;Business
Combinations&nbsp;(&#147;ASC 805&#148;). The acquisition method of accounting requires all of the following steps: (i)&nbsp;identifying the acquirer, (ii)&nbsp;determining the acquisition date, (iii)&nbsp;recognizing and measuring the identifiable
assets acquired, the liabilities assumed, and any noncontrolling interest in the acquiree, and (iv)&nbsp;recognizing and measuring goodwill or a gain from a bargain purchase. The consideration transferred in a business combination is measured as the
aggregate of the fair values at the date of exchange of the assets given, liabilities incurred, and equity instruments issued as well as the contingent considerations and all contractual contingencies as of the acquisition date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Group allocates the fair value of purchase consideration to the tangible assets acquired, liabilities assumed and intangible assets
acquired based on their estimated fair values. The excess of the fair value of purchase consideration over the fair values of these identifiable assets and liabilities is recorded as goodwill. Such valuations require management to make significant
estimates and assumptions, especially with respect to intangible assets. Significant estimates in valuing certain intangible assets may include, but are not limited to, future expected cash flows from acquired assets, timing and probability of
success of clinical events and regulatory approvals, and assumptions on useful lives of the patents and discount rates. Management&#146;s estimates of fair value are based upon assumptions believed to be reasonable, but which are inherently
uncertain and unpredictable and, as a result, actual results may differ from estimates. Additional information, such as that related to income tax and other contingencies, existing as of the acquisition date but unknown to us may become known during
the remainder of the measurement period, not to exceed one year from the acquisition date, which may result in changes to the amounts and allocations recorded. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Acquisitions that do not meet the accounting definition of a business combination are accounted for as asset acquisitions. For transactions
determined to be asset acquisitions, the Group allocates the total cost of the acquisition, including transaction costs, to the net assets acquired based on their relative fair values. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>I-MAB </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to the Consolidated Financial Statements </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(All amounts in thousands, except for share and per share data, unless otherwise noted) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2. Principal Accounting Policies&nbsp;(Continued) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>2.23 Segment information </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In accordance with ASC 280,&nbsp;Segment Reporting, the Group&#146;s chief operating decision maker, the Chief Executive Officer, reviews the
consolidated results when making decisions about allocating resources and assessing performance of the Group as a whole and hence, the Group has only one reportable segment. The Group does not distinguish between markets or segments for the purpose
of internal reporting. As the Group&#146;s long-lived assets are substantially located in and derived from the PRC, no geographical segments are presented. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>2.24 Loss per share </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Basic loss
per share is computed by dividing net loss attributable to ordinary shareholders by the weighted average number of ordinary shares outstanding during the period using <FONT STYLE="white-space:nowrap">the&nbsp;two-class&nbsp;method.</FONT> Under <FONT
STYLE="white-space:nowrap">the&nbsp;two-class&nbsp;method,</FONT> the net loss is allocated between ordinary shares and other participating securities based on their participating rights. Net loss is not allocated to other participating securities
if based on their contractual terms they are not obligated to share in the loss. Diluted loss per share is calculated by dividing net loss attributable to ordinary shareholders by the weighted average number of ordinary and dilutive ordinary
equivalent shares outstanding during the period. Ordinary equivalent shares consist of shares issuable upon the conversion of the preferred shares using <FONT STYLE="white-space:nowrap">the&nbsp;if-converted&nbsp;method,</FONT> shares issuable upon
the exercise of share options using the treasury stock method, shares issuable upon the conversion of the convertible promissory notes using <FONT STYLE="white-space:nowrap">the&nbsp;if-converted&nbsp;method,</FONT> and shares issuable upon the
exercise of warrants using the treasury stock method. Ordinary equivalent shares are not included in the denominator of the diluted loss per share calculation when inclusion of such shares would be anti-dilutive. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>2.25 Adopted accounting pronouncements </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In 2016, the FASB issued ASU <FONT STYLE="white-space:nowrap">2016-02,</FONT> Leases (Topic 842). This ASU requires lessees to recognize lease
assets and lease liabilities on the balance sheet for the rights and obligations created by all leases with terms greater than 12 months. As we are not a lessor, other changes in the guidance applicable to lessors do not apply. Additionally, in
2018, the FASB issued codification and targeted improvements to this guidance effective for fiscal years and interim periods within those years beginning after December&nbsp;15, 2018, with early adoption permitted. The Group adopted the new guidance
on January&nbsp;1, 2019, using the alternative transition approach. For additional information, see Note 6&#151;&#147;Leases.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In
November 2016, the FASB issued ASU <FONT STYLE="white-space:nowrap">2016-18,</FONT> Statement of Cash Flows (Topic 230) <FONT STYLE="white-space:nowrap">(&#147;ASU&nbsp;2016-18&#148;).</FONT> This ASU affects all entities that have restricted cash
or restricted cash equivalents and are required to present a statement of cash flows under Topic 230. ASU <FONT STYLE="white-space:nowrap">2016-18</FONT> requires that a statement of cash flows explain the change during the period in the total of
cash, cash equivalents, and amounts generally described as restricted cash or restricted cash equivalents. This update was required to be adopted for fiscal years beginning after December&nbsp;15, 2018, and interim periods within fiscal years
beginning after December&nbsp;15, 2019, and early adoption is permitted in any interim or annual period. The Group elected to early adopt this ASU and applied this guidance retrospectively to all periods presented. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>2.26 Recent accounting pronouncements </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In June 2016, the FASB issued ASU <FONT STYLE="white-space:nowrap">2016-13,</FONT> Financial Instruments&#151;Credit Losses (Topic 326):
Measurement of Credit Losses on Financial Instruments (&#147;ASU <FONT STYLE="white-space:nowrap">2016-13&#148;).</FONT> This guidance requires that financial </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>I-MAB </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to the Consolidated Financial Statements </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(All amounts in thousands, except for share and per share data, unless otherwise noted) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2. Principal Accounting Policies&nbsp;(Continued) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>2.26 Recent accounting pronouncements&nbsp;(Continued) </I></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
assets measured at amortized cost be presented at the net amount expected to be collected. The measurement of expected credit losses is based on historical experience, current conditions, and
reasonable and supportable forecasts that affect the collectability. In November 2018, the FASB issued ASU <FONT STYLE="white-space:nowrap">2018-19,</FONT> Codification Improvements to Topic 326, Financial Instruments-Credit Losses (&#147;ASU <FONT
STYLE="white-space:nowrap">2018-19&#148;),</FONT> which clarifies certain topics included within ASU <FONT STYLE="white-space:nowrap">2016-13.</FONT> ASU <FONT STYLE="white-space:nowrap">2016-13</FONT> and ASU
<FONT STYLE="white-space:nowrap">2018-19</FONT> are effective for the annual reporting period beginning after December&nbsp;15, 2019, including interim periods within that reporting period. The impact of this ASU to the consolidated financial
statements is immaterial. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In August 2018 the FASB issued ASU <FONT STYLE="white-space:nowrap">No.&nbsp;2018-13,</FONT> Fair Value
Measurement (Topic 820): Disclosure Framework&#151;Changes to the Disclosure Requirements for Fair Value Measurement. This standard modifies certain disclosure requirements on fair value measurements. This standard became effective for us on
January&nbsp;1, 2020. The impact of this ASU to the consolidated financial statements is immaterial. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In November 2018 the FASB issued ASU
<FONT STYLE="white-space:nowrap">No.&nbsp;2018-18,</FONT> Collaborative Arrangements (Topic 808): Clarifying the Interaction between Topic 808 and Topic 606. This standard makes targeted improvements for collaborative arrangements as follows: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Clarifies that certain transactions between collaborative arrangement participants should be accounted for as
revenue under ASC 606, Revenue from Contracts with Customers, when the collaborative arrangement participant is a customer in the context of a unit of account. In those situations, all the guidance in ASC 606 should be applied, including
recognition, measurement, presentation and disclosure requirements; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Adds <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">unit-of-account</FONT></FONT> guidance to
ASC 808, Collaborative Arrangements, to align with the guidance in ASC 606 (that is, a distinct good or service) when an entity is assessing whether the collaborative arrangement or a part of the arrangement is within the scope of ASC 606; and
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Precludes a company from presenting transactions with collaborative arrangement participants that are not
directly related to sales to third parties with revenue recognized under ASC 606 if the collaborative arrangement participant is not a customer. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">This standard became effective for us on January&nbsp;1, 2020. A retrospective transition approach is required for either all contracts or
only for contracts that are not completed at the date of initial application of ASC 606, with a cumulative adjustment to opening retained earnings, as of January&nbsp;1, 2018. The impact of this ASU to the consolidated financial statements is
immaterial. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>I-MAB </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to the Consolidated Financial Statements </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(All amounts in thousands, except for share and per share data, unless otherwise noted) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>3. Prepayments&nbsp;and&nbsp;Other&nbsp;Receivables </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="72%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="60%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>As&nbsp;of&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>RMB</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>RMB</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>US$&nbsp;(Note&nbsp;2.5)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepayments:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&#151;Prepayments to CRO vendors</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">71,894</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">78,740</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,145</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&#151;Prepayments for other services</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,160</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">880</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">125</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Receivables due from employees (Note)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,201</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,293</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Value-added tax recoverable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,235</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,517</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,772</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Rental deposits</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,012</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">546</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">77</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest receivables</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,502</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">764</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">108</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Others</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,169</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26,388</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,735</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">88,972</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">136,036</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,255</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Note: The balance mainly represented the receivables due from employees, which were arising from the
Group&#146;s obligation to pay the withholding individual income tax (&#147;IIT&#148;) for those employees&#146; stock option activities and was collected by the Group in January 2020. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>4. Other Financial Assets </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Def.-Times; font-size:8pt" ALIGN="center">


<TR STYLE="visibility:hidden; line-height:0pt; color:white">

<TD WIDTH="65%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD nowrap STYLE="font-size:10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD nowrap STYLE="font-size:10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD nowrap STYLE="font-size:10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Def.-Times; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><FONT STYLE="font-family:Times New Roman; "><B>As&nbsp;of&nbsp;December&nbsp;31,</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Def.-Times; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><FONT STYLE="font-family:Times New Roman; "><B>2018</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><FONT STYLE="font-family:Times New Roman; "><B>2019</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Def.-Times; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>RMB</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>RMB</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>US$&nbsp;(Note&nbsp;2.5)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Def.-Times; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Financial asset at fair value through profit or loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; ">215,571</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; ">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; ">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Def.-Times; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Note receivables</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; ">40,387</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; ">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; ">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Def.-Times; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; ">255,958</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; ">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; ">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Group placed the principal amount for investments through a contractual arrangement with a third party for
the period from June&nbsp;30, 2017 to June&nbsp;30, 2020 (&#147;Principal Amount&#148;). The Principal Amount can be redeemed from the third party at the discretion of the Group from time to time whereby the Group is expecting to earn an income on
the Principal Amount with an average yield in the range from 4.50% to 5.25% per annum. The Group initially records these assets at cost, which approximates its fair value at inception and subsequently records these assets at fair value. Changes in
the fair value are reflected in the consolidated statements of comprehensive loss. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">On June&nbsp;22, 2019, the Group entered into an
agreement with the relevant party involved for early termination of the contractual arrangement (&#147;Termination Agreement&#148;). Pursuant to the Termination Agreement, the Group shall receive cash with an amount of RMB95,056 and commercial bills
with a total face value of RMB160,944 (including those commercial bills redeemed during the year ended December&nbsp;31, 2018 with a face value of RMB40,387). No material gain or loss was arising from such termination. As of December&nbsp;31, 2019,
cash of RMB95,056 was received and all commercial bills have been collected upon maturity. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-23 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>I-MAB </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to the Consolidated Financial Statements </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(All amounts in thousands, except for share and per share data, unless otherwise noted) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>5. Property, Equipment and Software </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Property, equipment and software consist of the following: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="72%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="52%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>As&nbsp;of&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>As of December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>RMB</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>RMB</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>US$&nbsp;(Note&nbsp;2.5)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cost</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Laboratory equipment</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20,796</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24,265</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,434</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Leasehold improvement</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,271</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,856</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,678</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Software</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,632</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,220</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,447</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Office furniture and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,350</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,526</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">216</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total property, equipment and software</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">36,049</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">47,867</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,775</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Less: accumulated depreciation and amortization</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(8,390</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(18,221</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,579</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net book value</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27,659</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">29,646</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,196</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Construction in process</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">423</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">60</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total net book value of property, equipment and software</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27,659</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30,069</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,256</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The total amounts charged to the consolidated statements of comprehensive loss for depreciation and
amortization expenses amounted to approximately RMB1.6 million, RMB6.7&nbsp;million and RMB9.8&nbsp;million for the years ended December&nbsp;31, 2017, 2018 and 2019, respectively. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>6. Leases </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2019,
the Company has operating leases recorded on its balance sheet for certain office spaces and facilities that expire on various dates through 2027. The Group does not plan to cancel the existing lease agreements for its existing facilities prior to
their respective expiration dates. When determining the lease term, the Group includes options to extend or terminate the lease when it is reasonably certain that it will exercise that option, if any. All of the Group&#146;s leases qualify as
operating leases. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>I-MAB </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to the Consolidated Financial Statements </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(All amounts in thousands, except for share and per share data, unless otherwise noted) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>6. Leases&nbsp;(Continued) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Information related to operating leases as of December&nbsp;31, 2019 is as follows (in
thousands, except for percentages and years). </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="72%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="68%"></TD>

<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>As&nbsp;of&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>RMB</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>US$&nbsp;(Note&nbsp;2.5)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating lease
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT> assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,435</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,326</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Liabilities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating lease liabilities, current</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,807</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">963</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating lease liabilities, <FONT STYLE="white-space:nowrap">non-current</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,492</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,060</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted average remaining lease term (years)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted average discount rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Information related to operating lease activity during the year ended December&nbsp;31, 2019 is as follows:
</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="72%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="70%"></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>For&nbsp;the&nbsp;Year&nbsp;Ended</B><br><B>December&nbsp;31,&nbsp;2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>RMB</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>US$&nbsp;(Note&nbsp;2.5)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating lease rental expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Amortization of
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT> assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,260</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">745</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expense for short-term leases within 12&nbsp;months</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">592</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">84</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest of lease liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">543</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">76</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,395</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">905</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Future annual minimum lease payments for operating leases as of December&nbsp;31, 2018 under ASC 840 were as
follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="72%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="77%"></TD>

<TD VALIGN="bottom" WIDTH="14%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Operating&nbsp;Leases</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>RMB</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2019</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,754</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2020</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,274</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2021</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,511</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2022</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">60</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2023</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">60</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Thereafter</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">276</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>14,935</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-25 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>I-MAB </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to the Consolidated Financial Statements </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(All amounts in thousands, except for share and per share data, unless otherwise noted) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>6. Leases&nbsp;(Continued) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Maturities of lease liabilities were as follows: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="72%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="68%"></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>As&nbsp;of&nbsp;December&nbsp;31,&nbsp;2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>RMB</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>US$&nbsp;(Note&nbsp;2.5)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2020</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,634</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,081</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2021</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,617</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">795</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2022</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,885</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">267</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2023</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">60</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2024</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">60</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Thereafter</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">181</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total undiscounted lease payments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,437</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,185</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Less: imputed interest</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,138</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(161</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total lease liabilities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>14,299</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>2,024</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>7. Intangible Assets </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Intangible assets as of December&nbsp;31, 2018 and 2019 are summarized as follows: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="72%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="53%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>As&nbsp;of&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>RMB</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>RMB</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>US$&nbsp;(Note&nbsp;2.5)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cost</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">IPR&amp;D</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">148,844</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">148,844</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21,068</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Less: accumulated amortization</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net book value</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">148,844</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">148,844</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21,068</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">IPR&amp;D represents the fair value assigned to research and development assets that the Group acquired from
business combination of <FONT STYLE="white-space:nowrap">I-Mab</FONT> Tianjin and its subsidiaries including Chengdu Tasgen Bio-Tech Co., Ltd. and Shanghai Tianyunjian Bio-Tech Co., Ltd. (together the &#147;Tasgen Group&#148;) in 2017 and had not
reached technological feasibility at the date of acquisition. Upon commercialization, the Group will determine the estimated useful life and amortize these amounts based upon an economic consumption method. As of December&nbsp;31, 2018 and 2019,
there was no impairment of the value of the Group&#146;s intangible assets. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>8. Goodwill </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">On July 15, 2017, the Group acquired 66.67% of the equity interests in the Tasgen Group by issuing convertible preferred shares, and
controlled the board of directors and business of I-Mab Tianjin since then. Tasgen Group is principally engaged in the research and development of innovative medicines and the Group acquired Tasgen Group for its research team, technical experience,
and IPR&amp;D pipeline assets (see Note 7). As of December 31, 2018 and 2019, the goodwill of RMB162,574 (US$23,011) represented the goodwill generated from the aforementioned acquisition of Tasgen Group and the business of Tasgen Group was fully
integrated into the Company after the acquisition. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-26 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>I-MAB </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to the Consolidated Financial Statements </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(All amounts in thousands, except for share and per share data, unless otherwise noted) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>8. Goodwill&nbsp;(Continued) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2018 and 2019, the Group performed a qualitative assessment by
evaluating relevant events and circumstances that would affect the Group&#146;s single reporting unit and did not note any indicator that it is more likely than not that the fair value of the Group&#146;s reporting unit is less than its carrying
amount and therefore the Group&#146;s goodwill was not impaired. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>9. Short-term Borrowings </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In July 2018, <FONT STYLE="white-space:nowrap">I-Mab</FONT> <FONT STYLE="white-space:nowrap">Bio-tech</FONT> (Tianjin) Co., Ltd. borrowed a
loan of RMB80,000 from China Merchant Bank Co., Ltd. for a term of one year and at the interest rate of 4.20% per annum. To facilitate this borrowing, another subsidiary of the Company in Hong Kong placed cash deposits of US$13,500 (equivalent to
approximately RMB92,653) with the bank. The use of such cash deposits and the interest earned thereon are restricted by the bank during the period of the borrowing. The deposits have a <FONT STYLE="white-space:nowrap">one-year</FONT> term and bear
interest at 3.26% per annum. The borrowing was fully repaid during the year ended December&nbsp;31, 2019. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In June 2019, <FONT
STYLE="white-space:nowrap">I-Mab</FONT> <FONT STYLE="white-space:nowrap">Bio-tech</FONT> (Tianjin) Co., Ltd. borrowed a loan of RMB50,000 from China Merchant Bank Co., Ltd. for a term of one year and at the interest rate of 4.15% per annum. To
facilitate this borrowing, another subsidiary of the Company in Hong Kong placed cash deposits of US$8,000 (equivalent to approximately RMB55,810) with the bank. The use of such cash deposits and the interest earned thereon are restricted by the
bank during the period of the borrowing. The deposits have a <FONT STYLE="white-space:nowrap">one-year</FONT> term and bear interest at 2.63% per annum. The borrowing will be due for repayment in June 2020. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>10. Accruals and Other Payables </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="62%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>As&nbsp;of&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>RMB</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>RMB</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>US$&nbsp;(Note&nbsp;2.5)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Staff salaries and welfare payables</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,869</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30,166</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,270</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued external research and development activities related expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">39,068</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">144,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20,382</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued initial public offering costs payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17,504</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,478</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Withholding IIT payable related to stock options</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,201</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,293</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued traveling expenses, office expenses and others</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,737</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">65,682</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,296</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">67,674</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">273,553</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">38,719</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>11. Income Taxes </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Cayman Islands </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><FONT
STYLE="white-space:nowrap">I-Mab&nbsp;is</FONT> incorporated in the Cayman Islands. Under the current laws of the Cayman <FONT STYLE="white-space:nowrap">Islands,&nbsp;I-Mab&nbsp;is</FONT> not subject to tax on income or capital gain. Additionally,
the Cayman Islands does not impose a withholding tax on payments of dividends to shareholders. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-27 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>I-MAB </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to the Consolidated Financial Statements </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(All amounts in thousands, except for share and per share data, unless otherwise noted) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>11. Income Taxes&nbsp;(Continued) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Hong Kong </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">I-Mab&nbsp;Biopharma</FONT> Hong Kong Limited is incorporated in Hong Kong. Companies registered in Hong Kong
are subject to Hong Kong profits tax on the taxable income as reported in their respective statutory financial statements adjusted in accordance with the relevant Hong Kong tax laws. The applicable tax rate in Hong Kong is 16.5%. For the years ended
December&nbsp;31, 2017, 2018 and <FONT STYLE="white-space:nowrap">2019,&nbsp;I-Mab&nbsp;Biopharma</FONT> Hong Kong Limited did not make any provisions for Hong Kong profit tax as there were no assessable profits derived from or earnings in Hong Kong
for any of the periods presented. Under the Hong Kong tax <FONT STYLE="white-space:nowrap">law,&nbsp;I-Mab&nbsp;Biopharma</FONT> Hong Kong Limited is exempted from income tax on its foreign-derived income and there are no withholding taxes in Hong
Kong on remittance of dividends. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Australia </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Mab&nbsp;Biopharma Australia Pty Ltd is incorporated in Australia. Companies registered in Australia are subject to Australia profits tax on
the taxable income as reported in their respective statutory financial statements adjusted in accordance with the relevant Australia tax laws. The applicable tax rate in Australia is
<FONT STYLE="white-space:nowrap">30%.&nbsp;I-Mab&nbsp;Biopharma</FONT> Australia Pty Ltd has no taxable income for all periods presented, therefore, no provision for income taxes is required. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>United States </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">I-Mab Biopharma US
Ltd. is incorporated in U.S. and is subject to U.S. federal corporate income tax at a rate of 21%. <FONT STYLE="white-space:nowrap">I-Mab</FONT> Biopharma US Ltd. is also subject to state income tax in Maryland of 8.25%. <FONT
STYLE="white-space:nowrap">I-Mab</FONT> Biopharma US Ltd. has no taxable income for all periods presented, therefore, no provision for income taxes is required. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>China </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">On March&nbsp;16, 2007,
the National People&#146;s Congress of PRC enacted a new Enterprise Income Tax Law (&#147;new EIT law&#148;), under which Foreign Investment Enterprises (&#147;FIEs&#148;) and domestic companies would be subject to corporate income tax at a uniform
rate of 25%. The new EIT law became effective on January&nbsp;1, 2008. Under the new EIT law, preferential tax treatments will continue to be granted to entities which conduct businesses in certain encouraged sectors and to entities otherwise
classified as &#147;High and New Technology Enterprises&#148;. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">I-Mab&nbsp;Shanghai</FONT> has been
qualified as &#147;High and New Technology Enterprise&#148; and enjoys a preferential income tax rate of 15% from 2018 to 2020. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The
Company&#146;s other PRC subsidiaries are subject to the statutory income tax rate of 25%. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">No provision for income taxes has been made
because the Group are in cumulative loss positions for all the periods presented. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-28 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>I-MAB </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to the Consolidated Financial Statements </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(All amounts in thousands, except for share and per share data, unless otherwise noted) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>11. Income Taxes&nbsp;(Continued) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>China&nbsp;(Continued) </I></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Reconciliations of the differences between the PRC statutory income tax rate and the
Group&#146;s effective income tax rate for the years ended December&nbsp;31, 2017, 2018 and 2019 are as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="85.5%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="50%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Year&nbsp;Ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>RMB</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>RMB</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>RMB</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>US$<BR>(Note&nbsp;2.5)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss before income tax</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(298,240</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(401,111</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,451,950</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(205,510</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income tax computed at respective applicable tax rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(37,672</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(56,093</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(148,871</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(21,071</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Non-deductible</FONT> expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,889</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,548</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">87,021</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,317</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development expenses plus deduction</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,846</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(6,762</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(9,254</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,310</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Changes in valuation allowance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">36,629</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">62,029</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">71,104</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,064</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,722</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Effect of tax holidays entitled by the PRC subsidiaries on basic loss per share</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.07</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9.55</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.35</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The principal components of the deferred tax assets and liabilities are as follows: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="85.5%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="55%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Year&nbsp;Ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>RMB</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>RMB</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>RMB</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>US$<BR>(Note&nbsp;2.5)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred tax assets:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net operating loss carryforward</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">73,105</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">92,185</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">136,443</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,312</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Depreciation and amortization of property, equipment, software and intangible asset, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,405</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">44,398</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,285</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrual expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,647</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21,132</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21,867</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,095</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Less: valuation allowance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(49,541</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(94,511</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(165,497</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(23,425</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total deferred tax assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">37,211</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">37,211</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">37,211</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,267</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred tax liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Acquired intangible assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">37,211</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">37,211</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">37,211</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,267</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total deferred tax liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">37,211</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">37,211</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">37,211</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,267</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred tax assets, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-29 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>I-MAB </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to the Consolidated Financial Statements </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(All amounts in thousands, except for share and per share data, unless otherwise noted) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>11. Income Taxes&nbsp;(Continued) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>China&nbsp;(Continued) </I></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Movement of the valuation allowance is as follows: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="85.5%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="55%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Year&nbsp;Ended&nbsp;December&nbsp;31</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>RMB</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>RMB</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>RMB</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>US$<BR>(Note&nbsp;2.5)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Balance as of January&nbsp;1</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(6,472</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(49,541</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(94,511</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(13,377</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Business combination</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(6,440</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Additions</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(36,629</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(62,029</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(71,104</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(10,065</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Decrease due to the change of tax rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17,059</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">118</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Balance as of December&nbsp;31</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(49,541</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(94,511</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(165,497</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(23,425</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2019, the Group had a majority of net operating losses of approximately RMB715,156
which arose from the subsidiaries established in the PRC. The tax losses carried forward various in the PRC will expire during the period beginning from 2021 to 2029 based on entity&#146;s preferential tax status. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">A valuation allowance is provided to reduce the amount of deferred tax assets if it is considered as more likely than not that some portion or
all of the deferred tax assets will not be realized in the foreseeable future. In making such determination, the Group evaluates a variety of positive and negative factors including the Group&#146;s operating history, accumulated deficit, the
existence of taxable temporary differences and reversal periods. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Group has incurred net accumulated operating losses for income tax
purposes since its inception. The Group believes that it is more likely than not that these net accumulated operating losses together with other deferred tax assets will not be utilized in the foreseeable future. Therefore, the Group has provided
full valuation allowances for the deferred tax assets as of December&nbsp;31, 2018 and 2019. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Group evaluates each uncertain tax
position (including the potential application of interest and penalties) based on the technical merits, and measure the unrecognized benefits associated with the tax positions. As of December&nbsp;31, 2018 and 2019, the Group did not have any
significant unrecognized uncertain tax positions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>12. Ordinary Shares </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2018 and 2019, 500,000,000 ordinary shares had been authorized by the Company. Each ordinary share is entitled to one
vote. The holders of ordinary shares are also entitled to receive dividends whenever funds are legally available and when declared by the Board of Directors of the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">On October&nbsp;29, 2019, the Company&#146;s shareholders and board of directors approved that immediately prior to the completion of initial
public offering, the Company&#146;s authorized share capital will be changed into US$80,000 divided into 800,000,000 ordinary shares of a par value of US$0.0001 each. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>13. Convertible Preferred Shares </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">On
October&nbsp;18, 2016, the Company issued 5,141,587 shares of Series <FONT STYLE="white-space:nowrap">A-1</FONT> and <FONT STYLE="white-space:nowrap">A-2</FONT> Preferred Shares with a consideration of US$11,282 (equivalent to approximately
RMB74,742). In connection with the Series <FONT STYLE="white-space:nowrap">A-1</FONT> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-30 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>I-MAB </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to the Consolidated Financial Statements </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(All amounts in thousands, except for share and per share data, unless otherwise noted) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>13. Convertible Preferred Shares&nbsp;(Continued) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
and <FONT STYLE="white-space:nowrap">A-2</FONT> Preferred Shares issuance, the Company also issued 2,246,744 warrant to purchase its Series <FONT STYLE="white-space:nowrap">A-3</FONT> Preferred
Shares (&#147;Series <FONT STYLE="white-space:nowrap">A-3</FONT> Warrants&#148; and see Note 15). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">On September&nbsp;6, 2017, in
connection with the Group&#146;s acquisition of Tasgen Group, the Company issued 16,723,646 shares of Series <FONT STYLE="white-space:nowrap">A-3</FONT> Preferred Shares at a price of US$2.55 per share with a total consideration of US$42,645
(equivalent to approximately RMB289,024). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Series <FONT STYLE="white-space:nowrap">A-1</FONT> Preferred Shares, Series <FONT
STYLE="white-space:nowrap">A-2</FONT> Preferred Shares and Series <FONT STYLE="white-space:nowrap">A-3</FONT> Preferred Shares are also referred to as Series A Preferred Shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">On September&nbsp;22, 2017, the Company issued 15,894,594 shares of Series B Preferred Shares with a consideration of US$52,546 (equivalent to
approximately RMB346,515). In connection with the Series B Preferred Shares issuance, the Company also issued convertible promissory notes that are convertible into Series <FONT STYLE="white-space:nowrap">B-1</FONT> Preferred Shares (&#147;2017
Notes&#148; and see Notes 14) and 5,633,780 warrants to purchase its Series <FONT STYLE="white-space:nowrap">B-2</FONT> Preferred Shares (&#147;Series B Warrant&#148; and see Note 15). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Concurrently with the Company&#146;s issuance of Series B Preferred Shares, the Company also completed a round of onshore financing with
respect to the Group&#146;s subsidiary <FONT STYLE="white-space:nowrap">I-MAB</FONT> Tianjin (&#147;Series B Onshore Financing&#148;). Series B Onshore Financing comprised 1) capital injection to <FONT STYLE="white-space:nowrap">I-Mab</FONT> Tianjin
by a number of investors (&#147;Series B Onshore Investors&#148;) (see Note 14), 2) <FONT STYLE="white-space:nowrap">I-Mab</FONT> Tianjin&#146;s issuance of convertible loans (&#147;Onshore Convertible Loans&#148; and see Note 14), and 3) the
Company&#146;s issuance of 2,620,842 warrants to purchase its Series <FONT STYLE="white-space:nowrap">B-2</FONT> Preferred Shares (&#147;Series B Warrants&#148; and see Note 15). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">On June&nbsp;29, 2018, the Company issued total 8,361,823 shares of Series <FONT STYLE="white-space:nowrap">A-3</FONT> Preferred Shares upon
exercise of Series <FONT STYLE="white-space:nowrap">A-3</FONT> Option held by its holder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">On June&nbsp;29, 2018, the Company issued
2,535,201 shares of Series <FONT STYLE="white-space:nowrap">B-1</FONT> Preferred Shares upon conversion of 2017 Notes and issued 2,253,512 shares of Series <FONT STYLE="white-space:nowrap">B-2</FONT> Preferred Shares upon exercise of Series B
Warrant by Series B preferred shareholders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">On June&nbsp;29, 2018, the Company issued 5,938,640 shares of Series B Preferred Shares upon
exercise of the Series B Option held by a Series B Onshore Investor and issued 947,218 shares of Series <FONT STYLE="white-space:nowrap">B-1</FONT> Preferred Shares upon conversion of Onshore Convertible Loans by a Series B Onshore Investor (see
Note 14), respectively. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">On July&nbsp;6, 2018, the Company issued 1,455,549 shares of Series B Preferred Shares upon exercise of the
Series B Option held by a Series B Onshore Investor, issued 232,161 shares of Series <FONT STYLE="white-space:nowrap">B-1</FONT> Preferred Shares upon conversion of Onshore Convertible Loans by a Series B Onshore Investor (see Note 14) and issued
1,048,337 shares of Series <FONT STYLE="white-space:nowrap">B-2</FONT> Preferred Shares upon exercise of Series B Warrant by Series B Onshore Investors, respectively. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Series B Preferred Shares, Series <FONT STYLE="white-space:nowrap">B-1</FONT> Preferred Shares and Series
<FONT STYLE="white-space:nowrap">B-2</FONT> Preferred Shares are also referred to as Series B Preferred Shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">On July 6, 2018, the
Company issued 31,046,360 shares of Series C Preferred Shares at a price of US$6.4419 per share with a total consideration of US$200,000 (equivalent to approximately RMB1,323,363). In </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-31 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>I-MAB </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to the Consolidated Financial Statements </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(All amounts in thousands, except for share and per share data, unless otherwise noted) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>13. Convertible Preferred Shares&nbsp;(Continued) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
connection with the offering of the Series C Preferred Shares, the Company incurred issuance costs of RMB16,730. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">On July&nbsp;25, 2019, the Group entered into a share purchase agreement with certain third party investors, under which these investors will
subscribe for an aggregate of 3,857,143 Series <FONT STYLE="white-space:nowrap">C-1</FONT> convertible preferred shares of the Company for an aggregate purchase price of US$27.0&nbsp;million. Out of the aforementioned subscription of 3,857,143
Series <FONT STYLE="white-space:nowrap">C-1</FONT> convertible preferred shares by certain third party investors, 1,428,571 Series <FONT STYLE="white-space:nowrap">C-1</FONT> convertible preferred shares were issued to an investor on
October&nbsp;17, 2019, and the Group also received the cash consideration of US$10,000 (equivalent to approximately RMB70,036). On November&nbsp;6, 2019, the Group received cash consideration of US$17,000 (equivalent to approximately RMB119,387) for
the remaining 2,428,572 Series <FONT STYLE="white-space:nowrap">C-1</FONT> convertible preferred shares from the investors and the issuance of such 2,428,572 Series <FONT STYLE="white-space:nowrap">C-1</FONT> convertible preferred shares was
consummated on that day. In connection with the offering of the Series <FONT STYLE="white-space:nowrap">C-1</FONT> convertible preferred shares, the Company incurred issuance costs of approximately US$840 (equivalent to approximately RMB5,887). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Series A Preferred Shares, Series B Preferred Shares, Series C Preferred Shares and Series <FONT STYLE="white-space:nowrap">C-1</FONT>
Preferred Shares are collectively referred to as Preferred Shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Key terms of the Preferred Shares are summarized as follows: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Dividends </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The holders of
Preferred Shares are entitled to receive dividends, out of any assets legally available therefore, prior and in preference to any declaration or payment of any dividend on the ordinary shares or any other class or series of shares of the Group at
the rate of eight percent (8%) of the original issue price per share per annum on each Preferred Share, payable in US$ and annually when, as and if declared by the Board of Directors. Such distributions shall not be cumulative. No dividend, whether
in cash, in property or in shares of the capital of the Group, shall be paid on or declared and set aside for any ordinary shares or any other class or series of shares of the Group unless and until all dividends have been paid in full on the
Preferred Shares (on an <FONT STYLE="white-space:nowrap">as-converted</FONT> basis). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Conversion </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Each Preferred Share may be converted at any time into ordinary shares at the option of the preferred shares holders at the then applicable
conversion price. The initial conversion ratio is 1:1, subject to adjustment in the event of (i)&nbsp;share splits, share combinations, share dividends or distribution, other dividends, recapitalizations and similar events, or (ii)&nbsp;issuance of
ordinary shares (excluding certain events such as issuance of ordinary shares pursuant to a public offering) at a price per share less than the conversion price in effect on the date of or immediately prior to such issuance. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Preferred Shares shall be automatically converted into ordinary shares immediately upon the closing of a public offering of the
Company&#146;s shares with an offering price (exclusive of underwriting commissions and expenses) that reflects a market capitalization (immediately prior to the public offering) of not less than US$1,000,000,000 or otherwise approved by all
directors and certain preferred shareholders as specified in the Company&#146;s memorandum and articles of association (the &#147;Qualified Public Offering&#148;). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-32 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>I-MAB </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to the Consolidated Financial Statements </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(All amounts in thousands, except for share and per share data, unless otherwise noted) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>13. Convertible Preferred Shares&nbsp;(Continued) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Conversion&nbsp;(Continued) </I></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Group determined that there were no beneficial conversion features (&#147;BCF&#148;)
identified for any of the Preferred Shares during any of the periods. In making this determination, the Company compared the fair value of the ordinary shares into which the Preferred Shares are convertible with the respective effective conversion
price at the issuance date. In all instances, the effective conversion price was greater than the fair value of the ordinary shares. To the extent a conversion price adjustment occurs, as described above, the Group will reevaluate whether or not a
beneficial conversion feature should be recognized. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Liquidation </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In the event of any liquidation (unless waived by the preferred shareholders) including deemed liquidation, dissolution or winding up of the
Company, holders of the Preferred Shares shall be entitled to receive a per share amount equal to one hundred percent (100%) of the original issue price on each Preferred Share, plus an amount representing an internal rate of return of twelve
percent (12%) per annum on the original issue price as adjusted for share dividends, share splits, combinations, recapitalizations or similar events, plus all accrued and declared but unpaid dividends thereon, in the sequence of Series C Preferred
Shares, Series B Preferred Shares and Series A Preferred Shares. After such liquidation amounts have been paid in full, any remaining funds or assets of the Company legally available for distribution to shareholders shall be distributed on a pro
rata basis among the holders of the Preferred Shares, on an <FONT STYLE="white-space:nowrap">as-converted</FONT> basis, together with the holders of the ordinary shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><I>Accounting of preferred shares </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Preferred Shares are redeemable by the holders upon a liquidation event, including a deemed liquidation event (e.g., change in control),
and as such are presented as mezzanine equity on the consolidated balance sheets. In accordance with ASC <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">480-10-S99,</FONT></FONT> each issuance of the convertible preferred shares
should be recognized at the date of issuance after deducting fair value allocated to the detachable warrants and issuance costs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><I>Modification of preferred shares </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Company assesses whether an amendment to the terms of its convertible preferred shares is an extinguishment or a modification using the
fair value model. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">When convertible redeemable preferred shares are extinguished, the difference between the fair value of the
consideration transferred to the convertible redeemable Preferred Shareholders and the carrying amount of such preferred shares (net of issuance costs) is treated as a deemed dividend to the Preferred Shareholders. When convertible redeemable
preferred shares are modified and such modification results in value transfer between Preferred Shareholders and ordinary shareholders, the change in fair value resulted from the amendment is treated as a deemed dividend to or from the Preferred
Shareholders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">On December&nbsp;25, 2019, the Company&#146;s shareholders and board of directors approved that, where the final offering
price of a Qualified Public Offering is no less than US$4.176 per ordinary share, the agreed provisions related to the number of shares to be converted into the Company&#146;s ordinary shares shall apply with
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-33 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>I-MAB </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to the Consolidated Financial Statements </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(All amounts in thousands, except for share and per share data, unless otherwise noted) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>13. Convertible Preferred Shares&nbsp;(Continued) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Liquidation&nbsp;(Continued) </I></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
respect to the Series <FONT STYLE="white-space:nowrap">C-1</FONT> Preferred Shares, Series C Preferred Shares, Series <FONT STYLE="white-space:nowrap">B-2</FONT> Preferred Shares and Series <FONT
STYLE="white-space:nowrap">B-1</FONT> Preferred Shares, which will generally give rise to a one to multiple conversion of the such rounds of Preferred Shares, provided that unanimous consent of the directors on the final offering price needs to be
obtained in the event that the final offering price per ordinary share of such IPO is fixed at a price equal to or higher than US$4.176 per ordinary share but lower than US$5.22 per ordinary share. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Company evaluated the aforementioned modifications and concluded that they represented modifications, rather than extinguishment, to
Series B-1, <FONT STYLE="white-space:nowrap">B-2</FONT> and C Preferred Shares, which resulted in a transfer of value from ordinary shareholders to preferred shareholders. The combined change in fair value of Series
<FONT STYLE="white-space:nowrap">B-1,</FONT> <FONT STYLE="white-space:nowrap">B-2</FONT> and C Preferred Shares immediately before and after the modification was US$4.0 million (equivalent to approximately RMB27.8 million) on December&nbsp;25, 2019.
This decrease in fair value of the ordinary shares of US$4.0&nbsp;million (equivalent to approximately RMB27.8 million) on December&nbsp;25, 2019 was, in substance, a transfer of wealth mostly from ordinary shareholders to preferred shareholders,
and therefore was recorded as a deemed dividend to the preferred shareholders<B>.</B> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Company evaluated the aforementioned
modifications and concluded that they represented extinguishment to Series <FONT STYLE="white-space:nowrap">C-1</FONT> Preferred Shares. The difference between the fair value of the modified Series <FONT STYLE="white-space:nowrap">C-1</FONT>
Preferred Shares and the carrying value of the original Series <FONT STYLE="white-space:nowrap">C-1</FONT> Preferred Shares was amounting US$0.8&nbsp;million on December&nbsp;25, 2019 and represented the fair value of the consideration transferred,
and therefore was recognized as a deemed dividend to the preferred shareholders and adjustment to the carrying amount of Series <FONT STYLE="white-space:nowrap">C-1</FONT> Preferred Shares<B>.</B> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-34 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>I-MAB </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to the Consolidated Financial Statements </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(All amounts in thousands, except for share and per share data, unless otherwise noted) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>13. Convertible Preferred Shares&nbsp;(Continued) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Liquidation&nbsp;(Continued) </I></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Company&#146;s convertible preferred shares activities for the years ended
December&nbsp;31, 2018 and 2019 are summarized below: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="76%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Series&nbsp;A Preferred&nbsp;Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Series&nbsp;B Preferred&nbsp;Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Series&nbsp;C&nbsp;Preferred&nbsp;Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B><FONT STYLE="white-space:nowrap">Series&nbsp;C-1&nbsp;Preferred&nbsp;Shares</FONT></B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Number&nbsp;of</B><br><B>shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Number&nbsp;of</B><br><B>shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Number&nbsp;of</B><br><B>shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Number&nbsp;of</B><br><B>shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:7pt; font-family:Times New Roman; " ALIGN="center"><B>US$</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:7pt; font-family:Times New Roman; " ALIGN="center"><B>RMB</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:7pt; font-family:Times New Roman; " ALIGN="center"><B>US$</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:7pt; font-family:Times New Roman; " ALIGN="center"><B>RMB</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:7pt; font-family:Times New Roman; " ALIGN="center"><B>US$</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:7pt; font-family:Times New Roman; " ALIGN="center"><B>RMB</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:7pt; font-family:Times New Roman; " ALIGN="center"><B>US$</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:7pt; font-family:Times New Roman; " ALIGN="center"><B>RMB</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Balance as of January&nbsp;1, 2018</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21,865,233</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">53,927</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">363,766</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,894,594</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">52,546</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">346,515</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Issuance of Series A Preferred Shares upon exercise of Series
<FONT STYLE="white-space:nowrap">A-3</FONT> Option</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,361,823</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">48,925</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">323,716</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Issuance of Series B Preferred Shares upon exercise of
<FONT STYLE="white-space:nowrap">Series-B</FONT> Option</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,394,189</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">44,083</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">291,677</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Issuance of Series B Preferred Shares upon conversion of 2017 Notes</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,535,201</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,401</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">101,906</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Issuance of Series B Preferred Shares upon conversion of Onshore Convertible Loans</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,179,379</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,165</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">47,407</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Issuance of Series B Preferred Shares upon exercise of Tranche I of Series&nbsp;B Warrants</P></TD>

<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,301,849</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20,212</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">133,738</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Issuance of Series C Preferred Shares, net of issuance costs</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">31,046,360</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">197,478</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,306,633</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Balance as of December&nbsp;31, 2018</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30,227,056</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">102,852</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">687,482</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30,305,212</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">139,407</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">921,243</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">31,046,360</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">197,478</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,306,633</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Balance as of January&nbsp;1, 2019</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">30,227,056</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">102,852</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">687,482</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">30,305,212</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">139,407</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">921,243</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">31,046,360</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">197,478</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">1,306,633</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Issuance of Series <FONT STYLE="white-space:nowrap">C-1</FONT> Preferred Shares, net of issuance
costs</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">3,857,143</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">26,160</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">183,536</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Adjustment at extinguishment of Series <FONT STYLE="white-space:nowrap">C-1</FONT> Preferred
Shares</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">754</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">5,283</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Balance as of December&nbsp;31, 2019</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">30,227,056</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">102,852</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">687,482</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">30,305,212</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">139,407</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">921,243</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">31,046,360</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">197,478</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">1,306,633</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">3,857,143</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">26,914</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">188,819</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-35 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>I-MAB </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to the Consolidated Financial Statements </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(All amounts in thousands, except for share and per share data, unless otherwise noted) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>14. Convertible Promissory Notes and Onshore Convertible Loans </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>2017 Notes </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">On September&nbsp;25,
2017, the Company issued US$11,520 convertible promissory notes (&#147;2017 Notes&#148;) to investors of Series B Preferred Shares (see Note 13) at a compound interest rate of 8% per annum, maturing on 36 months after the issuance date. Under the
agreement, the holder of the 2017 Notes may convert the outstanding principal amount into Series <FONT STYLE="white-space:nowrap">B-1</FONT> Preferred Shares at the conversion price of US$5.38 per share or a lower price as may be agreed by the
investors and the Company at any time from six months prior to the maturity date and prior to the repayment in full of the 2017 Note. No interest shall be accrued if the 2017 Notes have been converted into Series
<FONT STYLE="white-space:nowrap">B-1</FONT> Preferred Shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">As the fair value of the Company&#146;s ordinary shares on
September&nbsp;25, 2017 was lower than the effective conversion price of US$5.38, the Company did not record a BCF. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">On June&nbsp;29,
2018, the Company&#146;s 2017 Notes were converted into the Company&#146;s 2,535,201 Series <FONT STYLE="white-space:nowrap">B-1</FONT> Preferred Shares at the nominal conversion price of US$5.38 per share. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>2018 Notes </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">On February&nbsp;3,
2018, the Company issued US$9,000 (equivalent to approximately RMB59,704) convertible promissory notes (&#147;2018 Notes&#148;) to an investor of Series <FONT STYLE="white-space:nowrap">A-3</FONT> Preferred Shares at an annual interest rate of 0%,
maturing on 36 months after the issuance date. Under the agreement, the holder of the 2018 Notes may convert the 2018 Notes outstanding principal amount into Series <FONT STYLE="white-space:nowrap">B-1</FONT> Preferred Shares at the conversion price
being lower of US$10 per share and fair market value at any time prior to the maturity date. Alternatively, the 2018 Notes shall be automatically converted into the Company&#146;s Series B Preferred Shares upon the maturity. As the fair value of the
Company&#146;s ordinary shares on February&nbsp;3, 2018 of US$3.96 was equal to the effective conversion price (being lower of US$10 per share and fair market value), the Company did not record a BCF. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Onshore Convertible Loans </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">On
September&nbsp;25, 2017, <FONT STYLE="white-space:nowrap">I-Mab</FONT> Tianjin issued a US$5,359 convertible loan to Series B Onshore Investors at a compound interest rate of 8% per annum, maturing on 36 months after the issuance date. Under the
agreement, the holder of the Onshore Convertible Loans may convert the outstanding principal amount into <FONT STYLE="white-space:nowrap">I-Mab</FONT> Tianjin&#146;s equity interest a stipulated conversion price at any time from six months prior to
the maturity date and prior to the repayment in full of the Onshore Convertible Loans. No interest shall be accrued if the Onshore Convertible Loans have been converted into <FONT STYLE="white-space:nowrap">I-Mab</FONT> Tianjin&#146;s equity
interest. As the fair value of the <FONT STYLE="white-space:nowrap">I-Mab</FONT> Tianjin&#146;s ordinary shares on September&nbsp;25, 2017 was lower than the effective conversion price of US$4.31, the Company did not record a BCF. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In June and July 2018, the Company reached agreements with holders of Onshore Convertible Loans and the principal amount of Onshore
Convertible Loans were then effectively converted into 1,179,379 Series <FONT STYLE="white-space:nowrap">B-1</FONT> Preferred Shares of the Company and the accrued interests were waived, resulting in an extinguishment loss of RMB8,548. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-36 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>I-MAB </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to the Consolidated Financial Statements </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(All amounts in thousands, except for share and per share data, unless otherwise noted) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>15. Warrants </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In connection with the issuance of the Series <FONT STYLE="white-space:nowrap">A-1</FONT> and <FONT STYLE="white-space:nowrap">A-2</FONT>
Preferred Shares on October&nbsp;18, 2016, 2,246,744 Series <FONT STYLE="white-space:nowrap">A-3</FONT> Warrants were issued to Series <FONT STYLE="white-space:nowrap">A-1</FONT> and <FONT STYLE="white-space:nowrap">A-2</FONT> preferred
shareholders, which provided the holder the right to purchase Series <FONT STYLE="white-space:nowrap">A-3</FONT> Preferred Shares. The Series <FONT STYLE="white-space:nowrap">A-3</FONT> Warrants were later terminated on September&nbsp;6, 2017
without being exercised. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In connection with the issuance of the Series B Preferred Shares on September&nbsp;22, 2017, 5,633,780 Series B
Warrants were issued to Series B preferred shareholders, which provided the holders the right to purchase Series <FONT STYLE="white-space:nowrap">B-2</FONT> Preferred Shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In connection with the Company&#146;s Series B Onshore Financing that took place on September&nbsp;25, 2017, 2,620,842 Series B Warrants were
issued to Series B Onshore Investors, which provided the holders the right to purchase Series <FONT STYLE="white-space:nowrap">B-2</FONT> Preferred Shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">During the period from June&nbsp;29, 2018 to July&nbsp;6, 2018, 3,301,849 Series B Warrants (representing Tranche I of Series B Warrants) were
exercised to purchase 3,301,849 Series <FONT STYLE="white-space:nowrap">B-2</FONT> Preferred Shares with proceeds of US$20,000 (equivalent to approximately RMB132,332). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">On July&nbsp;6, 2018, the Series B Warrants holders agreed that the Series B Warrants shall be divided into two tranches and exercisable in
accordance with different time schedules, such that: (i)&nbsp;the holders have exercised part of the Series B Warrants in the total consideration of US$20,000 (&#147;Tranche I of Series B Warrants&#148;) and 3,301,849 Series <FONT
STYLE="white-space:nowrap">B-2</FONT> Preferred Shares of the Company in aggregate have been newly issued to such holders on a pro rata basis; (ii)&nbsp;only when the Company fails to submit a Qualified Public Offering application at an
internationally recognized securities exchange by March&nbsp;31, 2019, the Warrant Holders may exercise the remaining part of Series B Warrants, in the total consideration of US$30,000 (&#147;Tranche II of Series B Warrants&#148;) and 4,952,773
Series <FONT STYLE="white-space:nowrap">B-2</FONT> Preferred Shares of the Company in aggregate will be issued to such holders on a pro rata basis; (iii)&nbsp;provided that the Company successfully submits a Qualified Public Offering application at
an internationally recognized securities exchange by March&nbsp;31, 2019, the holders shall unconditionally and irrevocably waive and cancel Tranche II of Series B Warrants; and (iv)&nbsp;the Tranche II of Series B Warrants may only be concurrently
exercised by all the Warrant Holders in one lump. This is considered to be a modification to Series B Warrants. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">According to the
confirmations issued by the Company&#146;s Series B Warrants holders in July 2019, the holders of Series B Warrants has unconditionally and irrevocably waived and cancelled the Tranche II of Series B Warrants. The fair value gain of warrants for the
year ended December&nbsp;31, 2019 was amounting to RMB5,644. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Accounting of Warrants </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The warrant is a freestanding instrument and is recorded as liability in accordance with ASC 480, <I>Distinguishing Liabilities from
Equity</I>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">As the Company&#146;s issuance of warrants were bundled with other instruments (such as convertible preferred shares,
convertible promissory notes, etc.), out of total considerations, the warrants are initially recognized at fair value and the remaining were allocated to other instruments on a relative fair value basis (if
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-37 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>I-MAB </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to the Consolidated Financial Statements </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(All amounts in thousands, except for share and per share data, unless otherwise noted) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>15. Warrants&nbsp;(Continued) </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Accounting of
Warrants&nbsp;(Continued) </I></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
applicable). The fair value changes of the warrants (including the fair value changes arising from modification of warrants) up to the time of exercise or termination were recognized in earnings.
Upon exercise, the total carrying value of the associated warrant liabilities was reclassified into the carrying value of the Preferred Shares into which it was converted. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Company determined the fair value of the warrants with the assistance of an independent third party valuation firm. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Group has measured the warrant liabilities at fair values on a recurring basis using significant unobservable inputs (Level 3) for the
years ended December&nbsp;31, 2018. The Group used the binomial model to estimate the fair value of warrant liabilities using the following assumptions: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="72%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="66%"></TD>

<TD VALIGN="bottom" WIDTH="32%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>As&nbsp;of&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Risk-free rate of return</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.49</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Maturity date</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">September&nbsp;25,&nbsp;2019</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Estimated volatility rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50.9</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercise price</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">US$</TD>
<TD VALIGN="bottom" ALIGN="right">6.06</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fair value of underlying convertible preferred shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">US$</TD>
<TD VALIGN="bottom" ALIGN="right">6.91</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The model requires the input of highly subjective assumptions including the risk-free rate of return, maturity
date, estimated volatility rate and fair value of underlying preferred shares. The risk-free rate for periods within the contractual life is based on the US treasury strip bond with maturity similar to the maturity of the warrants as of valuation
dates plus a China country risk premium. For expected volatilities, the Group has made reference to the historical daily stock prices volatilities of ordinary shares of several comparable companies in the same industry as the Group. The estimated
fair value of the preferred shares was determined with assistance from an independent third party valuation firm. The Group&#146;s management is ultimately responsible for the determination of the estimated fair value of its preferred shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The significant unobservable inputs used in the fair value measurement of the warrant liabilities include risk-free rate of return, interval
between valuation date and maturity date, estimated volatility rate and fair value of underlying preferred shares. Significant decreases in interval between valuation date and maturity date, estimated volatility rate and fair value of underlying
preferred shares would result in a significantly lower fair value measurement. Significant increases in risk-free rate of return would result in a significantly lower fair value measurement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>16. Redeemable <FONT STYLE="white-space:nowrap">Non-Controlling</FONT> Interests </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In connection with the Company&#146;s acquisition of Tasgen Group on September&nbsp;6, 2017, the Company also entered into an option agreement
with the third party investor of <FONT STYLE="white-space:nowrap">I-Mab</FONT> Tianjin, pursuant to which the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-38 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>I-MAB </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to the Consolidated Financial Statements </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(All amounts in thousands, except for share and per share data, unless otherwise noted) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>16. Redeemable <FONT STYLE="white-space:nowrap">Non-Controlling</FONT> Interests&nbsp;(Continued) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Company granted the third party investor an option to subscribe for certain number of Series <FONT STYLE="white-space:nowrap">A-3</FONT> Preferred Shares of the Company at a price that stipulated
in the agreement, and at the same time, the third party investor transferred its equity interests in <FONT STYLE="white-space:nowrap">I-Mab</FONT> Tianjin to the Company at the same price (&#147;Series <FONT STYLE="white-space:nowrap">A-3</FONT>
Option&#148;). This Series <FONT STYLE="white-space:nowrap">A-3</FONT> can be exercised at any time at the holder&#146;s own discretion or upon the request of the Company if the shareholders of the Company approves an initial public offering. In
addition, in the event that the exercise of Series <FONT STYLE="white-space:nowrap">A-3</FONT> Option has not been completed within 6 months after the option holder delivers the share purchase option notice, the Company shall purchase the third
party investor&#146;s equity interest in <FONT STYLE="white-space:nowrap">I-Mab</FONT> Tianjin and the Series <FONT STYLE="white-space:nowrap">A-3</FONT> Option at a price that stipulated in the agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Concurrently with the Company&#146;s issuance of Series B Preferred Shares (see Note 13), on September&nbsp;25, 2017, the Group&#146;s
subsidiary <FONT STYLE="white-space:nowrap">I-MAB</FONT> Tianjin entered into a capital increase subscription agreement with Series B Onshore Investors, pursuant to which Series B Onshore Investors subscribed for additional equity in <FONT
STYLE="white-space:nowrap">I-MAB</FONT> Tianjin of US$24,444 (equivalent to approximately RMB161,196). On September&nbsp;25, 2017 and in tandem with the aforementioned <FONT STYLE="white-space:nowrap">I-Mab</FONT> Tianjin&#146;s capital increase
subscription agreement, the Company also entered into option agreements with Series B Onshore Investors, pursuant to which the Company granted Series B Onshore Investors options to subscribe for certain numbers of Series <FONT
STYLE="white-space:nowrap">B-1</FONT> Preferred Shares of the Company at a price that stipulated in the agreements, and at the same time, the Series B Onshore Investors shall transfer their equity interests in
<FONT STYLE="white-space:nowrap">I-Mab</FONT> Tianjin to the Company at the same price (&#147;Series B Option&#148;). The Series B Option can be exercised at any time at the holders&#146; own discretion or upon the request of the Company if the
shareholders of the Company approve an initial public offering. In addition, in the event that the exercise of Series B Option has not been completed within 6 months after the option holders deliver the share purchase option notice, the Company
shall purchase the third party investor&#146;s equity interest in <FONT STYLE="white-space:nowrap">I-Mab</FONT> Tianjin and the Series B Option at a price that stipulated in the agreements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Based on the accounting assessments, the Company considers that the aforementioned Series <FONT STYLE="white-space:nowrap">A-3</FONT> and
Series B Options are embedded features of the <FONT STYLE="white-space:nowrap">non-controlling</FONT> interests that are not required to be bifurcated. Since the aforementioned <FONT STYLE="white-space:nowrap">non-controlling</FONT> interests in <FONT
STYLE="white-space:nowrap">I-Mab</FONT> Tianjin are redeemable at a determinable price, upon occurrence of an event that is not solely within the control of <FONT STYLE="white-space:nowrap">I-Mab</FONT> Tianjin, the aforementioned <FONT
STYLE="white-space:nowrap">non-controlling</FONT> interests in <FONT STYLE="white-space:nowrap">I-Mab</FONT> Tianjin are accounted for as redeemable <FONT STYLE="white-space:nowrap">non-controlling</FONT> interests in the Group&#146;s consolidated
balance sheets. Subsequently, the redeemable <FONT STYLE="white-space:nowrap">non-controlling</FONT> interests should be carried at the higher of (1)&nbsp;the carrying amount after the attribution of net income of the Company and (2)&nbsp;the
expected redemption value. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Series <FONT STYLE="white-space:nowrap">A-3</FONT> Option and Series B Option were exercised by respective
holders on June&nbsp;29, 2018 and July&nbsp;6, 2018 to acquire 8,361,823 Series <FONT STYLE="white-space:nowrap">A-3</FONT> Preferred Shares and 7,394,189 Series B Preferred Shares, respectively. The transactions were accounted for as equity
transactions, and the differences between the carrying amount of redeemable <FONT STYLE="white-space:nowrap">non-controlling</FONT> interests of RMB305,708 and the fair value of convertible preferred shares of RMB615,393 that issued was recognized
in additional <FONT STYLE="white-space:nowrap">paid-in</FONT> capital. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-39 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>I-MAB </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to the Consolidated Financial Statements </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(All amounts in thousands, except for share and per share data, unless otherwise noted) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>16. Redeemable <FONT STYLE="white-space:nowrap">Non-Controlling</FONT> Interests&nbsp;(Continued) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Group&#146;s redeemable <FONT STYLE="white-space:nowrap">non-controlling</FONT> interest
activities for the years ended December&nbsp;31, 2017, 2018 and 2019 is summarized as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="85.5%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="55%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Year&nbsp;Ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>RMB</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>RMB</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>RMB</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>US$&nbsp;(Note&nbsp;2.5)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Beginning balance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">305,708</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Capital injection by Series B Onshore Investors</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">161,196</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Redeemable <FONT STYLE="white-space:nowrap">non-controlling</FONT> interests arising from
business combination</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">144,512</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercise of Series <FONT STYLE="white-space:nowrap">A-3</FONT> Option</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(144,512</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercise of Series B Option</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(161,196</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ending balance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">305,708</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>17. Share-Based Compensation </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>(a) Restricted Shares </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">During the
year ended December&nbsp;31, 2016, the Company issued 4,019,554 ordinary shares to Mr.&nbsp;Zang Jingwu Zhang, Ms.&nbsp;Qian Lili, Mr.&nbsp;Wang Zhengyi and Mr.&nbsp;Fang Lei (collectively the &#147;Founders&#148;), including the 369,301 shares
which represented the equity interests of Third Venture held by the Founders, and the Company recorded share-based compensation expense of RMB18.7&nbsp;million for issuance and grant of 3,650,253 ordinary shares to the Founders in June 2016. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In October 2016, the Founders entered into an arrangement with other investors of the Company, and the 87,441 ordinary shares issued to the
Founders in June 2016 were canceled and out of the remaining 3,932,113 ordinary shares held by the Founders, 70% became restricted and subject to service vesting conditions, that should vest 20%, 20% and 30% over the next three years, respectively.
There shall be no acceleration of the vesting schedule except that, in case of a change of control of the Company or a Qualified Public Offering, or the termination of the Founder&#146;s employment with the Group without cause. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Deferred share-based compensation was measured for the restricted shares using the estimated fair value of the Company&#146;s ordinary shares
of US$0.77 at the date of imposition of the restriction in October 2016, and was amortized to the consolidated statements of comprehensive loss by using graded vesting method over the vesting term of 3 years. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-40 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>I-MAB </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to the Consolidated Financial Statements </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(All amounts in thousands, except for share and per share data, unless otherwise noted) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>17. Share-Based Compensation&nbsp;(Continued) </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>(a)
Restricted Shares&nbsp;(Continued) </I></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The following table summarizes the Group&#146;s Founders&#146; restricted shares activities:
</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="72%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="68%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Numbers<BR>of&nbsp;shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Weighted-<BR>average<BR>grant&nbsp;date<BR>fair&nbsp;value</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outstanding at December&nbsp;31, 2016</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,752,479</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.77</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Vested</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(786,423</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outstanding at December&nbsp;31, 2017</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,966,056</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.77</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Vested</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(786,423</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outstanding at December&nbsp;31, 2018</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,179,633</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.77</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Vested</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,179,633</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outstanding at December&nbsp;31, 2019</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The amounts of shared-based compensation expense in relation to the restricted shares recognized in the years
ended December&nbsp;31, 2017, 2018 and 2019 were RMB7,039, RMB3,520 and RMB1,566, respectively. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Share-based compensation expenses related
to restricted shares were included in: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="85.5%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="58%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Year&nbsp;Ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>RMB</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>RMB</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>RMB</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>US$&nbsp;(Note&nbsp;2.5)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,112</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,056</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">470</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">67</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Administrative expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,927</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,464</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,096</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">155</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,039</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,520</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,566</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">222</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>(b) 2017 Employee Stock Option Plan (&#147;2017 Plan&#148;) </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In October 2017, the Company adopted the 2017 Plan. Under the 2017 Plan, a maximum aggregate number of 13,376,865 shares that may be issued
pursuant to all awards granted was approved. Stock options granted to an employee under the 2017 Plan will be exercisable upon the Company completes a listing and the employee renders service to the Company in accordance with a stipulated service
schedule starting from the employee&#146;s date of employment. Employees are generally subject to a three-year service schedule, under which an employee earns an entitlement to vest in 50% of the option grants on the second anniversary of the grant
date, a vesting of the remaining 50% on the third anniversary of the applicable grant date. The stock option under 2017 Plan, to the extent then vested, shall become exercisable only upon the earlier of (i)&nbsp;a listing, and (ii)&nbsp;occurrence
of a change in control. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">On December&nbsp;25, 2019, the Second Amended and Restated 2017 Plan was approved by the shareholders and board
of directors of the Company, pursuant to which, in connection with the Company&#146;s IPO, the maximum </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-41 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>I-MAB </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to the Consolidated Financial Statements </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(All amounts in thousands, except for share and per share data, unless otherwise noted) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>17. Share-Based Compensation&nbsp;(Continued) </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>(b)
2017 Employee Stock Option Plan (&#147;2017 Plan&#148;)&nbsp;(Continued) </I></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
aggregate number of shares that may be granted pursuant to all awards under 2017 Plan shall be adjusted in accordance with a formula <FONT STYLE="white-space:nowrap">pre-approved</FONT> by the
shareholders. In connection with above amendments to 2017 Plan, each of the Company&#146;s founders, namely Zheru Zhang, Lili Qian, Zhengyi Wang and Lei Fang, is willing to irrevocably surrender by him or her, for no consideration, a portion of the
unvested options granted to him or her, which, if vested, would entitle him or her to acquire up to 130,000 ordinary shares of the Company, par value US$0.0001 per share, at an exercise price of US$1.0, respectively, under the Second Amended and
Restated 2017 Plan (in respect of each individual, the &#147;Founder&#146;s Surrendered Options&#148;). On December&nbsp;25, 2019, the board of directors of the Company approved that the Company accepts all Founder&#146;s Surrendered Options from
each of the founders, Zheru Zhang, Lili Qian, Zhengyi Wang and Lei Fang, for no consideration, with effect immediately prior to the completion of the IPO and such surrendered options be cancelled with effect immediately prior to the completion of
the IPO. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Prior to the Company completes a listing, all stock options granted to an employee shall be forfeited at the time the employee
terminates his employment with the Group. After the Company completes a listing, vested options not exercised by an employee shall be exercised until later of: (i) 90 days after the date when the options become exercisable, or (ii) 30 days after the
date of cessation of employment or directorship, or such longer period as the Board of Directors may otherwise determine. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">For the years
ended December&nbsp;31, 2017, 2018 and 2019, the Group granted 11,051,230 stock options, 1,470,000 stock options and 640,000 stock options, respectively, to its employees (all with an exercise price of US$1). No options are exercisable as of
December&nbsp;31, 2017, 2018, and 2019 and prior to the Group completes a listing. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-42 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>I-MAB </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to the Consolidated Financial Statements </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(All amounts in thousands, except for share and per share data, unless otherwise noted) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>17. Share-Based Compensation&nbsp;(Continued) </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>(b)
2017 Employee Stock Option Plan (&#147;2017 Plan&#148;)&nbsp;(Continued) </I></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The following table sets forth the stock options activities of 2017 Plan for the periods
presented: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="55%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Number&nbsp;of</B><br><B>shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Weighted</B><br><B>average</B><br><B>exercise</B><br><B>price</B><br><B>US$</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Weighted</B><br><B>average</B><br><B>remaining</B><br><B>contractual</B><br><B>term</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Aggregate</B><br><B>intrinsic</B><br><B>value</B><br><B>US$</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outstanding as of December&nbsp;31, 2016</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Granted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,051,230</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other addition (note)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">710,366</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.06</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outstanding as of December&nbsp;31, 2017</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,761,596</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.94</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9.50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24,890</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Granted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,470,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Forfeited</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(226,000</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outstanding as of December&nbsp;31, 2018</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,005,596</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.95</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.61</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">70,129</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Granted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">640,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Forfeited</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(397,500</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Repurchased (Note 17(d))</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,435,215</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outstanding as of December&nbsp;31 ,2019</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,812,881</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.93</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.76</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">47,671</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercisable as of December&nbsp;31, 2019</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:12.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">Note:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Other addition represented the modified share options that originally granted to two senior management
employees in October 2016 (see (f)&nbsp;other share-based compensation). </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Stock options granted to the employees were
measured at fair value on the dates of grant using the Binomial Option Pricing Model with the following assumptions: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="72%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="56%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Year&nbsp;ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected volatility</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">62.34</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">61.32%-62.13</FONT></TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">54.64</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Risk-free interest rate (per annum)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.32</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">2.81%-3.06</FONT></TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.15</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercise multiple</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.80</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.80</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.80</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected dividend yield</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Contractual term (in years)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The expected volatility was estimated based on the historical volatility of comparable peer public companies
with a time horizon close to the expected term of the Group&#146;s options. The risk-free interest rate was estimated based on the yield to maturity of U.S. treasury bonds denominated in US$ for a term consistent with the expected term of the
Group&#146;s options in effect at the option valuation date. The expected exercise multiple was estimated as the average ratio of the stock price to the exercise price when employees would decide to voluntarily exercise their vested options. As the
Group did not have sufficient information of past employee exercise history, it was estimated by referencing to a widely-accepted academic research publication. Expected </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-43 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>I-MAB </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to the Consolidated Financial Statements </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(All amounts in thousands, except for share and per share data, unless otherwise noted) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>17. Share-Based Compensation&nbsp;(Continued) </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>(b)
2017 Employee Stock Option Plan (&#147;2017 Plan&#148;)&nbsp;(Continued) </I></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
dividend yield is zero as the Group has never declared or paid any cash dividends on its shares, and the Group does not anticipate any dividend payments in the foreseeable future. Expected term
is the contract life of the option. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">There were 640,000 stock options granted to employees under 2017 Plan for the year ended
December&nbsp;31, 2019. Since the exercisability is dependent upon the listing, and it is not probable that this performance condition can be achieved until a listing, no share-based compensation expense relating to the 2017 Plan was recorded for
the years ended December&nbsp;31, 2017, 2018 and 2019. The Group will recognize compensation expenses relating to options vested cumulatively upon the completion of the Company&#146;s listing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>(c) 2018 Employee Stock Option Plan (&#147;2018 Plan&#148;) </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">On February&nbsp;22, 2019, the Group adopted the 2018 Plan, which was subsequently amended on July&nbsp;22, 2019. Under the amended and
restated 2018 Plan, the maximum aggregate number of ordinary shares which may be issued pursuant to all awards is 14,005,745, and if the Group successfully lists on an internationally recognized securities exchange for a Qualified Public Offering by
December&nbsp;31, 2019, the maximum aggregate number of ordinary shares which may be issued shall be 15,452,620. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">On December&nbsp;25,
2019, the Second Amended and Restated 2018 Plan were approved by the shareholders and board of directors of the Company, pursuant to which, in connection with the Company&#146;s IPO, the maximum aggregate number of shares that may be granted
pursuant to all awards under 2018 Plan shall be adjusted in accordance with a formula <FONT STYLE="white-space:nowrap">pre-approved</FONT> by the shareholders. In connection with above amendments to 2018 Plan, the director of the Company,
Dr.&nbsp;Jingwu Zhang Zang is willing to irrevocably surrender by him, for no consideration, of the right to acquire a certain amount of ordinary shares of the Company, par value US$0.0001 per share, at an exercise price of US$1.0 pursuant to the
options granted to him under the Second Amended and Restated 2018 Plan (the &#147;Dr.&nbsp;Zang&#146;s Surrendered Options&#148;). On December&nbsp;25, 2019, the board of directors of the Company approved that the Company accepts the irrevocable
surrender of Dr.&nbsp;Zang&#146;s Surrendered Options for no consideration, with effect immediately prior to the completion of the IPO and such surrendered options be cancelled with effect immediately prior to the completion of the IPO. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Stock options granted to an employee under the 2018 Plan will be generally exercisable when the Company completes a listing and the employee
renders service to the Company in accordance with a stipulated service schedule starting from the employee&#146;s date of employment. The vesting schedule shall generally be a <FONT STYLE="white-space:nowrap">two-year</FONT> vesting schedule
consisting of a cliff vesting 50% on the first anniversary of the applicable vesting commencement date, and a vesting of the remaining 50% on the second anniversary of the applicable vesting commencement date. If a listing occurs at anytime prior to
any option granted under the 2018 Plan becoming full vested, and to the extent such option has been granted and outstanding, any such option shall vest in full with immediate effect upon the listing. Except as otherwise approved by the board of
directors, vested portion of option shall become exercisable upon the earlier of six months after a listing or the occurrence of a change in control; provided, however that in each case, no option of an employee shall become exercisable until the
third anniversary of such employee&#146;s employment commencement date. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-44 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>I-MAB </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to the Consolidated Financial Statements </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(All amounts in thousands, except for share and per share data, unless otherwise noted) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>17. Share-Based Compensation&nbsp;(Continued) </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>(c)
2018 Employee Stock Option Plan (&#147;2018 Plan&#148;)&nbsp;(Continued) </I></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Pursuant to the Board of Director&#146;s approval of 2018 Plan on February&nbsp;22, 2019, the
10,893,028 stock options granted to a director of the Group under 2018 Plan were fully vested and exercisable upon the adoption of 2018 Plan. Out of aforementioned total 10,893,028 stock options, 454,940 stock options were repurchased by the Group
(see Note 17 (d) for further details). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The amounts of shared-based compensation expense in relation to the aforementioned grant of stock
options to a director of the Group (except for those repurchased by the Group as described in Note 17(d)) recognized in the year ended December&nbsp;31, 2019 was RMB365,329, included in administrative expenses. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The following table sets forth the stock options activities of 2018 Plan for the year ended December&nbsp;31, 2019: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="85.5%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="52%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Number&nbsp;of</B><br><B>shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Weighted</B><br><B>average</B><br><B>exercise</B><br><B>price</B><br><B>US$</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Weighted</B><br><B>average</B><br><B>remaining</B><br><B>contractual</B><br><B>term</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Aggregate</B><br><B>intrinsic</B><br><B>value</B><br><B>US$</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outstanding as of January&nbsp;1, 2019</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Granted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,991,528</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Repurchased (Note 17 (d))</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(454,940</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outstanding as of December&nbsp;31, 2019</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,536,588</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.86</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">64,840</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercisable as of December&nbsp;31 , 2019</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,438,088</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9.15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">49,998</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Stock options granted to certain directors and employees of the Group were measured at fair value on the dates
of grant using the Binomial Option Pricing Model with the following assumptions: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="72%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="62%"></TD>

<TD VALIGN="bottom" WIDTH="22%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Year&nbsp;ended&nbsp;December&nbsp;31,&nbsp;2019</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected volatility</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">54.64%-56.31</FONT></TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Risk-free interest rate (per annum)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">2.15%-2.75</FONT></TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercise multiple</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.80</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected dividend yield</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Contractual term (in years)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The expected volatility was estimated based on the historical volatility of comparable peer public companies
with a time horizon close to the expected term of the Group&#146;s options. The risk-free interest rate was estimated based on the yield to maturity of U.S. treasury bonds denominated in US$ for a term consistent with the expected term of the
Group&#146;s options in effect at the option valuation date. The expected exercise multiple was estimated as the average ratio of the stock price to the exercise price when employees would decide to voluntarily exercise their vested options. As the
Group did not have sufficient information of past employee exercise history, it was estimated by referencing to a widely-accepted academic research publication. Expected dividend yield is zero as the Group has never declared or paid any cash
dividends on its shares, and the Group does not anticipate any dividend payments in the foreseeable future. Expected term is the contract life of the option. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-45 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>I-MAB </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to the Consolidated Financial Statements </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(All amounts in thousands, except for share and per share data, unless otherwise noted) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>17. Share-Based Compensation&nbsp;(Continued) </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>(c)
2018 Employee Stock Option Plan (&#147;2018 Plan&#148;)&nbsp;(Continued) </I></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Except for the aforementioned grant of stock options to a director of the Group under 2018
Plan, since the exercisability is dependent upon the listing, and it is not probable that this performance condition can be achieved until a listing, no share-based compensation expense related to the 2018 Plan was recorded for the year ended
December&nbsp;31, 2019. The Group will recognize compensation expenses relating to options vested cumulatively upon the completion of the Company&#146;s listing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>(d) Repurchase of Share Awards held by a Director </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">On February&nbsp;22, 2019, the amendment and restated 2017 equity incentive plan was approved by the Board of Directors of the Group, pursuant
to which only the 3,435,215 stock options held by the director (see Note 17(c)) under the 2017 equity incentive plan became fully vested and exercisable on February&nbsp;22, 2019. As a result of the performance condition being waived, the stock
options held by the director of the Group were accounted for as a Type III modification where a condition that the Group expects will not be satisfied is changed to a condition that the Group expects will be satisfied. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Additionally, on the same day, the Group repurchased such 3,435,215 stock options under the amendment and restated 2017 equity incentive plan
that was held by the director of the Group along with 454,940 of his stock options under the 2018 equity incentive plan for which the share awards also became fully vested and exercisable, at a total consideration of US$21,902 (equivalent to
approximately RMB148,308) at an average share price of US$5.63 per share. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">For the year ended December&nbsp;31, 2019, the Group recorded
the total payment of US$21,902 (equivalent to approximately RMB148,308) as share-based compensation costs (included in administrative expenses) in the consolidated statement of comprehensive loss. There was no impact to the overall
stockholder&#146;s equity balance as the amended shares vested immediately and were repurchased. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>(e) 2019 Share Incentive Plan (&#147;2019
Plan&#148;) </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">On October&nbsp;29, 2019, the Group adopted 2019 Share Incentive Plan (the &#147;2019 Plan&#148;), which will become
effective immediately prior to the completion of the Company&#146;s initial public offering. Under the 2019 Plan, the maximum aggregate number of ordinary shares available for issuance shall initially be 100,000. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>(f) Other Share-Based Compensation </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In October 2017, in connection with the adoption of 2017 Plan, the Group amended the stock option agreement with the two aforementioned
employees, under which the stock options would become exercisable only upon the earlier of (i)&nbsp;a listing, and (ii)&nbsp;occurrence of a change in control that defined in the stock option agreements. As the modification of terms and conditions
of share-based compensation were not beneficial to its employees, no further accounting impact was resulting from it. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-46 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>I-MAB </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to the Consolidated Financial Statements </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(All amounts in thousands, except for share and per share data, unless otherwise noted) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>17. Share-Based Compensation&nbsp;(Continued) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>(g) Establishment of Biomaster Trust </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Biomaster Trust was established under the trust deed dated October 23, 2019, between the Company and TMF Trust (HK) Limited, or TMF Trust, as
the trustee of the Biomaster Trust. Through the Biomaster Trust, the Company&#146;s ordinary shares and other rights and interests under awards granted pursuant to 2017 Plan and 2018 Plan may be provided to certain recipients of equity awards. Upon
satisfaction of vesting conditions, TMF Trust will exercise the equity awards and transfer the relevant ordinary shares and other rights and interests under the equity awards to the relevant grant recipients with the consent of the advisory
committee of Biomaster Trust. TMF Trust shall not exercise the voting rights attached to such ordinary shares unless otherwise directed by the advisory committee, whose members shall be appointed by I-Mab. The Company has the power to direct the
relevant activities of Biomaster Trust and it has the ability to use its power over the Biomaster Trust to affect its exposure to returns. Therefore, the assets and liabilities of the Biomaster Trust are included in the Group&#146;s consolidated
statement of financial position. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>18. Licensing and Collaboration Arrangements </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The following is a description of the Group&#146;s significant licensing and collaboration agreements entered into from January&nbsp;1, 2017
to December&nbsp;31, 2019. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>A. <FONT STYLE="white-space:nowrap">In-Licensing</FONT> Arrangements </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><I>Licensing Agreement with MorphoSys AG (&#147;MorphoSys&#148;) </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In November 2017, the Group entered into a license and collaboration agreement with MorphoSys, with respect to the development and
commercialization of MOR202/TJ202, MorphoSys&acute;s proprietary investigational antibody against CD38 (the &#147;CD38 product&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Under this agreement, MorphoSys granted to the Group an exclusive, royalty-bearing, sublicensable license to exploit MOR202/TJ202 for any
human therapeutic or diagnostic purpose in the licensed territory, namely mainland China, Hong Kong, Macau and Taiwan (collectively &#147;Greater China&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Pursuant to this agreement, the Group granted to MorphoSys an exclusive license to its rights in any inventions that the Group make while
exploiting the CD38 product under this agreement, solely to exploit the CD38 product outside of Greater China. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Pursuant to this
agreement, the Group paid to MorphoSys an upfront license fee of US$20.0&nbsp;million (equivalent to approximately RMB132.7 million). The Group also agreed to make milestone payments to MorphoSys, conditioned upon the achievement of certain
development, regulatory and commercial milestones, in the aggregate amount of US$98.5&nbsp;million (equivalent to approximately RMB653.5 million). Such milestones include first patient dosed in human clinical trials, marketing approval, and first
annual net sales of CD38 products covered by the agreement in excess of a certain amount. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In addition, the Group is required to pay
tiered <FONT STYLE="white-space:nowrap">low-double-digit</FONT> royalties to MorphoSys on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">country-by-country</FONT></FONT> and <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">product-by-product</FONT></FONT> basis during the term, commencing with the first commercial sale of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-47 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>I-MAB </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to the Consolidated Financial Statements </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(All amounts in thousands, except for share and per share data, unless otherwise noted) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>18. Licensing and Collaboration Arrangements&nbsp;(Continued) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>A. <FONT STYLE="white-space:nowrap">In-Licensing</FONT> Arrangements&nbsp;(Continued) </I></B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
a relevant licensed product in Greater China. Unless terminated earlier in accordance with the terms thereof, this agreement will remain in effect until the expiration of the Group&#146;s last
payment obligation under the agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In 2017, the Group paid US$20.0&nbsp;million (equivalent to approximately RMB132.7 million)
upfront fee to MorphoSys, which was recorded as research and development expense in the consolidated statement of comprehensive loss for the year ended December&nbsp;31, 2017. No additional payments were made in 2018. Due to the uncertainty involved
in meeting these development and commercialization based targets, the Group evaluated and concluded that the remaining milestones are still not probable as of December&nbsp;31, 2018. In March and April 2019, the project achieved the first and second
milestone and the Group paid US$8.0&nbsp;million (equivalent to approximately RMB55.7 million) of milestone fees to MorphoSys, which was recorded as research and development expense in the consolidated statement of comprehensive loss for the year
ended December&nbsp;31, 2019. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Summarized financial information related to the above agreement is presented below: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="26%"></TD>

<TD VALIGN="bottom" WIDTH="12%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="12%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="12%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="12%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="12%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Year&nbsp;ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>As&nbsp;of&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Research and Development Expense</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Upfront&nbsp;Fees</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Milestones</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Extension/Termination</B><br><B>of&nbsp;agreements</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Amortization&nbsp;of&nbsp;prepaid</B><br><B>research&nbsp;and</B><br><B>development</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Intangible&nbsp;asset&nbsp;balance</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2019</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">US$</TD>
<TD VALIGN="top" ALIGN="right">8,000</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2018</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2017</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">US$</TD>
<TD VALIGN="top" ALIGN="right">20,000</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><I>Licensing Agreement with Genexine, Inc. (&#147;Genexine&#148;) </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In December 2017, the Group entered into an intellectual property license agreement with Genexine with respect to <FONT
STYLE="white-space:nowrap">GX-I7/TJ107,</FONT> a long-acting <FONT STYLE="white-space:nowrap">IL-7</FONT> cytokine. Under this agreement, the Group obtained an exclusive, sublicensable and transferable license to use and otherwise exploit certain
intellectual property in connection with the <FONT STYLE="white-space:nowrap">pre-clinical</FONT> and clinical development, manufacturing, sale and distribution of GX-I7 to treat cancer in Greater China. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Under the terms of the agreement, the Group made an upfront payment of US$12.0&nbsp;million (equivalent to approximately RMB79.6 million) to
Genexine which was recorded as a research and development expense in January 2018. The Group also agreed to make milestone payments in the aggregate amount of US$23.0&nbsp;million (equivalent to approximately RMB152.6 million), conditioned upon the
achievement of certain development milestones, including completion of Phase 2 and Phase 3 clinical studies and new drug application (&#147;NDA&#148;) or biologic license application (&#147;BLA&#148;) approval in Greater China. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Further, the Group agreed to make milestone payments in the aggregate amount of US$525.0&nbsp;million (equivalent to approximately RMB3,482.7
million), conditioned upon the achievement of certain cumulative net </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-48 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>I-MAB </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to the Consolidated Financial Statements </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(All amounts in thousands, except for share and per share data, unless otherwise noted) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>18. Licensing and Collaboration Arrangements&nbsp;(Continued) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>A. <FONT STYLE="white-space:nowrap">In-Licensing</FONT> Arrangements&nbsp;(Continued) </I></B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
sales of GX<I>-I7 </I>up to US$2,000&nbsp;million. The Group also is required to pay Genexine a <FONT STYLE="white-space:nowrap">low-single-digit</FONT> percentage royalty in respect of the total
annual net sales of <FONT STYLE="white-space:nowrap">GX-I7.</FONT> The aforesaid milestones and royalties (other than the upfront payment) will be reduced by 50% following the entry of a generic version of
<FONT STYLE="white-space:nowrap">GX-I7</FONT> in China, Hong Kong, Macau and Taiwan without the consent or authorization of the Group or any of the Group&#146;s sublicensees. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Unless terminated earlier in accordance with the terms thereof, this agreement will remain in effect until the later of (i)&nbsp;the expiry of
the last to expire patent of the licensed intellectual property that includes a valid claim for Greater China and that covers the composition of GX-I7; and (ii) 15 years from the date of the first commercial sale of
<FONT STYLE="white-space:nowrap">GX-I7.</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">No additional payments to Genexine were made in the year ended December&nbsp;31, 2019. Due
to the uncertainty involved in meeting these development and commercialization based targets, the Group evaluated and concluded that the remaining milestones are still not probable as of December&nbsp;31, 2018 and 2019. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Summarized financial information related to the above agreement is presented below: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="30%"></TD>

<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Year&nbsp;ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>As&nbsp;of&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Research and Development Expense</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Upfront Fees</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Milestones</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Extension/Termination</B><br><B>of agreements</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Amortization&nbsp;of&nbsp;prepaid</B><br><B>research and</B><br><B>development</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Intangible&nbsp;asset&nbsp;balance</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2019</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2018</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">US$</TD>
<TD VALIGN="bottom" ALIGN="right">12,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><I>Licensing Agreement with MorphoSys </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In November 2018, the Group entered into a license and collaboration agreement with MorphoSys for MorphoSys&acute;s proprietary antibody
(MOR210/TJ210) directed against C5aR (the &#147;C5aR Agreement&#148;). Under this agreement, the Group obtained an exclusive, royalty-bearing license to explore, develop and commercialize certain anti-C5aR antibodies in Greater China and South
Korea. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Group will perform and fund all global development activities related to the development of MOR210/TJ210 in Greater China and
South Korea, including all relevant clinical trials (including in the U.S. and China) and all development activities required for IND filing in the US as well as CMC development of manufacturing processes. MorphoSys retains rights in respect of
development and commercialization of MOR210/TJ210 in the rest of the world. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Under the terms of the agreement, the Group also agreed to
make milestone payments conditional upon the achievement of certain development milestones and certain annual net sales of anti-C5aR antibodies. The Group is also required to pay to MorphoSys tiered
<FONT STYLE="white-space:nowrap">mid-single-digit</FONT> royalties on annual net sales of anti-C5aR antibody products within the licensed territory. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-49 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>I-MAB </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to the Consolidated Financial Statements </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(All amounts in thousands, except for share and per share data, unless otherwise noted) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>18. Licensing and Collaboration Arrangements&nbsp;(Continued) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>A. <FONT STYLE="white-space:nowrap">In-Licensing</FONT> Arrangements&nbsp;(Continued) </I></B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In 2018, the Group paid US$3.5&nbsp;million (equivalent to approximately RMB23.2 million)
upfront fee to MorphoSys, which was recorded as research and development expense in the consolidated statement of comprehensive loss for the year ended December&nbsp;31, 2018. No additional payments were made in the year ended December&nbsp;31,
2019. Due to the uncertainty involved in meeting these development and commercialization based targets, the Group evaluated and concluded that the remaining milestones are still not probable as of December&nbsp;31, 2018 and 2019. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Summarized financial information related to the above agreement is presented below: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="26%"></TD>

<TD VALIGN="bottom" WIDTH="12%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="12%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="12%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="12%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="12%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Years&nbsp;Ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>As&nbsp;of&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Research and Development Expense</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Upfront&nbsp;Fees</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Milestones</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Extension/Termination</B><br><B>of agreements</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Amortization&nbsp;of&nbsp;prepaid</B><br><B>research and</B><br><B>development</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Intangible&nbsp;asset&nbsp;balance</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2019</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2018</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">US$</TD>
<TD VALIGN="bottom" ALIGN="right">3,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><I>Licensing Agreement with MacroGenics </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In July 2019, the Group entered into a license and collaboration agreement with MacroGenics, Inc. for development and commercialization of an <FONT
STYLE="white-space:nowrap">Fc-optimized</FONT> antibody known as enoblituzumab that targets <FONT STYLE="white-space:nowrap">B7-H3,</FONT> including in combination with other agents, such as the <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">anti-PD-1</FONT></FONT> antibody known as MGA012, in the People&#146;s Republic of China, Hong Kong, Macau and Taiwan(&#147;Greater China&#148;). Under this agreement, the Group obtained an exclusive, sublicenseable,
royalty-bearing license to MacroGenics&#146; patents and <FONT STYLE="white-space:nowrap">know-how</FONT> to develop and commercialize the enoblituzumab product, and a combination regimen of enoblituzumab and MGA012, in Greater China during the term
of the agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In exchange for these rights, in addition to certain financial consideration, the Group will grant to MacroGenics a
royalty-free, sublicenseable, license outside of Greater China, to our patents and <FONT STYLE="white-space:nowrap">know-how</FONT> that are related to the enoblituzumab product or useful or necessary for MacroGenics to develop or commercialize the
enoblituzumab product or a product containing MGA012, and combinations thereof. The license is <FONT STYLE="white-space:nowrap">(i)&nbsp;non-exclusive</FONT> with respect to the enoblituzumab product, and (ii)&nbsp;exclusive with regard to MGA012.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Pursuant to the agreement, the Group paid an upfront fee of US$15.0&nbsp;million (equivalent to approximately RMB104.4 million) to
MacroGenics, which was recorded as research and development expense in the consolidated statement of comprehensive loss for the year ended December&nbsp;31, 2019. Under the terms of the agreement, the Group also agreed to pay MacroGenics development
milestone fees of up to US$75.0&nbsp;million and regulatory milestones fees of up to US$60.0&nbsp;million, respectively, and tiered double-digit royalties (ranging from <FONT STYLE="white-space:nowrap">mid-teens</FONT> to twenty percent) based on
annual net sales in the territories. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Group is responsible for all development costs in Greater China. MacroGenics is responsible for
all development costs in the rest of the world, except that the Group is responsible for 20% of the costs incurred in </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-50 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>I-MAB </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to the Consolidated Financial Statements </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(All amounts in thousands, except for share and per share data, unless otherwise noted) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>18. Licensing and Collaboration Arrangements&nbsp;(Continued) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>A. <FONT STYLE="white-space:nowrap">In-Licensing</FONT> Arrangements&nbsp;(Continued) </I></B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
(i)&nbsp;activities supporting global clinical trials in which we participate, (ii)&nbsp;certain CMC activities for material intended to be used in clinical trials in Greater China, and
(iii)&nbsp;companion diagnostic development and validation for indications being studied in Greater China. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Due to the uncertainty
involved in meeting these development and commercialization based targets, the Group evaluated and concluded that no milestones are probable as of December&nbsp;31, 2019. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="30%"></TD>

<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Year&nbsp;ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>As&nbsp;of&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Research and Development Expense</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Upfront Fees</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Milestones</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Extension/Termination</B><br><B>of agreements</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Amortization&nbsp;of&nbsp;prepaid</B><br><B>research and</B><br><B>development</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Intangible&nbsp;asset&nbsp;balance</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2019</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">US$</TD>
<TD VALIGN="bottom" ALIGN="right">15,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><I>Other <FONT STYLE="white-space:nowrap">In-Licensing</FONT> Arrangements </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In addition to the above arrangements, the Group has entered into other various <FONT STYLE="white-space:nowrap">in-licensing</FONT> and
collaboration agreements with third party licensors to develop and commercialize drug candidates. Based on the terms of these agreements the Group is contingently obligated to make additional material payments upon the achievement of certain
contractually defined milestones. The Group recorded US$0.6&nbsp;million (equivalent to approximately RMB4.0 million) upfront fee and US$0.3&nbsp;million (equivalent to approximately RMB2.0 million) milestone payment under these agreements for the
year ended December&nbsp;31, 2018. The Group recorded US$1.2&nbsp;million (equivalent to approximately RMB8.4 million) milestone payment during the year ended December&nbsp;31, 2019. Under the terms of the agreements, the licensors are eligible to
receive from the Group up to an aggregate of approximately US$164.4&nbsp;million (equivalent to approximately RMB1,144.5 million) in milestone payments upon the achievement of contractually specified development milestones and sales milestones, such
as regulatory approval for the drug candidates, which may be before the Group has commercialized the drug or received any revenue from sales of such drug candidate, which may never occur. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>B. <FONT STYLE="white-space:nowrap">Out-Licensing</FONT> and Collaboration Arrangements </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><I>Licensing Agreement among HDYM, <FONT STYLE="white-space:nowrap">I-Mab</FONT> and Hangzhou HealSun Biopharm Co., Ltd. (&#147;HealSun&#148;)
</I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In April 2017, one of the Company&#146;s subsidiaries, <FONT STYLE="white-space:nowrap">I-Mab</FONT> Shanghai, entered into a
technology transfer agreement with HDYM and HealSun with respect to <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-L1</FONT></FONT> humanized monoclonal antibodies. Under the agreement,
<FONT STYLE="white-space:nowrap">I-Mab</FONT> Shanghai agreed to grant to HDYM exclusive, worldwide and sublicensable rights to develop, manufacture, have manufactured, use, sell, have sold, import, or otherwise exploit certain <FONT
STYLE="white-space:nowrap">PD-L1</FONT> related patents, patent applications, know-hows, data and information of <FONT STYLE="white-space:nowrap">I-Mab</FONT> Shanghai, relevant cell lines as well as any <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">anti-PD-L1</FONT></FONT> monoclonal antibody arising from such cell lines for the treatment of diseases. Further, <FONT STYLE="white-space:nowrap">I-Mab</FONT> Shanghai and its cooperative party, HealSun agreed to provide
subsequent research and development services on such intellectual property to HDYM, including the selection and examination of innovative <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-L1</FONT></FONT>
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-51 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>I-MAB </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to the Consolidated Financial Statements </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(All amounts in thousands, except for share and per share data, unless otherwise noted) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>18. Licensing and Collaboration Arrangements&nbsp;(Continued) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>B. <FONT STYLE="white-space:nowrap">Out-Licensing</FONT> and Collaboration Arrangements&nbsp;(Continued) </I></B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
humanized monoclonal antibodies, cultivation and selection of stable cell lines, establishment of cell bank, research and development of manufacturing processes and preparation of samples,
toxicological and pharmacological testing, <FONT STYLE="white-space:nowrap">pre-clinical</FONT> pharmaceutical experiment report drafting, and application for and registration of clinical trials. HDYM agreed to make milestone payments conditioned
upon achieving certain contractually defined milestones. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Group determined that this collaboration is more reflective of a
vendor-customer relationship and therefore within the scope of ASC 606. Under this agreement, due to the early stage nature of the development, the Group determined the license to the intellectual property and research and development services are
not distinct and thus were accounted for as a single performance obligation that is satisfied over time. The Group would receive RMB51.0&nbsp;million (inclusive of VAT) milestone payments under this agreement, and considered that the achievements of
milestone II, III, IV are constrained such that the transaction price shall initially only include the milestones payment which have been achieved (that means when uncertainty associated with the variable consideration is subsequently resolved), the
additional milestone payment shall be included in the total transaction price when it is no longer probable that a significant reversal of cumulative revenue would occur in future periods. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Group used a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">cost-to-cost</FONT></FONT> input method to measure progress
as that method best depicts its performance under the agreement. For the year ended December&nbsp;31, 2017, the Group achieved milestones I and II and received milestone payments totaling of RMB29.0&nbsp;million (inclusive of VAT). The cumulative
percentage complete in the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">cost-to-cost</FONT></FONT> input method related to this agreement as of December&nbsp;31, 2017 is estimated to approximate 42%, the Group recognized
RMB11.6&nbsp;million (exclusive of VAT of RMB0.7 million) of revenue in the consolidated statement of comprehensive loss, and RMB15.8&nbsp;million (exclusive of VAT of RMB0.9 million) were deferred as contract liability related to this arrangement.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">During the year ended December&nbsp;31, 2018, the Group achieved milestones III and IV and received milestone III payment of
RMB11.0&nbsp;million (inclusive of VAT), milestone IV payment of RMB 11.0 million(inclusive of VAT) was recognized as contract assets as of December&nbsp;31, 2018. As of December&nbsp;31, 2018, the cumulative percentage complete in the <FONT
STYLE="white-space:nowrap">cost-to</FONT> cost input method related to this arrangement is estimated to approximate 100%. The Group recognized RMB36.5&nbsp;million (exclusive of VAT of RMB1.3 million) of revenue in the consolidated statement of
comprehensive loss for the year ended December&nbsp;31, 2018. All of the milestone payments were received by the Group as of December&nbsp;31, 2019. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><I>Collaboration Agreement with Everest (&#147;Everest&#148;) </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In January 2018, the Group entered into a collaboration agreement with Everest, which is controlled by the ultimate controlling party of a
principal shareholder of the Group. Under the agreement, both parties agreed to collaborate on programs to <FONT STYLE="white-space:nowrap">co-develop</FONT> MorphoSys&#146; proprietary anti-CD38 antibody for all indications in hematologic oncology
and commercialize of MOR202/TJ202 in Greater China. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">A joint steering committee with equal representation from each party was established
to coordinate and oversee the development and commercialization of the CD38 product. All decisions of the joint steering committee shall be made by unanimous vote. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-52 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>I-MAB </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to the Consolidated Financial Statements </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(All amounts in thousands, except for share and per share data, unless otherwise noted) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>18. Licensing and Collaboration Arrangements&nbsp;(Continued) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>B. <FONT STYLE="white-space:nowrap">Out-Licensing</FONT> and Collaboration Arrangements&nbsp;(Continued) </I></B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Under the agreement, the Group is primarily responsible for carrying out the development,
manufacture and supply of the CD38 product, as well as seeking regulatory approval of the CD38 product. Everest is primarily responsible for sharing the development costs of the CD38 product, including payments due to MorphoSys under the Licensing
Agreement, dated November&nbsp;30, 2017, in the proportion of 75% by Everest and 25% by the Group. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The joint steering committee will
decide which party shall be responsible for conducting the commercialization of the CD38 product pursuant to the commercialization plan approved by the committee. If Everest is selected to be responsible for commercialization, the Group shall grant
an exclusive royalty-free license to Everest to commercialize the CD38 product for all indications in hematologic oncology in Greater China. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Group and Everest will share the profit and loss and <FONT STYLE="white-space:nowrap">out-licensing</FONT> revenue derived from the CD 38
product in proportion to the costs that each party incur in developing the product. The parties will also split <FONT STYLE="white-space:nowrap">out-license</FONT> revenue according to the proportion of development costs incurred, with the Group
getting an additional five percent (5%) share and Everest receiving five percent (5%) less. Everest cannot share in any profit from the commercialization of CD38 product until it has fulfilled its payment obligations under this agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Upon any termination of this arrangement, the terminating party has the right to continue the development and commercialization of CD38
product. If Everest is the rightful terminating party, the Group shall reasonably cooperate with Everest to facilitate the following: (i)&nbsp;assign the MorphoSys license to Everest (subject to the terms and conditions of such license); (ii) grant
to Everest an exclusive license to all intellectual property rights that the Group owns or controls to further develop, manufacture, and commercialize the CD38 product; (iii)&nbsp;transfer the development, manufacture and commercialization of the
CD38 product to Everest. The terminating party shall be solely responsible for the cost and expense of such development and commercialization after termination. In the event that such continuing party successfully develops and commercializes the
CD38 product, it shall pay to the other party a percentage of the product profit and <FONT STYLE="white-space:nowrap">out-license</FONT> revenue generated therefrom in accordance with the terms of this agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">During the year ended December&nbsp;31, 2018, the US$26.0&nbsp;million in aggregate proceeds from Everest under the agreement represented the
funding available under the agreement, and was recorded as a research and development funding received liability (equivalent to approximately RMB178.7 million) on the consolidated balance sheet as of December&nbsp;31, 2018, in accordance with ASC
730, Research and Development. Because there is a significant related party relationship between the Group and Everest, the Group is treating its obligation to make payments under the commercialization stage as an implicit obligation to repay the
funds advanced by Everest (see Note 23). During the year ended December&nbsp;31, 2019, an additional US$7.6million (equivalent to approximately RMB53.1 million) of funding was received and recorded as a research and development funding received
liability. No additional milestone has been achieved in the year ended December&nbsp;31, 2019. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><I>Termination Agreement with Everest
</I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">On November&nbsp;4, 2019, the Group and Everest have terminated the collaboration agreement with respect to the <FONT
STYLE="white-space:nowrap">co-development</FONT> and commercialization of TJ202 in Greater China. Upon the termination, Everest will not </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-53 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>I-MAB </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to the Consolidated Financial Statements </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(All amounts in thousands, except for share and per share data, unless otherwise noted) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>18. Licensing and Collaboration Arrangements&nbsp;(Continued) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>B. <FONT STYLE="white-space:nowrap">Out-Licensing</FONT> and Collaboration Arrangements&nbsp;(Continued) </I></B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
retain any rights or entitlements to develop or commercialize TJ202 or any economic interest in its commercialization. All intellectual property rights in respect of TJ202 arising from its
development under the collaboration agreement are vested and owned by <FONT STYLE="white-space:nowrap">I-Mab,</FONT> and the Group holds all intellectual property rights and have maximum flexibility to further develop, manufacture and commercialize
TJ202 in Greater China. In consideration of the above arrangements, the board of directors of the Group has approved the issuance of a total value of US$37.0&nbsp;million of ordinary shares (the &#147;CPP Shares&#148;) to Everest, representing
Everest&#146;s historical contribution to the collaboration and the associated time cost. The CPP Shares will be issued concurrently with, and subject to, the completion of the Company&#146;s initial public offering within 180 days from termination
of the collaboration agreement. The total value of US$37.0&nbsp;million was calculated based on the sum of (1)&nbsp;US$33.7&nbsp;million, which equals cumulative <FONT STYLE="white-space:nowrap">paid-in</FONT> contributions historically made by
Everest under the collaboration agreement; and (2)&nbsp;a negotiated US$3.3&nbsp;million time cost of the foregoing historical contribution in light of <FONT STYLE="white-space:nowrap">I-Mab&#146;s</FONT> exclusive rights over the commercialization
of TJ202 after this termination. The issuance of the CPP Shares was approved by <FONT STYLE="white-space:nowrap">I-Mab&#146;s</FONT> existing shareholders on December&nbsp;25, 2019. In the event that the initial public offering has not been
completed within 180 days from the termination of the collaboration agreement, the Company will issue 4,762,751 ordinary shares (the &#147;Subject Shares&#148;) to Everest on the 181st day. As a result of the aforementioned termination of the
collaboration agreement with Everest, the Group derecognized the research and development funding received from Everest and recognized a liability that represented the ordinary shares to be issued to Everest, which was measured at fair value in
accordance with ASC 480, and the difference of US$3.3 million (equivalent to approximately RMB23.0 million) between the initial fair value of the liability and the carrying amount of research and development funding received was recognized as other
expenses in the consolidated statements of comprehensive loss. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><I>Licensing Agreement with ABL Bio </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In July 2018, the Group entered into a license and collaboration agreement with ABL Bio, under which the Group granted to ABL Bio exclusive,
worldwide (excluding Greater China), royalty-bearing rights to develop and commercialize a bispecific antibody (&#147;BsAb&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The
Group agreed to share costs fifty-fifty (50:50) with ABL Bio through the completion of in vivo studies, with ABL Bio responsible for all costs and activities following that time. For the year ended December 31, 2019, US$0.2 million (equivalent to
approximately RMB1.4 million) expenses were incurred by ABL Bio. Accordingly, the Group recorded US$0.1 million (equivalent to approximately RMB0.7 million ) (50% cost sharing) of expenses in the Group&#146;s consolidated statement of comprehensive
loss for the year ended December 31, 2019. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In consideration of the license and a memorandum of understanding signed with ABL Bio in
January 2020, ABL Bio agreed to pay the Group an upfront fee of US$2.5&nbsp;million (equivalent to approximately RMB17.2 million), and milestone payments in the aggregate amount of US$97.5&nbsp;million (equivalent to approximately RMB646.8 million)
conditioned upon achieving certain research, clinical development and sales milestones. These include clinical milestones of up to US$32.5 million (equivalent to approximately RMB215.6 million) and sales milestones of up to US$65&nbsp;million
(equivalent to approximately RMB431.2 million). Further, ABL Bio agreed to pay the Group royalties at <FONT STYLE="white-space:nowrap">mid-single-digit</FONT> percentages in respect of the total annual net sales of the licensed BsAb product. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-54 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>I-MAB </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to the Consolidated Financial Statements </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(All amounts in thousands, except for share and per share data, unless otherwise noted) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>18. Licensing and Collaboration Arrangements&nbsp;(Continued) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>B. <FONT STYLE="white-space:nowrap">Out-Licensing</FONT> and Collaboration Arrangements&nbsp;(Continued) </I></B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In addition, ABL Bio granted to the Group an exclusive, royalty-free, sublicensable license
to use the BsAb technology solely to exploit the licensed BsAb product for all indications in Greater China. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Group determined that
this collaboration is more reflective of a vendor-customer relationship and therefore within the scope of ASC 606. Under this agreement, the only one performance obligation was to grant the BsAb license to ABL Bio, considering that the achievements
of milestones are constrained such that the transaction price shall initially only include upfront payment and subsequently, once another milestone was achieved (that means when uncertainty associated with the variable consideration is subsequently
resolved), the additional milestone payment shall be included in the total transaction price when it is no longer probable that a significant reversal of cumulative revenue would occur in future periods. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2018 and 2019, no milestone has been achieved, and the Group recognized revenue of US$2.5&nbsp;million (equivalent to
RMB17.2 million) of revenue in the consolidated statements of comprehensive loss for the year ended December&nbsp;31, 2018, which was the upfront fee related to the grant of the rights of BsAb to ABL Bio as mentioned above. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><I>Collaboration Agreement with ABL Bio </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In July 2018, the Group and ABL Bio entered into a collaboration agreement (the &#147;ABL Bio Collaboration&#148;) whereby both parties agreed
to collaborate to develop three <FONT STYLE="white-space:nowrap">PD-L1</FONT> based bispecific antibodies by using ABL Bio&#146;s proprietary BsAb technology and commercialize them in their respective territories, which, collectively, include
Greater China and South Korea, and other territories throughout the rest of the world if both parties agree to do so in such other territories during the performance of the agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">At contract inception, as both <FONT STYLE="white-space:nowrap">I-Mab</FONT> and ABL Bio participate actively in the research and development
activity. Also, the parties share the risk of failure of the BsAb products and share the income of licensing, so this contract meet the criteria of the definition of a collaborative arrangement, the Group categorized this agreement within the scope
ASC 808. Prior to commercialization, the Group recorded the share of the expenses incurred by the collaboration for the development of three <FONT STYLE="white-space:nowrap">PD-L1</FONT> based bispecific antibodies products in research and
development expense in the consolidated statements of comprehensive loss. As of December&nbsp;31, 2018, RMB1.0&nbsp;million expenses were incurred by the Group and ABL Bio did not incur any expense. According to the terms set out in the agreement,
the Group recorded RMB0.5&nbsp;million (50% cost sharing) of expense in the Group&#146;s consolidated statement of comprehensive loss for the year ended December&nbsp;31, 2018. For the year ended December&nbsp;31, 2019, RMB11.2&nbsp;million expenses
were incurred by the Group and RMB8.0&nbsp;million expenses were incurred by ABL Bio. Accordingly, the Group recorded RMB9.6&nbsp;million (50% cost sharing) of expenses in the Group&#146;s consolidated statement of comprehensive loss for the year
ended December&nbsp;31, 2019. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><I>Collaboration Agreements with Tracon Pharmaceuticals, Inc. (&#147;Tracon&#148;) </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In November 2018, the Group entered into collaboration agreements with Tracon, under which both parties agreed to <FONT
STYLE="white-space:nowrap">co-develop</FONT> the Group&#146;s proprietary CD73 antibody, TJD5 (the &#147;TJD5 Agreement&#148;) and <FONT STYLE="white-space:nowrap">co-develop</FONT> up to five BsAbs (the &#147;BsAbs Agreement&#148;). Both agreements
may be terminated by either party for the other party&#146;s uncured material breach, bankruptcy or insolvency or for safety reasons. In addition, the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-55 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>I-MAB </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to the Consolidated Financial Statements </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(All amounts in thousands, except for share and per share data, unless otherwise noted) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>18. Licensing and Collaboration Arrangements&nbsp;(Continued) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>B. <FONT STYLE="white-space:nowrap">Out-Licensing</FONT> and Collaboration Arrangements&nbsp;(Continued) </I></B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
agreement in respect of TJD5 may be terminated by the Group: (i) for convenience within a certain period upon completing different clinical stages subject to certain payments and royalties, based
on the clinical stage, that would be owed to Tracon upon the exercise of such termination for convenience; (ii) in the event that Tracon causes the Phase 1 study timeline to be delayed beyond the agreed extension periods; or (iii) if the Group
decides to end the development of the collaborative product prior to its first commercial sale. Further, prior to the first commercial sale, Tracon may deem this agreement to be terminated by the Group if it reasonably believes that the Group has
discontinued all meaningful development of the collaborative product for at least 12 months and certain other conditions are met. As of December 31, 2019, no payments or royalties are due under this agreement. As of December&nbsp;31, 2019, the Group
has recorded US$4.0&nbsp;million (equivalent to approximately RMB27.8 million) of research and development costs in the consolidated statement of comprehensive loss for the year ended December&nbsp;31, 2019. Additionally, in March 2019, the Group
agreed with Tracon and F. Hoffmann-La Roche Ltd (&#147;Roche&#148;) on a clinical supply agreement for Roche to supply atezolizumab for use in clinical studies under the collaboration agreement with Tracon. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><I>Licensing Agreement with CSPC Pharmaceutical Group Limited (&#147;CSPC&#148;) </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In December 2018, the Group entered into a product development agreement with CSPC. The Group granted to CSPC exclusive, <FONT
STYLE="white-space:nowrap">non-transferable,</FONT> <FONT STYLE="white-space:nowrap">non-irrevocable</FONT> and sublicensable rights in the PRC (excluding Hong Kong, Macau and Taiwan) to develop and commercialize TJ103 for treating type 2 diabetes.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">CSPC is responsible for developing, obtaining market approval and commercializing the licensed products. The Group is responsible for
transferring the manufacturing technology of the licensed products to CSPC and assisting CSPC in the continued optimization of such manufacturing technology thereafter. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In consideration of the license, CSPC agreed to pay the Group an upfront fee of RMB15.0&nbsp;million and milestone payments in an aggregate
amount of RMB135.0&nbsp;million conditioned upon achieving certain clinical development and regulatory approval milestones. In addition, the Group is also entitled to royalties of up to <FONT STYLE="white-space:nowrap">low-double-digit</FONT>
percentages in respect of the total annual net sales of the products after its commercialization in the PRC. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Group determined that
this collaboration is more reflective of a vendor-customer relationship and therefore within the scope of ASC 606. Under this agreement, the only one performance obligation was to grant TJ103 license to CSPC. considering that the achievements of
milestones are constrained such that the transaction price shall initially only include upfront payment and subsequently, once another milestone was achieved (that means when uncertainty associated with the variable consideration is subsequently
resolved), the additional milestone payment shall be included in the total transaction price when it is no longer probable that a significant reversal of cumulative revenue would occur in future periods. As of December&nbsp;31, 2018, the amount
received of RMB14.2&nbsp;million (net of VAT) was recorded as advance from customers in the consolidated balance sheet. In February 2019, an additional amount of RMB0.8&nbsp;million (net of VAT) was received, and the license was also approved by
China intellectual property office in May 2019. The first milestone was achieved in September 2019 and the amount of RMB15.0&nbsp;million (net of VAT) was received according to the terms of the agreement. Accordingly, RMB30.0&nbsp;million was
recognized as revenue in the consolidated statements of comprehensive loss for the year ended December&nbsp;31, 2019. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-56 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>I-MAB </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to the Consolidated Financial Statements </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(All amounts in thousands, except for share and per share data, unless otherwise noted) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>19. Other Income (expenses), Net </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The following table summarizes other income (expenses), net recognized for the years ended December&nbsp;31, 2017, 2018 and 2019: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="67%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Year&nbsp;Ended&nbsp;December&nbsp;31</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Notes</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>RMB</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>RMB</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>RMB</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>US$<BR>(Note&nbsp;2.5)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss from conversion of 2017 Notes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(18,375</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss from conversion of Onshore Convertible Loans</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(8,548</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss from issuance of 2018 Notes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5,081</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss on termination agreement with Everest</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(23,039</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,261</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fair value change of short-term investments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">703</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income from other financial assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,572</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,622</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net foreign exchange gains (losses)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,873</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">742</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,619</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">229</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Subsidy income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">750</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">568</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">80</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fair value change of other financial assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">42</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Others</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(172</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">110</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(98</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(14</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,527</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(16,780</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(20,205</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,860</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>20. Net Loss Per Share </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Basic and diluted net loss per share for each of the periods presented are calculated as follows: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Year&nbsp;Ended&nbsp;December&nbsp;31</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>RMB</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>RMB</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>RMB</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>US$<BR>(Note&nbsp;2.5)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center"><B>(in thousands, except for loss per shares)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Numerator:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss attributable to I-Mab</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(298,240</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(402,833</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,451,950</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(205,510</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deemed dividend to Series C-1 preferred shareholders at extinguishment of Series&nbsp;C-1
Preferred Shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5,283</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(748</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deemed dividend to Series B-1, B-2 and C preferred shareholders at modification of Series B-1, B-2
and C Preferred Shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(27,768</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,930</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss attributable to ordinary shareholders</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(298,240</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(402,833</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,485,001</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(210,188</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Denominator:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted average number of ordinary shares outstanding&#151;basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,742,669</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,529,092</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,381,230</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,381,230</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss per share&#151;basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(51.93</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(61.70</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(201.19</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(28.48</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-57 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>I-MAB </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to the Consolidated Financial Statements </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(All amounts in thousands, except for share and per share data, unless otherwise noted) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>20. Net Loss Per Share&nbsp;(Continued) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">For the years ended December&nbsp;31, 2017, 2018 and 2019, the effects of all outstanding
convertible preferred shares, restricted shares, warrants and certain stock options have been excluded from the computation of diluted loss per share for the years ended December&nbsp;31, 2017, 2018 and 2019 as their effects would be anti-dilutive.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">For the years ended December&nbsp;31, 2017, 2018 and 2019, the Company also has certain dilutive potential stock options. These stock
options which cannot be exercised until the Company completes its listing are not included in the computation of diluted earnings per shares as such contingent event had not taken place. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The potentially dilutive securities that have not been included in the calculation of diluted net loss per share as their inclusion would be
anti-dilutive are as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="72%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="38%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Year&nbsp;Ended&nbsp;December&nbsp;31</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Convertible preferred shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,811,182</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">64,389,968</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">92,238,119</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Convertible promissory notes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">673,738</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Restricted shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,623,553</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,134,058</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stock options</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">not&nbsp;applicable</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">not&nbsp;applicable</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,388,776</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>21. Employee Benefits </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Full time employees of the Group in the PRC participate in a government mandated defined contribution plan, pursuant to which certain pension
benefits, medical care, employee housing fund and other welfare benefits are provided to the employees. Chinese labor regulations require that the PRC subsidiaries of the Group make contributions to the government for these benefits based on certain
percentage of the employees&#146; salaries, up to a maximum amount specified by the government. The Group has no legal obligation for the benefits beyond the contribution made. The total amounts charged to the consolidated statements of
comprehensive loss for such employee benefits amounted to approximately RMB5,120, RMB9,294 and RMB14,152 for the years ended December&nbsp;31, 2017, 2018 and 2019, respectively. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>22. Commitments and Contingencies </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Contingencies
</I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Group is a party to or an assignee of license and collaboration agreements that may require it to make future payments
relating to milestone fees and royalties on future sales of licensed products (Note 18). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Group did not have significant capital and
other commitments, long-term obligations, or guarantees as of December&nbsp;31, 2018 and 2019. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-58 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>I-MAB </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to the Consolidated Financial Statements </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(All amounts in thousands, except for share and per share data, unless otherwise noted) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>23. Related Party Balances and Transactions </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The table below sets forth the major related parties and their relationships with the Group as of December&nbsp;31, 2018 and 2019: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Name&nbsp;of&nbsp;related&nbsp;parties</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>Relationship&nbsp;with&nbsp;the&nbsp;Group</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Everest</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Controlled by the ultimate controlling party of a principal shareholder of the Group</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">CMAB Biopharma (Suzhou) Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Controlled by the ultimate controlling party of a principal shareholder of the Group</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Tasly Pharmaceutical Group Co., Ltd.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Controlled by the ultimate controlling party of a principal shareholder of the Group</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Details of related party balance as of December&nbsp;31, 2018 and 2019 are as follows: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Research and development funding received* </I></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Def.-Times; font-size:8pt" ALIGN="center">


<TR STYLE="visibility:hidden; line-height:0pt; color:white">

<TD WIDTH="68%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD nowrap STYLE="font-size:10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD nowrap STYLE="font-size:10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD nowrap STYLE="font-size:10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Def.-Times; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><FONT STYLE="font-family:Times New Roman; "><B>As&nbsp;of&nbsp;December&nbsp;31,</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Def.-Times; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><FONT STYLE="font-family:Times New Roman; "><B>2018</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><FONT STYLE="font-family:Times New Roman; "><B>2019</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Def.-Times; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>RMB</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>RMB</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>US$<BR>(Note&nbsp;2.5)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Def.-Times; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Everest</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; ">178,715</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; ">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; ">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Ordinary Shares to be issued to Everest* </I></B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Def.-Times; font-size:8pt" ALIGN="center">


<TR STYLE="visibility:hidden; line-height:0pt; color:white">

<TD WIDTH="67%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD nowrap STYLE="font-size:10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD nowrap STYLE="font-size:10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD nowrap STYLE="font-size:10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Def.-Times; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><FONT STYLE="font-family:Times New Roman; "><B>As&nbsp;of&nbsp;December&nbsp;31,</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Def.-Times; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><FONT STYLE="font-family:Times New Roman; "><B>2018</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><FONT STYLE="font-family:Times New Roman; "><B>2019</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Def.-Times; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>RMB</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>RMB</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>US$<BR>(Note&nbsp;2.5)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Def.-Times; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Everest</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; ">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; ">258,119</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; ">36,534</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; text-indent:-4%; font-size:10pt; font-family:Times New Roman">*Note: Please refer to Note 18 for further details. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Details of related party transactions for the years ended December&nbsp;31, 2017, 2018 and 2019 are as follows: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Receipt of CRO services&#151;recognized in research and development expenses </I></B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Def.-Times; font-size:8pt" ALIGN="center">


<TR STYLE="visibility:hidden; line-height:0pt; color:white">

<TD WIDTH="66%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD nowrap ><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD nowrap ><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD nowrap ><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD nowrap ><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Def.-Times; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><FONT STYLE="font-family:Times New Roman; "><B>For&nbsp;the&nbsp;year&nbsp;ended&nbsp;December&nbsp;31,</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Def.-Times; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><FONT STYLE="font-family:Times New Roman; "><B>2017</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><FONT STYLE="font-family:Times New Roman; "><B>2018</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><FONT STYLE="font-family:Times New Roman; "><B>2019</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Def.-Times; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>RMB</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>RMB</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>RMB</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>US$<BR>(Note&nbsp;2.5)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Def.-Times; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">CMAB Biopharma (Suzhou) Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; ">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; ">2,786</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; ">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; ">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Def.-Times; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Tasly Pharmaceutical Group Co., Ltd.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; ">752</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; ">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; ">5,590</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; ">791</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-59 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>I-MAB </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to the Consolidated Financial Statements </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(All amounts in thousands, except for share and per share data, unless otherwise noted) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>23. Related Party Balances and Transactions&nbsp;(Continued) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Receipt of research and development funding </I></B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="64%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>For&nbsp;the&nbsp;year&nbsp;ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>RMB</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>RMB</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>RMB</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>US$<BR>(Note&nbsp;2.5)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Everest (Note 18)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">178,715</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">53,148</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,523</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>24. Concentration of Credit Risk </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Financial instruments that are potentially subject to significant concentration of credit risk consist of cash and cash equivalents,
restricted cash, short-term investments, other financial assets, contract assets, and other receivables. The carrying amounts of cash and cash equivalents, restricted cash, short-term investments, contract assets, and other financial assets
represent the maximum amount of loss due to credit risk. As of December&nbsp;31, 2018 and 2019, all of the Group&#146;s cash and cash equivalents, restricted cash and short-term investments were held by major financial institutions located in the
PRC and international financial institutions outside of the PRC which management believes are of high credit quality and continually monitors the credit worthiness of these financial institutions. With respect to the contract assets, other
receivables and other financial assets, the Group performs <FONT STYLE="white-space:nowrap">on-going</FONT> credit evaluations of the financial condition of its customers and counterparties. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>25. Subsequent Events </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Group
evaluated subsequent events through April 29, 2020. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="6%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="1%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="91%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">i)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">On January&nbsp;17, 2020, the Company completed its IPO and became listed on the Nasdaq Global Market by issuing 7,407,400 American Depositary Shares (&#147;ADSs&#148;) at the price of US$14.00 per ADS for a total gross proceeds of
US$103.7&nbsp;million. On February&nbsp;10, 2020, the underwriters of the IPO have exercised their over-allotment option to purchase an additional 768,350 ADSs of the Company at the IPO price of US$14.00 per ADS. After giving effect to the exercise
of the over-allotment option, the Company has issued and sold a total of 8,175,750 ADSs in the IPO, for total gross proceeds of US$114,460,500. Each ten ADSs represent twenty-three ordinary shares of the Company.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">ii)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">On January&nbsp;17, 2020, the Company also issued 6,078,571 ordinary shares to Everest (see Note 18 for details).</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">iii)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Upon the completion of the IPO, the Company&#146;s then outstanding 30,227,056 Series A Preferred Shares, 23,288,783 Series B Preferred Shares, 3,714,580 Series <FONT STYLE="white-space:nowrap">B-1</FONT> Preferred Shares,
3,301,849 Series <FONT STYLE="white-space:nowrap">B-2</FONT> Preferred Shares, 31,046,360 Series C Preferred Shares and 3,857,143 Series <FONT STYLE="white-space:nowrap">C-1</FONT> Preferred Shares were converted into 30,227,056, 23,288,783,
3,714,580, 3,571,427, 34,420,469 and 4,537,814 ordinary shares, respectively.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">iv)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Upon the completion of the IPO and according to the amendments to 2017 Plan, the maximum aggregate number of shares which may be granted pursuant to all awards under 2017 Plan
was</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-60 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>I-MAB </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to the Consolidated Financial Statements </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(All amounts in thousands, except for share and per share data, unless otherwise noted) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>25. Subsequent Events&nbsp;(Continued) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="6%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="1%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="91%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">changed to 9,609,084. Each of the Company&#146;s founders, namely Zheru Zhang, Lili Qian, Zhengyi Wang and Lei Fang surrendered 83,142 unvested stock options that granted to him or her under 2017 Plan before, totally 332,566
unvested options, for no consideration, and these stock options were cancelled immediately. Upon the completion of the IPO and according to the amendments to 2018 Plan, the maximum aggregate number of shares which may be granted pursuant to all
awards under 2018 Plan was changed to 11,005,888. The director of the Company, Dr.&nbsp;Jingwu Zhang Zang surrendered 2,544,917 unvested options that granted to him under 2018 Plan, for no consideration, and these stock options were cancelled
immediately.</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">As of the date of these consolidated financial statements, <FONT STYLE="white-space:nowrap">I-Mab</FONT> has
not identified any significant impact on the Group&#146;s financial performance as a result of the <FONT STYLE="white-space:nowrap">COVID-19</FONT> outbreak. <FONT STYLE="white-space:nowrap">I-Mab</FONT> will continue to assess potential impact of <FONT
STYLE="white-space:nowrap">COVID-19</FONT> on its business. Currently, <FONT STYLE="white-space:nowrap">I-Mab</FONT> expects the <FONT STYLE="white-space:nowrap">COVID-19</FONT> worldwide health crisis to have immaterial impact on its business as
its operations in China are in conjunction with hospitals located in regions that were relatively less affected by <FONT STYLE="white-space:nowrap">COVID-19.</FONT> However, as research hospitals and government agencies focus clinical resources on
the pandemic, <FONT STYLE="white-space:nowrap">I-Mab</FONT> believes there could be some delays in regulatory interactions and inspections, and patient recruitment and participation, particularly in the first quarter of 2020. Similarly, the
worsening situation of <FONT STYLE="white-space:nowrap">COVID-19</FONT> in the U.S. may cause some delays in the <FONT STYLE="white-space:nowrap">on-going</FONT> clinical trials in the U.S. On the other hand,
<FONT STYLE="white-space:nowrap">I-Mab</FONT> clinical trials in both the U.S. and China involve many clinical sites and hospitals located in many different regions. While the full scope and duration of the crisis is far from clear at this time, <FONT
STYLE="white-space:nowrap">I-Mab</FONT> is actively and diligently working to minimize delays and disruptions to its clinical trials. At the present time, the <FONT STYLE="white-space:nowrap">COVID-19</FONT> situation has improved in China, and <FONT
STYLE="white-space:nowrap">I-Mab</FONT> will continue to execute on its regulatory and clinical development goals in China and the U.S. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">In March 2020, <FONT STYLE="white-space:nowrap">I-Mab</FONT> signed a strategic partnership with Kalbe Genexine
Biologics for first right of negotiation for an exclusive license to potentially commercialize I-Mab&#146;s CD73 antibody, in ASEAN, MENA and Sri Lanka. The deal package is valued up to approximately US$340 million. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Stock Repurchase Program (Unaudited) </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">On
July&nbsp;15, 2020, the Group announced that its Board of Directors has authorized a stock repurchase program under which the Group may repurchase up to US$20&nbsp;million of its ordinary shares in the form of American depositary shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">2020 Share Incentive Plan (Unaudited) </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">On
July&nbsp;15, 2020, the Group adopted 2020 Share Incentive Plan (the &#147;2020 Plan&#148;). Under the 2020 Plan, the maximum aggregate number of shares which may be issued pursuant to all awards shall be 10,760,513 ordinary shares, provided that
the maximum number of shares may be issued pursuant to awards in the form of restricted share units under this plan shall not exceed 7,686,081 ordinary shares. From August 2020 through September 2020, the Group granted 1,068,733 stock options and
4,892,918 restricted share units under 2020 Plan to its employees, respectively. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-61 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>I-MAB </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to the Consolidated Financial Statements </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(All amounts in thousands, except for share and per share data, unless otherwise noted) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>25. Subsequent Events&nbsp;(Continued) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Global Strategic Partnership with AbbVie (Unaudited) </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">On September&nbsp;3, 2020, the Group, through <FONT STYLE="white-space:nowrap">I-Mab</FONT> Biopharma (Shanghai) Co., Ltd. and <FONT
STYLE="white-space:nowrap">I-Mab</FONT> Biopharma US Limited, each a wholly-owned subsidiary of the Group, entered into a broad global strategic partnership with AbbVie Ireland Unlimited Group (&#147;AbbVie&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Pursuant to this collaboration, the Group will grant AbbVie a global license, excluding Mainland China, Macau, and Hong Kong, to develop and
commercialize lemzoparlimab (also known as TJC4), an innovative anti-CD47 monoclonal antibody internally discovered and developed by <FONT STYLE="white-space:nowrap">I-Mab</FONT> for the treatment of multiple cancers. The Group will retain all
rights to develop and commercialize lemzoparlimab (as well as certain other compounds directed against CD47) in Mainland China, Macau, and Hong Kong. AbbVie will conduct further global clinical trials (which the Group may elect to <FONT
STYLE="white-space:nowrap">co-fund)</FONT> to evaluate lemzoparlimab in multiple cancers. This deal also allows for potential collaboration on future CD47-related therapeutic agents, including CD47-based bispecific antibodies and combination
therapies with lemzoparlimab and AbbVie&#146;s venetoclax (Venclexta<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>). Each party will have the opportunity subject to rights of first negotiation to further licenses, to explore certain of
each other&#146;s related CD47-antibody programs in their respective territories. In addition, the Group and AbbVie will share manufacturing responsibilities, with AbbVie being the primary manufacturer supply outside of Mainland China, Hong Kong and
Macau and the Group being the primary manufacturer for supply for Mainland China, Hong Kong and Macau. The Group believes that this collaboration will accelerate its establishment of commercial production operations in China. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">AbbVie will pay the Group an upfront payment of US$180&nbsp;million. Additionally, in connection with the recently released clinical data from
the Phase 1 trial of lemzoparlimab in the United States, the Group expects to be paid a first milestone payment of US$20&nbsp;million. The Group will also be eligible to receive up to US$1.74&nbsp;billion in further success-based development,
regulatory and sales milestone payments for lemzoparlimab, of which US$840&nbsp;million are based on clinical development and regulatory approval milestones, with the remainder based on commercial milestones. Upon commercialization of lemzoparlimab,
AbbVie will also pay tiered royalties from low double-digit percentages on global net sales outside of Mainland China, Macau, and Hong Kong. In addition, AbbVie has a license and right of first negotiation to further develop and commercialize two
additional lemzoparlimab-based bispecific antibodies discovered and currently being developed by the Group and the Group cannot commercialize products containing these two additional lemzoparlimab-based bispecific antibodies outside of Mainland
China, Macau and Hong Kong even if AbbVie does not exercise its right of first negotiation or the both parties are unable to come to financial terms on such products. The potential value of each such license is minimum US$500&nbsp;million in upfront
and milestone payments, for a combined total of no less than US$1&nbsp;billion. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Private Placement (Unaudited) </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">On September&nbsp;4, 2020, the Group announced that it has entered into definitive subscription agreements with a consortium of institutional
investors (the &#147;Investors&#148;) to raise approximately US$418&nbsp;million through a private placement. The consortium is led by Hillhouse Capital Group (&#147;Hillhouse&#148;), with significant participation by GIC, and also includes certain
other leading Asian and U.S. biotech investment funds, such as Avidity Partners, OrbiMed, Octagon Capital Advisors, Invus, Lake Bleu Capital, Perceptive Advisors, Cormorant Asset Management, Sphera Healthcare and Alyeska Investment Group, L.P.
Hillhouse is entitled to nominate one representative to <FONT STYLE="white-space:nowrap">I-Mab&#146;s</FONT> Board of Directors. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-62 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>I-MAB </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to the Consolidated Financial Statements </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(All amounts in thousands, except for share and per share data, unless otherwise noted) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>25. Subsequent Events&nbsp;(Continued) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The private placement comprises (1)&nbsp;the sale to the Investors of approximately
US$418&nbsp;million of the Group&#146;s 29,133,502 ordinary shares (the &#147;Ordinary Shares&#148;) (equivalent to 12,666,740 ADSs) at a purchase price equivalent to US$33 per ADS; and (2)&nbsp;warrants (the &#147;Warrants&#148;) to subscribe for
an aggregate of 5,341,267 Ordinary Shares (equivalent to 2,322,290 ADSs) at an exercise price equivalent to US$45 per ADS, which may further increase the proceeds of approximately US$104.5&nbsp;million if the Warrants are fully exercised. The
Warrants will remain exercisable at the election of the Investors within 12 months after the closing of the private placement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Transfer of Equity
Interest of I-Mab Hangzhou (Unaudited) </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">On September&nbsp;15, 2020, <FONT STYLE="white-space:nowrap">I-Mab</FONT> Biopharma Hong Kong
Limited entered into an equity transfer and investment agreement with a group of domestic investors in China, to transfer 40% equity interest of <FONT STYLE="white-space:nowrap">I-Mab</FONT> Biopharma (Hangzhou) Limited <FONT
STYLE="white-space:nowrap">(&#147;I-Mab</FONT> Hangzhou&#148;) to these investors at the consideration of US$120&nbsp;million in cash and transfer 10% equity interest to the management team shareholding platform that holds the share awards that
granted <FONT STYLE="white-space:nowrap">I-Mab</FONT> Hangzhou&#146;s management team and 5% equity interest to the equity incentive shareholding platform that holds the shares for the purpose of future share awards grants respectively with no
consideration. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>26. Restricted Net Assets </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Group&#146;s ability to pay dividends may depend on the Group receiving distributions of funds from its PRC subsidiary. Relevant PRC
statutory laws and regulations permit payments of dividends by the Group&#146;s PRC subsidiary only out of its retained earnings, if any, as determined in accordance with PRC accounting standards and regulations. The results of operations reflected
in the consolidated financial statements prepared in accordance with U.S. GAAP differ from those reflected in the statutory financial statements of the Group&#146;s PRC subsidiary. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In accordance with the Company law of the PRC, a domestic enterprise is required to provide statutory reserves of at least 10% of its annual <FONT
STYLE="white-space:nowrap">after-tax</FONT> profit until such reserve has reached 50% of its respective registered capital based on the enterprise&#146;s PRC statutory accounts. A domestic enterprise is also required to provide discretionary surplus
reserve, at the discretion of the Board of Directors, from the profits determined in accordance with the enterprise&#146;s PRC statutory accounts. The aforementioned reserves can only be used for specific purposes and are not distributable as cash
dividends. The Group&#146;s PRC subsidiary was established as domestic invested enterprise and therefore is subject to the above mentioned restrictions on distributable profits. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">For the years ended December&nbsp;31, 2017, 2018 and 2019, no appropriation to statutory reserves was made because the PRC subsidiary had
substantial losses during such periods. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">As a result of these PRC laws and regulations subject to the limit discussed above that require
annual appropriations of 10% of <FONT STYLE="white-space:nowrap">after-tax</FONT> income to be set aside, prior to payment of dividends, as general reserve fund, the Group&#146;s PRC subsidiary is restricted in their ability to transfer a portion of
their net assets to the Group. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Foreign exchange and other regulations in the PRC further restrict the Company&#146;s PRC subsidiaries
from transferring funds to the Company in the form of dividends, loans and advances. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-63 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>I-MAB </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to the Consolidated Financial Statements </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(All amounts in thousands, except for share and per share data, unless otherwise noted) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>26. Restricted Net Assets&nbsp;(Continued) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Since the Group has a consolidated shareholders&#146; deficit, its net asset base for
purposes of calculating the proportionate share of restricted net assets of consolidated subsidiaries should be zero. Therefore, the restrictions placed on the net assets of the Company&#146;s PRC subsidiaries with positive equity would result in
the 25&nbsp;percent threshold being exceeded and a corresponding requirement to provide parent company financial information (Note 27). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>27. Condensed
Financial Information of the Parent Company </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Company performed a test on the restricted net assets of consolidated subsidiaries in
accordance with Securities and Exchange Commission Regulation <FONT STYLE="white-space:nowrap">S-X</FONT> <FONT STYLE="white-space:nowrap">Rule4-08</FONT> (e)(3), &#147;General Notes to Financial Statements&#148; and concluded that it was applicable
for the Company to disclose the financial statements for the parent company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The subsidiaries did not pay any dividends to the Company
for the years presented. For the purpose of presenting parent company only financial information, the Company records its investments in its subsidiaries under the equity method of accounting. Such investments are presented on the separate condensed
balance sheets of the Company as &#147;Investments (deficit) in subsidiaries&#148; and the loss of the subsidiaries is presented as &#147;share of losses of subsidiaries&#148;. Certain information and footnote disclosures generally included in
financial statements prepared in accordance with U.S. GAAP have been condensed and omitted. The footnote disclosures contain supplemental information relating to the operations of the Company, as such, these statements should be read in conjunction
with the notes to the consolidated financial statements of the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Company did not have significant capital and other
commitments, long-term obligations, other long-term debt, or guarantees as of December&nbsp;31, 2018 and 2019. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Company did not have
significant capital and other commitments, long-term obligations, other long-term debt, or guarantees as of December&nbsp;31, 2018 and 2019. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-64 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>I-MAB </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to the Consolidated Financial Statements </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(All amounts in thousands, except for share and per share data, unless otherwise noted) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>27. Condensed Financial Information of the Parent Company&nbsp;(Continued) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Balance&nbsp;sheets </I></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" ALIGN="center">


<TR>

<TD WIDTH="72%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>As&nbsp;of&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2018 </B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>RMB</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>RMB</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>US$</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>(Note&nbsp;2.5)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><B>Assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><B>Current&nbsp;assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9pt">603,234</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9pt">719,269</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9pt">101,806</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><B>Total current assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9pt">603,234</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9pt">719,269</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9pt">101,806</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Receivables due from subsidiaries</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9pt">1,455,048</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9pt">939,832</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9pt">133,024</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Other non-current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9pt">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9pt">18,331</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9pt">2,595</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><B>Total assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9pt"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9pt"><B>2,058,282</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9pt"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9pt"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9pt"><B>1,677,432</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9pt"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9pt"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9pt"><B>237,425</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9pt"><B>&nbsp;</B></FONT></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><B>Liabilities, mezzanine equity and shareholders&#146; deficit</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><B>Current liabilities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Accruals and other payables</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9pt">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9pt">117,977</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9pt">16,699</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Ordinary shares to be issued to Everest</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">258,119</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">36,534</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Warrant liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9pt">5,618</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9pt">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9pt">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><B>Total current liabilities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9pt">5,618</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9pt">376,096</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9pt">53,233</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Convertible promissory notes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9pt">67,026</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9pt">68,199</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9pt">9,653</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Deficit in subsidiaries</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9pt">25,384</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9pt">163,655</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9pt">23,163</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><B>Total liabilities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9pt"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9pt"><B>98,028</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9pt"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9pt"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9pt"><B>607,950</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9pt"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9pt"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9pt"><B>86,049</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9pt"><B>&nbsp;</B></FONT></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><B>Mezzanine equity</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Series A convertible preferred shares (US$0.0001 par value, 30,227,056 shares authorized, issued
and outstanding as of December&nbsp;31, 2018 and 2019)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9pt">687,482</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9pt">687,482</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9pt">97,037</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Series B convertible preferred shares (US$0.0001 par value, 30,305,212 shares authorized, issued
and outstanding as of December&nbsp;31, 2018 and 2019)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9pt">921,243</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9pt">921,243</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9pt">130,393</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Series C convertible preferred shares (US$0.0001 par value, 31,046,360 shares authorized, issued
and outstanding as of December&nbsp;31, 2018 and 2019, respectively)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9pt">1,306,633</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9pt">1,306,633</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9pt">184,942</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Series <FONT STYLE="white-space:nowrap">C-1</FONT> convertible preferred shares (US$0.0001 par
value, nil and 3,857,143 shares authorized, issued and outstanding as of December&nbsp;31, 2018 and 2019, respectively)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9pt">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9pt">188,819</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9pt">26,726</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><B>Total mezzanine equity</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9pt"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9pt"><B>2,915,358</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9pt"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9pt"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9pt"><B>3,104,177</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9pt"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9pt"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9pt"><B>439,368</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9pt"><B>&nbsp;</B></FONT></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><B>Shareholders&#146; deficit</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Ordinary shares (US$0.0001 par value, 500,000,000 shares authorized as of December&nbsp;31, 2018
and 2019, 8,363,719 shares authorized, issued and outstanding as of December&nbsp;31, 2018 and 2019, respectively)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9pt">6</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9pt">6</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9pt">1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Treasury stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9pt">(1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9pt">)&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9pt">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9pt">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Additional <FONT STYLE="white-space:nowrap">paid-in</FONT> capital</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9pt">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9pt">389,379</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9pt">55,113</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Accumulated other comprehensive income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9pt">59,380</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9pt">70,127</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9pt">9,926</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Accumulated deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9pt">(1,014,489</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9pt">)&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9pt">(2,494,207</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9pt">)&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9pt">(353,032</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9pt">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><B>Total shareholders&#146; deficit</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9pt"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9pt"><B>(955,104</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9pt"><B>)&nbsp;</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9pt"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9pt"><B>(2,034,695</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9pt"><B>)&nbsp;</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9pt"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9pt"><B>(287,992</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9pt"><B>)&nbsp;</B></FONT></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><B>Total liabilities, mezzanine equity and shareholders&#146; deficit</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9pt"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9pt"><B>2,058,282</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9pt"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9pt"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9pt"><B>1,677,432</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9pt"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9pt"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9pt"><B>237,425</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9pt"><B>&nbsp;</B></FONT></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-65 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>I-MAB </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to the Consolidated Financial Statements </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(All amounts in thousands, except for share and per share data, unless otherwise noted) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>27. Condensed Financial Information of the Parent Company&nbsp;(Continued) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Statements of comprehensive loss </I></B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="54%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Year&nbsp;Ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>RMB</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>RMB</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>RMB</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>US$<BR>(Note&nbsp;2.5)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Operating&nbsp;expenses</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(128,721</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(121,734</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(380,143</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(53,806</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Administrative expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(15,373</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(204,874</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(28,998</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total operating expenses</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(128,721</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(137,107</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(585,017</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(82,804</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest income (expenses), net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,892</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(7,467</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,995</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,405</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(23,492</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,325</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Share of losses of subsidiaries</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(151,600</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(319,664</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(866,080</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(122,585</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fair value change of warrants</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(14,027</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">61,405</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,644</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">799</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Loss before income tax expense</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(298,240</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(402,833</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(1,451,950</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(205,510</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net loss attributable to <FONT STYLE="white-space:nowrap">I-MAB</FONT></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(298,240</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(402,833</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(1,451,950</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(205,510</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deemed dividend to Series <FONT STYLE="white-space:nowrap">C-1</FONT> preferred shareholders at
extinguishment of Series <FONT STYLE="white-space:nowrap">C-1</FONT> Preferred Shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5,283</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(748</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deemed dividend to Series <FONT STYLE="white-space:nowrap">B-1,</FONT> <FONT
STYLE="white-space:nowrap">B-2</FONT> and C preferred shareholders at modification of Series <FONT STYLE="white-space:nowrap">B-1,</FONT> <FONT STYLE="white-space:nowrap">B-2</FONT> and C Preferred Shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(27,768</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,930</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net loss attributable to ordinary shareholders</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(298,240</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(402,833</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(1,485,001</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(210,188</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net loss attributable to <FONT STYLE="white-space:nowrap">I-MAB</FONT></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(298,240</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(402,833</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(1,451,950</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(205,510</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other comprehensive income:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Foreign currency translation adjustments, net of nil tax</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,918</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">53,689</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,747</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,521</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total comprehensive loss</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(292,322</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(349,144</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(1,441,203</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(203,989</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-66 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>I-MAB </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to the Consolidated Financial Statements </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(All amounts in thousands, except for share and per share data, unless otherwise noted) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>27. Condensed Financial Information of the Parent Company&nbsp;(Continued) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Statements of cash flows </I></B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="55%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Year&nbsp;Ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>RMB</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>RMB</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>RMB</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>US$<BR>(Note&nbsp;2.5)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net cash (used in) generated from operating activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(132,732</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">40,232</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(528,322</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(74,779</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net cash (used in) generated from investing activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(356,635</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,032,483</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">449,592</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">63,636</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net cash generated from financing activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">475,224</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,498,669</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">183,536</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25,978</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Effect of exchange rate changes on cash and cash equivalents</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,697</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">62,587</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,229</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,589</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net (decrease) increase in cash and cash equivalents</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(9,446</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">569,005</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">116,035</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,424</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents at beginning of the year</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">43,675</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">34,229</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">603,234</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">85,382</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Cash and cash equivalents at end of the year</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">34,229</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">603,234</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">719,269</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">101,806</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-67 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">I-MAB</FONT> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin98473_7"></A>Consolidated Balance Sheet as of December&nbsp;31, 2019 and </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Unaudited Interim Condensed Consolidated Balance Sheet </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>as of June&nbsp;30, 2020 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(All amounts in thousands, except for share and per share data, unless otherwise noted) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="63%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>As&nbsp;of&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>As of June&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Notes</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>RMB</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>RMB</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>US$<BR>(Note&nbsp;2.5)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD COLSPAN="5" VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Current assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,137,473</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,560,031</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">220,808</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Restricted cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">55,810</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Short-term investments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">32,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,926</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">273</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepayments and other receivables</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">136,036</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">131,130</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,560</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total current assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,361,319</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,693,087</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">239,641</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Property, equipment and software</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30,069</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26,625</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,769</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating lease
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT> assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,435</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17,592</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,490</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Intangible assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">148,844</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">148,844</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21,068</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Goodwill</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">162,574</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">162,574</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23,011</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other <FONT STYLE="white-space:nowrap">non-current</FONT> assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,331</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1,737,572</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>2,048,722</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>289,979</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Liabilities, mezzanine equity and shareholders&#146; equity (deficit)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Current liabilities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Short-term borrowings</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accruals and other payables</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">273,553</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">243,068</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">34,404</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating lease liabilities, current</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,807</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,202</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,161</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ordinary shares to be issued to Everest</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">258,119</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total current liabilities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">588,479</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">251,270</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">35,565</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Convertible promissory notes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">68,199</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">69,138</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,787</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating lease liabilities, <FONT STYLE="white-space:nowrap">non-current</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,492</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,254</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,027</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred subsidy income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,920</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,760</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,098</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other <FONT STYLE="white-space:nowrap">non-current</FONT> liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,424</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,334</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total liabilities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>668,090</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>344,846</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>48,811</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Commitments and contingencies</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-68 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">I-MAB</FONT> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Consolidated Balance Sheet as of December&nbsp;31, 2019 and </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Unaudited Interim Condensed Consolidated Balance Sheet </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>as of June&nbsp;30, 2020&nbsp;(Continued) </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(All amounts in thousands, except for share and per share data, unless otherwise noted) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="62%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>As&nbsp;of&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>As of June&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Notes</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>RMB</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>RMB</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>US$<BR>(Note&nbsp;2.5)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Mezzanine equity</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series A convertible preferred shares (US$0.0001 par value, 30,227,056 shares authorized, issued
and outstanding as of December&nbsp;31, 2019, and nil authorized, issued and outstanding as of June&nbsp;30, 2020)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">687,482</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series B convertible preferred shares (US$0.0001 par value, 30,305,212 shares authorized, issued
and outstanding as of December&nbsp;31, 2019, and nil authorized, issued and outstanding as of June&nbsp;30, 2020)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">921,243</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series C convertible preferred shares (US$0.0001 par value, 31,046,360 shares authorized, issued
and outstanding as of December&nbsp;31, 2019, and nil authorized, issued and outstanding as of June&nbsp;30, 2020)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,306,633</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series <FONT STYLE="white-space:nowrap">C-1</FONT> convertible preferred shares (US$0.0001 par
value, 3,857,143 shares authorized, issued and outstanding as of December&nbsp;31, 2019, and nil authorized, issued and outstanding as of June&nbsp;30, 2020)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">188,819</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total mezzanine equity</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>3,104,177</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Shareholders&#146; equity (deficit)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ordinary shares (US$0.0001 par value, 500,000,000 and 800,000,000 shares authorized as of
December&nbsp;31, 2019 and June&nbsp;30, 2020, respectively; 8,363,719 and 133,006,644 shares issued and outstanding as of December&nbsp;31, 2019 and June&nbsp;30, 2020, respectively)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">92</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Additional <FONT STYLE="white-space:nowrap">paid-in</FONT> capital</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">389,379</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,675,991</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">661,844</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated other comprehensive income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">70,127</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">104,853</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,841</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,494,207</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,077,060</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(435,530</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total shareholders&#146; equity (deficit)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(2,034,695</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1,703,876</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>241,168</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total liabilities, mezzanine equity and shareholders&#146; equity (deficit)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1,737,572</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>2,048,722</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>289,979</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The accompanying notes are an integral part of these unaudited interim condensed consolidated financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-69 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">I-MAB</FONT> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin98473_8"></A>Unaudited Interim Condensed Consolidated Statements of Comprehensive Loss </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>For the Six Months Ended June&nbsp;30, 2019 and 2020 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(All amounts in thousands, except for share and per share data, unless otherwise noted) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="61%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Six Months Ended June&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Notes</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>RMB</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>RMB</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>US$<BR>(Note 2.5)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Revenues</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Licensing and collaboration revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Expenses</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(265,084</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(442,291</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(62,602</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Administrative expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(574,584</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(171,384</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(24,258</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Loss from operations</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(824,668</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(613,675</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(86,860</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,818</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,955</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,683</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,936</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(957</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(135</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other income, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">303</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,824</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,815</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fair value change of warrants</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(43,854</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Loss before income tax expense</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(857,337</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(582,853</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(82,497</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income tax expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net loss attributable to <FONT STYLE="white-space:nowrap">I-MAB</FONT></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(857,337</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(582,853</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(82,497</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net loss attributable to ordinary shareholders</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(857,337</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(582,853</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(82,497</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net loss attributable to <FONT STYLE="white-space:nowrap">I-MAB</FONT></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(857,337</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(582,853</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(82,497</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Other comprehensive income (loss):</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Foreign currency translation adjustments, net of nil tax</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4,972</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">34,726</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,915</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total comprehensive loss attributable to
<FONT STYLE="white-space:nowrap">I-MAB</FONT></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(862,309</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(548,127</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(77,582</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net loss attributable to ordinary shareholders</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(857,337</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(582,853</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(82,497</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted-average number of ordinary shares used in calculating net loss per share&#151;basic and
diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,184,086</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">121,815,986</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">121,815,986</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net loss per share attributable to ordinary shareholders</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&#151;Basic</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(119.34</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4.78</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(0.68</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&#151;Diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(119.34</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4.78</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(0.68</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The accompanying notes are an integral part of these unaudited interim condensed consolidated financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-70 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">I-MAB</FONT> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin98473_9"></A>Unaudited Interim Condensed Consolidated Statements of Changes in Shareholders&#146; Equity (Deficit) </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>For the Six Months Ended June&nbsp;30, 2019 and 2020 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(All amounts in thousands, except for share and per share data, unless otherwise noted) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" ALIGN="center">


<TR>

<TD WIDTH="44%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD ROWSPAN="3" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Ordinary&nbsp;shares&nbsp;(Note&nbsp;10)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="3">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="3" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Treasury<BR>stock</B></TD>
<TD VALIGN="bottom" ROWSPAN="3">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="3">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="3" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Additional<BR><FONT STYLE="white-space:nowrap">paid-in</FONT><BR>capital</B></TD>
<TD VALIGN="bottom" ROWSPAN="3">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="3">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="3" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Accumulated<BR>other<BR>comprehensive<BR>income</B></TD>
<TD VALIGN="bottom" ROWSPAN="3">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="3">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="3" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Accumulated<BR>deficit</B></TD>
<TD VALIGN="bottom" ROWSPAN="3">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="3">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="3" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Total<BR>shareholders&#146;<BR>deficit</B></TD>
<TD VALIGN="bottom" ROWSPAN="3">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>(US$0.001 par value)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Number of</B><br><B>shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:7pt; font-family:Times New Roman; " ALIGN="center"><B>RMB</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:7pt; font-family:Times New Roman; " ALIGN="center"><B>RMB</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:7pt; font-family:Times New Roman; " ALIGN="center"><B>RMB</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:7pt; font-family:Times New Roman; " ALIGN="center"><B>RMB</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:7pt; font-family:Times New Roman; " ALIGN="center"><B>RMB</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:7pt; font-family:Times New Roman; " ALIGN="center"><B>RMB</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><B>Balance&nbsp;as&nbsp;of&nbsp;December&nbsp;31,&nbsp;2018</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>8,363,719</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>6</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(1</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>59,380</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(1,014,489</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(955,104</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Foreign currency translation adjustments</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4,972</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4,972</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(857,337</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(857,337</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Share-based&nbsp;compensation</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">366,356</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">366,356</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><B>Balance as of June&nbsp;30, 2019</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>8,363,719</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>6</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(1</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>366,356</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>54,408</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(1,871,826</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(1,451,057</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><B>Balance&nbsp;as&nbsp;of&nbsp;December&nbsp;31,&nbsp;2019</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>8,363,719</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>6</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>389,379</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>70,127</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(2,494,207</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(2,034,695</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Foreign currency translation adjustments</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">34,726</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">34,726</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(582,853</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(582,853</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Share-based&nbsp;compensation</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">138,744</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">138,744</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Capital&nbsp;contribution&nbsp;from&nbsp;stock
option&nbsp;surrender&nbsp;(Note&nbsp;14&nbsp;(h))</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">91,051</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">91,051</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Conversion&nbsp;of&nbsp;preferred&nbsp;shares to&nbsp;ordinary&nbsp;shares&nbsp;upon&nbsp;the
completion&nbsp;of&nbsp;initial&nbsp;public offering (&#147;IPO&#148;)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">99,760,129</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">69</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,104,108</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,104,177</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Issuance of ordinary shares to Everest</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,078,571</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">254,844</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">254,848</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Issuance&nbsp;of&nbsp;ordinary&nbsp;shares&nbsp;upon
<FONT STYLE="white-space:nowrap">IPO&nbsp;and&nbsp;over-allotment,&nbsp;net</FONT> of issuance cost</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,804,225</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">697,865</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">697,878</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><B>Balance as of June&nbsp;30, 2020</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>133,006,644</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>92</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>4,675,991</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>104,853</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(3,077,060</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1,703,876</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The accompanying notes are an integral part of these unaudited interim condensed consolidated financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-71 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">I-MAB</FONT> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin98473_10"></A>Unaudited Interim Condensed Consolidated Statements of Cash Flows </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>For the Six Months Ended June&nbsp;30, 2019 and 2020 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(All amounts in thousands, except for share and per share data, unless otherwise noted) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="72%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Six Months Ended June&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>RMB</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>RMB</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>US$</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>(Note&nbsp;2.5)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Cash flows from operating activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(857,337</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(582,853</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(82,497</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Adjustments to reconcile net loss to net cash used in operating activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Depreciation of property, equipment and software</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,458</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,092</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">721</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss on disposal of property, equipment and software</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fair value change of short-term investments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(415</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(59</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fair value change of warrants</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">43,854</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fair value change of other financial assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">508</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Share-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">366,356</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">229,795</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">32,525</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Amortization of <FONT STYLE="white-space:nowrap">right-of</FONT> use assets and interest of lease
liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,788</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,063</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">575</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Changes in operating assets and liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepayments and other receivables</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,122</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,906</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">694</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accruals and other payables</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,696</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(19,590</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,773</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Advance from customers</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(14,151</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development funding received</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">51,588</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred subsidy income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,420</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,840</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">544</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other <FONT STYLE="white-space:nowrap">non-current</FONT> liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,424</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,334</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Lease liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,336</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4,063</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(575</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net cash used in operating activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(389,034</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(349,793</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(49,510</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Cash flows from investing activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Purchase of property, equipment and software</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,930</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(135</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(19</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds from disposal of short-term investments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">143,511</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20,314</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Purchase of short-term investments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(113,022</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(15,997</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash received from disposal of other financial assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">159,974</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net cash generated from investing activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>158,056</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>30,354</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>4,298</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-72 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">I-MAB</FONT> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Unaudited Interim Condensed Consolidated Statements of Cash Flows&nbsp;(Continued) </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>For the Six Months Ended June&nbsp;30, 2019 and 2020 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(All amounts in thousands, except for share and per share data, unless otherwise noted) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="72%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Six Months Ended June&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>RMB</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>RMB</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>US$</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>(Note&nbsp;2.5)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Cash flows from financing activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds from IPO and over-allotment, net of payment of issuance cost</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">703,798</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">99,616</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds from bank borrowings</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Repayment of bank borrowings</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(80,000</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(50,000</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(7,077</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net cash (used in) generated from financing activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(30,000</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>653,798</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>92,539</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Effect of exchange rate changes on cash and cash equivalents and restricted cash</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,093</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">32,389</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,584</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net (decrease) increase in cash and cash equivalents and restricted cash</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(264,071</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>366,748</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>51,911</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash, cash equivalents, and restricted cash, beginning of period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,680,931</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,193,283</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">168,897</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash, cash equivalents, and restricted cash, end of the period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><B>1,416,860</B></TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><B>1,560,031</B></TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><B>220,808</B></TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Additional ASC 842 supplemental disclosures</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash paid for fixed operating lease costs included in the measurement of lease obligations in
operating activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,336</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,462</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">632</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Right-of-use</FONT></FONT>
assets obtained in exchange for operating lease obligations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,952</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,261</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">745</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Other supplemental cash flow disclosures</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest paid</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,936</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">957</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">135</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">Non-cash</FONT> activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Payables for purchase of property, equipment and software</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,521</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">215</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued initial public offering costs payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,094</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">721</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ordinary shares issued to Everest</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">254,848</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">36,071</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Conversion of preferred shares to ordinary shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,104,177</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">439,368</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The accompanying notes are an integral part of these unaudited interim condensed consolidated financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-73 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">I-MAB</FONT> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin98473_11"></A>Notes to the Unaudited Interim Condensed Consolidated Financial Statements </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(All amounts in thousands, except for share and per share data, unless otherwise noted) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1. Principal Activities and Organization </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">I-Mab</FONT> (the &#147;Company&#148;) was incorporated in the Cayman Islands on June&nbsp;30, 2016 as an
exempted company with limited liability under the Companies Law of the Cayman Islands. The Company and its subsidiaries (together the &#147;Group&#148;) are principally engaged in discovering and developing transformational biologics in the fields
of immuno-oncology and immuno-inflammation diseases in the People&#146;s Republic of China (the &#147;PRC&#148;) and other countries and regions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Prior to the incorporation of the Company, the Group carried out its operation in the PRC since November 2014 mainly through Third Venture
Biopharma (Nanjing) Co., Ltd. (&#147;Third Venture&#148;), which was incorporated on November&nbsp;17, 2014 in the PRC. For the purpose of introduction of overseas investors and in preparation for a listing of the Company&#146;s shares on the
overseas capital markets, the Group underwent a reorganization (the &#147;Reorganization&#148;) in 2016. The Reorganization was approved by the Board of Directors and a restructuring framework agreement was entered into by Third Venture, the
Company, and the shareholders of the Company based on Reorganization framework agreement, pursuant to which on July&nbsp;7, 2016, Third Venture transferred all of its assets and operations to the Company&#146;s wholly owned subsidiary, <FONT
STYLE="white-space:nowrap">I-Mab</FONT> Biopharma Co., Ltd. <FONT STYLE="white-space:nowrap">(&#147;I-Mab</FONT> Shanghai&#148;), which was a transaction in which shareholders had identical ownership interests before and after the transaction and
was accounted for in a manner similar to a common control transaction. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Reorganization, as described above has been accounted for at
historical cost. That Reorganization was reverse merger of Third Venture and Third Venture is the predecessor of the Company. As such, the assets and liabilities of Third Venture are consolidated in the Company&#146;s financial statements at
historical cost. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">On January&nbsp;17, 2020, the Company consummated its IPO on the Nasdaq Global Market, where 7,407,400 American
Depositary Shares (&#147;ADSs&#148;) were issued at the price of US$14.00 per ADS for total gross proceeds of US$104.0&nbsp;million. On February&nbsp;10, 2020, the underwriters of the IPO have exercised their over-allotment option to purchase an
additional 768,350 ADSs of the Company at the IPO price of US$14.00 per ADS. After giving effect to the exercise of the over-allotment option, the Company has issued and sold a total of 8,175,750 ADSs in the IPO, for total gross proceeds of
US$114.5&nbsp;million. Each ten ADSs represents twenty-three ordinary shares of the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">As of<B> </B>June&nbsp;30, 2020, the
Company&#146;s principal subsidiaries are as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="41%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="27%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Subsidiaries</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Place of<BR>incorporation</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Date of<BR>incorporation
or<BR>acquisition</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Percentage<BR>of direct<BR>or
indirect<BR>ownership<BR>by the<BR>Company</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Principal activities</B></P></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">I-Mab</FONT> Biopharma Hong Kong Limited</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Hong&nbsp;Kong</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">July&nbsp;8, 2016</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Investment&nbsp;holding</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">I-Mab</FONT> Shanghai</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">PRC</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">August&nbsp;24,&nbsp;2016</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">100</TD>
<TD NOWRAP VALIGN="top">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Research and development of innovative medicines</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">I-Mab</FONT> <FONT STYLE="white-space:nowrap">Bio-tech</FONT>
(Tianjin) Co., Ltd. <FONT STYLE="white-space:nowrap">(&#147;I-Mab</FONT> Tianjin&#148;)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">PRC</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">July&nbsp;15, 2017</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Research and development of innovative&nbsp;medicines</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">I-Mab</FONT> Biopharma US Ltd.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">U.S.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">February&nbsp;28,&nbsp;2018</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">100</TD>
<TD NOWRAP VALIGN="top">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Research and development of innovative medicines</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-74 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">I-MAB</FONT> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to the Unaudited Interim Condensed Consolidated Financial Statements </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(All amounts in thousands, except for share and per share data, unless otherwise noted) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2. Principal Accounting Policies </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>2.1 Basis of presentation </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The
accompanying unaudited interim condensed consolidated financial statements of the Group have been prepared in accordance with the accounting principles generally accepted in the United States of America (&#147;U.S. GAAP&#148;) for interim financial
information. Accordingly, they do not include all of the information and footnotes normally included in the annual financial statements prepared in accordance with U.S. GAAP. Certain information and footnote disclosures normally included in the
annual financial statements prepared in accordance with U.S. GAAP have been condensed or omitted consistent with Article 10 of Regulation <FONT STYLE="white-space:nowrap">S-X.</FONT> In the opinion of management, the Group&#146;s unaudited interim
condensed consolidated financial statements and accompanying notes include all adjustments (consisting of normal recurring adjustments) considered necessary for the fair statement of the Group&#146;s financial position as of June&nbsp;30, 2020, and
results of operations and cash flows for the six months ended June&nbsp;30, 2019 and 2020. Interim results of operations are not necessarily indicative of the results for the full year or for any future period. These unaudited interim condensed
consolidated financial statements should be read in conjunction with the audited consolidated financial statements as of and for the year ended December&nbsp;31, 2019, and related notes included in the Group&#146;s audited consolidated financial
statements. The financial information as of December&nbsp;31, 2019 presented in the unaudited interim condensed consolidated financial statements is derived from the audited consolidated financial statements as of December&nbsp;31, 2019. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Significant accounting policies followed by the Group in the preparation of the accompanying consolidated financial statements are summarized
below. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>2.2 Basis of consolidation </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The accompanying consolidated financial statements reflect the accounts of the Company and all of its subsidiaries in which a controlling
interest is maintained. All inter-company balances and transactions have been eliminated in consolidation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>2.3 Use of estimates </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions
that affect the reported amounts of assets and liabilities and the disclosures of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period.
Estimates are used when accounting for amounts recorded in connection with acquisitions, including initial fair value determinations of assets and liabilities and other intangible assets as well as subsequent fair value measurements. Additionally,
estimates are used in determining items such as fair value measurements of wealth management products, impairment of other receivables, long-lived assets, intangible assets and goodwill, useful lives of property, equipment and software, recognition
of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT> assets and lease liabilities, fair value measurements of warrant liabilities, variable consideration in collaboration revenue arrangements, determination
of the standalone selling price of each performance obligation in the Company&#146;s revenue arrangements, valuation of share-based compensation arrangements, deferred tax assets valuation allowances. Management bases the estimates on historical
experience, known trends and various other assumptions that are believed to be reasonable, the results of which form the basis for making judgments about the carrying values of assets and liabilities. Actual results could differ from those
estimates. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-75 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">I-MAB</FONT> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to the Unaudited Interim Condensed Consolidated Financial Statements </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(All amounts in thousands, except for share and per share data, unless otherwise noted) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2. Principal Accounting Policies&nbsp;(Continued) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>2.4 Fair value measurements </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Financial assets and liabilities of the Group primarily comprise of cash and cash equivalents, restricted cash, short-term investments, other
financial assets, contract assets, other receivables, short-term borrowings, accruals and other payables and warrants liabilities. As of December&nbsp;31, 2019, and June&nbsp;30, 2020, except for short-term investments, other financial assets and
warrant liabilities, the carrying values of these financial assets and liabilities approximated their fair values because of their generally short maturities. The Group reports short-term investments, other financial assets and warrant liabilities
at fair value at each balance sheet date and changes in fair value are reflected in the consolidated statements of comprehensive loss. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Group measures its financial assets and liabilities using inputs from the following three levels of the fair value hierarchy. The three
levels are as follows: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Level&nbsp;1 inputs are unadjusted quoted prices in active markets for identical assets that the management has
the ability to access at the measurement date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Level&nbsp;2 inputs include quoted prices for similar assets in active markets, quoted
prices for identical or similar assets in markets that are not active, inputs other than quoted prices that are observable for the asset (i.e., interest rates, yield curves, etc.), and inputs that are derived principally from or corroborated by
observable market data by correlation or other means (market corroborated inputs). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Level&nbsp;3 includes unobservable inputs that reflect
the management&#146;s assumptions about the assumptions that market participants would use in pricing the asset. The management develops these inputs based on the best information available, including the own data.</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><I>Assets and liabilities measured at fair value on a recurring basis </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Group measured its short-term investments at fair value on a recurring basis. As the Group&#146;s short-term investments are not traded in
an active market with readily observable prices, the Group uses significant unobservable inputs to measure the fair value of short-term investments. These instruments are categorized in the Level&nbsp;3 valuation hierarchy based on the significance
of unobservable factors in the overall fair value measurement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The following table summarizes the Group&#146;s financial assets measured
and recorded at fair value on a recurring basis as of December&nbsp;31, 2019 and June&nbsp;30, 2020: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="85.5%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="34%"></TD>

<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>As of December&nbsp;31, 2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Active&nbsp;market<BR>(Level&nbsp;1)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Observable&nbsp;input<BR>(Level 2)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B><FONT STYLE="white-space:nowrap">Non-observable&nbsp;input</FONT><BR>(Level 3)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>RMB</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>RMB</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>RMB</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>RMB</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Assets:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Short-term investments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">32,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">32,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-76 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">I-MAB</FONT> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to the Unaudited Interim Condensed Consolidated Financial Statements </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(All amounts in thousands, except for share and per share data, unless otherwise noted) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2. Principal Accounting Policies&nbsp;(Continued) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>2.4 Fair value measurements&nbsp;(Continued) </I></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="85.5%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="36%"></TD>

<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>As of June&nbsp;30, 2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Active&nbsp;market<BR>(Level&nbsp;1)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Observable&nbsp;input<BR>(Level 2)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B><FONT STYLE="white-space:nowrap">Non-observable&nbsp;input</FONT><BR>(Level 3)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>RMB</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>RMB</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>RMB</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>RMB</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Assets:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Short-term investments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,926</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,926</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The roll forward of major Level&nbsp;3 financial assets are as follows: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="72%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="70%"></TD>

<TD VALIGN="bottom" WIDTH="19%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B><FONT STYLE="white-space:nowrap">Short-term&nbsp;investments</FONT></B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fair value of Level&nbsp;3 financial asset as of December&nbsp;31, 2019</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">32,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Purchase of short-term investments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">113,022</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Disposal of short-term investments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(143,511</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fair value changes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">415</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fair value of Level&nbsp;3 financial asset as of June&nbsp;30, 2020</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,926</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>2.5 Foreign currency translation </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Group uses Chinese Renminbi (&#147;RMB&#148;) as its reporting currency. The United States Dollar (&#147;US$&#148;) is the functional
currency of the Group&#146;s entities incorporated in the Cayman Islands, the United States of America (&#147;U.S.&#148;) and Hong Kong, the Australia Dollar (&#147;AUD&#148;) is the functional currency of the Group&#146;s entity incorporated in
Australia and the RMB is the functional currency of the Company&#146;s PRC subsidiaries. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Transactions denominated in other than the
functional currencies are translated into the functional currency of the entity at the exchange rates prevailing on the transaction dates. Assets and liabilities denominated in other than the functional currencies are translated at the balance sheet
date exchange rate. The resulting exchange differences are recorded in the consolidated statements of comprehensive loss. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The unaudited
interim condensed consolidated financial statements of the Group are translated from the functional currency to the reporting currency, RMB. Assets and liabilities of the subsidiaries are translated into RMB using the exchange rate in effect at each
balance sheet date. Income and expenses are translated at the average exchange rates prevailing for the year. Foreign currency translation adjustments arising from these are reflected in the accumulated other comprehensive income. The exchange rates
used for translation on December&nbsp;31, 2019 and June&nbsp;30, 2020 were US$1.00 = RMB6.9762 and RMB7.0795 respectively, representing the index rates stipulated by the People&#146;s Bank of China. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Translations of balances in the consolidated balance sheets, consolidated statements of comprehensive loss, consolidated statements of changes
in shareholders&#146; equity (deficit) and consolidated statements of cash flows from RMB into US$ as of and for the six months ended June&nbsp;30, 2020 are solely for the convenience of the readers and were calculated at the rate of
US$1.00=RMB7.0651, representing the noon buying rate in The City of New York for cable transfers of RMB as certified for customs purposes by the Federal Reserve Bank of New </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-77 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">I-MAB</FONT> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to the Unaudited Interim Condensed Consolidated Financial Statements </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(All amounts in thousands, except for share and per share data, unless otherwise noted) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2. Principal Accounting Policies&nbsp;(Continued) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
York on June&nbsp;30, 2020. No representation is made that the RMB amounts could have been, or could be, converted, realized or settled into US$ at that rate on June&nbsp;30, 2020, or at any
other rate. The US$ convenience translation is not required under U.S. GAAP and all US$ convenience translation amounts in the accompanying consolidated financial statements are unaudited. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>2.6 Cash and cash equivalents </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents consist of cash on hand and bank deposits, which are unrestricted as to withdrawal and use. The Company considers
all highly liquid investments with an original maturity date of three months or less at the date of purchase to be cash equivalents. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>2.7 Restricted
cash </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Restricted cash consists of the guarantee deposits held in a designated bank account as security deposits under bank
borrowing agreements. Such restricted cash was released when the Group repaid the related bank borrowings. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>2.8 Short-term investments </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Short-term investments represent the investments issued by commercial banks or other financial institutions with a variable interest rate
indexed to the performance of underlying assets within one year. These investments are stated at fair value. Changes in the fair value are reflected in the consolidated statements of comprehensive loss. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>2.9 Property, equipment and software </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Property, equipment and software are stated at cost less accumulated depreciation and amortization. Depreciation and amortization is computed
using the straight-line method over the following estimated useful lives, taking into account any estimated residual value: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="85.5%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="62%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="35%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Laboratory equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3&nbsp;to&nbsp;5&nbsp;years</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Software</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2 to 5 years</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Office furniture and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">5 years</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Leasehold improvements</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Lesser&nbsp;of&nbsp;useful&nbsp;life&nbsp;or&nbsp;lease&nbsp;term</P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Group recognized the gain or loss on the disposal of property, equipment and software in the consolidated
statements of comprehensive loss. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>2.10 Intangible assets </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Intangible assets with definite useful lives are amortized to their estimated residual values over their estimated useful lives and reviewed
for impairment if certain events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Amortization is initiated for <FONT STYLE="white-space:nowrap">in-process</FONT> research and development (IPR&amp;D)
intangible assets that are acquired from business combination when their useful lives have been determined. IPR&amp;D intangible assets which are determined to have an impairment in their fair value are
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-78 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">I-MAB</FONT> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to the Unaudited Interim Condensed Consolidated Financial Statements </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(All amounts in thousands, except for share and per share data, unless otherwise noted) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2. Principal Accounting Policies&nbsp;(Continued) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>2.10 Intangible assets&nbsp;(Continued) </I></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
adjusted downward and an expense recognized in research and development in the consolidated statements of comprehensive loss. These IPR&amp;D intangible assets are tested at least on an annual
basis on December&nbsp;31 or when a triggering event occurs that could indicate a potential impairment (see Note 5). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>2.11 Impairment of long-lived
assets </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Long-lived assets are reviewed for impairment in accordance with authoritative guidance for impairment or disposal of
long-lived assets. Long-lived assets are reviewed for events or changes in circumstances, which indicate that their carrying value may not be recoverable. Long-lived assets are reported at the lower of carrying amount or fair value less cost to
sell. For the year ended December&nbsp;31, 2019 and six months ended June&nbsp;30, 2020, there was no impairment of the value of the Group&#146;s long-lived assets. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>2.12 Goodwill </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Goodwill is an
asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized. The Group allocates the cost of an acquired entity to the assets acquired
and liabilities assumed based on their estimated fair values at the date of acquisition. The excess of the purchase price for acquisitions over the fair value of the net assets acquired, including other intangible assets, is recorded as goodwill.
Goodwill is not amortized, but impairment of goodwill assessment is performed on at least an annual basis on December&nbsp;31 or whenever events or changes in circumstances indicate that the carrying value of the asset may not be recoverable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Group has elected to first assess qualitative factors to determine whether it is more likely than not that the fair value of the
Group&#146;s reporting unit is less than its carrying amount, including goodwill. The qualitative assessment includes the Group&#146;s evaluation of relevant events and circumstances affecting the Group&#146;s single reporting unit, including
macroeconomic, industry, market conditions and the Group&#146;s overall financial performance. If qualitative factors indicate that it is more likely than not that the Group&#146;s reporting unit&#146;s fair value is less than its carrying amount,
then the Group will perform the quantitative impairment test by comparing the reporting unit&#146;s carrying amount, including goodwill, to its fair value. If the carrying amount of the reporting unit exceeds its fair value, an impairment loss will
be recognized in an amount equal to that excess. For the year ended December&nbsp;31, 2019 and six months ended June&nbsp;30, 2020, the Group determined that there were no indicators of impairment of the goodwill. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>2.13 Deferred subsidy income </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Deferred subsidy income consists of deferred income from government grants. Government grants mainly consist of cash subsidies received by the
Group&#146;s subsidiaries in the PRC from local governments as support on expenses relating to certain projects. Grants received with government specified performance obligations are recognized when all the obligations have been fulfilled. If such
obligations are not satisfied, the Group may be required to refund the subsidy. Cash grants of RMB3,920 was recorded in deferred subsidy income as of December&nbsp;31, 2019. As of June&nbsp;30, 2020, cash grants of RMB7,760 was recorded in deferred
subsidy income, which will be recognized when the government specified performance obligation is satisfied, which is expected to be more than 12 months after June&nbsp;30, 2020. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-79 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">I-MAB</FONT> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to the Unaudited Interim Condensed Consolidated Financial Statements </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(All amounts in thousands, except for share and per share data, unless otherwise noted) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2. Principal Accounting Policies&nbsp;(Continued) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>2.14 Revenue recognition </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Group adopted Accounting Standard Codification (&#147;ASC&#148;) 606, <I>Revenue from Contracts with Customers</I> (Topic 606) (&#147;ASC
606&#148;) for all periods presented. Consistent with the criteria of Topic 606, the Group recognizes revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects
to receive in exchange for those goods or services. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Under ASC 606, an entity recognizes revenue when its customer obtains control of
promised goods or services, in an amount that reflects the consideration that the entity expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that an entity determines are within the scope of
ASC 606, the entity performs the following five steps: (i)&nbsp;identify the contract(s) with a customer; (ii)&nbsp;identify the performance obligations in the contract; (iii)&nbsp;determine the transaction price, including variable consideration,
if any; (iv)&nbsp;allocate the transaction price to the performance obligations in the contract; and (v)&nbsp;recognize revenue when (or as) the entity satisfies a performance obligation. The Group only applies the five-step model to contracts when
it is probable that the entity will collect substantially all the consideration to which it is entitled in exchange for the goods or services it transfers to the customer. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Once a contract is determined to be within the scope of ASC 606 at contract inception, the Group audits the contract to determine which
performance obligations it must deliver and which of these performance obligations are distinct. The Group recognizes as revenue the amount of the transaction price that is allocated to each performance obligation when that performance obligation is
satisfied or as it is satisfied. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><I>Collaboration revenue </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">At contract inception, the Group analyzes its collaboration arrangements to assess whether they are within the scope of ASC
808,<I>&nbsp;Collaborative Arrangements</I>&nbsp;(&#147;ASC 808&#148;) to determine whether such arrangements involve joint operating activities performed by parties that are both active participants in the activities and exposed to significant
risks and rewards dependent on the commercial success of such activities.&nbsp;For collaboration arrangements within the scope of ASC 808 that contain multiple elements, the Group first determines if the collaboration is deemed to be within the
scope of ASC 808. For any units of account that are reflective of a vendor-customer relationship those units of account are accounted for within the scope of ASC 606. For any units of account that are not accounted for under ASC 606 and therefore
accounted for pursuant to ASC 808, an appropriate recognition method is determined and applied consistently.</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Group&#146;s
collaborative arrangements may contain more than one unit of account, or performance obligation, including grants of licenses to intellectual property rights, agreement to provide research and development services and other deliverables. The
collaborative arrangements do not include a right of return for any deliverable. As part of the accounting for these arrangements, the Group must develop assumptions that require judgment to determine the stand-alone selling price for each
performance obligation identified in the contract.&nbsp;In developing the stand-alone selling price for a performance obligation, the Group considers competitor pricing for a similar or identical product, market awareness of and perception of the
product, expected product life and current market trends. In general, the consideration allocated to each performance obligation is recognized when the respective obligation is satisfied either by delivering a good or providing a service, limited to
the consideration that is not constrained. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-80 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">I-MAB</FONT> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to the Unaudited Interim Condensed Consolidated Financial Statements </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(All amounts in thousands, except for share and per share data, unless otherwise noted) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2. Principal Accounting Policies&nbsp;(Continued) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>2.14 Revenue recognition&nbsp;(Continued) </I></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">When the timing of the delivery of product is different from the timing of payments made by
the customers, the Group recognizes either a contract asset (performance precedes the contractual due date) or a contract liability (customer payment precedes performance). The Group&#146;s contractual payment terms are typically due in no more than
30 days from invoicing. In limited situations, certain customer contractual payment terms require the Group to bill in arrears; thus, the Group satisfies some or all of the performance obligations before the Group is contractually entitled to bill
the customer. In these situations, billing occurs subsequent to revenue recognition, which results in a contract asset. A receivable is recorded when the Group has an unconditional right to consideration. A right to consideration is unconditional if
only the passage of the time is required before payment of the consideration is due. A contract asset is recorded when the Group has transferred products or services to the customer before payment is received or is due, and the Group&#146;s right to
consideration is conditional on future performance or other factors in the contract. For example, certain of the contractual arrangements do not permit the Group to bill until the completion of the production of the samples. In other limited
situations, certain customer contractual payment terms allow the Group to bill in advance; thus, the Group receives customer cash payment before satisfying some or all of its performance obligations. In these situations, billing occurs in advance of
revenue recognition, which results in contract liabilities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I>Licenses of Intellectual Property:</I> Upfront <FONT
STYLE="white-space:nowrap">non-refundable</FONT> payments for licensing the Group&#146;s intellectual property are evaluated to determine if the license is distinct from the other performance obligations identified in the arrangement. For licenses
determined to be distinct, the Group recognizes revenues from <FONT STYLE="white-space:nowrap">non-refundable,</FONT> <FONT STYLE="white-space:nowrap">up-front</FONT> fees allocated to the license at a point in time, when the license is transferred
to the licensee and the licensee is able to use and benefit from the license. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I>Research and Development Services: </I>The portion of
the transaction price allocated to research and development services performance obligations is deferred and recognized as revenue over time as delivery or performance of such services provided to the Group&#146;s customers occurs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I>Milestone Payments</I>: At the inception of each arrangement that includes development, commercialization, and regulatory milestone
payments, the Group evaluates whether the milestones are considered probable of being reached and to the extent that a significant reversal of cumulative revenue would not occur in future periods, estimates the amount to be included in the
transaction price using the most likely amount method. The transaction price is then allocated to each performance obligation on a relative stand-alone selling price basis, for which the Group recognizes revenue as or when the performance
obligations under the contract are satisfied. At the end of each subsequent reporting period, the Group <FONT STYLE="white-space:nowrap">re-evaluates</FONT> the probability of achieving such development milestones and any related constraint, and if
necessary, adjust the estimate of the overall transaction price. Any such adjustments are recorded on a cumulative <FONT STYLE="white-space:nowrap">catch-up</FONT> basis, which would affect revenues and earnings in the period of adjustment. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I>Royalties</I>: For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and the
license is deemed to be the predominant item to which the royalties or milestone payments based on the level of sales relate, the Group recognizes revenue at the later of (i)&nbsp;when the related sales occur, or (ii)&nbsp;when the performance
obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-81 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">I-MAB</FONT> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to the Unaudited Interim Condensed Consolidated Financial Statements </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(All amounts in thousands, except for share and per share data, unless otherwise noted) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2. Principal Accounting Policies&nbsp;(Continued) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>2.15 <FONT STYLE="white-space:nowrap">Value-added-tax</FONT> (&#147;VAT&#148;) recoverable and
surcharges </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Value added tax recoverable represent amounts paid by the Group for purchases. The surcharges (i.e., Urban
construction and maintenance tax, educational surtax, local educational surtax), vary from 6% to 17% of <FONT STYLE="white-space:nowrap">the&nbsp;value-added-tax&nbsp;depending</FONT> on
<FONT STYLE="white-space:nowrap">the&nbsp;tax-payer&#146;s&nbsp;location.</FONT> The deductible input VAT balance is reflected in the prepayments and other receivables, and VAT payable balance is recorded in the accruals and other payables. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>2.16 Research and development expenses </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Elements of research and development expenses primarily include (1)&nbsp;payroll and other related expenses of personnel engaged in research
and development activities, <FONT STYLE="white-space:nowrap">(2)&nbsp;in-licensed</FONT> patent rights fee of exclusive development rights of drugs granted to the Group, (3)&nbsp;expenses related to preclinical testing of the Group&#146;s
technologies under development and clinical trials such as payments to contract research organizations (&#147;CRO&#148;), investigators and clinical trial sites that conduct the clinical studies (4)&nbsp;expenses to develop the product candidates,
including raw materials and supplies, product testing, depreciation, and facility related expenses, (5)&nbsp;other research and development expenses. Research and development expenses are charged to expense as incurred when these expenditures relate
to the Group&#146;s research and development services and have no alternative future uses. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Group has acquired rights to develop and
commercialize product candidates. Upfront payments that relate to the acquisition of a new drug compound, as well as <FONT STYLE="white-space:nowrap">pre-commercial</FONT> milestone payments, are immediately expensed as acquired <FONT
STYLE="white-space:nowrap">in-process</FONT> research and development in the period in which they are incurred, provided that the new drug compound did not also include processes or activities that would constitute a &#147;business&#148; as defined
under U.S. GAAP, the drug has not achieved regulatory approval for marketing and, absent obtaining such approval, has no established alternative future use. Milestone payments made to third parties subsequent to regulatory approval would be
capitalized as intangible assets and amortized over the estimated remaining useful life of the related product. The conditions enabling capitalization of development expenses as an asset have not yet been met and, therefore, all development
expenditures are recognized in profit or loss when incurred. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>2.17 Leases </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In accordance with ASC 842 adopted on January&nbsp;1, 2019, the Group determines if an arrangement is a lease at inception. Operating leases
are included in operating lease <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT> (&#147;ROU&#148;) assets, operating lease liability, and operating lease liability,
<FONT STYLE="white-space:nowrap">non-current</FONT> in the Group&#146;s consolidated balance sheets. The Group does not have any finance leases since the adoption date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">ROU assets represent the Group&#146;s right to use an underlying asset for the lease term and lease liabilities represent the Group&#146;s
obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. When determining the lease term, the Group
includes options to extend or terminate the lease when it is reasonably certain that it will exercise that option, if any. As the Group&#146;s leases do not provide an implicit rate, the Group uses its incremental borrowing rate, which it calculates
based on the credit quality of the Group and by comparing interest rates available in the market for similar borrowings, and adjusting this amount based on the impact of collateral over the term of each lease. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-82 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">I-MAB</FONT> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to the Unaudited Interim Condensed Consolidated Financial Statements </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(All amounts in thousands, except for share and per share data, unless otherwise noted) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2. Principal Accounting Policies&nbsp;(Continued) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>2.17 Leases&nbsp;(Continued) </I></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Group has elected to adopt the following lease policies in conjunction with the adoption
of ASU <FONT STYLE="white-space:nowrap">2016-02:</FONT> (i) elect for each lease not to separate <FONT STYLE="white-space:nowrap">non-lease</FONT> components from lease components and instead to account for each separate lease component and the <FONT
STYLE="white-space:nowrap">non-lease</FONT> components associated with that lease component as a single lease component; (ii)&nbsp;for leases that have lease terms of 12 months or less and does not include a purchase option that is reasonably
certain to exercise, the Group elected not to apply ASC 842 recognition requirements; and (iii)&nbsp;the Group elected to apply the package of practical expedients for existing arrangements entered into prior to January&nbsp;1, 2019 to not reassess
(a)&nbsp;whether an arrangement is or contains a lease, (b)&nbsp;the lease classification applied to existing leases, and (c)&nbsp;initial direct costs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In connection with the adoption of ASC 842, on January&nbsp;1, 2019, the Company recorded an impact of RMB13,100 on its assets and RMB11,333
on its liabilities for the recognition of operating lease <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use-assets</FONT></FONT></FONT> and operating lease liabilities, respectively,
which are primarily related to the lease of the Group&#146;s offices and warehouses. The adoption of ASC 842 did not have a material impact on the Company&#146;s results of operations or cash flows. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>2.18 Comprehensive loss </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Comprehensive loss is defined as the changes in equity of the Group during a period from transactions and other events and circumstances
excluding transactions resulting from investments by owners and distributions to owners. Among other disclosures, ASC 220,&nbsp;Comprehensive Income, requires that all items that are required to be recognized under current accounting standards as
components of comprehensive loss be reported in a financial statement that is displayed with the same prominence as other financial statements. For each of the periods presented, the Group&#146;s comprehensive loss includes net loss and foreign
currency translation adjustments, which are presented in the consolidated statements of comprehensive loss. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>2.19 Share-based compensation
</I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Company grants restricted shares and stock options to eligible employees and accounts for share-based compensation in
accordance with ASC 718, Compensation&#151;Stock Compensation.</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Employees&#146; share-based compensation awards are measured at the grant
date fair value of the awards and recognized as expenses a) immediately at the grant date if no vesting conditions are required; or b) for share based awards granted with only service conditions, using the graded vesting method net of estimated
forfeitures over the vesting period; or c) for share-based awards granted with service conditions and the occurrence of an initial public offering (&#147;IPO&#148;) as performance condition cumulative share-based compensation expenses for the
options that have satisfied the service condition should be recorded upon the completion of the IPO using the graded vesting method.</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">A
change in any of the terms or conditions of share-based awards is accounted for as a modification of the awards. The Group calculates incremental compensation expense of a modification as the excess of the fair value of the modified awards over the
fair value of the original awards immediately before its terms are modified at the modification date. For vested awards, the Group recognizes incremental compensation cost in the period when the modification occurs. For awards not being fully
vested, the Group recognizes the sum of the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-83 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">I-MAB</FONT> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to the Unaudited Interim Condensed Consolidated Financial Statements </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(All amounts in thousands, except for share and per share data, unless otherwise noted) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2. Principal Accounting Policies&nbsp;(Continued) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>2.19 Share-based compensation&nbsp;(Continued) </I></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
incremental compensation expense and the remaining unrecognized compensation expense for the original awards over the remaining requisite service period after modification. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Share-based compensation in relation to the restricted shares is measured based on the fair market value of the Group&#146;s ordinary shares
at the grant date of the award. Prior to the listing, estimation of the fair value of the Group&#146;s ordinary shares involves significant assumptions that might not be observable in the market, and a number of complex and subjective variables,
including discount rate, and subjective judgments regarding the Group&#146;s projected financial and operating results, its unique business risks, the liquidity of its ordinary shares and its operating history and prospects at the time the grants
are made. Share-based compensation in relation to the share options is estimated using the Binominal Option Pricing Model. The determination of the fair value of share options is affected by the share price of the Group&#146;s ordinary shares as
well as the assumptions regarding a number of complex and subjective variables, including the expected share price volatility, risk-free interest rate, exercise multiple and expected dividend yield. The fair value of these awards was determined with
the assistance from an independent valuation firm. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>2.20 Income taxes </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Group accounts for income taxes under the liability method. Under the liability method, deferred income tax assets and liabilities are
determined based on the differences between the financial reporting and income tax bases of assets and liabilities and are measured using the tax income rates that will be in effect when the differences are expected to reverse. A valuation allowance
is recorded if it is more likely than not that some portion or all of the deferred income tax assets will not be utilized in the foreseeable future. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Group evaluates its uncertain tax positions using the provisions of ASC <FONT STYLE="white-space:nowrap">740-10,&nbsp;Income</FONT> Taxes,
which prescribes a recognition threshold that a tax position is required to meet before being recognized in the financial statements. The Group recognizes in the financial statements the benefit of a tax position which is &#145;&#145;more likely
than not&#146;&#146; to be sustained under examination based solely on the technical merits of the position assuming a review by tax authorities having all relevant information. Tax positions that meet the recognition threshold are measured using a
cumulative probability approach, at the largest amount of tax benefit that has a greater than fifty percent likelihood of being realized upon settlement. It is the Group&#146;s policy to recognize interest and penalties related to unrecognized tax
benefits, if any, as a component of income tax expense. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>2.21 Borrowings </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Borrowings are recognized initially at fair value, net of transaction costs incurred. Borrowings are subsequently stated at amortized cost;
any difference between the proceeds (net&nbsp;of transaction costs) and the redemption value is recognized in the consolidated statements of comprehensive loss over the period of the borrowings using the effective interest method. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>2.22 Segment information </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In
accordance with ASC 280,&nbsp;Segment Reporting, the Group&#146;s chief operating decision maker, the Chief Executive Officer, reviews the consolidated results when making decisions about allocating resources and
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-84 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">I-MAB</FONT> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to the Unaudited Interim Condensed Consolidated Financial Statements </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(All amounts in thousands, except for share and per share data, unless otherwise noted) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2. Principal Accounting Policies&nbsp;(Continued) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>2.22 Segment information&nbsp;(Continued) </I></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
assessing performance of the Group as a whole and hence, the Group has only one reportable segment. The Group does not distinguish between markets or segments for the purpose of internal
reporting. As the Group&#146;s long-lived assets are substantially located in and derived from the PRC, no geographical segments are presented. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>2.23 Loss per share </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Basic loss
per share is computed by dividing net loss attributable to ordinary shareholders by the weighted average number of ordinary shares outstanding during the period using <FONT STYLE="white-space:nowrap">the&nbsp;two-class&nbsp;method.</FONT> Under <FONT
STYLE="white-space:nowrap">the&nbsp;two-class&nbsp;method,</FONT> the net loss is allocated between ordinary shares and other participating securities based on their participating rights. Net loss is not allocated to other participating securities
if based on their contractual terms they are not obligated to share in the loss. Diluted loss per share is calculated by dividing net loss attributable to ordinary shareholders by the weighted average number of ordinary and dilutive ordinary
equivalent shares outstanding during the period. Ordinary equivalent shares consist of shares issuable upon the conversion of the preferred shares using <FONT STYLE="white-space:nowrap">the&nbsp;if-converted&nbsp;method,</FONT> shares issuable upon
the exercise of share options using the treasury stock method, shares issuable upon the conversion of the convertible promissory notes using <FONT STYLE="white-space:nowrap">the&nbsp;if-converted&nbsp;method,</FONT> and shares issuable upon the
exercise of warrants using the treasury stock method. Ordinary equivalent shares are not included in the denominator of the diluted loss per share calculation when inclusion of such shares would be anti-dilutive. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>2.24 Adopted accounting pronouncements </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In June 2016, the FASB issued ASU <FONT STYLE="white-space:nowrap">2016-13,</FONT> Financial Instruments&#151;Credit Losses (Topic 326):
Measurement of Credit Losses on Financial Instruments (&#147;ASU <FONT STYLE="white-space:nowrap">2016-13&#148;).</FONT> This guidance requires that financial assets measured at amortized cost be presented at the net amount expected to be collected.
The measurement of expected credit losses is based on historical experience, current conditions, and reasonable and supportable forecasts that affect the collectability. In November 2018, the FASB issued ASU
<FONT STYLE="white-space:nowrap">2018-19,</FONT> Codification Improvements to Topic 326, Financial Instruments-Credit Losses (&#147;ASU <FONT STYLE="white-space:nowrap">2018-19&#148;),</FONT> which clarifies certain topics included within ASU <FONT
STYLE="white-space:nowrap">2016-13.</FONT> ASU <FONT STYLE="white-space:nowrap">2016-13</FONT> and ASU <FONT STYLE="white-space:nowrap">2018-19</FONT> are effective for the annual reporting period beginning after December&nbsp;15, 2019, including
interim periods within that reporting period. The impact of this ASU to the consolidated financial statements is immaterial. The Group elected to adopt this ASU and applied this guidance retrospectively to all periods presented. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In January 2017, the FASB issued ASU <FONT STYLE="white-space:nowrap">2017-04,</FONT> Intangibles&#151;Goodwill and Other (Topic 350), which
simplifies the subsequent measurement of goodwill by removing the second step of the <FONT STYLE="white-space:nowrap">two-step</FONT> impairment test. The amendment requires an entity to perform its annual or interim goodwill impairment test by
comparing the fair value of a reporting unit with its carrying amount. A goodwill impairment will be the amount by which a reporting unit&#146;s carrying value exceeds its fair value, not to exceed the carrying amount of goodwill. The Group adopted
this ASU on January&nbsp;1, 2020 and the adoption of this ASU does not have a material impact to its consolidated financial statements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In August 2018 the FASB issued ASU <FONT STYLE="white-space:nowrap">No.&nbsp;2018-13,</FONT> Fair Value Measurement (Topic 820): Disclosure
Framework&#151;Changes to the Disclosure Requirements for Fair Value Measurement. This standard modifies certain disclosure requirements on fair value measurements. This standard became effective for us on January&nbsp;1, 2020. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-85 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">I-MAB</FONT> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to the Unaudited Interim Condensed Consolidated Financial Statements </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(All amounts in thousands, except for share and per share data, unless otherwise noted) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2. Principal Accounting Policies&nbsp;(Continued) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>2.24 Adopted accounting pronouncements&nbsp;(Continued) </I></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In November 2018 the FASB issued
<FONT STYLE="white-space:nowrap">ASU&nbsp;No.&nbsp;2018-18,&nbsp;Collaborative</FONT> Arrangements (Topic 808): Clarifying the Interaction between Topic 808 and Topic 606. This standard makes targeted improvements for collaborative arrangements as
follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Clarifies that certain transactions between collaborative arrangement participants should be accounted for as
revenue under ASC 606, Revenue from Contracts with Customers, when the collaborative arrangement participant is a customer in the context of a unit of account. In those situations, all the guidance in ASC 606 should be applied, including
recognition, measurement, presentation and disclosure requirements; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
<P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Adds&nbsp;unit-of-account&nbsp;guidance</FONT></FONT> to ASC 808,
Collaborative Arrangements, to align with the guidance in ASC 606 (that is, a distinct good or service) when an entity is assessing whether the collaborative arrangement or a part of the arrangement is within the scope of ASC 606; and
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Precludes a company from presenting transactions with collaborative arrangement participants that are not
directly related to sales to third parties with revenue recognized under ASC 606 if the collaborative arrangement participant is not a customer. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">This standard became effective for the Group on January&nbsp;1, 2020. A retrospective transition approach is required for either all contracts
or only for contracts that are not completed at the date of initial application of ASC 606, with a cumulative adjustment to opening retained earnings. Since the Group&#146;s all relevant units of accounts were accounted for under ASC 606, the
adoption of this ASU does not have a material impact to the Group&#146;s consolidated financial statements, with no adjustment to its opening retained earnings. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>2.25 Recent accounting pronouncements </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In December 2019, the FASB issued ASU <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">2019-12-Income</FONT></FONT> Taxes
(Topic 740): Simplifying the Accounting for Income Taxes. The amendments in ASU <FONT STYLE="white-space:nowrap">2019-12</FONT> simplify the accounting for income taxes by removing certain exceptions to the general principles in Topic 740. The
amendments also improve consistent application of and simplify GAAP for other areas of Topic 740 by clarifying and amending existing guidance. ASU <FONT STYLE="white-space:nowrap">2019-12</FONT> is effective for the Company beginning on
January&nbsp;1, 2022. Early adoption of the amendments is permitted. The Company is currently evaluating the impact of ASU <FONT STYLE="white-space:nowrap">2019-12</FONT> on its consolidated financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-86 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">I-MAB</FONT> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to the Unaudited Interim Condensed Consolidated Financial Statements </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(All amounts in thousands, except for share and per share data, unless otherwise noted) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>3. Prepayments and Other Receivables </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="72%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="53%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>As&nbsp;of&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>As of June&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>RMB</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>RMB</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>US$<BR>(Note&nbsp;2.5)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepayments:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&#151;Prepayments to CRO vendors</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">78,740</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">82,742</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,711</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&#151;Prepayments for other services</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">880</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,153</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">163</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Receivables due from employees (Note)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,201</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Value-added tax recoverable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,517</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,856</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,244</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Rental deposits</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">546</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,478</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">209</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest receivables</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">764</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,987</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">423</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Others</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26,388</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26,914</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,810</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">136,036</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">131,130</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,560</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Note: The balance mainly represented the receivables due from employees, which were arising from the
Group&#146;s obligation to pay the withholding individual income tax (&#147;IIT&#148;) for those employees&#146; stock option activities and was collected by the Group in January 2020. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>4. Property, Equipment and Software </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Property, equipment and software consist of the following: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="72%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="48%"></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>As&nbsp;of&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>As of June&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>RMB</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>RMB</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>US$<BR>(Note&nbsp;2.5)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cost</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Laboratory equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24,265</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24,634</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,487</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Leasehold improvement</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,856</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,222</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,730</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Software</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,220</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,230</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,448</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Office furniture and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,526</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,526</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">216</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total property, equipment and software</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">47,867</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">48,612</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,881</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Less: accumulated depreciation and amortization</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(18,221</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(23,312</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,300</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net book value</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">29,646</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25,300</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,581</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Construction in progress</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">423</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,325</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">188</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total net book value of property, equipment and software</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30,069</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26,625</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,769</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-87 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">I-MAB</FONT> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to the Unaudited Interim Condensed Consolidated Financial Statements </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(All amounts in thousands, except for share and per share data, unless otherwise noted) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>4. Property, Equipment and Software&nbsp;(Continued) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The total amounts charged to the interim condensed consolidated statements of comprehensive
loss for depreciation and amortization expenses amounted to approximately RMB4.5&nbsp;million and RMB5.1&nbsp;million for the six months ended June&nbsp;30, 2019 and 2020, respectively. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>5. Intangible Assets </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Intangible assets
as of December&nbsp;31, 2019 and June&nbsp;30, 2020 are summarized as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="72%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="47%"></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>As&nbsp;of&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>As of June&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>RMB</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>RMB</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>US$<BR>(Note&nbsp;2.5)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cost</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">IPR&amp;D</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">148,844</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">148,844</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21,068</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Less: accumulated amortization</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net book value</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">148,844</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">148,844</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21,068</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">IPR&amp;D represents the fair value assigned to research and development assets that the Group acquired from
business combination of <FONT STYLE="white-space:nowrap">I-Mab</FONT> Tianjin and its subsidiaries including Chengdu Tasgen <FONT STYLE="white-space:nowrap">Bio-Tech</FONT> Co., Ltd. and Shanghai Tianyunjian
<FONT STYLE="white-space:nowrap">Bio-Tech</FONT> Co., Ltd. (together the &#147;Tasgen Group&#148;) in 2017 and had not reached technological feasibility at the date of acquisition. Upon commercialization, the Group will determine the estimated
useful life and amortize these amounts based upon an economic consumption method. As of December&nbsp;31, 2019, and June&nbsp;30, 2020, there was no impairment of the value of the Group&#146;s intangible assets. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>6. Goodwill </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">On July&nbsp;15, 2017, the
Group acquired 66.67% of the equity interests in the Tasgen Group by issuing convertible preferred shares and controlled the board of directors and business of <FONT STYLE="white-space:nowrap">I-Mab</FONT> Tianjin since then. Tasgen Group is
principally engaged in the research and development of innovative medicines and the Group acquired Tasgen Group for its research team, technical experience, and IPR&amp;D pipeline assets (see Note 5). As of December&nbsp;31, 2019 and June&nbsp;30,
2020, the goodwill of RMB162,574 (US$23,011) represented the goodwill generated from the aforementioned acquisition of Tasgen Group and the business of Tasgen Group was fully integrated into the Company after the acquisition. There was no impairment
of the value of the Group&#146;s goodwill. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2019 and June&nbsp;30, 2020, the Group performed a qualitative
assessment by evaluating relevant events and circumstances that would affect the Group&#146;s single reporting unit and did not note any indicator that it is more likely than not that the fair value of the Group&#146;s reporting unit is less than
its carrying amount and therefore the Group&#146;s goodwill was not impaired. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>7. Short-term Borrowings </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In June 2019, <FONT STYLE="white-space:nowrap">I-Mab</FONT> <FONT STYLE="white-space:nowrap">Bio-tech</FONT> (Tianjin) Co., Ltd. borrowed a
loan of RMB50,000 from China Merchant Bank Co., Ltd. for a term of one year and at the interest rate of 4.15% per annum. To facilitate this borrowing, another subsidiary of the Company in Hong Kong placed cash deposits of US$8,000 (equivalent to
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-88 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">I-MAB</FONT> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to the Unaudited Interim Condensed Consolidated Financial Statements </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(All amounts in thousands, except for share and per share data, unless otherwise noted) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>7. Short-term Borrowings&nbsp;(Continued) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
approximately RMB55,810) with the bank. The use of such cash deposits and the interest earned thereon are restricted by the bank during the period of the borrowing. The deposits have a <FONT
STYLE="white-space:nowrap">one-year</FONT> term and bear interest at 2.63% per annum. The borrowing was repaid in June 2020. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>8. Accruals and Other
Payables </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="72%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="57%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>As&nbsp;of&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>As of June&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>RMB</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>RMB</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>US$<BR>(Note&nbsp;2.5)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Staff salaries and welfare payables</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30,166</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,875</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,672</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued external research and development activities related expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">144,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">155,973</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,077</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued initial public offering costs payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17,504</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,094</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">721</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Withholding IIT payable related to stock options</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,201</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Non-refundable</FONT> incentive payment from depositary bank
(Note)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,630</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">372</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued traveling expenses, office expenses and others</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">65,682</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">60,496</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,562</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">273,553</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">243,068</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">34,404</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Non-current:</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Non-refundable</FONT> incentive payment from depositary bank
(Note)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,424</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,334</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Note: The Group received a <FONT STYLE="white-space:nowrap">non-refundable</FONT> incentive payment&nbsp;of
US$1,857&nbsp;(equivalent to approximately RMB13,150) from depositary bank in April 2020.&nbsp;The amount will be recorded ratably as other gains over a five-year arrangement period. For the six months ended June&nbsp;30, 2020, the Group has
recorded RMB1,090 as other income in the interim condensed consolidated financial statements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>9. Income Taxes </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Group has incurred net accumulated operating losses for income tax purposes since its inception. The Group believes that it is more likely
than not that these net accumulated operating losses will not be utilized in the future. Therefore, the Group has provided full valuation allowances for the deferred tax assets as of December&nbsp;31, 2019 and June&nbsp;30, 2020. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>10. Ordinary Shares </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">As of
December&nbsp;31, 2019 and June&nbsp;30, 2020, 500,000,000 ordinary shares had been authorized by the Company. Each ordinary share is entitled to one vote. The holders of ordinary shares are also entitled to receive dividends whenever funds are
legally available and when declared by the Board of Directors of the Company. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-89 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">I-MAB</FONT> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to the Unaudited Interim Condensed Consolidated Financial Statements </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(All amounts in thousands, except for share and per share data, unless otherwise noted) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>10. Ordinary Shares&nbsp;(Continued) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">On October&nbsp;29, 2019, the Company&#146;s shareholders and board of directors approved
that immediately prior to the completion of initial public offering, the Company&#146;s authorized share capital will be changed into US$80,000 divided into 800,000,000 ordinary shares of a par value of US$0.0001 each. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">On January&nbsp;17, 2020, the Company completed its IPO and became listed on the Nasdaq Global Market by issuing 7,407,400 American Depositary
Shares (&#147;ADSs&#148;) at the price of US$14.00 per ADS for total gross proceeds of US$103.7&nbsp;million. On February&nbsp;10, 2020, the underwriters of the IPO have exercised their over-allotment option to purchase an additional 768,350 ADSs of
the Company at the IPO price of US$14.00 per ADS. After giving effect to the exercise of the over-allotment option, the Company has issued and sold a total of 8,175,750 ADSs in the IPO, for total net proceeds of US$101.3 million(equivalent to
RMB697,788), netting of issuance cost from total gross proceeds of US$114.5&nbsp;million. Each ten ADSs represent twenty-three ordinary shares of the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">On January&nbsp;17, 2020, the Company also issued 6,078,571 ordinary shares to Everest (see Note 15 for details). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Upon the completion of the IPO, the Company&#146;s then outstanding 30,227,056 Series A Preferred Shares, 23,288,783 Series B Preferred
Shares, 3,714,580 Series <FONT STYLE="white-space:nowrap">B-1</FONT> Preferred Shares, 3,301,849 Series <FONT STYLE="white-space:nowrap">B-2</FONT> Preferred Shares, 31,046,360 Series C Preferred Shares and 3,857,143 Series <FONT
STYLE="white-space:nowrap">C-1</FONT> Preferred Shares were converted into 30,227,056, 23,288,783, 3,714,580, 3,571,427, 34,420,469 and 4,537,814 ordinary shares, respectively. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>11. Convertible Preferred Shares </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">On
January&nbsp;17, 2020, immediately prior to the completion of the Company&#146;s IPO, all of the convertible redeemable preferred shares were converted to ordinary shares. Prior to their conversion, the convertible redeemable preferred shares were
entitled to certain privileges over ordinary shares with respect to dividends, conversion, and liquidation. The transactions and impact are disclosed as below. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">On October&nbsp;18, 2016, the Company issued 5,141,587 shares of Series <FONT STYLE="white-space:nowrap">A-1</FONT> and <FONT
STYLE="white-space:nowrap">A-2</FONT> Preferred Shares with a consideration of US$11,282 (equivalent to approximately RMB74,742). In connection with the Series <FONT STYLE="white-space:nowrap">A-1</FONT> and
<FONT STYLE="white-space:nowrap">A-2</FONT> Preferred Shares issuance, the Company also issued 2,246,744 warrant to purchase its Series <FONT STYLE="white-space:nowrap">A-3</FONT> Preferred Shares (&#147;Series
<FONT STYLE="white-space:nowrap">A-3</FONT> Warrants&#148; and see Note 13). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">On September&nbsp;6, 2017, in connection with the
Group&#146;s acquisition of Tasgen Group, the Company issued 16,723,646 shares of Series <FONT STYLE="white-space:nowrap">A-3</FONT> Preferred Shares at a price of US$2.55 per share with a total consideration of US$42,645 (equivalent to
approximately RMB289,024). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Series <FONT STYLE="white-space:nowrap">A-1</FONT> Preferred Shares, Series
<FONT STYLE="white-space:nowrap">A-2</FONT> Preferred Shares and Series <FONT STYLE="white-space:nowrap">A-3</FONT> Preferred Shares are also referred to as Series A Preferred Shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">On September&nbsp;22, 2017, the Company issued 15,894,594 shares of Series B Preferred Shares with a consideration of US$52,546 (equivalent to
approximately RMB346,515). In connection with the Series B Preferred Shares issuance, the Company also issued convertible promissory notes that are convertible into Series <FONT STYLE="white-space:nowrap">B-1</FONT> Preferred Shares (&#147;2017
Notes&#148; and see Notes 12) and 5,633,780 warrants to purchase its Series <FONT STYLE="white-space:nowrap">B-2</FONT> Preferred Shares (&#147;Series B Warrant&#148; and see Note 13). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-90 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">I-MAB</FONT> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to the Unaudited Interim Condensed Consolidated Financial Statements </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(All amounts in thousands, except for share and per share data, unless otherwise noted) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>11. Convertible Preferred Shares&nbsp;(Continued) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Concurrently with the Company&#146;s issuance of Series B Preferred Shares, the Company also
completed a round of onshore financing with respect to the Group&#146;s subsidiary <FONT STYLE="white-space:nowrap">I-MAB</FONT> Tianjin (&#147;Series B Onshore Financing&#148;). Series B Onshore Financing comprised 1) capital injection to <FONT
STYLE="white-space:nowrap">I-Mab</FONT> Tianjin by a number of investors (&#147;Series B Onshore Investors&#148;) (see Note 12), 2) <FONT STYLE="white-space:nowrap">I-Mab</FONT> Tianjin&#146;s issuance of convertible loans (&#147;Onshore Convertible
Loans&#148; and see Note 12), and 3) the Company&#146;s issuance of 2,620,842 warrants to purchase its Series <FONT STYLE="white-space:nowrap">B-2</FONT> Preferred Shares (&#147;Series B Warrants&#148; and see Note 13). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">On June&nbsp;29, 2018, the Company issued total 8,361,823 shares of Series <FONT STYLE="white-space:nowrap">A-3</FONT> Preferred Shares upon
exercise of Series <FONT STYLE="white-space:nowrap">A-3</FONT> Option held by its holder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">On June&nbsp;29, 2018, the Company issued
2,535,201 shares of Series <FONT STYLE="white-space:nowrap">B-1</FONT> Preferred Shares upon conversion of 2017 Notes and issued 2,253,512 shares of Series <FONT STYLE="white-space:nowrap">B-2</FONT> Preferred Shares upon exercise of Series B
Warrant by Series B preferred shareholders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">On June&nbsp;29, 2018, the Company issued 5,938,640 shares of Series B Preferred Shares upon
exercise of the Series B Option held by a Series B Onshore Investor and issued 947,218 shares of Series <FONT STYLE="white-space:nowrap">B-1</FONT> Preferred Shares upon conversion of Onshore Convertible Loans by a Series B Onshore Investor (see
Note 12), respectively. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">On July&nbsp;6, 2018, the Company issued 1,455,549 shares of Series B Preferred Shares upon exercise of the
Series B Option held by a Series B Onshore Investor, issued 232,161 shares of Series <FONT STYLE="white-space:nowrap">B-1</FONT> Preferred Shares upon conversion of Onshore Convertible Loans by a Series B Onshore Investor (see Note 12) and issued
1,048,337 shares of Series <FONT STYLE="white-space:nowrap">B-2</FONT> Preferred Shares upon exercise of Series B Warrant by Series B Onshore Investors, respectively. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Series B Preferred Shares, Series <FONT STYLE="white-space:nowrap">B-1</FONT> Preferred Shares and Series
<FONT STYLE="white-space:nowrap">B-2</FONT> Preferred Shares are also referred to as Series B Preferred Shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">On July&nbsp;6, 2018, the
Company issued 31,046,360 shares of Series C Preferred Shares at a price of US$6.4419 per share with a total consideration of US$200,000 (equivalent to approximately RMB1,323,363). In connection with the offering of the Series C Preferred Shares,
the Company incurred issuance costs of RMB16,730. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">On July&nbsp;25, 2019, the Group entered into a share purchase agreement with certain
third party investors, under which these investors will subscribe for an aggregate of 3,857,143 Series <FONT STYLE="white-space:nowrap">C-1</FONT> convertible preferred shares of the Company for an aggregate purchase price of US$27.0&nbsp;million.
Out of the aforementioned subscription of 3,857,143 Series <FONT STYLE="white-space:nowrap">C-1</FONT> convertible preferred shares by certain third party investors, 1,428,571 Series <FONT STYLE="white-space:nowrap">C-1</FONT> convertible preferred
shares were issued to an investor on October&nbsp;17, 2019, and the Group also received the cash consideration of US$10,000 (equivalent to approximately RMB70,036). On November&nbsp;6, 2019, the Group received cash consideration of US$17,000
(equivalent to approximately RMB119,387) for the remaining 2,428,572 Series <FONT STYLE="white-space:nowrap">C-1</FONT> convertible preferred shares from the investors and the issuance of such 2,428,572 Series
<FONT STYLE="white-space:nowrap">C-1</FONT> convertible preferred shares were consummated on that day. In connection with the offering of the Series <FONT STYLE="white-space:nowrap">C-1</FONT> convertible preferred shares, the Company incurred
issuance costs of approximately US$840 (equivalent to approximately RMB5,887). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-91 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">I-MAB</FONT> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to the Unaudited Interim Condensed Consolidated Financial Statements </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(All amounts in thousands, except for share and per share data, unless otherwise noted) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>11. Convertible Preferred Shares&nbsp;(Continued) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Upon the completion of the IPO on January&nbsp;17, 2020, all outstanding 30,227,056 Series A
Preferred Shares, 23,288,783 Series B Preferred Shares, 3,714,580 Series <FONT STYLE="white-space:nowrap">B-1</FONT> Preferred Shares, 3,301,849 Series <FONT STYLE="white-space:nowrap">B-2</FONT> Preferred Shares, 31,046,360 Series C Preferred
Shares and 3,857,143 Series <FONT STYLE="white-space:nowrap">C-1</FONT> Preferred Shares were converted into 30,227,056, 23,288,783, 3,714,580, 3,571,427, 34,420,469 and 4,537,814 ordinary shares, respectively. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Series A Preferred Shares, Series B Preferred Shares, Series C Preferred Shares and Series <FONT STYLE="white-space:nowrap">C-1</FONT>
Preferred Shares are collectively referred to as Preferred Shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Key terms of the Preferred Shares are summarized as follows: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Dividends </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The holders of
Preferred Shares are entitled to receive dividends, out of any assets legally available therefore, prior and in preference to any declaration or payment of any dividend on the ordinary shares or any other class or series of shares of the Group at
the rate of eight percent (8%) of the original issue price per share per annum on each Preferred Share, payable in US$ and annually when, as and if declared by the Board of Directors. Such distributions shall not be cumulative. No dividend, whether
in cash, in property or in shares of the capital of the Group, shall be paid on or declared and set aside for any ordinary shares or any other class or series of shares of the Group unless and until all dividends have been paid in full on the
Preferred Shares (on an <FONT STYLE="white-space:nowrap">as-converted</FONT> basis). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Conversion </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Each Preferred Share may be converted at any time into ordinary shares at the option of the preferred shares holders at the then applicable
conversion price. The initial conversion ratio is 1:1, subject to adjustment in the event of (i)&nbsp;share splits, share combinations, share dividends or distribution, other dividends, recapitalizations and similar events, or (ii)&nbsp;issuance of
ordinary shares (excluding certain events such as issuance of ordinary shares pursuant to a public offering) at a price per share less than the conversion price in effect on the date of or immediately prior to such issuance. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Preferred Shares shall be automatically converted into ordinary shares immediately upon the closing of a public offering of the
Company&#146;s shares with an offering price (exclusive of underwriting commissions and expenses) that reflects a market capitalization (immediately prior to the public offering) of not less than US$1,000,000,000 or otherwise approved by all
directors and certain preferred shareholders as specified in the Company&#146;s memorandum and articles of association (the &#147;Qualified Public Offering&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Group determined that there were no beneficial conversion features (&#147;BCF&#148;) identified for any of the Preferred Shares during any
of the periods. In making this determination, the Company compared the fair value of the ordinary shares into which the Preferred Shares are convertible with the respective effective conversion price at the issuance date. In all instances, the
effective conversion price was greater than the fair value of the ordinary shares. To the extent a conversion price adjustment occurs, as described above, the Group will reevaluate whether or not a beneficial conversion feature should be recognized.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-92 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">I-MAB</FONT> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to the Unaudited Interim Condensed Consolidated Financial Statements </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(All amounts in thousands, except for share and per share data, unless otherwise noted) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>11. Convertible Preferred Shares&nbsp;(Continued) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Liquidation </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In the event of any liquidation (unless waived by the preferred shareholders) including deemed liquidation, dissolution or winding up of the
Company, holders of the Preferred Shares shall be entitled to receive a per share amount equal to one hundred percent (100%) of the original issue price on each Preferred Share, plus an amount representing an internal rate of return of twelve
percent (12%) per annum on the original issue price as adjusted for share dividends, share splits, combinations, recapitalizations or similar events, plus all accrued and declared but unpaid dividends thereon, in the sequence of Series C Preferred
Shares, Series B Preferred Shares and Series A Preferred Shares. After such liquidation amounts have been paid in full, any remaining funds or assets of the Company legally available for distribution to shareholders shall be distributed on a pro
rata basis among the holders of the Preferred Shares, on an <FONT STYLE="white-space:nowrap">as-converted</FONT> basis, together with the holders of the ordinary shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><I>Accounting of preferred shares </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Preferred Shares are redeemable by the holders upon a liquidation event, including a deemed liquidation event (e.g., change in control),
and as such are presented as mezzanine equity on the consolidated balance sheets. In accordance with ASC <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">480-10-S99,</FONT></FONT> each issuance of the convertible preferred shares
should be recognized at the date of issuance after deducting fair value allocated to the detachable warrants and issuance costs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><I>Modification of preferred shares </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Company assesses whether an amendment to the terms of its convertible preferred shares is an extinguishment or a modification using the
fair value model.</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">When convertible redeemable preferred shares are extinguished, the difference between the fair value of the
consideration transferred to the convertible redeemable Preferred Shareholders and the carrying amount of such preferred shares (net of issuance costs) is treated as a deemed dividend to the Preferred Shareholders. When convertible redeemable
preferred shares are modified and such modification results in value transfer between Preferred Shareholders and ordinary shareholders, the change in fair value resulted from the amendment is treated as a deemed dividend to or from the Preferred
Shareholders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">On December&nbsp;25, 2019, the Company&#146;s shareholders and board of directors approved that, where the final offering
price of a Qualified Public Offering is no less than US$4.176 per ordinary share, the agreed provisions related to the number of shares to be converted into the Company&#146;s ordinary shares shall apply with respect to the Series <FONT
STYLE="white-space:nowrap">C-1</FONT> Preferred Shares, Series C Preferred Shares, Series <FONT STYLE="white-space:nowrap">B-2</FONT> Preferred Shares and Series <FONT STYLE="white-space:nowrap">B-1</FONT> Preferred Shares, which will generally give
rise to a one to multiple conversion of the such rounds of Preferred Shares, provided that unanimous consent of the directors on the final offering price needs to be obtained in the event that the final offering price per ordinary share of such IPO
is fixed at a price equal to or higher than US$4.176 per ordinary share but lower than US$5.22 per ordinary share. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Company evaluated
the aforementioned modifications and concluded that they represented modifications, rather than extinguishment, to Series <FONT STYLE="white-space:nowrap">B-1,</FONT> <FONT STYLE="white-space:nowrap">B-2</FONT> and C Preferred Shares, which resulted
in a transfer of value from ordinary shareholders to preferred shareholders. The combined change in fair value of Series <FONT STYLE="white-space:nowrap">B-1,</FONT> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-93 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">I-MAB</FONT> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to the Unaudited Interim Condensed Consolidated Financial Statements </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(All amounts in thousands, except for share and per share data, unless otherwise noted) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>11. Convertible Preferred Shares&nbsp;(Continued) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Liquidation&nbsp;(Continued) </I></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
<FONT STYLE="white-space:nowrap">B-2</FONT> and C Preferred Shares immediately before and after the modification was US$4.0&nbsp;million (equivalent to approximately RMB27.8 million) on
December&nbsp;25, 2019. This decrease in fair value of the ordinary shares of US$4.0&nbsp;million (equivalent to approximately RMB27.8 million) on December&nbsp;25, 2019 was, in substance, a transfer of wealth mostly from ordinary shareholders to
preferred shareholders, and therefore was recorded as a deemed dividend to the preferred shareholders<B>.</B> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Company evaluated the
aforementioned modifications and concluded that they represented extinguishment to Series <FONT STYLE="white-space:nowrap">C-1</FONT> Preferred Shares. The difference between the fair value of the modified Series
<FONT STYLE="white-space:nowrap">C-1</FONT> Preferred Shares and the carrying value of the original Series <FONT STYLE="white-space:nowrap">C-1</FONT> Preferred Shares was amounting US$0.8&nbsp;million on December&nbsp;25, 2019 and represented the
fair value of the consideration transferred, and therefore was recognized as a deemed dividend to the preferred shareholders and adjustment to the carrying amount of Series <FONT STYLE="white-space:nowrap">C-1</FONT> Preferred Shares<B>.</B> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Company&#146;s convertible preferred shares activities for the six months ended June&nbsp;30, 2019 and 2020 are summarized below: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:7.5pt" ALIGN="center">


<TR>

<TD WIDTH="13%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Series A Preferred</B><br><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Series B Preferred</B><br><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Series C Preferred</B><br><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Series <FONT STYLE="white-space:nowrap">C-1</FONT> Preferred</B><br><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Number&nbsp;of<BR>shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Number&nbsp;of<BR>shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Number&nbsp;of<BR>shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Number&nbsp;of<BR>shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:7pt; font-family:Times New Roman; " ALIGN="center"><B>US$</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:7pt; font-family:Times New Roman; " ALIGN="center"><B>RMB</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:7pt; font-family:Times New Roman; " ALIGN="center"><B>US$</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:7pt; font-family:Times New Roman; " ALIGN="center"><B>RMB</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:7pt; font-family:Times New Roman; " ALIGN="center"><B>US$</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:7pt; font-family:Times New Roman; " ALIGN="center"><B>RMB</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:7pt; font-family:Times New Roman; " ALIGN="center"><B>US$</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:7pt; font-family:Times New Roman; " ALIGN="center"><B>RMB</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7.5pt; font-family:Times New Roman">Balance as of January&nbsp;1, 2019 and June&nbsp;30, 2019</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30,227,056</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">102,852</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">687,482</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30,305,212</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">139,407</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">921,243</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">31,046,360</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">197,478</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,306,633</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7.5pt; font-family:Times New Roman">Balance as of January&nbsp;1, 2020</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30,227,056</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">102,852</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">687,482</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30,305,212</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">139,407</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">921,243</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">31,046,360</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">197,478</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,306,633</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,857,143</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26,914</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">188,819</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7.5pt; font-family:Times New Roman">Conversion to ordinary shares upon IPO</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(30,227,056</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(102,852</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(687,482</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(30,305,212</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(139,407</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(921,243</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(31,046,360</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(197,478</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,306,633</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,857,143</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(26,914</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(188,819</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7.5pt; font-family:Times New Roman">Balance as of June&nbsp;30, 2020</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>12. Convertible Promissory Notes </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">On February&nbsp;3, 2018, the Company issued US$9,000 (equivalent to approximately RMB59,704) convertible promissory notes (&#147;2018
Notes&#148;) to an investor of Series <FONT STYLE="white-space:nowrap">A-3</FONT> Preferred Shares at an annual interest rate of 0%, maturing on 36 months after the issuance date. Under the agreement, the holder of the 2018 Notes may convert the
2018 Notes outstanding principal amount into Series <FONT STYLE="white-space:nowrap">B-1</FONT> Preferred Shares at the conversion price being lower of US$10 per share and fair market value at any time prior to the maturity date. Alternatively, the
2018 Notes shall be automatically converted into the Company&#146;s Series B Preferred Shares upon the maturity. As the fair value of the Company&#146;s ordinary shares on February&nbsp;3, 2018 of US$3.96 was equal to the effective conversion price
(being lower of US$10 per share and fair market value), the Company did not record a BCF. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-94 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">I-MAB</FONT> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to the Unaudited Interim Condensed Consolidated Financial Statements </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(All amounts in thousands, except for share and per share data, unless otherwise noted) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>13. Warrants </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In connection with the issuance of the Series B Preferred Shares on September&nbsp;22, 2017, 5,633,780 Series B Warrants were issued to Series
B preferred shareholders, which provided the holders the right to purchase <FONT STYLE="white-space:nowrap">Series&nbsp;B-2&nbsp;Preferred</FONT> Shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In connection with the Company&#146;s Series B Onshore Financing that took place on September&nbsp;25, 2017, 2,620,842 Series B Warrants were
issued to Series B Onshore Investors, which provided the holders the right to purchase <FONT STYLE="white-space:nowrap">Series&nbsp;B-2&nbsp;Preferred</FONT> Shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">During the period from June&nbsp;29, 2018 to July&nbsp;6, 2018, 3,301,849 Series B Warrants (representing Tranche I of Series B Warrants) were
exercised to purchase 3,301,849 <FONT STYLE="white-space:nowrap">Series&nbsp;B-2&nbsp;Preferred</FONT> Shares with proceeds of US$20,000 (equivalent to approximately RMB132,332). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">On July&nbsp;6, 2018, the Series B Warrants holders agreed that the Series B Warrants shall be divided into two tranches and exercisable in
accordance with different time schedules, such that: (i)&nbsp;the holders have exercised part of the Series B Warrants in the total consideration of US$20,000 (&#147;Tranche I of Series B Warrants&#148;) and 3,301,849
<FONT STYLE="white-space:nowrap">Series&nbsp;B-2&nbsp;Preferred</FONT> Shares of the Company in aggregate have been newly issued to such holders on a pro rata basis; (ii)&nbsp;only when the Company fails to submit a Qualified Public Offering
application at an internationally recognized securities exchange by March&nbsp;31, 2019, the Warrant Holders may exercise the remaining part of Series B Warrants, in the total consideration of US$30,000 (&#147;Tranche II of Series B Warrants&#148;)
and 4,952,773 <FONT STYLE="white-space:nowrap">Series&nbsp;B-2&nbsp;Preferred</FONT> Shares of the Company in aggregate will be issued to such holders on a pro rata basis; (iii)&nbsp;provided that the Company successfully submits a Qualified Public
Offering application at an internationally recognized securities exchange by March&nbsp;31, 2019, the holders shall unconditionally and irrevocably waive and cancel Tranche II of Series B Warrants; and (iv)&nbsp;the Tranche II of Series B Warrants
may only be concurrently exercised by all the Warrant Holders in one lump. This is considered to be a modification to Series B Warrants. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">According to the confirmations issued by the Company&#146;s Series B Warrants holders in July 2019, the holders of Series B Warrants has
unconditionally and irrevocably waived and cancelled the Tranche II of Series&nbsp;B Warrants. The fair value gain of warrants for the six months ended June&nbsp;30, 2019 and 2020 was amounting to RMB43,854 and nil, respectively. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Accounting of warrants </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The
warrant is a freestanding instrument and is recorded as liability in accordance with ASC&nbsp;480,<I>&nbsp;Distinguishing Liabilities from Equity</I>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">As the Company&#146;s issuance of warrants were bundled with other instruments (such as convertible preferred shares, convertible promissory
notes, etc.), out of total considerations, the warrants are initially recognized at fair value and the remaining were allocated to other instruments on a relative fair value basis (if applicable). The fair value changes of the warrants (including
the fair value changes arising from modification of warrants) up to the time of exercise or termination were recognized in earnings. Upon exercise, the total carrying value of the associated warrant liabilities was reclassified into the carrying
value of the Preferred Shares into which it was converted. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Company determined the fair value of the warrants with the assistance of
an independent third-party valuation firm. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-95 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">I-MAB</FONT> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to the Unaudited Interim Condensed Consolidated Financial Statements </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(All amounts in thousands, except for share and per share data, unless otherwise noted) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>14. Share-based Compensation </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>(a) Restricted shares </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">During the
year ended December&nbsp;31, 2016, the Company issued 4,019,554 ordinary shares to Mr.&nbsp;Zang Jingwu Zhang, Ms.&nbsp;Qian Lili, Mr.&nbsp;Wang Zhengyi and Mr.&nbsp;Fang Lei (collectively the &#147;Founders&#148;), including the 369,301 shares
which represented the equity interests of Third Venture held by the Founders, and the Company recorded share-based compensation expense of RMB18.7&nbsp;million for issuance and grant of 3,650,253 ordinary shares to the Founders in June 2016. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In October 2016, the Founders entered into an arrangement with other investors of the Company, and the 87,441 ordinary shares issued to the
Founders in June 2016 were canceled and out of the remaining 3,932,113 ordinary shares held by the Founders, 70% became restricted and subject to service vesting conditions, that should vest 20%, 20% and 30% over the next three years, respectively.
There shall be no acceleration of the vesting schedule except that, in case of a change of control of the Company or a Qualified Public Offering, or the termination of the Founder&#146;s employment with the Group without cause. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Deferred share-based compensation was measured for the restricted shares using the estimated fair value of the Company&#146;s ordinary shares
of US$0.77 at the date of imposition of the restriction in October 2016, and was amortized to the interim condensed consolidated statements of comprehensive loss by using graded vesting method over the vesting term of 3 years. As of
December&nbsp;31, 2019, all the restricted shares were fully vested. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The amounts of shared-based compensation expense in relation to the
restricted shares recognized in the year ended December&nbsp;31, 2019 was RMB1,566, of which RMB1,026 was recognized in the six months ended June&nbsp;30, 2019. No share-based compensation expense was recognized in the six months ended June&nbsp;30,
2020. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Share-based compensation expenses related to restricted shares are included in: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="85.5%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="48%"></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Year&nbsp;Ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Six&nbsp;Months&nbsp;Ended&nbsp;June&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>RMB</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>RMB</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>RMB</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>US$&nbsp;(Note&nbsp;2.5)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Research and development expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">470</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">308</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Administrative expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,096</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">718</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,566</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,026</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>(b) 2017 Employee Stock Option Plan (&#147;2017 Plan&#148;) </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In October 2017, the Company adopted the 2017 Plan. Under the 2017 Plan, a maximum aggregate number of 13,376,865 shares that may be issued
pursuant to all awards granted was approved. Stock options granted to an employee under the 2017 Plan will be exercisable upon the Company completes a listing and the employee renders service to the Company in accordance with a stipulated service
schedule starting from the employee&#146;s date of employment. Employees are generally subject to a three-year service schedule, under which an employee earns an entitlement to vest in 50% of the option grants on the second anniversary of the grant
date, a vesting of the remaining 50% on the third anniversary of the applicable grant date. The stock option under 2017 Plan, to the extent then vested, shall become exercisable only upon the earlier of (i)&nbsp;a listing, and (ii)&nbsp;occurrence
of a change in control. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-96 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">I-MAB</FONT> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to the Unaudited Interim Condensed Consolidated Financial Statements </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(All amounts in thousands, except for share and per share data, unless otherwise noted) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>14. Share-based Compensation&nbsp;(Continued) </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>(b)
2017 Employee Stock Option Plan (&#147;2017 Plan&#148;)&nbsp;(Continued) </I></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">On December&nbsp;25, 2019, the Second Amended and Restated 2017 Plan was approved by the
shareholders and board of directors of the Company, pursuant to which, in connection with the Company&#146;s IPO, the maximum aggregate number of shares that may be granted pursuant to all awards under 2017 Plan shall be adjusted in accordance with
a formula <FONT STYLE="white-space:nowrap">pre-approved</FONT> by the shareholders. In connection with above amendments to 2017 Plan, each of the Company&#146;s founders, namely Zheru Zhang, Lili Qian, Zhengyi Wang and Lei Fang, is willing to
irrevocably surrender by him or her, for no consideration, a portion of the unvested options granted to him or her, which, if vested, would entitle him or her to acquire up to 130,000 ordinary shares of the Company, par value US$0.0001 per share, at
an exercise price of US$1.0, respectively, under the Second Amended and Restated 2017 Plan (in respect of each individual, the &#147;Founder&#146;s Surrendered Options&#148;). On December&nbsp;25, 2019, the board of directors of the Company approved
that the Company accepts all Founder&#146;s Surrendered Options from each of the founders, Zheru Zhang, Lili Qian, Zhengyi Wang and Lei Fang, for no consideration, with effect immediately prior to the completion of the IPO and such surrendered
options be cancelled with effect immediately prior to the completion of the IPO. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Prior to the Company completes a listing, all stock
options granted to an employee shall be forfeited at the time the employee terminates his employment with the Group. After the Company completes a listing, vested options not exercised by an employee shall be exercised until later of: (i) 90 days
after the date when the options become exercisable, or (ii) 30 days after the date of cessation of employment or directorship, or such longer period as the Board of Directors may otherwise determine. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Group did not grant any stock options to employees for the year ended December&nbsp;31, 2019 and the six months ended June&nbsp;30, 2020.
No options are exercisable as of December&nbsp;31, 2019 and 4,061,176 stock options are exercisable as of June&nbsp;30, 2020. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The
following table sets forth the stock options activities of 2017 Plan for the six months ended June&nbsp;30, 2020 is presented below: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="85.5%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Number&nbsp;of</B><br><B>shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Weighted</B><br><B>average</B><br><B>exercise</B><br><B>price</B><br><B>US$</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Weighted</B><br><B>average</B><br><B>remaining</B><br><B>contractual</B><br><B>term</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Aggregate</B><br><B>intrinsic</B><br><B>value</B><br><B>US$</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outstanding as of December&nbsp;31, 2019</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,812,881</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.93</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.76</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">47,671</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Forfeited</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(329,377</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Surrendered (Note 14 (h))</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(332,566</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outstanding as of June&nbsp;30,2020</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,150,938</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.93</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">110,598</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercisable as of June&nbsp;30, 2020</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,061,176</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">48,787</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-97 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">I-MAB</FONT> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to the Unaudited Interim Condensed Consolidated Financial Statements </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(All amounts in thousands, except for share and per share data, unless otherwise noted) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>14. Share-based Compensation&nbsp;(Continued) </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>(b)
2017 Employee Stock Option Plan (&#147;2017 Plan&#148;)&nbsp;(Continued) </I></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">A summary of <FONT STYLE="white-space:nowrap">non-vested</FONT> stock option activities for
the six months ended June&nbsp;30, 2020 is presented below: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="72%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="50%"></TD>

<TD VALIGN="bottom" WIDTH="15%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="15%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Number&nbsp;of&nbsp;shares</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Weighted&nbsp;average</B><br><B>Grant&nbsp;date&nbsp;fair&nbsp;value</B><br><B>US$</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Non-vested</FONT> at December&nbsp;31, 2019</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,812,881</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Vested</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4,061,176</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.62</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Forfeited</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(329,377</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Surrendered</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(332,566</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.47</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Non-vested</FONT> at June&nbsp;30, 2020</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,089,762</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.53</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Since the exercisability is dependent upon the listing, and it is not probable that this performance condition
can be achieved until a listing, no share-based compensation expense relating to the 2017 Plan was recorded for the year ended December&nbsp;31, 2019. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">On January&nbsp;17, 2020, the Group completed its IPO. After achieving this performance condition, the options continue to vest based only on
service period completed according to the graded vesting schedule. The Group has begun recognizing share-based compensation expense for the options granted using the graded vesting method with a cumulative
<FONT STYLE="white-space:nowrap">catch-up</FONT> for the service period completed to date during the six months ended June&nbsp;30, 2020 and recognized RMB53,362 and RMB66,837 share-based compensation expenses in administrative expenses and research
and development expenses respectively relating to options vested cumulatively. According to the amendments to 2017 Plan, the maximum aggregate number of shares which may be granted pursuant to all awards under 2017 Plan was changed to 9,609,084.
Each of the Group&#146;s founders, namely Zheru Zhang, Lili Qian, Zhengyi Wang and Lei Fang surrendered 83,142 unvested stock options that were granted to him or her under 2017 Plan before, totally 332,566 unvested options, for no consideration, and
these stock options were cancelled immediately. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>(c) 2018 Employee Stock Option Plan (&#147;2018 Plan&#148;) </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">On February&nbsp;22, 2019, the Group adopted the 2018 Plan, which was subsequently amended on July&nbsp;22, 2019.Under the amended and
restated 2018 Plan, the maximum aggregate number of ordinary shares which may be issued pursuant to all awards is 14,005,745, and if the Group successfully lists on an internationally recognized securities exchange for a Qualified Public Offering by
December&nbsp;31, 2019, the maximum aggregate number of ordinary shares which may be issued shall be 15,452,620. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">On December&nbsp;25,
2019, the Second Amended and Restated 2018 Plan were approved by the shareholders and board of directors of the Company, pursuant to which, in connection with the Company&#146;s IPO, the maximum aggregate number of shares that may be granted
pursuant to all awards under 2018 Plan shall be adjusted in accordance with a formula <FONT STYLE="white-space:nowrap">pre-approved</FONT> by the shareholders. In connection with above amendments to 2018 Plan, the director of the Company,
Dr.&nbsp;Jingwu Zhang Zang is willing to irrevocably surrender by him, for no consideration, of the right to acquire a certain amount of ordinary shares of the Company, par value </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-98 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">I-MAB</FONT> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to the Unaudited Interim Condensed Consolidated Financial Statements </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(All amounts in thousands, except for share and per share data, unless otherwise noted) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>14. Share-based Compensation&nbsp;(Continued) </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>(c)
2018 Employee Stock Option Plan (&#147;2018 Plan&#148;)&nbsp;(Continued) </I></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
US$0.0001 per share, at an exercise price of US$1.0 pursuant to the options granted to him under the Second Amended and Restated 2018 Plan (the &#147;Dr.&nbsp;Zang&#146;s Surrendered
Options&#148;). On December&nbsp;25, 2019, the board of directors of the Company approved that the Company accepts the irrevocable surrender of Dr.&nbsp;Zang&#146;s Surrendered Options for no consideration, with effect immediately prior to the
completion of the IPO and such surrendered options be cancelled with effect immediately prior to the completion of the IPO. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Stock options
granted to an employee under the 2018 Plan will be generally exercisable when the Company completes a listing and the employee renders service to the Company in accordance with a stipulated service schedule starting from the employee&#146;s date of
employment. The vesting schedule shall generally be a <FONT STYLE="white-space:nowrap">two-year</FONT> vesting schedule consisting of a cliff vesting 50% on the first anniversary of the applicable vesting commencement date, and a vesting of the
remaining 50% on the second anniversary of the applicable vesting commencement date. If a listing occurs at anytime prior to any option granted under the 2018 Plan becoming full vested, and to the extent such option has been granted and outstanding,
any such option shall vest in full with immediate effect upon the listing. Except as otherwise approved by the board of directors, vested portion of option shall become exercisable upon the earlier of six months after a listing or the occurrence of
a change in control; provided, however that in each case, no option of an employee shall become exercisable until the third anniversary of such employee&#146;s employment commencement date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Pursuant to the Board of Director&#146;s approval of 2018 Plan on February&nbsp;22, 2019, the 10,893,028 stock options granted to a director
of the Group under 2018 Plan were fully vested and exercisable upon the adoption of 2018 Plan. Out of aforementioned total 10,893,028 stock options, 454,940 stock options were repurchased by the Group (see Note14(d) for further details). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The amounts of shared-based compensation expense in relation to the aforementioned grant of stock options to a director of the Group (except
for those repurchased by the Group as described in Note 14(d)) recognized in the six months ended June 30, 2019 and in the year ended December&nbsp;31, 2019 was RMB365,330, included in administrative expenses. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The following table sets forth the stock options activities of 2018 Plan for the six months ended June&nbsp;30, 2020: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="85.5%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="50%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Number&nbsp;of</B><br><B>shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Weighted</B><br><B>average</B><br><B>exercise</B><br><B>price</B><br><B>US$</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Weighted</B><br><B>average</B><br><B>remaining</B><br><B>contractual</B><br><B>term</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Aggregate</B><br><B>intrinsic</B><br><B>value</B><br><B>US$</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outstanding as of December&nbsp;31, 2019</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,536,588</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9.15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">64,840</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Surrendered (Note 14 (h))</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,544,917</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outstanding as of June&nbsp;30, 2020</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,991,671</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.65</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">132.043</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercisable as of June&nbsp;30, 2020</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,565,171</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.65</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">114,907</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-99 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">I-MAB</FONT> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to the Unaudited Interim Condensed Consolidated Financial Statements </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(All amounts in thousands, except for share and per share data, unless otherwise noted) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>14. Share-based Compensation&nbsp;(Continued) </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>(c)
2018 Employee Stock Option Plan (&#147;2018 Plan&#148;)&nbsp;(Continued) </I></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">A summary of <FONT STYLE="white-space:nowrap">non-vested</FONT> stock option activities for
the six months ended June&nbsp;30, 2020 is presented below: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="72%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="68%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Number&nbsp;of<BR>shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Weighted<BR>average</B><br><B>grant-<BR>date fair<BR>value</B><br><B>US$</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Non-vested</FONT> at December&nbsp;31, 2019</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,098,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.57</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Vested</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,672,000</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.57</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Non-vested</FONT> at June&nbsp;30, 2020</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,426,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.57</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Except for the aforementioned grant of stock options to a director of the Group under 2018 Plan, since the
exercisability is dependent upon the listing, and it is not probable that this performance condition can be achieved until a listing, no share-based compensation expense related to the 2018 Plan was recorded for the year ended December&nbsp;31,
2019. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">On January&nbsp;17, 2020, the Group completed its IPO. After achieving this performance condition, the options continue to vest
based only on service period completed according to the graded vesting schedule. The Group has begun recognizing share-based compensation expense for the options granted using the graded vesting method with a cumulative <FONT
STYLE="white-space:nowrap">catch-up</FONT> for the service period completed to date during the six months ended June&nbsp;30, 2020 and recognized RMB43,410 and RMB65,887 share-based compensation expense in administrative expenses and research and
development expenses, respectively relating to options vested cumulatively. According to the amendments to 2018 Plan, the maximum aggregate number of shares which may be granted pursuant to all awards under 2018 Plan was changed to 11,005,888. The
director of the Company, Dr.&nbsp;Jingwu Zhang Zang surrendered 2,544,917 unvested options that were granted to him under 2018 Plan, for no consideration, and these stock options were cancelled immediately. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>(d) Repurchase of share awards held by a director </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">On February&nbsp;22, 2019, the amendment and restated 2017 equity incentive plan was approved by the Board of Directors of the Group, pursuant
to which only the 3,435,215 stock options held by the director under the 2017 equity incentive plan became fully vested and exercisable on February&nbsp;22, 2019. As a result of the performance condition being waived, the stock options held by the
director of the Group were accounted for as a Type III modification where a condition that the Group expects will not be satisfied is changed to a condition that the Group expects will be satisfied. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Additionally, on the same day, the Group repurchased such 3,435,215 stock options under the amendment and restated 2017 equity incentive plan
that was held by the director of the Group along with 454,940 of his stock options under the 2018 equity incentive plan for which the share awards also became fully vested and exercisable, at a total consideration of US$21,902 (equivalent to
approximately RMB148,308) at an average share price of US$5.63 per share. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-100 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">I-MAB</FONT> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to the Unaudited Interim Condensed Consolidated Financial Statements </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(All amounts in thousands, except for share and per share data, unless otherwise noted) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>14. Share-based Compensation&nbsp;(Continued) </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>(d)
Repurchase of share awards held by a director&nbsp;(Continued) </I></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">For the six months ended June&nbsp;30, 2019, the Group recorded the total payment of
US$21,902 (equivalent to approximately RMB148,308) as share-based compensation costs (included in administrative expenses) in the condensed consolidated statement of comprehensive loss. There was no impact to the overall stockholder&#146;s equity
balance as the amended shares vested immediately and were repurchased. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>(e) 2019 Share Incentive Plan (&#147;2019 Plan&#148;) </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">On October&nbsp;29, 2019, the Group adopted 2019 Share Incentive Plan (the &#147;2019 Plan&#148;), which will become effective immediately
prior to the completion of the Group&#146;s initial public offering. Under the 2019 Plan, the maximum aggregate number of ordinary shares available for issuance shall initially be 100,000. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The options shall vest when the Group completes a listing and the employee renders service to the Group in accordance with a stipulated
service schedule starting from the employee&#146;s date of employment. Stock options granted to 3 independence directors under the 2019 Plan will be generally exercisable under the following terms:(a) a cliff vesting of 1/3 of the option on the
first anniversary of the vesting commencement date(January 17, 2020);(b) a cliff vesting of 1/3 of the option on the second anniversary of the vesting commencement date(January 17, 2020);(c) a vesting of the remaining 1/3 of the option on the third
anniversary of the vesting commencement date. In the last year of the grantee&#146;s service, the options shall vest on a prorated basis to reflect the portion of the year during which the grantee provided services to the Group. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">For the six months ended June&nbsp;30, 2020, the Group granted 72,000 stock options to 3 independent directors (all with an exercise price of
US$6.09) and recognized RMB299 share-based compensation expenses relating to the options vested. No options were exercisable as of June&nbsp;30, 2020. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The following table sets forth the stock options activities of 2019 Plan for the periods presented: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="85.5%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Number&nbsp;of</B><br><B>shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Weighted</B><br><B>average</B><br><B>exercise</B><br><B>price</B><br><B>US$</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Weighted</B><br><B>average</B><br><B>remaining</B><br><B>contractual</B><br><B>term</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Aggregate</B><br><B>intrinsic</B><br><B>value</B><br><B>US$</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outstanding as of December&nbsp;31, 2019</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Granted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">72,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.09</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outstanding as of June&nbsp;30, 2020</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">72,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.09</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9.84</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">498</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercisable as of June&nbsp;30, 2020</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">A summary of <FONT STYLE="white-space:nowrap">non-vested</FONT> share option activity for the six months ended
June&nbsp;30, 2020 is presented below: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="72%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="59%"></TD>

<TD VALIGN="bottom" WIDTH="13%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="13%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Number&nbsp;of<BR>shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Weighted&nbsp;average</B><br><B><FONT STYLE="white-space:nowrap">grant-date&nbsp;fair&nbsp;value</FONT></B><br><B>US$</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Non-vested</FONT> at December&nbsp;31, 2019</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Granted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">72,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.09</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Non-vested</FONT> at June&nbsp;30, 2020</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">72,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.09</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-101 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">I-MAB</FONT> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to the Unaudited Interim Condensed Consolidated Financial Statements </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(All amounts in thousands, except for share and per share data, unless otherwise noted) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>14. Share-based Compensation&nbsp;(Continued) </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>(e)
2019 Share Incentive Plan (&#147;2019 Plan&#148;)&nbsp;(Continued) </I></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Stock options granted to the employees were measured at fair value on the dates of grant
using the Binomial Option Pricing Model with the following assumptions: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="72%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="66%"></TD>

<TD VALIGN="bottom" WIDTH="28%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Six&nbsp;Months&nbsp;Ended&nbsp;June&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected volatility</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">54.88</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Risk-free interest rate (per annum)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.79</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercise multiple</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.80</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected dividend yield</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Contractual term (in years)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The expected volatility was estimated based on the historical volatility of comparable peer public companies
with a time horizon close to the expected term of the Group&#146;s options. The risk-free interest rate was estimated based on the yield to maturity of U.S. treasury bonds denominated in US$ for a term consistent with the expected term of the
Group&#146;s options in effect at the option valuation date. The expected exercise multiple was estimated as the average ratio of the stock price to the exercise price when employees would decide to voluntarily exercise their vested options. As the
Group did not have sufficient information of past employee exercise history, it was estimated by referencing to a widely-accepted academic research publication. Expected dividend yield is zero as the Group has never declared or paid any cash
dividends on its shares, and the Group does not anticipate any dividend payments in the foreseeable future. Expected term is the contract life of the option. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>(f) Establishment of Biomaster Trust </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Biomaster Trust was established under the trust deed dated October&nbsp;23, 2019, between the Company and TMF Trust (HK) Limited, or TMF
Trust, as the trustee of the Biomaster Trust. Through the Biomaster Trust, the Company&#146;s ordinary shares and other rights and interests under awards granted pursuant to 2017 Plan and 2018 Plan may be provided to certain recipients of equity
awards. Upon satisfaction of vesting conditions, TMF Trust will exercise the equity awards and transfer the relevant ordinary shares and other rights and interests under the equity awards to the relevant grant recipients with the consent of the
advisory committee of Biomaster Trust. TMF Trust shall not exercise the voting rights attached to such ordinary shares unless otherwise directed by the advisory committee, whose members shall be appointed by
<FONT STYLE="white-space:nowrap">I-Mab.</FONT> The Company has the power to direct the relevant activities of Biomaster Trust and it has the ability to use its power over the Biomaster Trust to affect its exposure to returns. Therefore, the assets
and liabilities of the Biomaster Trust are included in the Group&#146;s consolidated statement of financial position. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>(g) Surrender of stock
options </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">On January&nbsp;17, 2020, the Group completed its IPO. According to the amendments to 2017 Plan, the maximum aggregate
number of shares which may be granted pursuant to all awards under 2017 Plan was changed to 9,609,084. Each of the Company&#146;s founders, namely Zheru Zhang, Lili Qian, Zhengyi Wang and Lei Fang surrendered 83,142 unvested stock options that were
granted to him or her under 2017 Plan before, totally 332,566 unvested options, for no consideration, and these stock options were cancelled immediately. According to the amendments to 2018 Plan, the maximum aggregate number of shares which may be
granted pursuant to all </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-102 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">I-MAB</FONT> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to the Unaudited Interim Condensed Consolidated Financial Statements </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(All amounts in thousands, except for share and per share data, unless otherwise noted) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>14. Share-based Compensation&nbsp;(Continued) </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>(g)
Surrender of stock options&nbsp;(Continued) </I></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
awards under 2018 Plan was changed to 11,005,888. The director of the Company, Dr.&nbsp;Jingwu Zhang Zang surrendered 2,544,917 unvested options that were granted to him under 2018 Plan, for no
consideration, and these stock options were cancelled immediately. Upon the completion of the Company&#146;s IPO in January 2020, the Group has recorded RMB91,051 share-based compensation expense related to these surrendered options. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The stock options surrendered by the founders should be accounted for as capital contribution. As the founders did not get the title of the
options to be surrendered and the number of share options would not be determined until listing, the capital contribution was not accounted for during the year ended December&nbsp;31, 2019. For the six months ended June&nbsp;30, 2020, the Group has
reclassified RMB91,051 from additional <FONT STYLE="white-space:nowrap">paid-in</FONT> capital&#151;share-based compensation to additional <FONT STYLE="white-space:nowrap">paid-in</FONT> capital&#151;capital contribution relating to the options
surrendered in the condensed consolidated financial statement of comprehensive loss. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><I>Share-Based Compensation Expense </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The allocation of share-based compensation expense was as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="85.5%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="41%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Year&nbsp;Ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Six Months Ended June&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>RMB</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>RMB</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>RMB</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>US$<BR>(Note&nbsp;2.5)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">470</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">308</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">132,724</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,786</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Administrative expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">514,733</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">514,356</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">97,071</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,739</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>515,203</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>514,664</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>229,795</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>32,525</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>15. Licensing and Collaboration Arrangements </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The following is a description of the Group&#146;s significant licensing and collaboration agreements entered into from January&nbsp;1, 2017
to June&nbsp;30, 2020. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>A. <FONT STYLE="white-space:nowrap">In-Licensing</FONT> Arrangements </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><I>Licensing Agreement with MorphoSys AG (&#147;MorphoSys&#148;) </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In November 2017, the Group entered into a license and collaboration agreement with MorphoSys, with respect to the development and
commercialization of MOR202/TJ202, MorphoSys&acute;s proprietary investigational antibody against CD38 (the &#147;CD38 product&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Under this agreement, MorphoSys granted to the Group an exclusive, royalty-bearing, sublicensable license to exploit MOR202/TJ202 for any
human therapeutic or diagnostic purpose in the licensed territory, namely mainland China, Hong Kong, Macau and Taiwan (collectively &#147;Greater China&#148;). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-103 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">I-MAB</FONT> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to the Unaudited Interim Condensed Consolidated Financial Statements </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(All amounts in thousands, except for share and per share data, unless otherwise noted) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>15. Licensing and Collaboration Arrangements&nbsp;(Continued) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>A. <FONT STYLE="white-space:nowrap">In-Licensing</FONT> Arrangements&nbsp;(Continued) </I></B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Pursuant to this agreement, the Group granted to MorphoSys an exclusive license to its rights
in any inventions that the Group make while exploiting the CD38 product under this agreement, solely to exploit the CD38 product outside of Greater China. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Pursuant to this agreement, the Group paid to MorphoSys an upfront license fee of US$20.0&nbsp;million (equivalent to approximately RMB132.7
million). The Group also agreed to make milestone payments to MorphoSys, conditioned upon the achievement of certain development, regulatory and commercial milestones, in the aggregate amount of US$98.5&nbsp;million (equivalent to approximately
RMB653.5 million). Such milestones include first patient dosed in human clinical trials, marketing approval, and first annual net sales of CD38 products covered by the agreement in excess of a certain amount. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In addition, the Group is required to pay tiered <FONT STYLE="white-space:nowrap">low-double-digit</FONT> royalties to MorphoSys on a <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">country-by-country</FONT></FONT> and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">product-by-product</FONT></FONT> basis during the term, commencing with the first
commercial sale of a relevant licensed product in Greater China. Unless terminated earlier in accordance with the terms thereof, this agreement will remain in effect until the expiration of the Group&#146;s last payment obligation under the
agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In 2017, the Group paid US$20.0&nbsp;million (equivalent to approximately RMB132.7 million) upfront fee to MorphoSys, which
was recorded as research and development expense. No additional payments were made in 2018. Due to the uncertainty involved in meeting these developments and commercialization based targets, the Group evaluated and concluded that the remaining
milestones are still not probable as of December&nbsp;31, 2018. In March and April 2019, the project achieved the first and second milestone and the Group paid US$8.0&nbsp;million (equivalent to approximately RMB55.7 million) of milestone fees to
MorphoSys, which was recorded as research and development expense in the interim condensed consolidated statement of comprehensive loss for the six months ended June 30, 2019 and for the year ended December&nbsp;31, 2019. No additional payments were
made for the six months ended June&nbsp;30, 2020 as no milestone has been achieved. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><I>Licensing Agreement with Genexine, Inc.
(&#147;Genexine&#148;) </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In December 2017, the Group entered into an intellectual property license agreement with Genexine with respect
to <FONT STYLE="white-space:nowrap">GX-I7/TJ107,</FONT> a long-acting <FONT STYLE="white-space:nowrap">IL-7</FONT> cytokine. Under this agreement, the Group obtained an exclusive, sublicensable and transferable license to use and otherwise exploit
certain intellectual property in connection with the <FONT STYLE="white-space:nowrap">pre-clinical</FONT> and clinical development, manufacturing, sale and distribution of GX-I7 to treat cancer in Greater China. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Under the terms of the agreement, the Group made an upfront payment of US$12.0&nbsp;million (equivalent to approximately RMB79.6 million) to
Genexine which was recorded as a research and development expense in January 2018. The Group also agreed to make milestone payments in the aggregate amount of US$23.0&nbsp;million (equivalent to approximately RMB152.6 million), conditioned upon the
achievement of certain development milestones, including completion of Phase 2 and Phase 3 clinical studies and new drug application (&#147;NDA&#148;) or biologic license application (&#147;BLA&#148;) approval in Greater China. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Further, the Group agreed to make milestone payments in the aggregate amount of US$525.0&nbsp;million (equivalent to approximately RMB3,482.7
million), conditioned upon the achievement of certain cumulative net </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-104 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">I-MAB</FONT> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to the Unaudited Interim Condensed Consolidated Financial Statements </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(All amounts in thousands, except for share and per share data, unless otherwise noted) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>15. Licensing and Collaboration Arrangements&nbsp;(Continued) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>A. <FONT STYLE="white-space:nowrap">In-Licensing</FONT> Arrangements&nbsp;(Continued) </I></B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
sales of GX<I>-I7 </I>up to US$2,000&nbsp;million. The Group also is required to pay Genexine a <FONT STYLE="white-space:nowrap">low-single-digit</FONT> percentage royalty in respect of the total
annual net sales of <FONT STYLE="white-space:nowrap">GX-I7.</FONT> The aforesaid milestones and royalties (other than the upfront payment) will be reduced by 50% following the entry of a generic version of
<FONT STYLE="white-space:nowrap">GX-I7</FONT> in China, Hong Kong, Macau and Taiwan without the consent or authorization of the Group or any of the Group&#146;s sublicensees. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Unless terminated earlier in accordance with the terms thereof, this agreement will remain in effect until the later of (i)&nbsp;the expiry of
the last to expire patent of the licensed intellectual property that includes a valid claim for Greater China and that covers the composition of GX-I7; and (ii) 15 years from the date of the first commercial sale of
<FONT STYLE="white-space:nowrap">GX-I7.</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">No additional payments to Genexine were made in the six months ended June&nbsp;30, 2019
and 2020. Due to the uncertainty involved in meeting these developments and commercialization based targets, the Group evaluated and concluded that the remaining milestones are still not probable as of December&nbsp;31, 2019 and June&nbsp;30, 2020.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In May 2020, the Group and Genexine entered into an amendment to this agreement whereby both parties desire to establish collaboration on
TJ107 GBM Study in Greater China. Under the terms of the expanded collaboration, the Group will be mainly responsible for using commercially reasonable efforts to conduct the Phase 2 GBM clinical trial in Greater China, and Genexine will share the
development strategies, data and costs for success of this clinical trial. The Group shall undertake to bear <FONT STYLE="white-space:nowrap">two-thirds</FONT> (2/3) proportion of the clinical development costs and Genexine shall undertake to bear <FONT
STYLE="white-space:nowrap">one-third</FONT> (1/3) proportion of these costs. As of June&nbsp;30, 2020, the costs incurred for the development of this new indication was immaterial and thus no material impact to the unaudited interim condensed
consolidated financial statements for the first six months ended June&nbsp;30, 2020. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><I>Licensing Agreement with MorphoSys </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In November 2018, the Group entered into a license and collaboration agreement with MorphoSys for MorphoSys&acute;s proprietary antibody
(MOR210/TJ210) directed against C5aR (the &#147;C5aR Agreement&#148;). Under this agreement, the Group obtained an exclusive, royalty-bearing license to explore, develop and commercialize certain anti-C5aR antibodies in Greater China and South
Korea. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Group will perform and fund all global development activities related to the development of MOR210/TJ210 in Greater China and
South Korea, including all relevant clinical trials (including in the U.S. and China) and all development activities required for IND filing in the US as well as CMC development of manufacturing processes. MorphoSys retains rights in respect of
development and commercialization of MOR210/TJ210 in the rest of the world. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Under the terms of the agreement, the Group also agreed to
make milestone payments conditional upon the achievement of certain development milestones and certain annual net sales of anti-C5aR antibodies. The Group is also required to pay to MorphoSys tiered
<FONT STYLE="white-space:nowrap">mid-single-digit</FONT> royalties on annual net sales of anti-C5aR antibody products within the licensed territory. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-105 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">I-MAB</FONT> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to the Unaudited Interim Condensed Consolidated Financial Statements </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(All amounts in thousands, except for share and per share data, unless otherwise noted) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>15. Licensing and Collaboration Arrangements&nbsp;(Continued) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>A. <FONT STYLE="white-space:nowrap">In-Licensing</FONT> Arrangements&nbsp;(Continued) </I></B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In 2018, the Group paid US$3.5&nbsp;million (equivalent to approximately RMB23.2 million)
upfront fee to MorphoSys, which was recorded as research and development expense. No additional payments were made in the year ended December&nbsp;31, 2019 and in the six months ended June&nbsp;30, 2020. Due to the uncertainty involved in meeting
these development and commercialization based targets, the Group evaluated and concluded that the remaining milestones are still not probable as of December&nbsp;31, 2019 and June&nbsp;30, 2020. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><I>Licensing Agreement with MacroGenics </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In July 2019, the Group entered into a license and collaboration agreement with MacroGenics, Inc. for development and commercialization of an <FONT
STYLE="white-space:nowrap">Fc-optimized</FONT> antibody known as enoblituzumab that targets <FONT STYLE="white-space:nowrap">B7-H3,</FONT> including in combination with other agents, such as the <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">anti-PD-1</FONT></FONT> antibody known as MGA012, in the People&#146;s Republic of China, Hong Kong, Macau and Taiwan(&#147;Greater China&#148;). Under this agreement, the Group obtained an exclusive, sublicenseable,
royalty-bearing license to MacroGenics&#146; patents and <FONT STYLE="white-space:nowrap">know-how</FONT> to develop and commercialize the enoblituzumab product, and a combination regimen of enoblituzumab and MGA012, in Greater China during the term
of the agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In exchange for these rights, in addition to certain financial consideration, the Group will grant to MacroGenics a
royalty-free, sublicenseable, license outside of Greater China, to the patents and <FONT STYLE="white-space:nowrap">know-how</FONT> that are related to the enoblituzumab product or useful or necessary for MacroGenics to develop or commercialize the
enoblituzumab product or a product containing MGA012, and combinations thereof. The license is <FONT STYLE="white-space:nowrap">(i)&nbsp;non-exclusive</FONT> with respect to the enoblituzumab product, and (ii)&nbsp;exclusive with regard to MGA012.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Pursuant to the agreement, the Group paid an upfront fee of US$15.0&nbsp;million (equivalent to approximately RMB104.4 million) to
MacroGenics, which was recorded as research and development expense in the consolidated statement of comprehensive loss for the year ended December&nbsp;31, 2019. No additional payments were made in the six months ended June&nbsp;30, 2020. Under the
terms of the agreement, the Group also agreed to pay MacroGenics development milestone fees of up to US$75.0&nbsp;million and regulatory milestones fees of up to US$60.0&nbsp;million, respectively, and tiered double-digit royalties (ranging from <FONT
STYLE="white-space:nowrap">mid-teens</FONT> to twenty percent) based on annual net sales in the territories. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Group is responsible for
all development costs in Greater China. MacroGenics is responsible for all development costs in the rest of the world, except that the Group is responsible for 20% of the costs incurred in (i)&nbsp;activities supporting global clinical trials in
which the Group participates, (ii)&nbsp;certain CMC activities for material intended to be used in clinical trials in Greater China, and (iii)&nbsp;companion diagnostic development and validation for indications being studied in Greater China. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Due to the uncertainty involved in meeting these developments and commercialization based targets, the Group evaluated and concluded that no
milestones are probable as of December&nbsp;31, 2019 and June&nbsp;30, 2020. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><I>Other
<FONT STYLE="white-space:nowrap">In-Licensing</FONT> Arrangements </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In addition to the above arrangements, the Group has entered into
other various <FONT STYLE="white-space:nowrap">in-licensing</FONT> and collaboration agreements with third party licensors to develop and commercialize drug candidates. Based on the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-106 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">I-MAB</FONT> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to the Unaudited Interim Condensed Consolidated Financial Statements </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(All amounts in thousands, except for share and per share data, unless otherwise noted) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>15. Licensing and Collaboration Arrangements&nbsp;(Continued) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>A. <FONT STYLE="white-space:nowrap">In-Licensing</FONT> Arrangements&nbsp;(Continued) </I></B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
terms of these agreements the Group is contingently obligated to make additional material payments upon the achievement of certain contractually defined milestones. The Group recorded
US$1.2&nbsp;million (equivalent to approximately RMB8.4 million) milestone payment under these agreements during the year ended December&nbsp;31, 2019 and made in total US$1.5&nbsp;million (equivalent to approximately RMB10.5 million) milestone
payment as of December&nbsp;31, 2019, of which US$0.2 million (equivalent to approximately RMB1.4 million) milestone payment was recorded during the six months ended June 30, 2019. The Group additionally recorded US$0.2&nbsp;million (equivalent to
approximately RMB1.4 million) milestone payment during the six months ended June&nbsp;30, 2020. Under the terms of the agreements, the licensors are eligible to receive from the Group up to an aggregate of approximately US$164.4&nbsp;million
(equivalent to approximately RMB1,144.5 million) in milestone payments upon the achievement of contractually specified development milestones and sales milestones, such as regulatory approval for the drug candidates, which may be before the Group
has commercialized the drug or received any revenue from sales of such drug candidate, which may never occur. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>B.
<FONT STYLE="white-space:nowrap">Out-Licensing</FONT> and collaboration Arrangements </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><I>Licensing Agreement among HDYM, <FONT
STYLE="white-space:nowrap">I-Mab</FONT> and Hangzhou HealSun Biopharm Co., Ltd. (&#147;HealSun&#148;) </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In April 2017, one of the
Company&#146;s subsidiaries, <FONT STYLE="white-space:nowrap">I-Mab</FONT> Shanghai, entered into a technology transfer agreement with HDYM and HealSun with respect to
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-L1</FONT></FONT> humanized monoclonal antibodies. Under the agreement, <FONT STYLE="white-space:nowrap">I-Mab</FONT> Shanghai agreed to grant to HDYM exclusive, worldwide and
sublicensable rights to develop, manufacture, have manufactured, use, sell, have sold, import, or otherwise exploit certain <FONT STYLE="white-space:nowrap">PD-L1</FONT> related patents, patent applications, know-hows, data and information of <FONT
STYLE="white-space:nowrap">I-Mab</FONT> Shanghai, relevant cell lines as well as any <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-L1</FONT></FONT> monoclonal antibody arising from such cell lines for the treatment of
diseases. Further, <FONT STYLE="white-space:nowrap">I-Mab</FONT> Shanghai and its cooperative party, HealSun agreed to provide subsequent research and development services on such intellectual property to HDYM, including the selection and
examination of innovative <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-L1</FONT></FONT> humanized monoclonal antibodies, cultivation and selection of stable cell lines, establishment of cell bank, research and
development of manufacturing processes and preparation of samples, toxicological and pharmacological testing, <FONT STYLE="white-space:nowrap">pre-clinical</FONT> pharmaceutical experiment report drafting, and application for and registration of
clinical trials. HDYM agreed to make milestone payments conditioned upon achieving certain contractually defined milestones. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Group
determined that this collaboration is reflective of a vendor-customer relationship and therefore within the scope of ASC 606. Under this agreement, due to the early stage nature of the development, in which the underlying intellectual property is
significantly modified by the development activities being performed, the Group determined the license to the intellectual property and research and development services are not distinct and thus were accounted for as a single performance obligation
that is satisfied over time. The Group would receive RMB51.0&nbsp;million (inclusive of VAT) milestone payments under this agreement, and considered that the achievements of milestone II, III, IV are constrained such that the transaction price shall
initially only include the milestones payment which have been achieved (that means when uncertainty associated with the variable consideration is subsequently resolved), the additional milestone payment shall be included in the total transaction
price when it is no longer probable that a significant reversal of cumulative revenue would occur in future periods. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-107 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">I-MAB</FONT> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to the Unaudited Interim Condensed Consolidated Financial Statements </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(All amounts in thousands, except for share and per share data, unless otherwise noted) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>15. Licensing and Collaboration Arrangements&nbsp;(Continued) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>B. <FONT STYLE="white-space:nowrap">Out-Licensing</FONT> and collaboration Arrangements&nbsp;(Continued) </I></B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">All the revenue has been recognized before the year ended December&nbsp;31, 2019 and all the
milestone payments were received by the Group as of December&nbsp;31, 2019. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><I>Collaboration Agreement with Everest (&#147;Everest&#148;)
</I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In January 2018, the Group entered into a collaboration agreement with Everest, which is controlled by the ultimate controlling party
of a principal shareholder of the Group. Under the agreement, both parties agreed to collaborate on programs to <FONT STYLE="white-space:nowrap">co-develop</FONT> MorphoSys&#146; proprietary anti-CD38 antibody for all indications in hematologic
oncology and commercialize of MOR202/TJ202 in Greater China. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">A joint steering committee with equal representation from each party was
established to coordinate and oversee the development and commercialization of the CD38 product. All decisions of the joint steering committee shall be made by unanimous vote. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Under the agreement, the Group is primarily responsible for carrying out the development, manufacture and supply of the CD38 product, as well
as seeking regulatory approval of the CD38 product. Everest is primarily responsible for sharing the development costs of the CD38 product, including payments due to MorphoSys under the Licensing Agreement, dated November&nbsp;30, 2017, in the
proportion of 75% by Everest and 25% by the Group. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The joint steering committee will decide which party shall be responsible for
conducting the commercialization of the CD38 product pursuant to the commercialization plan approved by the committee. If Everest is selected to be responsible for commercialization, the Group shall grant an exclusive royalty-free license to Everest
to commercialize the CD38 product for all indications in hematologic oncology in Greater China. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Group and Everest will share the
profit and loss and <FONT STYLE="white-space:nowrap">out-licensing</FONT> revenue derived from the CD 38 product in proportion to the costs that each party incur in developing the product. The parties will also split
<FONT STYLE="white-space:nowrap">out-license</FONT> revenue according to the proportion of development costs incurred, with the Group getting an additional five percent (5%) share and Everest receiving five percent (5%) less. Everest cannot share in
any profit from the commercialization of CD38 product until it has fulfilled its payment obligations under this agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Upon any
termination of this arrangement, the terminating party has the right to continue the development and commercialization of CD38 product. If Everest is the rightful terminating party, the Group shall reasonably cooperate with Everest to facilitate the
following: (i)&nbsp;assign the MorphoSys license to Everest (subject to the terms and conditions of such license); (ii) grant to Everest an exclusive license to all intellectual property rights that the Group owns or controls to further develop,
manufacture, and commercialize the CD38 product; (iii)&nbsp;transfer the development, manufacture and commercialization of the CD38 product to Everest. The terminating party shall be solely responsible for the cost and expense of such development
and commercialization after termination. In the event that such continuing party successfully develops and commercializes the CD38 product, it shall pay to the other party a percentage of the product profit and
<FONT STYLE="white-space:nowrap">out-license</FONT> revenue generated therefrom in accordance with the terms of this agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-108 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">I-MAB</FONT> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to the Unaudited Interim Condensed Consolidated Financial Statements </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(All amounts in thousands, except for share and per share data, unless otherwise noted) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>15. Licensing and Collaboration Arrangements&nbsp;(Continued) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>B. <FONT STYLE="white-space:nowrap">Out-Licensing</FONT> and collaboration Arrangements&nbsp;(Continued) </I></B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">During the year ended December&nbsp;31, 2018, the US$26.0&nbsp;million in aggregate proceeds
from Everest under the agreement represented the funding available under the agreement and was recorded as a research and development funding received liability (equivalent to approximately RMB178.7 million) on the consolidated balance sheet as of
December&nbsp;31, 2018, in accordance with ASC 730, Research and Development. Because there is a significant related party relationship between the Group and Everest, the Group is treating its obligation to make payments under the commercialization
stage as an implicit obligation to repay the funds advanced by Everest (see Note 20). During the six months ended June 30, 2019, an additional US$7.6&nbsp;million (equivalent to approximately RMB51.6 million) of funding was received and recorded as
a research and development funding received liability, no further funding received from July 1, 2019 to the date of termination agreement entered into with Everest. No additional milestone has been achieved in the year ended December&nbsp;31, 2019.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><I>Termination Agreement with Everest </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">On November&nbsp;4, 2019, the Group and Everest have terminated the collaboration agreement with respect to the
<FONT STYLE="white-space:nowrap">co-development</FONT> and commercialization of TJ202 in Greater China. Upon the termination, Everest will not retain any rights or entitlements to develop or commercialize TJ202 or any economic interest in its
commercialization. All intellectual property rights in respect of TJ202 arising from its development under the collaboration agreement are vested and owned by <FONT STYLE="white-space:nowrap">I-Mab,</FONT> and the Group holds all intellectual
property rights and have maximum flexibility to further develop, manufacture and commercialize TJ202 in Greater China. In consideration of the above arrangements, the board of directors of the Group has approved the issuance of a total value of
US$37.0&nbsp;million (equivalent to approximately RMB258.1 million) of ordinary shares (the &#147;CPP Shares&#148;) to Everest, representing Everest&#146;s historical contribution to the collaboration and the associated time cost. The CPP Shares
will be issued concurrently with, and subject to, the completion of the Company&#146;s initial public offering within 180 days from termination of the collaboration agreement. The total value of US$37.0&nbsp;million was calculated based on the sum
of (1)&nbsp;US$33.7&nbsp;million, which equals cumulative <FONT STYLE="white-space:nowrap">paid-in</FONT> contributions historically made by Everest under the collaboration agreement; and (2)&nbsp;a negotiated US$3.3&nbsp;million time cost of the
foregoing historical contribution in light of <FONT STYLE="white-space:nowrap">I-Mab&#146;s</FONT> exclusive rights over the commercialization of TJ202 after this termination. The issuance of the CPP Shares was approved by <FONT
STYLE="white-space:nowrap">I-Mab&#146;s</FONT> existing shareholders on December&nbsp;25, 2019. In the event that the initial public offering has not been completed within 180 days from the termination of the collaboration agreement, the Company
will issue 4,762,751 ordinary shares (the &#147;Subject Shares&#148;) to Everest on the 181st day. As a result of the aforementioned termination of the collaboration agreement with Everest, the Group derecognized the research and development funding
received from Everest and recognized a liability that represented the ordinary shares to be issued to Everest, which was measured at fair value in accordance with ASC 480, and the difference of US$3.3&nbsp;million (equivalent to approximately
RMB23.0 million) between the initial fair value of the liability and the carrying amount of research and development funding received was recognized as other expenses in the consolidated statements of comprehensive loss for the year ended
December&nbsp;31, 2019. Upon the completion of the IPO in January 2020, the Group issued 6,078,571 ordinary shares to Everest. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><I>Licensing Agreement with ABL Bio </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In July 2018, the Group entered into a license and collaboration agreement with ABL Bio, under which the Group granted to ABL Bio exclusive,
worldwide (excluding Greater China), royalty-bearing rights to develop and commercialize a bispecific antibody (&#147;BsAb&#148;). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-109 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">I-MAB</FONT> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to the Unaudited Interim Condensed Consolidated Financial Statements </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(All amounts in thousands, except for share and per share data, unless otherwise noted) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>15. Licensing and Collaboration Arrangements&nbsp;(Continued) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>B. <FONT STYLE="white-space:nowrap">Out-Licensing</FONT> and collaboration Arrangements&nbsp;(Continued) </I></B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Group agreed to share costs fifty-fifty (50:50) with ABL Bio through the completion of in
vivo studies, with ABL Bio responsible for all costs and activities following that time. As of December&nbsp;31, 2019, in total US$0.2&nbsp;million (equivalent to approximately RMB1.4 million) expenses were incurred by ABL Bio, of which US$0.06
million (equivalent to approximately RMB0.4 million) were incurred for the six months ended June 30, 2019. In the six months ended June&nbsp;30, 2020, US$0.04&nbsp;million (equivalent to approximately RMB0.3 million) expenses were incurred by ABL
Bio. Accordingly, the Group recorded US$0.02&nbsp;million (equivalent to approximately RMB0.15 million) (50% cost sharing) of expenses in the Group&#146;s consolidated statement of comprehensive loss for the year six months ended June&nbsp;30, 2020.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Pursuant to the license and collaboration agreement that signed in July 2018 and memorandum of understanding that subsequently entered
into with ABL Bio in January 2020, ABL Bio agreed to pay the Group an upfront fee of US$2.5&nbsp;million (equivalent to approximately RMB17.2 million), and milestone payments in the aggregate amount of US$97.5&nbsp;million (equivalent to
approximately RMB690.3 million) conditioned upon achieving certain research, clinical development and sales milestones. These include clinical milestones of up to US$32.5&nbsp;million (equivalent to approximately RMB230.1 million) and sales
milestones of up to US$65&nbsp;million (equivalent to approximately RMB460.2 million). Further, ABL Bio agreed to pay the Group royalties at <FONT STYLE="white-space:nowrap">mid-single-digit</FONT> percentages in respect of the total annual net
sales of the licensed BsAb product. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In addition, ABL Bio granted to the Group an exclusive, royalty-free, sublicensable license to use
the BsAb technology solely to exploit the licensed BsAb product for all indications in Greater China. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Group determined that this
collaboration is reflective of a vendor-customer relationship and therefore within the scope of ASC 606. Under this agreement, the only one performance obligation was to grant the BsAb license to ABL Bio. If it is probable that a significant revenue
reversal would not occur, the associated milestone value is included in the transaction price. Achievement of milestones that are not within the control of the Group or the licensee, such as regulatory approvals, are not considered probable until
the approvals are achieved. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Group recognized revenue of US$2.5&nbsp;million (equivalent to RMB17.2 million) of revenue in the
consolidated statements of comprehensive loss for the year ended December&nbsp;31, 2018, which was the upfront fee related to the grant of the rights of BsAb to ABL Bio as mentioned above. As of December&nbsp;31, 2019 and June&nbsp;30, 2020, no
other milestone has been achieved. No revenue was recognized for the six months ended June 30, 2020 and 2019. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><I>Collaboration Agreement
with ABL Bio </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In July 2018, the Group and ABL Bio entered into a collaboration agreement (the &#147;ABL Bio Collaboration&#148;)
whereby both parties agreed to collaborate to develop three <FONT STYLE="white-space:nowrap">PD-L1</FONT> based bispecific antibodies by using ABL Bio&#146;s proprietary BsAb technology and commercialize them in their respective territories, which,
collectively, include Greater China and South Korea, and other territories throughout the rest of the world if both parties agree to do so in such other territories during the performance of the agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">At contract inception, as both <FONT STYLE="white-space:nowrap">I-Mab</FONT> and ABL Bio participate actively in the research and development
activity. Also, the parties share the risk of failure of the BsAb products and share the income of licensing, so this </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-110 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">I-MAB</FONT> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to the Unaudited Interim Condensed Consolidated Financial Statements </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(All amounts in thousands, except for share and per share data, unless otherwise noted) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>15. Licensing and Collaboration Arrangements&nbsp;(Continued) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>B. <FONT STYLE="white-space:nowrap">Out-Licensing</FONT> and collaboration Arrangements&nbsp;(Continued) </I></B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
contract meet the criteria of the definition of a collaborative arrangement, the Group categorized this agreement within the scope ASC 808. Prior to commercialization, the Group recorded the
share of the expenses incurred by the collaboration for the development of three <FONT STYLE="white-space:nowrap">PD-L1</FONT> based bispecific antibodies products in research and development expense in the interim condensed consolidated statements
of comprehensive loss. As of December&nbsp;31, 2019, in total RMB12.2&nbsp;million expenses were incurred by the Group and RMB8.0&nbsp;million expenses were incurred by ABL, of which, RMB3.49&nbsp;million expenses were incurred by the Group and
RMB3.41&nbsp;million expenses were incurred by ABL for the six months ended June&nbsp;30, 2019. According to the terms set out in the agreement, the Group recorded RMB3.45&nbsp;million (50% cost sharing) of expenses in the Group&#146;s interim
condensed consolidated statements of comprehensive loss for the six months ended June&nbsp;30, 2019. For the six months ended June&nbsp;30, 2020, RMB11.1&nbsp;million expenses were incurred by the Group and RMB33.4&nbsp;million expenses were
incurred by ABL. According to the terms set out in the agreement, the Group recorded RMB22.3&nbsp;million (50% cost sharing) of expenses in the Group&#146;s interim condensed consolidated statements of comprehensive loss for the six months ended
June&nbsp;30, 2020. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><I>Collaboration Agreements with Tracon Pharmaceuticals, Inc. (&#147;Tracon&#148;) </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In November 2018, the Group entered into collaboration agreements with Tracon, under which both parties agreed to <FONT
STYLE="white-space:nowrap">co-develop</FONT> the Group&#146;s proprietary CD73 antibody, TJD5 (the &#147;TJD5 Agreement&#148;) and <FONT STYLE="white-space:nowrap">co-develop</FONT> up to five BsAbs (the &#147;BsAbs Agreement&#148;). Both agreements
may be terminated by either party for the other party&#146;s uncured material breach, bankruptcy or insolvency or for safety reasons. In addition, the agreement in respect of TJD5 may be terminated by the Group: (i)&nbsp;for convenience within a
certain period upon completing different clinical stages subject to certain payments and royalties, based on the clinical stage, that would be owed to Tracon upon the exercise of such termination for convenience; (ii)&nbsp;in the event that Tracon
causes the Phase 1 study timeline to be delayed beyond the agreed extension periods; or (iii)&nbsp;if the Group decides to end the development of the collaborative product prior to its first commercial sale. Further, prior to the first commercial
sale, Tracon may deem this agreement to be terminated by the Group if it reasonably believes that the Group has discontinued all meaningful development of the collaborative product for at least 12 months and certain other conditions are met.
Additionally, in March 2019, the Group agreed with Tracon and F. <FONT STYLE="white-space:nowrap">Hoffmann-La</FONT> Roche Ltd (&#147;Roche&#148;) on a clinical supply agreement for Roche to supply atezolizumab for use in clinical studies under the
collaboration agreement with Tracon. As of December&nbsp;31, 2019, the Group has recorded US$4.0&nbsp;million (equivalent to approximately RMB27.8 million) of research and development costs in the consolidated statement of comprehensive loss for the
year ended December&nbsp;31, 2019, of which US$0.6 million (equivalent to approximately RMB4.4 million) was recorded in the six months ended June 30, 2019. As of June&nbsp;30, 2020, no payments or royalties are due under this agreement. For the six
months ended June&nbsp;30, 2020, the Group has recorded US$0.02&nbsp;million (equivalent to approximately RMB0.1 million) of research and development costs in the interim condensed consolidated statements of comprehensive loss. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><I>Licensing Agreement with CSPC Pharmaceutical Group Limited (&#147;CSPC&#148;) </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In December 2018, the Group entered into a product development agreement with CSPC. The Group granted to CSPC exclusive, <FONT
STYLE="white-space:nowrap">non-transferable,</FONT> <FONT STYLE="white-space:nowrap">non-irrevocable</FONT> and sublicensable rights in the PRC (excluding Hong Kong, Macau and Taiwan) to develop and commercialize TJ103 for treating type 2 diabetes.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-111 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">I-MAB</FONT> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to the Unaudited Interim Condensed Consolidated Financial Statements </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(All amounts in thousands, except for share and per share data, unless otherwise noted) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>15. Licensing and Collaboration Arrangements&nbsp;(Continued) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>B. <FONT STYLE="white-space:nowrap">Out-Licensing</FONT> and collaboration Arrangements&nbsp;(Continued) </I></B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">CSPC is responsible for developing, obtaining market approval and commercializing the
licensed products. The Group is responsible for transferring the manufacturing technology of the licensed products to CSPC and assisting CSPC in the continued optimization of such manufacturing technology thereafter. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In consideration of the license, CSPC agreed to pay the Group an upfront fee of RMB15.0&nbsp;million and milestone payments in an aggregate
amount of RMB135.0&nbsp;million conditioned upon achieving certain clinical development and regulatory approval milestones. In addition, the Group is also entitled to royalties of up to <FONT STYLE="white-space:nowrap">low-double-digit</FONT>
percentages in respect of the total annual net sales of the products after its commercialization in the PRC. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Group determined that
this collaboration is reflective of a vendor-customer relationship and therefore within the scope of ASC 606. Under this agreement, the only one performance obligation was to grant TJ103 license to CSPC. considering that the achievements of
milestones are constrained such that the transaction price shall initially only include upfront payment and subsequently, once another milestone was achieved (that means when uncertainty associated with the variable consideration is subsequently
resolved), the additional milestone payment shall be included in the total transaction price when it is no longer probable that a significant reversal of cumulative revenue would occur in future periods. As of December&nbsp;31, 2018, the amount
received of RMB14.2&nbsp;million (net of VAT) was recorded as advance from customers in the consolidated balance sheet. In February 2019, an additional amount of RMB0.8&nbsp;million (net of VAT) was received, and the license was also approved by
China intellectual property office in May 2019. The first milestone was achieved in September 2019 and the amount of RMB15.0&nbsp;million (net of VAT) was received according to the terms of the agreement. Accordingly, RMB30.0&nbsp;million was
recognized as revenue in the consolidated statements of comprehensive loss for the year ended December&nbsp;31, 2019, of which RMB15.0 million of upfront payment was recognized for the six&nbsp;months ended June 30, 2019. No additional revenue was
recognized in the six months ended June&nbsp;30, 2020 as no further milestone has been achieved. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><I>Strategic Alliance Agreement with PT
Kalbe Genexine Biologics (&#147;KG Bio&#148;) </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In March 2020, the Group entered into a strategic partnership with Kalbe Genexine
Biologics (&#147;KG Bio&#148;) to grant a right of first negotiation for an exclusive license for the development and commercialization of two <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">I-Mab-discovered</FONT></FONT> product
candidates: uliledlimab, a highly differentiated anti-CD73 antibody in Phase&nbsp;1 development for advanced solid tumors (&#147;First Program&#148;), and an I-Mab product candidate (&#147;Second Program&#148;) to be agreed upon by both parties in
certain regions. Through this agreement, both parties intend to negotiate the terms that will be reflected in definitive agreements for each prospective program covered under this agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">If and when the Group and KG Bio enter into the definitive licensing agreement, the Group will be eligible to receive from KG Bio an aggregate
amount of up to approximately US$340&nbsp;million, including an upfront payment and subsequent payments conditional upon achieving certain development and commercial milestones. KG Bio will pay the Group tiered royalties in the low to <FONT
STYLE="white-space:nowrap">mid-teen</FONT> percentages on net sales from certain regions. As the right of first negotiation has not been exercised and the definitive agreement has not been entered into as of June&nbsp;30, 2020, no revenue was
recognized during the six months ended June&nbsp;30, 2020. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-112 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">I-MAB</FONT> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to the Unaudited Interim Condensed Consolidated Financial Statements </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(All amounts in thousands, except for share and per share data, unless otherwise noted) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>16. Other Income, Net </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The following table summarizes other income and expenses, recognized for the six months ended June&nbsp;30, 2019 and 2020: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="85.5%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="73%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Six Months Ended June&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>RMB</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>RMB</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>US$</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>(Note&nbsp;2.5)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fair value change of short-term investments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">415</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">59</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income of incentive payment from depository bank (Note&nbsp;7)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,090</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">154</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net foreign exchange gains</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">140</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">947</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">134</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Subsidy income (Note (i))</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,408</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,473</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fair value change of other financial assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(508</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Others</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">571</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(36</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">303</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,824</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,815</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Note: </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">(i) For the six months ended June 30, 2020, subsidy income consists primarily of RMB10 million. The government grant was granted from the
project management office of Shanghai Zhangjiang Science City to support the research and development activities in the local region. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>17. Net Loss Per
Share </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Basic and diluted net loss per share for each of the periods presented are calculated as follows: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="85.5%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="57%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Six Months Ended June&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>RMB</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>RMB</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>US$&nbsp;(Note&nbsp;2.5)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Numerator:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss attributable to <FONT STYLE="white-space:nowrap">I-Mab</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(857,337</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(582,853</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(82,497</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss attributable to ordinary shareholders</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(857,337</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(582,853</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(82,497</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Denominator:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted average number of ordinary shares outstanding&#151;basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,184,086</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">121,815,986</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">121,815,986</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss per share&#151;basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(119.34</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4.78</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(0.68</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">For the six months ended June&nbsp;30, 2019 and 2020, the effects of all outstanding convertible preferred
shares, restricted shares, convertible promissory notes and certain stock options have been excluded from the computation of diluted loss per share for the six months ended June&nbsp;30, 2019 and 2020 as their effects would be anti-dilutive. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">For the six months ended June&nbsp;30, 2019 and 2020, the Company also has certain dilutive potential stock options. These stock options which
cannot be exercised until the Company completes its listing are not included in the computation of diluted earnings per shares as such contingent event had not taken place. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-113 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">I-MAB</FONT> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to the Unaudited Interim Condensed Consolidated Financial Statements </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(All amounts in thousands, except for share and per share data, unless otherwise noted) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>17. Net Loss Per Share&nbsp;(Continued) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The potentially dilutive securities that have not been included in the calculation of diluted
net loss per share as their inclusion would be anti-dilutive are as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="72%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="64%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Six Months Ended June&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Convertible preferred shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">91,578,628</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Convertible promissory notes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,167,779</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Restricted shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">252,099</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stock options</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,803,305</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27,019,861</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>18. Employee Benefits </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Full time employees of the Group in the PRC participate in a government mandated defined contribution plan, pursuant to which certain pension
benefits, medical care, employee housing fund and other welfare benefits are provided to the employees. Chinese labor regulations require that the PRC subsidiaries of the Group make contributions to the government for these benefits based on certain
percentage of the employees&#146; salaries, up to a maximum amount specified by the government. The Group has no legal obligation for the benefits beyond the contribution made. The total amounts charged to the interim condensed consolidated
statements of comprehensive loss for such employee benefits amounted to approximately RMB5,204 and RMB5,411 for the six months ended June&nbsp;30, 2019 and 2020, respectively. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>19. Commitments and Contingencies </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Contingencies
</I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Group is a party to or an assignee of license and collaboration agreements that may require it to make future payments
relating to milestone fees and royalties on future sales of licensed products (Note 15). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Group did not have significant capital and
other commitments, long-term obligations, or guarantees as of December&nbsp;31, 2019 and June&nbsp;30, 2020. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>20. Related Party Balances and
Transactions </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The table below sets forth the major related parties and their relationships with the Group as of December&nbsp;31, 2019
and June&nbsp;30, 2020: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="50%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name of related parties</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Relationship with the Group</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Everest</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Controlled by the ultimate controlling party of a principal shareholder of the Group</P></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Tasly Pharmaceutical Group Co., Ltd.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Controlled by the ultimate controlling party of a principal shareholder of the Group</P></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">CMAB Biopharma (Suzhou) Inc.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Controlled by the ultimate controlling party of a principal shareholder of the Group</P></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-114 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">I-MAB</FONT> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to the Unaudited Interim Condensed Consolidated Financial Statements </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(All amounts in thousands, except for share and per share data, unless otherwise noted) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>20. Related Party Balances and Transactions&nbsp;(Continued) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Details of related party balance as of December&nbsp;31, 2019 and June&nbsp;30, 2020 are as
follows: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><I>Ordinary Shares to be issued to Everest* </I></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="72%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="47%"></TD>

<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>As&nbsp;of&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>As of June&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>RMB</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>RMB</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>US$&nbsp;(Note&nbsp;2.5)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Everest</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">258,119</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Note: Please refer to Note 15 for further details. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Details of related party transactions for the six months ended June&nbsp;30, 2019 and 2020 are as follows: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><I>Receipt of CRO services&#151;recognized in research and development expenses </I></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="72%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="59%"></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Six&nbsp;Months&nbsp;Ended&nbsp;June&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>RMB</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>RMB</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>US$&nbsp;(Note&nbsp;2.5)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Tasly Pharmaceutical Group Co., Ltd.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,590</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><I>Receipt of research and development funding </I></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="72%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="60%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Six Months Ended June 30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>RMB</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>RMB</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>US$&nbsp;(Note&nbsp;2.5)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Everest (Note 15)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">51,588</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><I>Project development fee&#151;recognized in research and development expenses </I></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="72%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="63%"></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Six Months Ended June 30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>RMB</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>RMB</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>US$&nbsp;(Note&nbsp;2.5)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">CMAB Biopharma (Suzhou) Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">695</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">98</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>21. Concentration of Credit Risk </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Financial instruments that are potentially subject to significant concentration of credit risk consist of cash and cash equivalents,
restricted cash, short-term investments and other receivables. The carrying amounts of cash and cash equivalents, restricted cash, and short-term investments represent the maximum amount of loss due to credit risk. As of December&nbsp;31, 2019 and
June&nbsp;30, 2020, all of the Group&#146;s cash and cash equivalents, restricted cash and short-term investments were held by major financial institutions located in the PRC and international financial institutions outside of the PRC which
management believes are of high credit quality and continually monitors the credit worthiness of these financial institutions. With respect to the contract assets, other receivables and other financial assets, the Group performs <FONT
STYLE="white-space:nowrap">on-going</FONT> credit evaluations of the financial condition of its customers and counterparties. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-115 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">I-MAB</FONT> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to the Unaudited Interim Condensed Consolidated Financial Statements </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(All amounts in thousands, except for share and per share data, unless otherwise noted) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>22. Subsequent Events </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Group evaluated subsequent events through October 21, 2020. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">On July&nbsp;15, 2020, the Group announced that its Board of Directors has authorized a stock repurchase
program under which the Group may repurchase up to US$20&nbsp;million of its ordinary shares in the form of American depositary shares. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">On July&nbsp;15, 2020, the Group adopted 2020 Share Incentive Plan (the &#147;2020 Plan&#148;). Under the 2020
Plan, the maximum aggregate number of shares which may be issued pursuant to all awards shall be 10,760,513 ordinary shares, provided that the maximum number of shares may be issued pursuant to awards in the form of restricted share units under this
plan shall not exceed 7,686,081 ordinary shares. From August 2020 through September 2020, the Group granted 1,068,733 stock options and 4,892,918 restricted share units under 2020 Plan to its employees, respectively. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">On September&nbsp;3, 2020, the Group, through <FONT STYLE="white-space:nowrap">I-Mab</FONT> Biopharma
(Shanghai) Co., Ltd. and <FONT STYLE="white-space:nowrap">I-Mab</FONT> Biopharma US Limited, each a wholly-owned subsidiary of the Group, entered into a broad global strategic partnership with AbbVie Ireland Unlimited Group (&#147;AbbVie&#148;).
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:12%; font-size:10pt; font-family:Times New Roman">Pursuant to this collaboration, the Group will grant AbbVie a global license, excluding Mainland China, Macau, and
Hong Kong, to develop and commercialize lemzoparlimab (also known as TJC4), an innovative anti-CD47 monoclonal antibody internally discovered and developed by <FONT STYLE="white-space:nowrap">I-Mab</FONT> for the treatment of multiple cancers. The
Group will retain all rights to develop and commercialize lemzoparlimab (as well as certain other compounds directed against CD47) in Mainland China, Macau, and Hong Kong. AbbVie will conduct further global clinical trials (which the Group may elect
to co-fund) to evaluate lemzoparlimab in multiple cancers. This deal also allows for potential collaboration on future CD47-related therapeutic agents, including CD47-based bispecific antibodies and combination therapies with lemzoparlimab and
AbbVie&#146;s venetoclax (Venclexta<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>). Each party will have the opportunity subject to rights of first negotiation to further licenses, to explore certain of each other&#146;s related
CD47-antibody programs in their respective territories. In addition, the Group and AbbVie will share manufacturing responsibilities, with AbbVie being the primary manufacturer supply outside of Mainland China, Hong Kong and Macau and the Group being
the primary manufacturer for supply for Mainland China, Hong Kong and Macau. The Group believes that this collaboration will accelerate its establishment of commercial production operations in China. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:12%; font-size:10pt; font-family:Times New Roman">AbbVie will pay the Group an upfront payment of US$180 million. Additionally, in connection with the recently released clinical data from the
Phase 1 trial of lemzoparlimab in the United States, the Group expects to be paid a first milestone payment of US$20 million. The Group will also be eligible to receive up to US$1.74 billion in further success-based development, regulatory and sales
milestone payments for lemzoparlimab, of which US$840 million are based on clinical development and regulatory approval milestones, with the remainder based on commercial milestones. Upon commercialization of lemzoparlimab, AbbVie will also pay
tiered royalties from low double-digit percentages on global net sales outside of Mainland China, Macau, and Hong Kong. In addition, AbbVie has a license and right of first negotiation to further develop and commercialize two additional
lemzoparlimab-based bispecific antibodies discovered and currently being developed by the Group and the Group cannot commercialize products containing these two </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-116 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">I-MAB</FONT> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to the Unaudited Interim Condensed Consolidated Financial Statements </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(All amounts in thousands, except for share and per share data, unless otherwise noted) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>22. Subsequent Events&nbsp;(Continued) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:12%; font-size:10pt; font-family:Times New Roman">
additional lemzoparlimab-based bispecific antibodies outside of Mainland China, Macau and Hong Kong even if AbbVie does not exercise its right of first negotiation or the both parties are unable
to come to financial terms on such products. The potential value of each such license is minimum US$500 million in upfront and milestone payments, for a combined total of no less than US$1&nbsp;billion. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">On September&nbsp;4, 2020, the Group announced that it has entered into definitive subscription agreements with
a consortium of institutional investors (the &#147;Investors&#148;) to raise approximately US$418&nbsp;million through a private placement. The consortium is led by Hillhouse Capital Group (&#147;Hillhouse&#148;), with significant participation by
GIC Private Limited, and also includes certain other leading Asian and U.S. biotech investment funds. Hillhouse is entitled to nominate one representative to <FONT STYLE="white-space:nowrap">I-Mab&#146;s</FONT> Board of Directors.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:12%; font-size:10pt; font-family:Times New Roman">The private placement comprises (1) the sale to the Investors of approximately US$418 million of the Group&#146;s
29,133,502 ordinary shares (the &#147;Ordinary Shares&#148;) (equivalent to 12,666,740 ADSs) at a purchase price equivalent to US$33 per ADS; and (2) warrants (the &#147;Warrants&#148;) to subscribe for an aggregate of 5,341,267 Ordinary Shares
(equivalent to 2,322,290 ADSs) at an exercise price equivalent to US$45 per ADS, which may further increase the proceeds of approximately US$104.5 million if the Warrants are fully exercised. The Warrants will remain exercisable at the election of
the Investors within 12 months after the closing of the private placement. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(e)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">On September&nbsp;15, 2020, <FONT STYLE="white-space:nowrap">I-Mab</FONT> Biopharma Hong Kong Limited entered
into an equity transfer and investment agreement with a group of domestic investors in China, to transfer 40% equity interest of <FONT STYLE="white-space:nowrap">I-Mab</FONT> Biopharma (Hangzhou) Limited
<FONT STYLE="white-space:nowrap">(&#147;I-Mab</FONT> Hangzhou&#148;) to these investors at the consideration of US$120&nbsp;million in cash and transfer 10% equity interest to the management team shareholding platform that holds the share awards
which are granted to I-Mab Hangzhou&#146;s management team and 5% equity interest to the equity incentive shareholding platform that holds the shares for the purpose of future share awards grants respectively with no consideration.
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-117 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g98473g00i34.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g98473g00i34.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_[1WB4&AO=&]S:&]P(#,N,  X0DE-! 0
M     $H< 5H  QLE1QP!6@ #&R5'' (   (  !P"4  (<G(U,#DQ-C<< @4
M(4UI8W)O<V]F="!7;W)D("T@1V5N97-I<R!&+3$N9&]C>#A"24T$)0
M$")*^(M6HN%I'>),'8-E9Y0X0DE-!#H      .4    0     0      "W!R
M:6YT3W5T<'5T    !0    !0<W138F]O; $     26YT965N=6T     26YT
M90    !#;')M    #W!R:6YT4VEX=&5E;D)I=&)O;VP     "W!R:6YT97).
M86UE5$585     $       ]P<FEN=%!R;V]F4V5T=7!/8FIC    # !0 '(
M;P!O &8 ( !3 &4 = !U '        IP<F]O9E-E='5P     0    !";'1N
M96YU;0    QB=6EL=&EN4')O;V8    )<')O;V9#35E+ #A"24T$.P     "
M+0   !     !       2<')I;G1/=71P=71/<'1I;VYS    %P    !#<'1N
M8F]O;       0VQB<F)O;VP      %)G<TUB;V]L      !#<FY#8F]O;
M    0VYT0V)O;VP      $QB;'-B;V]L      !.9W1V8F]O;       16UL
M1&)O;VP      $EN=')B;V]L      !"8VMG3V)J8P    $       !21T)#
M     P    !29" @9&]U8D!OX            $=R;B!D;W5B0&_@
M    0FP@(&1O=6) ;^            !"<F1456YT1B-2;'0
M  !";&0@56YT1B-2;'0               !2<VQT56YT1B-0>&Q <L
M      IV96-T;W)$871A8F]O; $     4&=0<V5N=6T     4&=0<P    !0
M9U!#     $QE9G15;G1&(U)L=                %1O<"!5;G1&(U)L=
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M____   X0DE-! T       0   !X.$))3009       $    'CA"24T#\P
M    "0           0 X0DE-)Q        H  0         !.$))30/U
M  !( "]F9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &       ! #(    !
M %H    &       ! #4    ! "T    &       !.$))30/X      !P  #_
M____________________________ ^@     ________________________
M_____P/H     /____________________________\#Z     #_________
M____________________ ^@  #A"24T$"       $     $   )    "0
M   X0DE-!!X       0     .$))300:      ,U    !@             !
M[0   [X          0                         !              .^
M   ![0                     !                         !     !
M        ;G5L;     (    &8F]U;F1S3V)J8P    $       !28W0Q
M!     !4;W @;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG
M   ![0    !29VAT;&]N9P   [X    &<VQI8V5S5FQ,<P    %/8FIC
M 0      !7-L:6-E    $@    =S;&EC94E$;&]N9P         '9W)O=7!)
M1&QO;F<         !F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U
M=&]'96YE<F%T960     5'EP965N=6T    *15-L:6-E5'EP90    !);6<@
M    !F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
M         $QE9G1L;VYG          !"=&]M;&]N9P   >T     4F=H=&QO
M;F<   .^     W5R;%1%6%0    !        ;G5L;%1%6%0    !
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M300H       ,     C_P        .$))3001       ! 0 X0DE-!!0
M  0    $.$))300,     !-3     0   *    !2   !X   F<   !,W !@
M ?_8_^T #$%D;V)E7T--  +_[@ .061O8F4 9(     !_]L A  ," @("0@,
M"0D,$0L*"Q$5#PP,#Q48$Q,5$Q,8$0P,# P,#!$,# P,# P,# P,# P,# P,
M# P,# P,# P,# P, 0T+"PT.#1 .#A 4#@X.%!0.#@X.%!$,# P,#!$1# P,
M# P,$0P,# P,# P,# P,# P,# P,# P,# P,# P,# S_P  1" !2 * # 2(
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MS)NW;<F_?B_^:ZEG[1R=]%VQ)3O=%MR3;U.B^]^2,;,].I]@8'!CJ,;)]/\
M05TLVLLR+-GL^@M-<2/K7=TKZQ9/2[<-K[^HYH+&MN$G]!B5;:#8RNM[O28R
MS],_'_2V_9_\'ZBV+?K)F8N?97G=,OQ\!K6[,LEA&\]KG!_V:JMWT&O^T_\
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M)Z))0JM9=4RVLRRQH>T^3AN:IIJPBC14DD@9V0<;#NO;JZMCG,'BZ/8W^T]
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M?SUGT.?I4_SW_=G_ +D?R_LZ^:$DE/TH[\W_ )/_ )[*Y^%OT?\ NS_Y8_\
M7U8;_3:OZ+_A./Y[Z3_YK_W8_P"$]5?,:22'Z3Q_H4?\G_S3_P";XX=_,?\
M ?Z5'POHXW]$^A7_ #''\V?Z-_P7^A_[K+YE224_1G0_^1\+^A?S+?YOZ'%'
M]'_[K_Z'_@/L2L8/_+F5_1_Z+1_-?SG\]F\_\#_[L>NOFM))3]5)+Y5224_5
M22^54DE/U4DOE5))3__9 #A"24T$(0      50    $!    #P!! &0 ;P!B
M &4 ( !0 &@ ;P!T &\ <P!H &\ <    !, 00!D &\ 8@!E "  4 !H &\
M= !O ', : !O '  ( !# %, -@    $ .$))300B      %&34T *@    @
M" $2  ,    !  $   $:  4    !    ;@$;  4    !    =@$H  ,    !
M  (   $Q  (    >    ?@$R  (    4    G $[  (    )    L(=I  0
M   !    O    .@ +<;    G$  MQL   "<0061O8F4@4&AO=&]S:&]P($-3
M-B H5VEN9&]W<RD ,C Q.3HP-SHR,2 Q.3HU-CHP, !R<C4P.3$V-P
M Z !  ,    !__\  * "  0    !   #OJ #  0    !   ![0         &
M 0,  P    $ !@   1H !0    $   $V 1L !0    $   $^ 2@  P    $
M @   @$ !     $   %& @( !     $              $@    !    2
M  $X0DE- _T       @          /_A 4A-30 J    "  ( 1(  P    $
M     1H !0    $   !N 1L !0    $   !V 2@  P    $  @   3$  @
M !X   !^ 3(  @   !0   "< 3L  @    D   "PAVD !     $   "\
MZ    \     !   #P     %!9&]B92!0:&]T;W-H;W @0U,V("A7:6YD;W=S
M*0 R,#$Y.C W.C(Q(#$Y.C4V.C P ')R-3 Y,38W       #H $  P    '_
M_P  H ( !     $   .^H , !     $   'M          8! P #     0 &
M   !&@ %     0   38!&P %     0   3X!*  #     0 "   " 0 $
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M3Q$\14 _*;U?\RM/4!.#O)O&,2:%QU@LPXRR*ZL/?INR4J^V>ED490/Y[S3
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M=H*[&0,3^+%))Y2#D/XFI^1^D(^DM_ Y'/5& "?:N^H5R_8LZ$?M31S:$4V
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M'19RLM*N;0VBP.)C+R'*U?R?+DHVZU7D-73F"Y+JZ4T<D5>.Q*<D89Y4H2G
M7:...*!W8(A$=50(/J+KM6FA]^9I0,ZIPB0-! +]FXLW;RM(["[]N[D77R[O
M)3M3B^+=N0,)6T[GTJB,1%%%C3L=&8Y6!E0J5QH@D,):DY[!)<8CI$,C@BU:
M/H@2C[ATQ-EF!7<@T7311CO#N86>&7IM&E0JV[4L30C)9L:4+11.Y/+'[=&]
M4BL1S/[9$%N.P(R0Q21-&8N[Y%ZD%Z)HI#(08O)V$(2=W_9^Y8Y'!V^>G!Q?
MHG9W=GZ4>H93=L?'+&6.:Y.3_IGEUOL_<V+618;'%K2J+#X@](D)S2(>'@HZ
M%-P)FV7UTD%("P;=XU_$M(8(LL[<DH\]WUW6R?4*Q(VC!0X[R0Q *&C').V7
MK,$81A1VI;D]B:*\;L_L;,LQ@;.->\S",4X]$4,V8PO <MBL+]G'T+30/Y>7
MNUFB &<!^[P"+.W7E$[OV#P+HJ 46*^7F&2.H;:%&(!:M3R/HFND8(B.9 U7
MLS_K\ ^JURD/<II,F8MK'9')_P!%0<R>MD6K( ^$M7C5P^V\W6O2'1X5S?-Y
M/<.7/I:VUR;-ARVJ/4.KJT,JA=*E([$T$U.Y6TKMFF=<?%QS)!=B$@F?]!+_
M .(^;U._"IR;@<V(.AR'A=+@539V[^A)HG=P)]R2I!R>NTL16@U*FAG8V5H?
M4V#_ (VV%R.9V8JH^D;UB+P>GB)XB>(GB)XB>(GB*(\HSO->T*OCWV_E$TE3
M<UM%_P#37"B:,OM PUKB%[*YSC.$7"<8!6EAOG&=5-D7B_\ ;.FWUQ%+/=WF
M&9!]XL7(NZ<C??JWIS#G4G?^A-5@U&'[/U(7W;[71D=8/H3R[3[\;G/N<X/$
M:_;N)'B\1HR\IW6!F_YD9Z^AQ#W.^Q8X(^NB%V>49P$$DX4O&Y*'%R".R 8^
M"G@)M@U*AC0<HU59$A188^279$1I!FNLT?,7:"S9TV5407242WVUS*U2Z\='
M%_.G:?.7_P 1C8]60DJU&\P0ZD3)!$ >EJ<P8!^&SQN4.Z1KV(;'GY27#%HA
M<[M,4"!ZN6ZL89AR[5'/]#;#6I B]EGB)XB>(M;VM;]:4=#W<^MB8B81$6;E
MLR5,%]U\Z*OGF=_U6#)FS0=$"3]?5)91)D/:.G6R*#A?"/X6ZRFFOU-;.Q:A
MWM2W#2J 0@\TSOTYGWX@ BQ')(3,3L$8D3B)%UT+NTIX=PGE?J!N0\;X;AW=
M_:GBEG"C2&-B&O P^]8GFGDAK5:\;F G8LS0PM))''Y^Y)&)9!"YK$[%BH.<
M08^,E,2DK'0D#/AW&KH>19[[;I_D15U^F==TEDU6[E!75-PT=(K-7*2+A%5+
M3OIW*NA5ANTIX[-6P#20SPDQQR _;=L[?NSLXD+]$!,0DS$+LVLWL'9XQL:'
M'^0YMO(VLJP570SKT3PV:LXLQ>,@/\.)@02Q2 Y130G'-$9Q2 98Q<MN1&BZ
MYD%G3?\ EE0@)0*P0&1X6L;DTDD<J/BXE#8?%@K?;14O*9E+C@.+1L9JHCH]
M-%V*"SALCNHX2R5J5I:-]>Q=H$G!GH: S;CQ" HQ5\5>]%%:R%1(B)F[XH+C
M#P!9D#L&>5B5)/2H=X*?1%*8:34*_4%ZE(ZV:R"/.RI%WY/M+D +B*;&.HN?
MQ2<Z BY3"UB-NP-FWE4:-.S@\3( #AP=30*!2!&-'QK4FS459*D1#]AA;]QO
MNC@BXXCMSCF0%H8!"=3<_%3=BJ,48&(86Y!7)*8+$Y&<AP]".,DC>S@NN\E\
M:/Q1NBR3655DPA\!UUR50W:8(N7OV9R.FO8#;?INAM5ZI_#FRTLVM",;0/1>
M3LX3HK*\?S7_ +&CK,B#&)++D/P(MY*\; G&Z1-;1KL1=!->[N/H$TD6YOHR
MGE3$;K8E;3F(#+$B#V:/X.-@>]G9*B(U_,ID7^7\"U3E8Q'5/39Z <-C*><"
MEM7GB+[P_N7D.;-6&P?HVF-"SNM$;==Q=W9D*3E 2 [1!O/7A\X%3.+.A[(1
M#W*<C+KJ8R@Q!_\ O*JO\5MH\V(M[06S*\L^+#)Q7$VB\[AAO+_ :5Q(V/D$
M=+?Q9)X&([#3 M=RP?:,RH]\/7W;+JZ)NVBZ.=OO3VQ@B\^'S-'.AW]W1$2Q
M!U;'^::HJ^NK0D5HV3P,-[7U%/9K;YVL[-D03!EJ13!NZ?:*4Y(BL-C+-.6R
M&*3"0RM'=T.A:Z"9%<OPE.;'LWC/F"PK?9&!]H3*D:\D4\:'8NPA)-*3E(XQ
M=%=E8B,'!V4<;K.5-UF =(0+V8CU&J"XUBXU5:I$56?S=]&7A36]7 :0M.90
M,KF@.Q;F>CH;.(Q52VA:FH7"2$/L8W+YBS=BK CM<ECCER6YZ%YU.6FF935U
M278Q]?74BC_5G;/14F[D#E0=T3.U)%)^G+:HU'C!-]$8/%BO.<0^/2.=&5I:
M@^#R,>WD%>RF=W"X'J;65*#^H9)"99ASY=(<-_61(K$N&9O9]@=Q?(0?MRDB
ME RW-?\ $K/: F)W"+%=ZCFX;H/],O\ U%7Y F RF1^]3[&6'/[C;\.?V--?
MOT^I%;5XB>(L6FH,Y)8L9!QJ:&:[.D6NJ(V:QX;&#!F/KZKI*Y>,1DS!R2,/
M%-TT]VVZ1<&0;_A74VT2T<:HK)9-.:&O9AGL4X="",G>2G8DLQ0SCXNW@<E.
M>M9!F=V)GBGC+L69W<7=G^3$B A$RC)VZ8Q8'(7_ *LQB8/_ /<+M_DM <P\
MV'.; A2+;7O8EJQ)V4E)\7'9K'*J$MP$AG,WD5A3(RR(P6!14X\6/2>4%WFS
M(L4?BAB3C#,.P8-$6R*.]Y)R*'D4T5G\CS\NT$56"2Q2L:DI3UZ-*OGTX3CO
M7[4(#!6K0AYQ1A+(X^<IF1$[X]6L]47#WY9@<C)AD&%O$I)"E,F>.,'?R,R?
MIW=F^S,S+8UA\\4#;AAI(;5I"H[+/L!Z(AB<GU<Q"7EV8INY=O4!C4E( Y!X
M@/0>$'[M%DDMJV3<O7:^B>JKE;;?7T-_=RHCKY>SJYT$DCS'#1T+=2(Y7$ >
M4HX)HP*1PC 7-Q<G$ %WZ$6;LDKUYG8I8(929F9BDB W9F=W9F<A=V9G=W9O
MZN_]5L\($#1H.*CT=$C ( &/9B @,*Q:BQ <4.;IM& P6-9)(,V ]BU22;-&
M;5%)NV033113T3TUUQK9IIK$LMBQ+)//-(<LTTQE++++(3D<DLAN1R2&3N1F
M3N1$[N[N[KM9F%F$681%F819F9F9FZ9F9OAF9OAF;X9EV?NM<IXB>(O);=/.
MJ/*/S"26VXW.U=]%*\?]N,HNUCJ#/9V$6M!<1:M7_LMGZ:.B#2$![%F \PW8
MYW5'CFP9R.RI^T7]:?J/NR;OX?<W7+/<K/ .78?<[3N;M6RZGMW;S,4;GW8Q
MM2S1DA]QOXLSS,;AU ]A^@D,<GJG?X9/.(4O57A_(N#EYCT$>GLQ#;XR3_/B
M3U^7Y6%8%W;OQ A;I_U+UF-W"#MN@[:JZ+MG2*3ANNEMC=-9!;351)5/;']M
MM%$]M=]-L?VSKG&<?[?56)"8B0NSB3,0NWV<7;MG;_)V?M5_+%)#))#*!1RQ
M&<4L9MT021DXF!,_RQ"3.+L_V=G9?;W*^$\1/$3Q$\1/$3Q%$?F[&978_4UO
M[YPHVE%OHUE&E]=OR)J12BX^SABWX-_KG_Y.;%<V.KG7'TU_.HMMKCZ;?=M%
M>/?WK0Y-K/\ (V=9LVL_W;Z7$@"F3,_]/S$M$OCX[)_W[5T>J3_D_%O2'A+?
MIER.$GRS5C=O$QV/4+2GW0]T>F_B-QB'BP=OV7M@#._;>(RX]*E2ZI;@?_V@
M#H'_ /:[I3__ $7-_$5TGB)XB>(H$WQ\;?+%\ # U_"<020F3^TF<3J![-Q\
MHV+JK.UWJCA4FV+#WC4DH^<[OVKAAMA53;19'=!=%)72#;OIWQC=KRQR4_HK
M$L_U+WJ+C':]UW,C=WE&6,QD<S]P"C=G=_(7$A$F]&>G7XIO5_TZTJ-JMO\
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MSG,;>I'IT?2=:L^A"P36.D[B;Q,2E/WHC5@T$?KN)#JVP]46V#,&(11]G?\
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M6VT20;H(Z;JK+*[ZII)Z;;[[:ZZYS@BJ=LCY%N'.CN4[JR.,6=;=363:T\X
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6)XB>(GB)XB>(GB)XB>(GB)XB>(O_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g98473g01c14.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g98473g01c14.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_[1=.4&AO=&]S:&]P(#,N,  X0DE-! 0
M     $H< 5H  QLE1QP!6@ #&R5'' (   (  !P"4  (<G(U,#DQ-C<< @4
M(4UI8W)O<V]F="!7;W)D("T@1V5N97-I<R!&+3$N9&]C>#A"24T$)0
M$")*^(M6HN%I'>),'8-E9Y0X0DE-!#H      .4    0     0      "W!R
M:6YT3W5T<'5T    !0    !0<W138F]O; $     26YT965N=6T     26YT
M90    !#;')M    #W!R:6YT4VEX=&5E;D)I=&)O;VP     "W!R:6YT97).
M86UE5$585     $       ]P<FEN=%!R;V]F4V5T=7!/8FIC    # !0 '(
M;P!O &8 ( !3 &4 = !U '        IP<F]O9E-E='5P     0    !";'1N
M96YU;0    QB=6EL=&EN4')O;V8    )<')O;V9#35E+ #A"24T$.P     "
M+0   !     !       2<')I;G1/=71P=71/<'1I;VYS    %P    !#<'1N
M8F]O;       0VQB<F)O;VP      %)G<TUB;V]L      !#<FY#8F]O;
M    0VYT0V)O;VP      $QB;'-B;V]L      !.9W1V8F]O;       16UL
M1&)O;VP      $EN=')B;V]L      !"8VMG3V)J8P    $       !21T)#
M     P    !29" @9&]U8D!OX            $=R;B!D;W5B0&_@
M    0FP@(&1O=6) ;^            !"<F1456YT1B-2;'0
M  !";&0@56YT1B-2;'0               !2<VQT56YT1B-0>&Q <L
M      IV96-T;W)$871A8F]O; $     4&=0<V5N=6T     4&=0<P    !0
M9U!#     $QE9G15;G1&(U)L=                %1O<"!5;G1&(U)L=
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M____   X0DE-! T       0   !X.$))3009       $    'CA"24T#\P
M    "0           0 X0DE-)Q        H  0         !.$))30/T
M   2 #4    ! "T    &       !.$))30/W       <  #_____________
M________________ ^@  #A"24T$"       $     $   )    "0      X
M0DE-!!X       0     .$))300:      ,U    !@             #*@
M!RH          0                         !              <J   #
M*@                     !                         !     !
M    ;G5L;     (    &8F]U;F1S3V)J8P    $       !28W0Q    !
M  !4;W @;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG   #
M*@    !29VAT;&]N9P  !RH    &<VQI8V5S5FQ,<P    %/8FIC     0
M    !7-L:6-E    $@    =S;&EC94E$;&]N9P         '9W)O=7!)1&QO
M;F<         !F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U=&]'
M96YE<F%T960     5'EP965N=6T    *15-L:6-E5'EP90    !);6<@
M!F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
M     $QE9G1L;VYG          !"=&]M;&]N9P   RH     4F=H=&QO;F<
M  <J     W5R;%1%6%0    !        ;G5L;%1%6%0    !        37-G
M951%6%0    !       &86QT5&%G5$585     $       YC96QL5&5X=$ES
M2%1-3&)O;VP!    "&-E;&Q497AT5$585     $       EH;W)Z06QI9VYE
M;G5M    #T53;&EC94AO<GI!;&EG;@    =D969A=6QT    "79E<G1!;&EG
M;F5N=6T    /15-L:6-E5F5R=$%L:6=N    !V1E9F%U;'0    +8F=#;VQO
M<E1Y<&5E;G5M    $453;&EC94)'0V]L;W)4>7!E     $YO;F4    )=&]P
M3W5T<V5T;&]N9P         *;&5F=$]U='-E=&QO;F<         #&)O='1O
M;4]U='-E=&QO;F<         "W)I9VAT3W5T<V5T;&]N9P      .$))300H
M       ,     C_P        .$))3001       ! 0 X0DE-!!0       0
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M!0$! 0$! 0         !  (#! 4&!P@)"@L0  $$ 0,"! (%!P8(!0,,,P$
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MNM:'OV.+ZZJX+W$?SK_6_P# %KJ+&-8"&\$EVI)U<=SN?Y124X_[0^L#F/\
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M300A      !5     0$    / $$ 9 !O &( 90 @ %  : !O '0 ;P!S &@
M;P!P    $P!! &0 ;P!B &4 ( !0 &@ ;P!T &\ <P!H &\ <  @ $, 4P V
M     0 X0DE-!"(      49-30 J    "  ( 1(  P    $  0   1H !0
M  $   !N 1L !0    $   !V 2@  P    $  @   3$  @   !X   !^ 3(
M @   !0   "< 3L  @    D   "PAVD !     $   "\    Z  MQL   "<0
M "W&P   )Q!!9&]B92!0:&]T;W-H;W @0U,V("A7:6YD;W=S*0 R,#$Y.C W
M.C(Q(#(P.C P.C(T ')R-3 Y,38W       #H $  P    '__P  H ( !
M  $   <JH , !     $   ,J          8! P #     0 &   !&@ %
M 0   38!&P %     0   3X!*  #     0 "   " 0 $     0   48" @ $
M     0              2     $   !(     3A"24T#_0      "
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M     0   RH         !@$#  ,    !  8   $:  4    !   !-@$;  4
M   !   !/@$H  ,    !  (   (!  0    !   !1@("  0    !
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M05%8=YBXUB0G56%Q@9&A\"4F,D=26=@I-6F'L?_$ !0! 0
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M6L:/2AZ]?F9(1Y5:)E=,FP728# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
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MQ(\J$)\B#+S\FMOD-O8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
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MUM7@<4=]MG7*(6*8# 8# 8# 8# 8# 8&C?2EUL//%(6!;;L6ZD1"."D&</B
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M7C49FT:/'T(T1:B7H^0+!Q9-T12"/F9X&[9E>V_+%RV,BET5^TB#3I8-D8#
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MUF[2201.3QTL2AU=U''5FR"":,DMN9P@822018A5RK_\J/5#K>F/R$W)O?!
MO2_C&$OT^/N3BO*WI/T,DU[^S?>DCLC%1*B(!(.-;4X[YZB'H &AWKGI%T^U
MO[^0[8!\?7GC983*[B9S+U7/@KK@@.FGJ>7/KA_2BB7?WI%8K7A5)G3->OTN
M_P"Z17K>M(A^%U_=<Z^_?7>PVUZ;].T7XRI"87W?\U$U[5\!%[</7KC[>GA!
MS]OX0J,18*CO3L[)#3G\(<# C$E'+MRIQSKE)NFLND&B?C<]EE_>?G+OT6_K
M\W6P>16),Q4(CQZ,F8X]4@HE0?\ LX2VX.D%GLI4=(.E4R4H0!Q(0[-MR@T
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M#A(:-];^(?1-^^B)%8\6YIP96[6'U^ ' 2-G6.#.71R/G<%EDYBMW(M*RE+
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M/B30L\F]NR&9FV??459Q]$,';?L?ZQ]--M&;DECSQK0[CE,KJHJKDO'/I60
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M$?AUF^0*/B#6SVDF V'+2DJ0"5BQDY^502:5U^O2@P]VX%<B&C$>D%_& P&
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M5U;'=FW'%TB2]1)5X%2D[D#MS/.R1QUVI7J#-48EP%R55?X+ZW_S"A_^KP[
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M]+[CXMFE3* ,O:/\);=66@X;V[/," =PX;6J23?I)LPN$JK_  7UO_F%#_\
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MWUUUO>PV)K6M?7>M:UOK?UZWK7T^N_IKGZ[_ .??TUK7UW_R:UK^36L#]P&
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MTZH\%^(9964"D44C4@ED=*Q($N*DC>W;_$<&6W ]NCM[V'=60@[".5%4N]/
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MCLS*F3 NV*/ Z W2SM,,"4^13QBFT7(:O$*N.0(LA_))G')N_'/$7B,]65D
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M6)2C<5D(D_J.RD7,8KT2CAS8IVZ_2CC#E='IX*??@/6VE4]JH<:[Y^H6+X#
M8# 8# 8# 8# 8# 8# 8# 8# 8# U;<5<.+1AJ<?''TXN=$RV!SN,'W C]H&
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MG'7)/ITJTZ[8\,W23OH)8X# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
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M)+HZVC$AB UIN)VM-8N!5#!I5UV?T(>1D0%=,2)'?*I=-7]4Y323=\)\!*_
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MUZ%J6 P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P&
MP& P& P& P& P&!^;UK?\NM;^G\GUU]?I]=?3?\ \=;WK_V;^F!^;YYW_+SS
MO]WV_OUK_P##_P#I_P#9^[^3^3 ?9QO^7CG_ )O_ ,.OY/W_ +OY/_7O_P".
M_P#GP'V\_P#Z>?\ EU_)K^3>_KO7_OW^_?\ S[_EP'V\_7Z_;S]=_77U^FOK
M]-[^N]?^_?[]_P#/O^7 _/PT]<_;KCC[=?OUS]NOM^N_KK>_I]/I^_6]Z_\
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C QN2<P";RN+-BAQ@2<LAAMWPS[05_!52"9. P& P& P/_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>g98473g02s93.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g98473g02s93.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_[1C^4&AO=&]S:&]P(#,N,  X0DE-! 0
M     $L< 5H  QLE1QP!6@ #&R5'' (   (  !P"4  (<G(U,# W,# < @4
M(DUI8W)O<V]F="!7;W)D("T@5$I-,B!,051%4U1?1FEN86P .$))300E
M   0V:N'Y2'T3<WW. [ AX81:3A"24T$.@      Y0   !     !       +
M<')I;G1/=71P=70    %     %!S=%-B;V]L 0    !);G1E96YU;0    !)
M;G1E     $-L<FT    /<')I;G13:7AT965N0FET8F]O;      +<')I;G1E
M<DYA;65415A4     0      #W!R:6YT4')O;V93971U<$]B:F,    , %
M<@!O &\ 9@ @ %, 90!T '4 <       "G!R;V]F4V5T=7     !     $)L
M=&YE;G5M    #&)U:6QT:6Y0<F]O9@    EP<F]O9D--64L .$))300[
M  (M    $     $      !)P<FEN=$]U='!U=$]P=&EO;G,    7     $-P
M=&YB;V]L      !#;&)R8F]O;       4F=S36)O;VP      $-R;D-B;V]L
M      !#;G1#8F]O;       3&)L<V)O;VP      $YG='9B;V]L      !%
M;6Q$8F]O;       26YT<F)O;VP      $)C:V=/8FIC     0       %)'
M0D,    #     %)D("!D;W5B0&_@            1W)N(&1O=6) ;^
M      !";" @9&]U8D!OX            $)R9%15;G1&(U)L=
M     $)L9"!5;G1&(U)L=                %)S;'15;G1&(U!X;$!Q;ZX0
M        "G9E8W1O<D1A=&%B;V]L 0    !09U!S96YU;0    !09U!S
M %!G4$,     3&5F=%5N=$8C4FQT                5&]P(%5N=$8C4FQT
M                4V-L(%5N=$8C4')C0%D            08W)O<%=H96Y0
M<FEN=&EN9V)O;VP     #F-R;W!296-T0F]T=&]M;&]N9P         ,8W)O
M<%)E8W1,969T;&]N9P         -8W)O<%)E8W12:6=H=&QO;F<
M"V-R;W!296-T5&]P;&]N9P      .$))30/M       0 \     !  $#P
M  $  3A"24T$)@      #@             _@   .$))30/R       *  #_
M______\  #A"24T$#0      !    '@X0DE-!!D       0    >.$))30/S
M       )           ! #A"24TG$       "@ !          $X0DE- _4
M     $@ +V9F  $ ;&9F  8       $ +V9F  $ H9F:  8       $ ,@
M  $ 6@    8       $ -0    $ +0    8       $X0DE- _@      '
M /____________________________\#Z     #_____________________
M________ ^@     _____________________________P/H     /______
M______________________\#Z   .$))300(       0     0   D    )
M     #A"24T$'@      !      X0DE-!!H      S4    &
M  +^   &Q          !                          $
M!L0   +^                      $                         $
M  $       !N=6QL     @    9B;W5N9'-/8FIC     0       %)C=#$
M   $     %1O<"!L;VYG          !,969T;&]N9P          0G1O;6QO
M;F<   +^     %)G:'1L;VYG   &Q     9S;&EC97-6;$QS     4]B:F,
M   !       %<VQI8V4    2    !W-L:6-E241L;VYG          =G<F]U
M<$E$;&]N9P         &;W)I9VEN96YU;0    Q%4VQI8V5/<FEG:6X    -
M875T;T=E;F5R871E9     !4>7!E96YU;0    I%4VQI8V54>7!E     $EM
M9R     &8F]U;F1S3V)J8P    $       !28W0Q    !     !4;W @;&]N
M9P          3&5F=&QO;F<          $)T;VUL;VYG   "_@    !29VAT
M;&]N9P  !L0    #=7)L5$585     $       !N=6QL5$585     $
M  !-<V=E5$585     $       9A;'1486=415A4     0      #F-E;&Q4
M97AT27-(5$U,8F]O; $    (8V5L;%1E>'1415A4     0      "6AO<GI!
M;&EG;F5N=6T    /15-L:6-E2&]R>D%L:6=N    !V1E9F%U;'0    )=F5R
M=$%L:6=N96YU;0    ]%4VQI8V5697)T06QI9VX    '9&5F875L=     MB
M9T-O;&]R5'EP965N=6T    115-L:6-E0D=#;VQO<E1Y<&4     3F]N90
M  ET;W!/=71S971L;VYG          IL969T3W5T<V5T;&]N9P         ,
M8F]T=&]M3W5T<V5T;&]N9P         +<FEG:'1/=71S971L;VYG       X
M0DE-!"@       P    "/_         X0DE-!!$       $! #A"24T$%
M    !     0X0DE-! P     #FX    !    H    $<   '@  "%(   #E(
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M9[E#DY.)BXEE&-;=76<I\,9Z5KMQ$?G,N]CM[Z_YQ+[#AXW5L9KK0W)LKV,
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MYWT]]?K?HO\ M.OGI))+](]/=4S%=8UN1NO.XT6FU[:R'.WLKMKK?M]V[?\
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M $$ 9 !O &( 90 @ %  : !O '0 ;P!S &@ ;P!P    $P!! &0 ;P!B &4
M( !0 &@ ;P!T &\ <P!H &\ <  @ $, 4P V     0 X0DE-!"(      49-
M30 J    "  ( 1(  P    $  0   1H !0    $   !N 1L !0    $   !V
M 2@  P    $  @   3$  @   !X   !^ 3(  @   !0   "< 3L  @    D
M  "PAVD !     $   "\    Z  JD:@  "<0 "J1J   )Q!!9&]B92!0:&]T
M;W-H;W @0U,V("A7:6YD;W=S*0 R,#(P.C Q.C S(# Y.C4W.C0U ')R-3 P
M-S P       #H $  P    '__P  H ( !     $   ;$H , !     $   +^
M          8! P #     0 &   !&@ %     0   38!&P %     0   3X!
M*  #     0 "   " 0 $     0   48" @ $     0              2
M  $   !(     3A"24T#_0      "           _^$!2$U- "H    (  @!
M$@ #     0     !&@ %     0   &X!&P %     0   '8!*  #     0 "
M   !,0 "    '@   'X!,@ "    %    )P!.P "    "0   +"':0 $
M 0   +P   #H   #P     $   /      4%D;V)E(%!H;W1O<VAO<"!#4S8@
M*%=I;F1O=W,I #(P,C Z,#$Z,#,@,#DZ-3<Z-#4 <G(U,# W,#        .@
M 0 #     ?__  "@ @ $     0  !L2@ P $     0   OX         !@$#
M  ,    !  8   $:  4    !   !-@$;  4    !   !/@$H  ,    !  (
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M 0$! 0$! 0$!_\  $0@!" )4 P$1  (1 0,1 ?_$ !X  0 " P # 0$
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MM2L'^5/O?J^7'A$_/EM2O6_0*(4X.\52:B2\(+'@".OUN&><%!B7,/108ZW
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M0^!1NP#)H0(6;C?>C@!F'B4#K=QDD G,Q!.-\ G^E37P? NZ7VI=7ON$VO\
MO)<M]5^T_EJO?^[\:? NZ7VI=7ON$VO^\EQ]5^T_EIW_ +OQI\"[I?:EU>^X
M3:_[R7'U7[3^6G?^[\:? NZ7VI=7ON$VO^\EQ]5^T_EIW_N_&GP+NE]J75[[
MA-K_ +R7'U7[3^6G?^[\:? NZ7VI=7ON$VO^\EQ]5^T_EIW_ +OQI\"[I?:E
MU>^X3:_[R7'U7[3^6G?^[\:? NZ7VI=7ON$VO^\EQ]5^T_EIW_N_&GP+NE]J
M75[[A-K_ +R7'U7[3^6G?^[\:CYC0^_1IV0M SW1T>RRR9I,I86.J-T:G))-
MD\?I$D^6;[ )/,3/>.<S6"2'<2GCGW[U_'/+:D8&IZ!L)&(,B.D'/G4:59]7
M/GOUK1"NF]S-A@:X90_9S%5V+K)]+C( GI+*OPL=396:!LLI4@(IW>"P0ZS)
M6.+C; ? CL-Q1DW' RI CAPC#[;6G]9[^(?G2%3/=^/O\_&MB@.LVWZI9VKM
M5XSH16[FQ+6^>9MT#T_L\/9VIS86(W%_F6YZ.WR-*HE;RF'B$W"027@NRXBH
MW$R\;[B+Z0J0<$NQM$@B)D#/0TA7W>O,&>OG[*^.Q]5=G7&P3=LMU;]GS:K5
M9@8^,L=FLG32P3EAL$;$J<7%1\W-2F]BI*6!C%.NJCQ#R2& \N+R.VWE:LY:
MD?K/>\4@]$>XUJ.Z>E>U]\4V[4JZG=,6PMCR]-F[Q*1G5&?<E[891;G!7N!:
MM*Y[=4[&VL#$_78]PV.M$;,A&#>NPXQXN^=,I<;20275!(( )$"01C.(F1',
M4A6?5$\Q(-8+6/0*W:JK<'6H:)Z,3;59-*-KLG:>HLY*2E=2]=2=AAQE7R/N
ML"-J%?@KF2NQUNMU*-@X&!FL?&8V.'F'2#WI+J"9EQ. (20!CP),S$GJ:C0?
M#<GGSY?.?&I0$ZN;6CX^F1 $'T !BM< VV,U[&"=.K(/'42,OPSP5[CJ8"UO
MA M7!NP9)(EN$@V@6+(,0\Q,MF-.N(54*0).IZ3$D* F-IZP8BITJYZ3Y^.^
MP'SXYK#A]/+Q'NQY %(]G4"1$&TN2BGP^D\L*]&26MQI$/7<C'N,;P;4$=0A
M)B7%I90V6GZL-*R3$&L%HXE#LZT_K/9^]RZ;[4A7W?;),]=O.//G7IC^F5OB
M$Q:(J@>SBC$P6:HJ$3'=(9(),,JB2,A,4=45@;=S>(]5-EY>6E*KD3T<UZ1E
M)$V)]T)-(<<C6C]9[WC\Z0K[NY//G\CW5LM9ZR[>I1=0D*=$]!JH?KZ-G(:@
MFUKI]9X(NCQ%FDBIBR150(B]\B/5J-L,N<;*3@4,L(:6D2R33VR"7W7%-2#,
MJ>SOD9VWZ[#W"FE7W?#P\-MOPY5GG]']A2K8B^%'=)"KRV:/)-7,CJM>'[6U
M("1N(40YNQ.]@E3"#!89*8@<E)F'F(M*8]I:!,89Q&IN(EV.DIC.^-LD32%?
M=^.\G.WC6E&]1K_)13D%(TWV=Q\(]*VJ<=AS>E<T5%.S=ZCR(F[S#D>_O-P1
M<I<HHLN,M4@IG)=ACBB I=XL9YQM4ZT_KO;1ZPV.XWVR<>-1I5]WYY[;B)!W
MK("=7-J@/B%!070 0J/O)>SP"1NG-C'?"V4>"/%F[#$=9WNA8UY,C1!(XJVL
MY1/D BCB/2"V&6FTM:/UGL_>'Y^)]]-*ON^63^.?C4P_ NZ7VI=7ON$VO^\E
MROU7[3^6K=[[OQI\"[I?:EU>^X3:_P"\EQ]5^T_EIW_N_&GP+NE]J75[[A-K
M_O)<?5?M/Y:=_P"[\:? NZ7VI=7ON$VO^\EQ]5^T_EIW_N_&GP+NE]J75[[A
M-K_O)<?5?M/Y:=_[OQI\"[I?:EU>^X3:_P"\EQ]5^T_EIW_N_&GP+NE]J75[
M[A-K_O)<?5?M/Y:=_P"[\:? NZ7VI=7ON$VO^\EQ]5^T_EIW_N_&GP+NE]J7
M5[[A-K_O)<?5?M/Y:=_[OQK=-%7"^6R MHVR7JB9;*7L6TT@Z3H\+,UVNRK$
M-[B0$<)"3UCMDG'O+%D6F"VGI\]#A+#C[.66G4L-U4 #W9@@$3OGK25?JS[?
MGSJEKFS.H5CLVOI/5_9NH[/VY<K?4:^X0!W*F!=C89M)P\<N3K6J8FSRU;/-
MA3SAYJ1U.5KV$IB8P:;:D8D)(CD<3H"942 (&$Z 1 .QQ@?>WF*J08 $F3.J
M8S!_H.OPKH7? [&=2YB,K47#V":D11HM4=/6R>H4<9'2!8P-A<^EE6@K)/P)
M[,"_)EQ!43$/$YEV01TE1:'5R@60,$&8C.!,$9&#OGK5SL>>/GPKE=4O9HW*
MGUAZDB[,%FH&[4+K3K&XFV27L$O.Z_U]U=[6;9["Z_J=!/+CGS+O[O0MP2&C
MF;);#ZO+M"TBI7^3;G9$F2K;6Y=0220KUI VGN:>\0K&8.RI$@[F:0J (&/'
M._+I[^>/"P'4SIS8>OUCHDC8K+$2\?IGJW3NI6NLPK\DZ78J;3KE+SR+U=69
M"."9 M4O#B4D-V(CGYL,"4%M)J)PUB9%'!HXI*AW9DJU&=DX @9,SUP8@>5@
M"#MY[9._2?"#R^.J;JT)1M9;BZ+V*NSNZ9(]WMLY&+'V#V1[$;:@\#D]7>S;
M[CK=8VKM*YUIB02L1M(\LQ$MRHC+A(XIK(YA;;] <*V&.@Z@\AUJU7#9[(Z'
M(L*:FSM:F.691(XF(%,NSF4]X*.7&#(R'X>LE)$@VX&RXI.&G"6W&DKRM"L8
MQ[5O7V>M/:;:)$Y\*V^COZ.T[)>C];2=/7?RSY9J;>:5C3BE.*4XI3BE.*4X
MI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE
M.*5 $M_*FU_^H#;_ />+H_EOL?ZOZ4J?^5I7,O;^U>GK<K:IE?8RC6[>%6M\
MS"?029[F6+4UFB9B!M94).42L4JGVX-<)9HWW,R K\*)1,EW>6#BQ+#(G?&B
M;'G5),I!  C$("I,<YWG[6=JH08,9,^.!OCRZC/2N@TRQ:XVE&"U=$=;;@%!
MX'B,7*=)JD?8)=@9+33EAL57K$Z3!)/=3ETV2@ZD?D1UQ3P4,I*4#XSD%4["
M9@9@=!/]:M]GKC;K7*<WV;5\&K>SHBO[&#<9VSK[NSIM,!<+5<[H%J'7G<N4
MUG/R)51ML['%VF^R=,ME!G+=B*M>('$X7L.3A6;- QE>C73NCM4$][60-!!@
M J*)P0%8"@8&5:>6( II4-@.O6/+RYGG ]LZZ%Z4S6F]C:].798P_7NFK1W.
MMU%<P9)$W2R2/<?;X.X9,2VL/1@L9&!:Z.DKE6HY8,M..6@%VLRSS5;>C"8P
MG-2D%.-6HA(SLD)F<SF<<A&3.2#;(P  .H'L$#\?*3%:IWCT-1Z]KN"V0#.;
MF(L+G</HS**CIOL=V&LU"P58.]_7I@YM&JK'M&5U>U',(DB%0L.U3T1%:>;
M(KH,4_%1;H9HC7F(T.\A_P"6O^ONHJ0G&^/Q'R/C7$?VB?M(NZ75[NA)U*O6
MKM#&:049<F 0).@:CKB+&<,YDM3.J;!,:.G8^PTZK-)C\?%7BK9-/1);^)"0
MCY-I[WS\[](/2#B/"^+LM-)?%I .E;+80^H@%26G2RJ4HD"=1.8)2<C[S@O
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M>*XYVV[JJA2'T(&<&BX",@<GZ =R8R4K*B<DY\P1,$'V^-9XR.4X\#G!!\?
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M-J)S:'Q"NQMA189D.WPU>*V1"D]]048)A6" G5D+@S'0GG $Q&1Z@&-L01.
M,=)YP=N1KI-/M[(N>HG$U"1B]7[.LU0CG CK97C+<!2)Z4"$=D$2-?B;-5"I
M0N&R\8,.V/9@&FY)D<EQTH9EP4G'"5[:@%;3,@'K&9\L^%:;CS]GS\[U%M/Z
M_P Y'Q'7N(MUEII &B)RRVAJ!H%'FZE69Z==KUDIE!<R%9M@;!F&A*I6K?.R
M4UF;GK))VK8C<+>6Y."?B\1C]BY)68RL $SMD%40 !, >"<<S4!,>.<?T'LD
MUIW6OIM#=>)ZM2S5L<LXVM-#5GK'J4/X+F(>K.FZE:)6Q10$^7F6DTV:T/#+
MJD+(SK(T((^Q313AX<,F8DTY+6%;)TR9.9DP!C @3)S)SO4@'F9]D=?'Y]T1
M'NKK=UVU+N+HO9]5Z$TMK.RO]MW(EZPZ^U;1J9./11?5WLX05&.RU<@HT]R/
M)("#?("61D9YX49QQI2V&LIA))"@28*3SZ$'\0*FIWK_ ,^^.V<X_1'Z]8S_
M $?]LG9W_P _S?S_ #_FYP)'_?W3B/H; W[W^=<_9Z>,[XKL4?\ W<U /_C;
MB3$#_)M1@[$B#(Y8ZU;GG97'OD4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4X
MI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE0!+?RIM?_J V_P#W
MBZ/Y;['^K^E*G_E:5RC[G[BL77_9L2'K4BHTZ2O5;!+C41YL7%STU>9RR3<$
M989"OR5^@:;8E>^JI5?2/:=?6ZQV/Z32!]0F(I='L#S'0W"AI49Y *VSI@)7
M!*>9C ZG-9J\CXD9Y$[8F0=_9Y]':#99JT4&+LIT!*1<G("2) ,18P#*S,F
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M;#;=Z_9OM#2IMN\N.)V2T@0GZKB"$J3W8PUV)U=XJ4<U,6P[-M"B:_'DJI1
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ME"%E*&5J)[!UU;9?&E33:D+2JN@P,B!)BCFQQHAX1;:7A# B6"Q2F5?Z+HQ
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MM^N->[!%0%?:)3;N&VK*FQ+=6(2R#-J4GRJ4VQ,@FM(5E/Y.<I3C.<?+QY!
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M=8J14Q<BW!#Q*2\W 098)=3*EU3=:;!A:_.3R)<RO0<O%ZCU"F,:5&2$C?(
M.YY>\@8@UF?UO&/+D<'D<](QMFNE]R59D5B853I"M1-DP+CX;+7 (^2K,2KU
M6\$RDQ%Q<G"'RHL<%DDW$4/.P.9-UAH!<]"M$.2@F28U#5J(Z)C5MB)\8]E7
M,QC!\?GE[:H91.U.\3YWHK!7RFT")=[-SN_8*[$1+-E1AR-U=3+[;M>7_7PL
MC)Y(@Z]M.!JM?NC-?MF)V;K\);6( PQZ6CWY-RRTI25@3*2!DCV@B-P9Z1M%
M0#.9QTQOYGY/PK+=3.XMB[ V*C1UDK41# ;EZOU#MIK9,,-),F5ZBW"XRD -
M3;P](2)[)]J!ARJ;).2L8Q"AER!UFC4P@S4$,;)RM*4C!5(,&1@X!D8$1,09
MG!!BDF9Y=!DSM^.?(9C-:CNO?5%V=N'HO7*] [HCCF^VSDFX_L#K?V(U-!9%
M&ZN]FV'&D6?:>KJ;6GSUN%L^A$LRSDH6S@E\8-X<0MUBJ1 4<>J>8.Y _K4^
M'D1N-C._LV_I5#>V-JZ55?N906JA=].ZWM1T!UW@6;+KJ)UD9)P5H9[D5DA!
M+#1M<L=9C)R(B!K;(SD@7%^^!1(*$V%>8A0H[WS/$'[!CB+(6\W;O+3:(4I"
M4%PJ^GL%AM04D@:CJA4$H2"K  KZ6Q:O7N&O*[)QYH*O%)*E.:8^@.AP84#!
M)1$>LH0),UV+ZPXO\Q0PKI?-LV_89DZY8 DQD]!:RAHN(S!VZ=AV2H[Z"T"H
MR#A!(4>.@K$F?(C97A;@XXZE_+VK4.]DA;KRW5K0E1"DM!*51D([-M!B3]HJ
MP!!WGQ;LM=LI++";="%$!*5NK)Q]HNN+\Q$1L9JS'.FN6G%*<4IQ2G%*<4IQ
M2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*
M@"6_E3:__4!M_P#O%T?RWV/]7]*5/_*TKE?VCN$C+;B'H<?L2NP$Y$Q=&S9Z
M:BH=A"'MG REXM9U.JI[E$/CH(ROC!MMH-;9DS$622D;+7[((742#*I([MX$
M1ZV9.G&(.=\GW0,$R*H>9'+'/?K[!^),\SU/Q]6/GX_+'S_G_IYA5Q7S%&AA
M89R86*)@DE@,?)3[0^""R7,-#"LY=6C#I)#JDML,(\SKKBL(;2I6<8XI7J9E
M(P@\R*'D0'Y2.;&=D(UDP=T\!HQ*EB.&!H<40*V4E"U#+?;0E]*%9:RK"<YP
M@[QCK2J<>T QC\7ZO9SCQSCMC[/_ ,O]&<]].M:?'_Q_Y<T;];>.ZN?+0H_T
M_K3N[J2%0%  _K*24I/^E1"O,"J*][?9@-;SE[#MPC;&L:"F(>L<X*M[3T0)
M,DO2KHQ$3$S6P)C:4!'R2VI9ORQSUBQ&PF)25?P^..&<4TOQ>*<&:XLMI:G
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MXI3BE.*4XI3BE.*5 $M_*FU_^H#;_P#>+H_EOL?ZOZ4J?^5I7+ON) PL_N^
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MUI]5:D^2B/P-1M^*UHH7Q^C5*?UUE7^EG4%NN^F,KQG/BI+F=462F^HVO/\
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ME.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE0!+?RIM?_J
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M_P N*@['R/X5!G77_5U*?KD['_XB=I<WN?\ -_\ Z3'_ -!NO#]'?_ASO_\
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M%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4J );^5-K_P#4!M_^\71_+?8_U?TI4_\
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M7O<X+86'$75L75Y>VKP9NWD?1[%FZ:4S:6CMTYK6Y?VJTK4EE:$I#:TR4DK
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M2\^@E&JT<3M>O2,--SA\9<ZH)7&!WII%RH=PK3HOO&7,8]T=/A4@3[;/I_\
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M7&TY0VLX 4M;:,Y\V4(40TXI*<J^>4ISC&<_/P\>:(>=:D-.N-A7K:%J1JC
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MV;NQMFBT7;<Z(<+I2M!+8[P3DT5Q"FRC*B)TF05*(]52LQ!,P!D3,39?P_\
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M0%*2"?LE0!VG8[XZ3'.,5TJ]&/2,,N7*>"<3?M&DI4[>VEHY>6384-0[2[M
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MRK*[4E*&YYW%L8W( ?05*C<)2D$J.P SO6EHDE3JH[HMKD$X'>+*PE.=RHF
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MC'S\N?%/C\O_ &<_/'\V?JY,GJ<3&=IW]_.FE)Y#W>,_ Y'0U\IL='R(ZQ)
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MQ2G%*<4IQ2G%*<4IQ2H EOY4VO\ ]0&W_P"\71_+?8_U?TI4_P#*TKE1*:T
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M_0TC"4I0A./+C"<82GZLXQC'U>'YO#^;\W/CSN9,F<G>?&><U^TIB ! Q@
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M3BE.*5 79EMK.GYQ:TISGZ1:S1G.?_<SM&F9SC^;Y^'S_H^7U<]ST=@\69!
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MI6K7EC-KS>W[-*UXAK64+U)AJU-"/@-Q\Q&%&;2D6[^HG$O8-F/NS9\J/H"
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M%Y2#@@:DK1/)2=OWE)U('B2J!UWIV2C&DH5/18!_A5"I\(_I4[@RL;) QLD
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M5'L[Z#1HJ$KO4G=URBRDJF$6RV>S8[)6Z=L>9=7OZ)0N=(ZW>F4PZT\TF.9
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M[UNE2B -2@R\@%4 "2)@#I71=7-Q>J2N]N'KM:!I2NZ=<N%)2<D)4ZI9 )Y
M@5ZF+]T5&:RR-TLVBPSGS^+3/LN>QK;6?4QG#G\&CK=A/Y>,YPOY?E8S^5X\
MASB?%7;E-X[Q*]<O$ !%TY?O+N4!((2$OJ>+J0 2  H0"0,&B;FX1;JM$7#R
M;56K5;)=<3;JUQKU,A0;.J!JE/>@3,56*IT[V:>DMV0N[XWK[VAKEI,MY3U
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MRWEL^5_"FF\(7C&58S(,3XB*5(O(I3BE.*4XI3BE.*4XI4=G:YCSMLUG;:Y
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M5X+:AV-K[BO1$QE:5/RL#("0SCS2(T-]N=9SW4Y_>Q,3'>Y@#>?"*B#C.?\
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M[;K?"Q52F+?:Y4M/J%'"52*DF5ENE21MFF;S/2TLL(F)"7*44L*"C]I2I,Q
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M$VABP%GV7<?9^=T)*LQ35*:+%S(U=6L6M8F89P3EA^D"UU*&AP/=+@$JG4D
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M,*S0;#6%0H85><B!&<G=P#ZP2 O]Z3N9,F(!/.I3/*-.?^.G+SVS!K/]//\
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MRESB9.JQS!4\"4 T[->3I,#?'@#^!%-0SX?'R_/:JV#[/ZU7_M[?ZOL#2--
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MP_Z'G]++S/J>7U$>:I4E/K$)\R!^-6"5*PE)4? $_A6J?AWT?]LNJ?O#J/\
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MC!W@X\MLG?/7^M2!!=JYBT[$WMJ:M:2M,U?=,!Z_D6P@KOK0N"GA]CD7 :)
MFK%'V<X:@V>&:I,C-V>J6 =R: K$U3I>+'FWK,)'-BT  2L!)G.E4$@?9Q)D
MXF(YTU&8CS'3Y]D'>M0JW>Z!M7XJ1@VI+]&1?:N9DZM!-S,SKT6U5&RPT1=9
M::3)TQBVES%DJ==Q0Y5JP7JGYF:XT+,5*<A")^!FWI*,%J-7>DIR1I5@0""2
M1 D3 D[;QFIU'I@QS',Q C.-Y/EY3SJ?L!5]P7_?%#K<7,C.:$NE<I$S-R"!
M6XRS2%BHL!>4R%;2T^Z4[$!CSR(KWTUD3W\T,HJ/:)B7 )$RJD%&F3DB8Z3F
M#XP<CD<4!GRY=<8..GSX"*HWN=6)I&8R/H]F"O,MV@O/4ZDTBPR%= +M>Q->
MT^Q;#L4MF6A)*RQD35!Z!3;=<$F..&RN(F%]W=AFIHMN);D(!5&L0$ZBJ#'C
M',YQRYT), QSVYP1CX_T%;BSV;ZZ6_1VO=HW:VU6LZUWS6E8@(;:!,+&$6%J
M3J<M/V"D'0)A9@TO-QE>B;(BS5X!<NA+$-,XQDP)A;RP0O40D24&9$$;X,[>
M/]C0D:>][O;\Y_":T?6&XNA.KJC+':>OG7VHTUI^!=EB:!*5<6,>3,TH_8%?
M-6N$5GWZ)SKR-G+@)(L^\1$;3X&RS62!(>O3CX$E#Q.E042)P?$Y^)^-1*1D
M>'X''PY^%:-O?:'6:?W1H"(V+J+7FWH.X"V]JL[M+8K%NBJ2S':LM&ZI*-"6
MB.ECIB/L56I<!*X A2W@I%F;KTF0.]C$9@R4I6$#2I045=U !SL-4X'4<SC,
M8J#I,$[1OT\#_P <\3O%MJQN_3EJMS^N*QL2H25WCPY$E=-%EQ&Y](D 2)'6
M'(L.ZMHLKZ*2!T?$VQD)EYRI2QP,38FXR1+'%<S*%) )20#L3S^?CRJP4"8%
M2QRM6IQ2G%*<4IQ2G%*<4IQ2O!QM#J%MN(2XVXE2%H7C"DK0K'@I*DY^2DJQ
MG.,XS\LXSG&?EQ0B=ZUFHTBG4&+5!T>L051A,EDGIA:W&"0T0R69E"BWQ8P!
MI@$113B/7)P*PRE\E;Q3J5$/ONN64I2C*B2=L^']S[Z@ #85 W3S_4L7^O3M
M?_BIW/R#O[!^ J:M%R*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4
MXI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE0+VIAY:P]8>QU?@(N1G)Z=T
M/MZ&A(6(")DI:8EY37UA!C8N+C@FGS#Y&0-?8$""$9>)*)>:88:<=<0C,C!!
M\:5H<3VVU6S"Q8A-/[1)=9C 6'VL]'^Z2O*XT*TAQ&<IT I.?!:<ISG&5)SX
M?+.<< $9! (R"%#'QJ")!$ ^!R#[*Q..PO7/&/EJ/?6/GG.?#V?W;WYYS]><
M_P#HY_\ SCFG:O'=U?\ \T_[JXCPVP/K65H=\_1F<D[G+?@/ZSN<1;=[Z*M-
M-F**S5.U57@+#Y&)U%3Z/=RX(N1BWGQ_C45@L7KOAT!NP1C+T)(24;D2;%CR
MWG8:3BY-H.0%T:N'6W4O%16XVF&E*<DMJ&4*29/J*[P&!JSUJ'N'6KMHY9);
M0Q;/X?;8;0V'6U8=;5H"8[5'<6H=[2<$8C 4?:'6O7F)^+J>N^S411YQ,6XW
MK5CHKW$508.3C_>$ERU;KZ^N>6H-Z=1D!R:CP7&X4F2C&YYF,'GY.?E)>7+E
MYS2I2OKDZOKPN'%)(3"5$*R$D$@G/>/*LK;A-I:(<889;;LW @_00V@VC;B)
MEQIHITM=H-(6A*=!*0O3J*B=V_&%ZY^'A^"/?6,>'AY<>S_[>^'AX>'AC_T=
M/'P_Y?\ =S+M7M^U7/\ ZI_W5M^C.'DR;&TG'_\ #,\L#_\ =SM6R,=M]0C,
MM##4WLZ...TAE@=GHUW1:99::3A#333:.OZ4-MMH3A"&T)2E*<82G&,8QC%#
MJ425&23))4"23N229)KL2E*0$I2E*4C2E*0 $@0  !   &P$;=*I4$J@1U#[
M0T@"[=LHO':#<5EVI8)F,]G1VX][K\==H*HU"X44(6;T?.AFQ<Q4*FF)8F<H
M!G8LJ6/E0BDDM1Z [2)22D$ 1&L"8V,\OPH03N1Y1Y<]XW\8YUIUETOTRML9
M+T>?K7<"1U%8I4*U6+7+W23N=A$S= >JY/3=N;*L2.OR3TA.Z65$X>B6AT+^
MFU;@[0/)#MMGQ,A;7CU43UE.VH*B)SG$DR!MG-"">?G$^S\X^)Q67LU7TK=:
M7N:D7"6[366.['5GZ$;S*F?9R]L)$FT58#5T'JJL)K+16A' *?/UF+BY.RAR
MZQ)\%ZYVF>EW() *(*(A)#@"@0A.)@!8 DDDS!E0F,'E*?$1I/7,X_MU^><U
M(#5\%C=@3EP@-A]DHV+S4VZ718,[V97<6Q25'K0,,*%&P";1.:M,)F8=Z<%9
MMMI5\.BK)<9@6)'F+-F'@(*-CHURG24I.9]8 ZIDF1G(D020 21!S33&=SB<
MD B-MO[[':H9L>C.G%C@!([X;WBJLOGLI%=G9J1UUU<]HIK>$E+>-MJJ[8EX
M1BF4?6,!7@H:2D*C' QIY(\I9JT81(6^*G,721DIX^%+43. (B"H'D<F<$R2
M=JD"!^!Z3TWV]OGTL;OR[:5[$,0U9O,=V:=UQ&V'75R=JR?9\]PGYUJY:OV-
M![(K5AKEV>T/F0K!#\A7P(>74+'E'9B/7S R5>E'UR?(0K1. 3F#K@;1D B>
MHR(,'.Q$3!'X;^W/CR-0WV0@=1=A=BR&PG9WM54WR]5T368\6U[/3N7-L#_0
M/L/1>PX,ZX0]IJ-<(6=,T*/K949A#+>(LPLMLS!:6<-@8'78^L-X@C?;F.=,
MSR/CX<N7OY>55"/UWBC[O,DJ!4NQ-KJUHV!/[EQ;[%T)[?N0,9?IWM]N[N-%
MQFPZT+4:3892(U/L[;;LIJ:0 A-FJ&);]=V)JDBF8E;3JE:- !B9(([I.D)2
M!!.TQR(SG&]5A7ARC,"<"8^&?9TJ?MIZ\UC,;AE>PVNISM;$7D#K50>M<'2#
M^A/<I=0M6N==-;Q+>H]Y>(T0;&2$7L>4W88Y.RA-3/763:C2IF#CG%QDV#9*
MAPY"@(6O6KO")D$&!^KF!_:I*3 SL('N'//2=OCFMWZ$[+ T=4K?'; UOV6A
M\S2->CAKDNC7<M[8$B71*2#K?#]FEXRK[>AY*OATRIT*(IB1IZ.D6&HV;(FH
M84R02MV'2E>DI@>MCNI !/=VB3&Y.=ARJ4@@F?#.X\?C)]M7Z_&^U/\ [)=H
MOZCW=3_(#F4'P]X_.K5B9/M!HN;]',SKCL9+^[>I[MF3Z&]R#_0]7R>KZ/O?
M7IWTO4]-'J>GY?/Y$>;Q\N/"JD)5A24*'WM)_&I2I222E2DD_JJ(_ UBOQ@^
MM_V/[W__ *?G;S]W3D=BW^HW[D5?M73NXY_&K\ZJYL"/T)=[#L>=CYONI14;
M+BJY#2<=4O9[;PQB""J8;[<#]$IF?Z83MFKY,7,&R=KCS0YM)8%HDRY4)X=6
M!FQ^5RR*G%.M/&V4M"4$M-VA/=F#J=9<5.20)T@Y"1F>EN]4EM#;K*+A+:U+
M2'7;D E<2%);=0DCN@>K,8)(Q5J'NQV@35)(E]9]A9F0RRPV3)R703M\2<:M
MEE#.'B7E=<\>+BDHQXI0E#:,>"&D(;2E&.LMI405)0HC8G22/*:Y$N+2(2I:
M!T"B!\#7M"[(]?8PIHV-U9V!CS6?-Z)8707N$(4UYT*;7Z1#'7=MUOSMK6VK
MRKQYD+4G/BE6<9!M*3(2@'J- /O%%+6K"EJ4.BE$_B:B+L/M+66]JS1ZZ-GL
M_3L4O<^G-RI+5[/[NE8?B4AI?8<#LN!@W!U:7AO=@)6?K<8-+$MO.$_"LECA
MX&*?;,'T3@R0#@CU@-Q!^%4,\C'C\_/CR,1;4A-!;HV/=-E;"/[BRTI(U^D0
M&L@F.A7;4 74K>O]GZMWI72XY8W7-#EM?!W;I^H;!&7:,%D,K^)U]13\&\$-
M'V2H) A"2023*P9!!!$8 P=_ >,Q"I.<'Q./'>?8#X;9K3"]3]6I$N]R![/;
M\@S=A!BNPF?Q$^X^!]K1I&['=XA06&'-!.JJT5"RLA8J)%I#=D"TZVLTI$&%
M&61B(ML9?M.B$0(TY3B$E.>N\G:3DR<U70>N?SW_ +\_"MXFR:%(V78VT(NS
M]F:]O#9&NZMJ&5V;$^S=[C1^5:XJ]UL-O;!D82'U#$$REID![(?6G+<BP1Q4
M%&?]+I8-6E2##7X[2 D!([I)$K"L\L$Q R8(,J)Y8JVDG<[[CPB,$0>G3VU]
M9Q&J+D#IV#VF1V'MM<TE;]?;$H\97/9H]M=?OUZY:TF)Z0K'T5D8?2)I54J3
M$8? 5HFN1V73S8"MJBC+&_&V2R R,:X"H2 5""=>),2J)B3DX@"3&( :3.__
M ".8G?;YQ-9KKOCK+UHO.ZKG0@^]4DUN60H)3T!>.MOM'MA@U8/7]!@J%&1T
M.1L'65K+>]42$01\0)7\1%#<%KHQ"8"'B01:*)5O$Y),IR29^>M3'_&-OG^E
M:;"QVH(HXJQNRG: FZQ7:V\=MM<V-'L\.Z##-*NVQ*)9]76JOEQ3NH2T62NG
MZ\NUMKF,Y,AY%KXRJ007@H47+=@H#[((*=)!4D\YD=#/NY140KK[8\\?A\:R
M$B#H8;7O5#6=+5VQKU=ZH72+ND ]+=">YEDE+D:!JW8VJR\6,EO1D&RR7,@;
M/LEBDCX\5O"[&D0A@-@%#X#\%4J4HA/>Y I 'E'D!@9$[4@QOY?EY'WCQJ@%
MLZ^U?6E/TW7=:Q_;+:H-!U?H?19;S?0SMI6[8!2]#]?=P==(B69;-J.MQ9!5
M^I.YK&-L7X??8-X/(@CD#79?!JAXK5*T]XD)!.TZ5"2M*B8,C !Q'QBJJ2>1
MP3F,<MICY,>9M9LFB:VW)1^O85@L':+6MZTC/S6Q!)S6'0#NX(+';+=U_P#0
M77\K5&2M0-IC(75 PT$N&KLBB9AK2-6HZ'M0DA"&SD?+1VL*44@:=.D J&TR
M9S]HDD@1N1M4Z<08WD_ATZ 9ZYY"L+U<M!>L^QMZV'<-7;["BB[%OHEJ?_$6
M[C."FQ.[MBA['GW]8XAZ5)O5YV[6JM4ZT['BK#J^IY=EXY?A,W"6:>M,J6I*
MD  CNA$#NC(!!D[F)C?<SMFH2"")\<_/Y<]^5=0/QOM3_P"R7:+^H]W4_P @
M.80?#WC\ZTI^-]J?_9+M%_4>[J?Y <0?#WC\Z4_&^U/_ +)=HOZCW=3_ " X
M@^'O'YTI^-]J?_9+M%_4>[J?Y <0?#WC\Z4_&^U/_LEVB_J/=U/\@.(/A[Q^
M=*?C?:G_ -DNT7]1[NI_D!Q!\/>/SI3\;[4_^R7:+^H]W4_R X@^'O'YTI^-
M]J?_ &2[1?U'NZG^0'$'P]X_.E/QOM3_ .R7:+^H]W4_R X@^'O'YTI^-]J?
M_9+M%_4>[J?Y <0?#WC\Z5Y=.V)!K1@A,E!V:N.S6U.Q5I"B;A5[%2K(W!W#
ML3M2UULR3JMMBX6RP;DK79F+EF 9N)CY! AS"WQ6LK\O!W]P]PB@,U:#D4IQ
?2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4K_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>g98473g05c03.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g98473g05c03.jpg
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M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!_\
M$0@!%@)@ P$1  (1 0,1 ?_$ !X  0  !P$! 0             #! 8'" D*
M!0(!_\0 8!    8"  ,#! H($08. P$  0(#! 4&  <($1(3%!4)(565%B(Q
M-CAWE-/4UA<9-4%4=+.U&",R45=8<7-UDI:QM+:WP]$T0E9XE[(D,S=#4F%B
M9':3Q-+7XB5&@8?_Q  = 0$  04! 0$              00%!@<( @,)_\0
M6Q$  0(# @0+$0P(!04! 0    $" P01!2$&$C'P!Q,V05%A<76!H;$4%R(T
M4E-5<G.1DI2SM,'1TA46,C-4@Y.5LL/3U"-#1%9TM<+A0G:BU?$D-6.%XF*"
M_]H # ,!  (1 Q$ /P#OV,(E*8P%,<0*(@0O3U'$ Y@4O68A.HP^8.HY2\Q]
ML8H<Q #3K#U[B#BZ$2LSDCQ)7:M0FM;NPK]YAB\0M&VI:>)9]0M?-:6>Q5^R
M;.O-L8T^&E(W8'=K"^LJ&@?9-8X]6<;.3U]M?)<>MNZN6EU*7W+LKQ^C;&XD
M)N(@8EU((1[Z1(G#MY\R3E9HAWIT9HS>N(TH-'':D!XL=1%!<6P"B  *I3>;
M!Y*IP!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P
M!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# &
M , 8 P!@# & , 8 P!@# *;MOW"7_'(?\\Q^ 5)@# & , 8 P!@# & , 8 P
M!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# &
M , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@$G(OD(N/
M?2;DCM1M',W3YPFP8/91\=!H@=PJ1E&1K=W(R+LR:9BMV$>U<O7:PD;M6ZRZ
MB:9@-5<;QG;@L<?LX79JSJJ1IC?=-^8CL#6MUA2Q\'0-.:'VG3=0V5K:9*L@
M]N2Z.W)]6_3U>>*=K$Z\GUJE&MHY^RLT>)IFE^NJ5XLFOE-DL_**NJE&O'$8
M_9+RQJXNLQ.EVBT4LY?QKE1M(&#H!(S4YC-E3]/+MBB'2'/S""N\ 8 P!@#
M& , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
M P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
M & , 8!X<G6*W-%(29KT'+$3EV,^F23B6#\I)Z,312C9LA73=4"R\>DV;IL9
M(H \:)H(D063*D0"@2]M^X2_XY#_ )YC\ J3 & , 8 P!@# & , 8 P!@# &
M , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
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M,%?67NM3=NG7Q2301(DV=0A&R9$B%3;D3EH],A4"%*!4BD( $(5,"@4@ 4
M/-@%58 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & ,
M8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@
M# & , 8 P!@# & , 8!\G.1(AU53E333*8ZBAS 0A"$ 3'.<YA I2E* F,8P
M@!0 1$0 , Q^#BIT(,(-A]GR98HIU%#J'K=O3=(PR4&VLZUS7C#U\LHWUNC6
MWC2P+;/79IZ\2A'3:44LY6*Z2Y@+O6P0&"7$! 0%W#B AYP$!F8_D(#]\!P"
MI< 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
MP!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
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MSR9TX"<\N=>$AC#)"@Y0[_+\G*Q5C*!*.P72$HB;LVRW:=:"(\^1DDQ*00Y
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MXCS*')GDSIP$4W>_GQDOX*EW4[3O\STG<=X%;Q5YWHINCH[(CGM.U(WY>V[
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M@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# &
M, 8 P!@# & , 8 P!@# & , 8 P!@# -7,[P_7R4UI['!T)W^*93'&^QKFM'
MDOJU@R@+5O7;3R_Z4W4P%I;W5>A6M/@)"QP3N5AW1MFU)]<I5>MUB01,[77$
MHNW?=??DONY-9387/M)9K4HUJO)H/'3,U<0F'KAB<RLJJB_C4G+A J3QNFQ6
M=.2BY$QDWB9 ,*0(^X<!!:79'OL??O#'^B)9E%E])P^VB?;4L4]TR_<9]A"A
M,N!2# & 75U-]V9+^#/_ %3?+1;'Q$+NO]#BX6=\:_N?]331QY='_E!X?O\
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M+X(EC%3(FFWL<?H39W#)^?FV+^I1LDEWA-">-7'; BS98JW0]?QKQ$CDA"*
MU4!$X=H"QB%(H I]8F#SB"N\ 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
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ME3ZP/CX/=8?VT+[[(]Z;[]_8_P!+2S'[+Z<A]K$^PI=Y[I=W;-Y3&K,H+&,
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M@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# &
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MD[DSE<7JS_B%[H[D:6@NWOJFOQO^Y2R]2/2D#M/2I;9KIB+VWH0I;*LIQ@#
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MQ1 W9^UYB C@@K; & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
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MFX-(BS.5T#;L# <0HNP5;;?N$O\ CD/^>8_ *DP!@# & , 8 P!@# & , 8
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MN146\XBU)QNHRE685V 3/)/CO4GR:,D#V((=5%4&$48TH9N1B0$A1(1ZW?.
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M#G0!O%90 >:MKX$*"C3I8>U5'J8\V8B0WWO^$"Y#E][GY\XNT0-6F$F^D?\
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MIU4EVT<U72^+-?\ ZF:2R*KNXK!3:(688J1TYDEDTY:M5$CUE]J!6.J(B_\
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M)N5WW^-[ZI&D!!454Q>=?8IKF0#L! 14 P=(MT\WZQ7> , 8 P!@# & , 8
MP!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
M& , 8 P!@# , N)S@!U[Q,;*@-DS:U0B'<&PATI.'=ZO@[''[+>Q\VT:NFNZ
M1<2D<IM.DFU2^V!JR"H,^!8:N([-LMQ:K.;+'5)>NB46G_-.]L;NU0SU:-&K
M!JV8L6S=DR9-T6C-FT13;M6C5LF5%NV;-T2D20;H(D(DBBD0J:29"D(4I2@
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MDTCK(D4.4HE(95,IA 3E 0(N , 8 P!@# & , 8 P!@# & , 8 P!@# & ,
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MBT4LY?QCA1M(F*!01,U.8S=4XE .V((<@YX(*[P!@# & , 8 P!@# & , 8
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M7%,JTD;;E0VTH1A7Y>;H>VZ/97FYGH.I?<E<9<BUJB__ -+R4VZI0Z$,'@8
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M)@SS<O#-'DFI$1;V3F7<=''=JJG9LG,O)KM4!(BJ_=G(*YP6Y53;+VX(& ,
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M3$/#!7[U1Y5G.RS%E#2C6Z5$T6_>#984KT,\I7].N5;O]?:VBIR7BD*[=2[
MC@S1]'.6\G7YA_79^(DHR4;,I2)F(&?BI.#FXB49M)*)EX]['/VK=VV61(!4
M^ , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P#%B[>^J:_&_[E+,MD>E(
M':>E3'YKIB+VWH0I;*LIQ@# +SZA]VP?N17\\CECMG]F^>^Z+I9OZ[YO[PYO
M?+4?"YK_ ,25._K3?<Z4T$M1\QOY.^:6>:,T4]4L'>J5\XFS45FX#6PP!@&V
MGR,'POY#XGKK^>JAFHM&O4=#WYD?(3AL;0NU3.WMF_*2YU;YR8=%'BS,.>8\
M)Z)F:A_"IIC,'\&=(-?%2,@6 T-+=NU==XA7O:@+YJCW9=444>S=)=)@,!B5
M/\*UB>0RZ\#LB(9;!LT+OVO;"M\]1G$^RL##B(D*I(6%U&0J%OAWD>_HJ% H
M=8UT67G[$RCZ'5FE3EF\D86<S&!GGFADK/PK*/J<=&MS/"MH(U<:,0!^\3,9
M%D_C6: />Q62*_#L2%ZR/"+)'4_313ZP P 5U@# & , UL/.&#B%E.'9]PH.
M9+4<;K&N:[=ZXJ-UCK3?_LAW6-C;-6QHTC84&-1@BZLE(>EQ$@C:'U8M6PG]
MFM[AC-1+VH-VJB"PFM]=>M:4X=E3VG/!G>6NN]L:ZJ>X[56$+7O^,VK7K>M/
MM=@7ZT58'FL)H8+;MRW/2-IV2<EM?N:M-T_63MA+K&1UW ZU@)V0<(QDBV*)
MKM(MU-A."G?7;KD*_A.$.(=[HO6S]GV"R;(;RR.D%JTA)WBTP[.2GM0A(R+6
MQ;%UE1QI&F;++L[0>'GJXY=4F13CGT4S>M&T6Y8,@((KZ<ZY<]M2CN%;@\G^
M':UTVQ/[*%M3;Z#6UM8T)R][%NA*7<V][:6=R\TLRNKB084RD;-CG**&S*[!
M)U&)[_J73ZD56W0-Y)Q'A6ZGHIW\]=3/_! P!@# & , 8 P#'7B,U*&UXFB)
MCJG46Y1IEU7M*-.W/8K%6JJ5PYI=NJ'C+=U"4W8K!]+,6EI>-F\99*+.11F[
M]U(LUXB>C8B12#9,=2\+.Z&'"7O+4:]FIVP]S;4TW':2C+?<+5;HR&:5>-TW
M':S8FF+.>J72UO$F%FD-A;(1:.HB8DGLE<GL;)V-T\7=6,XFJ5KDOK=NU_L5
M=MKA=V/LW:.N]S,=G-:M8X&8U*XEZ>YBXVVUNJP5*DI2P6V'U[87M<BI@ZUI
MG)1%:7D'T3"JVPE>J9YI-@WJ]?C(L*^GU7\%=RI=&]479B&XGNQ]=LJS*C8-
M'O:"X);)>3AX^(L=7NK:SUAIWN$37G(V*O439KM$SEFA&<K(U65@*5*EK=E;
M Y9(!K;=3&6*X/+*QK,J2PZ>T-M)5_O.T[5A-8;0W+MFX5ZF(6C4M9H,B^-N
M"T:OL]JV597]CAK#9P#8&MG9:XPN+6!J4Y$-M?UM1V%;\M-Q/[IGK%^#ZFWF
M;AL2T":]Q*UA;ZSU5J9QNQ2QV@;Q.1O@L!5-W;$41<0[QQ";$-"%L\SK==2Q
M68KZVKPS^T2T:0CTXAKUXM;:X*\1YN]>%.'OT-6F>L:WK"A6.FTI[7*G=W=5
MC'L[7$:I69=EJ"FQ*2L#((I46'M$SXI8FKA9TS7J3.PZZ4K$[6MGVY) *_V]
M>[GK(1M<:MW8C?\ 3EAVO+QLXOK:F;Y1E+&UG&LT^>/=FWNHJZ_I*4LWJ-#<
M69A3Z%67*5JLDC1ZBI-33:G/$FDK()3KY(1_;DOXS,/ & , 8 P!@# & :ZM
MD<*6QK!LRSV_64)J/4\K/62\SLMNVOW*]CMB]QMXTI-ZE1JMMKBU,681\/3Y
MB;@MEQ+-GL28J[ZUZGJ+IG3*O+V-]8JP)1=F]-CAS3A+_P#V,+I%\1.J[;6J
M_0(S3.O-%[!U,1).V3C2WLE[9/ZIFH9*&I:-!7KQX*#;ZK:1 G6OS-T=":,Y
M28D\'(TE1'*>EH2D;(I;S="^P8VD1Z=ZW%8-@U?V&W">M9QA9J)@HPC:>+-T
M&CEBY1 8)-8R$>>=:'!X=,'Q>Z@=R!B#,<$NTK3KG3\(ALQ.FV?1B]/I=692
M$1!6>L/ZKKWB)J-\-M%NJ+%Q)M-B['U]KRH+2S:0[R2,G$'M9;.HV'G;;+V
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M(>R78BNSCI$&BKA!0*7+M*GI*2XC9W8KV_[-K5<V"&NFU2X;*S=:P9_<AU]
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M# -M/D8/A?R'Q/77\]5#-1:->HZ'OS(^0G#8VA=JF=O;-^4ESJWSDPZ*& ,
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MZMWQ?]9S<^6H^%S7_B2IW]:;[G2N@EJ/F-_)WS2SS1FBGJE@[U2OG$V:BLW
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M & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & ,
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M1<-8:VV5<$?)X?HV-M6);:<M4U+! TNFTZ<F&<%$Q.EUHLM]OS68>R9XXK>
MIM3F3*1[1]*Q23=5031*JFW1,]WUEW;SQV;,UO+R&MK7I2#6W ?<$#KB'CM?
MRNY]O4U."G=&RF\5K-)_8WT!.[1<NH5I!2=/7C8?6#ID]D5H:Q.9>"A74PE7
MPHFS=2N1-FER5OXM?8/Q;CPVH<S"4_0Z-:M 0&H^$[:>V8C8MTN-+V757/$Q
MN?9^FWU/KU$EM0MG,D\HKG6C^SH2=R>4!S9&3J/BEZ[7%I!>0B!%$IEUU3)L
M4V]O^ZF0/"?L'<NP#<00[;)4Q:T_B+V91J$M6YAS).4JK79(J#2*E6ZM*J2+
M<(M!1H5D\%Q.R$B+AYX@[2%HW,Z!4I3;1%,<%/*![ :4:DWQUI"I*L-\:A@=
MZ<.D<VVO*D=3-&FMNZ UBG'[;<+:Q%.@V48SB6U=;P2K"&PF"2RUMJZJXGJ[
M&>M0FFWDRW;2K=??DVCYO/E [=KM:5J%SIVBZ/?JU>]JTJ;G=@[UG*AI:3D]
M<:YTSM&'JU3O+K5#JP26PMBUW=D.A7*H[IK14@4K9$LS6G@@8J(GP1*_V2_8
MV<EV6NP5I1>,_9M@>5R6M6DX.I44FSM+Z&V,=S>IHNQZGM_<FM-;W9LE'45Y
M0FK.0J54M6UJAKF;5EK/ V91V6T6M."0B*^P:6413UYW[2\6R6VBN.O8,9K"
MOVNMZDA;!4ZAPH:<XF=C2=WW).&NQ*[L*T["K3VLU[NVKI)K;[1'Q^O)&82G
M)Z4JC&2>K-XQRV9)NCRC,%2G?5.\75HW&A9]A<2B>DJ_4M6KQ;/9>XJ'<XQM
MM25DMZ:TA-1HSK5IL?86J&M!+&UFE;2FH^$"@2;V[%2=0%QHTJDK*/K2ZAJR
M%*)NY+KEX=K(NV;"<$# & , 8 P!@# & , P8<\ FF7/$\AQ5*1]?->F]P1L
M2<6?6>LE84D>G45F9TTS*U8\FE?G&RU$=IJ[H3?%VGV[-K1$[&2C%/$*":W4
MSR_\W;=<IG/@@8 P"CIV@52RV.K6R;C5GL[2QEAKCD):9:MF(SK(8V6[:*9R
M#>)DP>,!,T.$JQ? 1 ZA$@3!0_4!;?\ 0PZ%\"+6AUM##"@Z4<&:&<RYC+-%
M8-M5E:XY=FDA>NJ2K4V;*H*T%RY5I*E09,JJ>OFK[-M&I!55+\X P!@# & ,
M 8 P!@# & , 8 P!@# & , 8 P#6[Q%^3 T5Q,[6G-OWBY;:A['/LH1B[852
M9IS.$22@8EI#M#-D)>CS;XJBK9FFHX%615*9<QS)%23$J9=EX-Z*5O8,63 L
M:1DK(C2TN^.]D2;@SKXZK,1GQWHYT&>@0U1'O5&TAMHVB+5:JN#6W@!8]O6C
M&M.;FK2A1XS83',EHLJR$B08383<5L64BOJK6(KJO6^M*)<6/#R(G"X @/V1
MM^^80'WQZ[^]_P#YCE]Y^6%78W!_Q:T?]T+3SJ,'OEML_3R/^WFU#9FJJ)N"
MJFIFPH529A"R43-L5&4Q.5F?@K! /$I""LM5MM5DH2UU&SPKY$CF)LE7FHB<
MCE>L6;]$%% -I<V>BT+3$X/.']&NQM<;5>U,QC+3.74EN8;<W$PVK(V>SQK6
M%LLK8]SL[\AMRUGL4)'Q,'/-K/=I=E,0D#7(>1;.8VN036/$U7/)LY,A;NC\
M VC8;5NC=?WR.D;]+Z9T?H[2#JQ,+-L+7T)L&&T&U27H3RXZ]JU[)6+$A7+6
MK,W"G1EQ+;STB8GY16#DB.';QXZ"JW[==C7VRL7'!%PR/'MR>O\ 7C^2"]P.
MX*M.QLGL7:$G7FE<W^N[>;H@ZC5W]T<5S7T9LB0>KREG:4&*K2+V7[&7 J<F
MU;.D0JMVUFF[36J7<E-*ZPFI*?EY2J-G<C:+KKC8D\Z,_ETS2%SU&[K[[74X
M<B,@FDBM6756@%F[5LFBP>C'$+*-7Q%G)5A!;!GP9<-[".MT2WH#SPVY1!:^
MY9N+]LEXC58!*RI7-M!ZH*\N"_V$X=A;FL;9XR+TZ-%8Q<]!UR6CD&KZM0"\
M<%>+:3->$DW'!/PYN:^_K)JO=$(Z9F;-/61TPW;O.,L5PD+K!5FM7(MXM\=L
MAK;+S&6Z'IM8;V>#MTW-0D^O#-)&6CW<EVKM037.B9IP&4C)DSC6;2.CVK=B
MP8-D&3%DT13;M&;-JD1!LU:MTBD20;MT4R)(HI$*FDF0I"%*4H  @F< 8!;M
M_K2#D7SM^L\E2+/'"SE4J2S,$RG6.90P)@=B<P$ 3"!0,<P\O=,(^?+E#M28
MA0V0VL@JUC6L15:^M&I1*TB(E=FB(4+Y&&][GJ]Z*YRN5$Q:7K6[H0PUG!Q[
MUH_1>2QEF3E!TD559F*9E$%"JD*H!&)#"03% # 4Y3"'/D8!\^(EJ3$6&^&Y
MD%&O:YBJC7UHY*+2L14KL510R0A,>UZ/B*K'-<B+BTJU45*]#M'MS=)J]CGZ
M9:)J)2?3VOI.6F*=('7>)'A)*<KTI5)5TBB@X2;.3.Z_-2<:8CY%TDFF[,LB
MFFY3163MI7%E)/A"X>9*/DHYO0G%7"6V9=-PO)37EUV!K&RAL;8[11EL*QLK
M;KJU5>TQ8WENLJ%OB8R89P=C54.YF(QXY,*V 5.VX<=(L8U2&C]=PL9#GD=)
MRA(B+5DHR+:N^'.8K<]I,(^.8/F[.,9Z^E*?6EXB-CT6L:X2B6[.4:/V)EVR
MH9]\]';&CM<[L91[#8#*SKHQK>98H*U/8VQ]:/UXFQMVS6P0$I*:TME1DYJM
M3J+)D$Q69EV_@)([%BL\C5EF351($6A9N<X+M4J;5T_MBD)/]?R>KMJ*;.=U
MF'F[HKKVPKJ:5O\ I@Z$?K$ER8ZPJ%D6B[E&/'E]BJ2XLC]I7#0KQ19.:=/F
MPFMU.#C3.A,,>!;A?C8V3B6= FR,I""K=8:=KM7;[EY4JW2[G";$HL#K:2=7
MU:2U5#T"\5R#L^OH[6CNIM*'+1C5S4$H82" A5<Z;GIX2KJKPG:!IA'80-$4
M(M(P^TH*4D):W7FR3$LPW8:A*[7/,3=DLLM+R\G>G.LJ0]G9R2>NIM>1ACR2
M<@D_EIIQ(B*Y[A/6'A@T?9VRB$G3%T5QK>K*FTF(*VW:K6>%AM*2%PE-7!6+
M;6+'#V>J2M2=7^YE:6*M2\387K.QR<;*RC^.6!H4*KLYKE*,LO!#PR6VMQ51
MF]>2!ZY&4^R4%Q%QFQMHP"5IJ=OEG-ALT7L96 NL8YVD>9L[^2MKR2V0M:I4
MUPEIFW$?$LDQ)RCL35<_1L<!<:*X>]4PNS%=N,H2<4NIG%@?,C2=^V%-U. E
M+8FDC:)JHZYFK4_UU2Y^Q))JISD_4JI"S,H1_,%>OEPFY@'PBNL7IP!@# &
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KK!6)Q-(V9Y:)NPB:W4IG=M5X_4;!\$# & , 8 P!@# & , 8 P!@# /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>g98473g11b01.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g98473g11b01.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_[19*4&AO=&]S:&]P(#,N,  X0DE-! 0
M     $H< 5H  QLE1QP!6@ #&R5'' (   (  !P"4  (<G(U,#DQ-C<< @4
M(4UI8W)O<V]F="!7;W)D("T@1V5N97-I<R!&+3$N9&]C>#A"24T$)0
M$")*^(M6HN%I'>),'8-E9Y0X0DE-!#H      .4    0     0      "W!R
M:6YT3W5T<'5T    !0    !0<W138F]O; $     26YT965N=6T     26YT
M90    !#;')M    #W!R:6YT4VEX=&5E;D)I=&)O;VP     "W!R:6YT97).
M86UE5$585     $       ]P<FEN=%!R;V]F4V5T=7!/8FIC    # !0 '(
M;P!O &8 ( !3 &4 = !U '        IP<F]O9E-E='5P     0    !";'1N
M96YU;0    QB=6EL=&EN4')O;V8    )<')O;V9#35E+ #A"24T$.P     "
M+0   !     !       2<')I;G1/=71P=71/<'1I;VYS    %P    !#<'1N
M8F]O;       0VQB<F)O;VP      %)G<TUB;V]L      !#<FY#8F]O;
M    0VYT0V)O;VP      $QB;'-B;V]L      !.9W1V8F]O;       16UL
M1&)O;VP      $EN=')B;V]L      !"8VMG3V)J8P    $       !21T)#
M     P    !29" @9&]U8D!OX            $=R;B!D;W5B0&_@
M    0FP@(&1O=6) ;^            !"<F1456YT1B-2;'0
M  !";&0@56YT1B-2;'0               !2<VQT56YT1B-0>&Q <L
M      IV96-T;W)$871A8F]O; $     4&=0<V5N=6T     4&=0<P    !0
M9U!#     $QE9G15;G1&(U)L=                %1O<"!5;G1&(U)L=
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M____   X0DE-! T       0   !X.$))3009       $    'CA"24T#\P
M    "0           0 X0DE-)Q        H  0         !.$))30/U
M  !( "]F9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &       ! #(    !
M %H    &       ! #4    ! "T    &       !.$))30/X      !P  #_
M____________________________ ^@     ________________________
M_____P/H     /____________________________\#Z     #_________
M____________________ ^@  #A"24T$"       $     $   )    "0
M   X0DE-!!X       0     .$))300:      ,U    !@             !
M\0  !T,          0                         !              =#
M   !\0                     !                         !     !
M        ;G5L;     (    &8F]U;F1S3V)J8P    $       !28W0Q
M!     !4;W @;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG
M   !\0    !29VAT;&]N9P  !T,    &<VQI8V5S5FQ,<P    %/8FIC
M 0      !7-L:6-E    $@    =S;&EC94E$;&]N9P         '9W)O=7!)
M1&QO;F<         !F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U
M=&]'96YE<F%T960     5'EP965N=6T    *15-L:6-E5'EP90    !);6<@
M    !F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
M         $QE9G1L;VYG          !"=&]M;&]N9P   ?$     4F=H=&QO
M;F<   =#     W5R;%1%6%0    !        ;G5L;%1%6%0    !
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M300H       ,     C_P        .$))3001       ! 0 X0DE-!!0
M  0    $.$))300,      N[     0   *     K   !X   4*    N? !@
M ?_8_^T #$%D;V)E7T--  +_[@ .061O8F4 9(     !_]L A  ," @("0@,
M"0D,$0L*"Q$5#PP,#Q48$Q,5$Q,8$0P,# P,#!$,# P,# P,# P,# P,# P,
M# P,# P,# P,# P, 0T+"PT.#1 .#A 4#@X.%!0.#@X.%!$,# P,#!$1# P,
M# P,$0P,# P,# P,# P,# P,# P,# P,# P,# P,# S_P  1"  K * # 2(
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MMI)*?__9 #A"24T$(0      50    $!    #P!! &0 ;P!B &4 ( !0 &@
M;P!T &\ <P!H &\ <    !, 00!D &\ 8@!E "  4 !H &\ = !O ', : !O
M '  ( !# %, -@    $ .$))300B      %&34T *@    @ " $2  ,    !
M  $   $:  4    !    ;@$;  4    !    =@$H  ,    !  (   $Q  (
M   >    ?@$R  (    4    G $[  (    )    L(=I  0    !    O
M .@ +<;    G$  MQL   "<0061O8F4@4&AO=&]S:&]P($-3-B H5VEN9&]W
M<RD ,C Q.3HP-SHR,2 Q.3HS.3HR, !R<C4P.3$V-P       Z !  ,    !
M__\  * "  0    !   '0Z #  0    !   !\0         & 0,  P    $
M!@   1H !0    $   $V 1L !0    $   $^ 2@  P    $  @   @$ !
M  $   %& @( !     $              $@    !    2     $X0DE- _T
M      @          /_A 4A-30 J    "  ( 1(  P    $      1H !0
M  $   !N 1L !0    $   !V 2@  P    $  @   3$  @   !X   !^ 3(
M @   !0   "< 3L  @    D   "PAVD !     $   "\    Z    \     !
M   #P     %!9&]B92!0:&]T;W-H;W @0U,V("A7:6YD;W=S*0 R,#$Y.C W
M.C(Q(#$Y.C,Y.C(P ')R-3 Y,38W       #H $  P    '__P  H ( !
M  $   =#H , !     $   'Q          8! P #     0 &   !&@ %
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M%:R*MIRA4865A7S]O:]J?O$RYITD=.N;)6_:F)K6Q!XE4X 6NQ++,DPRIR?
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M650TE!M>TT^;/L>S_36(YIC60W.8Z=S2XS3$C+CN09;CF,2,KQS%,HBX;/\
MM>QJ5,A&8?3XWQG>V<$R/"\\S?6.Z['3T3 *#]8G2^;CV!KO:LN\Q5MG91CY
M!&IJ6 W8F)2 -%F\&L":$H+K&[AR5LVXF4E8A&PCB$:\]\]7D<8MU:KQBGS7
M"&55L7IX?U.RQ4C]7ZEW_L7 *"ZUZW,HM;DG]HE#CK#;#P=@M@/Q46)1\DMZ
MZIDW,1#-G<0B6NF#*=P5X<FT1OT-SD.R=/1Z0,+=+<?-7XEOO7UPR:'$]AQI
M<,*T53G_ 'JI]+M#!0R6RZ;):Y<AKX;,1RO&C$0BUY2C",AC$8((F/*4I7M&
M,8QM5SR$>Y4:QC&HKGO<J-:U%551$XA&M/8_7)69UG>I]:]+6W--"LL_FY-7
MDS+8N.Y5D&/&S"-0Q,FU1KUE/!O,&M(%5O>DAYW;X)M>/(NL7O(.O;>%AD;*
M[:PAC"A%9=&ZXR.5G>B]F].VN=WZJSFOF1M6=0@;*PTK>Z>A1,)Z@-A3.I7"
MMKY/8CC;?V#G)+2==6&M<QIZSTK7WV$7]?/BPK//QHA&\GB$0[M+J!TKI211
MPMJ[/PC 9^3(=:")E>0U](^P''EP*XLQQ)IAB@U K6VIZF1=V#XM/&M+BIKC
MS1S;.""0A&JN1FE]UNXIT]8QU)>ABNN=W9M97NL,KT-<91A&;Z*ZJ-3TV<S0
M:*VREQ,M[ N9:[L:+(<JQ[-ZHF+5ECL;5Q,=R'"H==*K(^2(1M;T@NX!ZYIZ
M[>P\=-LRCD6=!=Y#BA&MQ_.8M/82(--G\&K^2XR3,Z<4*^LL2,22N+VTR?21
MY]G"A1;*6A$M\0BE/4?U7GU/>9CK[%]>9]E]YBFG0;:SG*L-AX]=EUAA63VV
M6XECN;1\&GV\3*-F)2W>(7USD>-8556UK"H*=2,BS[*TIJ:R0C63HS)R[8GX
M+J^JMJO>.9;BTIEF.;NU#U22KS>;-69U55N.9P3;%?ETLA+RYZ/NI"30UD6K
MA8_:_P!DN2S+'6%O@=#$:+*L4$BGOZ>V:-N73;J"%TN:/-BE[;XO7UE5>['V
M):QL9@GQS6FO:W+,GO,XFXI@M1/ERB8_K["8UB6OIXI#!"*'$++'"JP'96PT
M5CL]+=4>H=\V=O0X/8Y-7Y-3TM/E;\5S[!LPUME%I@N1J5N-;#Q^ASBFH[+(
M,"R @#QZ[*J@$NK;8 D5$XT*WCG@#0BP_$(<0AQ"'$(<0CY,M 7>GV?69R>X
MK,6R*#U,WO49LK'LGN#9G2V^8WFJ?L3.ZFQ/F&D!ZXBT6L\,IDU]A)L6S"GR
M(>:Y!B=YC>47>873\@DX^9#3:W\?L+Q]9;>_;Y7NOY_[D_'_ #X@/=_K%,LK
M[K]032:-7LOZH?4IV7MW[*NW^E_Y[?GQJ\4+L6H=(GS8N-;!R.NAQ<)V,7 )
MHO<>ZFBQBDR)+#U1JT(W#N!O2)Z#OVC"QE1[E7L_[J=EBXH3ERE2\/-$F<I*
M@B84YLJBDY2 :&N]'U#1N^!8W@^!Q F<;X.>-2 I"A)3CI^ 8)))!5)2<X51
MP<M 0]8U3]&71IUR:>V/MS(-E]1Q 4V5S'NA' 5FPG9?8+8.D_I.>HRD+X6*
M$?#58BQ8BN,U">V1OM8T9_//?A/X9^*>#X_BF(XGQM,^1BYCR99)Q&8YBK.K
MM !((%,J'!<"P$?5/XU_B]^"7QI\*?!G"OA+\/EX3B?!L*)>-FM_A P2>S"5
M85$_#!4SB.:;WRI;2Q58(7,(&QKJDU;E.XNFW:.KL<DP9.591B:P*\5L5:^J
MOYT*1#L'T5P< C)#J,H;")26[VQI @0+*2JQS#:HG^E("@D!1=0%3N=_&/CY
M925J*$9$%2BA#YLJ23E3F8$Y0P<@/%+MYP]U]0F+QXM%TAY'AM#A[<!_M'BY
MG::^I=C;1PB@V-B5YGNA-</QO)+F+883EN)UMRZ;(OLEQ>COI8*_'B5[8]I,
MEPKHL_;?WYON3M2#-^AC=6?1]Y6T'1%W0X=-Z?>I7]536=GD>/ M=+9KE.::
MBL]8T5)#@9,:HP3+QR<=S'*L5'061ZO7HYRPZF]KCF;':BOEH3X7].?RC$=@
M].MQA'6OF&M;+IER/9&K\OUMO?)-"ZUQ&TQ6+50+^QP;I&QRWV='@6F84D2F
M6JV<RQEVF0O[9#5Y)+/F]57S+1'V;T(XVSNE'KFN,EJ9<73EM(VCC\+9^)9W
MMO$WX9&79V.7G2-F^ 8_=R=JWVPB;$R%V3;-E4D\^!!QS$<-P.^? FQ*J2:M
M;D!D(E+=W2'O >6ZPH-2=,=?0Q=?V'2);XYG.'TV"&("GH,KQ>PW^&WS#)\]
MBVN#SE0F3#O\1U]B(F[.JI$^QR7([TUI)@,<OG6'OWUC']8]%^[<#U;CFO3=
M-F0%RFJUK58!H7)J.RPC'Z'IPVO1;PV'DN8;45D#*XQ:>OS>ENL2RD.88Y!G
MY%D=73&PB[KX\:86(]"-K/1!T]$UMTQ-PG:. UM7G6=9#MJQV\&<V!+L\V=D
M>RLY?53<HM:Z1+6Y][A$VECQ62)LA8-(Z'3L9%%$2(%%"6\.EN;\VH_.,QZ)
M=3V^E=-WV!6N(Q<&!'WMU'WV-8W '5@KH>$99O3/LEP@U;$IWO@P:^;BUI53
M(4!B"+"C&''/'C%&X T5BWG$(<0AQ"'$(<0CQ5S47LKFHO[E5$7Y[_E_L7_<
MO!(%RW7WSA]*QXJ]OEV0C?A/O(BM54_P]O\ 1.R^2]_R^?PX^MN<4N^P+>@-
M_&-)'61]0':&C>M75FB<2NL:!@MP77:YTRSQ.5:6T 66Y(^ 7V%@.PC^N^;7
M,\0^A'>M>1R%>R2O[#GEWQ/\9XGA'Q7P?@TKLSA\7D_,J9>9 FK*$@%-"JY;
M*0-:1]J_@W_X>_ASX]_ WXU^/^(2,6KCO!U<41P@HX@9&%F'!85$Y)FRK#^H
MI8=2QF8!3@M&Z^,[R$TO=RM<Q'(BIV[HY5^>W9.R_'^J_'PGPG/3D+SH2MWS
M-6M:\ZU_<4K'Q6I.51![N0D$."Q%W:A;E'+145.Z?*+R^ +AX_>(0XA#B$.(
M0XA#B$.(0XA#B$.(0XA&FCJDZ'8%AG./U^H=>;5N[O9=EE438N2^CIR1IO(,
M,V[U#X]M/=]1OO(+^3"W'/)#QV+*9J>1AHBWN&&I,8%A%[67<,TH:$;']+=/
M^.:4/E5I"RW86P,IS(>-0+S,]GY(/)\IDT.%0IM?A^/.L(]=5!+7X_&L[5X9
M4F+(N[.=:V-G?6UK8RR2>(1+64T$?*\8R/%I<RPKHN2T-O02;"HD-B6T&/<5
M\BN-,K);Q'9%L(PY+CPI#@F:&2P1'"(C58J$:[L(Z!8."W=9KBBN<@QW1VJH
MP\EZ6<VP[-I]+NCIXL;H;:;8.DJJ?-K;>)EFDLBA@C9#3TF5DNJNH.8F-.Q]
MT#%\#F42$7TUCK?$]/Z^Q'6."P35V)8120Z&BBRILJRF-AQ&K^VG6,XIIEA8
M2S.++GSI12'ES#GD%<KR+Q",[XA%$]Y]&U;M;9>ILCQZ@TAA5)K[*L-S,F:1
M-:G_ +=Z"TQ#;+-M653K/.*ZXKJS%*795HZRJL_<ZJ+*LX61Y26<ET2[].$A
M%[.(0XA%>]D=..%YQE&%;$H'KK?:.#;"AY[!V%A];6Q;R\9*A4N.9SBF8(X#
M197C.PL&HZ[$KZ%<^Z=&;3XI?UCXM[AF,S*]"+"<0BI/6KKW-]B:5]M@U')S
MF3BF<83GF2ZCCW+L?_MLP?%;D<[+M5?:_OJR/'FY%3ND2J&-:3XM!;9-5TM-
MDIA8]86A1H17KIEQ_+MD87M;4U78[EJNFJ'G%&+ K#=N*[QUGND&MLJPJ3/S
M?3-!DN47&O-N5\O6.=&@-Q';)I=W[:BDEP:%+O"XW]M 0B_^MM:8;J3$X>%8
M)6'K*.+,M+,BS[:WR&YM;B]L9-O>7N09'D,ZTR#(KZZM9DJPM;J[LY]G/E&>
M21)>OBC4(KCUO:RRG8^L,5F8YB1=IP-;[*H-AYQHI)H88-ZX#75.0463Z_[3
M)U=4SKJ)$R%N=874WTL%#<9WAN,UEK)@1I;K."A&!]%?]J,C',AIJN?LBGT5
MA6X)@M2?K ZYSVBVYD>EK36]?8NP&:#9DG']@5K=:;8NK+'\<SG+Z:VGY#AF
M)1Z5H[418^8R$(O7CN-8[B%1&Q_%*&GQFBADFFB4M!6PZBJBEL9TFSL"1Z^
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M'%A;^R:LQRFFRUK]5DQND!C;<@I+!X<SR#'9N9Q4LWT46*,5>2R11MM;_?\
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M3Z8R"/H*38!R7,]O8"FWL<RV'EV/MM[/(M8CH]>[C%3Y$"FL 7$$ZG!5WRP
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ME<ULMMR-JT=;CEUEMW@LN;"UWZ^64.,86=D* D=UB1[]^^<(^K).W9.WX?\
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M+BEZ$&S>_6/L=Z7BJ?INT(96(-2:=UP]6(O=&*[$:ARM_P#ZJO;M_ESN,/\
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MQ"'$(<0AQ"'$(<0C"]BYYC>L,$R_8F73OL[%\)QZVR;()S1O.Z)4TT,LZ>=
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M1KP.)QAF85*42P%!@&  -J4]0+[1*FR]>W&*1\)NZX=S<8ID]%EA:+(+.!'
M&794T]X+:#7()YA./7Q/2DC()47U"'>)O@/S788PJ"3DJXJ1Z'UU_G2X$253
M@->[2P>POH3??K%)M\4^TLPB8V/ WD'&BR"/G B3W0I3RJK?0,8SG-0X ^+_
M ":Q/GR^4=XJU><F2YAL:O4"Y]+^N\>G?#6)X5A)&-'$D2YE%]CVC. HD@!P
M]BPZN:1.FO<ES7#F@2--DP[:?0_8M]]FM,@),>?%6'.:YO@]W@7R*CO_ .;G
M)XHJ\VV![4,6:C7-]6IX?(VC@^,S,+.FS52 $([0Y4@9:,-!R]WB3MB83=XU
M0X=E48%S9X=?BO@4^06U:.&UF35-B+]((4!P7G%*''AOCE;)8YJ.>28)&^41
MZ),Q!4P)METUN&;?^ U8U^$"%JREGS ZU:C;7-Q:HWBCN^,5VOF-UC<_!93A
M5D=GC,CQ[!\1(QF2%(V1+12,0XO1=X,1>WE_A5/W\],EJ49A26 H14>_"PY-
M'IGP[C>%2\)/DXF7+[9$M60D!U$EZ.*FU-2_6)]PW)+W$[%TB/92*<EC2V-'
M;'@I)"$L2SA/#)B%<QI7( QFL]-'.?X$<QO_ $U3DSA06ZLP+/0<V'TW<N^C
M1P?%U22J>0 D=J5(8,R22#KLPY:/6)GV7K6UQW7V)Y[61[BTQ:XE6<=M[:P$
MAC';P)K8]M7UIPOD,L@AC/C$D2$](@3.-&5G]W\EVN+2TLY=M=WU<GPT\1&G
MP&4SA4#4 TI6UW^NA-8UW;&PG;&0;%H+K&;!\7'(RP5<@IKXXHCPR/5E^YC*
M[^]M*SL)51'=V.[?DG.:F)F',4FFNU:-7F1]K/ZOP?B7!,-PG%2L5*EJQ*@0
MDJ2%*?NL;4+:"XK6L6AJLGD8[=Q'P)IJF1,K;:ODR8HR-1*V=$6-81B,&BJH
M9?F((VO7LYY6(SY[(FVX8)@S:C<5W!<FQKHPK81YQQ(R\JPL!9G+S2B?_P!-
M#NR1JX%15G/.)EV;KJQQK L-V/6Q[>QQ+(+NRIC7TT8!PQ9#"C1#2:6&4#WO
M(K&N(28\C!D$5"HOGX/\9F)2H))9]/%CYZ!_G1]?@LBIH068 I ?4TUMX[TC
M7ED^'[5MMOU>34MEWQ0$BN+Z+9BH"+$8K5E1#P7N:DE#KYHY_BOFUS>_^'FA
MFI50Z:>%]MC2NCM'J>'Q_"I7 URBE'YA 4%%0&8FM;6J .\]-7,6>!DDRCMX
MJ@EEKB3&38DEX$3TW0I,=S)(G-5>[P*A!C]-._9SD[?+>;;A>8K2X9)3Y,YK
MS-A?UCSCB79S94M; "I %F.FXK<'Y1,>:Z]LJ_6^)[(@ N+#&K&\)06]O+&!
M8<7(_LJ',=5AEQR.<XJB85",(P91,$)'*OF[QFXY!*2S53:@((8M2]M--]8O
M#C+$XI-&-"?F?EK>-?Y,.VRNZ Y&.>I<,9.]TQC9ZK'2M:+LM>2"UR.0RN[?
MM%:CG=O/S3NWG-*0M*B*FK:,*_-@S;F\>G3,?PG_  >3(R2SB<IS=T$DT %=
M'J[MHVL666_D0[*M6/*]L:0^<$BM<]B^Q/%-'F#>[Y\1.&5!]G*]7^3>WRC>
MVUP0*2"?=&^OB*QPF-[-4J;D"4J6I*DC8)!/-N5?WE[(L'LX&K<:V("/;V-2
M^[90W\R0&*L2EO3Q#S8M463&7]G,?7,[#C&:A617!<\CE+V;,Q8691R:C30A
MV#FNGSTC2X&=+DXV49Z 98(S$U N-FJ]PS5\:#T&,;>C;F+D4^6:5AC9\F3Z
M#IKGP9$!4\H\%D9'M>/P<C6/7Q:]O9_9WSSF2)@/>"G)W(8:DT/T\6CUS%<1
MX(OADJ7+ERLY!=(0,SD=VM&J[NX+UBPEM<O9-J48]@3OL3O8P0W>X:Q0=GO:
M_NKVB1Y&":G=4(]43\6KVW&%)RI%ZN.0(J/&O\M'F\]$LB:ILHS%@VF[G_=Z
M>0FQ^!E#I2NV!5_:MM60\G^RKYLL0E%2R+*PO7U@V.%Y'C FA:I8*/:G["2Y
M>S45$Y+Q"9B91RZ@@$4;J? [MXQKL)/E2<;([=+H"TER Q:FC4Y>%Q%$<+QK
M<$#;LZ\N9Q96))+F$:)TSU8<R&]?.&"/%;]YGHM08WO1&*Q6.3Y7G/@+S]Y^
M=S^]"S;QZSC\;P:;PB0A")(F,:4S$GH!M<EK-%ALCO&.=C\1PQLF/N3FC*-C
MW']L\(V':XC?)?;L(R,SQ=W\BO=V3NBJDV2E=*'W;D?I2K.(\[GR0E*E!60*
M(8:-RI3H[4#B)KJL&EIIW(\JJ"RYK*F^EDR"%+]J-L*OFV->$-C7$4JR71)%
MNZ6POIL[-($C6_\ 23FQFA9DDU<%O.U-'U_F-=@YLB3CI9Q(S2G<E0<.?'5Z
M&M#O%"M=8QN"KVQ87602Y$K'GOG$?ZDWUHDYIW=XK(P$<GH-&SQ_P-3P1%^%
M<JJFG0)IS&OZC<TU]7)VH][1ZCC<=P:9PV6F7+E"9V;!@,Y4-S<5N][EHLAF
M5HBUU'#<5!&_2$I8D<+7++<U:XC9)!E3NOM&E2.UZ$7Q4[V.;W=R3+$P .+6
MO6M[:>%_+AI<JBE$Y$5 !8 I#N&Y^%#IK.F%TERW#\^F4YY/O+&(5\N%+C0C
M5\J)$@^O82HJG(TXI49@H?NGQVN>HV>*]T5RIM2I1E.!I3[.U6I9_._.IF2Y
M/%)?:C-(,Q+FI#!5[4!%'WK%*-2X?NFCV/<V^72I$K&2CD-:PMBLF-9%<=I(
MI(,=KW$C!:SS]1C6C1C51G94:BKIQF[56?57(ZO=BW.F[1ZEQC&\%7PN6B3+
MDYRD;441?^UW.]-*:VZ9*@(R+)(5/>B=,:V&C/-ZP7 %W>Y?)KV,2<P0@HK5
M1[G/>B]D7OLY7^:CJG[_ "OTZOY>I"F60"A!S-T)H .1(VZO'W8=- O0Z=M%
MA[H[T=1Z\'Y-3LU?#%*I.[47Y[?'Y_/[_GGHN'_R)/\ _6CY"//\3_[B</\
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MP8D)# Z7<FAW^7EI+1/4ELY#!@.]MON/8UC%18G=R)L>^NSQ91B^I]CQ6&C
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MA&+^"HO_ ,OW=_\ )?\ P_?RA)! ;QOKR_BL 0;1Y-=W5R=V_"_@B_/;_/\
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MS%*5*58&C5I;YQ1ZMZZ=/&/>GRB+^_EX)(!,5A\_N3_>O_ARG>'^GUA'@4C
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ML;(F8>8626!:S5%&4W/?EX=[L9E92QZROB2(Y9$FN9);(B2EDQ;])C?<U\A
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MFG4\RXS^_CTY:R+^DZY/*I==STO:>KI)/F(J,*BOC[]_./IE9W[+W3MV^/\
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ML2G+6T/39=]..0XM;["S>;9YW8V1:[(YV54UK[,-:&5"@8\VGK:MWN(UY/\
MD@  2_S86Q+E.)2$AC<J1D2PT<G=[%C,%4()1)RO8S)4Q2PH@627 :A21Y^-
MQ]-W<F1Z]CZ5M]D:S%KK5]%U:LTWD==09./8>29!U-83M/#(?]K#S2'U,6LQ
M&'M>XE9!(QTMG-S^YK:B\DAHSQS0CXA+&1*%?VX<8<;%(R=Y0_N)" [US9B_
M>C+VK3A."3_[C\PKDK,24I %LQ/AI9MI0<:RS"-/U6*:W@X?)R_%L-H<?QV%
MD)[*CPPLRFKH%:@YAJ.MLK.NJT!&*D=L&LDD"B!&@$9Y*V^<\Q2U)89U+.V4
M*)- *4!8>$8D)"$(20^4(!:I.5J\Z^](AWH=T]M/I^Z;-=Z5VS*P*ROM;5OZ
M-5UOKV9D,NHMJ,':1&GS&9)4U,R%:DER9@Y$, Y41D<48@Y9"$*P8W0P_2B6
MC7]*$!'F<H/7E%U<RCHI2U\W6HJ/+6G)HB/ZJOFG1+LQ[1*88K[69I0T7LBP
MP[(Q<DISOO-3TQA:\A$<OCZ;7>2>/?FOXH_Y&>PT36FX<^'AY7W7 /\ \MA
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MBA:,3PO:YBC[^:I(GE2I;W=[/MKXO$7#*"5L3E[M[D$"GF?2HC75ENL<]O\
M:53E\"W;%HQ'AG41)!1D"*&K5+%9&^&F:5K.SE>C>ZN<C_/X[<_,03,4JX#%
MMK'FVS$CJ[QZ7@^/\,D<$5A%RT]H4E*U4J5 ZY@[/M1G%6$6.=9&#, K))(B
MS7$ 9L9K_2(!4<20%S!.:K@,5!HP?Y.5J?Z;7 )[R<PM9WY'7V#:/..*2PE
MGRU,A3D)!9\S"@=CI=NM7BR&>:VF5NHL4V?43IEK0&L U=K(DQ11QUN0GBH^
M36A..2[W#FJ-7N1@&%8@P-*BO*J)L,5W4Y@;):UKV8O[I$3!%)F@+:AU'[4V
MC7AD>J<ZM-OP<UAWHA4(C193HWN#^M'!&1&D@,C]E"09D145ZN[?ME<1$5._
M.;4GO%1-7INST]DNQ/*/5$<;X3*X/*P>1\4A)S/1U%FJ#Z$,Q'43G9S&"G12
M-3TYAY:F$,+'-&UJ([W/9&$:X(D87T.W[1J.[-541>_)^#,UPP[M=R=*B_4V
MC@<?+,XKGOE%1E-'YC0!@'T?E$YWFN[2!IRAV-"9.F4:9(''LA(>.%I*2\("
M?*@0"RQ%>5B2HK7J$1!"(H'!*Y7,(Q4G8HJ[$FQK04TI\K\XTN'Q")>+DHFI
M)3G%6Y.VCUT]  \4(@ZIV _<#\OD6@IF,,F/L1"-+,1WI+\B@-B*[Q:V,J-;
MZB)]YC4>G=RHG.=(<DEW!KNQ=P14N]+VW$>N3.,\,D\(DR$2QF 4Z&=04:@G
MO,0:FUC$Y7EB$4VM&Y6L*2P>]H1#<K?31CDD?*O:]@6^JQKE5S^SV]^R-^>;
M3"%:6J6I=[Z4K]!R>.$FJE8A"ED925&C-ZTY.QYM$WMUQ*AZ5C[!JCS9U/!R
M9*NYCR0,8:I)8V$\L,;9##O,V-)(BNCH<+2&:=Z-1&"3FRG9C*(-=QM6C7L/
M'2-1)Q$G#XN6F<,TL+!?R8@T:V_5A:C>*:]V;"VY-RJ==LF8\0\XXPI.)*:>
M-(\DC1%AKW&-(W=K45?%$5B^*KWYSZDD.2#55'^7RO;2EO2\9Q?@ZN$2DRY?
M]7(1ER@G,0P<DGR:VM&B?<CNR#;31&J()Y-P\L=K6*AO 8%#)[D:ODD=O]U!
MZ:IXN(O?\'*O)F'"LS!VK_.K -O2D<(E"9HF%("$+(=["H%3XBUHG7$]?29N
MC\TSJNE/FMI<BE+95LL<4+XL"06J]Q85\GW"2"@+.DN5&(!S1R0E8Q$17KS9
M3 KLR0^P#='(OY?(%HU^= Q<H3$A:$$<Q2E*UU'B[;4#Q?7VS8&U9&33;AQ*
M$TF61O:>>0Z7%,CW AOBN[>D\2.&YZN8WMZ:^*K^/-&$*$U1(N27(WH!8GJ+
M681Z;B.-<'7PA,E$M(F)0Q30FB:&^Y-&J_1K%Y)/&"EK E*@CR,J%(A 0?D]
MRBKBCE*)ZJCV"8JC9)<J(CNXU\5?^.QE@  @5%==#XC6YYQP(*9J)N5.5*IA
M:AL7W]=N=A-VNL9G%PC8=[330),(5 RZR37Q)L>= ]@0TZ5%F'(YPYX5BP_)
M@(ZO&)C7*]KG)S8*![ L&I772_0'?<VC3IG2D<0DIF@+0E:2_(*TK71[VIN:
M::LUGMC%]CY!>9!<K(H3#F#8BV!)26:'((T9_H/[^BT3$[N54:J.1&-:J?/-
M%+0H3'(54TKX#WIH-O3.+<6X7/X7)E2T)"PR3W0]$D$.2?W?>+)SC5Q6,:20
M]MB!9+Q1FC:X7V6^*;W!SR%5%"\5DV&P VM?ZG[3LJ=NW-MAU*"T/H069FK]
M'KTCS6=+:3,46">]E3M2E-*.1IZ&/OAZ6Q.!TU: "Y[2.%IK6HU(Q>[7JW#Z
M=%<U4_%JKW5/WI\\]$PU9$K_ ()^7O\ >\>?3_\ .F_\U?.)XYFC%#B$.(0X
MA#B$>*N1%1%7\>Z)_JGX_P"?^[B#^V,4SRCY^H-I%?W](?4G^*=O_2_TO_DO
MRG^B\0BYW$(<0AQ"'$(<0AQ"'$(<0AQ"'$(<0AQ"'$(<0AQ"'$(<-"'$(<0A
MQ"'$(<0AQ"'$(<0AQ"'$(<0AQ"'$(<0C7O\ 5(5/U)]KHYS$:^5A#'H1.XWL
M?FU"UPW]VN;X/:JM<KT\$:J^:HWOR%Q!*582:%.Q L^XVKRC8<+FF1CL/-3=
M*QZT^L?'V#&+TP83+2%,LJ6WG2J_&/M(3C,61']NI(D6P/ZKS!CO,-[HSW=H
M[2"1DI!M5J<),P F$%:'#L#4NU&Y"V^S:1Z7(XPN5F,F9E4Y*F:]; <[_P -
M(S%QNBJ+7$\>QH4B[FEA F9)8.:X]#[;U&W,3'01B)%6+:=PME3Y G2O;]X<
M7P$I#ESR<'*D,M*,J@6.Q9WI;;7<1#Q/%<5B%C\UB)IE$@Y7[INWTUWUC.-I
MY;;;5T3A^G[*G:IM96<J^Q'-(0GMF5<<L7T)M?/>!$(*#*>T!?656C8037/1
M7M0B9\1).)0X8$ O0MRIY$CK2\6\-X@K"8^7,22F05'.AG27(HS>-38MJ(JA
M3UF;MB-3)*.!=^^:RFH[U\D02+91RQE(V2='H&Q*V*]C7NG,"_\ ;J0DDCA/
M5VM5A#,I-2R4TH&]0*^FU8Z7$<70E4Q>'F-GJP).CLQ&H:PY7C)<:L<GJ;&V
M#32D@$G19---'$] \-M>;]E*44A/5$1%^\U)0%5S%>B#4:]U7/*E(D$%LK4#
M/6FM'\=HT4_$+Q&8S5%3Z$F]#KKR/TB2L[S++,XT]CVG[3TS4V#Y"?(L4R48
MWLN,;F'B>U) #*$C31H$E/ G83V?M41[E5_IN;=-3V@TI<!WL;@WY-IJT1,!
M/G82<I;JRJ4X&P<&CT+-MRI%?:N%F,"(4UU50;=DF8&MJ;Q\@,=[Y85%[J,9
MP"(*4\@9,=33)H0%C]T(\SU<Y60%<.1,<J32[./L#1W]:1TR.-)35$TYB.\
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M4)/9*2@J+]]JN;$<P& IOK?WTU7:UDJ7+FR0.EF"Z*43?;G",)?3,K M$XS
MH14'YJ)RN16N&4G=R,Y)E24A(#$$6(I\J/K4T>U(A8B;VH$MW0BF7Y4#4/2F
MSWS<UODA,1EXL^PD'QR59CO15I"JD6%;":YB6$=%1&@*YCE&3Q[(1O;R3NB+
MR^:D+24*J*@FS^+..O(>,-".S45C]3N:_P  CK;QC!98\E'5EE1:V&V/%:R
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MKVZRMM&;;@;==F678ED&;X;7BU@?$$S&1!R_'<7NI6/7L6J-1S3P)D%]@"9
ML0Q&;](N5F8 $U94E(6M"F<@A)!J Z2"*&%2[?Z4J<LV59RI4'(<%5.M(Z:C
M^IITFWN.9+E@,HSJMQS%=7Y[MV==9-I_:N*5\_$]43(-;M:-C\K)<1JA9#E&
MLK>RA4V<8K3.FW=#;%?728GNHDX<85,E]#V>4N"%)FJ2A$P&CI*U!+TKU$&+
MLVI'_<$E67KE2I3;),9]2=<&F\EILOL<>H]W7-SA%UCM/=X#"Z?]QILQ@,PK
M9MQB62AU]+PR-E#L*R6KK+254YH6O!C1BULVM+9AMHQ:]K]+: *4FE<JD@*4
MA;U"BE04-&-":M0<B[@+'-).4%.X<-36.MK^OSIVO;?"Z3$Y^QLXL,\U/"W?
M3Q\%TUM?,20M:S2Y1#%>9$''</L)6-2DNL0N,9=C]Y'@Y&[)_9X\*J):RQQ>
M6NZIB7K+2A:F-,LQ)7+8@.<R10,[Q6K)+44I:4EQ4RR$KO;*35_G2(YS'ZDF
MM:.[U#0XYK3=&46^P^H->GS+L:/K#.\9S?5V0$U!D&X:^=D&&W6-#MY:7..5
MU-.IX@6Q@6%#:V>01[-X\8M87,B05+2G](4F80HD!+R@"L9C1P%!QHPO:**.
M5*BX[I0&>I[4E*&'^Y08<Z<QGAOJ%=,L6PRR+,R3+H57BU-M:Z!F4[6>P8.O
M\W%H^OM;+:U?K+.Y6.AQ78EUAD2BO#6%1BEK93)8Z6X-4,L05-B6+C"P4=H7
M8)[2HRJ,O,$=HD&Z"5)8[$*L03>$*4M,L %2EB70A@L_VJ/]ITKJ""Q$2U0[
MPG[9TQ*VEH'#+')+&R5@\%I=O5V:Z,@9&(TN$./D,H^3X3.RB%B,JKEK?5=S
M$P^R6\KQ,961R$DL<R];HN*O46:XJ]JB,:%!6]&% [E@:;W :E79XZ'I+W]D
M74/KS)<DRW"ZO",IP;;&S]/9)!QG)CYIA-O>:ORB7B]I?X-EDNAQB;>XU.FQ
M"@$>90UDN%:1+2ID@<:O(4@5"% ]V8DJ#AC12D^1RDC<,12*D$+4*.@@."6J
MD*9M%!P%#0^$19]30K0]&.UR$<U@T)B'FKF>HU6_IC1=V*SNWS1_^'P[_>54
M3Y_!8F/+86:>0^8ZQ,P*<^*DI_W?0Q\EN03#1J.B>:(@DIW3+,XYH0CEN?/4
M"R'S&.1HF/$P3&!"YCV1F.\58UWF]W(S,:&2D,&!O0"UG-B!\S5GCM\)PU<R
M8420N9,46RH!)=S2E;Z[:VC#L&K!YM<Q_:2)L6L?.2+/RFLCDFU6*K-<\,";
M:R@HX25H9GIMG1WD&YT9A2B7NWE94P3@QJ0'<>]Z'SO&;$R%X<F5B910H,R%
MAB2+W.C&SB,RNI.24LR;CUX]:674/F8]>BK7'(*]L@2"19,83HR--(AR?31X
M@,5@',<BG>K?'O=VO9$I9AN]WU)\ZW/SLD]G-E*.506 X)T\+4+"UQ&$7=C!
MB536J%D*!#F++0A2Q%#&(@V1I+G>H!?/W*^GV]P\@QHWMZ:/+Y<B8C&H9DD.
M^FY\J#TY1-PO"YT]BC-,-'RI)+7\ZT8.#'2T *RZO8,.!))7P92R2,MPO8]*
MH48836!&L&K02!0&/)8N@"5R3*Z/)>(:DCO5I"S/%*.UF_DBI87UK&3$82;A
MV$Q!24O10*:6Y:[TY;9[;.NL5EY#B=D=8A@/=09*.NDA+'O/9SV$:^%)&CW&
M@R5&*;#)'5JK#,UYGN$O+B#+JU?0UU/K6U&TB"2I>;ND . 15COZ>=AM'%[>
M KXP4:R/65,><DD<8AHQ/&41$$TISFCM_;N&U$<%SG [*OW7*O,7YI#MFJ+^
M_L:4B5)X7/F@*E(5,4;A(4[GI4/_ !RYN/51[QQKZ*WVV/1)B?:%O%>-S:Y)
M:J9/(+%8.0K8_K2D#'!X'& WI#5['>.0$3 'U+ZG5GI2C6^U,,V6O#'LUA25
M[+%QS=_7H6B2LK]_BY+3$2^,B@98UJ6]A3@%)]^K $D030+=B.4<*;#E>]&T
M1Q"E"(!9*.<)&LH#V3U%:]6LY.X-"&OK&)$CM.^:*JP-]7]T&H>CPO>6\>G&
M)AC AT26(I881BQ6(Z2BN:U'2U$I#2% WP^7D&U4<GH.^'+C., HHL-RSM72
M^MMZQ/P_",3."IDH3%@).;*Y &I+4#.U^5X[BDK#V8[3(:YT.+5U3??SFOD,
M"9T669!HD43&,%-,)GD?T6(-Q0QWN8USAJU*YC,% XU.A\^;-72(,U*I*BA0
M(4"Q=PQ%[Z^?/:,LS(YJM_Z//&)(40@#.LJUWFZS%91128R"E,7Y@&"K"B&[
MQ>CC*AO!.P^9BL2DJ2X_35_#[!C]HPR\.9BW2Y)/4@^SRNYWB*)61I3,!7O)
M'C1G6'O8X'>T88LL0_28]#.9ZQE:-ZIZ/WP.<Y5<U7=N\(\0"5Y34)_NH'T?
M3W7:-QAN!8E84N4B8MN\O(@E(U[QM0;WW:.RH_"]+=%,:-7.KVI/CPS%:TEW
M7%-XG]BH@A&:?6,<,\Z"@AN2*XD@/FP+U3,B>)M7II[8>-*4WB/B)"Y2B"A3
M@L2Q]MSIM$A9&)]:V-C[%$*O2)!FRY5>93K;1)K63()GN\D8,+6R1QU&QZ(A
MVJA$54[)4@ $D@$7VWUJ_EY5B&E!G%F=5$L!:XYW'RB$Y5NRNGAASYP"5Q;4
M<W[*8^/ ),]LXB!1AVC=,4B#<@GJUQ!^7=R-^$Y'F8T Y01<5-K;EOY\XV&&
MX3B)R%S$2IA1*JLI02 S7(%>?[&.;7.D3B7MC83JRN]N@9E6) JU;LKS(V16
M"?'"T(;*+&<*<-LM@A60 RO2*V4+TB294U,R@;<&@ZBONWC'6@!P+"BBQH;6
MYL-/VRC)H)B_8P989,"$:IB3F$20\\:X=91U.*8(@&-1(#1^$9@']W"F#DC,
M_P V]FYB,H!--?3FV]Q9GZ8DRPJ@)40"VC@/L]ATS O:(\#DZ4\C[/,^O> T
MA#AKD;#AK(D-$<,0ODC%EE43BN5&*5XG+\E;V3MR/,QB0 @*#:EWYOMLW2M7
MB4GA6,FH,]$I:I0U""S5J6%@SG4#6)8+38+-U@[,_P"T$<'9H,E6N/KT]&^.
M*;2.$CQW,&]C,;#>;S<@BQ9 &)V8Y4>UZ-861)F)4 "KD/%CIZT%:V#1J5I4
MF8X+.6)-+7KK6V];7C"+EIK*'7R7Q20*DL=CA1TDJUUQ*&KO54KD57""-6N$
M\/C\%:]'HBHG:DPA&8%G>GSO>K:\]X578N*$ 7(YL2WUY!C&+1LD=",M<K(3
M!&(THZQ/2$3S$PPXI>_B^418Q'J]&>?IE5$\V^"-Y%_.9%%#.!_=JW2S"FG2
M-A_A>,G2DS.PF(E90<V4@+LQ>A-M=J[1,P:K6]GJL64?IU+!MJ)E!H,[ )=(
MH($C%R1QNB9#4W41K(TD@);"1K*'-$A5]4!!>*(Y'20M*T@@OR;32O)V_@F(
M8EJDJR*#@$DJ-,I&]GK<UU&C1%%\R5:LB2)OE&QQH6.%& 1/6L[!"$ 1DCP?
MZ@O25CG-&_\ 9^AV,HW>352A( <G[1>^?]+TLS5^W6MCS$=;4Y *L).K!P:I
MP)T4HF02M8]XU[.]K+1QO*1YQ2^)V-8\+'O;W<-[?N\L_- '("X2Y!>[W3TZ
M]8S'A^(4@3>Q6$FW=(LSUJ3H/D(F"S;JL^K:2R@Y+D3-OALFBN:&34UT;'7T
M[7&5LB'.B/\ <GD1V,CE\SB1#L,YI1!])2ER"8%AS2]VZN&:PY^D81*F)4V@
MJ22;C?\ :V]X@RP-+R$C"2CN!CT)C$<P2N3WTA'HCE*K'-]5SB=FM U5&U55
M55WY7." :->^@T?7Z,PU O6!W4J[I51+G]1Y:/0]!YQS*V[AU/OZZLCQQMF0
MSUY8ST88H8Q5&1KA>IZBA*A6#(CPM"Y5<HWD<-5[QUXI,M12%6\>ONFO.)2N
M'XA$LSE2IB4$$!126--W:FQM6](EJRDZWEZZQA(LJ^B;/B6$N/?#+&KFX_*H
M"*_V$BM/&""6VQ 5[F20R'2VG:]I4<-$[<N$W.!H#JZ;Z.=7Y[ZF-=V),P9J
M ,2:VITOR;0Q ]O*L<CDQXZ2!LH8[7-/Z"N:DHS"N:]93D[=V^3/%HD(@6O:
MY%:JIVY31V&47VJ'OI\WZ #*0)2LI+E7Z4ZD4J!KM2.^H[.#3&+!J(\94?%F
MP2,(YAO%\L+F>Y:!['L%)8YR$89J(Y'-1C2=_P ;?SC?TQW@":I9];7+5?QZ
M1*7@9XE=N9<Q$LB[$4OF>Q%-14/SB5;"XPHN"8Q$$*R#EL"5+CWDPZ1'PYH'
MG>Z 2 (01F82,!R,FO+*(JL<UJ#7LA>9Y:PI"K@FK']M2S\RQ:L:Q2&6 H]V
MC:G-2U']-M3$86%I)LBJ $J4M:!JB<V.Q0/51D;Y%D&[H_Q3R:UC&_<<Q455
M\U[)D 8.UG+OZ<F\=CM%ZFS)1GJJP:JJ.S<]F(-!2,HQBVBT\P$@8DF>B.2Q
M GDN5Q7D$4<0GIO<K61QR'M)X%&I'.;V1S6]^8_S02Z0>;W/,7TL#0TB2OA\
M]$LS5R9B4D%(401XC8:N0*G4&)9S+,<-DXWBU9CM;:)=UM21<DM9"QFQKZP.
M1A6E!%8/UZ\L!5=",]9<D$H:"F,0+W(-TF3B$J*4JH7%:UM3W7UC3S,.05*#
MJ8$BFS\C;H0UH^WKI4(TW3)T]F8WP:72VLR-;Y>7BCL.IU1/+_I=N_;R^>_;
MOWYV4C_)E?\ !/RCDIK]HM[YB_G$^\RQ9#B$.(0XA#B$<8L.(<L>0>+&,>(]
MQ(IB@$0L8CV^#WQR/:KPO>S[KG#5JN;]U55/CB$1YMG9E/J+!,GS>T@6%Z>C
MH;NWJ<0QX8IF79K84U3+M&8QB-.\HC7F160HA!0*V(A#%=][P1C%5$4^OOY_
M.*T]*?6GC/4/?97K?+, R/1G4+A;[X^6Z@S"/+E23XYC^5V&)"R[#\V;2U6.
M;!Q@EB! 2+'&3S6T=A*^S+4<60\2G0;5WV\?7U;E9I;ZF=_1NGG4F<[$K\3M
M=I97B5#'O:K4>'RX:Y[F0I%Y6T38^/5A5(<Y'2[(0F%6/[59'A'+("XB.1"M
M/7R^\<OISW#I_?.NA;8TR^#]C9=;3I.514IQ4&4U6>P&Q:?):+8M&X4>TJ,^
MQ\E=&H\@KKP#;6*L",%[B1617*AJWCKO7W6I%*1$O5KU=3>G"FKYF'Z8S3J#
ML1R[ ^<T6N9<$DO \4IHE=-M[2Z&@; Y[Z7%MX28GA;(@[;+RK('6D8V*][D
M+G4-O0%^NT3?T_;1U%M_4V+9IHV5!)K5X)=%20(5!,Q']'"XQ-/066*S<1LJ
MZHL<4L<;GUYZB=CMA55TNI-%=%)$"C&IQ >_YU^[U,5KWCUY8!H[=>N,!S7$
MKJ;I7.<7-99#U+4Z N]3ZKRLF9,Q#&:'9-E%">)CU;>W I$']*)$Y*^AMV0(
MMVR &:R:-#GX>]V/2GA%[9%G6PZXMO+L(46I!$6>>SDRXX*\$%HO6=,--*1L
M8<1H?VSI#RH%!?M%?X_/$5C6K;=>.-Q.H*)K?=O3YFF%Z>/FD*ETAU'7N.VF
M68/DFRV7N/8?12I+ZO%)];K6ORZQS5(&KL^M\C'6Y6@;2-&F032XD>4AO7RT
MC9LU?NIW[(OX*G=%^>_RGQ\?[.(1K[Z4^M/7/4ELG-\-RC6-QI/J!P>9GU5C
MF.;"J0PK_9&E:/8%CC$?9NK[Z3"AR<CP"\N<<CDOJV&OKXY? B@N8OIDIK&<
MA%NMQY[:ZOUEF.>T6#Y%LJ\QRH)+IL"Q,7JWV56Q2BAUM/!51F;'23-D 25-
M>$[*^$DF<\!FQU$Y"*Z]*/6)C_40;)L%R7!;_3/4+@\1+;9&GLHJKX1XE2;(
M[O$ZC-</RFVQW':W9."7<O&I+*S+\<'(A)X"@RTBRVH#B*>.WMM']T:,MZNN
MIEW2EK&FV0FJ]@[D;8Y]B^'2L/U=6.N\U;67;ILBZR*HHA!*:\=C5+6V%R:F
MB^C*L11EBPR^Y()KT*^6NG2I>VKW\HF/4VS]>;GU[B^TM49/39CK_-JP=YCF
M1T16&@6,>40OKJJ-1A8TZ/+;(B6L"6,4ZOLP2X4\(9@#B8AJ:_M[\]XJGU:]
M80>GG)L:Q'(>GG96U=7Y!4Q).W<]QG'I.28[@F(9->.Q!%+BD"GN[K8DACR2
MK')L8H(!YE;B0I-O(%( Y([D5WK%MM>YU@>>ZXQ#8>O;VGN=;Y1BM1DF(9!4
MN''HIN*6%<&943X+G- R- =7/"YC7C![9B>#Q!4;F,10'>_R]^]HHOGWU'];
M:]ZC\DT=E^N\QC8/@-QKG&\^WJ\U!(Q+ LPVM7P[76TG),8;-7+Z_7&2%F#Q
MZ'N!E:3"8.;"-C-A-B2(YI0T [5/D+=+O&QJ1-APXRRY<J-%BM]-'2)!PA W
MU7-&)%,1[1)ZCWL8-//[[WM:WNKD145C7/H;ZC>NMW[A=K&TUQF6M WF9;*P
MC36<9::AF4.R\LU+;V]'L##2LJI<JQUSLNI93V5[$U]F0:[(+K#'#R.O::*\
MT<2*?QX5^='TC9%V_P"SYXBL?G9/W)_NXA'K.$<D)8YFM>(PWB*QR=VO&1JL
M>Q4_<YJJU?\ )5Y:M(6DI-B""10L0Q8AB"1J("E1<1K-@?3OR.)IZ[Z8S=3F
M9%Z9@8U-QS6FO@Z^PD69:]C1;./=X (FS9+9T[**[5MK!K#8E"F44"3,AU-=
M79599#%');+ * 0ZR5R^R*9@[JLTE22A1:Y9(2IWS!WJ8H  590 %F85I(<*
M[5*A,H?]145<C41EU!T*6)MF8MN_9^[;38FW:3;6!;&M,AB8+28;06=#K/6>
MV-<8A@5;B]?9V+::#'=N++<JL[L]K<6EC=RR :D6J;!A5X)"9@6D =Z>I0_U
M*G2DR7?_ &2TI2GI6\6K1G2$YE!A)2"Y-)4WMF(_WJ<*-*6M6&-^?3EM;GIN
MRW ]:9G,OL\K-,=<6$81!MHU520;V_ZO\Q3/NUE9GD'CU(\3M "J()WB/'FQ
M7K,GM"K%$L>9)S90@U1)PN'NS(DXG#3LX/\ U,LB@L2;AXS%;DJ(M.F3P'IF
M7*FRVL2P[4D4H0-GC(<H^G!D.PPW62["ZBK7+-H9!E&K)]M<6^LL837=]@>H
M,<SRAQ'6>;:GJ[>NI,RI1V.R<ISBRDS[4 )V>)16XZF+4T4&@;(* %*4FA7,
M5-F$USK,M,I*A8)*):0$T(W$8D#* X#IEHEH8ET)2K/E!!U43FW%'UCO-:_3
M8H=9:FR?5=#NG.ZW](>D^'TKQ,RQFNK,2RG&X$#+]JY=$SW'I%.9D:KOHY]H
MR(L>! #%@Q1TT9\4@/<*./68,Y67(SC#<_\ VTKL@39\P<FS$TI%R>[EH.Z9
MZK,YGK"STRLPC$<#^E['UT%EQBFXZ_',\A]2.%=2=/:8OIO%\=P:IR#%]*V>
MAK/'@Z\B7A!2*O(L(O+F5(L9>0FN@9-*%=&G3T ^&>XETRTD I0J>2/]0Q"4
MI4GEE">Z:FI?1B@% @B\N2AW_NDS%34S#1BIU5#-01V-A],>)=8O)UC>;VR6
MQT]B]#U#5NCL'3"L>B6&K[3J)Q/.\+NK:YRT$Q+#80<+QW9.7U6%5LZ)1M#"
MLA_;\J]GPHE@+%V8R!)+D2!ATKU$H&6P:Q.64A)4:EB=3%P6>U$TU_K">I-0
M%3 5$&AT*E%B#?I%SMN:<S'-^GN[TOK;;UWIG*K'#JG#:K;=#1P[G(,=B1&U
M\*SGU=9)G0 @L[.GC3:^/81["+/I#V"6M5+#808AF7S@)RBI5 I94I(=B"22
M@U!RDGV:Q:@!  J62P+LQ8 *ZAOEM'KZ8M+Y!H#5%)JRZR[%LN@8KVK\4?B&
MMHNKZBEQH,6**)3_ &%&R7*G3YK93)L^??2[1]A;2IY9$]"RU-*D5-6Y:7#6
M2$C^T)T H!04BT AZN[7 <G51(N57,5P^JK8/K.BG8DIIXD1GZ4:I!(F3Y*0
MX<.+)V?B8)$N1)5KFA%&$1QWO<GCXL5'?"\C8R4J=AYDM'ZE"G@7B9@IG98F
M4LA\JK>!CY0>HG [#,L8R_#HUF.IMI+BQQ6\,J28TH@9#3-.V0!ZI(KI[41O
MF%SFECO;(9Y-<B<\WQ$J8F8I!?,%E%;L "^E3IKTCU/X<Q\G!XV7B9X9!4&(
M(-" ]_%]QXQ%^AJC<73]J[(L'J\T$HMAOKL<R6%4PQE@/I)-LTCHTQTF/Y$.
M(Y)1O>-1A6L.H D8Q7+R9P\+02E7^FI.@V&AYZWVC8_%/%N&<2FH5ATLL*"B
MK<'1J..=*N3:)_VAKW*,2OM63_TA'?4N;41[2ER,\677";92 V-=-@2BD>AB
M6L*W$L(,A7/=)>2*\:)ZO?DO&AJN[I-=>6K^-=?#G<(43#EHFM0!_:"XIL"Y
MMUO%1]L:DR?:6$&I:"S#36<>='D+[IYQBF(#S&6')]%SG,:KGM(UWIO:A!HU
MRNYH<1+=+CKY EO'KL>4=9P+C6$X-B%#%I2L%PD$.&<G0$VL+BC$1ZL UUE>
M"4F+XK/F/M9S+RI/,+7CDD"! O*LDC1-\3N#$K"34^?2]=KWB(BM=V61@>U2
MH)-K#KIX'E4L8Q_$'$\+CYRL3A\J4%-$"F7K0: /3IK%D=BX5;878ZVN:RXD
M7%/GE#D(::\-"-7K[\<JPH95257'5"&<]K/3D"*\)/?1QM>C1-Y-Q 4D:[$\
MNAKU!&O*.;P,U,T+0X;,Y#/M9K/32O)XJ7M_4.1[2QJ'4T]G'J)D"T64\,I9
M'MY2+'((@9+A+ZC"!7]HUGBY$<B*J]N[N:J=+42XU+;,WU-OYIUG N+X3A*E
M?F0E85F9]JL* [[,+1(FN<#O\<J*S$+ LJV6-%ACM35L"5,021S!8DSVD5'$
M],2O\&*1?%4*K7.1"IWEX%,S,$U(!I3P.SZ4I47C0\=XC(Q^,5B9 0F600P[
MH=W?1M: 4U#5BPV>ZPN<5CXE.QFXFWN+YO29C'IY\JN-6'+;8W-:R91,"XY
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MIKN?'4?+>GF^.5*6E,R4P2I2E,U;[6-QSLXB>\XUI?U&K<,V="DOM\7R"Q=
MERQP?:BI[X-<V7(J2O8<K2'0+7$9W],A *TSQM<[MR=BT94NG:WO2C4TZB(N
M$6CMDI67=GZ:,[]0_P!*T(GZ.S"9MT&?"R*,RF2>":Z*A)+)B#8C4=6M9W4+
MP*O=7N\OO"5&J-7-\EY]065*40ST#FS':YH-69X]-/'^'R^$2,$H@S)2"D@
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
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>g98473g19d04.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g98473g19d04.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_[19B4&AO=&]S:&]P(#,N,  X0DE-! 0
M     $H< 5H  QLE1QP!6@ #&R5'' (   (  !P"4  (<G(U,#DQ-C<< @4
M(4UI8W)O<V]F="!7;W)D("T@1V5N97-I<R!&+3$N9&]C>#A"24T$)0
M$")*^(M6HN%I'>),'8-E9Y0X0DE-!#H      .4    0     0      "W!R
M:6YT3W5T<'5T    !0    !0<W138F]O; $     26YT965N=6T     26YT
M90    !#;')M    #W!R:6YT4VEX=&5E;D)I=&)O;VP     "W!R:6YT97).
M86UE5$585     $       ]P<FEN=%!R;V]F4V5T=7!/8FIC    # !0 '(
M;P!O &8 ( !3 &4 = !U '        IP<F]O9E-E='5P     0    !";'1N
M96YU;0    QB=6EL=&EN4')O;V8    )<')O;V9#35E+ #A"24T$.P     "
M+0   !     !       2<')I;G1/=71P=71/<'1I;VYS    %P    !#<'1N
M8F]O;       0VQB<F)O;VP      %)G<TUB;V]L      !#<FY#8F]O;
M    0VYT0V)O;VP      $QB;'-B;V]L      !.9W1V8F]O;       16UL
M1&)O;VP      $EN=')B;V]L      !"8VMG3V)J8P    $       !21T)#
M     P    !29" @9&]U8D!OX            $=R;B!D;W5B0&_@
M    0FP@(&1O=6) ;^            !"<F1456YT1B-2;'0
M  !";&0@56YT1B-2;'0               !2<VQT56YT1B-0>&Q <L
M      IV96-T;W)$871A8F]O; $     4&=0<V5N=6T     4&=0<P    !0
M9U!#     $QE9G15;G1&(U)L=                %1O<"!5;G1&(U)L=
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M____   X0DE-! T       0   !X.$))3009       $    'CA"24T#\P
M    "0           0 X0DE-)Q        H  0         !.$))30/U
M  !( "]F9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &       ! #(    !
M %H    &       ! #4    ! "T    &       !.$))30/X      !P  #_
M____________________________ ^@     ________________________
M_____P/H     /____________________________\#Z     #_________
M____________________ ^@  #A"24T$"       $     $   )    "0
M   X0DE-!!X       0     .$))300:      ,U    !@             "
M3   !.<          0                         !              3G
M   "3                      !                         !     !
M        ;G5L;     (    &8F]U;F1S3V)J8P    $       !28W0Q
M!     !4;W @;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG
M   "3     !29VAT;&]N9P  !.<    &<VQI8V5S5FQ,<P    %/8FIC
M 0      !7-L:6-E    $@    =S;&EC94E$;&]N9P         '9W)O=7!)
M1&QO;F<         !F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U
M=&]'96YE<F%T960     5'EP965N=6T    *15-L:6-E5'EP90    !);6<@
M    !F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
M         $QE9G1L;VYG          !"=&]M;&]N9P   DP     4F=H=&QO
M;F<   3G     W5R;%1%6%0    !        ;G5L;%1%6%0    !
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M300H       ,     C_P        .$))3001       ! 0 X0DE-!!0
M  0    &.$))300,      O3     0   *    !+   !X   C*    NW !@
M ?_8_^T #$%D;V)E7T--  +_[@ .061O8F4 9(     !_]L A  ," @("0@,
M"0D,$0L*"Q$5#PP,#Q48$Q,5$Q,8$0P,# P,#!$,# P,# P,# P,# P,# P,
M# P,# P,# P,# P, 0T+"PT.#1 .#A 4#@X.%!0.#@X.%!$,# P,#!$1# P,
M# P,$0P,# P,# P,# P,# P,# P,# P,# P,# P,# S_P  1" !+ * # 2(
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ME2KZG8;/2;96^T<T7!U-OR:/5>_^QCI*=1,J@Z@0=MU%C2.=D6_]"HNO_P#
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M)25!R,<W^G^ELJ]-P?\ HS&Z#.Q_[U?\A&224__9 #A"24T$(0      50
M  $!    #P!! &0 ;P!B &4 ( !0 &@ ;P!T &\ <P!H &\ <    !, 00!D
M &\ 8@!E "  4 !H &\ = !O ', : !O '  ( !# %, -@    $ .$))300B
M      %&34T *@    @ " $2  ,    !  $   $:  4    !    ;@$;  4
M   !    =@$H  ,    !  (   $Q  (    >    ?@$R  (    4    G $[
M  (    )    L(=I  0    !    O    .@ +<;    G$  MQL   "<0061O
M8F4@4&AO=&]S:&]P($-3-B H5VEN9&]W<RD ,C Q.3HP-SHR,2 Q.3HU,#HR
M.0!R<C4P.3$V-P       Z !  ,    !__\  * "  0    !   $YZ #  0
M   !   "3          & 0,  P    $ !@   1H !0    $   $V 1L !0
M  $   $^ 2@  P    $  @   @$ !     $   %& @( !     $
M     $@    !    2     $X0DE- _T       @          /_A 4A-30 J
M    "  ( 1(  P    $      1H !0    $   !N 1L !0    $   !V 2@
M P    $  @   3$  @   !X   !^ 3(  @   !0   "< 3L  @    D   "P
MAVD !     $   "\    Z    \     !   #P     %!9&]B92!0:&]T;W-H
M;W @0U,V("A7:6YD;W=S*0 R,#$Y.C W.C(Q(#$Y.C4P.C(Y ')R-3 Y,38W
M       #H $  P    '__P  H ( !     $   3GH , !     $   ),
M      8! P #     0 &   !&@ %     0   38!&P %     0   3X!*  #
M     0 "   " 0 $     0   48" @ $     0             #P     $
M  /      ?_A0 !H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O #P_>'!A
M8VME="!B96=I;CTB[[N_(B!I9#TB5S5-,$UP0V5H:4AZ<F53>DY48WIK8SED
M(C\^/'@Z>&UP;65T82!X;6QN<SIX/2)A9&]B93IN<SIM971A+R(@>#IX;7!T
M:STB061O8F4@6$U0($-O<F4@-2XS+6,P,3$@-C8N,30U-C8Q+" R,#$R+S R
M+S V+3$T.C4V.C(W(" @(" @(" B/@H@(" \<F1F.E)$1B!X;6QN<SIR9&8]
M(FAT=' Z+R]W=W<N=S,N;W)G+S$Y.3DO,#(O,C(M<F1F+7-Y;G1A>"UN<R,B
M/@H@(" @(" \<F1F.D1E<V-R:7!T:6]N(')D9CIA8F]U=#TB(@H@(" @(" @
M(" @("!X;6QN<SIX;7 ](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"\B
M/@H@(" @(" @(" \>&UP.D-R96%T941A=&4^,C Q.2TP-RTR,50Q,3HT-3HS
M-RLP-3HS,#PO>&UP.D-R96%T941A=&4^"B @(" @(" @(#QX;7 Z0W)E871O
M<E1O;VP^061O8F4@4&AO=&]S:&]P($-3-B H5VEN9&]W<RD\+WAM<#I#<F5A
M=&]R5&]O;#X*(" @(" @(" @/'AM<#I-;V1I9GE$871E/C(P,3DM,#<M,C%4
M,3DZ-3 Z,CDK,#4Z,S \+WAM<#I-;V1I9GE$871E/@H@(" @(" @(" \>&UP
M.DUE=&%D871A1&%T93XR,#$Y+3 W+3(Q5#$Y.C4P.C(Y*S U.C,P/"]X;7 Z
M365T861A=&%$871E/@H@(" @(" \+W)D9CI$97-C<FEP=&EO;CX*(" @(" @
M/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O=70](B(*(" @(" @(" @(" @>&UL
M;G,Z<&1F/2)H='1P.B\O;G,N861O8F4N8V]M+W!D9B\Q+C,O(CX*(" @(" @
M(" @/'!D9CI0<F]D=6-E<CY!8W)O8F%T($1I<W1I;&QE<B Q,"XQ+C$V("A7
M:6YD;W=S*3PO<&1F.E!R;V1U8V5R/@H@(" @(" \+W)D9CI$97-C<FEP=&EO
M;CX*(" @(" @/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O=70](B(*(" @(" @
M(" @(" @>&UL;G,Z9&,](FAT=' Z+R]P=7)L+F]R9R]D8R]E;&5M96YT<R\Q
M+C$O(CX*(" @(" @(" @/&1C.G1I=&QE/@H@(" @(" @(" @(" \<F1F.D%L
M=#X*(" @(" @(" @(" @(" @/')D9CIL:2!X;6PZ;&%N9STB>"UD969A=6QT
M(CY-:6-R;W-O9G0@5V]R9" M($=E;F5S:7,@1BTQ+F1O8W@\+W)D9CIL:3X*
M(" @(" @(" @(" @/"]R9&8Z06QT/@H@(" @(" @(" \+V1C.G1I=&QE/@H@
M(" @(" @(" \9&,Z8W)E871O<CX*(" @(" @(" @(" @/')D9CI397$^"B @
M(" @(" @(" @(" @(#QR9&8Z;&D^<G(U,#DQ-C<\+W)D9CIL:3X*(" @(" @
M(" @(" @/"]R9&8Z4V5Q/@H@(" @(" @(" \+V1C.F-R96%T;W(^"B @(" @
M(" @(#QD8SIF;W)M870^:6UA9V4O97!S9CPO9&,Z9F]R;6%T/@H@(" @(" \
M+W)D9CI$97-C<FEP=&EO;CX*(" @(" @/')D9CI$97-C<FEP=&EO;B!R9&8Z
M86)O=70](B(*(" @(" @(" @(" @>&UL;G,Z>&UP34T](FAT=' Z+R]N<RYA
M9&]B92YC;VTO>&%P+S$N,"]M;2\B"B @(" @(" @(" @('AM;&YS.G-T179T
M/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O<U1Y<&4O4F5S;W5R8V5%
M=F5N=",B"B @(" @(" @(" @('AM;&YS.G-T4F5F/2)H='1P.B\O;G,N861O
M8F4N8V]M+WAA<"\Q+C O<U1Y<&4O4F5S;W5R8V52968C(CX*(" @(" @(" @
M/'AM<$U-.DEN<W1A;F-E240^>&UP+FEI9#HV,T5%0T(U1$(Y04)%.3$Q.$4W
M0T$P,# S-49&,S@R,SPO>&UP34TZ26YS=&%N8V5)1#X*(" @(" @(" @/'AM
M<$U-.D1O8W5M96YT240^>&UP+F1I9#HS0T,S1D5"0S@T04)%.3$Q0D%%,#@P
M1# Q0S5!-T4W13PO>&UP34TZ1&]C=6UE;G1)1#X*(" @(" @(" @/'AM<$U-
M.D]R:6=I;F%L1&]C=6UE;G1)1#YX;7 N9&ED.C-#0S-&14)#.#1!0D4Y,3%"
M044P.#!$,#%#-4$W13=%/"]X;7!-33I/<FEG:6YA;$1O8W5M96YT240^"B @
M(" @(" @(#QX;7!-33I(:7-T;W)Y/@H@(" @(" @(" @(" \<F1F.E-E<3X*
M(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C
M92(^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IA8W1I;VX^<V%V960\+W-T
M179T.F%C=&EO;CX*(" @(" @(" @(" @(" @(" @/'-T179T.FEN<W1A;F-E
M240^>&UP+FEI9#HS0T,S1D5"0S@T04)%.3$Q0D%%,#@P1# Q0S5!-T4W13PO
M<W1%=G0Z:6YS=&%N8V5)1#X*(" @(" @(" @(" @(" @(" @/'-T179T.G=H
M96X^,C Q.2TP-RTR,50Q,CHS.#HP."LP-3HS,#PO<W1%=G0Z=VAE;CX*(" @
M(" @(" @(" @(" @(" @/'-T179T.G-O9G1W87)E06=E;G0^061O8F4@4&AO
M=&]S:&]P($-3-B H5VEN9&]W<RD\+W-T179T.G-O9G1W87)E06=E;G0^"B @
M(" @(" @(" @(" @(" @(#QS=$5V=#IC:&%N9V5D/B\\+W-T179T.F-H86YG
M960^"B @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" \
M<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @
M(" @(" @/'-T179T.F%C=&EO;CYS879E9#PO<W1%=G0Z86-T:6]N/@H@(" @
M(" @(" @(" @(" @(" \<W1%=G0Z:6YS=&%N8V5)1#YX;7 N:6ED.C8R145#
M0C5$0CE!0D4Y,3$X13=#03 P,#,U1D8S.#(S/"]S=$5V=#II;G-T86YC94E$
M/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z=VAE;CXR,#$Y+3 W+3(Q5#$Y
M.C4P.C(Y*S U.C,P/"]S=$5V=#IW:&5N/@H@(" @(" @(" @(" @(" @(" \
M<W1%=G0Z<V]F='=A<F5!9V5N=#Y!9&]B92!0:&]T;W-H;W @0U,V("A7:6YD
M;W=S*3PO<W1%=G0Z<V]F='=A<F5!9V5N=#X*(" @(" @(" @(" @(" @(" @
M/'-T179T.F-H86YG960^+SPO<W1%=G0Z8VAA;F=E9#X*(" @(" @(" @(" @
M(" @/"]R9&8Z;&D^"B @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E
M5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z86-T
M:6]N/F-O;G9E<G1E9#PO<W1%=G0Z86-T:6]N/@H@(" @(" @(" @(" @(" @
M(" \<W1%=G0Z<&%R86UE=&5R<SYF<F]M(&%P<&QI8V%T:6]N+W9N9"YA9&]B
M92YP:&]T;W-H;W @=&\@:6UA9V4O97!S9CPO<W1%=G0Z<&%R86UE=&5R<SX*
M(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @(" @(#QR9&8Z
M;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @
M(" \<W1%=G0Z86-T:6]N/F1E<FEV960\+W-T179T.F%C=&EO;CX*(" @(" @
M(" @(" @(" @(" @/'-T179T.G!A<F%M971E<G,^8V]N=F5R=&5D(&9R;VT@
M87!P;&EC871I;VXO=FYD+F%D;V)E+G!H;W1O<VAO<"!T;R!I;6%G92]E<'-F
M/"]S=$5V=#IP87)A;65T97)S/@H@(" @(" @(" @(" @(" \+W)D9CIL:3X*
M(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C
M92(^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IA8W1I;VX^<V%V960\+W-T
M179T.F%C=&EO;CX*(" @(" @(" @(" @(" @(" @/'-T179T.FEN<W1A;F-E
M240^>&UP+FEI9#HV,T5%0T(U1$(Y04)%.3$Q.$4W0T$P,# S-49&,S@R,SPO
M<W1%=G0Z:6YS=&%N8V5)1#X*(" @(" @(" @(" @(" @(" @/'-T179T.G=H
M96X^,C Q.2TP-RTR,50Q.3HU,#HR.2LP-3HS,#PO<W1%=G0Z=VAE;CX*(" @
M(" @(" @(" @(" @(" @/'-T179T.G-O9G1W87)E06=E;G0^061O8F4@4&AO
M=&]S:&]P($-3-B H5VEN9&]W<RD\+W-T179T.G-O9G1W87)E06=E;G0^"B @
M(" @(" @(" @(" @(" @(#QS=$5V=#IC:&%N9V5D/B\\+W-T179T.F-H86YG
M960^"B @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" \+W)D
M9CI397$^"B @(" @(" @(#PO>&UP34TZ2&ES=&]R>3X*(" @(" @(" @/'AM
M<$U-.D1E<FEV961&<F]M(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @
M(" @(" @(" @/'-T4F5F.FEN<W1A;F-E240^>&UP+FEI9#HV,D5%0T(U1$(Y
M04)%.3$Q.$4W0T$P,# S-49&,S@R,SPO<W12968Z:6YS=&%N8V5)1#X*(" @
M(" @(" @(" @/'-T4F5F.F1O8W5M96YT240^>&UP+F1I9#HS0T,S1D5"0S@T
M04)%.3$Q0D%%,#@P1# Q0S5!-T4W13PO<W12968Z9&]C=6UE;G1)1#X*(" @
M(" @(" @(" @/'-T4F5F.F]R:6=I;F%L1&]C=6UE;G1)1#YX;7 N9&ED.C-#
M0S-&14)#.#1!0D4Y,3%"044P.#!$,#%#-4$W13=%/"]S=%)E9CIO<FEG:6YA
M;$1O8W5M96YT240^"B @(" @(" @(#PO>&UP34TZ1&5R:79E9$9R;VT^"B @
M(" @(#PO<F1F.D1E<V-R:7!T:6]N/@H@(" @(" \<F1F.D1E<V-R:7!T:6]N
M(')D9CIA8F]U=#TB(@H@(" @(" @(" @("!X;6QN<SIP:&]T;W-H;W ](FAT
M=' Z+R]N<RYA9&]B92YC;VTO<&AO=&]S:&]P+S$N,"\B/@H@(" @(" @(" \
M<&AO=&]S:&]P.D-O;&]R36]D93XT/"]P:&]T;W-H;W Z0V]L;W)-;V1E/@H@
M(" @(" \+W)D9CI$97-C<FEP=&EO;CX*(" @/"]R9&8Z4D1&/@H\+W@Z>&UP
M;65T83X*(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" */#]X<&%C
M:V5T(&5N9#TB=R(_/O_; $,  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! ?_; $,! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! ?_  !$( +P!D@,!$0 "$0$#$0'_Q  >  $  @(#
M 0$!            !P@%"0$"!@0#"O_$ % 0   & @$# @(%"0,%# L   $"
M P0%!@ '$0@2$Q0A%3$)%B(S01<C)%%A<7*QLC)6E1A$4F.!)C538F1T@J&S
MP=/P&2<T0D94A9'1U?'_Q  ; 0$  @,! 0               08#! 4' O_$
M #\1  (" @$"! ,#"P,#! ,!   ! @,$$042(083,4$B4? 4,F$'%2-"<8&1
MH;'!T212X3.2\31#4V,61()B_]H # ,!  (1 Q$ /P#^_C & , 8!'ENV3!T
MRV:NITFWD%I+;-FFZK7EFB2)VC60@:39;X[5DSJ+)*(MCQ-6?H('03<',]4;
M)F3(D8ZJ8$AX P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@''XC^X/^_ .
M< 8 P#\EU2H(K+F 1*BDHJ8 ^8E3()Q .?;D0#VY_' /!ZIV+$;=UM2=G0#5
M\QA;U78VRQC23(B20;LY- KA%)X1!59$JY"& % 354( _(PX!(. , 8 P!@#
M & , 8 P!@# & , 8 P!@# ,6H(^0_N/]LWX_P#&' ,I@+T0P!@# -:^^[3K
MF ZONB9LSA[2WMD_U";&KDG*R-<V''5Y5=[TR;J=I?#9V;BT:5*F6<L6J":,
M _65-Y%%4N4F[H ^)3A!P4GIV2Z(_C)IM+]NHO\ @9JL>Z^-\J82FL>G[1=K
M]2F-E=4IM?)2M@GKTZMOLFULHS[,(P!@# & , 8 P!@# & , 8 P!@# & ,
M8 P!@''XC^X/YC@'. , 8!%FVQI05H/KO%3DM'BJX!HC!0=OG7";ST+GA59O
M3F;Q\BB"7D**SHA6H',4@F\IB ($1]"@HCT<=-7IRG(W_(_2_ 10BJ:A$?A*
M'C*=-<"K)G*3M Q%B@J4P"50 , X(7]W_4M?@D8 P!@# & , 8 P!@# & ,
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MR&6E/?==T^Z:]SQYQ<6XR34HMQDGM-2B]--/NFFFFGW3]3O@@8 P!@# & ,
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M,QT"D\?15TO$ 2F FE*&4#$$IB& L&V !(8AU""40 !*)%%"B'':<P<&$/\
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M.$3\_C^'XX!6;H?]^D+IS]^?_5-4??\ ^FIX(7]W_7^_J6HP2, 8 P!@# &
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MTZL.ESJEJ01JDM!+MY0J"$M2=CL6+44) 5?S4:N+\SFOO)(BZ8+,TF$DY=F
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M6/#?929* "!@ 2B @(<@(#R @/R$!#V$,VS@-:[/LUV:?L<X P!@# & , 8
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M_P"1QTU>G,8[?\C]+\!SG54.='X2CXCG47$RQSF3[3&.L(JF,(F4$3B. O\
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M$#]3M CF-:";K83<;-2DP[-)NV%E=I"X36CWJRA/3S4F>-12,N!3]C)! Y!
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MR7W^T8]<I8=CT^]N+6G/'DWKX\12K^6+'O)UDLO1CTX315F!+1N#4)UUCG&
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M$3-QD6*#E9J<0X\K-R<@N&:P<_96:JI*E'W*<!]\ A.Q=,U0E%#O8.=M5:E
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M'$<J<JE8,6+(#>F9MDD@-?6Q8Y-#KEZ8WH0[UJHXV]M,II-6ER<2U=@/3KM
M>U&TN-05EA,B;M 03;;,M1E (*A6[@$#+L0-GV , 8 P!@# & , 8 P!@# &
M , \1;-=5"Z"1>;B2_%$4A0:6",7<0]C8I"(B*+2=C%6LFFU,)A%9B9P=@Y
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M9W3_ *;ZF:XB4 6F=86%"F691,!X.J.M]JIOX-1P).XWA8[#$#'$"D H"(E
MPU2WUTU1ULA8J?B-N=,]P6DFB+2L;&@[]K>K2SY58J:,<D^26>:GGDG*QRI
M1C+. 5$Q>PQ1$. -@P"!@ Q1 Q3  E, @(" AR @(>P@(>X"'L(8!S@&*4^\
M4_C-_4. 97 & , 8!KHW-$%;]6O2=(P[ZB'F'6XMG%4;HRL\\GD2#TY[7,I\
M8C#3BS%L7A,H',SC68E5,@'<!3G*H!?+MN/O^=K7S+V_H\I\N [^?TKY]W/;
MQ^''/O@#MN'_  M:^1O\WE/GW?9_SGY=O'=[<]WR'C ';<.0X5K7' <_H\IS
MSQ]KC]*^7=\OV?,.<#O]?+W_ +G %N/XJUGG[7R;RGZQ[?\ .OU<=W[>>/;
M';<?;\[6?F'/Z/*?V>T.[C])^?=SQ^';P ^_O@'/;<. X5K7/ ]WZ/*<<]P]
MO >J^79QSR//=R(#QP&!]?X..VX\_>UGCN#C]'E.>WM#N_SK^UW\\?AV\<^_
M(X!R);C[\*UKY>W+>4^?</'/Z5\NWC_I<^_& !+</P5K7S#YMY3Y<!S\G7S[
MN>/E[<>W.  +<?Q5K7]GVX;RG]KD?^5?V>./V\\^_'M@?7UV';<.?O:UQS_\
MO*<\=H<?YU\^[G_H\?(><#Z7U]?L EN' <*UKN[?M<MY3CN[AXX_2N>WLX^?
MN!N?F'' ?2 %N'/NK6N.??AO*<\<!Q_G/S[N?V<<?CS@#MN/'WU:Y_YM*<?,
M>?\ .O\ 1X_V\^_& !+</P5K7'=^+>4_L\!_RG^USS^SCC\>< X[;C[_ )ZL
M_(./T>4^?(\\_I7R[>./V\_A@?3^M?X(VLNU%:G8OJS,.H1*1,C37!1*T=@W
M\-YMJE*AC>1:42,/BFD3FD!!+M;,C)K$%9012#)"N5B;CKLY)[??<:+LA]OE
MY=$TG[RU'WV??ER\M6=NE^=KYOR%1U_O_P!1#2^2D_8C%EU3QKZS1U5(R].^
ME7D4@T<NVL>DS.QGK$C5(*9X"VF?*-Y6?73CTX=!DM:H\A5)*9@(R*%-X?X4
M9-)ZZ>\8OJ:VI64?::H]*;;=E"<]Q3C6TU:X=M_'NX^ZC9-=I+<*;'3;+;6E
MT6+I49=,I[BZXRV]6[+W=I>_CO[0[NWGM[N/M=O/(\<\\<B(\?/('_!VP!@'
M'XC^X/YC@'. , 8!!F_89.:J+=!6)5EP2>+K @CKQCL<R0A'NR^88M^Y;)L2
MAR)?7D,8X"8$0+PKS@$+]#%F(SZ.^FMI]7K2<&^H*6W[T*\HDB/AB42<II$5
M$J2?V/LIEY*0."%'@ P1Z?CZ_P V_P!W[O8M;];B^_\ N;MW^!+>_OQ[?G?_
M "'O@G]W_'U^ ^MQ?[MV[_ EOU<_\+Q_LYYY]N,#]W[_ *[CZW%_NW;O\"6_
M;_K?_P"\AQ@?N^OKZ]-OK<3^[EN_P%;]G^L_;_U#S@C?X/Z^OKOH%N*//^YN
MW>WZX);]OR'R\#\OP_6'Z\$_\?S_ ,>X^MQ?[MV[_ EO_%P -N+_ ';MWX?*
M"6_'G_6\?A[_ +PP/W?7_/\ Y'UN+_=NW?X$M_XO_GC 'UN*/_PW;O\  E@_
MFK@#ZW$XY^KEN^?'^\2W/_:?+]V /K<7^[=N_P "6_\ %XP!];B_W;MW^!*_
MM_UO[/Y8 ^MQ?[MV[_ EOV?ZW]OR^?L. /K<3^[=N^7/^\*WZA'C[SY^W_W$
M,#]W]/\ (^MQ?[MV[_ EOV?ZW]O[_G@'Q/I^-DVRC.3IUBD&:A1\K5_6/5ME
M"\>X*(N!42,''X&*/ZOG[8!BG&V:C'QYY)V+YC%MD&:RCYP@U;L4&SXQTH]4
M[@[PJ"2+LR1R-#B<I%Q3.5$3B0P ?;6^VWTK\9:4M?MTT]?)I^Z#36WTOMO?
MX)/3;WZ)23B]^C31FJSL"OVYX^909W#I6,4%"2.4K=1&/<]A5"M'IV[E?TSI
M0AN]-!8I#G*!A ."CCVWKMMK?MN+U)?MCVVO;:(W[>^MZ_!^C_?_ "/0J?>*
M?QF_J'!)E< 8 P!@%&=T'*;J?Z.R!K]["F#<FS1&YJDIX-)T Z;]N\I(FBYU
MY9A%7[P/BT0R3X:CY#%4\!5 +S8 P!@# & , 8 P!@# & , 8 P!@# /'V+7
MM!N#A-W;:14;0Z29FCTG-BKD/-N$V!W*3TS%-:29N5",S/$$'8MBF!$7**2X
MD\J9# TMMZ[O2;]VHMM)_/3;:^3;UZD[>DMO2<FEMZ3G%1FTO1.44HR:^]%)
M/:/Q/K772CAJZ4H5,.Z93GUG9.3U>$,NTLG8DE]86RPL140G/&@@G\62,5_V
M(I%]1VID I=FI+M)=2379I3^^D_5=?ZVOO>^R-)IIK:ETN2]I."U!M>_0NT=
M_=79:/;8 P!@''XC^X/YC@'. , 8!&NT3PI*Z(S>P7>NVXF<>*39SD'!'?+>
MC7_0#.9UF];K%$O<MX42$7Y3 X'["F 0(;Z%A(/1UTUBFN9TG^1^F>-R8Y%#
M."?"4>U<5$P*FH*Q>%!.0H$/W=Q0 H@&"%_=_P!66NP2, 8 P!@# & , 8 P
M!@# & , 8!U,4#E,4?D8HE'C]0AP/_4.0UM-/T:U_$+MW*UM.F6!9M2LBWF\
M*MT8Z$C69%OJDH#-.N+3(P:R8&JPD778,9^4C %X5PDNV7(LX25?HI.R_<IR
MFFI/:EU=7HM^93''L:TNW53",>WIK<>EGU9.5CZGI-3G8M>TI7+(7[5&Y=23
M[:;4E):UZW4^CJUIYQ,FK,O8G<?)L(B+90\RYCG3* C8=S+O$&D6LVC&<BN"
M[R;D'+IQ,/91V<ZA"$7312*GCJ^'ITG\47U/[W3"N-5</ETPA!)-ISEZSE)]
MSXUZ=WJ/7I>W59/KLG\]RE[)J$5VC%+L2HI]XI_&;^H<^23*X!B9^70K\%-3
MSE)9=M"1,C+N$&Q2F<+(1K-9ZJD@4YB$,LHFB8B13'*43B4#&*'(@!KM_P#2
M*1GY&#;.+J\_QXEV6IQZF:\M"Q0E;]. =4"TNG;/JV*ZC<M!$L 5/ZL%*:_&
M+!BY+%"$_@%D-2=2,=L:/V_*V&M+45EJK9S6@ )I12TN)J.EM>:ZV+ V%9K$
M1":T0Y?QFQ6#1W!$+*_#';)P!Y5R4P^(" .H_?>K(C;?1Y97T[*%@Z_N*_+S
M+]M3+P_+'HO^GO;<8S57185MRX!-=^Z;MBF*B8 45+WB4O)@#:?H]DO&ZZ^E
MHKQ./-LEZ5^LV6>(L1UWM ':K-LJW0<.DVPTOS';(+.VJ*RY2"DDJY03.8IU
MDP,!V)UT]+JCA9H38S\[MLDW7<-2:YVD9P@BZ,N5JJLB%*%1)-R9JY*@<Y2E
M6,W7!,3"DIV@<(==72XY.Y3;['?.%&3@&KPB.NMHJG:.A00= V<E)2C"@N+5
MTV<>%4"J>!P@KV^-5,Q@.C7KNZ6'S<SMELMV\:D6=MS.6NO-GN&Y7$>Y79/T
M#+)4LZ8+,GC9RT=IB;O;.6ZR"Q2*I'*4#J;KQZ521_Q8^S718H&@/QDC:]V>
M5@#$4@7!YZP:8#?THH""P./)XA2$%._L]\ _5SUU=+;(B:CS9#YJFJY;,TCN
M==;10(J[>KIM6;5,RE+*4[AVZ52;MD2B*BZZB:213*'*40.5>NGI=05;(+;&
M?HK/53H,TE=<[135=K)H*NE$6R9Z4!EU2-FZ[@Z:0&,5!%54P FF<P <&ZZN
MEPKI)B;8[XKU9NN[19FUUM$'2K5LHW1<N4VXTKRG;MU7;5)98I!324<MR',4
MRR8& Y+UT=+IW"S0FQGYW3=)NNX;%USM$SA!%T9P1JLLB%*%1-)P=HZ*@H<H
M$5,W7*F)A2.!0.K?KKZ6G9W:379+URHP<^B?)M]=[06.R>>G;O/2.R)TLQF[
MGTCMJZ\"P$5].Y;K=OC63,8#E#KJZ6W2(N6VQWSAN!W"0KH:ZVBJB"C1=5LZ
M3%5.EF(!VSA%9!P7N[D5DE$E *<AB@!^"G7GTIHQIIE;9[A*((S^('E5-?[.
M)'%8>(%_7&>FI@-BM/ (+>I%4$?$(*=_9[X!]#CKIZ76A"*.MC/VR:B[9JF=
MQKG:*)#NGCA-JS;D,I2B@9=TZ62;-D2B*BZZJ:*13*'*40"O73TNH*M4%]C/
MT5GJIT&:*NN=HIJNUTVZSM1%LF>E 9=5-JV<.3II 8Y6Z"RQ@!-(YB@<#UU=
M+97:4>;9#XKY=NN\19&UUM$':K1JJW1<NDVXTL%3MVZSQHDNN4@I)*.FY%#%
M,LF!@!.NKI;4=+L4]D/CO6J+9RY9DUUM$SINW>'<ILUUVX4L54D71V3PC950
MA2+G:N2I&,*"H% Y1ZZ.EUP=PFAL:06.T6],Z(EKG:2AFSCPHN/ X*2E"**W
M@<(+^)0"G\2R2G;V*$$0.K?KLZ6G:!G379+URV*HY2,X0UWM!9 JK)=5J\3,
MLG2S)E4:.4%V[D@F R"Z*J2H%.F<H 6JBI2/G(N-FXAVC(14PP9RD8_;F[F[
MV/D&Z;MD[0,( )D7+99)9(P@')#E'@, ^_ & <?B/[@_F. <X!X)WM'7C&]L
M=8O+?"-[]),BR#&KJNREDW#91O)/$>U/CQE<.64-,/FK,ZA7CIA$RCUL@JUC
MWBR('C(;J4T+8IJ#KD'M6G2D[9K(]J%>BF<H19Y,V%A"O;&Y81R12\N@""CG
MTH@[2[F+MFU65:N5@*. 2S.,&,A&/$W[)H]3(V<J$3=MD7)"'!!0.\I%B'*4
M_ B'<  / B'/ X!6WH=*!.D'IR*4H%*74M0*4I0 "E*$8D!0* >P  <  !P
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MFXX#CN$>. X^6 ?"<I0.< *4  Q@       1    ]@  ^08!E\ 8 P!@# &
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MR:AG+Y1XH4/KZ_D7+P!@# & , 8 P!@# '[?_/X__G & , 8 P!@# & , 8
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M , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
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1HD($MX P!@# & , 8 P#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>g98473g21v73.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g98473g21v73.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_[25P4&AO=&]S:&]P(#,N,  X0DE-! 0
M     %X< 5H  QLE1QP!6@ #&R5'' (   (  !P"4  (<G(R-C0V,3<< @4
M-4UI8W)O<V]F="!0;W=E<E!O:6YT("T@25!/('!R;V1U8W0@9&EA9W)A;7,@
M,#<R,BYP<'1M.$))300E       0*]X2)5P^CK[\D2Y'K/^1]CA"24T$.@
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M36)O;VP      $-R;D-B;V]L      !#;G1#8F]O;       3&)L<V)O;VP
M     $YG='9B;V]L      !%;6Q$8F]O;       26YT<F)O;VP      $)C
M:V=/8FIC     0       %)'0D,    #     %)D("!D;W5B0&_@
M    1W)N(&1O=6) ;^            !";" @9&]U8D!OX            $)R
M9%15;G1&(U)L=                $)L9"!5;G1&(U)L=
M %)S;'15;G1&(U!X;$!RP           "G9E8W1O<D1A=&%B;V]L 0    !0
M9U!S96YU;0    !09U!S     %!G4$,     3&5F=%5N=$8C4FQT
M        5&]P(%5N=$8C4FQT                4V-L(%5N=$8C4')C0%D
M           08W)O<%=H96Y0<FEN=&EN9V)O;VP     #F-R;W!296-T0F]T
M=&]M;&]N9P         ,8W)O<%)E8W1,969T;&]N9P         -8W)O<%)E
M8W12:6=H=&QO;F<         "V-R;W!296-T5&]P;&]N9P      .$))30/M
M       0 \     !  $#P     $  3A"24T$)@      #@             _
M@   .$))30/R       *  #_______\  #A"24T$#0      !    !XX0DE-
M!!D       0    >.$))30/S       )           ! #A"24TG$
M"@ !          $X0DE- _4      $@ +V9F  $ ;&9F  8       $ +V9F
M  $ H9F:  8       $ ,@    $ 6@    8       $ -0    $ +0    8
M      $X0DE- _@      '   /____________________________\#Z
M  #_____________________________ ^@     ____________________
M_________P/H     /____________________________\#Z   .$))300(
M       0     0   D    )      #A"24T$'@      !      X0DE-!!H
M     S4    &              -%   #>          !
M          $              W@   -%                      $
M                    $     $       !N=6QL     @    9B;W5N9'-/
M8FIC     0       %)C=#$    $     %1O<"!L;VYG          !,969T
M;&]N9P          0G1O;6QO;F<   -%     %)G:'1L;VYG   #>     9S
M;&EC97-6;$QS     4]B:F,    !       %<VQI8V4    2    !W-L:6-E
M241L;VYG          =G<F]U<$E$;&]N9P         &;W)I9VEN96YU;0
M  Q%4VQI8V5/<FEG:6X    -875T;T=E;F5R871E9     !4>7!E96YU;0
M  I%4VQI8V54>7!E     $EM9R     &8F]U;F1S3V)J8P    $       !2
M8W0Q    !     !4;W @;&]N9P          3&5F=&QO;F<          $)T
M;VUL;VYG   #10    !29VAT;&]N9P   W@    #=7)L5$585     $
M  !N=6QL5$585     $       !-<V=E5$585     $       9A;'1486=4
M15A4     0      #F-E;&Q497AT27-(5$U,8F]O; $    (8V5L;%1E>'14
M15A4     0      "6AO<GI!;&EG;F5N=6T    /15-L:6-E2&]R>D%L:6=N
M    !V1E9F%U;'0    )=F5R=$%L:6=N96YU;0    ]%4VQI8V5697)T06QI
M9VX    '9&5F875L=     MB9T-O;&]R5'EP965N=6T    115-L:6-E0D=#
M;VQO<E1Y<&4     3F]N90    ET;W!/=71S971L;VYG          IL969T
M3W5T<V5T;&]N9P         ,8F]T=&]M3W5T<V5T;&]N9P         +<FEG
M:'1/=71S971L;VYG       X0DE-!"@       P    "/_         X0DE-
M!!$       $! #A"24T$%       !     0X0DE-! P     &LX    !
MH    )<   '@  $;(   &K( &  !_]C_[0 ,061O8F5?0TT  O_N  Y!9&]B
M90!D@     '_VP"$  P(" @)" P)"0P1"PH+$14/# P/%1@3$Q43$Q@1# P,
M# P,$0P,# P,# P,# P,# P,# P,# P,# P,# P,# P!#0L+#0X-$ X.$!0.
M#@X4% X.#@X4$0P,# P,$1$,# P,# P1# P,# P,# P,# P,# P,# P,# P,
M# P,# P,#/_  !$( )< H ,!(@ "$0$#$0'_W0 $  K_Q $_   !!0$! 0$!
M 0         #  $"! 4&!P@)"@L!  $% 0$! 0$!          $  @,$!08'
M" D*"Q   00! P($ @4'!@@% PPS 0 "$0,$(1(Q!4%181,B<8$R!A21H;%"
M(R054L%B,S1R@M%#!R624_#A\6-S-1:BLH,F1)-49$7"HW0V%])5XF7RLX3#
MTW7C\T8GE*2%M)7$U.3TI;7%U>7U5F9VAI:FML;6YO8W1U=G=X>7I[?'U^?W
M$0 " @$"! 0#! 4&!P<&!34!  (1 R$Q$@1!46%Q(A,%,H&1%*&Q0B/!4M'P
M,R1BX7*"DD-3%6-S-/$E!A:BLH,')C7"TD235*,79$55-G1EXO*SA,/3=>/S
M1I2DA;25Q-3D]*6UQ=7E]59F=H:6IK;&UN;V)S='5V=WAY>GM\?_V@ , P$
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M69&)914_TWO$!VOCJTQ^]]%8F?T?[)B->"ZYQ,6P!L#8/^#]SE+"=;J>.5C
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MOZ"V[WLM%OTE\Q))*?_9.$))300A      !5     0$    / $$ 9 !O &(
M90 @ %  : !O '0 ;P!S &@ ;P!P    $P!! &0 ;P!B &4 ( !0 &@ ;P!T
M &\ <P!H &\ <  @ $, 4P V     0 X0DE-!"(      49-30 J    "  (
M 1(  P    $  0   1H !0    $   !N 1L !0    $   !V 2@  P    $
M @   3$  @   !X   !^ 3(  @   !0   "< 3L  @    D   "PAVD !
M  $   "\    Z  MQL   "<0 "W&P   )Q!!9&]B92!0:&]T;W-H;W @0U,V
M("A7:6YD;W=S*0 R,#$Y.C W.C(R(#$S.C$V.C(W ')R,C8T-C$W       #
MH $  P    '__P  H ( !     $   -XH , !     $   -%          8!
M P #     0 &   !&@ %     0   38!&P %     0   3X!*  #     0 "
M   " 0 $     0   48" @ $     0              2     $   !(
M 3A"24T#_0      "           _^$!2$U- "H    (  @!$@ #     0
M   !&@ %     0   &X!&P %     0   '8!*  #     0 "   !,0 "
M'@   'X!,@ "    %    )P!.P "    "0   +"':0 $     0   +P   #H
M   #P     $   /      4%D;V)E(%!H;W1O<VAO<"!#4S8@*%=I;F1O=W,I
M #(P,3DZ,#<Z,C(@,3,Z,38Z,C< <G(R-C0V,3<       .@ 0 #     ?__
M  "@ @ $     0   WB@ P $     0   T4         !@$#  ,    !  8
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M8I66H=,F-#=VDK*V_\0 ' $!  (# 0$!              $" P0%!@<(_\0
M21$  @$"! ,%!@4"! 0$ PD  0(1  ,$$B$Q!4%1$R)A<? &,H&1H=$40E*Q
MP2/A8G*2\0<5,Z*"D\+2%E3B)#1#4V-S@Z/3_]H # ,!  (1 Q$ /P#[^.*4
MXI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI7A51$555$1$5555]$1$_BJJO\
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M7MC84X=*;I,9U]:/DH<K\CLK2%?J-MI;@&*:1S /N58GSEJL0[?Z\\J1K/\
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MZF^BATA]1TIGL_\ L[7D/&@U6L%L3R[U(G*QYH%0.95LK )7HJBH;(67./\
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M(@/O,6/3NB//\WE(/05NWYRZYE.*4XI3BE.*55OO3Q7Q?<DQ.AAGFS&Y<+'
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M$STC<URPHC7R21-DF9&V9^C@+F.N62W$+-NQ>%QP%MMF4VQ&1I#, 3W@1FF
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M5Q6.P^'Q%O"7+H1[]UQ8M93WV!((E5(7WE S%1) !,Q5@KLI@2JP3'+E4C6
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M:+*X[0":G.5+Z2B CKKL%2?MRON*O<A&%-;&:9!]L800,D!,L38FM5OMV+.
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M1ZRJ41TUUW),^1RJYTDKW9U5F>YRJYSI?>JJOJJ^O-L<1X@H@8_&@#0 8J^
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MHJO-]U9P$BP=E*V3-[. 6-TTPV>4LBQJ;OXF?O?9UAYMD/:2M:]T,-@(3*C
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MGK0]]D-=HJ+45172E'I,I@-#7&0'N&9I1,;K;_$WUL2&5)L<4?)D];'=4*-
M2.T:(F5[VA ([VX\I&8=#K2NQJO"7I>@DL9*$_M2F_:'."9C9-"[<WOIO@1[
MS:Z4HO</)NB)M+<W5]V-MK.^N#Y'GVQ&@,^ZF=&T>.&3<8[Y3T[HTT TTT@
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MN5<$F(DQTG3Y5CGERKNVM:QJ-8UK6I^$:U$:U/\ J1/1$Y%*XIM=7V4$@UB
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MB00HY9M5QLW(?$U2')[#2X:]#TN4N#*6Y"E26(L63T^5/<CGP&0N]T!HD_\
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MK+(P"8V]T.D[)[$GV=_;Z6:O.M4+N;<R>:XF0,F"X/:S)S@ =!#*1(F  JP
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M3BE.*4XI3BE.*4XI7A4]45$54545/5/3U3^]/5%3U3^*>J*G]J*G%*^>:O\
MIF^3?77U7.H_+:P[+G[[ZAN]UMM'K]%:04&7V&!-,ZEV6:H8M'E*,6GS-L"Q
M%H,Z#J,A6"3SO^!EOG:B&-IA70_$VFPC6<O9N%4 "2&AE)@ZD3J2K&!!(.H
MS=H#;*Q! $>/>'/?J8/P/*KL?4 \K)L+6S=*]>6BP;"\":_:7(,R-(S-";$J
MQ4XT\;T<->7L#DDG?ZMGKJ9[98VMGM R18P>'[1A<<2@/=!_,0=_)3\S(Y5G
MPEC.>U<=Q3W1U;KY CXGR@Z.O1?[O\4_SYU\J]/X_:NG3T7^[_%/\^,B]/J?
MO2GHO]W^*?Y\9%Z?4_>E/1?[O\4_SXR+T^I^]*>B_P!W^*?Y\9%Z?4_>E;*O
MIAXN*Z[FU.Q(B;+'B,;+&(]?RH]OJ3&5X\S53\(KJ@.^@_CZ^V9R>GI^><_'
ML%MJ@'O-J?\ *)CYE3_M6GC6BVJ_J;Z+_<CY5O=YR:Y=>'.:UJN<J-:U%<YS
ME1&M:B>JJJK^$1$_*JOX1/RO%*TK>9V_R^][:B=EBAK,3-9X7.FVXCHY13[&
M&PLCB8Q"8U5A0P2',%0ACG1O)82V)71,9(_V'!K%VSA2;H*]I<+JAW"Y5"DC
MD3!,;QE-8G,G3I]ZTT=F5F!Z;N]"_K2DAHMUV#'*7J+D4LN1];5%EO)F$J()
M29!Z9]L>CBI(ZZ$9D,<$<D<;%2O>-['A]BYBLMS$'M+%@A;:%0%>XH&K1[P0
M=3J=#(# X',0!\=]O[_/>JT*JJJJJJJJJJJJJJJJJ^JJJK^555_*JOY5?RO.
M_6.LMQ6RM\+>C7E1(OJQ6QG!.>YHUD$KD640E$]4]'(GNAE]KGCS(R9B*K5:
M[#B+%O$VC:N;'56W9&Y,O\B1F$B1H1()!D5MS\?;7 ]B7N=L;8J!^>L("7M'
M,G:-'^KPQ>L55:/;*Q('QS>]'1K*V,F:.")KI1RF?+\[]H?Q^#P>(7#*WXA"
MH)09F%IC#7;0@YM"-8)49CHRR-NQD9QG]TSN8&;E)T_O4F=\TF*I-)70Y!H(
M\DU>^2X K)6R!BSMF]HKDCC>^,6>>+Y/E&C^-J,BAF6)KIE?+SO9O$8_$86Z
MV.-Q@MP"Q<N@AW6)<9B)95,96),R1)C3)B%17 2)CO ;#:-N9YC[U43MOL03
MJCKO3;TP-UDVA%@</7,F093CSSA:RO%<0L<WP0R&FP?<3I#,Z$=)960RN8V-
MWI[5LW;BVP8+<X)@ $DP/ &!SK7K%/'WN<?O+!KK$J4H[ *W,H[>L84ID$)H
ML(I<<PI+HH))!B0CA9426%CX9EG'596PMGEMB+)L7,A8,"H93$&"2-1RU'4]
M?"E6$K*>WNYW"TU786I+(UF?!6AD&S,B:J(LKXQHY',C151%>Y$;ZJB>OJO-
M.]B+&'4-?NV[*DA0UQU0$GD"Q )T)@:^%2 3L"?($_M407/2G7EGV17=G6^7
M8[>4+8QA["68X?XB FS0#3FU:31A$65>V1T0I1@LA0JQ#>Q[7A"+!LKB'-GL
MTN3:<3W2K J==&U[K<X,$'H3,'QY?Q]J[[L#2S8S"[+7#BQ'3Y?+WN@A"FD?
M#"7+45A)[!I96->^..9T"1O>QKG-:Y7(BJGIR$7,Z+,9G528F Q )B1M,[TK
M-,D#;[%^> IZZ8^ZT;:Z,"L#3Y)9C+&.)\8\2N]J>UKI/WI9%9''&UTLKF1M
M<Y,5QUM([W&"H@8LQV $ZD;GR$DG04$GSK;QXY^(0_6-K7[O<V(USL!1WNK*
M@*-74^=*)B=%*2XJ1?DMK.(>22"*9(1PQ'RS201E3,%-B\IQ'BQQ2FS94I9)
M[S-[]P R! T120"1J3 !($BLJK&O/]O[_2KQ\XM7IQ2G%*<4JLWDEY+TOCD/
MUPEGF#=)8=G[*;%T"/T>3Q&<#L1:"TT3VWNUW-M29BG+LQJJ6LS%<:?&1HK\
MD2K&6%CB"QM[!8)\:;V5P@L6Q=?N7+KE2ZIW+5I7N,%+!KA A$!8SH#!,?$Q
M5<.S?J6=>]8DW$%AUMK[+]GMGWEE+9L.CZ_IRI(^A9NOHM,500:335$>FN+I
M>PZY,KD:@F;0W<P)HP@TDRP-DW+'!+U\*1>MKGM86XO<O./_ +6+QMAS;ML;
M:KV+=I<89$!!)B349A^XY<OCXUE(WU$.IA.UM3UUL\_HL'0YJU["I7]CWY^9
M6B^^ZPPN>[$U:V^>$N9=MG08\[HPFUME89U0;*Z:[/Q3LN9A R*'@^(.'MWK
M;I=>XMAA91;F>,1=>S;RN4%IVSH<RAY5>^1E!(F1/KI/GMX5:?JGO#J_NT30
MF=9Z5VA9DK>//:@>>CT>>L<[H'@CV3Z*ZJM-44UG770H98\EA5E"1G5KY6P'
MP#$>L2:&(PM_"E!?3)VBY[9#(ZNDE<ZLC,K*2" P)#1H2*G>I8YKTIQ2G%*<
M4IQ2J_>2O?-)X]]:6.P.2$R_-<ZIQU%)(K77&@GB>Z%)$;ZO96UT;76%I/\
MNHP:'[>-_P!X6)%+FL63>N!!H-V/19$GZZ>-9;-HWG"C0;L>@^YV%?,CH-!<
M:J\MM)H+ BUN[RP*M+2Q+=\A!9QLKIR)I%7\)[GO5&1L1L<4:,BB:R-C&-]
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M$\NRLC%74JRF&4[@C<>MZS R)'.L%[9Z["[7Z]TN"/,?717PL#8+&.%"7 '
MG"V=>7]NLD/W$<1H<#IQTFA6>#Y86S0N>DC;6KAM7$N  E3L=)!!!'@8)@P8
M/*E8MT!TP)T;A%R45LMZ<9;F7EO:_:?8Q$&E0BB,C%$6<I\ XX0(D*)(1,^6
M9LQ"K&DR0Q6Q%XW[F<J%&4*%F8 DZF!,DGD(&G*E7JZ3[1H>O5O!;T$M\%K]
MI-$?70PD$QR").Q!9XI9AU4>1)UDC>R1WQRHY'QJV3Y(_*>T'!\5Q/L'PUQ
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MP3V$LW>Q-^VZ%BG<NI%M\TF267O2 1F[HBL]RT+65@9!,&=]CJ(Y>&^VM;@
MM3FK(,2Q OZ8L$X: P,J"R#DA)%)C;-!/$]LRH^.6-[7L<GX5JHO.4;=Q259
M&!4D$%3((,$'3D:BN5^N4O\ ZXJ__B G_P![D9'_ $M_I/VI3]<I?_7%7_\
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MBI7+QN+X8,@Q2"'0JEV![R$PIT_,I,=2"!K$5=#!CKMZ\OVJZ?.!66K>]/\
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M0"JY!U-=/C?^3P=7 68\^^\D=UJ:F.9KR*[*82BQ!A$35570I9VM_O&0^_\
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M7R_%%))[&N]C'.]$721@KHQDA75C&\!@3$Q^]*L%T5T/NNV2*W/9X5D0%0(
M)?Z<IDK:.I;"/#$]5E]K7EF2M:KPZP=%*G16OE085LQ4.CC<?9P:EKAEVDI:
M4C.V_P ED:LT <I;NU*J3_)K=1TST7B^E*1P&>@<=<G1Q?KFG.CC_5+61B(O
MQM]ON:#6QR(KA:T=RQ1?\Y/(46LI4OCL7C+V,N9[AA03DMJ3E0?^ICS8[\@
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MY/:0/4Q$RS1+_06PK_WDC,!L#\0?H(WT,3OS@UD6P-V/*8&OSZ1MK/E7TR>
MGA;/<6>;[+V.99G>LLA]H1A\R17H#'IC@4:M43#6NCB2++5+FQEQ3+$V"W+B
M'A'0@%AJOYV+Q0"FU;,LPAC/NCI.V8[:'0;ZQ&#%7U13:MD9CHQ4Z(/TB.?+
MP_?>USE5S*<4JLO<WBYC>Z=92:R[N+JG*K@(ZFQAJ$"_VO7#DSE"Q+,5!/\
M9D0R%DL4EL1'O@D;'\3711R-Z.#XE?P=I[5M48,V92^8Y&( ) ! ,@#0\QXF
M:E9YGU/WKE;+IC*9'I;<YKK+K^AEMILI;#5T$M<-8VMD;*))$D\QY[9S+&T8
MQ[Y0/N2'JI;!X8OC9[&MK:Q=V[B[-W$7W@74).8A57-,  @*O6(T))FD0" .
MM:-B!IPR)Q"X"!2AI7P$C$PO@('GC<K9(9X)49+%+&Y%:^.1K7M5%1R(O/<
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M<LVM1M\=FZK0Z1L-K88O0AU=H<!FK2P%R7LSL7C*BBW;63,*B(B:@">Z%9B
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M[_@O&%NJ2Q_T:. ")VC3.@C-$ 0 PRD#X:"F]=)GO!3H#-KE60!;>U!Z];B
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K[TQEC:EVL$#"G3VMHC7MC.G8ZI8L "!I&PUTTB>E23/K;R^=6!Y6HK__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>g98473g25k48.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g98473g25k48.jpg
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M 0<(  D2$1,4%18A%R(C"C%A,C="47>V_\0 '@$  00# 0$!
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ME=69[Z/F*.-IB_'V+5%E(+2S<^NP.:Y]Q:>)A*1LGN$#,$B8WF-]J0[@G?\
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M?7<=@E'*K*]B ()*E#LP8;'&8DA))[S^(9OIEZBW=:-RM++5*=*_176M5UU
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MFHH)*?'#YQ])M^Z4##/+2EQ[#",9RAQW*)1RB_K-[5NERD>=O$T,A2@I^V+
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MU'ZY>N6&L+TXC&Z&T%C9?D59C.4DY;5F;8TK=NN>.QS2]K5&S)O!#; NJ\)
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M>D+*/,O$<CBJ[DD+,<J)U#2OF6/C+LYUD1=@VV_J LXDGW ]D*DC)2ZQW5'
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&U.CHZ__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>g98473g27e81.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g98473g27e81.jpg
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M.4%"45-76'=XE[;2Y2364F%QAY.ET=<F,V*!D9*W_\0 '0$!  (# 0$! 0
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MHU=KM6CK'6JHK./BU68F+?74KA#6=S*3%V>VJ/&:]SBX<N6NY]F\9K8,# &
M, 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P
M!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# &
M , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
MP!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
M& , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
M P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & ?)S%(4QS#R*0HF,/^0I
M0$1'_P#8 P#"FO<:<#/5J+L8Z^L[ Q*Y*7J^0CXZD38-:4:(::WD'LE9X2S1
ME=ES3Y(K9\)8D*ZP8.$I&L1LW*0\U).1KT98AFGMEO7B]JF92,G&N7KR-;R#
M%>1CP1,_8(NVZKUB5P3N-S/&I%#+M@73]NB*R9 5)[8G4'IP8.]@# & , 8
MP!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
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M_8TYXS!^X=EG[.'K=X\:-"Z'NY#.G*#8IQML"($%=4J0&$ CP$0*)N8@ \Q
M.6?+^83:3&.=^D$BN*USJ<YS"5HBK2NJK0^F\UV0<YK>@\XF,Y&UYY@W56GQ
M#W+S\'/UX8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
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M,)B.?Q,JS;R$9*,G4=(L':1%VKY@^04;/&;E$X"19NY;JJ(K)' 2*)G,0P"
MB& 8Y(\(ND(]17R%7Y"M,W[^77G8F!F7K*(LL3/^9!IFJ3; YETEJM(J:YIX
MN(UIX-7PL:]ATW9(*Q6>+F0K[>WMDWD(IX]FZ"7#KQ'K)H(IK.=$2YG"I$R$
M47,G-,TTS+'*4#*BFF $()Q,)2 !2\@#EGL>9][]<&_G.#H<>8PT]ZMN=H1=
M+337SM\Y.& 52#]VH?XTC_I:.:XVQ1<V_P U39!V6%G&><A_0$S^>9VH, 8
MP!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
M& , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# /DYP3
M(=0P&$I"F.8"$.J<0* F$"))%.HH80#VI$R&.<>12%,80 0,=$^*K3YE#-UW
MMK8/&DG)1T\QD:#<F+RHI1#>@O)&9N"#B%(:MP3)GM+7[M_)R@H)1;>PJ*RI
M6):Y;_-X"(N/G^#CQ$_[!YKZ\:9['F?>_7!OYS@Z''F,-/>K;G:$72TTT<[?
M.3A@%4@_=J'^-(_Z6CFN-L47-O\ -4V0=EA9QGG(?T!,_GF=J# & , 8 P!@
M# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & ,
M 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P#KNT/%-7+4%W
M#87+=9 '+10$G3?O)F3[[94Q3@FX2ZNXBH)#@10I3"4P!R$#$]GP;Z_:>4S!
M;[\96S/K&M>Q;):VA&M^B+>WUPTL]8L$16]<0L&PAIQ'6$$,@YJ$75[$LXE+
M4]\O ]L<@Y.,U^SOINZ>#@+#X\V3-OP\\2CI!LBDY?Z)E3O5TTRE5='0F&2"
M)ES@'-0R2)03()A'I( %#T!GL>9][]<&_G.#H<>7PT]ZMN=H1=+33;SM\Y.&
M 52#]VH?XTC_ *6CFN-L47-O\U39!V6%G&><AO\ CAVU9D*H[<MVJ9C=!3N%
MDT"&.(";I*94Q2B;I*(](#SY (\N0#G\]6L>]:,:YZI>J-:KEIOT1%.TG.:V
M]SFM3)5RHFDZ?ER%_CB+^4&GZ[/O4(_68OU;_4?.K0NNP_#;ZQY<A?XXB_E!
MI^NQJ$?K,7ZM_J&K0NNP_#;ZSE1E8MPH5%O),%UC\^A)%XW54/TE$QNE,BAC
M&Y% 3#R >10$1] #F'0HK45SH<1K4RJYCD1*W7JJ4RW&4B0W+1L1CE7(B.:J
MKNY$4[^:S[& , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
MP!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
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MN(V4:$*+M;1LFX4!Z4LFS,HVF&220#&R0.XX$N@ !1 &@(+FYG734.(F'UN
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M943 82N79I873UOS#T-'JSAH4.92H@41 0.4\"P4/(G,K+=4J4I'0%L$\0A
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MKSSKGA[3.1DV2M24/7%_*7:FY2/L:J4 ]81IG+IK-JI12Z1'RA$# 8L\?/\
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M5I=NGHQGYL>Z& , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & ,
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M['M6(J.:YJJUS5145%5%N-R'.+SJ88 P!@# & , 8 P!@# & , 8 P!@# &
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MHER\9?61S>, 8!:(^OA?R1-]<DP"[L 8 P!@# & , 8 P!@# & , 8 P!@#
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M1<X"N88+XP!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# &
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M"0]7WQY8!]$"P=V.[BD/V 2_ML!$7H*G7Y&],<(KB1-+GT^AR54_+J]MZ0Y
M=<2VGPBX K7_ !_B@%L86\CX0&7+TE7)XKO&==7WC)G*ER_Q.> =H0G/%K"5
M2)\#X,0;E%)YXL)#H+R,L<%NR9GW.OF0A"K='2 'Z@$1 X"ELW98=2L%X@'!
MO*8E;R'9,U[@= ,"BYZTW'9Z@,9P91,5.0@4"\PP#Z,6Q_VRZ%83TF)Y'ZD'
MP]!>X/<\I<G =TPI=($\+V@!3F)@$O(, Y"!/>(C^XI$"U!L 2H$1> X.[Z#
M\QCS&7%--MW.WR*Y*JKT <!/U"40 ZPEM7@E !6O^4?%\TC"WDO! Q[?]RH3
MQ7?%WW?3UE4!'M^CHZO3@':,$[XMV)%(D&(LS Q*9)X+LK_H3Z#.S@L")V?<
M[HF(BF182"F ' P&$0.$I;+VXWK5@^\"Y_*XE0?@F=MWR]L(T!<"9)<&W4!S
M.A63%?I,4H)@)1 &+9.F3Z%8/K%1/R-U(/\ I(CWC=T)/DY 55!;] )BU[)0
M6ZC& 2"!0 YB!.^*8BHI$BR!H4),I$7@.C/^VIUF8F,N**;3N]D2D<$46!,%
M $XF$H@!U.FU^!Y=ZO>4_&<^KPTEX'P':_N>WXKQ'C.]Z>ON=GM>CHZ_;8!V
ME GO%/Q24B 9"T,$651%X+HC[MI=)GYRK@DHT[W>$Q&Y$EA3%( .!@,(@<92
MV/IC.M6$Z@44\L]*#\"G2[I>T$8 N!%)0$.L%!="L45>D2@! $H@?ABV7M27
M0K!]X5R>2!,@_P"T1MWC=P)( <@=1?P_2!#-C))@MU"8HDY% #F*$[XMJ)U(
MGP(,R@]*5%YXLS_H4ZC-3BOV2L^YVA*14AUN@% %3J$H@!U0+:O!)@*U?\H^
M+YK&!M(^"%CT?W*9/%=\'?<]/6904>CT='5Z< [)PG^_(=M2(!J+<?)0'1>B
MN1UT$Y#(&*N":C?K[G,K8J2G1T !N8&$0/@I;%SC>M2%Y )_+'2@^ 3AUAT>
M3>;@>T()\^OQ7=YGY"'(O,, ^#%LW8?=*L%XD7!?)@F;R H%:]P>L'Q0<@HH
MX[7("F;F33!3F(E$H@  <X!.^+2$RD3X'P8 L4$7GBQ?]!N9DCBN*(,^YTB!
M#D,MT=0"IU<AP#K 6T^$;@96 \=XH1=&!O(^$%ER]!6Y!<BL5US^^=0YDN7^
M)@'.<+!W9'MJ0X("E_:D#HO15(OR+Z9$2K@11+GU>AL"1^73Z?OX!^$+8>N.
MZU(84P*/E?H0? <Y^?M?)PBX$J9>GES\2"H\_2 @'HP#B$MH\,[ JL#XP7("
MQ,+>0\,5GS'J!V4'7=,YZ>7(R)R)<^?,@A@'8Y3GB^?<B? ^#Y=/:>>+\?T?
MW77WNSX/N?XG1WNCT=SJ]. =<"VCPS0#*P/BP<F%^(-Y#PQFG4'2#0HN>Z1S
MT\^HRQSI=7+D3EZ, Y3EL/7)="D,!!*7R1UH/A.0W/VWE(0< "A>G^Y\*"0\
M_2(B'HP#](%@[L=W%(<4 2_ML!$7H*G7Y&],<)EQ(FESZ?0Y*J?EU>V](<@.
M 2VGPBX%5@/'>* 6IA;R/A 9<O25<@.N\9US^\9,Y4N7^)SP#LB$YXM42J1/
M@?!B"!12>"[!_P!!>1E3@L")F?<ZN9"$*MT=( IU<Q$#KE+9^RQZE8'Q .#>
M4Q*WD 1,U[@= ,2BY$Z;CM=0&,X,HF*G(0*!0$! AG?F@*WQ)422UQLYLW?U
M<9N+GX=O&/I>'=$?Q?BTT#R;QFX!54A4'BH=IKV2'4$#'YE* 9>8/X0VE@S:
M'1.RGPH<UJ$27QHT)L9FIQ58KTQ'7556-HNY>5-LV+(V])\X6BR(^7U6'&I"
MB.A.QX>-BKC-OIKEJFZ87$]B"X2O$1XJ5NPBU!N 2H$O-H!P=WT'ZC1YC.!3
M3;]SMB!7)%5.@#@)^H2B'M^G'AO\JD/[?!/)]+#!3Y/.>.Q3K#[$#PK>"4 *
MY,>4?%\TC#=[;X(&'1_<J$!WWQ=]ST]95 1Z/1T=7IQTX\-_E4A_;X(Z6&"G
MR><\=BDAZV]C&X;M2[(@-E4F"F&LW3G:4U55I"WV*0[$\V3 &ZLDV57!H[CP
M.=?N(%3(J8@I@!P,!A&!:G-1PMMBSYNS)V8DW2D[!= CMAR4*&]8;J51KTO:
MMV5+R99_,_P;LR=EI^5@S39B5B)%@J^;B/:CVUHKFK<Y+\BF2>U G>]6?$J1
M(N01>^4!01>%0,CXM+M@R*HN90B@(>@XKF4**OI* $]&>7LC'Q8V+BTQF8V-
M6M*.R4R;N6NX>BM#%QF8V-7$=BTIEJF6J9.(B<0E>3SI/']0F)X#FFYY%)UF
MZ_&<E0$YA3Z0(*/0 'ZA$!+R#+GW37=1EUESLE;\:_+3>I>5VLUO5_QWIW,6
M[34^RA(]YMU&9>'!$/%@5-<%C..DW,6QA4$A4>OHY%5*=3I P"81$! F/5M<
M2E-=1%KC46N+?1$K3+5:5O,:VB]56NMO2E.&ZJKQ4)%U<6Q#)/P:JPH/_!G$
MQET'QFG@O$->90(FX(MXKN](@83]KM\PZ.KD(55JX_.T/'Q:ZLG4HJ)34W[Z
MJN6I82&+JS\7&IJ5^,J*M<9M<B)<4O8(2/GI8>DS+PXIM?" 9-<5BN/)K+D+
MDP* 0R/7U\RI%(ITB4 , @(COL[5.<X=%92D7$N6J.U5_57T5*UR46E#3.XO
M/#^JK5F->E*:FS)=6O'<66 2O)GS/']0&-X_DFYY&)UEZ/!\U>9#=OJ PK=8
M"?I$  O,!G>Z:WJ/XKG;_P"K?O;];^ C:S7=7_!>G=QKM%#\$)?H=])X[N"H
M7P(BFYZ"H]P>H'8 KS.IVN0%%$2%!3F(@)>08]TUW45KK;G9*WXU^6E,E+]P
M>YU;U=*:Z]M:T_5NR5WZW$^:G"9\GKB!XSR<#Q0'912=>-,]\"W]LW/WNP5K
MU=KVBJ9U>D%/;\Q+R\_:]=7A5I746UIDZM]<O#6G 6MGTU*)3KBY=[%;0T@)
MDU4\Y9D11L/D_O/@3*#F-\9Y1\:KS,<XM>R++HY\DRD!?KY"*@AZ,[E@):W.
M4OK[.YXQH>,NIS.H\[ZFES6ZKCI&QMU7+#IN5.28JV;SU&UL]J%'XJ8\#5=7
MQUO5=3Q-2Q=Q$1]=VA1"#7_#QW=3F1= X 982+,@;G:=9^98XID!42<=OM@!
MG)E4NOK'HZ1* 27):&J3.*Z2U+4UYT1S(^J)&Q6T695'XKH>-C52$C78N*F-
M6JK'19+$@8S9K5-4_P#)5'0<1855N@(K,9L2F+?$5S:UNI0^S&K?]M.A*<](
M$\B]2[#]['MCW/*G)O\ OH=WIZ/"=D03Y]7,P@(81+3_ /%QG2-U>?:,F-<F
M,F+SK6)K=;6NJX^NI2X^E60_\BC9S<YUJ^#==?SQ1FNUV34\6ZY;[S9M==P/
M8<RC)"0T-]PFN"D1D!B28,O+K#Q)5%5Q4:BZ%7TH'*B"14_0H0QO3G+K>>>G
M+$U)8"3/Z03&IK$;$6!74(F+CM:Y(BZS+BN377I1+CH!=0Z5[-52,L#H+!QT
MAJQ(NS,KBJYJL379*HNMNRWFL:(P/@U0*G+^/\8(H&%9EX,(_K+R*J0$.\+S
MM]0"H0X(=?2()]/,,ZD1+0U9E72>H:@FJ(C(^K<\XJU5BX^(D#&I1JM6)BUU
MU3GU5D]2=1LUJVJZQ5="U)(%4HCDQ,98N+6]'(RM%I2X[0FJGC' @C8? "U
M&A1<QOC"ON?I,X.#7LF:\OO$3(1;G_CYJ1+6U&'5]G<\:K[LJ0YG45@;B0TU
M7'2+PN5S. V5LW57T;/:CJ?N28\#5=6WWKJ>)J? UN-PE<I8P7G30P*G+>-"
MTP?E(QEF8M3$\J-^WX$@( JF8!Z.OQ!U $.KIY<P$-4\EH<[6IKI/4N<X_.B
M8D?5$=J+J\\+JF*YN6FIHU<E^4V2:R6KV?5LUJG/4+GA4="Q%;JJ4U%,3&1V
M2JQ%<F6[(;N&TPF_)-?\0I%"4'IO*/91=E$RWAUND676N8")='H$%^X<3>D!
M /1G#=D8VKQ*4IJ>NK7)CMR4W>,ZWM"FI-K7J[J;^*N7@I7)P$$"$QVE^1XW
MO]X/#"*3KM AS](+@"W69;E]X4Q*3G_B\LO_ '2B]16NMN=2G#?6O%<5/N=4
MZNE-=>VM>"ZE./OG+RD>]_=,O#^'^]VU^]XKI^_U=SH\/U?XO3W.GT=7/TYG
M7U_5Q:;RUK3?K2E>"M#&LI^M7&WTIB\5*XW=H79K\)SSG@NVI% Z[SWQ G1>
M"W%OX%UU B4%P4!;M]0 8YC)]?2(EZ0$!@6CC\Y1,;%KC,K1%R:HVE*K=PUJ
M2I/$YZ9BXU-=BU5.MNK6B<=*=_<*YM4)CSE/U'C>@8AOY-Z4G744GC'W+QPB
ML(*&Y]7X."8<NGT<^>:;)QN=HF+B[,ZE:Y<2'6M%R4IDOJ;)_%U=M<;J&XU%
M3)5V2[+QW<1&Q0D^MKU'8]L"?^-Z4W ',IR'\%$51*0G/EZ%@.;ES]/WLM/=
M*MZBGZURUK_#?I(.LHZF-6NMO2E*_K79:;U+SB$)GL*\CQGB>]^\B*3KL W_
M ,BI>]W!6Y_XQ# 3_P#3F/=:+?#K6ZYU*<-]:^0S[G5.KQ:7WMK7@NI3CJI,
MFI@EO'S_ &CQP-O)[0" HDY%?QO-QVC&,54$Q:@?K%0H%!42=(%. @(C3VQC
M8L"N+2KZ4K6M&UKN4WBQLZE8M*UUM:TI2KJ4\M>X1Y: F_+\CWU(L7(2KKQX
MI).P0,GWOO-"G6,H0_1S]*QCEZN7HY982F/SK+TQ-C;6M>II=2_+3+N$.8Q-
M7CUQNJ=2E.JKNW=37>OINE!$)3_Q?2>/]/3X#FFX]K[8>KQ?)7V_M>73V>CV
MW/GZ/1DGW374Q/X;G?\ VOONWJ&G6:WJOX\G<Q;M-3Z*$EW&O69CV02_\:!4
MW *&6Z3>EJ(J"4J75T^A4IS]/4'5S$! FJ5;7$I3741U:W]3?2F3+PC64=U5
M:ZV]*4K^M=EIO75,DM3@_"J!X\S0QO*3WL^$(L0H(\T^0*]XYQ%7KZ^8DZ2=
M/2'3S 1'S5I8W/3L;%KB,ZFM,G#>7<EBZ@W%K3&=EI6M;\GD),RO)8P!@%HC
MZ^%_)$WUR3 +NP!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@
M# & , 8 P!@# & , 8 P!@# & , @W;?X;#?BKK]*EE]8W41^RAZ'%3:75PN
MQ=I0B'+HK1@$I:G]W9#XI4^F,\J;8VO#SR>8\L+.V5^;])I;U_\ 6Z8_EM/J
M]IDBS=I0?ZG*Q#3.[9B?0Y-A9V3B*, G[4_N%(?&RGT-GGG;8VQ#S*>>\N+.
MV)^<]%IHF37NS+?&;_Z4KG>L#8(.:A^8AQW&V6+G'^<I3,VFL8!M&3']Y@1_
MW?X/_F&/SE:#\-B_S#'_ ,:(=#1?@I3YE@\NPU<\ZI.>1@%STGUSJ/Y3P'UJ
MTR+/;2G.U9CDGDB4VU+=L0>4:;S>V?<>,^,A^BK9PA8^SQ<UZ;3L"T=B9G/1
M<0+GH2G& 7IKWUOB?Z=]7.\@6GM.+QP^4:2I+;,/Z?)O*SM;UC:?$S;Z;(9I
MLC:S\^[DX1LM#9TS;=+B,LM2", F+47X1.?S+#\]UE+;/40.RB:&EG9N6-Q,
MTN(_MOK-.?&3G](.6,GM67S3-!"F-GC9Q^E2W<DFD8!D?K+U62_'7GYY<\Q:
MFVW=@S07DCM=O9.TD@Y7$PM2Y3E@K\(M(UFER=]E2',1&OQ,M781TL'AG"I5
M!?V>4B8Q)(5TD6IN;HRQ3.B*@B=%)8Q /.ZL7KB_,UKZ-\8;;A+42[65*-9L
M]<4^2K5NDE]WUE)2%M#^G1-U8T[4L#K:5?0=*L,S8Z_-R=:2L-FE;-9[+7HF
MRJC*TW/^KN&E>&[>IE/01$[TVQ')7#=JDU)4R Q61>*KN')!E$Q7,[;'8MDV
M1DUNI-(B+M^"R0 L<Z!Q% HP7Q@# & , 8 P!@# & , 8 P!@# & , 8 P!@
M# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8!!NV_P -AOQ5U^E2R^L;
MJ(_90]#BIM+JX78NTH1#ET5HP"4M3^[LA\4J?3&>5-L;7AYY/,>6%G;*_-^D
MTMZ_^MTQ_+:?5[3)%F[2@_U.5B&F=VS$^AR;"SLG$48!/VI_<*0^-E/H;//.
MVQMB'F4\]Y<6=L3\YZ+31,FO=F6^,W_TI7.]8&P0<U#\Q#CN-LL7./\ .4IF
M;36, VC)C^\P(_[O\'_S#'YRM!^&Q?YAC_XT0Z&B_!2GS+!Y=AJYYU2<\C +
MGI/KG4?RG@/K5ID6>VE.=JS')/)$IMJ6[8@\HTWF]L^X\9\9#]%6SA"Q]GBY
MKTVG8%H[$S.>BX@7/0E., O37OK?$_T[ZN=Y M/:<7CA\HTE26V8?T^3>5G:
MWK&T^)FWTV0S39&UGY]W)PC9:&SIFVZ7$99:D$8!,6HOPB<_F6'Y[K*6V>H@
M=E$T-+.S<L;B9I<1_;?6:<^,G/Z0<L9/:LOFF:"%,;/&SC]*ENY)-(P#(_67
MJLE^.O/SRYYBU-MN[!F@O)':[>R=I)!RN)@P!@%HCZ^%_)$WUR3 +NP!@# &
M , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
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MY;XD?P8?XHZ'1_C0O"?]PO2CTN5K4DZ>/UV"J2[$S8A6BKA0X',N@KS,"K5
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M3B\</E&DJ2VS#^GR;RL[6]8VGQ,V^FR&:;(VL_/NY.$;+0V=,VW2XC++4@C
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MW"FV(NO7F+JVKN&/AU$NNSSVPK.VF1BY4HJY$31W:TWKEJJ[R&P[@^!@# &
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M7$PCS:M_+K&B6.XEKEEMSR(B95W%UJJP$]/R<W*LHE_),(H2P,5+J1#:269
MQ//2B"$+&JN4#R#M$JB8' P.@.,^[3)X9J62UJ$@RE8*/E&Z\&R%+:DO/6+3
M[<]-TU)5#>=_K[N4A*YM!FJ^F4YVX@%BFH&+=P#%")EW$H,TIWN%-*)Q>U%S
M\1<*J[$<HG8NFZ;:J$*BZ6.R,W?@I*)J'4:%;NUW1"(&$4%0?-F1Q5*(H$61
MY*B,%\8!QJ]T4E00%,JXIG[)E2F.D57I'MBJ4AB',F!^0G*4Y#&+S IBB("
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MVSU$#LHFAI9V;EC<3-+B/[;ZS3GQDY_2#EC)[5E\TS00IC9XV<?I4MW))I&
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M5F5ZUZ&SI-M9%$5]+[![X^E2B=[=RUX,MU]^2[A0]0L'R, 8 P!@# & , 8
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M8[WS8/G9:OMG 'FS'>^;!\[+5]LX \V8[WS8/G9:OMG 'FS'>^;!\[+5]LX
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MLNI:2E)' IDKD7V^VN]QGK;@P, 8 P!@# & , 8 P!@# & , 8 P!@# & ,
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M6IC556.1$JQR)552F5:')M;UC:?$S;Z;(8LC:S\^[DX0M#9TS;=+B,LM2",
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MFH5=Z9HU*5LV,Y.H*"  BD)$P N =[SLJWPD@?E=A^T8 \[*M\)('Y78?M&
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M=E6^$D#\KL/VC 'G95OA) _*[#]HP!YV5;X20/RNP_:, >=E6^$D#\KL/VC
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MJ< >4)[X.E^6&OZG 'E">^#I?EAK^IP!Y0GO@Z7Y8:_J< >4)[X.E^6&OZG
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M , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
MP#YZ2CZ1*41_]@8 Z2?^B7_^ P!T$_\ 1+__ %#_ .F ?H  >@   _\ 5Z,
M_< 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
MP!@# & , 8 P!@%*CYV$EG4LQBY>,D7L"\)'S;1B^;.G,0^4;INDV<D@@J=1
MDY.V627*BY*FH9,X' O+ *K@# & , 8 P!@# & , 8 P!@# & , 8 P!@# &
M , 8 P!@# & , P#XR.'K?NY;1JRP:7V6ZIS?7[Q>XR$6[G:JS9O+17RNX2
M0JB-@TYLE6J6^PU;8&P6Y]HB]D(ZIJP%9:N-8W)653F:D,HJ7U2OMQI[=Y<[
M8IB,7%QL89\_DS1S!FQ-)2JQ',I("T;IMQ?23A))!-=^[%/Q#Q9-!$BKA10Y
M$DRF @#!W\ 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P#6
MV]E^W9N;7/$W48+7NV]G4.$<Z3J\HXAZ9?;55XI>37NNQ6J\BM'PDJQ:*OEF
MS)FW5=G1,X40:-D3J"F@D4G3',<L.Q;2P7G(]HV/9=H1VVY-0FQIVSY2:BMA
M-D;->V&V)'@Q'I#:Y[W(Q%Q4<]RHE7*J_@_-/M>U9#""5@R-IVA)0761+Q'0
MI2=F9>&Z(Z<GVK$5D&*QJO5K&-5RIC*UK45:-2GF-6>*;B<7LE?07XC-[K(K
M3<2DLBKM[8*B2J2C]N11-1,]A$ATSD$2G(8!*8HB4P" B&?J,U@I@LV6F'-P
M;L!KFP(JM<ECV<BHJ0W*BHJ2U45%O14O13\_E\(\(73$!KK>ME46-"146U)Y
M45%>U%146/145+E1<IMH<6&UK]J9OH"0U_"62UN[;Q%52DV&EU E!"Q7*KR=
M'V-*/H*->;*GJI58U3Q\)%RJKYS:JZY*A%JMVLB8[@6+WA8ZY1*UXOM0P.M7
M$MQ'6Z^*5EM_9#ZQ3>\=]FU$.NZ!"\*\UN:#UQ">Q]U#=;*L>4+&XV9J1=DY
MV4^>7QU+(VV9L)8>53A32S-)N:N1XS1.!=;7=IU5./(5B\<0'%;HZF)UC;-H
M?L=H;UTM(U31"[^N:[E[)1-P,^(TVJZW;+K'Z\B'],M6Q'>J>(/1.Q-CT^G)
MS6O$9;2&VWM%BR5$STQPUOEOX4I6Z_?143=O0]8J7:X6[5J-LE><2KN)?E<)
MMG,W 3=8E%C,'2\>Y4=PEBB8.69G,Z:K"47$4T3<)]#IH0[-9!0X^2C;+>.V
M-?069.G+-4THW3%5JNJW4%,6SPPD$Z1B&$@F*4PE$>0B4HB', RRLMC(DPYL
M1C7MU)RT>U')7&9?1R*E;UOX2%/N<R"U6.<U=41*M56K3$?=5*$$^<,__'DQ
M\IO?U^7_ #K+?)X'U4/[I4ZO'Z]%^L?ZR^;[:[#6>&C9MUAI-=M:*UJC9ECA
M9=8B,@NSF8*OV&0B7IDI%)VV=BS=M&RI4'J#ALH"14ET541,F/F9]K63<9K&
MM:U%;1K41K4]S:MR)1$OOXR[DU5T"$KE5RJKJJJJJK[HY+U6_(>9^Y>,GB49
MZZ>R<?3]KZ/DV7L8?%QOME,7!IPW6!2Y;=UT7A:)2KW4FM*O6V$&JU4\_P"V
MK>0;G&U>N2AKA'E?UV<\F&2@(A*1$NR+KD3=R7\64F!#8/%'JE939=]LNV6W
M#Y6-N</L?)$XA8KAP9[.F:WLA]L'4>V59!QHJ):5NO:FU]8KWH;;,7.S9(6_
MI.:'M5K+O5M>N81L\"Y>.BY*[E^ZO OD+IU#QNQ[:#T>VVJ>Y2ECXB'&P]H0
MB[76EY.C1=7V]Y*;)TA55"5/7CR,G).(U1/4JLV-8LF:583C&4D;&N#E19NB
M,4R\'"G![>0])L&!@&!O&C3%=4<+/%KN?2%KL>DMF5O4NXMYN[5K]M457=PO
M=%U?;9J 7N;:[56XQ\PR2>M&":Y46C&05CHR,AR2243'-&2(REZHG"FDL.V<
M5>P.'][M*B'H=IW#"ZHMNHM<16SK=;Y":ONPME;X=U*5A(937VE- 34HWK-%
MKUFE7EAF(.NR\ZLWBZO%UZLVF2GIQW501*Y/9-\XI;V0*RP3#4[N9T8^B).W
M3M?B=A4J5/NN-O\ 1HFR\0LAP_P5])67W#HW/ Z\M2T3)7^@63?3K0:M[K[=
M.&AHPL\692@1FF6_11;J[^7BK0Z51XM>)-G3VZ<UJK5=RN]AW5QSP,&HMN>>
MK,#'T'AIVYLB%BF\D[CN'UXZ-*-XNO,Z7&$;P;Q279QC*XSLPA*R\G#, 5$W
MUW-S?2N_[9.$I;SV1:\1PU& ?:!9'OVRHO4-PH,)5[5MO9D06B;=UQN#8L>^
MN)]7\.%POL998-#2\[#RT/5];W&$([G(-^%J+$MYEY'C")7=W][<IOJF^2+'
M\:^PY*5K"RO#Z2JU9Z?A1B[FVOE^GJOM6FVSBN4C(F$K#G6KC5*Z .]>V:;C
M8N[C-6Z D"-DY-PPB%7[(D4Y"G#O^2_07YH??M]'A$L/$#Q!1<*E*4F/W7;)
MUO0)A:T>4*GK.?N)B@T\52]>)DF21E=7BVS!.*,D[*S8R+B3%Y)NVK$%2^[@
M\O=[Y9*W%YN9C=J9IJ1T5KEONB\V/72$;&M]ZSKW7$92]F:AXE]GQ-ADKNCI
M'RVO88:1X6M@5*3JC"CJ,7A'M:LK*V)M99>-C@HF_=Q<*)DKPD.S/LGCUG"4
MZPL-2U)0)+5NE=L6NBO]MRA-MFJFS&<E,7JR:FHT;JJ10V?3M-P<%/2-GLDA
M/4/Q"4+,*2,?5R-(SS@"B4K7?W.]7CX*DMM^+J\EOVN-?;'UE'TVYR\I0[8+
M#7^V?/&JN:)M#0_%I>ZVE8)B8U76WS^5C;%PTVZ"F:[$1[!B1P>G72-NTDS&
M5IB@4N5?;*G#PEC,_9#;8TK==?WS56K-<R]VIO#/L2!E[%ON43U-4Z?Q,06]
M9BON=K;&>Z:B'E3D8)UH.>KJR<94+#!RMGN-%BB6".9/I::B0IPW7[EZTIN=
MW?,Z]";#LVV-/T/9%OIS>@3URAS3CBI,YB2L#6*9NGKOR.9M-2]9ILG(H2,*
M6/E$G+VK02YR/0 T<@   C"DO8 P!@# & , 8 P!@# & , 8 P!@# & , 8
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M= #DM;JGESS7IL<N=PK"U"'@X91V],P%VL/DR$P!@# & , 8 P!@# & , 8
-P!@# & , 8 P!@'_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>g98473g27s64.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g98473g27s64.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_[1HF4&AO=&]S:&]P(#,N,  X0DE-! 0
M     $H< 5H  QLE1QP!6@ #&R5'' (   (  !P"4  (<G(U,#DQ-C<< @4
M(4UI8W)O<V]F="!7;W)D("T@1V5N97-I<R!&+3$N9&]C>#A"24T$)0
M$")*^(M6HN%I'>),'8-E9Y0X0DE-!#H      .4    0     0      "W!R
M:6YT3W5T<'5T    !0    !0<W138F]O; $     26YT965N=6T     26YT
M90    !#;')M    #W!R:6YT4VEX=&5E;D)I=&)O;VP     "W!R:6YT97).
M86UE5$585     $       ]P<FEN=%!R;V]F4V5T=7!/8FIC    # !0 '(
M;P!O &8 ( !3 &4 = !U '        IP<F]O9E-E='5P     0    !";'1N
M96YU;0    QB=6EL=&EN4')O;V8    )<')O;V9#35E+ #A"24T$.P     "
M+0   !     !       2<')I;G1/=71P=71/<'1I;VYS    %P    !#<'1N
M8F]O;       0VQB<F)O;VP      %)G<TUB;V]L      !#<FY#8F]O;
M    0VYT0V)O;VP      $QB;'-B;V]L      !.9W1V8F]O;       16UL
M1&)O;VP      $EN=')B;V]L      !"8VMG3V)J8P    $       !21T)#
M     P    !29" @9&]U8D!OX            $=R;B!D;W5B0&_@
M    0FP@(&1O=6) ;^            !"<F1456YT1B-2;'0
M  !";&0@56YT1B-2;'0               !2<VQT56YT1B-0>&Q <L
M      IV96-T;W)$871A8F]O; $     4&=0<V5N=6T     4&=0<P    !0
M9U!#     $QE9G15;G1&(U)L=                %1O<"!5;G1&(U)L=
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M____   X0DE-! T       0   !X.$))3009       $    'CA"24T#\P
M    "0           0 X0DE-)Q        H  0         !.$))30/U
M  !( "]F9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &       ! #(    !
M %H    &       ! #4    ! "T    &       !.$))30/X      !P  #_
M____________________________ ^@     ________________________
M_____P/H     /____________________________\#Z     #_________
M____________________ ^@  #A"24T$"       $     $   )    "0
M   X0DE-!!X       0     .$))300:      ,U    !@             "
M3   !#P          0                         !              0\
M   "3                      !                         !     !
M        ;G5L;     (    &8F]U;F1S3V)J8P    $       !28W0Q
M!     !4;W @;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG
M   "3     !29VAT;&]N9P  !#P    &<VQI8V5S5FQ,<P    %/8FIC
M 0      !7-L:6-E    $@    =S;&EC94E$;&]N9P         '9W)O=7!)
M1&QO;F<         !F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U
M=&]'96YE<F%T960     5'EP965N=6T    *15-L:6-E5'EP90    !);6<@
M    !F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
M         $QE9G1L;VYG          !"=&]M;&]N9P   DP     4F=H=&QO
M;F<   0\     W5R;%1%6%0    !        ;G5L;%1%6%0    !
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M300H       ,     C_P        .$))3001       ! 0 X0DE-!!0
M  0    ).$))300,      ^7     0   *    !7   !X   HR    ][ !@
M ?_8_^T #$%D;V)E7T--  +_[@ .061O8F4 9(     !_]L A  ," @("0@,
M"0D,$0L*"Q$5#PP,#Q48$Q,5$Q,8$0P,# P,#!$,# P,# P,# P,# P,# P,
M# P,# P,# P,# P, 0T+"PT.#1 .#A 4#@X.%!0.#@X.%!$,# P,#!$1# P,
M# P,$0P,# P,# P,# P,# P,# P,# P,# P,# P,# S_P  1" !7 * # 2(
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M0_Z3FM]3V?G+(ZCU'HS>KV4YF VZRFME=N66,<6UV]GS^D;C[;/^W'^DRO\
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M2G__V0 X0DE-!"$      %4    ! 0    \ 00!D &\ 8@!E "  4 !H &\
M= !O ', : !O '     3 $$ 9 !O &( 90 @ %  : !O '0 ;P!S &@ ;P!P
M "  0P!3 #8    ! #A"24T$(@     !1DU- "H    (  @!$@ #     0 !
M   !&@ %     0   &X!&P %     0   '8!*  #     0 "   !,0 "
M'@   'X!,@ "    %    )P!.P "    "0   +"':0 $     0   +P   #H
M "W&P   )Q  +<;    G$$%D;V)E(%!H;W1O<VAO<"!#4S8@*%=I;F1O=W,I
M #(P,3DZ,#<Z,C$@,3@Z,C,Z-#D <G(U,#DQ-C<       .@ 0 #     ?__
M  "@ @ $     0  !#R@ P $     0   DP         !@$#  ,    !  8
M  $:  4    !   !-@$;  4    !   !/@$H  ,    !  (   (!  0    !
M   !1@("  0    !              !(     0   $@    !.$))30/]
M   (          #_X0%(34T *@    @ " $2  ,    !      $:  4    !
M    ;@$;  4    !    =@$H  ,    !  (   $Q  (    >    ?@$R  (
M   4    G $[  (    )    L(=I  0    !    O    .@   /      0
M \     !061O8F4@4&AO=&]S:&]P($-3-B H5VEN9&]W<RD ,C Q.3HP-SHR
M,2 Q.#HR,SHT.0!R<C4P.3$V-P       Z !  ,    !__\  * "  0    !
M   $/* #  0    !   "3          & 0,  P    $ !@   1H !0    $
M  $V 1L !0    $   $^ 2@  P    $  @   @$ !     $   %& @( !
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MY;^]=KFJ)Y#_ !XV/FBXU5D4""HNJFB0 $1.JH5,@ 4/481,<0  * "(B(^
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M)Z^:SQ-HU1;I-$FZ!&J"::*+8B*94$44BE(DDDB4H)D32(4I4R%*!2%*4I0
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M-GBD7D/V>-VY3[N+RTY;4FFUEZWGZ<FT)VJ#%O9%S&ZYFSP>N)F42VHZ+T=
M2WHIII2!):RNIKF/?OS]/X^B>_?[??HMV_,HM0OQ0++V@L2F68EA.'=IK359
M.WU:^:7H/6?;,EQ6SV.F19+C'V3)8.TVS0JM>8.;;NC56[/Y*!B'$;)QK-O6
MUY6/)*R+V,)['O\ )3Q\."%G(7#K 6;I/:2CG?:-,/F+#MGV KW8^_2+(8&M
M-OJE>O59NM[CV5+.[;.F;*O#,(KLYQE/OCL4BR1%G!%L"X1.$6L7XQO]G?M7
M^L.MG^Z7%>$6SKA$X1.$6,W*XUO/JK/W:X2K>$K-9C',M,RCD%3D;,VI/4;V
MT&Z:SIVZ7.)&[)@S0</I!XL@R8MW#MPBBI(J5+-ZS!3J1.GLV9&Q0Q,UMSW'
MIMQ(:QK1MSY'EK(V!SWN:UI(U<YK&ESCIK1LD_+^?W =2>@ZK4CB-/V%YWQM
M/9W33:!0W=CRM9K-9K9H;+5ZCG^#O'LQ^ B/[BAL:\]&2Y9NE#8[,@THQUXZ
M?=SK-ZT1C'(R_+-F.,\5'A/Z@4\))+'B;+,D[B<7JT=>S:W/%8R'=3]:ZE.U
MMBI5$CS.VLRM8DCB^P*W#=G^F9F34[D+65NUEEE=CQ6AI.=,(9G/%\SM:Z2L
M\N;W?M&'9D8UOC6P"HLGNVVB+U2PM'3/-JVY.[QZKOTG#5:?D2&.@&O62-<D
M3.F==OZT\TBG27NQ<.Z7M;PA9>;C6U=\YKAV2ECO2M<VI"XNQ\+P6F5P'+W^
M5A'3F!<*C'=61N,Q D>T1R:S'9:Q'D9VO91KO+L76D#F&:0;;]*3QN ()&Q0
MC>-QQ.-EX[6:-L%E.=A=U.$3A%A*NE9TA/\ X56OM,1M'SB4?^&U;1!ISPOU
M_1[+((<[X) 7:WNI^TV!O[RGK)Z"#Z@\P#E<8VSW,Y&B+G.(^ZFW7%GM':Y8
M^P[3M>=VP0WDV0?)=UG"_$TF..89P[G7X@0OLG*-Q%]V.[O'S=I8[\*YK"&/
ME<'RF7D;RNYG#16;<GKA)PBAW3^P&/XP[AV6GW=A4',^4YH8D@SEEB2(D4]D
MR3=9A'NT3. 4^P-A4*X,'@Y4A(/JYQ,KQ'A,&^"/+9"*B^SONXE;*>U(/*6L
M+(W@N!UX=\W4=-%7?A/X<<;<=0W9^$\!9S<6.+1>=6GIL-8.;SA\K+%F&01\
MO7M0TQ@]"\'HI::.D'S9N\;'%1NZ12<('$ATQ.BLF55,_H4*10GJ(<H^DY2G
M*(^DQ2F 0#LL<U[6O:=M<T.:>HV' $'1T1L$'1 /S5,EB?!+)#*WEDAD?%(W
M;7<KXW%CV\S2YKM.!&VDM/F"1U78YLOFG")PB<(G")PB<(G"+\$ ,'@P 8!_
M,! ! ?[_ ,AX11Y8,AR>V"J-IS'/;(*XB*WU^EUN8]T16^8$5/J,8Y]P17_I
MA$_J$5?Z3^OX-R++1I3;[:I5EWO?:UXI-[.SOF8=[/4_?U4&?&8VSOO./HV-
M^?;U()=]>;KVD;M^+K^/7S6%CUCPA(!")SF'J@B/D%*&YEL^63,"HK$.@O2)
M"OK-CI',84#MSI&;E.H1$4R**%-'^B,</L56P_\ COEK:T=CE[N^+ET1X>77
M+UUK9W%. P__ "Z,=;Y&F^6B1UV.4TY("W1\N4C0) T"=T#[ ?"N9[!N-.UR
MN;//5>-J;2KHA6;:E;]4D7*M=L<C/'*VMENT)63CXYR1Z1HVBR)+-(\Z:SM(
MJBCM8G.%>X5%JXRQ%<?'&UL;>SG$UN3ZLD])IK!?RD'0:>C>I'F54,O\/F9'
M*07X,I-!'"R!O8VA:R4FX97R'ELVKQD;&X. ;&06QD.<WJXK;H'_ %_/EO7H
MZ<(G")PB<(G")PB<(G")PB<(G")PBU3]GXW7\<[HTKMQ7>K6@=N*6TZ^KXW
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MB>3D/P+ RZ$S9IG1W+AXZ!)W08(KR]\8V,9PA/FJD-2EAK4EG(42Z.Q8D-+
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M(E*H $5+Z5B$7+X6(50.?_5KA\$EF'Q\#COQ5:\=1_7S\=81.'7Q=#]K3OM
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M7B#F,>FG?*TC+YNB=@U$B%K6_0+%4J21!-8,<B9GW52G_I5CFC+572E!1+[
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M+\CKN=S*FC=?DINB1%X3T@*0Q:5323+M&#4**H1G3X]*"'W),@RW,=?R_/\
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MX%/8))GV?[#J-G=Y^6\S2B1ZOKC&N' %Q]!C0K5&-$Y3"T R7I.8BL)^IZZ
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M^9/.]U[$:'@'2;-].[5:]5TM%M7Q2IW4-ZKEP3H=ZM=BZR6W2_T5U\;0 +A
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
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>g98473g29v69.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g98473g29v69.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_[2QJ4&AO=&]S:&]P(#,N,  X0DE-! 0
M     $H< 5H  QLE1QP!6@ #&R5'' (   (  !P"4  (<G(U,#DQ-C<< @4
M(4UI8W)O<V]F="!7;W)D("T@1V5N97-I<R!&+3$N9&]C>#A"24T$)0
M$")*^(M6HN%I'>),'8-E9Y0X0DE-!#H      .4    0     0      "W!R
M:6YT3W5T<'5T    !0    !0<W138F]O; $     26YT965N=6T     26YT
M90    !#;')M    #W!R:6YT4VEX=&5E;D)I=&)O;VP     "W!R:6YT97).
M86UE5$585     $       ]P<FEN=%!R;V]F4V5T=7!/8FIC    # !0 '(
M;P!O &8 ( !3 &4 = !U '        IP<F]O9E-E='5P     0    !";'1N
M96YU;0    QB=6EL=&EN4')O;V8    )<')O;V9#35E+ #A"24T$.P     "
M+0   !     !       2<')I;G1/=71P=71/<'1I;VYS    %P    !#<'1N
M8F]O;       0VQB<F)O;VP      %)G<TUB;V]L      !#<FY#8F]O;
M    0VYT0V)O;VP      $QB;'-B;V]L      !.9W1V8F]O;       16UL
M1&)O;VP      $EN=')B;V]L      !"8VMG3V)J8P    $       !21T)#
M     P    !29" @9&]U8D!OX            $=R;B!D;W5B0&_@
M    0FP@(&1O=6) ;^            !"<F1456YT1B-2;'0
M  !";&0@56YT1B-2;'0               !2<VQT56YT1B-0>&Q <L
M      IV96-T;W)$871A8F]O; $     4&=0<V5N=6T     4&=0<P    !0
M9U!#     $QE9G15;G1&(U)L=                %1O<"!5;G1&(U)L=
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M____   X0DE-! T       0   !X.$))3009       $    'CA"24T#\P
M    "0           0 X0DE-)Q        H  0         !.$))30/U
M  !( "]F9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &       ! #(    !
M %H    &       ! #4    ! "T    &       !.$))30/X      !P  #_
M____________________________ ^@     ________________________
M_____P/H     /____________________________\#Z     #_________
M____________________ ^@  #A"24T$"       $     $   )    "0
M   X0DE-!!X       0     .$))300:      ,U    !@             "
ME0   T<          0                         !              -'
M   "E0                     !                         !     !
M        ;G5L;     (    &8F]U;F1S3V)J8P    $       !28W0Q
M!     !4;W @;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG
M   "E0    !29VAT;&]N9P   T<    &<VQI8V5S5FQ,<P    %/8FIC
M 0      !7-L:6-E    $@    =S;&EC94E$;&]N9P         '9W)O=7!)
M1&QO;F<         !F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U
M=&]'96YE<F%T960     5'EP965N=6T    *15-L:6-E5'EP90    !);6<@
M    !F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
M         $QE9G1L;VYG          !"=&]M;&]N9P   I4     4F=H=&QO
M;F<   -'     W5R;%1%6%0    !        ;G5L;%1%6%0    !
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M300H       ,     C_P        .$))3001       ! 0 X0DE-!!0
M  0    &.$))300,     "';     0   *    !^   !X   [$   "&_ !@
M ?_8_^(,6$E#0U]04D]&24Q%  $!   ,2$QI;F\"$   ;6YT<E)'0B!865H@
M!\X  @ )  8 ,0  86-S<$U31E0     245#('-21T(               $
M /;6  $     TRU(4" @
M                       18W!R=    5     S9&5S8P   80   !L=W1P
M=    ?     48FMP=    @0    4<EA96@   A@    49UA96@   BP    4
M8EA96@   D     49&UN9    E0   !P9&UD9    L0   "(=G5E9    TP
M  "&=FEE=P   ]0    D;'5M:0   _@    4;65A<P  ! P    D=&5C:
M!#     ,<E120P  !#P   @,9U120P  !#P   @,8E120P  !#P   @,=&5X
M=     !#;W!Y<FEG:'0@*&,I(#$Y.3@@2&5W;&5T="U086-K87)D($-O;7!A
M;GD  &1E<V,         $G-21T(@245#-C$Y-C8M,BXQ               2
M<U)'0B!)14,V,3DV-BTR+C$
M                             %A96B        #S40 !     1;,6%E:
M(                     !865H@        ;Z(  #CU   #D%A96B
M  !BF0  MX4  !C:6%E:(        "2@   /A   ML]D97-C         !9)
M14,@:'1T<#HO+W=W=RYI96,N8V@              !9)14,@:'1T<#HO+W=W
M=RYI96,N8V@
M            9&5S8P         N245#(#8Q.38V+3(N,2!$969A=6QT(%)'
M0B!C;VQO=7(@<W!A8V4@+2!S4D="               N245#(#8Q.38V+3(N
M,2!$969A=6QT(%)'0B!C;VQO=7(@<W!A8V4@+2!S4D="
M             &1E<V,         +%)E9F5R96YC92!6:65W:6YG($-O;F1I
M=&EO;B!I;B!)14,V,3DV-BTR+C$              "Q2969E<F5N8V4@5FEE
M=VEN9R!#;VYD:71I;VX@:6X@245#-C$Y-C8M,BXQ
M              !V:65W       3I/X %%\N !#/%  #[<P !!,+  -<G@
M  %865H@      !,"58 4    %<?YVUE87,          0
M          */     G-I9R      0U)4(&-U<G8        $      4 "@ /
M !0 &0 > ", *  M #( -P [ $  10!* $\ 5 !9 %X 8P!H &T <@!W 'P
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M8^/KY'/D_.6$Y@WFEN<?YZGH,NB\Z4;IT.I;ZN7K<.O[[(;M$>V<[BCNM.]
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MP  1" !^ * # 2(  A$! Q$!_]T !  *_\0!/P   04! 0$! 0$
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MW_92*Z]FV_Z7^D56SI?6P,<V=:M(%C34/LY(+FV6/V6"MC'^G?C_ *+](_\
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M #A"24T$(0      50    $!    #P!! &0 ;P!B &4 ( !0 &@ ;P!T &\
M<P!H &\ <    !, 00!D &\ 8@!E "  4 !H &\ = !O ', : !O '  ( !#
M %, -@    $ .$))300B      %&34T *@    @ " $2  ,    !  $   $:
M  4    !    ;@$;  4    !    =@$H  ,    !  (   $Q  (    >
M?@$R  (    4    G $[  (    )    L(=I  0    !    O    .@ +<;
M   G$  MQL   "<0061O8F4@4&AO=&]S:&]P($-3-B H5VEN9&]W<RD ,C Q
M.3HP-SHR,2 Q.3HT-3HU-P!R<C4P.3$V-P       Z !  ,    !__\  * "
M  0    !   #1Z #  0    !   "E0         & 0,  P    $ !@   1H
M!0    $   $V 1L !0    $   $^ 2@  P    $  @   @$ !     $   %&
M @( !     $              $@    !    2     $X0DE- _T       @
M         /_A 4A-30 J    "  ( 1(  P    $      1H !0    $   !N
M 1L !0    $   !V 2@  P    $  @   3$  @   !X   !^ 3(  @   !0
M  "< 3L  @    D   "PAVD !     $   "\    Z    \     !   #P
M  %!9&]B92!0:&]T;W-H;W @0U,V("A7:6YD;W=S*0 R,#$Y.C W.C(Q(#$Y
M.C0U.C4W ')R-3 Y,38W       #H $  P    '__P  H ( !     $   -'
MH , !     $   *5          8! P #     0 &   !&@ %     0   38!
M&P %     0   3X!*  #     0 "   " 0 $     0   48" @ $     0
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M$0$#$0'_Q  ?   " @$% 0$             "0<(!@$#!0H+! +_Q !D$
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MQ3JJ"Z"R9C)JHK)'*HDJF8Q%"&*<AA*("(#$- &@#0!H T : - &@#0!H T
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M-UJ:QQC]S$6&*D825;$<6MN9Q&RK-9@^0*NA.$71,JU753!5%0BB8F Z9R'
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M[P^R?2+/]M#OC\?2:6K=><KJ.G$%#KN5E 56<+1C-5=50$P2!114Z)E#G!(
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MGKA-V\3QB1-V[20%JDZ<DL,X5=PFU%5<6R:RH'4(@*ZPHE,"?:J=7KB,C$M
M&@$O]*Y_.V%_[NNGK_\ >:[J7.*_O,K^79;KW7YLY=5+[M6LK1\H#PC@U?\
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MDV?I_2PW'I:ZB0L8&@#0"T][P?QRJ//^KZX?]_4$?C_)YM</PI\*L_F8KO\
MC+3?)^\3\(/K21]T@*1ZY<L$:AWAZP_/K6+O7S/L88SK9080QQ8.[G;W0_\
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MX/*A[4>-H\'G^9F^I$>80C]0'/EQ#U]W_G]_AJ7XN^?-!]G 5MTORHO69O
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MV/DZ'$OIF9A5+3-R%YKE?91+$\G-N^PC4^J!S&P>CX-KF'G=EPI@5A@=O;[
M^\HXL^0*/ENSV!Y J'8,I.RY/H^0LJ-+,<B"BI8]L_O$D]ADE5FZC5@=91(X
M:=]^G=7C$.("'I#AH!8%6Z+_ !M$Y3W'WR]Y(R#D^I;BHRL+V*FRC_R'G6%I
MK.2LGY)2FSY+Q2K1+G,,FQ\BDK$!%23U16)K$#'03N2EX=E"1\(!EW1,-$(_
MHY-I;!J4Q&S+&)6C<AU55SD0;6&<11*99PHJNL8J9"@95951500$ZBASB)A
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M%_9H [%+[4G^ 7]F@/V!2E#@4 *'H   /B#0&N@#0!H T : - &@-! # )3
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M4UIAU)6*8<LH=5Z1J88]NW8-JT,AH T!^3%*<HE.4IBF 0,4P 8I@'O 0'B
M@/G >6@$SU+HW,N5.K8DK(W3#=C:87V69VVW5]K-UVS'96:^9XO^/K1)VRQH
MCX2DUK-2C<<1)H-LR;.9EY-O5E5U&3=@V56;_B#%,?\ 1?YKK-EP=,63(6%[
M%%XOI^W@U@AC5VW*>45XVO[?LR[?*5!-G+U59)/&60(7)["RWQJ]9JR48^CI
MZ%BV$NSL0/X\!A^QO!-[VS[9\?X.R',4R?G*&K9VS>7H;:99P3N)FK3,69D
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
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>g98473g30a67.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g98473g30a67.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_[1/F4&AO=&]S:&]P(#,N,  X0DE-! 0
M     $H< 5H  QLE1QP!6@ #&R5'' (   (  !P"4  (<G(U,#DQ-C<< @4
M(4UI8W)O<V]F="!7;W)D("T@1V5N97-I<R!&+3$N9&]C>#A"24T$)0
M$")*^(M6HN%I'>),'8-E9Y0X0DE-!#H      .4    0     0      "W!R
M:6YT3W5T<'5T    !0    !0<W138F]O; $     26YT965N=6T     26YT
M90    !#;')M    #W!R:6YT4VEX=&5E;D)I=&)O;VP     "W!R:6YT97).
M86UE5$585     $       ]P<FEN=%!R;V]F4V5T=7!/8FIC    # !0 '(
M;P!O &8 ( !3 &4 = !U '        IP<F]O9E-E='5P     0    !";'1N
M96YU;0    QB=6EL=&EN4')O;V8    )<')O;V9#35E+ #A"24T$.P     "
M+0   !     !       2<')I;G1/=71P=71/<'1I;VYS    %P    !#<'1N
M8F]O;       0VQB<F)O;VP      %)G<TUB;V]L      !#<FY#8F]O;
M    0VYT0V)O;VP      $QB;'-B;V]L      !.9W1V8F]O;       16UL
M1&)O;VP      $EN=')B;V]L      !"8VMG3V)J8P    $       !21T)#
M     P    !29" @9&]U8D!OX            $=R;B!D;W5B0&_@
M    0FP@(&1O=6) ;^            !"<F1456YT1B-2;'0
M  !";&0@56YT1B-2;'0               !2<VQT56YT1B-0>&Q <T[QL
M      IV96-T;W)$871A8F]O; $     4&=0<V5N=6T     4&=0<P    !0
M9U!#     $QE9G15;G1&(U)L=                %1O<"!5;G1&(U)L=
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M____   X0DE-! T       0   !X.$))3009       $    'CA"24T#\P
M    "0           0 X0DE-)Q        H  0         !.$))30/U
M  !( "]F9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &       ! #(    !
M %H    &       ! #4    ! "T    &       !.$))30/X      !P  #_
M____________________________ ^@     ________________________
M_____P/H     /____________________________\#Z     #_________
M____________________ ^@  #A"24T$"       $     $   )    "0
M   X0DE-!!X       0     .$))300:      ,U    !@             !
ME   !YP          0                         !              ><
M   !E                      !                         !     !
M        ;G5L;     (    &8F]U;F1S3V)J8P    $       !28W0Q
M!     !4;W @;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG
M   !E     !29VAT;&]N9P  !YP    &<VQI8V5S5FQ,<P    %/8FIC
M 0      !7-L:6-E    $@    =S;&EC94E$;&]N9P         '9W)O=7!)
M1&QO;F<         !F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U
M=&]'96YE<F%T960     5'EP965N=6T    *15-L:6-E5'EP90    !);6<@
M    !F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
M         $QE9G1L;VYG          !"=&]M;&]N9P   90     4F=H=&QO
M;F<   ><     W5R;%1%6%0    !        ;G5L;%1%6%0    !
M37-G951%6%0    !       &86QT5&%G5$585     $       YC96QL5&5X
M=$ES2%1-3&)O;VP!    "&-E;&Q497AT5$585     $       EH;W)Z06QI
M9VYE;G5M    #T53;&EC94AO<GI!;&EG;@    =D969A=6QT    "79E<G1!
M;&EG;F5N=6T    /15-L:6-E5F5R=$%L:6=N    !V1E9F%U;'0    +8F=#
M;VQO<E1Y<&5E;G5M    $453;&EC94)'0V]L;W)4>7!E     $YO;F4    )
M=&]P3W5T<V5T;&]N9P         *;&5F=$]U='-E=&QO;F<         #&)O
M='1O;4]U='-E=&QO;F<         "W)I9VAT3W5T<V5T;&]N9P      .$))
M300H       ,     C_P        .$))3001       ! 0 X0DE-!!0
M  0    %.$))300,      E8     0   *     A   !X   />    D\ !@
M ?_8_^T #$%D;V)E7T--  +_[@ .061O8F4 9(     !_]L A  ," @("0@,
M"0D,$0L*"Q$5#PP,#Q48$Q,5$Q,8$0P,# P,#!$,# P,# P,# P,# P,# P,
M# P,# P,# P,# P, 0T+"PT.#1 .#A 4#@X.%!0.#@X.%!$,# P,#!$1# P,
M# P,$0P,# P,# P,# P,# P,# P,# P,# P,# P,# S_P  1"  A * # 2(
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M(:UH)<3P .2@T9^%D"HT7-L%[0^HM,AS2)WL/R61TKZQ.ZEDOQ;&>BZ]@=C
M D@>C3=;ZSVO;]&R_P!GIJZWIF2*:JSD NK8UKW1=[B/SOZ7O_[=LN_KIXD#
MM]O]C!&0D+!3Y3,?&LLZK:YX^SX[VO )+?3!]=[O2_.L]BE3E666!EE)J#]Q
MJ)(.YK8][@WZ&[<JN;C.HZ)G5OL!G&M&\ Z?HW#=^DLL<[_MQ2H9MSFN])S-
M^X^H7;O4]M(WM9N=Z3?S=G^KRET4._(Q\=@?D6LI87-8'6.#07..RMDN_/>]
MVQB!?F6&]N+BUNL>Z?4OT-5, ']-[VO=8_=^CJJ_Z[Z*@,*NAY^S-:<JY[;;
MKK1N<0/398]WT?<ZNOTZF,V5L_<]B1-) LTS?U7I['/:;@376;G;07 ,&X;I
M8'?N.]J5V:YIH--?JLR&N<'EP9 :PVL]CO>[U/H^UOL4[*'G>Y^0]K'5EI#=
MK0WG]*UVW>U_]M*S&%OHD/)%8< XEQW;F^GN.U[&/_ZXRQ#7M2B .M^2.OJ6
M.:@^XBIWYS=7 ?VPWW*9^S/+.H^I[*ZW0Z?9L=M>Y\'^I])J _IESF[1?!\8
ML'_49#'*S<'##L%CMSA60]P&V3M]S@';MJ*$3<^PWM8_'>RBTAM-^YI#RYOJ
M?S4^K7[1^>U7%AX0ROLW3-QK^R13]G: ?4'Z%W\\[^;=_8K8MQ)2DDEF_;6Y
MF0QM!>VFF\L=8 1ZCZ][+*6-_.HK?_/9'\UO_1U_\$E 7LD=U6ECVML;Z8+W
ML+GV4@#TSL-D>MNV._[=9_A:ZU;JMJN8+*GML89 <TAPT,'W-55^)ER#7:T0
M][X<;3])VYG^'_-_T?\ -?Z/TV(K69P:T%],R=\,=$3^;^D24__0Z;K%5K<%
MS[ 6A_5&EC"W;H,JAK;';AN=NV_H[/\ 1;%SG3/Z7@_\;A?]7T->@=5Z5]O?
M6=E+@V"YUP<_5AWT[*FN8SV6?I?4_P"#]/\ /]2JAD]#Z)T^NNUU%3;6NFLL
MK> 37L?0S=7]H?1M^S8WZ;_@?T:GQ9Q")B03J@BW!SAKF_ULO_JNNHO4!I@_
M^&<[_P!OL=7ZZ.A.<?MA987[M^S&O&XN%FYVYWJ?GY&3^_\ SG_&>LXQNEY&
M6S%:ZEP8]P8'4W./J6.^TVN_P=-&ZRNKV[OTG\]Z_J^FJ$>7()-C5N\[S4>8
MP^V(F)XA*S_5:'U9!_;6)_Q3_P#VWPUW*S,3ZO\ 3\3(JR*:VM?4T@%H@[B*
MZ]VZ?H[*OYO_ ,P6FIH1X130A#A!%WK;2ZS/['SH$G[-;  G\QW957LO^T,]
M"EP;9O-EHL&][=E WXS'$LKW?0][J?3]]E?Z2Q:KV,>PL>T.8X$.:1((/((5
M.S" S:W5UN])XL=<\6.;M=%3*@UN[=L<UKO;7^C3E[6Q;KF5XE/3\%V'@EM@
M-;F"LLV@&H>FW?Z>^S?_ (-2-60\WFYUI:<FHL%8<#M;]G.MGM=Z++/4W>EZ
M5?\ .J=YQ\2][\RPT86VL5W67N:/5<ZW>S5_M]OH^YSD"G-Z6+<@7YM88'@X
M_P"M3-1KJ=O]MGM;ZKK/YQ(:&PDD[:#R#8OQW6/MW"ZZIV.YGHN(V.)+_:6'
M9O>YIV?I'[-BO4M#:6-#=@#0 S01 ^C[?;[5EX]W3+V?9J>I,NRW[VUN9=N=
M/O<W]"RWW>DP?^!JX[!=Z317<]ES=I-I+G [2TO_ $3G[/TD(V3NAMH64X-Q
MKG.T#6.))X@ HJ2"G&QJ;FX_3;K+'AKA3^JEK RJ*7;]D,]?M_A;[$>WZP]'
M98*F9#;[CLVUT?I"?4)95K7N8S>YO^$>K&9T_'S37Z[0]M;MQ8[5I'@63M_M
M*FX5XM]E-6#E>E6T"LT$"L@#?^CVWUO^E9Z>S9^8EHD5U:E]N;U9E]=S7583
MZK6'$JE]CRVU](=9D,]*EC;:F?T9N2S_ (RRI:M%>0R!74VEOJ$/+W;W.8-V
MW9M]M>[\RO\ P7^C5![\GT"P8V>;'DEMH=7+07.@;/M>SV,5S'H=>^K( OQ6
MUN=OHM=)?I['';;<UK&N1T[)O2AH&^DDD@M?_]'U5)?*J22GZJ27RJDDI^JD
ME\JI)*?JI)?*J22GZGM_FW? _D4*.'?$?]2Q?+:22GZH'927RJDDI^JDE\JI
M)*?JI)?*J22GZJ27RJDDI^JDE\JI)*?_V3A"24T$(0      50    $!
M#P!! &0 ;P!B &4 ( !0 &@ ;P!T &\ <P!H &\ <    !, 00!D &\ 8@!E
M "  4 !H &\ = !O ', : !O '  ( !# %, -@    $ .$))300B      %&
M34T *@    @ " $2  ,    !  $   $:  4    !    ;@$;  4    !
M=@$H  ,    !  (   $Q  (    >    ?@$R  (    4    G $[  (    )
M    L(=I  0    !    O    .@ +R.\   G$  O([P  "<0061O8F4@4&AO
M=&]S:&]P($-3-B H5VEN9&]W<RD ,C Q.3HP-SHR,2 Q.#HT-SHP,@!R<C4P
M.3$V-P       Z !  ,    !__\  * "  0    !   'G* #  0    !   !
ME          & 0,  P    $ !@   1H !0    $   $V 1L !0    $   $^
M 2@  P    $  @   @$ !     $   %& @( !     $              $@
M   !    2     $X0DE- _T       @          /_A 4A-30 J    "  (
M 1(  P    $      1H !0    $   !N 1L !0    $   !V 2@  P    $
M @   3$  @   !X   !^ 3(  @   !0   "< 3L  @    D   "PAVD !
M  $   "\    Z    \     !   #P     %!9&]B92!0:&]T;W-H;W @0U,V
M("A7:6YD;W=S*0 R,#$Y.C W.C(Q(#$X.C0W.C R ')R-3 Y,38W       #
MH $  P    '__P  H ( !     $   ><H , !     $   &4          8!
M P #     0 &   !&@ %     0   38!&P %     0   3X!*  #     0 "
M   " 0 $     0   48" @ $     0             #P     $   /
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M 0$! 0$! 0$! ?_  !$( 'X"70,!$0 "$0$#$0'_Q  >  $  @(" P$
M        !P@&"00% @,* ?_$ %@0  $$ @( ! (#" P("P<%  4" P0& 0<
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M$6EZ?J\$K<=YV 8:VO7]AO5BND:T^S7J.;TN;"[!"K*B'[5,)E:LDW8</!Q
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M)H0?*5)4G.,I5C.,9QG&<9QG'GCGQ]J0[9O/$=",IE""/1_I<ZZ!C6AQH-<
MYKC5:X$;@@]V""#X@CH0OG(\*W>.Y]C[LWD'V!M?8MV$S^NNRK-.&6JY6 ]
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M?5SZ @]_*Y^ S?3M_P!^J_#Z[+6'>YR+[^/3\3UX]D_Q)OA[^7_USW;]7_\
MI-E_O_Q<:=]^37WR+A?HV.Z?B5UW[ 8K[M-_:G_0L![N_BZ/"8_F;V>_)_\
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M\LKWRRRN<^261SGR2/<2YSWO<2Y[G.)+G.)))))W*EP      -@!T  \ !Z
M%"'5+\&3K[_0WKG]4Q7E_F_OCDSJ;W1YWY7R'Q?]ZEW7E7_>(?N4?Q_R1LI_
MY!KV57]P7"I!]Z=8 9>S !AJ;;KPN$)(%X$,G+01UK:PP]<6#(?;DOIFEY#
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MN/&C/<-VD?>>*^<N?'^U6]O?\8[V*/RSK7Z+@U^=6_Q9/B'?QF=*?YK:+_\
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M*GH#;F%2YF59SF=S,QO-T\RAO%5K.KY3,L99)IU(:G?-%#&W81#*(0Y@?*)
M[F./ ,DDBM/7=93T>>5P&/I3BQ..ZGRW=3&/D'!_=TZ61@XN>Z3@3:#W, Y1
MM/G/L-?;/V+'TRURZ5J[7!"VQ:Z8D5B++V4:(PY1]J!(6)C2ARJ'6<S6'IR8
MZ'(N+ %]PA66?FL#*_=-8SKN<A#I9,'3LQQ-,CJ]3.O99L!O4PP/L81L+)9
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MT?=@"21"&-%7.N$EM#I,F,6A>V6^@BPCP\ZCLFC=7*C6MK@2M=MT"S[(_P
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M+NN^QGLYS=+B[5.;TSHYCANZ#*9:&WE8NO6.S@L'%G=1U7G?;C9PM, [@R-
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MP FQA\FD#OH-9&L3UB\3/?)A9<6AO$K+'H96I*<.?$K&.=[@NTQVVVYS;K"
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MYG%3UJF8UFZW8AR%26"JU]7"\'6)63.CA#N+N)D<T'B=O K\ZQ[*US#\-GQ
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M/%HV7U@[(,<;?@$XODM&%KC2F8LU$>1AZ'F?!'3U1U3!T%^.14D[(U/I/J"
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M;ILR[;XS$+;-0M'7;4FGXENBF*!:A<D8"9CA)X;9+#!\ZD+6"!"+7LT^<Y;
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M3%8<015&[?Q]Y61BJZOH^K!>S-,[>@6+6FZ$QS'R"VUN%;UB04.QPST@JW"
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M6>K&V(V].M^CMO1JF0H.-@ZPIUCE44H%EUV?2B<P+$P7J+X2=&AR1_T:*MS
MK;*HS366H3;D;"HRV5J(I\X1=+9, \UT_BS18DVMY"E<6&%/A))098/,%_YM
M%FCELR$3XDB![AJ3"5'?3*96MA3+N',H41:V?"C[4@.X^B=C;GCZ'8T#<7=_
M;7J-RKN=>NZ_*6*)5K%(BZ\LIM$N''GV UC6[]8KUE+2GI*8]S 6D1&3"CCD
M08Y/7Q6T#A$X18*-U?K4-9D741KVD"KBW -BD6P=5 4*RH%V6QS+A8AJ#L:
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M44*$(36"9Y%G'21$:9%=2]DBRD1W%ZH6!@3*!]D-)EXQYTPR%?&[*J<QHJX
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?B<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(O_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>g98473g31j43.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g98473g31j43.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_[2*R4&AO=&]S:&]P(#,N,  X0DE-! 0
M     $H< 5H  QLE1QP!6@ #&R5'' (   (  !P"4  (<G(U,#DQ-C<< @4
M(4UI8W)O<V]F="!7;W)D("T@1V5N97-I<R!&+3$N9&]C>#A"24T$)0
M$")*^(M6HN%I'>),'8-E9Y0X0DE-!#H      .4    0     0      "W!R
M:6YT3W5T<'5T    !0    !0<W138F]O; $     26YT965N=6T     26YT
M90    !#;')M    #W!R:6YT4VEX=&5E;D)I=&)O;VP     "W!R:6YT97).
M86UE5$585     $       ]P<FEN=%!R;V]F4V5T=7!/8FIC    # !0 '(
M;P!O &8 ( !3 &4 = !U '        IP<F]O9E-E='5P     0    !";'1N
M96YU;0    QB=6EL=&EN4')O;V8    )<')O;V9#35E+ #A"24T$.P     "
M+0   !     !       2<')I;G1/=71P=71/<'1I;VYS    %P    !#<'1N
M8F]O;       0VQB<F)O;VP      %)G<TUB;V]L      !#<FY#8F]O;
M    0VYT0V)O;VP      $QB;'-B;V]L      !.9W1V8F]O;       16UL
M1&)O;VP      $EN=')B;V]L      !"8VMG3V)J8P    $       !21T)#
M     P    !29" @9&]U8D!OX            $=R;B!D;W5B0&_@
M    0FP@(&1O=6) ;^            !"<F1456YT1B-2;'0
M  !";&0@56YT1B-2;'0               !2<VQT56YT1B-0>&Q <L
M      IV96-T;W)$871A8F]O; $     4&=0<V5N=6T     4&=0<P    !0
M9U!#     $QE9G15;G1&(U)L=                %1O<"!5;G1&(U)L=
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M____   X0DE-! T       0   !X.$))3009       $    'CA"24T#\P
M    "0           0 X0DE-)Q        H  0         !.$))30/U
M  !( "]F9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &       ! #(    !
M %H    &       ! #4    ! "T    &       !.$))30/X      !P  #_
M____________________________ ^@     ________________________
M_____P/H     /____________________________\#Z     #_________
M____________________ ^@  #A"24T$"       $     $   )    "0
M   X0DE-!!X       0     .$))300:      ,U    !@             !
MQP   ^@          0                         !              /H
M   !QP                     !                         !     !
M        ;G5L;     (    &8F]U;F1S3V)J8P    $       !28W0Q
M!     !4;W @;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG
M   !QP    !29VAT;&]N9P   ^@    &<VQI8V5S5FQ,<P    %/8FIC
M 0      !7-L:6-E    $@    =S;&EC94E$;&]N9P         '9W)O=7!)
M1&QO;F<         !F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U
M=&]'96YE<F%T960     5'EP965N=6T    *15-L:6-E5'EP90    !);6<@
M    !F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
M         $QE9G1L;VYG          !"=&]M;&]N9P   <<     4F=H=&QO
M;F<   /H     W5R;%1%6%0    !        ;G5L;%1%6%0    !
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M300H       ,     C_P        .$))3001       ! 0 X0DE-!!0
M  0    (.$))300,     !@D     0   *    !)   !X   B.   !@( !@
M ?_8_^(,6$E#0U]04D]&24Q%  $!   ,2$QI;F\"$   ;6YT<E)'0B!865H@
M!\X  @ )  8 ,0  86-S<$U31E0     245#('-21T(               $
M /;6  $     TRU(4" @
M                       18W!R=    5     S9&5S8P   80   !L=W1P
M=    ?     48FMP=    @0    4<EA96@   A@    49UA96@   BP    4
M8EA96@   D     49&UN9    E0   !P9&UD9    L0   "(=G5E9    TP
M  "&=FEE=P   ]0    D;'5M:0   _@    4;65A<P  ! P    D=&5C:
M!#     ,<E120P  !#P   @,9U120P  !#P   @,8E120P  !#P   @,=&5X
M=     !#;W!Y<FEG:'0@*&,I(#$Y.3@@2&5W;&5T="U086-K87)D($-O;7!A
M;GD  &1E<V,         $G-21T(@245#-C$Y-C8M,BXQ               2
M<U)'0B!)14,V,3DV-BTR+C$
M                             %A96B        #S40 !     1;,6%E:
M(                     !865H@        ;Z(  #CU   #D%A96B
M  !BF0  MX4  !C:6%E:(        "2@   /A   ML]D97-C         !9)
M14,@:'1T<#HO+W=W=RYI96,N8V@              !9)14,@:'1T<#HO+W=W
M=RYI96,N8V@
M            9&5S8P         N245#(#8Q.38V+3(N,2!$969A=6QT(%)'
M0B!C;VQO=7(@<W!A8V4@+2!S4D="               N245#(#8Q.38V+3(N
M,2!$969A=6QT(%)'0B!C;VQO=7(@<W!A8V4@+2!S4D="
M             &1E<V,         +%)E9F5R96YC92!6:65W:6YG($-O;F1I
M=&EO;B!I;B!)14,V,3DV-BTR+C$              "Q2969E<F5N8V4@5FEE
M=VEN9R!#;VYD:71I;VX@:6X@245#-C$Y-C8M,BXQ
M              !V:65W       3I/X %%\N !#/%  #[<P !!,+  -<G@
M  %865H@      !,"58 4    %<?YVUE87,          0
M          */     G-I9R      0U)4(&-U<G8        $      4 "@ /
M !0 &0 > ", *  M #( -P [ $  10!* $\ 5 !9 %X 8P!H &T <@!W 'P
M@0"& (L D "5 )H GP"D *D K@"R +< O #! ,8 RP#0 -4 VP#@ .4 ZP#P
M /8 ^P$! 0<!#0$3 1D!'P$E 2L!,@$X 3X!10%, 5(!60%@ 6<!;@%U 7P!
M@P&+ 9(!F@&A :D!L0&Y <$!R0'1 =D!X0'I ?(!^@(# @P"% (= B8"+P(X
M D$"2P)4 ET"9P)Q GH"A *. I@"H@*L K8"P0++ M4"X +K O4#  ,+ Q8#
M(0,M S@#0P-/ UH#9@-R WX#B@.6 Z(#K@.Z \<#TP/@ ^P#^00&!!,$( 0M
M!#L$2 15!&,$<01^!(P$F@2H!+8$Q 33!.$$\ 3^!0T%' 4K!3H%2058!6<%
M=P6&!98%I@6U!<4%U07E!?8&!@86!B<&-P9(!ED&:@9[!HP&G0:O!L &T0;C
M!O4'!P<9!RL'/0=/!V$'= >&!YD'K >_!]('Y0?X" L('P@R"$8(6@AN"(((
ME@BJ"+X(T@CG"/L)$ DE"3H)3PED"7D)CPFD";H)SPGE"?L*$0HG"CT*5 IJ
M"H$*F JN"L4*W KS"PL+(@LY"U$+:0N "Y@+L O("^$+^0P2#"H,0PQ<#'4,
MC@RG#, ,V0SS#0T-)@U #5H-= V.#:D-PPW>#?@.$PXN#DD.9 Y_#IL.M@[2
M#NX/"0\E#T$/7@]Z#Y8/LP_/#^P0"1 F$$,081!^$)L0N1#7$/41$Q$Q$4\1
M;1&,$:H1R1'H$@<2)A)%$F02A!*C$L,2XQ,#$R,30Q-C$X,3I!/%$^44!A0G
M%$D4:A2+%*T4SA3P%1(5-!56%7@5FQ6]%> 6 Q8F%DD6;!:/%K(6UA;Z%QT7
M01=E%XD7KA?2%_<8&QA &&48BABO&-48^AD@&449:QF1&;<9W1H$&BH:41IW
M&IX:Q1KL&Q0;.QMC&XH;LAO:' (<*AQ2''L<HQS,'/4='AU''7 =F1W#'>P>
M%AY 'FH>E!Z^'ND?$Q\^'VD?E!^_'^H@%2!!(&P@F"#$(/ A'"%((74AH2'.
M(?LB)R)5(H(BKR+=(PHC."-F(Y0CPB/P)!\D321\)*LDVB4))3@E:"67)<<E
M]R8G)E<FAR:W)N@G&"=))WHGJR?<* TH/RAQ**(HU"D&*3@I:RF=*= J BHU
M*F@JFRK/*P(K-BMI*YTKT2P%+#DL;BRB+-<M#"U!+78MJRWA+A8N3"Z"+K<N
M[B\D+UHOD2_'+_XP-3!L,*0PVS$2,4HQ@C&Z,?(R*C)C,ILRU#,-,T8S?S.X
M,_$T*S1E-)XTV#43-4TUAS7"-?TV-S9R-JXVZ3<D-V WG#?7.!0X4#B,.,@Y
M!3E".7\YO#GY.C8Z=#JR.N\[+3MK.ZH[Z#PG/&4\I#SC/2(]83VA/> ^(#Y@
M/J ^X#\A/V$_HC_B0"- 9$"F0.=!*4%J0:Q![D(P0G)"M4+W0SI#?4/ 1 -$
M1T2*1,Y%$D5519I%WD8B1F=&JT;P1S5'>T? 2 5(2TB12-=)'4EC2:E)\$HW
M2GU*Q$L,2U-+FDOB3"I,<DRZ30)-2DV33=Q.)4YN3K=/ $])3Y-/W5 G4'%0
MNU$&45!1FU'F4C%2?%+'4Q-37U.J4_940E2/5-M5*%5U5<)6#U9<5JE6]U=$
M5Y)7X%@O6'U8RUD:66E9N%H'6E9:IEKU6T5;E5OE7#5<AES672==>%W)7AI>
M;%Z]7P]?85^S8 5@5V"J8/QA3V&B8?5B26*<8O!C0V.78^MD0&249.EE/662
M9>=F/6:29NAG/6>39^EH/VB6:.QI0VF::?%J2&J?:O=K3VNG:_]L5VRO;0AM
M8&VY;A)N:V[$;QYO>&_1<"MPAG#@<3IQE7'P<DMRIG,!<UUSN'04='!TS'4H
M=85UX78^=IMV^'=6=[-X$7AN>,QY*GF)>>=Z1GJE>P1[8WO"?"%\@7SA?4%]
MH7X!?F)^PG\C?X1_Y8!'@*B!"H%K@<V",(*2@O2#5X.ZA!V$@(3CA4>%JX8.
MAG*&UX<[AY^(!(AIB,Z),XF9B?Z*9(K*BS"+EHO\C&.,RHTQC9B-_XYFCLZ/
M-H^>D :0;I#6D3^1J)(1DGJ2XY--D[:4()2*E/257Y7)EC26GY<*EW67X)A,
MF+B9))F0F?R::)K5FT*;KYP<G(F<]YUDG=*>0)ZNGQV?BY_ZH&F@V*%'H;:B
M)J*6HP:C=J/FI%:DQZ4XI:FF&J:+IOVG;J?@J%*HQ*DWJ:FJ'*J/JP*K=:OI
MK%RLT*U$K;BN+:ZAKQ:OB[  L'6PZK%@L=:R2[+"LSBSKK0EM)RU$[6*M@&V
M>;;PMVBWX+A9N-&Y2KG"NCNZM;LNNZ>\(;R;O16]C[X*OH2^_[]ZO_7 <,#L
MP6?!X\)?PMO#6,/4Q%'$SL5+Q<C&1L;#QT''O\@]R+S).LFYRCC*M\LVR[;,
M-<RUS37-M<XVSK;/-\^XT#G0NM$\T;[2/]+!TT33QM1)U,O53M71UE76V-=<
MU^#89-CHV6S9\=IVVOO;@-P%W(K=$-V6WAS>HM\IWZ_@-N"]X43AS.)3XMOC
M8^/KY'/D_.6$Y@WFEN<?YZGH,NB\Z4;IT.I;ZN7K<.O[[(;M$>V<[BCNM.]
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MP  1" !) * # 2(  A$! Q$!_]T !  *_\0!/P   04! 0$! 0$
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MCW6.D'>,=KCL_-_H57_HS?\ HTYC=-))))2DDDDE*22224I))))2DDDDE/\
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MF:-_\#_T;$E/_]/U5))))3Q%%E8Z#UX%[9^TVZ2/WRB]">W]JN&X?\EXW?\
MX)BZ*W^D#XG\J5_TQ_5;^1'5?W:/U*(/1)!D>O=Q_7*WD'$_F1\3^5&0[K3N
M5))))(4DDDDI22222E))))*4DDDDI22222E))))*?__9.$))300A      !5
M     0$    / $$ 9 !O &( 90 @ %  : !O '0 ;P!S &@ ;P!P    $P!!
M &0 ;P!B &4 ( !0 &@ ;P!T &\ <P!H &\ <  @ $, 4P V     0 X0DE-
M!"(      49-30 J    "  ( 1(  P    $  0   1H !0    $   !N 1L
M!0    $   !V 2@  P    $  @   3$  @   !X   !^ 3(  @   !0   "<
M 3L  @    D   "PAVD !     $   "\    Z  MQL   "<0 "W&P   )Q!!
M9&]B92!0:&]T;W-H;W @0U,V("A7:6YD;W=S*0 R,#$Y.C W.C(Q(#$X.C0T
M.C W ')R-3 Y,38W       #H $  P    '__P  H ( !     $   /HH ,
M!     $   ''          8! P #     0 &   !&@ %     0   38!&P %
M     0   3X!*  #     0 "   " 0 $     0   48" @ $     0
M        2     $   !(     3A"24T#_0      "           _^$!2$U-
M "H    (  @!$@ #     0     !&@ %     0   &X!&P %     0   '8!
M*  #     0 "   !,0 "    '@   'X!,@ "    %    )P!.P "    "0
M +"':0 $     0   +P   #H   #P     $   /      4%D;V)E(%!H;W1O
M<VAO<"!#4S8@*%=I;F1O=W,I #(P,3DZ,#<Z,C$@,3@Z-#0Z,#< <G(U,#DQ
M-C<       .@ 0 #     ?__  "@ @ $     0   ^B@ P $     0   <<
M        !@$#  ,    !  8   $:  4    !   !-@$;  4    !   !/@$H
M  ,    !  (   (!  0    !   !1@("  0    !              /
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M @,! 0$            '" 8)! 4* 0(#_\0 5!    8" 0(# P,-"0P+
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MNS(W[0KHZJY-:LVR=&/B98\+9%.WU,V(B<=)JG#U!B?S5&<ET#J8",W*JX$
M3J()AU -_:*Z8M%:W?'245<^VW=^WP-=FLI*QS\;MIB7N@K,<PVGE?+P@N=$
MT XF*:OIJK C?AY_LW^*_P!@Y.[_ !2=MU8/-J+-3")A$PB81?A11-%,ZJRA
M$DDRB=110Q2)D(4.IC'.80*4I0#J(B(  =QSB][(V.DD<UC&-+GO>YK6M:-R
MYSG$-:T#<DD !%3G<_,2H:Z5<053:!=+:GXDQ:H*BG%L%>G89!RF!E \(_\
M=TP]X,/A$2$1.5?-":[Z>]/Z9EEMEEA=J"\L/ 8*<_T>%_+^D2 Y9@[%NT@R
M'!I8>)1U7<J>ERTGK)!S8SYO=Q$[#/=G/+;!RJ"6KD-R.NRRKA6W2-<9*&$R
M,=4_,KZ#8O<2D*Z9&+*+=>P&][D%P,(>A"]L\Z7?I2Z7]0N?+%<G6*G<264]
ML8*9S <D#KPQ\KW;\R\'8>G,+)?*LGXMD<0YAP9UCAMSS)XGI\@XSSSNNEH/
M(_<^K[3%RDA;[):H,CY L]6[+,/IMI)Q)U.CU!DI+.'1X>1(B8Z\>]CSM0*^
M3;A(%>1XN&:_3I;ILU_HZ\TQU)<JS4%EDD:RMI*US9Z@1$X=)1U+VMECGB;E
M[&/D="_!8YHXN-O."_5((;4MCF9Q .<(F0R,!VR#$&M('<YISN,M\4C>)7+!
M%VN A[+"N/>HF=C6<K'K^$2&4:O4"+I>,@]TU2E.!%4C?.24*=,WSBCGZ"45
M93W"CI:^DD$M+6015-/(.3X9F"2-V.S+7#(.X.Q5G!#@'#D0"/41D+NLRE]3
M")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A%HKWK
M N(WD;L-E) 83.IT))J=0!_NC&2:MG;,Q!$  Q"(JE2#H(E**1B=Q*/3\W=<
MVJ2EZ7M5TU:#Q2W-U;"YX\NGK6PU,#F]X$4K& CD6EO,*EW1A;7S\7)SF.'I
M#F- 'J&#]7U2Q4]9,IEFF/D%.)R%$!\(#_&Z=O3\G<._J/KWV]8]&4M?3,/5
M,/$T?-:>S)/H]&#Z!A(:7K&[CL[^7+L'U>WT+K;CQ]73(+Q@BHBNET5261ZI
MJ)G3$#%.F<GA,0Q#!U 0$! 0*(#U#(G4G1$R6,STT+HY6>/&^++)&.:2X.86
MX+7 @.!VW [DDHGL\9F1@Y'9OV<L'_3F%*6EN4]FU_(,Z-NIPZDZZ8Y&D9=5
MR'6E8;N5-).>.'4\E&EZ" R'A4D&_B\2YG:73R)G0O2_?=&5D&G.D22HK[*Y
MS*>CU)(QTE;;LX9&RYN'C5=& !FJ+7UD.29'3LX6QR-#=G,<(*PDC8,E(\8;
M8^,/SAGYV.(<W9&XV:-';5^U;OF3A%VS>().6KILJ1=NY;KD*HBN@LF8R:J2
MJ9BG34(8Q#E$#%$0$!SUY!/!500U--+'44]1&R:">%[989H9&A\<L4C"YCXY
M&$.8]I+7-((."K&"" 0<@[@C<$'D05R,[43"+@R4BRB63B1D7";5FU3,JNLH
M/0I2E_K,8P]BE#J8QA  #J.8M;64UOI9JRLE;!3P-XY9'G9HY#TEQ) :T9+B
M0 "4.VYY!:M-U\DK1M26<4G6*[B.K:+@S9[-M1$KB1$OB(8C-4O7PI]3=#/"
M"4?$ >YB4A?>G7C+772C?ND&X2:?TA)/0V*.0Q5-QARV6LQEKQ3R-SXHS@SM
M.SL>#GA'735NONKY'&"C=@;M=*TX)SMAAQL,_.!!_ND-RX]7KKCP8Z1'+MN=
M54_SU#J 8QC&,(&$QS& !,81Z]1$1#ODIH_HDAIX8I)8<O<.)[G@N>YQR27%
MV23O]?U+#@H'.'&[)).3V[]N_?OZ/2.^2;'J]A"L#=6Y"^ G8/ 7Z/7KTZ#Z
M=_7MWZ9=;II"DHJ9V(F@AO8T#< XSR[O8/J7?)2M8SR1Z=L<CZ!S]O9ZU0G9
M2#=%][L@!?&97PE ![]S"'P$?I[]A'T[=?7RIKRE;)74]!21B2IJ:J*"%C0>
M)\LCN!C6X'SW.:-MOT!1'5\<O5MW+B&C';EV!GGL/4?;LMWVAH)Y6M-ZYAI
MITWK:KQRSE%3J"C=20*:1%L<![E.V][!N8H_Q13\/PS]%M(T#[9IFQT+R2^F
MMM+&>+/$/BP_#@=PYO%PN'81CL5]C'#&QO<UH^H?;W^E9\TM59?STG565AA'
MEGA6C-_,5UK+,'$Y$L9$52Q[V2B4G!W[%H_,@N#-PZ;I).124!$Y_ ;I-MJJ
M9]1+2,J('U,+&234[96.GB9+Q=6^2($O8R3@?P.< '%I )P5)S6FZT]NI+O/
M;+A!::^:>FH;I-15,=NK*BE##4P4M:^,4U1-3B6,SQ12O?$'L+VM#AGOLR%'
MIA%QGKQI',W<@_<HLV+!LN\>NW"A4F[5HU2.NY<KJG$")HH(D.JJH80*0A3&
M,(  X18\I>:8C34]BN;776=!4@&UJ"Z/IA@QJY:R\9)2+:?5G7BZ$:A$+,%D
MGA)!9RFU]V4(L*@$$!PBZJG[8U;L)A"2M!V50+Q%V8)8U;DJA<:[96%@+ F;
MDG1A'D+(O6\J$*9VT++"Q47^3C.6X//)%9,#$660\U#V*-:S-?EHR=AWQ3G9
M2L._:R<:\(FJ=!0[5\R57:N"D6251.9%4X%53.F80.0P 1=GA$PB81,(F$3"
M)A$PB81,(F$3")A$PB81,(F$3")A$PBU^\W=1NI1A%;BKS4Z\C4VY8^U-T"^
M)5>M^<HLWDP(7YRAHARLJ5R( )BL'1USB5)D(AY<_"(T1431T'2':('2U5BC
M;2WR&)N72V?K'/BK T#+C02R2";F13S"5Q$5*[A@[U2&2-M3&,OB&'@;_%[G
MBQOG@<<G;R2X]@4;:$NC%VDU164((]$P$!$/0._H(]OZO3X=0SIZ,=1TE;30
M#C;DM;SWSM@_9[>9W!4=03#9IQW'._(9'LY#T_4M@S*#BYR.#YB1_&0/4 'J
M @'40^GKZ]?3J/PST;%1TM93CQ6D%NXVWSGM[-^['W*QLBCEC'(_5[@';'U\
MU47=VDV;ILZ51;$Z]#" ^$!'J(#V^D?7]A]=-](&@*2XTTQ; "7-.X:TYV//
M;L!VW_1RA:VBQD@8QN#]V!W_ '9]*BOC7O"1U+9D-47QZH:CRKSW>NR;Q01+
M591TK_<VIUCCT2@I!8_0X"/E1[Q0KD/*;K/#AK+HKUY6='U]BT/J2H>[3%QJ
M>JLU9.X$66NFD/#3O>]WB6VLD<6N&2REJ7-F\2*2H<N-KKG0O%+.XF,GAC<?
M[-Q.PS@>([/;Y)WV:<K:GGLU69,9QN=@BU9\KMUR%VLAM34YZ<D2S4*2QNVJ
MABBZ,<.GN '*/<JJ1P.XZ=0%N9-N)B^<\1'Q?TR:]K-6WTZ%T_4/;:Z20-N]
M1"2TU#W;&F:\8RQS7$R$?V3FQ<0,E3&ZNW>N.?!(3N0.N([CN&;$'<$%V1W-
MYDA9;HC3S-N@U67;EZ]""81 .H^@] Z_F$>HB/0?O9?NC?0M)0TT#C WBX6_
M-&^,8._WY/<5U4%'Y)(SGV]G\/Y=F+WI147!QH#T2)X$P^!0] ]/7Z0[^G0<
MW^VFIJ.GY- #>X#?&#C[^[D <@*P<#(F\AR]_?M]JI+O;8#!BV=I)K$Z@4Q0
M\(E#O\[IZ#][IW[@&:.Z1=3TM!2S@2M;XISW@8(SC(Y8P<=G-0-?4-&0.>=M
M\\_?<;<^63O5?COJMYO+:B4I)MC'I59<)2DZN<I@1=@103LX<A^G0RLFL02*
MDZE,6/3>*@<JA$04TYT/Z-J-=:M=JRXP$V.TR/-)U@(95U&2SC;D8<UN'1L<
M,X<)'M<'P8/&T49D>:F49:T^)D>4_M/82&@X&>TDGEA;!N7M,Y*W?53R%XP[
M#@M?7$PK"_5D6)TY29C?)\/R77;2!G252D5#>("2 Q"ZQSF1!"7@024=J>N]
M846IJZT24^EKE3VZN.>-TT1ZV:/A_%4]7ES:.0X(ZTP/=DCAEIR.,^ANA2^]
M%6G]84]=TM:8N.I;" P4\=)4-?24%4) 15W.SXA?>J5HQQ4OAT<;6AYDH;EQ
MMA;J2X.:EY@5Y]LBF56VU?26WHMXWD=G%VKI"1LEHM:4D]D#1<VEM%>4E&-P
MB7"Q'@M2LGZ"!%P=.4&*Q3JR+G4N@[1K&F=<J*GJJ.R7F)[9;M\+V">JJZSK
M7R=54"[&L?'70N(>6]6]K6N+BV/#B]WL_P#"!UGT(W2#2M^N]EN^OM%5<$M)
MI(Z/Z0*:U6BS/I(*<5EO?I".CI)['71,=")C/2R2&/J8I*AA:VEBV^:,I_*J
MN3LRYW[N'7VQX!Q$D0A(VGT#ZD7D?+@\14.^=/!64]Z;&9E60!MX0Z*J$5Z_
M,Z#N"QT>JJ>>=U_O%MN5.Z$-@BHK:ZB?'-Q@F1[W2R<;2S+0W;<@]F_BGI!O
M?0_=+?0Q='&B-2Z7N4=8Z2X55\U)\-05-%U#VMIX8.K9U,HG,<AER<L:68\9
M6=RS+4ZQ#8,:]F:%=X>-0%U(RM0LL;'MBG33,X>OH9ZU:H =4Z:1!67533 Z
MIR)E$W4YRE 1 BTV1W%SD70ZQI:+2JNS=MZQT_#\'MMW+3-RVBTNTG>MA4JH
M;WIVZ*M1PV1=!K$0^H4Z\T+MJ$H@2M1U0XL6O8XE-+&R[E90"++*+I?EWMC9
MVM+E<IS;VC(^L;&Y+N(79+*H<5(7;JFN+5KGC]&4XFQJHWJFTM:GE;-<*]L!
MBB[95=2T(UNLUD)5Y$@<$WA%>C@YKFZ:DXI:9UQL1H_972J5^2C[ C**PJ\D
M=X>RS;PCM\I7"D@1=R#9R@_7+$(MV":CDR;=JT3(#9(BM=A$PB81,(F$3")A
M$PB81,(F$3")A$PB81,(F$3")A$PB_DN@BY16;.4DUV[A)1!=!8A5$ED52B1
M5)5,X"11-0AC$.0P"4Q1$H@(#G7+%'/%)#-&R6*5CXY(Y&-?')'(TL>Q[' M
M>Q[26N:X%KFD@@@E",['<'8@]JU+[RTO-<?;,>[TQ!RZUC*/04.FEYBQZ>]<
MJ?X.>#W/\D*',!8M\H<?  @P=J>\E05>^*==Z'N71->G7^PQ35&B*VHXW-9Q
M2/T]42N^2U!/$X6][SPT54\G@RVFG>91')4U2X4#Z.3PB#)@<[+A_A%QQ@X^
M9_=/(; D$-)G/4&^6CMHW27=%\7A* @)@[=0 ![B;\/ZN@=.NW]$](U'<*:$
M&H82YK0/&'C>+R/C;;[=O=OG?(HJ_8 G<8YGOY?:#R]F^%/D_:XJ<C5.JJ9Q
M.GV].OI\WOW .X_U#T#MFQJVY4U;3N\9KLM&3M@;>O'(8]!QGMQ(2S,D9N1O
M@YVVSW>H?4M;6]*\S7,X71 OB 3" A]/<P=/3X_'IWZYY/Z5++3544[V-;GA
M+FNP 01N#L=L'';S.-LJMUC0'<3=COGU<^T'WQW*^G#[;#G9>KDH^9<F<V:C
M.$J[)KJG$[A\P*@"D))K"81.=19H4[)=4XF.NZCEW"AA,L.;]Z"=:S:PT1 R
MX2F6\:?F^!;A(]W%)4MIXV.HJMY)+G/FIBV.:1QXI*F">0^4%9K94&HI6\1+
MGQ_%O)YG'DN[SQ-(R>1(.%*F\[J.O]6VVS$_OAI&K)- Z^$#NER'*BD)O4OG
M" HE,'<ICE$.X9:^DW49TKHJ^7=F\T=))#3C. 9YFED;21NT/.6!PW:YP(WP
MLJIE$$$LI^8QSL=Y Y>WDM.NID??Y928E%A</7SM1X[<*B J+N'"PJK*G,(=
MS'4.<X_#J(].W?/$O1I3-EG^$:M_75-7.:FHFDPZ2625_&Y[W$;EQW/K/>J5
M$YTDSGO.7%Q)/^;F23SYD_=E;)ZE<8R#CT_GIE\*8?$O80#T[CT^D?7M]&>P
M[3>*6BIV9<T<+0.SL/H]//D,>H*PPSMB&<C89![,#OY[[[?H*CO:'(!JR9KI
M(NB@/A,7H4Y>O3O]_P"'?\/3J(#E3U=TET=!3RAM0P$-)\H#!&>9XMO1OW<L
M+'JKAS .2>P<^_&,]VW+OV.RI36("]<E[R:O5HBH1K98IY^=6 X14(T.;J)W
M:Q?$!W1R]?=V*8F<.#= \)$Q%0-!V2PZBZ8KX!&)Z;34$P=65S^)C9V,<08J
M=QW+7>2Z1N<8+69<#C#I*.:NEZR3+80=S_>[P._N<>SD,GEN8UEK:M:IJ,?4
M*PW%-HT+YKQXJ!/?9:14*0',D^4(4H'<+B0I2E  3;MTT6J)2HHIE#W'8+#;
MM-VNEM%K@9!2TL;6-#6M:7EK6LXW<( R0T #DUH#1L K:QC8VM8P!K6C  V
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MRSE914U,OVF[!J>L?<=06:VW:NE(,E764<$M0[ PUIE+.LX&# CCXN",>*P
M8 EJ2W4-#3P4M+2PPP4[ R)C6-\4#?)<07.<YQ+GO<2Y[BYSB223G=#TIJ+5
MYE%->:UI5/<K )5WT%78QC)N2CZE<RB;?Y1<E'Z%W*@9V6VP62SMX;5:K?;Q
MWTM)!"['<7L8'GEVN*S?1V#8>A2?DNB81,(F$3")A$PB81,(F$3")A$PB81,
M(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A%3GG3_  _1D=44
MQ#WS86[N.E'8$$!,*B\SO.@JK^$H"'B,C',GKH0$0#P-S]1#)O3_ (MP?/V4
MU!<ZAWH#+?4 ?^MS1[<<U6-7>/:&4P\NLNMDI6#M+I+M1DX'H8QY/9@'*_/.
MPX16AVUX$OS=7;BT%LQ8X")3(,*GN:DNYEP!P,7RP1A%)(ZAQ Q2H@H)B].H
M@T]X]QZC_?**XT@]+IJ&H;&#GODX1OVE?-7_ !=G;5XS\'7.SW [X(937.E=
M*<]F(3(3RVRKD9"*T)A$PB81,(JK<N^2Z_%O5KO83?6-TV6L!EFZ3>M,Q^0X
M-0J8&3D;M.E(Y4KL$8YBH@_3CI RC@2M_*3\P%BU75^ISI6U27)MJKKH6Y 9
M2,^)A.-I:V?#C34^2 9!'(<[8&<C;_0MT5,Z7=7P:9DU;8=*,(9(^6[3CX0N
M#"XA]+8+>71-N=Q#07^#NJJ8-C!EXW\)8=<G%CV@&Y[6G9]I;,U9R9VK&6U4
MC*KU#2&B(>1U32&T4Y<E5^2;:M:@LMBF'8J G*'EU"@U.F*12K%!N+?6^E.D
M&]5C*F[7.TZHNT5:0VDH['8(9+50,B>\'JJPU8J:J9^>&5TN TM  .!P^GNE
M_P#!NT)97VC2&E-8=%&CZRRL=/=[WT@=(M?2ZQU!+60Q%GAED9:#:;70P\)=
M2"B8XS-=QET9,HEV5Z/Y)J;LG9B#-H?D-J8(B)+*_*VY->(TV'E!,[2:?)\2
M\3FY07<D7S?>3-A23 &J2ROF?,\([,L>I#>YYH#8-16CJ8A+UUYMPHH9<O#.
MKA>)I>.09XBT@>*"<KROK_HM;H*WT->WI%Z,M9FMK'4G@6AM327RNI.&%\WA
M5; ^WT8AI#P=4V7C>3,]C.'?(LSEF6JE'&XYR5K&HMJ66#=F83=>UQ>)R'?%
M207,RE8FL2C^/=E1<I+-EC-W;=%8$G"*J"@D\"J2B8F*)%J68<_=\6IE<*/3
M:Q .5M;:%DIG8&R'+2T+6&(L+7AI4-],=E(N$ZDEJ($)*_WN$H[>@#-/K,B[
M9/+"Z@R5QR=*+(K'\7-B;.:;M@-2V'=%CWS7+5Q.IV^K#(W..UT2TZHO<I88
MB!9UXTGK.FT9@I6=DL']BF*_%VB)D)]@\U_/J1\XYB'/R?%D56--<SM\M=/Z
MBKFU6S)]+7B#T->*AL2JWEZZN<S7I_FQJ?C];&.PBV6AK1;9Y(QNQHB3%M!)
M/@<PBLY5R2T;(H,+>J120_\ :/;5K4!)6JW:BUXTA+17MERNJ!@[K<IV225U
MIRRUMQ6?K;!BV]#*_53DGFUJ]>64+0FUCGUVL1+56,;2TV_B53$7[:^T$Y$J
MO*16FG&]E:+I*U.T[5EXF )L*,+9-61^[I_5%/=T]"PUAJ]JLY<*U7%]DG-M
M M=95MO.TZK3J#5U.2<S7"+;[A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F
M$3")A$PB81,(F$5%N6#2QWS;O$K4=,FHJ#GS;)LV[GLK+P3BSL(F&U!3)-JQ
M>/X%K.5M9\@XN%XK+1N4LTQ CLR:XJ*E;F;+2E*RJ9:[U5TL\5-)X/!0,DGI
MGU+'FMF!EB8UE33%LA@@D=QE[P&!S>K)?Q-K=X,=1>--V]['2 5E3=7AD@C,
M;;;2N;%(\&.3C9X55PMX!P$N+7<>&EKL@V[HSD%MG5FP]96#=NKW</?*=8:J
M_00T)-L' I348X9 HU?CO!X#%V@HJ1=J]%F[!JX33<"U7\ORC0%$Z]T5735<
M=RH0^FGBE;FTS.!ZMP<0YHNK>)KAEKF\3>('&1S$S<Z.GN5NKJ"6.0QUE+/3
MN#9FL<!+&YH+7F&0,<TD.:XL>&N ):[&#)7%C8[S;/'G4EZE2F2L,G3HZ/MS
M90/"JRNU;\RLW9@J7L)%&5KAYAJ<IOG *7?)NZTO@5QJZ?B#VLF+HWM;P-?#
M*!+"]K.)_"U\3V/#>-_"#CB=C*PK!7FY6:WUC@6R24[63L<0YT=3 3!4QN(#
M07,GBD:?%;N/)')3_D>IA,(F$3"+^:J2:Z:B*R9%4E2&3434*4Y%$S@)3D.0
MP"4Y#E$2F*8!*8!$! 0'IGP@.!! ((((.X((P1[1LN37.8YKV.<Q['!S7-):
MYKFG+7-<,%KFD @@@@C(4*ZVXYZ<T_;KG==94UK2Y;8!6?U4LX-[)-*X]78J
MKK)/6U5*[&NQ3Y0[A3WAS%1K-1</^T$1.J*D);-.6:S5=;66NB912W#JS5L@
M?(RFD=&7D/;2!_@T4A+SQ/BB87; [9S>]4])VN-;66PV'5=]GOM%IHSBT37"
M"DFND$=0R-CX)KP8/A2L@:V)O515E7.V/YH\5G#-W3X_')Q4),(N.\9M)!HZ
M8/VK=\Q?-UV;UD[13<M'C1RD9%RU=-UBG1<-W")SI+(JD.FJF<Q#E,4P@)%3
MA#@=H1'=1]V'CI1U(_5&XN+6EN6]1-3&-H=ZJ#2;E^@LE4TKTO"J:R\=9)KV
M1N[[6#5(Q7S.DMY)LR=MB*RU"UAK75<6XA-8:\H^N(9VY]]=1-#J<#4(QT\!
M,J(.W#"OL(]JNY\DA$O/52,KY1"I^/PE  (OT76>N")1C<FOZ41"%:,V$,B2
MK094HEC'6"-MD>RC$RL0(P:,;3#1%D9MVH)(MI^*C9A$A)!BU<)$4?;7XW:H
MV[0W% F:ZRK[ 5V;R+EZG$UV.F8%VSV!6]I":-"0@Y:%<Q\I?JE7K)9J[.0T
MQ5K@[CDTK;!S;519NH18UK_A[Q^H=1KE2<:[JU^"K6VRWZ(GMB5*E3TRPNUO
MFC6"Q62$;M*S%5RGNI"5%-R6/HM?J\&R,W;!'Q37R2CA%9W")A$PB81,(F$3
M")A$PB81,(F$3")A$PB81,(F$3")A$PB81:DWWM7JH7DW>.+T1IJQ/K32;K*
MTI:PR%LC(N ?NXMT+4[U(K>(EI!!NL;YY4SM5%2%[#XAR2ALEUJ;>VYPBW^#
M/=.UC9:NH9.>HGF@<7,;02,;Q.A<6XE<,%N2#D"OS:DH*>XR6V2*KZZ)S&N>
MR.$Q9>QCQ@FH:\X#P#E@W!]"QKE!RI<\2MW(<DMIZ]3LK-YIQCJ^L56EW$7:
M\$F]MSJW66;5D)RJP:+E:P&;UED9JDV0%HG %,+EW[T!$,RAH[O<+;\&T\%N
MBQ7/JY9I:^I^,+(!#$P,9;"0(P9G9+CDR# &#F,N%?0VV]_#%2ZKF!M;+?34
M\5-#\3QU)J*B5TCZMO$9B(&<+6 -$&2YW$."5[Y[4+6.M^*>D.5]CUQ?%ZSO
M&;5@82JPCBOO)Z&=I#91\R3<OI&+CU$#$K3@?$U5.<IG")?+$ .8(NFM]?5U
M\MLA93FLADK8Y>*=[8 :&<T\Q9+U'&\%^#'F%A<T^,&D*<J+U1TMMI[K*V?P
M:I; 6-:QCIAX1&96!S.M#-@TAV)#ORRNDXJ[RDH;6N[=MP= D'.GKGM*Q[=I
M4&XL,0TM%99W2,B96XPKIB!5XH"N+X2S3T<DRDE$2-ID"JJ)K>--.2NL-?-/
M;Z9U+"VK@HXJ.HD%4#',:=SV02-/5!V13=3&\N RZ,X&-S$6.IIJ2GNU4R21
MU!4W*:OI8C%PRP>%LCEJHG#C+/&K.OF9P.<,2[G.RD+B#[1[6?,79M\U;3*%
M?*G-:^KHV.5>VH:Z:.=-PF6<+[NP/#S$@X,O[P\*KU7013\HANA_'T*.!7VV
MNMCJ9M;'"T5<<LD3H)C+^)ZCC#PZ*(M_'LX2.+.'9QMF6M=[H[NZH;2-G!IN
MKZPS1L8#UA>&\/#(\D_%NSD #;<Y6Q/,)3"81,(F$3")A$PB81,(F$3")A$P
MB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3"+QSM_NN^^?Q]
M6[U_I;Z?R_3^K-BVC^J=-].X_P#V-<M3W,_]+*OT24Y_]FG5V/;:B Z\JO</
M[T9_$/@D;.&F=WR;YW/+T$[>L=OHR=^W(U;Y,'T6_;LJI\K^G[S9[/CU^R0Z
M_/X=J_U?L/;KD78?ZXW'\YU)ZO.AW^_TK.O7]3+3]&V?LDBVA\5?N?TC_P"W
MEO7^;*?3_9F5<//,?TNSV<EPMOF&?V>OR/?^(5#?8;_;C<F_H^M<;O\ _/H3
M.O6OEV/\A<?LMN$T+^.NWJI?UZE>IO*6MBIA$PBJGR_W%N;2>JGMMTIIA[N*
MQD%<CI%NY\QI56::(J?+TC7V"I;+9VZ9P\)HR (DJ0@*.GC]DV1$RE4UA>;U
M9+3)66.R27NJ!(<QCQPTL8;DU$E.P^%530=NIIF\6,N>^-HR=P="FA]"Z]UA
M!9=?:[I]#VIXC,,DL7#->:AT@;\&TMRJ6&TVF5[<N%7<G/8YQ9#!35$K\,U7
M\+^5O+2WIW;:"6G]@<GK'9'#:-FD6>^=84ZF41".<OE&$5":H-'J/JB[5*LJ
M"\A+?PV90137( E\U=?5>B=6:MK65MU^!KEJBJJ7-BG;'?[/24-N$;GED$%I
M)ZZC=@X>^HQ+,T-<?[Q]?=.W0WT,V1^G](NUOIKHEMEJBEJZ!\_1UJV^7W43
MZJ&!E165^LA4MIKU"PQM,=-1?$4,LDD9/%PQQ[7=%;AWOL>>F8W;'%Z;T1$L
M(DCV,G939=2O"4U("[20-$ILJ\T;.&:A6QU7GO2XF0$J!D0 #G+TVQ8KQ?;E
M/-'==+5%ABCBXXIYKE0UPGDXPWJ1'2GC80TE_&[Q3C &3MXZZ0M$='FEK?05
M6CNERW](E94UCH*NW4>E+S8'T%,('R"M?47*>6*=KI6L@ZF,"0&0/SPM*L_E
MG6IE%^[WDC'Z7V\_AW+QG+,=7W]Y%O(]19&0:2+:J2RS)RQ6;B5PD\0<D25;
M*(&*L18I#)"!P*.$6HSBEL'DC2-S:PTG;&>Q]N.M><+KC>:.]F[8\;I;<HFP
MK]QJ>:]D;;:[6X"$?;3U65?9^LIA]8'SVUR<)565ND'0N]BK%5(N%9N6O(?5
M%AW[%36SX#S%.;<10Y=.Z,Z7&EXMZ3M/&=#:%3FGTS8;3$U)"N7"_1K+658M
MEQ<MJ>]LCF<4C5).Q3#6*;$4FNN3G,->@["OB5BTJU?473O%*180]5HDS>Z9
M:MB[XFF$?:;9'6Q"^,%Y>@0[/I(5V A%".E&\DX]]N;Y-%@]![^_^GUI]BCS
M;O)#E=5-=\@65PGZ;L.'BH7G9JB,CXG65GHDF_=Z4X]V';5#O;V?K6P5)9*2
MFW316ERD?5E*X@Z;JM)2NO86>;&5<$4LS?++D!1+Q9;'8'4/):CC-U[XTRSI
M5:U#/3]UBJ_JSB/9>1D-?6S]&[(O[S8W5BICZH-ZJV:0+"PM)ME'MY!K/)DD
MU2+!..'(_8_(?=>EWMEFF=D@J+R*W32Z[;JXE6THZWT]_P .*5L9F[FW6O+;
M===3+N'MUWL%<2?U>P/8I,8-LP6.I/Q\J[<D78O+G1W%ZY=_7:VM?Z]RVK]K
MWJQTEK0-J[,JGEZ>C=6.G&K9;7VJ*_8(RI7"DR=<(XM<[=EJU84$-E&GT)6P
M-)VJ1K"#(H^:[CO-*1BK1S=F?D#2D9[.NJVB42U'M/;Y)6S3;G96KXYBI.2G
MN^NI**V19Y%^QK8+,)X"/&\Y*L)VP-H!Q)*G(LWL#:VSWLF7\;4]U1EOEY^9
M;L5[/5+LOOMA!TZ]\C&WFZ5)L12=<25_;ZSH5F;:@E;0^F7+Z?8UAVY=J"F_
M.!2+))3?>^=8PMC3D;[K/6FG:URJ8<4F5S7U66,K&A=35/6[B<)MJU/Y*XE@
MUU+/:VD%JN!/)$A*'4W%KK3U\C,+-'#*5(L"<<P^8\[6RV*L2VM8I"L:_P!;
M6A%[(Z9M$I%[B1N_,O9O'B!O4<T-L.'D:Q3;QJ"M5C<<7!L7CZ21<V&(6;64
M*X"Z$N137L[:6YY?ACO]6>L+L^R-7\AFVK&-WI45(T>1LD!7=_:_8L)Q.+C9
M)ZI&.W]5E1BYP(I^,;) @_=)-VC-^>.;_/;[YPBI=LSF3N3;=4Y<0]@V%$T6
MB4.2EH<D+"R$'K^\H0M*YO5[54G;J9/U?8CO:8Z_8:?8D^NA:[5!Z_7AK?;%
MF\:0D,X;MXGZBV6<,YEA)W#D(UU9<K9L+C!'3.N_K-VNSVRU["BU;6ZK+\^V
MX;7.Q+I(34Y<]<Q;M.GN63Y&P6"!BKE*7BNPDDBC#KPT017TPB81,(F$3")A
M$PB81,(F$3")A$PB\G=@A(:3]J5NAM)1$7(MEMMRXJMW\>T>(*F.9 QQ42<H
MJIG$YA\1A,4PB81,/41$1SZ&DI9+8'24U.]SJFOXG/AC<YV*ZI R7-). ,;]
MFW8K1##$;="\QLXS&<NX1Q$@R8\;&<C Y]@5N?:TT*C0&M:TM TNHPBRC5J8
MZT16X:-5.8R!A$3*,F2!S=1[CU,.+=0T/$_%'2CQCC%/%WG_ ">CT=BQ[:R-
M[G<;&OWP.,!X&YY!V0-E5[D2U;+>R)X/$5;H*$+M*: I%$B'(0#2&VRB!2'
M2E#P]NW3MT#T],*C@@=<Q$Z&(QBIO&(S&W@;BIG(PS'",'E@;;X2"**2ZU3'
MQ1O8UKBV-S&N8TM,;00UP(;@$@8&P) VV5_>,^G]4R?#)_,R.M:(^EB0RQBR
M3NJ0;A^!P;G,!@=+,3K@8!_R@/U^CIZYW5%NM_AC3X%2YQG>GBYG'^7[>79Z
M.F>.-M4&-CC:SB X UH:1X@W:!CD3V>A5+]C@Q9,.8V^46+-LS1#5,J4$FJ"
M3=,"%O=/$A0(D4A?"7J/A#IT#KVSG<Z:G@J:+J((HOZ/6 ]6QK"?'H-CP@9
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4A$PB81,(F$3")A$PB81,(F$7_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>g98473g36d33.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g98473g36d33.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_[19"4&AO=&]S:&]P(#,N,  X0DE-! 0
M     $H< 5H  QLE1QP!6@ #&R5'' (   (  !P"4  (<G(U,#DQ-C<< @4
M(4UI8W)O<V]F="!7;W)D("T@1V5N97-I<R!&+3$N9&]C>#A"24T$)0
M$")*^(M6HN%I'>),'8-E9Y0X0DE-!#H      .4    0     0      "W!R
M:6YT3W5T<'5T    !0    !0<W138F]O; $     26YT965N=6T     26YT
M90    !#;')M    #W!R:6YT4VEX=&5E;D)I=&)O;VP     "W!R:6YT97).
M86UE5$585     $       ]P<FEN=%!R;V]F4V5T=7!/8FIC    # !0 '(
M;P!O &8 ( !3 &4 = !U '        IP<F]O9E-E='5P     0    !";'1N
M96YU;0    QB=6EL=&EN4')O;V8    )<')O;V9#35E+ #A"24T$.P     "
M+0   !     !       2<')I;G1/=71P=71/<'1I;VYS    %P    !#<'1N
M8F]O;       0VQB<F)O;VP      %)G<TUB;V]L      !#<FY#8F]O;
M    0VYT0V)O;VP      $QB;'-B;V]L      !.9W1V8F]O;       16UL
M1&)O;VP      $EN=')B;V]L      !"8VMG3V)J8P    $       !21T)#
M     P    !29" @9&]U8D!OX            $=R;B!D;W5B0&_@
M    0FP@(&1O=6) ;^            !"<F1456YT1B-2;'0
M  !";&0@56YT1B-2;'0               !2<VQT56YT1B-0>&Q <L
M      IV96-T;W)$871A8F]O; $     4&=0<V5N=6T     4&=0<P    !0
M9U!#     $QE9G15;G1&(U)L=                %1O<"!5;G1&(U)L=
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M____   X0DE-! T       0   !X.$))3009       $    'CA"24T#\P
M    "0           0 X0DE-)Q        H  0         !.$))30/U
M  !( "]F9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &       ! #(    !
M %H    &       ! #4    ! "T    &       !.$))30/X      !P  #_
M____________________________ ^@     ________________________
M_____P/H     /____________________________\#Z     #_________
M____________________ ^@  #A"24T$"       $     $   )    "0
M   X0DE-!!X       0     .$))300:      ,U    !@             "
M%   !SH          0                         !              <Z
M   "%                      !                         !     !
M        ;G5L;     (    &8F]U;F1S3V)J8P    $       !28W0Q
M!     !4;W @;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG
M   "%     !29VAT;&]N9P  !SH    &<VQI8V5S5FQ,<P    %/8FIC
M 0      !7-L:6-E    $@    =S;&EC94E$;&]N9P         '9W)O=7!)
M1&QO;F<         !F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U
M=&]'96YE<F%T960     5'EP965N=6T    *15-L:6-E5'EP90    !);6<@
M    !F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
M         $QE9G1L;VYG          !"=&]M;&]N9P   A0     4F=H=&QO
M;F<   <Z     W5R;%1%6%0    !        ;G5L;%1%6%0    !
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M300H       ,     C_P        .$))3001       ! 0 X0DE-!!0
M  0    %.$))300,      NT     0   *     N   !X   5D    N8 !@
M ?_8_^T #$%D;V)E7T--  +_[@ .061O8F4 9(     !_]L A  ," @("0@,
M"0D,$0L*"Q$5#PP,#Q48$Q,5$Q,8$0P,# P,#!$,# P,# P,# P,# P,# P,
M# P,# P,# P,# P, 0T+"PT.#1 .#A 4#@X.%!0.#@X.%!$,# P,#!$1# P,
M# P,$0P,# P,# P,# P,# P,# P,# P,# P,# P,# S_P  1"  N * # 2(
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M0DE-!"$      %4    ! 0    \ 00!D &\ 8@!E "  4 !H &\ = !O ',
M: !O '     3 $$ 9 !O &( 90 @ %  : !O '0 ;P!S &@ ;P!P "  0P!3
M #8    ! #A"24T$(@     !1DU- "H    (  @!$@ #     0 !   !&@ %
M     0   &X!&P %     0   '8!*  #     0 "   !,0 "    '@   'X!
M,@ "    %    )P!.P "    "0   +"':0 $     0   +P   #H "W&P
M)Q  +<;    G$$%D;V)E(%!H;W1O<VAO<"!#4S8@*%=I;F1O=W,I #(P,3DZ
M,#<Z,C$@,3,Z-34Z-30 <G(U,#DQ-C<       .@ 0 #     ?__  "@ @ $
M     0  !SJ@ P $     0   A0         !@$#  ,    !  8   $:  4
M   !   !-@$;  4    !   !/@$H  ,    !  (   (!  0    !   !1@("
M  0    !              !(     0   $@    !.$))30/]       (
M      #_X0%(34T *@    @ " $2  ,    !      $:  4    !    ;@$;
M  4    !    =@$H  ,    !  (   $Q  (    >    ?@$R  (    4
MG $[  (    )    L(=I  0    !    O    .@   /      0   \     !
M061O8F4@4&AO=&]S:&]P($-3-B H5VEN9&]W<RD ,C Q.3HP-SHR,2 Q,SHU
M-3HU- !R<C4P.3$V-P       Z !  ,    !__\  * "  0    !   '.J #
M  0    !   "%          & 0,  P    $ !@   1H !0    $   $V 1L
M!0    $   $^ 2@  P    $  @   @$ !     $   %& @( !     $
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M8^/"5%DRD&6+*,@2+(QZ R6'7AFDO-^(H4M\(G")PB<(G"+H2,7&2[#0TM'
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M&#5?*]S-6$/; T,<2UH@;)*V( =8)9 VP<0;J_H4LP)L1S=,/O:$%VBHV\6
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M322:0;?,1F =H(.W?GD=H-B"" 5Y->6$N&KV+V'78Q[;2,<PY2-<T. <2QX
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MX1.$3A$X1.$3A$X1.$3A$X1.$3A%J4ZS<6*W=0U)ITU<&Z1JRM1$?<"TRI3
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M*BGR!TH(3$20F52#2B<<<>==K8X)C^S]=R+.6,MP[X"FD^L1C4@EV2E\@%K
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MO)Q!]N;(E;(/:"<)-;A1(W+>#AD--HS%]TC94G*E.9\S%^.4#%QI?2Z9.IJ
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MOX^A2MZ4+ZP]Z-?_ #S2/\2MYY;:&>^IIW\7B/[VH?8IKQ_(N$7_ -)AZ/\
M$2^WR^%9E_J?#ZV#N?[]^QOS)UYS"<IOO@:._(*']X5RL7]RFDEO^QJ_+^11
M=&>W/+/);@^EC_""U?Z&9^7_ .VM=_T_8^+'PZWR@^Y:#Y3)Z(<>=:QR8=L,
M2^21>E/&W[/#UZ+7Z\GICY/G[;7_ &_8.P>WZ?M<[CIU[W^+[.U-'Z:CV=Y;
M+AW;&C^5>J15/TYGUUW=W^7T_P#B_L<4OY/?RGDR[A<$^+KOWC6*K&>V%?\
M"9]7A_AWE[=.I//]1:]^//LAS_X87;W_ &^</T$_K?HZH9YIKK7^4_\ 381\
MGJ?20+%[K]^MYQOW5T[\N2?-RY+_ 'W:WQ?B'U>E\/G6A\K8_,AAWC+#!_\
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MY"0)"0R/&(:4YZV1; >$3A%"]K^GCIW[D]N_PZ^X1:G-A:.W#(=6<Q; =:W
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MWD<-R_K+#=H_XJKR]H6(_1Q];2](/][[;O\ $I(\V'E?]\C0#X>'_OEJLO\
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M>+#!>Y^]6?/POK3ZUS=.N/[D]UOX[_\ =-UY]KWRFO/@^7][E>C)_-!I\?\
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M *@%W[^K-=\YSGOX?CSE6<_MY4K/X\\)9/9X7?OZLSW]_O\ #\N>_P##PH
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M;_U-$VVYU[71"T)6G'3M=%XQG'?'B;N.OEH5]M*DI5C]G&/DY/+*!]Z$-O\
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MJ,JRRAMMIOJ_JR4-H1A*4(3L.#2A"4X^APE.,)QC&,=L8[8QCY/+%O?<FO\
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MJ* V)3WK2[&DV>-Z<9T&L)G*S*UR<S=((:ION#*DTS)H]92,E_!S;S$F-AX
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'1.$3A%__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>g98473g36k00.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g98473g36k00.jpg
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M  (1 0,1 ?_$ !X  0 " @(# 0             &" 4'! D" PH!_\0 5Q
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M]>Y^?B  ^M'YOV]#YMYN+Z(='+^O<_/Q  ?6C\W[>A\V\W%]$.CE_7N?GX@
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M^@,',
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M\R?^*H %O&S^BQ[0[X08
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M18]H=\(,
M                   ^);^%'?EI1_W>5A_;1T*#M^'A'_LC^-I]7,3_ -51
MG^SV7_#) XL@   "@NF=';>U[:Z?>':<!;Y5AJ:QZ9OL?;9^4@E\S[;;%BOB
MNU:H_:5FTM)=KN T_F8O#-R6,?)YC*EA91W+14I$,2S,;+HKELUV;,ZS-;T*
MG-4\G:[9[3*(7A]!YL>P=>,M'Q%&M6X[U2X#$;LW?"]H/L*F9K[2N4VCS''Z
M\5IJ]1F[&\I5>V+1:JRK:#A>!UM".Q6*:Y1LBFDZ^LN?,<8.2*5V<SE7VU,)
MP+*Q3$A ,)OD=OIR96*9;"XT3E&1G(E6,DX=XHSIU!WQ#6&.==Z1LJXV)',)
M,T\PDI-W "L>U](G/AG&E<404XT\U9-A8>V;5CHJ3<)VZ6K)(OD?O?NV&MDE
MK75T!639\E-3>O:M#[!I5EMN8:<6G6V&ULDB+1\@M,SK5R*]S$1MG+=ILV-[
M;UT9NJ[[&M5UUE:H6FFE].4JB1$VWMT_!V1E8ZSLZ5O#PK]K&U%X5U392.>-
MXB8;Q=G@K%,1ZTM%QTK47B[&SLA%(_YLZ^C5JG'7E:QGVKR"M5)B8]SL^QWN
M?-7]P[9K.95A9'5592,=(13>F/V4J9>#9SKAL:15=2T3*)1IF5ISVAZN85B_
MA$;)PBFWA&&'O##\4.7RU6:TZ=V17[M +$KKA['V3>VYGZS:R1%2XDG7L2LW
M*TN4E)V.](6I-_R"-1D/-A3L]LQ\OE%%RZF(**+6,N4?FYWQ?G%6]J'J#>\+
M:=1ENML-8\T[>%YV+)6)6?G+ _4U-+<?+%KMKKJ?GY)E"LY>6/MJRP]HCV]=
MJU5@7]<H\98I^'1O6)&0FR7<N=>B] (  #J(Z>3_ %3/+_\ V!K#^W/6 -_A
M_P"]GBFW0!?D+YT?[T_F3_Q5  MXV?T6/:'?"#
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M<8R4Q<XS@Q<XQG&<9QG'E!FWC9_18]H=[X,
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M,V?VZ\F_WT ?4M^:3YNET-/L9L_MUY-_OH ^I;\TGS=+H:?8S9_;KR;_ 'T
M?4M^:78SQ1X=<<.#^LWVG>+FMT]6ZXD;;*7I[6TK5=[>5:U34=#1,G*]ZWZR
MVJ;3RZCZ_#M\LTI(D>CAGA5!HDLNY46,S,VIK,UE9D$
M
M    %#^DI_-'LO\ ZQ<3/VM]' L8^EKVE<:9N]6KT_6:Q-2Z4=-W$LZ>N-%T
M'?5R):S&XF)S^7$;GCV>6$9YSTQ7[IJ99!-8S;"V4%L$(U@RY/Z$D&<:_9[*
MA%FLJHEAJ;#>6(JFR6C*1-$GI%LI'$<P]3Q#[+UU*J7&618U5*.O=/>JS!&]
MCB%'8IWQ[PXY)72]S:QV(DV6I-OCK&F[EC0K?,>D^-E5[BIQ-[24P15HD<L6
M\IM@KMEC9PY2PDI$62MO(Z0=)V&&R^#9P
M
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M*^U^_?APW[ZRN""
M                                            #Y[_ .$6;[Y=\=>)
M5$NO'NF:UO6KY+<&MXC=#&TU*Y6&XU^:A=BTK86F)NMNZS=ZXR:UR8OU*0H]
ML:R$++OW[JT5MA".XQX_,Z2.GX<6;5J8M3,732E,K\=U_H[H>-<EO6:T)J:;
MY-1U(A=^SE(A9O:L!KF,F(BF5JV3#?$D]JT*SGK);97):PFZ1@'[YQ89 DK)
MQSV4:8:,WC=BV,32LTK2MU<:-W@@
M                                              *E<WEI$G'YPRC9
MZTUH]@W-Q:I\C+4NV66BV<E=NW*/3=0M3"+MU.E8.TP)IJLS<M"NGT%,1T@5
MC(.4T':65,F!8Q])G2)EX>I+I7Z3\J/?NYQ?B( K.[2.AZDNE?I/RH]^[G%^
M(@"L[M(Z'J2Z5^D_*CW[N<7XB *SNTCH\#<*=(D.FF>U\I2G5R8J1#<\.<!3
MJF(7)S%3+GD3C)\E(4QS8+C.<%+DV?)C&<@5G=I'1Y^I+I7Z3\J/?NYQ?B(
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M55,^2@U9FLQ$Q&D9<'9N#
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M77X-6/\ :/7VE;<&0
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M'1E_B'JT1#N31<>6C3>L9V*=QQ<^+N\U&STK6NE4GA2[TK.M/79*[8(
M "I'.?\ -BO?_F'4G]LNOP:L?[1Z^TK;@R
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MNEVE@P
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M&L7CQ?S&[=50I8LVHF9FS:B/#:QLSY9ILS=[@,
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M:3_H%_P .I2_FD_Z!?\   ZE+^:3_H%_P .I2_FD_P"@7_  ZE+^:3_H%_P
M.I2_FD_Z!?\  !0GI(TTR\<:CDJ9,9]<WHXOX\$+C/\ 'TA/&'&?X\8_[\?Q
M?_P#5G&?TV_X6E^@9
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M@9"T1T$\.J^@F%I6G6]<>R+19)!=!I-.*O8D(UP9/J72T))I)',=FL4H;G
M         !0CI)/S<:C]<WHXO[PKC"#5G&?TV_X6E]P9
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MML9*M'N4NH<$*IGR ?+80  J/3_S\>0_U1^&O]LG.\%V1QGVLK< @
M   *$=))^;C4?KF]'%_>%<80:LXS^FW_  M+[@R
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M!(3"*40)FOK?WWJN"" "H]/_ #\>0_U1^&O]LG.\%V1QGVLK< @
M *$=))^;C4?KF]'%_>%<80:LXS^FW_"TON#(
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M)^;C4?KF]'%_>%<80:LXS^FW_"TON#(
M                            I/?&6ZZ#RBLNVZ)I"3W!4KEH/6&NCG@K
M]KZI/X.Q438>Y+,_*^9WB<A3.F;Z,V%$99.8\[DN%FSU)P5+)$LJ%V1QGXZ)
M#Z<>27L37W[:= _'8(>G'DE[$U]^VG0/QV >G'DE[$U]^VG0/QV >G'DE[$U
M]^VG0/QV >G'DE[$U]^VG0/QV >G'DE[$U]^VG0/QV >G'DE[$U]^VG0/QV
M>G'DE[$U]^VG0/QV >G'DE[$U]^VG0/QV >G'DE[$U]^VG0/QV >G'DE[$U]
M^VG0/QV >G'DE[$U]^VG0/QV >G'DE[$U]^VG0/QV >G'DE[$U]^VG0/QV >
MG'DE[$U]^VG0/QV >G'DE[$U]^VG0/QV QND(G;\_P C]V[GV1J)]J&"M&DN
M.NL:Q%R]UI%PEI:6UI>^3MJL\@?%(EYEI'1R3/;E6;L^VN$G+MR60\Q'"3;"
MAR[(C?/.G1<D$          !0CI)/S<:C]<WHXO[PKC"#5G&?TV_X6E]P9
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MYO1Q?WA7&$&K.,_IM_PM+[@R
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M?OI.0<94=OWCETLJL<CG@
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M#W27KM3KMPDFA'4$)B(K3AC$\)]<MFV78H"
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M<':O$<.8N/>U"J.4H17!HE16OQYG#1;RNNTDKWW[MQ
M
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M.F]N.R>L(N-7)',G!G.%:32ZE;XVS7;,91DM("
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M[+[8[.V-=W]RY"5*!M\IKB-TSQ^U]M2&L4+'U)Z\G)F[NMZ8>*/C72NVJ&/
M1:>IX5HRRW8MU3*O[45V<ZF(5Y&DV5X\J=596_,.U:DH>MYNYVI+9M@N_&?5
M&VD)&[VBETF*D;5?Y.!@G-?:Q]'U7%1L?E22.[6@)61E$6#UW*&KSTT>9JP?
MN"TKSBZL[^]T3C1^MND2E;@^2CHJ@03"%F%ZX\KD[7MLHOYIRV)=>$K*32?-
M76LWD2FD[B.7*9\-V3A^=\2ASL8G(1)YIM8((4B.E,,:5OQNP]TFUYS@GK1L
M2L:M<5*)1B[-:TJN^O&=H-9.TQ3^Y[(YJ4N&S P:6L8B"EVL*[XMQIFAGKQD
MOW/>(W#AM*/84Y["*95GTX5K?=2MZ1-N2MZL%<X73=HF6VI:7NJ-NCC:6SDV
M\&SB26NM58BE'JD5(V]E,059A]OOLS]OKDB_(L^<15795J)D<R<^@Y5%*UQK
M=3AATS^8ET%RN:U_9!]7V)VWGZY6[C(U.R;:LDY UN31K/H'+R!B-XRT(Q@8
M2JETBNW4<Z;7V/'.XN$6VI&)LF;++>073C!3K$1QI3YVW)+R3WDTJ]!UG<]>
M[8KL/#2'*/4FK;59XJ2I$U#+12FWT=?;7IK^1FV<Y%1KZ(48V2"LF6AV%BJT
MO"R3<[R*?QCTB8B)RK=OUN_XKYOSG8\I=DV73ZE,:[Q R=!@4]4;/):FZ#**
MM\]0.5%@<3\W(/X>=K;J+/:N/[/7]/P1H^CY&[3D>Q6Q-*ODH14OAUONIP]<
M)KAL7VTS=6-^UE2[ WLD59Y%:K5C%E?13^.?=3975:AY63:R!8PYF["2SWBB
M]6CS)MU$47C=3#=-%9'RF:3&,4:6XW?EDY__ %N*9^P=PG!9PL\/F5N 0
M
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MP^96X!
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MX6>'S*W (
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MA8X!1ZB@G)1Q)(S^'>1\JV9OFYJS-^$?ZVI_ULXQ9F8V9K;^I/IOZ9\N/?\
M^>'XD09K.[2.AZD^F_IGRX]__GA^)$"L[M(Z'J3Z;^F?+CW_ /GA^)$"L[M(
MZ'J3Z;^F?+CW_P#GA^)$"L[M(Z'J3Z;^F?+CW_\ GA^)$"L[M(Z'J3Z;^F?+
MCW_^>'XD0*SNTCH>I/IOZ9\N/?\ ^>'XD0*SNTCH>I/IOZ9\N/?_ .>'XD0*
MSNTCHVYJ#1VO-&1MKC=?-[=_GS;LWNX2][V;LW;EKL=J\*U6CIRLK=-MW"[V
MYUV6HTBJ5]BR/-]W1\;!LT&31OC"N5!,U]+L(C?LXMN @
M
M      H?TB_Y!M<?7BZ-?^\+XQ@U9QG]-O\ A:7D7D8]L[9,'+YFW?267&(Y
MDNY12=O\LTNO=X9-U#E6=9:H9PLXP@13J$L]8KYI/XP98=.Y5!9!BZ1M5;5;
M2DMW!&.$YR,40D9WSE"]RL5BNLINY;SDE2]VMS*//.34QU/E(;R!S65@@9(I
M#QTW$2!%))W#D.RDF;HIY=@FX6?11#(+*8-),D6CI5VQQG+ILFV<'62(5%3)
M0RX
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M-FJZ;J(IRCG56OFU*ABMCN+$T;UJF22LRG(VW;)Y85]>.R^=OKMTNA?@$
M
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MR(PT+85(620<HMW+.0Q!6. F"MUT2'/'3$>[)YR#I(YA,3&,3'%LX$
M
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M*.^]6QP !4?C=^63G_\ 6XIG[!W"<%G"SP^96X!
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MQYX7J:%N=)L^-H*VZ/H>F/0Q%0R],;0*SJ)S1.-%)-+23]C87+-W)8QQLBI
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M<)P6<+/#YE;@$
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M#4N=F]Y^-LTJ(S+]^]HQ8LH]5GN?-GP\_EF+7F#[MS:<._Y5BP9DL.<86P?
M+./?KZ9-Y@@  *C\;ORR<_\ ZW%,_8.X3@LX6>'S*W (
M                                                      "AT7CD
M)IW<O*&6K7'9_M6I;DV_4=F5>RPNTM<5?J&$=QNT+J21BI*'MDI'R:$@VL>K
M9MP50B2C1Q'.V"R2V5#JIIENF(OB*1OSF=D;TY]-G)KV*K5]N>DOB("D9QSZ
M'ILY->Q5:OMSTE\1 4C..?0]-G)KV*K5]N>DOB("D9QSZ'ILY->Q5:OMSTE\
M1 4C..?0]-G)KV*K5]N>DOB("D9QSZ'ILY->Q5:OMSTE\1 4C..?0]-G)KV*
MK5]N>DOB("D9QSZ'ILY->Q5:OMSTE\1 4C..?0]-G)KV*K5]N>DOB("D9QSZ
M'ILY,Y_Z>%5J_B_CQ_IRTE_%G_Q_[1 4C..?0]-G)KV*K5]N>DOB("D9QSZ'
MILY->Q5:OMSTE\1 4C..?0]-G)KV*K5]N>DOB("D9QSZ'ILY->Q5:OMSTE\1
M 4C..?0]-G)KV*K5]N>DOB("D9QSZ'ILY->Q5:OMSTE\1 4C..?1RN+]7V9&
MS?)Z^[/H>-:O]T\@8G8=<J2MI@+=(,:S"<:>.FG<+RDI65W40F[?6/55C=HL
MT'*RB4:K'JKY(LN=),32ZDUI%^L_"UP(
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MQ>:86-1CGKI5TWL;>:BG\6^2(9BXBGS>6PXQ&*8= 4G+#%MX
M
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M7B9EA6IZ1K#.0+7(#7<31Q7=&WG7KW?6ZX(
K                                                     #__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>g98473g37e21.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g98473g37e21.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_[1_84&AO=&]S:&]P(#,N,  X0DE-! 0
M     $H< 5H  QLE1QP!6@ #&R5'' (   (  !P"4  (<G(U,#DQ-C<< @4
M(4UI8W)O<V]F="!7;W)D("T@1V5N97-I<R!&+3$N9&]C>#A"24T$)0
M$")*^(M6HN%I'>),'8-E9Y0X0DE-!#H      .4    0     0      "W!R
M:6YT3W5T<'5T    !0    !0<W138F]O; $     26YT965N=6T     26YT
M90    !#;')M    #W!R:6YT4VEX=&5E;D)I=&)O;VP     "W!R:6YT97).
M86UE5$585     $       ]P<FEN=%!R;V]F4V5T=7!/8FIC    # !0 '(
M;P!O &8 ( !3 &4 = !U '        IP<F]O9E-E='5P     0    !";'1N
M96YU;0    QB=6EL=&EN4')O;V8    )<')O;V9#35E+ #A"24T$.P     "
M+0   !     !       2<')I;G1/=71P=71/<'1I;VYS    %P    !#<'1N
M8F]O;       0VQB<F)O;VP      %)G<TUB;V]L      !#<FY#8F]O;
M    0VYT0V)O;VP      $QB;'-B;V]L      !.9W1V8F]O;       16UL
M1&)O;VP      $EN=')B;V]L      !"8VMG3V)J8P    $       !21T)#
M     P    !29" @9&]U8D!OX            $=R;B!D;W5B0&_@
M    0FP@(&1O=6) ;^            !"<F1456YT1B-2;'0
M  !";&0@56YT1B-2;'0               !2<VQT56YT1B-0>&Q <L
M      IV96-T;W)$871A8F]O; $     4&=0<V5N=6T     4&=0<P    !0
M9U!#     $QE9G15;G1&(U)L=                %1O<"!5;G1&(U)L=
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M____   X0DE-! T       0   !X.$))3009       $    'CA"24T#\P
M    "0           0 X0DE-)Q        H  0         !.$))30/T
M   2 #4    ! "T    &       !.$))30/W       <  #_____________
M________________ ^@  #A"24T$"       $     $   )    "0      X
M0DE-!!X       0     .$))300:      ,U    !@             "B
M L@          0                         !              +(   "
MB                      !                         !     !
M    ;G5L;     (    &8F]U;F1S3V)J8P    $       !28W0Q    !
M  !4;W @;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG   "
MB     !29VAT;&]N9P   L@    &<VQI8V5S5FQ,<P    %/8FIC     0
M    !7-L:6-E    $@    =S;&EC94E$;&]N9P         '9W)O=7!)1&QO
M;F<         !F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U=&]'
M96YE<F%T960     5'EP965N=6T    *15-L:6-E5'EP90    !);6<@
M!F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
M     $QE9G1L;VYG          !"=&]M;&]N9P   H@     4F=H=&QO;F<
M  +(     W5R;%1%6%0    !        ;G5L;%1%6%0    !        37-G
M951%6%0    !       &86QT5&%G5$585     $       YC96QL5&5X=$ES
M2%1-3&)O;VP!    "&-E;&Q497AT5$585     $       EH;W)Z06QI9VYE
M;G5M    #T53;&EC94AO<GI!;&EG;@    =D969A=6QT    "79E<G1!;&EG
M;F5N=6T    /15-L:6-E5F5R=$%L:6=N    !V1E9F%U;'0    +8F=#;VQO
M<E1Y<&5E;G5M    $453;&EC94)'0V]L;W)4>7!E     $YO;F4    )=&]P
M3W5T<V5T;&]N9P         *;&5F=$]U='-E=&QO;F<         #&)O='1O
M;4]U='-E=&QO;F<         "W)I9VAT3W5T<V5T;&]N9P      .$))300H
M       ,     C_P        .$))3001       ! 0 X0DE-!!0       0
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M!0$! 0$! 0         !  (#! 4&!P@)"@L0  $$ 0,"! (%!P8(!0,,,P$
M A$#!"$2,05!46$3(G&!,@84D:&Q0B,D%5+!8C,T<H+10P<EDE/PX?%C<S46
MHK*#)D235&1%PJ-T-A?25>)E\K.$P]-UX_-&)Y2DA;25Q-3D]*6UQ=7E]59F
M=H:6IK;&UN;V-T=79W>'EZ>WQ]?G]Q$  @(! @0$ P0%!@<'!@4U 0 "$0,A
M,1($05%A<2(3!3*!D12AL4(CP5+1\#,D8N%R@I)#4Q5C<S3Q)086HK*#!R8U
MPM)$DU2C%V1%539T9>+RLX3#TW7C\T:4I(6TE<34Y/2EM<75Y?569G:&EJ:V
MQM;F]B<W1U=G=X>7I[?'_]H # ,!  (1 Q$ /P#U-C&5L;76T,8P!K6M$  :
M-:UH0LRA]](96XL<VRM\ASFZ5V,M<V:RUVU[6;-G\W9]"W]&CI)*<JKI_4VX
MYJ;E"DEV07N ]5S_ %=_V9_J/])U+J'.:[9^E^A_.I=.Z?U#&RO5NM::#66B
MG>ZST_=O%53[6,>__P ,/=[_ &4_9V>DQ:J22G&LZOE-^LN/TH"O[/;5D/>8
M)?-0Q#7K(8W^E6;ELKGLDS]<NG#=,49GM]_A@?O_ *'_ +;_ /2BZ%)2DDDD
ME*22224I))))2DDDDE*22224I))))2DDDDE/_]#U5)95]N0>KMQ@8#MCP[UB
M-K #N_5O1].SU'UO9_.VO_/_ $7Z)7LS%;E4BIT#;95:"1.M5C,AO_2J24G3
M+,JZ/<S&..,IU(+KW'T0&[_7W[76[@ZSU:'6;V/KL8FPNBNQ;?4%C:]U+JGB
MENS4O==7Z.]UGV>K&WV>G77_ #OJ_IOYNI)2#.WM^MG2=UDM=1FEE>V(C[%^
M?_K]-;BY._'L_P">V Q]_JL%62YF\!UC/3&"[VVM=^C]7U?]'_-^I_I%T^2V
MYU+FT.VV'@_/W1(=[MOT?:DI6)D#*Q:<EK75MO8VP,?&X!PW[7['/9NU_,>J
MEW4"SJM5 W>@&O9<0&[1:3C>A]+]-]&_;^C_ $?ZQ_VR+ZL676]$QK+06!S&
MBNM[M[F-:UM9K?9[M_Z5EGYRAU"NEOUAZ9DD#U6U9#"8UVO=C5C_ #;K*V_]
M=L_TB2G4NM934ZQYV@=X)U/M:T-;[GN<[VM8SZ:%T[+^V85.0X /L8TV, (V
MO(!>S;9ML;M=^^BW55VU%EHEA@G4@@M.YK@YL.:YKF[MRH?5MNWHF(TN]2P5
MM%EA.YSW!H;ZKW_G>HP-?_Y@DIF[.>.KBCW>AL-9U9M]7V6M_1_TC^;?]/\
MF_\ @_\ "*SFVBK%L<2Z2TM8&?3+B-K!7_+5')9CM^L.+D0SUVT65.= W[+'
M5N;_ "]GJT-9_P!<5[-979AW-M;N9L<2..!ND$>YKF_FN24MT^[UL*EY+B[8
MT/WB'AP$/]0?O[D)N8T]6LP_6;[:6/%&F[<7/W.GZ7T/3]BCT&OTNCX=)DNI
MJ;4\DR2Y@V66.<?<YUCV^IN0VTL'77-WN+6TB]E6FT/+K:GV?1]3Z-C_ ,_T
M_>DITTDDDE*22224I))))3__T>[ZAD'$ZNRT,LM<YC26@P#6/4WBEK+*W9/V
M?])?96_'R=GK,_25^JMI9E]3OVQ78VROU"T ,(+BU@W\LVOV[W&_;<R[$_<_
M6/06BY[&"7N#02!),:N.UK?[3BDIDDH574W!QJ>VP-<6.+2##FZ/8[;^>U-7
M?1:UCJK&6-L!<PM<"'-$!SF;?I-]R2GF.K9M>+]<NE.L>[:69@>W98 UGI46
MNL]2U_H6M;]G_P"TU>__ ,%75KF^MX==WUHZ+9=-WIC)LK8Z(9/V7&?MV-98
MYKFW^]EK[&+I$E.5]77$8%51Y--%S1_)LJ:#_G7U7N1.J-<ZQNS5[,>ZQ@\7
MUOQK:_\ IL0>DEK<7I5C3++\-E4CNYK&74_]!N2KMD?M*@?\!=_U6,DIL;FO
MKW-(<UPD'L00L_H_L9Z79]-%P\MU8HVC^K]F_P"FK'3],%M9YHW4_P#;1=2'
M?VFLW*OB^QO3;.UE'HGXEC;V_P";]GL_STE+=3)%Q>/\#0;H\?2LJOC^UZ:N
MYDG#OVC<36^!,3[3W0GM#NI-:X2UV.\$>1<Q1QW./2MKC+ZZW5/)[NKW4V?]
M-B2F/2][-]+_ *193;$R '5BG;_VYC6*K9DLK^M==9X?A$/?K#'>JST&/]NS
M]/O?LW6?F?\ "L5MGZ/(PW\"VHU'S< VZK_-97D+)ZS795]9,+*HK?;%8;D5
M@M]/8;&!MKJWV4>ID,L]/T/YW_B?492DIZ1)18]MC&V,,L> YI\0=0I)*4DD
MDDI22222G__2[W(NGZPTUL(#FL:'M&S<&N]9S7/:#ZMM=NU_I_0^R^C99_AU
MI9.,S)J%;^ ^NP: ZUO9<SZ4_GUJADD'KM#7!P+6--9WEH)(O]3:PN-=OYGJ
M^RJW^:_27,_1K524YHZ)4<?[/9=::P;X#'N:"W(#VN;:S<^NST_4_1>WTZ_\
M'4HX_0JJLG[6^^Q]KJK*GAL5M_3/9=8ZGTQZV/\ I*_\%?\ G_I/4M]ZU$DE
M/%=?PLIW6ZL?'%MX.)G[<=UUP-H]+$C'KR+#^A>_(<QV]EWYGTUUV$XOQ*GE
M_J;VAP=J='>YGN<&N?M9^?M]ZQ<FO;]<NGOV.;OIR_>6U@.TPOHOK_6'?1_P
M_P#Z31^G]3M%MF(*0*VY ;CO<Z-U%@%WJ!C&V.K])UGH55V;/4]/\RSUJJDI
MLDEO2L6_O0VFTGP: UM[O^V'6HUG_*F/_P 1?_U>*GQ:F7=+IJ?JRRAK'#R<
MP-*KXUK[<G"?9_.?9KA9_7:_%9:/^W&N24V*/9DY=7B6W#PA[?2_\^8]CE7^
MCT;&N_T%=-Q/@U@8ZW_P'U&JQ=[,ZI_ MK?6?-S8MJ_Z'VA+"K;;TNBMXEKZ
M&-</(L *2ER!^T6GOZ)_ZIJ$WV-SZ> TNL8/Y-C-Y/\ :O\ 74<%[K+*"\S8
M,<ML/\MCA7;_ ."-<GS#Z>18X<78SP?C4=U8_P#9BU)3+(]N#3=WH-=A/@T0
MVX_]L.M5+KF(W+-K30,AU0Q;F-(!@U767;O>6_Z/](W_  C%IMJ;=A"E_P!&
MRK8[X.;M*J8>07/=D6R7#$J=: ).YIO]5H:/Y8<DIT&/:]C7M,M< 6GQ!4ED
M_5S)?9B/Q[#N?C66-:0]KP*O5M;BUE]0:WU*\>NO>W_IV;UK)*4DDDDI2222
M2G__T^^RGVU_6#&#"&MNJVN:0X%^TO=["S]'=Z+7/W^OZ?V?UM]?KVW?H]=9
M5QL_;++JMOI-#:,AT_GPZUE=FYPV[&Y#'T>C7;ZOK6>OZ7Z-:J2FL[J6 VPU
MG(K#VV>DYNX2UX:VWTW_ +CO3MJ=[O\ 2U?Z1/1U#"R'MKIN:][FEX:#KM!V
M./\ 9<J^7T3"RWO=>7EMI)M8'>U[7-IK=2[3<VO]4Q[?T>RSU*_YST[+*T]'
M1L:JQ[W/?>;0[UFV;2'O>!7;>]K&,_265,95M;^@]/Z%*2FEFU-9]:^E6 N)
M?1F;@7.+1 P_H,<=C/H_F*'5\(X>57G8P>'9654V[T?28XET8V/Z[GLW78M-
MUC\G_"7>H^S_  -ME:K''JH^NN"*FM8ST,R&-/&G3_\ ![W;/^VZUM=7:'45
MM<X,'J [G& "UKWL<X_R7M:DI-T_=]@QMT;O29.V0)VCZ,JG1%?6/0D#:S(>
MQLZEMCL2USX_=]=UR-T/+&;T?"R@ TVT5N<P'=M<6-+ZR2UCMU;O;[F,52[[
M4WZR56,!AU#JPS9+75A]#[+W9'^#?4Y]C?1_/_ZY^A2F_GPVNN__ $%K'_ $
M^C:?^V;;%+ !;@XS3H14P'_-"AU9CK.FY-36[O5K-;H:7PU_Z.VSTF^ZWTZW
M.L])G\[_ #:AT5SSTO&#M6MK8UC]IKW-#6[7^B[^:_JI*1XSZV=5NQ=P%C&.
MM#)&[9<YK_4V_N_:/M#47JK1Z#;3Q6[7X6-?C?\ H[>JWH9 ^L/K N ?3!=O
M'I^DPZ5_9OI?:/6M>[UOW/\ "_\ :9&Z_6^[HV90P[3?4^HV$%P8'M+/6V5_
MI'^ENW^Q)3<HTHK!YV-_(J.":V=4S,83OK:RPR'06W/ON:=\>G_.NN9MW?F(
M_2K'V=.QWO$$L ! +00-&OV6?I&;V^[8]5*L.QOUAMR9 +J:_4LWNE]8.3Z.
M/]G_ )EC:K+76>K_ .E;4E-;&M.'U!M;*K*Z;[\BS)+&-8P/WOJI==OVV6?:
M:OTM;Z/^XWK?S2WUF=3PJ,G,Q"YC1>S>ZBXMW&M[6S78WC=L<?\ J_WU=Q,@
MWU;G-V6L)9=7,[7CZ3>WM_/K=_A*O3M24F22224I))))3__4[_(LI9]8,:OT
MZA8^LN]0M#K"8L9_I:W4;6MVLN]#(]7U+:?T2UEB7WV/^LM%&Z&5M,,$6@^U
MUGJN:P.?A/\ YRGU<G]';6_T\:ZNVU]=NVDI22#D9>/C>GZ[M@M):UT$MEK'
MWNWO:-M3?2IL]]OL_MH5'5,+(?Z=;R'P7.#V/9MV_399ZC6>G<S=O]%_Z7T_
MTO\ -I*<S+;8/K=TQS@0PT9FTETCC"_P>WV?1_>6CU.MMK,>M_!OK,CD%LV5
MN']2QC'K/RV4?\Z^E6UP7/HS=S@9G^A#QV_FL6OD4&[TB'[/2L;9Q,@3[/[6
MY)37Z)2*^F8SB2^RVJNRQ[H!+O38SZ+ QC=K&,9[6HEC7_M*AX:2P47!S_S0
M2[&+6N_E/V/_ ,Q'JJJHJ932QM55;0VNM@#6M:-&L8QOM:UJFDIC8"YC@.2"
M!/BAX==E.'15;'J5UL:_:26[@T-=M<X,W-_L(R22D7V<'*&3O=(K-89IMU(?
MO^CZF[V_O[%*YKGTV,9 <YI#2>)(TF%-))2/'K=5CU5/(+F,:UQ'!($:2F&.
MT9+LG<[<]C:RW3;#2]^[C=N_2(J22D;Z*[+:[73OIDLAQ ]PVNW-:=K_ .VL
M;K;<NGJ.'DXM3K!OU8QH<7O%=[0YWJ%K*?0J+_?['W4V?X2ZC%Q[=U!NH]6R
MA^\M]"PV0 #NEEE.UV[_ (W?[4E,J;ZKZQ;2X/8[@CQ'M<UP/N:]KO:]COH(
MBJW8CQ:<G$<*\@_3:?YNV!MVW-'YVWVLO9^DK_X6K] IXV6VXNK<TU9#/YRE
MWT@#P]O^DJ=^9:S_ ,^>I6DI.DDDDI__U?4/LV/ZIN])GJDR;-HW2!L^G]+Z
M'M14DDE(K\:C(:&7,WM$G:9CW-=4Z?WOT=CT"CI6#0XO8PN<YI:_>YS]V[Z=
ME@L<YMESVM:Q]S_TGI_HOYM7$DE/,/HII^NV":@UNZC,]K8TTZ?^8UWM_P"V
MUTZP<NM[?K=TU[A#7T9FT^H]TZ8?^!?^BI_ZW_Y-;R2E))))*4DDDDI22222
ME))))*4DDDDI2SNN=)9U7#] AA>)+?4#BPR"TLL%3ZGNK_.=7OV/V?I%HI)*
M1X]1II947;MHB>!\&_2]C?S/<B)))*?_UO54DDDE*5"CK&+=M):^ECJ_4-EH
M#6M@"QU5ON_1VLJ?ZC_S%?0*\+$JM%U=366!GIAP$0V=VT)*>>ZIU/H6)]9.
MF9UF5BT5NJRVW9!>QH+B,7TV66S])S:_9O=^8M#_ )X_5/\ \N,+_M^O_P F
MK]C3]OH?N: *[6EI,.,FD^UGYVW9[D9E36/>\3-A#G221( 9I^[[6I*<K_GC
M]4__ "XPO_8BO_R:7_/'ZI_^7&%_V_7_ .36D,6D8]>,)].GT]FIG]$6OKEW
MTG?S;4-Y:<^JP6,VULLI>W<-WJ6&BRIFW^I6])31_P">/U3_ /+C"_[?K_\
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M22^54DE/U4DOE5))3]5)+Y5224__V0 X0DE-!"$      %4    ! 0    \
M00!D &\ 8@!E "  4 !H &\ = !O ', : !O '     3 $$ 9 !O &( 90 @
M %  : !O '0 ;P!S &@ ;P!P "  0P!3 #8    ! #A"24T$(@     !1DU-
M "H    (  @!$@ #     0 !   !&@ %     0   &X!&P %     0   '8!
M*  #     0 "   !,0 "    '@   'X!,@ "    %    )P!.P "    "0
M +"':0 $     0   +P   #H "W&P   )Q  +<;    G$$%D;V)E(%!H;W1O
M<VAO<"!#4S8@*%=I;F1O=W,I #(P,3DZ,#<Z,C$@,C Z,#4Z,S@ <G(U,#DQ
M-C<       .@ 0 #     ?__  "@ @ $     0   LB@ P $     0   H@
M        !@$#  ,    !  8   $:  4    !   !-@$;  4    !   !/@$H
M  ,    !  (   (!  0    !   !1@("  0    !              !(
M 0   $@    !.$))30/]       (          #_X0%(34T *@    @ " $2
M  ,    !      $:  4    !    ;@$;  4    !    =@$H  ,    !  (
M  $Q  (    >    ?@$R  (    4    G $[  (    )    L(=I  0    !
M    O    .@   /      0   \     !061O8F4@4&AO=&]S:&]P($-3-B H
M5VEN9&]W<RD ,C Q.3HP-SHR,2 R,#HP-3HS. !R<C4P.3$V-P       Z !
M  ,    !__\  * "  0    !   "R* #  0    !   "B          & 0,
M P    $ !@   1H !0    $   $V 1L !0    $   $^ 2@  P    $  @
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M 0$! 0$! 0'_P  1" #/ .0# 1$  A$! Q$!_\0 '@ !  (" P$! 0
M      @)!@<#! 4* @'_Q ! $  !! ("  4# 0,* P@#   $ @,%!@$'  @)
M$1(3%!46(2(7(S(8)#$V-SAW>+:X,W:U&24U.5%A=;=!M,'_Q  4 0$
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M&%S,UH':\*$U,R141&IS+4N8CGB"CPHF<):2(,2\6VVU&$9*>8;$4L5#ZBV
MR.O/.5SL;:(4H1(.-H:AJEX'8#6L@$BTZUG3J=L YPI3 JGRL0-RT_%L$.C#
MNE 1+/FRU@?VT!M785B@JC1+A9K-*@P=?@ZW,R,O+R3Z!@@ A@'UO/OO+SC"
M4IQCR2G'FXZXI#32%N+0A05W^$#LUF[=%M'5.1<9#MFL:<U3)"!7 W"LGL5J
MMV"R4VHS^8V[0L'(FQ\^/49!#4S$L&U[,O%SE?'DG)>NS8806@<!P' <!P'
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M]$,59K3NN2Z4;*R=:GJM&VZ.EYU]HB=G%71O-M/GIUYA@494W.R4T9+R^!!
MPT2)I* P@QDM#-!Y ?\ >2L7^!]+_P!>WW@>?=O8K6_M*6I>?;:O,+L33!/H
M\\?*F"(L3;-6=)SC'I4W&1NLK\*+[GEZ"+$M#2L+(RAP..V_WG]&_P#K^QWL
M7_JCKIY__P X'-V&0U&5^A7_ "O#+^L=P:WLZ2EJ]# 4/89O&K;N>6K.<)2(
M#KS8=N,><6K#;.&,$+SZ6<XX''NG^O\ U2_S!3'^V?L7P/3[(1TF;I'8!T$,
MLVQU"*%V5504)RM1]MU7+1^R:K'Y2G"E*1(6"JQH3J4XRI31"TX_.>!UMTR0
M4QK>G2\:0V7'2NW.LTB 4RK"V20CM]ZN)%(:6G.4K;>8=;<;5C.<*2K&<?C/
M SG:]);V5J_8NO'7LC)O%(M-326G\+#=GX0V,8-:5^,H>">);*97C.%-NLH6
MG.%)QG@:&V?=$;'Z.7K8#;>&?O3K3/6AP?'GYBOS>NR) D->,^2DN"$$.C.H
M5C"VW&EH5C"DYQ@);J3A6,I5C"DJQE*DJQC.%8SCRSC.,_C.,X_&<9_&<<",
M^D</1_7AZG$O>\3J]C8^I/4OSP0Y&ZOG;%2:T84C/ZFWIBIPT#.)PK_B,2;+
MZ,J:=0I01J@Z#::O/]8NQB)>$73\Z]ZFZKEH)J//:LK;4C"[;U^*^N5^<J/)
MA9&V]BJE)%QV(YIX9VE"F9*?2YE X67<!P' <!P' <!P' J4[@ Z:MO9:% O
MS3QDA2:EJ2?1/5[8W7%$Y1"ONW:8[<>70-TVB#L,.S9P)W$XS::(%+SQTM4J
ML0$$F1JL0@\+:^ X#@.!AFQ3&XZBVPYZPU"IM"P4@^NS7^,^M4F#2VPI69.T
MQ/W#4OJ,(+_Q3Q/N:"]YA*D?4Q//W4A4=X=,NQ.=]_%'D![[JC933@'1U&+5
MI:N?:E#*RUJG8R,C PWW_LOV3@LX]B2=Q:R?D%)4[\4+S]C ;UT-V_UK6]E=
MB.K#$5-$E]=C;-:*G-QRHEJL;&KMN,ONQ8C6VL3Y*0C(4RS:[ @[AKM^#)EP
M11GM:3OI+:%KUB5!A)77-K9O>W1;L/$2\ -;NMFLK,-"S^8C,W%C3ELNLD,#
M+?0):>A<2 [)*$%8BYJ4"2]A>!SB6\)<4'N]EE8BM5'7W#2EN:BL-0V\ZZTC
MUF,0.O+)&V"]H QC]7S)+70UOA$(1G"GVY1T;.<H>6E0<%KSA79W1JDYQG&=
M.]BLISC\XSC-GZZ9QG&?_P XSCRS_P"_ V1M*DL;*UGL+7A+OL,7JDVFHN$^
M7GD7[BA#8E):/+\I<%46DAI:?)2'&TK3G"DXS@([GW3]H\9T-O\ EI([MSV6
M!9B14J]?PC)GJ=O\\T%2O+'[P$M]X1W&<)4EQE:5)2K&<8"82T(<0IM:4K0M
M*D+0K&%)6A6,X4E2<^>%)5C.<9QG'EG&?+/ @[ X)"ZQZWJ9KN7B]9[WTWJ%
MQ]SSP^6-J7MA3M=1,F^VK];2YN$K<;.(2O\ *QY)EY.5-NH6H)R<" %I(8@.
MHW<.AH0G)&J\]BJZZ*UGT#A1=LBS]O4J-%_3Y('C==[/IX2$)QE#61U,I\DH
MPE(3_P"!&.':37-E]H:M[N7&K7 4O=8F%K].&';'1Y#4LM%A,Y_&60W=)1\Z
M8XWCR^=;E+>\G'\*<#7M]*%$Z$QJE2)<;-N:)U^BB$QL8=.3"MH(KE?(U<W!
MPD8#*2,Q-*O[%=5&1X4<:^^4AO\ <*;2YE(9)T:WDWOWK'IV[25AL<_>3M9Z
M[F-@/7*LMT^T9L-MI<+;/GF00U?K$7B-EAIALN%E*]$(KLB)A2(XE]X0U+02
MZX#@. X#@. X#@56=GYB(K_;VFY)+K0:2]9U6S'E,35DU_,P2J=9M@2Q,[;K
ME6NN&SPYN+.K4=,.4^LVC9E/]K[*O1,)&(9>G9L4+4^ X#@.!Y$\?(1<+)R,
M5!F6:2""?)!K\>7%@G3!+2,J:CQ3)HV.B1GR58PVV](GB"(5G"GGVT8RK 53
M=*9N>L/B.>*?)V2F2U!E78?HDV[6YJ4K<P>,TSJ/8J&"%GU.8G89Q!;>,/-H
M9D7'FD*P@AMISS1P([[[IDQUNW7;K*[.V*VZ=UUIC4M;#UY6=1R8USN8@IO;
M68IL?'[%*(,AK[/=?8^U%6VUBP[M3/.U47*SMQ.=-KLFB[A/[J;L&*OEKC&!
M(Z:@IJF=9-)U6U5RQ"BC2T-+83)SP>%NQITK#20,K7IV%FXR4@Y>4CGQ)) S
MA+,H))QX(3GFH>.L,/+0$P,V;$SD8?#R@;N,*:+CI,5T(T9S&?/&6WQGW6EX
MSCRRE><<"$NHIJ8F[GU-S9'5/VNOZ&[(T.Y/K5Z\D7;6UZT'KVZ/I7YJ]QMZ
MTUF7<:<]6?<;6A?GGU<"=O K_AEC1=JT]KUI.4O:P[U[<@7FTI](PX%WZ[=@
M=VU0 ''\. XJC[6K$0VVC] ZP'1D8QACRP%@' @Q=FOMRZ;@J>7E.MV7>G2K
M=8*5*]+8+%NVOK/5DA$",?C&$,RVCRK*:XWCR6;<5K=_>NY4X$Y^!7SV9<9K
MD7W*@DH^(+L?JF7L4%M*?),K9Z?%VR@WZ34K'EYD"UDC2L8YYY\\L-BX\\83
MP+!N!&+<N!:YM+5]N=SZ/N^H;ATFO"?4E+Q\U5&MMPA)2L?H6B/%T[9P \._
MP$61Q#.<+)RE8=JHT(?8G7'2<4J8DJY*Q-'U%:JU9(EL%^0@;)7J_!GQI[8L
MF,;''BN^EZ.EHXT9QF1ASY +"QG'VRF @YX<UI<U/J+36OMA&7K86T=ABZNI
ML-:5CUT>+8UT]H^6V]J](L<]*1AL91:S78_9U13(JS:YZ8O=*NKCQ:Q2H6-!
M"W;@. X#@. X#@.!5SVXK*K;V4U\#%:RH>TK)&U2A2 ,_/4:[3-FZV^]>KDR
M+M>%>K.G+_6]A?=*F3@P=>WV[ZYBX4_7CDT#)H:L$S(QP6C<#K&ONBAEDCA$
M23XXS[[,<&L1LL]UEI;C80KD@4" V04M*6&%FFB")=<2HDH=G"W4!7T!WU6;
M&TV5=T\;&COD".;98.O "S-9Q$SV3D>L, 5$ICJ_(!; DG[E#3<_,QHI]>#B
MJK"2! ,S.R[L/$2X8JOQ$9I4!DT30CC]D*TZQV@AZPYL\,?!O68FDRUS:M1<
MS]ENB1^UO7$KJSFK$L&P"+$: O.U,UY94^&$T)_L5HVJ'HB;3M*F5N76#'R6
M8F;FQ(^1:#E0V9 !UX1]Q+K6"0WVGV\*3C.4+QG@5]]++G4[]XCWBH62E6&*
ML\ 3#]$AV)>%+:. >?$U'L5DEILAG*FU+8=2IMU.,^:5XRG/YQP)_=AJ%%7[
M5EE9-.EX64J\9-VVJV2OOACSE<L,?6IV/Q(1ZI(&4BWDFPTK,P$H#*1<C'24
M',RD<6(ZT5GTA WPS:FU5ZQ3\&S4U:;@_P!=Z#7KU;;"4R1)V.>U1<+EI(8Y
M# @D?'QL6B UI##Q4?'@"MJ';S*2"Y*?E)F;E M@X%=%?D3ZGWX$U@N&E3(T
MVJ[ZVC7#(_$5]'K%1V:WUT).7+Y*E!9/+T[N.D[<,3B,CI/*2)D++^!QEO/L
M!8OP*ZMOV&'H_=KKU69!]8"=PWJ&MU<&:!-?:F+;1-#=H*3>S771!WVFC&Z[
M9=-@*<*RPC  #:W'O9$6IH+%>!7OW2EG*!?NM=V'K\K/)OFW]4Z(-&AB801Y
MN1F=[ZAVA6)B25.2T.,_'P@FL[J"AL9\J1;?LZE"!/-N%K;"PC@5T>)#/PVO
M-1%;*G9 &$AW*#O+4=CGY8T:.AH: V+JJ<LP+\F>8ZR*(F1V%K#7]= <><3[
MLC.C!M^;I:4J"Q)A]@IADD9YH@8EIM\<AAQ+K+[#R,.-/,NHRI#C3K:DK;<0
MK*5H5A2<YQG&>!%+N_)HJW6K8.R/D0X1&H<0>V69"=,^G1XH=$G8^:LK3L@E
M#KHF)BGM6*O.*':=)>'F'A&&"'",,.!F'5BS,W#K#H2R1IU>E%R>F-=O9?K\
MPB:K_P!2;J$4R8(-+#MXR0R%(M/@D.>PA]IUAYMT=M]M;20IKWR7<.K.P>GA
M-VV\+K.8TC!5_3L0!6*:';(+<A ?63=F:EL62"G0U6BQUV&V*],:I*I%'3'7
M"J![!EYTN;CF[K69Z$#Z!8@DTR)BRY('Z9(E1P1)\;EY).8\U\9ITH')",80
M_P#$?4XQ[R,82[[?K3C&%8QP/1X#@. X#@. X%979NK35RW) ;0JL3$3D!08
MJOUL&VQ$1HF6@&[U![&F/OBG;[MNQU.7BHZ_JX>8,Z/3J<F)LP<R7<\DNR<Z
MQ68$H+-> X$<GNIVAWI.GRWV<8P51Y:5FHAH2WW0../,EMC.;>6U;8D6PLQE
MYC8S9SF;Q78FY"3D96+#C!M?$C<Y6E08?_(3ZR_;R*OBE6'$.V^EII"=I;52
M>S5T5XJIHUBS,)NF)=K3+=9-+@V],-G)U>V 0ZA%32ZKW>!N3>4>DW3.R(QH
M%TU)%+FA&XX2LYM[I"5!+;2,/4V]?[4S/*5CR0B)1K>Z_*_#*:W)^>!EA3AX
M3$0J#[D>)W'*B#(3+;/2MS(!VNEZL(;]W66R5^M5/<T5UR6(ES&<+27G5\;\
M[&??Q)S&%8-6%V6R_P"SB_\ _)-J_P"A'\"LCI),S,-VNV]JTD6#9KXG5WJ_
MM6KN?<)'U[$3LJ(EF3F!JM] 2)]+?V-5MHRTC,8LV2F9"1#85">T>DY(6V\"
MF3>$SL"&[Z"7J&NUJAMGQ.J-JT#5&G *7%DUW;%<%G.KEFIC1<B9!'2L_$SM
MILNU8FXW.+FX</64<HDA]RN-4Z>F;6%S? I\[P623 [7]8IXW:@VG#M66>WD
M:P;(K<//_M"=O767L@_9'W1)44J0N8>+92]?4=6NZ*]#W-MV54ZW*,3-[UW(
M0X6TUHZ4E*Y 2<W%9@IJ1A8HZ7A%/I)5#RA8+!$A%9)1A*",QY;CHF7TI2EW
M+/N)QC"L8X%<?B#ZL<N;VKK/:=7G;KH-?VAUO;AJB!+U4=RJ7_\ E2:I4_.N
M5V\6&L5B=Q>:J631$S;LFN5JC:B(Q@9JMWJW2L8$Y]*URW5'4] K5\DU2]OA
M:U' SACDH7/.)*:;_0 Y89!MJ1LCD2/EF*<LDBTS(V%82IH]EHLYYM(5Z>,.
MJ:G.F^V-=!VFOZ\A[3JW9]G.O-C'9=8)F]70@-WK.L80LTP.*A[-L5X&16))
M23<LEZ#J]C@0(5^6G )*(">N@[I,W[6D?8)R2BI\A,[<H,&VP(*XR#NT'6K?
M-U^!ND0$HL]#8-GAXT.6;?",*ASUD.25?(?@#(QYP,:[-:PD-H4( :.!K,^Y
M4ITFVD4F[D&ATR]A_9UNJI->L,A'Q<\5%X#1:?NN E6Z]/8C;=6J\;F,7EG!
M P:UZ$Z]FZ3U]J<W/)@(\S9E;U?=FZS52#3H*M"C:2UA2!V6Y4^.A'Y>6GD4
M[[NL)Z8*&91-6 N-0Q)JCG+'.!G'8*$A[+>.KE>L$8%,P<YN:]P\Q$R0[1<?
M)Q4GU2[(!2,><*\E;1 9HC[PQ+#J5-O,N+;6G*59QP/>T[-RU;D9G1=TDRY2
MS4((>1IECER4OR>Q-2EOY$KMC)?5^HZRU(E.:+L!W*W3'YB/B+I(,Q@>Q($+
M(;^X#@. X#@. X%>^WH74U0V2[0IG<^Z8>!VK-"7J[=?]?ZW+V=6IURPRS$<
M3(6*5K6HKW<=74C84U!2*+&RY;*E7;,>Q<#(T@ EZX%D!81P' <!P,3OD47.
MTRS0X(0DB9)0QP8P!]FGJ8$6\^RI"!RK95Q3K%7F7<Y]+DM"ADR(:<Y=%96X
MG&.!4GX?%8E*?X@'BDP<O#1<$:S'=&WUQT-L:[[5 ;03JC8SK;B+CL*,B+,8
MXZG/K<$)"0, K/Q@UN,)2K(6Q;+_ +.+_P#\DVK_ *$?P*>>MN@K2C?$*[]B
MU,:RC:HZQ[/)W\S,QZ[.[12-N[ZO#4,D?Z&FU/6>;JA7[!)"%=/9J8.N!33Q
MYYP,6!HK@7><"/EM_O/:._P>[%_ZGZZ\"0? BSV EX>,VQTJ9E).,CWY'LA:
M1(UH\T41TXQWJEV5':&!00ZVLHIQ\@=EMD?#CJW7F6TIRMQM*@E-P-%]A(.T
M6.E5F*J58D;5(-[HT#8SA8X^N1RHVNT3==#V!99DEVRSD",\.%!58]+8<>^;
M+%G/ACAQSZ%ONCAO3@19[QYC_P"1GVL;D\"J'*Z\[@!8;+0VXV1)R-"G0(81
MIIW"L/&F2Y(0D<PA*GWY!X9D=*B%MIR$G G!W@Q'1%LN".BL."N#Y0IA8ZVD
M*96RIO\ 1EE3>4J;RC]&493E/X\N!Y5K1+NU>QM0 (<G.NP4LW#1TC(N1$>=
M*. /H #.E68^6=C1""LM-$'M1<BX(RM;Z 2E-X86&&Z/K%@I&E]1TNV,1@UH
MI^LZ+5K"Q"R+\O$-35>K$9$2:8N4*C8<F0C_ )@;V1#"(J.>?8RAQP(9:LM)
M#I;'H5BMUTT99(65A8\#5NQYB[3X<H$<49-@2FK=A:W3'1#XA8[,>6SF_.2V
M2C63&5XC4"883\E3[08CV6:<K](:W#!96W?M.D*LE/'821EZY_4UCP\MJ$E(
M8Y1106UVWPZP /@201&W95+M[$9(2U4BF>!J/HYV,)WC29U-G5LIBV(O&X96
M(8VE$T"(G7J!#[PV)0(*+98URYF%;D-?XJK%+N<3)LCVF&L(R'YI)@<Y!S$J
M$Z. X#@. X#@4_=XXJUN]HM4R='L]7A+"BJTY)4$G;^UJ+;;;5(BS;&G9\J5
MA:9VBT946:74CA*^PY-6>E[%+*%N5M.#A[&+23:E)!<#P' <!P,2ON*YFEV?
M%OKCMPJ^84[Z]5V:H5>79Z+]E7RXMNG Q\L995%M>IK$,-&'/'>KV4"NY5Z,
MA4GX>^-?)[_^*1C6.OB=8U+Z=T;^)4BM82FH'A"OV4;&^:5FD2\!6C0L'/\
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M5&QLGC*OEWM=TGS4B$^IE +\\^Q&XQ\45@9I&&L!<UP' <!P' <!P' <!P'
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M%27DD%X8QI@AH,GV3X+'2PJJ.-:ZU_MP&TYL%*<003W,[D^UB!8NE??N3/\
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M2!$=S.Y/R!)9A-C^\G7_ &=^H-])2G:]['S"2&OW#GQ&V,>_[H2'ZG]9=/\
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,@. X#@. X#@.!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>g98473g46b24.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g98473g46b24.jpg
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MTB4F,3<Y57=XDY6TMC(*,SA!<G5YM[C3UE%A<2<T0H'!_\0 '0$!   ' 0$
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M8RX\-ELU7PNR<UUK(H@&PL^]Q8L/%4\I'&RVYDT\CI&\HWQ9F]@#<#)<)3%
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M[[;8R/ 8I^'QK*DLQL6#-//9L&6>8S2S2N<'!UASWM:R$11-C&[&QL8:QH:
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M@V.M)+[.M+2F]114Q"IZ(<C/ZO/VXM+.[$&T&B63=*(S8OE0EHFNFT< 4>=
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M!:T&%K;C&6VMCW0++6S@"5H>+5):VQE%ALMG:61MQ[I+;9)LH\6I'TWX][[
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MXM:]1!0EK$X7TU0N)4"D1+YP%:[.0%P<H^XX(7^2C1Q0?Q?DTD&RTLS;$L.
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MDN-<"Y@&ABSMIKJ1[(\?QWO>W.7--'X)WG)/64.?,C\*SS4?JKZ G1K#:JQ
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MLU&>6J+>4[&KEJ&1,4,:3G4K7;66$@B:77$&88_>DSC.F=<8QC&%F"E#J3R
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MFS]"E<E9-9[B>_=-O?R85G,TF"/CXQMGV:8TU_>\>X[M'XPPGG[_ /[<G_2
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M^#I6U9&F/O6'<:SB7 ;I$DLDK6!K=&LF#VLT'!K&[I! "G??A>)OOD@+W2<
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M'11>FK4(,A*F&,Y_F@EQV@E0)O,:(NV@UGBT+8*QCYC8B U+B!PT.Z[B2SE
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M5?QPEPQK,#1\3:U.0!&%7 JE@9NX;"<0D$WJ.!5P!7O69>58 86:_P!_74+
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MLSU\.^Z,JY-/.1\@UU$4&P$Q)(W -1(6'>U#A%((R7:-):"7-<W=#^]/'0Z
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M3#8A+C%*&L<6%S',<0U[7-.K7.'%ITUU&A *I+U&IDZDU&]"+%6P&MFA<Y[
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MD<=--YVI].)[',=EZ6CW-<\@L;O"-@9&W1LH:&L:.#6@ G0G4M;IFW25AN:
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M6M'@ $7[R>DDDDDDE6B;L<[$6)9)Y]G*$LTKB^223EW.<X^$DS>]H !H
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M= ?@CS[FYV&+Y)V8=P"$ JI3XAXX03<^T>(ZOE%T6F/!;6Y7 5HY.\A9 M2
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M6V@S9./D%DO?\XL,3CXNWRJX BNN)B<J;0@-8$6'SOQ3N-CSQ-8.?]?_ "_
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M'KE>X)KF=,UOX:G0ZM"X:%IZ200YP()>Z0D$'@=YSCJ/ =.C@H-NV&G4/'0
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M)FR(KHK74_5V)<ZI4V*-8W3&=JZXKL]KM'(>M)=<45=Z@)$E53HRZ@CL*$&
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MJRL30W!+M;M9>GJ;?2WE1GRPVC@MO.:&M+YK2V1F8(JGJ]:69-K[37R&R3F
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MNQY8O:)^4_1/T48_VA?\1XY_PW7X?))ZB=RNT/BNQY8O:)^4_1/T48_VA?\
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M&#OV[J,Y(MI^X)G$JOC6&3%5\./3[',C@Y'"ITJV-M-IOF@%8-T^)-)C[O\
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M9F=58<-2-UI%I_84WXB%Q:E6N)1T1%:WE#3*$CI?+I6(P)*W0OQ70Z1:F=-
ML^*>DOEAP^]()?04+,-@A4W*WH(=E0IE83SUJ/#3X_\ _GYNG1%=]$Z5ZSN/
M,QKIT@'I]HY7)T&>V=5;6*HP*+;^6BOTM>FMR=:BA21+!4JFCH5P$[-7GM)K
MD'-'5U=J=;"J;M;:$^1]!'3]_P#GJ?\ +3B$71;TFU.UUCA=1.Z#$2/TKHDS
MWL'2@BYI2)DUXZT\87]U4]))?9M]/H>SZ"A)8]=(HX$E96P1Q1ZQXU\@?M]O
M[T6Q_A%"GQ-F"; V8M2,Q28'VFQMM#B;W,_"S+KIG7?,6-_=S)C3;&V=?;C7
M.,^S/A%S0Y%'ZFQRZS7]P.H(7#,?DP?9K[>R[=;9EMKPFNLO6XZFLNUOL7*9
M5A5E7+3Z_9N255-35JBS)$NZ<V-/ J!(H!?4?7"+03V4E(9DW_=Q#O!7DZ&6
M5>CL@".P'MZ@:<?RK2!_SAJT@0+:VRKQ1GLT^J[MO40&2<G&C(KJK3[U;I[I
M5*T3/8VM9G[5UW2PV:Y5?!&TM4_/^3%5KVOVCSDR#2KR^G\V)W2;-(YJ*P2V
M$Y7OK<3%5I.>GD5V.!NUG<?]-C#J,_3713!DJL/J16\IU;4JZJ]G7+K06.@7
M!\Q9*;IBJU;J1M<6GKZFU/LY$ :Z9\6XK<%LWG(K01K/4HA>8"7C7AC0K-U&
M![&HLDTTKVE5U'ZB/3?"OTFM8[^6R-=7W++!V5Q91'+MTI/!IT F0MQ]7\5M
M(J'^8'K?24ZHZL*P_LMS:Z\VLK P.JUU4H!8M:;3F5_YPY6K:[9R?HJVPE6T
M=69\S4RQXE<X+3J<+76OK[01=,/"+33U'_SN2_U<A_O-EYLG8S\G6?UU_P#
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MM0M#BXUQ%CFH>LAMO%9BKW1&(.M=M;%$]%1@@3+: F@[CZF>9PVN]7*&XNU
MR$!3P86%ZU^G+%"JPN CF3-<G=G#T<BFS/7E30J,ZZ)-ROK\%96Y^J*"CJG*
MLDN5-@4W%^UM-.B8;C[/XT2.DGMWPP'Q1*^N<U@RP-E S,R56T^CWT5PMO68
M@5666F:<GZ^XM\%KOJ<BIU^HDN[.)5^>LZDK9WPM&N^8.'K[S%VKK>FD21X!
MLZ$^-D"RUWQN)H1;E^$3PB>$6OJCJ5HU]0%HY=;Q%E=KTR&1WRG;Z&P*)OZI
M0%S^.V/_ +W&L1*%697K9<IZJ7SMO5TUCE%T16U.W?*6IXJ8BQ$\]7)5<['V
M;GC>L#Q).13K)1BXM]M'W1L6*G<7G2UNDQL6"Y%*Y4W7K0L-_=MF:U+3*^VY
MWL6.1K<&#VLO>^/Z2/\ )%,F>M1("/9)9>4='GGIF]?46H=9BMNI%]RMO>+=
MZ=*M55PJ9V>VL<KKH=-9S1,$"H^(.N;PEL8!'F)*YJ17K0O5(@O70JUSG-"Z
M%5G-AK3%N1]T),+-ZQ8$ZU(\8TBV";2[$(;+]!L"UX N-Q&P-2SBN_I\"-N@
M:-R+:'PB>$6FGJ/_ )W)?ZN0_P!YLO-D[&?DZS^NO_@0+3_9$_*M+]GM_F;"
MUZ\R]:_3PB>$3PB>$3PB>$3PB>$3PB>$3PB>$3PB>$3PB>$3PB>$5XTFDM[R
MWT6+-/AP1^Y(Q8R:;9&7C9VSC,DF<9Q\2:3V;:C#:[8DGDQG]_2+2::*VY3*
M5\77,TQWGNU$,((#YG@= Z=&C4%[R-& ^%Q:UUXPN%MYNV*U8;L;='6+#@3'
M7C)_"=T;SW:$11 ATC@>+6->]F_U6K*NHI14BF/;48?WMY)9=O?G*)D]GQRB
M-O9C&99MM<9SC7&L<>N-(H]-(]--<:EO7I\A9?:L.!>_0!H&C(V#7=C8/ UN
MO#4DDDN<2XDG?&,QM7$TXJ51I$4>I<YQU?+([3?ED/ %[R..@#6@!K0UK6@7
M#Y1JX)X1/")X1/")X1/"*GMOY,8?Z&1_LMO"+#_A%KR7?[A):9UJALB)K%AL
M@%4KUIF1RPA*G 2ZZ6>W0C;[.=H[+ GJ]4T7Y:XV&6Z7 R2''S$2YLE SB+"
MXMN.98M5;D>0I4)LE=QS;;72V:LL^*Q^,?(T5 Z@^UD<D9^UM))SBXVO.XZ>
MM;FUO-M%F7Y9]6E<Q\N*R.3KXC'99]!S(*EV"MG,KF8X7=O%N392Q6(%<V]8
MJK<U,^/[XRM;HUHU-O-VM9E!V!.2'PF(/JUZ%B1E#0*P#TC$NML<L\MY\@NK
M$;-66 E6W&FF%KD[LPJ;VY4$2RY3#XG&Q9D30W(71716Q$KKD<DEB6&W!%?@
M%<5F":I2B9D(9,B'L;)?94BC;^,QMGPF?SF7FV>,%BA89/CNW,_$VA+%'4@L
M4;,V,M=M&X_D+N2F?B[$.),;WQ8V2_-*_7M.1UPU6_$DT89S:F@(#%@':'(M
MCBK+L>G0(H7;:.M,S9]RREX?QD6B@N147:8CSY))-1)_X^*36AR6%CCR\E7'
M5YIH()<=5EH.R%1^4DN/J5G9"")@BCFEW+;K,;;$6/=#"UH,C.\<#<<1M%++
M@8KV6M5Z]BS!E;L639B[T6$CH,O7&XNU.\SRUX>4H-IS.J399EBRYY$,GWQC
MACK'2NDQ09&+W4A,5FU9::0LJ\2&SM*SH72G-1H2Z97LVUWK; E)7V![S236
M8T D]7N2(MW7.%DE\. P+GA\3;,L%CM^LY\%Z.6OCK&$P-7)YF=ECM8B_"RW
M=AAJ$%D4T<-AL<LXGJV&XWW3[3L9R4KJ<-FJ<7;#+6.D@M9:KM'M/=PVSU5]
M4VP<78EHX^Q8OAP?/7EGJ.E@JFO=JN^VGLEBJJ2^6.,A:]K^(-]* _BKK(=9
MDU8!8&EI.*V%8'?6:NJ &1"(F$,Z_:TV:1D *4,GE';@L=LK1R-O#471ST[F
M\#FJ9O026.2GFI5\=%&)(8A5R%F:2W)<@+)ACL>V":2.2TU]::.6VVR6)H[0
M9)DM:_C]PMV>R#<;:BJ">K!D;66L2F&Q8-W%4Z\5"&A8:^L<ME'6JT,L5)\=
MVOL>CF,(2)R&,D,S"=6OF.E&BW@'E,E$AW)D'@DVVDAAWGVWVBBDVVWCTSKI
MMMG;&<YP2XR*.W:9 U[8669V0MD<'O;$V5PC:][0&O>& !SF@!Q!( !6S*#Y
MI*-*2RZ-]B2I7?8?$QT<3YG0L=*Z.-Q+F1N>7%C'$N:TAI)()7Y$_/I>OCDN
M@W>";J%Z6^7IGPC6=(;^4;I$P%IEP64M>NVY/M$ I668\K2LLWY/Q#6UD^3
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M@%K"JIR@34W<D9M@.N)A=/;$M71Q$5,63>F$HRA6576>;99/W]G@Y\[@YX%
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M'9T.F^,15=H#Z8UY5L7-*;S*,FD.A^B6H>7G2R;"FS.81-8;G+G2O21DV4V
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M=Y-M8AI!H\>\3F3:,<B#3$<^VF^D$\.-[2XVG:IR6II&5IZS"8[#A^'TD02
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M/2M8VX=Q-Y_Z?HMK/8RMLJY[+SM3>T7J%*:<\&*G -S=J] EK,24-1M3B*P
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MC^$9\IOTIR$_P,OFW_0GRA?^;$?^#)_N^.4C^$9\IOTIR$_P,OFW_0GRA?\
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M?QT#<C>699"GA$\(GA$\(GA$\(GA$\(GA$\(GA%3VW\F,/\ 0R/]EMX18?\
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M"HEC$":UGXP^=5U;$GZL;/7WN!]2H]G+0VRK]II1Y<(==()(2'(3_ R^;?\
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M^R9P/!C+P2*%I[((<?-?Q6GND7LWB?&60MH!8\CYBP"N[B&Q70,VA54H6WV
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M/P.KC^V96QNVQ;.1+\EN>5G)!699<YW\(I>/A_%HE@Z6+D'+XTXEK^^Q5,=
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MD#:RN=M*T$Z,-X3T%!]U'LNMW.J=1AFM:UH%6.>0<JYFJKM]JSUAC==UF1S
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MXOSQ\_T+Z;UQ\.%8R!>;,3RE+W"U&!';J:/):D^9B(\V,2<EK&,K%Q%%#/\
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MV]DD*^H::U63RCKLDB8_E'![IV0;G) M#GG4.W^5UT#-2?O>N]WNFG?B :"
M=X[Q<&@;O#CX==[WOBZ>'QJP4/K?)>4CH'6L\R5K.4T>=;31F[+I@XEPL_8G
M"FDRJ*,MJI-/@1@UUK:KRMI8-X;W@*?#&&5P=4P:WMAMK.ZGNOCBY0F60%Y
MCU8V$%^KRX/+B\-87F,1G@= \N[U1,>A:-27.&NFG -XZDG774 :D ='AU"V
M?X'U@7NO%>7=B#60I(>DTE!;LI!V\3^-(0X!B)+39<PAKM&,JDO:=?.3]/ W
MWG&D^(&+)C>#2GGB,,TL1.O)O<S>(W=X-) =IJ=-1Q U/ ])4CANN<W770D:
M^_H>G]_2LN>>2@GA$\(GA$\(GA%6ZW_+ZC_3Q_\ :8\JJ/XY6_WT?^(*>/\
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M9?\ 4XO\<BRQ?/2VWO?YEQ/>@#EHKE8KK=5Z-33\K&\=BM7)=^)C:/;";;V
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MVEQT:&M#F]\'][ OU!&AUX $G70  '])=H-3H.@CB'<-V/*12)X1/"*MUO\
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M:'.A%(A<H4 @UT".V=0GCK3_ .XA2#>GW<TYD3\4>7Z=8CB7,A5A0>T?73Z
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M!U!T(56EYPMF.:'YLG0M)&M2VITP\70;9$"(%M"-!EPK!T:ZC*[;C473?6V
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M?G\/0BGEU>_$^$KBFRV>VV5W>A^E^GI>RYU3H_34NH;OGX7ISYMKV]S/:WH
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MJ[)6.GKBR XUS-$'1B<-<8B[E "6Z+EN%T;9HG31F6)LC'2Q!YC,D8<"^,2
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MKF,W^3W)2R1E#D(+=BOR-.PRLY[P)I'-D+S!H[?CB?&]CH9'G=;RS27L9O\
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M30@KVCECE!=%(R1H.A=&]KP#TZ$M)&NA!TZ>*GP%'5(I*AEG>Z4;$OPQ^^=
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MB_A2?SXZY_52N_WN9YMO[E[\M;5_LO'_ ,W,LJ[&OXYE/U:#^*]93[EVSO\
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M1P_#C^%H5F76/X>GN8U]S7V$3%;KN)=)\(4N)HUF$NDV%8.)=$V-,Q84Z2?
M]_59B/.8\ 8S@7W,YT^%[N<X\(OD-9K8^5FP]?20;)?CX3[0J@(LJ<$[;;DX
M69T'UR!\QOMMO/\ *_"^+MMMM)[V<YSX10M*G5HX(!8ZU7]!AC_JHP^B9=K
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M/MS1+S1AT@7-OG8GIEGH^IO 6 I 95CS#('8.IU*/J;?.V_U J.>'24V1V'
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MIWM=0+9>RU:A(R*9LSG/9R@,;6.&Z7.;Q+I&'75I\!&FG%8Z_=B\N_ZIN_\
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M/5/R^AR6:VJE"4VRUU98*N+ORYR0T NAU O]Q"XU$@Q:_F&A4SO/(Z,ZN)Y
M"\2Q3] 6ZR)3V]0C1OM]OG1;']DM_=Q;/O0JDD9V!0WY0,K/=UZJ7E5HKZ#9
MK #4"7YMQ!PG$&1+@+ )9UT//KI'>JOI6[,:Y!T6D*[%72*W9+;ZG+WQ3L'S
M-1:UFZ,^EUWGG,%PP3NA.ORNN%KJ$(_36EA!DLCBO.0N>W<D^W%J5F2^>/*8
M]&B52.U1<&Q%C:"L>H)+>1Z?H_[&]MM><<<FIS6%QU#;D:ZM,.W7SHO91K3=
MW^FU2Z2L0\4L%7XFL+O4;WISQA3@'Z9+7';8UNK?;[?;1%F1YT;I2M[Z@I[3
M6NFK3E/&Z4-2ZQS"K=)Z%7V%I7;W=BY:<]NL?,!43*PV J]4JKFP3)Q'*_[/
M*:&+(42(EU$169T9KW^M<7X"F2XNC&0.3E<=EZ(C0](OO576]5Y58[,W)O/-
M/MBM-4TMLZ16ZE539[#9C!)2K;.5?EBU.,Z!E(K/8=M]:(X]CF*H,@+I/57$
M+&L*^.7]LKTN:.\\[5JP:#>%^MB%MA'0Z%!UNT)VQ"2>AT]LWY>FN#L+*2\9
M/(KA9=B]6@["X%%U&577 >AMZ0,%7^.]&NMU35E-M>YZW?UP.%J:J6S/1XZ8
MC6[:5JUW&NT\SJU996@^K 4U]%9"*#.7ZFJL?Z1DR[:W,[(LY'7 ^PRGU2XV
MJJ6N\W2[\5AO,S^R0LXT52*I51K_ &%^(=93S2QH6J])5@V35B(J8Q]_]/Q?
M']O>]_P(MM.$&=*/Y_73NE5L*N-6]=K]FF%S9[,[L(KZVA;62VU^P*+,KQ/6
M,U)XSFKRE:):K0+]/"TA'CK@88B6&'V^WV"+-'A$\(GA$\(GA$\(GA%K[U7U
M$UWE#&S!G5"[VD6@<_%ZMTYQ58:KLOYSSHTVS!BV=Y%8[97&KC2:.D7AEHHI
M2VTOLKJ@XS],^?)KZ]X13FWJ7XG@JQ 1W3);&KOI:PP5KJW;F;4Y^,_L]6/5
MU96O0$GW8E58*5<%3K%,'?:)"JP^PVW"T5&[PD5/=^J#D*HK8(:QPL9Q+8NJ
M[67:(M.L TGLI-1?/1G;P5>E?)*580C4MT-KQ[2"KNA9DCR5>VU^4\(H^/5%
MP[,"N;6XE[2N'L-;#5Z4R][OXVQ4]'&!C9UO6L9L"4-E-TWF^BILY6 *6N.@
M4K=<<5':4>QQ%DZF=!I?0P96=(L2ZS+H8$),ARO>2<36&SUE-<T.WS&8]8MM
MF=5L2%_!%KMF7"QPN)ETCT+A]\BO'PB>$3PB>$3PBQMV6FNNB<CZ?0:XYTKU
M@NM MU52O)9#(H531\A/6 FD2KMXV,(T!),>Y,RV6%C%!B20":$O6&70BT9T
M].?J!^?8/:ZJYQS(<5D[^WJ?2WZBM%@U%OMQ+2QTI==N=\HH92_1ZEHUZI]/
MNA*QA=:@G95AO,UPS#P*I(O*[T]^J57?AKLOL 66<]37IX#W7<NEF"K4M?Z%
MZH[0@YW=E0B32;IFD%-ZSRZCZ="=,BK4F85RP6Y29]: #,M)%F#TX\B[;3[9
M-:NON5C;?%;M2!5'#;+5;V*U>YM:2R*U<C:XE.WY0X7P&VOL:6BP2KOBC+ V
M1BT<7>%^A%NCX1/"+F[ZS/\ G!K7]31_[[=><^]ES\NX[]DL_G+:PK:;\<@_
M5A_%E6H/FJ5CB>$3PB>$570OF]8;@O41TZUJMGU($+'VQC?3?'MQMIOKG&=)
M89=,[1$#RZ[PD0[[PS:;Q[[:YJZ-ZWC;<-VE,^O9KO#XI6'B#T%K@=6O8]I+
M9&.!8]A+7 M)"]89I*\K)H7EDC#JUP^<$=!!' @Z@@D$:%=6>)]H5]83;:2Z
M1+[8J@CR[4ZYV^%)IG.(]6BW.^=MI%\\F<:[Q;;;3 3[X'GVDTW&)*Z;V/VN
MJ[3U""&P9.LQO;E4$[I&H:+-?4DN@>[0%I)?"\B-Y(,<DF?XS)QY"+P,L1@<
MK%X/>Y1FO$L)_26$[KM>]<[.'F9*Z)X1/")X1/")X1/")X1/")X1/")X1/")
MX1/")X1/")X1/")X1/")X14]M_)C#_0R/]EMX18?\(GA$\(GA$\(GA$\(ORK
M^?(]<KIX1=8?PI/Y\=<_JI7?[W,\ZD^Y>_+6U?[+Q_\ -S+9?8U_',I^K0?Q
M7KH3>?5Q4*+8[?4RJ#TEP\J-@!02!+8^?KI7,9G+[QUK>SJX[9T"LS#T<6M<
MZMX/WB^B2HVMF2,Z_7BG)JQG@/LQ;=5)3^M"DV=IHKJ?,^TV3#)S)5JHU&J2
M1.ANET VF^XJ:A=VFU(%T-@J<"JX&6&%^0D%'%H%RD#+.V#4Z.2+&=C]:SE7
M=Q!(J:<KYTE:,(.B6AJDKAY=8BBZW<^3Q D#!=B"/TPI(XSVNS.[$A0W4:1"
MD2$+T6T6&I&A%L56NY++?=Z?17G*.A4QY9*O/T"NS7P?G< >JT3,L&9 )U-]
M?S&V$322'+9(@@9/JN,W5%V<-,N;AESD4'H'4;G4NNHJP/O21^=1<KO75KRZ
M;"NYWZ!1S][3%Y@L.PC(99IM8U]J9F)BBH-M ]Z>XP1$=H1IJ(16BJ]05RN<
M/'J94:TB4]=Z#SYS?;F'<HK2)4Z!!2E/-\W=<'G5< QN9T%LZI3ZVIU6E@KL
M@$N; 2VDG0QU]T^WV\B+$R7UT9O5YM--YPGI%CBR\HE.HCH*TG6')#YE5>\7
MJ_N;57JRK/L8JY-4>'L6W/JLJ7$6;H/UFMQD35;2PDS5DBA#>N[0>PBJ9T:"
MS)G'$];I3;2DWM-4BN_5";"DA4\\&KMT2"O*R,RHUTI-^9G.(R)JC7Y[0Y;X
M(K=9(?3$67AO54.EI?#&%UH5F(NW4Z5Q^Q6I#2MJ[.LYXTZ]8:31$8K<NXV>
MJ&$!&7^Y82*XE(S=T0&C>,9U<.B_.LQ%CUWZ_J='0;-:ZUROJC1RLYTRZBBK
MAT7.@)W-$%I 5U'NLI6_2,  H?EWU/"(3%'CW[<JYUF,"H%ZM-)8B+.-HZ!T
MY)U3E=#@SSN!58^=V^_7]FS%L&)U G-VU 66[=%)"VC$U@82=$41H]&>)=P]
M0V)ALQT46!_"*[N(=2CZYSFH6\A:0C>NJA3[)8$$H#D>% ?;:X!8]$T#!H %
M"WW70GZB%%KMR(-289-9,Q;YQ%@BR[X1/")X1/")X1/")X1/"+"71N T/I[@
M]O89K,)]Q506@WM8AL)BA1T:@@L&[,*F74*#WOJ",8NQ676/Y"58RW LUB3S
M,94SMDO)(J$R]+_,C6(;T.2TH+,JL%EM**SH;#.(Y0/;A<.A7.QG*Y)X2P],
MM#.J7Q3/ 6$6-BOOYUL<.F8!)X"*DF>D#BS7ZM"^7V*PJV9M@*'1NK.T,5HQ
MKC;BK[=E*33$D1@ZNXW N1T]B*,-)VS"O5KBER-4K6!D6.+1Z(4K.]<SOM?O
MS,1[0["98V+J[I-.B65ZQ((XR**:"R,<I4J1FJJ?%*Y5%IAE8L0T.LTMFD7R
MVW)KID1;#<0XVBX?46E41D9-U<7B\74PS:"8;&N;78SF"5"*.0>RD'2T2I?;
MG.JL)@O>(&IU%$#!$/ -&/$19A\(GA$\(GA%ICZC>N7WE/1:$?72'5O0S5]Y
M\?B=$UKN.AW>R9VEW3,( G]$LQ]CIH>!MQK3O3K32'5#'DTLC*&WK3X@%1%C
M33U6=P9!R;U*E\\N4"S6TM)+@N@O8E.N*Q!%Z;]_I55]D#$T%H,T[?;JFS9%
M3N8(6_)WDVR<=AN[K%6(KOH/J8ZQ8^RUCE=@YRE4B[%W)18+!,:,BTLN]0N_
M<*27:>?K']GB?F+89.45AT76P$-QG#3]*%,:6I0(G2E7HBL2_>I;MX=LNLE0
M0I&,/'Y^[-7E=#7L7""UUFA5\MQ54,=I0-'&^W1K!&AV&)3&+ZFVHC>QZZL:
M;;D0M6=] (KR0^J#IUQZY8N8U6EJ-@%W5DE*@M[Y.X !5)I0_4F59-&:Y98G
M19#E5C@B7=<0XVHTC&+I]<(GK *:9 ]M1%@NR^L_NU@X[8FB^E(N:V1[0.B-
M$+,N3Z^[K5W54A"P6<3DKM8=VV9?VP5O8V$ZG-MC32M!Z*]E;<PK_O3#@O#]
MO\]/GT1=9_"+F[ZS/^<&M?U-'_OMUYS[V7/R[COV2S^<MK"MIOQR#]6'\65:
M@^:I6.)X1/")X17=2*18.@V 2N5P3))A.??FFW][41>'IMKB<\^?&NV(!8,;
M8][;V;22R;1CP:2D2Q1;W7#8:_GK\6/Q\7*2R=\][M1%7B! ?/.\ [D;-1J=
M"YSBUC&ND<UIJ*M6:Y,V"!N\YW$D\&L:.E[SQT:->/222&M!<0#UFY;RVO\
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MR=6]81, 2-"W*U2$&K :3XD.#7"C@CSQC0QQ:D4KIR#DT8P@4?+^>1AKXIH
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M10-FL_Q!X?MROEP120.7WQ2Q8OHZZ0EA\0D?3Y?WIH\;?+SN V[_ /!6UO\
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MTK#>:,=3FVZ$,H]JWAH1-% NRYP%\[-+'$-\7??77)%[VZQRS0R==OTOG^K
M6H[7\D':Y5W4P>AZC:F;7:<;++$\51U#WT*VLDFFJ; V^L^3?A;8WR1%_6>5
MMB:H$JZ7S]F9?!SC*,(ON5<-)N8BSYC#(JJ0#,I);$.OR*5@Z=1H9$)\L1\Q
MM'\&3W2*2$[7QH\%&T ZWS(U99[!]IUMB)?:J2#8;5[\&GVTC+A:[CMK![Y(
MVGT8"0AC[Y$&ORWMECQL1#>U\:7!V)BPZUS(!?3WFM8MIQM\JHH=7LFTQ ^M
M>L1,[6.%(\VG$*@U4L]Q3\S#$1X'SO#)KJ13Q_6.6*C;0N:=*H"UA1UX;:Z
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M9CDEQ4C#MW&!A;-F*&67"&>71K\.*3?Y3W=-LX(IH^[<_59MVK3I'.%NW/\
M9;K?,'WRJAYI.SF?051K;L$-8\UO9J5)&,MPY^2R=/OI"+B63;77)%$WN-$C
M,,7[]#YYHP7U';H!X.]YJ^I@-#T'C,WNQ@V6F)AJCH)-"5M9)M-$VH\L<^3<
M1;Z[9(B^XT1N955ZKHG/&9][$,84@%?>:N:9<@%V"=F!M5&&:2S6$0#4(S8P
ME1H9"+@0G,^^F()?<(H"Z]<[;J!+ IZ9S5HA8$FA@.UU_J9J@TM9\O\ 411&
;0S:4,DE?\X)\[!#-O*)\T/\ 'UC^/%[Q%__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>g98473g53f99.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g98473g53f99.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_[19@4&AO=&]S:&]P(#,N,  X0DE-! 0
M     %8< 5H  QLE1QP"   " 0$< E  "')R,C8T-C$W' (% #5-:6-R;W-O
M9G0@4&]W97)0;VEN=" M($E03R!P<F]D=6-T(&1I86=R86US(# W,C(N<'!T
M;3A"24T$)0      $!AXZ)PG9:$FP@U%<#"ZD0DX0DE-!#H      .4    0
M     0      "W!R:6YT3W5T<'5T    !0    !0<W138F]O; $     26YT
M965N=6T     26YT90    !#;')M    #W!R:6YT4VEX=&5E;D)I=&)O;VP
M    "W!R:6YT97).86UE5$585     $       ]P<FEN=%!R;V]F4V5T=7!/
M8FIC    # !0 '( ;P!O &8 ( !3 &4 = !U '        IP<F]O9E-E='5P
M     0    !";'1N96YU;0    QB=6EL=&EN4')O;V8    )<')O;V9#35E+
M #A"24T$.P     "+0   !     !       2<')I;G1/=71P=71/<'1I;VYS
M    %P    !#<'1N8F]O;       0VQB<F)O;VP      %)G<TUB;V]L
M  !#<FY#8F]O;       0VYT0V)O;VP      $QB;'-B;V]L      !.9W1V
M8F]O;       16UL1&)O;VP      $EN=')B;V]L      !"8VMG3V)J8P
M  $       !21T)#     P    !29" @9&]U8D!OX            $=R;B!D
M;W5B0&_@            0FP@(&1O=6) ;^            !"<F1456YT1B-2
M;'0               !";&0@56YT1B-2;'0               !2<VQT56YT
M1B-0>&Q <L            IV96-T;W)$871A8F]O; $     4&=0<V5N=6T
M    4&=0<P    !09U!#     $QE9G15;G1&(U)L=                %1O
M<"!5;G1&(U)L=                %-C;"!5;G1&(U!R8T!9
M$&-R;W!7:&5N4')I;G1I;F=B;V]L      YC<F]P4F5C=$)O='1O;6QO;F<
M        #&-R;W!296-T3&5F=&QO;F<         #6-R;W!296-T4FEG:'1L
M;VYG          MC<F]P4F5C=%1O<&QO;F<      #A"24T#[0      $ /
M     0 ! \     !  $X0DE-!"8       X             /X   #A"24T$
M#0      !    !XX0DE-!!D       0    >.$))30/S       )
M   ! #A"24TG$       "@ !          $X0DE- _4      $@ +V9F  $
M;&9F  8       $ +V9F  $ H9F:  8       $ ,@    $ 6@    8
M  $ -0    $ +0    8       $X0DE- _@      '   /______________
M______________\#Z     #_____________________________ ^@
M_____________________________P/H     /______________________
M______\#Z   .$))300(       0     0   D    )      #A"24T$'@
M    !      X0DE-!!H      S4    &              )8   %AP
M   !                          $             !8<   )8
M              $                         $     $       !N=6QL
M     @    9B;W5N9'-/8FIC     0       %)C=#$    $     %1O<"!L
M;VYG          !,969T;&]N9P          0G1O;6QO;F<   )8     %)G
M:'1L;VYG   %AP    9S;&EC97-6;$QS     4]B:F,    !       %<VQI
M8V4    2    !W-L:6-E241L;VYG          =G<F]U<$E$;&]N9P
M   &;W)I9VEN96YU;0    Q%4VQI8V5/<FEG:6X    -875T;T=E;F5R871E
M9     !4>7!E96YU;0    I%4VQI8V54>7!E     $EM9R     &8F]U;F1S
M3V)J8P    $       !28W0Q    !     !4;W @;&]N9P          3&5F
M=&QO;F<          $)T;VUL;VYG   "6     !29VAT;&]N9P  !8<    #
M=7)L5$585     $       !N=6QL5$585     $       !-<V=E5$585
M  $       9A;'1486=415A4     0      #F-E;&Q497AT27-(5$U,8F]O
M; $    (8V5L;%1E>'1415A4     0      "6AO<GI!;&EG;F5N=6T    /
M15-L:6-E2&]R>D%L:6=N    !V1E9F%U;'0    )=F5R=$%L:6=N96YU;0
M  ]%4VQI8V5697)T06QI9VX    '9&5F875L=     MB9T-O;&]R5'EP965N
M=6T    115-L:6-E0D=#;VQO<E1Y<&4     3F]N90    ET;W!/=71S971L
M;VYG          IL969T3W5T<V5T;&]N9P         ,8F]T=&]M3W5T<V5T
M;&]N9P         +<FEG:'1/=71S971L;VYG       X0DE-!"@       P
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M9#LK'BRLM>'5$;F^D?3V._==]/<M7J->7;BFO#L%5[BW:XF._N]WTOH_N_\
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MP&7"1;]&?Y-EG^>N;SOH]3_].59/_@ZZT>K_ *-_!_-$S#O_ "2Y+.XZF?\
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M &( 90 @ %  : !O '0 ;P!S &@ ;P!P "  0P!3 #8    ! #A"24T$(@
M   !1DU- "H    (  @!$@ #     0 !   !&@ %     0   &X!&P %
M 0   '8!*  #     0 "   !,0 "    '@   'X!,@ "    %    )P!.P "
M    "0   +"':0 $     0   +P   #H "W&P   )Q  +<;    G$$%D;V)E
M(%!H;W1O<VAO<"!#4S8@*%=I;F1O=W,I #(P,3DZ,#<Z,C(@,3,Z,34Z,C$
M<G(R-C0V,3<       .@ 0 #     ?__  "@ @ $     0  !8>@ P $
M 0   E@         !@$#  ,    !  8   $:  4    !   !-@$;  4    !
M   !/@$H  ,    !  (   (!  0    !   !1@("  0    !
M  !(     0   $@    !.$))30/]       (          #_X0%(34T *@
M  @ " $2  ,    !      $:  4    !    ;@$;  4    !    =@$H  ,
M   !  (   $Q  (    >    ?@$R  (    4    G $[  (    )    L(=I
M  0    !    O    .@   /      0   \     !061O8F4@4&AO=&]S:&]P
M($-3-B H5VEN9&]W<RD ,C Q.3HP-SHR,B Q,SHQ-3HR,0!R<C(V-#8Q-P
M     Z !  ,    !__\  * "  0    !   %AZ #  0    !   "6
M   & 0,  P    $ !@   1H !0    $   $V 1L !0    $   $^ 2@  P
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MH-DM/F9LCP+$+TV88]&=#H,J-;8_7SRY'20WJKXE1=DD.LZZ*]?./#DA"_\
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M9$3^'\HO[?C_ $?[>5J%6WC%&^DCVWN0/RK7([VYD$%W7VLG6!OMWL<O9SC
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MK>"H_+O\-<3Q7XW;_>=TITD^/_'\GR_^;FL_V^\4;[>?CQ_!Y.TT_E_@[?\
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M?;V[?7VR.]<T( . RMV4Y&0 64$KZ@IRA.K8&NRDJS)AC;[?JIU'_P 3Z?\
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M;Q7B5M/."2]:$6\$4LS)-N4FD5"((2D9$D@>=H^HD?JZ(D8$!2:^V_%K\O\
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M6VQ[*K.S'.%1?=FU!( R .Q)8JHRS '$O;R&QA,TNQRRQQ1( 99YG[1PQ*2
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M_'ZRS@H,@FI.?)<4 J  #   ^P&!W.3[?<]_YU)BS$LQ)/L2QR3@  =R2<#
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M+N[L%1$499F9B JJ 222 !W-21'D=8XT:21V"(B*7=V8X555069F)   ))[
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M, NQX.1.I8U';9'4LEW4>(%T84J9'0(1V! .5>TJ:!S#'*G;W]QD=Y/\B/\
MB']HG@N)XKQ%PM_QL4:3\UQMS<<D\7ICN+FVO7MXYS%[1S/!TQ*1CJE5E8%F
M9W^\?V:N?YCEO#?.\=R<KR6W!\E:6_%K+ZI(+6[LA<26XE/>2&.X#F)3GH[-
M$I"JJ+@]+:Q741*;Y)5JTV%'FI%[KZ6RDQV6/V^/]WV.8]45ZHKU:UK4<C$5
MJ\LV;_T>D=1\?VQC3I;G3'X+,^_3SC?;MOC;&%S@ 5U@HH^)2,(4R?!,K&?3
M\S(YN%!'U/?74;=/.N07QL<UF'I0K(A,PM\C?'&6RQB+7R*:08(I X$^::4Q
M)HQ'&0/S!#C.2(1['*!SGG$C3C$477OV:O#/#<]XHY>]Y6(3S<)86UQQL3$!
M$NKB>1&N<'YI8(XOROX&<RCU(C+QO]J+Q3SGA_PKPUAQ$S6\'.W]U;\I*BDR
M/:VL,4BVVP/HBN))1UNV76,1$Z2.C]/6;5SPMA5*I6M\6QAI ;"$P=JTC_'W
ME1PW$5\M/PQ\9XA,_"A&U4?Y?:?X7Q_E+R87!=H7G5'W4!#&3TXV'RN7P.X^
M;8!,&OAO\2Y#S=G"UMHLRP%U,;9?J!3*X)RT:Q;'(/RZDN2",3!=IYX*\LNS
M?[GS1?9"0F/9 :!I?XU];$DN)"1BF.1Y7,*@W^:>I6HR)XSC_(VTYN='D:$-
M*7&K=1U$J!#V4Q*6.?==29/2#B0Y+D#?7, MMTB68H@4AAHC&)R^?4)6"C'U
MVPGJ]Z>+:6>?:IH_EN,UT@'E;K"C^V I?:Y(S', V,WY7@JC4HG/&T3VB5%>
MU67WXGCEO8(!,P$D4CF$R LQ4IIA\9&X9VQG+",Z8 .,=.5Y%K&XG,*EHY8T
M67ID*JMOU,H>S=,JBY]AN-\GWG;#:&=?9:5?8^"I'RE^\-B@\K;XQ48C$0@7
M :@/+Q.@A-0R^#N_X>U;5MQ=A)>7L#3,R0!.FH<!L,H9V+X]72;T'Z9^?O5V
MYY._CL[*=855YRW4)0LO9L1J$SE>LOK'U_@Q0FU<^6WA.1B#>@H;6TB0F>$]
M3A$]I'(H_E*Z?YM,%0E8@VE8T2=D=YVUXVP-A/<>9V>-I@LFXT!1V6-"GU,H
M"MD^H[@KZ<9N-R-^.0@MO+8CD6$LA0ER'1&E</GL(F+*1W U(?+>WNGVCG3Q
MWK_);56UY9*/^(!&T[D,$2S&M$)B. %I%10G]K?-&$=W:PJ/G=\9Q\+6(2X9
M5GE5)"9 ^\9!)F4XU3U )M@QC<' "G,;/DN0F6^,EODV\3O&HC9=90>T# G9
MCJ2^O^(0A&?4N*>W:.>)3/'\Q[F+-8U+Q8D?W#5PW/\ MZ/0"1OX_%3-<HE.
MC6N8C_6J(V\>)X_\0%OU6UZ!DZ'4]1<-J!O\V-<OIG?MMG3(JQ^*\@>/-QTE
MW\QTQ,(_0$UV/Y?MD-A-\:8.N-^YB2-K9XKZIZG;'486.:-((D9<(AB#609K
MQJKVE5J@5(JA&A!O42,)^4A'Q7',EZQN2PAD=5?=0(5"J07&/7ZB5+?*VNJ
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MGOZ,B-X)DQ_=_/,Z;E&%6WE9>E*0RQK&A>,.2%\C)(MPF?WL%Q(C?\[Y<(V
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M/2@N !HGDKB6,0KEHX"+*8')U9NLO4"DZ2K=%F9761:>O>2,DY;KQ(W4/9I
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MPP')"HT)CL(8U&$,71;L)F8T5E,4Y7Y3) >R]_)RLCNXP,L'VN'9N[!]P,E
M*Y2?50F6TG4>H4E :!'[!R.3D2" !GKS8D&X9;5\MXOXVK5PV0@4Y'JY+*H,
M.6PL@0A%YOW@5(5Y'DM&+8M;9+79F.; !##(@;L1,Y=IP,=*=2A"EB*V_P &
M-(;RXV&N;61I@%&/,FZ0.K$>VBA1%G/4C.V2!DR_T@%$C=I"E@%]NGWV(A)(
M?$"?V7-?#N;7'J\DAXWDB#5T:UM0/8HFOL*F$)QD*0()$?B-MI9,C-U(XKA@
MH=EQ!(4AN9 @(5R \4+9V(BFD.N S+E>+\><XW8#1HK@$E0<R(\,D2YP=1Z9
M'![>M%&<D \FM4JUN\=9N<\XVMVUA3G$C!=(DC1,RK%5\:.QKWR)#$3R"!K'
MN,5&C1CE=XKT"]_Y+N\!2?P^XP'8(A_N[]F<D!5/[S$@*,G(Q6W7_P#R9>=V
M']QN.Z@LP_N[]U !)8?0 $D]@*^MQT\#:@S:J-%*V1DEQ'+&!$$L.3/KZOV:
MW@R7-<T(*ZSJ8>*'@RV&&&:5:JO>1$M"Q7_/HC)F'6=@5M8&#LYW6.6;'*2+
MG):2*9[Q9$P3&O6E _)##CA8:'0 YFD!4*-694_NBM]D=%@*MD!B40G+ZU/V
M\JG;#JB17*2JG4:3P'CQRG255W5_4&S.Q[MCN>.1]IFOFRGME_-6/,LI0HSU
MBF?RU"DYDF5QB:.?ILK,%*306\ZV,7=P"O6C"*"FFZ1(6&ZBIR&/6,K\C1[
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M;-A0[MSG1)%7&O+J:]&/C2#P[@C?J7++CK^8G4*KY'Y4*3<;&F&(DC<I(]N
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M\XK2AT5LMZC:"V92IS(GEPI(93449-#J%*[VH[J >@0A#$8'83&4,#V5A*2
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M!UZ$<UVHVSMHL<15QKZ6U"@$95<L"#V-4,.PI;*6X@EA,-.MPQX$B5Y&;#?
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M.,Y1"[%$/W52<+_D!011*[R+'&KR#$CA%#./L[ 9;_,FH8,'Q./72:D5)#;
MF$862)WM(\I!^7J(IR$=(:\/DY N85JB1SD'XHYW>K3SM()6FE:5<:R&1S(N
M/;#YV&,GV/U/W-4$,*QF)88A$V=HQ&@C;/OL@74Y[9R#[#["N1?U?<?I:33F
MH6U5=&A>&QY<='!9V(X/Z8MR^!"N5Q"_S%5_<KWN\E7LOY7G1_AJ[ORG),[L
M[-9*6+,S%CUX_4Q).6_4Y/OW[FMJ\*(B74ZHBHJVNJJJA0J]6/TJ   /K@8&
M>_O5N?1KJJZ72;PL),0)YE?>X,D(Y$5SHWR*W*&F4;57P1SVM1%>K5<B=T:J
M=U[Y'Q.9A+Q"[-HT=X638Z,5>WP2N=21DX)&0"1FKOBM%,]DY52XBG4/@;!6
M>,E0V,@$@$@'!(&?:N0&G B/O[4\<K$>$VY,!"4:_P!UXBYQ4#(Q>W9>SF.5
MJ]E1>R_A4YTCDR1PO($$@CC+H@@D$$6LA!!&""#W!!R#W%;3> 'CKH$ @V4X
M((!!!@8$$'L01V(/8CWK[$7X#AY*\-6ZAA_# 99 F)[FE0SD1KR.DM*DDBO:
MUK7H0SFO:UK7(K6M1/FD7%P)#,)YA*PPT@E<.P[=BP;)'8>Y[8&*Y.8(&C6(
MP0F)>ZQF-#&I'U5-=0>Y.0/<D_6IJ;AF+6!8!9=)!*^L&P,+^6X;!!$OD,*B
M$Y@S!&Y5<P1F$8URN5&HKG=XK-*BNJ2R(LG:15=E5QW^< @-[GWS[G[FJM%$
M[(SQQNT?>-F16*$X[H2"5/8=UP>P^U>687BK)DNP;15_RIPRBDO<+S8]DAJM
M.C0/<X E,USFE<$8W$151RKW7N,LK(L;2R&-#E$+L40]^Z+G"GN>Z@'N:"*(
M.T@CC$C@!W"*'<#V#-C9A^A)'M]J\ P?%(U=+J0TD1L"<]I)05]KW&>-?(3E
M.\CI#5"O=0^!6^KNOK\?)>]3/.TBRM-*95P%D,CF10/;#YV&,G&#]3]ZH((%
MC,2PQ")L[1B-!&V??* :G/UR.]>"X%B!X<. 2AA.BP'O)&8B$:YKB*BD]AF$
M:8Z%5&J1IR$:16M\D7Q;V"><.\@FE$D@(D<2.&<'W#L#EA^AS0P0%$C,,1CB
M(,:&-"D9'L44@A2,GN #W-3*8=C"68+AM)!98QFB: [!JQH_0QHP.:!KDC^P
M+&M:(JB4K&M:C7IXM[4ZLHC,74DZ1;8Q;MTRW;U:9USV'?&:D8XS()3&AE"Z
MB4HID"_PAR-@/T!Q4,6$XH"1.E#HH#36(RAEJHU<P@SIV,Q@7N<("%[KY_'8
M)7+^>_!EE*QH992D7^$ID<K'[?("<(1@8*X(J@BB5G811AI?\1A&@:3';UD#
M+^Y^;.?K4!N X>VN?5)11/A/D)*<-5.I5D-:K&E24I5E-<C%5B(TR-\%<WMX
MN<BR\Q<=7K=>;K :B4RN9 OMJ'+;:_IG'<]N]4Z$'3Z(@A$).3$(TZ9.<Y*:
MZDY[Y(S4>5A.*30P 2:."\-8WUPF-8X2!'Y.>HE]3V*43B.<1PS*1CB.<1R*
M]SG+%9ID+E)9$,@(D*R.O4!]P^"-\Y.=L^Y^YJK11/H'BC<1D&/9%;0CL"F0
M=<?IBHB8=C#;3[RE+!2Q\49[O6O@G8:"1R1_+XR$]:(SVH'V>/X\N.K*8Q%U
M).D&V$6[=,-W]6F=<]SWQFJB.,2&41H)2NIE"+U->WIWQMKV';.*AP\)Q2 &
M>"+1PAAM&*.<-S'E:82N1Z"[%>_U":]$>P8?6P;VL>QK7,:J5::9RC/+*YCP
M(RTCL4QW&A))7! (UQC%42&&,,$BB0.27"QHH<GL2X  ;(]]LYR?O4LNOL,6
M$.O7'X2QA&60Q/YWN]JHB.<Z5[?E/:YK6M<QYG#<U$:YJHG*^8N.H9A/,)6&
MK2B5Q(RXQJ7VV*X P"<# P.PJ/EX.F(NA"8E.RQF)#&&SG8(5U#9^H&>Y^]3
M9,+Q8LV%8/HX/RJ\811'M&K&#9'1$CHX#'- 50HB()QAD<Q&M1KD1K>T1+*J
M/$LD@CD.SQAV".W;NR@X8]AW()[#["I&*)G61HXS(@(20HI= ?<*Q&P'<]@<
M=S]S7I,.Q=+&5;?9(+I\UAF23/$KVE20QPI"J![G1T=(&YS3O:)KS(Y_L<Y7
MN51FE,:Q&60Q(<I&78HI.22JYU!R2<@>Y/W-!%$)&E$:"5@ T@10[ >P9@-B
M!@>Y^@^PJ49@&'#A2:YE!"2++*TQF+[7$4@_/UN9(<59(?5YO0:!*-K&O>UJ
M(USD61N;@NLIGF,B#"2&1RZC[*V<@=SV!QW/WJG0@"-&((1&Y+/&(T",3[ED
M"ZD]AW(^E1I.$8I+@PJT])#?"KG.=#"U""4*D5'%[%$1AGH9S6N.A"/0SD1Q
M$<J(J46>9':1)I5D<$.ZR.'<'N=F!RV3W[D]^]5:&%U5'BC9$P41HU95*C"E
M5((7 [# &![5[;A>*ML&6C:*O2:,;!L(@>PVM8-!,5(W?XWL:-$8A5#[.R)_
M%^.4ZLO3Z/4DZ6VW2W;I[>^VF=<Y[YQG-.E'U.MTTZNNO5U7J:_P[XVU_3.*
M\Q,*Q2"*>&+1P1BM&**<Q6.(AA.<CU"BE>]1!1[6D:(*C&TC6$:U'L:J&FF<
MH7EE8Q@",M([&,#VT)8E,=L:XQ@?:BQ1('"11J)"3(%C10Y(P2X  ;([';/;
MM4'] X?]N2J^Q1/A)(^4C.YO;[^WC[/E>WY2KX)X*BF\59_ J>/XY+S$_4ZW
M7FZV,=7JOU",8P7VV(P ,9Q@#["H^7M^GT>A#T0<B+I)T\Y)SIKKG))SC.23
M44N$8F8T(Y*&O<2N&,,3L)6L8(2JHV$$QS12$8JJK?D,*J*JKW_*\B)I@KH)
M9 LG>11(X60_=U!PQ_5@34C#$S(YBC+Q]HV,:%D'V1L94?HI _2HKL.QA]D>
MW?207V$EI&G.\2O:3VL<,KW <Y8_M*QSFD-ZO:]'+Y/7NO<993&(C)(8@=A&
M7;IAN_<)G4'N>X&>YJO3C$AE$:"4KJ9 BB0K_"7QL1^A.*E18#AX84JO'0PD
MB32,+(8ON>]Q!^7J<P[RND!]2/>@T"4:,1[T:B(YR+(W%PSI(T\QDC "2&1R
MZ >P5B<J.Y[ X[G[FH"W@"/&(81&^2Z"- CD^Y90N&/8=R">P^U1)&#XG*@Q
M*T]'"=#@/<2()$(QPGO5%(ON&1IWH96M]R$(]#>+?8CO%.U%GG1VD6:59'!#
MNLCAV!]PS Y;/8G)/< U)H8618VBB:-,:(T:%$U^75""HQ],#M41V&8LZPBV
MBT<%)T-@61RM&K&L;'8T8%4#'-CD>!C6M$0@GO&UK4:Y/%O:@EE"-$))!&Q!
M:,.VC$?4IG4G]2,]A]A53%$760QQF11JLA1=U7^$/C8#] <=S]Z_8>&8M -.
MD1*2"(MD(H)G\M7L* ZHI@($CGB"$BHBO$%@QKV_N\--*ZHCRR,L8Q&K.S+&
M.W9 3A?8>V.P ^@JBQ1(SND<:M(<R,J*K.?NY !8]S\Q/O4DFO,+2&^ F/PD
MC/,DAR=S^[VM1R-5)2F^4UK6N<U!M,@T:JM\>W)>9N>H)?,3]4+J).K)N%_A
M#;9U[^V<&H^6M^F8NA#TBVQCZ4>A;.=BNNNW_6QGZ9Q4T;"<4.: <M% <2L&
M,4+L-S!B&)RO&QXF.:([6/57M0["]G*J_NJ]XB:55=%ED59?\11(P63_ +:@
MX;]<@Y]CVJ311,R.T<;/'WC8HI:/_L$C*_IKC'TJ*[$,9?:DNGTT)]D9KT+(
M>-7(12,49'N YRQU*0;G,(7U>U[55'/7NO'5EZ8AZDG2#;"+=NF&^X3.H/OW
MQ[DGZFJB.,2&41H)2NIDT7J%0<A=\;8_3-2@L"P\,69#'006QY[FNDM5I'/<
MK'*]B#,XBF T;E5PV@(-K%_NHB<D;B<NDAFF,D8Q&YD<N@^R,6)4?H"!41!
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2*4XI3BE.*4XI3BE.*4XI7__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>g98473g57c81.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g98473g57c81.jpg
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MIE6H/B%!"1+4 ]-2L.&_:V*&0BPQA.)D^T ;:65($K0$P/&Q3Q-A\>[=K_\
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MLOVXBG\O^M_[GQ\Q.U;Z[;/\@\.?J4^?W9']1=;^H?$OZ5/L$[9?MQ%/Y?\
M6_\ <^/F)VK?7;9_D'AS]2GS^[(_J+K?U#XE_2I]@G;+]N(I_+_K?^Y\?,3M
M6^NVS_(/#GZE/G]V1_476_J'Q+^E3[!.V7[<13^7_6_]SX^8G:M]=MG^0>'/
MU*?/[LC^HNM_4/B7]*GV"=LOVXBG\O\ K?\ N?'S$[5OKML_R#PY^I3Y_=D?
MU%UOZA\2_I4^P3ME^W$4_E_UO_<^/F)VK?7;9_D'AS]2GS^[(_J+K?U#XE_2
MI]@G;+]N(I_+_K?^Y\?,3M6^NVS_ "#PY^I3Y_=D?U%UOZA\2_I4^P3ME^W$
M4_E_UO\ W/CYB=JWUVV?Y!X<_4I\_NR/ZBZW]0^)?TJ?8)VR_;B*?R_ZW_N?
M'S$[5OKML_R#PY^I3Y_=D?U%UOZA\2_I4^P3ME^W$4_E_P!;_P!SX^8G:M]=
MMG^0>'/U*?/[LC^HNM_4/B7]*GV"=LOVXBG\O^M_[GQ\Q.U;Z[;/\@\.?J4^
M?W9']1=;^H?$OZ5/L$[9?MQ%/Y?];_W/CYB=JWUVV?Y!X<_4I\_NR/ZBZW]0
M^)?TJ?8)VR_;B*?R_P"M_P"Y\?,3M6^NVS_(/#GZE/G]V1_476_J'Q+^E3[!
M.V7[<13^7_6_]SX^8G:M]=MG^0>'/U*?/[LC^HNM_4/B7]*GV"=LOVXBG\O^
MM_[GQ\Q.U;Z[;/\ (/#GZE/G]V1_476_J'Q+^E3[!.V7[<13^7_6_P#<^/F)
MVK?7;9_D'AS]2GS^[(_J+K?U#XE_2I]@G;+]N(I_+_K?^Y\?,3M6^NVS_(/#
MGZE/G]V1_476_J'Q+^E3[!.V7[<13^7_ %O_ '/CYB=JWUVV?Y!X<_4I\_NR
M/ZBZW]0^)?TJ?8)VR_;B*?R_ZW_N?'S$[5OKML_R#PY^I3Y_=D?U%UOZA\2_
MI4^P3ME^W$4_E_UO_<^/F)VK?7;9_D'AS]2GS^[(_J+K?U#XE_2I]@G;+]N(
MI_+_ *W_ +GQ\Q.U;Z[;/\@\.?J4^?W9']1=;^H?$OZ5/L$[9?MQ%/Y?];_W
M/CYB=JWUVV?Y!X<_4I\_NR/ZBZW]0^)?TJRCJ76>[Z78IQ/9?8V9M\%("R($
M2MR=7U.DH@EG)PZ0P;25 S)$N0J/#C3H'P]U&(SN"69*EX=B-85Z?A3AKC;#
M9&:UQ)VB3<749*<D$6-DX8Q.%;!:=/7D9=]JHS232&.&*>#V=P$;O:#(3NB8
M#Y;B[B?@;-8Z"KPQV;P\'WX[L=B;)Q\59?.&>HV"S&^B:E^&.&,232P6/:&N
M,K#6$8&V5Y&PO/H"^=IPB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G"
M)PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G"*D>(0(\F+"D
M38C$R=[3W*(])9:DS/8IPM[W5A:TNR/9)SA3GLD+]FG.,J]&/T\(J"99:X.4
M000/A8"Q#$2453,*P8JAD:>XIF#(()??1F$Q->2IJ([)PTW)<2I#*EJQG'"(
M%LE>LF"BJZ>"GD@S1"MFE!2D$I@181"TM%0)3,%]_ \T,<6AL@+E^RG0EK2B
M2PTI6,9(CEDKK5@C5-T\%;M4P3)/1*RX4@HL$H'#E,09AF,&4_@B^)B3946'
M)(M1E0V)4EB.Z\EUYM"B*]<(G")PB<(K<4," D=$LT4'"(KLAF(W)*3HT".Y
M+DJRF/%0]+=:;7(?5C*664JRXZK&<(2K/"*X\(J54V$B:T.5+BI(/Q9$UB J
M0UB:]"B.QF)4MJ+E>'W(L9^;#9D2$(RTR[+C-N+2M]K"R+P8,"))&8'CE!T@
MN.;8>("V)T9TC!9E8]:,[,@MNJDQ6Y"?UF''VD)=Q^EO*L<(K0S>*5(M\O7T
M>WU=^^CP[-AGTAFP"7;?"K\A],:.<EUI$M1F,'?DK1'9)O0D0G7UI:0^IQ6$
MY(I1PB<(G"*F?F0XKD9J3*C1W9COL(C;[[3+DI_U<K]C&0XI*GW?42I?LVL*
M7ZJ<J]'HQG/"*IX14K$^#*S+Q&F19.8$A<.=AB0R]F%+;::?<BR_9K5[M(;8
M?8>6P]ZCJ6GFG%)PAQ&<D7B++"C<-! ,3'EX#JG$-SA<V-/AN+9<4T\A$F(X
MZRM33J5-N)2O.4.)4A6,*QG'"*SU*\4J_#Y1>B7"KW45!*3@<TG4K )L8^&:
M&+2V2#RIH>7,C1R@]Q:$3A[KJ)<1:TID,MY5C&2*4<(G"*WDRHL)"=(F20\0
M/8RWAZ>3F1X$)G+KB6FL.RI3C3#>7'5H;;PM>,K<4E"?2I6,9(JY*DK2E:%)
M6A:<*0M.<*2I*L>E*DJQZ<*2K&<9QG&<XSC/IQ^CA%3N383,J+!>EQ6ILU$A
MR%#<D-(E2T1,-JEKBQU+P[(1%2\SF0II"\,X=;RYE.%I])%X(,"'"CH-LH.6
M:8BHG/B$3HRBC,)Q?LVYCH_#N9;<5QS.$(D+:PRI>?52O*OT<(J,G:*R$?<B
MF;$"$2601>T/1R9<? ?:K-?7";/6)QF5(:<0"".$AS9<NI.!XU9"$F;(95*8
MPX1*S:*S=0(VTTVQ K;6#4?,H/8ZR7'G@):+AQ;.9(TN*D2A\^/AUIQK+T60
MZW[1M:/6]9"L8(K[PB<(G"*T$+ !$NH8*FQ Q]QO#K;) E#A.N-94I&'4-R7
MFUJ;RM"TX6G&4^LE2?3Z4YQ@BN;3K3[3;S+C;S+S:'6G6EI<:=:<3A;;C;B,
MY2MM:<X4A:<Y2I.<9QG.,XSPB\<38>9BAV)<7)!$5$U<##[69B8;CJV&Y:HO
MK^W3%6^TZRA_*,-*=;6VE>5H5C!%X1# @A+(0(!0=-G"7&F2L*).C298QYY&
M7&6B$9EU;T)QUO&5M-R4-J<1C*D8RG'IX16&P[!H51BV&;:[O4*Q"J(P8:M<
MNPV4,%BU@,;E38(8M89!*;&:"C"\T81AC)Y)<:+/E#YL>(ZZ[%?0V122!/@E
M8,(H+FQ"0PE$C3QQ&!)9F09\&8RB1$FPI<=;D>5$E1W&WXTEAQQE]EQ#K2U(
M4E62*KX1.$7QA^+GV=KU=\7"E;C?(WMK'AJ/]-VV8]>I5U/4QS.YMER[CV1\
MX78$&FT^AY<T#9Z7%BXN)43DHZTID3\0E)=B-EF:#LT&FCMVHZ:]![N@\W#^
MRPIV#Z][+V9OKM-+.;:UV6A[@\?;J5UTMD:R=?0EI58@6*2'-:]C6^7-O37G
M'6-&%648*5J DTW7[%+$3S2RHM=@=A#X/P\_R)_[)KH&]_2,D:'30DGJ/ ^/
M[+I75NT_915W3JO3U[H6BW]S>.;WLZR6FUTO0^HURW]?TW7]HM(PZ1#^6X N
MS;.64!PB!#9-G06LUC*1H<BZRK6.9DAYTJI \SI&UW?\26C\.IZ+3VT=SNRO
M8WJI7]A6:VT41MV^^ WWFW#:MP!]142!LIRP:PWK7ZO/CUF[!1X.VT8?<:D)
MGLS E0/B*B+N,\=>F*K+(UL1";*0!NTZZ<QG37IU![_@?R6V(;N3WGTUM'IU
MTPG;H@WNS]OJ'X=]MT?L-C5=2@R*SK1O%]F]UXST&:Q9<6$J.UK0ZX2P8LI0
MU,@S+8DL.E"U$8\845= 07:: ;M>_P"/T>OVGRU^_I]1O"HG")PB^8?QIM:V
M#L1W@ZTZ6HFL-3[_ +76>F';O:)74/9VT3*3H,0!(R*C416U:T='S_>)6YZV
M::D,01SH=<6& ]D<>LE/;'N6,:61G1I.I;[S1J._X].\#33K]OBM?=4=[NP.
MM-:>"QH_2G9V'!UWW.Z_:@UM9CVWJ16B6SM$G=9[9I-2M>SXJY8:VP"(?=46
M<7Z\ZQ%["*DPC%I;K)H011*40RP4EH)DZ=03IH>G<>GVCO\ L![@NK ZB!*K
MX_TBRBY5GD$MB>%7?+ ?:.W.VV41$GB^TVD*Q%8J8&PFB82BB%#0\1Z6!ID
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M*%K7F!'*"=22MC.%"<(L!ENK77<\%WA736GJ.5"]E)Z2>^AT\0W*8VM/;$0
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M)9M19COD%.BJW"C9415B.]KU9=MXXZ[ZZ#265I@)B95C."&0'7IWB,?^SO\
MQ7*/L)U"[+]?=TZ&IE0Z[WKLM5NO_4OI1KLB"K%8['535O;/8W7JXVZTB(MA
MM6I NQM<1V:$>Q7"PA/8.3K,4)E.HCON6(!&=F2BR->TAQ+MNY[SW@EH=IW
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M(0G*E9QC&<\D N(:T$DD  #4DGH  .I)/0 =Z@D-!<XAK6@ESB0  !J22>@
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M]B#ZH9WMYOS7&;)K7:P[9%CC:\KO7J;=!U$/[;S0Z\/NQBO6O!#_ .J8=?\
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M-+6C9"W#NINRO9ZP6/:UH,;L:CR)^M^]TL_09FUAI^P!"&J,V6/KDA4=,C:
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M_010K>J#I3=L.LO#-@48SM&PZUG2+"4C3=B5ER=LBKH71B%.AAJD4'XG3X?
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MW+%R>>"R'K6S_P!8V^/9V-Z16X0VO/O&D>@BZZ"'0 [CDA2QL*+#RRPWQ^+
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MT?@&'Q$>9P,A>P(K'(UIKF9;,WV70*3*O.8\")FZ2*J"?MF8@J2W,%Q<V)V
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MO&X'MB:^O$:Z:H$!]@;Z;US3I/V96.M[%Q2F]EQ![%G,RXYJ>M0Q_= X#7O
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M%.L"QA6.%DR^8X\K#[/5?I8M.DHU[LKX*_5E>9GN6)80\EG-+9"V"$S3?PY
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MDR,N-9:<5ZOLV4_K)QCT9]*&TJ_1Z?\ +T^CA6:XD@$_V\%$G_\ 7>_>N?\
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1T3^X>_X3PK,^D/O_ +%?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>g98473g59k87.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g98473g59k87.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_[2%L4&AO=&]S:&]P(#,N,  X0DE-! 0
M     $H< 5H  QLE1QP!6@ #&R5'' (   (  !P"4  (<G(U,#DQ-C<< @4
M(4UI8W)O<V]F="!7;W)D("T@1V5N97-I<R!&+3$N9&]C>#A"24T$)0
M$")*^(M6HN%I'>),'8-E9Y0X0DE-!#H      .4    0     0      "W!R
M:6YT3W5T<'5T    !0    !0<W138F]O; $     26YT965N=6T     26YT
M90    !#;')M    #W!R:6YT4VEX=&5E;D)I=&)O;VP     "W!R:6YT97).
M86UE5$585     $       ]P<FEN=%!R;V]F4V5T=7!/8FIC    # !0 '(
M;P!O &8 ( !3 &4 = !U '        IP<F]O9E-E='5P     0    !";'1N
M96YU;0    QB=6EL=&EN4')O;V8    )<')O;V9#35E+ #A"24T$.P     "
M+0   !     !       2<')I;G1/=71P=71/<'1I;VYS    %P    !#<'1N
M8F]O;       0VQB<F)O;VP      %)G<TUB;V]L      !#<FY#8F]O;
M    0VYT0V)O;VP      $QB;'-B;V]L      !.9W1V8F]O;       16UL
M1&)O;VP      $EN=')B;V]L      !"8VMG3V)J8P    $       !21T)#
M     P    !29" @9&]U8D!OX            $=R;B!D;W5B0&_@
M    0FP@(&1O=6) ;^            !"<F1456YT1B-2;'0
M  !";&0@56YT1B-2;'0               !2<VQT56YT1B-0>&Q <L
M      IV96-T;W)$871A8F]O; $     4&=0<V5N=6T     4&=0<P    !0
M9U!#     $QE9G15;G1&(U)L=                %1O<"!5;G1&(U)L=
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M____   X0DE-! T       0   !X.$))3009       $    'CA"24T#\P
M    "0           0 X0DE-)Q        H  0         !.$))30/U
M  !( "]F9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &       ! #(    !
M %H    &       ! #4    ! "T    &       !.$))30/X      !P  #_
M____________________________ ^@     ________________________
M_____P/H     /____________________________\#Z     #_________
M____________________ ^@  #A"24T$"       $     $   )    "0
M   X0DE-!!X       0     .$))300:      ,U    !@             #
MS0   _,          0                         !              /S
M   #S0                     !                         !     !
M        ;G5L;     (    &8F]U;F1S3V)J8P    $       !28W0Q
M!     !4;W @;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG
M   #S0    !29VAT;&]N9P   _,    &<VQI8V5S5FQ,<P    %/8FIC
M 0      !7-L:6-E    $@    =S;&EC94E$;&]N9P         '9W)O=7!)
M1&QO;F<         !F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U
M=&]'96YE<F%T960     5'EP965N=6T    *15-L:6-E5'EP90    !);6<@
M    !F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
M         $QE9G1L;VYG          !"=&]M;&]N9P   \T     4F=H=&QO
M;F<   /S     W5R;%1%6%0    !        ;G5L;%1%6%0    !
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M300H       ,     C_P        .$))3001       ! 0 X0DE-!!0
M  0    $.$))300,     !;=     0   *    ":   !X  !(,   !;! !@
M ?_8_^T #$%D;V)E7T--  +_[@ .061O8F4 9(     !_]L A  ," @("0@,
M"0D,$0L*"Q$5#PP,#Q48$Q,5$Q,8$0P,# P,#!$,# P,# P,# P,# P,# P,
M# P,# P,# P,# P, 0T+"PT.#1 .#A 4#@X.%!0.#@X.%!$,# P,#!$1# P,
M# P,$0P,# P,# P,# P,# P,# P,# P,# P,# P,# S_P  1" ": * # 2(
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MB)CXF159OLS;\AL$>G8*0W7\[]!CTV?]-*A^\/\ G*OP;2I]5Z?^T<-V-O\
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MGH_I-59O1K[KCG^J\O\ 3S+:Z]WYK &;6-_DM6DC(4:4#>JD.^AE]3JW$MW
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MN$G:]VX R=WTF!W^8FZ?CY^0;\F\;=U9JJ&TLW207%C'^]E3=GL]3WV_I/\
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M_C15Q#L?L+HWWTX]+[\BQM5-8W/L>0UH'BYSEEXS;>L9E74;F.KZ?C$NP*;
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M &0 ;P!B &4 ( !0 &@ ;P!T &\ <P!H &\ <    !, 00!D &\ 8@!E "
M4 !H &\ = !O ', : !O '  ( !# %, -@    $ .$))300B      %&34T
M*@    @ " $2  ,    !  $   $:  4    !    ;@$;  4    !    =@$H
M  ,    !  (   $Q  (    >    ?@$R  (    4    G $[  (    )
ML(=I  0    !    O    .@ +<;    G$  MQL   "<0061O8F4@4&AO=&]S
M:&]P($-3-B H5VEN9&]W<RD ,C Q.3HP-SHR,2 Q,SHU-CHP- !R<C4P.3$V
M-P       Z !  ,    !__\  * "  0    !   #\Z #  0    !   #S0
M       & 0,  P    $ !@   1H !0    $   $V 1L !0    $   $^ 2@
M P    $  @   @$ !     $   %& @( !     $              $@    !
M    2     $X0DE- _T       @          /_A 4A-30 J    "  ( 1(
M P    $      1H !0    $   !N 1L !0    $   !V 2@  P    $  @
M 3$  @   !X   !^ 3(  @   !0   "< 3L  @    D   "PAVD !     $
M  "\    Z    \     !   #P     %!9&]B92!0:&]T;W-H;W @0U,V("A7
M:6YD;W=S*0 R,#$Y.C W.C(Q(#$S.C4V.C T ')R-3 Y,38W       #H $
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M 0$! 0$! ?_  !$( 3<!1 ,!$0 "$0$#$0'_Q  >  $  @(# 0$!
M    !P@&"0$$!0,""O_$ %40   & @(! @,"!@T(!P4)  $" P0%!@ '"!$2
M$R$)%#$5(A88(S)!41<9)#A566%Q=9:7MM8T-W9W@;&TU24V0U)XD;4S1V)R
M\$)38X*AIK?1X?_$ !T! 0 " P$! 0$            %!@,$!P$"" G_Q !9
M$0 " 0,# @(%!081"0<#!0 ! @, !!$%$B$&,1-!!Q0B46$6,G&!D14C0G.A
M\#,T-3924U97=).4E;&SM-/4%R1B=;*UP=+50V-R=H+1\0C"X414@Y*C_]H
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MG@9\@?/X=OCY<YJH7)V:0H$>XV%#.RQ=EK3->RD=MSBBJL>O1KZ7 RXI^)U
M,2,:QBAC )A:2JR(^7J(@2D=53>H%=3M6,>H6#07,,B\.<"3="V,;HW C5E.
M1M=D(PY!PSL5.]?G(5(.?>.1]!['\GGG9;6)8\]6Z_-JHBW5F(6+E%$! 0]$
M[]D@Z.ET/N'@942AW[]![YV2WE\>W@F(VF6&.0J>ZET#%3\03@_14B.0#\*]
MS,U>UY9YR&3FD*X>5CB6!U&NIEM"&>MBRSB(9.6C-Y*(QPJ_-J1[5X_9-7#P
MJ(MTG+MNB=0JBR9391!,86N1#(;=)4@:<(W@K,ZNZ1&3&P2.D;NJ$[BJ,P&
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M*J)F(FY23<IK-E%$#F!4A'"*R!C% %4E"")1^U(5E9E#JK*Q1BP#@')4E2K
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M3^]II?\ +(_^GT^3^O\ [J+G^)D_Q-/Q&.9G\9#LO^ICK_'N/EYT3^]II?\
M+(_^GT^3^O\ [J+G^)D_Q5/Q&.9G\9#LO^ICK_'N/EYT3^]II?\ +(_^GT^3
M^O\ [J+G^)D_Q-/Q&>9G\9#LO^I;G_'N/EYT3^]II?\ +(_^GUY\GM?_ '47
M/\3)_BJ?B,<S/XR'9?\ 4MS_ (]Q\O.B?WM-+_ED?_3Z]^3VO_NHN?XF3_$T
M_$8YF?QD.R_ZF.O\>X^7G1/[VFE_RR/_ *?3Y/Z_^ZBY_B9/\37Z+P?YIH 8
M[?XC^Q#*"7H <4=95/OL!#LJEX6 /I^<!!-UV'T$<\/7?1#8W>C730,\[;U
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MKW)R+9<>N27+F/HFH=E[PTFXY.P?&;=VAVFOM0.-V;,_"F/UI<9^K7UO)OK
MZ:V.S6.*J\M&J=23I@I',%*Z7![X36S9RV:,C^<^FI-Q3==_#2B],'^T=E1T
MU&5OD.^Y ;]=32[2,J]Q=DE;7$ZBV,486Y.XQ]'1T;9Y".82*,@YD6*2E1EK
M/X>GQ(+%JTDUOZE2,AN'3&WOAX<:-/MVNR:<Z-8>)7$WD%%[#V1NUPY;VP8Y
M)?8K9XUF)6%E72=S=-*,W:'B'"ZR"+A2O5<?#YY_U%WR9I4?I*M[=TWQ2I'(
M.L?#WIU_OT0\KF[6G+G>]4V+:_P@@F6PZL_*OI+4\=9=?0T%?9^GQ-I<R2$
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MU';7=E=+JUN'>V6-HKM  Q6)Y#+O5<Y+12O--'Y,)IXW9#X0;!,C(YE495@
MPSV/;<>>1V\C]E119]Z+MX@$:G&,YN?<%#TSKR)XE@S(<1 B[XAF4A,H"?\
M-(5E$2(E-X*.OD6JI7J5<N^H72V<P>JM(5R9VN$2!5]X0++,7_[J*&27ON1!
MBL;2X!QL#=]Q( /EQW;GGR/GWQ5)B0-OY+[@@]-O)A&QOI)VPF-W24(U,E7-
M>:LBGX2@TX#?,R HS]_?H-(HZ$G)K3,G!C-/W ,HX8*,:5G3;2YZGU:&S:9K
MF+Q$GU.X1&BBCM8'WI!%[<C)O+;0\CF:61LR*B(B1X8U,T@7<6 ]IVP0!@C@
M \Y)\S@D^=;ZFC5NQ:MF31(B#1FW1:MD$P J:+=NF5)%(A0]BD33(4A0#V
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ME,4IBE,4IBE,4IBE,4IBE,4IBE,4K6'\7G]Y9:?].-?_ /KI,ZCZ'_UZVW\
MU#^I%5'K?]0)OX1;?UE;(:U_U<K_ /0D5_P"&<UNOTS<?CY?ZQJM4/Z%%^+3
M_9%>WF"LE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4K7Y\3G]Z59/]8&
MH/U!_P"\VL?K]LZ)Z+>>K[?_ %=K'^[;GW56>KOU$E_A5C_:HJV!!] _F#_=
MG.ZLU<XI3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I6L
M/XO/[RRT_P"G&O\ _P!=)G4?0_\ KUMOX!J']2*J/6_Z@3?PBV_K*V0UK_JY
M7_Z$BO\ @$,YK=?IFX_'R_UC5:H?T*+\6G^R*]O,%9*8I3%*8I3%*8I3%*8I
M3%*8I3%*8I3%*8I3%*8I6OSXG7[TFR?Z?Z@__DVL=?\ ZYT3T6_KOMO]7ZO_
M +MN,_DJL=7_ *B2_P )LO[5%6P(/H'\P?[LYW5GKG%*8I3%*8I3%*8I3%*8
MI3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*UA_%Y_>66G_3C7_P#ZZ3.H^A_]
M>MM_ -0_J151ZW_4";^$6W]96R&M?]7*_P#T)%?\ AG-;K],W'X^7^L:K5#^
MA1?BT_V17MY@K)3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*U]_$Z_>D
MV3_6!I_^3_WG5C.B>BW]=]N/?IVL#[=,N:K/5W&B2GW75C_:HJV!A] _F#_=
MG.ZLU<XI3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I6L
M/XO7[RRT?Z<:_P#_ %TN=1]#WZ];;^ :A_4BJCUO^H$W\(MOZRMD-:_ZN5_^
MA(K_ (!#.:W7Z9N/Q\O]8U6J']"B_%I_LBO;S!62F*4Q2F*4Q2F*4Q2F*4Q2
MF*4Q2F*4Q2F*4Q2F*5JN^+?*[,B^-\:2FUR.L55D;]3D+GVUDW$]$.&-AC)F
MI/8X&;HK8T?(ST:E 21'#-=85Y:-(T4345$<ZOZ((M,EZEE-Y<RVUY'I]XUC
MAXEMYE>"2&\27>C/XD<$IN(RCJNV*7>"JU3>MGNTTI!!$DD#W4 N"5=I$*RH
M\#+M8#:\BB)MRL274+R:V.:X=W:0H=2D-CL(>*O3^!CGUJB:^#O['B)EVW(X
M>13$[UR\=+)QIU/DCN%7!_F5D%'!"I)JD23YKJ26,=_>1Z;)--81W$L=I-<%
M#-- C%4E?PT1 9 -X4*-JL%.2"3:K1KA[:![M8TN6C5IDB#!$D89*+N9B=F=
MI)8Y()& 0!FN:5;%,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IB
ME,4IBE:P_B\_O++3_IQK_P#]=)G4?0_^O6V_@&H?U(JH];_J!-_"+;^LK9#6
MO^KE?_H2*_X!#.:W7Z9N/Q\O]8U6J']"B_%I_LBO;S!62F*4Q2F*4Q2F*5UW
M3MNS04<NET6Z")#**K+JD22(0@=F.=102D*4OZ3&, !^D<QR2QQ(TLDD<<:
MM)([!41!RQ+=A@<\U](CR.L<:-([L%1$4LS,>RJHR22> /,U5^^;U^T)>,IF
MMCIO9IW(M#KRRJIT8QNV:KD<NA45(*9OD$T4E%'SLYR-CM2*(IE= L)<YSJ7
M6IO[^#1^F)%EG>8&XU26,-I\$$88R99B"6+!1G 7&>3Y]%TOHA[33[C7.IXI
M;2PBA98;)#F^N;N3"V\:1INQN8\CE@/:*8!Q92'>DD&+9VD\;/TED4S%>-1*
M9NX/X_E%$1)]T4S& 1+T(]![#[@.=#MY4EB219HY1M"M)&08WD7B1D/N+ X
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M;O=0%EFL[6YG2&YN8F7VHW2-RJR+AHR^]2"H(M?15E9W_4FGV]\%:'=)((G
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M@NNH:5=7(OH;PXW'.G\V2<D":6%8V/L!_;S5N.,G(_C7R-A71Y>ER-8L4/\
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M@/):?;"V5$HE,="0(R[%)43%*1BL"!2_-.O4SP+X@G@/*2VT^1Y QQ^(I [
MAHUP>,9[UO" &P\1N&:>6$>YD6!) 3Y91_,<^T,]AG:N ]@ _K !_P#/*Q4-
M7.*4Q2G0>P]?3Z?R?H]O]F*5QT'??0=]==_IZ_5W^K%*X\"_>^Z7[P]F]@^\
M/ZS>WN/\^*5SXE[[Z#OOOOH.^^NN_P"?KV[^O7MBE<>!/O#XE[-^</B'WO\
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M !>5G9AX=60EI)?H/5>/5U53_K#L>X:ZN[B]E,US(TCGMG 5!^Q1!A44>2J
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MU(Z][JRL/.+Z^J41.3=IJC*=1C#WV,2C5&*E&_"(\PYCX@CZ0:J5HVXV<O\
M?>EHSB-<[?JYQK/B[&\J>8>J=G;#XM<1]BZ[U_RLB"<?(<..N\W?'>O:_>7^
MK/+OL=BM5HX\? EBY6T5Q-5NX&($I6RE9CP@D?B$\MK9HJH;9Y-<I],1Y/AH
MQ6U+.Z85F#JZ]@Y*2^_M_P"M6CB\25EHCEVA(05+5KTO)TR+6A7DD>%J4J^\
M$8U$7:E0K6>0OQ#^2&HV=]VM![1K7[!&[OAK\2[/KV=U>VD&&P]VUGDC"RO*
MOD$A$3E1='.S&$-4(N+ML0@G$13!>;DHMW'+H?-%?GV_/\_JI6:.^4?Q#ZB\
MY):UV&ZY8S=?^'71^0J%_P!@:QK\5$77E');GWS5(OBU,5^U3>L;S"F::WT"
M_M-FN%AKU.M#NJMHI].K0LG,L&!4U*\OCO>^4F[=C<+S;B4V;L.'TU\86_1>
MO+E9VEPM3EMH^0X-VV=A)5SL6QZ<TG.WBG$M=MEV,#L2QZ[KQ)1-XT8-'#UB
MC%KKJ5_6UBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IB
ME:<TO@E\5@DZ3-N;+M%Y,432')+1T6]6EJ\5-Y&<CYW;\N[N$LP1KJ<>_N6L
MFF^MM0>MY%1M\K%QERD?M!G(N1*OBE9A5OA%Z I6]6N\ZW8I=.36K5%A[+#S
MVM]!W)[-3>N].1>CJ_;(38UOU/-;6UQ(+4Z"@W$Q':XNU8AW\]&_::;)H,E-
M(R:E=-A\'_0T?0HC7R>Q=L*1</QVX<<;47AWE2^?5J7"S<J^ZZ!-JB6K W_"
M&T6%<T7;U"(%CE(8I2PS")>^3P5*\*P?!ET9:('8E(FMP[Q?:RL%,Y14[5&N
M%7NORP/'Q/F',.Y_=TQK^10H:-IL4G)R4A))UW]DV>NS2L14D_C(]L*2Q%$E
M*D?;GP^VFT/B"\-.6"JD8WIO%_4][@)YJM.R7VYL"[( G':.2E*NA#E@GD5K
M(EMVK;F$\ZFDY"/LLZS;QT,9!=T\14JW=EXY5*S\FM4\I7LQ84+KJ35.V-1P
M4$V5CPK,A!;=G=<S\Y(RJ*K!23/*QSG6T4C%':235H5!_( [:NE!;'04J&-A
M<&8RS<D93DUKG?.[-#6V_5NATW>=;UFOKQW4=XUC6K^3=5!K:V-_H-T?5^9C
MX^9E:R>T460K,^K67IXTKU)5)!XFI57-9?!7XZ:II4SK>L7&S-:6M==,VRKI
M,M<<>Z_=*VPTEO2M;[K56EMJ5?4$)LS9$4\LM5BX-^XV3:K/(!74B^@X3GB!
M."I6=4;X3VHZ'?>-%TCMH[)<-^+MQV7?:1$J0FIF4O*6':&R-M;*GF<YLR,U
MTRVM^!#B3VY(Q\IKF-NK&D6)G6*JYFH1U)MI5[+*5M3Q2F*4Q2F*4Q2F*4Q2
MF*4Q2F*8_P#:F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4
&Q2F*5__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>g98473g61j34.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g98473g61j34.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_[2*$4&AO=&]S:&]P(#,N,  X0DE-! 0
M     $H< 5H  QLE1QP!6@ #&R5'' (   (  !P"4  (<G(U,#DQ-C<< @4
M(4UI8W)O<V]F="!7;W)D("T@1V5N97-I<R!&+3$N9&]C>#A"24T$)0
M$")*^(M6HN%I'>),'8-E9Y0X0DE-!#H      .4    0     0      "W!R
M:6YT3W5T<'5T    !0    !0<W138F]O; $     26YT965N=6T     26YT
M90    !#;')M    #W!R:6YT4VEX=&5E;D)I=&)O;VP     "W!R:6YT97).
M86UE5$585     $       ]P<FEN=%!R;V]F4V5T=7!/8FIC    # !0 '(
M;P!O &8 ( !3 &4 = !U '        IP<F]O9E-E='5P     0    !";'1N
M96YU;0    QB=6EL=&EN4')O;V8    )<')O;V9#35E+ #A"24T$.P     "
M+0   !     !       2<')I;G1/=71P=71/<'1I;VYS    %P    !#<'1N
M8F]O;       0VQB<F)O;VP      %)G<TUB;V]L      !#<FY#8F]O;
M    0VYT0V)O;VP      $QB;'-B;V]L      !.9W1V8F]O;       16UL
M1&)O;VP      $EN=')B;V]L      !"8VMG3V)J8P    $       !21T)#
M     P    !29" @9&]U8D!OX            $=R;B!D;W5B0&_@
M    0FP@(&1O=6) ;^            !"<F1456YT1B-2;'0
M  !";&0@56YT1B-2;'0               !2<VQT56YT1B-0>&Q <L
M      IV96-T;W)$871A8F]O; $     4&=0<V5N=6T     4&=0<P    !0
M9U!#     $QE9G15;G1&(U)L=                %1O<"!5;G1&(U)L=
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M____   X0DE-! T       0   !X.$))3009       $    'CA"24T#\P
M    "0           0 X0DE-)Q        H  0         !.$))30/U
M  !( "]F9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &       ! #(    !
M %H    &       ! #4    ! "T    &       !.$))30/X      !P  #_
M____________________________ ^@     ________________________
M_____P/H     /____________________________\#Z     #_________
M____________________ ^@  #A"24T$"       $     $   )    "0
M   X0DE-!!X       0     .$))300:      ,U    !@             "
M?0   I,          0                         !              *3
M   "?0                     !                         !     !
M        ;G5L;     (    &8F]U;F1S3V)J8P    $       !28W0Q
M!     !4;W @;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG
M   "?0    !29VAT;&]N9P   I,    &<VQI8V5S5FQ,<P    %/8FIC
M 0      !7-L:6-E    $@    =S;&EC94E$;&]N9P         '9W)O=7!)
M1&QO;F<         !F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U
M=&]'96YE<F%T960     5'EP965N=6T    *15-L:6-E5'EP90    !);6<@
M    !F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
M         $QE9G1L;VYG          !"=&]M;&]N9P   GT     4F=H=&QO
M;F<   *3     W5R;%1%6%0    !        ;G5L;%1%6%0    !
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M300H       ,     C_P        .$))3001       ! 0 X0DE-!!0
M  0    *.$))300,     !?V     0   *    ";   !X  !(J   !?: !@
M ?_8_^T #$%D;V)E7T--  +_[@ .061O8F4 9(     !_]L A  ," @("0@,
M"0D,$0L*"Q$5#PP,#Q48$Q,5$Q,8$0P,# P,#!$,# P,# P,# P,# P,# P,
M# P,# P,# P,# P, 0T+"PT.#1 .#A 4#@X.%!0.#@X.%!$,# P,#!$1# P,
M# P,$0P,# P,# P,# P,# P,# P,# P,# P,# P,# S_P  1" "; * # 2(
M A$! Q$!_]T !  *_\0!/P   04! 0$! 0$          P ! @0%!@<("0H+
M 0 !!0$! 0$! 0         !  (#! 4&!P@)"@L0  $$ 0,"! (%!P8(!0,,
M,P$  A$#!"$2,05!46$3(G&!,@84D:&Q0B,D%5+!8C,T<H+10P<EDE/PX?%C
M<S46HK*#)D235&1%PJ-T-A?25>)E\K.$P]-UX_-&)Y2DA;25Q-3D]*6UQ=7E
M]59F=H:6IK;&UN;V-T=79W>'EZ>WQ]?G]Q$  @(! @0$ P0%!@<'!@4U 0 "
M$0,A,1($05%A<2(3!3*!D12AL4(CP5+1\#,D8N%R@I)#4Q5C<S3Q)086HK*#
M!R8UPM)$DU2C%V1%539T9>+RLX3#TW7C\T:4I(6TE<34Y/2EM<75Y?569G:&
MEJ:VQM;F]B<W1U=G=X>7I[?'_]H # ,!  (1 Q$ /P#U5)) NS</'L%=]S*[
M"QUH8YP!].O;ZMD?N5^HS<DI.LNY^2.OX;'D"IU.26AKCK!Q=OJ,^C[95RC/
MPLEYKQ[V6O:T/+6N!(:[Z+EG9+*Z?K-TXUM@WT99>9.L'$*2G922224I)9?3
M>JC)ZCU#!>[WXMVVL$ >WTZK(;M^EM=9^<M1)2DE4ZME78?2\S+H:U]V/1;;
M4Q\[2YC'/8U^WW;7.:GZ;GU]1P:<RL;1:V7,/+'CV6U._EU6M?6Y)3:225>W
M+;5F8^*><AMA:?\ B]A_[^DIL))))*4DDDDI22222E))))*?_]#U54>H=)Q^
MH6,?>^QH8RRL-80 19L=N,M<[>Q]-;ZU>224YF)]7\#$L?96;"; X$%Y&KS6
M^^QNS8[?>^BI]G_@?IK!ZG=]E^M_08>YU7K9=+F[]\"RIC:]_OL>W],*_P"<
M78KCOK3C?;>I8^*QS3;97EBDMN<XLO:VFW$>:W0W'_6*ZV>Q$!(%GZ%[%)4>
MB=0'4NE8N:"";JFN=&GN(&[17D$/$>J^KJG4<ZB&WX6>_P!<'0.HLKQV-NG]
MS'N9LN_<Q[+%V6-D5Y-#+Z_HO$P>0>',=_+8[V/7,44.<.JYM;/5LP^HW[Z3
MJ+*'5XXR\8M/M]]?O;_PE:L= ROL>6[ISGFS&NA^):3.YKF[Z'[B!N]:AOIV
M?]V\6_\ [D(D=0OE$4"/(_WG4^L()Z!U(#1WV6Z#Y^F^%D])RAB=4W$>GC=9
M<YSZC_@>H5#9F4_R?M+6>I_7J?8M;ZP_\@]1_P#"MW_4.6=US!B\M$-JZ@]I
MK>>*LZL?JMO\EF6QGV:[_P!2I#6PJ(!!'7<?3>+T*P.N7>A]8N@6%VUCGY%3
M_#](QC*Y_P#0CT6K0Z/U 9V(U[@6W,]MK'?2:X$L<U_\IKVN8Y9OUDPZ\WJ7
M3\6YQ;5?5DU.>/I-+AC^A;6?S;:LAM+ZG?Z1(+8BS7@?R>A25#HF;9F].8^_
M^E4EU&4--+JCZ5N@^CO<WU?[:OH(4DDDDI22222E))))*?_1[G%S<NSKMF([
M)M/IE[WT/JI;6*Q[:O3<U_VOZ3V?I7_SG^C8MQ<SC9+L?ZUV5Y!]2_)_1Q48
M8UH8VRJQU=S&.=^CKKK?Z&1D_IG_ .9O9[[Z\'(?C?TAM3S3[2_WAI]/]$TM
M=9[_ ,Q)387/]9JMR>KXF+L%3W493L:T.U]2MV';38?;[?>U'Z?G=:MR7_:,
M8^B*6/:-OIG>6T.C?8[Z3WV9?J5_X#[/7_I%3SL\O^M/106FK;]KJM!((]]=
M19JW_A&-1CO]I^Q()!!'35#]5LL8);@V>VC(F_&,$!NY_IY&*Z?\-AYCO0=^
M_3?B?\(NK7,=:Z:*<\6,@59;RYD_0%Y8:[J+8_P/4:/:_;_VHKIM_G*EI]*Z
MFVQ_V*]Q]=C0:R_Z3VQ,/_>N8W\]GZ/)K_6*?\-50B.VQ73 !L?++6/_ 'O^
M"T?JUF,_:G6\%T!XSK+JS^\W90VT?UJG[/\ MVM5LS!^RY9PF^P-)NP'CD,<
MX/LH'_A7)VW4_P AZIOIR:+L[J^(W=;B=3MWM_>!92S;_P!=:74?]<JL_P &
MNAZC55U?I569ANEX OQG]]1[F'^LWV/8GF(H$;2T/]685 BS$[2_ _HR19^;
M]N^JO4;0(N9BWLMK;R+&UNEK?ZWTZ_Y#U8H?C]>Z(-Q]N37#B.6O'YP_EU6#
M>N<SLTU]-RNH,EM.7CV8W4&#_!W!IKIR/[%MC&6?]U\JG_N*M9CCT7ZQ&@Z=
M/ZR2^KPKRA_.U_U<K^<_XY*,;!'Z8]0_P?F6FXR[$'["U\')NQLXVV"+7DUY
M;!H#=6&LM>P:?TNGTKV?\(KO5JZ<WJ.'BET#*Q,L5/'((=AV5VL_E5N_2-4>
MO8CJ[F9M4 6EM5L\"P']5L?_ "7[OLEKO^&I_P!$LVS*]/K_ $!Y)%+CE,DG
M4"YM3&5N;]+^ELV?\;_UM "R".H)_P (+I:$3CI>O]V38P,R_'M.<1^CR7MK
MZA5 'I9; VBS<W3;7E;*WU/_ --_X972UV,L8'L.YKN"%D=<QA479H9ZF/<S
MT.HU #W5'^;R!_PN*YW_ &U_44,<VTEKJ["-S06OF66 >W\_;[_S/TOI?Z/U
M:/\ "M(ZC8JF!\P^67_-/[KN)*IC9S;3LM&RR=O>"?W?=M<RS_@K/^M^I7^D
M5M!8I))))2DDDDE/_]+N**<@_61^4^FILAU6\7 G:UK7-=Z4>HZ[T_2_1^G3
MZ#+?Y^Y;JP<<M_YX94AN_P"SM#2-';?T9][(_>_[4_G_ -&_P"WDE*7*]<Q+
M\OJ/I8TMRF49-V(Z08OJ?AW4?X:WVN<STW;JJ?IKJED6UN9]8\-Q].'T94;&
M;7?2Q/YQ^YWJ?YJ(-$$=#:D]%F-UWHU=I'Z++J:Z.['<_P#;E%H_SV+'LI>Y
MYQ<R:<^D;J<H<.@[FY-3OSW,=_2Z?S_Y_P#G%8QGGHG6[,*[3I_5;3;A/[,R
M'>[)QG?N>N[]+2M?/P:LZCTWG8]IW56@ ECA]%VOTOY3/ST^0 /]67JB5T)"
MN&6W?]V7[SE?5JNZ['ZHS.I#'VYUXNJ!):06U,=M)_P=K?>FZ.]_2^J6]$O<
M35=NOPGGO^=?5_:_G_\ C/M:M?5YA9CY37_S@RK!8T$N:UPVLVUN=[O3VM]F
M[Z'\VF^L?3[LK$9DXG].P7"_'C4DMU?5'YWJ-2C0)@=I?A+]&2)BB:UIRNNX
MPP798G9BY];FDP"&7;7-QW^Z6[+MS\.W_C*%N=<Z8.I].LQ@=MPBS'L_<M9[
MJGS_ %O:JF1?B]9Z <IK0YI82^LZP1K;4[_-W,_ZVMI DQ(.THG_ **Z<A(
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MK&.QQ_XQO\W:W^NU2"4)?.*/[P0W@S'R6C(H>/>);=409']8;F6-_K(K0X-
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M[/3]?_ ?^#_;?M_VC_!)*>K22224I))))2DDDDE/_]DX0DE-!"$      %4
M   ! 0    \ 00!D &\ 8@!E "  4 !H &\ = !O ', : !O '     3 $$
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M     0   GT         !@$#  ,    !  8   $:  4    !   !-@$;  4
M   !   !/@$H  ,    !  (   (!  0    !   !1@("  0    !
M      !(     0   $@    !.$))30/]       (          #_X0%(34T
M*@    @ " $2  ,    !      $:  4    !    ;@$;  4    !    =@$H
M  ,    !  (   $Q  (    >    ?@$R  (    4    G $[  (    )
ML(=I  0    !    O    .@   /      0   \     !061O8F4@4&AO=&]S
M:&]P($-3-B H5VEN9&]W<RD ,C Q.3HP-SHR,2 R,#HQ,CHR-0!R<C4P.3$V
M-P       Z !  ,    !__\  * "  0    !   "DZ #  0    !   "?0
M       & 0,  P    $ !@   1H !0    $   $V 1L !0    $   $^ 2@
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M*7T4LL<L*XMU$XN:\2AVYE5O#58H;E5U:T4B"YD9;F(X/V:[[LIQV27'B1G
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M5,QRPF5=H.?"#'Q(F[YDM)6*>_@-&O:*N@=?Z?!='3^H-+B!L=6LS=PL@^!
MW\HM9,<";3YF:/GG[*T8X$%<1\-Z\R-=^(YSBJELE7 FW#*1KFN>[HJ-9%Q8
M=,5.C5V8KCTRINUY8X:&EA-*.D0\<H#-64;=4%0R=NX1??LTTBYB3=)H6OZA
M;7>W#&.#5(X[B&5@!E4:2,1 DXW\?B%<B.8=2VOP+JQCEB[X)AFFC<9/KAU.
M.V.:M8Y=Z7L.Q:E"WK69S1^YM220VJAR34_IWSU-,G^6:UYP^1T9EH40(U<
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M)=2MV#@6T38UFYG*4>1^B_C9ELD/:K(U692*FWGHXAODN"9$).-./IY>-CW
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MXXO8%PL<4C!+@*$W!F(I5-H5M]/MV$C[EINR@L9RV:K"T?#1Y.1/YUGL"_*
MPUXTK<S_ ,,51(?P0<@J+P$HHBR+R+B[O3I+<>+&PN;8_#-&I\I[%)HR-\,B
MY 96&.>&-4W7.E;K25^UVLHU/26)"7\",##@X:&_MVS+9W$9PDB2#;NSM<\"
MI1M=39O7I$+*DQUQ<)-TDXC+;$&=&U;>I,.GHGXN6RS9U3;DKU*#9^B\B[$/
M4$&<Q96!5&9H^JK600&[9_7DDWI^\&#Z/,?HE%W$C87S=Z3N[2"Z6BF:;>50
M*0.Y69C6;5RV+U4L$!")=KQP^OK_ &I6SL-.0UB8(RL!+1TU&N ZH/XMXW?-
M%0#Y#V+ME%$Q$!^1B]W<40$#  @(8I7*8I3%*8I3%*8I55?(B[SK/G+I[7T1
M?$*Y7K(GJR5O56F[*UA5K<:%N4^]J1:$)=?V>4!TRD6KGZ6QK>S59O86:K&*
M7721<.70J5:IBE,4IBE5C\I%ZV;>7%1%M)[?5G2\Q**+EC+MMAEUHGTH>Q?)
M[6O(1J=)-VE$HM/0/3B*PJ@W$R@* "E83S#G'W$#E'J;E_$^5IK7:)(S2/(E
M! O5B*+9RK(4VY2"/\@7L8Q"38%?="KIMV3=H10Q7!D5>J=)0IU9TSJO24N&
MU'3#)K73[-\>YE$=Y9QMW"2N8G*'REG9L @,(NZ/V6ZBO!Q'*!;W'. ,$M%(
M?ZOF4GT!'IFK:$%T'C=%RV52<M72*:Z"Z)RJ(KH+D!1)5(Y1$ITE4S%.0Y1$
MIB& 0$0'KG+&5D8JX*NI*LI!!5@<,"#R"#D$'D=JE!SR.QJN/DKQ]=T5_([K
MU&C*QK!8Y'&T:C5$P*Y<,$E_6'N5=C$P%NO,03PJ<T=@D@14SA%>0CEFSM9[
MZNP:?>1WD:Z=?[7_ /:32DC8X'EB>0$,BM\*R9XX5O*!CJ'3FO6VOV:]+=2&
M*<L,:-?W3D-%< !8K26XXDB60?=1W&["C;'*&58\91P">2<W6M_VR1>PTP%M
MY&6R:9V. *",59VWT/H;+W]NT$YUF"C]9HH=W'N#'59/ <-05632364^-?C6
M&;3X0CH8=+MHW23'B*XDG)5BO#%<@!L#<H#8 (%0/6MF^GWVEV4EO+;26V@Z
M?"\4VPRAHY+E27* !CZ!\ NJJV "*VYVIKB VW0+/KVRIB:+LL8LR%=, ]3'
MO #RQ\JR,8!\;V,?$0>MC=!**B($4*=(YR&C],U"?2K^VU"V/WMM(K[3\,B<
MB2)_=)4+(WR8D8.#5+= ZLC=F&/R^8^8JM[X<6QK!K^3V-PFVBKZ:Y:5FI0]
M$\PG*G(T5=9%Z$=&J+G%9RRC2R+67@A$3B:M3+=HF(F@GOCZ)^T+3[>_CT[K
M/3!NL]9AB%]M&?#OE4IXD@ PCR>&T,_;^40EC_/IG1LG*%[5^#"?(.WDSD*.
M^0H(P<_"0!\)K-^2>@HEYO[C[L-MY8]Q&[JID^R=M5$T/.NI*)DL5=<@<@E<
M,I,WI9\&11*HJZ;NGY![XI(AZKI.HRBPU&U+922PN$=<!OAC)ADY#;2I)CW
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M^Y9BOH,C&X#Y-E9%]@^WN#6XW&8?X\<P/V<G9 /_ &?U"/\ U_Z_CE0ZC_\
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M_=F:5YQ2F*54[R?;1)>2/%5PD:)]Q-S(I8*@CH6>@9'YZ\V.!_-N%=((><_
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M$PJ%,.9I0/A^U'T92C);Q]5^F(SXQOUI]_?Z+O>3G*TZAL_MZ>U]I/3?Y_\
M^'O[^HXI7 S_  @U]6XYLK*S&]$5I?D#7XN*,3E!R"6$] F[*P:-8XWCV:()
MD69'72.10/5IE-U,H!OK8I7-G^'[5/1/RDDMX^K-NB-?LA'E-OWZNJBST0H_
M9]?TG]H :&))D!L?K(&$X%*<%3$$%*]3_#]JOHGI226\/5&W2P?M#?K3;]#M
MU26<C%'C,!'9_:'6()($],;J_,)NTIO(8@@I7NM\/VIBTD2I26\ <GW)&OF(
M_K3;^^KJTLI$&?M '])W:'='$DR^F/\ PX1-T*<#F3$%*X6-X0:\L2%Q1A)C
M>BKN"WVPBQ$_*#D"@#:BQSNJNYV.(979H HD,6XDP*3ZSI4RXD24[^SM5@'C
M]1^G'Y5S+_X?M4,\MHLY+>!6JVT]?O*T'ZTV_@\>NFR5*^FK7ZVSNY,5U$+:
M/@7$7BOF#TQP!1OT5FO61^'[5C/;B9A);O*T7VGK9Y5P'E-OT/%KIJE0_IXU
MZ'V=W)"X4;7'H@N(O%@7_@IB^5OT4^O_ #7#6_@_0*Y]*7[N8WFVC)/=.GXR
MG&2Y0<@E3)TZ9>:Y@[&Q$A=FF.B5[,K6@BA7 >H CD543E2,@(*5S<K\/VJ'
M<W08Z3W@1!QL;7SJJ!^M/OXOAHK9*G!=F_0^SA%+U"B%I^Q7[G:HK +8Q040
MQ2O:8^'[4CKW48N2W@1%>_:Z<U,/UIM_%\-+:C4/IR@/DV?U3%P"-H^Q7ZNE
MO*'I1+Y$.BGU^?UQ_A7B<^']4U'%V&(DMWD17ONL7-2#]:??Q/%36CFFCL%#
MHIL[JEZE!"U!X7'<X7\H>D$HJ(=%8YX_/G\N<?Y5CRW"+7\Y8MP0M<F=Z"XK
M6R-0MXI$W*#D$@1C5W$909VZMDE%MF]I@>13F?5,0XG744<"DV.10R0%5FLA
MFOA^U-1S?!BI+>)&[BXZW7IH?K3[^**%6:GJOT\2Z*;/ZHBX(C8^B;GJX7\@
M>E$OD1Z*?E2=^'[4U'%_&'D]X$1<V;7:M+#]:;?Q/! -E8#Z<I]%-G]4?.DG
M-AV.1%5;O#THE$R712D]Q#J&JI2U;#A)G<K3V6]:9=Z\/(<B]WV&/0(I9:Q&
MV5![ S6PI*,?LWKAT[0<L9MB\:ND5C_8F2$H H>QJS/%*8I3%*8I3%*TQY0<
MD:-IBTZ]A;729BVJLTC;4</XZ10CR5.#B;?3]6K3Z""IP-/R;>5VM'>.!ZH)
MKQH23KU0.6S5NNI6YV*4Q2O4XG AQ3*!U *82$,;L*<X (E*)^TW:!C= $W:
M;M >O:/3IBE:W<==CIWY;<T>WH1::C0MP6&J2,DTLOTIA+=;#Q\38+C)0<B:
M.C%/!$3DTO7)1'TQ4FM@BI>/2 /0G#%*V3Q2F*5IOLOD;3(#9NS-;[(H\O'P
MNE]74;D-&W):9BA86I=U;9J!AXF%BVCP)!O*-+-!H1[8DR+9&4?/4D4FQD"E
M664J5^->[H_D?HS7&[8R"=5=KL&!]X^C;Z182SV!<)O7<>[BGDC%F,P=N&CI
MFLFHJU'Q&$/JXI4XXI7!6:0EHJ!E)&"B$)Z69M3+,8ES*H0;9XJ4Q>I',NY1
M<(Q[<A!.LLY.W7\::9A*BH?M(*E:9:#Y20&P=DU>BPNI['4VVWZ!M+=B=Q?3
MT5(P<K+ZZV)6]7V9I$()+FDI"+E1E(2P5NRD9QT1,P#EJZ9M0.LH!'U_A2MZ
ML4IBE:2<IN2T)I%RE'W_ %C+6NKIPDQL2#>UJR1QYE21U6Q0NYGLI7U/1K0U
M<:2C&-BDY]Q(N$W,^]C8DL0Z-(MTUU*G;0>XF&^=80VRHZ&>5]&3D;+$+Q+U
MP1RJV?5:QRE9D!36!)JX,U7>1*SAF$A'Q<D#95()"+8.O(V34J9<4KA;)(R,
M1 3$I$Q03DG'QSMXQB#/21I9%RW1,HDT,_41<E:%5,7M,N+=P*9>IBH*F $S
M*5HQIGEO4[OLJ CF>MI"E%W$2P.9.[V.><(P,K?-?V.PZP"CULZ\05"4LRL=
M1/?&T(\-5IPU=53?N(,'A'* *58#BE,4K2S>?)6FP6[M9\6EJ4XO=HVA'R]@
M3\5FBZ]%P$S48>:O])B9==RJ#WU5K=4.5]"=LBHBR)' XD"*-W2**RA^L5DE
M!Y4M+M6TYXNKMB&,6:MD NK68U.V5UR\J%LFZD]>05E;&8(3<.\>0:[N.D4V
M;8KAHLB?Q%$1S&1[C]:5M?F:4Q2F*4Q2HMO^E=6[2DZ[,W^FQ5FDJJKWPKE^
M#@!22&3BIHS!XF@NBE*1)YF"A)92'E"/(M62B(UZHT,X9(*$4J4L4IBE,4K%
MJ=2:MK^%&O4^&:P4.>6GYY1FU\IBK3-HFW]CL$DNJNHJNN\EIN4?R+Q=94YU
M'#E0>H%[2@I64XI3%*B-_HK54KL*5VE+5-O+W2;K#2ER[Z6?2DG&R%5CWBTD
MQ@W5<>O5ZXJP9R3AQ)-TC10BE(KK/2&!RH945*RC7FNJ/J>GPNO]<5F)IU,K
MR*Z$+781L5K&QZ3ETN^<%01 1$!6=N5W"AC&,8ZBIC&,/7%*S3%*QBZ4ZO;"
MJ=@I%L9*259M,6[A)V/2?R$8=]%ODQ1>-!?13IE(-TW*)C(JF:ND5#)'.3O[
M3& 5*CB"XZZDK=LIEXAZZ_;V?7U4D*-4))2TVMW[-495TR>R-?1:.YM=BO&N
MW47%+*H.FRX">*C.@@#!J"2GU^=3=BE,4J$;?QSTY?K/8;A<:<G8)NUU!.AV
M$\A+3JL=*5%$[I9&$7A0DRPY6R+MXM((G18IKI2?ADB*E?-F[A)2I H]$J>M
MZXUJ=*AD(.":.9%\1HBHX<*+R$Q(.9:7DWSUXLX?2$G*R;QU(2,B^<.'CUXX
M6<.5E%3F,*E9=BE<7.0T?8H>2@I5-9:-EF:[!ZFW=NV"YVS@@IJ B^8+MGK1
M7M'JFX:.$'")P!1)4AR@8%*B"&XV:5@)"K2<926Z3FF2CRP5\KB5G'S1M9I!
M[-R+RV.F#Z3<,92W.'UCG'2EIE&[R>%:3<G]PZF+VJ5.>*4Q2HCO^A]0;0EX
MJPWJ@U^=L<$A+MH:RG;&962+2G8"4J\F#"?CCM)=J=6"FI1@BHB\(HS(]559
MF0<=JI5*Y2H:GI%#K4-3ZFQDXBMU]F6/AHM*QV)9%@Q3.<Z31 [J477!!'O$
MB"9E3%12 B*0%23(0JE21BE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE:8\CN9T
M+QLOE2HU@TUMNY)7&C[#OS&YT]SJ5O3HV&U3"JV38!9M>Y[2J-A9+5JO@TF'
M1T*X\:O&D@@E$N)%^B^9M%*X6"^)-PPG;=!Z^)NJ(8WN<EH*N)UQY"6KM9V6
M?F&U::PCRQH02U2(JA:G\557L@2>4AVMAL%5BUI$KFVUDDLI7*/>>O'V7T1L
M#?6HK0WW- T.T52A*1-7%S$OY:]7Z:I\%0H)J>QLHWQL+@ZOU2D(&S%0<P$O
M7IIK889Y)QBJ2RBE80/Q/>)*-EVXP>7IXE1],PU)?VW:K2KW"8I/N%OM.W:J
M\8LW$/77KQS"5-SIRQO+#?T&ZVOFK(_E^DH!'R(MU*S5+GOQ^G+GI6IT"S([
M#0W)>&U#+.5[U232F2DS ;NDJLM9$)-DS53+8)_C]L:FE8)G"8C9V/:FD(Y)
MB\1<F4K=;%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%
M*8I4([;X\:KW>^B)'8L(\EW4'3MIT...UFI6**C6MS5=*GW]F<D<Z;%55E(%
M%-JV=J 9S&* +F/5;KB*@J5!K#X=G%*-<-73:ARGD9RC:81*M<;4ND+UIN&A
M;V1,JBK*F352_21K2HRQT%"F249L5X@Y1C7[QNLI]?Y5$NS>%^B^.?!W=FK]
M/1,[4ZI%IP>U8-$; \FWL#:-32U2MU +%O; 644)%U^4H5<(@R= [,LU;+D<
M+JKN5' J4LGPAN#UTKUDK-BH]\?UZV/FCY["+;CVBK%Q;%J;;:S6KUEBO:5F
MU9I[17>>SEF-:A4V<7'N[%[@P1;24=&/&C'I2H-TMQBU76]X1TE!L9..]Y^)
M1R W/(L47C<S!:TZ]T-<Z%5V)4U6*BZ%=8^_3MR/&(.$U5[W-RL\=[XGSA@=
=6/7\@/[S_M5UF*S3%*8I3%*8I3%*8I3%*8I7_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>g98473g61p76.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g98473g61p76.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_[2JV4&AO=&]S:&]P(#,N,  X0DE-! 0
M     $H< 5H  QLE1QP!6@ #&R5'' (   (  !P"4  (<G(U,#DQ-C<< @4
M(4UI8W)O<V]F="!7;W)D("T@1V5N97-I<R!&+3$N9&]C>#A"24T$)0
M$")*^(M6HN%I'>),'8-E9Y0X0DE-!#H      .4    0     0      "W!R
M:6YT3W5T<'5T    !0    !0<W138F]O; $     26YT965N=6T     26YT
M90    !#;')M    #W!R:6YT4VEX=&5E;D)I=&)O;VP     "W!R:6YT97).
M86UE5$585     $       ]P<FEN=%!R;V]F4V5T=7!/8FIC    # !0 '(
M;P!O &8 ( !3 &4 = !U '        IP<F]O9E-E='5P     0    !";'1N
M96YU;0    QB=6EL=&EN4')O;V8    )<')O;V9#35E+ #A"24T$.P     "
M+0   !     !       2<')I;G1/=71P=71/<'1I;VYS    %P    !#<'1N
M8F]O;       0VQB<F)O;VP      %)G<TUB;V]L      !#<FY#8F]O;
M    0VYT0V)O;VP      $QB;'-B;V]L      !.9W1V8F]O;       16UL
M1&)O;VP      $EN=')B;V]L      !"8VMG3V)J8P    $       !21T)#
M     P    !29" @9&]U8D!OX            $=R;B!D;W5B0&_@
M    0FP@(&1O=6) ;^            !"<F1456YT1B-2;'0
M  !";&0@56YT1B-2;'0               !2<VQT56YT1B-0>&Q <L
M      IV96-T;W)$871A8F]O; $     4&=0<V5N=6T     4&=0<P    !0
M9U!#     $QE9G15;G1&(U)L=                %1O<"!5;G1&(U)L=
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M____   X0DE-! T       0   !X.$))3009       $    'CA"24T#\P
M    "0           0 X0DE-)Q        H  0         !.$))30/U
M  !( "]F9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &       ! #(    !
M %H    &       ! #4    ! "T    &       !.$))30/X      !P  #_
M____________________________ ^@     ________________________
M_____P/H     /____________________________\#Z     #_________
M____________________ ^@  #A"24T$"       $     $   )    "0
M   X0DE-!!X       0     .$))300:      ,U    !@             #
MI   !?0          0                         !              7T
M   #I                      !                         !     !
M        ;G5L;     (    &8F]U;F1S3V)J8P    $       !28W0Q
M!     !4;W @;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG
M   #I     !29VAT;&]N9P  !?0    &<VQI8V5S5FQ,<P    %/8FIC
M 0      !7-L:6-E    $@    =S;&EC94E$;&]N9P         '9W)O=7!)
M1&QO;F<         !F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U
M=&]'96YE<F%T960     5'EP965N=6T    *15-L:6-E5'EP90    !);6<@
M    !F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
M         $QE9G1L;VYG          !"=&]M;&]N9P   Z0     4F=H=&QO
M;F<   7T     W5R;%1%6%0    !        ;G5L;%1%6%0    !
M37-G951%6%0    !       &86QT5&%G5$585     $       YC96QL5&5X
M=$ES2%1-3&)O;VP!    "&-E;&Q497AT5$585     $       EH;W)Z06QI
M9VYE;G5M    #T53;&EC94AO<GI!;&EG;@    =D969A=6QT    "79E<G1!
M;&EG;F5N=6T    /15-L:6-E5F5R=$%L:6=N    !V1E9F%U;'0    +8F=#
M;VQO<E1Y<&5E;G5M    $453;&EC94)'0V]L;W)4>7!E     $YO;F4    )
M=&]P3W5T<V5T;&]N9P         *;&5F=$]U='-E=&QO;F<         #&)O
M='1O;4]U='-E=&QO;F<         "W)I9VAT3W5T<V5T;&]N9P      .$))
M300H       ,     C_P        .$))3001       ! 0 X0DE-!!0
M  0    $.$))300,     " H     0   *    !B   !X   M\   " , !@
M ?_8_^(,6$E#0U]04D]&24Q%  $!   ,2$QI;F\"$   ;6YT<E)'0B!865H@
M!\X  @ )  8 ,0  86-S<$U31E0     245#('-21T(               $
M /;6  $     TRU(4" @
M                       18W!R=    5     S9&5S8P   80   !L=W1P
M=    ?     48FMP=    @0    4<EA96@   A@    49UA96@   BP    4
M8EA96@   D     49&UN9    E0   !P9&UD9    L0   "(=G5E9    TP
M  "&=FEE=P   ]0    D;'5M:0   _@    4;65A<P  ! P    D=&5C:
M!#     ,<E120P  !#P   @,9U120P  !#P   @,8E120P  !#P   @,=&5X
M=     !#;W!Y<FEG:'0@*&,I(#$Y.3@@2&5W;&5T="U086-K87)D($-O;7!A
M;GD  &1E<V,         $G-21T(@245#-C$Y-C8M,BXQ               2
M<U)'0B!)14,V,3DV-BTR+C$
M                             %A96B        #S40 !     1;,6%E:
M(                     !865H@        ;Z(  #CU   #D%A96B
M  !BF0  MX4  !C:6%E:(        "2@   /A   ML]D97-C         !9)
M14,@:'1T<#HO+W=W=RYI96,N8V@              !9)14,@:'1T<#HO+W=W
M=RYI96,N8V@
M            9&5S8P         N245#(#8Q.38V+3(N,2!$969A=6QT(%)'
M0B!C;VQO=7(@<W!A8V4@+2!S4D="               N245#(#8Q.38V+3(N
M,2!$969A=6QT(%)'0B!C;VQO=7(@<W!A8V4@+2!S4D="
M             &1E<V,         +%)E9F5R96YC92!6:65W:6YG($-O;F1I
M=&EO;B!I;B!)14,V,3DV-BTR+C$              "Q2969E<F5N8V4@5FEE
M=VEN9R!#;VYD:71I;VX@:6X@245#-C$Y-C8M,BXQ
M              !V:65W       3I/X %%\N !#/%  #[<P !!,+  -<G@
M  %865H@      !,"58 4    %<?YVUE87,          0
M          */     G-I9R      0U)4(&-U<G8        $      4 "@ /
M !0 &0 > ", *  M #( -P [ $  10!* $\ 5 !9 %X 8P!H &T <@!W 'P
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M8^/KY'/D_.6$Y@WFEN<?YZGH,NB\Z4;IT.I;ZN7K<.O[[(;M$>V<[BCNM.]
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MP  1" !B * # 2(  A$! Q$!_]T !  *_\0!/P   04! 0$! 0$
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M5XJ079>(PV!UU;33'J@N V;OH>IK[-_YNY&6*1A#.ZF:O0;D?JYR'-Q2'_\
M!.R<EWLS?;]!S?Z(EKT%]_!0 UUK]KKU74W-WTV-L;QN80X3SRU36+@G,>+*
M\&_%K:UH=M;BV5@.<'L8=;FM=_-M_P"$_P"+6GCLRVAIR+6V$-(<&,V@F?:X
M2Y[OH)(26WTT@&VQM8=H-Q#9_P Y.Q[+&A['![7:AS3(/S"R,O-Z-E=..9U>
MFLXE5VRM]C'6M)+O0KMK::O4_2.=L_F__ T7I#NGNR'NZ<UK<4XV.:@QI8-N
M_*VPPM:DIU$DDDE.*[%^MC+;#3G8ME;W.>P74NE@+G>E0WT7U[ZZZMGZ1_Z5
M]BL=/JZ^RX?M&_&NIV$$55O8_>"-CO<][?<S=ZO\O^;5^RP5M#B"07-;IK](
M[!^52D3'?P2375=1?976 ;'!@<0UNX@2XZ-:)_.<I+-ZW]A]/%^V_9MOVFH5
M?:JO5'J$[:_0]S?2R?\ 17?X-+7H+\ H"SO7B6ZW*QG6FEMK'6@P:PX%P(UC
M;.[LBK"R'MKSB:GXC+_5#6>I0\V2]_I[?4K+/I>H_P#XS^<_F_YO0KKZON=Z
MUU&TM]NRMP(?'/OL=[-Z2'__T^WP>FX/5:,IG4:&9(HSLGTPYH 'N-8V>G_P
M7L]ZT>GUMKMS6L:&M%X@#_BJ%FX?2\'JU&55U&D7,IS\@L E@F7,W?H7,WNV
M/V?I5I=.8RNS-:P;6C(T'_6J$E-U))0NL]*IUFTNVB8$ _\ 2+6I* LTTLRO
MU,VBYM9>["#GAPC0O:6.;SN]U6[Z/^DK5]K@X!S3((D$>!0L82QUAYM<7_+Z
M-?\ X$UB!BY369-V"X%GHEOHO=H'M>#9Z=?\JGZ&S]Q,% W^^?Q_]%99 R%#
M7VA_S>+U?^.3;J222>Q*22224XG3,D872+7XV-;D-JRKJVTU- >8N=4]X8]X
M;L:[>[_B_P#!JUA9+KLJ^^RFS')QJ'&JP O'NRO;MK+_ '*KTZS)/3<NSI;:
M[<AV;D0W(FMD^N]MTNI];?L;O]+_ $BH]>=U;[!E12+,YU6&UU6/8]H)==>Q
M[6O!ILV;7?O)43H$BB19H=2]0UP<T.'!$B1!U\BAG)QA><8VL%[6>J:=PWBN
M=GJFN=_I[AMWK%Q\7KIP:1:6M9Z5<XX>_<P[1O9[/0MMV._,LS?^N* P+_M0
MMQ,MC;?2+*Z&8S6,#]VZVR][M^1MV[:[\>ZW_1V_TGTK4KB-)'7PV3P$ZQUC
M_+YOW74RIS-C*'.-3'UO?94[;/N:]K6OGW,:W]+=_P!M_P"$3.&55G5N!;D-
M%3Y!;MN^E7]&T;:-O_![:OZZR\/I'6;^C=/J?G55&IF.]S:J[&M)86V6;K*<
MG'ML]7^Q3_W71GXO7F=6J-5LXPQK [](\,]0V5&O<VZG+;N]/U/S]Z!QB]95
M+\/2N]RM  8B]_ZSJG+8ZLFH38TM#JGRQPW$-]S=KG?]%6%@]6H^L#\3]'71
M=:VRHL+7/;8!ZM3K=MK&,_P;?>MY&CW!\ELN&A0(U._\5))))+7_U.SZ;TSI
M_5\3*&567U,ZAE.8UCW,;.]U.YII=7_*_MJVWJ73>EOR1F7MQVVY(95O),D4
MT>UL[EIY%#<C'MQWES6W,<QSF$M< X;26/;[F/\ Y2S?V'5==DG-J9?4Y[7X
MK766N((K94Y]N\^G6_\ 1_X%B7X?BD$7J"1V!X?Q]2=G7^AOG9GX[BT%SFBU
MA< #M,LW;OI+-ZO]8L;)P,[&Z18S)S*V;7@N%;&!X:[<^Z]U5?NJL]GIN>K8
MZ7ENPL=MC_UH.K^T'U[S66AP]?TMS]V]U7T-R:WZO85N2]EE+;,&^L_:6666
MN<^T&MM#G5O<ZIS*ZF.^E[_YM([55^9K_H_]\F) D)616HT$O^DQR/K'CXV;
MC8;F5GUW6-)%](+16SU?;2ZQMEO]5G\VK/[7Z-D&W'?DU37M]6JT["-PWU[F
MV[/W=RS>FY'3\X9-&-F5V9.YYQ*F77@LKV@5^M2Y]=K/=_.;/])_PB+_ ,WW
M,JJMJJH;G6.J^WV%UL6,K]KHL:[>][&._1>JU$F)'R_9^WYENVMMJOJ6*S*H
MQJ<RC(;>XM:QUS?5;#7V?HOINR?H?1_G/\)ZEBTUDCHQ_:(>6L&$QDUQ9;ZP
MN/M-C7;MK/T3GU>W])L5CI>-FX[;AEN:XNL)JVV6V?H_S0_[27;7_P#%^Q"@
M-K23?;^+>22220Y&%TSJ-/2[<=N0W%S+<BV\W,:+FM%ESK]K!<VO?NJ=L_2J
M5.%99DV49EYR+*ZL5[K=C&[G5VY%H=LVO8W=M6JLJCHYJR@ ]YQ&T-J#O7N]
M8O8^QXW[7LKV;;G_ /")*=5 .)2<LY1:TV.J]$G:)+02_;O^EM]WT%0_9F8<
M/);ZA;E.-GV4C)R2P SZ'K'U [<W\_8U&MZ:XVXYJ?8*P\G)W9%\ENQX:*HL
M^EZQJ^G^8E202+H[BBWF,96QM=;0QC1#6M$  <!K0I+!JRNE.ZM?AOSHC953
M0<C(;;ZK2\9'MLL:VQGOH;7Z7_#(HZ7U+]GVM=</MY+O2?Z^3Z4$R-WZ;U/H
M_P"9_P *DAV4EE6]-S3;B&NR*Q)S0<C)DF(C'_2?1W;_ .<_D(N)B9E'4+WN
M<#AN:T4 VW66 B-^]E[G4M]V[Z"2G022224__]7U5)?*J22GZJ27RJDDI^E\
M#^E-_H7\W;_1_P"<^G7]'_@?^Y'_  _I+37RJDDI^JDE\JI)*?JI)?*J22GZ
MJ27RJDDI^JDE\JI)*?I<_P!-;_0OZ0?^._F_S?\ NW^]_P!UEIKY5224_522
M^54DE/U4DOE5))3_ /_9.$))300A      !5     0$    / $$ 9 !O &(
M90 @ %  : !O '0 ;P!S &@ ;P!P    $P!! &0 ;P!B &4 ( !0 &@ ;P!T
M &\ <P!H &\ <  @ $, 4P V     0 X0DE-!"(      49-30 J    "  (
M 1(  P    $  0   1H !0    $   !N 1L !0    $   !V 2@  P    $
M @   3$  @   !X   !^ 3(  @   !0   "< 3L  @    D   "PAVD !
M  $   "\    Z  MQL   "<0 "W&P   )Q!!9&]B92!0:&]T;W-H;W @0U,V
M("A7:6YD;W=S*0 R,#$Y.C W.C(Q(#$Y.C0U.C,Q ')R-3 Y,38W       #
MH $  P    '__P  H ( !     $   7TH , !     $   .D          8!
M P #     0 &   !&@ %     0   38!&P %     0   3X!*  #     0 "
M   " 0 $     0   48" @ $     0              2     $   !(
M 3A"24T#_0      "           _^$!2$U- "H    (  @!$@ #     0
M   !&@ %     0   &X!&P %     0   '8!*  #     0 "   !,0 "
M'@   'X!,@ "    %    )P!.P "    "0   +"':0 $     0   +P   #H
M   #P     $   /      4%D;V)E(%!H;W1O<VAO<"!#4S8@*%=I;F1O=W,I
M #(P,3DZ,#<Z,C$@,3DZ-#4Z,S$ <G(U,#DQ-C<       .@ 0 #     ?__
M  "@ @ $     0  !?2@ P $     0   Z0         !@$#  ,    !  8
M  $:  4    !   !-@$;  4    !   !/@$H  ,    !  (   (!  0    !
M   !1@("  0    !              /      0   \     !_^%  &AT=' Z
M+R]N<RYA9&]B92YC;VTO>&%P+S$N,"\ /#]X<&%C:V5T(&)E9VEN/2+ON[\B
M(&ED/2)7-4TP37!#96AI2'IR95-Z3E1C>FMC.60B/SX\>#IX;7!M971A('AM
M;&YS.G@](F%D;V)E.FYS.FUE=&$O(B!X.GAM<'1K/2)!9&]B92!835 @0V]R
M92 U+C,M8S Q,2 V-BXQ-#4V-C$L(#(P,3(O,#(O,#8M,30Z-38Z,C<@(" @
M(" @("(^"B @(#QR9&8Z4D1&('AM;&YS.G)D9CTB:'1T<#HO+W=W=RYW,RYO
M<F<O,3DY.2\P,B\R,BUR9&8M<WEN=&%X+6YS(R(^"B @(" @(#QR9&8Z1&5S
M8W)I<'1I;VX@<F1F.F%B;W5T/2(B"B @(" @(" @(" @('AM;&YS.GAM<#TB
M:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+R(^"B @(" @(" @(#QX;7 Z
M0W)E871E1&%T93XR,#$Y+3 W+3(Q5#$Q.C0U.C,W*S U.C,P/"]X;7 Z0W)E
M871E1&%T93X*(" @(" @(" @/'AM<#I#<F5A=&]R5&]O;#Y!9&]B92!0:&]T
M;W-H;W @0U,V("A7:6YD;W=S*3PO>&UP.D-R96%T;W)4;V]L/@H@(" @(" @
M(" \>&UP.DUO9&EF>41A=&4^,C Q.2TP-RTR,50Q.3HT-3HS,2LP-3HS,#PO
M>&UP.DUO9&EF>41A=&4^"B @(" @(" @(#QX;7 Z365T861A=&%$871E/C(P
M,3DM,#<M,C%4,3DZ-#4Z,S$K,#4Z,S \+WAM<#I-971A9&%T841A=&4^"B @
M(" @(#PO<F1F.D1E<V-R:7!T:6]N/@H@(" @(" \<F1F.D1E<V-R:7!T:6]N
M(')D9CIA8F]U=#TB(@H@(" @(" @(" @("!X;6QN<SIP9&8](FAT=' Z+R]N
M<RYA9&]B92YC;VTO<&1F+S$N,R\B/@H@(" @(" @(" \<&1F.E!R;V1U8V5R
M/D%C<F]B870@1&ES=&EL;&5R(#$P+C$N,38@*%=I;F1O=W,I/"]P9&8Z4')O
M9'5C97(^"B @(" @(#PO<F1F.D1E<V-R:7!T:6]N/@H@(" @(" \<F1F.D1E
M<V-R:7!T:6]N(')D9CIA8F]U=#TB(@H@(" @(" @(" @("!X;6QN<SID8STB
M:'1T<#HO+W!U<FPN;W)G+V1C+V5L96UE;G1S+S$N,2\B/@H@(" @(" @(" \
M9&,Z=&ET;&4^"B @(" @(" @(" @(#QR9&8Z06QT/@H@(" @(" @(" @(" @
M(" \<F1F.FQI('AM;#IL86YG/2)X+61E9F%U;'0B/DUI8W)O<V]F="!7;W)D
M("T@1V5N97-I<R!&+3$N9&]C>#PO<F1F.FQI/@H@(" @(" @(" @(" \+W)D
M9CI!;'0^"B @(" @(" @(#PO9&,Z=&ET;&4^"B @(" @(" @(#QD8SIC<F5A
M=&]R/@H@(" @(" @(" @(" \<F1F.E-E<3X*(" @(" @(" @(" @(" @/')D
M9CIL:3YR<C4P.3$V-SPO<F1F.FQI/@H@(" @(" @(" @(" \+W)D9CI397$^
M"B @(" @(" @(#PO9&,Z8W)E871O<CX*(" @(" @(" @/&1C.F9O<FUA=#YI
M;6%G92]E<'-F/"]D8SIF;W)M870^"B @(" @(#PO<F1F.D1E<V-R:7!T:6]N
M/@H@(" @(" \<F1F.D1E<V-R:7!T:6]N(')D9CIA8F]U=#TB(@H@(" @(" @
M(" @("!X;6QN<SIX;7!-33TB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP
M+VUM+R(*(" @(" @(" @(" @>&UL;G,Z<W1%=G0](FAT=' Z+R]N<RYA9&]B
M92YC;VTO>&%P+S$N,"]S5'EP92]297-O=7)C945V96YT(R(*(" @(" @(" @
M(" @>&UL;G,Z<W12968](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]S
M5'EP92]297-O=7)C95)E9B,B/@H@(" @(" @(" \>&UP34TZ26YS=&%N8V5)
M1#YX;7 N:6ED.C-%.$$V,C%!0S%!0D4Y,3$X-D9!.4(R0S0S0S9"-T,S/"]X
M;7!-33I);G-T86YC94E$/@H@(" @(" @(" \>&UP34TZ1&]C=6UE;G1)1#YX
M;7 N9&ED.D4Y0S="0T4X.#A!0D4Y,3$X.3<Y0T4V0C!%-D$P-T9#/"]X;7!-
M33I$;V-U;65N=$E$/@H@(" @(" @(" \>&UP34TZ3W)I9VEN86Q$;V-U;65N
M=$E$/GAM<"YD:60Z13E#-T)#13@X.$%"13DQ,3@Y-SE#139",$4V03 W1D,\
M+WAM<$U-.D]R:6=I;F%L1&]C=6UE;G1)1#X*(" @(" @(" @/'AM<$U-.DAI
M<W1O<GD^"B @(" @(" @(" @(#QR9&8Z4V5Q/@H@(" @(" @(" @(" @(" \
M<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @
M(" @(" @/'-T179T.F%C=&EO;CYS879E9#PO<W1%=G0Z86-T:6]N/@H@(" @
M(" @(" @(" @(" @(" \<W1%=G0Z:6YS=&%N8V5)1#YX;7 N:6ED.D4Y0S="
M0T4X.#A!0D4Y,3$X.3<Y0T4V0C!%-D$P-T9#/"]S=$5V=#II;G-T86YC94E$
M/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z=VAE;CXR,#$Y+3 W+3(Q5#$S
M.C Q.C,T*S U.C,P/"]S=$5V=#IW:&5N/@H@(" @(" @(" @(" @(" @(" \
M<W1%=G0Z<V]F='=A<F5!9V5N=#Y!9&]B92!0:&]T;W-H;W @0U,V("A7:6YD
M;W=S*3PO<W1%=G0Z<V]F='=A<F5!9V5N=#X*(" @(" @(" @(" @(" @(" @
M/'-T179T.F-H86YG960^+SPO<W1%=G0Z8VAA;F=E9#X*(" @(" @(" @(" @
M(" @/"]R9&8Z;&D^"B @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E
M5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z86-T
M:6]N/G-A=F5D/"]S=$5V=#IA8W1I;VX^"B @(" @(" @(" @(" @(" @(#QS
M=$5V=#II;G-T86YC94E$/GAM<"YI:60Z,T0X038R,4%#,4%"13DQ,3@V1D$Y
M0C)#-#-#-D(W0S,\+W-T179T.FEN<W1A;F-E240^"B @(" @(" @(" @(" @
M(" @(#QS=$5V=#IW:&5N/C(P,3DM,#<M,C%4,3DZ-#4Z,S$K,#4Z,S \+W-T
M179T.G=H96X^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IS;V9T=V%R94%G
M96YT/D%D;V)E(%!H;W1O<VAO<"!#4S8@*%=I;F1O=W,I/"]S=$5V=#IS;V9T
M=V%R94%G96YT/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z8VAA;F=E9#XO
M/"]S=$5V=#IC:&%N9V5D/@H@(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @
M(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^
M"B @(" @(" @(" @(" @(" @(#QS=$5V=#IA8W1I;VX^8V]N=F5R=&5D/"]S
M=$5V=#IA8W1I;VX^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IP87)A;65T
M97)S/F9R;VT@87!P;&EC871I;VXO=FYD+F%D;V)E+G!H;W1O<VAO<"!T;R!I
M;6%G92]E<'-F/"]S=$5V=#IP87)A;65T97)S/@H@(" @(" @(" @(" @(" \
M+W)D9CIL:3X*(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E
M/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IA8W1I;VX^
M9&5R:79E9#PO<W1%=G0Z86-T:6]N/@H@(" @(" @(" @(" @(" @(" \<W1%
M=G0Z<&%R86UE=&5R<SYC;VYV97)T960@9G)O;2!A<'!L:6-A=&EO;B]V;F0N
M861O8F4N<&AO=&]S:&]P('1O(&EM86=E+V5P<V8\+W-T179T.G!A<F%M971E
M<G,^"B @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" \
M<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @
M(" @(" @/'-T179T.F%C=&EO;CYS879E9#PO<W1%=G0Z86-T:6]N/@H@(" @
M(" @(" @(" @(" @(" \<W1%=G0Z:6YS=&%N8V5)1#YX;7 N:6ED.C-%.$$V
M,C%!0S%!0D4Y,3$X-D9!.4(R0S0S0S9"-T,S/"]S=$5V=#II;G-T86YC94E$
M/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z=VAE;CXR,#$Y+3 W+3(Q5#$Y
M.C0U.C,Q*S U.C,P/"]S=$5V=#IW:&5N/@H@(" @(" @(" @(" @(" @(" \
M<W1%=G0Z<V]F='=A<F5!9V5N=#Y!9&]B92!0:&]T;W-H;W @0U,V("A7:6YD
M;W=S*3PO<W1%=G0Z<V]F='=A<F5!9V5N=#X*(" @(" @(" @(" @(" @(" @
M/'-T179T.F-H86YG960^+SPO<W1%=G0Z8VAA;F=E9#X*(" @(" @(" @(" @
M(" @/"]R9&8Z;&D^"B @(" @(" @(" @(#PO<F1F.E-E<3X*(" @(" @(" @
M/"]X;7!-33I(:7-T;W)Y/@H@(" @(" @(" \>&UP34TZ1&5R:79E9$9R;VT@
M<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" \<W12968Z
M:6YS=&%N8V5)1#YX;7 N:6ED.C-$.$$V,C%!0S%!0D4Y,3$X-D9!.4(R0S0S
M0S9"-T,S/"]S=%)E9CII;G-T86YC94E$/@H@(" @(" @(" @(" \<W12968Z
M9&]C=6UE;G1)1#YX;7 N9&ED.D4Y0S="0T4X.#A!0D4Y,3$X.3<Y0T4V0C!%
M-D$P-T9#/"]S=%)E9CID;V-U;65N=$E$/@H@(" @(" @(" @(" \<W12968Z
M;W)I9VEN86Q$;V-U;65N=$E$/GAM<"YD:60Z13E#-T)#13@X.$%"13DQ,3@Y
M-SE#139",$4V03 W1D,\+W-T4F5F.F]R:6=I;F%L1&]C=6UE;G1)1#X*(" @
M(" @(" @/"]X;7!-33I$97)I=F5D1G)O;3X*(" @(" @/"]R9&8Z1&5S8W)I
M<'1I;VX^"B @(" @(#QR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2(B"B @
M(" @(" @(" @('AM;&YS.G!H;W1O<VAO<#TB:'1T<#HO+VYS+F%D;V)E+F-O
M;2]P:&]T;W-H;W O,2XP+R(^"B @(" @(" @(#QP:&]T;W-H;W Z0V]L;W)-
M;V1E/C0\+W!H;W1O<VAO<#I#;VQO<DUO9&4^"B @(" @(#PO<F1F.D1E<V-R
M:7!T:6]N/@H@(" \+W)D9CI21$8^"CPO>#IX;7!M971A/@H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H\/WAP86-K970@96YD/2)W(C\^_]L
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MB<(L=/VZIU3X'VIL]>K6"DC,09D^:&A\$9>/1YQ8.2,F-\N1CW&_-B/[CO\
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MQ#]:?ES<S[Q9J?7(\8>QE<N4J:=BK]AI>(Z)#WH97J7K3TJLMEJ\UEHFY%%
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MX<-Z/*CO1FU\K!Z8U)&1 >GLV!@[B0EBKS.SM_\ 06TUNJ[;M9K[?/K1[?\
M:5,/4K4*=3^)!W%OMB\<HI,I) 6;B(&(LX5ZVY:F7$)+!#K,8WWKNX=>2;U%
M]V97G)NKXTX\]+F+=C8J\$J?"NRLOA_K2*E2R!:<R95L@[-5Z4/7G+<"D9Y:
MD+G:KB48D8E8AC$A;=G?=F?R;(T2D.%K4/4C^VSFPLS^FS$6P$[/V=A)W9_5
ME;RN]PB&$8H7B!=_=Q./^6(;FFNMVC-D!I?KFY@M.HN-=Z12:-%AONH><C$R
M-GA"Y4:/(DQIKK+2E\UVT=FHW_ES8[$LWVO;&8Q>.F'W>;L].Q;&\1BSBQQQ
MU3E B$2!G=F7WYR%_L=67_F8)I!]=M^8@\>V_H[FS.W=G=NZ]3]4[CW)I,2G
MW;Q!9PJ0^SEV3MNT="M BB4)HHVEU&26O="W#<E>CS(;$AQ;D2K K$TT[&9;
M1$5,7+AX]AX:N_\ +]6XWM]J+#T<GEIF?ARXL<L&-QYNQ.P.4=\X_MNQOP9C
M=>8M^G4D^XICCB%_O]TI96[?!XM_1MF7VQ>GG=^SM*S,[46K3[;N(F4MQ=T;
M-WF5CI7(6[+2M]X%HX4AZ/$2S#;2F,09E/O2)GOQ4L-1GA?J96+W!U'E]N;/
MU"Q^$B)V%F'81;-2N+GR-W<@)A80V)G=V?RTO7RT/=OA)8?;?OWW@9GVV;T?
M?N_;T;3OAS^%GO+I[V^WMV V9NT/L4-L$'81,>>)>-1[/LDM9K*$LCUOV8+(
MP7(,8H/R-E(:9C'#DA!":\Y%)H'J?9EVW6NL=)9_3. Q.#TX^)R.-.-[%@HJ
MK=*$898Y:T=JNX2W/-3.%F66>&+D;.;QM*3NM&A1NUK=J:Q;Z\4O\V&Y[;[L
M[%P)R&/BVX,(D_;X[,S*]KG*E,*M/NOXB/XHK 3#.BM@V]XK9I0+)DRV]3*8
MZV/;BR9#@:R*&'4FY4R.\[@=&:BQ4Y]EV2XZIME3+G.M9Z^_5,8';"7[CRV2
M@ZTK/4INP,)ETK'3G:4S%RZ8L _9(M]F=E^J? 7]&1_&N3(<O$336""GB8LB
MU&D4>=SP'9*:*(;V*:WCGH0UY0![4IS2NW,(A!BD:09TZPV"G9M3AVE-1NU*
MQ*]C'T6^@':Z;3EX?"G^\B$ZZZIV'Y3<1T2L92ER3'E-X3CVLYS=\=>]HU0M
M>5N4^>W[&] \$S;@![\'=W<??XL7;<A)MNR_/>K--EI3,SX<LU@,\\/-_/Z<
MR093'EPLV*W![  ##/O7ZI0[.XPRPGR?GLT)_P ;^RA%"31<_JT@7OETN-$
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M6'EQ;Q*7(?8KMBSD=,02V;<QY? U@*2:<^(Y;&5P$B>21]QCRM>(6;F;=*^
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MY5);MJW0$N?#E7R%5Z,]0R<F<8+XW1E )&BG"0=GULM:R%"N!QS1&[FPL3
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MVGKO"O\ K]R^ZUK^E0.]H=TH)F_+V2;.FM<4.TN5ZSB]BTC[)3D$BMA*8.3
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MG?5HQLT.)KCQZ_6"DS#HV'.R\_B/";1EY[.459;:P"7V@#OV4S2:=KN^7VZ
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M20W\S8PM_0^EX-:T8^SO.5>4,7J.*#=AKUJNH[H[%-/U;(,9\\8SC\F<>?\
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MG=Y9;5S+2$,39I0NPM/M9QBBV:&8UAM5Q$C.=;7^,@.:)?#3E4R5327N+ [
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M:!"Y<:@VD4-G2QM8DA656 D[\"+';ER?8=>4-?2YR_6NH@TEK_ Z>RE:/JC
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M>(=BA7\0/(Z>R33$UOQ%Q&$?(YV]#Y5X:L>I\/4O8K'Y-QM-%-<U!#%;U"\
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MU'!$Z+MG7D"L9H([8 .YRHDZ6$L6$TJ/77R5B*P6R[L"!?\ 660T?A8\UH[
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ME<'LPQ,4]29GBLQ"[R02L\<H@;.RR?FPHM.$3A$X1.$3A$X1.$3A%"SQ#=E
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M;JM;H;X:<+80TCZ42-GK=- 5 */LLYU FL,3#_VALA9+XJOUXJ395"Y;]0Z
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MYQJI:XN(]FJ#]B!.J&$I]8+"9\B+AMM4GR:;])%]FF-,4'0- 'ZUUM!+0:S
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MLV@"]96UF+M_9X:MR*B!4]*KT,75@UJ@ Z_,KYQ]=M"%@4(<3&71+-NBRV[
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K$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$7_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>g98473g61w04.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g98473g61w04.jpg
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M1.$3A$X1.$3A$X1.$3A$X1.$6/+3U"Q9(FB 0*K'0)DY(L2RU(*$E1([DA,
M:P^_&9>GR\MXCPVGI,=IR0XVAQ]I&<N)(N6 KU(K:0[A$>N*^N=X2"BQI;+:
M664KVDS+AUK%DR9G5MR8W7FP4E'B.RVDYA6(<B*604D.O)#YGP=-]VW^'O\
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M5\V>54E$1B2V0*E0M %UJNQI:W76(CI<RS$6N*^A^9'D(S&Q=R6(OXF4(,A
M]:60&D$#.(G<'\"^[D/;?Q;?9W9V=F=G9US]NC;H&,5R!X)"%C$'(#=Q?P?[
MLBVWW9VWZNW5FX=G>EG1_O7LK8?;/L=2;32MYV4#2V#REU.-"OM@):D4S:A8
M^"*LP:R2XXZ22)Q6Y$B+@2VX?^(R6^W1$NLYE_1LS(Z=RN,HT\A=KPPU+_#W
M.8;M"?O+.!'Q1QU[,LS@+"[2&X,$9N,<A#(0B5^WA\C0K5[MJ$ K6]N[F-JK
M,\N[.6X1PSR2.(L+L9\#"!; ;B1"*Z0;P[U:?TOJNW[$)S'A1.JP8\UNI[9
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M>G]'TI,?IW'!CJLTY69A:6Q8DEG(1!SDGM2SSGP@ @ O(X1BVP".[[[OB!A
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M0"WB"!0*5/C I4.!1OUBG9&U"](P9<.S0APS)DP)RILM(.0\(8B+S1%?.38
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M ##)SV&'(L"4;$1Y;K3Q*&AXBR?"+&#S08L\6C"BPPG( $\A3L<?/BS7@IG
M^ 6R)+-1G7%C2>!9462S F)9E?3R4"9\+Y>9'<<(AHT&K@DB>L)88!!"(;Y
ML:-3XHL2+@1D9=DSB)&<ZQ#A0X[:5./R9+S3+2,96XM*<9SPBR?")PB<(G")
MPB<(G")PB<(G")PB<(G")PB<(G")PB<(G"*O.^>J77_LZBO-[TUU"OR*K M
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*3A$X1.$3A%__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>25
<FILENAME>g98473g63r89.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g98473g63r89.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_[1\J4&AO=&]S:&]P(#,N,  X0DE-! 0
M     %8< 5H  QLE1QP"   "   < E  "')R,C8T-C$W' (% #5-:6-R;W-O
M9G0@4&]W97)0;VEN=" M($E03R!P<F]D=6-T(&1I86=R86US(# W,C(N<'!T
M;3A"24T$)0      $&9H976%ALX6Y+ 3M]'"\MPX0DE-!#H      .4    0
M     0      "W!R:6YT3W5T<'5T    !0    !0<W138F]O; $     26YT
M965N=6T     26YT90    !#;')M    #W!R:6YT4VEX=&5E;D)I=&)O;VP
M    "W!R:6YT97).86UE5$585     $       ]P<FEN=%!R;V]F4V5T=7!/
M8FIC    # !0 '( ;P!O &8 ( !3 &4 = !U '        IP<F]O9E-E='5P
M     0    !";'1N96YU;0    QB=6EL=&EN4')O;V8    )<')O;V9#35E+
M #A"24T$.P     "+0   !     !       2<')I;G1/=71P=71/<'1I;VYS
M    %P    !#<'1N8F]O;       0VQB<F)O;VP      %)G<TUB;V]L
M  !#<FY#8F]O;       0VYT0V)O;VP      $QB;'-B;V]L      !.9W1V
M8F]O;       16UL1&)O;VP      $EN=')B;V]L      !"8VMG3V)J8P
M  $       !21T)#     P    !29" @9&]U8D!OX            $=R;B!D
M;W5B0&_@            0FP@(&1O=6) ;^            !"<F1456YT1B-2
M;'0               !";&0@56YT1B-2;'0               !2<VQT56YT
M1B-0>&Q <L            IV96-T;W)$871A8F]O; $     4&=0<V5N=6T
M    4&=0<P    !09U!#     $QE9G15;G1&(U)L=                %1O
M<"!5;G1&(U)L=                %-C;"!5;G1&(U!R8T!9
M$&-R;W!7:&5N4')I;G1I;F=B;V]L      YC<F]P4F5C=$)O='1O;6QO;F<
M        #&-R;W!296-T3&5F=&QO;F<         #6-R;W!296-T4FEG:'1L
M;VYG          MC<F]P4F5C=%1O<&QO;F<      #A"24T#[0      $ /
M     0 ! \     !  $X0DE-!"8       X             /X   #A"24T$
M#0      !    !XX0DE-!!D       0    >.$))30/S       )
M   ! #A"24TG$       "@ !          $X0DE- _4      $@ +V9F  $
M;&9F  8       $ +V9F  $ H9F:  8       $ ,@    $ 6@    8
M  $ -0    $ +0    8       $X0DE- _@      '   /______________
M______________\#Z     #_____________________________ ^@
M_____________________________P/H     /______________________
M______\#Z   .$))300(       0     0   D    )      #A"24T$'@
M    !      X0DE-!!H      S4    &              *U   #,
M   !                          $              S    *U
M              $                         $     $       !N=6QL
M     @    9B;W5N9'-/8FIC     0       %)C=#$    $     %1O<"!L
M;VYG          !,969T;&]N9P          0G1O;6QO;F<   *U     %)G
M:'1L;VYG   #,     9S;&EC97-6;$QS     4]B:F,    !       %<VQI
M8V4    2    !W-L:6-E241L;VYG          =G<F]U<$E$;&]N9P
M   &;W)I9VEN96YU;0    Q%4VQI8V5/<FEG:6X    -875T;T=E;F5R871E
M9     !4>7!E96YU;0    I%4VQI8V54>7!E     $EM9R     &8F]U;F1S
M3V)J8P    $       !28W0Q    !     !4;W @;&]N9P          3&5F
M=&QO;F<          $)T;VUL;VYG   "M0    !29VAT;&]N9P   S     #
M=7)L5$585     $       !N=6QL5$585     $       !-<V=E5$585
M  $       9A;'1486=415A4     0      #F-E;&Q497AT27-(5$U,8F]O
M; $    (8V5L;%1E>'1415A4     0      "6AO<GI!;&EG;F5N=6T    /
M15-L:6-E2&]R>D%L:6=N    !V1E9F%U;'0    )=F5R=$%L:6=N96YU;0
M  ]%4VQI8V5697)T06QI9VX    '9&5F875L=     MB9T-O;&]R5'EP965N
M=6T    115-L:6-E0D=#;VQO<E1Y<&4     3F]N90    ET;W!/=71S971L
M;VYG          IL969T3W5T<V5T;&]N9P         ,8F]T=&]M3W5T<V5T
M;&]N9P         +<FEG:'1/=71S971L;VYG       X0DE-!"@       P
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MAC^ED_K%OI*SB=3?U7I^-:ZD4G(OV@->+6.92\N=?1<UK/5HL;3^CL]-F_\
MXO98C#YAYW]B9_*?$5]K_]/U#*QZ\K&NQK9].]CJWQSM>"QT?YRPNJ?57I9H
MLO+++"QV]K=P 8"?4>*PQK?;O?;;[_\ 2?Z/TO3Z),0"(.H/(24^>UX.';8[
M96\.])];P7@S4\;"6;65^YE>UO\ I/S_ -+^F5YG2L2P/<;+0ZV2]P-8DN%,
MZ>CL;[L3'L]O_GOV+7R^D-Q+G9&/7+'<D22T<D;?W?Y?^>LK*+Z&^I206?G
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M1@XWN97N?W>[4JQD45Y%1KLF#J'#0M(^B]COS7-0*\M]+QCYL->=*[^&6?\
MI.W_ (/_ +;3]9#3?J/^Z8^&(.HTZ'_N6V  (&@67U8SG8#?^%G[@Y:JR>IF
M>J8+?#<?N:Y-"<GR_4-W#Y?\OXJ=N'B7/;9=178]I:YKWL:X@UGU*G-<X?X)
MYWU_N*&)^?\ )6'.:UI<XAK1J2=  @NCLUF=+Z960YF)0QS7NL!;6P$/<WT[
M+!#?YQ]?Z-[_ -Q5^FXN*+778M-=&+7+,=E30QI)/Z>\-8 WWN;L_L(CGOZA
M^CIEF'_A+>#8/]'3_P '^_;_ -MJZUK6-#&@-:T0T#@ )WRC^L?^:CYC_5'_
M #G_U/550SLVRC+HH:^NIMC7/FP2;"TL;]GI]S/TCM_\O_BU?30#SV24X-'7
M\DU5V/=1:'$?S8(W U"]XK]]S_U:QVR[TJ\G^<K_ )G]+8RQBY S\6D/K8'W
MVN%A:!!94[<YWM==7^DVUU/V7WL_2_SBTK:&VQN<]L3]!SF<^.PM358M53_4
M!>Y\;07O<^ =3MWEVW="2FM?TBFQQ=4\U$\CEOW*/3\'&-8LL'J6M.U[7ZAC
MA])NQ:*HYKZL>P6L<67OT(: X. _TK"6_1_?W>HB #I]B#=V-?!AU?&#JV9%
M9V7U.&PM&I_.C^LWZ;-W_%_0NL4&=6==BGV 6D%@VG3>>/:[W;/SU&_,LR*P
MPM:""#ND]OY,?]_0/T51WV.:'.[G3GZ6UJ>(UNBM= ==VX[+>*FTTC8UH#0X
MZN@:*E;3NJ<P?G C7C4(M=U-AVL>UQ\._P!Q3FIOJ"R3N#=L3I'/T40:760=
MJI!0_)Q:]E=KH\#J!_4:[=L6KTZVVW%#K27.EPW'N ?)9SVJSC]1KIJ;58PC
M8(!;J"E(6- DF]7247ULL866-#V.T+7"04U5K;:FVLG:\!PG0P5-1;(:@PK:
M?Z)>ZMO^BL'J,_L[BVQG_;B!=A95U]=]K*WV4F6.98^L<S[F>G9_U2T7.:UI
M<XAK6B23H  N9K^O.,]E5GV5VU[;'OK#P;@UGOJ->.X-??ZN/Z659M_F*+=Z
M=QGK16\ Z:?E]CMM9U :,;12#R9=8?R4IQT]KW!V78[)<-0UT"L'RI;[/\_>
MJ73.OOS\_P"QC&!:VAMUF33:+J0Y_P!"H7!E;;-S?SF?N6?H_3_2K82XSTH>
M7\5< ZZ^?_>J22235S__U?54DDDE*22224I8G4;VVYSZV?2J:&Z\$_2_Z.[W
M*WU/.MH<VFGVO<-Q>=8$Q[5DM%8L#G";'DG=R23JX[E)")W71 UOZ)S8:ZM[
M@"X :#@N*SWN<YQ<XRX\E7,G6MOAN_@Y52U2!?!9NO*TL2YUE9#S+F&-Q[@_
M1G^4J=6-8_4#:T_G._[ZWZ3E=JK;4S:TDDZN<>Y0EJMR$$5U9N5=[2\AC>7$
M-'Q)A%L<[:=L%W:>)56_>]FT.VD_2C^" 1$?1Z-C&L8UC?HM  ^ 4E7Z?N^Q
M4;B'$, ENH,#;WA6%"M.ZQ (@Z@IMC9W0-P[QJI))*8M8Q@#6-#0-  ("DDD
MDI22222G_];U5))))2DDDDE-?+PJ<H-]26N;]%S>1/94<OIS,:KU:GN(:1N:
MZ.YV^W:&K65/JC'/PW$?F$/(\A]).C(V!>B07+@/;M=P4F4U-,F7$<;M8_L_
M10RYT>UVTZ:\J>]2KDVY,7(.]TF2(_-_VJ%IN(8VII-CX+&@27#7^Y!0BU'9
M'7SDOKKQ*K*S;%$. <ZL/?N-F^S]'8['V;/^$_3?\$I#'^LI(WXC7-(9,!K3
MO)=ZU9'VAVVMKO3K];_1?K/^#]);.+TS):^F^UX8YIW/K'N_L[Y6JF2EV*":
MV>>9?];*,<5UX&,3Z8-8:X@->XN_1VMLM&[TV_SUC+?YW^;W_P XK6!F==MS
MF,S,7T,9PM+S#20X%GV>L/9?;N9Z;G[KO39ZMO\ @ZEKI)BU22222E))))*4
MDDDDI__7]527RJDDI^JDE\JI)*?JI,0"(/"^5DDE/TQD]'8YCOLKO2>> Z2T
M#^3^<U5<+IE[K'59#2QM0(+APXS[-CC])J^<4E(./7R7CBX?K]7Z2KZ/DDQ9
M8QC>Y;+C^(:M2NBJIC&M:/T0VL)U('?W?RE\LI(3XNOX+3;]5)+Y523$/U4D
MOE5))3]5)+Y5224_522^54DE/U4DOE5))3__V0 X0DE-!"$      %4    !
M 0    \ 00!D &\ 8@!E "  4 !H &\ = !O ', : !O '     3 $$ 9 !O
M &( 90 @ %  : !O '0 ;P!S &@ ;P!P "  0P!3 #8    ! #A"24T$(@
M   !1DU- "H    (  @!$@ #     0 !   !&@ %     0   &X!&P %
M 0   '8!*  #     0 "   !,0 "    '@   'X!,@ "    %    )P!.P "
M    "0   +"':0 $     0   +P   #H "W&P   )Q  +<;    G$$%D;V)E
M(%!H;W1O<VAO<"!#4S8@*%=I;F1O=W,I #(P,3DZ,#<Z,C(@,3(Z-3DZ-3@
M<G(R-C0V,3<       .@ 0 #     ?__  "@ @ $     0   S"@ P $
M 0   K4         !@$#  ,    !  8   $:  4    !   !-@$;  4    !
M   !/@$H  ,    !  (   (!  0    !   !1@("  0    !
M  !(     0   $@    !.$))30/]       (          #_X0%(34T *@
M  @ " $2  ,    !      $:  4    !    ;@$;  4    !    =@$H  ,
M   !  (   $Q  (    >    ?@$R  (    4    G $[  (    )    L(=I
M  0    !    O    .@   /      0   \     !061O8F4@4&AO=&]S:&]P
M($-3-B H5VEN9&]W<RD ,C Q.3HP-SHR,B Q,CHU.3HU. !R<C(V-#8Q-P
M     Z !  ,    !__\  * "  0    !   #,* #  0    !   "M0
M   & 0,  P    $ !@   1H !0    $   $V 1L !0    $   $^ 2@  P
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M,I&A!R-"4K'!T15#8G+A\18S@J(D)5-CDC1SLP@U5++2_]H # ,!  (1 Q$
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M=,;[A 4A#JV+5Q3"(P$2)U-<Q"B<HBRY*B1\PS'*]48@VLM\FGO'8O9:?/\
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MT^^JDFE<12NDM(8EBKB$7ZWN)(C"<]7<.5>I%3SKT#LF\5Q>JZ A8K>XV+@
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MP?>1)^YH^C(/4!7U&/@%FV1+A/J+I*_*8MA8.LSLR3,:/<ADH0+ <O#84Z7
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M!D6CMX<6XMA3K')H0:^751989$ET:N'UV4X$32LX_E[_ )]*R -^=II,O'X
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M>_O[LX"P0+DD!F\(DD"L$SG: \K I$]5[M'KL>AV0=4[^_NG^SZ?:#):>=L
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M:4KYD*(+%(8@Q,1417D>UC$5RHC45SE1.5541$Y\JJ(GG2E:GE>:0,56MB+
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M<\D@<UA=BLFVWR?-<LG;=Q/9A7$<52XHIXI$6WV_L66V2@)B25,EQ!8Y3SE
MMK%IJ50T1K %I<0V2'6+I"YEBDB(#CKRK#E77U5O/Y\CH0*UZ?J5KJD GM7R
M =LD;#;+#)@$QRKY,,C!!9&'*,PYJU&M53Z:4KY&,&,(DB040 !8XAC&(P0A
M#8G4\A"/5K&,:B*KG.<C6HG*JB:4JI&&>L; =P<\W$PS$J6XL(&W)?:668%E
M4\:BL)WN),56UPGSG6)J_OP9S66GM?;$9'0S4[,B,0O!TG7[;6=2U&PLXI&3
M3&$=Q=LT0B:5F= L48<S.NZ*4=YL">#DX=";7VL[)W?8WL]HFN:Q<P+-KZM)
M9:7%'<-<)"D44S27-R8A:0LL<]NS0F4R_K<*K&.4)%^]/J#+E6*Y'A>+WM?"
M2\&&MO+BO66YM!C92N2Y2';C ^":YN(Z)0P%D2(<%#ST<LN(9!J^X06VR1'=
M<[<E$; +N!X?"3G:I\9P"<>7&*\1U3M%/=VUW;6QC1)$"33)O*6T#$A]TP4I
MWD_%NF2B;WX93BHIP:[Q3:*=A=UD=269-?1MSF;3PWQH\>ELI8GT>"XV>7,5
M@_8X5BXY)4*%LKKR:YLYX7?OEZ>S/=_8.SUW,N>^U6__ ++5Q@,;.UC2ZO64
M]?\ Q%Q);QN.AB39BHW9G2X[G5;%3AA86(U>X3;PM[=N]MI\# @?_1VL<TJ]
M2+B5W#$$5<+#/5IM9E<UE;+DR<<EE5J,)8DA2:Y5<K6_O)U?(D>U9U.X4\T$
M6,WPKS,5435-6=&."&3/ W#C\?+YUZDT+J,XR/,X^/K\*D+?7.'8%L[G>70"
M-?.C8\:-0N$_J0UW>.%3T*B<-54B.L[&&1.TO+AHJM<U/K2=;1B6>)"?"6!8
M_P"%?$W_ &@UQM:NS8Z7?7(X=(&6+_[TN(HO?B1U)]@:KEZ,]LJB!2WF;6%3
M73;"+:APK$K>5"C29<6GPJ RGN9M3-*QYHC+G+2Y*^8Z*X*RE /NN,-@E27?
M3OQ$KLJN.]E0':K,[;D#J.#L39C.<$DCK5<[%V*QVD]ZR*7EF$,+D D16R[&
M9#R5#S-*#T)VC.1BKUZYM7:J![EX!51JS=VI2/(?,P273Y;A(VS9J1*S%\VL
M1RKZ%%JV2$KV1XMG&NW(1T92##VF]2, %&V[4)FN[71-4/,EU!-I]\^,F6[T
MTI'%*[$9:26UEM]QSEBI)YR*H=O:I:SZ]I@4[+*>'4=/7<VV*SU,F2>*- VU
M8XKJ*ZVC;P& X&VMH]($"A)7Y19L&5N31)HX,DK9LM!%HYH(TB$TE?WO8O>.
M=#GJ.4L=9+$<0;3(-[F+7[XMN09\.,@8'W@2#SC/0CC.*[VB+'LF;'ZT,%)W
M-RA *Y7.WA@V#C/)&:NIJ#7>II2FE*:4JN_J7R"= P*/BE+U/OMQ;J!B%>(;
MU:5P)I6NGJB)_$,XT%6%Y5$1+)'+X1=6[L7:13:L]_<\6FCVTNHS,1E0\8(A
M_P"I&+3KCKW!'QIG;B\FATA-/M>;S6KJ+3H5'WBDIS-QYJX"V[=<"?.#BIEQ
M'&H.'XS1XQ6MXB4E;&@C>J(CSO$S]_*+QX4TN0XLDRIX<4KW(B<\:KNH7LNH
MWMU?3?\ ,NIGE8#HH8^"-?\ #&@6-/15 JS:=8PZ;8VMA ,16L*1*<8+E1XY
M&Q^U*Y:1SYLQ-;'J'4VFE*:4II2FE*B_>#=;&]F\'M,TR,S59%;[>JK&$8R9
M>7!F/6%506NY5Q3N8YYB=+F1(8I,TR(".14W00O/((T\^6;!PJCJQ^&>!U)X
M%<_5-2M]*LY;NX/"#$<8.&FE(.R)/=L9)QA5#,>%-<-*>'E?J,W-N,PS"48L
M4\QL^_F,<1D>)#1>(&.U'6KT -H&MBQF(Y71HC#33.+*<GN; [):0JB  XP@
M]3YN?7GD^IXZ=/$9Y[C5KV:[NFRTC;G(R$5>B0Q@D[54851R0/$<L23]MS,H
MG;DY/2;9[>PGSJF'.BT]'5U(VH.ZMU3V@71F,Z!) A,5T:$]RMCL"V3/>5(Y
M&.#B",0HTTIPQ4L[']E>N#[\9/7R'E7PXDNIX[2V1I&9Q'&B#EW)P  /(>IZ
M8+$@5V:].NQ]3L7M_#QX/8EY)9]JSS"Y&WS87+Q(U8\=[T0B5=6Q5AUHE1B*
MQI9CQ,E392NX=U<-<R%N0BY$:^BY\_\ $W5OPZ 5[/H6D1:-8I;C:T\F)+J4
M?WDI'0$\]W&/ @XXRV SM4]ZC5VJB_>3"&;@;=9'C[1,)8+#=8TKG(G6*XKD
M65"[;UX4:R7,?!*]JHOMI9V?#U37;[.ZF=(UBSO"VV(2"&Y]#;3827(\]@(E
M4=-\:''%<+M+I8UC1;VS"AIN[,]J>,K=0 O%M)^Z7(,+$<]W(X\Z\FQN9OSK
M;+&KF2936<>*M/<.<J]U;.I7VAC&Y1."S L!8.3\I;?SXUL[3Z:-*UN]MD79
M TGVFV ^Z(+C]8JK_AC8O"/>,CRK5V4U,ZMH5C<NV^=(S;7)/WC/;GNV9O\
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M[JM37L#NG,V93-L:D58JV]L7BC2+-L,+L@K!0D>A(<$[GLXBSGN&]SQO<-A
MQ90^>XPX?+]*UA?T>=JNT=EVOL+E;AV9?M4<"S77?Q22R+&69@QM+Z-XY8V2
M4Q!UC+Y3+IZ_VV[$WOZ<?T>=B+S]&6M6"PVKH\FFW-]-:Z:UE=6]M;R72I'$
M\:ZEHDL,\4J26XG:">X$.R7;'/KL#=3,;G>2GM#RB"HJ>S0;XHS*@ AMH_8?
M.GF<JOFV(B2&R%>Y.6.CJ@ A:\JN[=C^DP7NJ:-=WI_LZPO[DV<&GJW>!4GD
M>U%Q<.$3?L8I(\S(D4:\1@9;=3=;_P#TW0:'V.[7Z3H\?_$':+2=-&JW>OR1
M+%++/801ZH]CIT+22&V2X6.:UCM4EDGG9P]S))MC$?8'$]]+/!;W;Z2DM'XM
MF<@M?=59BL6..</V_=-"$[@@+ ($GG:83FBE"K6Q);>21',]*U2XBLKFSBED
M5&NY9+>!7.#-)'&TY5/+>(DDDQQX4(&21G\[]A[2\U33=:GM;>2:#28;74+Q
MXQN6U@N9TL3-(0>(C=/;1< D&4.?"'8=!,TR^KP?'IE_:*1Z"Z(\"OCIW)]O
M:R5[=?45P&]3Y$Z=(5HA#&UW0U7G)T@$5[>CINGSZI=QVD& 6R\LK\16\"#=
M-<3/T2*),LQ)&>%7+,H,K5-2M]*LY+RXW,%PD,,8W37-PYVPVT"#)>65\*H
M.!EVPBL1K^UF,6>/X_)GY%T+EN76DO*LI[:M<.-9V2#:*K ].>8M-7AAU@41
MY&=48I!O<PJ+J5KE[!=W:16>?[/T^".PL-V0SP0;BUPX./'<S/+.V0&Q(JL
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M8E:1LGMZ?:;0+B0#<PS&#SM7]\^A(SCT7GSX\O[8Z^9I&TBS?]3&P^V2(?\
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M-W^T.R]IGU-NO8[A1\E]]9QK;*J60&^Q],;B08>(RP?AYG6A&606?F/H?Q^
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MQ(W X\)Z#G[U=:/2]3DM&OH["^>P0E7ODM+A[2,KC>'N5C,";<C=F12."0.
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MFZ@-&;>XR6$9P0>Y=FV <]WW3?MBJUIEY-V@[)7-L7ECU2PA:TN4#,D_VFS
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MM8QC4:QC41K6M:G"-:B<(B(B<(B>$35 )))).2>23R23U)->B@      8 '
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MR@EH]PX)WR3;?")D3,=;]/[)/-=+JG::[_MC4!AH[<C_ ,OM//9'"559 IY
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M(FJR[O([22.TDCG+N[%G8GS9F)9C[DDU9XXXXD6.)$CC0!42-51% Z!54!5
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(2E-*4TI7_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>26
<FILENAME>g98473g75i90.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g98473g75i90.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_[1C<4&AO=&]S:&]P(#,N,  X0DE-! 0
M     %8< 5H  QLE1QP"   "   < E  "')R,C8T-C$W' (% #5-:6-R;W-O
M9G0@4&]W97)0;VEN=" M($E03R!P<F]D=6-T(&1I86=R86US(# W,C(N<'!T
M;3A"24T$)0      $&9H976%ALX6Y+ 3M]'"\MPX0DE-!#H      .4    0
M     0      "W!R:6YT3W5T<'5T    !0    !0<W138F]O; $     26YT
M965N=6T     26YT90    !#;')M    #W!R:6YT4VEX=&5E;D)I=&)O;VP
M    "W!R:6YT97).86UE5$585     $       ]P<FEN=%!R;V]F4V5T=7!/
M8FIC    # !0 '( ;P!O &8 ( !3 &4 = !U '        IP<F]O9E-E='5P
M     0    !";'1N96YU;0    QB=6EL=&EN4')O;V8    )<')O;V9#35E+
M #A"24T$.P     "+0   !     !       2<')I;G1/=71P=71/<'1I;VYS
M    %P    !#<'1N8F]O;       0VQB<F)O;VP      %)G<TUB;V]L
M  !#<FY#8F]O;       0VYT0V)O;VP      $QB;'-B;V]L      !.9W1V
M8F]O;       16UL1&)O;VP      $EN=')B;V]L      !"8VMG3V)J8P
M  $       !21T)#     P    !29" @9&]U8D!OX            $=R;B!D
M;W5B0&_@            0FP@(&1O=6) ;^            !"<F1456YT1B-2
M;'0               !";&0@56YT1B-2;'0               !2<VQT56YT
M1B-0>&Q <L            IV96-T;W)$871A8F]O; $     4&=0<V5N=6T
M    4&=0<P    !09U!#     $QE9G15;G1&(U)L=                %1O
M<"!5;G1&(U)L=                %-C;"!5;G1&(U!R8T!9
M$&-R;W!7:&5N4')I;G1I;F=B;V]L      YC<F]P4F5C=$)O='1O;6QO;F<
M        #&-R;W!296-T3&5F=&QO;F<         #6-R;W!296-T4FEG:'1L
M;VYG          MC<F]P4F5C=%1O<&QO;F<      #A"24T#[0      $ /
M     0 ! \     !  $X0DE-!"8       X             /X   #A"24T$
M#0      !    !XX0DE-!!D       0    >.$))30/S       )
M   ! #A"24TG$       "@ !          $X0DE- _4      $@ +V9F  $
M;&9F  8       $ +V9F  $ H9F:  8       $ ,@    $ 6@    8
M  $ -0    $ +0    8       $X0DE- _@      '   /______________
M______________\#Z     #_____________________________ ^@
M_____________________________P/H     /______________________
M______\#Z   .$))300(       0     0   D    )      #A"24T$'@
M    !      X0DE-!!H      S4    &              )[   #80
M   !                          $              V$   )[
M              $                         $     $       !N=6QL
M     @    9B;W5N9'-/8FIC     0       %)C=#$    $     %1O<"!L
M;VYG          !,969T;&]N9P          0G1O;6QO;F<   )[     %)G
M:'1L;VYG   #80    9S;&EC97-6;$QS     4]B:F,    !       %<VQI
M8V4    2    !W-L:6-E241L;VYG          =G<F]U<$E$;&]N9P
M   &;W)I9VEN96YU;0    Q%4VQI8V5/<FEG:6X    -875T;T=E;F5R871E
M9     !4>7!E96YU;0    I%4VQI8V54>7!E     $EM9R     &8F]U;F1S
M3V)J8P    $       !28W0Q    !     !4;W @;&]N9P          3&5F
M=&QO;F<          $)T;VUL;VYG   ">P    !29VAT;&]N9P   V$    #
M=7)L5$585     $       !N=6QL5$585     $       !-<V=E5$585
M  $       9A;'1486=415A4     0      #F-E;&Q497AT27-(5$U,8F]O
M; $    (8V5L;%1E>'1415A4     0      "6AO<GI!;&EG;F5N=6T    /
M15-L:6-E2&]R>D%L:6=N    !V1E9F%U;'0    )=F5R=$%L:6=N96YU;0
M  ]%4VQI8V5697)T06QI9VX    '9&5F875L=     MB9T-O;&]R5'EP965N
M=6T    115-L:6-E0D=#;VQO<E1Y<&4     3F]N90    ET;W!/=71S971L
M;VYG          IL969T3W5T<V5T;&]N9P         ,8F]T=&]M3W5T<V5T
M;&]N9P         +<FEG:'1/=71S971L;VYG       X0DE-!"@       P
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MYO-#B9?4+,AK,BCTZW&T3M.FWTO2W/W.9^=<W=_A=GL6@LW.LS,?*&0PN=1
MW-&K0!]/<!]'_C%8HZCCWV>DW<UQG;N$ QX) UH3]JIP) G$#AK7A_1_O-I)
M)).8E))))*?_T/54EAV9F7[FMSJ&$[I<YVHUV@^ZG;5_.,:QC]_^#_G_ -)Z
MKCJ&0X7!^;CM>-OI02T0TL?8??6=U=C'?SE?_J1.X"BW;26$.H9NVQPS,8-K
M@,<\^T@A@%CW-#MOO=^=_.6>I_8M.KZY6&EME=DN:'-[ALMWOW.#/S?]?42X
M?$*MTT$W.>2V@!T:&P_0'P_TCOZO^>F?-[S6TQ2TQ8X<N/\ HV_R?])_VVC
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M]WJ/_P".]=G\RNJ7RJDDHOU4DOE5))#]5)+Y5224_P#_V0 X0DE-!"$
M %4    ! 0    \ 00!D &\ 8@!E "  4 !H &\ = !O ', : !O '     3
M $$ 9 !O &( 90 @ %  : !O '0 ;P!S &@ ;P!P "  0P!3 #8    ! #A"
M24T$(@     !1DU- "H    (  @!$@ #     0 !   !&@ %     0   &X!
M&P %     0   '8!*  #     0 "   !,0 "    '@   'X!,@ "    %
M )P!.P "    "0   +"':0 $     0   +P   #H "W&P   )Q  +<;    G
M$$%D;V)E(%!H;W1O<VAO<"!#4S8@*%=I;F1O=W,I #(P,3DZ,#<Z,C(@,3,Z
M,#DZ-3$ <G(R-C0V,3<       .@ 0 #     ?__  "@ @ $     0   V&@
M P $     0   GL         !@$#  ,    !  8   $:  4    !   !-@$;
M  4    !   !/@$H  ,    !  (   (!  0    !   !1@("  0    !
M          !(     0   $@    !.$))30/]       (          #_X0%(
M34T *@    @ " $2  ,    !      $:  4    !    ;@$;  4    !
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M 2@  P    $  @   @$ !     $   %& @( !     $              \
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M[59.AOF6&^W<&[\E1:?R3I=61N^K\//&J-+UC4]OU'>*NHK3J7>M?LJIMOK
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M+#..&L7PHX6P@)\:7G.Z2:K<_P!ET7@X>7NF#%4C-XPA5T:12<N/FU=US/\
MHY\(D:]7_LYQ:0Q30,E\F.*"7@[<?6/ABLJR3S+PA&O'BF2W=5TQ$<^2*)[?
MX^Y,UKDR+:IM:;=1MT[;CM*N8[VCLM?+9=5];46TRQ5]O +8>3D!NP)AB"!1
MU(9(KXXUB[DCY2QXA;\0%R;<3 6MT]I*)H9(&YL:1R'"2A9-)65"K,JZ@<@8
MP3S?&.!WW VL%OC;$\2X=#Q2V-I=07D9M9I[FW75-;O)#S5EM9E=$D?05P3J
MR!8.;U0],4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4
MKY[;=V:NT%8<UVO*NO\ +^QPUB;F+L=+ID_./-%5IZU=7N_9Y/ HSM"KB9]%
MB (T75.?J&SKF49E<>?R#2F6$%@7##9ZTI6.NN]@;M-:3/014O+FLV!C[RTW
MVSWNHW3DWBZ_U3D_DJMXT'Y8V:OUW7!KZMY'H3+[C'W<S:'MMS2ZAR+MV_;2
M1M533"0#QD-_S_"E?9/%*8I3%*8I3%*8I3%*T543VJB?E7I_H^OU8I6+CNS!
M6I'K P^^;#%7:E9\R;!45L]+J%H"_8^9K'>";JRLX+:B.BM ZZMW^\I!J,QD
ME48&T64^"8EDTD_.'P=CQ;*M[.([5^*S11F&UD0S\6DO&FDE66%Q*B1WLT2P
MM\VRZ2X)SJ[P>'<Y:^D?A-FTW$8/!JSN9TNN)02BR\&8>%):P0/;W<36\L\_
M"+6ZDNXR+B.3F+"R1E56%U'8BTRG93PC[QMD8,9,CMJJ!0=5KZ+9:IO)=?RN
M!K0%0%1Q!Z5KM9M-?X8E9J3:Z-*@ZR#>Y22_/QZL7@C:Q","\NM&HFZB5+>.
M&XC\?3B*0)&D*K9P1W*>3';:!RGD0G4Y>I2X_2EQ2Y-P\G"^'M*8U%A<22\0
MFNK*X/ YO!Z:^FN9;MI.*7MQP^;,L_$3.QN88)!Y$?):^N*^+".-C^1;";=;
M?;G\C;B[=SH[2LH:^.KN9ZL"E+0!:4 )T@Q-=3TT*Q%K-X+Z]9HE;(64LDSP
MWAK</>_<W<MT;^Z\;<21PH(Y3&L3Z.4B95DCB&&R 4R,%VSR7'^/Q\;AX+"G
M"[;APX+PP<*B:WGNYC<6R7$UU&9A=32A72>YNFU1A=0FTMD1QXM[)2N<IBE,
M4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4K%;A#8+JV
MY0Y8K[&:T>%3RW ]<AMLT\4B/W[^;X4*#$:80^N:.*.)1MA+@#*\K2BLAB=5
MQULCN5X'<SS<3XO'*TI2%YECURB16'RWQM=2*'8QA41( KA&T0H%'+$9J*L9
M)'N;Q79RJ%@@9]2X\>X@-2C4=.%"QX(4XC4 : AK*G.JJ5IBE,4IBE,4IBE0
MQ.1N/G6*5#=ZT];59? 2M39:93EGZ]/ 03SOCK,JKT2)&=]5]C<P^,6^K1SX
M=?31S4U?NZL_PJ4/ ^-BW\;/!^*"UTZ_&3P^[\7T?6YW)Y>G]K5CTU\U>6N2
M;CD_9BW2S$RZZ,=()K5 Q'R#+"R91A#7@,[[#+BS]4J2.CE(A\TE<(OAM5)>
M.XA>RWD[("W*631#&FKRL'2&(&[.QW'<"%&-\_4'@7X*\.\%^#0W$T4'RC-:
MBYXE?S!-409!*\"2O]#;6Z^2VDJLC(9I-R OTJXZK+BET/4*K8)I)[H#7JL:
MSDEE4B5"XQ(TEAD(<YSIW#K_ ).Z=SG+,L7B*YRNZKV%LDD=O DIU2+$BN<Y
MRP4 []N^V3N>IKYAX[<VEYQKBMU81K%97%_=2VL:KH40O,[1D(,! RD-H  3
M.D  8KH\K5-S><<[A5:^Z;TN72%-$B'D6*<SPT;-/712(YO<DLQHYJ]BJYK>
M\2G><UO5R6WB226LZ1$B1HV"8V)./-'VAY/9UZCK6?P8NK*R\(.#W7$41[*&
M_@>XYBAT1->!*ZD'4L#%9B,'(CV!.U?/+A3DRTX]VFJ%85)[E+>Q&KKNGD61
MH4"'$1">EQAU5K 3ZZ1S)B9(XVN+#AF$*C?(@LHG)\,O9;6>.-F8P2,$>-R?
MFRQP'4'=2K'R@#N,Y!."/I#P^\$^'^$'!KJ_AAB7BEE:R7=I=PA UQ'#&TIM
MI748FBFC#<DDYCE*.C!#(LGT;BY&X^FL4IX=YT^6V=+X#:R/9:9Y[IE7N^"@
MC3%G6;KZO"2/O]?5W<Z_QBWU:.?#KSC1S4U9[M.K.?97S,W ^-I;^-OP?BBV
MNG5XRW#[M;?3UU<XPB/3C];5CTU,\S5%TQ2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2
MF*4Q2F*4Q2F*4Q2NN46*"/*6:2.&+ Q9)R2IHX((8V_"?+-*YD<;$^-SW(B?
M&N7*C.P1%9W8X55!9F)Z * 23Z *H2 "20 -R3L!ZS4#7D>OL$Z:C2W^[=7*
MQI=&%$/1]4_\;=CNR*JD+C3U=Y:PVPD:BITB5?5DA\FRQ'^V36]CVZ)W+3^H
MVUNLUPAZX$T<0SVBL//5OHE>7TH $_?<HA'V2WJK<XCE$WJZ"OTG7(53JU;
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MBQMDUNBV^CL=;V6L%N*2V'<,?7EL5T,T:JCVN:YJMDAGAE:R<8F!\9(I$<1
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MHD[N-2ZU3#:=;QE<D:'"AQ&')C"LW-$+Z1KUX1SNS(%.-B:\87M4\.GWFLU
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MSS(B%D[0?,E Z!P.WZKCRE_:7*G&OE3CS9N;+JMV+6B*NL?1UK=;V77-F-*
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M<<:M;,]['V#(^LF0G$.(P&.YM(IFCN NA7 95U@J3&)!YK$93)PH)\[:O5_
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MU^-W7JU,D;?,%C=W.VJ<I80GM <<ZZ=?2(DCA/[-R:P/Y<L:;X7,K8Z>3Y*
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MYC3XP^!)+*"=)97F#B4JY!=1)K<NBL$9F+%=6].1%DMH&2JJ>N"JXT@C.#C
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M>'DE3#R3_>2!@W.[P05.V]=CX,^$B>$D%U.EG)9BUF2$K)*)2Y="^H$1QX
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MK7& >9GEJ "0!_&N?C/M9Z1RKRV9Q3JU?*?,-J5?M\=_7W5):"K66&G<;;E
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MBE5PGL3\B?5F@>I]9^-=!6N4I6"H/(_/5'VFMWI+ZEWFUXM.L>4J7C6#WO\
M89=,(NHN/NQ>?QS'<[UJ6A;&3J^MD;7?=H@9VX[ Z6D&(9M$)TIJZO65];D
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M:GIE50V-4V2,$VO<9$1'%-J^L::1!)(I3G%#%:[I>I!F#%^/ 81KE/;%1S7
M,![*%V;.6)S^);XD[^DCIM50JKC"@$;9[<:0N/< /95H9;5:[POP'?G?\$R?
MX/\ 1R_;_P"5:T;KSU^S]YKM9,UJTQ@9SVTIC [NG2E,4IE  .GWTI@ #I2I
M=HOXT5WYIOV$G+7Z>W[C6M=_0-ZU_F%9!9BJ(K:_X*_J^M,4JN$]B?D3ZLT#
MU/K/QKH*URE*8I3HB].J>SUI_H7HJ=4^3U*J?D54Q2F*4Q2F*4Q2F*580_WO
M!^AB_<;F^.@]0^%0+^>WVF^)KFRM6TQ2F*4Q2F*4Q2F*4Q2J8Y,_"E?_ %!?
MM$N7IU]GWBI*Q\R3[0^%5E*U7QN:WVKTZ?J<B_\ #->_B>:W9(P"Q*X!(7.&
M4G<D#H#U/JJ3A8)(K-L &]/5& _B172\O+\B?23(+Y.N_P"[7_>Q?UUN>,1=
MY_=-/+R_(GTDQ\G7?]VO^]B_KIXQ%WG]TT\O+\B?23'R==_W:_[V+^NGC$7>
M?W33R\OR)]),?)UW_=K_ +V+^NGC$7>?W33R\OR)]),?)UW_ ':_[V+^NGC$
M7>?W37:@8Z-KD<G157K[>OQ9+\-@EMT=90 6;( 96VP!GR21UV[_ $8K5G=9
M&4J<@#'3';7/DG6"F*4Q2F*4Q2F*5+M%_&BN_--^PDY8_3V_<:UKOZ!O6O\
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$%*__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>27
<FILENAME>g98473g78e43.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g98473g78e43.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1CL4&AO=&]S:&]P(#,N,  X0DE-! 0
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M;V]L      !#;&)R8F]O;       4F=S36)O;VP      $-R;D-B;V]L
M  !#;G1#8F]O;       3&)L<V)O;VP      $YG='9B;V]L      !%;6Q$
M8F]O;       26YT<F)O;VP      $)C:V=/8FIC     0       %)'0D,
M   #     %)D("!D;W5B0&_@            1W)N(&1O=6) ;^
M  !";" @9&]U8D!OX            $)R9%15;G1&(U)L=
M $)L9"!5;G1&(U)L=                %)S;'15;G1&(U!X;$!RP
M    "G9E8W1O<D1A=&%B;V]L 0    !09U!S96YU;0    !09U!S     %!G
M4$,     3&5F=%5N=$8C4FQT                5&]P(%5N=$8C4FQT
M            4V-L(%5N=$8C4')C0%D            08W)O<%=H96Y0<FEN
M=&EN9V)O;VP     #F-R;W!296-T0F]T=&]M;&]N9P         ,8W)O<%)E
M8W1,969T;&]N9P         -8W)O<%)E8W12:6=H=&QO;F<         "V-R
M;W!296-T5&]P;&]N9P      .$))30/M       0 [_^-0 "  $#O_XU  (
M 3A"24T$)@      #@             _@   .$))300-       $    >#A"
M24T$&0      !    !XX0DE- _,       D           $ .$))32<0
M   *  $          3A"24T#]       $@ U     0 M    !@       3A"
M24T#]P      '   _____________________________P/H   X0DE-! @
M     !     !   "0    D      .$))300>       $     #A"24T$&@
M   #-0    8              ?$   5N          $
M         0             %;@   ?$                      0
M                   0     0       &YU;&P    "    !F)O=6YD<T]B
M:F,    !        4F-T,0    0     5&]P(&QO;F<          $QE9G1L
M;VYG          !"=&]M;&]N9P   ?$     4F=H=&QO;F<   5N    !G-L
M:6-E<U9L3',    !3V)J8P    $       5S;&EC90   !(    '<VQI8V5)
M1&QO;F<         !V=R;W5P241L;VYG          9O<FEG:6YE;G5M
M#$53;&EC94]R:6=I;@    UA=71O1V5N97)A=&5D     %1Y<&5E;G5M
M"D53;&EC951Y<&4     26UG(     9B;W5N9'-/8FIC     0       %)C
M=#$    $     %1O<"!L;VYG          !,969T;&]N9P          0G1O
M;6QO;F<   'Q     %)G:'1L;VYG   %;@    -U<FQ415A4     0
M &YU;&Q415A4     0       $US9V5415A4     0      !F%L=%1A9U1%
M6%0    !       .8V5L;%1E>'1)<TA434QB;V]L 0    AC96QL5&5X=%1%
M6%0    !       ):&]R>D%L:6=N96YU;0    ]%4VQI8V5(;W)Z06QI9VX
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MX,<'%AAP!F#X.3/MKK+0]P:7NVLGN[G:/N24S224*P
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                _^$_]&AT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"\
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MCQX\>/'CQX\>/'CQX\>57>R+_/9ZAO\ :>AO\$';O_;_ /[Y,[H3E+G3JP*
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MK9^3:O1S,HS)BQ4Z!@21 2Z9OD-D"C5JJR46PNWPM]=NLGIM'QYK&TKIJ.D
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M4YFQ(@I*#Q5O'6B<;V$:N-3A,2P*3YX#N62WYS#";.EM^<Y=,'3968M75O\
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M<=,6XHDN8&)M5'R*N4/N\JY7),MT_EW;/5-G*.VBOPWQM&-1F/PT *BT5#L
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M)MW:C9)1D@CAQOHOLMIM\$=M=OYH;$_:5K&@-C0=M!CD4" (QJS9RL?+FY5
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M]$M%0KC1TDKC5KE'Z2ZNS_Q-_6__ ,?OC'^)RE_YT\?B;^M__C]\8_Q.4O\
MSIY3G[&/TB*C^6;2KB'<[VU4W1022,19>=D*QB(VZ0D& K$"S%\X2L2,='0>
M.&IFK]D;.6->:"6FS,?C+\U+6."HIMOZ$J"M,#>%)5/<,7D;"7QZS:_BLW$2
M89'W\48FF,C#M2:+Y",%#$@)1W"N'']8$?G"[L6KC=DX(O%4=E]X%>R'_/9Z
MAO\ :>A_\$';WEJ/G&<XQC.<YQC&,9SG.<_#&,8_/.<YS^6,8Q^><Y_L\\T'
M=-/WGT!['@D$C_*YN*U]+-Z[KY_U;3]5RUM)9]24NA+=2R99;'0Z$T<<[R6&
MUD3<&8JUY0Z;HFY MAC0^%A+%!.:"70JX[ACG ]RA5!BE";?G/ >/S!\_BA7
MG2D G.S*1!2PT6OL;LNK(HZ>0L79B[]-VU,&8>JT!2,:T$$VP./;J*!F=6GL
M-Y^]H'0/1-(R&F^1>(C57<N]51WH>"R^=]#26.3BY1X*M9M!_P!6; CK2BSK
M:+HNG4]>/MU6YV3?)]P#O@CM]JVV:W.<P.KQ>TW'7'1=4U52ML;O3^#U>4M-
M'M@5Z(9Z&WVH1R(E!&(P9V^<E0^&9(HDI&V>&9)RY::*.]$<.5<_MJ)2N>U?
M8,(@UAE*DF,NATAC<:M$$(&GCE>F30MR/8S$(',Y^Z"!B/+N-2@MN3U48;/V
MS?+M%=#7=%2O;C'U@Q+FWG>7<N7G.(GVE3TF/BY5F,7/SO3[=L_E23]P;D<T
ML?9(8:<7+/Y?)<"Y*9GEEN#\HP8#LW2!'7;&OTNI])(<3'O797H  +' P0.^
M>Y0X4*'9-AH@.)&=U=(,AHL6.9)(,QXX>S01:,631%%LU;(I(())I)Z:8VC[
M7X[?$L]?/2L=YIFVT N4M$!C6*GT3N(L_6;[RL!F1QT1*,K-M(Z;EL9P7C <
MPH[8I-")9OE4D*3VV)L_-[^CX\P>S-A%+R%F>H)KRQ7+@F&=AH!*(5$+=F1*
M1)/2R!^4@XO9&Y4?78EWG9-!T7PRRK-W6&KW4>[8C6Q17TCH<8= %,_&<>RW
ML RGO^:S2'1GE2M&N<__ -"T>YV7,M]?[?RU,;Y^']FV,XQGS\U/7# RNV=I
MGT[WU-\;YSE9(AV?=41:K;9^/QSEE51ZO62.,_'./D:MVZ?P_+&GP\BIV?Z<
M>'[/YWG,1.1_I-0V9P+T"3X%:72G2=B1B0I$47 X^Q@\ZL.=CSC9-33=J<26
M$)Z[!G;[5)^+=;HDFT8?4%Z7./:5J.1*WI0I.[;HDBD;*RQ[U9SBS%AX7\K5
M_JWB57B9P*,C'39HXR[6DQT61?N"KA07]JRT9HCFNMW0;B/C".YUVC_(O,0/
M;3X_+L(H2JANVOQQ\,_#9G%$=L?'&/S^&?S_ +_-K!J;J&.8UQ'JJK<#C3.N
M=,!H-&!>-,Z?[S.N&(M#Y<Z?_E^'P^7^[X>:PZLJOG^VZ(E-5=%U<1M"G9=E
M@*.0J-0"?3HENOHZU?#"(P150<M,P[L4^:IO6DD"HLE@SK1);[Q:[*:_/%WU
M0<[41S)RQ$:[I^E)?34J7CL*D%YH3>NK4AI^26P1C#-&1O7)ZTPP]S+4QQ!H
M^8M](T0)QL W^FW&Z,F[Y+[59SX\>/'CQX\>/'CQX\QF1PJ&S'5IK+HE&93J
MPV6V8ZR,"*.:LMG&$\.-FF";1UAMLOA%'"V4<:95PDGC?YODU^'W H['XN/T
M$QD$'CHK155;08"&,A _19?;YEEM&8]!NVU56VQC953">-U-L?'?.<^=QX\J
MF]L/$%;=R4R(@DNYGF5XS:.9-F:NF,)F%>09_6<@<X%MWB)$U,[.K]\Y"RIH
MGIH]$,!\I%N5 S=V1:,2#$(ZS,KDNF:VY^H*!4_4E+%Z!@$(:D1H&M)"3C)P
M\-U6*O7SXL8-Q6:6"-,DI&1=.CKPDM+"9)TL^WW(_9G/S-49'?#'^K'_ )L>
M/AC_ %8_\V/*BO;EQ]QCU75$(ST\+CGZV0F=0)"OI!O-<0:8#@,VM&!1:?L!
M[Q DQ7)@GX)XHH0:NV[]D/=M6A9##-ZUU<XL#Y]IZAJ<IBOZKY^C<1%4W!0R
M@*##HV[1D ANQ2(/%R&Z9M9T4<%W[PTL2>FB;P@\($#3A^[(N5GRSC?.U%8I
M%U]M]EXV 6V5^/U-E0XY393YO]]\^=VV<[_'^_YLY^/]_G5JUQ7BVOR+0.&*
MZ?'&?D5BX-37XX_LS\N['./CC^[/P^./*E_9-Z5>??8Z1K@K(B@ZG2E<-';%
MG((!!&V)*6&OW^'SX&4>H24*%=@5=]$U&S=['7I84\V>.1!M@F2(M7,Z^?>,
MJ%Y_I>N:8"U=5;\574<;1MB_1KH6WR^;M55M]7CK!YY+33@BZ^KE<H_*2,N^
M)$5'1!PZRHYV3TW:WJ.J&FNVC2L:\:Z;;?/MHWA<;1UVW^&,?-MJF-UQG;X8
MQCYLX^/PQC'Q^&,>?1_1;67_  =03_T1C_\ \/\ *K>_?2%R![#YS")]:3R=
MUT7@D55B(Y.FM*_B*1,:L7?&=MCR[Z"&WY3=)R^4U9)+.\-AVN5]F"#=4@14
M=V"4ORS2M'5-7E/QB"Q-_':VB8>'A7I:'P_!5V."--&;5P3W%@1S)<BLDGKN
M]=ILD5'KG95VY^HZ7654V=_1;67_  =03_T1C_\ \/\ ']%M9?\ !U!/_1&/
M_P#P_P I_P#8AZ0^?^_[/KJRS;:#UV0@@\:%?K1Z'2=H6F\:9/RQ)6*R=U%[
M&B(C<3EV3V58DF(%I*QVF[ULG(E&CAJ@PM\JF !ZIK. 5E'A4>!@8!$(]#PX
M:)"W86,C!D>%MA;)D"%/RAM^P&-V[9--JW?&2KS1/7'VHB\7RHX4KM]D/^>S
MU#?[3T/_ ((.W?+4?/X43363W25TU425TV343WUQMHHGOKG7?3?7;&==M=M<
MYUVUSC.,XSG&<?#/E/YKTB<>X(N%*JG_ &CS5%GKA5R^K#FOM;HNIZG6V<;Y
MW70'UZ*G3F/19@IG.VFHR&M8X.;);929M6Z>-==9Y\P<DT%QS B%<\_0A6(@
MCLA<S"6$BTFE<ZF4XF+YB/&/99.9Y.S<DF4ND+D>*&L,D3IMZJW8,&8]GALQ
M:-VR4D/'D?\ J^_!?*W,/0O2YH&[DXN@J8LJWWL:8.4V3V1)5[$"TIP!:O54
METF*QC<9H.3>JHK),]G.'*B2FB6VFU?G)7LT)%A'33'V$..;N63_ #&MSH:E
M=B#+<5&4.ZAW4]:B9]6*:\QMEM$% LK8%'9*"F63Y;+,N;9L'8'?9 NW:Z13
M]2_LR]<E:<21>(V+WMQK I4WOCM,RXC4QZ8IF-'D!$K[3Z"E<7**B3$S9ODQ
M\CBYL-(P3S9##<L"+#2S!1=@];+J62?BW^JS]Y/P=_%M0W\^><_BW^JS]Y/P
M;_%M0W\^><?BW^JS]Y/P=_%M0W\^><_BW^JS]Y/P;_%M0W]__EY_\O[_ !^+
M?ZK/WD_!O\6U#?SYYQ^+?ZK,_P#ZD_!W\6U#8_\ ;//.?Q;_ %6?O)^#?XMJ
M&_GSSC\6_P!5G[R?@[_7_I;4-_/G_5_;YS^+?ZK/WD_!O\6U#?SYX_%O]5G[
MR?@W^+:AO^;_ /?G_;^W^SQ^+?ZK/WD_!O\ %M0W\^><?BW^JS]Y/P=_%M0W
M\^><_BW^JS]Y/P;_ !;4-_/G_;_Q9\?BW^JS]Y/P;_;\/]+:AOY\_L_Y?[/'
MXM_JL_>3\&_Q;4-_/GG'XM_JL_>3\'?Z_P#2VH;^?/\ J_M\Y_%O]5G[R?@W
M^+:AOY\\?BW^JS]Y/P;_ !;4-_/G_)_V^./'XM_JL_>3\&_Q;4-_/GC\6_U6
M?O)^#?XMJ&_GSQ^+?ZK/WD_!O\6]"_S[X_%O]5G[R?@W^+:AOY\\?BW^JS]Y
M/P;_ !;4-_/GC\6_U6?O)^#?XMJ&_GSQ^+?ZK/WD_!O\6]"_S[YQ^+?ZK/WD
M_!W\6U#?SYYS^+?ZK/WD_!O\6U#?SYX_%O\ 59^\GX-_U_Z6U#?SY_U?V^/Q
M;_59^\GX-_U_Z6U#?SY_U?V^/Q;_ %6?O)^#?XMZ%_GWQ^+?ZK/WD_!O\6]"
M_P ^^<?BW^JS]Y/P=_%M0W\^>8I(_9GZ=)@JU7EO>OKBE*S%-1)DM(^E.;S:
MK1);;7=9-KN3F#K=NFKMIILIHEG353;77.V,[:X^'<!O:IZDXX-;AX][$/7T
M"$,_JX:"@W4_/8L:U^NLHY7^S,6,W0;(X6<+*KJ_22UPHLJHKO\ '??;;/:?
MBW^JS]Y/P;_%M0W\^>/Q;_59^\GX-_BVH;^?/'XM_JL_>3\&_P 6U#?SYYQ^
M+?ZK/WD_!W\6U#?SY^7_ (_.?Q;_ %6?O)^#?]7^EM0W\^?]?]GC\6_U6?O)
M^#?XMJ&_GSSC\6_U6?O)^#OXMJ&_GSSG\6_U6?O)^#?XMJ&_O_\ +S_Y?W^<
M?BW^JS]Y/P=_%M0W\^>/Q;_59^\GX._BVH;^?/.?Q;_59^\GX-_BVH;^?/'X
MM_JL_>3\&_Q;T+_/OE;7??LR]<LUM[U;DX?WOQK*AM=^Q05.9^0CO3-,FF4(
MA27'O8,74ETM=#IDY0CL9TDLGC<>W.EMV@S4U( @O+K#THQ17F!V?[%9G!Q_
M+PKA05071TCZDC?05H0J>2JS2']![NJN::QVL.:/@DOK)A*E)"=ECQ]'XE$5
MQZFX)F]?$"I=PHT%J-E9[\MWL(ZAYLH3H\"(=1\/>U05Y;(\ ^7U=/ ;>>Q4
M7)<!G+K5%OH[5%[$=F.[O1!#1UE#[1HBEJIC37?'CQX\P2TJSA%T5I85/V8!
M;RFNK3A4HKN=QMVHX1;'HA,PCV.R,0LNT5;NV^A 01=M<N&CA!VWRKA9LNBO
MHFIK%GE'U]4%R-&K& 1-:P;6(6R7AQ2PIIT),5K=FLF;5O$0\#K6//BQQBBV
MS':^B0-@'BPY,=INTTPY?.W#TF[<O5>QZ5LWB3D.&!YWT"*K2%!I+)F,*AXU
MA4JTYFLZF9-N[>,8E *ZKZ'2F?SN2N&3!\^P$B4:,$$V#)X_6;ILVJZZ>E5^
MV?5BUH.+=-.YY0K*H)I9 ^G(V5?5U]@EA"W'\J:0O:KMZO>PYO:#"PA!]XDE
M)H:1AS20108F[D$D'BH^Q>%$(Q5CTYZ>.*CTEXI4E*H\Q5=X2J+SF66CSA:9
M. 0RU^@YZ^NG2&3/I32CAU#Q_1<I;X]G%4#$Z8-1@)_'0[A^LY1RNK8<#L?A
M^3]'2SDF-ZTM(.AX%7#&V)Q6H6$!BA*'P<F=0C@Y_)RC( O'P15Z2=-=FT6)
MEFTJ5&.VAS4+D(Z;D%>HZ:N#AKC\!%3]_"J]BF9X?5BT C$?I@E9EBS^0MF"
MQ9\*@E7U?!YE8LQ<BQ3=8F8_5R,$D@X_3[:44:-]]%-M;[=?>L!6K:'N!.<\
M_KP'J&T(M25$OVT'9*G;#M693)&O!\%%PS2+;31A(1,P7R%FK0U'AN:\6;/W
M$\VCK0<^<-XI<\].^GGES6$^ON,2A3!"@)P/Y ;RRWN<+2_57^ET&JT&LZZE
M72Y2CX_1)"P2+HF.;-$=9HT^^G1(:D,T<*/V>J\M:>ZT]:]^7M*>;:F*U5++
M>B>)MEP$UIDT&C\CS6<@;16R-*YL*0P 37=J*5_)'C8+-$ZVE4KWC1!3*!?5
MIE-7.F==-W1PIQZ*AY._A=?Q=U89I['J]B4:I,O:-CSTN+'[ES#6%5?54#FM
MB2G0$*3V)'W82,/6()CLDZ+N62*Z&RF!Z=;^L1Y!.<+#9SCGTC%.O;"!5-SF
MX&0L>_,V=8,B.KQ5*-"8LTC"TI&/0DB;.@<U5D 40TKXJV783EQ'G26Z6(F\
MT=-^GKG': ^OB%2A10M2-A;<<"))<'.%I-XV1N>)D-P?]&)CI$Y1\:HV06.]
M*;:,![-C,DU)"\<,D0J3U5ZSU7F+1/3WKFZ8MZQ*)I%_5$XL^KVIPA)02-0$
M0K @'B\P6KV4GX)*Y)!0\1M&-Q>>MUX7))'6IV6 P4H3^Y";]J0VT0V[KIZ^
MN"..TX8G?H^!1PW8KHPV@,)B=&'[:LJ8ZQQHD_DI".5C45?SFP"H2,,5V[N3
M2!I&U <>0=--C!!GEXUPMAI?I/UCR>(\[)(SF@"@CNDAFON;<Q2+ABYVTR!\
M892=;QT8)C1 N';!/NPD.D4@D8T4%ALC10C\I>BCSEJ,7C)RMUAZ@JYUI[@R
MLY)HZ*528:\8P&07!S7:D?!S6SJ205KAS7FO04QI"(4S.[36>Q%\R49@);NZ
ME1MNYQ'V3M1P@AM+[GOH[U[]3S665]1>M<S.4Q 0XDKAJYI$[$1TGA[.7&("
M\GM92&;5_'(];M>-)R ,Q!U/ZM*2^'-Y&/6$+&]'FR*2G'4'1WKZXX=Q(3?[
M:!1R2SIH:*Q2$Q&B));M@EP$9U0WDTL3KZGZ[G<T;0R-:NFWZPS)Z";1<-LN
MBD0+-U54T]L5G5S>LNR8]2-0KSBB26_L'BLGB?/+:OP<>,2>S8Z=K^3F#,HB
M.X*.&%0(D7&A9E3,TD;4='!$C08Q]Z]UD;U@'=Z Y@[=]0CG-3<L5A)Q.[F.
M-GE!UM([@YHM*NXS8<BHI@^ADAC@2[K+I6#5/8$[&9@YO0NTC,I=/2A$075'
M,5?HJ):2AY9Z;]=7:;Z8C.:W=6V&2@K,*8-CUZ;*PEZ[BLE7)-8S/HJUL&!Q
M5><UK)788LTCUDPK0_!3;H:\;#9 Y60WTQA58]P^K2X[L;<^UQ*ZAD5C%2\P
MCT45_H:.BJZL21U[H[4G<:JJYC=>C:>M:1P](>16D0*N9U)RHM :36<M-$AK
M_=OIGHKK'U#V5RQT&SE4TBIJEI+:TP]=,]F5 TA,;)E*5ZV+6NJI" 5AM5]3
MSTK)I6A%I<W<!I9#04JBK21_**R2<&Q[P4GG<)[+]343Y#DO0J4\J4)S_P X
MZ,ZML(_9=4E898\-E$5!"TFD)F55S.O8U;B5F%A:PQZ+B&8 G)I5]X-W4>#/
MTG:/S;7G73W ->= 5_R\=BC<C==EQ>OIK'8Q".3[3L@4/B-IRD_#()(YU-Z^
MJ&30.L@YR0Q:0M</[&DL6;CFHEV5*[L1*?V[/6]/=>^M7CF6BX'T&_KB)3(C
M$EK#=1N/T1*;.+16MFY%P(<6=8;2K*WFBE:UHB4:/!ZE@3_$;B.';)^AJ8VW
M8/,(1[Z7N[U"=$N)%Z_IY9$$82&\ D,C^2E5UX1U&:/)Y&F5NU[&1%^":TD5
M. K"GT'8-99"X62E>);+(R\;O ()\D38;K[%YH]A'JIZVF$2@-*%(F\D]@Q<
MW,:U:6+R[:-(L;1C$8;8?2,K5I^ZJ?K^/V2D '?.5,(P@H==#Q"+HNY;IC6C
MITC*'GFP^(NL ,\E7.J-,VS%:VM&4TS+)/%H,(<1Q"Q(6U#/)*%#G',?;"Y2
MR'H'Q>=9'%W1B,OMW"B0\P[5:NM$=+=*]C^LWD.<M*VOTK6<0FBD8;3HR%#4
M7)[$S X"]).!#2P;5?UK7$O&5) 71-H[9H32S'D4C2RK-[LF3V39.U$=)=.V
MUZD^@GMA>O.Q)_!Q$PLR#I_>^:RKY\W419;09O>;,)&;H&UN?JQ&QB=7#-+#
M$P)&1O9R7@RNIP9&W0]XV<J9_P R=]>K+KF5 H-29&(NI1+((0LR##+*YCLN
MB\6+7P=%HY+R^M2-WU'7@NQP8AD]:$2KR$OCNH\6MJ5=X1':[NM9,\[V!Q-U
ME%)7.^=&]-VQ"H99$OJ4Y+(O!!*L=VG4$6:-Y.-"&7<>:CY..8JOFN&TFC2Y
M:,%M%?JAS#]+3??7170G:GK!Y8LK:I+RD%51&<,1,?D$M9,*2D<U"U=')6]W
M'QF2W5+X'74FA](QP^ZTVP).VT=AHMZWQE\@ZV8_[I\Q3N,AZR3PYMQYT-(X
M3!Y+;59GND!(*MX:BYGBU3<Q%@UU2F=-R<8@DL:A8VEI!]TD_O1)NXGK%G(X
M]#$BY5L]39]QS9W3ZONL9&K$:=?0S]9OZ.%;@'!;4YKL.@7LDJAOEGAY9$,U
MOBJ*W3F\)'ZD6"I.21%0T*&MWK5T_<MVSA)7>2/.TUXPZRKG:W>=A]0VG6F9
M=-X.UFL?@ M,"3D->2<E#Y5H%>$HZQU."6A\2^;CY&(P]CQ]HFD5 %"8ITU>
MK1\NWMOU=<ZVXYH^X)/4L4L /M$-9JFA2Y^2P^J<V L@C!OZ;;,B=>'*VH_$
MN^TM7$?VMN60S4DP=LR3?.PYVV=*Z*ZFOKU26,3N'F>TMI$&?<ORJ&WA=,DK
M/E>XWL,KXARTE!>T_N>17A':(D]1[XVBL3C;^2PAG+7$EDP,WO"A33$H.,&>
M=Y\[]L^L;J(O)H]5CZ",9#$:Z3N U'[@YWG'.YO^B/=9)OO:@D7?]7UH\D5<
M-'"[9 E-H\D4C8I9VR3)$FFSUIA:17.LLXXZSJ2/WMST%JFRZDEA*7BHU-A=
M<L& LZY@DR/P&2JC$SD;%O78YM*8P:8L2R3786;:MDBX1X0#O6+]S':T.W?5
MQ35VK\]V/**DCUDC#D0B\K^2ESYF 5S*+!^Q_J+&+9N #7A2HZED<NU(CE(^
M#LF<18F21(CET&N4"#)1>.G4?27IOG4CF52VS941C4AXEG WJB?I0>IY+HR:
MEN0Y%%Y[,XPA+!=4'8O:BT$<EXWI<-45N6D4]#"RZ;,T+#*;JJ(R3H;L_P!9
M?1JEA-:^)5V"*55"FEF6  NNA)9S?)(W63U19%"S',=Z$K:L33JN?M""C5Q.
MAS%Y%F3O*31Z5;N5T$E9%<^2#D3JBG85?M"1RL; J.Q&I-]"YBUK-H&:GF0<
MZ4C;YVU'R.,AS";;0P&(MT%G0]!-ZDCH]9[.&+ALY6C=+NW/5S!;\_R:91)Z
MD'6JC-X[6);72ECY"NHQ:$N1:KQ6L)I=8RO'E,0FR)%H^8ZAX)+)\&E+Y=ZR
M:HBMG3QJBM#OH3LOTV6)(F8.W'E@UJ:XPE#3LLRV=\4=(ULAD-3,@5K-R8).
MY3S6@RL*NE)18K$,X'P]R_WDA%V*4"O7"*"FVTT*8[*]95["+9,0\Q6$8THF
M/CY?<(F[Z/D?-\HKR&%DG:HN;26(]!5W6<H9PDCAB\29S# E2-KNFZC/0GEW
MC"&9(T00Y1Z7I^O;[I2)5O-*HM2.-); Y5BL&H'4]'WVRFK0CJ'DT9#'A^JV
M4E/E0*"V3K&N,;;(:Z[:YS@/6WK^HCL6/5P$FSVR:R(U(XF>M?S.@9P[J:91
MT#94/(0&RH:T*A6B[7]49_$2*H>2B-Q^V5=4&+X<Y'$V+5ZE*JMJ[AM0UY!:
MIKL(VC4!K6(1R!PJ/--UE&P2*Q,0T! !2*KE19RMHQ%L6K;"[E99RM]/*JZJ
MJV^^^V:^/'CQX\K%[_YGO^QK9XGZMYE&5Q.[6XKLJTY/I2]L3 Q7<1M6'W-5
M!BK)6S86"'BLYWA\XCB#UF8B9,A$2PA;/WHQ?[M-'.BF\9^B.#NF.L.'S8>[
M:WY-0[++]'PRW8,G7@9!O'*3KO/4=+VE+80.MXQ%F$DF,X?5U66=)W8;:,0_
M:Q)"BR$N17W>Q;$G<9.A_7K[!K1=^U#F:&5CSZUY\]EG0L3GJW2<PO(OI*JE
MKU&L*/@,LV:4*,J8NK+)FWTJXL[B?U;)CC#0L1%.'RS5NS4<;V<P#B9S6/L^
ME76$%AM>1.HYCQ0G4<J=QUL-#3"7WR]Z$(V7(9A*Q@T4UR=>&HVJRW(S$F_=
M%'S]'1BOKLDW1WUZGN+FWI YTSQ]VWRU'ZSM.Q.6P]]0 [1-MSTO5@">06_P
M$5'DSL2L@5#+#3B<^B)>%!=VN"T0?##L<*'QBC\8XPVRZT9;?!70=]T#RL=M
MZ"<J[=BUMW#0'0DQD-7QEO'8U7-.1?K^+7S8%;P";E(\C*Y*00AL='(2 RN/
MC.]K341J:,#VBJR"VD1Y_P"NKV V,'[KX_Q6U"1SFOM3V/N.N"G3Y&\RQ"PH
M156)[2$R5C\;H5A4ZR3^Q'*5,(M1!(C: H2Q=2#91UJC@;JNXF!RU1/<A/V&
M3_I3K^@JH&PH,#L^N.6CM?\ 1#8L!H.GY,;"&70MA1S.G@N3UL7.3 #3%MVT
M8L==RV29,(O&0 P"V=I%-R]J\X=,.^KN5>YN58S5MMSSGN 7M3DIHFWK!,5.
M(ED&O/6$$%97";*%0BQT8S-XJ?K\2DY:%HBZ'R.+E"K'!(:\:M<.])V7P)?U
MRU9P?,;4A7*ZG7=*]NTE?-NR^J(JVA\<B5+1BZI3:$KK:MY*0 :2J0ZC&18+
MH35=MX[I94P&O982&C73I%)&)<C]=OL!GXSK/D-_6M!13F?I[VAFNURW3;N\
MBYFR(]5&+SK6WFD5BM%,*HPABQB258#Q30P4L]F(%9./%7".V62>7$UN9N5N
MS&'LAGO6]\17GZNXCI14[HAP^J*RK&L#>]6KNV([,*BDX>MK&CNK7F ?#(<'
M)IV)$X',2PZS;+D3^6&T2BK4:39YWUUSIU2([3I+OCDN(5)=4L@G/%I\P3BC
M+ALDW3K-W%;#FL-L018,%L81 K+;CY"$D<.0&20$5B^B)^,O?@R+-7[!%);6
M$XX NZQ 'K)L*P(GS"[ZHYQZJK2U>B[#J>%LZ\ -*E "[])E*[JUTX#[R4I'
MH_*;5$Y:B7NX-M+C21J=O108D24'H0^C'KQ]@<F#YY.F59T#!.<DO:K)N_"G
M1Z-YEY99A* L>JRG2L5@T.IAE4S!O&YN<72!1DA)"=GJL XMR=6PS=K*(LE=
MO>IWUM=8<=]#22PKO<5LG%TN?I74!)Y&+(-V&A/YR;Z4EEU");3L&-0"*#N4
M*;'QZ5E1Y.BH,1WBQ*6OF9142NXC;.1$I0=2\[=>P_NN)]\\A0JEKP/.^2#W
M(4XINZ+/D%-(AF"MJHVW$[/B$X"5[9J+[5$UN[#3>(/08E<H'0%.A)K+YM]%
M'%9)P!;4DEWJHMZ41KF]]T%S!;K&3]36;5T&'5@.)P5I0'14/9PZLV>HQP=>
MPV.V/<2"P&+OGHQENF\.2S(T60?.1^L%JB];G?4BK?F;CBY:IYV@O._.OL'G
M?:Y^\F]W&+(F]F@5;^NJ\8C6H.EVM41YE%G)YS: V+2XT5M!XBA'&)S=HU7=
M$DAVFX_4]ZJ[VY1O:U[CNYO%J]";<OQ7C^KJV@'15T=$!6<-C-D2V=;R:&EK
MH'M#=-UP+8E0$>K*EF#^4_JQJC)2Y20+ORV?KY[PQR!W_P \0_E[B>Q81QX_
MY(Y3<6 ,+7Q][GK"L_H&OB@Z<#8," TT>KX(.HV;NTIBCO:<NVLB;H/D6!H4
M"0?,)*ZV3T9/?6#T[7<.L#'.-3T<\VCWO"JGV(4U3S:>M*A@[SGZL:*JF"M8
M?@H(@AX;7QMQ)(22'M S"*EV0T7LV()Z+8V^QX[.R_5ET-TUSO[:)W?57<Y"
M.KN^6HA]1-4C)/FSH5SZ:KCFIMSQ!9!BXY)744>:61)QKF2*2F61J&CTQ00H
M@''O7;=9\W3RSISUG]&6CW32]]UC!:9AZX(GQN1+=>CK]O:+WC6L,YTDA,K;
M%.:T:UT-5#:(&WH^3+1(.^35A0UL.ETB_782=<M!Y!?=?0',?==7]D=,].\9
M0GFZZV/97/%2TM+0?1-BR> 9HZ<T[I8(J,S=HP$5K8K&SZH+A9ZJ]E];:J18
MV_/#=\MB:C,HMLWU+/N6O879G8=)9MNDZ$L?D7GQG69"OG,#N9G1[1[T"/K?
M>(S#JB<TNRJ>8DI:Z@BQV0"*)IQ.S049B ELV-$R!B0K#7$?TQQYZW^XB<4]
M8-!]<U#SM7%%>MT?.B)Z01JY2%UR[I S**;G],,HAB$N*EAH& P-Z)L8R4FR
M!:52U4RBP'!F[131==VVM:]=?)LDY%&=A1HM'X1%(G;/<UVWG4$;@'V-N"!U
M#,X[7 :&C,AAPX8.C3MEK%'[?:.L&^[08U3::(*[:;XT3BG>/+/>U5=8]J7I
MQI#>8;B"=_U524)D^W1L[DL._P GJ>TO"9/68Z1+Q 56M@C;LJ@Q&)"F>*P'
M8G$2KB2HDF&ZZ@DHNYVP;I#B'O.\^H*',;@>8!==<^+$3,<OZ,32PX](I-%Y
M1S+):DLBIR_)Y8%)ZH&368S\_P#/&KS#2YG(*[J1NWC81;#E0N*+ZFY#]=/:
M$F1]8]7]F4USI7=&^M:DK#KTEB.6\]OB2=/FI_SVZYQ=!"D4>U-!X[7]:NHN
M=D)R6""1^:N3CC00 PW699=$D+1/7/RI*N2(EU)#Y $AD: V5W'TE>56Q^";
MMM 0:H[).!G,"&8&,APQC'G;(6.RV6CS%OLS$)I(MFZVZ6-<:P[M?E#V!U-T
MQW?/.08GRK:4*]B6M-%"\MZ+E\E#N^;IG6U5"J6-*G*N8US-1?0==OXL$92>
M/Q;64P5RA('A2/E$]PJF"CF''1_I1[5EG:)CJ.$]3P*R$+(K_L>.S!"74^$A
MAZ%QZU.>1U.U'1,5+H2R0;O:S0;--P[%TV8@DJY=NY1/D@<DDLWD"JV^>8N
M>M[,G/!+?N&C^<J]I/@+D*S.;L0\!:KGH<KTX7M:IZ\I<_F9A"U20.+Q"KM8
ME#RA4A$WK^9.BQLB.8.,+CVBKW%C7K4Y?FG(U SFJIN.BH=P4ZFZRM2+"H8Y
M2< 1M>6Y?T[L&O6*"2#$<W&N&L1/"4'@=LVPV$.-%!Z"BJ3?7?:$\LY)]A--
M7KW"CRO%^3[#JKOZY(!<[^UN@I+(]SG.QL= *^K2P0I^CV]>R$/?T;R#K] U
M6HU&P(%J/,%EQA[Z+)KJ3<0RZ;]/76MI7]UU,JCA%#4^/N.)=I+%[EAW0=[+
M27JUKT1R\3INM:9N*BYB@>KN!-X98K@'.3LSCIYY&V:4.C^83# KQ=]]"77/
M?#'4-T7SSC8O=U$<Y5]47*G$\UY+$5,!LU7I%U?I2R%:?0D,CL5$Y4E?Q,+
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BCUGF[C LILU9;/6F-5]/D7RT0^;/QQ]/'P_.=?CQX\__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>28
<FILENAME>g98473g93a29.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g98473g93a29.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_[1M&4&AO=&]S:&]P(#,N,  X0DE-! 0
M     $H< 5H  QLE1QP!6@ #&R5'' (   (  !P"4  (<G(U,#DQ-C<< @4
M(4UI8W)O<V]F="!7;W)D("T@1V5N97-I<R!&+3$N9&]C>#A"24T$)0
M$")*^(M6HN%I'>),'8-E9Y0X0DE-!#H      .4    0     0      "W!R
M:6YT3W5T<'5T    !0    !0<W138F]O; $     26YT965N=6T     26YT
M90    !#;')M    #W!R:6YT4VEX=&5E;D)I=&)O;VP     "W!R:6YT97).
M86UE5$585     $       ]P<FEN=%!R;V]F4V5T=7!/8FIC    # !0 '(
M;P!O &8 ( !3 &4 = !U '        IP<F]O9E-E='5P     0    !";'1N
M96YU;0    QB=6EL=&EN4')O;V8    )<')O;V9#35E+ #A"24T$.P     "
M+0   !     !       2<')I;G1/=71P=71/<'1I;VYS    %P    !#<'1N
M8F]O;       0VQB<F)O;VP      %)G<TUB;V]L      !#<FY#8F]O;
M    0VYT0V)O;VP      $QB;'-B;V]L      !.9W1V8F]O;       16UL
M1&)O;VP      $EN=')B;V]L      !"8VMG3V)J8P    $       !21T)#
M     P    !29" @9&]U8D!OX            $=R;B!D;W5B0&_@
M    0FP@(&1O=6) ;^            !"<F1456YT1B-2;'0
M  !";&0@56YT1B-2;'0               !2<VQT56YT1B-0>&Q <L
M      IV96-T;W)$871A8F]O; $     4&=0<V5N=6T     4&=0<P    !0
M9U!#     $QE9G15;G1&(U)L=                %1O<"!5;G1&(U)L=
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M____   X0DE-! T       0   !X.$))3009       $    'CA"24T#\P
M    "0           0 X0DE-)Q        H  0         !.$))30/U
M  !( "]F9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &       ! #(    !
M %H    &       ! #4    ! "T    &       !.$))30/X      !P  #_
M____________________________ ^@     ________________________
M_____P/H     /____________________________\#Z     #_________
M____________________ ^@  #A"24T$"       $     $   )    "0
M   X0DE-!!X       0     .$))300:      ,U    !@             "
MY@  !<T          0                         !              7-
M   "Y@                     !                         !     !
M        ;G5L;     (    &8F]U;F1S3V)J8P    $       !28W0Q
M!     !4;W @;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG
M   "Y@    !29VAT;&]N9P  !<T    &<VQI8V5S5FQ,<P    %/8FIC
M 0      !7-L:6-E    $@    =S;&EC94E$;&]N9P         '9W)O=7!)
M1&QO;F<         !F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U
M=&]'96YE<F%T960     5'EP965N=6T    *15-L:6-E5'EP90    !);6<@
M    !F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
M         $QE9G1L;VYG          !"=&]M;&]N9P   N8     4F=H=&QO
M;F<   7-     W5R;%1%6%0    !        ;G5L;%1%6%0    !
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M300H       ,     C_P        .$))3001       ! 0 X0DE-!!0
M  0    (.$))300,     !"X     0   *    !0   !X   E@   !"< !@
M ?_8_^T #$%D;V)E7T--  +_[@ .061O8F4 9(     !_]L A  ," @("0@,
M"0D,$0L*"Q$5#PP,#Q48$Q,5$Q,8$0P,# P,#!$,# P,# P,# P,# P,# P,
M# P,# P,# P,# P, 0T+"PT.#1 .#A 4#@X.%!0.#@X.%!$,# P,#!$1# P,
M# P,$0P,# P,# P,# P,# P,# P,# P,# P,# P,# S_P  1" !0 * # 2(
M A$! Q$!_]T !  *_\0!/P   04! 0$! 0$          P ! @0%!@<("0H+
M 0 !!0$! 0$! 0         !  (#! 4&!P@)"@L0  $$ 0,"! (%!P8(!0,,
M,P$  A$#!"$2,05!46$3(G&!,@84D:&Q0B,D%5+!8C,T<H+10P<EDE/PX?%C
M<S46HK*#)D235&1%PJ-T-A?25>)E\K.$P]-UX_-&)Y2DA;25Q-3D]*6UQ=7E
M]59F=H:6IK;&UN;V-T=79W>'EZ>WQ]?G]Q$  @(! @0$ P0%!@<'!@4U 0 "
M$0,A,1($05%A<2(3!3*!D12AL4(CP5+1\#,D8N%R@I)#4Q5C<S3Q)086HK*#
M!R8UPM)$DU2C%V1%539T9>+RLX3#TW7C\T:4I(6TE<34Y/2EM<75Y?569G:&
MEJ:VQM;F]B<W1U=G=X>7I[?'_]H # ,!  (1 Q$ /P#NW_6G#K]3UL?)9Z1?
MN<*BYL,+F[@X?ON#6-_XQ6NE]9Q^INN955=4ZC;O%S-GTB_;MU=N_F]W\C_C
M%6/3/K '.]/JVUA<XAII8XM:2YS6M?8'._<;[TS^F_6.QA8[JK6:;0ZNEK2>
M_J?G;;=VW_@O^#22[22K8#<RO$;^T+&OR)<YY; :!)+&Z!GT*]N]_P"^H_M;
MI>X,&72Y[C#6-L:YQ/[C&-.][_Y#4K51HFM!N6VDA8UKK:A88AQ)9'[L^W=J
M??\ O(J2%)*GU;]GCI]IZF0,,;3:27#AS?3_ )OW_P [L^BN<P^I?5/,O92Z
MO(Q^/3??;8UI>70QFYF19^D_T>Y R -$TM,X@@$@$MGIV3UZGK61^T/4.&UM
MCK['@"EC6$G'LQH:WZ3?YS^<W_3L5^OZU=&LO]$6EH):&6N:0QQ=_*_,V_\
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MJN=Z?IM4D<?I)D-:L+)3U%'KJ]E7TWT\AM_VK)<&DD5.LED'=[7-CW_2_/\
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MQ*B7 'Z&_P!NWV_R5KBBMN/]GI_0L#-C/3@;!&UOIZ;6[/S4M>IO^Q,I76@
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M.QZ]H#*7-V%@'M:ST_S-O[J,I&H__]DX0DE-!"$      %4    ! 0    \
M00!D &\ 8@!E "  4 !H &\ = !O ', : !O '     3 $$ 9 !O &( 90 @
M %  : !O '0 ;P!S &@ ;P!P "  0P!3 #8    ! #A"24T$(@     !1DU-
M "H    (  @!$@ #     0 !   !&@ %     0   &X!&P %     0   '8!
M*  #     0 "   !,0 "    '@   'X!,@ "    %    )P!.P "    "0
M +"':0 $     0   +P   #H "W&P   )Q  +<;    G$$%D;V)E(%!H;W1O
M<VAO<"!#4S8@*%=I;F1O=W,I #(P,3DZ,#<Z,C$@,C Z,38Z-3D <G(U,#DQ
M-C<       .@ 0 #     ?__  "@ @ $     0  !<V@ P $     0   N8
M        !@$#  ,    !  8   $:  4    !   !-@$;  4    !   !/@$H
M  ,    !  (   (!  0    !   !1@("  0    !              !(
M 0   $@    !.$))30/]       (          #_X0%(34T *@    @ " $2
M  ,    !      $:  4    !    ;@$;  4    !    =@$H  ,    !  (
M  $Q  (    >    ?@$R  (    4    G $[  (    )    L(=I  0    !
M    O    .@   /      0   \     !061O8F4@4&AO=&]S:&]P($-3-B H
M5VEN9&]W<RD ,C Q.3HP-SHR,2 R,#HQ-CHU.0!R<C4P.3$V-P       Z !
M  ,    !__\  * "  0    !   %S: #  0    !   "Y@         & 0,
M P    $ !@   1H !0    $   $V 1L !0    $   $^ 2@  P    $  @
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M 0$! 0$! 0'_P  1" #M =L# 1$  A$! Q$!_\0 'P !  $$ P$! 0
M      D&!P@* P0% @$+_\0 6Q   00" 0,# @,#!@<'#PP# P$"! 4&!P (
M$1()$Q05(2(Q019181<C)#(S<1@E)E*!D:$*&4)55M'6&B<T4UABDI26E[&V
MP=/P-SE$1D=7<G-V=X*$E=35_\0 '0$!   ' 0$               (#! 4&
M!P@!"?_$ %$1  (! P,# @,$!P0%" D#!0$" P $$042(083,2)!!Q11(S)A
M<0@50H&1L? S4J'!%B14T?$T8G*"DI32X1<E-D-356.BTX.3LG.CL[3"_]H
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MRD!6-<*IGS!L:UEV(B$;&)(1/GL<T?N>\QK7[IZ'ZU^>2/2M9G_]8%]EK<R
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M;M ::]BLA96DF?#K#8WAA,JC+!NZR\BV<BLJ\KE4<$'VYMXTSW)Q?-G&8_\
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MC@>V.53Z3>^\"PNKQ[5?49K6AM,@Z8=_]*NTIN2ZJN\DAR,*VYN#8.W<>R;
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M?$+I+0^HXS+HVL:O#IE[&LTENQ%\KVT!2:%TDC9;F2%E8-C(&X,N5,*FB?7
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M)Y (H"R91A1XX!O,<YR,$$(AM5Q"E*]6L&-C45SWO<C6M15<J(BKSPD*"6(
M R23@ #R23P!42(\CK'&K/([!$1%+.[,<*JJH)9F)   )). *@0ZB?5LI:[>
M62Z;JLWUQJG6>&V<VARK9)KBRV)EN;!D18LH%EK2EP.&2MCQ8<=)L*P=:Y75
M2XLZ4$J3(\JGG5AJ+5>INAM*TF)WZD6^UJ[V21V>F6DU[:V4:3R6]S!J%U"Z
MK%>,5)A1&.W:K,I217&S]'^ /QIZL28Z;TI'H5HK(AN^K+^UT*6YB>*&X>:Q
ML+R[L]0GC-M(PCN45(5F!S(>S(M?> =>72+@6YM'66BMPV&3Z>R&AL-.9UBE
MC.N26%!EM_DF+2M>YS:Q+F.MC9K^+(:BRR29)D1ZN"OQY4\!)D,$NBZ<O[3J
M?4X[+0;N*5K;3+ZXELKAC:3M';+%,)((;D)-=R*B21E;9)F7>&DV1AI!B77O
MP9^)/PHN= U'6-!E3HWY:[TF[U/2M1L];TBRO)GM9=+>]NK&[NS:RW$@FMH6
MONPTID94>1_09Z3Q8<X2,DQXTP#_ !>C#B%($[MV<QZ-(U['=OLYKNR_HJ+R
M],H888 CW# $<?@:QED208=5=?.&4,/J#@@BNPB(U$1J(B(G9$1.R(B?DB(G
MV1.>U%7[Q2G%*<4IQ2H[_4RZRY713TZ2L^H(D:9F^470<0PY)B-=$@V,J,>3
M(MC!>U[)*P0!1L>.]KAK)D!*9A0!( N7]%]/0Z_J<BW986&GVYO+M4)5I@)$
MBAME<?V?>D<;GP66-7*#>%JTZQ?O8VZ=D SW$ABC)&0@",[RE?VMBKP/&YEW
M<9K3WG=86\MGY#(R/-]J9E;64Z2^2]77]D*,)SG*]&!C E-$(0E56A8UO@%O
M9@FC8G;F\H[&SMHQ#:6EM;Q*,+%'#$%"CR&PNYV\9=BSGDLQ.36O[B:>1RTL
M\LC$\L[NV.!XYP./8# ]A6:VB^M+>&OYT&;1;+R5PXY1%?7V5I(LZ^0Q&HU1
M2(\PA6&&YJ>*(3S:WLBHWNU.6>_T33;Z/9<V4,A//<2)8Y!Y\2*H;<2?O;O;
M'()J0FH:A8ON@N9 N<X9BR\<X(.<\9\C)))(X(K9[Z.>J^FZG,')+.R+69Q0
M-&')*<!45CVN1C1V<-CNS_BG>Y&N[(K&$5$16JY0BTQU'H$FAW>U6:6SFRUM
M,PP<<YC?'&]1]/(YP.:V'HNL1ZK!D@1W,8'>BSGSX=??:?'Y^."*RHRFFJLF
MQZZQ6Y09*[**FTH)<9[T:Z5%LX$B++"-/)KW.^*0SU0:^36M<_[(U53&)XHY
MXI+>4!H[B.2%U./4DB,KC\<J3X_.LITN_NM*U&QU:R9DNM+O+74+>0#/:GM+
MB.:%SD$ "9$'J!4DA2#G!US>DWT=:376Q\TVGU89% A83!V).J\#PB3;1H$'
M)$/<? I[2XLDL%8*!?3BC^B4XRMLYHSA$=D-4]N1IS1OAU%#</==2/;I:6MP
MUO:VW=5%O,2]N"XN)=RB-)LJ8;9296)&^0,0E=Y_$/\ 2>DNK--*^$$.H:AK
M>LZ2NKZIJ*V,\K=,K+9"[U+3[&R[<IN[W3@L_P WJDB"PLXXSV(YR#/%L=T=
M%2XU4P:+':JOI*6M R-7U=5$!!@0XXT[,%&BQV#")B)]^S&IW55<O=555W)#
M#%;Q)#!''#%&H6..)%1$4> J* H'Y 5P1?7][JEW<:AJ5W<7U]=R--<W=W-)
M<7$\KG+/++*S.[$^[$_0<5ZW)E4E.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE
M.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE6JV1C^T;F?ALW7&;5.*!H[6=.R:M
MMZ9;6-E< M>2-#J2$8]A:\0I1/E/D1U0_FP2L=V8\9+-JEKK%Q<Z7+IFI0V,
M%K<R2ZC!+:_,?K"W:!XX[8/O4P!96$ID7+94 <9!O&F76D6]MJD6IZ;-?3W5
MM%%IUQ%=&W_5\ZS!Y;@Q[&%P7B7M"-BJ@,QSG!%CMJ[;W;@U) QQD#5V.Y]G
M.30\/UGE66VME+PJTNY WV!(-A252Q[U]D:H@6YZ^,"0".]T9I))1C&0;KG.
M[*@6.2&.>0A(1,':-I,;F7"LC,5178#<,[<>,UBNIS7$<"P6-U96VH7<@@L#
MJ =H99@&E>,10LLDDGR\<TJ(C#[A)]((.K_UU$W#E_5A:83M[93ME9AB\B'2
M0BU<*QQK"J'XX72["908NZXN5K@!9\HUA*20U\^+$&61&]U2([1WQ(^+O4/3
MND:UT];'2K.TMX;N#5=1@TZT75-8M+Q8431S-<Q7#PVLER56,K<+*9S&PF41
M@'Z-_HN? +0K#I#0OB=U_JEUU3K=PT'46B:;:->Z)HW3]W9W4D-C?6]E9ZDW
MZPUB3T01W5\1 (;CL_*[9)G;"^ZGV%%//6V$.75R1^$CX4\:CFB#,;\N+\H!
M%:41BQS".HBL&]$(URC:UR)S0NFW5O?6<-S:SQ7D9WHUU ^ZWDFB<I/VI#_:
MJ)-R;X]RY4@'C=7T$35H[E%FBN;:=)-RA[=P\3-$QBE",I92$D1D.TXRI'D'
M/B%R)I/;4C6O]LC"C4C47P(Q>[7-7R\FKV[HKF.:_P 55$<G=>7 "=5E6.6:
M'O1O%(T4AC)C?!8$Y164D#*29C; #(W%0/<Q2;>ZD,O;D66(21I)LF7^SEC#
MJVR9,GMRJ!(A)"D!FS=NOR?#(&"2,AJ[>SK,TCY-7A&"/*_I]?!DUTQQ'K%(
M]L6]I&SH<;VCM6%8PCS"#E,,UD=\_#DGZNM.J[:&,1MICZ3<.;A4"075S;7,
M+QKE=QTZ_6WFD9T=+BVNQ#OB;[1G@QZ>YU&ZU5+6>.&?0VTVY[Y:%98VN!<Q
M"+&UUFLKDQS2(\;B>WNA$G:V/W>S)[Z0_6!84_4EF&K-A75O.I=T@'.QV:K8
M4BL@;(6065-F7MB<3;LRY5'"RNKY$N=*%$LO@U38PV3@DC]V=":]H.H?#K2I
MIY=/T[J6/7KK3;V"XU0RZIK!:"WEMKV&UFD9U0),ENZ1@Q P;X9)%+[/E'\?
M/@3?]&?%+K2_Z*T+4KSH_6-.'Q O+K3M+G.BZ+=7\\]MJ]K+?1]RU617TYK\
M1*T2Q02E.Q$%4R;3/,FKG*G%*<4IQ2G%*<4K7M]6'K&SP65772W@19..8Y$J
MZHFQ;H*N%9Y,2WA@M0X_%,GXHN/C@RH3[!P? UK)<:&5Z0 O%,U!U_U1<1W$
MN@VV8H1%&;V3D//W5$@A4@';"$*F0C#.6*GT [N=?BUUK?+>W'2EDQMK2.&$
MZG*!]K=M.B3BW0\%+9(WB,FWF9V:-B(T(DAXU;AL64&78O",LH,I(S%>U'NC
MB]H9?-C5[^+BJ]45Z?B[,5$5.Z\Y^ZEUI[1HH=[)&Z=P[<C<=Y7!( ^[C@$Y
M.?'@UIJTL)-1!VC**V",CGT@\CS[_3VSYKQ]E8J:%D;2.B,!'EPH[HY1M5K9
M*B:K#O(J-1/?&]48]/S]I N7^MRKZ<U6.\T\E)6DDBE=958Y:(G!50.#VR!E
M#GSN%-0LY=/D2,IMC=-T;X.U@/O8.,;OJ,#SGCQ7@TVOKB]K;^SJHB3!8S#!
M9V\<2N?+!5%DLAOLF1^WD2)%DGC#F/&Y71VR!F<Q0H5XLD@%Y<F?Y>VEEBM;
M8W5Q,I0K%&)$C]2%^X>7!+*I51C)SC;7V>AR:AH.J:S;:A9O<Z3<6BSZ(/F#
MJ;Z?<K*)M8B @^6?3[.<6UK<!9S<B2Z60PI"AD?9$]&J%K<&C<P=C]6\&PQ9
M<0.=V4D2>]+C/CL)0!A2/O\ XM#&:7M&_"YDI2D*URN&[FZ?AJUF^EW3Q+_K
MGS)%TYY8H5!@53[1A=V%X]>XD'(QOOX+'37T"\>WCVZ@+PI?NRC<4**ULJL/
M,83+8!^^S'G(-2\W%O6T%397ES-C5M13P95G9V$PK0184"$%\F7*D&>J,$$
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M'.2,!\-SOPL2$-.R[0Z?^(;V\<-GKT<UU%$@BBU*$AKR.-1MB2YC<A;N.(9
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MX$I'@E/\;YH/35UK5Q=6A6:UFCLI+BW>:)TB>9)856*1G48217<;ERRL <$
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M]-AS36;:N%'R.VBK619QK0B?T./5EE.L2'\7':.(OLA(=6"=F.IB[?3KR.Q
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MLK:VAMYKYHP0>U-=/,D9D W]B,JK!7D5M<G]H_+[J]RJO=5557NOW^ZN7O\
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M!.^]3ZHTS1+'4M5US5]-TJPLXVNWEO;B*SAM;->W&V^:5E[K=UBP)9G/<2)
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MM"S&-&935T>,:9+F/16.9X,$CR-8,:%<5[.S^W@O?MW\>>K]4A!EEN([>WC
M#F5D1"6. "[E57G"@@Y)X %83T!UC\&= ^'NMZ-UE\()?B1UYJ74$UWH^IOK
MFI=-V>D:0-,L8K>)K[0[Q-2O-MZE_=2Z?\M;QX=&:^;=LCN!37PI4NZIX2K
MGUB]SO(#NT,F1W\G(-SV*>5&?XOD (X957MY-5J$5EKE168D $'!5_*29 (
M<':<KR!DY'/-9'U3\![VP^#_ ,-OCN^L6/4&F7L33=0?#>_UY;;5M$T"VZCU
M"VT>TT(W=W+JMST_-80107S1)+>:8]S)=H9X&FEM91?3'VWBNMNH^G%E]N,,
M?(:"9AJ6LM1(V-<7#HDFK).<U1LBLL"Q6Q6E\?;:X[45?#NYN7_#J^MM,ZD4
MW16)+VW>RCDX4),[1-$'\ !RACR.-YP  3C'NGK?58==L?B]>=#Z7T-T%\2-
M2USIOIW_ $?BO8>F+76])^2>[TZQ74+_ %"YMHY'R8N_<F*:<7:6D<26LL4,
MXH;CK5O*;JRI 4.M8L^CM+S'^F#(K1;C')&3BGU46=7W>4M"MW#%7T#[3Z5%
ML8,,+KJTIY)30X495*[>A;J&0:W$([*,)NCT:9C(KS,\8?N3C,BJD1D$2D &
M26)R55,$]F=CX4V<WPXO9+G6Y_F8X;WK[38#!>6UF+>=HOE;1F6VN.]J#VYF
MN;<RR_*V-RABE>9EC7%_T=(NV\0T]N?46\Z>VHMG:VWC>#R"#</<8Q5R:CI+
MAEG%F=E#95MN?Y-E7VD8I8TZ/*:81%[JB8]\/;:[T^PU33+U'2>SU:4D2'+$
M7,$,QDSR&$DF]PX)WEBV>:V+^E%J&C]1=0]%]6Z#/:W.F:YT;!##-9KM@/ZJ
MU&^MUC5-L8A-O#+#;M;,B2VYB,4R)(I%5=M[KZR'IIW1N"BW)#QV[U;C+H$/
M G8GC4O&\E/<66G-@;GB5%]DN2Y_/HK6PFP=>3<-HH51C];(N\CNZXJ-ACCE
MB2-@US#7FY!ZJ-5BLO*2WW3ELV-C./S\@KH>2@R3"9 ;4L!=Q!H99X+K$!Z.
MJN).BL^+;VEF1D3$J=V-W-J\@+6P#2/\J5653Z@\_/=2]1V?8-J*QJ9.A] 9
M)M1UODU_3W.'WF7UECM6DK<;HC8U+29E>*S9FJ+:]AYM5'A5=[BMKC]A5.0M
MH\<%2K24?JFGH<D/@F5:X_EDDNR7+H>,;9T4>LI-7;#Q+$\.UM=65WBI\^RL
MU5)NZ'+M@R,+RZI@YW;4]*/$LAR']HWNBDH ,C^OXTK]KO5D=,-;3!=/=Q?T
M#<-K<_H3XAG]-8W$C%(>FL@VSG-E:4US3T$Z,RC/B]WAM L2-*9E%_".,3H(
M(LLT=2O?S/U5,>2BSJTU-K.!FJX0R3.6=DNT\0Q&ER>AA]0M]HB5DF&E"EW.
MRC&XK<1R/,[K(JZ(M-C%,3'&W$QK[<[JY2O'IO5BHU&ZJD:;SC)[\,QM$QE?
M(Q?%[*TR.PRZFHZDHL/L,AN;*MUR^+DE9 3:TFR/C4O,(-KB@A!N1)$:I4DV
MA=MQ-[:APC;$/'K7$AYA6R91\9NRQ)%G1V%=9SJ6UK9$J 0D.8V+9ULL<>;&
M<@9L5 RF,$AO:8I5WN*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI7AY+C5
M#F./W&*Y150KS'K^ODU5Q46(6R(4^!,$X4B.<3OLK7L<O9S5:\;T:0;F$:UR
M2IX(;F&2"XC2:&9&CEBD4,DB."K*RG((8$@BJ[3-3U#1M0LM6TJ\N-/U+3KB
M*[L;VUD,5Q;7$+AXY8I%Y5E8#\",@@@D5JI];OH1[!@9'=9]TH3HN38Y8R9-
M@37MI+;#OZEQS(](L"3**R);1AJYR-DH<,]PT;[]?*D(6=(TQK?P[O[662?1
M-M]9,6<64D@CO+<'G9%)(#'=(H]*!WCE"X7,A'/?_P /_P!)WI+J2UMK'K^4
M])=2(@CGUN*UEN>F]8E"DFZGAM$DO-$NI6&Z9(K:ZT\R.7B^6!$:Q&L]-3KO
M6[;1?X.FQG34+[3E_9R];"1Z.[+_ (R?6MA>TO\ P9*&]GQ5'^?;[\Q :!KC
M2=H:%JPD\ -9-LY./[7(A !SD]P#'O[UNUNM^A$M/GV^)'P_-GL[A=.J;)YM
M@\XM4S>%R,!8Q;=[/':#<"Y6I>E7/:S+<8QOJ,UEU*8QJ^WFVTHU!KK5\RHE
M9(*@KSS[,39F83,<2VL&-AE8-)!YY?;_ !U<68\HX3ML:A^C]#IRS]0/U-I.
MKVME9V4\B6BK<=0J]R8EGL[:S,DUI9=EI"&N(97,B*<QB08KEC7/TW]*LM#N
MI;#X>:]=Z]!=7UO9Z9;M&VA-9P.8K?5/F%DAUG5I+F,]Z;3.W82[-X^;*"-3
MLD0+3I$R;I_UW@72)@U7D\C5NR\%O(^O)<N9@F:8_D]BDK%9LW,6WSJ^P_:
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MLK*.>;]87\ MH9;F&XGMFCC@M+BXN(77>Z7(MI53TAA:?K:SOJ$K.D>JM=2
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M#S$G9?)R-<[LWLOE_5[+WX:22&&[F@_MX;&_F@QG/?ALYY(2N,G<)%5E('!
M-7/0[:UO=>T"RO@&L;S7M$M+U6("M:7&J6L-PCDD (\3NCY.-K$5I@ZIJ:M]
M5&>]&D>0+"/<]4>\I'IY$<]ZKW<]7JKGN<O=RJKE[]^1_##2=,N;:)Y2C.ZA
MG9V4.2[!V9LDLQWEBQ8Y/O\ 2MC_ ![ZAUZVUBZ$*R;1(ZHBJ0L:KN"H@7*J
ML8 C &%(' \5^[/@PX$)T^&5L29 5DZ)*"Y&EBRXA&GBG"1'(]A!%&THWM<B
MM<-'-5%3OSWXG:7I]E";BU*QRP[9(I%904=3E9$*D,K1L X*X*D#;@\U[\!]
M<UO4=0BM;Q'E@NOL+B%TW)+!*&CFA=2"&25',;JW&UCD'&#MZ= %_;Y'I6/:
MVXWAD60\;N3QW(YK8UE=8I43[0#!.1%$ULDB/\%:U>[_ +IY=UY<M3E-S#I%
MW(-L]WI=M<7"X *R.N2IP <@D@;AG"X\UJ"2SM]-U?J+2[)^Y8Z;KVI6-F^[
M>&M[6YDAC(?]K,:(Q;]HMGP16='+34RG%*<4IQ2G%*^'%&QPV/(QCRN5HF.>
MUKBN:QQ'-&U517N:QKGJC4548USE^R*O%*^^*4XI3BE.*4XI41'J*=%F,[>K
M9&<2VL@1H4AMNN01_92QP^[*T<698^$DH13:&[$R.&V@N*Q&26#F(X3QAD1L
M_P"D.H9+)UM"=S%2D<39V3QY+",L Q62/+&/"G=G!(QD8GKNEAR]XG *CN<_
M<<$@2;20&5L^H9X(!\"H=JOH\V14D:R'8XG:UW9'Q;,4^;'8>.K?,4CV%KR^
M*$'XO\1&DL[+^ SV]G\V*=<M&RS1W$;Y.5,3,!GVSP,\_4#\C6$R:=<%B5*%
M3D[@V??//']?6LK>F*OT3J'<.+1=DYM"MK^3)8DDE4+Y=13$&\1(U664A$;'
M+-EH/Y9"N;-)#$Z,&$+Y"))L>NMJVH:?-\C;,D87.UB5EE!'+*IY. "43WR#
M]!5PTB.QLKV W<XW[LY !56!X!)/I4$\^?%;)L:3'F1P2XAA28LD(Y$>0%[2
M!. S$((HB,56O&1CFO8]JJCFJBHO9>:8(*DJP(92001@@@X((]B#P16T000"
M.00"/R/(KFYY7M.*5QB*(XAF 09@E8T@BB>T@B#>B.:\9&*K7L<BHK7-545%
M1454XI4=/J([&L<*P* *"JH@85A=(-R=P'LOD0Z>H4J>*^XV&>P-(<)RJ-WX
M%>WNC'-S+HZS6YO)"V <QQ@^X4DN^#Y&X)M)'./<>:Q?JB[:WM4"YYW/P<9*
M[5 (YR/7G]U:PF9QY=V:=/L3FG39IB29<N2]QC23$\E>0I%_$YSE3O\ HC43
MQ:B-1$YNB$"/8B@*B#"JH"J /P&!R//')\Y\UK8.S-W,^LDEN?.?/\_;'D^,
MU@?M3&K"ME"NJ:7,J[>JE L:NTKS$B3Z^=$+[T6;#E!5A8\F.9C'B*QR.:]J
M?G]^]WA=7!23UQN-C(X&QU88*G/U'(.#@@8]P:V-]K C_/SP,?O''X>V!FMA
MB-2]>O6+Z?6HMK=/^^\TQBWJ<=)49YJG&"1,:FYG(J?*/:V^.9/60XN2"G%L
M%F.9CK[9*^1$2,E>@3"9#)R#\9-"UZVU6];IV^F$2QAY--@*Q22YW,98)T E
M>8@JKP,Z))M#(5?(;M;]&KJ[X767:TGXB]/::+F>]?\ 5_6%]&]_!9HW:V6&
MIV5R\UK:PQLKM;ZM9P1RQ&3L7J/!]O#,EJK1F*;*I.EC>UU9;$I=A:MU31T-
M3&;D$V"*,^PI*^%FE/E%/.CG=9RK&;!^#??4.\@IJZ*7S'*AQSBLVGZ9#?IH
M.L3M?17MEIT<2QF:2)<RQ(+F.ZMV'VCM(H$G<]6Z-3D;15OZHZPU+IN\^)W0
MMG:].7VA=1=47]U<W)TZWNIF%O?22Z7=:3J,$BFWABB99K,6[-!MFD.QDE8'
M-OF35IVH]?4\V]MG0W2=E&U],7I:',<3R+&9"%'#JYS)]9,F/@3*Z0&UK;2.
M@3K("_W&1O>8\3/!Z-5S78EUK?WNF:%+>V%T;2>*ZM/M1'%(.W),L<BE9HY$
M((?). >."*WI^CMTUTUU;\1H]!ZIT./7]-NM!UR2*Q>\O;#;>V=J+NWG2>PF
M@G#J(9(PNYD(D)9#BHN^D?UM]@91.J<5W]JMMJ><449F0X-'?'MGO<UC$>ZG
M5/I]@9[T<YP0-I&_B1HW/=XL?K_1?BG<F=+75;1+S<0HN-/C=+ACX!-L6>.1
MF8KQ&\7DA5)P*Z4ZV_0]T2[L;K5NA]6N^G9X8WG.D]13K?:05 +%(=76."\L
MT0!O5=PWQVC+RC#$;'%#<!R"EJKR/%L8(+:!%L P[>!(J[2,.4%IF!L*Z6QD
MJ#+&UZ-/%D,88)$<,C4<BIS=,4@FBCE59$$B*X65&BD4, P62-P'C<9PR, R
MG((!%<!7UH^GWMW8R2VT\EG<36SSV5Q%=VDK0R-&TEM=0,T-Q Y7=%-$S)(A
M#*2#7@U6R->7N5WF!TF>X9<9SC V&R7#*K**.PRO'@E0#AEO,=B3C6]2,C94
M9S'SX<=KDD 5JJAA^4RJ2H_]Y=">=9WM#8FS-9;Z%J.UVG?1GV\>%C=LA35/
M\B?\ETJ.LV@S/&)-I?0K"&'-*";*]R-6RQ'0D YVLGC4J@;/TT=B%%;3*7JN
MS^HR2XG2ID^U=.V)*BV4:P/L^5>44VN=L\805&4+E>!U5Z^I=76(Z37=?%J)
ME<9*DU,_K^OZ_P \JR1Z3NG4^A\ESA,EW8?;&87&,XM&BTTFUOWLP'$XF19Q
M)#5TM'>9EE!XV,I;2Y.,T-C+&EP6LPF)66MQ;2ZPBQE*SAXI3BE.*4XI3BE.
M*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI15[?=?LB?=57].*4
MXI77E2HT&.:7,D!BQ8XW%/(D$8$(1M3NYY"/5K&-3]5<J)P 2< 9)\ <FE1V
M677_ *#V/L#*]+4F.YSGF#0*/)*38>SJO$KUN!4.6@8Y@=?2+&96!$V[G0!S
M)_SII:^KCL;7_'E373'K$RQ>E=4M[.#499;.VFE:*6VLIKF W4UJP):[[0=A
M\NI 5@<EAOR !AK4^JVW<>)1<-VR09HHY/LYE;"1JP"L)]XS'MP00I!SXU=<
M_P %QJGV9E=/TX; PW8>-CN92P<37*ZFGR6@^08YEIH4V\F5V/9=%KE8L9LC
M'+NQEQWJR+,BH\3I)M4LSZ1JMY#TCJNEZG KDMIL5]%;7%D\C;G@MI+LQ6]Y
M;PR;E5H+EY(H]L<BL48GKB.W_P!)^F])OOB?TWKW2^IRVRQMK-QI-Q<Z=JBQ
MILBOKRWTU)M0T2YN8L/)%J&GV]M+*))+><(.V/?UKH#(-@[!QNFW-D6'8%2'
MF,F)A9\VQF=GF;-B(LA:BJJJFTL?AQ97AX3IDLS938OO#@PC&<A U5OIFI]2
MZI:0]37UAIEH7W_JUM3LI]2U+L?:-:PQ03RB-6V@2N[*Q0X526R+9J&O]/\
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MFHZS8]>=/W>F:-,BZE,T#+:7$B1N5AN(I)7C<;HY%C12S;"6&"&4'@ZLZ2Z
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M'FULMAZR+5R"R;41&.CQ9>"]>ZUIEKITFES0Q7M[=H#%;MXM1R4NY'7E&7S
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ME2FLV=TN]Y5@EP=\4C! I\_9EFY7'N?'^-3[FUG3D)O7)&Y<LI)/X<GS]/'
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M2WCW[],ZY=<Q#,D L?V6JDDM.*PQVU"9SDCHA2Q[+$L:GQGE1[H\JDKS@49
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I&,;6L&QB(UC&,1&M8UJ=D:UK41&HB=D1$1.*5]<4IQ2G%*<4IQ2O_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>29
<FILENAME>g98473g93m30.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g98473g93m30.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_[2HP4&AO=&]S:&]P(#,N,  X0DE-! 0
M     %8< 5H  QLE1QP"   " 0$< E  "')R,C8T-C$W' (% #5-:6-R;W-O
M9G0@4&]W97)0;VEN=" M($E03R!P<F]D=6-T(&1I86=R86US(# W,C(N<'!T
M;3A"24T$)0      $!AXZ)PG9:$FP@U%<#"ZD0DX0DE-!#H      .4    0
M     0      "W!R:6YT3W5T<'5T    !0    !0<W138F]O; $     26YT
M965N=6T     26YT90    !#;')M    #W!R:6YT4VEX=&5E;D)I=&)O;VP
M    "W!R:6YT97).86UE5$585     $       ]P<FEN=%!R;V]F4V5T=7!/
M8FIC    # !0 '( ;P!O &8 ( !3 &4 = !U '        IP<F]O9E-E='5P
M     0    !";'1N96YU;0    QB=6EL=&EN4')O;V8    )<')O;V9#35E+
M #A"24T$.P     "+0   !     !       2<')I;G1/=71P=71/<'1I;VYS
M    %P    !#<'1N8F]O;       0VQB<F)O;VP      %)G<TUB;V]L
M  !#<FY#8F]O;       0VYT0V)O;VP      $QB;'-B;V]L      !.9W1V
M8F]O;       16UL1&)O;VP      $EN=')B;V]L      !"8VMG3V)J8P
M  $       !21T)#     P    !29" @9&]U8D!OX            $=R;B!D
M;W5B0&_@            0FP@(&1O=6) ;^            !"<F1456YT1B-2
M;'0               !";&0@56YT1B-2;'0               !2<VQT56YT
M1B-0>&Q <L            IV96-T;W)$871A8F]O; $     4&=0<V5N=6T
M    4&=0<P    !09U!#     $QE9G15;G1&(U)L=                %1O
M<"!5;G1&(U)L=                %-C;"!5;G1&(U!R8T!9
M$&-R;W!7:&5N4')I;G1I;F=B;V]L      YC<F]P4F5C=$)O='1O;6QO;F<
M        #&-R;W!296-T3&5F=&QO;F<         #6-R;W!296-T4FEG:'1L
M;VYG          MC<F]P4F5C=%1O<&QO;F<      #A"24T#[0      $ /
M     0 ! \     !  $X0DE-!"8       X             /X   #A"24T$
M#0      !    !XX0DE-!!D       0    >.$))30/S       )
M   ! #A"24TG$       "@ !          $X0DE- _0      !( -0    $
M+0    8       $X0DE- _<      !P  /__________________________
M__\#Z   .$))300(       0     0   D    )      #A"24T$'@
M!      X0DE-!!H      S4    &              )-   $%          !
M                          $             !!0   )-
M          $                         $     $       !N=6QL
M @    9B;W5N9'-/8FIC     0       %)C=#$    $     %1O<"!L;VYG
M          !,969T;&]N9P          0G1O;6QO;F<   )-     %)G:'1L
M;VYG   $%     9S;&EC97-6;$QS     4]B:F,    !       %<VQI8V4
M   2    !W-L:6-E241L;VYG          =G<F]U<$E$;&]N9P         &
M;W)I9VEN96YU;0    Q%4VQI8V5/<FEG:6X    -875T;T=E;F5R871E9
M  !4>7!E96YU;0    I%4VQI8V54>7!E     $EM9R     &8F]U;F1S3V)J
M8P    $       !28W0Q    !     !4;W @;&]N9P          3&5F=&QO
M;F<          $)T;VUL;VYG   "30    !29VAT;&]N9P  !!0    #=7)L
M5$585     $       !N=6QL5$585     $       !-<V=E5$585     $
M      9A;'1486=415A4     0      #F-E;&Q497AT27-(5$U,8F]O; $
M   (8V5L;%1E>'1415A4     0      "6AO<GI!;&EG;F5N=6T    /15-L
M:6-E2&]R>D%L:6=N    !V1E9F%U;'0    )=F5R=$%L:6=N96YU;0    ]%
M4VQI8V5697)T06QI9VX    '9&5F875L=     MB9T-O;&]R5'EP965N=6T
M   115-L:6-E0D=#;VQO<E1Y<&4     3F]N90    ET;W!/=71S971L;VYG
M          IL969T3W5T<V5T;&]N9P         ,8F]T=&]M3W5T<V5T;&]N
M9P         +<FEG:'1/=71S971L;VYG       X0DE-!"@       P    "
M/_         X0DE-!!$       $! #A"24T$%       !     (X0DE-! P
M    (#4    !    H    %H   '@  "HP   (!D &  !_]C_X@Q824-#7U!2
M3T9)3$4  0$   Q(3&EN;P(0  !M;G1R4D="(%A96B 'S@ "  D !@ Q  !A
M8W-P35-&5     !)14,@<U)'0@                  ]M8  0    #3+4A0
M("
M     !%C<')T   !4    #-D97-C   !A    &QW='!T   !\    !1B:W!T
M   "!    !1R6%E:   "&    !1G6%E:   "+    !1B6%E:   "0    !1D
M;6YD   "5    '!D;61D   "Q    (AV=65D   #3    (9V:65W   #U
M "1L=6UI   #^    !1M96%S   $#    "1T96-H   $,     QR5%)#   $
M/   " QG5%)#   $/   " QB5%)#   $/   " QT97AT     $-O<'ER:6=H
M=" H8RD@,3DY."!(97=L971T+5!A8VMA<F0@0V]M<&%N>0  9&5S8P
M   2<U)'0B!)14,V,3DV-BTR+C$              !)S4D="($E%0S8Q.38V
M+3(N,0
M            6%E:(        /-1  $    !%LQ865H@
M     %A96B        !OH@  ./4   .06%E:(        &*9  "WA0  &-I8
M65H@        )*    ^$  "VSV1E<V,         %DE%0R!H='1P.B\O=W=W
M+FEE8RYC:               %DE%0R!H='1P.B\O=W=W+FEE8RYC:
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M<VEG(     !#4E0@8W5R=@        0     !0 *  \ %  9 !X (P H "T
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M.K(Z[SLM.VL[JCOH/"<\93RD/.,](CUA/:$]X#X@/F ^H#[@/R$_83^B/^)
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MIK;&UN;V)S='5V=WAY>GM\?_V@ , P$  A$#$0 _ /4V,:QH8P!K&@!K0(
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MQ:+7N+7$#:#^D?9O8"75>ZO]'_@OTM?HI*?_T?0#EM9UZVJZXM97C>I74X@
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ML!#J]U9)]ON;ZMMG\YNM_1N_FO0_G?TR.>K]3K(%_3RP]S-K_P#VUQLJIO\
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M6XY CJ[ZF-(HLW;1)V/;^CLL;N9>[8ZWU-]O_GNQ7>F95#VNH&:W-N:YQ+A
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M>PN;[4=)3__3]$JJO_;EUQ8YM1I#"[\UT%CJW_RG>^^O]^OT?W+J%:R,+&R
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M &4 ( !0 &@ ;P!T &\ <P!H &\ <    !, 00!D &\ 8@!E "  4 !H &\
M= !O ', : !O '  ( !# %, -@    $ .$))300B      %&34T *@    @
M" $2  ,    !  $   $:  4    !    ;@$;  4    !    =@$H  ,    !
M  (   $Q  (    >    ?@$R  (    4    G $[  (    )    L(=I  0
M   !    O    .@ +<;    G$  MQL   "<0061O8F4@4&AO=&]S:&]P($-3
M-B H5VEN9&]W<RD ,C Q.3HP-SHR,B Q,SHQ,#HR,0!R<C(V-#8Q-P
M Z !  ,    !__\  * "  0    !   $%* #  0    !   "30         &
M 0,  P    $ !@   1H !0    $   $V 1L !0    $   $^ 2@  P    $
M @   @$ !     $   %& @( !     $              $@    !    2
M  $X0DE- _T       @          /_A 4A-30 J    "  ( 1(  P    $
M     1H !0    $   !N 1L !0    $   !V 2@  P    $  @   3$  @
M !X   !^ 3(  @   !0   "< 3L  @    D   "PAVD !     $   "\
MZ    \     !   #P     %!9&]B92!0:&]T;W-H;W @0U,V("A7:6YD;W=S
M*0 R,#$Y.C W.C(R(#$S.C$P.C(Q ')R,C8T-C$W       #H $  P    '_
M_P  H ( !     $   04H , !     $   )-          8! P #     0 &
M   !&@ %     0   38!&P %     0   3X!*  #     0 "   " 0 $
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M*#,T0D=2T?_$ !0! 0                    #_Q  4$0$
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MMKC>1/N-6/2"Q7+=H[D2:L#^S-OVK''HA";[#=)1$/F"R3D6]17%MPY4'\K
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MD[J4P+8NUC[,V)DY.,2B*N8S'Y*:>O@(T,EF7DD8P"WKVA9Z"."<4JZ=677
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MWCJ^@:\73TG$B3TCT"IDT?D<O8:/5B#T60U:0L6J4$ADPVB=0^[&_;N362Q
MT?959Q2M!U7X*G+4R-C4I^UUH4W6=U(00G6JFV\HCAZ)QRRV(Z5;F-4F;8V.
M6:#UB.J^ZC0+W<!P' <!P' <!P' <"J@KH[U&"ICD1O7BIVZ EB,&,FVT0'.
M6NHP/"K#K<:.7:NM%VSUBV@-LV5$,,WR+ELH FI\<LFHW?;Z\#&U/'=T?5%1
M *KU<I?<? B!$O$--H2,RX"%BIB.R%Z50?YT^H+$MST0B9EN_=NG#IB3B\<>
ML56[@&+4:!.-?T'3E5DVIFO*[B\1*,H<WKYJ^"#M6;A"%-9.>F;:-)[Z[[?"
M)1E,HD)W1MZ>F")=ZX]?57.,!&]D=).I5P@!L4M?KO4=CQH/:YN\18.:PD-)
M1K&VI*6?G)'.VS8LW=)IG) 4*$71M7&OL%?G%T7Z#AOOE+@1?W^ICH9-:I2M
M[OQ459V76=!:.SXTA8L-<SA**+R@@!!KZ!P+)H0=OW4D))1X1D>B/>8(+89M
ME4=D?C] K:Q[+>.Z#7D*MP?3K:.V3)*MIAK"YO'NO-EXM\XVM@Q:M60>#,ZV
M%U@G+1SU0?U[)1<<01;*/G49%! NVC6'(1UP1"."]X^'XV.DK^.U3#I^OV4
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MQ?DFTDCL1^W!!=S%$UY(N$:1*V?$7*%(O7=9]<(F]JJ:JUX^86"2K"50VJI
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M]MS5N?28M):*W]UI*[QLDNWT'D!+IBJ<:Y"D [B.19T## D/''UW3KX'%'C
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M&>2V@_,30/5N+M8SWQ$6Y.\!ZJA,TBXCII74ID,&T/&8S&;!E-+R2N2%'L7
MBL@KLU)(JVE-.'W+H,!0'NXR1(N=$M0C.*=C_.#0$"G2<5Z5QSNA3543B5 8
M'-KKOE&@.WL_J(&P%FHY+)M%Y="1L%*F68(GF-E#K4NF:E,GBLD+J!-\/1RI
M,*[T3YX>\4+7T=]PO'S/I6-O"LX;VOHEAUB1D,Y,P"AK-=OPP"O[(VWA;4*T
MF,:<@4R1,S+S<*T5^V QH\^5SKHDW"V(7])8Z)HN]AMKUGVBH<JDLDW7'6-"
M*R(/O>4QZ[:M0]=W!.)(\VT]-OA;I </W&NN-FK);51+*@9?+_TD;Q<1TS7
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M4UB2EOUC#K#4C.AK9EDQH"4E(@IN+3)[#1^7^C/*.KK9DVV6QOLCIG4*+-?
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M:&<$SJA4(GL7QYUI*B; S"I9)*Y,."&&LR+LG1(T1D<$>3Z669(X2PRJ=',
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M74B'&)EIV.)CB$%3CV=(N@5:KL\!/0/J9Y/_ *1$G]S=X:COZP*_N(?9<$+
MJ.)=900@0TJBU(25BDG'0B4V*E80^3FIJ!46:F6+!N 9,'QIED@;:AD4 [B%
M]3.[U<10A"8_=XL['!<+ 0N!L3EMV:P4'"&,@B"S_!LVPA3N7/9:@,&2XFQL
M5I)FQ@FZE.D6D@PJ!%CW;0,\"=8NVQ>@[HK6V+I:2R96I4>L;;F&L^F[9@&L
M=U-;2<E28HL-C,>+1:+NZ],UE'MF\88--5GL=,[K L;.5RAP,;%=6.\"K%@S
MD/9!SC9D_)*.=H_9DO$,B.KN:U HN]8LAL!%/0#)_7<?M@6QA^Q@X*A9J7CM
MXH^;*HM3D=#&3_63R,R,_N:6O* B?D%XBX8)";)LW34DJRWL078"FB2\"V2A
M;F<PH[#X^FI%\_38\;%/)D#"CCK1!<J$KVEU<[+V$"JC"MI1IW.(!!C4?:S1
MZ[<,'H(](8Y%!!Z2$=&4)>ZS^8/]Q,A2"6#&$Z&<Q#8PW*,XD54T?CG@<TOU
MK[)9IF#P.O[!%5$8!V18<I?BX;8<PR$$0\ZZE+J%P8+)\PID7,!X\Y*"'B@Y
M['0PIOAID2W;/ [)!L\"O:="]]Y5,9M5LML,N[ARM:RL3BPW5@29K'-GR0JC
MR-/M0@Y*(HN7TB83*(6*G,IHF^6D1./RV7HRE'7=. (& GKK]!NWL-[$!P]O
MR@[.H*"KB:(EYVWDY1*'R,BY<UTVAVZD'<1X>#;2DD296/+G2X8INXAZ9]W7
M>HQ2#QVOI 9#91P-6_?6HK>NQ;,&;U9:4QK*0@34,=O:-7Z7%3:P:8#6[&0J
M3G';Z,,RT"U89U>("#%,R"5$UV[E,JZ#-RS%DBF&QJ"YD^8F#^V(<6 D6K!+
M0@&#2-[+V W*>VZ;9JG)2(2./#*R;+5M\Z^5"L<*OLN?:T50U3<+!EW <!P-
M T[\-O7;N1;#+MC)$PT N:(3+LS$X_:T( RIG;P<T+[/6L^B$Q:G\V6E6)E_
M#5D<C1HF?4Q-PQ>+%Y)%94V.B'P9&.A\TGC1[&]S>D?EP[0]<VL!J=M$H;(K
M*JT3 IF<D]$UI>4A&6,WTB\<Z\RB0GYE6%/3BU8LRQ-:>IDH_P U4R4%D(-&
MG4#U+O2*8?:+4?E$ZDVK8H6BW4CG-6]DGN$49-UTM>KI[&+0K@BX(# [1K8&
M[4"6@P,::-FA :'3%.9O('81$J,;0"4290@TPJ&P_&?7&,_W_?P' <!P' <!
MP&<>O _/PX_W_P!_K]_ U91GQ#=2F5_7->MAPT%=^MU+3]R<K:X8G'9]7PAY
M8TV;3H^]% 9.T+,LO%":"C9%RX;*+-6+MTT'[,FCAPV6# ;/\'G30XDZ(=<"
MU]] 9HJGOAM+NC-X3JA6:6^V_NZZNJV$$7U3/&N5<:>^GB#MW2R":;;5\DDF
MCJF%35^EOFHZPNW;^K?(!9/;R L]=MF<?.OJ6C%OZI8133T24#W_ %5:$-L)
M_G9+*ZN=^P-#LU%5U=6^S-#"*&@=@+\B?<&N30V)7-<_62I)<4<99C8-Y ^L
M%W=*'Q)]G3":# -V2@-N7_U9GCM5SKMC&M>DC&ZB:VGP-4MT\)K!?-WVT[TP
MZ+JR67^/D5:H9,,Z,)2GJ7VUJ.R03]B@,W(-RK1E? WK"27'.<IYQ[8U0NZP
MCNDHU^>SMMC4-9'C)\K$.C92?0[NE>@FMOMO()+.(L3M>NC5/P^,2&26C,MB
M49WMM>Q+4I0]@\L^U<C]V]B!7[-V*>#%V)%;9-SJ'TL@)''Y6''R&+G!$C %
MFR3T4< DF9<.39K:_&B['DAZSAD];*Z_>FNV652WQ]^NV<9]>!W'P:_W?Z_V
M_CP(SGM)TU:K+<;9]2UG8X]3.<[LIW!(O+FNVVVN=,[90/BR">=LZ;;:YV^'
MU^'.=?7TSG' IX_\3GCL5=[D8YU5KNK"NVVF^"]#+R?KR7263WV42<MRE&GZ
M^?MW:2F^VZ;M!=-SIMGUU5QP.,Y\=+,1\.:I[H>0*HMD5%%&R+'LZ8N8:CC?
M3&N$-AG:0#?+91LGMC7=%+&--T<X]M)5-'91/<(,M3QHW=8XU4?+^R=!]EV^
MB3?5JR[O^/OKY='KNBIA57=<M5#CKX\QNXVUT]54VWNH*ZX71SC;7&N0JTW\
M8?:>L5LN*IJ[JW&O;5S\2W4WN?W\Z :.FR2BCAOJC6L=SV#J;XL+;[:Y'%AI
M =KIOG"2B2.F&VX:Z>]I#S"5JM6=.USV!MBCRV[>8]BTW/:3LYTTM:%2]#JR
MF L"-UM"IM#*KIB_#3JP+2<UW!B;&>I: C0DZHV,[$&2Q[1H%WZC\LOD5S6-
M?6;8/5D-/XY,H9$9H@\8=9>[M8ID14ICC$ZV<@)?1->^0.M#S)3YU/9@:TD8
M5@_8;IO5&P[5337(9YI^D>=<X*_^E=C.N]_TNLDMJB[-8S7Y@&AC?9+75;2/
M3*5U==BR6WQJ[)Z?J93=K8;+)H-E7&44%0M;5_GP\0]KND1P;O#4\4*+.MF&
MK"V=)/3>WSVF^NBK-,A9X"*!72R.VZ>%<,2;I-/"B>^RGMJ:;[!LXKNXZCMX
M4F=J>T:[LX(JGHJF8KV:QJ:#-TE,>J:FK^-DR37.BF/]#;"OIM^S@2/C.,_A
MP// <!P(!K.66N?L^XH]+UZ^VB$ D#(%']8V%D;*2/,FX[&I@+<F'I.1$AFW
MR0@_N+?HLAK?YPDVU(MU&;93([0)^X#@:<O(]9%C06VJU<19Q-I9" 5-VK-K
M)KN!77V!I%[% ,?D<%V7O.3G>OU:S4T<BL3%[& 3F-DGJQ-ZH64?Q&)&EQAM
MRS#;^+73<C1SE%5-=%PQ:+I+).=WB2R:K=-315)VKKHHZ34UVQOHY4TUW7US
MA7?77;;.,!SN X#@0/UQ_LZ-?QN[.?XD[9X&7V33M4W#"996]I5W#9]!)T,<
M!Y?%)5'1AD+(1SI35=5 FR>-U$W&<.=$WB"^?1PU?(H/FRJ3M!%;0/B%\DWC
MX[[5MY5^J:-05[W([2=!X,PK689DM?JM#]X4L%"2\XZDT-@_9!=C'K);3& B
MX['RE9;RJSWDD/BQL)@LHDIP.BS9[!L<MWR6=H.N]21^6TUV<KKMA10>S8]
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MAL*Z>#GB?KZZ[Y0<;Y24UV25QHIKMK@,XX#@. X#@.!!/7S^JLW_ ([=@O\
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M;YQC'Q;;9]<Y#E\!P' <!P&<8SC.,_?C/W9Q_JSP*(W[XV.GW8>39LF15?\
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M>!/' <!P' <!P' <!P' <!P' <!P' <!P' <!P' <!P' <!P' <!P' <!P'
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M&_*AW.<KLE.!G_T'L;^]6D_R G7\RW ?0>QO[U:3_("=?S+<!]![&_O5I/\
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M!'A:*]L5+1A1%I:=3YB#2#62S/;(4S,FX?61/SM7+17! !OV5^:*$<CQTO\
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M3"1;#];=<6)H*W<-\#-&VGRT7SB)MP2:86UX#@. X#@. X#@. X#@. X#@.
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MVHA$R.NX)8</#Q/6[G,4%P=NY,2Z'" :\MT,S^$Z2>OG!<9,8J)(F7YD8V(
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IHWTWT=,&CY#"2;HAL^0"V' <!P' <!P' <!P' <!P' <!P' <!P/_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>30
<FILENAME>g98473g93q99.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g98473g93q99.jpg
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M 0$! 0$!_\  $0@!+0&F P$1  (1 0,1 ?_$ !\  0 " @,! 0$!
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MQ^](U4.(^$-$PN[=MV;8T17GV7\8]1\$#/,QI[P^,"/E,..BX]E2>*B3G'N
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MB4=D37]_W_"F[!!]"#@>XDX[GU[Y./2I;]AO#Y[$T;5G;D[7M9U9?[]=-J[
MVUU0N.JM?J3V8C]U[/[G1/;G7Q.T]AVF3@8&K:GU'=8R)KD\U&R,^-,54+-G
M+3%JC\54]5 PR"?<#Z8"[>W.3Y_'ZUTEN\$S8L&N=C-+2_6]-7%CM90].C=B
M5^T8?. B?#TMG0^Y.W1<' 2"2).!(F1-TT.08<D'9BRGV6+G<0!)B;&^]:;^
M<G/<DX][!OY>GOK9+OA&[B!LVTA:[LG3<7K^YP/7=AO*:_;"+3;+AIW<'4R^
MRMYGEV#%J-UU,3%6ZZSU?LD1K>XXH.U)R<HMKL=$JE@HSLO-J;AZ')W?0@CY
MX)SV]U3;Z*=.MB]5;[V=EK'-:LS0-M7&/GM<4W7,18,NUI*+AM:V622D;#=L
M25UCXVSD["CB@-4$7:^4S7EB#N4Q09>'B+Z15H55"<X_G\O[SZ8JQ[BHTXI3
MBE.*4XI3BE.*4XI3BE.*4XI3BE.*571XC&V[W&42@=5=#S3L)V5[L6@[3.N9
M\+U+.U9KT>,S*[][ +0A3:FQ]0:S6<5"/X>:6YL:?H$:UAUR1PWE4EQW/8<_
M'T'S/Y5MV\1<%TAZ+7\+0U>AH>%ZL]7KR=JVO2H[YL.A6I=93$K6V;"V$3&&
MRR3S80=^QDMFA24R^3(%N'-'%K*PJG<\^9Y^9JHJL^-9>-&P%AK7;/7D1MW:
M(1NL)NK%=9ZN508ZQT38?5>L]G)09^H;)V5=B_KY4QY<JE0T5$6TQ&Q)@J 4
M(#5FWI)T54]@/X<^?!Y\\=^.#\/=S4HK5XQNNJQ:]BUG] FVCVZF3>X*G2^)
M6A@C['N5&V[UATT37 @#+"B6JC1MF[::M?3+VL&/9%"8M"EC.KB6,2"J;#CN
M/ASZ,?3T4]LUIZ"\6O84IHVZR-FU/.0&QZ=1=L[5N%XJ0=%DZCKNGUSO!V#Z
MKT&O&4^P[)Q*6JZGL:6%'G7J]*R%:7)24C/LR$9'- QKRJ;>?=P/3.0/<<=Z
MR*-\6R=B#;/9=J:BMU6BZ:=XA,%'ZZKK%!F2MD+ZJ=LM$]:J')BVY6Q245>:
MDY[:[=8FXZ1&8@B)UFV6!HT>IPU1D+6JNWT.?P_4J2?+W5+3LGVXW'K?I+*[
MW@M0O:@W8;M#5>EXZ@;L8#M<93;/M#LW2>N35PE4:\MH@=ZJ(C-N_2)5_H"W
MPV;= _0[1)E?(/,9 50#)QW')],@ GY=O^M:)*\36:Z]7[3/6OLK 5G<N]+Q
M<9J LU\ZKX1G7D;4R.P;6B:+:SZ)9K5/VV$N+9$B',;CUK&S]N7K > N9R+%
M,L@QT82IMSDC@#U]PR>0/=CWDCCOC+^A/=_;W9S8H53V%$T,",(ZJUS=BW*K
M#34<9BW2W:?L]I4D1+LE9)EK$$FI:;JI3(>6,FIG2ILQ<BX&6''1ZA'&?>/S
M&:M?XJ-.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*5_*T(<0IMQ*5MK3E"T+
MQA2%H5CR4E2<^>%)5C.<9QG&<9QGRSQ0''(X(Y!'E7]<4IQ2G%*<4IQ2G%*<
M4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4KX%
M%"@BDFFDL!A!L/%%EE/-CBBBCMJ>())(>4AIAAAI"W7GG5I;:;2I:U)2G.<*
M55;T.%*[2;@W!XEEH&?S7-EAD:(Z61I[3C2H#J31;$^\=LH<5Y++@DGV<V4$
M;L9UT@5);FN('5 V"'!V5)RJ3< +Z<M_O>GR''U]:LNO=(J^S*/<M;W>+Q.4
MO8-4L5(M\+DR0CL2]7M<09 S\7F0B2@)0'$A$GEB9,C3@Y ;W?>#*'(0V\A4
M:@V#X5'1&*HPVO8K3<Y&0HUE,M2Y@#=N_1=B2)TE0F-62<5.;:;VCC:=@ITG
MK04:@R%!F[C(4<NHCL03U>5'L,LH5+<V<Y_(?PQCX>GE6;6SPZ>F]V=LQ%AT
M][I5N>V&5,&1M_VA F(/VE:].WFYR<*3 W6-=K4J5;] :?L,+)UQ44=4)*D
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MEUKL):ZZ>9<86#*)A+%2)7944\;"SQ49.0ICM!@+!;BHB;C8Z8C8&NV*0DP
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M(,..$&!CQ1@01&6QQ PV&AA1AVDX0TR.PRE#3++:,82VVVA*$)QC"<8QCFZ
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M0K"IRYW2R,=TLK\Y>1SRS')] ,X4 <5=7VI7>HNAN' CA7P[:VB7P[:UB_\
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M/(0Q")7& "\LLK8\S)(S>>.=I /O''%75_>->RPR$MM@LK"RC#8&U+.TAM^
M"0%9T>0<Y]LD^T37=5VI5VIYGLUV+9BDV:Q2-LFFAEO>P789= R9632.MQ;
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M(Y*6"!W\L.X0[AE]ES*?0ZA2E*Y/%*<4IQ2G%*<4IQ2J\]I?]9-U2_W"[_\
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MU^U;18\FO3-Q_1KJ.)H]!D$.U 6L5JI0$O6Y!BHM1,E+N'S\[)14E6U"V1C
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M7N3(<IM89:,Y+2, H!(8+;[TR[IPG4S8VRV;/7F=M:OO$&'$V'6WQ\:X Y;
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M>U5F;ZZG](=P[AL!]WW ?1-\6+;W7VRN?4'L,C6NS8C;-!U-NJLZ2CZZ'%3
MMBA9ZP:NMVWI*-@PF$'W")B)>=#8*$K9CX[^_IS4@3CU'/EGS!/]FMD]F>IG
M5R\46G26Y+9.:GQK<P@.*W=!;:,T]?EE[ KV=86,"S;.$D(DBQ$[0BI9$!/M
MSSYIM@ERP3 UM6!J.,950$_'W?//:MT4*]=9=53E&Z=479.I*S=Z!KJNPU&Z
M]#;$K:]E0VM:A718VO*"H1DX_=WX&+K<8-AJ5? (0L 7);Y;J<./94Y[_GY9
MJ07%4IQ2G%*<4KR=^*[XA-KVQL&V=;]5SI4+IVBRI=;NAD22M@C9EKBGU#33
M!Y;"DJ=IL'(M/1L?%-K4#-&B/SIRCF%PK4;];_9+]G5II.G6G4NK6Z3ZS?Q+
M<V23(&72[250T#1HP(%[/&1+),1OAC=8(Q&PG,O#>N.JY[ZZGTBQE:.PMG:*
MX:,X:\G0E9 S#DV\3 HL8.V1E,C[QX02DOG<:YS4V:1T![!7_54=M:":H33-
MAJ]DN],U]*WN&CMK7RG5)3R9^RT^BO*R?*Q@/P[ZDY4Z,24VEEP,8A!T=DO1
M[[[0NG=/U:329SJ!:WNK6QO=1BL)Y=)L+V\V_=[6\OU'APRON7/#(A+!V4QR
MA-CMNEM5NK%+Z,6H$L,MS;VCW4:7UU;P9\2:WMC[3HNTXY#,,%5.Y-V VCJ/
MN2IZ(U;V+.C8@W76W["W5J@J)DUG3JILAV?9##DXG C>0E'NUJ60&I)#^'E,
M(1^JMU*>7]KUAHMWK^J]-QRS)J6C6YNKSQHA'!X"BW:1XI=Y\3PQ<Q%_97 8
MGD#-6LV@ZA!IEEJS)&UI?RB"#PWW2^(3*%5X]HV[C#(%Y.2!ZUUW9KJ]M'J9
M>XC76VFZ^W8YJH@70-%<F/IH),-(R\Y",8?*^%$PV8DZO2*76$H6E#>&5X=5
M[GI3Z]+]5:5U?83:EI!N3;07DEDYN8? <S1PP3MM3>^4\.YCPQ().X8XYAK.
MBWNA7,=I?>%XTD"W"^#)XB^&TDD8RVU<-NB?(YXQSS6T-4= =_[CUW7MB57.
MNPF[RS:B-84JS[ @Z]L3:[%*R0BS/:\J9J\$S;<4\(4R0IY\'R]C)&/^1N,$
MNXK5OM#Z>T74KG3;O]).;!K1=4OK73I[C3=):]VFU&HW:>S!XH="NU9/Q;?Q
MAE%]8]*ZKJ%I%=P?=%%R)VL[::ZCBN[T6^1,;6!N9-A5@<E>V?PD$_'670??
MVV-=0FQ:TBA!)N3-Q(UK1K+>X6O[)VHQK]3[=Q=U[4#E)*G,03PI3)J'7@7$
MJ84XA"V'!WGI:I]H/3VDZE/IMR=0?[D;)=3O[:PGN-,TIM1VFR&HWB#;!]X5
MT9"%<$-@D,&5:6?2VJWUI'=PBU7[P+AK2VFNHXKN]6UR+@VL#<R>$5(894\9
MQ@@GKX;I+M"5T3!=AC;GI>J4BT0=[GJO&739L35[E9F-=2DI#V0&O5J48:(F
MI9N1BU#"QT<\2\^Z?%-J]IR081GTFZYTJ+7KCIU++6[N^M)["WNY;+2Y;JRM
M6U***:VDN;J)BL$)CEWO+*JJHCE/(C8U"/IN]?38M5:XTZ"WGBN984N+Q(;B
M86KO',D4+@-)('3:$0L260<%A4.^;G6OU8WX<G>N?Z<;-1$R[GQVC=ASP.=F
M026$K?BS'&18EG8,,MM&2,3,(".(W)"XRXW/006(QQK!@L,;&\Q^T?[/;'K#
M3IKJVAC@ZAM(6:RNU 0W8C!86%V1CQ(Y<%8)'RUM*P=3X1FCDW'I/JFXT*[C
MAFD>32IW"W$+$L("QQ]Y@')1DSF1%]F9 01O$;IZ'2_%,UG?RRH/ISH[L=W@
MGFB'XY,YI?6Y-3T>%+,N*:R--=C=TDZVT^D5*T*]XFJV*XD-IPK+8#ZFW4-_
M$[*R,R.K(Z,5=6!5E93AE8'D,"""#R",&OHA0&4,&7:P#*<YR&&00!DX(P0<
M8(((XKXXKGBQ;]_:6+8'7'H!2C/VJ875\&9VW[",C*_4R&;?=A1]"T96)#*,
MJ=R[&ZOV:*.ZEO#1I*<JRF-5]D>1;X\#\LG\Q7<U_P */JP=,Q]O[%N;4[O7
MV-(08'9NY&QY?<L)'%)\U95 :=>1"Z#J[27E+=8:KNJHU3&5YPEW/GG*E-Y\
ML+_NC'O[]_SJQ:!@(&K0\?7JQ"1%<@(D= <5!P,:'$0\8(WY^V+'QD>R.$&.
MCSSZ&!F&VD^>?2G'%1KM^*4XI4.>W^F;9LJI,S&OPAI.V08Y#>(<@G BY<!?
M[7X<1Y:<L_&-N>OVFGULMO8=5C+V%I0E>P:!J<-A.RW.X02%264%MC=B2!SC
M;Y@$C':LQI6H):&2*7_92D$-C.Q@,<@<E6&,]\$#C';RA;]1MFJ;#5"S\1*Z
M^'CT&M2%4E8;Z.=/?<RK#);!)3:5J895Y*PL12FG?3CR<QA6?/M6EW.ES:;,
M\4,=[/*Z-%>QSEC JD;HVB!(!;MAMIP>Q*UM,'+I-#,&@"D%4VLC,<;3D$[2
MIQV]X(.3B!DQ\6ULA%H9KU?'>]E;9LFB-PW+OF(SA+9*7FVTCY>RC'EDUU"R
MEH]+>'<)3CF\6.LQ+HGW":?4'?Q/U<329M!"<Y7&2Y7!SX?$><';GO:/81OJ
M\>H_=;(E(RIF:-S<[\G#C+>&"/)PGBC.-Y& -\=?>J>Z^SFU6ZY38^?F<V L
M HLPYI]JKU.,9PMI4D<?[&6P@T(6ZZYE6'""G<H;::*(4RA6 ZAZDLK&QA><
M06T-LL@ B ^\WDLC*5#9RS,N-J!<(BDL?+%U<2I;&>XGF;PV*E(V/8JN D29
M!.3DDX[GD\5[@NL6AXCK3I&C:;AY)Z:9J@#R39E]G ZY66D"GI"4-0-A;N!1
MW#"'4"#Y==6R*AE#KSSN%NK^;M7U*35]0N+^1!&9F&R,'<(XT4)&F[ W$(HW
M' RV3@9K2;RY-W<23E=N[ 50<[54!5&?,X')\SFM^<QM6M.*4XI3BE.*4XI3
MBE.*4XI3BE.*4XI3BE.*4XI42NTO65S?<$V]7;+]4KG'#J9 />8^(BSVO-2T
M"2;;:,DH2E:E>T4.K*VO7G"VG4X3A.;T;6GTIR&B$\#D%TSM8>648@@'MD8Y
MQP5/-9/3]2>RS&5WP,<E1PRGS*G(SGS4\$CN,FO,5OWH'VHU]>9.Q3VK+=:W
MGA5QP]HH(4A<X8F/R[[K:O8A4%%1ZU*90I7Q\>,ZCTI3G.?/RSU_3^L=/O--
M33XK^&WC5Q.UK=!+>59<8R)&&)%&2!LD89/;.,[+;7EA(_CQRQK(RA")'$;A
M=V<$,0.X'()'H>]0!D=#[R"M:Y0VD[('>(1]'-QQT#-B"Y<]7H3E 183.<E9
MQC"?+/F[C/JRE/GG/-QMNIK<:?%8JVFD1DN9TDC$[#)]EY-Y&WG)P!V'EDU[
MHJ&Z-V+IF)CV>']Y!@51GVE3)16).6;C)[YJRCI7X0&T]K6Z.N>UZX5K75I1
MC<Q-DRC#D=:[3YJ0MT2(B2V4%L9+QC#:Y<T9H-+>7"!LENX0VO2^I^O;:%!'
M;W O[Z*+P+=5<2V]JF3C<XRFU#SX*$LS<-M'-6-YJ5I9^+X!CEN78LPC(9 Y
MQEY7'!;L=HSN.,X%>M:D4FKZXJ->HM+B!X*JU:+&AX.)%]>60@14>AM'K<4M
MYYU:O4\02^XX040XZ00ZX\ZM:N'7%Q-=SRW-Q(TL\[M))(V,LS')[8  [*H
M"J H  %:C)(\KO)(Q9W8LS'N2?X>X#@#M65<\:A3BE8];8%NU52S5AY:4-6.
MO34"ZM>%Y0AN8C28]:U8;6VYE*4D9RK#;B%YQC/H6E7EG"E4D:(\$^B:2W+K
M+;H%DKY)NN+I V\4<<.W(?>>A#FC6VVEF6<H5+BE-XPG) [S6,_RVU8^7%1V
M_P!X'\@*O8XJ5>?OM+UU[.QG=Z>[,43KO>]R4B#[<=$]L P^OK+J,"UVFF:D
MZK=QM:;$-@0]D[*U_$-D5JX;5H\:\)/S<&]((F,EPZ9$8(YT>GF?@/YU,$$
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M=ZXK-#-;RO#<120S1L5DBE1HY$8=PR, P/Q%='Y_S?S?O\O^[S\O_P >>?\
M\YY<5Y4XI3BE///SQY_+/[\?Z_+_ %\4IY_S?S9XI3BE?TE*EJ2A"5+6M24(
M0G&5*6M:L)0A*<>>5*4K.$I3C&<J5G&,8SG/(NZ1(\DCK''&I=Y'8(B(HRS.
MS$*JJ 26)  Y)J2JSLJ(K.[$*JJ"S,3P JC)))[ #)J]3J'X.N_[- 1^Y+IL
M ?K?L"'DX"T:CAK)K:%VH2/*P\D-*CR>SM>S\I"A8A2$CI&3552\99\J><+*
M+KI( [)OS?\ :;]K5K+:W73O2UQXYN%>WU'6(C^I6%@4EM=/<?[5IEW)+=K^
MJ6(D6[2-)XL/6>CNAYDGAU76HO#$166UL)!^L,@Y2:Z7]@1GVD@/ML^#*%5=
MDEK?VB/$5Z^^378[I_6^SE*$^96X>AEG]VVM!I_9(+G.K.ZI6#MF"LJ3@@L7
M6NUMHD^VYGX&+<4CV.?--=?PI[''^]_4?S _E6]=%>(7U [#V)="HFY(>%VV
M,I#,GHO:L;.Z8WM$F9QG#P9FH-J1E1OKRQG,*9>,C(.0BU.8QD>0?:<9<<50
MJ1R1P>Q\C4TN*I3BE.*4XI5:OBZ:,L79?H?L;159B+A,G;(VIU0@I%JA %R-
MKC*FGMMHV0O%HBF F"'V/J;3 IZV'266LCQ$="ERIBFQ WW$*DAVMGT#?/V3
M@?,\51?JZ \7C6;-%K\B)NS7MCGNUG9F:VI9M<Z=M5X@-H[7C]F=6ZM3[Q/"
MQ\,0 %J/:-$C=R6R+L>P)NJZ<5#%V!\RS$6R)I@V52]GGMV7&?3:<COY'';)
MXX\ZV[:SO$#V;L;6L=?@.ZL=1],]IZ3/W0^NZ@MWH*"B?$<[1!QLO7,O:YF4
M;$JL'U<G=&2[TQ2Q+! MT^.@S3CB&(JR-(4X XVY/O[949^><CGSS\:S*JR/
MB=P,ITN>FK)W2F[#=6=(6:SQTA0VSZ,'<)?M]7:WV2J&_B0==#B4"BUOI['E
M3M$9ODE6UN6$R6EJQ.3EZ+2UB@SY^@^OG3V>>WF.^?V3@CG)RV,^0\P*BY0#
M^^/;"@:=N&)_MO>Z_ ['TALN"V4Y2I6/-J^UA>M/B?U39LKJ>P.44,4RAI:)
MZOU4VRPC4U ,W.VM1\=86;[*RZVZU7V1GL,C&#VQN3'GWX8\^6":G9I"E]N[
MGV<ZIW[=&N-FN8KW9/25ZM=GF]<$0#,6F7\$JSTO9-CL4B) QK:1VNQ5CE*%
M*FRKJV8>]FII#*PB&!8EEZ_E]!_/-0..<>G_ /+^E>B+BHTXI3BE.*4XI3BE
M.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4X
MI3BE.*4XI4>=[]4^OO9:-3'[FUC7K<0.QD>.L.6GHFW1#><J4EN+MD.Z#/B#
MI=5[R@$GJC2'4IR6&0GS1G8M ZLZAZ8E,FBZI<6:LP:2WRLUG,>,F6TF62W=
MB!M\3PQ*H)V.IYK%:GHFE:PFS4+.*<@827!2>,<_@GC*RJ 3G;NV$_B4U3?M
MSP$ZF<\4?HW>$S74JRMP>M;+@Q[$+A2\Y5AENTUU<(6(,UG]1O#]:ER<M^7N
MDNN)4XYVC1_M_O(U2/7="AN<<-=:9.UL_'F;2X$Z.Q'?;<PKGLH!P.?W_P!F
M%NY9]-U*2'S$-Y&)E^ FB,;*!Y9BD..Y)Y,!;GX*_=ZL.NI@837.Q6D95[;M
M2O\ 'Q^74X_DY]N^#4M2%YQ^]&<Y3A7GC"U8\E9Z!9?;=T-=*#<3ZEII/=;O
M3Y)<'XV#7N1[_P A6K7'V=]20D^%'9W8\C!=*F1\+E;?'O\ YUHB1\,7OA%N
M*;)ZY6UU2<YQG,=,4R8;SY?_  NQ%F.:7C_5E"U8S_-Y\S\7VI= R@%>I+09
MY_6PWL)^8FM4(K&/T9U.AP=)G/\ N26\@^J3,*^(7AF][)!Q+;'7"YMJ5GRQ
MDT^JQC?[_+]9V1L(K2<?[5+QCR^?GY<D_P!I_048RW4MD?\ <CNY3](K9S^5
M47HWJ9C@:1<#_>>!!]7E4?G6Z*AX-'>JS.-(EZ32J"TYE/F3;]BULEMI*O\
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MQLAH5[*?9=?&):96K KJ6['3K*ZU*[@A@CWRS,) 6[,H8$L22/97S)/ [9)
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M_N:O&C!1'''XCF1LX/ZV1O9#ODC;&B# "YN'M1>6]FWCRO+M=KJ*1 BQ$O\
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MIQ+.$1E8[/4B*PTK8E&;6TQ<P6\[!I31$65)A1:JD C(\L9'O]WN]//U]:M
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M#GH=;0XE2$JC67\4K0_9+K=JOM9JF:U#MR(+-@I J/FX*>@SWH*[:]N\"_\
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MH7X.O$X_P]>R7Y.XR/?]#_2FW_$OUI]Z10OP=>)Q_AZ]DOR=QD>_Z'^E-O\
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M1DLWJ<QC"<82G&$I3C&$IQC&,8QC'EC&,8^6,8Q\L8Q\L8Y\H5]9 8X' '
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'E.*4XI7_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>31
<FILENAME>g98473g95b62.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g98473g95b62.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_[13R4&AO=&]S:&]P(#,N,  X0DE-! 0
M     $H< 5H  QLE1QP!6@ #&R5'' (   (  !P"4  (<G(U,#DQ-C<< @4
M(4UI8W)O<V]F="!7;W)D("T@1V5N97-I<R!&+3$N9&]C>#A"24T$)0
M$")*^(M6HN%I'>),'8-E9Y0X0DE-!#H      .4    0     0      "W!R
M:6YT3W5T<'5T    !0    !0<W138F]O; $     26YT965N=6T     26YT
M90    !#;')M    #W!R:6YT4VEX=&5E;D)I=&)O;VP     "W!R:6YT97).
M86UE5$585     $       ]P<FEN=%!R;V]F4V5T=7!/8FIC    # !0 '(
M;P!O &8 ( !3 &4 = !U '        IP<F]O9E-E='5P     0    !";'1N
M96YU;0    QB=6EL=&EN4')O;V8    )<')O;V9#35E+ #A"24T$.P     "
M+0   !     !       2<')I;G1/=71P=71/<'1I;VYS    %P    !#<'1N
M8F]O;       0VQB<F)O;VP      %)G<TUB;V]L      !#<FY#8F]O;
M    0VYT0V)O;VP      $QB;'-B;V]L      !.9W1V8F]O;       16UL
M1&)O;VP      $EN=')B;V]L      !"8VMG3V)J8P    $       !21T)#
M     P    !29" @9&]U8D!OX            $=R;B!D;W5B0&_@
M    0FP@(&1O=6) ;^            !"<F1456YT1B-2;'0
M  !";&0@56YT1B-2;'0               !2<VQT56YT1B-0>&Q <Q(,4
M      IV96-T;W)$871A8F]O; $     4&=0<V5N=6T     4&=0<P    !0
M9U!#     $QE9G15;G1&(U)L=                %1O<"!5;G1&(U)L=
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M____   X0DE-! T       0   !X.$))3009       $    'CA"24T#\P
M    "0           0 X0DE-)Q        H  0         !.$))30/U
M  !( "]F9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &       ! #(    !
M %H    &       ! #4    ! "T    &       !.$))30/X      !P  #_
M____________________________ ^@     ________________________
M_____P/H     /____________________________\#Z     #_________
M____________________ ^@  #A"24T$"       $     $   )    "0
M   X0DE-!!X       0     .$))300:      ,U    !@             !
MQ   !X0          0                         !              >$
M   !Q                      !                         !     !
M        ;G5L;     (    &8F]U;F1S3V)J8P    $       !28W0Q
M!     !4;W @;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG
M   !Q     !29VAT;&]N9P  !X0    &<VQI8V5S5FQ,<P    %/8FIC
M 0      !7-L:6-E    $@    =S;&EC94E$;&]N9P         '9W)O=7!)
M1&QO;F<         !F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U
M=&]'96YE<F%T960     5'EP965N=6T    *15-L:6-E5'EP90    !);6<@
M    !F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
M         $QE9G1L;VYG          !"=&]M;&]N9P   <0     4F=H=&QO
M;F<   >$     W5R;%1%6%0    !        ;G5L;%1%6%0    !
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M300H       ,     C_P        .$))3001       ! 0 X0DE-!!0
M  0    '.$))300,      IC     0   *     F   !X   1T    I' !@
M ?_8_^T #$%D;V)E7T--  +_[@ .061O8F4 9(     !_]L A  ," @("0@,
M"0D,$0L*"Q$5#PP,#Q48$Q,5$Q,8$0P,# P,#!$,# P,# P,# P,# P,# P,
M# P,# P,# P,# P, 0T+"PT.#1 .#A 4#@X.%!0.#@X.%!$,# P,#!$1# P,
M# P,$0P,# P,# P,# P,# P,# P,# P,# P,# P,# S_P  1"  F * # 2(
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MGI5O#M_M]C*_S+/^FMB^QU5+WM;O>![&3$N_-;N_-24MDUWV5;:+?1?N82^
M3M#VNM: \.;^DJWUJKB5=9&6ZS-OH=C;2UE5+'-.Z6EMCWV.?^;O:B69%K++
M8?6YS*P_T"8(_G/?ZCC]%^S]QGT/YQ&#[W-!#&B1.KI_ZEJ->(5:5)#C(/+F
M#^R3_P!^3U->RIC7NWO:T!SXC<0-7;?Y2"FAUFRNREV%8[*QF6^G.9B^TLE_
MM'K#=MW.K].SV?0N6DL#(MR[\1]EF2W8,AS11L;N<UF2]E7O#OW&,_-_P/\
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M"F)AK-K8U_X)2^WX'_<FK_/;_>E]OP/^Y-7^>W^]"AV1^Q?T;/S'/9\7[O\
MSXVQ+&JR*WWNNM]5MCPZIL1L:&,86?\ ;K;+/[:;]H8$3]IJCQWM_O4Z\O%M
M=LJNK>^)VM<"8'D"E2FCD"S]HWEE;<G]6K'V8EHW2^[W>_\ J_G*MAY62SI[
MZV5$/?F65-:[: &/R'^IM]+\RK&WOK>K>?CXM=KLV[*=AFQC*?5!8W1ILLV[
M[6O^EO5'I>3@UWNR+<^C:!;5L=8T.W#(O?ZCO<UGO8YOYB*;;^+3:^IV2^EG
MVC(8QSMSC&XL:"P:.]-C?H(IPQ]J=<&QNK#-'D-T<]_T-OTO?])-^U^DQ/VW
M'C_C6=_[2?\ :_2?^YN/KQ^E9_Y)"@I)Z 'YL_VO]BB[&8;*7>F9KLW@[N#L
MLKW1_P!<VJ'[7Z3_ -S<?_MUG_DDOVOTG_N;CZ<_I6?^22H*MM&MCC+F@DC;
M)'8_FJL.E=+%@M&'0+ [>'BIF[<(]^[;]+VM5H$. (,@Z@A.BA__T?3LWT/L
MK_M&[T=-_I[]W(X]#]+_ )BAD?9/MF+ZN_UY?]GV[]L[?TOJ>G^A^A_W(_ZV
MOE]))3]-Q6<C-& [9G_H_5=<+75#3]%M:XLJ_F_I?9G?\:J6*,4?5_\ 7BYV
M'NT] 90?&\<[W/ZA_2-W\CTO^!7SBDDI^G\C[']OQ?5W_:8L^S[?4V1 ];U/
M3_5_H_0^T?\ 6DV+]B^W9GH;_M,U_:=WJ;?H_HO2]7]#]#_N-_UQ?,*22GZ@
MS6XKJK6W.V.-;@7U_P Z&P[<ZK:'6;OI_0:HY;,5SJ-SWL+;6EOI3JX!WLO]
M-KOT/[_J>Q?,*22GZ<<S'^W.L8]QM] AM1D8\;IWEP9Z?K;OY?J^G^8JW3/7
M<,L9;?3<YY]S+++(>6C=]E;=C8^VIK=GI>EZ_O7S8DDE^EC3A?LFJL7Y J 9
MMN:'_:" YOI[@VOUO=_Q7T%8N9CNS<5WJ6M>WU-C*MWI.D#=]IV-=7[?\%ZK
MV+YA220_5#]FWWQM\^$"MM0IO =<07V%Y=OW@GZ0HD>IL;_@?1_ZTOEY))3]
M,VUXQZ94TVY0I&S:]@M]<P1L]3:S[3_QFYBCE'-_:N-[&FG<[TW-LM;H6M]?
M[3771;CNV^[[/ZU]7O7S0DDI^GZFTCJ%[FON-I8S>QV_T0-=GH[F^AN_?])R
M'2S'&%E-;9DECG6[W/\ 5]5I(]_V7>WUMK?\!Z#?^*7S(DDI^I,0,&+4*R]S
M QNUUN[>1&AL]7;9O_KHR^54DE/_V0 X0DE-!"$      %4    ! 0    \
M00!D &\ 8@!E "  4 !H &\ = !O ', : !O '     3 $$ 9 !O &( 90 @
M %  : !O '0 ;P!S &@ ;P!P "  0P!3 #8    ! #A"24T$(@     !1DU-
M "H    (  @!$@ #     0 !   !&@ %     0   &X!&P %     0   '8!
M*  #     0 "   !,0 "    '@   'X!,@ "    %    )P!.P "    "0
M +"':0 $     0   +P   #H "Z/$   )Q  +H\0   G$$%D;V)E(%!H;W1O
M<VAO<"!#4S8@*%=I;F1O=W,I #(P,3DZ,#<Z,C$@,3@Z,S(Z,C, <G(U,#DQ
M-C<       .@ 0 #     ?__  "@ @ $     0  !X2@ P $     0   <0
M        !@$#  ,    !  8   $:  4    !   !-@$;  4    !   !/@$H
M  ,    !  (   (!  0    !   !1@("  0    !              !(
M 0   $@    !.$))30/]       (          #_X0%(34T *@    @ " $2
M  ,    !      $:  4    !    ;@$;  4    !    =@$H  ,    !  (
M  $Q  (    >    ?@$R  (    4    G $[  (    )    L(=I  0    !
M    O    .@   /      0   \     !061O8F4@4&AO=&]S:&]P($-3-B H
M5VEN9&]W<RD ,C Q.3HP-SHR,2 Q.#HS,CHR,P!R<C4P.3$V-P       Z !
M  ,    !__\  * "  0    !   'A* #  0    !   !Q          & 0,
M P    $ !@   1H !0    $   $V 1L !0    $   $^ 2@  P    $  @
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M 0$! 0$! 0'_P  1" ". ET# 1$  A$! Q$!_\0 '@ !  (" @,!
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M<YVW-'8M6;$-=E6*>>66.M&YSXZ[)'ES88W/]8LC!#&EW4@#?59F@AK07<Q
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M82M^7,?9CLH6ZXE.<U>O+:FC@A&Y)#H;(:UH )<][CT9'&T%\CW>JQC7.<=
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MVPA<WMG@#Z\FW=3UZE5XJT,//R-_G'F1W,2_UG=Y'-O7LT-!2BA#1PQE$<=
MA#X[>,);8A16(C*$X_!*&F&VT)QC\L)3C&.<RY\DA+I)'R./4ND>Y[B?:2XD
MJQK]%]O/*)PB<(G")PB<(G")PB<(G"*F_KA(VS7O:/;UILDB @:K-.;7N^*4
M,W-FR2QYR?8:U\&>GZ\=W2=P$FVF)(39'XT+3E69$N%93+Y-,I,AXZ\^?/\
M@\^=_GXJY#A%7][5G^YL]X/]&K:O^[$[A%-2@_VB4K_-*N?['A\(LMX1.$3/
M"*IK2/:O71?NSVRUU6:9M2QE*HL&PDN&%0R8DK(KG@->D1XKR1,IOY%8Y4,=
M"1&?).SV/BY2&L,,>]5]#RG!UVMPIPQE+&8K,99;:>ZG:NN'H[;[Q:H'E:)
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M)E;*%I^)9\^\3DA:'RQ,+'RATC&F.,\LD@<X#D8[DDT]^^5IY'Z)'JN[C!Z
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MFB_IG_)PBG[PB]5J]"%K]*E^A*E>A&/4M7IQG/I0GZ>I2O'A././.<XQP.I
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M4QR9G*0/,9!]61M;!V6.'K07V]'*">I>HXRE]R^P>RZ3M&_3]@$:W6W9.+#
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M+;9V=F2O$^=A;R%LCF@N!9L\A![V[Z'HNAH"^*5891L+,B(6"ZR"2*6!MD-
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M1CQX\)0E./'X>/&,8_+FRT/9KX=/R6L+G.ZN<YQ/>7$DG[R5U0RMUT(X4>#
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M=OV/YA[ %'GM=UB+;BT)L'75;NVSWC]E%M0X&57^3&8<>;EL/X;FLR78HMV
MO#7IEM.-X6ZSE64>MY+>,Z/B3A^3*8:W2@MY S2]D6#TU[&O='+&\,D!+8W1
M.Y-2,( >PN'?I=#PI\H$^)S,=EF)X%HLDJY"E):R/"[[D%2+(49Z4UB-N//S
MF;4<<[GU##,T-G#.<MB+]R>U?67Z9KFC5&5()RY-9J@$$_*-3L$RTAT6,C0W
M'2)%*EIG3%K:SE^2A:D.N>5(SZ?'-_C:QIX^E4<^61U:K! 7SO[69YBC:SFE
MD_;D/+MS^]QV3U*XGB/*R9S/YK,RQXZ&7*Y2]D)(L16DIXN-]NQ).YF/J3 3
M5Z;2\BO#*.TCCY6O]8%9WRZM,G")PB<(G")PB<(G"*E;:NK*]N_V@M0/ZDFZ
M8@6.@V$9)OC5AID -=AYK2EJUV9VS8O+NG[,WN*19Z-M35M$K,@OLW7TG6I+
M.+15G3<R+/8A1W_IY\^(168[#[#4K6NWM':6."KC*M6_"]H#U$F*K4V34!DF
MJ5$[<IR;+:G?AQ V7,&5\@@2'8D3#D];3LI U(R+,G,2BC\1[NZ9O*^S6M%Y
M/4Y_5%0V"P];;HT$$5"Y)KEA.ZHM#U0G,G)I%WY!LL>]3'XIX6!GE";T%X!$
M+#Y\68YY>]C&ESW!K6@EQ=T 'C_BO+W-8TO>X-:T$N<>@:!XDGH![U6][#,G
M1J#J")6C5SNT"]HTMIR/;*EL0I#BBZT:J0J=6R@L#E<UQ$O#"61_PZ\H8>@"
MUQ0J6G4#/B7>9P_#KL1ELYE77K=AO$,S++*\\LSXJAJES71QM?$QK3V<\! :
M]W)$60@%D0<?LW'G'T7%W 7R>\.U\+BZ0^3ZI)B+.2I4F5K&1=E*U>S#)/)V
MA>2+%/),L ,<VQ;C?D'/:^X(67?Z<W'5]V5HC:JGEW(P;82M;=<>1(2E<T.M
MM$E;:I$6)ZVE>\0M.6\+PE*DI=RA[#C+?4+XWY\CO5*O7_LU==L]I.Z5?5L.
MO%Z9IG:).[5H=$U44+39<\0*,5RF06$5$J/F%H241I1'XN:]-P@O7 ACWT.6
M1?:SH\?Z1AL9GLU_**CD'<3/G;AZ5;$W18IU:<\T&1,I["IVSN:M5I"2">W&
MZ-\\SIV]J8F=QQ)\H_R;9"APU@78+B@Y#@JC:Q>>9#;FH26+%=T3KT%?TJOF
MNWFAR_SL!.VCB8H('TZPBF$+;#9%^R-L%]VGJJ];1W#*,E[[#V1;:H'EGXLI
MI\;6"*QMR?C#\S$,J2U+*GWDR/<1H[7]1-)RJ1(S)D/<SP%%;FJVK>3LF[=;
M8DACG+7-$<,C8;4C8N9SB ^Q*\NT0!IHT3SD\CD..N'OE M_.7"N#SO#F!Q@
M=C:>+S^6.8N.E9H^GR6W1L<9#BQB<6&DR".'%,,;QVTK5.K7>\(-ELFU K\>
M_35TF[NU=EMVAR,PT*8ALR'61Q"OQIK,]"''<K5)G/,YQ">&.Y\+D/9Q]"\^
M=>?L54>=K;N;07?1Y'4:S2,YQ]Q<YT (9S_VTS#7QR/V_P!@9SX_+S].$\^?
M/Y+46L)/84;/V([LFO"# Z1=)BJ(R(L,5N7%J6&FW8GQ*9F,1U.*4_EA2<R6
M74R(DC.4*CN15\(MOILY9&/ZJHMJ9\?BMAZKS6OQ\?=Q'LF9*OV_V+CZ?Z^$
M6F-1;/L97[?8ME VF"R*OAD.)P=AY/?&CX6&LMR!BA,1"8XW]:GW&7LO>_\
M7GT/N>Z7X(MPYO@Y/T<!W1&?QQC[&6)WSC]OEB ZG'^12L*_/QX^O"+TSL(.
MG/A0B[8SX\^,4&Y.8\?]IH(XC_5ZO./SQCSCR1><;"!YQCR/N*,Y_O5T*Z)5
MC_+C('Z<>>[^'>GV>?:O;](->\><LV9.?S2JE7%*L?R9QD%],_R9X3[/\//N
M7OC8%:SC&<J.)_D54[4E6/Y,IR%QG&<?GC/(W\?N*+Q^D*J__JB?^NM6;'_?
MY#_3_7R47H_L*J)8>6F?(6M#3BDH^3&%94I*,Y2G"%PFDJSG/T]*G6\9\^,N
M(QY5@BP'KI>1.Q=;M68& 17!KMALD%D>U4OL6TIP<6?BRI2 ^2!+RM^4V]F5
M*R\C+TU,A"FL*9RXYCBBBA9R0QQQ,VYW)$QL;.9QYG.Y6@#;G$EQ[R3LDE6;
M=VYD)C8OV[5VP61QF>W/+9F,<31'%'VLSWOY(V-#&-WRL8 UH &EO;F15DX1
M<3[C33#SK_CW+;3CCWE.5X]TA&5.>48QG*L>C&?*<8SE7X8QGSXX14^]*]58
M)]J=G[^U@;T?*T?/&FH\&)1:F#K%JCC]G =6;(U36I=08TC2R5%EUJF$9I6R
MF,;2NCE^7;!,@R%&2X#$8&3_ !_/XZ_3W=58@.[&:X)[UO/7B.JRMWW76N V
MTK/+G5<N.J35:.DY0N(D59I[$:#82##L1;I%H#\RB#$+1'G36"/O(+9%69W3
M[BZB[)^S/[@.T1JXB"ULUB<UA4*S<:ZX%LEHL>T-81;OK"0'AP)99K(>^U \
M*L 2?+E0W8462J-8(P0I&E0&,$]B"#L6SDZLSLJQM:PR%\LH<0SE'0 M:XN<
M\MC:T$O>UH)%>>[%1-=\KY(W368X('11S3/[=_,YG*VNR20$"-[^8-TT,WO>
M@< ]C_L000H.Z6==TL"J5]I9#Y44(.Y9NT<@&B8A+$QFSP,:-?$#D3A3P%TC
M+9:E2"Q53CN5Q'HV=KD>!Z? S\7%6IQU3Q%AJ6<:8L96Q['12,:T5Y'5[MP2
M6JO:,;8AYNSKF5O8R2MDYE]$XIXLSW'%%N4R?$^:XCJX3-9#"UAF,C;O2U(;
M#6VJ=EC+4-<PMR+*]@.<88YY'4QV\4;FM8+7]%;9>N>IG;E<F#P$F-5891L3
M;TAHUC@#1,N6TF5*'!(<!EB*\S#=5#5F+ZY249=2ZZAQO.-=)(V*.21YTR-C
MGN/]5K2YQ^X%<73JSWK=:E689+-NQ#6@8.A?-/(V.)NST&WN:-G0'>2 %!P/
MHO1&HZ3MZZ:>N,$#N[;4 U&GQ(%[;L02@+.H-&9L S7(.2"E56GC<$#5F:*1
M)I)YJO3&1$R!)=BMHY/@SA/AS#W\GGZ4SJMD-DS&6,-[M65(H9766TFPCM6-
M9+8?'7':Q2O[1P='RAO*/M7RB?Z0N9XVKXSA?/WL#Q#PGP;$*D;C0@=>NLIU
MHZ,^<L6*MB&W%:=%!-+7;4GHQ&-XCL,F=SN,9O8C:]AC &XXC=BUV?#UF_C2
MK;5'R;>D$#V(AT&).FY)=B-AX8H3#DEZY$0SZX\@PX_*1&FP4,M^.'N)^->,
M+%RSQKQ!)GGT+3YL?VX8)*WI;I>:*+LZE1HH1N9(ZE"6O,8>''LRUL3/GG'O
M&7R2\=9'#/\ DIQ%3$XS 4K$.491H9+&5[UYUZW6Q5V>MDK]^6:\[$58[-VT
MUS&/L6V5]V'4!8?<$"W?5I>U=E:_?M,N<4IB1&55IBH&\387S%C#ZO=RHPI:
MBWKRI'PF8JGDNQEJD)4XVA3J>R7(>?X>?Q6T,V&Q3\)^1U"6E"T^I,VSSF $
M7TY_@JQ#CMES?K\?7+$L5!5^"5+;SG.4D6GAFG]@B]TV/<?VV$$$G:F* -T5
MX9/B!(4N(^K,N6P31,ES6W'(S$-+4AR)*;4\]/6H<TE4;#1%N'[5$!Z?^<=5
M,#\)SA*YP9.+0+^OT]2/EC:3B6\?BIR4 BH0GZJ5C'GP1:\3OJD/;9@:PCVJ
MIKFS:S*L/PBYTYLVWB,[EM32V%PDCV$>G#CB_B9K+[>&'&ELX>4VG)%LUZ]4
MF,K")%PJ[*\^?"'3XI"L^,8SGPE4O&?IC.,Y^GTQ]>$7RYV+1?5A*;4%>4K^
M#B/-;DY5X_P?A\N>K_5Y^OG'XXSPB9V#5_/AN04D>?PS#K5FF)5_V5Q1#J,_
MZE?R<(N/[?B,JPEH3='\J^J<HHMN2WGQ_P#NOAV6D_7Z??6GS^7G'UX1<Z;>
MZYG'N:C<7<9_!2A<.+C_ "93/)Q%I_\ [H3X_/QPB\YLQC/T:H5L5Y_!3DJF
MLH_D]7JMF7<?MS^ISXQY^GGZ<(N')ZWK5X9H3R4YQ_"FV0(QXSYQC[V(BB.<
M8\?7.4^OZ8SXQG/C&2>?/BH.]V.II7M;4:B*?UWKV.9KMX"D\&Y9^7++,@)T
MN/!LS",, @J7&E0%(F2F%E7''FH&6X*43U17T:/,</8S.,B;>B>'1/<YLM>0
MP3:>WD>PR-&W,D;]8'JUS6O86O:'#L.%^-\OPI),ZM6PV6KS1L9Z!Q)B:N=Q
M\,D<C98;-:K=:]M:Q&\:,D)8)8G/@L-FA>YBL$"!Q]>#"  F,S"%@QD 0-AQ
MTY0Q$@#8K4*'&90I2U(:8CLMM-IRM>4H3C&5*SCSG<11,@BCAB:&1Q1LCC8.
MYK&-#6M'?T#0 .I7*3S26)YK$I:99Y9)I"QC(FE\KW2/Y8XFLCC;S..F1L9&
MP::QC6@-':<R+$G"+2W8?:]8TCIRZ;*N3I.-6 <<3 ,3P\P>.("HUI/BJE@T
MR1*288\>V%>.-E9,Z5(;;B18;TC[ZFTH410S]F$ U'$U/9K7J'?GZ; UN)!D
M38J%!(#]8DU.'-JJ"MHKX:WW3#.QM@9&/6>\VN22@*O,Y<,VR"$-8Q'X19V]
MWF^&U9VRV,0T[8PD_K)N!W3<.GG+-7V2-\-3 VMIM6,2"8C)L54 UAG[,#H<
M4^\;F! S:RA.*B?\0#B$5<OM#.X%$W-U5T$.(0FZ=M,YOBJ[*+:WE27[!"AA
M.LV[RU9VZ@9;&@D8<?C8*TXW&JCS8J.6,Q7())ZNCVUOLL>32FR;FXV".1SK
MI97?(R+M&013S15732E[HX6-#K#&L,TT3'/>T=H.];+"Y6OALYBLA8;,X4[/
MI\<<!U+)+0;Z3%&TAS2WGF;$PD$$-+W#JW2G7UO[/T.;U6L.T*?6HU%!189&
MZU37PYJ(4("!Q1V4N8%:#.(IN)<X98Q=G;FCXB8R6(K"78+TQG,?+V>]@H.%
MLOE.'*TL$\&.G9)!-59%'5EAMQMG#J[899H^R[4R@%KR1W/:UVVK?<4Y:]Q/
M7P7%F1MV+V0RM&2AD[-R:2>V_(X67T8FQ)*Y\KI'8R7%R$O(+GO?W]7&90G8
M[)?2+&T9'QD-J90G[7G#L!B&0;]0EV<TW@6Q,-M-35YPA#$#XN<YE];;"\+>
MSEG%.S*V"O/,_?+%%)([EZ.(:TG3>CO6.M-]5Q)T TGH>6JQ3SV88:U4W9WR
ML;%4'-_K+]@B$ENG-;)]5[@1RL)=L ;5 'LV=M7VP=7>V6R=J;;VI3I,*Z;4
M#Q+4UK]RU#X%?&C"EI=E(G_9N3*@%()^U'2$@8T=$M)ENQD1?A'%(5G39B@_
MAW"085ECB'$.DPL7$$\F0B&2+;_$N+K79'0SC&T^1E8-B^C/9<E@SL<YKPYK
M=S%\L'!>0NLX@SOR/8+$XBC)!<MXK$?/N/@M4/2ILK:I/GQKX*;[#8;+L>ZS
M9KOG[.*)DCB6:%BWLL(;9SK'2;\:O$[8,H;BPAHEF/L3HY)#[$Y:3L@C*+S)
MDR6Y"2EFOC)DJ1G$8&,_J5$1HC+C)TO E2:/$0R6[+K<T4D\3)'MTYO,_F>"
MXN<7EC7,KQ.)]6&/30T/<%1X@XUX=^47,GB7A;$SX/ARO6AQ^*Q=FS-9>RU#
M!$W-920S%QCL9:]VD\C&N>&MT3(]\LFI+Z8NMY(6/<RIVI2401"V"[ K9D7:
M(9!FQCT#(<A$^/'LTH"H? ?CR8A-C$1#[#SY68VE6<1L..]R->'GQ^WO_@M8
M !W #X>?/7VE;\R;N3N<?#T=MI.?S)V@?&5C]GJ2.B&,?Y?"U>/R\_G/GSY*
ME1\I<_='Z>=JIG2J 3K#0:M.@JNU?+*L@*DRTN_,O?,NP",!MR,[%1\1F/71
M*<MD8'H>6I,C#Q%(/YG?4^?74:\O&/\ Z%SE9\Y_+QAZI,?3]OG.,_LQGA%I
M/)G=&-_(0O7M/^Q7Z.'7_F#-@4Y8LD?G+4=43$MYF-%PWZ_0]C.8&<_"84UE
M?O?&>1H;WX_#S[/N^*GF.M;.O9LZ[]]W=WG?Q6[?M!:4_P!<H1%7_P#&/5QS
MZ_G_ &00B?=_P<_CG^^2CDJ//GR%Y19CV?/O->VAOZ_3P1I:_./SS]VU>?\
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M9IIQN,A+>?=X+5W,Y""_=R^3?<^:\A3N4XMF*"OB;T3,-<C;4C;'7B;1%/#
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M:S^2AL,AI3/%[MVL#)HZK86UZE>2%D+2VY9G$3G<G/"^6P_;F0;7VO\ TH>
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M=OB_\=\(G],6D_Q#?:+?NWQ/_O>^$4Q=$;FK'834M,W'3AUD#UV[P9DR")N
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M]7; LNNU$Z&]\$/\U$UFM?-@3>8C>8\&8U&RI[W/OW2*47"*+';W?=IZY:Q
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M < R2ACCLV#& DB>?A_!:HZ6=K(^W=E[AT@#UEK_ %[1=2(,/:_A:^GYQ\J
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M;H$C\@VOU]:>&4#3\':^U]APD7"J3OL@*L&O7++=!>N2M:ES8S135-\QL^N
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MQEA&%MJ:(BWW%OP)2%I=BO\ I?94AU"%I(ODHFB--:PL=@N&O=94RH6NUCQ
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BQ_DQPB\\(G")PB<(G")PB<(G")PB<(G")PB<(G")PB__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>32
<FILENAME>g98473g95p44.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g98473g95p44.jpg
M_]C_X  02D9)1@ ! 0(!>@%Z  #_X81S:'1T<#HO+VYS+F%D;V)E+F-O;2]X
M87 O,2XP+P \/WAP86-K970@8F5G:6X](N^[OR(@:60](E<U33!-<$-E:&E(
M>G)E4WI.5&-Z:V,Y9"(_/CQX.GAM<&UE=&$@>&UL;G,Z>#TB861O8F4Z;G,Z
M;65T82\B('@Z>&UP=&L](D%D;V)E(%A-4"!#;W)E(#4N,RUC,#$Q(#8V+C$T
M-38V,2P@,C Q,B\P,B\P-BTQ-#HU-CHR-R @(" @(" @(CX*(" @/')D9CI2
M1$8@>&UL;G,Z<F1F/2)H='1P.B\O=W=W+G<S+F]R9R\Q.3DY+S R+S(R+7)D
M9BUS>6YT87@M;G,C(CX*(" @(" @/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O
M=70](B(*(" @(" @(" @(" @>&UL;G,Z>&UP/2)H='1P.B\O;G,N861O8F4N
M8V]M+WAA<"\Q+C O(@H@(" @(" @(" @("!X;6QN<SIX;7!'26UG/2)H='1P
M.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O9R]I;6<O(CX*(" @(" @(" @/'AM
M<#I#<F5A=&5$871E/C(P,C M,#$M,#=4,3$Z-#DZ,C0K,#4Z,S \+WAM<#I#
M<F5A=&5$871E/@H@(" @(" @(" \>&UP.D-R96%T;W)4;V]L/D%D;V)E($EL
M;'5S=')A=&]R($-3-B H5VEN9&]W<RD\+WAM<#I#<F5A=&]R5&]O;#X*(" @
M(" @(" @/'AM<#I-;V1I9GE$871E/C(P,C M,#$M,#=4,3$Z-#DZ,C0K,#4Z
M,S \+WAM<#I-;V1I9GE$871E/@H@(" @(" @(" \>&UP.DUE=&%D871A1&%T
M93XR,#(P+3 Q+3 W5#$Q.C0Y.C(T*S U.C,P/"]X;7 Z365T861A=&%$871E
M/@H@(" @(" @(" \>&UP.E1H=6UB;F%I;',^"B @(" @(" @(" @(#QR9&8Z
M06QT/@H@(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E
M<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @/'AM<$=);6<Z=VED=&@^,C4V
M/"]X;7!'26UG.G=I9'1H/@H@(" @(" @(" @(" @(" @(" \>&UP1TEM9SIH
M96EG:'0^,C$R/"]X;7!'26UG.FAE:6=H=#X*(" @(" @(" @(" @(" @(" @
M/'AM<$=);6<Z9F]R;6%T/DI014<\+WAM<$=);6<Z9F]R;6%T/@H@(" @(" @
M(" @(" @(" @(" \>&UP1TEM9SII;6%G93XO.6HO-$%!45-K6DI29T%"06=%
M05-!0DE!040O-U%!<U5':'9D1SEZ84<Y=TE$375-04$T46ML3D$K,$%!04%!
M04)!05-!04%!045!)B-X03M!44))04%!04%104(O*S1!1&M&:V(R2FQ!1U1!
M04%!04%F+V)!25%!0F=114)!545"9U5&0F=K1T)164I#=V='0F=G3$1!;TM#
M=V]+)B-X03M$0D%-1$%W341!=U%$031014$X3T1"351&0E%417AW8D=X<V-(
M>#AF2'@X9DAX.&9(=T5(0G=C3D1!,%E%0D%91VA54D92;V9(>#AF)B-X03M(
M>#AF2'@X9DAX.&9(>#AF2'@X9DAX.&9(>#AF2'@X9DAX.&9(>#AF2'@X9DAX
M.&9(>#AF2'@X9DAX.&8O.$%!15%G03%!14%!=T52)B-X03M!04E205%-4D%F
M+T5!84E!04%!2$%114)!445!04%!04%!04%!05%&07=)1T%104A#06M+0W=%
M04%G241!445"05%%04%!04%!04%!)B-X03M!44%#07=11D)G8TE#46],14%!
M0T%1341!9U%#0F=C1$)!24=!;DU"06=-4D)!049)4DEX459%1T4R16EC6455
M37!':$)X5WA1:5!")B-X03M5=$AH37A::3A#4GEG=D5L47I25&MQ2WE9,U!#
M3E51;FLV3WI.:&156DA41#!U24E*;TU*0VAG6FA*4D92<5,P5G1.5DM"<GDT
M+U!%)B-X03LQ3U0P6EA71FQA5S%X9%AL.5=:,FAP86UT<V)7-799,U(Q9&YD
M-&58<#=F2#$K9C-/16A984AI26U+:31Y3FIO*T-K-5-6;'!E66U:)B-X03MQ
M8FY*,F5N-4MJ<$M7;7 V:7!Q<75S<F$V=F]204%)0T%1241"455%0E%914-!
M341B445!06A%1$)#15--545&55).:$EG6GAG6D5Y)B-X03MO8DAW1DU(4C13
M3D-&5DII8W9%>DI$4D1G:&%357E7:5DW3$-",U!33F5*16=X9%5K=V=*0VAG
M6DIJ6D9':61K9$95,SAQ3WIW>6=P)B-X03LP*U!Z:$I3:W1-5%4U4%)L9%E7
M5G!B6$8Q95@Q4FQ:;61O85=P<F)',75B,E(Q9&YD-&58<#=F2#$K9C-/16A9
M84AI26U+:31Y3FIO)B-X03LK1&Q*5U=L-6E:;7!U8VY:-F9K<4]K<&%A;G%+
M;7%Q-GET<G$K=B]A04%W1$%104-%44U2040X03E5-'%P6&0S83)D<DQD,V,P
M9'9A)B-X03MW25I*-VE69VMA26]Q>D\W14)10C%*>%9:<"MP861Q5FY(9F%D
M9%$S=&Q-0UEB<3-K5U=*=T-64$8P3$MA145B2$97<$=I=G1/8S)S)B-X03MQ
M4U(S351#1UI'1$E1-C!69WDQ<4XK,DMV;GI14"MC8V90,FXV:&)83C%R9&Q/
M<U%S:UAI.7=$0CE6;%9Y.$DY34%S231Z1793<7E0)B-X03MU3VI+;VEY+TI8
M>E1*<$]J851&9&%28S-':'A'3SEL6%5B='I+0F5Y>6TQ:VE-1&A,9'=R4D]O
M<#A64W=B9W%G<6I*4'E..#9Y864Q)B-X03MJ2DQP,'-A>E=%.#-Q6&PR-F%G
M8D$P4#%X2DQE5&E:;&51<V55;%!G441G;4MP<#52+TQ(.#-.23%04W8P;#5O
M4SDP;E1:<F-T8G@S)B-X03MD-FAM9VE5<7EY4G-'5'5T1G)X26I&4E8S3T)8
M<VA)07%D9TU64WDS.# K5TQI25,R*W(R53!294M-4U(S151+6'5/0FA3;UEJ
M;$HV)B-X03MQ8T(K,7E&3V]X5DTX5F1I<G-69&ER=W)Z<#57+U!E-C@Y6&PQ
M;SEZ9"\T5V$Y5U9B84151F=K:W1F<3AA>7AX07EP-F9);WEP.6UJ)B-X03MT
M>7%0=$)66EEE5V9Z=VAT-S905DIT675:6FXP;S)S=&IQ1FY337A7<%,X:S1Z
M>E)-85,P4' X;%=2.3(U3%5-5EAA6C5E+U!/1V16)B-X03MU6DY4861K:VI7
M-RMV,G-T<6IY,G=H95(T;6U6>7!U4SEW;$59;V]214-68T)60FYY1"MF5G)P
M='5K3W-A:&0S8RMN3S Q9%$T0S)U)B-X03M8=&)I3U-!;5-E4G!(85DR-WAY
M9SA665!X.4YA06A61TAY9"]Z:U,Q=DQ*93-T-#$R3#%N=$5T.5-6159:8D]2
M5FMK<DUO84='-5=%)B-X03MM36<Q*U T5T(S2W,U.&I.*V0W-CE9=C5T45$V
M5T9U0F5X4DY9=7!F9U!28FQ'0DIX-6AZ4F1W<&I"-4533F=6-F9I<G-69&EQ
M0UA7)B-X03LY1V)66#!H8BLR8E9O,$5R-F5*;WIC3$=A56-X5C5H9"MT3593
M1#AZ+TQL,35Q.&XS,VQN5'(R2WHQ4RLK<GEW4$MX57%L=&1W>7E/)B-X03M!
M;UHY9W1.:#%)<E1&6&M.;B]Z:F@U,T9T8S(Y-7$K;G4Q>DLP:W1Y4%9K36EY
M6'1V8V5M.%5K6'!S<UET-4A65W%P95)G44)6:7%J)B-X03MO4'EF.'IA9F8V
M8F0S,F]A8G!4<F111&MM<%AK:&QD2DE:4%91>GA236)P,6=K:4QC:5=356=&
M5E)52E959CA!22]Z<V)35F]N,'E#)B-X03LT65AK349K=#5D=F)1>#,Y:F17
M:W-I4U!B3DIY-5A%5$93<#5L0WI0>6-N07%&=B]!4&Y(,WIT8S-';U-7,F\R
M1FAB86AP+S%%,F-5)B-X03MJ:$DR4S-T5D1R-E9R8G@O=G!R5#DW>&E8-%1S
M0V1S5E1$5"]!37!0>F=S4DAA,B]M84-$4V]I2DEB1S)U-S9!4DM::$MB6E-I
M8V93)B-X03M2955A3495,&5P2'=);TMV6G)V5V1(<S=I2S)U-S8S=')I6C0T
M-%E:6E52,V59<W-3<7)%16PR4F=O2%=H<&=65W1B,GIU,5IR5V5/)B-X03LT
M5D-&9&]N5G='2VAW0U9*;V5,02]):D968D95=#AY-D\R=&58=%,P:%IV<7I8
M.71,8FDT-&QU0FM1<GDT<3!B1VQE>D0U:D98;E58)B-X03LU1S-#-FQ&<45U
M=DQ.36A%:DQ*84Y)0DM,-%AX9%AL=4I*5TA)559:;FM!3E<S2D]&5R]-+W=#
M6&5I-DXU8C K-'9T5U14<D11<E=3)B-X03MY:6YT<D(U1U=7-DUK1G1*1D9%
M-W-(.6$U4G!&5E<Y4C%5+T141E=(*U<O25!K:34P>E5.3#!V>DEW4U14;79B
M839V.49M=#1,9E1R)B-X03MI84=5>G1,3W1V1S932F%S;G%&=WI,,&%I67%Z
M2%1.23AH,FUM:E1R=GIH<'0V2&MS2DI$3$QB,6M.=&5Z6'E65G!N<C9P:TE"
M+WEA)B-X03LW-'%X4S(X:&57-&)A4%1D3S@Q-E9Q.',P1FQB:C%R840P2&=B
M52]6:EE-<S914V-0<3 Y65EI2&1Q<S%45$9582]K;CAV2'1B,GAU)B-X03MV
M3BMM9E=B5U-1*W)D>'AX.$)C3%ES,&YX>GAT2C8P56%I5U=.=W-J4W0P*WII
M<6972#5(=$9Q079P.617-35,0T-6<S!I64ML<$IA)B-X03MV-E12>6-&-4Q-
M94)+3557:7%D9U$R<5DS4#55,V(V:70W86%R2%I,9%<V5S)S5W-D<4=39%-%
M.58T;F1Y,75Z3VY-96Y15D-M;&52)B-X03M:=%AO;4)867%G4$U&:$YQ3V<V
M;' X1$MK,35A>C(X5'531D13>'-I;&E!5%-P.$U6955A9"M6,S5O-F9::3%T
M9%IT-')73S-K1G9:)B-X03M7.35D5V-58WHS:'5&5G9Q:T5-4FI61'A,4E%X
M33%33FQP47%M9FU$>6@U:G-.1W1W4$U%96AA9&%N5GAE86DK<%A52W K:V)O
M3F%3)B-X03MK=4%R=499<%-2=C-B3E9#>'=+:U!L<E0O3D=Q86IF2F)E9G1-
M,7$Y97=9,FQP639X9$U"8W1'27!*;FEI9'ES84Y)=U%Q2T$X1S0X)B-X03MS
M2W-P,$0X=E!.='!P;7)1,RMQ9S,K<7AA5$A,93(Y>F-#871M<7!D=#8T5T]8
M;$EO8FDT,TYD-EE&63102U U;3)+45=D>G)1,6$K)B-X03M33S%I=7)/,S%J
M531:1$1*9G%22V5#=DY%<VE*24I*>7I%049505595E)';69L+RM9.'1H9'=3
M96%J3G%&<6)I,UIR9E9R-75-.#!K)B-X03M5;DM1<VIE:S1T5S1R1U594C%6
M,3-A=4MO<%!Y+W=$>EEE6FUU4$U%9D8R<RM0;S,Q*W%X<DA%63=G*VUY=#9P
M2$PT05A66$MH<$%7)B-X03LU5E960BM6,G8R:W0P=6MP65%A8G%M;7E7;#59
M4WE42#!,:5,P5T98=&EI2V]62D569FHU37%!.%11:$9697%G14%!;7!(8SE4
M.3)")B-X03M867$X,S@V9FLO3#5M,5158C V>CE6:79F4F5+0G)D<FQ9-6]2
M179->%141S%E<7=5+W5!.4-16$LO1&EQ,GDO2G1B83(Q5TPY27=0)B-X03M*
M<61R<61O6GI:+W9&1W!R1#A43S W4$IX94HR9FLS>&,V1&=":7)Z+UAV2G9K
M85!53F)T6E!.:S%V8S9)3%<W,75#1%-,;64S=%%K)B-X03MA>$5X;$$O<'%Y
M96M&0U-%;VE%8G)Z;U9:4R]K9GEP6F$T9%%U4$Y&;'!C56HV5F4R=6Q445(R
M37-.=EIQ.%9V2$I(3$Q'-#5E<45")B-X03MA3E="2$5G;D951C5R.'%F;#EQ
M2G5T5U1Z:G!Q5S0O4TXS<45585)89G%F6%5L9FY30UI:>5DT1DE)52]V1FI&
M4CA/>7%8=C5(.'%T)B-X03MQ,7AR*V\K861+<S-U<&(W5'9R145%3'E59#4U
M56UL=5E:+U1I8FA$24=,2V\Y365L<U)81E4R,#,X<%!,;7 S5C0O;'9Z4' S
M;U)A)B-X03MJ1&9Y46%D83(X>&A:4%=#>$]Y>E-C2TQ+4D=50V-A8V=/5RM+
M<"]B+VLQ075H1%(W:2MH;&A31S-I9VQJ=&UJ844R,7ID4V=X:C%N)B-X03LK
M,41E;4PT;4IQ0S5,33)W5FQN;$AY+W%':E=L>75O-F=.5'9R=5=/5S1U,6=7
M,E9M:G1O8F%V<$E3:3AH0GDR-E9P,GA64&-69&ER)B-X03MS5E-Z>DHU97-F
M34=K=G!D.#!I5S!K='9->&E)5BM6<D]L=V=Q=UE53'A#=3-41E=/,R\U85=3
M95=D5# S4W!N1C-C*UA%.'17<C-,)B-X03MG>&E+,VEM4T(U3T-6-6-R9SAY
M0CAL>%9I9'HO04TT-6%),3-P-W<V:&0K:5HW=5A743AK6$IX9E=J=UA*9W!"
M44Y/+W!H-C=+;U!$)B-X03MI,U9633=4+T%*>#<X:S)T;%HR560S<4IG<S)T
M,U943D8X9C%7-&YU55=3:U$U07E85%8Y9W9C5DMQ0W50*V-:=DE&>&%Y,G-L
M-7%F)B-X03MO>D,R1'%S='5V>%=56&]14'1".7!9>31063AI4T-E2D-R,6E#
M1DE92315<G=I54ET971&1D)I<2]&6%EQ-T9867$W1E5P.#%E6'AR)B-X03LK
M:B]O,'HO5G@Y6G,W;C%1=E X03-J=31R<FI3<2]B.4AJ5W4Q83<T<7<R6#AR
M<G944$HK<E=/;C-:=C<V6'EQ4$QT<$555T@Q2F)D)B-X03M,:WAY8VUC:&95
M839P46UI,#8T<7=R568K8V-T6&$U<TIO9%I,+U=R>58Y45-/05)*85)8145X
M6F]6335Q<T5R2TQD0B]D<S=..%94)B-X03M1<6UE;68X04]/33EJ2UI"-6]C
M<UHY3FPU2F%C1SE05$5A3E5$975X1%-+=S5-2V0Y<4=M0E9H+S5X<$UK,&-L
M,35N;'5&5G)1>E)V)B-X03MB1FA)=&Y(1D=54$]D+V=M14Y:1C9%:$]Y54MR
M,7IY-7!",&)Y.7!E:G1/8G!T3G1)3%$S3$1I6D1"17-F37)6<6-U3F%63TMP
M:FER)B-X03MS5F1I<G-69&ER1&)J.'%F3&,Y-35R=3-M=6A,-7=G4S(Q44(P
M;VE):&I"9RM$-%11+W1C<U93;GI4*U,K;&5A=D]T-S5G,64T;&II)B-X03MF
M5#1B0WE&<$EQ>4M'.61,<U-#4T]22U-25$)&23-&5S9(:6-64VI19BMC8W1!
M:# R039X<48U3'%S;&ML<G%*=#5)4F)S>3)4,D-M)B-X03M0;$%(06IH;5E*
M6'(Q87!X5D9X+S@T-653,'4R=D)Q1W%'.&$U:'928TY,8G,V>C(V=7-,071B
M;C=(<59O86=M;DMU2W-N.&<O;&PU)B-X03ME.&I2,T5E:E-83'!C>'A1=4QL
M,&5I=WEZ>DQX-&]N-U8R-#,W52ML5FQU2W5X5DQN.'@K6&M-06963%)49%13
M5S%Q1%!%1$Q00WA3)B-X03M72T]R9D4V34-'56)G.6-65S)8;6IY>F9V1VQJ
M<3EL9%!,2#9S4W=8155H85 Q9E$U<499,5@Q9F=R+TYT,7A633A69&ER<U9E
M9C9B)B-X03M.*V%T;S%N1&5X=F92,T9W:E@P>E%756I2479&0C9I2SAD-W!V
M<'%K<&U#<TEP;3<W,$A*5D(K5CE-+TU:4$UU9UA7;W!F46%:8F%B)B-X03M(
M6C9J8EA.>D9/:E-O:S-/859K=7!E8W)396U0-W!Y5F]425!I5$98<&U+=7A6
M,DMQ3C%E5V1P14IB=65/,VE:,&E74U8Q4E1*2W=3)B-X03M.05=)2$HS64MO
M-VLP>%9!=C5R.'))<&0Y67-64F)K,DQ-8FU%05A1-C(U4$PK.2]Y4'1E,DMO
M>7@Q3%1T46=7-'-,<4<W9V169$I9)B-X03M*1FM2;&-65F=Y16=H:#!/2V]J
M1EA9<3=&6&YY5"]M=&%A<C9C:U5L.7!L>F-/.&HK:%EY4$1#8FU25FIJ8UAU
M;6U-0S-#37).2$\Q)B-X03M383E/2E964$M&;#5S=#=V4EI,*WHQ2T=*;SE2
M1V]26%8W2&1*8G9,2D,Y=6IS8G%D-6="1S9O+WA-2VYA3E1X0W)08U9D:7)S
M5E5:)B-X03MR-GEG;FAT-7)I3TLT=4$U9VAD,58U0D=/5#A&2G$S16)T5'!I
M<5=$>G(U3DUA4VI8=$\Y2U-+4V5.+W)C2$9O65-22DEP-3!+259))B-X03M:
M=6<W-'%M<T9X8GIP>F=L4U9+,#5)=UE6-CE2:7%P:7)S5EEP-7I(;G!,<3%U
M9DQ433!514UJ5#)G4S%K4V%5>7A+;V1:,V=C.%EJ)B-X03M+=T-4>#%)04Q9
M<6Q-,%AN<2]H36PS<#DT3&U84TQU3U9)8FA.3VA.-DQH5&%*=W0Y474S:69G
M<D9P2354.$HK,2MW1E=B-E19=EEA)B-X03M86C),,T5T,CER0DA#,3%/>&57
M57AO1DUK:DU34WI5<5-4,7A61EEQ-T9867%W1%4O=T%R<GI5=FAU9%AJ150S
M1C8P=VIT0W)M,G9B)B-X03LR0R\Y3DA--T9*16QT9U!5-D94.6EO1$)65$@U
M53-A-FA:87A&<D551W4R.&]K;G9O8DI1:VE":U523$1*3$EQ3#9+=795;FTO
M4'%!)B-X03M-3G$Y1'=+:'13;6MG<THU;WI34D5*53ED+W!Y54):<&I),$=+
M+S1L,68X03,V4"M!6"MM6F9G>&%01FLW+T5U<B\W.4@O04PO5$AW)B-X03M9
M<C1S;F8T;#%F.$$S-E K05@K;5!G>%AX6DYP-6LQ675O36]O4T%F9U@K;5!G
M>%AX0WI,34IY6%EQ;&9M8E-,=E9T2F%Y=$QM3S!N)B-X03LY83-N4V572G P
M0G0U,&YO63%K:$HU96Y4-V5+<U)F.' U;E)K9E956D=1,E1+8E5K2%1J,6E0
M-S<O96XO;#0O-%1$87 S-4DX;5A()B-X03ML66%H04Y2*W0V9F1Y<$YA,FAH
M0T="=5!'5#DX6&ML;35!24%:1TQ!2TYY86Y!<DHX5E%E<'EY4F]H4FEP2DYA
M6EIJ1G-*;$QV<F1Z)B-X03LO=C%V=GEZ:$1$:4M",4QZ5'!M;&Q2<65R5SEI
M6%5U;W5:,&AQ:7-Q;&AZ6F1G>G%#9D5J>'@T471L15=7<W@S.7)(95=.-G0Q
M851$)B-X03ML1&-14T-33GA7;%9D4U90,%DX25=Y<F97-VXO04@V,S,T.$E8
M:4MA864W=F)H;EES86YC-59-8G1K95-*>41*279-,VQQ9EA*8D5F)B-X03M7
M,70W4S).>CE::CE*;FQK1GAB4U=W.4]14TE)>6]M6G%L1W)T,'A6:3!8-5)Y
M4U@X=#%Q3W!W6&$S86]B-D),3C1&96%#1S5G=#)I)B-X03MA3S0Y4TI54S=*
M6E%X2EIE4W-L5%96:R]K<GEZ9657.4=B4S4Y4B]355-4>5-7:FU#3S--8TUH
M1&5M=VHR8S@K5$9Z=5,R2W O:7%6)B-X03M8,7A/;# V<DEY<4M505!S375G
M0E1626TP4#A!5S=N+T%(-C,S-4QH0T])=2MT,U K+U<K+TAH0SA29#EB=68Y
M*W0Y*U!#1C1I;4]M)B-X03M3>5-)-61I>$)&2S58:T9--$9'6E=Z9&ER<U9D
M:7)S5E%E<R\X8W$V+W=#35IY95 V9WAN>4Q"37HS15-,5R]/+VQF4DPP,E=Q
M6'8Q)B-X03MA-%<S3C)6355R1#!G2D=R>E)'6&M20DE1=&52-&UG=T=10U)%
M;$YB0RMT3"MY9W9R3U9:-U,U:E=70UIE:DDT<7!&9F)#:$92+S-I)B-X03MF
M369R=T91.49Z6$]A-T9867$W1EA9<3=&54)Q+W=$9'@O32]Q>7I'=VUK96]A
M:F%A9F)I-'5N2U).2D9#1U9(9C0U-49I:D)#0FE!)B-X03M88T-V4614=&QR
M5SAP+TXS>3,U33@V6'--9#4U:B]2:RML=$YP-SA92DIK5V1L9W5N.5)G55%+
M:U9!86YJ>5E#=DEC8VI)5WE"<&TR)B-X03MN-GA$-6(P;5,P,74X12\V36=G
M:T5T=&)8<VMG=%=1<7-K>4TQ,TQY-7=Y,7$U;W$Q8G9K;4Q)8D<O=$PV,RMS
M5W-N<5$X-4EU5D-0)B-X03MJ:&MA2U%564$O0S9%67%N*VUF-WEJ+U=/535/
M8F)$:VDX9WED:7)S5F1I<G-64V)59CA!97E4-E K26I,-&-M;5A.:FYN4S0Q
M;3(X)B-X03MP879C84ER=')%5G!+.6=S84-6>DU%4$1J1U%W63$V0VAY4E%'
M1"M1+TUV;CET66I(;E%89'!!,7-%5TE76E<S83=L,4=E,U)426QQ)B-X03LS
M*S8O4C1K>G!T4G5,:&EY9T5P240Q3$I)5%!34#=U5#5J.5=5-4=Y0U!Y=&TW
M1EA9<3=&6%EQ9SE:+S0U5C$O>&I/5'@O54=-*U)E)B-X03MA87IR165L45)4
M>5<X,7=K:W-C2CE(,#9O6D=#2WA%:G@Q*TEG8U9Q>#=+8WII86-10FA(;4HO
M2BMQ-G10*VQ,0RM3+S%7,VLP151Q)B-X03ML=7AH5TY425!48T=49SAX=E%G
M-C<W37$P3U%.37AA95<K<&%2-5%G:#!-=F-445%.65=T:$=%4FEI,U K:GAX
M.'%Q6$E-16LP:%!2)B-X03MF;T=3=71K5F)).4@Q0TQ58E<S=DDP94E3;C1O
M6D])94XQ8FDX8CA3>3AK649446M62%A$97E/<C O3F,U:G-69&ER<U9D:7)S
M5E%')B-X03MR+S-C9GI0-G-S>'-*<V0Q>E-%,6)4,G-M=5IR44=32U54,B]P
M*V]'9VQ75F%E<6MQ9F%15G%U5W1A450O;&8U6FMT=%%T,&$V:5A5)B-X03MB
M<C8Y2DE,:#5*27)G<5%:24AM.55X37A9<WA88SE$.$AW-$M7,695+TE6;'%.
M:DQ:6$=O6&)1,T9P83)6,GHO049E6C5K<WI)5F52)B-X03MP-%IA>4]::5AA
M;&%H4W9%:75';'103DPP,DQ4-U9O23):=SAS,#=U.4]2931L85HK9T=W6GE"
M-UEQ>4Q44#A!955F-GAY;DIZ8EEC)B-X03MK6&M'5'-69&ER<U9D:7%486HO
M=EI*.4@O15)L.$]45$QM.')V9$HO34<U,514>&(O6#=+>70W*RM-.&AU66XY
M4S-U8F]'3C(O=T)+)B-X03MQ16ET>69357AY52MZ=U1:<T\V;WI2=% X.7<K
M5SE9,'95575(;FE%4S)&+SEB0FYU3&5G17%2.%AE4T-527 K3G!78FTS,GIX
M0GA6)B-X03M&*U5T4#@P=S8Y9%A&*W0S1G P:VPT,&-&,4]*9W%V.55%06],
M:38S<DA/4GA904%N-$4U0F-1<&5J-E(O9'EF369Q>79)>F=J.'):)B-X03MU
M>%8R2W5X5C)+;U!79CA!:FQ86"]'33502#E167HU1C5R<65I,D=P=F%V9&E5
M=%I3:31T;6EN;6=+>4)3=%0V3'!Y*T9I2TY554IZ)B-X03M/26-11DPR.&DK
M5T@P:#E(;'1P6CE/:V535F]*<G$U;"M/6D=2>4=K:UHQ<4AB64=L4U0Q,W=C
M251X1E<Q1'ED-5HQ2U9:3E$P*TLW)B-X03M+2D1'9VY":U96=&U:-'5)66M+
M45I'<5)U=TY'<4U*:49S<'!P;&QB,DU&=F%7>6Q966%+9TI,2')U4U1U4U1U
M4V5U4%)8<&UA-7I()B-X03M9<3=&6%EQ-T9867%K,VUE-6MG=#17:G!5=5%A
M-SES=G=#>3%:5%%9-RML8G8O2BLW36IG1%1X1F<O-6<O;5 U=3!#-U).2G1,
M5S1T)B-X03LT.4UV.5)U,W5!.54K<4MG:C0X5U=O36MQ:&PV,#=I;5%L1VU5
M5&%E95103W0Y<G5G>%@P>E<W6$%K;6EL3G5$-F)E;DMY>'E+<%IY)B-X03MQ
M>E)H6E9"62]#=S-),WE566=H0DY*-2ML8G8O04-F=7<X05)X1FQ79U-V3'!K
M8VHO85ET5VYS>$=9;5562GE-6C)42$LR8G-69&ER)B-X03MS5F1I<51A:B]V
M6DHY2"]%4FPX3U143&UH<VUH,DMU>%9-.4DO=350;5 Q6E1K8DE)+TLR8G-6
M64PU-3%0>C5A*UID2VDX=E)Y>3),)B-X03MW>DYD4D-!4$4X=$0V6658,&XT
M:6]&87EX539J,40X24MP2%DK65!Z1W1D5# V-VXO4U=P*U@U,D9V2D4R;7)(
M96=E<V=.>$Q(-E9V)B-X03LV9GAY96Y48CDP<E-C4V%.:7(Q8D%Q1#%N+VIL
M,TDO>41K.&8Q0FI0:W=B,#50-40Y>'I/='A+9#9C;CAH*S0T,G1/.4]4*U$O
M8V-B)B-X03M7;#!C8VYQ3#A*-FIS9DA%;$E$,%!.8S5J<U9C83 R-C1Q.&(P
M=GDS*V)$>G=,<45U<$I$3F1V3C9Y,S!A=&%M85-Z3"MO9W5::$Y$)B-X03M(
M1DAC<D=!86-M<C9+8D93<DY0>35T9D]&:F(S,FXK630U<$9T,VI';C9L4&-R
M3S X4E%G9WAH<%AJ6D])3&,U2$I::CA4059W2WI$)B-X03M&56@X,R\W>7=F
M.$%'42]Q>DDP+TUT3V)K=T1Z3F0S;'!P6#%I,#EB,55U3&)K3&5%,T5H:4YW
M9VQ(<'%K<D5E;GEQ47113CES>5,P)B-X03MH:49X<6XU9W!:5%AL<V)M5G)A
M9CDO85!::C%'6FMF,4E91CE*4%9H:$E6:V9K0R\K+T0Y;&]75U9"2&$S<F5R
M47A4>E=C5V]7:'4W)B-X03M7>&UT>$191V%56$4O<DQ),7=)-$IZ5TY)-&A+
M;U5L44%"47-U16Q!1$HY0VUV6G)";G9/4FPK<UA+>',V96U40W1X27-*-#!8
M<D5&)B-X03MO930S-S5)24PP5'DQ+WAY269M+R]%:FU(;2MP>4UF,'!N;%19
M;'9M8415<"],;7%W85EZ<G%5='!/;&LP8FE.>$TP8D--<35)0VYL)B-X03M3
M:')T:7)Z2%%02V8U;%!9=EHV:&1A=&%3=D1D<70X.3A*4W-,4$E966921CE-
M,S%G>6-816YR17)(.$AR06I9<7HS>4=03D,V1S!0)B-X03MM5S)A1%5O6C5%
M.59R:$QN,30Y:6MQ;$%O4F0K255I=G<Q3S5W2WE01EAK+S5U-E!R*W)8.6AA
M-DYF5&%C5G9O<$PV-V=C;S97>3(P)B-X03MT9&=Y8R\S:%0T5%56,TMS05)M
M6&I"35$T.'HV:7=Z>6Q9+VU"8655.5,P-U5J9$QR3GIB4W1P='A036PP,%5Y
M5S!58F-P5$DT<DIC)B-X03MS.&M3;'%C9C5A57EW6%1%,6%R1'!N;FDQ;C!E
M*VE3-7505%$R*V\V83$R56HT0S9Q<W!-,#DR9E4T3TAB.30U-' V66(T<V%+
M3$-/)B-X03LQ2WHX=T=A5&I$9E1R2F,S>&UK=')R,&PK<G9:;$E&:E5Y>&Q$
M>31"94,O1$E'9F%T4VTQ1#%0>4=T,'5K0F)T9SDP;VI&=S8W2UI!)B-X03MG
M-6ME>&)-9E!Z1&1I-4UL>6AT9&ER<U9D:7)S5E-0>GHO>6E/<2\X=S=F=WI)
M,&XY-T@S=$]O+W5Z-VYZ,VY3=6AD:7)S5E9B8B]E)B-X03MI3"]86#EE4FQY
M5$AM*VTX-5(V3C)+=7A6,DMU>%8R2W-++TY(5V)N4SE/<W!)16IK36MZ2W=K
M1$5F6G)T>$LU;C9$14IY3G5*<DUH)B-X03MJ14503U X04A7<68X<SET+W=!
M1$HO,55Z6B]L23DU9&8K86PS0E O04,Y9F%R<DYU<W%M,VE9,TUD=55%37(X
M5F1K57E%*W-U=TUG)B-X03LV9E-6<4LT,F%%64=T*U8X+W=":FM9<'EM3#(U
M+VIQ;&US96%D5# W54AT4DAB4W%%:FM347!):$M44G)+=%8Y5G%(:31Q2VYF
M3'-E)B-X03MN:DM.-R]J-$Y75%!+2G)B.&9&0B]W0T]T52\U6C=B+T%)1U0O
M<7!K+W=!<$AV3$0X,4QU1#%N.'8Y46TQ1'EV8EA5>7%J=3!O2W!5)B-X03M+
M3TUH1S%3>"](3E!R24-/46=/,# P>DM!2EI(;4LS=7A6,DMU>%8R2W9.=DU6
M,W%6>C5Y,414-V0P:D5%16-S64U44T\W1E5!5#=A)B-X03M$8W0T,3=!13!'
M8E1$0TEX0U(V;'=-:W!(25%/-4M.6&XQ<7<Q>7HP=4]E0UE8<VYP2DTP5%(P
M651T8G169E5B8FMH22M,<#1:9&IJ)B-X03M#541+:G0K<3)R2DM56D-/,B\X
M05EP>EAU<VI4-VTW9VMI;6$P6FA.07-02FQ466\U36-S<3!:4U<U5C0P1WI(
M<U)#2$5!979N*WA4)B-X03M/5D5J<"M/.5)H,7)51U943$UI34EO2C51<T)E
M:7IY:%!H+V5J:U96,6)T=E9D<59-:FAJ,V0O6'4K1$5:2F9D,#<O:7IF.$%,
M4%5,)B-X03LR-W1T4U,W-&5P8EA0<&9U+W,Q555*-FY-1%A115-+-FAY.4Q-
M:T<K:%IN;4,U8G-69&ER<U9D:7%2*V5F*U52,5@O;4AB*T=:1VLO)B-X03MV
M62LY<#%(.3)F8RME.#96,$QS5F1I<7)B9C<P4F8V-B]R>4UU4UDX,S S;DM0
M4G5X5C)+=7A6,DMU>%8U,RMD2"](2C W+VU)8B]I)B-X03M'8E!S>C9J-VY!
M,2\P:C-V361',"]W1%-&.3E7-%-333!5>F]K4#)I,&-43W4Q1W%/4VEU8F),
M4&A&*S4Q,D](16%:4EDV2DA&36QJ)B-X03M"93-T;DIC2W-T=7%Y8U9L:VED
M94YW=$9294PQ+V1C:4YX.75T06-395=X6D%.9FEV,2]C-55C44)O16HX8R\Q
M24\R,%,K,5,T:5A5)B-X03M%=3=U94MA-F=U4D=W9#0Q='EJ=6514U%U,T]D
M=DAL<T(Q>6-S;V=05%%&1#=F-T=S67I)-S)E9C)F,G!"<61R2&$S2WA2;&EP
M:&=L)B-X03M)9C=137-+4TU.9T]H8DUM17)(>BLY;VY':3EP+TLS+T%*475Z
M+S$U=BM4<EIO9&8O96XT3S,P9CDR1U=::'55-T9867$W1EA9<3A9)B-X03LX
M-U)A,V0K9DY65%)98G%35T9B4S-U6'0R:FI!*W1205)Q>DY,1V5,.%-$,CAC
M,BMM>7AJ:4%L6%@X8VY86CA5<%I#63,K4&EX2%A.)B-X03M8,7EW83)B5F9R
M,T\K.4MA,FM:-#4S6F\P1%(O16MZ<W)Q:S1013!)1$$P,T=:5U!*02]30G0K
M3S=Y8V5E3U$U:S<O:G9B=4QZ5W)E)B-X03LP=3<Y,G5M=&I).$8W4$900DM#
M-U)I4U):1$A/,6%R44Y8=E)4.%<R27EW2D%O95@T<%1I:T%46B](>%$Q=#5G
M=C0W4#%R95,W:71H)B-X03M!='I14$=G345D>5EL8FHV=S5"8FAJ454R3E0P
M,WE5<'A*,T$O03DS8VE-1%=X4#10=C<S<78U2WHX-TQ7<F1K94]A,7904FY3
M5&IY)B-X03M%:7)2:#A,3TYI4$A.6C)H3&E-5#5/9&\T.$E).#-P1V$Y>DA9
M<3=&6%EQ-T95:C@X+SA!2TDV<B]W07<W9G=Z23!N.3=(,W1/;R]U)B-X03MZ
M-VYZ,VY3=6AD:7)S5E9B8B]E:4PO6%@Y95)L>51(;2MM.#52-DXR2W5X5C)+
M=7A6,DMV3%!Z.#%),D]J85<T:CE14&-/0TLP+UER)B-X03LT2$YJ,F-A:V9C
M-%=T04U29F4X52]W055N+VQM+W=#2"]W0V)C,C-'6%<X35AF-'!0+TQ.+W=!
M4"]W03(T.%I8:&DW+T%"4S%+9E9T)B-X03MV.68O04IT>#1I=D1&>#@P<U15
M,C(O.$%R+SA!3G50158T679O6#AM3#ER,WE,8GES;U%#95I654=U=V5V6#5N
M3DIR=C=W=3(P9R]D)B-X03MH;D]98FMU>%8R2W5X5C)+=D-V4%AN6'I$-5<O
M35A7,C!J-G!3.$9I,#1U5U-P.4-$-%9O6DEY06953F9O>EI98V-*-'AX9$QC
M5UEY)B-X03M#4DU29'-&,7)Z6')/<U$R4#%X3$U896U.1CE1=6\U,$)J:FE2
M5CE-;S!R27=:;S%E=$LQ<C).0FMW:D-.,&5B5%!(;&Q6>#-#-F9Z)B-X03ML
M<C%X4&5Y,T56:$]L*VYP>E%Z>D-D2T)'445E<D\W1F=71&AM66M&5C=+0FE)
M449B;F(X9'E41$UF-&9X.#!V9S%+-VIT0F%V8C)5)B-X03MY9E4R<T-Z>F=.
M-F)80G51+W=!37EJ;7)M9S(T,'!68VU41S=V<F)!66-T5G<Y2V5V9FMR<D1X
M861R=6\S<V9),V5O3$I-,7-6:U--)B-X03MY<515,%II1G%A9'E-,2MT<7="
M,$1L64E305!%2W-V6#AW6$ED:7)&=DY(;GDQ,$16-V94-6)D<$9E,VMU<FEE
M:S%%4F%I3D5-8TUS)B-X03M::VM:4T974C1W97A*,GA62C=0.#%:>')L<G!E
M<F%42' X9'E20V12*W5+.7%,:W-P.4I:2&EH1&9U6D9.9'8S:DQ(5&9L:'!8
M;T]")B-X03M5:C@X+W=$2TDV<B]!37<W9G=Z23!N.3=(,W1/;R]U>C=N>C-N
M4W5H6E(U5G-03%9Z84)T565&2E)E4DLU;&U-6DU$36=92V]:84-H)B-X03M9
M;'%(-7)4-'-0551Y02MM*UAD,2](-$QL64EW23E896Q'=E=L<F)A<&-,6D5.
M65!*23%K-%E0>6E%:DEP<C$V;V5V>GDO1$EM279N)B-X03LQ86-S44IB8W5I
M1'1V.39)=CED9C$U3UA*:$AM*VTX-5(V3C)+=7A6-3)0>F)E9&]F<4=K+U=F
M56UM47AT3DI"34E5;G1B94IL:FQG)B-X03M8;DI+.2]',490<#AD+U5*;T-Q
M;B]K9GIP1#5O<S=I47=,6EAT;39W,W1G6E)*3$9)5BM)3VA73U)">41+4%52
M5TI6=FA&359:3&ER)B-X03MY1"]N2D0O:FAA4B]Z1E O04UM.#)(6B\Q2#-/
M2')F<$AV94):=&Y7<VXX=F9L-7(K=F%,3G)&:5E26C(X:S!5>&M:9WET0D%*
M,C)#)B-X03MT<WEM:3<Y9D1+36UO:D-62&TS63A%<$-W;&YM8GDW9F589&%U
M9$AV;6EE-71I;V0T5S5O95-H:%%K2V5J9'=-;FIY0V-B1$1*07A.)B-X03M&
M2SAS65!P;CAH=B]!0UAS2"]-4E O>$Q.3')V-W@R,FPK9U!1.'<S25%'=C9T
M2&\K:#9J<3!K5'IP<#ET3F1.0DAU.&=H479W5"]+)B-X03MB:E%9<7=U4#@Q
M3E-M:&QE,3!)6&-S85-X:4-'831%<'9):V%6;V91;7,T8F=)<V%N:S5J-6,O
M9T5:3D-3<DMV2U!M:7DX>F%-;7%7)B-X03M:45)S-WAT1VMQ5$UJ265J;4UK
M2WA"1&-E=D5I=E=M0E4U>%8X=2]N;"\U36Y5=CE3,R\U34IM># O,$)U:'E9
M1FPW2C)+=7A6-UHK)B-X03M32"]+12M94"M9<40O:EA-3%9C=S%:2'5E66I"
M,DMO5S4P<E,W<3=T-WDU<S1*-W4Q1$,Q=4I),&5325-#:BMM-T%S=DE$96Y8
M1E5+)B-X03MN;%1Y=6QT1&%P;SEI=')B2&QB=T,R:$5C6CE14S%2471&+V5+
M2#(O84%06$95,'A622]04"]+239R+WI$="]$36I39C-S9F4P-FHK)B-X03LW
M4'5E2"M8-7)#1S1M93EA25)E:39H2E4U.&U),D-F=35A3E@O5B\Q;'IF-6=3
M0EAF*T]V-B]C-F)%441U;F-E;RM5,VM&=DEK16--)B-X03LY<D-*3'(V=5=-
M339Y<V%+06]:*TMU=DYT=69';3EC;TU-;E!F;65V369J-4XT;FHU8F-U-SAF
M=%,S5#<O5')/2TYG24I42$AC:#!M)B-X03MT,&QA4U)Q0TDQ:U(V3#EK.61Q
M3C U8C)Z:$M2-CE/=C0O1DY56E)!*V920EAS;'1*<DQ08F-F4V%69#!89VAB
M8FM554%C5DQ62VEM)B-X03MW>6-!4DAD:$EJ:3)F4T=C=3E!-T9867%L;SAS
M95=X3$9-3DIS>$Q"3S$S1$HY6&DU2F-Y541Z2V5.4DDS159C8FY&5F5X,&93
M8D-7)B-X03MA5WAS<F4P;'5!9W5*24EK:F%14F=Q;DUQ05<T9S!7=E1&55AI
M<GE$+VY*1"]J:&%2+WI&4"]Y8GI99&XO569C-&5T*VME.31D<$YG)B-X03ML
M.61T8G9+66=)6C51-%AN=D1#.&]7;DIF=&-+5C=D84AP;3!N2V<V*T5B3E!1
M3D0P>GI*<#EI=6LV5'(W5SEV<45-='A$86TS:DEU)B-X03M(8TI&8T=-8W!(
M95 P:%97549J43!19D52:'IL16UZ2&LU:TE3:4M%=6%846%*-6DX-S9K:E@X
M<$]O>50S9W9*=G%G1G=O=%ER94UE)B-X03MS<U%5;C0S4D%T4&=*2DIP:WI/
M3TEB8W1U=G9A>$-743<X.2MN=5EF<6QH.5%U;&<U*W!Y:&=M<58T:V5V0VMV
M16EP*WIZ<&U41U9H)B-X03MX-5)O=F\W.&AV.$%Y6'-(+TU24"]W05-Z5#8W
M*SAD<'!F;T0P4$U.>49K.$5-.$UK13AA>7=Y<55L:6-";%I71D=6;$]X0DA5
M67%L)B-X03LY=#58.'17<F@W8E-B2T)X03%Q1VIT-&M)=#-9=3!.5E5F=3)9
M:VQE;&-64E9J<&UM-F5K<5=&<$1A2DY),#!Y=U)R1TAL96=A4F=G)B-X03M&
M5TY"56YF1E54:7(U9"]03"]Y6D]P9C9L=CA!.&U%>EDV9C9!,U$U34-Y.6LW
M1EA9<3ES+TI$+T%*46YZ0B]Z1E%F.&$U:&%R;4=R)B-X03M).7IZ15E/>%8R
M2W5X5C)+<$@U-2]W0U52,5@O04IH,B]H;5)P4#<R4'9A9%(O9&XS4&YV3VQD
M0S=&6%EQ<3(S*SE%6"MU=C8X:DQK)B-X03MM4$XY3C5Y:C!B<U9D:7)S5F1I
M<G-695%F.#5)9CAC3%-0.$%M2V8O04I.-7-/>B]!2VHW;D0Q=C!J,W9#8DLK
M=F)'-%<U<W)I5S%U)B-X03M&0D-Z474P8F=-3TQ!37!",T)O8S)H:41S6%A!
M:V-L539Z<35M:6Y..6-'94)%:6AL.58K85)X:T9%5G$Q5E9)1D%/;5!!3S50
M1V4Y)B-X03M9,G V:WI";75P;5I:;75667E-4THU2V,U46$O8F)I3U1D5%%E
M1U!#3S5E23DV:DY03D\O<51/,&HP5F5416LX5D%64G8R5E%!4&)#)B-X03M"
M4T-B9E,S-41F.$%K=EE0*UEI9B]I5V%B6&8S:G1D3#E!96@U:'51-T9867$W
M1EA9<2M89GIY+SAM5'%8*W!B+W=$2FA-,D]N*V=.)B-X03LP3U1!<W9:3WA6
M,DMV8E!Y42\U46YZ0B]Z1E%F.&$U:&%R;4=R23EZ>D593WA6,DMU>%8R2W!(
M-34O-5)(5F8K661V-%IK850K.6HW)B-X03LR;E5F,UHY>C4W>G!8475X5C)+
M<71T+W921B]R<BMV27DU2FIZ9E1E8V\Y1S=&6%EQ-T9867$W1EAK4"]!1&MA
M,&$V2'!(<4M72#%M)B-X03M46E-&3F94.7<R6G5I;G=K=&540C1G<39E0RMR
M868W-FLO-4=$+VUJ3FHT>&%V-4](93<Q8E0O9E5N+TEW9CA!3D=0:D9F-4](
M93<Q)B-X03MB5"]F56XO27=F.$%.1U!J1F8U3TAE-S%B5"]F56XO27=F.$%.
M1U!J1F8U3TAE*VEV>5IV2C=4>4YP6$-"5W-R=39M:F%2<%0V<4\P)B-X03MJ
M2W1%169&:#A/-35$-4A.5G$U6$YU:&DT0G=V5'-X;6)S5F1I<G-69&ER-60O
M4$PO=T%M5'%8*W!B+SAM17I9-F8V03-1-4U3.'5A)B-X03MD0G%F;4A3.4YU
M1UI)3#(W9W1P6%%G37%3>7%J1E-14E5"=31Y,E)O17!,3%!/2&MF>3=9958W
M6%AF3#EZ9%AS57-Z2D\P9T1):V9Q)B-X03MY>$)M<$A%>41N1'A2;2LS=CA+
M56]A;UI#6E5503=S1'DY:SES+TI$+VQ#9DU(+TU60B]X<FU&<75987-J,U!-
M4F<W1E5V,518.4@P)B-X03MQ5WII,4,V4S-K=C5(:71&87!,=$9%.#<Y06%+
M<V-417-D=3%A:UEQ;&UN9FU*-5 Q1%5)9$]T<C5V<C@X66QJ=%I93&E'47%:
M4%-&)B-X03M6;&I1<3-,9FED*U!X,#0W-'%Y4$95:C@X+SA!2TDV<B]W07<W
M9G=Z23!N.3=(,W1/;R]U>C=N>C-N4W5H9&ER<U968F(O96E,+UA8)B-X03LY
M95)L>51(;2MM.#52-DXR2W5X5FI5,S5K95-O6$M0<5%*5S1N=$A+4E1/<5,R
M<GAX>F,R4D=61E-384Y/8D5,>5E#=%1I<6%A2#5H)B-X03LP:EA,5#8S<&1X
M.5EG1D%Z8TAJ2W-Y:"M$<DEQ<W)H5T)+:U9&9'AI<5DT<3AE+S5Y4R\T-%=J
M+T%0359*+WEB>DLP=DUT;4XT1&UC)B-X03LR3WA6,DMU>%8Y2&9L3B\U3&91
M9BLR:2\O2C4X,3)O*W-T32MB,4A+1TQI46]*2F]"=5-E;$U667)&*V%0:U=A
M,2MT=S9K6F)5=T<U)B-X03M79$QE-5I'44YX-'%W:DEA43 R:DAX:V)H86(T
M<7E$5&15<TY4=$9V3$-96$9Q-5I5;5=V16Q4>&%H249A34-$-S=9<6ES5F9,
M=C4U)B-X03MF*U1*,4PO570O.$%K=VUB2%0O44<V2$I#871P9FLK1T=75%1:
M-V$Y=#1,1S%K859B:5-/6C=G6%!P>D))-2]397-K44Q&4D<S1&(U)B-X03MK
M>$UU<6DS86QP=FQU1%=D4&PP*V4S9E,Y445N<E=+,T1K:&MB;6M&>E)Y66\R
M9F=T9E9B;U=$;EDT9VUT*V%P9G)I84$R;4(W4S-T)B-X03LW93EI1FMJ;3)M
M;&1:1VQI;6QN25=74U4O0E=*2&]A0FAT.7)*4G4P:#96*U-(+TM%*UE0*UEQ
M1"]J6$UB5F-W,35(=659:D(R2W-F)B-X03LX>2M29DPO;4\Y<V(S53%N32MN
M:5)94%-U2F]K36,V;$I9,U)'0TUR-V-Q:F5G2%-O2W%7="M6,FMU.7!C3G%7
M;V9P1S!M.68Y2G!*)B-X03M$1F-Y=GEJ,FME2TI!5CE+3#!E24%(0FU(5FEC
M5EIL:7)(4'I'=4=T+TDR<WIO07I2,GI%2S%A2&-D845(3#E.+V5$,W179C9$
M-VYZ)B-X03M$+VEU-R\U6F)F-W!F*W%M9$)X1C!V0T=8*U5V3%!N1'I467!E
M-F)"<#8R-U-3>$9P;75&-'1%14HU8U,S,G952$@V8W@X=7)%1%)B)B-X03LX
M96Q->%EP261F=G19,%!66G1-=DQA,4TX25%S53EE:$5I0C$R9&MD5%)T,5I1
M4C-'5S0X=D5,1%A01G=M:6<W6'I69&TV:$@Q83,S)B-X03MD93!V:5 X06EZ
M2E-K85)'27-0<GI/6F0V-T9867%W<7DO2U1Y>%E445!95#,P14U-+W)T871C
M=&-2>41L8E V3"]74D\O<&E3>&E9)B-X03MC5T1D4GDT:VI&53(X<2M43D\X
M<W9E+V\K-758=#<Q:V8V;$LV;3-G6D%19G$X4TEI>$(K6'A+=3)W04%!07A6
M4#A695!F.$%/4U@O)B-X03M!0G=T2"\U:7!0.$%K,VU6<&5:8DUB=TA--7-:
M:C5'=&9*33%Q-#AX2W)4>39J65%133 U:$-7-W,W6$QU07DO=2M#8U=B<U-.
M>&Q/)B-X03M1>39D>D4R;%!N2%0Y3W-T8F8X05)F03988WAX>C),2DE*1DM-
M;T15*T]2:R]E2W<T3WA:96A*27%:=TI),S5P0U-:3DPV3R]+8B]Y)B-X03M7
M*V<O.71&+RM4>C5R=%(Y6F%:.#-Q3U5-5D153$<R,4-W=6)#-E5V83-C5'=4
M;W)-:$UC:6Q'061#<G%A2'%P0DAB1E=*-E@K5DAL)B-X03MR5$$X544Q,4Q:
M3TIY8D<V:U,V:#E7-41O.'IF5T5K9#-%56AJ061I;DAQ<$\K2W Q-58X<C)V
M;'94<$Y0=$QU-W5R6G!N;6E&-4PV)B-X03MZ4D)W0C956DE&23$T,4%.9'ED
M.3A65&Y&6'DW*V58+T%*36Y5=CA!570O*U1#6G-D4#A!44<V2$IG5UAS;EEQ
M-T98=&XU268X;U0U)B-X03MG+S5I;U X06I834Q68W<Q6DAU95EJ0C)+=7A6
M,DMU>%9I+S5O9CA!:W8X05AF.$%M1F(Y67DO5&8S9SDW5FTK9RLU.'(V6%E*
M97E4)B-X03MX=$M9;6ET-7 P;W9)35E9>DIX4'A,>'%Q;F9F-5IV6E-P,459
M,GIZ>3%,-7,P>3!U-U!Y-7)S:4=Y-%AK5F=L<VMK<VE83G5S:E V)B-X03MD
M6E=**W=L4&E52'%6,G)I6D]#4D)K3V9M-55"24%I2C5E4U)00DYR='!"9#9V
M96QB9W<S1G=B<&)A3FHV9'5S5G9%2C5G.%<Q675/)B-X03LT3$%K541L-EIB
M9D%A02LQ<C1E25=4.6E3,V1G=&AR6715:TUS85-2=$9)>3A'6D@T=6A:2W1X
M8FEW<71443=:64I81S)V:#1:52MY)B-X03LX-3$S5'-69&ER<U9D:7)S5F50
M9C@U2F8X8TQ2+W=$;4MK+S5.-6QA6&U7>D<X83AP4'!S97)I6%5,:3)T-V5.
M1V(O5$E8;FEK655P)B-X03M&>%-+-$LX+S5U1W=R5&5M6F,W<EIM5U$R;7$O
M;#AR86)B1T5F5FUS5G0Y4FYN=%)Z4S178WE'5W%.23AN37-194Q)=VI#9TUD
M,$Y:)B-X03MJ3&1'-F@U9G5V2TYO-W<S:SEV3$=:<C)0-C8Y=E=4,&HY6#E#
M6DDU3&4V5#1L4UAI:%A9:S%:2VAS36A)<6)9,7)-;&Y*94LQ;48Y)B-X03M)
M5SES<CA&-$M:5G0P5U4P;U X061G87 W;F9,27-G*V=0>6TO=T1*8C9$+T%.
M=$8O=T1K."M91V\K<W1-*V(Q2$M'3'-69&ER<U9D)B-X03MI<C5D+U!,+T%-
M;51Q6"MP8B\X04IH33)/;BMG3C!/5$%S=EI/>%8R2W9A=GE69F@U13AX=GA,
M;$QI2F=I-W,Q07!O4&,U:&%R;4=R)B-X03M)>7(X>B],;'@U:G5V2SDP;6\R
M,FIM1V1U34=O>2MH3C9H;70U=55#<GE$>D-/,F50:E5F1$DR+UDT:D)G+S52
M+VQR3&]V;3-3.61I)B-X03LX>39.<75N,E9S=',V,D8T2$HU>%-23U9#4G%N
M2#9X37$X3U9(4#=X+W="-51&6#!(:7)S5F1I<D8O>E!P+V=$6$MM9TYS,5-E
M9S-()B-X03MH;#)N3E1$1$I%>6E12'ET85A.>%IT23%P<4)T,FUJ84=5>$Y-
M:&5.+W1),T925E<W9S=:=6IK:65B9T12-5)Y*SE%9G!R5U!R:EAV)B-X03LV
M6FTK=4YX1%A0<3-(<6YI=D)A=E1L<W T:F9P:V5+1E97>DPX<FUU+W="2S(P
M,5A5<DM&-$Q05G!,84=13W-K8TUK.&%S<V=!9%=#)B-X03MG5D1C4E5(0UI1
M4$U+3DQM2$PW,4].=E@Q1DHU-W1:6G!*43AK:F5O5UII,5-34W9F2'A),5-"
M;SAL,E@R3&%A:D1C>GI7-%-32V%!)B-X03M+>G!)=D@T6$Q"5T(V145X=#DR
M84(R2TMX5C)+=7A6,DMU>%8T.2]Z:VPO>'=T2"]!3UEQ5"]K,VU6<&5:8DUB
M=TA--7-D:7)S5F1I)B-X03MR-D\O2V(O>5<K9R\Y=$8O*U1Z-7)T4CE:85HX
M,F4S=FUV>719,V)75C=R1FIA,VET1VI7,#%Z1$A+2&U"35-L1UE.5U-H-&IV
M,GEH)B-X03MI:61,,6I39%=T9G)E;%AT=G%&<GE+9E=,5U9*;RM3+V%8;D=7
M5V\W:D956&ER<U9D:7(U9"]03"]W06U4<5@K<&(O.&U%>EDV9C9!)B-X03LS
M435-0WDY:S=&6%EQ.7,O2D0O;$-F34@O359"+W=!835H87)M1W)).48X.&9L
M-4(U<3%44DPK4R]K<WIO.&IL;S0Q-65T2$I*0DMY)B-X03MF855!.')64E9G
M=V]4.%!,:7DT:D)I.6XK4C$S66I36G)0>D<P97!A4S9P0F935W8Q9R]5;VU1
M=S)3<F-45&-962M,=4%385--1UAI)B-X03M&5F-697)9<3=&6%EQ>&(X,'8X
M07E8=74O=T1-2S,V>&QM2#9W>6IZ9DI/8E)U5&Y2+TIV;5173$U8;6TR9C%I
M0G!X86AH2D5P.55M)B-X03M.86-76E<T9WIX9W14:4]1<6-H3$E">E%3;&PW
M6EA6:F54,F0S1UEB<3)D;W T;39Q-D=J03 Y.&M$85=R5"]E<4@O6%@Y67A+
M=G-M)B-X03M$+VQ)-S<O;41T4"M4='IM;V-D36-69&ER<U9D:7)S5F599FYV
M;T8W<D]K85A&871':&EU2%IJ25-"47!48FE'>DHP>&]L;D%V1V8K)B-X03M6
M8V$U+W8V,B]W0T1K+S5O>DXT;7DS9CAQ-#%Z+V8Q="]W04A*+WI2:GA,8G8K
M5F-A-2]V-C(O-$]4+VUJ2&E7,V8X04MU3F,O=T(O)B-X03M7,R]">68X04Y'
M4$5T=F%V26QJ9F%2*U@R:U=V<')C,U5/;VEK85!X5G5C>D4P6F=+559Q.4\R
M64=C*W!Q;GI94BM:4&MF>5!E96),)B-X03LR*S%F>F%.2W96;E,V;C W-FY*
M8RMJ3&8R46I:2C5);550155S96)$-%%S669M94Q":%-X6C$K4T=L95=T2#!7
M*S S43EB3W5+<VM%)B-X03MS,7<X17-%:3%T;S1O-FU1;FQ'-G<K<$148C R
M2$=Q.%1G5C92:7)S5F1I<C4V+TXS>6)Q,G K9DPK.'0S:%=+4DE!;V1M1&9$
M0VEN)B-X03MO<#A->CA%<6<R>$]Z1&8K5F1A-R]V>3,O=T-$9B]M:DQU3FQB
M=CA!;%A7=2]W0R],9CA!-$XO*V%-94YB9"]Y<G)89CDK5R\O0G8O)B-X03M!
M33!9.&$R.58O2W918C-2+THR=5)84E)J3&-1<W!J2DEO3TDW:&-X3E-B26$U
M;#=&;4MW9&ER15!/9&XU;'4Y6#!T9$=I=DDQ:E,T)B-X03ME5%598FA)-V5+
M57AL655N=#)N:3E65V,Q6FI(2GA!*T568FMQ<D=,2%)0>DIS3E0P-U9,95!5
M<FEY-4-'-3!/.#%+3C)J9T5Y2&Y*)B-X03M-,',V>5-C,F57;TI0<$PV5E)Y
M<&A6-G1G5FDS-7!F*U,Y,3,O;49B.5EY>D0Y65I2-79L2W=S2DPQ-6MJ:U)'
M:&AK;F\O3#1H0W!D)B-X03ML6&E'*TQI0V0V1#-Z6FLP,TTT,%=,>E!P96PR
M+W=#:3E4<UHW3%1:671D84%08W V:E-%3%-73C!I-4-&8E Q1%5$63%5;FM-
M<&Q2)B-X03M/-#AM2E-76%1R>GI233)Q4G@R,6YC6$Q8:S T53-$97)*17=N
M;&)I1FU%86A,:%9"2D-G2U-336YF1'-N:VMS,6I*639U3%=2,6M-)B-X03MC
M:6-:62M80C!A:DDV8V=R8UA5:&A503 W6DLW0U@R1$(O>6MD.2]Z0C)N+T%#
M9'5C,4QJ<&II<G-6955R;VXU:%AK.6\O;S9V<'--)B-X03ML-4U8:F9566Y.
M<W)3,EE76GET,4PV.%)T-')I:V926D@R:7!X8TMS;2],;3$X-%=.=F9A9C5J
M:FUK5S-E36%F<54Y>7,W5'A&0T-$)B-X03M'1VQE3FLT9W1Z:V-L;5!X34)8
M1E=967%X1#AY4"M/9F%F.$%'52\X4GI),"]-<V]S07I,8DAK<S)V.$$U<U)8
M1V]X>7=89SE/3S1J)B-X03LP<S(Y:DA-:W)W4GE*-FMZ.%8T1G!),&5/9TEB
M;%1I=S-7;35)5#=Y<G%0;FTR.#)83VUE6G!7;7-M:D-713919G5:2FQI:FQ)
M5UI))B-X03MO:%5+6#5&<4)Y1'A63TI'4T).-W%Z>DQ%<S8X=F8X04M/-E@O
M=T)T0F8Q;DU,3CE45DQM9SEF+T%#4#AJ-C-Q.3%Q='@Y8VAU<C)3)B-X03M+
M831%5G=X:F%327DO1T5L16=5<THR1E9P=S9X.$=Q>'!1;D9J-4PP,WDK;7$S
M;6I*8VU7.5,U;6LP-C-E2T-/5S1M67EC,%5,1D=K)B-X03MU>7AO-4EO;TA)
M,7$R2W-/,#=Y,2M99#-&2D9C>6%T<&I4,C O=T,K92M765%)-&1K=%923#$R
M95I:>4-S+W%":D911U)',E5Q>F)Y)B-X03M'4$Y#-D<P4&U7,F%$56]:-44Y
M5G)H3&XQ-#EI:W%L06]29"M)56EV=S%/-7=+>5!&6&U(;FXO;$I,:B]!1EDO
M*TE$33=$.4Q:2&LX)B-X03MV+TU$4V9/9#@Q<69,5C Y=E=+-6IU9W-V<$%-
M145L=30S1R]Q<'<K5&(W6DM14%),16)J>7(K87,X8S$W83-D.5IU3&UL='!C
M,F]E)B-X03MU=W0Q=&IX6G P;%)'651+07$X97!R25I&>4A$2EAR1FY/.#%U
M2&5/4TIG>DE5;4-H+V=9<'DK16QA3G@U0VY9-6%&6G U82\U4F)6)B-X03M0
M*TUS9C8Q>D8Q2$U-2G918W@R3'-69&ER<U9D:7)&=GI3+SAL-W)V+TU+,S9X
M;&U(-G=Y:GIF2U9H<4XS65!+.7-51%1W>5<X:&5/)B-X03M/5#DS2W9&=W9Q
M2S-%;&1U4S<K*V)-:3(U1C)8;6983$A5;#%+,75V5'964TM.6G5%6F]L=G=%
M4V=&4W1&15-J<#!&34)G0TM25%9P)B-X03LU:S%A,6=A1T8T=4IE5U%&-$E*
M1U8U,59:1U(S4FU2:4DQ;U9)2SEQ5D]*9T-T26,S8SDU<6DS33="<%I:5EII
M049(56)!0V=!2%%!)B-X03M986]*9EAC9#)5.#,S5G0V17)#4WAT5RMS2V]-
M4S!L=69H63%Q0V4R,F%H>#-I8VYL1"]N250P;W=T,W%&9E(Q0T]53'%55E10
M3%E2)B-X03M2>'E6855F03DT<VIX53-J0C9*,'=Q.6PX9S)E=C)8;%-Y=%!-
M1'9*<3!";5-E4U-4,6EY:60O5$EK3'ES>2MN>#0X,DPX86-Z>7)G)B-X03M6
M:T=+=7A6,DMS42]-:B]J;C)N+T%";% O16-Y3E!Z3$M,>3-Z16PX,FTO-D1&
M3DYC3%!B=4DW95)9;DM*3VI31&MZ>$Q49T151G1X)B-X03MT;5-78D=,>E-F
M4#<O<$<U17I#-%<K8694-$QE-E!P=F)T0TEX2%(Q:5=09T9"2$I80FM*2EAO
M-&E15E)E=E<O;6$W<V)O5S%T9%$S)B-X03M&>%I79W0T-$QL44EB;FQ-6F=8
M13ES5TM65&LS3#1T<4)Q1F-*=%=1-DY(95(R4E<W3&U5>C-$2C9J8VTY2G S
M84E%,5 K-GET4$%B)B-X03M:24LY23AV9CAO-W!F+V)16#E:>D1Z9E4Q>35S
M,'EL1'-69&ER<U9D:7)Z1'IZ+WEK;'@O<7@O.%%'6C)(-E=Y4$HU9W9L6%5:
M3#(Q)B-X03M&>EHR4#%+1S=V<FAP635N1G=Q,U1S-F5N*S1(16XQ1SE25F1A
M;6YX159";'=P9'!F;%!6-U11.5,P95IR85=Z;$59<U5"8W,P86EJ)B-X03MW
M5#%667=J2V]4.3)O1D-X-&ET35)%,'%*.'0K6#E4<W113C5E45=T<7IF5W95
M:G,U1VM2=EA-2$-G84M';$9G4$MT4U1V6#1I06=+)B-X03LY53AT9CAO='%N
M+T=74#A!5W59*V\U:&A.-D1M3WAD:7)S5F1I<G-64U!Z=EEX6#-L4%9,4U5S
M<V,P0E9Y;$$Q2VIP54A,35@Q0DUE)B-X03MB=TM4.'903#AA33=46&9&05=A
M:GAN66(Y0DAM=S1I,C)X,6@K5G%Q5R]41G=615)N3$M#>2MM27I.>7%)0TXP
M5FEO-FUJ06)Q85(X)B-X03M68E)M:V%.*U@K<UAB,FUM-FQC,T4X8V%Z1E%1
M;TM-<5!61V%&5F5I>DIY-&LX95%R4W5%6DQ7,#=T+WDV,$E4>&M46%91>6M6
M95!X)B-X03LO=T--945Y2S(K9S10*U5J=G8X06U$=% K5'1Z;7)A6&EH+TE(
M>E1D86]B>31M<TQ/1#DK-'-R939U3&E0;3!B<D=+,TYS87!+-TE:)B-X03MW
M+TE/5DQ30UAM06A6-G(U0C!(>D)O1VU385!Q53%T8U=&;59J,'$T:4UZ6$US
M9D=S:VPT6E-2-G)Y16XT3G-#<VYX5C)+=7A6:3-N)B-X03LK,6MU3$LQ5D-"
M>&Q*2F(O049F8758-$126E)E4V%R-70X<3969GE71B]Q:U5.,44T:FM4,#4R
M54U5.55G=6MB2CA%6D10=CA!24Q5)B-X03MQ37E0141/,#%V<&)7>'4T<E,U
M;31Z4WAY5$1H1E!):7AX0W)V2392<VMA*T)C:7 R1RM(:D,R<%=L.7!T,UE#
M+W0W=$AT4SA54F9H)B-X03M+<D-39&Q73TYK6D$V=51)=G=K5D9D-EDX65<Q
M83!E,74U>$)"8TM:;2MS04EY4V]4.55L14TS,C!8-TUJ064Y86EO,W@T=W1S
M+S!A)B-X03LS94119$U2-D4O6#%)2395<3)9;5DS2G)L>EIF;%-(67$W1EA9
M<3=&6&HO-7EE67)J46(K,6UT-')A=#-C3$1.8S-C8W-K84)B6C56)B-X03M7
M:TEA5&Q+.%EJ4V=/-V)+,U1-:45I27-W>&)19E!-.2]O;FUE-VYS-TTV:F]T
M>'%%9&Q:4FYG.#!6:T%63'$Y4TML;$1-3G0K,U1*)B-X03MI6E-S:#@X6$U5
M*VM46'-6;4Y*,4I05&MU;&=P271Y3'(P1%))6G)T4%1.55)3<G-#>F-U6$5%
M63A:4F%0,4QZ3$IB5'1%6# K,6%3)B-X03LU=G)E0T\T:5!.1G1B47I*23E*
M135J:W9.=4E(=T]O,DEQ5'A&8F5H-D9)2F9*,7IC1T0V=3@T9VME1V="471W
M2E4P-VET37!Y;F--)B-X03M:339Y;$1S5F1I<G-69&EQ5V5:+RM59G8O=T1J
M16-N:BMO2DA.-#-F,SAD:VM,>4DW<DY.2$)63U!W;59G:7,S27(X4$EG8E90
M=&UE)B-X03M3,E!.4C58.&QO,7!P,$HQ87I855EB<3%E0TM324I+1&-3>&U/
M64QY1&5N2F-0=S0O0V]O6% R8W)O2VYJ861O,FAE6C=R5C=#2S=%)B-X03MR
M>5%186ES2S)X9UI:-#%J:6A53UDU1CE(,#0S051F-#9!3E=I;6=#<DUD279O
M-S9#,G5O,&%-4T5C;W!+8S!:5S1U:CA3>3AK6494)B-X03M1:U8W-4\Y;&5X
M=V8X<$AF9CAW9' O>61U8S%R56U/2W5X5C)+=7A6,DMP3#5P='!:-V%&67=#
M435*<6%D<W1X1VEK4$$O3E=G9FQN)B-X03MF-FYE4S,S;4M914TK<7I7.6Y.
M-CER1E!"03A,>E532V%0,6=L<WA#35,S-W,X5G!Z0G-*1$LR53-7;&%08U%E
M6&9-3C5E4&9V>%-/)B-X03MW=7)7,D5R,U144BMP54I$1$Q/:7-S6F1L47%O
M05!,87501491=6<K5W9,8F9P5WDP<E9:>6QR9'AY6%9U>D)98E-B5'!L:V8P
M:V%*)B-X03M),&ID+VAB:CA*04E1:FIS9VA56&]T:G!%1W!1>7@S,7I03F--
M-S(P9'I#,%%4.4PO=T-L<5 W:4QI1#E825AN=4=Q:DAK44U0149E)B-X03MK
M4E)01G!E;'AV<WDS>58K;&U/551/-T5S:WE#2%EQ-T9867$W1EAN6#5I*UIF
M3#)G86A'9%-N:TXU9F-6<V)'0D]C<S=";S1U2U9+)B-X03MO4&IL459D;$<O
M6$QO5&]-9U5K.'5E6B],,G8K67)R4C=E0S=T.50P*T):6F9R8TM2<W%3<D1)
M>45",FMJ23E605$V<GE)4$AL>$Y*)B-X03ME26TQ9S@V95=N;'15:2MS>G@S
M='IC5V-%.$%G;&HY5S,T04LO0U9M47EV27%O<D%.6#=156(T*TET<'1Q1GAP
M=&YQ0G-(4V56:3%O)B-X03MS,&E,1UDQ*W934$)&>C5/<%!X4E5A9TY!4F@T
M,71/9$MN9W5V2C%X95%#4D9N6D,P36]54U)U:V=2-#,T1C$U239L5V]X1E)S
M5&Q5)B-X03MZ6EEL;6U6;V1I<4<Q3S9L=$Y.=3=Q1T4S171V1$I,2$%V5U)K
M57-%2'5X1DU695I74#5R-C%(<65N2%5P3DYN.'8S<D,S6%=,3T]F)B-X03MJ
M2E V>4E8:E%35'-)-GI*8C<Q+V5N;'E#<59W<3E72D$O,G$T1E,O6&]:8FY2
M-W4S9U%V3DI'5E)A57%F<'EC1%)#43AW=B]!378Y)B-X03M:=C!I4S5S2E-S
M37-D>$=%;4UF-WE*=5-%*VTV.&=$=GA/,W1M5V-S93EN65,K-"]+0C=N5$4P
M>34P;5=E>5(S;%=/5S1K8VE34GDW)B-X03M.>F%5=EAK>#-R,TDV2$(T:T9S
M2SDW*U8Q+V4S85AC*VYZ:65/4DIK84LT94@Y-4=R2W)%4E-*>2M&>7!R,4=X
M>#A32&5T:$AA9#5')B-X03LQ=7EI9W0T8D(Q:&AO0E8Q63!"<5-35TI*4%5N
M1#1S93EB1#!A>&%A5%=B-C9A,VQH9TU-145B4T%$;3!4>DUX54%K.&8S:3=M
M;5E,)B-X03M7;6=.8U9D:7)$9E!0;3=73D8Q9E(Y4# P5VY057515DQW4U9N
M:T9X8E%,0D-Y3V=6*TYY.')%.'9H42]$5&MY<7)V>34X-UA0;5<S)B-X03MV
M;TY15T=(5CE-94]/.71O16-+4%51;%I!>&%337))>71X.4]2>'A!4$DX:&ER
M3"M1.2]U3TMO4%5O-4IO,$5A;&E$53=5-V4K4VE5)B-X03MH-6I$*U)/:E%P
M9GA2,VUQ3$)Q54UL=F57-GIX<$4V3TI64W%*1W$O=6AC4'=8-TYF:4E,04A*
M5T4R;6QZ*U8X9#4U6F@X=5AL>&-4)B-X03LV9F%.1#E39&\W57I24G=13$-Q
M8VYI9%,R>DXV9U5/0S-W:T5!-#)&=$5N.'5,439Z96%P>75L+U-%57-&-UI,
M27$R,'%Y<7%694Y6)B-X03M(2FQO>%9I83%D=DA'=VAU4'E"2TPU3'5E-W4W
M:W(Y5#5W>65J-F)'=U8O4U!W>'$K.&MN<4Y6:CA11DM$8D=W<DE:;W(Q;7-,
M6F)3)B-X03M1<$A/<SAT>E=0,#!#5BM%:FPV:%DY<4E2-S5%;$)4<TU$-"]C
M8VER94MS1#AY*V1036QP-6=V.4HP;$Q'4S1G=%=L=#=/-$)%>$-W)B-X03LK
M<V)X,TTP368Q9FQ71V@T+T@Q:U595E1N>4@U=&HX,&%',2\X2UA%33AL=&0R
M-G!+;F]Y>#!0<'0V<6]X8FEY<V%#9W)4=&=6:UA-)B-X03ME+S-(1E=*96-0
M275H*UHW<4-85F)!,VAT2W1A4'IK:F%.;4%"9$1'>45-2V9#,U5(8U5Y64E3
M174P=CAS9$$P:E5)3"]38D(W0S1H)B-X03M(12MH3$EQ4U(K:6M!:FQ1<U9D
M5E=*0W12<WDQ-W15,D4R=G5F>3$X=C-7;50V6F-A83!L:&-34$Y,05IP<48U
M26I#84@Q2W%"1V5+)B-X03MQ<&]V-TE'3FA55&0K4G10=7 T<#5B85E014Q5
M24DW:65.9CE"9#5,9FMQ4TM'-%!+>#,K,2LQ5V=O,D9T1T135' S;'=A5%I7
M:W)!)B-X03MT2$A#:2]%44%W6FYK9&HX>7A*<50W-45L:5=40F=F2#=J:U9B
M>%8R2W5X5C)+=7A6,DMU>%8R2W5X5C)+=7A6,DMU>%8R2W5X5C)+)B-X03MU
M>%8R2W5X5C)+=7A6,DMU>%8R2W5X5C)+=7A6,DMU>%8R2W5X5C)+=7A6+R\Y
M:ST\+WAM<$=);6<Z:6UA9V4^"B @(" @(" @(" @(" @(#PO<F1F.FQI/@H@
M(" @(" @(" @(" \+W)D9CI!;'0^"B @(" @(" @(#PO>&UP.E1H=6UB;F%I
M;',^"B @(" @(#PO<F1F.D1E<V-R:7!T:6]N/@H@(" @(" \<F1F.D1E<V-R
M:7!T:6]N(')D9CIA8F]U=#TB(@H@(" @(" @(" @("!X;6QN<SIP9&8](FAT
M=' Z+R]N<RYA9&]B92YC;VTO<&1F+S$N,R\B/@H@(" @(" @(" \<&1F.E!R
M;V1U8V5R/D%D;V)E(%!$1B!L:6)R87)Y(#$P+C Q/"]P9&8Z4')O9'5C97(^
M"B @(" @(#PO<F1F.D1E<V-R:7!T:6]N/@H@(" @(" \<F1F.D1E<V-R:7!T
M:6]N(')D9CIA8F]U=#TB(@H@(" @(" @(" @("!X;6QN<SID8STB:'1T<#HO
M+W!U<FPN;W)G+V1C+V5L96UE;G1S+S$N,2\B/@H@(" @(" @(" \9&,Z9F]R
M;6%T/F%P<&QI8V%T:6]N+W!O<W1S8W)I<'0\+V1C.F9O<FUA=#X*(" @(" @
M(" @/&1C.G1I=&QE/@H@(" @(" @(" @(" \<F1F.D%L=#X*(" @(" @(" @
M(" @(" @/')D9CIL:2!X;6PZ;&%N9STB>"UD969A=6QT(CYG.35P-#0\+W)D
M9CIL:3X*(" @(" @(" @(" @/"]R9&8Z06QT/@H@(" @(" @(" \+V1C.G1I
M=&QE/@H@(" @(" @(" \9&,Z9&5S8W)I<'1I;VX^"B @(" @(" @(" @(#QR
M9&8Z06QT/@H@(" @(" @(" @(" @(" \<F1F.FQI('AM;#IL86YG/2)X+7)E
M<&%I<B(^1FEL92!.86UE.B @(" @(" @(" @(" @('!G,3,V+F%I)B-X03M5
M<V5R;F%M93H@(" @(" @(" @(" @(')R,CDU-38T)B-X03M,;V-A;"!4:6UE
M.B @(" @(" @(" @(" R,2U*=6PM,C Q.2 Q-#HQ-SHQ,R8C>$$[15-4(%1I
M;64Z(" @(" @(" @(" @(" R,2U*=6PM,C Q.2 P-#HT-SHQ,R8C>$$[4V-R
M:7!T(%9E<G-I;VXZ(" @(" @(" @,BXU)B-X03M);&QU<W1R871O<B!697)S
M:6]N.B @(" Q-BXP+C F(WA!.T=R87!H:6,@='EP93H@(" @(" @(" @0F%R
M($-H87)T)B-X03LF(WA!.^* HB Q.2!#35E+(&)L86-K(&]B:F5C=',@8VAA
M;F=E9"!T;R!G<F%Y<V-A;&4N)B-X03LF(WA!.U1H92!F;VQL;W=I;F<@9F]N
M=',@87)E('!R97-E;G0@:6X@=&AE(&1O8W5M96YT.B8C>$$[)B-X03M!<FEA
M;"U";VQD350F(WA!.T%R:6%L350F(WA!.R8C>$$[+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM)B-X03M&:6QE($YA
M;64Z(" @(" @(" @(" @(" @9SDU<#0T+F%I)B-X03M5<V5R;F%M93H@(" @
M(" @(" @(" @(')R,CDU-38T)B-X03M,;V-A;"!4:6UE.B @(" @(" @(" @
M(" R,2U*=6PM,C Q.2 R,#HR-3HS-"8C>$$[15-4(%1I;64Z(" @(" @(" @
M(" @(" R,2U*=6PM,C Q.2 Q,#HU-3HS-"8C>$$[4V-R:7!T(%9E<G-I;VXZ
M(" @(" @(" @,BXU)B-X03M);&QU<W1R871O<B!697)S:6]N.B @(" Q-BXP
M+C F(WA!.T=R87!H:6,@='EP93H@(" @(" @(" @0F%R($-H87)T)B-X03LF
M(WA!.RHJ*E1H92!P<F5F;&EG:'0@8VAE8VL@:7,@8V]M<&QE=&4N(%!L96%S
M92!E;G-U<F4@;6%N=6%L(&-H96-K<R!A<F4@8V]M<&QE=&5D('!E<B!P<F]C
M97-S+BHJ*B8C>$$[)B-X03M4:&4@9F]L;&]W:6YG(&9O;G1S(&%R92!P<F5S
M96YT(&EN('1H92!D;V-U;65N=#HF(WA!.R8C>$$[07)I86PM0F]L9$U4)B-X
M03M!<FEA;$U4)B-X03LF(WA!.RTM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+28C>$$[1FEL92!.86UE.B @(" @(" @
M(" @(" @(&<Y-7 T-"YA:28C>$$[57-E<FYA;64Z(" @(" @(" @(" @("!R
M<C,U.#8U,28C>$$[3&]C86P@5&EM93H@(" @(" @(" @(" @,#<M2F%N+3(P
M,C @,3$Z-#DZ,38F(WA!.T535"!4:6UE.B @(" @(" @(" @(" @,#<M2F%N
M+3(P,C @,#(Z,3DZ,38F(WA!.U-C<FEP="!697)S:6]N.B @(" @(" @(#(N
M-28C>$$[26QL=7-T<F%T;W(@5F5R<VEO;CH@(" @,38N,"XP)B-X03M'<F%P
M:&EC('1Y<&4Z(" @(" @(" @($)A<B!#:&%R="8C>$$[)B-X03LJ*BI4:&4@
M<')E9FQI9VAT(&-H96-K(&ES(&-O;7!L971E+B!0;&5A<V4@96YS=7)E(&UA
M;G5A;"!C:&5C:W,@87)E(&-O;7!L971E9"!P97(@<')O8V5S<RXJ*BHF(WA!
M.R8C>$$[5&AE(&9O;&QO=VEN9R!F;VYT<R!A<F4@<')E<V5N="!I;B!T:&4@
M9&]C=6UE;G0Z)B-X03LF(WA!.U1R861E1V]T:&EC+4)O;&0F(WA!.U1R861E
M1V]T:&EC)B-X03LF(WA!.RTM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+28C>$$[/"]R9&8Z;&D^"B @(" @(" @(" @
M(#PO<F1F.D%L=#X*(" @(" @(" @/"]D8SID97-C<FEP=&EO;CX*(" @(" @
M(" @/&1C.F-R96%T;W(^"B @(" @(" @(" @(#QR9&8Z4V5Q/@H@(" @(" @
M(" @(" @(" \<F1F.FQI/G)R-3 Y,38W/"]R9&8Z;&D^"B @(" @(" @(" @
M(#PO<F1F.E-E<3X*(" @(" @(" @/"]D8SIC<F5A=&]R/@H@(" @(" \+W)D
M9CI$97-C<FEP=&EO;CX*(" @(" @/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O
M=70](B(*(" @(" @(" @(" @>&UL;G,Z>&UP5%!G/2)H='1P.B\O;G,N861O
M8F4N8V]M+WAA<"\Q+C O="]P9R\B"B @(" @(" @(" @('AM;&YS.G-T1&EM
M/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O<U1Y<&4O1&EM96YS:6]N
M<R,B"B @(" @(" @(" @('AM;&YS.G-T1FYT/2)H='1P.B\O;G,N861O8F4N
M8V]M+WAA<"\Q+C O<U1Y<&4O1F]N=",B"B @(" @(" @(" @('AM;&YS.GAM
M<$<](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]G+R(^"B @(" @(" @
M(#QX;7!44&<Z3E!A9V5S/C$\+WAM<%109SI.4&%G97,^"B @(" @(" @(#QX
M;7!44&<Z2&%S5FES:6)L951R86YS<&%R96YC>3Y&86QS93PO>&UP5%!G.DAA
M<U9I<VEB;&54<F%N<W!A<F5N8WD^"B @(" @(" @(#QX;7!44&<Z2&%S5FES
M:6)L94]V97)P<FEN=#Y4<G5E/"]X;7!44&<Z2&%S5FES:6)L94]V97)P<FEN
M=#X*(" @(" @(" @/'AM<%109SI-87A086=E4VEZ92!R9&8Z<&%R<V54>7!E
M/2)297-O=7)C92(^"B @(" @(" @(" @(#QS=$1I;3IW/C8Q,BXP,# P,# \
M+W-T1&EM.G<^"B @(" @(" @(" @(#QS=$1I;3IH/C<Y,BXP,# P,# \+W-T
M1&EM.F@^"B @(" @(" @(" @(#QS=$1I;3IU;FET/E!O:6YT<SPO<W1$:6TZ
M=6YI=#X*(" @(" @(" @/"]X;7!44&<Z36%X4&%G95-I>F4^"B @(" @(" @
M(#QX;7!44&<Z1F]N=',^"B @(" @(" @(" @(#QR9&8Z0F%G/@H@(" @(" @
M(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @
M(" @(" @(" @(" @(" @/'-T1FYT.F9O;G1.86UE/E1R861E1V]T:&EC+4)O
M;&0\+W-T1FYT.F9O;G1.86UE/@H@(" @(" @(" @(" @(" @(" \<W1&;G0Z
M9F]N=$9A;6EL>3Y4<F%D92!';W1H:6,\+W-T1FYT.F9O;G1&86UI;'D^"B @
M(" @(" @(" @(" @(" @(#QS=$9N=#IF;VYT1F%C93Y";VQD/"]S=$9N=#IF
M;VYT1F%C93X*(" @(" @(" @(" @(" @(" @/'-T1FYT.F9O;G14>7!E/E1Y
M<&4@,3PO<W1&;G0Z9F]N=%1Y<&4^"B @(" @(" @(" @(" @(" @(#QS=$9N
M=#IV97)S:6]N4W1R:6YG/C P,2XP,#$\+W-T1FYT.G9E<G-I;VY3=')I;F<^
M"B @(" @(" @(" @(" @(" @(#QS=$9N=#IC;VUP;W-I=&4^1F%L<V4\+W-T
M1FYT.F-O;7!O<VET93X*(" @(" @(" @(" @(" @(" @/'-T1FYT.F9O;G1&
M:6QE3F%M93Y41T)?7U]?+E!&0CL@5$="7U]?7RY01DT\+W-T1FYT.F9O;G1&
M:6QE3F%M93X*(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @
M(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @
M(" @(" @(" @(" \<W1&;G0Z9F]N=$YA;64^5')A9&5';W1H:6,\+W-T1FYT
M.F9O;G1.86UE/@H@(" @(" @(" @(" @(" @(" \<W1&;G0Z9F]N=$9A;6EL
M>3Y4<F%D92!';W1H:6,\+W-T1FYT.F9O;G1&86UI;'D^"B @(" @(" @(" @
M(" @(" @(#QS=$9N=#IF;VYT1F%C93Y-961I=6T\+W-T1FYT.F9O;G1&86-E
M/@H@(" @(" @(" @(" @(" @(" \<W1&;G0Z9F]N=%1Y<&4^5'EP92 Q/"]S
M=$9N=#IF;VYT5'EP93X*(" @(" @(" @(" @(" @(" @/'-T1FYT.G9E<G-I
M;VY3=')I;F<^,# Q+C P,3PO<W1&;G0Z=F5R<VEO;E-T<FEN9SX*(" @(" @
M(" @(" @(" @(" @/'-T1FYT.F-O;7!O<VET93Y&86QS93PO<W1&;G0Z8V]M
M<&]S:71E/@H@(" @(" @(" @(" @(" @(" \<W1&;G0Z9F]N=$9I;&5.86UE
M/E1'7U]?7U\N4$9".R!41U]?7U]?+E!&33PO<W1&;G0Z9F]N=$9I;&5.86UE
M/@H@(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @/"]R9&8Z
M0F%G/@H@(" @(" @(" \+WAM<%109SI&;VYT<SX*(" @(" @(" @/'AM<%10
M9SI0;&%T94YA;65S/@H@(" @(" @(" @(" \<F1F.E-E<3X*(" @(" @(" @
M(" @(" @/')D9CIL:3Y#>6%N/"]R9&8Z;&D^"B @(" @(" @(" @(" @(#QR
M9&8Z;&D^36%G96YT83PO<F1F.FQI/@H@(" @(" @(" @(" @(" \<F1F.FQI
M/EEE;&QO=SPO<F1F.FQI/@H@(" @(" @(" @(" @(" \<F1F.FQI/D)L86-K
M/"]R9&8Z;&D^"B @(" @(" @(" @(#PO<F1F.E-E<3X*(" @(" @(" @/"]X
M;7!44&<Z4&QA=&5.86UE<SX*(" @(" @(" @/'AM<%109SI3=V%T8VA'<F]U
M<',^"B @(" @(" @(" @(#QR9&8Z4V5Q/@H@(" @(" @(" @(" @(" \<F1F
M.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @
M(" @/'AM<$<Z9W)O=7!.86UE/D1E9F%U;'0@4W=A=&-H($=R;W5P/"]X;7!'
M.F=R;W5P3F%M93X*(" @(" @(" @(" @(" @(" @/'AM<$<Z9W)O=7!4>7!E
M/C \+WAM<$<Z9W)O=7!4>7!E/@H@(" @(" @(" @(" @(" \+W)D9CIL:3X*
M(" @(" @(" @(" @/"]R9&8Z4V5Q/@H@(" @(" @(" \+WAM<%109SI3=V%T
M8VA'<F]U<',^"B @(" @(#PO<F1F.D1E<V-R:7!T:6]N/@H@(" @(" \<F1F
M.D1E<V-R:7!T:6]N(')D9CIA8F]U=#TB(@H@(" @(" @(" @("!X;6QN<SIX
M;7!-33TB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+VUM+R(*(" @(" @
M(" @(" @>&UL;G,Z<W12968](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N
M,"]S5'EP92]297-O=7)C95)E9B,B"B @(" @(" @(" @('AM;&YS.G-T179T
M/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O<U1Y<&4O4F5S;W5R8V5%
M=F5N=",B/@H@(" @(" @(" \>&UP34TZ1&]C=6UE;G1)1#YX;7 N9&ED.D,S
M,C<W.4(X,30S,45!,3%"0T1&0SDR149"-S$S-4(P/"]X;7!-33I$;V-U;65N
M=$E$/@H@(" @(" @(" \>&UP34TZ26YS=&%N8V5)1#YX;7 N:6ED.D,S,C<W
M.4(X,30S,45!,3%"0T1&0SDR149"-S$S-4(P/"]X;7!-33I);G-T86YC94E$
M/@H@(" @(" @(" \>&UP34TZ3W)I9VEN86Q$;V-U;65N=$E$/GAM<"YD:60Z
M,T4Q.38V1$(X0T%"13DQ,3E%,D%%,#@Y,S!$,# T-$(\+WAM<$U-.D]R:6=I
M;F%L1&]C=6UE;G1)1#X*(" @(" @(" @/'AM<$U-.E)E;F1I=&EO;D-L87-S
M/F1E9F%U;'0\+WAM<$U-.E)E;F1I=&EO;D-L87-S/@H@(" @(" @(" \>&UP
M34TZ1&5R:79E9$9R;VT@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @
M(" @(" @(" \<W12968Z:6YS=&%N8V5)1#YX;7 N:6ED.D,R,C<W.4(X,30S
M,45!,3%"0T1&0SDR149"-S$S-4(P/"]S=%)E9CII;G-T86YC94E$/@H@(" @
M(" @(" @(" \<W12968Z9&]C=6UE;G1)1#YX;7 N9&ED.D,R,C<W.4(X,30S
M,45!,3%"0T1&0SDR149"-S$S-4(P/"]S=%)E9CID;V-U;65N=$E$/@H@(" @
M(" @(" @(" \<W12968Z;W)I9VEN86Q$;V-U;65N=$E$/GAM<"YD:60Z,T4Q
M.38V1$(X0T%"13DQ,3E%,D%%,#@Y,S!$,# T-$(\+W-T4F5F.F]R:6=I;F%L
M1&]C=6UE;G1)1#X*(" @(" @(" @(" @/'-T4F5F.G)E;F1I=&EO;D-L87-S
M/F1E9F%U;'0\+W-T4F5F.G)E;F1I=&EO;D-L87-S/@H@(" @(" @(" \+WAM
M<$U-.D1E<FEV961&<F]M/@H@(" @(" @(" \>&UP34TZ2&ES=&]R>3X*(" @
M(" @(" @(" @/')D9CI397$^"B @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F
M.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" \<W1%
M=G0Z86-T:6]N/G-A=F5D/"]S=$5V=#IA8W1I;VX^"B @(" @(" @(" @(" @
M(" @(#QS=$5V=#II;G-T86YC94E$/GAM<"YI:60Z,T4Q.38V1$(X0T%"13DQ
M,3E%,D%%,#@Y,S!$,# T-$(\+W-T179T.FEN<W1A;F-E240^"B @(" @(" @
M(" @(" @(" @(#QS=$5V=#IW:&5N/C(P,3DM,#<M,C%4,30Z,#<Z,C<K,#4Z
M,S \+W-T179T.G=H96X^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IS;V9T
M=V%R94%G96YT/D%D;V)E($EL;'5S=')A=&]R($-3-B H5VEN9&]W<RD\+W-T
M179T.G-O9G1W87)E06=E;G0^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IC
M:&%N9V5D/B\\+W-T179T.F-H86YG960^"B @(" @(" @(" @(" @(#PO<F1F
M.FQI/@H@(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E
M<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @/'-T179T.F%C=&EO;CYS879E
M9#PO<W1%=G0Z86-T:6]N/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z:6YS
M=&%N8V5)1#YX;7 N:6ED.D,S,C<W.4(X,30S,45!,3%"0T1&0SDR149"-S$S
M-4(P/"]S=$5V=#II;G-T86YC94E$/@H@(" @(" @(" @(" @(" @(" \<W1%
M=G0Z=VAE;CXR,#(P+3 Q+3 W5#$Q.C0Y.C(T*S U.C,P/"]S=$5V=#IW:&5N
M/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z<V]F='=A<F5!9V5N=#Y!9&]B
M92!);&QU<W1R871O<B!#4S8@*%=I;F1O=W,I/"]S=$5V=#IS;V9T=V%R94%G
M96YT/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z8VAA;F=E9#XO/"]S=$5V
M=#IC:&%N9V5D/@H@(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @
M(" @/"]R9&8Z4V5Q/@H@(" @(" @(" \+WAM<$U-.DAI<W1O<GD^"B @(" @
M(#PO<F1F.D1E<V-R:7!T:6]N/@H@(" \+W)D9CI21$8^"CPO>#IX;7!M971A
M/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"CP_>'!A8VME="!E;F0](G<B/S[_
MVP!#  $! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_VP!# 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0'_P  1" %@ :\# 1$  A$! Q$!_\0 '@ !  (# 0$! 0$           <(
M!@D*!00# @'_Q !?$  !! ("  $%!@T,$ 4$ @,% P0&!P$"  @)$1(3%!4*
M%A<W=[88(38X5%=S=GBRM=77(C$S-563E)66E[G3&2,R-$%14U9T=;2WN-+4
MUB1RF+&S)4*2T6)Q)E)A_\0 ' $!  $% 0$               4! @0&!P,(
M_\0 8A$  0," P($#! )"P(% @<  0 " P01!1(A$S$&(D%1!Q0T87%T@9&Q
ML]'P%2,R,S524U1R<Y*4H;+!TA9"=9.TPL/3U"0V1%5B@Y6BM=7A0_$7)59D
M@H3B149CA:3$Q?_:  P# 0 "$0,1 #\ [^.$3A$X1.$3A$X1:MO%_FO8*%=1
M&F_5V=F:[NV67M1,!A,@!IH+.UB4RGXX,@#<-W"*Z;D8?<+MQ11MKIA5=BY7
M32434VUWP5[+7U%P 2M)=>]_NQ79>=2*7FNQEE49UR[7=L.F3&#K"S,<A)NE
M.MLR"^(/''",7E4@"/6\'<6S)>JU<R@F<>I;$72,GP+059K%\H\IY^=U6UAN
M!(!Y]2<O)RD9B-.:^X+P>NW>GN_8U_\ 27VO=EG*AIL'\.2/RZ4OS$$'4<^1
MMR5]J<6'K:$)Q$WYL].>R-=4FU U5)H8E' @FT\A5WID(G)0R#VJK897:#1S
M]-;Z9;6/6)UN;G=JIW5[(W6L2L%6L^_=B67UOD?8GJ/UNLOL.9-5< )J3RPN
MT3B.=@)_UD',Q#Y.GZ2CD*+ Z4'S4CDC$"DPW=D:[>O7P!:6$RI8<K;:.-M>
M;2_+>^NA[@NOJ:]D[KEK&EH3"^^]@EKTW[+=@*DH2*Y*U>,B,MHFB.]TY@1;
MM=VHG+H0F.L2!.*)B+*IXX*8L1KBR;!TVWA"9F;%SIJ.%2PO>VF4'EWEE[#7
MG.O,!KUX;[+]UNS"-M6MV)BW;.PZOA$FJFV;TZ@U ./Q)"!6"PI[M-1/6"K8
MXXATG!&-YL.O\*TLFT\!@JS:2%&%FAW3!TSP";((4-]?H5X:+;KFX!TUU:7'
MO:=BQ[*O65\7?L&.E'>9?X'*E2@G5Q]=:D!:DY0W:3JQM>NO:J*]>Y#!Q\?8
M6(7FTDEUX#2I+-5R!O5T1BL2LQ]"X*6TL!.3,";JJ\\HTUU-NP 1>Y.ENOUM
M5N8ZL6@>N[K;15RRA>$KG[7JN$6,3^#ER0>PAJXF8!E(<#HX_+.'!(BP%)$$
MQGM)YENN17:+/=AXST^!K4K2+$CFT4]\(G")PB<(G")PB<(G")PB\.3DUPL:
MD)EKHBHZ$@RQ-LFXUWW0W78,'#I'1?5-1)39'91+7"FJ:J>^=,[8U4TVSC;!
M%RXU%X\W8^;1SJLZ/U-26\I+5)V)LCN"#!#IX/1C;QAUDOGM)U%%5<N_GAA6
M*(VI7%(/C4O5F6D\55:/%=8]H,U33><+TR#C6)Y,OR@TW[%^LO>L3QCNWM.0
MM@ULXIU4CTFUGE%D)+;37K]V&F=>QZJ+RZ1VMVP1'J5!"[P?6,ZDD,D-;8A9
M.<LYDZC^T5(J3$I#0R0HCA,@:#KK:V@N+WS!O-;EO;N7Y5<Y;OGW3#RGIT>E
MU=T("!=BZ]K>92#K"+9SV2=CA485I%_978BXB4YTE0R&5? :0F.8_!QH625_
M+<S1<RR&JS4'+SH>/HE2S;&U]#8._%WZ<AN2+G>.PH_JKQ!>[T]@[5](SO2N
MOUY_TYZQ]^6-M2V*VB K;KE05V&Y\C88*PHV\MUR^NF85N!B8A< <%3BCPDH
M)ER.Y$6%:BVS8F2S=/5;RWDU(M8WM87ONUMSZJ.KI\6;M]$:DZEG $$I^O;
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MW'M:4=K+RG,TOEZ&J/L3U'NV\.JE:R"2"A0 4"BUT9I6BCD %OLH9>2.SH-
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M=OY%D6E W)2UH#Y'URKO1A#]BFT'8#)'+D[ )"(LP^"47L>.&;*M/<S&ZYF
M*,E CL/!'<LE<'C]1TC[S:]9*'K(CNY4OIV//FYS?S%K=== !L2+M<R6#$(R
MRG-\VG+XS&2C51@]%QU8PB 0**,%<:*,M; )1\I::+=9-%YJE.M-RC=L6W?-
MTBIY^?@5A^$3A$X1:TCO1TZ:[.3>[$&M0 EI/V&K:\A-Q#QIS?L%' $+I*I*
MADE2C'*3 >'3CT]'5[)@Y4F_D1=DRBUA&L-(E[XVHXPT*M].Y;K;R?HNHSC/
MAW3:'5@-BPE]$'<\AH&JX-#K!<W+V2TD*@>J(!;T !3-N^,2"5@X)YS*W3*J
M]%M(3-JQ*!GDJB4H,R,<?CCV E7-<];6^@Y;>3?W5;V+]?)NF"[70N:3 8['
M=B=0[II/HMHX"RM@7?=9*PZ_3%\O%=1Z80"LW(UBG-(RL&D1%'?$DW#KL!.(
MZ@^-E3FZWEO]JKQ+>C%CV4V2*2665K")$8E5>1>> :\#'-X7)>N BN'M46U7
MZ/K^HL@S/6W&27KFJV6J@Z(IQ&L8QNO*&T*WD!LE^[Y>?KVY.RODB7AYNQ)$
M:A('\7D V*67 I4(/R"76[.3,NCL-[ :7NU;%X7,I$^KNOR[$BBAKOK#Q11N
M?F&SV:-GL-9/5(?@E_!;DYK;]Z]%]TEMN1VC+)S)['CCEF]<66T ::$YN[TV
M"3/M-2]_1Q+2#J*,:[@*T8B-69K\OF&!5C=@R+.+*G<L/ES:HV/%6X T\]"#
MX;^3EGLOU?6/]8VO7HV2CY='>>QR3&U20M5Y'S( 9V#&7 6C[P6XU4RY3+ &
M;F-JIN--VJCESG=?39IG?7)4OK?K6^BRA&4]$B!ZQ;;D;K,6E0.;'9W.(VXE
MME]A1[\8:G47C0!Y%$XC"9U'8A$LCG$>2<@[ABV^\N!#6<39CH?I((BWEY(E
M_/3R;N<&]U@CCJAV*,%B-?2 K$# 2>=?)S6<SLXVZ*F#$&%3R]I5-&#"$2!,
M"((V)8=?P\F/:-);,1,1(R^4L0]F2,K@Z/("3Y5! [%P>OH#]N_Z%(D$Z334
M,6J163R6!KBZ*9T?"XKL&'%E24^B5)G)P<832P?:#=%NUL$FXE ]PU&L-RXT
M#(-)I)V\C>J3=,5&RI?0]?O#4;N]YV4?D_#SL)_'SM?BK$CL-BTZK>R878\@
M /YV\6E_ORJ>?5D!;D*N)O\ ,/8FXT[DT7-_"[!I!7T^)PV'(T\6:DH\]TD#
M(@.[EMNZUK>=N3D64*]*;*21#R*,/89!K/7G<GDI6:I6YV"L4P 0D@JC ;UX
M\)6:4D J[1I)C1<=4,5;/(;%XGY[*&*QX['I)#24PG!+^ C<.O;=NU4[#.MY
M%]3KFH).TB:NHBX9\8C$P5:IE#(RLYM94@F2CZ*.5F6I.)6;K7\M)5GB4#WK
M$D(/)O9T*?J:98C7!+^?GO&[3N==8)$NLET!6D.B$JL)G,(>QN:L9T855,RA
MUN,$TXB7E; [&6$D>%=(H4LFPQE<,"=20OV+4-<0\,>U@Z"+@@JQ)$\FG_/T
M_1R:+8)PJ)PB<(G")PB<(G"+FM\3J16D[["]IFL>O_L=6@RJZF\*9]#0=0WS
M:%5@61#L)WLLVE;9(.@T'DP4>1?RBO%T1"[QXW5<(+"PK]%35X('JH%Z- LW
M0:N=?3F#2/"KB!JB>Q/Q8:Y@C*]^UA.  NC+BV-:_DG:"[))!3,[@5BUW2@@
MW)XD9F3L%)5"$0<NR$G3,L7B<HFKU[.#F'LG=+D=Z<MNL?L\JMOH=!O&MARW
M\^MR*O';'Q4^PU ]G.T]9P]K2$R 4>"N1:+U6ZC,F4M-VG _#;&=R@5@2,V+
ML;&SF&[VBW=UR_:#X")37$G$&J,F3/-4%MJJK6@@:VW?2[+] U4(2;QA.S<6
M'"6K&P^I<YU"G^Q@]M8P:"2%"*=E_@9M+HY'XU'J?9,[Z+-0,@DP7LQ8T<?K
M#)#:'GGJ_P#7QP=ME H/9E4-'7_%T!W7#M^G.!S6![JR2?>)=>-O5_V%@["6
M0Z(2"L'22Q$C4SXY'; B1:*>+]+>JP<&;>MI>1?!-)30L'C+X\+<M6+@ZO)C
M!1#T$:.LPS<F0"V_6V_KL!/TE8IV!\5/LB<DG;.#53<=(1.)53.ZD?Q*U,5X
ML-6@8,!XCU==5;&CLV3>7Z_-F8\J()D$YO*9C#:.V*,P\YVKU@M#3<1LIF0-
M&EP=QOKSL)%M-^XC4\@-BLL=^)I>E76CB QMS2X@,MV[OX$O%IJC9,PFG8!N
MX\44'U(4@U.F)1=*CN)R>)0"8DK9?L(Z%G49%;,A8B.UU"( UPR3*F46)UY.
MYQ;ZZ<ITY.ZKS^&QW7OWM'8%HQNZ,5>H+&TO5-P0KX/8;(HD\"Z3:^NW=-E8
M[('!V?39*3;)LNNL>/-"[)M&,).SQ9CN+601:+ZD<T "U]Y'>#3S==;>.%8G
M")PB<(G")PB<(G")PB<(HSNF4EH/3ELS4#N@F<A]9SN4AE'2.KEMH6C\6*EA
MV[AOMG&JZ&KQHCLJCMG&JJ>-M,YQC;R\*HU('76EKIY=7?SLK8[N+&NV$(C8
MPAT'Z?=J1OJ/6:)/EQ,O[6A;2RX"[J*S1KD@+@9"N$GS)17T&\@T,*M': [1
MFFHN5Q  &GXSAOW@6\OT*<>LG<RXXOX2>/$%[)'!]WRU2C#'9)U&HA%!%4H,
MH\TBS4AI7 Y1LZD#1VN@]&%7*4K?-DEE_;";5<9HD.346H-0#SJA S6&FX<^
M_E6*&/&"7CTAQ%#'64IJ;@]@SV)7]@=;0=X.KF.POLI5/6=M*H,\<0T>O:CL
MU)+AB\CS''3&OMAH-H:2V+O"#5FW(53+U^QV;7M_ROUA?C#,I),HY$C/7<K'
M])U,H,!@Q-O9HXW@G'I9=?92AB,A.,\0X;L (!)EUK./F\>0<&DS$=DX=[L;
M%D&K\5H3+I>_-]-C]NO7Y]Z^2&>*),I*/GMOH0*.JP$ATP\-CL+6M72:?1Z#
M+AYAW3EU]!SX606<^$O79_4<SB$+:" D2@LGFLD+#W >!P20R.2L0VY5+>3E
MS/;\D#RG[2!JHXKCQ9K,O,\T*C:L>5I49F1>%EF)E1Q>-OY[H0[HW>ZKB>0R
M;)288>'/XRBY$%P[8B B\-E;4*!,OFQ4.=DL<<QVE]+]CZ53+;KZN'6T /9O
MKV.R%Z(WQN'!N(#SXCJB5W-RY>M9#7 $C<X5DTD537!2'<6[8%-Y"<;0,CF)
MR-0;TPGH>301$5(\!%CX!X/E!_.'+'%57+H3?07OIR@M%A\H<RW1U#8C.WJF
MJ^V!PYR''V?7<*L1@)>JI+O!;.:QH9)6HYVNAC""SED@3T;+JHXPDHJEONGC
M&F<8X5ATT4B<(G")PB<(G")PB<(G")PBYV?&,F=IC+"M]C";OO:JF58^$UVM
M[)1=I3]QV#5C;-OUK;M,B8?)S2$(/A4SV1HR2F6&S(KJZ:.6CW=NNGNEY->%
M>S> 0#=S1J.0WNIKEU)/(1WS\-2#!>PW<16'2RH^QLWF<8,=MK[-@IP?H-:@
M9/ 59J+)SERRE311]84G92Q@<1>M)D#<M0<C2("V#5LF5+Z'=O'(.6_67U=L
M?$0NRBN\3*@XCM4)>'M6?5I=*LS$>..;ALO%[H=OT)D]AA]C/&:+%C7*E#P8
MH[T;UO*?*A(':1-^-2<LME" "U^<D=86R[_E>>\:]TO&F[3;4FC+_A(Z=+E'
M0,G,,VBA7\FQ6C,HMX=Q;N8E0FXC'85;&UB12RAK>F"A7:;X*.T30M5U7[&2
MZ9&D*<W.?)?K*N47MK]OJK#DU[W=WVD"YO%+OJQ:R[J5J-,0NN97"NH'B8S]
M!6O7A\#<57EJ%@W5=S2)O0HA+=RL;(N7%WV*XW.;!QRQ@A& SN/;B-P171_5
M5#!Q2>5S!UC?-?P+^N\WBB]C(A,.WM)TA9-;,VM=]8>Q!4/(6,%5TLBK++I"
MC*AMAX0W.$KD6,RPR_;3N0-LDW=&1VLPCAU#]P<RL@S&["CR94:T$ D'>-.<
M$V')IWS?FY5YUU>*-?O7TQ>&T)D_71^H-M>X)5M,) SLV40^_"-/=./#MG\=
MJBFQAKL$]800U?A;L#+G,&90,K(!;(/$VI$7 IC*BDUF!\@;>V_R:NWZ<EO^
M0%L0Z=]UK]NSN/<%+6+BK]JU"*=QL01O$X;(P,N#(]9NYSSKD"]\LC)SZ2#)
M0XDT57;%2ZH^,15%J68Z99-L(.'&FSEMV?HMY4<T  B_XO+SM#MUNOSE;>.%
M8G")PB<(G")PB<(G")PB<(O)= 03]5RN^"B7B[Q,>D[6=#F;A5TD(>;D!2;E
M19'?==,8_4W?#]%<[:LGF^[EMA-;;.^2+Z\L&.7V"F633)/5ILPU(Y;(^O:L
M=UM'&[+#OS/6,--W">B^S;"GH=EM-%<Z9WUQM@BBZ*475\+L6U[7 QANE/;J
M-A9!8!]XLX)."+\# 8=63'0?H_4<) F"D/@,48$!H;1DQ)N!29%^W</U%7&Y
M/L7GO.NM-/K'KNU%8(&3EE4PR=0&!8:(89@(_'+&E-=S64I-8NV]%'LD'$GJ
MN%%V!?<=L3$.QBR@QTUR0?\ K!5N;6Y#]EQ]I4E:Q")Z;OU=(O'=%"J^SHHI
MJ$&Z[DG.[W4GNX?[X;8V>+[DM-"&RKC*BFSW35WG;*^N%,%1?.K!80MH826A
MT553D/KGM]-6/"%-#GM%9)R0]L:;L\ZD_7G"""[SUW"_K2R*2J_G[IZ;8(OK
MWBD6W<#W>\: ;NA!%\7%.=PX[9P,+%,[[$R@];+;*C(B1V54R^>MMDW+O*F^
M7"JF=]O*1?6P!A12FZHL0+&JJ-TFBBC >T9J;M4'#QVBVWW;I)[;-T79!^Z2
M1VSE--P^>+::X4<K;;D7J<(G")PB<(G")PB<(G")PB<(O(D $1*@)N+R!BF3
M R002 FQJVRNB) 089+#R3%7=!1);1-VR<+(;[(JIJZZJ9RFIIOC&V"*+:VZ
M[TO4!=,[6T"&14NE5%7T=H]9.R[A36J:73D*57PSS2!%XED?$$Y7(=6#G.F2
M;C!-;)%\]SHAE(ESX3W3O\ 476ETUJ^:=+9WT;@B>:CJ:54R?I./:1]!8WM!
MHP:$.!"6PML;(*+D=AJ3G91%(B2VV6VQYJKCR9\[!5N;WY;W7@9\.;I9NI!%
MW%$ 'CNN9A(I['7S\_-GY!U*I9.@MFR A,7[V3KO+&;$+!C<=E_L:PUY0$:'
M0 5ZQ'-E!3#U<ESS\ENX!;P*,*H\*CJ3 8&0B<NA/PHGS4RVFAN>'3,O#GW+
MP7;5HVW"& ? >6::Q 5#S%MRYK@7$E@PN39*ER$G8$G)LCJJ52XFW,!;Z WP
M!3,ZZ"]1'49&Q#-,BV@,+$:#@H1,5))N%)!(OU=?R,G08X*?$2=C(!"U:O9=
M)5 Y0<3;%W:9EZV,OR;53".I4S'GYSW]_?LOQC7A^=/(<ZCKR,4B$";Q0?3P
MP$@Q/3-,>T;=?["4M2F=UA>9)L,(/J\G:RQN/E"31X32T77$.'C@&NJ-W)<^
M'Z=Z\Z->')TGA[9ZTC= 1<6V?2S$U412*RY;5J;3@MFUFR1%>M2)?(2-AX-<
MUJ1^/0L/EC#8VWG<A<@0(Y^\R[U)<]__ (/A U5N(E%(]!(I&(/$AB(6*0V/
M!8I&0S?==5N)CT>&MA 48@HZ57<J(L!K-LU2W<+K+[Z):[*JJ*9VWR5%D/")
MPB<(G")PB<(G")PB<(O*?@@A3=90F&%$=W YP'<;OQ[1WNN)>*)*NQ:VSA%3
M*HYTJBBJX9;YV;+J));JI;;)ZYP1?3N/'JNF;Y1BS4>CTG*#!YNV1W=,47F$
M=7B+-QMIE9LDZPV;X<IH[Z:+X;HX5QMA+3S2*,1]'5D,N277ZWC2*EIS>(UY
M!SDD>.'+W.L>JYU93N'("6+I55B#=L][<GJ+TD(;LWY=F9PS)N'35FS21)?2
MW(+GOVOX O+E?7*EYI):QE1^!!%R-0R>93&$M6K?4>#;2.?0XW!)63+1]EA
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M%6TF@LE0MY9\[ "!+]V51< -Z9DS9=F82'OGZRC;9FT]6W2<+E6V[KZ>??6
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MD.-JZ8KIW-C8XVS.D?&2&.>!D=(+B-KL[KY +!QRW+B;-*R1$TR/:,UFQM>
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M93&4WA9D.I>1Q8!+F<0F+A5Q=3RC"DJ1C[_V-5IBT5HO,H^\5A^SXJ7UZW_
M!-OIZ_*KZ42ZMAY7S9:Y!RXR6^VI"DT;$D(FTD>T72+.4XTO+64!D,M@K.2K
MB]4=R"41D90,HGELYT]G/'#L..*A\_,J8^$3A%4WME]3L3_UT]_V''-MX)=4
MU?Q#/&+6>$W4]-\<[ZBY#KG\/^S9]#N^%GN!DF>3=W8G:-:A*N#QB)L'DT;6
MQ&H7'\R9Y+?,WDLC$%1C!ZW 1=V1&AQQ1IN7407=Z(>CDZC"YI8\3FL\R.EK
M.E80R,&03LC9G,GJW-<&D-87-:",UKV6)!B<,;\-A#F",0T?3,SGO(CV+Y'9
M R^1K@2"YX!<0<M[*_O28:8KG:V6L@J655&P["]E[6M6KJ_(B8VR=PZ ,*_J
M\(JZE@:*&BPB&[2"1Q\V5;#VSASC+L\SV(9:D2V-%)3#VNBV^:!\ JJR:>&(
MM8#'$(H6DR-C<YL>=['. N=7"]G.LHW$")=@6SLG-+200S2ASB))3+,ZS'/
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M_J:B_-G[R?A-C_\ 6M7\L?=3Z)J_?MJ2O^&)?U''X(\&OZFHOS9^\GX38_\
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M;1)1^ZV5M_ CA+<GT)%W -)Z<PVY#22T$]-W(:7.(!T!<2-Y51PNP( -&)D
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M4,M0ZEJ(8W-A+&,=6UY-7.'N>0(FPQU$5953.!!;4@0LFF]*(4AE;2SU=9'
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M&R;,\/&]IZ#8L3;-+;;=)J7:-;:20)-D]]]]DT'J:R6FV^VVNN,[9SGT?C^
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M2^1K@VY)M<DGMG0T?GP:M.S@C_\ ,Y!:"G@IFG^2TFI93QQ,+M;9BTN( %[
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MC@V]SE!#;DFUR2?&3#,/PEP@PVBIJ*&0;5\5/$R-CI"2PR%H%B\M8UN:U[-
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M*AHK=1,9%W9!VX(KZ#3D!KR>G!J1%RHJHX8@YW,9@#&M-5,H1\>-;19JFW;
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M;-\P]2R\C9 ;%K7,(Y'!Q:>X6EHL=18N%KD$5Z_GR>11B*H-X.@S6 O;"*2
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M&"&2(]@W\_;R[;>A:MTD_.V^GMYOES]//,IC&QL9&P6;&UK&CF:T!H'< "O
ML !N MWENE\.GXI)C\HSWYLQGG/>%_LA3]IM\=.HC$?76?%_K.7H^&W]:XI^
M$WWQ_P".OLAS4U@'?W!X KX\*B<(G")PBB><7E5-;R(/%)K,&80X:2'N4FV[
M(N];BAY@QK'0I>6$Q@]Z*A (Y(MO>\#/3)Z!#&CVBH86^=DT56NA+>?GO7YC
MKYJ N6D8(9/0CTO$Y,$AQU@AEUNLUD<AE;V""Q[?_P -C0IA2;"C41=O16ST
M>+DD?D@0JZ9$8X<;CR*7.$3A$X11!;W[7!_]-<?_  8YG4/JY/@CPKW@WN[
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MMQ\AGD3Z!3KQ^X!_^5);^MX_"7&??3?F]/\ NDZ>J?;CY#/(GT"G7C]P#_\
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!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>33
<FILENAME>g98473g97t57.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g98473g97t57.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1WV4&AO=&]S:&]P(#,N,  X0DE-! 0
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M;V]L      !#;&)R8F]O;       4F=S36)O;VP      $-R;D-B;V]L
M  !#;G1#8F]O;       3&)L<V)O;VP      $YG='9B;V]L      !%;6Q$
M8F]O;       26YT<F)O;VP      $)C:V=/8FIC     0       %)'0D,
M   #     %)D("!D;W5B0&_@            1W)N(&1O=6) ;^
M  !";" @9&]U8D!OX            $)R9%15;G1&(U)L=
M $)L9"!5;G1&(U)L=                %)S;'15;G1&(U!X;$!S0D&0
M    "G9E8W1O<D1A=&%B;V]L 0    !09U!S96YU;0    !09U!S     %!G
M4$,     3&5F=%5N=$8C4FQT                5&]P(%5N=$8C4FQT
M            4V-L(%5N=$8C4')C0%D            08W)O<%=H96Y0<FEN
M=&EN9V)O;VP     #F-R;W!296-T0F]T=&]M;&]N9P         ,8W)O<%)E
M8W1,969T;&]N9P         -8W)O<%)E8W12:6=H=&QO;F<         "V-R
M;W!296-T5&]P;&]N9P      .$))30/M       0 [_^-0 "  $#O_XU  (
M 3A"24T$)@      #@             _@   .$))300-       $    >#A"
M24T$&0      !    !XX0DE- _,       D           $ .$))32<0
M   *  $          3A"24T#]       $@ U     0 M    !@       3A"
M24T#]P      '   _____________________________P/H   X0DE-! @
M     !     !   "0    D      .$))300>       $     #A"24T$&@
M   #-0    8              Y8   >7          $
M         0             'EP   Y8                      0
M                   0     0       &YU;&P    "    !F)O=6YD<T]B
M:F,    !        4F-T,0    0     5&]P(&QO;F<          $QE9G1L
M;VYG          !"=&]M;&]N9P   Y8     4F=H=&QO;F<   >7    !G-L
M:6-E<U9L3',    !3V)J8P    $       5S;&EC90   !(    '<VQI8V5)
M1&QO;F<         !V=R;W5P241L;VYG          9O<FEG:6YE;G5M
M#$53;&EC94]R:6=I;@    UA=71O1V5N97)A=&5D     %1Y<&5E;G5M
M"D53;&EC951Y<&4     26UG(     9B;W5N9'-/8FIC     0       %)C
M=#$    $     %1O<"!L;VYG          !,969T;&]N9P          0G1O
M;6QO;F<   .6     %)G:'1L;VYG   'EP    -U<FQ415A4     0
M &YU;&Q415A4     0       $US9V5415A4     0      !F%L=%1A9U1%
M6%0    !       .8V5L;%1E>'1)<TA434QB;V]L 0    AC96QL5&5X=%1%
M6%0    !       ):&]R>D%L:6=N96YU;0    ]%4VQI8V5(;W)Z06QI9VX
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M50
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                        _^$_
M]&AT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"\ /#]X<&%C:V5T(&)E9VEN
M/2+ON[\B(&ED/2)7-4TP37!#96AI2'IR95-Z3E1C>FMC.60B/SX*/'@Z>&UP
M;65T82!X;6QN<SIX/2)A9&]B93IN<SIM971A+R(@>#IX;7!T:STB061O8F4@
M6$U0($-O<F4@-2XS+6,P,3$@-C8N,30U-C8Q+" R,#$R+S R+S V+3$T.C4V
M.C(W(" @(" @(" B/@H@(" \<F1F.E)$1B!X;6QN<SIR9&8](FAT=' Z+R]W
M=W<N=S,N;W)G+S$Y.3DO,#(O,C(M<F1F+7-Y;G1A>"UN<R,B/@H@(" @(" \
M<F1F.D1E<V-R:7!T:6]N(')D9CIA8F]U=#TB(@H@(" @(" @(" @("!X;6QN
M<SIX;7 ](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"\B/@H@(" @(" @
M(" \>&UP.D-R96%T941A=&4^,C R,"TQ,2TP-50Q.#HU,#HQ-2LP-3HS,#PO
M>&UP.D-R96%T941A=&4^"B @(" @(" @(#QX;7 Z0W)E871O<E1O;VP^4%-C
M<FEP=#4N9&QL(%9E<G-I;VX@-2XR+C(\+WAM<#I#<F5A=&]R5&]O;#X*(" @
M(" @(" @/'AM<#I-;V1I9GE$871E/C(P,C M,3$M,#54,3@Z-3<Z,#DK,#4Z
M,S \+WAM<#I-;V1I9GE$871E/@H@(" @(" @(" \>&UP.DUE=&%D871A1&%T
M93XR,#(P+3$Q+3 U5#$X.C4W.C Y*S U.C,P/"]X;7 Z365T861A=&%$871E
M/@H@(" @(" \+W)D9CI$97-C<FEP=&EO;CX*(" @(" @/')D9CI$97-C<FEP
M=&EO;B!R9&8Z86)O=70](B(*(" @(" @(" @(" @>&UL;G,Z<&1F/2)H='1P
M.B\O;G,N861O8F4N8V]M+W!D9B\Q+C,O(CX*(" @(" @(" @/'!D9CI0<F]D
M=6-E<CY!8W)O8F%T($1I<W1I;&QE<B Q,"XP+C @*%=I;F1O=W,I/"]P9&8Z
M4')O9'5C97(^"B @(" @(#PO<F1F.D1E<V-R:7!T:6]N/@H@(" @(" \<F1F
M.D1E<V-R:7!T:6]N(')D9CIA8F]U=#TB(@H@(" @(" @(" @("!X;6QN<SID
M8STB:'1T<#HO+W!U<FPN;W)G+V1C+V5L96UE;G1S+S$N,2\B/@H@(" @(" @
M(" \9&,Z=&ET;&4^"B @(" @(" @(" @(#QR9&8Z06QT/@H@(" @(" @(" @
M(" @(" \<F1F.FQI('AM;#IL86YG/2)X+61E9F%U;'0B/DUI8W)O<V]F="!7
M;W)D("T@4DE$15(@0CPO<F1F.FQI/@H@(" @(" @(" @(" \+W)D9CI!;'0^
M"B @(" @(" @(#PO9&,Z=&ET;&4^"B @(" @(" @(#QD8SIC<F5A=&]R/@H@
M(" @(" @(" @(" \<F1F.E-E<3X*(" @(" @(" @(" @(" @/')D9CIL:3YR
M<C4P.3$V-SPO<F1F.FQI/@H@(" @(" @(" @(" \+W)D9CI397$^"B @(" @
M(" @(#PO9&,Z8W)E871O<CX*(" @(" @(" @/&1C.F9O<FUA=#YI;6%G92]E
M<'-F/"]D8SIF;W)M870^"B @(" @(#PO<F1F.D1E<V-R:7!T:6]N/@H@(" @
M(" \<F1F.D1E<V-R:7!T:6]N(')D9CIA8F]U=#TB(@H@(" @(" @(" @("!X
M;6QN<SIX;7!-33TB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+VUM+R(*
M(" @(" @(" @(" @>&UL;G,Z<W1%=G0](FAT=' Z+R]N<RYA9&]B92YC;VTO
M>&%P+S$N,"]S5'EP92]297-O=7)C945V96YT(R(*(" @(" @(" @(" @>&UL
M;G,Z<W12968](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]S5'EP92]2
M97-O=7)C95)E9B,B/@H@(" @(" @(" \>&UP34TZ26YS=&%N8V5)1#YX;7 N
M:6ED.C1!0S R.3DV-D$Q1D5",3$Y0T(S.4,X-C0R-#,T,D$Y/"]X;7!-33I)
M;G-T86YC94E$/@H@(" @(" @(" \>&UP34TZ1&]C=6UE;G1)1#YX;7 N9&ED
M.C0X0S R.3DV-D$Q1D5",3$Y0T(S.4,X-C0R-#,T,D$Y/"]X;7!-33I$;V-U
M;65N=$E$/@H@(" @(" @(" \>&UP34TZ3W)I9VEN86Q$;V-U;65N=$E$/GAM
M<"YD:60Z-#A#,#(Y.38V03%&14(Q,3E#0C,Y0S@V-#(T,S0R03D\+WAM<$U-
M.D]R:6=I;F%L1&]C=6UE;G1)1#X*(" @(" @(" @/'AM<$U-.DAI<W1O<GD^
M"B @(" @(" @(" @(#QR9&8Z4V5Q/@H@(" @(" @(" @(" @(" \<F1F.FQI
M(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @
M/'-T179T.F%C=&EO;CYS879E9#PO<W1%=G0Z86-T:6]N/@H@(" @(" @(" @
M(" @(" @(" \<W1%=G0Z:6YS=&%N8V5)1#YX;7 N:6ED.C0X0S R.3DV-D$Q
M1D5",3$Y0T(S.4,X-C0R-#,T,D$Y/"]S=$5V=#II;G-T86YC94E$/@H@(" @
M(" @(" @(" @(" @(" \<W1%=G0Z=VAE;CXR,#(P+3$Q+3 U5#$X.C4W.C Q
M*S U.C,P/"]S=$5V=#IW:&5N/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z
M<V]F='=A<F5!9V5N=#Y!9&]B92!0:&]T;W-H;W @0U,V("A7:6YD;W=S*3PO
M<W1%=G0Z<V]F='=A<F5!9V5N=#X*(" @(" @(" @(" @(" @(" @/'-T179T
M.F-H86YG960^+SPO<W1%=G0Z8VAA;F=E9#X*(" @(" @(" @(" @(" @/"]R
M9&8Z;&D^"B @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB
M4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z86-T:6]N/G-A
M=F5D/"]S=$5V=#IA8W1I;VX^"B @(" @(" @(" @(" @(" @(#QS=$5V=#II
M;G-T86YC94E$/GAM<"YI:60Z-#E#,#(Y.38V03%&14(Q,3E#0C,Y0S@V-#(T
M,S0R03D\+W-T179T.FEN<W1A;F-E240^"B @(" @(" @(" @(" @(" @(#QS
M=$5V=#IW:&5N/C(P,C M,3$M,#54,3@Z-3<Z,#DK,#4Z,S \+W-T179T.G=H
M96X^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IS;V9T=V%R94%G96YT/D%D
M;V)E(%!H;W1O<VAO<"!#4S8@*%=I;F1O=W,I/"]S=$5V=#IS;V9T=V%R94%G
M96YT/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z8VAA;F=E9#XO/"]S=$5V
M=#IC:&%N9V5D/@H@(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @
M(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @
M(" @(" @(" @(" @(#QS=$5V=#IA8W1I;VX^8V]N=F5R=&5D/"]S=$5V=#IA
M8W1I;VX^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IP87)A;65T97)S/F9R
M;VT@87!P;&EC871I;VXO=FYD+F%D;V)E+G!H;W1O<VAO<"!T;R!I;6%G92]E
M<'-F/"]S=$5V=#IP87)A;65T97)S/@H@(" @(" @(" @(" @(" \+W)D9CIL
M:3X*(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O
M=7)C92(^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IA8W1I;VX^9&5R:79E
M9#PO<W1%=G0Z86-T:6]N/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z<&%R
M86UE=&5R<SYC;VYV97)T960@9G)O;2!A<'!L:6-A=&EO;B]V;F0N861O8F4N
M<&AO=&]S:&]P('1O(&EM86=E+V5P<V8\+W-T179T.G!A<F%M971E<G,^"B @
M(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" \<F1F.FQI
M(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @
M/'-T179T.F%C=&EO;CYS879E9#PO<W1%=G0Z86-T:6]N/@H@(" @(" @(" @
M(" @(" @(" \<W1%=G0Z:6YS=&%N8V5)1#YX;7 N:6ED.C1!0S R.3DV-D$Q
M1D5",3$Y0T(S.4,X-C0R-#,T,D$Y/"]S=$5V=#II;G-T86YC94E$/@H@(" @
M(" @(" @(" @(" @(" \<W1%=G0Z=VAE;CXR,#(P+3$Q+3 U5#$X.C4W.C Y
M*S U.C,P/"]S=$5V=#IW:&5N/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z
M<V]F='=A<F5!9V5N=#Y!9&]B92!0:&]T;W-H;W @0U,V("A7:6YD;W=S*3PO
M<W1%=G0Z<V]F='=A<F5!9V5N=#X*(" @(" @(" @(" @(" @(" @/'-T179T
M.F-H86YG960^+SPO<W1%=G0Z8VAA;F=E9#X*(" @(" @(" @(" @(" @/"]R
M9&8Z;&D^"B @(" @(" @(" @(#PO<F1F.E-E<3X*(" @(" @(" @/"]X;7!-
M33I(:7-T;W)Y/@H@(" @(" @(" \>&UP34TZ1&5R:79E9$9R;VT@<F1F.G!A
M<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" \<W12968Z:6YS=&%N
M8V5)1#YX;7 N:6ED.C0Y0S R.3DV-D$Q1D5",3$Y0T(S.4,X-C0R-#,T,D$Y
M/"]S=%)E9CII;G-T86YC94E$/@H@(" @(" @(" @(" \<W12968Z9&]C=6UE
M;G1)1#YX;7 N9&ED.C0X0S R.3DV-D$Q1D5",3$Y0T(S.4,X-C0R-#,T,D$Y
M/"]S=%)E9CID;V-U;65N=$E$/@H@(" @(" @(" @(" \<W12968Z;W)I9VEN
M86Q$;V-U;65N=$E$/GAM<"YD:60Z-#A#,#(Y.38V03%&14(Q,3E#0C,Y0S@V
M-#(T,S0R03D\+W-T4F5F.F]R:6=I;F%L1&]C=6UE;G1)1#X*(" @(" @(" @
M/"]X;7!-33I$97)I=F5D1G)O;3X*(" @(" @/"]R9&8Z1&5S8W)I<'1I;VX^
M"B @(" @(#QR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2(B"B @(" @(" @
M(" @('AM;&YS.G!H;W1O<VAO<#TB:'1T<#HO+VYS+F%D;V)E+F-O;2]P:&]T
M;W-H;W O,2XP+R(^"B @(" @(" @(#QP:&]T;W-H;W Z0V]L;W)-;V1E/C$\
M+W!H;W1O<VAO<#I#;VQO<DUO9&4^"B @(" @(#PO<F1F.D1E<V-R:7!T:6]N
M/@H@(" \+W)D9CI21$8^"CPO>#IX;7!M971A/@H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H\/WAP86-K970@96YD/2)W(C\^_]L 0P ! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$!_\  "P@!'@)= 0$1 /_$ !X   (" @,! 0
M      <(!@D !0$"! ,*_\0 ?A    <  0$"!P<(#10.!@(3 0(#! 4&!P@
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MEG(V09UQR\2GGZ=5=(Q\:W6;L%P307 !,<69Q+6'X.>J1.!\>?">T3:]3T_
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M=54"6.*DY-TK)/WC-XUEDS%1=,.X7TU4>%5JD9B&;\#:!3L)Y'U&(6\)%"[
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M^'NHNOJ.X?#)Q6<'XPV(CICR*KKR.8AJF5J*3+XE'T%-.*05).^)9JK(JKN
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M<SE=NF>Y?X>.4'J/W+VW8C])^N!W?D^(" \'[B(" @(#MN(B @/H$! ;/V"
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MLF_#WYW[/Q?)T/J.Z*$.FIQ6L"B:A#$434UC)5"*$. E.0Y#3HE.0Y1$IB&
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MAIREA=599I'E*S<$K<@V7;QC\P!(.XU5(TD==R45S/CU$'/Y>7#_ /PG:O\
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M$?>X(.:\12P(B>&24?%_/7X4?7*-R;XP>"9Y"5O*ZOF[?3>?5:;K5^+0B)
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MSMOL=N?V"8@HBP3B-?BH]6>.S6=*OC,R @"PG0!4$4[%U>5G&/QBG\L'C?\
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M9UG7&C#,]LV+ZDTYDY-):MQX5SF$H3VP0')>XUNV4JDU&ZTEXQND?=;A8&T
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MJ^KH3[SI1L:Q#7]<3C_=97,LSO%]1B^Q3LDEZG6I*<08G%$!5*FZ69$05.F
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MCMND9)J199,J@KJ$(W365(!/.JPKZ[I;V>Z7]#_E_P#/LZY#E7A8" A;I4!
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M&9M8!*Z6#67N<04@E""D5F,?$E5;.R-729P=E9%!\*QUUS&C=VV/F!4]2O\
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MZF&[!&@1C[IT5K[HNO*7[<QV3+Q[LK4'#T40:M'*J:Y^=1EG]C->]A&Q#_\
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M;PETK(P_*R99S>I5I%.PNYQM"LC+,TF<!-P"$7<(R-4<,CV-VBX4 TP+QMR
M*+KN?J<>/"#*Q6T0O%Z"M+L]>Q\LDU:\38VKQ6=JPQTI]-JU<2S>IQQK:9RS
M=I/U578Q:4.4Z9$99;,;RRYZ7<=1F>-//,TU>.06%\CIJ-1K.3A">_/C_3_>
M34H=NV5M"KDM6E8@QCV5@L\6D'KHYCL92-2'Q/0':<&L!BX-6N07'GG] PT5
M.Q-ASYK%9QQH15SV0AM ;:.P\6^4;*R.C-T9EFWCR-]D=Z*F2 (,4F4J9C*=
M5R>%"J\%AF8<%,^J^7\J63-SX2YAM\K.;G YVWFK5<+[)'G;1%5X]+E64:H_
MDIA1P^C8I:,CF;?RE5NF_0:)-T$K"5-^?^,4_E?.18?5F] TVH]H?5?$/^[_
M .,/3V_G?<Z?#\_]7WD5]YM1^/[_ /\ 9_8ZC-9TJ"IHV$:KQ>WF &UV63N-
MD&.H]21]VK5,@@66GG_;H1O&R+\&K<'*P=T#@B3L(7L],F^'Y_ZOO(K[S:C\
M?W__ +/['46<;R_-LO%9V&!<A /%\BZ[(ILU*A4R.I0Z5'T) (Z,+[_#)K2"
MH.!73274;(B@W<G%<#D(FK=@/+&:#_BF<LOO%HOXS/M#UYW?*:1?M7+%]Q#Y
M6/&3UNLT>-'6?T)=LZ:N4S(N&SA!72C)K(+I',DJDH4Q%$SF(<HE,("+LBON
M=8)"2=<QS@7R/SV%F9=6=EF->SFC-RR,LH@@T\J=K*Z>LX6%NS;-F3)$ZPMX
M]B@@R8HMVJ2:)2QYV4UZIG++[Q:+^,SI#>>7)*5L$1QS36XU<EX$L?R,C)$I
MYNF4QN$B8F1ZZT]SHT&^A.?'2)RO!=D26\0B+1H[4%<%$TTE5L^'Y_ZOO(O[
M7^XVH_3_ -'[/6?#\_\ 5]Y%_'Z/]QM1^[^6!\?\.WJ*U/1J_1&TPTIO%S>*
MXVL%CF;?-H1E&J2"<G:+"N5U.3KL!T,_?D)1P4JSM4.Z"B@ ($*'HZE/P_2'
MJ^\BOO-J/T_ZUL+ODB3D!Q1?EX_\A3*16URSTC#WHU(KV5,;$=?9BRBDQOOB
MEGQ2NS/3)+JMD_(FCQ0JQEDTD%KF?.QF_5,Y9_>)1?QE]>.0Y0O)9@]BY3B!
MRID8R2:N&$A'OL]H#IF^9.T3H.F;MLMI)T7#9P@H=%=%4ADU4SF(<IBB(=#;
M(M"S_!:X[J>.\#^26?5U]*N)M_&U_.Z.@F]EG22#=5\\66U!=TZ6*U:M6: K
MKJ%:,FS9DU*BU011(5/.QFO5,Y9?-_2)1?C^;\LOI!.=W)&5GE.,HK<:^2\"
M$9NDL^($U3*:@:3,?#=@9>0QA6^A.?'/B%=B^.DL+=(&+-ZJ"PJI)H++K\/S
M_P!7WD7]YM1^G_6!O\@ ]H<?>18"'I 0IM1^,/B_W_\ 46J.D0%"CGL33.+F
M\5J,DIV;L[]E%4>I(-W=ALC]64GI=8@Z$?O/9:065>/50$ 474,8"@ ]G4I^
M'Y_ZOO(O[S:C]/\ K5U??)%/E!Q'DR<?^0JIXG2=$=)Q@5&I%DI<R^"ZBR,U
MB$AOGB7#IN5R+Y=-==J0K%LY5(HHL5-!2YKSL9KU3.6?WB47\9?6MF>3*MBB
M). G>'7*:8A)N/=Q4O$R6>4!Y'R<;((*-7K!ZT7TDZ+EH[;**H.$%2&352.<
MARB41#J!9+I%%PFK&I>0<$N2E!K"DB[EUXF!SNCHINI1]W <R#Q=;3UWCUTH
MFBBW*L[<+'2:MVS1$4VS=!),G^=C->J9RR^\6B_C,^WU7CSMY'RD]:.*BJW&
M[DK ^Y>IWYR1*:IE.16E1<8CH3,6L61OH+D%W3<KCRY=-<[9,K%NY6*J=5(B
M*@&^'Y_ZOO(K[S:C]/\ ^'Z/7AE-J+-QLA#3'&[D!*1,JR<QTG&OZ-3G+)^Q
M>)'0=LW;=6_&36;N$%#I*IG*)3D,("'IZC%!N]3RR +5L[XJ;K4:^#QU(#&1
M-(JI$E7[PP&=/7"J^B+NG3I?N)E.NY<+* DFDB4P(HI)EFOP_2'J^\BOO-J/
MT_Z%%EW1\IN7&]Z.#\@$ACIS5%"L5*C50?R0NLGL;04XQ(+T9)<[4JGE;L%E
MVP)M$U%$S*J%*D9K?.(D/5SY+?>33?QB]:Z7W%*P14E!3G&+D5+PLRQ=1DM%
M2%!I3IC(QSY$[=XR>-U=$,FNV<H*'253. @8AA#[?49SZ_U+**XG4<WXD<@*
M=6TGCN0")AZ'4B(*/WYP4>OG"KC2W#MV\<F*0%7+MPLL8B:20'!)%(A)OYQ$
MAZN?);[R:;^,7I:MCW=\\V'C<['!>0;,T=*:X<K-[4*HD]DA=YH_;"6,22OB
MZ:YF@&\I> LLV!)J4QR"L< 3$@?#\_\ 5]Y%_>;4?I_UK)G94+%$2<#/<;-^
MF(699.8V5BI&BTYTQD&#M,R+EH[;JWXR:J"R1A(<A@'T#VAV" #UH*)?*OF%
M>1JF?<5MVJ5<;NG;XD5$4BJD;F>OE?'/7JZB^B+.73QTIV&7=.EUEU.XF0R@
MD(0I9E\/S_U?>1?WFU'Z?]":9W1\?D+Q[?C@^_D-'Q^T%+'GJ%5"1D/+*8Q1
M$T<B%Z%%8K+L\>^%9PW\4B)3) L;M(#7><1(>KGR6^\FF_C%ZU$_M+2U0DK6
M[)Q=Y$3M?G&#F,F(>3H%)=Q\E'NTS).6;MLKH@D5163,)3%$.T![#%$IRE,&
MCH.B5;+:VVI^=\2N0%0K+1P[>(Q$/0Z@FW%X_6%P^>KJK:4NZ>/7BPBHY>/'
M"[E8P% ZH@0H%F?G$2'JY\EOO)IOXQ>E;U[='SOD!QRD!P;D"S-'P.Z)E8/*
MA5$Y&2\N@*BF*D8BG>UDETF (@H_,LX;BB19$4BKB<Q2D_X?G_J^\B_O,J/X
MP.AGH4SG.L*PB^D\0-HN:U;6<+0:LW0JHNI'B[\3Y8B0Z6B(F69/?)T ?1KH
M7$<]!%,';58"% --:)I&PZYD6P-,0Y(0L[D\==H!%DVH%,59S]9O$2U8/(5R
M(:,@+ D>^CHV58+HD<%(HU.W%N!%O&)^:7BL3GH%&L3'";6W\ WM$_=48Q7/
MJL1%*U6I=9S9II-1#2$G)7%B6<+FFT@6!I)D5.B\;+(&\7U(K3,9Q=HY[$6S
MA[LD[%R%=BJB[CWV>T\6IZQ!R24Q#0222.A)%;1T;*((O6B+4$/$KI)B4W=(
M4H1[+G\?E]QUNZQV$\C'<CJLY6'9VQ,^ID>RK-:I=3C:G5JC%(I:,OXQC&-V
M;QX+DXHBLO(F3*U1(W**AL^'Y_ZOO(K[S:C\?W__ +/['1WX-79>W[GR:D5:
M+?:@9'/N-K4(ZYQ41&2:P$E>01P=(H,)V71,T.)Q3(H9R105$U ,D  4QK-^
M('Y0-4_NBU']U>[],QUG6=9UG6=9UG6=9UG2=>$"V_0^-W#??-OR=I!/]'SV
MFIR].965FK(03N;<3D1%MF\DT1?QBBS=;R\Z?85^U AS$4,J!2" UX\</"Z.
M]#>\A+3I=04:57&L_P",C.2SNIQ<>WOU3W71WM]JVKT:R2UIM</6D6-?N53(
MA&/I>1@V32(%-VYD')GR =,C"^%KXR6"CP5]C(?4'$5-X]R.V4[0E>@#OXF(
MXM33:OZC7) 26HS!6S$E'((P!8M](P,NFF=P$ZW0,D=3PMO"_<4E)S5XM\RT
MZ'CL7RJ*UB]621K4,6,CXN:J-7N47")QS6S.;0>8D8ZW13*+?*5]&J2\P1]'
MQ=E>*-#F';,/"N<=I/.;=>F-=T-W+T6[5.B6;/6BN9OK#&REYK[BU55\I9V.
MDN<K/$2L"T=."NT]".JUD&ZU?>-D+"3W+&HSPRO(#/\ E-@'@D=]RU655HND
M<ZLUEH0LXQ+&S#7R1X^B)&/DV1%W2*+Z.E8Y\Q<>3.W;111N95HZ<MCI+J/@
MI_/%/^>;_P"(>AIL=CF:?D>HVVN)>/L%9SVXS\&EW"J]^6B:_(/F'\:,!BJ]
MQR@FIXHQ1!3N]P0$#=@I#P'T"\V2:TJL6&ZV;0:^PSOCO?V$]:9I>PO6-MT_
M/3SUTAVLDZ45<(1JKY)"69P@*>1PJ;P6L<@U9F31"R;J(N/R\>('^$[5^S[P
M-)ZONZ"')FZ6?-^.>\Z#2D17N%(QW2+75TP2(X'W?@*A+RD0<&ZA3D<>*?-4
M%?)SD.5?N>*$I@/V#7GX+[2M#L5GWG/K%HEQU:EUBD<5]#@+;=K*YMTJPN6S
MXRUN&CUUO./U%WP183)&T_'P9W!F5>2FA81:#./%NU3M[ZKI\(K_ $$XP_X3
MT5^XQM7\/\O2J]"/?K7/T7#=@NE53%2RU7-;G/P( F5822T9 /G3%<$3E.58
M6RZ9'()&(<JGBNX8ABF$HJQP=N=OF)/7JC-7&RW^MUIAB5A@;+:IQS99-&9T
M7)X*UV^%),/55W9V2<PZ&691RBQT(A&4!BQ3;LB(()V!]:R!_-(\._C_ "^9
MC]P3:OX#]KJ]/I;>8VA7#)N*/(S3,^(8UWHF,Z'::H8J*;DR$[#5F1>QSPK9
M4BB;D6+A(CP&ZB:A%_$>*,0P'$HIOX,J^WJ;D^1N>SV@W#5*90)#!IFG7*[V
M9S<9M.4U'"JE>[W7??$_6<OW+%A9'ZDNR8.'*J<*A/%C&0(,4&S9&UKJN#PA
M_P#/.*/^$',_]W[;/E_AV]*]T".4-TLV<\<]NO=,,9.UU/,[=.5]8B1%SM91
ME$.%&SXB)RG(J9@?^32IF(8IQ;@42B B'2_\'KA;IEUNE.F[?8[]6Z)9LW&I
M6>TS;BRRXFNF356X6>&/.O%%WCUNPGI)P[:H.%U?<U&3+'MO%-4$4$WWZU51
M_-:\+_F^%/3/^[OK7;_DZO5Z5/G/H]TR#AUR5T[.EE&MXI..7F?K#]%)-=:+
MEF4(Y,WF$D%2*I+*0XB,F1(Z9RJ&: 4Q# /8*Q^#3O=WFGG*3-YV^6S3Z3DN
MF9S'YW=KK9'-PGUV]YP_/] ML"XM#]9S(RR$-:Y^07: ]=.%(QK*I1*!TV;)
ML@C:1U67X0_^FWA]_?=T?]P/2O1^SV_H=+GUHK.TL4A7)QC499A VEY%O6M>
MFY2.&7CHB870.FPDGL459N,BV9.#$<*LO'I Y*GXDQRE.(]*/X/^SWFV\<6<
MIH]TF-!MS74-L@I&V3AB _DT:[JMKA6'\82_C#%HV9,D&S*.; #9@T22:-P!
M)(H=.KT';5^: XN_W0:_^XY9^G"Z6?F5?+;F/%K<KY17"S*V5N@RKR%D6Y"*
M.(EPH9!HI,(%.4Y!6B6SA:02$Q3 51L4_9]3T..%%GL\DCR!I<Q:K)>JWE^T
M^]6B6VV3KJTSKR%D,_I=ID8EY8WZSF0F/<.>G)%!%=^Y<.FZ#A-B984FJ2:;
MO]*ON'Y=W%S_ *6VC]RI_P!$CI9N9%[M>9\8]AN](=+Q]GA*N48R4;%*9S#B
M_E(^+=S" '(<H+1;%ZY>I*"4?$J(E6#L\7VA">&5FLTM&;G59JSV"ZP>:;C-
M4VD6BSS+BQS;RO#5JK/+QKVP/%5WTP:#F)B18I.GSAP[31%-HJL<&Q0*Y_0<
MG.SSEN-?S^YNZ_GC_N%C_3\P?-V!\?R].'TJ7.#0+?EW%;8;O1'[F(M$3!1R
M$?-,P*+N"1F+%#PLE-M3&*<J;B+C)!X[07$HBV52*X 2BD!@B7".U6F:@]XJ
ML]9[!=H3+>0EQH-$MEIF7%DG9"JM(>N2Y8^0L3Q5P_FU(*4EI"-(_D'+EZ*2
M9&RZZ@MP[':Z47:?S27&'^YWD%_V=IG_ (?/T6NHA?F-NDZ99(^AV)C4;@[C
M%D8&SR4.6P,X-X8Q!-(J0JBS=*140; N+5NLJ5 78H&7!1$JB9ZPX'9-5C_!
M<UZ^KWN?EM6M"GO$'2I)X;WP-Y"W;>^H'OF,\+Z6;N)BG8J1RB  2-.@T*V(
M0C=,I=%=F_(N(W&WT)KJ24W*<AG&EU/C])UG:= 62R1OF]'K2ZK*]U1DN-.B
MY>P(HRQG]C;0SVT52R2Z$F1=03(IEB=7Y%W4N=[GE5NTR]FVF*Q.??9U=(>2
M=+5)(N-1,Y(.K"C8UW328?S]NGHJ:,XFEH(C:PU2&C!>O4W;Y5LK;9CEQ=Z'
MDF87U^CY._N= J%G?( 0$P2>S<"PD792IAZ"%!PX4[A ]!2B!0^+HD=2KB;V
M><)R4[?L:<:OD_\ MQR&^V'1CXU;QIE>R"&AXOB9N5N8,K/IR;:QP4SBR,5*
M$-J-S4,LR2FM4BI0B::ASH&!W'ME!42,)"&3,F<YW\Y'7/4IY$?J[@7XY.L\
MY'6_4IY$?J[@7XY.L\Y'7/4IY$?J[@7XY.L\Y+6_4IY$?J[@7XY.L\Y'7/4I
MY$?J[@7XY/3^AUGG(ZWZE/(C]7<#_')UGG):YZE/(C]7<"_')UGG(ZYZE/(C
M]7<"_')UGG(ZWZE/(C]7<"_')UGG(ZWZE/(C]7<#_')UGG(ZWZE/(C]7<"_'
M)T(]WL]HY%9)=,6T3A1R?&F7V/;1L\$%;<"BI?R9I)L9=(&4A\+K@&RGE<<W
M[Q_$J=Y/OI]GU?:"@V;B1F\_=];TB/X0\Q:9>-DT#'-5L5@INC<>XQ:)T;#T
M9-&FV^O,7FF244A).23$@>R(R["9C9M9P9=9@DN'?ZC#_A'GKVB0=!2XE\]8
MYG#Q6_UYQ/L-AX^%M-AJ_)N2+-Z_6K#+.M$=$=Q5@FREEVQFS5E)1;T#"S?I
MH'.@;<V+AID]UG%YB]\&>8]X;AECW(H>#L^HX2^C*O6Y*F5ZBR#FLN4]6;S\
M6_<0M8BUT6GNVK6XJ:!Y-PM?C9%^Z<*[!3BS#+5FLPJW&3GX>P4W1H[3ZKHA
M=:XXH7" L,73Y"A-6T2U;7M&CL(D:K*R#!TT:TU)=Z\=*SKQVO/F]U.JK/"M
M5\N&85X,'":?QTWG.Z'E7.&FOJ?\*-JR^T3-A5DIJ5L"U98RM;ODRLM**OI9
MT6/6G$HYBFV!-)U)@*?C#/,KM-^\8I_*P;8 ]\_H&1R3T?5#Z!$-)$/SQ#]#
MKY'V:]J$.FIQ>VI1-0IB'(=]D9R'(<!*<AR&T@2F(8HB4Q3 )3 (@(" ]12G
MVA7.F+R+H7"W1J3'2+]65?L*NRQ.!:O9)<"E5?ND([0&R:[I0I2D%=0IC]PH
M$ 0* !U+?AIOWJP;9^J&2?C(ZBR^R7TVR<5G(<:-E(O'\BZX]:,E)+)RKS#E
M.CZ"D2+8'^$;R=-XJ191P0[Y=HS!%JN!W)51134NQ\Y+6_4IY$?J[@7XY.OF
MMR,U9PBJ@XX2<A%D%TSHK(K36 *)*I*E$BB2J9]C,11-0AC$.0P"4Q1$I@$!
M$.H%G-Y>8_#O:_E7@Y]5SB#D91U-R$124.-E9CGLP]!,KJ3=M(C66B+A\N1)
M)-1RJ0RHII)I]X")D*!!\Y'7/4IY$?)_Z]P+Y?\ WR?=Z0SGEO&ES,1QR+(\
M3-TKA6/(R-?MCRDOBZWNHZ)D>O-BQ3((O4Y$Q'ITG2STIWA6S/R9BY*+H'!F
MZ*ZU?#3?O5@VS]4,D_&1U\U=DO2Z2J"W%S:%D5DSHK(JOLB42525*)%$E4SZ
M.8ATU"&,0Y#%,4Y3"4P" B'47IUJ7SF,6A*%POT>DQ#EZO)N(NKM,5@F+B0=
M 4'#Y9K':"W25=+ 0A3KG*90Q"$)WNX0H!+/AIOWJP;9^J&2?C(ZUT+LU_+R
M XHO4^,FSF<QVURSMI&FDLE3<S*YL0U]J,?'J'T<K1-T5%RJ_,9^X9MA:LG!
M2+BZ,W07N9'DCK@?\2GD1^A.X%^.3KXN>1.IO&Z[1WPBY!.FKI%5NY;.)CC^
MLW<-UB&360714V(R:J*J9C)JI*%,0Y#&*8HE$0Z@^<WQ_D$"K5\J\'5K&<UM
M>1=RZ\%2DN-U:BEI1\)!>2*S&(UIHW5>N?%IE6<J)F5.5-,@G$B92EGWG):Y
MZE/(C]7<"_')T@?.[>-*F%.,HR/$[<ZX$?NDL[;!)R^+K&EUS89L#0T>Q"+U
M.0[CHB#E:0,9[Y*U%HQ=%*X%R9NW77/X:;]ZL&V?JADGXR.OBXV"[O&Z[1UQ
M9V9TU=(JMG+5P[R%=NY;KD,DL@NBIHYDUD5DS&3524*8BA#&(<HE$0&.4^W.
ML[B1K]#X9:32H,72[\T/6&V+04<9Z[$#.7AV<?H+=$SE<2E\:N8@J' I"B82
ME* 2GX:;]ZL&V?JADGXR.M95]FOY.4'$>02XR;.J[C=)T-=G$#)9*1[-J+8+
MJ315I'**:01DFX;-UU9%49!VR0,U:+D254=&0;K7-^<EK?J4\B/U=P+\<G7D
M?\@].E&+R,D^#N_2,;(M7#&08/97CZZ9/63M(Z#IH[;+["=%PV<HG.BN@J0Z
M:J9S$.4Q#"'40SO0I3(JX2H99X.[6\[JR;QW($KU+)QOK<.#]^IXUZ]]SXG6
MVK873I3L,NX,F*JG=*!C"!2@$Z\Y'6_4IY$?J[@7XY.J\.=VZZ1,6CBHI(\4
M-RKIHW4[^X:(R<MC*ZLRJMB.A-%&<?[EZC()D<-D%U)!4SX[1 S1JX*BJJY\
M4@H!OAIOWJP;9^J&2?C(ZY#:;_Z.SC#MG;V^CLD,D[>WVD]O6BKN@35.CAA:
MIQ U2L1(OI*3&*@BXU$L/=*9?+R<L_%FST-%'RR3D73A^_<"3QKMVX5<+&.H
MH8P[SX:;]ZL&V?JADGXR.A19=@O*FY\;W9^-NQHK,9S5#MX]1_E8O)4SC*+&
MV538B31#-BG9)',]<"\<-2"V2."!E5Q(B=K_ (<=!]53=OU2QOXO:A\?\.SK
MROMBN<HR>1DEQ(VR1CI%JNQ?Q[YWBSIF^9NDC(N6CMJOIIT7#9PB<Z2R*I#I
MJIF,0Y1*(AUH:?=WV=0:%6H7"?5*37&JSAPV@*NWPR!B4'#Q05G3A./CM);-
M@6<JB*BZP)^,5-Z3F$0#LE ;CH/R\5=V_5+&P_\ ^H#TM.Q[%>76P\;72O&O
M9F*S"4UPS9@[?Y0+F6%UFCY!4C S;1EVY#,4Q%VZ\M7:@*!1!N*RPE2&??#3
M?O5@VS]4,D_&3UXY#6;?+,'D7*\4]ADHR1;+LI"/?N,?=LGS-RF9)PU=M5]&
M41<-UTC&3515(9-0AA*8H@/9UIZE=I"@0C:LT?ASIU.KK-1=9K!5I'%X6*;K
M.E!7<K),&&A(-RJN53"JNJ"?C%3CWCF,/4D^&F_>K!MGZH9)^,CH43&P7D_(
M;CV]-QNV--=E'[.5O&&?Y5Y=)E=4QBDN9D8-#%H4K @ X=^5N6QC(F &P+J
M) :_X<=!]53=OU2QO\:'\/C_ #_!)ZY;YR.?0TSQ$VB7B91HNPDXN27Q1]'R
M+)TF9%PS>,W.FJMW+9PD<R:R"R:B:A#"4Q1 >SK4U&^26?032JT7A7JU,K3
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MZL%K^/[)^:_Z]^SUU-J>Q'*8A^+]J.0Y1*<IM-S42F*8! Q3 +T0$I@$0$!
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M%4A1[.I9*V.]SR+QI.\-'4VWD6#>(D&LQ;\BDT'\6Q< ];13U!\9=-W'M'8
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M/@_K1-TIO0;5G_A8E,4N-<C[&>VPJ=GRNRO*U)2$!8UH.M.I2%E"HH2#%9[
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MD!!/]AS/3Z;2<@Q?,KMIV#H<:'>DN9ZT7-W#8PDJX$E58P*U8@62X1J+]^M
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MYY&UN3G)GBQVDM89 YG;EWW#-BJ>@C<A?J0/BD_MPG.(4;*0 3F$ ^%"WCV
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MN_$]UP.G[4(" YME8@(" @.KVT0$!] @(#CW8("'QAUT2TK94$RI(9EDZ"1
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2WQ-B-TD4W7;XA<5#I=B8*?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>34
<FILENAME>g98473g99a02.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g98473g99a02.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_[2,.4&AO=&]S:&]P(#,N,  X0DE-! 0
M     $H< 5H  QLE1QP!6@ #&R5'' (   (  !P"4  (<G(U,#DQ-C<< @4
M(4UI8W)O<V]F="!7;W)D("T@1V5N97-I<R!&+3$N9&]C>#A"24T$)0
M$")*^(M6HN%I'>),'8-E9Y0X0DE-!#H      .4    0     0      "W!R
M:6YT3W5T<'5T    !0    !0<W138F]O; $     26YT965N=6T     26YT
M90    !#;')M    #W!R:6YT4VEX=&5E;D)I=&)O;VP     "W!R:6YT97).
M86UE5$585     $       ]P<FEN=%!R;V]F4V5T=7!/8FIC    # !0 '(
M;P!O &8 ( !3 &4 = !U '        IP<F]O9E-E='5P     0    !";'1N
M96YU;0    QB=6EL=&EN4')O;V8    )<')O;V9#35E+ #A"24T$.P     "
M+0   !     !       2<')I;G1/=71P=71/<'1I;VYS    %P    !#<'1N
M8F]O;       0VQB<F)O;VP      %)G<TUB;V]L      !#<FY#8F]O;
M    0VYT0V)O;VP      $QB;'-B;V]L      !.9W1V8F]O;       16UL
M1&)O;VP      $EN=')B;V]L      !"8VMG3V)J8P    $       !21T)#
M     P    !29" @9&]U8D!OX            $=R;B!D;W5B0&_@
M    0FP@(&1O=6) ;^            !"<F1456YT1B-2;'0
M  !";&0@56YT1B-2;'0               !2<VQT56YT1B-0>&Q <L
M      IV96-T;W)$871A8F]O; $     4&=0<V5N=6T     4&=0<P    !0
M9U!#     $QE9G15;G1&(U)L=                %1O<"!5;G1&(U)L=
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M____   X0DE-! T       0   !X.$))3009       $    'CA"24T#\P
M    "0           0 X0DE-)Q        H  0         !.$))30/U
M  !( "]F9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &       ! #(    !
M %H    &       ! #4    ! "T    &       !.$))30/X      !P  #_
M____________________________ ^@     ________________________
M_____P/H     /____________________________\#Z     #_________
M____________________ ^@  #A"24T$"       $     $   )    "0
M   X0DE-!!X       0     .$))300:      ,U    !@             "
M!   !=P          0                         !              7<
M   "!                      !                         !     !
M        ;G5L;     (    &8F]U;F1S3V)J8P    $       !28W0Q
M!     !4;W @;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG
M   "!     !29VAT;&]N9P  !=P    &<VQI8V5S5FQ,<P    %/8FIC
M 0      !7-L:6-E    $@    =S;&EC94E$;&]N9P         '9W)O=7!)
M1&QO;F<         !F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U
M=&]'96YE<F%T960     5'EP965N=6T    *15-L:6-E5'EP90    !);6<@
M    !F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
M         $QE9G1L;VYG          !"=&]M;&]N9P   @0     4F=H=&QO
M;F<   7<     W5R;%1%6%0    !        ;G5L;%1%6%0    !
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M300H       ,     C_P        .$))3001       ! 0 X0DE-!!0
M  0    (.$))300,     !A_     0   *     W   !X   9R   !AC !@
M ?_8_^(,6$E#0U]04D]&24Q%  $!   ,2$QI;F\"$   ;6YT<E)'0B!865H@
M!\X  @ )  8 ,0  86-S<$U31E0     245#('-21T(               $
M /;6  $     TRU(4" @
M                       18W!R=    5     S9&5S8P   80   !L=W1P
M=    ?     48FMP=    @0    4<EA96@   A@    49UA96@   BP    4
M8EA96@   D     49&UN9    E0   !P9&UD9    L0   "(=G5E9    TP
M  "&=FEE=P   ]0    D;'5M:0   _@    4;65A<P  ! P    D=&5C:
M!#     ,<E120P  !#P   @,9U120P  !#P   @,8E120P  !#P   @,=&5X
M=     !#;W!Y<FEG:'0@*&,I(#$Y.3@@2&5W;&5T="U086-K87)D($-O;7!A
M;GD  &1E<V,         $G-21T(@245#-C$Y-C8M,BXQ               2
M<U)'0B!)14,V,3DV-BTR+C$
M                             %A96B        #S40 !     1;,6%E:
M(                     !865H@        ;Z(  #CU   #D%A96B
M  !BF0  MX4  !C:6%E:(        "2@   /A   ML]D97-C         !9)
M14,@:'1T<#HO+W=W=RYI96,N8V@              !9)14,@:'1T<#HO+W=W
M=RYI96,N8V@
M            9&5S8P         N245#(#8Q.38V+3(N,2!$969A=6QT(%)'
M0B!C;VQO=7(@<W!A8V4@+2!S4D="               N245#(#8Q.38V+3(N
M,2!$969A=6QT(%)'0B!C;VQO=7(@<W!A8V4@+2!S4D="
M             &1E<V,         +%)E9F5R96YC92!6:65W:6YG($-O;F1I
M=&EO;B!I;B!)14,V,3DV-BTR+C$              "Q2969E<F5N8V4@5FEE
M=VEN9R!#;VYD:71I;VX@:6X@245#-C$Y-C8M,BXQ
M              !V:65W       3I/X %%\N !#/%  #[<P !!,+  -<G@
M  %865H@      !,"58 4    %<?YVUE87,          0
M          */     G-I9R      0U)4(&-U<G8        $      4 "@ /
M !0 &0 > ", *  M #( -P [ $  10!* $\ 5 !9 %X 8P!H &T <@!W 'P
M@0"& (L D "5 )H GP"D *D K@"R +< O #! ,8 RP#0 -4 VP#@ .4 ZP#P
M /8 ^P$! 0<!#0$3 1D!'P$E 2L!,@$X 3X!10%, 5(!60%@ 6<!;@%U 7P!
M@P&+ 9(!F@&A :D!L0&Y <$!R0'1 =D!X0'I ?(!^@(# @P"% (= B8"+P(X
M D$"2P)4 ET"9P)Q GH"A *. I@"H@*L K8"P0++ M4"X +K O4#  ,+ Q8#
M(0,M S@#0P-/ UH#9@-R WX#B@.6 Z(#K@.Z \<#TP/@ ^P#^00&!!,$( 0M
M!#L$2 15!&,$<01^!(P$F@2H!+8$Q 33!.$$\ 3^!0T%' 4K!3H%2058!6<%
M=P6&!98%I@6U!<4%U07E!?8&!@86!B<&-P9(!ED&:@9[!HP&G0:O!L &T0;C
M!O4'!P<9!RL'/0=/!V$'= >&!YD'K >_!]('Y0?X" L('P@R"$8(6@AN"(((
ME@BJ"+X(T@CG"/L)$ DE"3H)3PED"7D)CPFD";H)SPGE"?L*$0HG"CT*5 IJ
M"H$*F JN"L4*W KS"PL+(@LY"U$+:0N "Y@+L O("^$+^0P2#"H,0PQ<#'4,
MC@RG#, ,V0SS#0T-)@U #5H-= V.#:D-PPW>#?@.$PXN#DD.9 Y_#IL.M@[2
M#NX/"0\E#T$/7@]Z#Y8/LP_/#^P0"1 F$$,081!^$)L0N1#7$/41$Q$Q$4\1
M;1&,$:H1R1'H$@<2)A)%$F02A!*C$L,2XQ,#$R,30Q-C$X,3I!/%$^44!A0G
M%$D4:A2+%*T4SA3P%1(5-!56%7@5FQ6]%> 6 Q8F%DD6;!:/%K(6UA;Z%QT7
M01=E%XD7KA?2%_<8&QA &&48BABO&-48^AD@&449:QF1&;<9W1H$&BH:41IW
M&IX:Q1KL&Q0;.QMC&XH;LAO:' (<*AQ2''L<HQS,'/4='AU''7 =F1W#'>P>
M%AY 'FH>E!Z^'ND?$Q\^'VD?E!^_'^H@%2!!(&P@F"#$(/ A'"%((74AH2'.
M(?LB)R)5(H(BKR+=(PHC."-F(Y0CPB/P)!\D321\)*LDVB4))3@E:"67)<<E
M]R8G)E<FAR:W)N@G&"=))WHGJR?<* TH/RAQ**(HU"D&*3@I:RF=*= J BHU
M*F@JFRK/*P(K-BMI*YTKT2P%+#DL;BRB+-<M#"U!+78MJRWA+A8N3"Z"+K<N
M[B\D+UHOD2_'+_XP-3!L,*0PVS$2,4HQ@C&Z,?(R*C)C,ILRU#,-,T8S?S.X
M,_$T*S1E-)XTV#43-4TUAS7"-?TV-S9R-JXVZ3<D-V WG#?7.!0X4#B,.,@Y
M!3E".7\YO#GY.C8Z=#JR.N\[+3MK.ZH[Z#PG/&4\I#SC/2(]83VA/> ^(#Y@
M/J ^X#\A/V$_HC_B0"- 9$"F0.=!*4%J0:Q![D(P0G)"M4+W0SI#?4/ 1 -$
M1T2*1,Y%$D5519I%WD8B1F=&JT;P1S5'>T? 2 5(2TB12-=)'4EC2:E)\$HW
M2GU*Q$L,2U-+FDOB3"I,<DRZ30)-2DV33=Q.)4YN3K=/ $])3Y-/W5 G4'%0
MNU$&45!1FU'F4C%2?%+'4Q-37U.J4_940E2/5-M5*%5U5<)6#U9<5JE6]U=$
M5Y)7X%@O6'U8RUD:66E9N%H'6E9:IEKU6T5;E5OE7#5<AES672==>%W)7AI>
M;%Z]7P]?85^S8 5@5V"J8/QA3V&B8?5B26*<8O!C0V.78^MD0&249.EE/662
M9>=F/6:29NAG/6>39^EH/VB6:.QI0VF::?%J2&J?:O=K3VNG:_]L5VRO;0AM
M8&VY;A)N:V[$;QYO>&_1<"MPAG#@<3IQE7'P<DMRIG,!<UUSN'04='!TS'4H
M=85UX78^=IMV^'=6=[-X$7AN>,QY*GF)>>=Z1GJE>P1[8WO"?"%\@7SA?4%]
MH7X!?F)^PG\C?X1_Y8!'@*B!"H%K@<V",(*2@O2#5X.ZA!V$@(3CA4>%JX8.
MAG*&UX<[AY^(!(AIB,Z),XF9B?Z*9(K*BS"+EHO\C&.,RHTQC9B-_XYFCLZ/
M-H^>D :0;I#6D3^1J)(1DGJ2XY--D[:4()2*E/257Y7)EC26GY<*EW67X)A,
MF+B9))F0F?R::)K5FT*;KYP<G(F<]YUDG=*>0)ZNGQV?BY_ZH&F@V*%'H;:B
M)J*6HP:C=J/FI%:DQZ4XI:FF&J:+IOVG;J?@J%*HQ*DWJ:FJ'*J/JP*K=:OI
MK%RLT*U$K;BN+:ZAKQ:OB[  L'6PZK%@L=:R2[+"LSBSKK0EM)RU$[6*M@&V
M>;;PMVBWX+A9N-&Y2KG"NCNZM;LNNZ>\(;R;O16]C[X*OH2^_[]ZO_7 <,#L
MP6?!X\)?PMO#6,/4Q%'$SL5+Q<C&1L;#QT''O\@]R+S).LFYRCC*M\LVR[;,
M-<RUS37-M<XVSK;/-\^XT#G0NM$\T;[2/]+!TT33QM1)U,O53M71UE76V-=<
MU^#89-CHV6S9\=IVVOO;@-P%W(K=$-V6WAS>HM\IWZ_@-N"]X43AS.)3XMOC
M8^/KY'/D_.6$Y@WFEN<?YZGH,NB\Z4;IT.I;ZN7K<.O[[(;M$>V<[BCNM.]
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MP  1"  W * # 2(  A$! Q$!_]T !  *_\0!/P   04! 0$! 0$
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M7](VA?,J22GZ<ZQ1TB_%#.KFL8V\$&Y_IMWP[;[]S/=MWJ>95TZSISZLPUC
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M(IQ-G2#4<7=/Z!P>W=#?SFN?^9L7S&DDI^JDE\JI)*?_V0 X0DE-!"$
M %4    ! 0    \ 00!D &\ 8@!E "  4 !H &\ = !O ', : !O '     3
M $$ 9 !O &( 90 @ %  : !O '0 ;P!S &@ ;P!P "  0P!3 #8    ! #A"
M24T$(@     !1DU- "H    (  @!$@ #     0 !   !&@ %     0   &X!
M&P %     0   '8!*  #     0 "   !,0 "    '@   'X!,@ "    %
M )P!.P "    "0   +"':0 $     0   +P   #H "W&P   )Q  +<;    G
M$$%D;V)E(%!H;W1O<VAO<"!#4S8@*%=I;F1O=W,I #(P,3DZ,#<Z,C$@,3@Z
M,S Z,30 <G(U,#DQ-C<       .@ 0 #     ?__  "@ @ $     0  !=R@
M P $     0   @0         !@$#  ,    !  8   $:  4    !   !-@$;
M  4    !   !/@$H  ,    !  (   (!  0    !   !1@("  0    !
M          !(     0   $@    !.$))30/]       (          #_X0%(
M34T *@    @ " $2  ,    !      $:  4    !    ;@$;  4    !
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M 2@  P    $  @   @$ !     $   %& @( !     $              \
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M P$! 0             !!0($!@,'"/_$ %D1  $# P(#! 8&! 8+$ (#  $
M @,$!1$2(083,4%18? 4(G&!D:$'%3*QP=$C,^'Q)#1"4G*2%C5%4V)T=H*%
MHK07)4-$559C<W63E;*UML32-K-&PM7_V@ , P$  A$#$0 _ /W\81,(HIWO
ML]/26D=P;D5ASV%/5&L;WL<\ F]+''FRTFL2ED&))(&;O"L32(1ON@/!:.@;
M"MYWNZW@\LQ%2_B[SSN6W]GZ]T]NW0B6D[AN?CRSY-Z9E:WLMKM.EWC78K5E
M&<BW4H>IT:9K=XK/TQKJ\G!/(!U'KM'JCAA-N0;^%4-QY_8AV/G/XCYK9-A$
MPB81,(F$3")A%IZJ'M@]7W"[2FMFNM+''WR"Y=VSBY*5Z1G(]NNK$P,-L^1B
M-QP9SLRC-4^<D]5V"KJMVR958BPMW3!V\.HV3!R4D$?#/;Y[1X=G599Q(]IN
M3G-"3TOQJTV2UA2M05>W7AQ.;+A8*(A=QW6+3F(/135\E"RCV0DHQA[T:XW0
M8IM U]\W&'01E95-\V8DQCK\M_V?-3;Q6Y?VO>.JMA[KV[J> X_:VH4KL.)7
ML#[:\7=4CGU%:[94-DR,Q[I6X%"!AH*2J$@Y:2"KEV$C&&*[,DS\(I"'GSY_
M!01CSW^?P\3TD[[4CA15M?1.S+1M*8K%:G+ ZKT6C8]9;/@K(\%C6VMS>V!&
MI2E1:V4]-:T]\RM+BY$BS5M.$=MG1I+Q+$2$IP>GXA=54/:*U&[;_A='P-&>
M/FEAY!7'1</?6=DCGD')(5?C56N23.\,4$&HF<P]@A+,UA8]NDY,;Q$"4]Y4
M;K$;@R H\^?([O;L<PB81,(F$3")A$PB81,(F$3")A$PB81:S^+O/^3Y+\E=
M[:-95'2]:B=';,W!K:21'D2SF=\R?U4V-C6BW170:6OV3V+HU@?2#=-*P+7)
M=NR7.1KX7:IT_&\^?V94D><;=._/8MF&%"81,(F$3")A$PB81:;O:W4?81X[
MCE?=?<FN1.CG-BY':%X^SD#J"^-*I7IBL[=V.UAK!//F2L)(+.+;'QSA1&$D
M#.?=&H%(#A@Z(4Q3%([=@>W<9\YZ?BJD7/G_ ,O..FN[PBUG:/=Z-KOF1/\
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MBK#UI/5QZ22@)AE,5:5AI=J^B)))%^R.B]*0CM!%4Q#BF7HG0Y[5K+Y5\/\
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MR6RW4_;;1+>%:VU,P58F]<W'BI-ZFJG%B!U'(%5&M5"M[5D(J>B!?B:KQ4/
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M[64\D[\]N TGI@'(4\P'H'G_ #'CYD!>$MVVU]X@C..6[E# 82D&61UO I*
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MFZ'T QS"'J81&MM[&B:Z$-:";B>@ /\ $Z/'SR?:2NUXOEEDH>!Q))(\#@Z
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M3/BNXP/]S8G S_9P!G&^/J$G&>N,]BS"W:TU[?D01NE*K%G*3KRE)J%8/G*
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M>_U0U=6U-951$^UE0YAQ[L++ZYLH(#JRFA.X#9P:8^/JSLC(\<A3+ V;6D@
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MM8\A=T<K[]4M,,;&L]@^-.K'-1MR?*G:>A*WJ:\V6[[K:HW=2CT.$G8G:#I
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M.TL: UHS@ 8&%DUIO]5IPMT)F3+\4>@;X9 1R#B5L4L8@=B2+@HY-S)O>AZ
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MLJ<W3@BIP*CA.Z6\]K[1Q(2W)[>3=K9<'$#L8*AI/36.J!*[Q8=^]T[7=A3
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MIJ&Y5]#!=(?1:^"DJJFGAKZ?5JY%8R![65$.=^7,',W.VY4QB4HAT)2B'XA
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M8B**KA\JY8F7(91!MXR@Y4(K'$(5,I2$*4A"% I"$ "E*4H=%*4H  %*
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M!5!,XI@KX!/X#^'OPCU*+),(F$3")A$PB81,(F$3"*!>2.C$>0NL5*&6W2M
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M].6*=)9Y_5FH]>Z^FK"GY_DS4I4:K%P3^20]Z$7/N[MRQ45;^\#Y_DF)YO\
M">+)4%3=A%JQ]J7P^Y%\Q-;4BI:/V!KV 8T^U1%TE*-L&,L_PNX6F%M-6D*M
M,KS]:GXPS5"F,6=CD&\+*Q4Y%2TH[8K*M47S"-?,GGSL5(('49^'GX'9=+Q"
MX6;ETORTV?MZ]HZ[:5!:-WU&P5DI\W(/+3MUQO?D 7>#.6O<&[KT>:O'U?'
MI2(9NYLEM4=)N7#EBZCV/\74)MC8=WR&-O;U*VT84+U.!A(8"" &$I@*(]B
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MP\$RF-D/UV+I-M7&Z$N\^>U3GP[B?G^>/<OT,%*!"E*'R*4"AWZCT =!V/\
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MGM'J7VYP$A19^'LR-PU-7M)W3<M<9OD[^^^++66M6O:B-'7/5*Y&J2%9B'<
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E!2@&$7881,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>35
<FILENAME>g98473g99f98.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g98473g99f98.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_[17>4&AO=&]S:&]P(#,N,  X0DE-! 0
M     $H< 5H  QLE1QP!6@ #&R5'' (   (  !P"4  (<G(U,#DQ-C<< @4
M(4UI8W)O<V]F="!7;W)D("T@1V5N97-I<R!&+3$N9&]C>#A"24T$)0
M$")*^(M6HN%I'>),'8-E9Y0X0DE-!#H      .4    0     0      "W!R
M:6YT3W5T<'5T    !0    !0<W138F]O; $     26YT965N=6T     26YT
M90    !#;')M    #W!R:6YT4VEX=&5E;D)I=&)O;VP     "W!R:6YT97).
M86UE5$585     $       ]P<FEN=%!R;V]F4V5T=7!/8FIC    # !0 '(
M;P!O &8 ( !3 &4 = !U '        IP<F]O9E-E='5P     0    !";'1N
M96YU;0    QB=6EL=&EN4')O;V8    )<')O;V9#35E+ #A"24T$.P     "
M+0   !     !       2<')I;G1/=71P=71/<'1I;VYS    %P    !#<'1N
M8F]O;       0VQB<F)O;VP      %)G<TUB;V]L      !#<FY#8F]O;
M    0VYT0V)O;VP      $QB;'-B;V]L      !.9W1V8F]O;       16UL
M1&)O;VP      $EN=')B;V]L      !"8VMG3V)J8P    $       !21T)#
M     P    !29" @9&]U8D!OX            $=R;B!D;W5B0&_@
M    0FP@(&1O=6) ;^            !"<F1456YT1B-2;'0
M  !";&0@56YT1B-2;'0               !2<VQT56YT1B-0>&Q <NEPH
M      IV96-T;W)$871A8F]O; $     4&=0<V5N=6T     4&=0<P    !0
M9U!#     $QE9G15;G1&(U)L=                %1O<"!5;G1&(U)L=
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M____   X0DE-! T       0   !X.$))3009       $    'CA"24T#\P
M    "0           0 X0DE-)Q        H  0         !.$))30/U
M  !( "]F9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &       ! #(    !
M %H    &       ! #4    ! "T    &       !.$))30/X      !P  #_
M____________________________ ^@     ________________________
M_____P/H     /____________________________\#Z     #_________
M____________________ ^@  #A"24T$"       $     $   )    "0
M   X0DE-!!X       0     .$))300:      ,U    !@             "
M;   !W0          0                         !              =T
M   ";                      !                         !     !
M        ;G5L;     (    &8F]U;F1S3V)J8P    $       !28W0Q
M!     !4;W @;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG
M   ";     !29VAT;&]N9P  !W0    &<VQI8V5S5FQ,<P    %/8FIC
M 0      !7-L:6-E    $@    =S;&EC94E$;&]N9P         '9W)O=7!)
M1&QO;F<         !F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U
M=&]'96YE<F%T960     5'EP965N=6T    *15-L:6-E5'EP90    !);6<@
M    !F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
M         $QE9G1L;VYG          !"=&]M;&]N9P   FP     4F=H=&QO
M;F<   =T     W5R;%1%6%0    !        ;G5L;%1%6%0    !
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M300H       ,     C_P        .$))3001       ! 0 X0DE-!!0
M  0    $.$))300,      M0     0   *     T   !X   88    LT !@
M ?_8_^T #$%D;V)E7T--  +_[@ .061O8F4 9(     !_]L A  ," @("0@,
M"0D,$0L*"Q$5#PP,#Q48$Q,5$Q,8$0P,# P,#!$,# P,# P,# P,# P,# P,
M# P,# P,# P,# P, 0T+"PT.#1 .#A 4#@X.%!0.#@X.%!$,# P,#!$1# P,
M# P,$0P,# P,# P,# P,# P,# P,# P,# P,# P,# S_P  1"  T * # 2(
M A$! Q$!_]T !  *_\0!/P   04! 0$! 0$          P ! @0%!@<("0H+
M 0 !!0$! 0$! 0         !  (#! 4&!P@)"@L0  $$ 0,"! (%!P8(!0,,
M,P$  A$#!"$2,05!46$3(G&!,@84D:&Q0B,D%5+!8C,T<H+10P<EDE/PX?%C
M<S46HK*#)D235&1%PJ-T-A?25>)E\K.$P]-UX_-&)Y2DA;25Q-3D]*6UQ=7E
M]59F=H:6IK;&UN;V-T=79W>'EZ>WQ]?G]Q$  @(! @0$ P0%!@<'!@4U 0 "
M$0,A,1($05%A<2(3!3*!D12AL4(CP5+1\#,D8N%R@I)#4Q5C<S3Q)086HK*#
M!R8UPM)$DU2C%V1%539T9>+RLX3#TW7C\T:4I(6TE<34Y/2EM<75Y?569G:&
MEJ:VQM;F]B<W1U=G=X>7I[?'_]H # ,!  (1 Q$ /P#T?[.W%ZA;G/R;G_:V
MLJ;C'W5M-8<]OH5M;O8_^??;[OTG_6JU8^TL_<L_[;=_Y%5\C(HMR,/TK&6;
M,IU;]K@8>VG(WUNV_1L;^XKR2D/VIG[EG_;;O_(I?:F?N6?]MN_\BC))*0_:
MF?N6?]MN_P#(I?:JY$A[9(:"6. DG:W\W]Y&0<O^:'_&5?\ GQB2DR2222E)
M)))*<W.QW8V8[K3#DY#JL?T/L-)!:^7A_J-J?M;ZS?W]_P#-H^!U#[8'!U%N
M+:P!SJK@ [:XV,8[V.>WW>B]$S,NK"QGY-P>:ZX+A6USW:G;[:ZPY[N53Z;F
MTYV;?D4A[6&BD1:QU;M+,MOT+&M24Z:2222E))*GGL9>:L8B3O;;NYV>FYKJ
M[&M_TGJ[/3W_ */_  GZ3T_32*FTVQC]P8X.V':Z#,']TH;\JMF37C%MA?8U
MS@X5O-8#8TLO:WT:W_N,>]1PZ;*?6#[?5W6%S26D$-AHV.<YS_5X_G/9_P 6
MHVM><^EP9<6"MX<]KVBH$[=HMJWML?9_HWMK]B%^"AXZ,*>ILMN93]GR&.?H
M2^LAK3M-OZ1XW-;QZ>[Z'K?HU=7-NQ\L -%74@8 BG(J@>Q_M#7/9M_XU[&?
MID?&HRVV6%U&<1(VB[(8YGTZM6^F][F[8_[:]7_2HJ?_T.LZ4YI],U0]G[9R
MBTM=NEIKRG-=N_JN709&1E,;^@Q'7.[2]C&_YV]SO^@L;I[7V"L4VG(&-U7(
M#O4 :YK6LR*S5N#K?7]/?_.O]]GYZV[;LAH_1T%Y\"YK1_WY.W 4X.3;UO#R
M7=6S-M&-5!M8;1Z8K^CL#)]UG[GM]1]RW\?*JRJ*\G'/J4W-#ZWC@M<-S3JN
M8^L'2?K5ULMJ+<7'PZW;VTBYY<YWYK[W>CM]G^#8S_P15>EGJ71>J=*Z3G.K
MV5FT-%+RX%F23Z3+=[*_<S)J_1_R'HY!"&,2,@9F0'"#^C)?AQRRS,8CY83G
M?^SCQ_\ .^5[7<?W3^']Z%E$FH:$?I*O#_2,1-[_ /1G[Q_>@Y+G&MLL(_25
M:R/](SS3%B-N%ECU _,<X.:YC/: 6@_0=I^>S]Y$JQKF7>J[(<\=ZR/;$-:W
M^J[<W?\ VT"KHXJN98W+R88\/%9LEI@.'IND?S3O4]S?WU#]B35Z1S<H#=OE
MMFTSM-7TPW=L]WJ>E_->I^8G5'][\%.FDHUM+*VL+B\M !<8DP/I.VPU235-
M+)ZO@8E]M.38*112,BVQY 8&%QJ;J3N^FW]U"Z=FXF=G7Y.):VZEU%(#VG26
MV9;7!6;<; JR'=2N:QES:O1?>\P!5N]38[<=FW>@XEM%O4;WX[VV5&BF'5D%
MLA^7N@M]OTDE-]))))2EFAV3DY5[:R:"+6!MHVNFFK;N]K]^U]N5]KH]WYE?
MJ_Z-7LB^K'I??<X,KK!<YQT0.FX[J<??9/JWD66!Q)@D-;L:#]#Z/N;_ *7U
M$V6I ^U='0\7[NW7U)J*&4!X87NWN+W;WN?J0![?4<[8WV_S;/8AV=/PK<VK
MJ%E0=EX['5U6ZRUKX]1O[ONV*RDG 4@DDV3;5PNF86 '#%K]/?\ 2U)[N</I
M%WT=ZM)))(?_T>S^KKJS5::(>S]J94/DPX1;W.YWM_F_["Z";/W1]_\ L53+
MK^S4UV8M;&-IL-CVM8XR"VQA].J@;GV.>]J@^_JC#67LJV6>V&M>YX<1[ \,
MW5M9_I+'6[&))OP;KC='M8TGS<1_WURX7KW3LX]6#LS)J9?F$$.9N#:6M/IX
M_N=M^A9[]_\ P?J+K+KNKUO:P"DBSVL+6VOAVD&S;#&5;-[GN?;_ "/\(L3-
M^KO5<K,WY>578_($!S*7D -_,=[_ $Z:F,=[-UOJ6?\ "/4.>$I "(,M>]!1
MSY\4?U '&3 \6G^2G'-$>O\ KXXO2XOVP8[&Y08Z\ "QU9.TD?GM#FC;N_<3
M91?Z;9  ]2KO_P (SR5/&=UBCTL3(=5<_: V]K+((:#O?D.<=E;OYK_"/?;9
M9_->FB;NH69#<:]M8;++-];7D;6'<[<]^RMK][6M:QKK/WU*-AO]5&5ZT!>M
M=ESTENTAN5DL\-MD1\H]W]M.>E Z_:\J1)GU?'Y*7[,IV[1;<WL-MCA'R'M3
MGIM1@^M?(DSZKN_S3> ?N_BGW\W\O_15.Z=6YKFFVV'%A^GJ#7M U_E[/TN_
MZ:573JJKFW,LMEF@:7DMC:*MKF_G>UK?[:=W3Z'!P<7D/+"?<0?T8 9[Q[_S
M?WDJNGT4VMM:7[FP!+B1 :*ML?U6I<(OY0KWLNUZ'0Z]-DUU%.14ZF]C;:GZ
M.8X2T]_<TJGAXN-B]1R*L:EE%?H4'96T,;)?E3[6 +0631T-K<O(LL%7V>UV
MYC:_5:_W.LN?ZK_7]/\ GK['^RM/6NF^VIAA[VM/,$@(5G4,"IKG6Y-3&LC<
M7/:(G1LZKG<W&^K='4<EG6'X+FAE>VNQKW7>D?5+&V/MMM_/%COT;/Z_^#0Z
M,7ZGW9>3O=TRW&<QCPQC(?Z;=W\^]UCJ]S;'?FL_K_F(:]_P2ZV7EX_4'78M
MX%6!C6U&[*>]K6/(-=U%5?NW>[(]-EF_\S^;_GO85^==FO?5@6#'91<QEV5:
MT%KY%=IIQ6.<WU?59;Z7VC^;9_@_76)Z?U.=EWV9%O3;,.P,+:PV;'/8-P?:
M\VN98YG^#VU?^>D]57U/MZA9O?TZRBTU&FL-_2FT_0?98^S99;JS8YM?J_S?
MJ?S=:,:%G<]S_P!ZIZ3#Q_0%P^T6Y)LM+W&UP=L)#1Z->QK&UU-V[O35E<QT
MQGU?LZM?AX-V+Z3QZHQ<<6LL+X_377/;:*'6_P#6O6L9_.?S"V,3 R,;-M>Q
M[&X;FM#*@'FR1,^I9;:]G?\ P=?_ )[2)M#?22224__2]527RJDDI^H\_?\
M8<C9ZF_TG[?1_G)VF/1_X7_1K$^K7[3^TV?;OM\[';OMGI^GNFO;Z/H>W=_/
M?1_,7SNDDI^JDE\JI)*?JI)?*J22GZJ27RJDDI^JDE\JI)*?J=WHZ[]OG,>7
M_F*@?LF\3Z>_:[;]&=NGJ1_(^AO7RVDDI^IOT$_F3&G'"3?0D;=D]HB5\LI)
M*?J5GV7]'L]/C]%MCB/\''\G]U%7RJDDI^JDE\JI)*?_V3A"24T$(0
M50    $!    #P!! &0 ;P!B &4 ( !0 &@ ;P!T &\ <P!H &\ <    !,
M00!D &\ 8@!E "  4 !H &\ = !O ', : !O '  ( !# %, -@    $ .$))
M300B      %&34T *@    @ " $2  ,    !  $   $:  4    !    ;@$;
M  4    !    =@$H  ,    !  (   $Q  (    >    ?@$R  (    4
MG $[  (    )    L(=I  0    !    O    .@ +BOL   G$  N*^P  "<0
M061O8F4@4&AO=&]S:&]P($-3-B H5VEN9&]W<RD ,C Q.3HP-SHR,2 Q.3HS
M,SHQ.0!R<C4P.3$V-P       Z !  ,    !__\  * "  0    !   '=* #
M  0    !   ";          & 0,  P    $ !@   1H !0    $   $V 1L
M!0    $   $^ 2@  P    $  @   @$ !     $   %& @( !     $
M         $@    !    2     $X0DE- _T       @          /_A 4A-
M30 J    "  ( 1(  P    $      1H !0    $   !N 1L !0    $   !V
M 2@  P    $  @   3$  @   !X   !^ 3(  @   !0   "< 3L  @    D
M  "PAVD !     $   "\    Z    \     !   #P     %!9&]B92!0:&]T
M;W-H;W @0U,V("A7:6YD;W=S*0 R,#$Y.C W.C(Q(#$Y.C,S.C$Y ')R-3 Y
M,38W       #H $  P    '__P  H ( !     $   =TH , !     $   )L
M          8! P #     0 &   !&@ %     0   38!&P %     0   3X!
M*  #     0 "   " 0 $     0   48" @ $     0             #P
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M 0$! 0$! 0$! 0$! 0$! 0$! ?_  !$( ,4"70,!$0 "$0$#$0'_Q  >  $
M @(# 0$!            " D&!P0%"@$# O_$ %D0  $$ @( ! ($!@P("@@'
M  0" P4& 0< " D1$A,4(146%Y8B,4%65]4C-3<X475XM+:XU-88&21387>2
MEPHF)W%S@9'1V/ E,C-&6)BQP31'8G*%X?'_Q  > 0$  00# 0$
M    !@,$!0<! @@)"O_$ %L1  $$ 0," P,%"@@)!PL%  (  0,$!081$A,A
M!Q0Q(D%1"!4C,O 60E1A<8&1E:'1)#-25I*4TM,70V)R=+'4X?$))C6"A*+!
M&"4T15-59G.3L\)VA;2VU?_:  P# 0 "$0,1 #\ ]_'"+S[=C/%0WEJKQ(ZO
MK.K0M$-Z(ZYW'U]ZJ=F;P?&&/VV&[ =F*QL&PU0B'LC,DW%Q59HF!-<BW1!@
M#RA#+ D)YQ#LBRL,B]!/")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<
M(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G"+SJ>*[XE.].I?;6
ML:=I&_\ 3O7O7J>G-]["+F=G:-LVYW;]LFL78B @=9CCU2R0<Q!#V4%E6&I<
M1#Z8YT8E\A!"76D-$5PW2+>%N[*]1>NN_+]"5FN77;6IZC>+1!TV9'GJO&S4
MW&M$G,0DD-(RZ% ^]E3C83LH>9%*6J*D"WS@B7%$4I>$3A$X1.$3A$X1.$3A
M$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.
M$3A$SY^6?+\?Y//\7G^3SX1>?*Y?\'TT+M+3W8T+:>Q;':.U78':.RMQK[*@
M$7NOQ]-O5MMOUFII,9I\/93E0D@*".+&0@K<D^[(' C.Y9DHU?P. "*^.BQ%
M@K])I\#;+"W;;3"5:OQ%EM3,=F':LT_&Q(@<Q8&XE1DCF,1,R#)$BF/S('9#
MP3@?XLGV_>6195PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(
MG")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G"*JWMCX?FX]U=K:GVRT1VDB^
MO]TA>NEGZUS<=.Z,@]R@3%-M=Q1<)(\-J>M]?!C97!3 H[*B8Z492D?U*2MM
MYYA1%*KI/U.I/1WK!JCJ[KV<L%FK&K(B2"9L=H6-F:G92>GY:TV"5*8!:8!
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MZ.Z+]T8#]7\(GV7ZS_1W1?NC ?J_A$^R_6?Z.Z+]T8#]7\(GV7ZS_1W1?NC
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MW=_5]O5GVS\>G;<F%DSHV\2U.*083B+*5!O-/(,YQP>1>3S#RRQUII(Q8/:
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M9N\0, %&#%Q:/5-30.KX=7V\T>KIQJS1F+70:*2_,!"PA5EQ\M5\6$<1=V<
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M-6<^9FMP[2EK1L)-B;U\Q-53;-E.M;TQLZ@'AZEU;'NT6XE2M:Q'Z\J@2(]
MT;AMPBW9JOHUUHTY<MHW>G4)UZ1VXJ0;L</:[#8+M3X>,FKG,;(GZ]1:;:Y&
M6K=$K-BV+/S%[G8"KQL;%R=I-^E"!U."A)&(M5^&B #%:-VY&180D;&Q_>3Q
M  @(\ 9D,$$,7N1NED80,0=#8XHH[*$-,#L-H:9:0EMM"4)QC!%89PB<(G")
MPB<(G")PB<(G")PB<(G")PB<(H<6=*-M]OJ545I615.LU/7M:>1CR6&1M?9C
M,Q4-;B$)SA2%%5BEA7^P^WGR<&)L-<.1Y92A7,#-M>SD$'K#B8?.2M[GNVF.
M*J!-[BB@::8=GWW,7[;*(6=LKJZE4V<JNFJ;Y6?W@^6R8S4\<!-Z.=:B%^QL
M_<7LUI&]RD/=<8^F]7?+_P#,!['_ %?9]?OES(VOXZA_I;__ ,*ZMI8+_H_5
MO_Z<B_\ [-IQ; Y>J.+792DXVO"I^6,_9]9_E\O//G8ZA^+'X\__ -?\W+(O
M^D8O]"G[?DGK=U)8M_N.OOL^WW2XAM_=_P!%YO\ XK8G+U1I.$3A%AE\V/KS
M5D NU[.OE-US5FRQ@'+)>[/"5& ;.,RI(8:YBP'1\<DHI2%I&'41AY_*%8:0
MK*<^1%6Y7/&O\-.T=F[+U2CNS=)'OU9CR"W[?+'"Q&F9:0 '2;)UVO[</*8I
MDM.1P:LD.ML2.(XQ31(45)2,D(6$P168T^Z4_85<C;A0;76KQ4IE#[D1:*A.
MQ=EKLJV*4^"2N-FX8HV-.0.:,2(^H8EW#10[S#F4NM+0DBA)(^(9J6BUNYSN
MTHVWQC],N'9425CM>T>[[0>A-:=<]ISVMI?9]M^JE?-^J\">_&QRUN26&FD'
M2!;0;IL="3<E'D^S+I[%W<L8$G(7,"$T5 Z&A]U36BV)O;6^X_56RMAV:E6A
M5.V3(ZY@[-76*(^W4IX*QCQ%>GK['S-S9JLH2RJ :,B,FD^WV^WO5C'")PB<
M(G")PB<(O,/XP/6?0,[W:Z_6577"I;/W?O75NVFY"W[Q[M;(ZJZ+8A]48U2(
M/%I=J&2Y0_8GT48.J$A*S(U.(,A6+'-6*(MT@(/(UHBNH\/:B1FL^H>HJ3$:
MYT]J@"##LC+5'T/LZ7W-K.,4_<)\ITJ&V=/BBS=PD)=U]<O8Y.52^=BQ&R@S
MY9:A_?611+\15[+'<WPE'$^7GGLCL1O\+\7D]00F5?P?/TKSZ?\ ]7E^/\69
MUI%M\3KIO_A>1^W^3>JE_P""LK?\91_TMO\ [$RN$Y!5>IPB<(G")PBJ[\1S
ML+7X>BR?7^ />)NUN^@WK8T*A:1X&F*+3).L'EYQAK)MCP"W'M1K2ED?1A1)
MA.&&5BY)(J2V,J$=;($4H0AESWF"!59&(8>POW</,/LY0ZR\EW]E2ZVI+B7,
M8<2KUXQGA%?'T3[7N[=A6]4WIYYS9-0@\$BSA#J%INU>!?:#P>M2EY>S88QM
MX)N<PM/D=[J91E6?<+:&(K%>$3A$X1.$3A$X1.$3A$X1.$73V']H)S^)Y/\
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M]CO^?NK"[]>C_IH>GXHI5:CG767'B2"+WL8ATE[+RLXLR0F6OP&VTLC!Q8
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M\3SY6&:..**2%N/4FH!&#R1M7W<Y([$TI20B4@D!#TGP-#/>;M]":$81E?C
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MIXDLPPE;8XPP[2%NOOO.(::;2I:U)2G.>=XXY)3"*&,Y99"8(XHQ(Y)#)]A
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M88)]-ZERV(;ET*]ESJ.;NY%3L"T]5W)_4FAD #?O[8%WWW6S*-GSE2"QV9Y
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MI.H/Q?\ HE^Y??M2J?\ FKA_NXV)_P#3ZK>?./FRU\:GZQQ_^OS6R=0?B_\
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MF4/=[=!#UN+L#I%^27*7Z:U9]3$ZWM[NPH_8L' .64FGR=(9C7)\68(BL,O
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MAK[)D]ZU)K76X]B0@LY.":57L$&RQ>864ASS9S7,4[*3,7#IEPQ,23+Z4('
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MLC=/J6[LYV)S;?;D?U0#EW:.$.,,3=MHP%MF]%]T--:=Q.D-/872V!K^6P^
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M@H ] B&$26"%NRKD@",V60Z\,)EAWS:2EW&<N9DF(P$.'NY.U!,9QY"/%1!
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MJD/GX:F-KGAZU*V30A6,)-^43 >LZ1U7N\!M*<WC<=TCWS:J=6R^J:+*XUA
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M"C06F P11PPQ0@!6&FF\N*0X2\00]5TWIG&Z6HG0QO7();!V9IK,C2SS32"
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M^/O3UQY3PU+,L+;;[RQPF4;<??N3-V]_I[U@-5WKV,TSJ#(XV/JY"CALE;I
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M1.T5BNUN2-Y(^FTL;$YAC=)[C]@2Z_7+3;X[5JXV^:9["VVM UZ*LS)L/:]
MLDL/&S!$A./,GQ-GD!2'OHD5@5^.$4,TF3==;><=H5\_E'BBFL!1<;..R\\0
MP!.SQV<3L+N922DQQ3EN_381*)MAZLGUE98KQ*UA+1HY')5\ \&7TOK+)48J
M<%YI:V0TB!B\MHY;3C+6ORQF7EXPC."-P'S!$)$7+KG=#9K<98E7*Q:?]R5T
MIK/;M0L%.KULLD=5)+8=I#J[&O;#!!V-T^R61QPMM<3@>0KK;LAAQ,A\-&X<
M>%[Q:@M[3>8EQ[,>-H9"O-7AL3! =ZPU<*DT0SN<\CD3=(@.NQEV,0'=U4H^
M)V<:"X^4N:9WL:5P6I<=<Q=/(WH<=-F<A%CQPUVI%=*:_=,I&>KTYJ3',Q-,
M(0,YA^M-[7]AK^YKVD08^N8R\6;=^Y-22L_9*M/A1S4?K*G1-R9G,U6/MLB1
M'3#X1)P)$1FP2 GQJ1U?%L-I>QE7SF4M/5K -,+,N4R&.DEEAG&-AIUAM-*U
M<9S(9'$G!XGG(>3;]5M]F[XSQ!UCERP^*J1X2#*W=5:ETY8N7J-R.!H<%C*^
M3&WY"'(SR0VCBDEBDJO<FCZK#]* ,ZQ:S]O-R6->TZY3[/42(F2T[NVY4.[Q
M6O[/750I>K#QPRTPI4K<BR[2I\+Z3"1-/PM>8 LC#$@*+)Q@S@9-*?.WY2NP
M5IJY1GC<K:J6@J31=(L=($9,+R6C*P[\S%I&BA!I09Q:0-V?'W_$;4MU\_2Q
ME[''6L:8U5E<1EH,/D*GE9=/RQQGY8Y\F<M]CB>>)K)5J(PW0&:..Q #PGV*
M^U>]J_2H0(:W:>D)BE]6HCL+9[):(F<S]H[9I)S =/@&1+>S@.7'"CD"S]A^
M(DOBK*8PD:% 8>RRGM)F\E#7%AGQY25L&&8GEFBE8;C&4O"O S6?8,0BXS3N
M<S/+)&XPBQ.+5G\0-6T\55C#(::FM8OP^K:TOWLC6MLV;:4Y@CQM08LD/1L!
M%"T=R[SGZE^0&"K$!N#26TONO;6W=U7>&R'3J]K&B5S5LT?%DQ\R_>RSMIZO
MB[@+'8D?I!J(&;K\NZ8V6\N,]XT9QL5+##K"B7,O0R%V]D;47&O#3JQTS(""
M1[1%=I16!!RYM&'1D<V)^F[F+B+,+BY%.-,ZIU#J/5&5J]+&TL%B:& M30'#
M:++23:@P4&2CAZSRA6 :5AY&D-X.<@$T; !"YEJ'>KC$IVSU57]9[:NT7L>/
MN%6M^U B-C&!ZTJ&JHX- SE0)J+A8T,18MBOY8S%1*13Y<I9!DF6L:+=&<;L
M,E])G:$5*[:"W'/!8OCYN0:4&/$79X#KN30E-=+BT0<"E^O*Y"''>.:J*.QX
MAZ?IX+464KYR#)8_):@A/-R18/':>AC8'QLF->0:LES-GQ\M6:*6T;R2V)7C
MKD!#+9<SL>R:YW8W'6?6Z+A'R&QX#7TO494@F.KB@XM;=5;O)$CE]N-M\0<Z
MV_9QFV_@ L894ACT^XC.=YVYJN08):GF&>U%4. B((G:/:NUERY<9XS=GF$6
MXBW'8>ZV(]C-7<+J@8+V$;)139NIA[&.L')!2>.!VQXY4Y^H,&1KRD)7XQ%X
M8O9=@=MQ57=$VUN34!.X8-@'9)$P'IW484F--78W?J*[N"VV"3@)78S"ZJ?;
MRXN&>B4GVI=8$PT04Q$ XS%#-G!(3#:MW(T3OPB%XI QV/8QFLGEGAR%B:2$
M[HM =DPB*/E8*N.SN$(NT4?-M]#XG46IM-2:DJC#G)+,6F=,Q6 M92;6 TM2
MY&W9I6<T/S?-DI*]8J[29$J$?$Y0K0N\$8RQLTI>B>V(QW3UJB9B^V>SR\3N
M39-6JI^SR)P2SVA Q!1]=B G+4T(9)RRXD%T@R%CTN%Q+F"!R@@G6U,XS6FK
M@'0FC*S8G.+(WJ\)WGE&>9AED*(&><1,SZ8[N MN'<7%MME//"74->33>1KV
M,Q?OV*VJ<[CL?-GSMQ7[[1R234ZT99$(I)[+UHB.2K Q25GYA)%$8N#1@T1<
MMD;7B2*^1*V(#<&^M2WVY1>PU;TMDM!1J8&_QC$S7YC7T> *!J-G##:J[ 2]
M=:D9&+#62AMQ9;K[+6&QEFW>!XG.8,AE,?:LA;^=)Y8PZ-F(983I@+!C]N30
MPR5P,P%I'WZC.SP72.4SFH:ITY)[D.H]7Z=S&5KYE]69&S3@:GF:\=JE9Q$,
M,<6G!X-Y*I9I#/-7B>01=Y',!V1I+<TK%7W6<+L:3N5AJT0<=&:Z.@YPV6@#
MG=E;%G*A W&S2MCD(>T7:K1Y+V-;Z[)5"R3BP(B4OTH&$'+5]X:^Q]^0;%4+
M<D\L $X5)(Y#DA-[ER2O#--),4<UF%G(:5(^D;N$4ER5A&6)QSFE]36*^7P=
M3-39.Y2K2S08:6I;ELTYGSF:MXRGE+]B]/6OY/'PR%\Q88WJSD\->QF+$445
MBD06X<FB]#)PB<(G")PB\^W2;J_W%U9N?L)9*]KV'TSL0BE[BKULW!N*,$NV
MM>RFV;GW&NFU=8[0<A==[*A[M<HVF]?I8BK-R$])4J8K9-JBZ@,V5&5@B/9(
ML[Z9:O\ %;JFM]E !7WIO1FY#M5V^LCD9LGK/V#5,RI-H[*;-GRK?"^QV.KR
M,4.Z/R#EIUZE0AKR:7*PB7YVP/87,FD4N,5;Q9_R[P\/?_JZR=BO_%9P^_N_
M:B^?5;Q9_P!.'A[?_+)V*_\ %9PBB?WCZ\>)UNWJON.FW/9_3.VQ -3.O+%3
MUAUS[!1]_M,QKUO-TA:O5""^Q]G%S-623A!X,%I^NS277Y!"41Q+WM)Y8Y*A
M'DJDE24S 3<"8PVY"0$QB^S]B;=MG%_5O1Q)F)L1GL+4U#B;F'O/,-:[&(&<
M!L$T91R!-%)&3L0N4<L8'Q,2 MN)B[.ZA)I'P/MUA:RJA=@*Z<S\M8(F.LY6
M-L:P[??7>OJGHT,_ZI3":;VVH$(E^MY=S%NX;J\<3DE@A9*/=7E*,I0M34JP
M0'6P5PA?=Y[.E=+G(_;;CN6()^+,S;,1&3ON3D[N[J:XG67B%B<?6Q[>)GB-
M=:M&T;6+FM-0=8A;ZHL->_!!''&/&.*.*(&",1%W,N4A?OL_P"]W["#BA8#8
M_3K4CT<24^2=KK5G:IXB99(&]I 4HS?^V-Y!^'&?2T6PX ("9AQ"VU%*8>6W
MSO9N2V!%@KX>F8%N,M'3.EH)-G;B0D[X0Q(7%W[<=V+NQ;<F+C*ZP\0<K6\L
M7B;XE4?I!D>>AK?/!,7#?Z,FM6[<!Q$^SDQ0.3.+%&<9>TMFUSP3MM05>@X(
MP+PZ[._#Q0$:_8K%I/N$_.SKX0K0[TQ,.1_<^.CERDBXVHLY0$> '\0\Y\*&
M,QZ&49"'/7J[#T8<,)"+ Q_<YISJD+,S>W(V)9R)]MR?9N3]]F7=]7:Q*((9
M-9ZQF &%FZ^JL]*Y.#;,9\LAL1OW<BV[N[O[U#OM1X&/9'ZWZAOE1L76P*-D
M=E:IUE8]9Z5T?V!53T0E@NCF)S9%U3:-^7RTB0L-&F99N)L+8ZXUBO"#J9/A
MSF$RN+UM593E!(4@!-6,CC\I2PU6M-N/L!>KCB3\Q%$3,48PR53]HPE.4'$0
MYCU3FVK6J]F_=R+V>3A9R.5S=BQ4,XSBDDKNV4CA,C$V)ANPVXX9@CLU@AL@
MTRL(QX3.]\8:PF&\-''L>K#/_(+W$Q[.%YQZL-XQW6_8_7Y8RKT>G"LXQYX^
M6.70:^U:&_#+</\ ,HXT=^VW?:FWY/R*,S1#9=WL'/.[ON[S6;$N[_'VY24,
M(K_@Y^[HWLO)]C']U=39@"1D)653H>6TEO%[3()\O$KC'G!6A^P8VR'&1WW7
MI8,,W8I8S4@XE+C;T>PR BY?Q$U0X?\ IWT[@$;S>4QNVPNVYB'D>33$S.Q$
M4A![<A#&)D)!0\C6VX\'X,[DP]27;D[,SOMU-M]F9M]MW9FW?MWF#_B@]N?+
M*J+X5KN<>6/4_P!8^U!"U8Q^1:G^XSBG/E\L^YE>,X^6<9Q\N4/\(&L=]_GN
M=N^[<:],=OR<:S;;>YQV=ERU"HS;= ?SN3_M<MU$/4G@T;ZZK;ZBZO6*GTKW
M1$=A@]D3<Q<]L]>.QNS-=Z##H*:Y)0U,B@9'L9\#"M7LFSF#P9<O(/V$Q%8(
M%S*2;([K3=Q;\2-860C&/,6Z7$N<A4K-N%YI.[<RY6)!B;N3]*N,,+D^_3]D
M.'#8^DWK7B/X<XP+9O<V[CW_ "ON_P"/NI-[C\&3;.Z-<737,O3O"CI[=S@S
MH;-TUWTVW54M@5A\M.,LSM2LXO9EY^(FP"$MD#/Y9)%?RC(T@&: ^2(]@[6J
M=37F=KFH<U99_49LG<,/?M[#R\=N[]N.S;[>BJA5K1_4KP _Q&(!?]+"RTQU
M4_X/UL7JSK-S7/M>&IV ,+L$C89#8?8SJ)MG8E]*>/;%':C&9!GL+"QD9"1H
MH;#049&10C675$FE*(-+(?7@7<B=R)]R?N[N[N[O\7)^[[_;=5UVW93P";GV
M7UUG7DI6O#"U%EJ9!G ;OH/J1NC6-] +!;)8^&3-@]D#A3HDT<M]D^(EXV1
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M.  AGS7<*:97C-C>O1T CEF%^@\@C/-R$1K1D3 TTG)VW!I"!B8=R87(V9V
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M]@1,=I?::2:N;812S84>0R551VLKD10#'F/AG'T^AA?K4C/EC/!7*@")'9@
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M.G<)''D1X7P#%40"X')CX61&!AF#F+'Q-B'FS'MR[KNXG5VMH$.NQ\)0J?$
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M>\;UOOPFQG]A:DHV].W6OMC[47.Z^B M[:?U_==GZYTS>#*K7M=-QUDEK/\
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M<.^).BM73=4C&]FXBB!]/T+K@.V+U7K9-V-=8G.TX9RM<1EAL$C/BB/I'==
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8B<(G")PB<(G")PB<(G")PB<(G")PB__9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
